British American Tobacco p.l.c. 
(Exact name of Registrant as specified in its charter)

<table>
<thead>
<tr>
<th>Securities registered or to be registered pursuant to Section 12(b) of the Act.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title of each class</strong></td>
</tr>
<tr>
<td>American Depositary Shares (evidenced by American Depositary Receipts) each representing one ordinary share</td>
</tr>
<tr>
<td>Ordinary shares, nominal value 25 pence per share</td>
</tr>
<tr>
<td>1.668% Notes due 2026</td>
</tr>
<tr>
<td>2.259% Notes due 2028</td>
</tr>
<tr>
<td>2.726% Notes due 2031</td>
</tr>
<tr>
<td>3.734% Notes due 2040</td>
</tr>
<tr>
<td>3.984% Notes due 2050</td>
</tr>
<tr>
<td>4.700% Notes due 2027</td>
</tr>
<tr>
<td>4.906% Notes due 2030</td>
</tr>
<tr>
<td>5.282% Notes due 2050</td>
</tr>
<tr>
<td>2.789% Notes due 2024</td>
</tr>
<tr>
<td>3.215% Notes due 2026</td>
</tr>
<tr>
<td>3.462% Notes due 2029</td>
</tr>
<tr>
<td>4.758% Notes due 2049</td>
</tr>
<tr>
<td>2.764% Notes due 2022</td>
</tr>
<tr>
<td>3.222% Notes due 2024</td>
</tr>
</tbody>
</table>
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☒ Yes ☐ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. ☐ Yes ☒ No

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with US GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

US GAAP ☐ International Financial Reporting Standards as issued by the International Accounting Standards Board ☒ Other ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. ☐ Item 17 ☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

Name of the auditor’s firm KPMG LLP
Auditors’ firm ID/ PCAOB issued Audit Firm Identifier 1118
Auditors’ Location – City, State/Province, Country 15 Canada Square, London, E14 5GL

For the forward-looking non-GAAP information contained in this Annual Report on Form 20-F, no comparable GAAP or IFRS information is available on a forward-looking basis and our forward-looking revenue cannot be estimated, as the effect of rates of exchange, which could be significant, may be highly variable and cannot be estimated with reasonable certainty. In addition, other components of the Group’s results, including the revenue generated from combustibles, cannot be estimated with reasonable certainty due to, among other things, the impact of foreign exchange, pricing and volume, which could be significant, being highly variable. As such, no reconciliations for this forward-looking non-GAAP information are available and we are unable to: present revenue before presenting New Category revenue or constant currency revenue.
2021 was a pivotal year, marking our 20th year in the Dow Jones Sustainability Indices and 20 years since we produced our first Social Report. We’ve learned a lot along the way. Now we are building on these strong foundations to accelerate progress towards a sustainable future and create A Better Tomorrow™ for all our stakeholders.
Accelerating Our A Better Tomorrow™ ambitions in numbers

- **£5 billion** in New Category revenues
- **100%** of plastic packaging capable of being reusable, recyclable or compostable and unnecessary single-use plastic removed
- **Zero** child labour ambition for our tobacco supply chain
- **Carbon Neutral** operations (Scope 1 and 2)
- **50 million** non-combustible product consumers
- **Net Zero** value chain

- **2025**
- **2030**
- **2050**

**2013**
- Our first vapour product launched in the UK

**2014**
- Thrive farmer livelihoods programme developed

**2016**
- Our first tobacco heating product launched

**2017**
- Enhanced global ethics programme, ‘Delivery with Integrity’, introduced

**2019**
- CO₂e targets approved by the Science-Based Targets Initiative

**2020**
- Listed in the Dow Jones Sustainability Indices for the 20th consecutive year
- Signed up to the UN-backed Race to Zero global campaign

**2021**
- BAT celebrates 120th anniversary
Our Purpose

To reduce the health impact of our business by offering a greater choice of enjoyable and less risky products

We are clear that combustible cigarettes pose serious health risks. The only way to avoid these risks is not to start or to quit. However, we encourage those who would otherwise continue to smoke to switch completely to scientifically-substantiated, reduced-risk alternatives.¹

In order to deliver this, BAT is transforming into a truly multi-category consumer products business, with a mission to stimulate the senses of new adult generations.

20 years of Sustainability reporting

Sustainability isn’t new at BAT: 2021 was a pivotal year, marking our 20th year in the Dow Jones Sustainability Indices and 20 years since producing our first Social Report. We’ve learned a lot along the way. And how we are building on these strong foundations to accelerate progress towards a sustainable future and create A Better Tomorrow™ for all our stakeholders.

Member of
Dow Jones Sustainability Indices
Powered by the S&P Global CSA

¹ Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
² Our products assessed in the US, including Vuse, Vuse, Onity, Kyhe and Camel Shisha, are subject to FDA regulation and reduced-risk claims will be made in line with these products without agency clearance.
This document constitutes the Annual Report and Accounts of British American Tobacco p.l.c. (the Company) and the British American Tobacco Group in accordance with UK requirements and the Annual Report on Form 20-F, as filed with the US Securities and Exchange Commission (the SEC) and the rules promulgated thereunder for the year ended 31 December 2021, except that certain phrases, paragraphs or similar sections denoted with a » symbol do not form part of the Annual Report on Form 20-F as filed with the US Securities and Exchange Commission (the SEC) and certain phrases, paragraphs or similar sections denoted with a @ symbol do not form part of the Annual Report of Accounts. In addition, the Board of Directors report on pages 176 and 177 will only be included in the Annual Report on Form 20-F. Moreover, the information in this document may be updated or supplemented as inactive textual references only. These websites and the information contained therein or connected thereto are sold.

Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. The material in this Annual Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

The material in this Annual Report is not provided for the purpose of giving information about the Company to investors only and is not intended for general consumption. The Company, its Directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and are not responsible for any liability or loss or damage which may arise as a result of the use of this material. The material in this Annual Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

References in this document to British American Tobacco p.l.c. and BAT, Group, “we”, “us” and “our” when denoting opinions refer to British American Tobacco p.l.c. and when denoting business activity refer to British American Tobacco Group operating companies, collectively or individually as the case may be.

The material in this Annual Report is provided for the purpose of giving information about the Company to investors only and is not intended for general consumption. The Company, its Directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and are not responsible for any liability or loss or damage which may arise as a result of the use of this material. The material in this Annual Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

The material in this Annual Report is not provided for the purpose of giving information about the Company to investors only and is not intended for general consumption. The Company, its Directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and are not responsible for any liability or loss or damage which may arise as a result of the use of this material. The material in this Annual Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

References in this document to British American Tobacco p.l.c. and BAT, Group, “we”, “us” and “our” when denoting opinions refer to British American Tobacco p.l.c. and when denoting business activity refer to British American Tobacco Group operating companies, collectively or individually as the case may be.

The material in this Annual Report is provided for the purpose of giving information about the Company to investors only and is not intended for general consumption. The Company, its Directors, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and are not responsible for any liability or loss or damage which may arise as a result of the use of this material. The material in this Annual Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.
Welcome to our combined Annual Report and Form 20-F for 2021.

2021 has been a year of accelerated delivery, important strategic progress and continued adaptation – all achieved in the face of the ongoing pandemic.

Our teams around the world have worked tirelessly to deliver strong results across the business. Their efforts have helped ensure our continued adaptability and growth.

My appointment as Chairman was a great honour. I have enormous respect for the responsibilities that come with the role and I will do my utmost to provide thoughtful leadership to the Board and support for Jack Bowles and his team as we advance BAT’s transformation.

The strong position BAT occupies is a mark of the work done by my predecessor as Chairman, Richard Burrows. During his tenure, Richard did an outstanding job of guiding the Group through challenging times. I want to thank him, on behalf of the Board, for his dedication.

Having served as a Non-Executive Director prior to my appointment as Chairman, I am fortunate to have worked with many colleagues on the Board for some time. I believe we have a wide-ranging combination of diversity, expertise, experience and knowledge that will help steer BAT through a landscape that is both uncertain and full of opportunities.

Enhancing Organisational Culture and Capabilities

The Board is very encouraged by the progress we have made this year in terms of talent and culture. We continue to embed our ethos and have strengthened skills in numerous key areas, notably digital capabilities and the supply chain of our New Category products.

Our people have continued to demonstrate resilience and effectiveness in very testing conditions. Their commitment to our transformation has brought tangible improvements to execution across the Group.

Jack and his leadership team have developed a very coherent and compelling cultural agenda founded on purpose and responsibility. This has helped unite and inspire colleagues. Our purpose to build A Better TomorrowTM encapsulates why we exist and what we aspire to accomplish as an organisation.

Strong ESG Foundations

BAT has been on its sustainability journey for more than 20 years. Sustainability and ESG are a core part of our long-term business strategy and are ingrained in our identity as a responsible, purpose-led business.

We continue to invest significant resources and energy in our sustainability agenda. BAT has set ambitious targets, including reducing 50 million consumers of its non-combustible products by 2030, and becoming carbon neutral in its operations for Scope 1 and 2 by 2030 and net zero across its wider value chain for Scope 1, 2 and 3 by 2050.

The performance of our New Category products has propelled the number of non-combustible product consumers to 18.3 million, ensuring we are well on track to meet our 2030 target of 50 million consumers.

Our commitment to delivering carbon neutrality was highlighted earlier this year when Vuse became the first global carbon neutral vape brand.*

Dividends and Share Buyback

The Board has declared a dividend of 217.8p per ordinary share, payable in four equal instalments of 54.45p per ordinary share, to shareholders registered on the UK main register or the South Africa branch register and to American Depository Shares (ADS) holders, each on the applicable record dates. The dividends receivable by ADS holders in US dollars will be calculated based on the exchange rate on the applicable payment dates. Further information on dividends can be found on pages 79 and 354.

The Board has also announced a £2 billion share repurchase programme for 2022, as part of our commitment to enhance shareholder returns.

Board Composition

Krishnan ‘Kandy’ Anand will join the Board as an independent Non-Executive Director and member of the Nominations and Remuneration Committees from 14 February 2022. Dr Marion Helmes will step down as a Non-Executive Director from the conclusion of the 2022 Annual General Meeting and will not stand for re-election.

Looking Forward

2021 was a pivotal year for BAT. Our performance was strong, we are building capabilities, actively managing our portfolio and transforming our culture. We expect 2022 to be a year of further strategic progress and we remain confident that we will meet our medium-term targets as we continue to build A Better TomorrowTM.

Luc Jobin
Chairman
As the global COVID-19 pandemic continues to evolve, so does the Group’s response. We remain fully committed to supporting all our stakeholders throughout the pandemic and have responded rapidly to the evolving situation, taking action to protect their interests.

Keeping the Group Operating
In a Time of Crisis
The COVID-19 pandemic continues to impact the lives of many people around the world, with temporary restrictions and lockdowns across many countries leading to changes in consumer behaviour and in our operating environments.

The Group continues to navigate the challenges associated with the pandemic with effective crisis management and risk management processes in place, and remains a financially resilient business.

Our Board has maintained close oversight of the Group’s response to the impact of COVID-19 throughout this period.

Looking After our People
Throughout the pandemic, we have prioritised the health and wellbeing of our people. We have not furloughed any staff or utilised any government schemes (or subsidies) as a result of the pandemic, other than in respect of the deferral of tax instalment payments, largely in the U.S. in 2020.

We continue to strictly adhere to guidance from governments and public health authorities, as well as our own health and safety risk assessments, to ensure that our workplaces are COVID-19 secure.

Our digital transformation has enabled us to continue to utilise remote home working when needed, ensuring all employees and customers stay connected, while continuing to invest in the development of new capabilities through virtual training programmes.

In many parts of the world, including our global headquarters in the UK, we have introduced a hybrid working model as appropriate and as the local regulations allow. We have implemented COVID-19-secure workplace measures for employees who have returned to their workplace. These include regular cleaning and sanitising, temperature checkpoints and COVID-19 testing.

For all employees, we are also making sure they are aware of the extensive wellbeing support available to them, including:

– Online medical consultations;
– Counselling services; and
– Mental health support.

Vaccine Development
In December of 2020 an initial New Drug Application for our COVID candidate vaccine was approved by the U.S. Food and Drug Administration (FDA) and we progressed into a Phase 1 study. This study has now been fully recruited and remains ongoing. We expect data to be available during Q1 of 2022 and will determine next steps based on these data, but also the rapidly evolving COVID-19 and treatment landscape.

In addition to the ongoing clinical studies, further pre-clinical work was also completed which reinforced the potential of the plant-based platform. The team successfully produced 19 different monoclonal antibodies that met pharmaceutical requirements in about 10 days, demonstrating the flexibility, consistency and speed of the plant-based system to produce clinical-quality antibodies.

To accelerate the research, development and production of novel treatments, BAT launched KBio Holdings Limited (KBio) in January 2022. The company has been created to leverage the existing and extensive plant-based technology capabilities of BAT and Kentucky BioProcessing Inc (KBP), the existing BAT-owned U.S. plant biologics organisation.

Testing and Logistical Support
The forms of direct support we have deployed to address the global impact of COVID-19 have continued to evolve. We have:

– Provided personal protective equipment and other essential items to communities in which we operate;
– Loaned testing equipment to the UK Government;
– Provided access to 3D printers to help produce protective face shields; and
– Donated to many funds around the world focusing on supporting local COVID-19 responses.

Supporting our Suppliers
and Communities
Protecting the communities where we operate is an important pillar of our response to the pandemic.

We have harnessed our strengths in science, engineering and logistics to support national responses to COVID-19.

We have distributed thousands of items of PPE, sanitation kits, food and other essential items to our contracted farmers and their communities. We have also leveraged our existing farmer communication channels, including mobile apps, web portals, local media spots, videos and fact sheets, to rapidly deploy essential COVID-19 information, often to remote rural communities.

Some tobacco growing communities may be particularly vulnerable to both the virus and the economic implications of a global pandemic. We are taking great care that we don’t increase the immediate vulnerability of these communities and are committed to supporting them during the inevitable economic recovery that will follow.
Overview

Chief Executive’s Review
A pivotal year on our journey to build A Better Tomorrow™

2021 was a pivotal year in BAT’s transformation. Our commitment to change, while delivering value to stakeholders, can be seen in the progress that has been made on our strategic priorities.

As part of a new longer-term active capital allocation framework, we have announced a £2 billion share repurchase programme for 2022, to enhance shareholder returns, in addition to growing our dividend.

With strong foundations in place, we now embark on the next phase of our journey – Faster Transformation – towards A Better Tomorrow™.

As consumer preferences and technology rapidly evolve, the availability of scientifically-substantiated, less risky*† products is crucial to effective tobacco harm reduction and we are determined to transform our business.*

Dear Stakeholders,

2021 was a pivotal year in BAT’s transformation. Our commitment to change, while delivering value to stakeholders, can be seen in the progress that has been made on our strategic priorities.

We reached a total of 18.3 million (up 4.8 million) consumers of our non-combustible products and New Categories losses^ reduced for the first time, contributing to earnings growth.

Foreign exchange has been a significant headwind on our reported results, with revenue down 0.4%. However, at constant rates of exchange, we have delivered strong financial results, with revenue up 6.9%.

As part of a new longer-term active capital allocation framework, we have announced a £2 billion share repurchase programme for 2022, in addition to maintaining a growing dividend. This reflects our commitment to enhance shareholder returns.

I would like to thank all our people and our partners for their continued focus and commitment in delivering our strong results throughout this difficult COVID-19 period.

With strong foundations in place, we now embark on the next phase of our journey – Faster Transformation – towards A Better Tomorrow™. £5 billion of revenue and profitability from New Categories by 2025 and development of opportunities Beyond Nicotine, leveraging our knowledge and capabilities from New Categories.

Building A Better Tomorrow™
Our purpose of building A Better Tomorrow™ by reducing the health impact of our business means that we are committed to our business transformation.

During 2021, our focus has been on developing and delivering consumer-focused products and brands:

- The growth, from 13.5 million to 18.3 million, in consumers of non-combustible products was our strongest to date;
- Non-combustible products now account for 12% of Group revenue, up from 4% in 2017;
- Revenue from our vapour products was up 52%, with our global brand, Vuse, now the leading global vapour brand by value share;
- Following volume share gains in ENA and Japan, revenue from our THP, glo, was up 34%; and
- Revenue in the Modern Oral category, largely through Velo, was up 39%.

As consumer preferences and technology rapidly evolve, the availability of scientifically-substantiated, less risky† products is crucial to effective tobacco harm reduction and we are determined to transform our business.

ESG Front and Centre
Sustainability has been central to our business and ethos for more than two decades.

In 2001, we established our first group-wide environment, health and safety systems, the BAT Biodiversity Partnership and a programme of independently facilitated social dialogue. This year, we published our 20th ESG Report.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk-free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

^ New Categories losses reduced for the first time.
Our strategy has a clear focus on environmental, social and governance (ESG) priorities, including addressing climate change and excellence in environmental management, delivering a positive social impact and ensuring robust corporate governance.

We have many bold ESG targets, including becoming a carbon neutral business by 2030 and making all plastic packaging reusable, recyclable or compostable by 2025.

In 2021, we also signed up to the UN-backed Race to Zero global campaign and continued to setting science-based targets aiming for net zero value chain emissions by 2050.

Our sustainability actions have long been recognised externally and, in 2021, we were named in the Dow Jones Sustainability Indices (DJSI) for the 20th consecutive year.

We continue to strive for excellence and look for new ways to reduce our resource use, preserve the natural environment, improve the lives of farmers and communities, and uphold robust corporate governance standards.

Our Performance for Year Ended 31 December 2021

We performed strongly across our key indicators during the year ended 31 December 2021. Due to a foreign currency headwind of 7.3%, revenue was lower than 2020 (down 0.4%) at £25,684 million. At constant rates of exchange, the Group revenue increased 6.9%.

Currency headwinds also impacted profit from operations, increasing by 2.7% to £10,234 million with diluted earnings per share up 6.0%.

Excluding adjusting items and the impact of foreign exchange, the Group revenue increased 6.9%.

Delivering a Step Change in New Categories

Fundamental to building A Better Tomorrow™ is the acceleration of our transformation and investing to provide our consumers with enjoyable, less risky*† products.

We encourage those consumers who would otherwise continue to smoke to switch completely to scientifically-substantiated, reduced-risk alternatives*†.

Each of our New Category brands grew revenue by more than 30%, with total New Categories revenue up 42.4% to £2,054 million. Excluding the impact of foreign exchange, adjusted revenue from New Categories, at constant rates of exchange, grew 50.9%.

The performance of our reduced-risk*† portfolio of New Category products, encompassing our strong global brands, Vuse, glo and Velo, places us on track to reach the targets we set ourselves of:

– £5 billion of revenue and profitability in our New Categories by 2025; and
– 50 million consumers of non-combustible products by 2030.

Driving Value from Combustibles

The continued performance of our combustibles business will generate the funds necessary to invest in New Categories and transform the business.

Group cigarette value share increased by 10 bps compared with 2020, driven by the continued positive performance of the strategic cigarette brands in the U.S. (up 80 bps).

Group cigarette volume share fell 10 bps. Pricing continued to be strong, with combustibles price/mix of 4.3%.

Group cigarette volume was largely in line with 2020, down just 0.1% to 637 bn sticks, (with the industry estimated to be broadly in line with 2020), driven by our performance in emerging markets and partly due to trade inventory movements in the U.S. (mainly linked to the timing of price increases and uncertainty about a potential excise increase) which are expected to unwind in early 2022.

* Based upon Category Contribution – defined as profit from the sale of brands after directly attributable costs (including marketing expenses) and before the allocation of overheads.
Overview

Chief Executive’s Review

Continued

The next phase of our transformation to build A Better Tomorrow™ focuses on creating a sustainable Enterprise of the Future.

Across the business, we are already seeing the benefits of our organisational transformation programme, Quest, which has been designed to enhance our existing strengths and extract further value for the business. The five Quest accelerators are:

- **Quantum**, our multi-year simplification programme, which continues to drive efficiencies and, in 2021, enabled incremental annual savings of £595 million;
- **Unleashing Innovation** is becoming increasingly ingrained across the business. Our digital hubs, corporate venturing initiative and innovation centres are helping us stay ahead, while our continued investment in R&D enables us to satisfy or anticipate consumer preferences and generate growth for the business across all categories;
- **Empowering our Organisation** and enabling our people to deliver remains a key driver of growth. We are providing more tools and training across the business to support and drive new ways of working;
- **Shaping Sustainability** continues to be front and centre in our decision-making, finding ways of accelerating and connecting our sustainability journey with our purpose; and
- **Technology and Digital** is advancing at speed, with new digital channels, data and analytics supporting growth of our New Categories in e-commerce with margins above other retail channels and higher customer loyalty.

The BAT of tomorrow will be a high-growth, consumer goods company: global, consumer-centric and multi-category.

We are confident in delivering a faster transformation, continued robust financial performance and superior cash returns to shareholders in what remains a turbulent external environment.

Through this transformation we are committed to generating sustainable shareholder and societal value – building A Better Tomorrow™.

Jack Bowles
Chief Executive

Confidence in Our Future

The BAT of tomorrow will be a high-growth, consumer goods company: global, consumer-centric and multi-category.

We are confident in delivering a faster transformation, continued robust financial performance and superior cash returns to shareholders in what remains a turbulent external environment.

Through this transformation we are committed to generating sustainable shareholder and societal value – building A Better Tomorrow™.

Jack Bowles
Chief Executive
In this pivotal year, we have grown New Categories revenue, invested in the future of the business and deleveraged. This has allowed us to continue to reward shareholders with higher dividends and announce a £2 billion share repurchase programme. We believe we are well placed to maximise our future potential.

Revenue growth from New Categories performance and strong combustibles pricing, particularly in the U.S., more than offset by foreign exchange headwinds.

Group Transformation Underpinned by Financial Delivery
2021 was a pivotal year in our transformational journey. We have delivered a step change in New Categories, reconfigured our business capabilities for the future, delivered value through combustibles and deleveraged the balance sheet. We believe these achievements position us well for the future.

Pricing and New Categories Drive Revenue Growth
Revenue declined 0.4% to £25,684 million compared to 2020 (while 2020 was marginally lower than 2019, down 0.4% to £25,776 million). Revenue from New Categories was up 42.4% in 2021 and 14.9% in 2020, while combustibles pricing remained strong (particularly in the U.S.), with Group price/mix of 4.3% in 2021 compared to 7% in 2020. Price/mix was lower largely due to negative geographic mix as markets began to recover from the impact of COVID-19, the impact of structural excise changes and a competitive environment in Australasia (estimated at £260 million) and the disposal of the Group’s operations in Iran. These were partly offset by the benefit of trade inventory movements in the U.S. (the impact of which is expected to unwind in 2022). A translational currency headwind, due to the relative strength of sterling, negatively impacted both periods, by approximately 7.3% in 2021 and 3.5% in 2020.

Growth in Profit from Operations While Investing in New Categories
Profit from operations increased by 2.7% to £10,234 million, with 2020 up 10.5% to £9,962 million. Revenue growth, a reduction in losses from New Categories and operational efficiencies achieved under the Group’s restructuring programme (Project Quantum) were partly outweighed by the translational foreign exchange headwinds and a transactional foreign exchange headwind of 1.7. 2021 included a number of one-off items, including in respect of the disposal of the Group’s subsidiary in Iran (£358 million related to foreign exchange losses and asset write-off costs), an impairment charge of £54 million in Peru and a combined credit in the U.S. of £36 million related to the partial buy-out of the pension fund and the finalisation of the dissenting shareholders litigation. However, these were lower than those recognised in 2020 in respect of goodwill impairment (£209 million largely related to Malaysia) and charges in the U.S. (£320 million) largely related to the state settlement agreements in respect of brands sold to a third party in a prior period.

Our operating margin was 120 bps higher at 39.6% in 2021 (2020: up 380 bps to 38.6%). On an adjusted constant currency basis, profit from operations grew by 5.2% (2020: up 4.8%). This was driven by higher revenue and efficiencies delivered in both 2021 and 2020 as part of Project Quantum and lower losses from New Categories. Adjusted operating margin (at current rates) fell 70 bps to 43.4% (2020: up 100 bps to 44.1%), partly due to the proportionate growth in New Categories revenue (with the Group continuing to invest in those categories), higher revenue in lower margin markets and a transactional foreign exchange headwind of 1.7%.
**Future Funding De-Risked Through Proactive Action**

Our liquidity profile remains strong, with average debt maturity close to 10 years and maximum debt maturities in any one calendar year of around £4 billion.

In September 2021, the Group issued perpetual hybrid bonds totalling £2 billion. These euro-denominated securities contribute to a more efficient alignment of the Group’s earnings currency. They also contribute to the diversification of the Group’s sources of funding and further strengthen its capital structure. The issuance provides the additional benefit of supporting the deleveraging journey with the addition of a small benefit to the credit metrics.

Net finance costs in 2021 were £1,486 million, a decrease of 14.8% on 2020 (£1,745 million, itself an increase of 8.9%). The reduction in 2021 was partly driven by a foreign exchange tailwind. However, 2020 included net charges of £142 million in respect of the early redemption and tender offer in that year as the Group reduced future refinancing risk by raising £8.9 billion in the US dollar, euro and sterling markets, using the proceeds to repurchase and redeem £3.1 billion of bonds. This de-risked the future repayment profile by securing lower interest rates and future liquidity in uncertain times. On an adjusted, constant rate basis, net finance costs declined 4.5% in 2021 (2020: up 5.9%).

As part of the Group’s de-risking of future funding, during 2020 gross interest cover ceased to be a covenant in the Group’s debt facilities.

**EPS Growth Underpins Dividend Increase**

On a reported basis, basic EPS was up 6.0% at 296.9p (2020: up 12.1% at 280.0p) with diluted EPS up 6.0% to 296.9p (2020: up 12.0% to 278.9p), largely due to the net reduction in adjusting charges in 2021 and lower net finance costs, which more than offset the impact of foreign exchange on the Group’s operations.

Excluding the adjusting items (discussed on pages 76 and 77) and the effect of foreign exchange on the Group’s results, adjusted diluted earnings per share, at constant rates, increased by 6.6% to 353.5p, with 2020 ahead of 2019 by 5.0%.

**Cash Generation Drives Debt Deleveraging**

We continue to focus on a balanced approach of deleveraging, while investing for the future and providing a return via dividends to shareholders.

The Group’s cash conversion ratio, based upon net cash generated from operations, was 95% (2020: 98%). The Group realised £3.7 billion (2020: £3.8 billion) of net cash generated from operating activities.

Consequently, in 2021, total borrowings (including lease liabilities) have reduced from £39,658 million in 2020 to £39,658 million in 2021, due to the net repayment of borrowings in the year (including refinancing via issuance of perpetual hybrid bonds) and a currency tailwind of £409 million (2020: tailwind of £219 million).

**Active Capital Allocation Framework**

Our deleveraging and cash flow generation provide the flexibility to adopt a more active capital allocation framework to deliver long-term value for shareholders.

This will include:

- continuing to grow the dividend;
- maintaining our target leverage corridor;
- potential bolt-on M&A opportunities; and
- share buybacks to enhance shareholder returns.

The Board will prioritise capital allocation opportunities each year in line with this new longer-term active capital allocation framework, while continuing to take into account macro and fiscal influences, and potential regulatory and litigation outcomes.

As a first step, we have announced a dividend increase of 1.0% to 217.8p (with a dividend pay-out ratio of 66.2%) and a £2 billion share repurchase programme for 2022.

Tadeu Marroco  
Finance and Transformation Director
## Our Year in Numbers

### Our performance metrics

<table>
<thead>
<tr>
<th></th>
<th>Target/Ambition</th>
<th>2021</th>
<th>%</th>
<th>2020</th>
<th>%</th>
<th>2019</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Consumer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of Non-Combustible Product Consumers</td>
<td>50 million consumers by 2030</td>
<td>18.3m</td>
<td>13.5m</td>
<td>10.5m</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Market Share</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarette and THP volume share growth (bps)</td>
<td>Grow by 0-10 bps (2021)</td>
<td>+10 bps</td>
<td>+30 bps</td>
<td>+20 bps</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarette and THP volume share growth (bps)</td>
<td>Grow by 0-10 bps (2021)</td>
<td>+20 bps</td>
<td>+20 bps</td>
<td>+30 bps</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Volume</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarettes (bn sticks)</td>
<td></td>
<td>637</td>
<td>0%</td>
<td>638</td>
<td>-5%</td>
<td>668</td>
<td></td>
</tr>
<tr>
<td>Other Tobacco Products (bn stick equivalents)</td>
<td></td>
<td>18</td>
<td>-9%</td>
<td>20</td>
<td>-2%</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Vapour (mn 10ml units/pods)</td>
<td></td>
<td>535</td>
<td>+56%</td>
<td>344</td>
<td>+52%</td>
<td>226</td>
<td></td>
</tr>
<tr>
<td>THP (bn sticks)</td>
<td></td>
<td>19</td>
<td>+79%</td>
<td>11</td>
<td>+19%</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Modern Oral (mn pouches)</td>
<td></td>
<td>3,296</td>
<td>+70%</td>
<td>1,934</td>
<td>+62%</td>
<td>1,194</td>
<td></td>
</tr>
<tr>
<td>Traditional Oral (bn stick equivalents)</td>
<td></td>
<td>8</td>
<td>-4%</td>
<td>8</td>
<td>-1%</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>Financial</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue (£m)</td>
<td></td>
<td>25,684</td>
<td>-0.4%</td>
<td>25,776</td>
<td>-0.4%</td>
<td>25,877</td>
<td></td>
</tr>
<tr>
<td>Adjusted Revenue at cc (%)</td>
<td></td>
<td>+6.9%</td>
<td>3-5% CAGR</td>
<td>3-5% CAGR</td>
<td>+3.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue from New Categories (£m)</td>
<td></td>
<td>2,054</td>
<td>+42.4%</td>
<td>1,443</td>
<td>+14.9%</td>
<td>1,255</td>
<td></td>
</tr>
<tr>
<td>Revenue from New Categories at cc (%)</td>
<td></td>
<td>+50.9%</td>
<td>+15.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit from Operations (£m)</td>
<td></td>
<td>10,234</td>
<td>+2.7%</td>
<td>9,562</td>
<td>+10.5%</td>
<td>9,016</td>
<td></td>
</tr>
<tr>
<td>Adjusted Profit from Operations at cc (%)</td>
<td></td>
<td>+5.2%</td>
<td>+4.8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating Margin (%)</td>
<td></td>
<td>39.8%</td>
<td>38.6%</td>
<td>34.8%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diluted Earnings per Share (p)</td>
<td></td>
<td>219.9</td>
<td>+12.0%</td>
<td>240.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted Diluted Earnings per Share (p)</td>
<td></td>
<td>331.7</td>
<td>+2.4%</td>
<td>323.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividends per Share (p)</td>
<td></td>
<td>215.6</td>
<td>+1.0%</td>
<td>210.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividend Pay-Out Ratio (%)</td>
<td></td>
<td>66%</td>
<td>65%</td>
<td>65%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Cash Generated from Operating Activities (£m)</td>
<td>9,717</td>
<td>-0.7%</td>
<td>9,786</td>
<td>+8.8%</td>
<td>8,996</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash Conversion (%)</td>
<td></td>
<td>98%</td>
<td>100%</td>
<td>100%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borrowings, including Lease Liabilities (£m)</td>
<td>39,658</td>
<td>-9.8%</td>
<td>43,968</td>
<td>-3.1%</td>
<td>45,366</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Shareholder Return (rank)</td>
<td>17 of 24</td>
<td>20 of 24</td>
<td>21 of 23</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ESG

**Find our key ESG goals, targets and metrics in our ESG Roadmap on page 47.**

1. Where measures are presented ‘at constant rates’ or ‘at cc’, the measures are calculated based on a re-translation, at the prior year’s exchange rates, of the current year results of the Group and, where applicable, its segments. See page 83 for the major foreign exchange rates used for Group reporting.

2. Where measures are presented as ‘adjusted’, they are presented before the impact of adjusting items. Adjusting items represent certain items of income and expense which the Group considers distinctive based on their size, nature or incidence.

Please refer to pages 304 to 315 for definitions of the Non-GAAP measures. See the section ‘Non-Financial Measures’ on page 302 for more information on these non-financial KPIs.
Overview

Investment Case

Transformation Driving Sustainable Growth

Delivering growth by reducing harm and expanding our portfolio

Our corporate purpose is to build A Better Tomorrow™. Reducing the health impact of our business, by encouraging those smokers who would otherwise continue to smoke to switch completely to scientifically-substantiated, reduced-risk alternatives*, is the greatest contribution we can make to society. This means growing our New Categories business as fast as possible and developing opportunities Beyond Nicotine to consolidate our position as a high growth, multi-category consumer products company.

Revenue growth in the global nicotine industry is accelerating through the development of New Categories, which offer reduced-risk alternatives to combustible products.*†

To capitalise on this growth, our established consumer-centric, multi-category strategy is activated on a global scale, leveraging our insights on consumer satisfaction, innovation needs and taste. We are building strong global brands, specifically positioned in each target consumer segment. In addition, we are taking a disciplined approach to our Beyond Nicotine strategy to further drive our transformation and long-term business sustainability.

We have set ourselves ambitious targets to reach 50 million consumers of our non-combustible products by 2030, with revenue reaching £5 billion (and profitability) from New Categories by 2025. These ambitions will be met through the delivery of our three clear strategic priorities:

– to drive a step change in New Categories, to accelerate growth supported by increased investment;
– to generate value through Combustibles, to provide the capabilities and funding; and
– to simplify the Group, to create a stronger, faster, more agile organisation.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

Reducing the Health and Environmental Impact of our Business

Creating value for all our stakeholders

Our work to reduce the health and environmental impact of the business will drive growth and create shared value, delivering results that benefit shareholders and wider society.

We will continue to create a stronger BAT by:

– focusing on excellence in environmental management;
– delivering a positive social impact; and
– adhering to robust corporate governance.

This builds on our strong ESG foundations including our status as:

– the first tobacco company to produce a Sustainability Report in 2001;
– publication of a Human Rights focus report in 2020, the first of its kind by a tobacco company to be aligned with the UN framework of Human Rights reporting;
– named in the Dow Jones Sustainability Indices for 20 consecutive years; and
– named third highest ESG-rated FTSE 100 company by Refinitiv in 2020^.

Our commitments are anchored in challenging targets against which we will track and share the progress of our transformation – including achieving Net Zero across our supply chain by 2050.

Meanwhile, our ‘delivery with integrity’ programme is focused on ensuring that our ethical standards are never compromised for the sake of results.

^ A rating, whether by Refinitiv or any other organisation, is not a recommendation to buy, sell or hold securities. A rating may be subject to withdrawal or revision at any time. Each rating should be evaluated separately from any other rating. In addition, the criteria used in ratings may differ among ESG rating organisations. Companies may also supply different information to such organisations (or none at all) and this lack of consistency may impact rankings. Companies may also supply different information to such organisations (or none at all) and this lack of consistency may impact rankings.

Carbon Neutral
Scope 1 and Scope 2 (CO₂ emissions) by 2030

100% of plastic packaging capable of being reusable, recyclable or compostable and unnecessary single-use plastic removed by 2025

11 bn consumers in global combustibles market with the potential to convert to reduced-risk products†

50mn Non-Combustible product consumers targeted by 2030

12% Group revenue from Non-Combustibles

£5bn New Categories revenue targeted by 2025
Creating the Enterprise of the Future

Leveraging proven expertise and developing new capabilities to deliver our ambitions

Our New Category portfolio benefits from decades of insights and expertise that have driven our No. 1 global revenue position in combustibles (excl. China). This combined with increased investment behind new capabilities gives us confidence that we can deliver our medium- to long-term ambitions.

Our three global New Category brands leverage the benefits of our world-class R&D and our manufacturing, distribution, marketing and brand building capabilities, which are supported by our unrivalled global footprint across 175+ markets, with more than 11 million points of sale, reaching more than 150 million consumers daily.

Together with our long-standing experience operating within complex regulatory, legal and fiscal frameworks, these provide BAT with a compelling competitive advantage to drive portfolio growth and transformation within the wider tobacco industry.

Building on Quantum’s success to date, Quest will accelerate our organisational and business transformation programme, driving next generation innovations:

– new digital capabilities;
– empowering our people; and
– enhancing our future sustainability.

Through Quest, we are creating the Enterprise of the Future.

We are attracting new senior talent from a diverse range of industries globally to further enhance our capabilities, which will enable us to deliver on our growth ambitions over the medium to long term.

Continuing our Track Record of Delivery

Commitment to deliver returns and cash to shareholders

We are confident in our growth outlook, and have a proven track record of performance whatever the external environment.

Over the last 10 years, we have delivered 9% adjusted diluted EPS growth (at constant rates) and a 6% dividend CAGR and are confident in our medium-term targets of 3-5% revenue growth, increased operating margin and high-single digit adjusted EPS growth (at constant rates).

This will be driven by:

– accelerated New Category revenue growth;
– continued value growth in combustibles; and
– business simplification to eliminate cost and improve returns, to become a stronger, simpler, more agile organisation.

We have adopted a more active capital allocation framework to deliver long-term value for shareholders. This will include:

– continuing to grow the dividend;
– maintaining our target leverage corridor;
– considering potential bolt-on M&A opportunities; and
– share buybacks to enhance shareholder returns.
To build A Better Tomorrow™, our marketplace analysis delivers insights regarding consumer trends and segmentation, which facilitates our geographic brand prioritisation across over 175 markets. Our business is divided into four complementary regions, with a balanced presence in both high-growth emerging markets and highly profitable developed markets.

To achieve a step-change in New Categories, we are creating the Enterprise of the Future – building new capabilities around the world focused on science, innovation and digital information.

Consumer preferences and technology are evolving rapidly, and we are staying ahead of the curve with our digital hubs, the creation of innovation hubs and further development of our world-class R&D laboratories. We are also leveraging the expertise of our external partners and are looking forward to exciting results from our venturing initiative, Btomorrow Ventures.

"Our performance across New Categories is accelerating, and we now have over 18m consumers of non-combustible products."

Paul Lageweg
Director, New Categories

"The U.S. business continues its accelerated journey towards A Better Tomorrow™. We delivered a year of outstanding results, with vapour fast approaching value leadership."

Guy Meldrum
President and CEO (Reynolds American Inc.)

"The growth of New Categories across AmSSA, including our Canadian subsidiary cementing its leadership of the closed system vapour category, demonstrates our excellent post-COVID-19 recovery."

Luciano Comin
Regional Director, AmSSA
Our supply chain has shown exceptional resilience against major global challenges, including the semiconductor shortage and unprecedented logistics volatility. This is testament to our industry-leading capabilities, collaboration with our suppliers and the commitment of our people throughout the pandemic.

Zafer Khan
Director, Operations

Across ENA, revenue from New Categories grew 74%, powered by the roll-out of glo Hyper. It augurs well that, in key THP markets, our segment share is approaching overtaking combustibles.

Johan Vandermeulen
Regional Director, ENA

I’m delighted that APME approached 4m active consumers of non-combustible products in 2021, driven by a strong performance from our New Category platforms.

Michael Mihovil
Dijamovic
Regional Director, APME

In 2021, we published the 6-month results from our one-year study of our flagship THP, glo. The biggest study we have ever undertaken, it makes a significant contribution to the evidence-base for this category.

Dr David O’Reilly
Director, Scientific Research

Map is accurate as at 31 Dec 2021 and is representative of general geographic regions and does not suggest that the Group operates in each country of every region.
Our Consumer-Centric Multi-Category Portfolio

BAT is a leading consumer-centric, multi-category consumer goods business dedicated to stimulating the senses of adult consumers worldwide. Our portfolio reflects our commitment to meeting the evolving and varied needs of today’s adult consumer who seeks sensorial enjoyment for different moods and moments.

Strategic Portfolio

These are our key brands in both the combustible and non-combustible categories. This ensures focus and investment on the brands and categories that will underpin the Group’s future performance. The strategic portfolio is:

Non-Combustibles

All brands within New Categories and the strategic traditional oral brands in moist snus.

Combustibles

Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport (U.S.), Natural American Spirit (U.S.), Camel (U.S.).

Revenue by product category

£25.7bn Total revenue

Strategic Portfolio Category

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapour</td>
<td>Handheld, battery-powered devices that heat a liquid (called an e-liquid, usually containing nicotine) and creates a vapour to be inhaled.</td>
</tr>
<tr>
<td>THP</td>
<td>THPs do not burn tobacco, so no smoke (which is a key source of toxicants) is produced. Research indicates that by heating tobacco rather than burning it, THPs have the potential to be reduced-risk compared to smoking.</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>This is our most recent innovation across oral products – offering consumers a satisfying experience with a range of different flavours. Two formulations are available: one containing lower levels of tobacco, and one that contains nicotine but no tobacco.</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>Traditional Oral products contain tobacco but there is no burning. There is strong epidemiological evidence, from countries such as Sweden, that switching completely to snus can reduce risk compared to smoking.</td>
</tr>
</tbody>
</table>

*Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

†Our products are sold in the U.S., including Vuse, Velo, Goodwell, Kool and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

The Group sold 637 billion cigarette sticks and 7 billion OTP stick equivalents in 2021. The Group operates in over 175 markets, with 42 fully integrated cigarette manufacturing facilities in 40 markets.
<table>
<thead>
<tr>
<th>Global Drive Brands</th>
<th>Market Footprint</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>vuse</strong></td>
<td>30 markets where our vapour products are currently available</td>
</tr>
<tr>
<td><strong>glo™</strong></td>
<td>25 markets where our THPs are currently available</td>
</tr>
<tr>
<td><strong>VELO</strong></td>
<td>23 markets where our modern oral products are currently available</td>
</tr>
<tr>
<td><strong>GRIZZLY</strong></td>
<td>3 markets where our traditional oral products are currently available</td>
</tr>
</tbody>
</table>

**U.S. specific**

- **EST. 1907**
- **DUNHILL**
- **PALL MALL**
- **LUCKY STRIKE**
- **Newport**
- **AMERICAN SPIRIT**
- **KENT**
- **Rothmans**
- **CAMEL**
Strategic Management

Our Nine-Step Business Model

Our global business understands our diverse consumers, develops products to satisfy their preferences and ultimately distributes them across over 175 markets.

Seven key enablers support us in turning powerful insights into products that provide enjoyment to our consumers, while engagement helps our key stakeholders benefit from our sustainable growth.

SPOTLIGHT: Source

Tobacco
Subject to the industry’s Sustainable Tobacco Programme, supported by farm-level monitoring and, in selected countries, human rights impact assessments

58% BAT leaf operations, contracting 75,000+ farmers

Total tobacco sourced

42% third parties sourcing from 250,000+ farmers

Other materials, goods and services
Subject to human rights risk assessments and independent audits by Intertek for those with the highest risks

1,500+ tier 1 suppliers of filters, paper, adhesives, vapour devices, e-liquids, etc

Indirect goods and services

30,000+ suppliers of logistics, marketing, IT services, facilities management, etc
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
A Better Tomorrow™ for:

**Consumers**
Our consumers are at the core of everything we do and our success is underpinned by addressing their preferences, offering them a choice of enjoyable, innovative and less risky products.

**Measured by**
- 25 countries where tobacco heating products are available
- 30 countries where vapour products are available
- 23 countries where modern oral products are available

**Suppliers**
Across the BAT Group, we work with thousands of different suppliers worldwide. Our suppliers are valued business partners and we believe, by working together, we can raise our cards. Innovative, sustainable practices, create shared value and build A Better Tomorrow™ for all.

**Customers**
Our customers include retailers, distributors and wholesalers, who are essential for driving growth and implementing responsible marketing practices.

**Society**
The greatest contribution we can make to society is by reducing the health impact of our business. We will do this by encouraging those people who would otherwise continue to smoke to switch completely to scientifically-substantiated, reduced-risk stimulants.

**Measured by**
- 18.3m consumers of non-combustible products
- 76% of plastic packaging that is reusable, recyclable or compostable
- 43.7% reduction in Scope 1 & 2 emissions from our 2017 baseline

**People**
We employ 52,000+ people worldwide. Attracting and retaining a diverse and welcoming workforce and providing a welcoming, inclusive environment and key drivers in BAT’s transformation journey to build A Better Tomorrow™.

**Measured by**
- Accredited as Global Top Employer by the Top Employers Institute
- 76% Engagement Index score in our Your Voice employee survey
- 0.20 Lost Workday Case Incident Rate (LWCR) in 2020
- proportion of women in management roles grew to 39%

**Shareholders & Investors**
We are committed to delivering sustainable and superior returns to our shareholders and investors.

**Measured by**
- 3% revenue growth over the medium term

**Non-financial Information Statement**
Non-financial information reporting required under the UK Companies Act is included in this annual report, and a reference is made to pages 55 and 57.

**Our reporting in the following areas includes information about the policies and principles that govern our approach, due diligence processes, outcomes and non-financial performance indicators:**
- Environmental matters
- Social matters
- Anti-bribery and anti-corruption matters
- Respect for human rights
- Employees
- Further details of our Group policies and principles can be found at www.bat.com
**SPOTLIGHT: Science**

**Why Harm Reduction Matters**

"Tobacco harm reduction" is an important public health strategy that aims to minimise the harm caused by combustible products. Key to this is encouraging adult smokers, who would otherwise continue to smoke, to switch completely to scientifically substantiated, reduced-risk alternatives.

For harm reduction to be effective, alternatives are needed that deliver comparable satisfaction in nicotine delivery, use, and sensorial aspects. To enable consumer choice, we have three New Category alternatives available – vapour products, tobacco heating products and modern oral products – backed by world-class science.

**Assessing the Reduced-Risk Potential of our Products**

To achieve tobacco harm reduction, reduced-risk assessments need to be supported by robust science. That’s why we created our leading scientific research programme – and openly share its findings.

Most non-combustible products remain relatively new to the market. This means they lack the epidemiological data required to establish harm reduction potential over decades of use. It’s necessary to take a weight-of-evidence approach, based on the emissions, exposure and risk levels of each product. Our rigorous, peer-reviewed, scientific assessment framework follows nine steps.

**World-Class Science for A Better Tomorrow™**

For more than 60 years, research and development has been a critical part of our business. The table to the right highlights how we aim to create A Better Tomorrow™ through world-class science. We invest in R&D to deliver innovations that satisfy or anticipate consumer preferences. This helps us generate business growth across all our categories. But the main focus of our investment is in reduced-risk products.

---

1. **Emissions**
   - Combustion studies
   - Ultrasound studies
   - Toxicological studies
2. **Exposure**
   - Use behaviour
   - Respiratory studies
   - Clinical exposure
3. **Risk**
   - Clinical individual risk
   - Population risk
   - Post Marketing Surveillance (PMS)
   - Epidemiological data

---

*Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk-free and are addictive.

1. Our products as sold in the U.S., including Vuse, Velo, Gritty, Koko, and Camel Snus, are subject to PMA regulation and increased risk claims will be made as to these products without agency clearance.
Engaging with our Stakeholders

We work with, take into account and respond to the views and concerns of our stakeholders, adapting to emerging risks and striving to meet the expectations placed upon us as a multinational business. Listening to our stakeholders helps us better understand their views and concerns, and enables us to respond to them appropriately. It gives us valuable inputs to, and feedback on, our strategic approach, as well as our policies, procedures and ways of working.

Why this stakeholder is important to us

- Product harms, addiction and social considerations
- Product quality
- Affordability and price
- Ingredient and excise tax levels
- Photocopying, consumption product waste
- COVID-19 impacts
- Development of innovative products
- Product stewardship, quality and safety standards
- Clear and accurate product information
- International Marketing Principles
- Circular economy strategy and product sustainability initiatives
- Inability to develop, commercialise and deliver new categories
- Significant excise increases

Examples of how we engaged in 2021

- Annual General Meeting
- Investor relations programme and shareholder engagement on proposed new Directors’ Remuneration Policy
- Institutional shareholder meetings
- Capital Markets Days
- Investor roadshows
- Results announcements
- Annual Report & Form 20-F
- ESG Report
- Stock exchange announcements
- Shareholder information on website

What matters to our stakeholders

- Business performance
- ESG Agenda
- Corporate governance
- Strength of Group leadership
- Board succession planning
- Regular dialogue and communications with shareholders and investors
- Robust corporate governance
- Enhanced ESG reporting
- Continual improvement of our Delivery with Integrity programme
- Our range of enjoyable and innovative products
- Product quality and safety standards
- International Marketing Principles
- Extensive communications and virtual engagement with our people worldwide during the pandemic
- Board review of and feedback on workforce engagement
- Training and development programme
- Diversity & Inclusion Strategy
- Delivery with Integrity programme
- Director market and site visits
- Virtual forums
- Employee town halls
- Global and regional webcasts
- Your Voice employee survey
- Works councils and European Employee Council meetings
- Graduate and management trainee events
- Individual performance reviews
- Speak Up channels
- Reward
- Career development
- Diversity and inclusion
- Corporate responsibility
- Health and safety
- Business ethics
- Injury, illnes or death in the workplace
- Geopolitical tensions
Suppliers
- Extension Services farmer support
- Ongoing dialogue and relationship management
- ‘Supplier Voice’ survey, events and supplier summits
- Strategic partnerships

Customers
- Ongoing dialogue and account management
- ‘Customer Voice’ survey
- Audits, performance reviews
- Sales calls and visits by trade reps
- B2B programmes

Governments and wider society
- Meetings and ongoing dialogue
- Submissions to governments and advisory committees
- Multi-stakeholder partnerships and working groups, such as the ECCT Foundation
- External Scientific Panel
- Peer-reviewed research
- Attending events at COP 25
- Community investment programmes and NGO partnerships

UK Companies Act: Section 72(1) Statement
Our Directors have a duty, individually and collectively, to act as they consider most likely to promote the success of the Company for the benefit of our members as a whole.
As part of this duty, our Directors must have regard for long-term consequences of decisions and the desirability of maximising a reputation for high standards of business conduct. Our Directors must also have regard for our employees’ interests, business relationships with our wider stakeholders, the impact of our operations on the environment and communities in which we operate and the need to act fairly between shareholders. Consideration of these factors and other relevant matters is embedded into all Board decision-making, strategy development and risk assessment throughout the year.
Our key stakeholders and primary ways in which we engage with them are set out in the table to the left. Pages 106 to 109 and 163 to 165 provide further explanation of our Board’s approach to understanding stakeholder interests to enable relevant considerations to be drawn on in Board decision making.
Where the Board delegates authority for decision making to management, our Group governance framework discussed on page 103 mandates consideration of these factors and other relevant matters as a critical part of delegated authorities. Examples of some of the ways that these factors have shaped Group strategy and initiatives during the year are illustrated in the table to the right. Examples of how these factors have been taken into account in Board decision making and strategy development during the year are provided on page 110.
Our Markets and Megatrends

We are a global business, operating at scale, in a fast-paced world. Our markets are shaped by long-term consumer, economic, cultural and social trends, as well as the regulatory environment. Generational differences and shifts in taste are continuing to emerge, as health and wellness become ever-more important. We continue to respond to this changing environment by advancing our strategy and long-term priorities.

Megatrend: Product Innovation

Consumer Expectations
It is widely accepted that most of the harm associated with tobacco is caused by inhaling the smoke produced by its combustion — not by nicotine.

Around the world, adult consumers are increasingly driven by health considerations, looking for products and experiences more tailored to their lifestyle.

As part of this, they are seeking new options that pleasurable provide nicotine but with reduced risk?” including new and potentially unfamiliar delivery formats such as patches and pouches.

Scientific Evidence
There is wide agreement among many policymakers and bodies within the public health community on the need for a wide and robust science, to which we are keen to contribute, to inform policy and educate consumers about reduced-risk products.”

Consumers must have access to clear, factual information so they are aware of all of their options and to help build trust in reduced-risk products.”

Rigorous science can establish whether products are safer or less risky compared with ongoing cigarettes.

Regulatory and Policy Regimes
Science increasingly points to the likely individual and public health benefits of reduced-risk products as an alternative to smoking.”

For these products to realise their potential, they must be supported by effective regulatory and policy regimes that enable responsibly-managed growth and promote informed consumer choice.

Megatrend: Climate Change

Impacts on Biodiversity
There is increasing awareness of the interconnectedness between climate change and biodiversity. The threats posed by climate change, including longer periods of drought and more extreme heat, are tightly linked to a second challenge: biodiversity loss and ecosystem degradation.

However, biodiversity, through its support of ecosystem services, also makes an important contribution to both climate change mitigation and adaptation.

As a business, we recognise that we have both an impact and a dependence on biodiversity, through our business operations and use of ecosystem services, such as forest products, soil and water. We have a long-standing commitment to protecting biodiversity, including the prevention of deforestation and fragmentation of habitats.

Agriculture
Crops such as tobacco need suitable soil, water, sunlight and heat to grow. In some areas, climate change may benefit the types of crops that are typically planted there or allow farmers to shift to crops that are currently grown in warmer areas. Conversely, more extreme temperatures and weather events, especially floods and droughts, can harm crops and reduce yields.

Substantial investments in adaptation of farming practices and the adoption of new methods will be required to offset yield losses. Examples might include crop rotation to match water availability, adjusting sowing dates to minilize and temperature patterns and using crop varieties suited to changed conditions.

Megatrend: Technological Progress

The Internet of Things: The Internet of Things (IoT) — an ecosystem of smart devices that work together and are connected 24/7 — is changing the way people consume news, make connections and shop. By 2025, over 40 billion devices are expected to be connected to the IoT.

E-commerce platforms, available on the move, have led the established social platforms to adapt their business models to leverage social commerce, enabling retailers to extend their reach and build brand awareness and loyalty.

Post-pandemic Realities
The pandemic has accelerated the shift towards a more digital world and led to changes in the way we live. These changes include online shopping behaviours and shift in the way people work that are likely to have lasting effects.

Convenience of choice and delivery and the savings that easy comparison can offer have boosted online shopping since the onset of the pandemic.

While physical stores have gradually reopened, this trend will continue as the benefits of e-commerce to buyers and sellers become even more widespread and are adopted by new businesses and product types. Companies which invest in their online business are likely to emerge as market leaders.

Meanwhile, many businesses around the world are having to deal with the “hybrid” in-person/remote work model that has the potential to become the new normal in many workplaces.
Overview

Today, the tobacco and nicotine market serves a growing base of more than one billion adult consumers. Generational differences and shifts in taste are continuing to emerge, as health and wellness become ever-more important. We anticipate growth in new categories of products, including – and beyond – tobacco and nicotine. Consumers expect these to provide stimulation and pleasure, in ways previously associated with combustible products. We believe such growth will offset the predicted decline in cigarette consumption.

Global Combustible Market

The most recent sales data for the legal global tobacco market (2020) indicate it was worth approximately US$650 billion.

The largest global tobacco category remains combustible cigarettes. With over 2.7 billion cigarettes consumed annually (excl. China), it is valued at US$444 billion in 2020. Over 19% of the world’s adult population (incl. China) still chooses to smoke and will likely continue to do so unless offered suitable alternatives.

However, excluding China, the global cigarette market experienced a 4.2% volume decline in 2020 vs 2019. This is largely due to increased regulation and changing societal attitudes to smoking.

The illicit market

A further reason for the decline of legal tobacco volumes is the continued rise in illicit product consumption. While global (excl. China) illicit cigarette penetration declined from 11.9% in 2019 to 11.7% in 2020, price and mobility restrictions resulting from the pandemic hindered consumer access to black market products. Analysts expect illicit volume growth to return in several markets as travel measures ease, pressures on disposable income grow and governments raise excise.

Price differentials between markets, regulatory changes and broader macroeconomic pressures have the potential to further exacerbate the problem. It is generally accepted that there is a direct correlation between steep or ad hoc increases in taxes and illicit sales. The current sanctions in many countries often fail to deter criminals in search of profit.

Global combustible regulation

As one of the world’s most regulated and taxed industries, tobacco contributes billions of dollars to government treasuries annually. Manufacturers are subject to wide-ranging regulation, varying considerably from market to market.

Over the years, legislators have largely focused on the introduction of plain packaging, product-specific regulations, graphic health warnings on packs, tougher restrictions on smoking in enclosed public places and bans on shops displaying tobacco products at the point of sale.

They have also begun considering and adopting regulations aimed at menthols flavourings.

Environmental concerns resulting from litter associated with cigarette consumption have led to an increased number of policy initiatives, with the EU leading the way with its Single-Use Plastics legislation.

Impact of COVID-19

Beyond disruption to supply chains, the short-term impact of COVID-19 on the tobacco industry is likely to be relatively limited.

The impact on volumes is expected to be felt unequally across geographies, with resilience seen in more developed markets while developing markets experience potentially greater numbers of consumers turning to the illicit market. A case in point is the U.S., where, although the general trend is a gradual decline in annual volumes, the Federal Trade Commission, in its annual Cigarette Report, said that manufacturers sold 203.7 billion cigarettes in 2020, up from 202.9 billion in 2019 – an increase of 0.4%.

Production of the principal raw material – tobacco leaf – remains broadly diversified across a number of continents. The industry has proven adept at dealing with supply-side shocks.

Global New Categories Market

Over recent years, innovation in the tobacco and nicotine marketplace has developed new nicotine products that do not involve the combustion of tobacco leaf and the inhalation of smoke. These growing smoke-free categories include vapour products, tobacco heating products (THP) and modern oral nicotine pouches.

The success of these New Categories in offering viable alternatives to displace the use of cigarettes is based on many factors. One is their ability to offer consumers satisfaction in circumstances where using combustible tobacco is no longer permitted or socially acceptable.

Another is their ability to offer a less risky but fulfilling alternative to cigarettes. There is also a growing focus on leading a healthier, personalised lifestyle among the new generation of adult consumers. This, in addition to technological innovation, is expected to further accelerate the growth of new categories, as these products better meet evolving preferences and demands.

Evidence of this shift can be seen in global revenues from vapour and THPs, with both currently standing at around US$21 billion, an increase from 2019 of US$8.8 billion and US$5.8 billion, respectively.

Traditional oral products show steady, incremental growth. Meanwhile, growing sales of Modern Oral nicotine pouches registered an accelerated volume expansion especially in established oral tobacco markets such as the U.S. and Scandinavia. With a global value of US$1.2 billion in 2020, the category is projected to expand to over US$6 billion by 2025.

New Categories Regulations

At a global level, the THP and vapour markets are still emerging. Regulation is growing alongside the growth in the categories, but perception and attitudes towards these products have been mixed and regulation is often not designed around their characteristics and potential for risk reduction.* †

Whereas some regulators, including those in the UK and New Zealand, aim to encourage their use as less risky alternatives to cigarettes, while being mindful of the risks of youth usage, other governments view them with greater scepticism, with some imposing bans.

Beyond Nicotine

The emerging and rapidly growing market for well-being and ‘new active’ products is expected to continue to grow as the consumer trend towards bespoke lifestyles evolves. One such market, cannabidiol (CBD), is expected to gain wider use, as evidenced by its recent growth in market size and certain governments, such as that of Germany, considering the legalisation of its recreational use.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
Strategic Management

The Foundations of our Evolved Strategy

We are committed to providing A Better Tomorrow™ for all our stakeholders. Our ambition is to deliver long-term sustainable growth with a range of innovative and less harmful products that stimulate the senses of new adult generations.

Strong Foundations

- >175 markets in which we operate
- >150m daily consumer interactions
- >11m points of sale across over 175 markets

Our wide range of capabilities make us exceptionally well-placed for future growth:
- our unique global marketing and distribution reach;
- our track record of R&D and innovation;
- our decades’ worth of consumer insights and brand-building expertise; and
- our New Categories business aims to generate £5bn in revenue in 2025.

Satisfying Consumer Tastes and Moments

20 years ago combustible products fulfilled a multitude of consumer moments.

For decades, combustible products satisfied a need for sensorial enjoyment for many individuals. While occasions for tobacco consumption are now reduced, new opportunities have arisen:
- new products provide us with an opportunity to capture, in a focused way, the consumer moments previously associated with tobacco; and
- evolving and fragmenting consumer needs provide us with opportunities for additional growth in a variety of new categories.
A wider portfolio of products that offer sensorial enjoyment for different moods and moments will allow us to capture the consumer moments previously associated with tobacco use, as well as satisfy new evolving consumer needs, through:

- scientifically-substantiated, reduced-risk<sup>1</sup> tobacco and nicotine products;
- building the brands of the future; and
- ultimately, a portfolio of products beyond nicotine that leverages our proven expertise.

<sup>1</sup> Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

<sup>2</sup> Our products as sold in the U.S., including Vuse, Volo, Grizzly, Kernel and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

Our new growth opportunities will capitalise on our core business strengths, creating clear boundaries for our portfolio development:

- reducing the health and environmental impacts of our business;
- leveraging our global marketing reach and scale;
- building on our knowledge of delivery platforms and technology;
- relying on our experience in managing complex regulatory and scientific matters; and
- meeting stringent strategic and financial metrics.
In 2021, 12% of Group revenue was from non-combustible products. This was achieved through a multi-category approach which is the very essence of our purpose to build A Better Tomorrow™ – providing adult consumers with a range of enjoyable and less risky† choices for every mood and moment.

The model below outlines the key components of how we are building A Better Tomorrow™, from our mission to stimulate the senses of adult consumers worldwide and the outcomes this will deliver for stakeholders, to the ethos that guides our decision making.

**OUR MISSION**

Stimulating the Senses of New Adult Generations

**HOW WE WIN**

- **Where**
  - High Growth Segments
  - Priority Markets

- **How**
  - Inspirational foresights
  - Remarkable innovation
  - Powerful brands
  - Connected organisation
  - People & partnerships
  - U.S. focus

---

**Our Mission**

**Stimulating the Senses of New Adult Generations**

Today, we see opportunities to capture consumer moments which have, over time, become limited by societal and regulatory shifts, and to satisfy evolving consumer needs and preferences.

Our mission is to anticipate and satisfy this ever-evolving consumer: provide pleasure, reduce risk, increase choice and stimulate the senses of adult consumers worldwide.

**Must Wins**

**High Growth Segments**

Driven by our unique and data-driven consumer insight platform (PRISM), we will focus on product categories and consumer segments across our global business that have the best potential for long-term sustainable growth.

**Priority Markets**

By relying on a rigorous market prioritisation system (MAPS), we will focus the strengths of our unparalleled retail and marketing reach, as well as our regulatory and scientific expertise, on those markets and marketplaces with the greatest opportunities for growth.

**How We Win**

**Inspirational Foresights**

Built on our successful history, we have a unique view of the consumer across all of our product categories, which is increasingly driven by powerful data and analytics. These insights ensure that the development and responsible marketing of our products is fit to satisfy consumer needs.

---

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk-free and are addictive.

† Our products as sold in the U.S., including Vuse, Velo, Grizo, Kustak and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
2021 was indeed a pivotal year, with constant currency New Category revenue growth of over 50% combined with our reaching a total of 18.3 million consumers (up 4.8 million) of our non-combustible products. It is clear that our transformation towards A Better Tomorrow™ is accelerating.

Kingsley Wheaton
Chief Marketing Officer

People and Partnerships
Our highly-motivated people are being empowered through a new ethos that is responsive to constant change, embodies a learning culture and is dedicated to continuous improvement. But we cannot succeed on our own, and our partnerships with farmers, suppliers and customers are also key for ensuring sustainable future growth.

U.S. Focus
The United States comprises nearly half of our global business. It is also the single largest economy in the world, the largest single centre for technology and the key driver of global consumer trends, and is where we have the deep consumer understanding and financial strength to support the delivery of our mission to stimulate consumer senses around the rest of the world.

Our Purpose
By stimulating the senses of new adult generations, our purpose is to create A Better Tomorrow™ for all our stakeholders. We will create A Better Tomorrow™ for:
- **Consumers**
  By responsibly offering enjoyable and stimulating choices for every mood and every moment, today and tomorrow;
- **Society**
  By reducing the health impact of our business by offering a range of alternative products, as well as by reducing our environmental and social impacts;
- **Employees**
  By creating a dynamic, inspiring and purposeful place to work; and
- **Shareholders & Investors**
  By delivering sustainable and superior returns.

For more information about our purpose see inside front cover.

Short-Term Deliverables to Fuel A Better Tomorrow™

1. **Simplify the Business**
   For more key detail see pages 29 to 33
2. **Ensure a Step Change in New Categories Performance**
   With our unique cross-category consumer understanding, we are clear there is a huge opportunity for our New Categories.
   For more key detail see pages 35 to 40
3. **Drive Value From Combustibles**
   We drive value from Combustibles to fuel our investment in, and transition revenue to, New Categories.
   For more key detail see pages 42 to 43
**Strategic Management**

**Short-Term Deliverables to Fuel A Better Tomorrow™**

Our purpose is to build A Better Tomorrow™ by reducing the health impact of our business through offering a greater choice of enjoyable and less risky products* † for our consumers. To accelerate this, we must become a stronger, simpler and faster organisation, which will be achieved through the delivery of three short-term priorities.

- **Simplify the Business**
  - Through Quantum we have fundamentally re-evaluated how we are organised and have reduced management layers to eliminate duplication and entrenched accountability.
  - We continue to create new capabilities and release valuable funds for further investment in our growth ambition, ensuring the Group is stronger, faster and more agile.
  - We are steadfast in realising operational efficiencies, supply chain productivity and a focus on excellence in our route-to-market.

- **Ensure a Step Change in New Categories Performance**
  - Over the years, consumer moments that used to be satisfied by cigarettes have been replaced by other products.
  - With our unique cross-category consumer understanding, we are clear there is a huge opportunity to recapture these moments with a broader portfolio of products that are less risky than combustible products.*†
  - We are clear that any portfolio expansion will leverage our strengths. We will maximise and seek to constantly improve our delivery platforms in vapour, THP and modern oral, thereby reducing the health impact and making a positive environmental contribution.
  - We aim to increase our consumers of non-combustible products from 11 million (2019) to 50 million by 2030, driving revenue from New Categories to at least £2 billion by 2025.
  - We are building new capabilities around the world focused on science, innovation, and digital information. Consumer preferences and technology are evolving rapidly, and we are staying ahead of the curve with our digital hubs, the creation of innovation super centres, and further development of our world-class R&D laboratories. We are also leveraging the expertise of our external partners, and are looking forward to exciting results from our venturing initiative.
  - Our ambition is to increasingly transition our revenues from cigarettes to New Categories over time.
  - In order to fund the development of our New Categories, we will continue to focus on generating value from our Combustibles business, driving sustainable increases in revenue, with volume share and value share growth.
  - Our performance is a direct function of the strength of our brand portfolio. We will continue to develop and invest in our brands for equity and future value by offering winning brand and product propositions, enabled by purposeful innovation.
  - Revenue Growth Management is a critical enabler to unlock future value, and our resource allocation is focused and prioritised to deliver better results with fewer initiatives.
  - We will further consolidate our portfolio of strategic brands and deliver efficiencies through a much leaner portfolio, with far fewer stock-keeping units designed to a margin.

- **Drive Value From Combustibles**
  - Our ambition is to increasingly transition our revenues from cigarettes to New Categories over time.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
To enable us to deliver on our commitments and to become a simpler, faster and stronger organisation, we embarked on our Quantum journey in 2019. Quantum is our ongoing simplification programme that is fueling New Category investment and delivery against our financial guidance.

The first phase of Quantum delivered a large-scale organisational change and the journey continued in 2020 and 2021. This has enabled us to remain agile in a fast-paced and ever-changing environment. The effects of the global pandemic have demonstrated the importance of retaining simplification at the heart of our agenda.

In 2021, we continued to realise benefits from Quantum, generating more than £595 million of savings in the year. These benefits came through various simplification initiatives:

- In our UK Headquarters, we have implemented a new organisational design. This has been key to ensuring decision-making where the knowledge sits and seizing the opportunities from synergies and integration.
- In our markets, we have assessed and streamlined our footprint through an Operating Model review. This optimisation of our footprint is expected to deliver more than £100 million of annualised savings, enabling a sharper focus on New Categories.
- Our initiatives addressing both our Centre and End Markets are underpinned by our BAT Digital Business Services* (DBS) transformation and enabled by Technology & Digital simplification.
- In 2021, our DBS organisation has built new capabilities in consumer, customer, and Business Intelligence areas. Simultaneously, within our existing capabilities, DBS delivered optimisations to drive excellence and efficiency.

* Prior to 2021, Digital Business Services was called Global Shared Services.
Strategic Management

Simplifying the Business and Accelerating the Enterprise of the Future

BAT is moving towards the Enterprise of the Future – a global, consumer-centric, multi-category company, with sustainability at its core. We are redefining ourselves, not by the products we sell, but the consumer needs that we meet.

We are creating brands with purpose, and are reshaping our product portfolio, building a multi-category portfolio of non-combustible products backed by science, and expanding “beyond nicotine”. We are driven by digital transformation, technology and innovation, and by our people, living our ethos.

Quest is accelerating our transformation towards the Enterprise of the Future: it is delivering the capabilities required to build our multi-category platform business, enhance our future sustainability and deliver our digital transformation. It is underpinned by five accelerators.

Five ‘Accelerators’ to enable the Enterprise of the Future...

Deliver Quantum
Quantum is generating the resources to be reinvested in our New Categories by optimising our organisational design; leveraging our shared services; embedding productivity discipline; and delivering Revenue Growth Management (RGM) and Marketing Spend Effectiveness (MSE) initiatives.

Unleash Innovation
Unleash Innovation is delivering a step change in critical capabilities, enabling BAT to further build and successfully execute consumer focused and remarkable innovation. Utilising Quantum productivity savings, we are fuelling an ambitious portfolio transformation towards a multi-category product company.

Empowered Organisation
Developing our people, teams and culture is at the heart of Quest. The Empowered Organisation programme is building an engaged, agile and high-performing organisation with capabilities to deliver our Enterprise of the Future.

Shaping Sustainability
Shaping Sustainability is accelerating our corporate journey towards a sustainable enterprise, fulfilling our A Better Tomorrow™ purpose. Developing world-class science to support our new portfolio and embedding industry leading ESG ambitions is at the heart of this programme.

Technology & Digital
Technology & Digital underpins all Quest initiatives to accelerate our transformation towards a top quartile, digitally-enabled consumer packaged goods (CPG) business. Our digital transformation is focusing on digital marketing; agile organisation; value from data & analytics and intelligent automation at scale.
We Are Well On-track with our Journey Across all Accelerators

Quantum is continuing to simplify the organisation and generate funds to fuel growth in New Categories. In 2021, our new organisational design was announced and implemented, focused on simpler ways of working in our UK Headquarters. Our DBS Hubs are transforming to drive efficiencies in existing capabilities and build additional capabilities at the same time. We have reviewed and streamlined our End Markets Operating Model, simplifying and optimising our business footprint. Additionally, we continue to deploy our Revenue Growth Management and Marketing Spend Effectiveness tools, which have delivered £100m+ value creation in the U.S. and other key markets in relation to pricing, assortment, promotions and trade investment.

Unleash Innovation is transforming our capabilities to win as a multi-category business

As we evolve the range of consumer needs we serve, we are transforming capabilities in R&D and across the value chain to ensure BAT is positioned to make a step change in innovation. This transformation takes a multifaceted approach from sharpening the insights and foresights approach that drives our technology and product investments; how we are actively managing the innovation portfolio; how we partner externally; and also how we execute with excellence across our innovation pipeline.

We have achieved many milestones, including the initiation of our New Categories R&D Transformation, the launch of our “Innovation Hub” in Trieste, Italy, with further hubs planned, hosting a manufacturing site for our New Category products, a digital boutique, innovation lab and centre of excellence for digital transformation and marketing. Additionally, our venture organisation Blomorrow Ventures is leading investments in creative and innovative companies aligned with our vision for A Better Tomorrow™.

Empowered Organisation is strengthening our talent pool

In 2021, the Empowered Organisation Programme launched a new Employee Brand Proposition which is fully aligned with our A Better Tomorrow™ strategy along with a modern best-in-class career website.

Our focus on developing our people led to continuous investment in learning & development. This resulted in a global portfolio of 57 programmes all delivered 100% virtually, while providing online learning tools to all managers and global graduates enabling anytime anywhere access to learning and development support from both internal and external experts. We have also implemented a transformational leadership assessment across all management helping our people to develop qualities required that are bigger, broader, more complex and challenging. We have recruited more than 1,300 new people in 2021 to further accelerate our transformation.

Our dedicated focus on Diversity & Inclusion also led to an industry-first National Equality Standard (NES) and Global Equality Standard (GES) certification. This is a reflection of our focus on our D&I strategy and of our inclusive culture and practices.

Shaping Sustainability continues to put sustainability front and centre of everything we do

In 2021, Vuse became the first global carbon neutral vape brand*, demonstrating our commitment to carbon neutrality and to reducing our impact on the environment. Vuse Solo became the first vaping product to receive marketing granted orders from the U.S. Food and Drug Administration (FDA), which confirms that the marketing of Vuse Solo products is appropriate for the protection of the public health and is evidence of our robust, world-class science.

As verified by Vertis based on product Life Cycle Assessment data provided by an independent third party, taking into account the Group’s purchase of carbon credits through reforestation projects.

We are building awareness and confidence in the science that underpins our New Category products, engaging with external stakeholders (including regulators) to ensure these new products can help build A Better Tomorrow™. In 2021, we also accelerated our targets, including to have 100% of operations sites be zero waste to landfill by 2025, and to be net zero across our value chain by 2050. We are proud that our ESG efforts continue to be recognised externally.

Technology & Digital is creating new channels to connect with our consumers and enabling the simplification of our organisation

Through digital marketing initiatives, our e-commerce footprint is developing quickly, with consumer subscription programmes growing in priority New Category markets, enabling us to provide a more personalised experience for our consumers. End-to-end simplification through automation has improved our data analytics capabilities, our enterprise agility and efficiency, and our ability to respond faster to an ever-changing environment. We continue to digitally transform manufacturing in order to reduce waste, lessen energy usage, limit stoppages to production and save personnel time. Our ongoing ranking in the Gartner Supply Chain Top 25 demonstrates how the digital transformation and increased automation of our supply chain is having a positive impact.

100m+

value creation in the U.S. and other key markets in areas related to pricing, assortment, promotions and trade investment.
Strategic Management

Technology & Digital Unlocking the Enterprise of the Future

Digital Transformation across BAT is about leveraging technology to deliver value for all our stakeholders. We are investing in digital skills, providing tools and capabilities to our people and driving an entrepreneurial mindset, which is essential for identifying and scaling up solutions across the enterprise to maximise the value of our investments.

“Our business has delivered exceptional results enabled by the further acceleration of our digital transformation in 2021. Our focus is to leverage data & insights, apply technology, and agile new ways of working to unlock commercial value at pace.”

Marina Bellini
Director, Digital and Information

Consumers and Customers

1.8m
New Categories followers on social media

+200%
customer engagements increase through Hyper personalisation and dynamic content pilots

Finance, HR and Legal

75%+
increase in hours saved through digital bots and automation of back-office activities

Manufacturing and Supply Chain

+20 ppt
increase in demand forecasting accuracy (YoY) for New Categories through deployment of advanced statistical forecasting technologies

>1,000
employees trained as Citizen Developers, democratising automation through a culture of self-sufficiency

£30m
generated through scale up of digital innovation ideas across the enterprise

300+
employees trained in Design Thinking, driving innovative and agile ways of working

>50%
agile delivery of technology solutions across our organisation

200
new roles with new capabilities in Global Business Solutions

12,800
online connections during four-day Automation Summit with 45 speakers and over 20 hours of content
Leveraging Technology and Data to Grow at Speed

We have over 150 million daily consumer interactions and over 11 million retail points of sale. Digital channels and capabilities allow us to connect with them, ensuring better consumer engagement with brands, innovations and services that can stimulate the senses of new adult generations.

- Social listening and responding capabilities deployed in 48 countries to enable sentiment tracking and ability to influence our brands’ share of positive mentions – enhancing brand reputation and industry-leading Youth Access Prevention.
- World-class Enterprise Data Platform (EDP) – building the foundation for automation and analytics.
- Leveraging deep consumer insights to develop personalised consumer journeys – enabling the delivery of compelling communications to the right consumer at the right time and 200 million automated and personalised messages. For example, targeting and journey management of 15+ micro-consumer segments across 25+ consumer journeys helped to add 760,000 THP consumers in Japan.
- Global deployment of a mobile-first, best-in-class New Categories e-commerce user experience, winning four e-commerce awards for user experience and website design.
- Over 45 direct-to-consumer owned e-commerce store fronts – with a further 45+ branded and unbranded sites worldwide.
- Connected Consumer Devices successfully tested in two markets – creating enriched experiences, higher loyalty and strong digital relationships, resulting in new revenue streams and a shift to D2C channels.
- New consumer Loyalty capability successfully piloted – opening the path for seamless cross-channel activation and collaboration with customer and Big Tech partners.
- Global Trade Platform enabling B2B engagement across 75 countries, 15,000 trade partners and servicing two million retailers.
- Over 5,000 employees, 50 startups, 100s of suppliers and tech partners can now leverage BAT’s global BTomorrow Innovation Platform for researching and reporting innovations.
- World-class conversion rate of proofs-of-concept scale is double the average rate of other corporations, demonstrating the commitment of BAT regions and functions to delivering efficiently and quickly on innovations.
- Our Investment in Control Tower and Logistics Visibility technologies continue to improve how we proactively manage supply chain risks.
- Our continued investments in digitalising our manufacturing facilities are driving cost reductions and improving operational sustainability. Deployment of IoT technology is enabling smart management of energy and water across our factories, reducing energy consumption by as much as 50% in pilot locations.

Best-in-class commercial digital experience and launch of new connected services
Expanding our modern marketing technology stack with new capabilities to build lifetime value through subscriptions, loyalty and added-value connected services.

+42% increase of active subscribers of New Categories

Digital innovation accelerating digital transformation
Digital and data delivering value across BAT, accelerating our Transformation to a Better Tomorrow™.

+23 pts improvement in Dow Jones Sustainability Index Cyber Security score, close to best-in-class in Industry
A BETTER TOMORROW™
for consumers

By responsibly offering enjoyable and stimulating choices for every mood and every moment, today and tomorrow.

Our consumers are at the core of everything we do and our success is underpinned by addressing their preferences, offering them a choice of enjoyable, innovative and less risky products1 through:

- a wide choice of high quality and stimulating products for every mood and moment;
- brands they can trust that are manufactured to high quality and safety standards;
- reduced-risk alternatives to combustible products;²
- transparent, clear and accurate information, based on robust science, about the relative risks and
- responsible marketing that doesn’t engage or appeal to youth.

1 No device has been shown to reduce these risk conditions.
² Based on the weight of evidence and assuming a complete switch from cigarettes smoking. These products are not risk free and are addictive.
Strategic Management

Short-Term Deliverables to Fuel A Better Tomorrow™

Ensure a Step Change in New Categories Performance

Vapour products are battery-powered devices that heat liquid formulations—e-liquids—to create a vapour which is inhaled. Most e-liquids contain water, propylene glycol and glycerol, flavourings and nicotine, although some e-liquids don’t contain any nicotine. The products contain no tobacco and no combustion takes place.

Highlights

- Vuse achieves Global value leadership.
- Vuse value share up 800 bps vs 2020 to reach 33.5% share in our Top 5 markets.
- Consumer acquisition up 1.8m reaching 8.4m, with growth in all Top 5 markets.
- Vapour volume up 56% with revenue 59% higher at constant rates of exchange.
- Vuse first global vapour brand independently verified by Vertis as carbon neutral in May 2021.

Toxicology tests

<table>
<thead>
<tr>
<th>Cigarette vs ePen 2</th>
<th>Mutagenicity (Whole Animal)</th>
<th>Genotoxicity</th>
<th>Carcinogenicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

1. No observed mutagenicity under these test conditions.
2. No observed genotoxicity under these test conditions.

The Scientific Evidence*

There is growing consensus among many in the public health community and academia about the role of vapour products as a reduced-risk alternative to smoking. This is supported by a wealth of global reviews, studies and reports.

In the UK, for example, Public Health England issued a series of expert reviews of the latest evidence, concluding: “based on current knowledge, vaping is at least 95% less harmful than smoking”. According to the UK’s Office for National Statistics, vaping now stands at 6.3% of the population, and smoking levels have dropped to 14.1%, from 23% in 2012, which means the UK has one of the lowest smoking incidences in Europe.

In 2021, we published a comprehensive review of the scientific evidence for vaping products, their potential health effects, and their role in tobacco harm reduction. This is a summary of more than 300 peer-reviewed scientific papers and other evidence published by around 50 institutions over the past decade.

According to adult population modelling studies cited in the review, a significant reduction in premature deaths could be achieved if current smokers switched exclusively to vaping rather than continuing to smoke cigarettes.

Notes:

1. Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
2. Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
3. As verified by Vertis based on product Life Cycle Assessment data provided by an independent third party, taking into account the Group’s purchase of carbon credits through reforestation projects.
4. Public Health England was replaced in Oct 2021 by UK Health Security Agency and Office for Health Improvement and Disparities.
Vuse Certified as Carbon Neutral

Vuse is one example of how we are driving our ESG purpose. We are very proud that Vuse has been independently certified by Vertis as the first global carbon neutral* vapour brand. We have removed all unnecessary single use plastics from our Vuse packaging and implemented Device Take Back schemes in all our vapour markets – examples of our many projects aimed at making Vuse one of the most sustainable and trusted vaping brand worldwide with a clear consumer-led purpose.

Regulation and PMTA

The future of tobacco harm reduction has always depended on robust science, and ensuring that this is accessible to audiences outside the scientific community is critical. This need is growing stronger than ever – with a number of cases of acute lung diseases (referred to as EVALI) reported among vapers in the U.S. in 2019, consumers want to be clear on the risk profile of these products. In addition, consumer perceptions of nicotine are evolving with many consumers over-estimating the risks associated with nicotine generally.

This also demonstrates the importance of having, and enforcing, a robust and effective regulatory framework that ensures high product standards and prevents access and appeal to youth – things we have long advocated. Robust science has to be at the centre of any regulatory development and engagement.

We are fully committed to working in a regulated environment. To ensure that our products meet the FDA’s criteria as “appropriate for the protection of the public health and underpinned by prevention of the public health”, we have long advocated. Robust science has to be at the centre of any regulatory development and engagement. This underscores the importance of having, and enforcing, a robust and effective regulatory framework that ensures high product standards and prevents access and appeal to youth – things we have long advocated. Robust science has to be at the centre of any regulatory development and engagement.

PPMTAs are based on a summary of all research findings to demonstrate that the marketing of a product meets the FDA’s criteria as “appropriate for the protection of the public health”. In October 2021, Vuse Solo received the first of its kind FDA marketing authorization for vapour products. Vuse Alto PPMTA, which was submitted nearly a year after Vuse Solo, shares the same foundational science. We are confident in the quality of our applications. We support efforts by the FDA to both address the increasing availability of flavoured synthetic nicotine products and enhance enforcement actions against flavoured disposable vapour products. The FDA is under increased scrutiny from Congress to act against these types of products, including clarifying the regulatory framework within which such products should be regulated and enforced, which we believe is likely to lead to substantive action by the FDA.

Performance Summary

Vapour continued its strong momentum driven by Vuse. Total volume of consumables was up 56% to 535 million units, having grown 52% (to 344 million units) in 2020. Combined with consumable pricing across all T5 markets, this drove revenue up 52% to £327 million, or 59% at constant rates of exchange, with 2020 up 52% to £211 million (or an increase of 53% at 2019 rates of exchange).

In 2021, Vuse achieved global vapour value share leadership (in July 2021) with a full year value share of 33.5% (up 780 bps vs 2020). Vuse is now driving or approaching value share leadership in all T5 markets. We consolidated our volume share leadership of devices in all T5 markets, driven by industry leading consumer acquisition up 1.8 million to 6.4 million consumers.

In the U.S., we are approaching vapour value leadership, driven by Vuse Alto, with total vapour value share for the year up 760 bps to 32.5%, maintaining the momentum of 2020 which was up from 16.6% in 2019. Vuse consumables volume grew 67% in 2021, having grown 70% (to 174 million units) in 2020, outperforming the total vapour industry in both years (up 21% in 2021 and down 13% in 2020). In 2020, the industry in the U.S. was impacted by the EVALI crisis in 2019 and implementation of flavour regulations in early 2020. We retained leadership (by volume) of closed system devices, with growth of 500 bps to 57.4% compared to 2020.

We performed well in 2021 and 2020 in the other top vapour markets, and extended our leadership positions, with all T5 Vype migrations to Vuse completed during the year. Specifically:

- In the UK, total vapour value share of the category was 31%, compared to 36% in 2020. Vuse performed well, with value share up 210 bps to 18.9% driven by both ePen 3 and ePod;
- In France, vapour value share reached 45.7% in 2021, an increase of 14.2 bps (versus 2020), driven by ePen 3 and ePod;
- In Canada, having gained value share leadership in 2020, we continued to grow, with total vapour value share up 34.3 bps to 80.4% in 2021, driven by ePod; and
- In Germany, our value share of total vapour was 59.9%, up 10.1 bps (2020: 49.9%), driven by ePen 3 and ePod.

In January 2021, we pilot-launched our first CBD vapour product (Vuse CBD Zone) as a city test in Manchester, England, providing valuable insights into the product and consumer behaviour.

We continued the expansion of e-commerce, with Vuse ranked No.1 overall for branded consumer search and web traffic across all our T5 markets. Despite the impact of regulatory changes in the U.S., the number of consumers utilising our subscription programme globally increased to around 25,000, up 43% compared to 2020.

2020 value share in Germany has been rebased by AC Nielsen from 35.1% to 49.9%.

* As verified by Vertis based on product Life Cycle Assessment data provided by an independent third party, taking into account the Group’s purchase of carbon credits through reforestation projects.
Our Tobacco Heating Products (THPs)*

THPs heat tobacco to generate a nicotine-containing aerosol, with a tobacco taste, which the user inhales. Because the tobacco is heated instead of burned, the resulting aerosol comprises mainly water, glycerol, nicotine and tobacco flavours – dramatically different to cigarette smoke.

**Highlights**
- glo THP category volume share up 480 bps in Top 9 markets vs 2020 to reach 18.1%.
- glo consumer acquisition up 2.7m reaching 6.7m with growth in all T9 markets.
- glo consumable volume up 79%, over three times industry volume growth of 26%.
- glo revenue growth up 34% with year on year and sequential growth accelerating in H2 2021.

**The Scientific Evidence**

By heating tobacco rather than burning, THPs offer a reduced risk*† alternative compared to smoking for those who completely switch. To date, most research has been conducted by industry scientists, but an increasing number of independent reports are broadly aligned with these findings and support the role of THPs as a less risky*† alternative to smoking.

For example, a study commissioned by the UK Department of Health in 2017 found that people using THPs were exposed to around 50–90% less of the “harmful and potentially harmful” compounds compared with conventional cigarettes. In 2018, Public Health England**, while highlighting the need for more research, found that “compared with cigarettes, heated tobacco products are likely to expose users and bystanders to lower levels of particulate matter, and harmful and potentially harmful compounds”.

**Compared with cigarettes, heated tobacco products are likely to expose users and bystanders to lower levels of particulate matter, and harmful and potentially harmful compounds.**

Public Health England**, 2018

**25**

Number of markets where the Group’s Tobacco Heating Products are sold

**THP Top 9 markets**
Japan, South Korea, Russia, Italy, Romania, Germany, Ukraine, Poland and the Czech Republic.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
** Public Health England was replaced in Oct 2021 by UK Health Security Agency and Office for Health Improvement and Disparities.
Our commitment to reducing the health impact of our business is helping to deliver ground-breaking scientific advances and supports consumer choice.

The results of 329 tests and studies we have conducted have generated evidence that supports our belief that glo is a reduced-risk product compared to continuing to smoke. While glo is not risk free and nicotine is addictive, the aerosol contains considerably fewer and lower levels of certain toxic substances compared to cigarette smoke, and has a significantly reduced impact in various toxicology tests.

As more long-term data is needed to support the category, we undertook a year-long clinical study to evaluate the reduced risk potential of glo. The first real-world evidence that people switching from cigarettes to exclusive use of glo can significantly reduce their exposure to certain toxicants and smoking-related diseases, compared with continuing to smoke, and has a significantly reduced impact in various toxicology tests.

Designed with Purpose

Our new glo pro, Hyper, and Hyper+ models feature induction heating, enabling devices to reach their operating temperatures of around 240-280°C faster. This makes them more efficient and enjoyable for consumers to use. The system also requires fewer components susceptible to temperature degradation, enabling the use of a wider range of temperatures, which are still substantially lower than temperatures needed for combustion. This helps to unlock a broader range of sensory experiences.

This more-powerful heating system produces a much faster and more precise device, offering consumers more flexibility, while still tightly controlling temperature and avoiding combustion.

Performance Summary

Driven by the continued success of glo Hyper in Japan and across ENA, total consumable volume grew 79% to 19.1 billion sticks in 2021. In 2020, consumables grew by 19% to 10.7 billion sticks, having been impacted by the withdrawal of Sens in that period. Excluding Sens, THP consumable volume would have increased 29% in 2020, demonstrating an acceleration in 2021 as average daily consumption increased across our key markets.

In 2021, glo achieved record THP category volume share in the T9 markets, up 480 bps in 2021 to 18.1%, with growth in all T9 markets. This performance was underpinned by glo Hyper, which was launched in April 2020 initially in Japan (and accounts for 72% of the glo portfolio), with subsequent launches in other markets (notably in ENA) from the second half of 2020 and continuing in 2021. glo Hyper is the first-to-world THP launched with induction heating which provides a step change in consumer satisfaction with 30% more tobacco, faster heating and a boost button. The success of glo Hyper was achieved despite the impact of COVID-19 restrictions as the launches and ongoing marketing campaigns were successfully switched to digital platforms.

Revenue increased 34.4% to £853 million (2020: down 12.9% to £634 million) largely driven by the higher volume, with growth increasing sequentially between the first and second half of 2021. The decrease in 2020 was largely due to the decision to withdraw glo Sens from the market (being a reduction to revenue of £50 million) and the impact of price harmonisation in Japan. Excluding Sens, THP consumable volume would have grown by 19% to 10.7 billion sticks, having been impacted by the withdrawal of Sens in that period.

In APME, where the most mature THP markets are, our consumable volume grew 27%, with device volume up 36% as we continued to invest in consumer acquisition. Revenue was up 2.8% or 13.0% at constant exchange, with acceleration in the second half of 2021 driven by consumable pricing and as we lap the impact of the Sens withdrawal in the prior year comparator, partly offset by excise increases in Japan in October. In Japan, glo’s category volume share of THP reached 21.2%, an increase of 180 bps on 2020 (2020: 19.4%).

In ENA, which has seen strong industry volume growth of 41% in 2021, we grew around five times faster than the market, with glo volume up 195%, with consecutive quarterly growth in our key markets. Accordingly, revenue increased 150% or 167% at constant currency, having grown 143% (or 159% at constant rates of exchange) in 2020. Notably in Russia, glo’s volume share of THP was up 1,070 bps at 19.3%, while in Ukraine our volume share of THP was 20.9% (an increase of 990 bps) on 2020. Furthermore, in Italy, glo reached 12.6% THP category volume share, up 870 bps, with Hyper driving 100% of the growth, and in Romania glo reached 22.1% category volume share, up 530 bps on 2020.

COVID-19 continued to impact our consumer engagement plans in 2020 and 2021, yet we still made good progress in Kazakhstan, Poland, Egypt, the Czech Republic and across other smaller ENA launch markets, and Hyper is now in 22 of glo’s 25 markets, with further market roll-outs planned in 2022.
**Highlights**

- Continued strong global volume growth (up 70.5%), with consumer numbers up 0.6m to 2.1m.
- ENA revenue up 44%, with volume up 46% driving volume share to 69.4%, up 380 bps.
- US volume up 272%, with volume share of Modern Oral at 11.7%, up 410 bps vs 2020 in a highly competitive market.

**The Scientific Evidence**

Laboratory chemical studies for our Modern Oral products show they produce substantially lower levels of toxicants than cigarette smoke and even lower levels than snus – a traditional oral tobacco product which is already regarded as a reduced risk† alternative to smoking. Toxicology tests assessing the biological effects of our Modern Oral products on human cells also show they have little effect relative to snus and cigarettes.

In 2021, we published new peer-reviewed evidence, which suggests our Modern Oral tobacco-free nicotine pouches have a toxicant profile that is comparable to nicotine replacement therapy products (NRT). The pouches were also found to have a toxicant profile that is far lower than snus.

**Toxicology tests**

<table>
<thead>
<tr>
<th>Cigarette vs Velo</th>
<th>Velo</th>
<th>Modern Oral</th>
<th>Positive†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0%</td>
<td>100%</td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>0%</td>
<td>Positive</td>
</tr>
<tr>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Positive</td>
</tr>
<tr>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Positive</td>
</tr>
<tr>
<td>Toxtracker assay</td>
<td>(rtkn and bscl2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Notes:            | 1. Toxtracker assay (rtkn and bscl2). 2. All equivalent nicotine doses (7.85μg/ml vela vs. 4.34μg/ml cigarette). 3. High content screening. 4. Reduced risk when compared to cigarettes.

**Smokeless tobacco products are much cleaner and less hazardous than cigarettes. Their use could reduce harm to smokers if they switched entirely to these products.**

Professor Neal Benowitz  
Professor of Medicine at the University of California, San Francisco

Number of markets where the Group’s Modern Oral products are sold

**Modern Oral Top 5 markets**

U.S., Sweden, Norway, Denmark and Switzerland

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

† Our products as sold in the U.S., including Vuse, Velo, Ghostly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
This study compared BAT’s nicotine pouch products to both snus and NRTs. Each was tested for 26 compounds, some of which are known harmful and potentially harmful constituents (HPHCs). For our products, 22 of the 26 compounds tested were below measurable limits. For NRTs, 20-22 compounds were below measurable limits, whereas snus was found to have 11 compounds below measurable limits. On the basis of our evidence and informed by the wealth of independent evidence regarding snus, switching completely to Modern Oral products can be expected to reduce the risk of smoking-related disease when compared to continued smoking. That is why we are investing so much in refining and improving these innovative products. This is part of our commitment to providing adult consumers with a wide range of enjoyable and less risky alternatives to cigarettes.

Our Products
Our Modern Oral products are white in colour and contain high-purity nicotine, water and other high-quality food-grade ingredients, including eucalyptus and pine tree fibres, flavouring and sweeteners.

Originating in Scandinavia, Velo is now a leading global brand of nicotine pouches. These typically appeal to a broader audience than traditional oral tobacco, and because of their affordability and lack of batteries, they can be particularly popular in low-to-middle income countries. For example, our subsidiary in Indonesia has delivered encouraging results from its expansion activities in Jakarta. Following a promising performance in June 2020, the test has been expanded to 5,000 consumers, which is being closely monitored to gain consumer insights.

We are also delivering a step-change in Modern Oral manufacturing. Truly living our ethos, our Modern Oral factory in Pécs, Hungary, put together a bold plan to implement food industry standards for Modern Oral manufacturing. This was largely driven by the U.S., where our volume share of Modern Oral increased by 410 bps as volume grew 72% to 602 million pouches (2020: up 45% to 162 million pouches). This growth was due to the acquisition of the nicotine pouch products of Dryft Sciences, LLC (Dryft) in October 2020. These products are now present in over 110,000 stores nationally, driving volume share expansion to 11.7%, up 410 bps on 2020 in a highly competitive market. Due to discounting to drive consumer trial, which is recognised as a deduction to revenue under IFRS, revenue declined 82% to £2 million, having grown 14% to £10 million in 2020.

While we are excited about the long-term potential of the Modern Oral market in the U.S., it currently represents less than 2% of the nicotine industry by revenue (in the U.S.) and 51% and 38% of global Modern Oral volume and value share, respectively.

The majority of Velo consumers (in the U.S.) adopted the brand as their first in Modern Oral, sourced evenly from Combustible, snus, Traditional Oral and Vapour consumers. Our insights suggest that a high percentage of Modern Oral users are already poly-users of other categories.

In ENA, we are volume share leaders of the Modern Oral category in 15 of the 17 markets where we are active. Revenue increased by 44% (2020: up 59%) or 46% (2020: up 59%) at constant rates of exchange. We continue to drive innovation in the category, with the success of our Sachet, Black range and Velo Mini launches, as well as new flavours generated alongside consumers in our LAB co-creation hubs in Sweden.
Our Traditional Oral Products

The most common products in traditional oral are largely moist oral tobacco popular in the U.S., with the main brands of Grizzly and Kodiak. These products are less finely ground than another traditional oral product referred to as Swedish-style snus. Both of these traditional oral products are available in loose form, as well as in pre-packed pouches.

Our Products

We also sell a range of traditional oral products, including Swedish-style snus and American moist snuff, available in loose tobacco form or as pre-packed pouches. We have long sold snus in Sweden and Norway through our Fiedler & Lundgren business, whose brands include Granit and Mocca; and in the US we market snus under the Camel brand. Our American moist snuff products include our flagship Grizzly brand, as well as the premium moist snuff brand Kodiak. The Modified Risk Tobacco Product (MRTP) applications for Camel Snus were discussed by the Tobacco Products Scientific Advisory Committee (TPSAC) of the FDA in September 2018. After extensive additional work with the FDA, we expect that the applications will remain under review until the second half of 2022.

Performance Summary

In 2021, volume was lower (down 3.9%) on the prior year (at 8.0 billion stick equivalents), with 2020 0.9% lower than 2019.

Total revenue declined 3.6% to £1,118 million (2020: up 7.2% to £1,160 million), as pricing in both 2021 and 2020 was more than offset in 2021 by a translational foreign exchange headwind of 6.6% due to the relative strength of sterling in the year. On a constant rates basis, revenue grew 3.0% in 2021 and 7.7% in 2020.

In the U.S., which accounts for approximately 96% of the Group’s revenue from Traditional Oral, volume declined 5.1% in 2021 (2020: down 1.3%). Value share of moist was up 10 bps, while volume share was down 50 bps, compared to 2020. This followed a decline in value share in 2020 of 25 bps. The improvement in 2021 was driven by Grizzly through the use of RGM capabilities which stabilised the performance from the second half of 2020 and delivered value growth in 2021.

Outside the U.S., being 4% of Group revenue from the category, volume was 6.1% higher in 2021, driven by Sweden where the Group’s volume share (as a proportion of total oral) increased 50 bps (2020: down 80 bps). This was driven by growth in Lundgrens in both periods offset, in 2020, by declines in the remainder of the portfolio.

Proportion of traditional oral revenue by region in 2021 (£m)

<table>
<thead>
<tr>
<th>Region</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>1,077</td>
<td>1,026</td>
</tr>
<tr>
<td>AmSSA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENA</td>
<td>41</td>
<td>34</td>
</tr>
<tr>
<td>APME</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,118</td>
<td>1,150</td>
</tr>
</tbody>
</table>
Strategic Management

Short-Term Deliverables to Fuel a Better Tomorrow™

Drive Value From Combustibles

Our Combustible Products

We are focused on growing our strategic brands of Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport (U.S.), Natural American Spirit (U.S.) and Camel (U.S.) which now account for 66% of our combustible volume.

Our combustibles business is founded on understanding and meeting the preferences of adult smokers in all parts of the world.

Highlights

- Group value share up 10 bps, driven by the U.S. up 60 bps.
- Volume share down 10 bps.
- Strong price/mix +4.3%.

Value and Volume Share

Group cigarette value share increased 10 bps in 2021 (2020: up 20 bps), driven by the continued performance of the strategic cigarette brands in the U.S. (up 80 bps), with total U.S. value share up 60 bps. This combined with higher cigarette value share (in Japan, Bangladesh, Germany, Turkey, Taiwan, Pakistan, the Czech Republic, Colombia and Malaysia) to more than offset lower value share in Indonesia, Saudi Arabia, Canada, Australia, South Africa, Poland, France and Italy.

Group cigarette volume share was down 10 bps in 2021 (2020: up 40 bps). The decrease in 2021 was driven by the U.S. (as we focused on value generation), South Africa, Australia, Saudi Arabia, Brazil, New Zealand and Russia more than offset lower volume share in Indonesia, Saudi Arabia, Canada, Australia, South Africa, Poland, France and Italy.

Group cigarette volume share was down 10 bps in 2021 (2020: up 20 bps). The decrease in 2021 was driven by the U.S. (as we focused on value generation), South Africa, Australia, Saudi Arabia, Brazil, New Zealand and Russia more than offset lower volume share in Indonesia, Saudi Arabia, Canada, Australia, South Africa, Poland, France and Italy.

Value Performance

In 2021, Group cigarette volume was in line with 2020, at 637 billion sticks (2020: down 4.6% to 638 billion), with the total cigarette market also estimated to be largely in line with 2020, having declined between 5.0-5.5% against 2019.

In 2021, cigarette volume grew in South Africa (which recovered from the impact of the COVID-19 lockdown and sales ban in 2020), Pakistan (due to lower illicit trade), Bangladesh (due to the strength of the local portfolio) and Vietnam (as the market recovered from COVID-19). However, these were more than offset by the disposal of the Group's operations in Iran partway through the year, while volume was lower in both Indonesia (as the Group focused on value delivery with pricing ahead of the industry) and the U.S.

In the U.S., Group cigarette volume was down 5.0% to 69.5 billion, having increased 0.5% to 73.1 billion in 2020. The movement in 2021 was partly benefiting from trade inventory movements (mainly linked to the timing of price increases and uncertainty about a potential excise increase) which are expected to unwind in 2022.

In 2020, Group cigarette volume was also negatively impacted by the COVID-19 production and other supply chain restrictions.

Volume Performance

| Proportion of combustibles revenue by region in 2021 (£m) |
|-----------------|---------------|---------------|
|                 | 2021          | 2020          |
| U.S.            | 10,015        | 9,926         |
| Arr/SSA         | 3,435         | 3,535         |
| EMA             | 5,024         | 5,356         |
| APME            | 3,655         | 3,935         |
| Total           | 22,029        | 22,752        |
This affected sales in several markets including Canada and Mexico. While not a significant part of the Group, travel restrictions due to COVID-19 impacted our Global Travel Retail (GTR) business (which did not recover in 2021), negatively impacting Group cigarette and THP volume by an estimated 1.0% (in 2020 compared to 2019). Furthermore, volume declined in Indonesia (due to the impact of tax increases and minimum retail price compliance) and in Pakistan, where illicit trade grew significantly following excise-led price increases in prior years. These were partly offset by growth in Brazil (where enhanced border security and restricted population mobility due to COVID-19 led to an increase in duty paid volume), in Turkey (driven by Kent and the local portfolio), and in Bangladesh (driven by the continued strength of the local portfolio).

Developed markets were generally relatively resilient, with little evidence of accelerated downtrading despite the pressures of COVID-19.

**Strategic Brand Performance**

The performance was underpinned by the strategic cigarette brands, with value share 20 bps higher in 2021 (2020: up 40 bps):

- Dunhill’s overall value share was down 10 bps (2020: down 10 bps) as growth in Romania, Pakistan, Taiwan and Brazil was more than offset by declines in Indonesia, South Korea, Australia and Saudi Arabia. Volume was 8.9% lower (2020: down 17%), largely due to the impact of the tax increases and minimum retail price compliance in Indonesia;
- Kent’s value share was stable (2020: stable) as growth in Turkey, Russia, South Korea, Saudi Arabia and Ukraine was offset by lower value share in Japan, Romania and Brazil. Volume was down 2.6% (2020: up 2.0%) as growth in Turkey was more than offset by lower volume in Japan and the Middle East (due to the sale of the business in Iran partway through the year);
- Lucky Strike’s value share grew 30 bps (2020: up 10 bps), as growth in the U.S. (following launch in December 2020), AMSSA (particularly Brazil, Colombia and Chile), Japan, Russia and Germany more than offset lower value share in Indonesia, France and Spain. Volume grew 19.6% (2020: down 2.0%) driven by Russia, the U.S., Brazil, Algeria and Japan, partially offset by the impact of the tax increases and minimum retail price compliance in Indonesia;
- Rothmans’ value share was 10 bps lower (2020: up 10 bps) as growth in Brazil, the Czech Republic and Malaysia was offset by lower value share in Russia, Australia, New Zealand, Poland, South Korea, South Africa, Ukraine and the UK. Volume was 3.0% lower (2020: up 6.1%) as growth in Brazil and Cuba was more than offset by lower volume in Russia, Ukraine and Kazakhstan; and
- Pall Mall’s value share was 20 bps lower (2020: stable) as growth in Mexico and Germany was more than offset by lower value share in the U.S., Saudi Arabia, Australia, Canada, Chile, Romania and New Zealand. Volume was up 2.2% (2020: down 0.8%) largely driven by Pakistan.

The Group’s US domestic strategic combustible portfolio performed well:

- Newport value share increased 70 bps (2020: up 50 bps), while volume declined 3.3% (2020: up 2.3%);
- Natural American Spirit performed well with value share up 20 bps (2020: up 20 bps).

Volume was marginally lower than 2020 (down 0.8%), having increased 6.0% in 2020 vs 2019; and
- Camel’s value share declined 30 bps in the US (2020: stable) with volume 9.0% down (2020: up 1.2%), driven by competitive pricing pressures.

Volume of other tobacco products (OTP) declined 9.2% to 18.3 billion sticks equivalent (2020: 1.7% decline), being 3% of the Group portfolio (2020: 3%).

**Revenue**

In 2021, revenue from combustibles was down 3.2% at £22,029 million (2020: £22,752 million, down 1.1%). 2021 benefited from an estimated £200 million benefit from the U.S. trade inventory movement discussed earlier. This was more than offset by the estimated £260 million impact of structural excise change and competitive pricing in Australasia and the impact of the sale of the Group’s operations in Iran (as described on page 196). While pricing in both years was strong, this led to 2021 price/mix at 4.3% being lower than 2020 (7.3%).

A translational foreign exchange headwind of 7.2% led to the decline in revenue in 2021 from combustibles.

Revenue in 2020 was also negatively impacted by the COVID-19 volume disruption and a translational foreign exchange headwind of 3.7%. COVID-19 continued to affect the Group as travel restrictions impacted GTR in 2021 and 2020. After adjusting for the short-term impact of excise on bought-in goods (impacting 2019) and the currency headwinds, adjusted revenue from combustibles at constant rates of exchange was up 4.0% to £23,669 million. In 2020, this was an increase of 2.8%. 
As consumers increasingly seek products offering wellbeing and stimulation characteristics, we are working with our venturing unit, Btomorrow Ventures (BTV), and selected third-parties to strengthen our understanding of this market. We are applying these learnings and developing our own portfolio of products addressing consumer needs not just today, but into the future.

BTV has completed 17 investments since launch in 2020, with 9 new investments during 2021, in innovative consumer, new sciences and technology businesses and one fund investment.

The companies in which we invest are carefully selected for original ideas across a range of criteria, as well as a cultural fit which allows us to work together to leverage the strength of the BAT Group in helping entrepreneurial candidates accelerate and sustain growth. This approach provides us with evolving capabilities for the future across both our New Categories and Beyond Nicotine.

In March 2021, we entered a strategic collaboration agreement with Organigram Inc., a wholly owned subsidiary of publicly traded Organigram Holdings Inc., focused on research and product development activities of next generation adult cannabis products, with an initial focus on cannabidiol (CBD).

As described on page 213, under the terms of the transaction, a Group subsidiary acquired a 19.9% equity stake in Organigram Holdings Inc. (listed on both the Nasdaq and Toronto Stock Exchange under the symbol “OGI”) to become its largest shareholder.

In January 2022, we announced the launch of KBio Holdings Limited (KBio) to accelerate the research, development and production of novel treatments for rare and infectious diseases. KBio will leverage the existing plant-based technology capabilities of BAT and Kentucky BioProcessing Inc. (KBP), the existing BAT-owned U.S. plant biologics organisation.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
A BETTER TOMORROW™
for society and the environment

By reducing the health impact of our business by offering a range of alternative products, as well as by reducing our environmental and social impacts.

Sustainability is front and centre in all that we do. As we set about creating the enterprise of the future, we are driving a step-change in our sustainability ambition. We have developed a set of goals and targets that will act as a catalyst for action and build A Better Tomorrow™ for all our stakeholders. These include:

- increasing our number of non-combustible product consumers to 50 million by 2030;
- achieving carbon neutrality for our business operations by 2030 (Scope 1 and 2) and net zero across our value chain (Scope 1, 2 and 3) by 2050; and
- net positive impact on forests in our tobacco supply chain by 2025.
Strategic Management

ESG Front and Centre

Our Sustainability Agenda is integral to our Group strategy and purpose to build A Better Tomorrow™. It reflects our commitment to reducing the health impact of our business as our principal focus area. This is underpinned by excellence across environmental, social and governance (ESG) priorities.

Our strategic approach is driven by extensive stakeholder insights. Each year, we commission an independent assessment to identify our most material ESG topics. Through this robust process, we engage with a wide range of stakeholders to understand what matters most to them, complemented with ongoing risk monitoring, research and benchmarking.

This ensures we keep pace with emerging topics and stakeholder expectations.

Outlined below are the priority areas that form the core of our Sustainability Agenda. These are backed by clear and measurable goals and targets for each area, as detailed in our ESG Roadmap on the next page.

Details of how we identify our focus areas can be found in the Materiality section of our 2021 ESG Report at www.bat.com/esgreport.

All energy and emissions data in the table on page 47 are calculated in accordance with the Greenhouse Gas (GHG) Protocol Corporate Standard. For further details of our energy and emissions methodologies, please see www.bat.com/reporting.

1. UK-based activities include 2,276 tonnes of Scope 1 CO₂e emissions (2020: 2,200) and 173 tonnes of our Scope 2 CO₂e emissions (2020: 156). The reductions between 2019 and 2020 were achieved through a combination of the principal measures taken for the purposes of increasing energy efficiency across the Group.

2. Due to the complexity of consolidating and verifying Scope 3 data in accordance with the GHG Protocol, we report one year behind. As such, 2021 Scope 3 data will be reported in the 2022 Report.

3. Energy consumption from activities for which the Company is responsible (in million kWh): 2021: 1,508, 2020: 1,572, 2019: 1,820. Of the total figure reported for the Group for 2021, 10 million kWh is from the UK-based activities (2020: 10 million kWh). Energy consumption resulting from the purchase of electricity by the Company for its own use (in million kWh): 2021: 972, 2020: 996, 2019: 1,054. Of the total figure reported for the Group for 2021, 16 million kWh is from the UK-based activities (2020: 17 million kWh).
<table>
<thead>
<tr>
<th>Topic</th>
<th>Goals and targets</th>
<th>Metrics</th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
<th>Progressing</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hem reduction</td>
<td>£5 bn by 2025 in New Categories revenues</td>
<td>New Category revenues (£bn)</td>
<td>2.1</td>
<td>1.4</td>
<td>1.3</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50m by 2030 consumption of our environmental life products</td>
<td>No. of consumers</td>
<td>10.3</td>
<td>13.5</td>
<td>10.6</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Climate change</td>
<td>Net Zero active carbon-neutral operations (Scope 1 and 2 CO2e emissions) by 2030 and net zero emissions across our value chain by 2050</td>
<td>Scope 1 &amp; 2 CO2e emissions (thousand tonnes)</td>
<td>325</td>
<td>342</td>
<td>396</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scope 2 (CICE power-based) emissions (thousand tonnes)</td>
<td>170</td>
<td>193</td>
<td>306</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total Scope 1 &amp; 2 CO2e emissions (thousand tonnes)</td>
<td>495</td>
<td>541</td>
<td>782</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scope 1 and scope 2 CO2e emissions intensity ratio (tonnes per £bn revenue)</td>
<td>18.3</td>
<td>20.3</td>
<td>30.4</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scope 3 CO2e emissions (thousand tonnes) including biogenic emissions and biogenic removals</td>
<td>11%</td>
<td>5.56%</td>
<td>6.78%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Waste</td>
<td>30% by 2025 of total energy from renewable sources</td>
<td>Total direct energy use (GWh)</td>
<td>2.46G</td>
<td>2.56G</td>
<td>2.60G</td>
<td>2.67%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100% by 2030 of electricity sourced for operations sites that is renewable</td>
<td>Renewable energy as a % of total direct energy use</td>
<td>28.6%</td>
<td>26.8%</td>
<td>10.8%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% of electricity sourced for operations sites that is renewable</td>
<td>64.4%</td>
<td>68.3%</td>
<td>10.7%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100% by 2025 of operations sites to achieve zero waste to landfill</td>
<td>Waste sent to landfill (thousand tonnes)</td>
<td>11.93K</td>
<td>12.73K</td>
<td>13.95K</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% of operations sites reporting zero waste to landfill</td>
<td>35%</td>
<td>27%</td>
<td>NA</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>-35% by 2025 of total amount of water withdrawn (as 2017 baseline)</td>
<td>Total water withdrawn/municipal matrix m³</td>
<td>5.76</td>
<td>4.03</td>
<td>4.61</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Biodiversity &amp; reforestation</td>
<td>Net Zero Deforestation by 2025</td>
<td>% of sources of wood used by our contracted farmers for curing that are from sustainable sources</td>
<td>99.9%</td>
<td>99.7%</td>
<td>93.6%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% paper and pulp volumes that is certified sustainable</td>
<td>89%</td>
<td>NA</td>
<td>NA</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Farmer livelihoods</td>
<td>Livelihoods committed to enabling prosperous livelihoods for all farmers in our tobacco supply chain</td>
<td>% of tobacco farmers reported to grow other crops for food or as additional sources of income</td>
<td>95.6%</td>
<td>93.4%</td>
<td>92%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Human rights</td>
<td>Zero by 2025 earning for zero child labour in our tobacco supply chain by 2025</td>
<td>% of farms with incidents of child labour identified</td>
<td>0.77%</td>
<td>0.60%</td>
<td>0.57%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Health &amp; safety</td>
<td>Zero working for zero accidents Group-wide each year</td>
<td>Number of work-related accidents (including those resulting in injury, causing absence of one shift or more)</td>
<td>95.3%</td>
<td>114%</td>
<td>186%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>People &amp; culture</td>
<td>45% by 2025 increase the proportion of women in management roles to 67%</td>
<td>Lost working case incident rate*</td>
<td>0.20%</td>
<td>0.23%</td>
<td>0.27%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Number of serious injuries and fatalities to employees and operations</td>
<td>31</td>
<td>39</td>
<td>38</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Business ethics</td>
<td>100% aiming for full adherence to our Standards of Business Conduct (SoBC)</td>
<td>% of markets aligned to the VAP Guidelines**, where our products are sold</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>Responsible marketing</td>
<td>100% aiming for full adherence to our Standards of Business Conduct (SoBC)</td>
<td>Number of established SoBC breaches</td>
<td>99</td>
<td>116%</td>
<td>130%</td>
<td>★</td>
<td></td>
</tr>
</tbody>
</table>

1. Due to the complexity of consolidating and verifying Scope 3 data from our suppliers and other third-party sources, we report figures one year behind our other metrics.
3. In 2021, we changed the reporting period for our health and safety metrics from December to November period each year, from January to December. This is in alignment with our environmental reporting and to enable more time for the consent dialogue and verification of our data for reporting. To enable year-on-year comparison, we have re-stated our 2020 data to align with the new reporting period. Number of work-related accidents, 74% (June 2018 to June 2019) vs 72% (January 2019 to December 2019).
4. 100% of cases reported as received by end of the reporting period.
5. Values from VAP Guidelines are granted where there is a government ban on point-of-sale materials or VAP retailer engagement is not permitted due to practical or cultural limitations.
We have a clearly defined governance framework to ensure Board level oversight and management of our Sustainability Agenda and ESG priority areas across the Group. This provides a flexible channel for the structured flow of information, management and oversight of ESG from local business units up to Board level.

Management of ESG priorities are embedded across relevant business areas at Group, regional and local levels. This approach provides a flexible channel for the structured flow of information, monitoring and oversight of ESG at the level and format best suited to the context.

Our Group policies (indicated by* in the table below) are endorsed at Board level and aligned with international standards.

Our Group policies are adopted by all Group companies and support the effective identification, management and mitigation of risks and issues for our business in these and other areas. They are underpinned by a range of principles, statements, operational procedures, standards, guidelines and controls to help ensure effective implementation of our policy commitments.

Full details and downloads of our policies and standards can be found at bat.com/principles.

<table>
<thead>
<tr>
<th>Name (*Board endorsed)</th>
<th>Summary of areas covered</th>
<th>Stakeholder groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standards of Business Conduct (SoBC)</strong></td>
<td>Sets out our policies for: Speak Up, respect in the workplace, human rights, health, safety and welfare, environment, lobbying and engagement, conflicts of interest, anti-bribery and corruption (ABAC), gifts and entertainment, political contributions, community investment, corporate assets and financial integrity, competition and anti-trust, anti-money laundering and tax evasion, sanctions, anti-illicit trade, data privacy and information security.</td>
<td>Our People, Governments and wider Society</td>
</tr>
<tr>
<td><strong>Supplier Code of Conduct</strong></td>
<td>Covers: human rights, health and safety, environmental sustainability, responsible marketing, anti-illicit trade, ABAC, gifts and entertainment, conflicts of interest, tax evasion, sanctions, data privacy and cyber risk.</td>
<td>Customers, Suppliers</td>
</tr>
<tr>
<td><strong>Environmental Policy</strong></td>
<td>Our commitments to following high standards of environmental protection, adhering to the principles of sustainable development and protecting biodiversity covering our direct operations and supply chain, including agricultural, manufacturing and distribution operations.</td>
<td>Our People, Suppliers, Customers, Governments and wider Society</td>
</tr>
<tr>
<td><strong>International Marketing Principles (IMP)</strong></td>
<td>The standards that govern marketing across all our product categories and including the requirement for all our marketing to be targeted at adult consumers only.</td>
<td>Consumers, Customers, Suppliers</td>
</tr>
<tr>
<td><strong>Youth Access Prevention (YAP) Guidelines</strong></td>
<td>Support our strict IMP requirement to only direct marketing at adult consumers by setting out clear requirements for YAP activities in all markets where our products are sold.</td>
<td>Consumers, Customers</td>
</tr>
<tr>
<td><strong>Biodiversity Statement</strong></td>
<td>Sets out the principles we follow to manage our biodiversity footprint across our operations.</td>
<td>Suppliers, Governments and wider Society</td>
</tr>
<tr>
<td><strong>Circular Economy Position Statement</strong></td>
<td>Our commitment to applying circular economy principles across our operations and product categories.</td>
<td>Consumers, Governments and wider Society</td>
</tr>
<tr>
<td><strong>Operational standard on child labour prevention</strong></td>
<td>Detailed guidance and procedures for our leaf operations in tackling the risk of child labour in our tobacco supply chain.</td>
<td>Suppliers, Our People, Governments and wider Society</td>
</tr>
<tr>
<td><strong>Community Investment Framework</strong></td>
<td>Sets out the Group strategy for community investment and charitable donations, aligned to the United Nations Sustainable Development Goals.</td>
<td>Our People, Governments and wider Society</td>
</tr>
<tr>
<td><strong>Group Quality Policy Statement</strong></td>
<td>Formalises how we strive to deliver defect-free products, processes and capabilities that create sustainable value for our brands.</td>
<td>Consumers, Governments and wider Society</td>
</tr>
</tbody>
</table>
Awards and Recognition

2021 was a pivotal year for sustainability at BAT. It marks the 20th year of our inclusion in the Dow Jones Sustainability Indices, as well as the 20th anniversary of publishing our first Social Report. We are proud of how much we have achieved over the last 20 years. Today, we are building on these strong foundations to accelerate progress towards A Better Tomorrow™.

Sustainability Ratings

- **Dow Jones Sustainability Indices (DJSI)**
  - We have achieved inclusion in the indices for 20 consecutive years. In 2021, we were the only company in our industry listed in the prestigious World Index, representing the world’s top 10% ESG performers.\(^{15}\)

- **Sustainalytics**
  - We achieved a score of 26.8 in the most recent Sustainalytics ESG Risk Ratings. This gives investors insights into financial material ESG risks in their portfolios.\(^{17}\)

- **MSCI**
  - We achieved a ‘BBB’ rating in the most recent MSCI ESG Ratings. This helps investors identify and understand financial material ESG portfolio risks.\(^{16}\)

- **CDP**
  - A scores in CDP Climate and Water assessments. In 2021, we achieved A scores in the CDP Climate and Water assessments. We were honoured to once again be named on the CDP Supplier Engagement Leader Board in 2021. This recognises our actions to engage our suppliers to manage climate risk and reduce carbon emissions in our supply chain.

- **Vigeo Eiris**
  - We scored 48% (top by top from 2020) in the most recent Vigeo Eiris rating. This evaluates organisations’ integration of ESG factors into their strategies, operations and management.

- **Best-in-class ISS Score**
  - We achieved the highest rating for the ISS Social Responsibility QualityScore. This identifies best-in-class sustainability disclosure practices.

A rating and award is not a recommendation to buy, sell or hold securities. A rating and award may be subject to withdrawal or revision at any time. Each rating and award should be evaluated separately of any other rating. The methodologies of any rating or award presented here may not be the same as those of other ratings, awards or methodologies that may be used by our stakeholders, and may emphasize different aspects of ESG practices and performance, and, thus, may not be representative of our ESG performance in all respects.

Awards and Recognition

- **Sustainability Award**
  - **Gold Class 2021**
    - We were once again awarded the highest Gold Class in the S&P Global Sustainability Yearbook 2021.

- **Global Top Employer**
  - We have been recognised as a Global Top Employer for four consecutive years, acknowledging our commitment to best-in-class working environments and career opportunities.

- **Financial Times Climate Leader**
  - We were named as a 2021 Climate Leader by the Financial Times in an inaugural European ranking. This recognises the top 300 of more than 4,000 companies across Europe.

- **SEEL**
  - **Sustainable Product Award for Vuse**
    - In 2021, Vuse, our global No. 1 vaping brand, won the Sustainable Product Award in the prestigious 2021 SEEL Business Sustainability Awards. SEAL recognises innovative and impactful products that are ‘purpose-built for a sustainable future’.

15. Our listing in the Dow Jones Sustainability Indices (DJSI) is based on November 2021 score in the S&P Global Corporate Sustainability Assessment.
16. An MSCI ESG Rating is designed to measure a company’s resilience to long-term, industry material environmental, social and governance (ESG) risks.
17. A Sustainalytics score of zero out of 100 represents the lowest ESG risk. BAT’s ESG Risk Rating places the company in the 16th percentile of the industry group which we are assessed in.
Strategic Management

Reducing the Health Impact of Our Business

We have a clear purpose to build A Better Tomorrow™ by reducing the health impact of our business. That’s why we are changing: creating new products, backed by science and industry-leading standards, that provide adult smokers with less risky alternatives*†.

Why harm reduction matters

We know combustible products pose serious health risks. The only way to avoid those risks is to not start — or to quit — smoking. Yet more than 1.1 billion people today continue to consume tobacco and nicotine products globally. ‘Tobacco harm reduction’ is a well-recognised public health strategy that aims to minimise the harm caused by combustible cigarettes by encouraging adult smokers, who would otherwise continue to smoke, to switch completely to scientifically substantiated, reduced-risk alternatives*†.

Some 100 million adult smokers worldwide have already switched to reduced risk tobacco and nicotine products. We encourage those who would otherwise continue to smoke, to switch. This means enabling consumer choice through making available a range of alternatives to smoking that deliver comparable satisfaction in nicotine delivery, use and sensorial aspects.

For example, some studies suggest that vapour products are more successful than nicotine replacement therapy in providing a satisfactory alternative to cigarettes,1,2 despite not being smoking cessation products nor marketed as such. These products need to be supported by world-class science and industry-leading standards.

Responsible, science-backed and well-thought-through regulation is also crucial for enabling adult consumers to access and enjoy reduced-risk products*† with confidence, while governments and health bodies can be assured that these products are manufactured to high safety and quality standards.

---

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

Consumer choice
We are creating new products, backed by science and industry-leading standards, that provide adult smokers with less risky alternatives*†.

Fuelled by our deep consumer insights, innovation is a driving force within our business, enabling us to anticipate trends to meet evolving consumer needs.

We do this through our growing global network of digital hubs, innovation centres and world-class R&D laboratories. Collaborations with external partners and our corporate venturing initiative are also helping us to stay ahead of the curve.

For example, in 2020, we established our Open Innovation team, as part of our New Categories R&D function. Working in partnership with Btomorrow Ventures, the Group’s corporate venture capital unit, the team is focused on identifying partners (including start-ups) that have innovative technologies and materials that hold promise for our product pipeline.

Find out more about our New Category products on pages 35 to 40

World-class science
For more than 60 years, research and development has been a critical part of our business. We invest almost £350 million a year in R&D to deliver innovations that satisfy or anticipate consumer preferences.

The main focus of our R&D investment is on developing and scientifically substantiating New Category products to assess their reduced-risk profile*†.

We use a wide range of analytical techniques, specialised laboratory technology and expertise to test our products and ensure they meet high quality standards. This is supplemented by collaborations with global external researchers who bring independent and specialist expertise that augment and enhance our internal capabilities.

We follow strict best practice standards for all our scientific research. And, regardless of the results, we submit to high-quality, peer-reviewed journals owned by leading publishers, with well-respected standards for how they run the peer-review process. We work to make our science accessible and understandable to a wider audience. We refreshed our dedicated bat-science.com website in 2021, and published a new Science and Innovation Report. We also introduced new quarterly science updates to provide the latest information in this rapidly evolving area in a concise way.

Find details of our world-class science on pages 35, 37 and 39

Standards and regulation
Regulation of New Category products continues to evolve. Globally, there are regulators passing progressive laws that allow and encourage adult smokers to switch to New Category products, and some regulators who view them more cautiously.

As the science and evidence to substantiate these products grows, we expect to see more countries passing progressive regulations, further accelerating New Category growth.

We believe a stakeholder-inclusive, whole-of-society dialogue that includes regulators, policymakers, consumers and the industry is key to developing effective policies that can accelerate tobacco harm reduction as fast as possible. Any regulation around New Category products should be founded in science, not opinion.

We hold ourselves to high standards and hope these will become an industry benchmark and are used as the basis for future regulation. That’s why we share our approach, information and expertise with industry groups, governmental technical advisory committees, standards bodies and other key stakeholders.
Excellence in Environmental Management

We have a global footprint and rely on natural resources to run our business. Securing resources in a climate-resilient supply chain is key to delivering our business strategy. We are driving environmental excellence for a greener tomorrow.

Tackling climate change
Climate change is a global issue impacting the planet and society, as well as our business and supply chain. We have an integrated climate strategy focused on building climate-resilience across our value chain.

- By 2030/2050: Carbon neutral operations (Scope 1 and 2 CO2e emissions) by 2030 and net zero carbon emissions across our value chain (Scope 1, 2 and 3) by 2050.

 Eliminating waste
Circularity – and driving a zero-waste economy – is at the core of our bold strategy to deliver a greener tomorrow. From using less plastic and recycling more, to being smarter about how our products are designed.

- By 2025: 100% plastic packaging to be recyclable, reusable, recyclable or compostable, and 100% of our operations sites to be zero waste to landfill.

Sustainable water stewardship
From eliminating loss and leaks to increasing water recycling, we are decreasing water use in our operations. And we are helping our contracted farmers to irrigate their crops more sustainably.

- By 2025: 100% of manufacturing sites to be Alliance for Water Stewardship certified and 50% reduction in amount of water withdrawn (vs 2017 baseline).

Biodiversity and reforestation
We work with our contracted farmers to increase biodiversity and forest resource and support community-based reforestation programmes around the world.

- By 2025: Net zero deforestation of managed forests in our supply chain and no positive impact on forests in our tobacco supply chain.

Our Environmental Policy is adopted by all our Group companies. It outlines our commitment to high standards of environmental protection, adhering to the principles of sustainable development and protecting biodiversity.

Tackling Climate Change
Our ambition is to be a carbon neutral (Scope 1 and 2) business by 2030 is supported by a range of operational targets. Already, we’re making significant progress with a reduction of 42.7% in Scope 1 and 2 CO2e emissions against our 2017 baseline.

We also recognise the importance of looking beyond the operations we directly control – so we have set a target for net zero carbon emissions across our value chain by 2050.

To deliver these stretching targets, we have an integrated climate strategy covering both our own business operations and our wider value chain. This includes utilising multiple opportunities, from on-site renewable energy generation and purchasing renewable electricity, to transitioning our distribution fleet to electric and hybrid vehicles.

In addition, in 2021, we incorporated internal carbon pricing into business plans to ensure the impact on environmental performance and targets is formally considered and quantified. This has supported the prioritisation of sustainability projects such as on-site renewable energy generation.

By the end of 2021, 32 of our operations sites were purchasing 100% renewable electricity and 19 were generating renewable energy on-site, such as with solar panels. As of last year, we had on-site generation solar coming online in Pakistan, Indonesia, Germany, and South Korea. In places like South Africa, solar plays an important role in the overall site’s electricity decarbonisation. In 2021 the site generated green electricity equivalent to avoiding 1,840 tCO2. Factories in Brazil and Chile, and Switzerland’s manufacturing and commercial sites also passed independent carbon neutral certification in 2021 against PAS 2060 – an internationally recognised certification on carbon neutrality.

In our tobacco supply chain, we support over 75,000 contracted farmers globally, helping them to reduce emissions through innovative technologies and ‘carbon-smart’ farming practices throughout the growing cycle. We also continue to actively work with our largest 30 direct product materials suppliers that represent 15% of CO2e emissions for this part of our supply chain. In 2021, they participated in a detailed, one-to-one assessment of their current ESG practices and performance, with a strong focus on carbon emissions, as well as waste, water and biodiversity.

Our products are intrinsically linked to our sustainability ambitions. By building sustainable brands with purpose, we are bringing our consumers on our journey with us. So, in 2021, we were proud to announce that Vuse was certified as the first global carbon neutral vape brand.¹

Eliminating Waste
Our Circular Economy Position Statement sets out our key principles across our operations and product categories. In 2021, we developed new Circular Economy Guidelines and training to provide our people with a common understanding and details of how to apply these principles across different business areas, products and geographies.

We have conducted studies to map our waste footprint intensity across our value chain and have established cross-functional sustainability workstreams for all our product categories.

We are focused on eliminating unnecessary single-use plastic across all packaging and, by the end of 2021, had achieved a 13% reduction in total weight. ¹

¹. Based on ePod, ePen, eTank mini, Alto devices and consumers internal sales forecast (calculated March 2021) for 12 months starting from April 2021.
Examples of initiatives undertaken include: removing silicone caps from e-liquid pods, replacing plastic trays with a pulp-based alternative and removing plastic film overwrap.

We’ve also aimed for 100% of plastic packaging to be capable of being reusable, recyclable or compostable by 2025 – by the end of 2021, this was achieved for 75% of our packaging.

To help drive responsible disposal, we have take-back schemes for consumers to return our vapour and THP devices in all markets where they are available.

In 2021, we also supported 12 consumer education and awareness-raising initiatives to prevent cigarette butt littering in five countries. And we are actively looking for new, innovative ways to tackle the issue. For example, we are partnering with an innovative start-up to test a new solution to processing factory waste and cigarette butts from the streets to extract the cellulose acetate.

In our operations, we’re driving a zero waste to landfill mindset with an ambitious target for 100% of sites to achieve this by 2025. Despite challenges in some locations that have limited recycling and waste management facilities, 35% of our sites had reached zero waste to landfill by the end of 2021, and a further 7% are close to achieving this and are recycling at least 95% of total waste generated.

Our Integrated Work Systems (IWS) are crucial in helping to achieve this through optimising our overall performance, minimising machine unplanned downtime, reducing waste, optimising energy and water usage and reducing personnel time and effort. Significant benefits have been obtained in the last year ranging from a 5 to 15% reduction in waste to a smaller carbon footprint, 4% efficiency improvement, lower energy consumption and utility costs, and the saving of 1,000s of man hours.

Sustainable Water Stewardship

While our manufacturing facilities are not particularly water intensive compared to other industries, with the changing climate, water scarcity is a growing concern.

Our sites implement a range of initiatives to eliminate water losses and improve water efficiency. As a result, we have been making steady progress decreasing water use, with a 27.6% reduction achieved from our 2017 baseline year. At the same time, we’ve also increased the amount of water we recycle to 16.7% (compared to 15.3% in 2020).

To accelerate progress and deliver further water stewardship opportunities, we are members of the Alliance for Water Stewardship (AWS). AWS is a global collaboration of businesses, NGOs and the public sector that are contributing to the sustainability of local water-resources through adoption of the global AWS Standard.

We have committed to 100% of our manufacturing sites being certified against the AWS standard by 2025. In 2021, 11 sites achieved AWS certification and a further 23 sites are expected to complete the certification process during 2022.

Water stewardship in tobacco growing

Water management is vital to sustainable farming, especially given that agriculture accounts for an average of 70% of freshwater withdrawals globally. Rainwater is commonly sufficient for watering many tobacco crops – due to the variety of locations in which we source our tobacco, only 31% require irrigation.

Our leaf operations in these areas are actively looking at ways to work with our contracted farmers to reduce water usage, with different techniques applied depending on the local circumstances and growing conditions.

Our global leaf agronomy centre in Brazil is playing a vital role in researching, developing and customising cutting-edge innovations to drive water efficiency in tobacco growing. For example, innovative ‘floating’ systems for growing tobacco seedlings, based on hydroponics, use about 85% less water per hectare. These have been successfully introduced to some 17,000 contracted farmers in six countries, with trials underway in six more countries.

We have also developed innovative drip irrigation technology, that increases water-usage efficiency by up to 90% – so far, this is being used by our contracted farmers in six countries.

Biodiversity and Afforestation

Our Biodiversity Statement sets out the principles we follow to manage our biodiversity footprint across our operations.

In 2021, we announced a new commitment for net-zero deforestation of managed forests across our tobacco and paper- and pulp-based product supply chains by 2025. This means that for every tree that is chopped down, we will aim for another to be planted by ourselves or others in our supply chain. In our tobacco supply chain, we take this further by aiming to have a net positive impact on forests by 2025. This means that not only will a tree be planted for each one used, but we will strive to have a net positive impact – planting more trees than are removed.

To achieve these ambitious targets, our leaf operations and third-party suppliers continue to work with tobacco farmers in our supply chain to provide training in forest and biodiversity management, distribute tree saplings for a sustainable source of fuel for curing and help farmers to switch to locally available alternative fuels.

In 2021, monitoring of our contracted farmers wood fuel use for tobacco curing showed that 99.9% is from sustainable sources.

In addition, we support afforestation, biodiversity and environmental conservation programmes around the world as part of our wider community-based initiatives. In 2021, this included 18 projects in 13 countries, including long-standing afforestation programmes in Bangladesh, Brazil, Kenya, Pakistan and Vietnam that have collectively distributed an estimated 380 million trees over the last 40 years.

In our paper- and pulp-based product supply chain, we are committed to working with suppliers that can demonstrate that the material is sourced sustainably, with certification from the Forest Stewardship Council (FSC) or the Programme for the Endorsement of Forest Certification (PEFC). So far, this is the case for 89% of the paper and pulp volumes we purchase – we aim to reach 100% by 2025 as part of our net zero deforestation target.

In addition, we signed up in 2021 as a signatory to Business for Nature’s Call to Action, a global coalition uniting influential organisations and forward-thinking businesses to amplify calls for collective action to reverse nature loss in this decade.

**Digital farmer sustainability management**

We are leveraging the power of technology to enhance and accelerate our connectivity with our contracted farmers and farming communities.

Our Farmer Sustainability Management (FSM) system is a digital platform that supports the work of our field technicians by enabling a consistent approach to farm monitoring and overall sustainability management.

Our field technicians visit our contracted farmers approximately once a month during the growing season, acting as a direct link between the farmers and BAT.

Details of each farm visit are recorded in FSM, including any issues identified and details of prompt actions taken to redmediate them.

In 2021, the majority of issues recorded in FSM (96.5%) related to the safe handling, use and storage of agrochemicals.
Delivering a Positive Social Impact

We have an important role to play in delivering a positive social impact for our employees and people across our supply chain. By enhancing farmer livelihoods, respecting human rights and ensuring a safe, diverse and inclusive working environment, we can help ensure the long-term sustainability of our business and build a fairer tomorrow for society.

Community investment

In many parts of the world, we partner with NGOs and other stakeholders on projects to support the local communities where we operate. These programmes focus on a range of issues, such as women’s empowerment, financial inclusion, access to healthcare, clean water and sanitation and supporting national responses to the COVID-19 pandemic.

Our community investment policy in our SoBC is supported by our Community Investment Framework, which sets out how Group companies should develop, deliver and monitor community investment programmes. In 2021, the Framework was revised to align our community investment strategy with the UN Sustainable Development Goals. Across the Group, £19 million was reported for community investment programmes in 2021, including £12.6 million in cash spend and a further £6.4 million estimated for in-kind donations. This includes £0.96 million given for charitable purposes by UK Group companies.

Human Rights

Our integrated human rights strategy is aligned to the UNGPs and includes policies, due diligence, grievance channels and remediation procedures for our own business operations and supply chain.

Our Human Rights policy forms part of our Standards of Business Conduct and is reflected in our Supplier Code of Conduct. This is complemented by our operational standard on child labour prevention, which provides detailed guidance and procedures for our leaf operations in tackling the risk of child labour in our tobacco supply chain.

Tobacco supply chain

The most significant challenges for human rights are in our tobacco supply chain and this has been a priority area for us for many years.

Human rights issues in agriculture can be complex, and we know that the situation on the ground can be nuanced and that remediation requires cooperation and dialogue, rather than confrontation. This is why our approach emphasises working with families and communities to find sustainable solutions while respecting local context and the challenges of operating small, family-run farms.

Farmer Livelihoods

If farmers have sustainable living incomes, farming is more attractive to the next generation. It also reduces the risks of exploitation, as well as child and forced labour, and helps encourage improved adherence to safety and environmental standards. That’s why enhancing farmer livelihoods is such an important priority area of our Sustainability Agenda and is central to our tobacco supply chain strategy.

Our Extension Services of expert field technicians support our 75,000+ contracted farmers throughout the growing cycle, helping to develop their skills, promote better yields and build their resilience.

This includes providing new tobacco varieties that produce higher quality leaf and increase yields by up to 20%, as well as mechanised solutions and technology to help farmers scale up production and reduce manual labour.

We have been measuring farmers’ yields, profit margins and revenues from tobacco as part of our Thrive assessments since 2015. In 2021, we took a step-change in building upon, and strengthening, this approach, undertaking further assessments of the living income generation in our farmer base.
This is where our direct contracts with farmers enables us to have a real impact. Our field technicians visit our contracted farms approximately once a month during the growing season. As well as providing agronomy and livelihoods support, this is an important way of monitoring the farms.

In 2021, a total of 1,790 incidents of child labour were identified on 0.7% of our contracted farms and those supplying our strategic third-party suppliers. The majority related to under-18s working on tasks such as preparing bales, watering and weeding, and harvesting and stitching tobacco. Of these, 100% were reported as resolved, where a remediation plan that considers the individual circumstances is implemented with the farmer.

Wherever possible, this plan involves local community or school support. In a small number of cases, where there is persistent non-compliance, the farmer’s contract is not renewed for the next growing season.

We maintain a relentless focus on addressing the root causes. Our leaf operations and strategic third-party suppliers deliver human rights training and communication programmes for farmers and community members. More than 350,000 people were reported to be engaged via this training in 2021.

We support a range of local community-based programmes in collaboration with local stakeholders. These include child labour prevention programmes in Brazil, Kenya and Mexico. We also continue as active members of the Eliminating Child Labour in Tobacco Growing (ECLT) Foundation which, since 2011, has supported over one million children, farmers and families.

In addition, human rights impact assessments, aligned to the UNGPs, have been conducted in six of our tobacco sourcing countries, covering nine parties – India and Indonesia in 2019, Mozambique in 2020, and Macedonia, Turkey and Zimbabwe in 2021. Collectively, these assessments have engaged over 2,200 rights holders and used a best practice approach to identifying, assessing and responding to actual and potential human rights impacts, including the root causes and how they manifest.

### Product materials supply chain

Beyond tobacco, we source product materials like paper and filters for cigarettes and, for our New Category products, we have a growing supply chain in consumer electronics and e-liquids. Labour factors are considered right at the outset, before we even start working with a new supplier. This includes mandatory scoring criteria as part of the supplier selection process.

Once selected, suppliers must then undergo an independent labour audit performed by our partner Intertek. The audit assesses workplace conditions, and we expect suppliers to achieve a minimum score of 70% to qualify. We maintain a rigorous focus on human rights in the supply chain and conduct an annual risk assessment on 100% of our existing materials suppliers. Using independent human rights indices developed by Verisk Maplecroft, we assess suppliers’ inherent risk exposure based on their country location and the goods or services they provide. Suppliers identified as high risk are then prioritised for audits.

In 2021, 142 audits were conducted by Intertek on our suppliers in 38 countries. Over the last three years, 22% of our product materials suppliers have undergone at least one independent labour audit, and we’re committed to achieving 100% by 2025.

### Human rights risk assessments

The policies, procedures and controls adopted by Group companies help to substantially mitigate human rights risks in our businesses. We recognise that circumstances in some countries present a higher risk for human rights issues, such as where regulation or enforcement is weak, or there are high levels of corruption, criminality or unrest.

We have a defined process in place to identify and categorically monitor BAT operations in high-risk countries. This process includes an annual risk assessment of all countries with Group company employees present, using Verisk Maplecroft’s human rights indices (including its Modern Slavery Index). Our operating companies in each high-risk country identified must complete a human rights assessment, confirming compliance with Group policies, standards and controls and providing details of measures in place to enhance human rights management.

The process is reviewed by the Audit Committee at each stage, including action plans for any areas for improvement identified. In 2021, our operations in 26 countries were identified as high risk from a human rights perspective and completed the risk assessment.

### Health and Safety

We are always working to protect the health, safety and wellbeing of people – through the COVID-19 pandemic and beyond – as well as striving for zero accidents Group-wide. We have a mature and well-established approach, based on risk management and assessment, employee training and awareness, and tailored initiatives for specific issues and higher-risk areas.

For example, in Trade Marketing & Distribution, the highest risks relate to road traffic accidents, particularly in countries with poor road infrastructure and driving behaviour, or attacks and assaults from armed robbers where our goods have a high street value. So, we have comprehensive driver safety and security programmes in place, including regular training and awareness campaigns, telematic systems in all our vehicles and clear security protocols.

Overall, total accidents across the Group reduced by 19% – from 155 accidents in 2020, down to 126 in 2021. Sadly, however, there were 3 fatalities in 2021 to one employee and two contractors in Brazil, Mexico and Bangladesh (compared to three contractors in 2020). In addition, 4 members of the public lost their lives in road traffic accidents involving BAT vehicles in Bangladesh, Honduras, Poland and Zambia. Our drivers were found not to be at fault in three cases, while an employee in Zambia was charged with dangerous driving and is facing disciplinary action.

We are always working to protect the health, safety and wellbeing of people – through the COVID-19 pandemic and beyond – as well as striving for zero accidents Group-wide. We have a mature and well-established approach, based on risk management and assessment, employee training and awareness, and tailored initiatives for specific issues and higher-risk areas.

For example, in Trade Marketing & Distribution, the highest risks relate to road traffic accidents, particularly in countries with poor road infrastructure and driving behaviour, or attacks and assaults from armed robbers where our goods have a high street value. So, we have comprehensive driver safety and security programmes in place, including regular training and awareness campaigns, telematic systems in all our vehicles and clear security protocols.

Overall, total accidents across the Group reduced by 19% – from 155 accidents in 2020, down to 126 in 2021. Sadly, however, there were 3 fatalities in 2021 to one employee and two contractors in Brazil, Mexico and Bangladesh (compared to three contractors in 2020). In addition, 4 members of the public lost their lives in road traffic accidents involving BAT vehicles in Bangladesh, Honduras, Poland and Zambia. Our drivers were found not to be at fault in three cases, while an employee in Zambia was charged with dangerous driving and is facing disciplinary action.

### People and Culture

Attracting and retaining an increasingly diverse workforce and providing a welcoming, inclusive working environment are key drivers in BAT’s transformation journey to build A Better Tomorrow™.

We are creating value for our employees by having a diverse range of excellent people, engaged teams and being a great place to work.

We have extensive health and wellbeing support available to our employees, including medical and counselling services, and health insurance. We also offer regular webinars and information on a range of topics, including mindfulness, stress management and financial wellbeing. During the COVID-19 pandemic, this support has played an even more important role in keeping our people connected and supporting one another during such difficult times.
Robust governance is key to our sustainable long-term growth. We are committed to achieving our business objectives in an honest, transparent and accountable way, and sustaining a culture of integrity in everything we do. Our policies and standards set out how we do this consistently, everywhere we operate.

**Business Ethics**

Unethical behaviour can damage our business, reputation and consumer trust. We have a strong culture of responsible behaviour, underpinned by our ethics and Standards of Business Conduct. Our Group-wide Delivery with Integrity programme helps everyone at BAT understand and play their role in maintaining our standards.

**Responsible marketing**

Responsible marketing practices are crucial for ensuring any adult consumers access and use our products. We have strict International Marketing Principles in place for all our product categories and work with our retail partners on youth access prevention programmes.

**Regulation and policy engagement**

Effective regulation needs dialogue between governments and industry, and we have a legitimate role to play in policy-related debate that affects our business. By sharing our expertise, engaging transparently and with high regard for accuracy and integrity, we can make a valuable contribution to policy development relating to our industry.

**2021 performance highlights**

- 94% industry-leading score in the Codes of Conduct category of the Dow Jones Sustainability Index assessment (Score date: 12 November 2021)
- 100% of markets aligned to the VAT guideline****, where our products are sold

This included external benchmarking against peer companies, external legal reviews in the UK and U.S., and drew on extensive insights from investor ratings and indices. The updated versions of our SoBC and Supplier Code of Conduct were approved by the Board in 2021 and took effect from January 2022.

**Business Ethics**

Our Standards of Business Conduct (SoBC) express the high standards we are committed to upholding. Our SoBC comprise our policies referenced on page 48, including anti-bribery and corruption (ABAC), political contributions, anti-money laundering and tax evasion, and is available in 14 languages. SoBC awareness and understanding are promoted through regular training and communications. Our SoBC are complemented by our Supplier Code of Conduct, which outlines the minimum standards expected of our suppliers.

We conduct a detailed review of our SoBC and Supplier Code of Conduct every two years to ensure they remain at the forefront of best practice, with the most recent review taking place in 2021.

**Delivery with Integrity**

Our Delivery with Integrity global compliance programme promotes an ethical culture and communicates expected behaviours as set out in our SoBC.

Over the past five years, we have strengthened our procedures and guidelines across areas including ABAC, anti-money laundering and tax evasion, competition law, sanctions and data privacy. With these strong foundations in place, we are now focusing on automation and data analytics to identify and mitigate such risks as they arise, improving the lifecycle risk management of the third parties BAT engages with.

While policies and procedures are key to a consistent approach to compliance, we know that engagement and awareness are crucial to sustaining a culture of integrity across the Group. That’s why we have focused on ensuring everyone at BAT understands their role from day one in the organisation and that this is sustained throughout the year.

Our SoBC app provides easy access to SoBC policies, procedures and guidance, as well as our global ‘Speak Up’ channels, which are multilingual. From 2022, the app now incorporates our Supplier Code of Conduct in 15 languages to help increase accessibility for suppliers. To date, the app has been downloaded more than 27,500 times. In 2021, we launched our new SoBC e-induction training and automated conflicts of interest disclosure requirement for all new management-level employees. We also launched new training targeted at relevant employees on areas such as sanctions, competing fairly and ethically and data privacy.

In 2021, we held two global integrity events at the start and middle of the year. The first week-long campaign focused on the role of line managers in leading by example as SoBC role models. It also included our new campaign – ‘Speak-Listen-Act’ – focused on raising awareness of our Speak Up channels and for them to be seen as a trusted tool by our people. Later in the year, our global 24-hour ‘integrity pledge’ event focused on reaffirming our commitment to ethical behaviour, with employees making personal pledges across the Group.
We ended the year with our global SoBc compliance campaign. Our Group company employees completed a formal SoBc sign-off during which they completed training and assessment, affirmed their commitment to the SoBc and declared any new or existing personal conflicts of interest. In 2021, this was successfully completed by 100% of our Group company employees.

Over 24,000 did this through our online SoBc portal and remaining Group company employees were given various options to complete the process, including via our SoBc app. The app has proved important in helping everyone to participate in training and sign-off safely, given COVID-19 continued to hinder usual face-to-face gatherings in many of our markets.

Speak Up and SoBc compliance
Our SoBc and Supplier Code of Conduct make it clear that our employees, partners and suppliers should speak up if they have a concern about actual or suspected wrongdoing, including in relation to accounting or auditing matters. We will always listen to these concerns and do not tolerate victimisation or reprisals of any kind against anyone raising a concern: such conduct is itself a breach of the SoBc and is a serious disciplinary matter. Our speak up channels include an independently managed Speak Up online portal and telephone hotlines, available 24 hours a day. Speak Up channels can be used in confidence, and anonymously where preferred, and are available in multiple local languages.

Not all contacts made via our SoBc Portal involve alleged SoBc breaches; sometimes, it’s just questions regarding the SoBc or other matters. In 2021, there were 581 SoBc contacts (2020: 554), of which 304 SoBc contacts were assessed as alleged SoBc breaches and reported to the Audit Committee (2020: 321), including 145 contacts where the person raising the case chose to remain anonymous.

Our SoBc Assurance Procedure defines how all reports of alleged SoBc breaches should be investigated and remediated fairly and objectively. And our Business Integrity Panel promotes a consistent approach to investigation and remediation of all alleged breaches of the SoBc. For the detailed investigations conducted into all of the reported cases in 2021:

- No wrongdoing was found in 154 cases (2020: 158).
- The investigation continued at year-end for 51 cases (2020: 47); and
- 99 cases were established as breaches and appropriate action taken (2020: 116).

We take strong action for all cases established as breaches, which will vary from case to case depending on the circumstances. In 2021, established SoBc breaches resulted in 46 people leaving the Group and 72 written warnings. In addition, where any weakness in internal controls is identified, appropriate measures are taken to strengthen them. Our SoBc, and information on the total number of breaches reported under it, are available at bat.com/sobc.

Please refer to the Governance Report for more information about Board and Audit Committee oversight and monitoring of SoBc compliance.

Responsible Marketing
Our International Marketing Principles (IMP) govern our approach to marketing our products across the Group. Our IMP are applied consistently everywhere we operate, even when they are stricter than applicable local laws. All marketing materials are subject to review by our Legal & External Affairs (LEX) function. Our Supplier Code of Conduct also includes a requirement for our suppliers, agents and third parties to comply with the IMP. To support our strict requirement to only direct marketing at adult consumers, our markets are expected to adhere to our global Youth Access Prevention (YAP) Guidelines. These apply to all markets where our products are sold, including where distributed through third parties. IMP and YAP compliance is monitored by our Regional Audit and CSR Committees and by the Audit Committee annually. All of our markets reported alignment with our YAP Guidelines in 2021. We report further on compliance in our 2021 ESG Report at www.bat.com/esgreport.

As we accelerate our transformation, driving growth in New Categories, building strong brands of the future and digitising our business, our new e-commerce and social media channels are playing an ever more prominent role in our marketing strategy.

Digitisation around the world has been rapidly accelerated by the COVID-19 pandemic and, in this changing environment, we continue to embed new digital channels and ensure our people and partners have the right tools and capabilities to support IMP and YAP compliance. Our digital marketing toolkit includes in-depth guidance on topics such as content standards, social media and search engines, and ensuring robust online age verification procedures. And our digital marketing hub supports our markets by providing guidance on how to achieve long-term consumer satisfaction and product awareness in a responsible way.

In 2021, we reinforced this work with new toolkits and guidance, such as for applying our YAP Guidelines and age verification standards on our own and third-party e-commerce sites. We also launched a new training programme, called iCommit, covering measures for digital channels with a mix of theory and practical training, based on real-life scenarios.

Regulation and Engagement
Our SoBc includes our Lobbying and Engagement Policy and Political Contributions Policy, adopted by all Group companies and applicable to all Group company employees. These policies require all our engagement activities with external stakeholders to be conducted with transparency, openness and integrity.

We are committed to conducting all our engagement activities with external stakeholders with transparency, openness and integrity. For global regulatory priorities, the views we advocate are the same as those we publish on our website, and we have long supported the OECD’s Principles for Transparency and Integrity in Lobbying. We also respect the call for transparent and accountable interaction between governments and the tobacco industry established in Article 5.3 of the World Health Organization’s Framework Convention on Tobacco Control (FCTC). We are open about what we think and always try to offer constructive solutions that will best meet the objectives of regulation, while minimising any negative unintended consequences.

Regulatory engagement by our businesses is monitored throughout the year by our Regional Audit and CSR Committees. The Management Board’s Regulation Committee, chaired by the Legal and External Affairs Director, meets three times a year and is responsible for reviewing key regulatory and excise trends, Group priority focus areas, and the execution of global plans regarding regulation and monitoring progress. Our Board is kept updated on regulatory engagement activities during the year. Details of any political contributions are reported twice each year to the Audit Committee. The Group does not make contributions to UK or EU political organisations or incur UK or EU political expenditure. Details of all political contributions outside these jurisdictions are set out on page 127.

Find details of our other governance priorities, including data privacy and cyber security, in our 2021 ESG Report at www.bat.com/esgreport.
We recognise the importance of providing consistent and reliable climate-related information to investors and other stakeholders. We have aligned our reporting with the recommendations and recommended disclosures of the Task Force on Climate-related Financial Disclosures (TCFD). A summary of our response to each of the TCFD recommendations and recommended disclosures, together with references to further information in this report, is set out below. Our reporting against other frameworks, including the Sustainable Accounting Standards Board (SASB) framework, can be found at www.bat.com/esgreport.

Since 2019, we have worked with an external consultancy with expertise in TCFD reporting and climate scenario modelling to deliver an iterative process to identify, measure, manage, assure and report on climate-related risks and opportunities.

We have taken a phased approach, integrating TCFD into our Group risk management process. This included generation of a climate related gap analysis to highlight and understand key areas for improvement. We selected appropriate climate scenarios and performed initial high-level, scenario-based modelling of material risks and business impacts, to prioritise the climate-related risks and opportunities for BAT.

In 2021, we undertook detailed financial modelling to further understand the timing and materiality of these key risks and opportunities. This process included:

- Selection of risks and opportunities for deep dive modelling based on relative strategic importance, and availability of value adding methodologies and data. This process was supported by two external consultancies. We will broaden and deepen this analysis in future years as data and methodologies improve.
- Engagement with colleagues across the Group, which was crucial to gather data and test assumptions. Multiple workshops and interviews were held with teams across the organisation, including our Management Board, and our Risk Management, Finance, Treasury, New Categories, Legal, Government Affairs, Investor Relations, Supply Chain and Leaf teams.

An overview of our approach to identifying, assessing and managing climate risk is provided on page 59.

**Management’s role**

The assessment and management of climate-related risks is embedded across relevant business areas at Group, regional and local levels, with appropriate management oversight at each level, as shown on the chart on page 59.

This approach provides a flexible channel for the structured flow of information, monitoring and oversight of climate-related risks and environmental matters at the level and format best suited to the context.

All relevant employees, from the Management Board to managers at Group, regional and local level, have individual performance objectives that are linked to remuneration, including delivery against ESG- and climate-related priorities and metrics, that form part of their responsibilities.

The Management Board receive regular updates on material risks and strategic plans, including those relating to climate change, along with associated risk mitigation plans. This includes regular monitoring by the Group Risk Management Committee, chaired by the Finance and Transformation Director.

The Chief Marketing Officer has overall responsibility for the delivery of the Group Sustainability Agenda, supported by the Business Communications and Sustainability (BC&S) team, including the Head of ESG and sustainability subject-matter experts.

The Shaping Sustainability Programme Board oversees the cross-functional delivery of the ‘Shaping Sustainability’ of our QUEST transformation programme. Members of the programme board include the Chief Marketing Officer, the Director, Operations and the Group Head of BC&S. This is underpinned by a drive team, including the Head of ESG and Head of Operations Development and Sustainability.

The Director, Operations has overall responsibility for delivery of the Group’s climate strategy and environmental targets, supported by the Group Head of Operations Development and Sustainability, and the Operations Sustainability team, including the central Sustainability team and regional sustainability managers.

Reporting units that contribute to 98% of Group Scope 1 & 2 CO2e emissions (excluding all factories and green leaf thriving plants) report quarterly, those contributing to around 2% of Group Scope 1 & 2 CO2e emissions report semi-annually and annual reporting is completed by units reporting less than 0.3% of emissions. Monitoring and reporting of consolidated Group performance and metrics is completed quarterly by the Group Operations Sustainability team. Each directly-reporting business unit of the Group (DDBU) has an Environment, Health & Safety (EHS) Steering Committee, with overall responsibility to deliver environmental targets at site level held by the General Manager or site manager. EHS is also a standing agenda item for management meetings and governance committees at area, regional and global levels.
These local management meetings and committees report into the Operations Sustainability Forum, chaired by the Director Operations. This acts as a conduit for tracking delivery of environmental targets and gaining visibility of new and emerging risks posed by climate change.

The Operations Sustainability Forum oversees business plans to mitigate risks identified, reviews performance and tracks progress of our regions and business units in delivering the Group’s environmental targets. The Environmental Sustainability Committee, also chaired by the Director, is responsible for reviewing environmental roadmaps and strategies for the Operations Leadership Team.

Read more about our Quest programme for accelerating our transformation towards the Enterprise of the Future on pages 35-37.

TCFD at a glance
Summary of our response

a) Describe the organisation’s processes for identifying and assessing climate-related risks.

Our Board has oversight of our climate-related risks and opportunities. The Board reviews the Group’s environment strategy, targets and performance twice per year and reviews the Group risk register, which includes climate-related risks, annually. In 2021, the Board also received a deep dive ESG briefing covering our climate strategy, performance and approach to reporting in alignment with the TCFD framework. The Audit Committee reviews the Group risk register twice per year.

Read more on page 58

b) Describe the organisation’s processes for managing climate-related risks.

Mitigation plans are required to be in place to manage risks identified, and progress against those plans is monitored. At Group level, specific responsibility for managing each identified risk is allocated to a member of the Management Board.

Read more on page 54-67

c) Describe how processes for identifying, assessing, and managing climate-related risks are integrated into the organisation’s overall risk management.

The assessment and management of climate-related risks is embedded across relevant business areas and markets at Group, regional and local levels.

Read more on pages 61-64

Strategy:
Disclose the actual and potential impacts of climate-related risks and opportunities on the organisation’s businesses, strategy, and financial planning where such information is material.

a) Describe the climate-related risks and opportunities the organisation has identified over the short, medium, and long term.

We have identified 11 climate-related risks and opportunities. For each, the level of likelihood and impact has been assessed across three time horizons: short-term (2020-2025), medium-term (2026-2035) and long-term (2036-2050).

Read more on pages 61-64

b) Describe the impact of climate-related risks and opportunities on the organisation’s businesses, strategy, and financial planning.

We have assessed the impact of these risks and opportunities on our strategy and financial planning. The results show that, while there are financial risks that would need to be managed, these are not substantive enough to require a material change to our business model.

Read more on page 64-67

c) Describe the resilience of the organisation’s strategy, taking into consideration different climate-related scenarios, including a 2°C or lower scenario.

We have conducted an assessment of the resilience of our strategy, taking into consideration two climate-related scenarios: sustainable transition (based on a global temperature increase scenario of 1.5°C) and climate change inaction (based on a global temperature increase scenario of 3°C or more).

Read more on pages 62-64

Risk management:
Disclose how the organisation identifies, assesses, and manages climate-related risks.

a) Describe the organisation’s processes for identifying and assessing climate-related risks.

DRBUs and functions identify risks and opportunities, including climate-related physical risks, which are captured on risk registers and assessed against the materiality thresholds defined by our Risk Management Framework. Transitional risks of climate change have been assessed centrally and are included as a risk on our Group risk register.

Read more on pages 62-66

b) Describe the organisation’s processes for managing climate-related risks.

Mitigation plans are required to be in place to manage risks identified, and progress against those plans is monitored. At Group level, specific responsibility for managing each identified risk is allocated to a member of the Management Board.

Read more on pages 62-66

c) Describe how processes for identifying, assessing, and managing climate-related risks are integrated into the organisation’s overall risk management.

Our processes for identifying, assessing, and managing climate-related risks are integrated into our Risk Management Framework. This includes regular reviews of the Group risk register by our Group Risk Management Committee, chaired by the Finance and Transformation Director. The Group risk register is also reviewed annually by the Board and biannually by Audit Committee.

Read more on pages 62-66

Metrics and targets:
Disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material.

a) Describe the metrics used by the organisation to assess climate-related risks and opportunities in line with its strategy and risk management process.

We have clearly defined metrics for each of our ESG priority areas, including climate change, against which we report on our performance and progress each year.

Read more on pages 47 and 61

b) Describe Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions, and the related risks.

We disclose Scope 1, Scope 2 and Scope 3 emissions and the related risks in our reporting.

Read more on pages 47 and 61

c) Describe the targets used by the organisation to manage climate-related risks and opportunities and performance against targets.

Our targets to manage climate-related risks and opportunities include targets for carbon neutrality across our operations (Scopes 1 and 2) by 2030 and net zero carbon emissions across our value chain (Scopes 1, 2 and 3) by 2050. These are supported by a range of other environmental targets against which we report our performance and progress each year.

Read more on pages 47 and 61
Strategic Management

TCFD Reporting Continued

**Governance of ESG & Sustainability**

- **Board of Directors**
  - Meets at least seven times per year
  - Chaired by the Chief Executive and comprises the Executive Directors and Non-Executive Directors
  - Responsible for overseeing the implementation of the Group's strategy, policies and monitoring Group operating performance, including in relation to climate and the environment.

- **Audit Committee**
  - Meets at least twice per year
  - Chaired by the Finance and Transformation Director and composed of Non-Executive Directors
  - Oversees the implementation of the Group's strategy, policies and monitoring Group operating performance, including in relation to climate and the environment.

- **Management Board**
  - Meets at least seven times per year
  - Chaired by the Chief Executive and comprises the Executive Directors and Non-Executive Directors
  - Responsible for overseeing the implementation of the Group's strategy, policies and monitoring Group operating performance, including in relation to climate and the environment.

- **Group Risk Management Committee**
  - Meets twice per year
  - Chaired by the Finance and Transformation Director and composed of senior leadership
  - Oversees assessment and monitoring of risks to the Group.

- **Corporate Audit Committee (CAC) and Regional Audit & Compliance Committees (RACCs)**
  - Meets at least twice a year
  - Chaired by a Regional Director and composed of senior leadership
  - Reviews the effectiveness of the accounting, internal control and business risk identification and management systems within the central business functions for the CAC and the regions for the RACCs.

- **Shaping Sustainability Programme Board**
  - Meets the Group at least twice per year
  - Chaired by the Chief Marketing Officer and comprised of Management Board Directors and senior leadership.
  - Oversees the implementation of the Group's transformation programme and sustainability agenda.

- **Environmental Sustainability Committee**
  - Meets at least six times per year
  - Chaired by the Operations Director and composed of senior leadership
  - Reviews environmental targets, strategy, risks and opportunities.

- **Operations Sustainability Forum**
  - Meets around six times per year
  - Chaired by the Operations Director and composed of senior leadership
  - Reviews performance against environmental and social metrics and targets.

- **Leaf Sustainability Forum**
  - Meets around four times per year
  - Chaired by the Group Head of Leaf and composed of senior leadership
  - Reviews strategic direction and targets for addressing ESG risks across the tobacco supply chain, and performance against supply chain targets.

- **Supply Chain Due Diligence Committee**
  - Meets around three times per year
  - Chaired by the Group Head of Procurement and composed of senior leadership
  - Reviews direct materials supply chain performance and leaf against environmental and social metrics and targets.

- **Group Sustainability Department**
  - Chaired by the Group Sustainability Director and composed of senior leadership
  - Responsible for the Group's strategy, policies and monitoring Group operating performance, including in relation to climate and the environment.

- **Business Functions, Regions and Markets**
  - Implementation and execution of the Group Sustainability Agenda, including by Leadership Teams and cross-functional workstreams and programmes
  - Tracking and monitoring performance.
Strategy

Our purpose to build A Better Tomorrow™ and our Group strategy is set-out on pages 26-27. Our Sustainability Agenda, with climate change as a key priority under the environmental pillar, is set out on page 46.

Taking an active approach to tackling climate change isn’t new at BAT. As a business that depends on natural resources, we have been focusing on addressing our environmental impacts and preparing our business for the risks ahead for over 20 years. Yet with the impacts of climate change rapidly increasing, we are making a step-change in our ambition and accelerating the pace of progress.

In 2021, we signed up to the UN-backed Race to Zero global campaign. This campaign aims to halve global carbon emissions by 2030 and achieve net zero carbon emissions by 2050. BAT has previously committed to Science Based Targets, aligned to a 2°C pathway; subject to approval from the Science Based Targets initiative (SBTi), we intend to align our targets to a 1.5°C pathway in 2022.

To meet our ambitions for carbon neutrality across our operations by 2030 (Scopes 1 and 2 CO2e emissions) and across our value chain by 2050, we have an integrated climate strategy, highlighted below, covering our own operations and our wider value chain. This focuses on reducing our impact on the environment, addressing climate-related risks and opportunities, and building climate resilience for the future.

Key attributes of our climate strategy include:

- the performance of climate scenario analysis to inform our understanding of risks and opportunities;
- the performance of life cycle assessments of our products and the incorporation of end of life treatment to reduce their environmental impact. Reducing the use of embodied carbon and single use plastic, and increasing recyclability to reduce the level of waste generated;
- enhancing the resilience of our internal supply chain and wider value chain to maintain access to critical raw materials, and insulating our business from the impact of supply constraint-driven inflationary pressures;
- the environmental impact of our direct operations, including the reduction of CO2e generated by our sites and fleet through energy saving initiatives and increased use of renewable energy (both purchased and self-generated), as well as reducing the waste generated and maximising the share of waste directed to recycling;
- ensuring effective and efficient use of natural resources throughout our value chain, including where possible greater use of green energy and reduction of water usage and waste generation. This supports the allocation of these critical natural resources to food generation and other activities, and reduces our susceptibility to energy cost premiums and future carbon taxes; and
- continued investment in R&D activity to underpin product innovations, technical deployment of agronomy best practices, low carbon curing technologies and farming techniques based on science.

Financial planning is key to the execution of our strategy. Through our embedded governance, we consider the impact of climate change on future anticipated operating costs (including the cost of regulation), access to capital and potential growth opportunities to facilitate resource allocation and to ensure that decision making is robust.

In 2021, internal carbon pricing (ICP) was incorporated into our financial appraisal to facilitate delivery against our glidepaths. These actions position us to be successful now and into the future as climate challenges arise.

To further enhance our strategy to mitigate the impacts of climate change, we performed an assessment of risks and opportunities using two climate evolution scenarios and over three time horizons. The approach taken to this assessment, outcomes, and mitigations are set out below on pages 62 to 64.
Climate scenario modelling

Identification
Identification of risks and opportunities posed by climate change is an ongoing process and draws upon internal and external expertise, resources and other information, including:

- Internal senior management spanning all functions of the Group, based at DRBU, Regional, and Group level;
- External consultants supporting our preparations for and resilience to climate change;
- Relevant industry publications outlining expected impacts of climate change on our key inputs (including agriculture);
- Relevant regulation (enacted or draft) that may impact the Group’s products, locations, or operations;
- TCFD guidance on potential risks and opportunities; and
- Existing risks and opportunities identified and managed as part of our Group risk management processes.

A comprehensive list of potential climate related risks and opportunities were identified and refined down to 11 material risks and opportunities detailed on page 64, using the methodology defined in the Group Risk Management Framework and overseen by the Group Risk Management Committee. This materiality assessment will be reassessed annually to ensure it remains appropriate in the context of a dynamic business and physical environment, and to take account of improved data or modelling which may become available.

Assessment
We have considered the impact of risks and opportunities arising from climate change and the overall resilience of our business, calibrating these against two potential climate scenarios and three time horizons.

The two climate scenarios are aligned with the UN Intergovernmental Panel on Climate Change (IPCC) methodology, and greenhouse gas concentration trajectories known as Representative Concentration Pathways (RCP) 2.6 and 8.5, with differing levels of transitional and physical risk arising from each trajectory.
Whilst the impact of climate change is indefinite, for the purposes of assessment, we considered these risks and opportunities across three time horizons: short term (2021 – 2025), medium term (2026 – 2035), and longer term (2036 – 2050). These time horizons reflect how these risks and opportunities are internally considered and prioritised and are aligned to a number of our key ESG-related targets.

Climate-related risks and opportunities have the potential to impact our business over time. Through the identification and measurement processes outlined above, which are aligned to TCFD recommendations, we are taking the necessary steps to assess the likelihood and severity of these impacts to enable us to maximise positive impacts and minimise adverse impacts on our business.

Scenario analysis was performed to model how the impact and likelihood of our material risks and opportunities might change under each time horizon and climate scenario. We identified three climate-related opportunity areas and eight climate-related threats, which span transitional and physical risks in nature. The results of the scenario analysis performed is shown on page 64. Material risks are those that could have a significant effect on our operations, strategy and financial planning if they are not managed appropriately. In contrast, material opportunities may improve our financial performance over time in the event they can be realised.

Through our ESG strategy we aim to effectively manage the impact of our business on the planet over time.

We have also undertaken a deep-dive modelling and financial impact analysis on six risks and opportunities, drawing on internal and external data sources, such as carbon pricing projections, potential future surcharges on single-use plastics in our products, Group financial data, energy consumption and costs by BAT site, business growth projections and consumer trends. This allowed us to refine our initial qualitative assessment and quantify the expected financial impact based on assumptions of future developments. We will continue to revise these assumptions to reflect new and emerging developments.

Specifically, in relation to future access to tobacco and nicotine, a detailed assessment of future growing conditions was undertaken across our 10 largest tobacco source countries, utilising a UN IPCC model for climate change. Regional temperature behaviour, precipitation and soil water levels (surplus or deficit) were assessed, enabling us to estimate the likely impact on crop yields, and the cost of, or access to, tobacco in the future.

### BAT Greenhouse Gas Emissions

<table>
<thead>
<tr>
<th>Emission Source</th>
<th>Category</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope 1</td>
<td>–</td>
<td>415</td>
<td>396</td>
<td>342</td>
<td></td>
</tr>
<tr>
<td>Scope 2 Market-based</td>
<td>–</td>
<td>426</td>
<td>386</td>
<td>199</td>
<td></td>
</tr>
<tr>
<td>Scope 2 Location-based</td>
<td>–</td>
<td>490</td>
<td>453</td>
<td>418</td>
<td></td>
</tr>
<tr>
<td>Total Scope 3</td>
<td>–</td>
<td>6,956</td>
<td>6,781</td>
<td>5,587</td>
<td></td>
</tr>
<tr>
<td>Purchased Goods and Services</td>
<td>Category 1 Total</td>
<td>4,363</td>
<td>4,049</td>
<td>4,011</td>
<td></td>
</tr>
<tr>
<td>Purchased goods – Directs (excluding NGP)</td>
<td>Category 1</td>
<td>1,550</td>
<td>1,488</td>
<td>1,140</td>
<td></td>
</tr>
<tr>
<td>Purchased goods – NGP</td>
<td>Category 1</td>
<td>43</td>
<td>55</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Purchased Services</td>
<td>Category 1</td>
<td>35</td>
<td>107</td>
<td>720</td>
<td></td>
</tr>
<tr>
<td>Purchased Tobacco Leaf – Combustibles</td>
<td>Category 1</td>
<td>2,550</td>
<td>2,184</td>
<td>1,966</td>
<td></td>
</tr>
<tr>
<td>Tobacco Leaf – NGP</td>
<td>Category 1</td>
<td>18</td>
<td>5</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Other Purchased Goods &amp; Services</td>
<td>Category 1</td>
<td>167</td>
<td>210</td>
<td>135</td>
<td></td>
</tr>
<tr>
<td>Capital Goods</td>
<td>Category 2 Total</td>
<td>519</td>
<td>463</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>Fuel and Energy Related Emissions</td>
<td>Category 3 Total</td>
<td>177</td>
<td>166</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>Upstream Transportation &amp; Distribution</td>
<td>Category 4 Total</td>
<td>182</td>
<td>197</td>
<td>225</td>
<td></td>
</tr>
<tr>
<td>Waste Generated in Operations</td>
<td>Category 5 Total</td>
<td>5</td>
<td>5</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Business Travel</td>
<td>Category 6 Total</td>
<td>38</td>
<td>33</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Employee Commuting</td>
<td>Category 7 Total</td>
<td>27</td>
<td>23</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Use of Sold Products</td>
<td>Category 11 Total</td>
<td>662</td>
<td>587</td>
<td>641</td>
<td></td>
</tr>
<tr>
<td>End-of-Life Treatment of Sold Products</td>
<td>Category 12 Total</td>
<td>967</td>
<td>1,253</td>
<td>324</td>
<td></td>
</tr>
<tr>
<td>Franchises</td>
<td>Category 14 Total</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Note: Total emissions include biogenic and biogenic removals.
### Material climate-related risks and opportunities identified

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opportunities associated with transitioning to low carbon economy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Products &amp; services</td>
<td></td>
<td>1.5°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy sourcing</td>
<td></td>
<td>&gt;3.4°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resource efficiency</td>
<td></td>
<td>&gt;3.4°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Transition risks associated with transitioning to low carbon economy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emerging regulation</td>
<td></td>
<td>1.5°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emerging regulation</td>
<td></td>
<td>&gt;3.4°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Market</td>
<td></td>
<td>1.5°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Market</td>
<td></td>
<td>&gt;3.4°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Market</td>
<td></td>
<td>1.5°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical risks associated with physical impacts of climate change – either acute risks (such as relating to extreme weather events) or chronic risks (such as relating to longer-term shifts in climate patterns and higher temperatures)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute</td>
<td></td>
<td>1.5°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td></td>
<td>&gt;3.4°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td></td>
<td>1.5°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td></td>
<td>&gt;3.4°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Advanced financial scenario modelling conducted

The analysis demonstrated that whilst there were some favourable and unfavourable impacts on yield, the potential financial impact on annual cost of tobacco is less than 5% and current climate change trajectories indicate it is unlikely that the Group would face reduced production capacity as a consequence of consistent supply constraints. We believe the impacts on yield can be effectively mitigated through agronomy action plans to avoid yield driven cost of production increases.

In 2021, we also built on our decades of experience in agriculture to develop a new carbon-smart farming programme. This takes a strategic approach focused on reducing emissions from tobacco farming and leveraging the positive effect agriculture could have in removing carbon from the atmosphere.

Scenario analysis highlighted the increased cost of compliance with emerging regulation, cost of green energy and carbon taxation arising from Government policies seeking to deliver a Sustainable Transition (Scenario 1). Potential adverse impacts from higher costs and reduced access to both insurance and capital markets were identified.

Given the nature of transition risks, we anticipate the magnitude of these risks will be lower, and impact delayed, under Climate Inaction (Scenario 2) as little or no change to current regulation is projected. We will continue to update both our scenario analysis and business plans to ensure our business remains resilient and best able to mitigate the impact of climate policies as they emerge.
Carbon-smart farming

In 2021, we built on our decades of experience in sustainable agriculture, to develop a new carbon-smart farming programme. This takes a strategic approach focused on both reducing emissions from tobacco farming and, crucially, leveraging the positive effect agriculture could have in removing carbon from the atmosphere.

The latter can be achieved by planting trees, as well as through methods like cover crops and conservation tillage that may keep the soil covered and undisturbed, to reduce the possibility of carbon escaping.

As well as storing carbon, these methods may also increase water-retention capacity, improving drainage and making the soil richer and more fertile. This results in increased yields and better-quality crops for farmers helping to boost their profits.

Many of our contracted farmers already use these best practices. The challenge has been to find effective ways to measure impact and quantify the amount of carbon they remove, compared to how much they emit.

So, in 2021, we conducted a detailed analysis to estimate removals resulting from carbon-smart farming best practice, against international methodologies, such as those of the Intergovernmental Panel on Climate Change (IPCC) and Greenhouse Gas (GHG) Protocol.

We are now working in partnership with a specialist consultancy to validate this approach and to monitor, report and verify the results. This will enable us to develop a system that can be easily applied by small farmers. The systems will form the basis of our carbon-smart farming programme, empowering our contracted farmers to incorporate carbon-smart farming into their business model.

It will also provide us with verified data to measure progress against our 2050 ambition and to validate the impact of different carbon-smart strategies. In 2021, 35 of our contracted farmers in Brazil signed up as the first pilot group for the programme. We will expand the pilot to farmers in Bangladesh, Mexico and Pakistan in 2022. Learnings from the pilots will help in further developing and scaling up the programme as part of our wider climate strategy.

“To me it is an honour to be one of the first farmers participating in this programme. I am excited to learn new conservation practices to deploy on my farm. And I think getting to see real data showing the tangible impact this will have in both reducing and removing carbon emissions will be a game-changer and provide new opportunities for income generation.”

Lasercio Celestino Adamo
BAT contracted tobacco farmer, Brazil
While the products we offer continue to evolve, we will continue to need to access raw materials, including tobacco and tobacco extracts. This increases our exposure to the physical risks of climate change due to the increased risk of asset production disruption, damage or loss. In contrast to transition risks, physical risks are most severe under Climate Inaction (Scenario 2) given this scenario sees a world where warming exceeds a 3°C threshold, increasing the frequency and severity of climate-related events and likely financial impact on our business. In response, more extensive mitigation may be required including investments in working capital to increase our supply chain resilience.

While a sustainable transition (Scenario 1) is not anticipated to fully shield our operations from such climatic events, we assessed these may be less frequent and more controllable through tailored adjustments to our existing risk management policies.

While there are challenges ahead, we believe that the Group is well placed to address them. Supported by our global reach, supply chain flexibility, diverse product portfolio, leading brands and capital strength, we believe that we have the resilience and agility to transition and create new growth opportunities.

The insights gained from the modelling performed further strengthen the importance and relevance of our climate strategy and net zero carbon emissions target to mitigate these risks. We will continue to review each material climate-related risk and opportunity and build upon our existing mitigation strategies to enhance the resilience of our business to climate change.

**Risk Management**

Our Risk Management Framework and procedures are clearly defined and well-established across the Group.

Risk registers, based on a standardised methodology, are used at Group, functional, and DRBU level to identify, assess, monitor and mitigate the risks (both financial and non-financial).

Risks, including climate-related risks, are assessed and prioritised at three levels by reference to their impact (high/medium/low) and likelihood (probable/possible/unlikely), as defined in our Group Risk Management Manual. Mitigation plans are required to be in place to manage the risks identified, and progress against these plans is monitored. Decisions on how to manage the risk are based on a variety of considerations including risk score, our ability to influence or control the risk, and cost and effectiveness of mitigation. The risk registers are reviewed on a biannual basis.

At the Group level, specific responsibility for managing each identified risk is allocated to a member of the Management Board. The Group risk register is reviewed biannually by the Group Risk Management Committee, chaired by the Finance and Transformation Director. In addition, the Group risk register is reviewed annually by the Board and biannually by the Audit Committee.

During 2021, we continued to integrate and embed climate-related risks into our Group risk management procedures. This followed an update to our Group risk register in 2020 to incorporate transitional risks of climate change as a Group risk.

Each of our DRBUs and functions is required to identify and assess risks and opportunities, including climate-related physical risks, which are captured on risk registers and assessed against the materiality thresholds defined in our Risk Management Framework. Additionally, the transitional risks of climate change have been assessed centrally and are captured on our Group risk register in accordance with our Risk Management Framework.

Transitional risks of climate change takes into account factors including net zero commitments, stakeholder interests and emerging and current climate-related regulations.

In recognition of ESG being fundamental to all that we do in the organisation and the global risks of climate change, in 2021 our risks were updated to incorporate ESG factors across all relevant risks across the Group.

In 2022, we plan to further enhance our assessment of the transitional and physical climate risks and opportunities through conducting further analysis.

It is envisaged that the transitional climate risk will remain as a separate risk, and the physical climate risks and opportunities will be reflected further as necessary, in individual DRBU and functional risks.

See our Group risk factor for climate change on page 321 and details of our risk management and internal control procedures on pages 124.
Metrics and Targets

We have been reporting against energy and carbon emissions metrics since 2001 and set out our first long-term targets in our 2007 Annual Report to reduce Scopes 1 and 2 CO2e emissions intensity by 50% by 2030 and 80% by 2050 against our 2000 baseline. By the end of 2017, we had achieved a 42.7% reduction from that baseline.

In 2019, we set new long-term CO2e targets, and gained the Science Based Targets initiative’s (SBTi) formal approval for these. Since then, we have developed our commitment to addressing climate change, including accelerating our existing environmental targets to 2025 and committing to be carbon neutral across our operations (Scopes 1 and 2) by 2030 and net zero across our value chain (Scopes 1, 2 and 3) by 2050. In addition, we have incorporated internal carbon pricing into business plans to ensure the impact on environmental performance and targets are formally considered and quantified. This has supported the prioritisation of sustainability projects such as on-site renewable energy generation.

These actions are complemented by a range of other environmental targets and metrics, covering areas such as renewable energy, eliminating waste, water stewardship and biodiversity and afforestation.

Our goals, targets and metrics are summarised in our ESG Roadmap on page 47, including performance in 2019, 2020 and 2021 in relation to carbon emissions, renewable energy, waste, water, and biodiversity to demonstrate trends and how we are consistently delivering improvements to our environmental performance.

In 2021, we signed up to the UN-backed Race to Zero campaign. Race to Zero is the largest ever alliance aiming to halve global emissions by 2030 and achieve net zero carbon emissions by 2050. The campaign represents over 4,000 businesses estimated to cover nearly 25% of global CO2 emissions and more than 50% of GDP.

Limiting the rise in average global temperature to 1.5°C above pre-industrial levels requires major and widespread action and companies have an important role to play. We are realigning our existing CO2e emission targets with this trajectory and set a new target for net-zero carbon emissions across our value chain (Scopes 1, 2 and 3) by no later than 2050.

Next Steps

We recognise that the impact of climate change is uncertain and will be affected by multiple factors including severity of climate variation and extent of government regulation.

Through the adoption of the TCFD recommendations we have sought to analyse, as best as possible, the impact of potential outcomes considering two climate scenarios over the short, medium, and long term time horizons, however our assessments will need to continually evolve to respond to new information and insights.

In light of this evolving landscape, our work will continue in 2022 to further strengthen our approach including the consideration of the following focus areas:

- further embedding climate-related considerations into our business and strategic decision making, financial planning, as well as governance and risk management frameworks;
- continuing to identify opportunities to further strengthen our activities to manage and mitigate climate-related risks and build climate-change resilience;
- continuing to work with our suppliers to enhance data relating to our Scope 3 emissions;
- continuing to monitor ESG measures and drive performance across our comprehensive suite of objectives across all areas of ESG;
- continuing to identify, assess, manage, and disclose climate-related risks and opportunities;
- reviewing our metrics and targets to ensure they remain aligned with our strategy and risk management processes, and best practice guidelines;
- enhancing our assessment of the transitional and physical climate risks and opportunities through further analysis; and
- tailoring future disclosures, taking into account key government, investor, and other stakeholder frameworks and guidance.

* Via the Science-Based Targets Business Ambition for 1.5°C Campaign.

** Science Based Targets must represent reductions needed to restrict global warming to 1.5 degrees Celsius from pre-industrial levels. BAT had previously committed to Science Based Targets, aligned to a 2°C pathway, and free-standing targets to become carbon neutral across its operations by 2030 and value chain by 2050. These will be realigned to the 1.5°C pathway (subject to SBTi verification) and accommodate net-zero criteria and definitions.
A BETTER TOMORROW™
for employees

By creating a dynamic, inspiring and purposeful place to work.

Attracting and retaining an increasingly diverse workforce and providing a welcoming and inclusive working environment are key drivers in BAT’s transformation journey. We are creating value for our employees by:

– providing opportunities for a rewarding career with a major international business;
– creating a diverse and inclusive workplace culture that treats everyone equally; and
– listening to their views and safeguarding their wellbeing.
Ethos

Our purpose is to build A Better Tomorrow™ by reducing the health impact of our business through offering a greater choice of enjoyable and less risky products for our consumers.

A key driver to delivering this is our Ethos, which guides our culture and behaviours across the entire Group. Developed with significant input from our employees, it ensures an organisation that is future fit for sustainable growth. These five key principles – bold, fast, empowered, diverse, responsible – underpin how we deliver on both our purpose and our strategy.

We are Bold
- Dream big – with innovative ideas
- Make tough decisions quickly and proudly stand accountable for them
- Resilient and fearless to compete

We are Fast
- Speed matters. Set clear direction and move fast
- Keep it simple. Focus on outcomes
- Learn quickly and share learnings

We are Empowered
- Set the context for our teams and trust their expertise
- Challenge each other. Once in agreement, we commit collectively
- Collaborate and hold each other accountable to deliver

We are Responsible
- Take action to reduce the health impact of our business
- Ensure the best quality products for our consumers, the best place to work for our people, and the best results for shareholders
- Act with integrity, never compromising our standards and ethics

We are Diverse
- Value different perspectives
- Build on each others’ ideas, knowledge and experiences
- Challenge ourselves to be open-minded recognising unconscious bias

Our ongoing commitment to fostering a diverse and inclusive culture at BAT is underpinned by our ethos, which encourages our employees to be Bold, Fast, Empowered, Responsible and Diverse. Our transformation is driven by our people. By combining existing and new capabilities, we are radically redefining our organisation. Together, we will build A Better Tomorrow.

Hae In Kim
Director, Talent, Culture and Inclusion
Strategic Management

People and Culture

Investing in Leaders

We are accelerating our transformation agenda and delivering A Better Tomorrow™ by attracting the right talent with new experiences and developing our ‘must win’ capabilities.

In 2021, we launched our new Employer Brand – ‘Be the change’ – reflecting our corporate purpose and Ethos. The new brand has been brought to life through our social media channels and on our revamped website – careers.bat.com. The updated site leverages the latest technologies to personalise a candidate’s experience, with round-the-clock support in 14 languages. In 2021, 44% of our external recruits brought new capabilities into the organisation to accelerate our business transformation.

Our unwavering commitment and investment into the development of leadership and functional ‘must win’ capabilities has resulted in an average of 17.9 training hours delivered per full-time equivalent (FTE), with an average of £311 invested per FTE in 2021. This included 239 training programmes delivered across our leadership, functional and digital portfolios.

All functional ‘must win’ capabilities have foundational learning programmes in place, creating a level playing field of knowledge and skills, with 31% of programmes developing advanced level capabilities. In the leadership space, over 6,600 employees attended our core leadership programmes, including four international cohorts of our Women in Leadership programme and two cohorts of our Global Graduate Academy.

To enable quantity, while ensuring quality of all our programmes, we have shifted all our programmes to 100% virtual format. This has been a game changer, making it more accessible for more people across the Group. Our digital learning platform, The GRID, is the gateway to our learning portfolio – accessible to 100% of our management population, providing digital learning anytime, anywhere. In addition, over 13,000 managers have completed our leadership potential assessment – Leadmeter, which enables early identification of talent for accelerated development.

You can read about our Group risk factor related to talent on page 320.

Inclusive Culture

We are focused on creating a supportive and inclusive culture where all our people can flourish.

Our SoBC Respect in the Workplace Policy makes clear our commitment to providing equal opportunities to, and fair treatment of, all our employees and to creating an inclusive workplace by promoting employment equality. The policy was updated in 2021 to include enhanced provisions relating to not practising any form of unlawful discrimination, providing fair wages and benefits and supporting employees’ work-life balance. Our revised SoBC takes effect from January 2022.

We are official signatories to the UK Race at Work Charter for supporting equality and race in the workplace. We are also certified as a level 1 Disability Confident Committed employer under the UK Government’s accreditation scheme. This demonstrates our commitment to providing equal opportunities for disabled employees, training and development for them, and reasonable adjustments and support in the workplace and in recruitment processes.

Employee retention

In 2021, total voluntary turnover of management-grade employees was 1,238, representing 8.6% of our Group’s total management population.

Voluntary turnover rate for all employees across our Group in 2021 was 9.1%.

Diversity

Representation of women on senior leadership teams was 24% in 2019, 27% in 2020 and 27% in 2021.

Senior managers: Companies Act 2006

For the purposes of disclosure under Section 414C(8) of the Companies Act 2006, the Group had 181 male and 42 female senior managers as at 31 December 2021. Senior managers are defined here as the members of the Management Board (excluding the Executive Directors) and the Directors of the Group’s principal subsidiary undertakings. The principal subsidiary undertakings, as set out in the Financial Statements, represented approximately 66% of the Group’s employees and contributed over 89% of Group revenue and 100% of profit from operations in 2021.

Nationalities represented

<table>
<thead>
<tr>
<th>Nationality</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main Board</td>
<td>7</td>
</tr>
<tr>
<td>Global headquarters</td>
<td>81</td>
</tr>
<tr>
<td>Management level globally</td>
<td>141</td>
</tr>
</tbody>
</table>
Our D&I Strategy

We are proud to be a diverse global company and, as our Ethos shows, diversity is one of our core values. As we transform our business, we need fresh, diverse skills, perspectives and mindsets to challenge the status quo and drive innovation. Our diversity and inclusion (D&I) strategy is built on the following three pillars and underpinned by an inclusive culture.

### Pillar 1: Driving ownership and accountability

Ensuring ownership of, and accountability for, our D&I strategy across all business areas and leadership teams is key to driving progress and achieving our 2025 ambitions.

Our Director for Talent, Culture and Inclusion has overall responsibility for all employee and human resources matters, while our Management Board oversees the development and management of talent within the Group’s regions and functions.

Our D&I governance structure ensures clear accountability for our business leaders and leadership teams for achieving our 2025 ambitions. This includes a D&I dashboard and quarterly reviews by our Management Board to ensure close monitoring of progress and plans. Diversity also remains fully embedded in our talent review processes and meetings across all levels of the Group.

Our ‘Diversity Champions’ continue to be key in driving D&I initiatives throughout the organisation. Our ‘Mastering Inclusion’ training helps to further empower our people and increase their awareness. In 2021, more than 8,300 employees completed the training. We also launched a new D&I toolkit for all our managers in 2021, as well as LGBT+ and Race and Ethnicity Allyship Guides.

### Pillar 2: Building diverse talent pipelines

We focus on building diverse talent pipelines at all levels of the organisation through recruiting, developing and retaining the best diverse talent.

In 2021, the proportion of women in management roles was 39% and 27% on senior leadership teams – we are committed to increase these by 2025 to 45% and 40% respectively. To achieve this, we are focused on recruiting, developing and retaining the best female talent.

In 2021, 47% of our external management-level recruits were women. Women also comprised 51% of our new graduate intake in 2021, helping to build a sustainable pipeline of future female leaders. We also provide a range of training, mentoring, coaching and sponsorship programmes to support women’s development.

As well as striving for gender balance, we focus on diversity of nationalities and ethnicities. Our target is for at least a 50% spread of distinct nationalities in all our regional and functional leadership teams. We have 141 different nationalities, from a wide range of ethnic backgrounds, in management roles across the Group.

### Pillar 3: Creating enablers

To realise our diversity ambitions, we know we must have enablers in place that provide a supportive environment for people to thrive and realise their full potential.

We provide women and diverse groups with an opportunity to connect, engage and share experiences, such as through our Women in BAT UK and our B-United LGBT+ communities. And our Parents@BAT programme continues to provide a range of benefits to support new parents working in all BAT businesses worldwide. In 2021, the return rate from parental leave was 95% for women and 95% for men.

We work to continually raise awareness of diversity issues through campaigns and events that showcase best practice and provide platforms for role models to amplify their profiles across the Group. For example, each year, we celebrate events such as National Inclusion Week, International Women’s Day and International Day of Women and Girls in Science.

Following a successful pilot in the UK in 2020, we launched our IGNITE programme in eight more countries in 2021. IGNITE focuses on supporting experienced professionals returning to the workplace after a career break.

Read about our Global Graduate Programmes at www.bat.com/graduates
Strategic Management

People and Culture

Continued

Workforce Engagement

Ensuring we have open engagement, where we can listen and learn from our people, is crucial to an inclusive culture. The Group has a range of well-established engagement channels worldwide covering the Group’s global workforce, including:

- market and site visits by our Directors and Management Board members to meet local employees;
- town halls and listening sessions;
- meetings with works councils, trade unions and the European Employee Council;
- global, functional and regional webcasts, and webcasts and podcasts with the Chief Executive and Management Board members;
- our global ‘Your Voice’ employee survey every two years, most recently in 2021; and
- our annual global leaders meeting with the top 120 senior leaders across the Group; and
- global, independently-managed and multilingual Speak Up channels, discussed further on page 57.

These engagement channels are implemented as appropriate for the composition of local workforce populations, at market, regional or functional levels. With COVID-19 continuing to affect our ways of working throughout the year, workforce engagement forums in 2021 continued to be conducted primarily through virtual formats, leveraging the success of Group digital transformation initiatives.

Given the scale, spread and diversity of the Group’s workforce, the Board considers it effective to use these established engagement channels, augmented by Group-wide reporting structures to capture feedback from engagement at market, regional and functional levels. Employee feedback from workforce engagement channels is collected across the Group and analysed to define priority themes. Consolidated feedback and themes from engagement are reviewed by our Board each year, as part of our Workforce Voice in the Boardroom programme. This focuses on ensuring the Board understands the views of our workforce, and reviews details of the key themes identified and how we have responded. Feedback from the Board, with associated action planning, is cascaded back across our workforce and the Board is kept updated on progress against identified actions during the year.

Find out about how our Board engages with our global workforce on page 103.

The overarching themes identified from engagement in 2021 related to transformation, innovation and staying connected (particularly in the context of the COVID-19 pandemic). We have responded to this feedback with a range of initiatives, including enhanced communications activities to increase our connectivity and provide greater visibility of the Group’s work around transformation and innovation.

For example, we held a virtual TIME: Technology Inspiring a Modern Enterprise Automation summit in 2021, demonstrating how our digital transformation can empower our people. Broadcast live and available to all Group company employees, the four-day summit saw speakers from the business and tech world join BAT senior leaders to discuss how automation is changing our lives.

We also held a global competition for employees to develop creative and engaging videos about the Group’s strategic purpose. This provided an opportunity for employees to share what makes them proud to work for BAT and what it means to be part of the Group’s transformation. In addition, we published a new Science & Innovation Report in 2021 and introduced quarterly science updates, providing our employees with details of the latest developments in tobacco harm reduction science and innovation in a concise and engaging way.

Your Voice

In our 2021 Your Voice global employee survey, we were pleased to surpass our 2019 response rate with 93% of all employees globally choosing to respond (7% higher than our global FMCG comparator group).

Our 2021 Your Voice results outperform our FMCG comparator group in most categories, with strong results in diversity and inclusion, people management, corporate responsibility and empowerment. Our 2021 results were 1% higher than our FMCG comparator group for our High Performance Index. These results reflect our commitment to connected, committed, energised and high performing organisation.

We use these results as the basis for further shaping the priorities of the organisation.
Our Employment Principles

Our Employment Principles set out a common approach for our Group companies' policies and procedures, recognising that each Group company must take account of local labour law and practice, and the local political, economic and cultural context.

In developing our Employment Principles, we have sought the views of a cross-section of internal and external stakeholders, and have consulted with employee representatives and (where relevant) with our works councils. All Group companies have adopted our Employment Principles and, through our internal audit processes, are required to demonstrate how these are embedded into the workplace.

In addition to our Employment Principles, our Board Diversity Policy applies specifically to our Board and Management Board, discussed at page 119.

Responsible restructuring

Our Employment Principles make clear that, where restructuring is necessary, we are committed to doing so in a responsible manner. Where such situations do occur, our companies adopt responsible local approaches and procedures to address each instance, such as severance pay and outplacement support to help displaced employees find alternative employment.

In 2021, we continued Project Quantum to restructure our business globally by redesigning management layers and eliminating duplications, while simultaneously reinvesting in new capabilities and roles to ensure delivery of our strategy.

Rewarding People

Our SoBC makes clear our commitment to providing fair, clear and competitive wages and benefits. In line with good equal pay practices, we have clearly defined pay scales for all roles across the Group worldwide. This approach ensures pay, bonuses and benefits are consistently applied and not influenced by factors such as gender or ethnicity.

Reward is a key pillar in ensuring that we have the right people to drive the business forward. Reward is necessarily local and we strongly support this through global frameworks to ensure leading edge policies, processes and technology are available to all markets.

Base pay rewards core competence relative to skills, experience and contribution to the Group, while annual bonuses, long-term incentives, recognition schemes and ad hoc incentives provide the right mix to ensure that sustained high performance is recognised and rewarded.

Our annual bonus and long-term incentive plans are aligned throughout the organisation, with eligible employees participating in plans with the same performance metrics as the Executive Directors, supporting line of sight throughout the organisation. We also offer our UK employees the chance to share in our success via our Sharesave Scheme, Partnership Share Scheme and Share Reward Scheme, and operate several similar schemes for employees in our Group companies. Our approach to rewarding Group company employees is discussed further at page 163.

Equal pay for equal work

We have been reporting data relating to UK gender pay gaps since 2017 in accordance with UK statutory requirements. For 2021, we have extended the scope of our voluntary reporting to include, for the first time, gender pay gap data for an additional eight markets, representing approximately 40% of our Group company employees. We have also published ethnicity pay gap data for UK employees for 2021.

We recognise that we have a gender pay gap in the UK, which refers to the percentage difference between the average pay for men and women and is not to be confused with equal pay for equal work. This situation is particular to the UK, which is home to our global headquarters, where at present we have more men than women in senior leadership roles.

Gender pay data from our international markets provides a broader assessment of our business and demonstrates that pay gaps are negligible or are in favour of women. In addition, we worked with a specialist consultancy in 2021 to conduct a Pay Equity Review on the data across nine countries, including the UK. The consolidated results show men and women are paid within 1% of one another for doing the same work or work of equal value across those countries. This confirms that our global efforts to provide fair compensation based on legitimate drivers of pay are working. In early 2022, we gained independent accreditation for our Pay Equity Review from Fair Pay Workplace, a non-profit organisation. Certification demonstrates a further commitment to Pay Equity, moving from self-disclosure to demonstrable actions.

Find out more, including our statutory UK gender pay gap data, in our 2021 Diversity and Inclusion Report, available at www.bat.com/genderpayreport
A BETTER TOMORROW™
for shareholders and investors

By delivering sustainable and superior returns.

We are confident in our growth outlook and have a proven record of performance, whatever the external environment. We aim to deliver:

– 3-5% constant currency revenue growth over the medium term;
– enhance shareholder returns via share repurchase programmes; and
– deleverage of the balance sheet.
Financial Performance Summary

- New Categories revenue growth and strong pricing in combustibles offset by currency headwinds, with revenue down 0.4%;
- Profit from operations was up 2.7%. On an adjusted, constant currency basis, profit from operations grew 5.2%, despite a further incremental increase in New Category investment;
- Diluted EPS up 6.0%. Adjusted diluted EPS up 6.6% at constant rates of exchange;
- Deleveraging continued, driven by strong cash generation;
- Dividend per share up 1.0% at 217.8p; and
- Share repurchase programme of £2 billion announced for 2022.

Non-GAAP Measures

In the reporting of financial information, the Group uses certain measures that are not defined by IFRS, the Generally Accepted Accounting Principles (GAAP) under which the Group reports. The Group believes that these additional measures, which are used internally, are useful to users of the financial information in helping them understand the underlying business performance. The principal non-GAAP measures which the Group uses are adjusted revenue, adjusted revenue from New Categories, adjusted profit from operations, adjusted diluted earnings per share and adjusted profit from operations. Adjusting items are significant items in revenue, profit from operations, net finance costs, taxation and the Group’s share of the post-tax results of associates and joint ventures which individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group’s underlying financial performance. As an additional measure to indicate the results of the Group before the impact of exchange rates on the Group’s results, the movement in adjusted revenue, revenue from New Categories, adjusted profit from operations, adjusted net finance costs and adjusted diluted earnings per share are all also shown at constant rates of exchange.

These non-GAAP measures are explained, defined and reconciled from the most comparable GAAP metric on pages 304 to 313 and note 2 in the Notes on the Accounts. As reported in 2020, from 2021 adjusted revenue from the Strategic Portfolio ceased to be a KPI.

Revenue

In 2021, revenue was £25,684 million (down 0.4%), with 2020 also marginally lower (down 0.4%) than 2019 at £25,776 million. New Categories performed well in both years with revenue up 42.4% in 2021 and 14.9% in 2020. Strong pricing in combustibles drove price/mix of 4.3% in 2021 (2020: 7%), with 2021 lower than 2020 due to negative geographic mix as markets began to recover from COVID-19, an estimated £260 million impact in Australasia (due to a structural change in excise and competitive pricing environment) and the negative impact of the sale of the Group’s operations in Iran, partially offset by an estimated £200 million benefit from trade inventory movements in the U.S. mainly linked to the timing of price increases and uncertainty about a potential increase in excise. Cigarette volume was largely in line with 2020 at 637 billion sticks (2020: 4.6% decline to 638 billion sticks).

COVID-19 was a headwind in 2020 of approximately 2.5%, largely due to restrictions in South Africa and a number of other markets across the Group, including the Group’s Global Travel Retail (GTR) business. During 2021, GTR continued to be impacted by the ongoing global travel restrictions.

Translational foreign exchange impacted both years, being a headwind of 7.3% in 2021 and 3.5% in 2020, due to the relative strength of sterling, which more than offset the operational performance and led to the decline in both years. Excluding the impact of currency (and excise on bought-in goods which affected 2019), adjusted revenue at constant rates of exchange increased 6.9% (2020: up 3.3%).

Reconciliation of revenue to adjusted revenue at constant rates

<table>
<thead>
<tr>
<th></th>
<th>2021 (vs 2020)</th>
<th>2020 (vs 2019)</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>£25,684</td>
<td>-0.4%</td>
<td>£25,776</td>
</tr>
<tr>
<td>Adjusting items</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted revenue</td>
<td>£25,684</td>
<td>-0.4%</td>
<td>£25,776</td>
</tr>
<tr>
<td>Impact of exchange</td>
<td>1,877</td>
<td>894</td>
<td></td>
</tr>
<tr>
<td>Adjusted revenue at constant rates</td>
<td>£27,561</td>
<td>+6.9%</td>
<td>£26,670</td>
</tr>
</tbody>
</table>
Financial Review

Financial Performance Summary

Continued

Profit From Operations

Profit from operations increased 2.7% to £10,234 million, compared to an increase of 10.5% to £9,962 million in 2020, largely driven by a translational foreign exchange headwind due to the relative strength of sterling compared to the Group’s operating currencies, including the US dollar. During 2021, Project Quantum (the Group’s restructuring and efficiency programme) delivered savings of £595 million in 2021, following £660 million in 2020.

Raw materials and other consumables costs decreased 0.9% to £4,542 million in 2021, following a decline of 0.3% to £4,583 million in 2020. In 2021, our raw material costs were negatively impacted by a transactional foreign exchange headwind of 1.1%, offset by savings and translational tailwind (on costs). The decrease in 2020 was mainly due to the end of the contract manufacturing arrangement, which, due to excise recognition on bought-in products under that arrangement, led to an increase (in prior years) in revenue and in raw materials and other consumables.

Employee benefit costs declined 1.0% to £2,717 million (2020: down 14.8% to £2,744 million). The reduction was partly due to translational foreign exchange, offsetting wage inflation and to operational efficiencies achieved through Quantum.

Depreciation, amortisation and impairment costs decreased by £374 million to £1,676 million in 2021 compared to a decrease of £62 million to £1,450 million in 2020. This includes the amortisation and impairment charges of £306 million (2020: £339 million) largely related to the trademarks and similar intangible assets acquired following recent acquisitions. Also included were goodwill impairment charges of £54 million in Peru and £3 million following the exit from Malaysia (both in 2021) and £197 million (in 2020) in respect of Malaysia, recognised due to the ongoing operational challenges in those markets.

Other operating expenses declined by £199 million to £7,468 million (2020: decrease of £164 million to £7,662 million). The Group continued to incrementally increase the investment behind New Categories, with an increase in 2021 (compared to 2020) of £377 million, itself an increase on 2019 of £346 million, in part funded by the efficiencies delivered by Quantum.

Adjusting items included within profit from operations totalled £916 million in 2021 (2020: £1,403 million). These related to:

- trademark amortisation and impairment (2021: £306 million; 2020: £339 million);
- other litigation costs of £80 million (2020: £487 million) which in 2021 was in respect of other litigation costs of £54 million (2020: £87 million) including Engie progeny and the net charge from settlements in Turkey and South Korea (£26 million). 2020 also included a £400 million charge largely in respect of developments in cases regarding payment obligations under the state settlement agreements with Florida, Texas, Minnesota and Mississippi for brands previously sold to a third party;
- restructuring and integration costs of £150 million (2020: £408 million) partly related to Quantum which will simplify the business and create a more efficient and agile organisation to support the growth of New Categories;
- adjustments in respect of the partial buy-out of the pension fund in the U.S.; and
- charges in respect of the sale of the Group’s operations in Iran (£354 million) in 2021, largely in respect of the write-off of certain assets and the reclassification, from reserves to the income statement, of foreign exchange.

The Group also recognised charges in respect of the impairment of goodwill of £57 million in 2021 (related to Peru and Myanmar) and £209 million in 2020 (mainly in respect of Malaysia and Twisp) which was partly offset by a credit, in 2020, of £40 million (related to the 2019 charge associated with the excise dispute in Russia).

2020 also included an estimated £145 million in additional supply chain costs to maintain supply as a number of markets experienced temporary disruption due to COVID-19, with no material additional costs incurred in 2021.

Expenditure on research and development was £304 million in 2021 (2020: £307 million) with a focus on products that could potentially reduce the risk associated with smoking conventional cigarettes.

Analysis of profit from operations, net finance costs and results from associates and joint ventures

<table>
<thead>
<tr>
<th>Incurred</th>
<th>Adjusted</th>
<th>Adjusted</th>
<th>Impact of exchange</th>
<th>Adjusted at CC</th>
<th>Reported</th>
<th>Adjusting</th>
<th>Adjusted</th>
<th>Impact of exchange</th>
<th>Reported</th>
<th>Adjusting</th>
<th>Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit from operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>5,566</td>
<td>321</td>
<td>5,887</td>
<td>456</td>
<td>6,343</td>
<td>4,975</td>
<td>809</td>
<td>5,784</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APME</td>
<td>1,287</td>
<td>430</td>
<td>1,717</td>
<td>116</td>
<td>1,833</td>
<td>1,472</td>
<td>381</td>
<td>1,853</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AmSSA</td>
<td>1,496</td>
<td>94</td>
<td>1,590</td>
<td>98</td>
<td>1,688</td>
<td>1,553</td>
<td>65</td>
<td>1,618</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENA</td>
<td>1,885</td>
<td>71</td>
<td>1,956</td>
<td>132</td>
<td>2,088</td>
<td>1,962</td>
<td>148</td>
<td>2,110</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total regions</td>
<td>10,234</td>
<td>916</td>
<td>11,150</td>
<td>802</td>
<td>11,952</td>
<td>9,962</td>
<td>1,403</td>
<td>11,365</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net finance (costs)/income</td>
<td>(1,466)</td>
<td>55</td>
<td>(1,431)</td>
<td>(89)</td>
<td>(1,520)</td>
<td>(1,745)</td>
<td>153</td>
<td>(1,592)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associates and joint ventures</td>
<td>415</td>
<td>12</td>
<td>427</td>
<td>29</td>
<td>456</td>
<td>455</td>
<td>(13)</td>
<td>442</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit before tax</td>
<td>9,163</td>
<td>983</td>
<td>10,146</td>
<td>742</td>
<td>10,888</td>
<td>8,872</td>
<td>1,543</td>
<td>10,215</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Change in adjusted profit from operations at constant rates (+5.2%)

Definition: Change in profit from operations before the impact of adjusting items and the impact of fluctuations in foreign exchange rates.

- a credit, in 2021, of £59 million as an accrual related to the Reynolds American dissenting shareholders was released on successful conclusion of that complaint;
- a credit, in 2021, of £35 million following the partial buy-out of the pension fund in the U.S.; and
- charges in respect of the sale of the Group’s operations in Iran (£354 million) in 2021, largely in respect of the write-off of certain assets and the reclassification, from reserves to the income statement, of foreign exchange.

The Group also recognised charges in respect of the impairment of goodwill of £57 million in 2021 (related to Peru and Myanmar) and £209 million in 2020 (mainly in respect of Malaysia and Twisp) which was partly offset by a credit, in 2020, of £40 million (related to the 2019 charge associated with the excise dispute in Russia).

2020 also included an estimated £145 million in additional supply chain costs to maintain supply as a number of markets experienced temporary disruption due to COVID-19, with no material additional costs incurred in 2021.

Expenditure on research and development was £304 million in 2021 (2020: £307 million) with a focus on products that could potentially reduce the risk associated with smoking conventional cigarettes.
Adjusted profit from operations is the Group’s profit from operations before adjusting items referred to above. Adjusted profit from operations fell 1.9% to £11,150 million, driven by the foreign exchange headwind. On a constant currency basis this would have been an increase of 5.2%. In 2020, adjusted profit from operations grew 2.1% to £11,365 million, being an increase of 4.8% on a constant currency basis.

Operating Margin
Operating margin in 2021 increased by 120 bps to 39.8% largely driven by lower charges in respect of items such as trademark amortisation, goodwill impairment, litigation and Quantum in 2021 compared to 2020, despite the impact of Iran described earlier. In 2020, operating margin was 38.6%, an increase of 360 bps as 2019 was impacted by a number of items (including Quebec and Russia) that did not repeat. These are described in note 6 in the Notes on the Accounts.

In 2021, adjusted operating margin declined 70 bps to 43.4%, compared to a growth of 100 bps in 2020. Operating margin in 2021 increased by 120 bps to 39.8% on a constant currency basis this would have been an increase of 5.2%. In 2020, adjusted profit from operations grew 2.1% to £11,365 million, being an increase of 4.8% on a constant currency basis.

Net Finance Costs
In 2021, net finance costs were £1,486 million, a decrease of £259 million on 2020 which, at £1,745 million, were £143 million higher than 2019.

The movement in 2021 was partly due to the impact of the charges incurred in 2020 (in relation to the redemptions and tender offer to repurchase certain bonds undertaken to de-risk the Group’s future financing programme which did not repeat) and a translational foreign exchange tailwind due to the strength of sterling. Also in 2021, the Group issued perpetual hybrid bonds totalling £2 billion, recognised, in line with IAS 32 Financial Instruments, as equity. Interest on such instruments are recognised in reserves rather than as a charge to the income statement in net finance costs. In 2021, in line with IAS 33 Earnings Per Share, £12 million has been recognised as a deduction to EPS similar to non-controlling interest. The increase in 2020 was also driven by a change in mix of borrowings towards the US dollar during the year (as the Group issued bonds totalling US$6.7 billion, £1.7 billion and £0.5 billion).

Before adjusting items in respect of interest on a settlement in Turkey in 2021 (£11 million), the Franked Investment Income Group Litigation Order (FIIGLO), as discussed on page 201 (£20 million; 2020: £21 million) and, in 2020, net costs of £142 million in respect of the bond redemption combined with a net credit of £10 million (largely in respect of interest in relation to the Russia excise dispute) and the translation impact of foreign exchange (in both years), adjusted net finance costs were 4.5% lower in 2021 and 5.9% higher in 2020. The Group’s average cost of debt in 2021 was 3.5%, compared to 3.6% in 2020.

Associates and Joint Ventures
Associates largely comprised the Group’s shareholding in its Indian associate, ITC. The Group’s share of post-tax results of associates and joint ventures, included at the pre-tax level under IFRS, decreased from £455 million to £415 million in 2021. This follows a decline in 2020 of 8.6% (from £498 million in 2019), as ITC continued to experience difficult trading conditions, including business disruption due to the impact of COVID-19.

Included in the results for 2021 and 2020 are adjusting items, which included a gain of £8 million in 2021 (2020: £17 million), arising on the deemed disposal of part of the Group’s shareholding in ITC (due to issuances of ordinary shares under the ITC Employee Share Option Scheme).

In 2021, this was more than offset by other charges, including an £18 million charge in 2021 as the Group recognised an impairment in Yemen. In 2020, the Group recognised a £4 million charge being the Group’s share of charges recognised by ITC in respect of the cost of leaf tobacco stocks destroyed in a third-party warehouse fire. Excluding such adjusting items and the impact of translational foreign exchange, the Group’s share of associates and joint ventures on an adjusted, constant currency basis increased 3.3% in 2021, to £456 million. In 2020, this was a decrease of 1.2% on 2019.

Analysis of profit from operations, net finance costs and results from associates and joint ventures

<table>
<thead>
<tr>
<th></th>
<th>Reported £m</th>
<th>Adjusting items £m</th>
<th>Adjusted £m</th>
<th>Impact of exchange £m</th>
<th>Adjusted at CC £m</th>
<th>Reported £m</th>
<th>Adjusting items £m</th>
<th>Adjusted £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profit from operations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>4,975</td>
<td>809</td>
<td>5,784</td>
<td>32</td>
<td>5,816</td>
<td>4,410</td>
<td>626</td>
<td>5,036</td>
</tr>
<tr>
<td>APME</td>
<td>1,472</td>
<td>381</td>
<td>1,853</td>
<td>56</td>
<td>1,909</td>
<td>1,753</td>
<td>306</td>
<td>2,059</td>
</tr>
<tr>
<td>AmSSA</td>
<td>1,553</td>
<td>65</td>
<td>1,618</td>
<td>178</td>
<td>1,796</td>
<td>1,204</td>
<td>638</td>
<td>1,842</td>
</tr>
<tr>
<td>EMA</td>
<td>1,962</td>
<td>148</td>
<td>2,110</td>
<td>30</td>
<td>2,140</td>
<td>1,649</td>
<td>544</td>
<td>2,193</td>
</tr>
<tr>
<td><strong>Total regions</strong></td>
<td>9,962</td>
<td>1,403</td>
<td>11,365</td>
<td>296</td>
<td>11,661</td>
<td>9,016</td>
<td>2,114</td>
<td>11,130</td>
</tr>
<tr>
<td><strong>Net finance (costs)/income</strong></td>
<td>(1,745)</td>
<td>(13)</td>
<td>(1,592)</td>
<td>(20)</td>
<td>(1,612)</td>
<td>(1,602)</td>
<td>80</td>
<td>(1,522)</td>
</tr>
<tr>
<td><strong>Associates and joint ventures</strong></td>
<td>455</td>
<td>442</td>
<td>498</td>
<td>26</td>
<td>473</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit before tax</strong></td>
<td>8,672</td>
<td>1,543</td>
<td>10,215</td>
<td>302</td>
<td>10,517</td>
<td>7,912</td>
<td>2,169</td>
<td>10,081</td>
</tr>
</tbody>
</table>
In 2021, the tax charge in the income statement was £2,189 million, compared to £2,108 million in 2020 and £2,063 million in 2019.

The effective tax rates in the income statement are therefore a charge of 23.9% in 2021, 24.3% in 2020 and 26.1% in 2019. These are also affected by the inclusion of adjusting items described earlier and the associates and joint ventures’ post-tax profit in the Group’s pre-tax results. Excluding these items, the underlying tax rate for subsidiaries was 24.7% in 2021, 24.9% in 2020 and 26.0% in 2019. The decrease in underlying tax rate in 2021 largely reflects the prior and current year tax reclains in Brazil together with mix of profits.

See the section Non-GAAP measures on page 309 for the computation of underlying tax rates for the periods presented.

### Tax strategy

The Group’s global tax strategy is reviewed regularly by the Board. The operation of the strategy is managed by the Finance and Transformation Director and Group Head of Tax with the Group’s tax position reported to the Audit Committee on a regular basis. The Board considers tax risks that may arise as a result of our business operations. In summary, the strategy includes:

- complying with all applicable laws and regulations in countries in which we operate;
- being open and transparent with tax authorities and operating to build mature professional relationships;
- supporting the business strategy of the Group by undertaking efficient management of our tax affairs in line with the Group’s commercial activity;
- transacting on an arm’s-length basis for exchanges of goods and services between companies within the Group; and
- engaging in pro-active discussions with tax authorities on occasions of differing legal interpretation.

Where legislative uncertainty exists, resulting in differing interpretations, the Group seeks to establish that its position would be more likely than not to prevail. Transactions between Group subsidiaries are conducted on arm’s-length terms in accordance with appropriate transfer pricing rules and OECD principles.

The tax strategy outlined above is applicable to all Group companies, including the UK Group companies. Reference to tax authorities includes HMRC.

The publication of this strategy is considered to constitute compliance with the duty under paragraph 16(2) Schedule 19 Part 2 of the UK Finance Act 2016.

The taxation on ordinary activities was a charge of £2.2 billion in 2021, £2.1 billion in 2020 and £2.1 billion in 2019. Corporation Tax paid (due to the timing of Corporation Tax instalment payments which straddle different financial years) was £2.2 billion in 2021, £2.1 billion in 2020 and £2.2 billion in 2019.

Our tax footprint extends beyond Corporation Tax, including significant payment of employment taxes and other indirect taxes including customs and import duties. The Group also collects taxes on behalf of governments (including tobacco excise, employee taxes, VAT and other sales taxes). The total tax paid in 2021 of £40.5 billion (2020: £41.1 billion, 2019: £41.4 billion) therefore consists of both taxes borne and taxes collected as shown in the table provided.

In addition to the major taxes, there are a host of other taxes the Group bears and collects such as transport taxes, energy and environmental taxes, and banking and insurance taxes. The movements in deferred tax, taken through other comprehensive income, mainly relate to the change in the valuation of retirement benefits in the year, as disclosed in note 16 in the Notes on the Accounts.

### Deferred tax asset/(liability)

Where legislative uncertainty exists, resulting in differing interpretations, the Group seeks to establish that its position would be more likely than not to prevail. Transactions between Group subsidiaries are conducted on arm’s-length terms in accordance with appropriate transfer pricing rules and OECD principles.

The tax strategy outlined above is applicable to all Group companies, including the UK Group companies. Reference to tax authorities includes HMRC.

The publication of this strategy is considered to constitute compliance with the duty under paragraph 16(2) Schedule 19 Part 2 of the UK Finance Act 2016.

The taxation on ordinary activities was a charge of £2.2 billion in 2021, £2.1 billion in 2020 and £2.1 billion in 2019. Corporation Tax paid (due to the timing of Corporation Tax instalment payments which straddle different financial years) was £2.2 billion in 2021, £2.1 billion in 2020 and £2.2 billion in 2019.

Our tax footprint extends beyond Corporation Tax, including significant payment of employment taxes and other indirect taxes including customs and import duties. The Group also collects taxes on behalf of governments (including tobacco excise, employee taxes, VAT and other sales taxes). The total tax paid in 2021 of £40.5 billion (2020: £41.1 billion, 2019: £41.4 billion) therefore consists of both taxes borne and taxes collected as shown in the table provided.

In addition to the major taxes, there are a host of other taxes the Group bears and collects such as transport taxes, energy and environmental taxes, and banking and insurance taxes. The movements in deferred tax, taken through other comprehensive income, mainly relate to the change in the valuation of retirement benefits in the year, as disclosed in note 16 in the Notes on the Accounts.

### Tax strategy

The Group’s global tax strategy is reviewed regularly by the Board. The operation of the strategy is managed by the Finance and Transformation Director and Group Head of Tax with the Group’s tax position reported to the Audit Committee on a regular basis. The Board considers tax risks that may arise as a result of our business operations. In summary, the strategy includes:

- complying with all applicable laws and regulations in countries in which we operate;
- being open and transparent with tax authorities and operating to build mature professional relationships;
- supporting the business strategy of the Group by undertaking efficient management of our tax affairs in line with the Group’s commercial activity;
- transacting on an arm’s-length basis for exchanges of goods and services between companies within the Group; and
- engaging in pro-active discussions with tax authorities on occasions of differing legal interpretation.

Where resolution is not possible, tax disputes may proceed to litigation. The Group seeks to establish strong technical tax positions.
Earnings Per Share
Profit for the year was £6,974 million, a 6.2% increase compared to £6,564 million in 2020 (itself an increase of 12.2% on 2019). While the Group was impacted by foreign exchange headwinds, a good operational performance in both years was enhanced by efficiencies realised through Quantum and from a lower effective tax rate. Both 2021 and 2020 were impacted by a number of charges as described earlier with the improvement in profit for the year in 2020 (compared to 2019) also due to charges in relation to Quebec and Russia in 2018.

Consequently, and after accounting for the movement in non-controlling interests in the year, basic earnings per share were 6.0% higher at 296.9p (2020: 280.0p; 2019: 249.7p). After accounting for the dilutive effect of employee share schemes, diluted earnings per share were 295.6p, 6.0% higher than 2020 (2020: 278.9p; 2019: 249.0p).

Earnings per share are impacted by the adjusting items discussed earlier. Adjusted diluted EPS, as calculated in note 11 in the Notes on the Accounts, was down against the prior year by 0.8% at 329.0p, with 2020 ahead of 2019 by 2.4% at 331.7p. Adjusted diluted EPS at constant rates would have been 6.6% ahead of 2020 at 353.5p. This represents 8.6% lower and 2020 up 5.5% against 2019.

Dividends
The Group pays its dividends to shareholders over four quarterly interim dividends. Quarterly dividends provide shareholders with a more regular flow of dividend income and allow the Company to spread its substantial dividend payments more evenly over the year, aligning better with the cash flow generation of the Group and so enable the Company to fund the payments more efficiently. The Board seeks to reward shareholders with an increase in dividend, by reference to 65% of adjusted diluted EPS over the mid to long term.

The Board has declared an interim dividend of 217.8p per ordinary share of 25p, payable in four equal quarterly installments of 54.45p per ordinary share in May 2022, August 2022, November 2022 and February 2023. This represents an increase of 1.0% on 2020 (2020: 215.6p per share, up 2.5%) and a payout ratio, on 2021 adjusted diluted earnings per share, of 66.2% (2020: 65.0%).

The quarterly dividends will be paid to shareholders registered on either the UK main register or the South Africa branch register and to ADS holders, each on the applicable record dates.

The cash flow, prepared in accordance with IFRS, reflects the total cash paid in the period. Further details of the total amounts of dividends paid in 2021 and 2020 (with 2019 comparative) are given in note 22 in the Notes on the Accounts.

Dividends are declared and payable in sterling except for those shareholders on the branch register in South Africa, where dividends are payable in rand. The equivalent dividends receivable by holders of ADSs in US dollars are calculated based on the exchange rate on the applicable payment date.

Further details of the quarterly dividends and key dates are set out under ‘Shareholder information’ on pages 354 and 355.

The discussion of 2019 results that are not necessary to an understanding of the Group’s financial condition, changes in financial condition and results of operations is excluded from this Financial Review in accordance with applicable US Securities laws. Discussion of such 2019 metrics is contained in the Group’s Annual Report on Form 20-F 2020, which is available at bat.com/annualreport and has been filed with the SEC. Information contained in pages 34 to 42, pages 65 to the first column on page 72 and from the heading ‘Retirement benefit schemes’ on page 72 to page 73 of the Annual Report on Form 20-F 2020 are accordingly incorporated by reference into this Annual Report on Form 20-F 2021 only to the extent such information pertains to the Group’s financial condition and results of operations for the fiscal year ended 31 December 2019.
Financial Review

Treasury and Cash Flow

Treasury, Liquidity and Capital Structure

The Treasury Function is responsible for raising finance for the Group and managing the Group’s cash resources and the financial risks arising from underlying operations. Clear parameters have been established, including levels of authority, on the type and use of financial instruments to manage the financial risks facing the Group. Such instruments are only used if they relate to an underlying exposure; speculative transactions are expressly forbidden under the Group’s treasury policy. All these activities are carried out under defined policies, procedures and limits, reviewed and approved by the Board, delegating oversight to the Finance and Transformation Director and Treasury Function. See note 26 in the Notes on the Accounts for further detail.

It is the policy of the Group to maximise financial flexibility and minimise refinancing risk by issuing debt with a range of maturities, generally matching the projected cash flows of the Group and obtaining this financing from a wide range of sources. The Group targets an average centrally managed debt maturity of at least five years of which no more than 20% matures in a single rolling year. As at 31 December 2021, the average centrally managed debt maturity was 10.1 years (2020: 9.9 years) with the highest proportion maturing in a single rolling 12-month period was 18.6% (2020: 16.4%).

In order to manage its interest rate risk, the Group maintains both floating rate and fixed rate debt. The Group sets targets (within overall guidelines) for the desired ratio of floating to fixed rate debt on a net basis (at least 50% fixed on a net basis in the short to medium term). At 31 December 2021, the relevant ratio of floating to fixed rate borrowings was 10.90:1 (2020: 7.93). As part of the management of liquidity, funding and interest rate risk, the Group regularly evaluates market conditions and may enter into transactions, from time to time, to repurchase outstanding debt, pursuant to open market purchases, tender offers or other means.

The Group continues to maintain investment grade credit ratings*, with ratings from Moody’s/S&P at Baa2 (stable outlook)/BBB+ (stable outlook). The strength of the ratings has underpinned debt issuance and the Group is confident of its ability to successfully access the debt capital markets.

As at 31 December 2021, the Group’s floating rate borrowings have no exposure in relation to IBOR reform as its floating rate bond of US$750 million is due to mature in August 2022 before the USD LIBOR ceases.

Additionally, the Group has hedging instruments that are indexed to sterling LIBOR interest rates. The Group signed up to the ISDA 2020 IBORFallback Protocol as published by the International Swaps and Derivative Association Inc., ensuring that appropriate fallback rates will apply in relation to derivatives that are impacted by LIBOR cessation and therefore certainty on the basis of the further cash flows. The hedge relationship on these derivatives will continue with the resulting ineffective likelihood to be immaterial.

Available facilities

The Group maintains a £25 billion Euro Medium Term Note (EMTN) programme, and US (US$4 billion) and European (£3 billion) commercial paper programmes to accommodate the liquidity needs of the Group. At 31 December 2021, there was £269 million commercial paper outstanding (2020: nil outstanding). Cashflows relating to commercial paper that have maturity periods of three months or less are presented on a net basis in the Group’s cashflow statement.

The Group’s main bank facility is a syndicated £5.85 billion committed revolving credit facility. This facility was undrawn at 31 December 2021 (2020: £5.85 billion undrawn). In 2021, the Group exercised the first of the one-year extension options on both tranches of the revolving credit facility, with the second one-year extension subsequently exercised in February 2022. Effective March 2022, therefore, the £2.85 billion 364-day tranche will be extended to March 2023 at the reduced amount of £2.7 billion and £2.5 billion of the five-year tranche will be extended from March 2026 to March 2027 (with £3.0 billion of this tranche remaining available until March 2025 and £2.85 billion remaining available from March 2025 to March 2026).

During 2021, the Group extended short-term bilateral facilities totalling £2.5 billion until March or April 2022, some with extension options to extend for further periods. As at 31 December 2021, £500 million was drawn on a short-term basis. Of such short-term bilateral facilities, in December 2021, the Group amended and extended a total of £300 million until December 2022 and subsequent to year end, the Group amended and extended a further £500 million until January 2023 and effective April 2022, an additional £350 million was agreed to be extended until October 2022 and £500 million until April 2023. Cashflows relating to bilateral facilities that have maturity periods of three months or less are presented on a net basis in the Group’s cashflow statement.

In July 2019, the Group filed a shelf registration statement on Form F-3 with the SEC pursuant to which B.A.T Capital Corporation and B.A.T. International Finance p.l.c. may issue debt securities guaranteed by certain members of the Group from time to time. This forms part of the Group’s strategy to ensure flexible and agile access to capital markets and the registration statement is initially valid for three years.

Use of facilities

These facilities ensure that the Group has access to funding to supplement the cash available or generated by the business in the period to meet the operational (including working capital) and general corporate requirements including, but not limited to, the timing of payments in relation to:
- dividends (2021: £4.9 billion; 2020: £4.8 billion);
- capital expenditure (2021: £0.6 billion; 2020: £0.6 billion);
- MSA in the U.S. (2021: £2.7 billion; 2020: £2.2 billion);
- refinancing obligations;
- share repurchase programme, as announced for 2022 (£2 billion); and
- other corporate activity such as litigation or acquisitions as relevant.

Management believes that the Group has sufficient working capital for present requirements, taking into account the amounts of undrawn borrowing facilities and levels of cash and cash equivalents, and the ongoing ability to generate cash.

Issuance, drawdowns and repayment in the period

In 2021, the Group repaid:
- £650 million, £500 million, £1.1 billion, CHF 400 million and £500 million bonds at maturity; and
- the £1,929 million term loan that had a maturity date in January 2022.

Also in 2021, the Group issued perpetual hybrid bonds totalling £2 billion. The issuance allowed the Group to raise incremental euro-denominated securities, which contributed to a more efficient alignment of the Group’s earnings currency. It also contributes to the diversification of the Group’s sources of funding and further strengthens its capital structure. The issuance provided the additional benefit of supporting the deleveraging journey with the addition of a small benefit to the credit metrics.
During 2020, in light of the uncertainty and volatility in the external markets, the Group has de-risked future financing requirements by accessing the debt capital markets, raising a total of US$8.7 billion in the U.S. market, and €1.7 billion and £0.5 billion in the European market (in aggregate £8.9 billion). Also in 2020 as part of the de-risking programme, the Group repurchased and redeemed £3.1 billion of debt maturing in 2021 and 2022, reducing the ‘tower’ of debt due for repayment in 2022.

### Cash Flow

#### Net cash generated from operating activities

Net cash generated from operating activities decreased by 0.7% to £9,717 million in 2021, compared to an increase of £780 million to £9,786 million in 2020. 2021 was negatively impacted by a translational foreign exchange headwind and the timing of MSA payments in the U.S. and higher tax payments (mainly in Canada and the U.S.). These were largely offset by favourable movement in inventories (as stock builds in Australia in 2020 did not repeat), and lower payments in respect of litigation (2021: £248 million; 2020: £464 million). 2020 included the payment of the settlement agreed in 2019 in respect of the excise dispute in Russia (£205 million), U.S. litigation (including £169 million in respect of the Florida judgment described earlier). These were largely offset by lower payments in respect of litigation (2021: £464 million; 2020: £819 million), the disposals of the Group’s operations in Iran (£98 million) and the purchase of the equity stake in Organigram. Purchases of property, plant and equipment were largely in line with 2020, at £527 million (2020: £511 million).

In 2021, the Group invested £664 million, in gross capital expenditure, an increase of 2.5% on the prior year (2020: £648 million). This includes purchases of property, plant and equipment and certain intangibles, and the investment in the Group’s global operational infrastructure (including, but not limited to, the manufacturing network, trade marketing software and IT systems and the expansion of our New Categories portfolio). The Group expects gross capital expenditure in 2022 of £750 million.

#### Net cash used in financing activities

Net cash used in financing activities was an outflow, with the outflow in each year largely driven by:

- dividend payments (2021: £4,904 million, up 3.4%; 2020: £4,745 million), with the growth in both years driven by the higher dividend per share; and
- the net repayment of borrowings (2021: £3,865 million; 2020: £3,865 million) partly offset by the issuance of the hybrid bonds (£1,685 million in 2021).

In 2021, interest paid declined 14.9% to £1,479 million (2020: £1,737 million), with the movements largely driven by changes in relation to the refinancing programme in 2020 that did not repeat.

### Summary cash flow

<table>
<thead>
<tr>
<th>Description</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash generated from operations</td>
<td>11,678</td>
<td>11,567</td>
<td>10,948</td>
</tr>
<tr>
<td>Dividends received from associates</td>
<td>353</td>
<td>351</td>
<td>252</td>
</tr>
<tr>
<td>Tax paid</td>
<td>(2,314)</td>
<td>(2,132)</td>
<td>(2,204)</td>
</tr>
<tr>
<td><strong>Net cash generated from operating activities</strong></td>
<td>9,717</td>
<td>9,786</td>
<td>8,996</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(1,140)</td>
<td>(783)</td>
<td>(639)</td>
</tr>
<tr>
<td><strong>Net cash used in financing activities</strong></td>
<td>(8,749)</td>
<td>(7,897)</td>
<td>(8,593)</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(253)</td>
<td>(253)</td>
<td>(57)</td>
</tr>
<tr>
<td><strong>(Decrease)increase in net cash and cash equivalents</strong></td>
<td>(425)</td>
<td>853</td>
<td>(293)</td>
</tr>
</tbody>
</table>

In 2021, the Group repaid borrowings of €4.8 billion and issued €1.0 billion of new borrowings, while the Group issued perpetual hybrid bonds totalling £2 billion (£1.7 billion). The Group repaid borrowings of £10.6 billion in 2020, including £3.1 billion as part of the Group’s liquidity management strategy to de-risk future financing, largely offset by new borrowings of £3.8 billion. Please refer to note 26 in the Notes on the Accounts for further details.

#### Cash flow conversion

The conversion of profit from operations to net cash generated from operating activities may indicate the Group’s ability to generate cash from the profits earned. Based upon net cash generated from operating activities, the Group’s conversion rate was 95% compared to 98% in 2020, which was largely in line with 2019.

#### Restricted cash

Cash and cash equivalents include restricted amounts of £1,024 million (2020: £676 million) due to subsidiaries in CCAA protection (as described in note 32 in the Notes on the Accounts), as well as €305 million (2020: €455 million) principally due to exchange control restrictions, including amounts of €32 million (2020: €141 million) where the underlying restrictions are expected to be short-term in nature.
Borrowings and Net Debt
Total borrowings (which includes lease liabilities) declined to £39,658 million in 2021 (2020: £43,968 million) largely due to the refinancing undertaken in 2021 (with the €2 billion perpetual hybrid bonds issued in the year recognised as equity) and the net repayment of borrowings in the year (partly due to the cash flow generated by the business in the period). The value of borrowings is also impacted by the relative movement of sterling against other currencies, particularly the US dollar and the euro. In 2021, this was a tailwind of £409 million compared to a tailwind of £215 million in 2020.

Total borrowings includes £754 million (31 December 2020: £790 million) in respect of the purchase price adjustments related to the acquisition of Reynolds American Inc. As discussed on page 80, the Group remains confident about its ability to access the debt capital markets successfully and reviews its options on a continuing basis.

Net debt is a non-GAAP measure and is defined as total borrowings (including related derivatives and lease liabilities) less cash and cash equivalents and current investments held at fair value.

Net debt, at 31 December 2021, was £36,302 million (2020: £40,241 million; 2019: £42,574 million), with the movement in net debt largely due to the net repayment of borrowings (partly enabled by the issuance of perpetual hybrid bonds) and a foreign exchange headwind of £124 million, primarily due to the movement of the US dollar against sterling (2020: £69 million tailwind).

Retirement Benefit Schemes
The Group’s subsidiary undertakings operate defined benefit schemes, including pension and post-retirement healthcare schemes, and defined contribution schemes. The most significant arrangements are in the U.S., UK, Canada, Germany, Switzerland and the Netherlands. Together, schemes in these territories account for over 80% of the total underlying obligations of the Group’s defined benefit arrangements and over 70% of the defined benefit net costs charged to adjusted profit from operations. Benefits provided through defined contribution schemes are charged as an expense as payments fall due. The liabilities arising in respect of defined benefit schemes are determined in accordance with the advice of independent, professionally qualified actuaries, using the projected unit credit method. It is Group policy that all schemes are formally valued at least every three years. Contributions to the defined benefit schemes are determined after consultation with the respective trustees and actuaries of the individual externally funded schemes, taking into account regulatory environments.

The present total value of funded scheme liabilities as at 31 December 2021 was £10,084 million (2020: £12,223 million), while unfunded scheme liabilities amounted to £1,037 million (2020: £1,147 million). The schemes’ assets decreased to £10,816 million from £12,576 million in 2020, itself an increase from £11,860 million in 2019. The overall net liability for all pension and healthcare schemes in Group subsidiaries amounted to £321 million at the end of 2021, compared to £810 million at the end of 2020.

In addition, during 2021, the risk profiles and values of amounts relating to retirement benefit arrangements were impacted by a partial buy-out in the U.S. and through buy-ins in the UK and Canada. Please refer to note 15 in the Notes on the Accounts for further details.

Litigation and Settlements
As discussed in note 31 in the Notes on the Accounts, various legal proceedings or claims are pending or may be instituted against the Group.
Government Activity
The marketing, sale, taxation and use of tobacco products have been subject to substantial regulation by government and health officials for many years. For information relating to the risks related to regulation, see page 94 and pages 325 to 334.

Off-balance Sheet Arrangements and Contractual Obligations
Except for certain indemnities, the Group has no significant off-balance sheet arrangements other than in respect of leaf purchase obligations. The Group has contractual obligations to make future payments on debt guarantees. In the normal course of business, it enters into contractual arrangements where the Group commits to future purchases of goods and services from unaffiliated and related parties. See page 316 for a summary of the contractual obligations as at 31 December 2021.

Accounting Policies
The application of the accounting standards and the accounting policies adopted by the Group are set out in the Group Manual of Accounting Policies and Procedures (GMAPP). GMAPP includes the Group instructions in respect of the accounting and reporting of business activities, such as revenue recognition, asset valuations and impairment testing, adjusting items, the accrual of obligations and the appraisal of contingent liabilities, which include taxes and litigation. Formal processes are in place for central management and end-market management to ensure and confirm adherence to the principles and the procedures and to the completeness of reporting. Central analyses and revision of information are also performed to ensure and confirm adherence.

In order to prepare the Group’s consolidated financial information in accordance with IFRS, management has used estimates and assumptions that affect the reported amounts of revenue, expenses and assets, and the disclosure of contingent liabilities, at the date of the financial statements. The critical accounting estimates are described in note 1 in the Notes on the Accounts and include:

- review of asset values, including goodwill and impairment testing;
- estimation and accounting for retirement benefit costs; and
- estimation of provisions, including as related to taxation and legal matters.

The critical accounting judgements are described in note 1 in the Notes on the Accounts and include:

- identification and quantification of adjusting items;
- determination as to whether to recognise provisions and the exposures to contingent liabilities related to pending litigation or other outstanding claims;
- determination as to whether control (subsidiaries), joint control (joint arrangements), or significant influence (associates) exist in relation to investments held by the Group;
- review of applicable exchange rates for transactions with and translation of entities in territories where there are restrictions on the free access to foreign currency or multiple exchange rates; and
- the determination as to whether perpetual hybrid bonds should be classified as equity instead of borrowings.

Foreign Exchange Rates
The principal exchange rates used to convert the results of the Group’s foreign operations to sterling, for the purposes of inclusion and consolidation within the Group’s financial statements, are indicated in the table below.

Where the Group has provided results at constant rates of exchange, this refers to the translation of the results from the foreign operations at rates of exchange prevailing in the prior period – thereby eliminating the potentially distorting impact of the movement in foreign exchange on the reported results.

Going Concern
A description of the Group’s business activities, its financial position, cash flows, liquidity position, facilities and borrowings position, together with the factors likely to affect its future development, performance and position, are set out in this Annual Report and Form 20-F.

The key Group risks include analyses of financial risk and the Group’s approach to financial risk management. Notes 23 and 26 in the Notes on the Accounts provide further detail on the Group’s borrowings and management of financial risks.

The Group has, at the date of this report, sufficient existing financing available for its estimated requirements for at least the next 12 months and beyond in respect of general corporate purposes. This includes the payments arising in respect of the Master Settlement Agreement due in the U.S. in 2022 and other known liabilities or future payments (including interim dividends), as they fall due. Actions undertaken during 2021 and 2020 to de-risk future funding requirements, as previously described, provide further assurance with regards to the Group’s financial viability.

During 2021 and 2020, COVID-19 has demonstrated the Group’s ability to navigate the uncertainties arising through operational, economic and societal volatility. Such challenges have been met through the Group’s geographic diversity and ability to flex operations. This, together with the ability to generate cash from trading activities, the performance of the Group’s Strategic Portfolio and its leading market positions in a number of countries, as well as numerous contracts with established customers and suppliers across different geographical areas and industries, provides the Directors with the confidence that the Group is well placed to manage its business risks successfully in the context of current financial conditions and the general outlook in the global economy.

After reviewing the Group’s annual budget, plans and financing arrangements, the Directors consider that the Group has adequate resources to continue operating and that it is therefore appropriate to continue to adopt the going concern basis in preparing the Annual Report and Form 20-F.

### Foreign exchange rates

<table>
<thead>
<tr>
<th>Currency</th>
<th>Average 2021</th>
<th>Average 2020</th>
<th>Average 2019</th>
<th>Closing 2021</th>
<th>Closing 2020</th>
<th>Closing 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian dollar</td>
<td>1.832</td>
<td>1.862</td>
<td>1.836</td>
<td>1.863</td>
<td>1.771</td>
<td>1.885</td>
</tr>
<tr>
<td>Brazilian real</td>
<td>7.421</td>
<td>6.616</td>
<td>5.035</td>
<td>7.544</td>
<td>7.100</td>
<td>5.329</td>
</tr>
<tr>
<td>Canadian dollar</td>
<td>1.274</td>
<td>1.720</td>
<td>1.694</td>
<td>1.711</td>
<td>1.741</td>
<td>1.718</td>
</tr>
<tr>
<td>Euro</td>
<td>1.164</td>
<td>1.125</td>
<td>1.140</td>
<td>1.191</td>
<td>1.117</td>
<td>1.180</td>
</tr>
<tr>
<td>Indian rupee</td>
<td>101.702</td>
<td>95.097</td>
<td>89.898</td>
<td>100.684</td>
<td>99.880</td>
<td>94.558</td>
</tr>
<tr>
<td>Japanese yen</td>
<td>151.124</td>
<td>137.017</td>
<td>139.234</td>
<td>155.972</td>
<td>141.131</td>
<td>143.967</td>
</tr>
<tr>
<td>Russian rouble</td>
<td>101.388</td>
<td>92.844</td>
<td>82.623</td>
<td>101.592</td>
<td>101.106</td>
<td>82.282</td>
</tr>
<tr>
<td>US dollar</td>
<td>1.376</td>
<td>1.284</td>
<td>1.277</td>
<td>1.354</td>
<td>1.367</td>
<td>1.325</td>
</tr>
</tbody>
</table>
Regional Review

U.S.
United States

With Vuse approaching value leadership and strong pricing, we are delivering value across our portfolio.

Guy Meldrum
President and CEO (Reynolds American Inc.)

Volume

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>vs 2020</th>
<th>2020</th>
<th>vs 2019</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>units</td>
<td></td>
<td>units</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarettes (bn sticks)</td>
<td>70</td>
<td>-5.0%</td>
<td>73</td>
<td>+0.5%</td>
<td>73</td>
</tr>
<tr>
<td>Other (bn sticks eq)*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Combustibles (bn sticks)</td>
<td>70</td>
<td>-5.0%</td>
<td>73</td>
<td>+0.5%</td>
<td>73</td>
</tr>
<tr>
<td>New Categories:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapour (bn 10ml/pods)</td>
<td>291</td>
<td>+66.7%</td>
<td>174</td>
<td>+69.7%</td>
<td>103</td>
</tr>
<tr>
<td>THP (bn sticks)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Modern Oral (bn pouches)</td>
<td>602</td>
<td>+272%</td>
<td>162</td>
<td>+45.0%</td>
<td>112</td>
</tr>
<tr>
<td>Traditional Oral (bn sticks eq)</td>
<td>7</td>
<td>-6.1%</td>
<td>8</td>
<td>-1.3%</td>
<td>8</td>
</tr>
</tbody>
</table>

* Other includes MYO/RYO.

Revenue

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>vs 2020</th>
<th>2020</th>
<th>vs 2019</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£m</td>
<td>adj at cc</td>
<td>£m</td>
<td>adj at cc</td>
<td>£m</td>
</tr>
<tr>
<td>Combustibles</td>
<td>10,015</td>
<td>+0.9%</td>
<td>9,926</td>
<td>+3.3%</td>
<td>9,957</td>
</tr>
<tr>
<td>New Categories:</td>
<td></td>
<td></td>
<td>9,926</td>
<td>+3.3%</td>
<td>9,957</td>
</tr>
<tr>
<td>Vapour</td>
<td>561</td>
<td>+46.4%</td>
<td>383</td>
<td>+85.1%</td>
<td>+86.1%</td>
</tr>
<tr>
<td>THP</td>
<td>1</td>
<td>-21.8%</td>
<td>1</td>
<td>+0.0%</td>
<td>+0.5%</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>2</td>
<td>-81.5%</td>
<td>10</td>
<td>+13.5%</td>
<td>+14.1%</td>
</tr>
<tr>
<td>Total New Categories</td>
<td>564</td>
<td>+43.0%</td>
<td>394</td>
<td>+81.9%</td>
<td>+82.9%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,077</td>
<td>-4.3%</td>
<td>1,126</td>
<td>+7.0%</td>
<td>+7.6%</td>
</tr>
<tr>
<td>Other</td>
<td>35</td>
<td>+28.6%</td>
<td>27</td>
<td>+4.6%</td>
<td>+5.1%</td>
</tr>
<tr>
<td>Revenue</td>
<td>11,691</td>
<td>+1.9%</td>
<td>11,473</td>
<td>+10.6%</td>
<td>+11.2%</td>
</tr>
</tbody>
</table>

Profit from operations/Operating margin

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>vs 2020</th>
<th>2020</th>
<th>vs 2019</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£m</td>
<td>adj at cc</td>
<td>£m</td>
<td>adj at cc</td>
<td>£m</td>
</tr>
<tr>
<td>Profit from operations</td>
<td>5,566</td>
<td>+11.9%</td>
<td>4,975</td>
<td>+12.8%</td>
<td>+15.5%</td>
</tr>
<tr>
<td>Operating margin (%)</td>
<td>47.6%</td>
<td>+420 bps</td>
<td>42.4%</td>
<td>+50 bps</td>
<td>+150 bps</td>
</tr>
</tbody>
</table>

Revenue by category

- Cigarette value share change: +60 bps
- Owned manufacturing (inc R&D) sites: 7
- Number of employees: 4,405

Key Markets
Our products are available in all regions of the U.S.

Revenue and Profit from Operations

In 2021, reported revenue grew 1.9% to £11,691 million, with 2020 up 10.6% to £11,473 million. Excluding the impact of translational foreign exchange, this was an increase of 9.2% in 2021 (2020: up 11.2%). This was driven, in both years, by pricing (supported by our Revenue Growth Management (RGM) capabilities) in cigarettes, Vapour and Traditional Oral and the continued growth in vapour volume. 2021 also benefited (by an estimated £200 million) from trade inventory movements mainly linked to the timing of price increases and uncertainty about a potential excise increase. This was offset by a decline in combustible volume (lapping a strong comparator period). 2020 volume was positively impacted by resilient consumer demand resulting from the increase in fiscal stimulus, lower gas prices and an extra selling day combined with higher supply chain inventories.

Reported profit from operations increased 11.9% to £5,366 million in 2021 (2020: up 12.8% to £4,975 million). This was driven by the higher revenue (in both years), lower losses from Vuse in 2021, initiatives including marketing spend effectiveness and the benefit from trade inventory movements. This was also driven by lower adjusting items in 2021, related to the ongoing efficiency programmes (Quantum), credits related to the partial buy-out of the pension fund (£35 million) and the finalisation of the dissenting shareholders litigation (£59 million). These were lower than in 2020, which included a £400 million charge related to payment obligations under the state settlement agreements with Florida, Texas, Minnesota and Mississippi for brands previously sold to a third party.

Excluding the adjusting items and the impact of a translational foreign exchange headwind, adjusted profit from operations increased by 9.7% (2020: 15.5%) on a constant currency basis.

New Categories
In 2021, Vuse performed well, gaining significant vapour value share and approaching value leadership, up 760 bps to 32.5% from 24.9% in 2020 and 16.6% in 2019.
Vapour consumable volume increased 67% (2020: up 70%), with revenue increasing 46.4% to £561 million (2020: up 85.1% to £383 million). This was a growth of 56.9% (2020: 86.1% increase), at constant rates of exchange, with pricing on consumables in the second half of 2021 offsetting the roll-over impact of the negative mix from the successful launch of the quad-pack in 2020. The Alto variant now represents over 90% of Vuse revenues in the U.S., up from 83% in 2020 and 50% in 2019.

Industry vapour volumes were up 21.2% in 2021, following a decline of 13.1% in 2020 as the industry recovered from the effects of the EVALI crisis in 2019 and implementation of the flavour regulations in early 2020.

In October 2021, Vuse Solo received the first marketing authorisation from the U.S. FDA as discussed below. We remain confident in the quality of the applications submitted for the rest of our New Category products, which are supported by scientific evidence that the continued marketing of our Vuse and Velo products is appropriate for the protection of public health.

In Modern Oral, volume increased by over 270% (2020: 45% higher) with volume share up 410 bps in 2021. Revenue declined 81.5% (2020: up 13.5%). The performance in 2021 was driven by promotional pricing and the national roll-out of the Velo-branded nicotine pouch products (available in over 110,000 stores), that were acquired in October 2020 from Dryft Sciences, LLC (Dryft). While growing year-on-year, driven by distribution expansion, the Modern Oral segment remains small, representing only 1.6% of total nicotine volume share.

Combustibles

Combustibles revenue was 0.9% higher in 2021 at £10,015 million (2020: up 9.3% to £9,926 million). However, excluding a translational foreign exchange headwind in both years, this was an increase of 8.1% (2020: 9.9% higher) at constant rates of exchange. The growth was driven by strong pricing (with four price increases announced in both 2021 and 2020, supported by our RGM capabilities) which more than offset a decline in volume of 5.0% to 70 billion sticks in 2021 (2020: 73 billion sticks; 0.5% increase). In 2021, the Group benefited from trade inventory movements (mainly linked to the timing of price increases and uncertainty about a potential excise increase) which are expected to unwind in 2022. Excluding this, volume would have been down 7.0%. Industry volume was down 6.5%, driven by rising gas prices and the partial unwinding of last year’s additional supply chain inventories and stronger consumption trends.

Value share of cigarettes increased 60 bps (2020: up 45 bps), driven by our strategic brands (up 80 bps) including Newport and Natural American Spirit. Total volume share declined 40 bps (2020: 10 bps increase) as we focused on value generation from combustibles in 2021.

Delivering on our New Categories

The U.S. business continues its accelerated journey towards A Better Tomorrow™, delivering a year of outstanding results in New Categories.

That success was mainly driven by Vuse – no market share (by value) was up 760 bps to 2020, despite an increasingly competitive environment, and is approaching national market leadership. This was balanced with continued investment and quick learning with Velo in the fast-growing Modern Oral category.

Vuse’s exceptional performance is underpinned by a relentless focus on consumer acquisition and a unique device customisation platform, “Vuse by U”, a leading innovation for adult consumers taking personal expression. Vuse’s adult consumer-centred platform is focused on driving conversion and retention with an expansive portfolio spanning three flavours, across three nicotine levels and three pod pack formats with the introduction of Single and Quad Pods.

Vuse growth in the U.S. has been fuelled by an evolving marketing plan focused on local brand-building plans tailored to the consumer needs in key cities. Vuse is now the value share market leader in 27 states.

Through collaboration with local artists and leveraging the Live Nation partnership and through the Vuse device customisation platform, we have generated significant consumer and media interest. This has all been underpinned by investments in improving data, marketing technology and digital engagement, while the expanding of the vapour pod format options during the year gave consumers more choice.

We have also made progress in improving the brand’s profitability in the U.S. We have focused on value generation, through RGM, while also unlocking cost savings (including in product costs and efficient marketing and trade spend), with the brand achieving profitability in the final quarter of 2021.
Leadership of vapour in Canada demonstrates our resilience in a challenging environment

Luciano Comin
Regional Director

Volume

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 units</th>
<th>2020 units</th>
<th>vs 2020 %</th>
<th>2019 units</th>
<th>vs 2019 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cigarettes (bn sticks)</td>
<td>147</td>
<td>147</td>
<td>+0.1%</td>
<td>152</td>
<td>-3.9%</td>
</tr>
<tr>
<td>Other (bn sticks eq)*</td>
<td>1</td>
<td>2</td>
<td>-7.7%</td>
<td>2</td>
<td>-1.7%</td>
</tr>
<tr>
<td>Combustibles (bn sticks)</td>
<td>148</td>
<td>149</td>
<td>0.0%</td>
<td>154</td>
<td>-3.8%</td>
</tr>
</tbody>
</table>

New Categories:

- Vapour (mn 10ml/pods): 62 (+102% vs 2020), 31 (+118% vs 2019)
- Modern Oral (mn pouches): -100% vs 2020, +142% vs 2019

Revenue

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>vs 2020 %</th>
<th>2019 £m</th>
<th>vs 2019 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustibles</td>
<td>3,435</td>
<td>3,535</td>
<td>-2.8%</td>
<td>3,772</td>
<td>-11.4%</td>
</tr>
<tr>
<td>New Categories:</td>
<td></td>
<td></td>
<td>+4.1%</td>
<td></td>
<td>+1.3%</td>
</tr>
<tr>
<td>Vapour</td>
<td>141</td>
<td>65</td>
<td>+115%</td>
<td>1</td>
<td>+118%</td>
</tr>
<tr>
<td>THP</td>
<td>-</td>
<td>-</td>
<td>-100%</td>
<td>-</td>
<td>-100%</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>-</td>
<td>1</td>
<td>-49.8%</td>
<td>-49.8%</td>
<td>-47.3%</td>
</tr>
<tr>
<td>Total New Categories</td>
<td>141</td>
<td>66</td>
<td>+114%</td>
<td>14</td>
<td>+114%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>225</td>
<td>171</td>
<td>+32.3%</td>
<td>243</td>
<td>-7.2%</td>
</tr>
<tr>
<td>Revenue</td>
<td>3,601</td>
<td>3,772</td>
<td>-11.5%</td>
<td>3,533</td>
<td>+1.4%</td>
</tr>
</tbody>
</table>

Profit from operations/Operating margin

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>vs 2020 %</th>
<th>2019 £m</th>
<th>vs 2019 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit from operations</td>
<td>1,496</td>
<td>1,553</td>
<td>-3.7%</td>
<td>1,589</td>
<td>-2.5%</td>
</tr>
<tr>
<td>Operating margin (%)</td>
<td>39.3%</td>
<td>39.3%</td>
<td>-4.3%</td>
<td>39.3%</td>
<td>-4.3%</td>
</tr>
</tbody>
</table>

-70 bps 27

Cigarette value share change  Owned manufacturing (inc R&D) sites

15,565

Number of employees

Key markets

Argentina, Brazil, Canada, Chile, Colombia, Mexico, Nigeria, South Africa

Revenue and Profit from Operations

In 2021, reported revenue increased 0.8% to £3,801 million (2020: 11.5% decrease to £3,772 million). The reported results were negatively impacted by translational foreign exchange headwinds due to the relative strength of sterling against a number of currencies, particularly the Brazilian real, Argentinian peso, Nigerian naira and Kenyan shilling. Excluding the translational headwind, on a constant currency basis, revenue grew by 7.8% in 2021 (2020: increase of 1.4%), driven by combustibles pricing and growth in New Categories in both years. The lower growth rate in 2020 was due to the negative impact of COVID-19 in that year, as a number of markets implemented temporary restrictions in response to the pandemic, with South Africa in particular restricting the production and sale of tobacco products for a period of five months.

Reported profit from operations fell 3.7% to £1,496 million partly due to the recognition of a £54 million charge related to goodwill in Peru and by the impact of translational foreign exchange on our reported results. In 2020, this was an increase of 29.0% to £1,553 million, with the growth largely from the absence of the £436 million charge in 2019 in relation to the Quebec Class Action. Excluding the adjusting items (largely related to Quantum and Peru) and the impact of foreign exchange in both periods, adjusted profit from operations increased 4.3% (2020: decrease of 2.5%) on a constant currency basis, largely driven by the growth in adjusted revenue. However, in 2021, this was partially offset by transactional foreign exchange headwinds and increased investment in New Categories. In 2020, the higher revenue was more than offset by the impact of COVID-19 which led to supply restrictions in South Africa noted above and additional supply chain costs elsewhere (estimated to be £57 million) to manage the operational volatility.

While not yet back to pre-COVID-19 levels, South Africa has recovered during 2021 and as such the risk of impairment of goodwill has reduced. Please refer to page 209.
New Categories

In 2021, New Categories revenue more than doubled, up 114% to £141 million (2021: up 51.3% to £66 million) driven by the growth of vapour in both years. Having gained value leadership of the total vapour category in Canada in 2020, Vuse consolidated its leadership position with total value share up 34.3 ppts in 2021, having grown 22.2 ppts in 2020. This was driven by the growth of the ePod variant, including the upgraded 2.0 variant. In South Africa, vapour revenue recovered following the suspension, alongside those of cigarettes, between March and August 2020 as part of the country’s COVID-19 response. While this was a headwind in 2020, volume recovered and almost tripled in 2021, supported by the completion of the migration of Twisp to Vuse. In Kenya, we continue to engage with the relevant authorities on the regulatory and fiscal framework to support a commercially sustainable re-entry into the Modern Oral category. We continue to believe that Modern Oral presents an exciting opportunity to offer affordable New Category alternatives* to adult nicotine consumers in emerging markets, given the absence of an electronic device and a pre-existing ritual of oral product consumption in a number of markets.

Combustibles

Combustibles revenue declined 2.8% to £3,435 million (2020: 11.4% decrease to £3,535 million). A translational foreign exchange headwind impacted both years with revenue, on a constant currency basis, up 4.1% in 2021 and 1.3% in 2020. Combustibles pricing in both years, supported by our RGM capabilities, was, in 2021, partially offset by negative mix as volume recovered from the impact of COVID-19 in a number of markets, including in South Africa (impacted by the sales suspension in 2020, with the market still recovering from the growth in illicit trade in 2020) and Colombia. In Brazil, COVID-19 related lockdowns (in 2020 and 2021) and increased border security led to growth in the duty paid industry, with some growth in consumption at the lower end of the market. Having declined by 3.9% in 2020, combustible volume in AmSSA was flat in 2021. Value share declined 70 bps driven by Canada, South Africa, Mexico, and Brazil. This compared to an increase in 2020 of 30 bps.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
Regional Review

ENA
Europe and North Africa

I am delighted that our multi-category approach is delivering excellent results

Johan Vandermeulen
Regional Director

Volume

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 units</th>
<th>vs 2020</th>
<th>2020 units</th>
<th>vs 2019</th>
<th>2019 units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cigarettes (bn sticks)</td>
<td>214</td>
<td>-2.7%</td>
<td>220</td>
<td>-4.2%</td>
<td>230</td>
</tr>
<tr>
<td>Other (bn sticks eq)*</td>
<td>15</td>
<td>-8.7%</td>
<td>16</td>
<td>-2.5%</td>
<td>17</td>
</tr>
<tr>
<td>Combustibles (bn sticks)</td>
<td>229</td>
<td>-3.1%</td>
<td>236</td>
<td>-4.1%</td>
<td>247</td>
</tr>
</tbody>
</table>

New Categories:

- Vapour (mn 10ml/pods)
  - 2021: 173
  - 2020: 133
  - 2019: 108
- THP (bn sticks)
  - 2021: 9.8
  - 2020: 11.5
  - 2019: 13.1
- Modern Oral (mn pouches)
  - 2021: 2,440
  - 2020: 1,667
  - 2019: 1,071
- Traditional Oral (bn sticks eq)
  - 2021: 1
  - 2020: 1
  - 2019: 1

* Other combustibles includes MYO/RYO.

Revenue

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 £m</th>
<th>vs 2020</th>
<th>2020 £m</th>
<th>vs 2019</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustibles</td>
<td>5,024</td>
<td>-6.2%</td>
<td>5,356</td>
<td>-3.4%</td>
<td>5,385</td>
</tr>
<tr>
<td>New Categories:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapour</td>
<td>207</td>
<td>+40.2%</td>
<td>148</td>
<td>+0.4%</td>
<td>147</td>
</tr>
<tr>
<td>THP</td>
<td>341</td>
<td>+150%</td>
<td>136</td>
<td>+143%</td>
<td>111</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>266</td>
<td>+43.9%</td>
<td>185</td>
<td>+58.5%</td>
<td>119</td>
</tr>
<tr>
<td>Total New Categories</td>
<td>814</td>
<td>+73.6%</td>
<td>469</td>
<td>+46.7%</td>
<td>269</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>41</td>
<td>+18.2%</td>
<td>34</td>
<td>+16.2%</td>
<td>29</td>
</tr>
<tr>
<td>Other</td>
<td>122</td>
<td>-8.9%</td>
<td>135</td>
<td>-31.6%</td>
<td>196</td>
</tr>
<tr>
<td>Revenue</td>
<td>6,001</td>
<td>+6.1%</td>
<td>5,994</td>
<td>-1.6%</td>
<td>6,026</td>
</tr>
</tbody>
</table>

Profit from operations/Operating margin

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 £m</th>
<th>vs 2020</th>
<th>2020 £m</th>
<th>vs 2019</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit from operations</td>
<td>1,885</td>
<td>-3.9%</td>
<td>1,962</td>
<td>+19.0%</td>
<td>1,590</td>
</tr>
<tr>
<td>Operating margin (%)</td>
<td>31.4%</td>
<td>-130 bps</td>
<td>32.7%</td>
<td>+560 bps</td>
<td>-160 bps</td>
</tr>
</tbody>
</table>

Key markets

Algeria, Belgium, Bulgaria, Czech Republic, Denmark, Egypt, France, Germany, Italy, Kazakhstan, Morocco, Netherlands, Poland, Romania, Russia, Spain, Sweden, Switzerland, Turkey, Ukraine, UK

Revenue and Profit from Operations

Reported revenue in 2021 was marginally higher than 2020 (2020: down 1.6%) as good pricing in Combustibles and growth in New Categories revenue (2021: up 80%, 2020: up 50%) in both years was largely offset by lower combustible volume (down 3.1% in 2021 and 4.1% in 2020) and a translational foreign exchange headwind of 7.2% (2020: 3.7% headwind).

Excluding the impact of adjusting items (that affected revenue in 2019) and the impact of currency, revenue grew 7.3% on an adjusted constant rates basis (2020: up 2.1%).

Reported profit from operations declined by 3.9% to £1,885 million as the strong New Category revenue growth, in combination with tight control of overheads and Quantum cost savings, were more than offset by incremental investment in New Categories and foreign exchange headwinds.

In 2020, reported profit from operations increased 19% to £1,962 million, largely due to the absence of the £202 million charge in respect of the Russian excise dispute that impacted the prior year (2019: down 13%). Excluding the impact of currency and adjusting items (in respect of Quantum and the factory rationalisation programme), adjusted profit from operations at constant rates was down 1.0% in 2021 (2020: down 2.4%) as the region continued to invest in New Categories.

New Categories

In 2021, revenue from Vapour was up 40.2% reflecting strong volume growth (up 30%), driven by an increase in industry volume, and higher consumables pricing. In 2020, revenue from Vapour was marginally higher than 2019 as the impact of COVID-19 on our vape stores and an increase in marketing investment to drive consumer activation (recognised as a deduction to revenue in line with IFRS 15), largely offset higher volume (up 23%).

Revenue by category

<table>
<thead>
<tr>
<th>Category</th>
<th>2021 £m</th>
<th>vs 2020</th>
<th>2020 £m</th>
<th>vs 2019</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustibles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Categories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modern Oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total New Categories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traditional Oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cigarette value share change

-20 bps 20

Owned manufacturing (inc R&D) sites

22,333

Number of employees
Vype was migrated to Vuse, with Vuse growing across the region, extending its value leadership position in all key markets. In the UK and France, trade margin optimisation, together with growth ahead of incremental marketing investment led to a reduced drag on regional profit from operations. In 2021, THP volume grew by 195% (2020: up 203%), with revenue 150% higher at £341 million (2020: up 143% to £136 million). This was driven by the roll-out of glo Hyper, which has now been launched in 18 markets in the region. glo continued to increase volume share of the THP category in key markets for 2021, including in:

- Russia, reaching 19.3% up 1,070 bps on 2020;
- Italy, increasing by 870 bps to 12.8%;
- Ukraine, being 20.9%, an increase of 990 bps; and
- Romania, 530 bps higher than 2020 at 22.1%

Hyper also continued to make good progress in Kazakhstan, Poland, Egypt, the Czech Republic and across other smaller ENA launch markets.

From 1 January 2022, the markets of North Africa (being Algeria, Egypt, Libya, Morocco, Sudan and Tunisia) will be reported under APME. From that date, ENA will be known as Europe.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

In 2021, Modern Oral revenue grew 44% (2020: up 59%), led by 46% volume growth (2020: 56% increase). In both years, the Group continued to grow its volume share of the total oral category in more established markets such as Sweden and Norway, while also building the overall category, and our volume share of Modern Oral itself, in Denmark and Switzerland.

In Germany, sales of Modern Oral were suspended during the year, pending engagement with authorities regarding the classification of tobacco-free nicotine pouches.

In January 2021, we pilot-launched our first CBD vaping product, Vuse CBD Zone. This allowed us, for the first time, to offer adult consumers a range of high-quality CBD vaping products from our trusted, global brand, Vuse, gaining valuable insights into the product and consumer behaviour.

**Combustibles**

In 2021, revenue was 6.2% lower, compared to a decline of 3.4% in 2020. Good price/mix in both years (up 4% in 2021 and 5% in 2020) was more than offset by the impact of lower combustible volume, down 3.1% in 2021 and 4.1% in 2020, and the foreign exchange headwind described earlier. At constant rates of exchange, revenue increased 1.1% (2020: 0.5%).

The decrease in combustible volume in 2021 was driven by lower volume in Ukraine, Russia and Kazakhstan, in part due to industry contraction in those markets. In 2020, the decline in combustible volume was despite higher volume in Turkey (driven by Kent and the local portfolio) as this was more than offset by industry volume contraction in a number of markets, partly due to COVID-19.

Cigarette volume share was down 20 bps in 2021, while 2020 was in line with 2019. Cigarette volume share declined 30 bps (2020: up 30 bps) as growth in Turkey, Germany and the Czech Republic was more than offset by reductions in Russia, Poland, France, Italy, Spain, Romania, the UK, Ukraine and Denmark. The growth in 2020 was largely driven by Russia and Turkey, partly offset by lower volume share in France, Spain, the Netherlands, Denmark, Switzerland and the UK.

In 2020, menthol bans were introduced in Turkey, the UK and the EU. The Group has a long-standing track record of managing regulatory shifts. In 2021, the Group did not experience a material impact from the introduction of the new regulations.

---

In 2021, Modern Oral revenue grew 44% (2020: up 59%), led by 46% volume growth (2020: 56% increase). In both years, the Group continued to grow its volume share of the total oral category in more established markets such as Sweden and Norway, while also building the overall category, and our volume share of Modern Oral itself, in Denmark and Switzerland.

In Germany, sales of Modern Oral were suspended during the year, pending engagement with authorities regarding the classification of tobacco-free nicotine pouches.

In January 2021, we pilot-launched our first CBD vaping product, Vuse CBD Zone. This allowed us, for the first time, to offer adult consumers a range of high-quality CBD vaping products from our trusted, global brand, Vuse, gaining valuable insights into the product and consumer behaviour.

**Combustibles**

In 2021, revenue was 6.2% lower, compared to a decline of 3.4% in 2020. Good price/mix in both years (up 4% in 2021 and 5% in 2020) was more than offset by the impact of lower combustible volume, down 3.1% in 2021 and 4.1% in 2020, and the foreign exchange headwind described earlier. At constant rates of exchange, revenue increased 1.1% (2020: 0.5%).

The decrease in combustible volume in 2021 was driven by lower volume in Ukraine, Russia and Kazakhstan, in part due to industry contraction in those markets. In 2020, the decline in combustible volume was despite higher volume in Turkey (driven by Kent and the local portfolio) as this was more than offset by industry volume contraction in a number of markets, partly due to COVID-19.

Cigarette volume share was down 20 bps in 2021, while 2020 was in line with 2019. Cigarette volume share declined 30 bps (2020: up 30 bps) as growth in Turkey, Germany and the Czech Republic was more than offset by reductions in Russia, Poland, France, Italy, Spain, Romania, the UK, Ukraine and Denmark. The growth in 2020 was largely driven by Russia and Turkey, partly offset by lower volume share in France, Spain, the Netherlands, Denmark, Switzerland and the UK.

In 2020, menthol bans were introduced in Turkey, the UK and the EU. The Group has a long-standing track record of managing regulatory shifts. In 2021, the Group did not experience a material impact from the introduction of the new regulations.

---

In 2021, Modern Oral revenue grew 44% (2020: up 59%), led by 46% volume growth (2020: 56% increase). In both years, the Group continued to grow its volume share of the total oral category in more established markets such as Sweden and Norway, while also building the overall category, and our volume share of Modern Oral itself, in Denmark and Switzerland.

In Germany, sales of Modern Oral were suspended during the year, pending engagement with authorities regarding the classification of tobacco-free nicotine pouches.

In January 2021, we pilot-launched our first CBD vaping product, Vuse CBD Zone. This allowed us, for the first time, to offer adult consumers a range of high-quality CBD vaping products from our trusted, global brand, Vuse, gaining valuable insights into the product and consumer behaviour.

**Combustibles**

In 2021, revenue was 6.2% lower, compared to a decline of 3.4% in 2020. Good price/mix in both years (up 4% in 2021 and 5% in 2020) was more than offset by the impact of lower combustible volume, down 3.1% in 2021 and 4.1% in 2020, and the foreign exchange headwind described earlier. At constant rates of exchange, revenue increased 1.1% (2020: 0.5%).

The decrease in combustible volume in 2021 was driven by lower volume in Ukraine, Russia and Kazakhstan, in part due to industry contraction in those markets. In 2020, the decline in combustible volume was despite higher volume in Turkey (driven by Kent and the local portfolio) as this was more than offset by industry volume contraction in a number of markets, partly due to COVID-19.

Cigarette volume share was down 20 bps in 2021, while 2020 was in line with 2019. Cigarette volume share declined 30 bps (2020: up 30 bps) as growth in Turkey, Germany and the Czech Republic was more than offset by reductions in Russia, Poland, France, Italy, Spain, Romania, the UK, Ukraine and Denmark. The growth in 2020 was largely driven by Russia and Turkey, partly offset by lower volume share in France, Spain, the Netherlands, Denmark, Switzerland and the UK.

In 2020, menthol bans were introduced in Turkey, the UK and the EU. The Group has a long-standing track record of managing regulatory shifts. In 2021, the Group did not experience a material impact from the introduction of the new regulations.
Our New Categories continue to grow despite difficult trading conditions in key markets.

Michael (Mihovil) Dijanosic
Regional Director

Cigarettes (bn sticks)

<table>
<thead>
<tr>
<th>2021 units</th>
<th>vs 2020 %</th>
<th>2020 units</th>
<th>vs 2019 %</th>
<th>2019 units</th>
</tr>
</thead>
<tbody>
<tr>
<td>206</td>
<td>+4.6%</td>
<td>198</td>
<td>-7.3%</td>
<td>213</td>
</tr>
</tbody>
</table>

Other (bn sticks eq)*

| 2         | -14.1%    | 2          | +3.3%     | 2          |

Combustibles (bn sticks)

| 208        | +4.4%     | 200        | -7.2%     | 215        |

New Categories:

- **Vapour** (mn 10ml/pods)
  - 2021: 9
  - 2020: 6
  - 2019: 1
  - vs 2020: +65.6%

- **THP** (bn sticks)
  - 2021: 9
  - 2020: 7
  - 2019: 8
  - vs 2020: +26.5%

- **Modern Oral** (mn pouches)
  - 2021: 254
  - 2020: 200
  - 2019: 213
  - vs 2020: +4.4%

- **New Categories**: Vapour (mn 10ml/pods)
  - 2021: 9
  - 2020: 6
  - 2019: 1
  - vs 2020: +65.6%

- **THP** (bn sticks)
  - 2021: 9
  - 2020: 7
  - 2019: 8
  - vs 2020: +26.5%

- **Modern Oral** (mn pouches)
  - 2021: 254
  - 2020: 200
  - 2019: 213
  - vs 2020: +4.4%

- **New Categories**: Vapour (mn 10ml/pods)
  - 2021: 9
  - 2020: 6
  - 2019: 1
  - vs 2020: +65.6%

- **THP** (bn sticks)
  - 2021: 9
  - 2020: 7
  - 2019: 8
  - vs 2020: +26.5%

- **Modern Oral** (mn pouches)
  - 2021: 254
  - 2020: 200
  - 2019: 213
  - vs 2020: +4.4%

- **New Categories**: Vapour (mn 10ml/pods)
  - 2021: 9
  - 2020: 6
  - 2019: 1
  - vs 2020: +65.6%

- **THP** (bn sticks)
  - 2021: 9
  - 2020: 7
  - 2019: 8
  - vs 2020: +26.5%

- **Modern Oral** (mn pouches)
  - 2021: 254
  - 2020: 200
  - 2019: 213
  - vs 2020: +4.4%

Other combustibles includes MYO/RYO.

Revenue

<table>
<thead>
<tr>
<th>2021 £m</th>
<th>vs 2020 %</th>
<th>2020 £m</th>
<th>vs 2019 %</th>
<th>2019 £m</th>
</tr>
</thead>
</table>

- **Combustibles**
  - 2021: 3,555
  - 2020: -9.6%
  - 2019: -2.3%

- **New Categories**:
  - **Vapour**
    - 2021: 18
    - 2020: +26.0%
    - 2019: +255%
  - **THP**
    - 2021: 511
    - 2020: +2.8%
    - 2019: +13.0%
  - **Modern Oral**
    - 2021: 6
    - 2020: +179%
    - 2019: +13.0%

- **Total New Categories**
  - 2021: 535
  - 2020: +4.2%
  - 2019: +14.2%

- **Other**
  - 2021: 101
  - 2020: +13.0%
  - 2019: +20.1%

- **Total Revenue**
  - 2021: 4,191
  - 2020: -7.6%
  - 2019: 0.0%

Profit from operations/Operating margin

<table>
<thead>
<tr>
<th>2021 £m</th>
<th>vs 2020 %</th>
<th>2020 £m</th>
<th>vs 2019 %</th>
<th>2019 £m</th>
</tr>
</thead>
</table>

- **Profit from operations**
  - 2021: 1,287
  - 2020: -12.6%
  - 2019: -1.1%

- **Operating margin (%)**
  - 2021: 30.7%
  - 2020: -170 bps
  - 2019: -40 bps

Revenue by category

- **Cigarette volume share change**
  - 2021: -20 bps

- **Number of employees**
  - 2021: 9,747

Key markets

- Australia, Bangladesh, Indonesia, Japan, Malaysia, Middle East (inc KSA), New Zealand, Pakistan, South Korea, Taiwan, Vietnam

Revenue and Profit from Operations

Reported revenue declined 7.6% to £4,191 million (2020: declined 11.9% to £4,537 million).

The performance in 2021 was impacted by the structural excise changes in Australia and New Zealand, and competitive pricing dynamics in Australia (in combination, an estimated headwind of £260 million), and negative geographic mix due to volume share growth and recovery from COVID-19 in emerging markets, leading to a growth in combustible volume of 4.4% (largely due to Bangladesh, Vietnam and Pakistan).

Revenue in 2021 was also negatively impacted by the sale of the Group’s operations in Iran, part way through the year.

In 2020, the decline in revenue was largely driven by lower cigarette volume (which fell 7.3%). This was partly due to the negative impact of COVID-19 on GTR and other markets in the region and the impact of excise increases and minimum pricing in Indonesia. Revenue in 2020 was also impacted by the excise harmonisation of THP in Japan and a £50 million charge in respect of the withdrawal of glo Sens.

Excluding the impact of translational foreign exchange, in 2021 revenue was in line with 2020 (2020: declined 9.9%) on an adjusted constant rate basis.

Reported profit from operations declined 12.6% to £1,287 million, driven by the lower revenue and due to the £358 million charge (mainly in respect of foreign exchange previously charged to other comprehensive income) recognised in respect of the sale of the Group’s operations in Iran, and costs associated with the withdrawal from Myanmar.

In 2020, reported profit from operations was a decrease of 16.0% to £1,472 million, as the impact of COVID-19 in a number of markets including GTR, the recognition of costs related to the ongoing factory rationalisation programme (principally in Southeast Asia), an impairment in goodwill in respect of the Group’s performance in Malaysia (£197 million) and unfavourable foreign exchange movements more than offset the efficiencies realised through Quantum.
Excluding adjusting items in 2021 (largely related to Iran, Myanmar and Quantum) and the impact of translational foreign exchange, adjusted profit from operations at constant rates of exchange declined 1.1% in 2021 (2020: fell 7.3%), driven by the reduction in revenue and continued investment in New Categories.

**New Categories**

Total revenue from New Categories increased 4.2% to £535 million (2020: declined 24.0% to £514 million).

In 2021, this was driven by a 28.5% increase in THP consumable volume to 9.3 billion sticks, compared to a decline of 8.5% to 7.4 billion sticks in 2020. 2021 was underpinned by the success of glo Hyper (the first-to-world THP that uses induction heating technology to provide a step change in taste delivery leading to an increase in consumer satisfaction, driven by 30% more tobacco, faster heating and a boost function), launched in 2020. 2020 was impacted by excise harmonisation affecting the industry and a strong comparator period (2019) that included the launch of glo Pro, glo Nano and glo Sens.

Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

In Japan, the largest THP market in the world, glo is the fastest growing THP brand (by volume), with volume share increasing to 6.8% in 2021, up 140 bps, maintaining the momentum of 2020 which was up 50 bps on 2019.

Our Modern Oral pilot launches in emerging markets, including in Pakistan and Indonesia, continue to deliver valuable insights, as we roll out in key urban markets. We believe that Modern Oral is an exciting longer-term opportunity to commercialise reduced-risk products* by offering affordable New Category alternatives to adult nicotine consumers.

**Combustibles**

Revenue from combustibles declined 9.6% to £3,555 million (2020: down 10.3% to £3,935 million), or by 2.3% (2020: down 7.7%) at constant rates of exchange.

In 2021, this was despite an increase in combustible volume (up 4.4%) as emerging markets recovered from COVID-19. However, this led to a negative geographic mix which, combined with structural excise changes in Australia and New Zealand and competitive pricing dynamics in Australia (totalling approximately £260 million) and the negative impact of the sale of operations in Iran part way through the year, drove revenue down.

In 2021, value share decreased 20 bps (2020: up 10 bps), with volume share up 20 bps (2020: 55 bps higher), as volume share gains (including in Bangladesh, Japan, Pakistan and Taiwan) more than offset losses in Indonesia (as the Group drove for value growth with pricing ahead of the industry) and Saudi Arabia.

In 2020, pricing in Australia and Pakistan was more than offset by a 7.2% decline in combustible volume. Higher volume in Bangladesh was more than offset by the impact of COVID-19 in a number of markets, notably within GTR, an increase in local taxes and the minimum retail price compliance in Indonesia, and the continued increase in illicit trade in Pakistan (following an excise-led price increase in 2019).
Overview
The principal risks that may affect the Group are set out on the following pages. Each risk is considered in the context of the Group’s strategy and business model, as set out in this Strategic Report on pages 16 to 19, and 26 to 28. On the following pages is a summary of each principal risk and its potential impact. Clear accountability is attached to each risk through the risk owner. BAT define the principal risks as those assessed with a high impact and probable likelihood. Additionally, the risks “Inability to commercialise and deliver New Categories”, “Litigation”, “Solvency and liquidity” are also recognised as principal risks; even though they are not assessed as having high impact and probable likelihood, they are material to the Group and the delivery of its strategic objectives.

This section focuses on those risks that the Directors believe to be the principal risks to the Group. Not all of these risks are within the control of the Group and other risks besides those listed may affect the Group’s performance. Some risks may be unknown at present. Other risks, currently regarded as less material, could become material in the future.

The risks listed in this section should be considered in the context of the Group’s internal control framework. This is described in the section on risk management and internal control in the corporate governance statement on pages 125 to 126. This section should also be read in the context of the cautionary statement on page 352.

A summary of all the risk factors (including the principal risks) which are monitored by the Board through the Group’s risk register is set out in the Additional Disclosures section on pages 317 to 339.
**Risks**

**Competition from illicit trade**

Increased competition from illicit trade and illegal products – either local duty evaded, smuggled, counterfeits, or non-regulatory compliant, including products diverted from one country to another.

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium-term</td>
<td>Erosion of goodwill, with lower volumes and/or increased operational costs (e.g. track and trace costs) and reduced profits. Reduced ability to take price increases.</td>
<td>Society</td>
</tr>
<tr>
<td></td>
<td>Investment in trade marketing and distribution is undermined and the product is commoditised.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Counterfeit products (especially in New Categories) and other illicit products could harm consumers, damaging goodwill, and/or the category (with lower volumes and reduced profits), potentially leading to misplaced claims against BAT, further regulation and a failure to deliver the corporate harm reduction objective. Breach of legislation, criminal offences, contract breaches under the EU Cooperation Agreement, allegations of facilitating smuggling and reputational damage, including negative perceptions of our governance and our ESG credentials.</td>
<td></td>
</tr>
</tbody>
</table>

**Geopolitical tensions**

Geopolitical tensions, civil unrest, economic policy changes, global health crises, terrorism and organised crime have the potential to disrupt the Group’s business in multiple markets.

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium-term</td>
<td>Potential injury or loss of life, loss of assets and disruption to supply chains and normal business processes. Increased costs due to more complex supply chain and security arrangements and/or the cost of building new facilities or maintaining inefficient facilities. Lower volumes as a result of not being able to trade in a country. Higher taxes or other costs of doing business as a foreign company or the loss of assets as a result of nationalisation. Reputational damage, including negative perceptions of our governance and protection of our people and our ESG credentials.</td>
<td>Society, Employees</td>
</tr>
</tbody>
</table>

93
Group Principal Risks

Continued

Tobacco, New Categories and other regulation interrupts growth strategy

The enactment of, proposals for, or rumours of, regulation that significantly impairs the Group’s ability to communicate, differentiate, market or launch its products, and/or the lack of appropriate regulation for New Categories.

Impact

A lack of acceptance or rejection of tobacco harm reduction as a tobacco control policy could prevent a balanced regulatory framework for New Categories.

Restricted ability to sell and communicate New Categories could lead to failure of the harm reduction objective and loss of confidence in the Group’s ESG performance.

Inappropriate regulations for New Categories (e.g. pharma or food) or total bans of tobacco and/or New Categories products in certain markets.

Reduced ability to make scientific claims and compete in future product categories and make new market entries.

Erosion of brand value through commoditisation and the inability to launch innovations may negatively affect our ability to generate value growth.

Regulation with respect to bans or severe restrictions on menthol flavours, product design & features and nicotine levels may adversely impact individual brand portfolios.

Reduced consumer acceptability of new product specifications, leading to consumers seeking alternatives in illegal markets or irresponsible operators exploiting regulatory loopholes.

Shocks to share price on rumours, the announcement or enactment of restrictive regulation (e.g. sales ban to future generations).

Increased scope and severity of compliance regimes in new regulation (e.g. Extended Producer Responsibility (EPR) schemes) leading to higher costs, greater complexity and potential reputational damage or fines for breach, including inadvertent breach.

Please refer to pages 325 to 327 for details of tobacco and nicotine regulatory regimes under which the Group’s businesses operate.
Litigation

Product liability, regulatory or other significant cases (including investigations) may be lost or settled resulting in a material loss or other consequence.

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic Impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium/Long-term</td>
<td>-</td>
<td>Shareholders</td>
</tr>
</tbody>
</table>

Impact

Damages and fines, negative impact on reputation (including ESG credentials), disruption and loss of focus on the business.

Consolidated results of operations, cash flows and financial position could be materially affected by an unfavourable outcome or settlement of pending or future litigation, criminal prosecution or other contentious action.

Inability to sell products as a result of patent infringement action may restrict growth plans and competitiveness.

Potential share price impact.

Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.

Significant increases or structural changes in tobacco, nicotine and New Categories related taxes

The Group is exposed to unexpected and/or significant increases or structural changes in tobacco, nicotine and New Categories related taxes in key markets.

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic Impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium/Long-term</td>
<td>-</td>
<td>Consumers, Society</td>
</tr>
</tbody>
</table>

Impact

Consumers reject the Group’s legitimate tax-paid products for products from illicit sources or cheaper alternatives.

Reduced legal industry volumes.

Reduced sales volume and/or portfolio erosion.

Partial absorption of excise increases leading to lower profitability.
Group Principal Risks

Group Principal Risks
Continued

Inability to develop, commercialise and deliver the New Categories strategy

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic Impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium/Long-term</td>
<td>New Categories</td>
<td>Shareholders</td>
</tr>
</tbody>
</table>

**Risk of not capitalising on the opportunities in developing and commercialising successful, safe and consumer-appealing innovations.**

**Impact**
Failure to deliver Group strategic imperative, 2025 growth ambition and 2030 consumer targets.
Potentially missed opportunities, unrecoverable costs and/or erosion of brand, with lower volumes and reduced profits.
Reputational damage and recall costs may arise in the event of defective product design or manufacture.
Loss of market share due to non-compliance of product portfolio with regulatory requirements.
Loss of investor confidence in ESG performance.
Failure to deliver our corporate purpose of harm reduction.

**Injury, illness or death in the workplace**

The risk of injury, death or ill health to employees and those who work with the business is a fundamental concern of the Group and can have a significant effect on its operations.

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic Impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term</td>
<td>Incapacitation</td>
<td>Employees</td>
</tr>
</tbody>
</table>

**Impact**
Serious injuries, ill health, disability or loss of life suffered by employees and the people who work with the Group.
Exposure to civil and criminal liability and the risk of prosecution from enforcement bodies and the cost of associated legal costs, fines and/or penalties.
Interruption of Group operations if issues are not addressed immediately.
High staff turnover or difficulty recruiting employees if perceived to have a poor Environment, Health and Safety (EHS) record.
Reputational damage to the Group.

**Disputed taxes, interest and penalties**

The Group may face significant financial penalties, including the payment of interest, in the event of an unfavourable ruling by a tax authority in a disputed area.

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Strategic Impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium-term</td>
<td>New Categories</td>
<td>Shareholders</td>
</tr>
</tbody>
</table>

**Impact**
Significant fines and potential legal penalties.
Disruption and loss of focus on the business due to diversion of management time.
Impact on profit and dividend.

*Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.*
Solvency and liquidity

Liquidity (access to cash and sources of finance) is essential to maintaining the Group as a going concern in the short term (liquidity) and medium term (solvency).

<table>
<thead>
<tr>
<th>Time frame</th>
<th>Strategic impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium-term</td>
<td>New Categories, Combinations</td>
<td>Shareholders</td>
</tr>
</tbody>
</table>

Impact

Inability to fund the business under the current capital structure resulting in missed strategic opportunities or inability to respond to threats.

Decline in our creditworthiness and increased funding costs for the Group.

Requirement to issue equity or seek new sources of capital.

Reputational risk of failure to manage the financial risk profile of the business, resulting in an erosion of shareholder value reflected in an underperforming share price.

Foreign exchange rate exposures

The Group faces translational and transactional foreign exchange (FX) rate exposure for earnings/cash flows from its global businesses.

<table>
<thead>
<tr>
<th>Time frame</th>
<th>Strategic impact</th>
<th>Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short/Medium-term</td>
<td>New Categories, Combinations</td>
<td>Shareholders</td>
</tr>
</tbody>
</table>

Impact

Fluctuations in FX rates of key currencies against sterling introduce volatility in reported earnings per share (EPS), cash flow and the balance sheet driven by translation into sterling of our financial results and these exposures are not normally hedged.

The dividend may be impacted if the payout ratio is not adjusted.

Differences in translation between earnings and net debt may affect key ratios used by credit rating agencies.

Volatility and/or increased costs in our business, due to transactional FX, may adversely impact financial performance.

The Strategic Report was approved by the Board of Directors on 10 February 2022 and signed on its behalf by Paul McCrory, Company Secretary.
Dear Shareholder

As your incoming Chairman, I’ve spent 2021 immersing myself fully in the work and culture of the Board and wider organisation, building on my prior experience as one of your Non-Executive Directors. My sentiments are unchanged: this is an outstanding organisation that is fully committed to realising its corporate purpose of building A Better Tomorrow™.

I’m grateful to my predecessor, Richard Burrows, the Board and the management team, who have recognised that achieving this purpose is predicated on a consumer-centric strategy and empowering ethos. Our ambitious sustainability agenda, strong corporate governance, and robust control environment underpin the delivery of our corporate purpose more so than ever.

Strategic focus

We are clear on, and delivering against, our three commercial priorities of combustible value growth; step-change in New Categories; and simplifying the commercial priorities of combustible value growth; step-change in New Categories; and simplifying the commercial priorities of combustible value growth; step-change in New Categories; and simplifying the commercial priorities of combustible value growth; step-change in New Categories; and simplifying the commercial priorities of combustible value growth; step-change in New Categories; and simplifying

With regard to our new longer-term active capital allocation framework, we are growing the dividend and have announced a £2 billion share repurchase programme for 2022.

Action on climate change is a vital pillar of our sustainability agenda, and momentum in this area must be maintained. The Board has reviewed progress against the glidepath towards achieving the Group’s commitment to net zero value chain emissions by 2050. This is also the first year we report to you in full alignment with the TCFD framework.

Given the importance of the sustainability agenda to our strategy, we extended the scope of external assurance of our reported ESG metrics this year (discussed on page 126) and our Audit Committee’s terms of reference were revised to formalise its oversight role in this area (see page 121). This enhanced assurance is something our stakeholders and society are rightly coming to expect as part of good corporate governance.

Culture and values

The Board recognises its role in shaping and overseeing Group culture and values. Acting with integrity is an important part of our ethos, and the Board ensures that embedding integrity across our business practices remains a priority.

In January 2022, we launched our revised Standards of Business Conduct (SoBC) and Supplier Code of Conduct (discussed on page 110). Regular evolution of these long-standing policies keeps them in step with our strategy, ethos, external requirements and stakeholder expectations.

These policies mandate responsible business practices without compromise, and the Company takes seriously any non-compliance with our standards or our legal obligations. As we accelerate our multi-category platform initiatives, I firmly believe these standards foster sustainable growth. You can read about our SoBC and Delivery with Integrity programme on page 56.

Stakeholder engagement

We had an active shareholder and investor engagement programme in 2021.

I met with a number of shareholders in the year, and the Remuneration Committee Chair has engaged extensively on our new Directors’ Remuneration Policy. My fellow Board members and I look forward to further dialogue with you ahead of the 2022 AGM, which we plan to hold in person subject to prevailing guidance at the time.

We also listen to the perspectives of our wider stakeholders and we review how we engage with them across the Group, which you can read about on pages 106 to 109.

Our people

The continuing resilience and commitment of our people to overcome the challenges of COVID-19 has been inspirational to the Board. Their safety and well-being remains our top priority, and we devote time to satisfy ourselves that the right support is available and is responsive to change.

The Board maintains effective engagement with our people worldwide through a range of channels (discussed at page 108).

Board efficacy

While much of the Board’s interaction remained virtual in 2021, we have operated effectively and engaged consistently with management and staff throughout the year.

This year, I led an internal evaluation of the Board, its Committees and each individual Director, set out on page 114. The Board considers that it continues to function effectively and its working relationships with its Committees continue to be sound.

I’m confident that the corporate governance framework that I now oversee as your Chairman enables the Group’s strategic objectives. On behalf of the Board, I confirm that we believe that this combined Annual Report and Form 20-F is fair, balanced and understandable, and presents the information necessary to assess the Company’s position, performance, business model and strategy.

Luc Jobin
Chairman
Throughout the year ended 31 December 2021, we applied the Principles of the UK Corporate Governance Code 2018. The Company was compliant with all provisions of the Code during the year.

The Board considers that this Annual Report and Form 20-F, and notably this Governance section, provides the information shareholders need to evaluate how we have complied with our obligations under the Code.

Pages noted opposite refer to particular discussion on the application of Principles of the Code in this Annual Report and Form 20-F.

For reference, we prepare a separate voluntary annual compliance report by reference to each Principle and Provision of the Code, available at bat.com/governance.

Disclosure guidance and transparency rules
We comply with the Disclosure Guidance and Transparency Rules requirements for corporate governance statements by virtue of the information included in this section, together with the information contained in the Other Information section.

The UK Corporate Governance Code 2018 is available at frc.org.uk.

US corporate governance
As a result of the listing of the Company’s American Depositary Shares (ADSs) on the NYSE, the Company is required to meet certain NYSE requirements relating to corporate governance matters.

Certain exceptions to these requirements apply to the Company as a foreign private issuer. For details of the significant differences between the NYSE requirements and the Company’s practices, please see page 349.
Luc Jobin Chairman (62)

Jack Bowles Chief Executive (58)

Tadeu Marroco Finance and Transformation Director (56)

Karen Guerra Non-Executive Director (65)

Dr Marion Helmes Non-Executive Director (56)

Sue Farr Non-Executive Director (65)

Savio Kwan Non-Executive Director (73)

Holly Keller Koepele Non-Executive Director (63)

Savio brings significant business leadership experience to the Board, together with a deep knowledge of Greater China and Asia, an important region for the Group.

Relevant skills and contribution to the Board: Savio’s extensive international operational and financial management experience in a range of industry sectors enables her to make important contributions to the Board.

External appointments: Co-Founder and CEO of A&K Consulting Co Ltd; Non-Executive Director of the Alibaba Hong Kong Entrepreneur Fund and Crossborder Innovative Ventures International Limited; Non-Executive Director and Advisory Board member of Hony Financial; Independent Non-Executive Director of GOGOX and Southern England Wines Ltd.

Nationality: British

Appointed: January 2014

Experience: During his extensive career Savio has worked broadly in technology for General Electric, BTR plc and Alibaba Group, China’s largest internet business, where he was both Chief Operating Officer and, later, a Non-Executive Director.

Relevant skills and contribution to the Board: Savio brings significant business leadership experience to the Board, together with a deep knowledge of Greater China and Asia, an important region for the Group.

External appointments: Co-Founder and CEO of A&K Consulting Co Ltd; Non-Executive Director of the Alibaba Hong Kong Entrepreneur Fund and Crossborder Innovative Ventures International Limited; Non-Executive Director and Advisory Board member of Hony Financial; Independent Non-Executive Director of GOGOX and Southern England Wines Ltd.

Nationality: Brazilian

Appointed: August 2019

Experience: Tadeu joined the Group in Brazil in 1992 and joined the Management Board as Director, Business Development in 2014, later becoming Regional Director, Western Europe in 2016, then Regional Director, Europe and North Africa in January 2018. He was appointed Director, Group Transformation in January 2019 and, in addition to this role, he was appointed Deputy Finance Director in March 2019, before joining the Board as Finance Director in August 2019. As Finance and Transformation Director, Tadeu is responsible for effective leadership and delivery of the Group’s Quest transformation programme to accelerate delivery of Group strategy.

Relevant skills and contribution to the Board: Tadeu brings broad experience gained in various national, regional and global finance and general leadership roles, through his previous roles across the Group. These experiences make Tadeu particularly well-placed to contribute to the Group’s transformation and broader strategic agenda.

External appointments: No external appointments.

Nationality: American

Appointed: July 2017

Experience: In April 2018, Holly was a Senior Advisor to Corsair Capital LLC, where she had previously served as Managing Partner and Co-Head of Infrastructure from 2015 until her retirement in 2017. From 2010 to 2015, she served as Co-Head of CIT Infrastructure Investors and prior to 2010 she held financial and executive management roles with American Electric Power Company, Inc. and Consolidated Natural Gas Company. Holly previously served as an independent Non-Executive Director of Reynolds American Inc. from 2005 until its acquisition by the Group.

Relevant skills and contribution to the Board: Holly’s extensive international operational and financial management experience in a range of industry sectors enables her to make important contributions to the Board.

External appointments: Non-Executive Director of Fuber Entertainment plc; Director and Chair of the Governance Committee of AES Corporation; and Director of Arch Coal Inc.

Nationality: German

Appointed: August 2016 Experience: Marion has held a variety of executive roles, including Chief Financial Officer positions at Celestis, Q-Cells and ThyssenKrupp Elevator Technology and, more recently, she has served as a member of a variety of supervisory boards.

Relevant skills and contribution to the Board: Marion brings significant financial expertise and operational experience gained at an international level, having spent her working life managing businesses across Europe, the Americas and Asia. Her experience as a member of various supervisory boards enables Marion to bring a range of insights to the Board’s discussions.

External appointments: Vice Chairwoman of the Supervisory Board and Co-Chairwoman of the Presiding and Nomination Committee of ProSwasth.in; Trustee of Trustee Board member and Chairman of the Audit Committee of Siemens Healthcare AG and independent director of LON Don Q (nominated for election on 5 May 2022).

Nationality: French

Appointed: Chief Executive since April 2019; Executive Director since January 2019.

Experience: Jack joined the Group in 2004 and was appointed as Chairman of British American Tobacco France in 2005, before becoming Managing Director of British American Tobacco Malawi in 2007. He joined the Management Board as Regional Director for Western Europe in 2009, becoming Regional Director for the Americas in 2011, then Regional Director for Asia-Pacifi c in 2013. He became Chief Operating Officer in August 2016, and Designate in November 2018, before being appointed to the Board in January 2019.

Relevant skills and contribution to the Board: Jack brings significant management, innovation, and strategic leadership to the Board, developed through his previous roles across many of the Group’s key geographies and areas of business. This enables him to effectively lead the Group and deliver our ambition to build A Better TomorrowTM.

External appointments: No external appointments.

Nationality: Canadian

Appointed: Chairman since April 2021; Non-Executive Director since July 2017.

Experience: Luc was President and Chief Executive Officer of Canadian National Railway Company from July 2016 until March 2018, having served as Executive Vice President and Chief Financial Officer from 2012 to 2016. He was named President and Chief Operating Officer of the International Tower Power Corporation (an international financial services company) from 2005 to 2009. Luc was Chief Executive Officer of Imperial Tobacco Canada from 2003 to 2005 and Executive Vice President and Chief Financial Officer from 1998 to 2003. Luc previously served as an independent Non-Executive Director of Reynolds American Inc. from 2008 until its acquisition by the Group.

Relevant skills and contribution to the Board: Luc brings valuable international experience, particularly in marketing, sales and areas of business. This enables him to effectively lead the Group and deliver our ambition to build A Better TomorrowTM.

External appointments: Gildan Activewear Inc.

Karen Guerra Non-Executive Director (65)

Dr Marion Helmes Non-Executive Director (56)

Sue Farr Non-Executive Director (65)

Holly Keller Koepele Non-Executive Director (63)

Savio Kwan Non-Executive Director (73)

Nationality: British

Appointed: September 2020

Experience: Karen has held a variety of executive roles, including President and Director General of Cotesa Palmarie France, and Chairman and Managing Director of Cotesa Palmarie UK Limited. She was formerly a Non-Executive Director of Electrocomponents p.l.c.; David Campani-Mauro S.p.A, Paypad PLC, Inchcape PLC, Sambhavest BV and Swedish Match AB.

Relevant skills and contribution to the Board: Karen brings valuable international experience, particularly in marketing, sales and consumer goods insight to the Board.

External appointments: Non-Executive Director of Amor p.l.c.

Nationality: British

Appointed: February 2015

Experience: Sue’s extensive career includes Director, Strategic and Business Development of China Group and a number of senior marketing and communications positions, including: Director of Marketing BBC, Corporate Affairs Director of Thames Television and Director of Communications of Vauxhall Motors. Sue is a former Chairman of both the Marketing Society and the Marketing Group of Greater London.

Relevant skills and contribution to the Board: Sue contributes considerable expertise in relation to marketing, branding and consumer issues, which are key areas of focus for the Board.

External appointments: Non-Executive Director and Chair of the Remuneration Committee of Accsys Technologies PLC; Non-Executive Director of Heistal plc; and Non-Executive Director of Unlimited Group Ltd.

Sue Farr Non-Executive Director (65)
### Attendance at Board meetings in 2021

<table>
<thead>
<tr>
<th>Name</th>
<th>Director since</th>
<th>Attended/Eligible to attend</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luc Jobin</td>
<td>2017</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Jack Bowles</td>
<td>2019</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>2019</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Sue Farr</td>
<td>2015</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Karen Guerra</td>
<td>2020</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Dr Marion Helmes</td>
<td>2016</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Holly Keller Koeppel</td>
<td>2017</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Savio Kwan</td>
<td>2014</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Dimitri Panayotopoulos</td>
<td>2015</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Darrell Thomas</td>
<td>2020</td>
<td>6/6</td>
<td>2/2</td>
</tr>
<tr>
<td>Richard Burrows</td>
<td>2009-2021</td>
<td>2/2</td>
<td>2/2</td>
</tr>
<tr>
<td>Jerry Forde</td>
<td>2019-2021</td>
<td>1/1</td>
<td>2/2</td>
</tr>
</tbody>
</table>

Notes:
1. Number of meetings in 2021: The Board held eight meetings in 2021, two of which were ad hoc and convened at short notice, to review Board Committee and Management Board appointments.
2. Dimitri Panayotopoulos did not attend the ad hoc meeting in March due to prior commitments. Directors that are unable to attend Board or Committee meetings have the opportunity to provide their comments to the Chairman in advance of the meeting.
3. Composition: The Board of Directors is shown as at the date of this Annual Report and Form 20-F: (a) Richard Burrows retired as Chairman at the conclusion of the Company’s Annual General Meeting on 28 April 2021; and (b) Jerry Forde stepped down from the Board with effect from 1 April 2021.
4. Number of meetings in 2022: Six Board meetings are scheduled for 2022.
Goverance
Management Board
As at 10 February 2022
Board Leadership and Purpose

Leadership Overview

Board Leadership
The Board is collectively responsible to our shareholders for the long-term sustainable success of the Company and for the Group’s strategic direction, purpose, values and governance. The Board provides the leadership necessary for the Group to meet its business objectives within a robust framework of internal controls. The Board’s primary responsibilities are summarised on page 111.

The Board has a comprehensive annual programme of meetings to review the Group’s strategy and monitor performance across all elements of the Group’s business model. The Board’s strategic priorities for 2021 are identified within the key performance indicators set out on page 9. The Chairman sets structured meeting agendas in consultation with the Chief Executive and the Company Secretary.

Key activities of the Board in 2021 are set out on pages 104 to 105. The Board considers stakeholder interests in its decision-making on an ongoing basis. Examples of principal decisions made by the Board during the year, and how it considered the long-term consequences of decisions, stakeholder interests, the impact of operations on the environment and corporate reputation in those contexts, are discussed on page 110.

Oversight of the impact of COVID-19 and the Group’s response remained an important focus for the Board throughout 2021.

How our governance framework supports our strategy
An overview of our governance framework, including the structure of the Board and its principal Committees, is set out on page 111. As part of our internal controls framework, the Board has delegated certain authorities to executive management through our Group Statement of Delegated Authorities (SoDA) to enable effective delivery of Group strategy.

Our SoDA is designed to empower management at the right level of our organisation and promote high levels of accountability and ownership. Overseeing the implementation of Group strategy through our SoDA is one of the ways that the Board promotes robust corporate governance, risk management and internal controls across our Group. Our SoDA supports our Board members in managing their responsibility for promoting the success of the Company, in line with their directors’ duties.

Our Purpose and Ethos
Our purpose, to build A Better Tomorrow™ for all our stakeholders, is underpinned by our ethos.

We launched the BAT ethos in 2020, developed with significant employee input. It guides our culture and behaviours across our Group, enabling an organisation that is future fit for sustainable growth. We believe our ethos empowers our people and fosters a vibrant, rewarding and responsible workplace. Its focus on diversity and inclusion enables better understanding, connectivity and insights across our business.

The Board is committed to supporting the Management Board in continuing to promote the BAT ethos in every area of our business.

Shaping and Overseeing Culture
The Board considers the Group’s culture and activities promoting our ethos in a range of contexts throughout the year, including through workforce engagement. Key examples of the Board’s oversight of culture are highlighted on page 105.

During 2021, Board oversight and monitoring of culture was supported by the Board’s annual review of the Group culture dashboard. This dashboard presents a series of insights measured over time across the organisation, including diversity at different levels, employee engagement (measured through our Your Voice global employee survey), leadership stability, employee retention, health and safety, and business conduct, including Speak Up allegations.

Following review, the Board is satisfied that our culture is aligned with the Group’s purpose, strategy and ethos, and reflected consistently in our workplace policies and practices.

Outside of the boardroom, the Directors typically participate in regular market and site visits to give them direct experience of our organisational culture in context. The Directors’ market and site visit programme continued to be impacted by travel restrictions in place due to COVID-19. Direct workforce engagement was instead enabled primarily through virtual forums in 2021 (discussed on page 108).

Delivery with integrity
How we execute our strategy is as important as its successful delivery. The Board remains focused on ensuring that we deliver with integrity in every aspect of our business. It is essential to our Group’s long-term, sustainable success that all our people act with consistently high standards of behaviour. We articulate this through our Group Standards of Business Conduct (SoBC). Compliance with our SoBC, in letter and spirit, is mandatory for all our people worldwide.

Our SoBC holds everyone responsible for compliance, and every line manager across our business must act as a role model for high standards of behaviour. The SoBC includes our Speak Up policy, reflecting the range of Speak Up channels for raising any concerns in confidence (anonymously if preferred) and without fear of reprisal. The SoBC also includes our Lobbying and Engagement policy, reinforcing the requirement for all our engagement activities with governments, regulators and other external stakeholders to be conducted with transparency, openness and integrity.

Our SoBC is regularly reviewed and updated. A revised version of our SoBC was introduced in January 2022 (discussed on page 110).

The Audit Committee is kept updated on SoBC allegations, and reports to the Board on a quarterly basis. During 2021, 168 cases of possible malpractice were investigated by the Board, the Group’s General Counsel and the Group’s Ethics Officer. All allegations of malpractice were fully investigated, and correct action taken.

The Board’s annual review of the Group’s code of conduct, its principles and the regulatory framework in which we operate, is set out on page 111.
Board Leadership and Purpose

Board Activities in 2021

Simplify the Business
The Board understands our business is enabled by simplifying our structures, embracing digital transformation, and rigorous cost management.

Activities in 2021
- reviewing Quantum implementation (part of Quest), including: effectiveness of Phase 1 organisational design and business unit simplification; impact of Phase 2 end market operating model and route-to-market optimisation; and progress in implementing Phase 3 UK head office restructuring;
- oversight of progress against target savings to be realised through efficiencies implemented under Quantum to release funds for investment;
- oversight of initiatives to drive a step-change in portfolio complexity reduction, including drive brand portfolio consolidation and stock-keeping unit rationalisation, as part of the Group’s focus on stronger, global brands;
- reviewing revenue growth management capabilities and use of data and analytics to power insights and enhance forecasting and decision-making; and
- reviewing key aspects of digital transformation to deliver enhanced user experience for consumers and customers, leverage Digital Business Solutions technology hubs to increase efficiencies, and cyber security developments.

Step Change in New Categories Performance
Continued investment and development of New Categories to accelerate growth is a strategic focus of the Board’s agenda.

Activities in 2021
- reviewing Group performance against strategy to accelerate New Categories growth and KPIs; including New Categories revenue growth and market share;
- reviewing industry and Group performance outlook in total nicotine and by product portfolio;
- reviewing consumer adoption, trading environment and competitor landscape across New Categories portfolios;
- reviewing our New Categories investment glidepath and innovation pipeline across all product portfolios;
- reviewing the Group’s New Categories supply chain, its resilience, sourcing footprint and risk mitigation strategies (including in response to COVID-19); and
- overseeing the development of strategic opportunities beyond nicotine, including Altria Ventures’ portfolio investments and the Group’s acquisition of a 19.9% investment in Organagram Holdings Inc.; and
- assessing principles for laying foundations in wellbeing and stimulation.

Drive Value From Combustibles
Driving value from combustibles is a core priority for the Board, to deliver today and build A Better Tomorrow™.

Activities in 2021
- reviewing Group performance against strategy to drive value from combustibles and KPIs, including value share growth;
- reviewing industry outlook, trading environment and competitor landscape;
- understanding the impact of growth in illicit trade, particularly in developing markets;
- assessing the continuing impact of COVID-19 in highly impacted markets (such as South Africa and Brazil);
- reviewing the impact of evolving tax regimes, with focus on excise tax developments in the U.S. and Asia-Pacific;
- assessing principles applied to prioritise development and investment in our brand portfolio to generate sustainable value to fund New Categories development; and
- reviewing combustible product portfolios, product development pipelines and developments in blending and product differentiation across the Group’s drive brand portfolio, emphasising innovation that is consumer relevant whilst reducing environmental impact.

The Enterprise of the Future
The Board supports management’s drive to implement our Quest programme, as it recognises that, for the Group to reach its long-term sustainability ambitions and to deliver its corporate purpose, it cannot rely on incremental delivery alone.

In 2021, the Board reviewed progress on Quest’s five capability accelerators (discussed to the right), via updates from the Executive Directors and other Management Board members.

The Finance and Transformation Director is the programme director for Quest and responsible for Quest implementation.

Quantum
Quantum’s objective is to simplify the organisation and generate funds through cost savings to reinvest in New Categories. Board oversight of Quantum is discussed above.

Unleash Innovation
Increasing focus and investment in transformational R&D, product innovation and partnering to create a powerful innovation eco-system.

Empowered Organisation
Building an engaged, agile and high performing organisation that can deliver the Enterprise of the Future, with winning capabilities, accountable and empowered leaders, a fit-for-purpose organisational design with an ambitious diversity and inclusion agenda.

Shaping Sustainability
Accelerating our path to becoming a truly sustainable enterprise and fulfilling our A Better Tomorrow™ purpose, through transparent engagement with scientists, regulators and policy-makers so that our strategy takes account of our views, and developing our New Categories science programmes whilst advocating for appropriate standards and regulations.

Technology and Digital
Driving digital transformation to unlock commercial value across our entire value chain, using data and analytics and developing enhanced digital capabilities.

Read more about our Quest programme and capability accelerators on pages 30 to 31.
Financial and Risk

The Board pays close attention to Group performance and financial matters, internal control, and integrity of reporting and risk management.

Activities in 2021

- approval of Group budget, consideration of capital allocation priorities, and oversight of resource allocation activities, to support strategy execution;
- reviewing Group financial performance against key performance metrics, current outlook, challenges and opportunities for growth in each region, and FX impacts;
- reviewing Group half-year results, trading updates, year-end results and the Annual Report and Form 20-F;
- reviewing share price performance and investor and broker perspectives;
- review of interim dividend proposals and assessment of distributable reserves of the Company prior to dividend payments;
- determining Group viability, taking into account current position and principal risks;
- reviewing compliance with Group financing principles, including liquidity, capital allocation and net debt/EBITDA;
- reviewing the Group’s revolving credit facilities, refinancings, the Euro hybrid bond issuance, and debt issuance programmes;
- reviewing Group cash flow performance and opportunities to optimise the balance sheet to enable investment, while reducing the carrying value of debt;
- reviewing the appropriate level of authority to allot shares to maintain future flexibility for the Company;
- reviewing the Group risk register, and risk appetite in the context of strategic objectives and emerging risks;
- reviewing evolving global product regulation, including U.S. FDA regulation of menthol and flavours and evolving EU product and excise regulation;
- reviewing status of litigation involving Group companies, including updates on the Canadian Companies’ Creditors Arrangement Act (CCAA) process in relation to Imperial Tobacco Canada;
- reviewing Group insurance coverage; and

Environmental Social, Governance

The Board emphasises that our strategy, business, and product portfolio be sustainable for the long term and meet our existing societal responsibilities.

Activities in 2021

- oversight of climate-related issues and opportunities for the Group and the approach to embedding the elements of the TCFD framework across the Group;
- reviewing environmental performance for the preceding year and progress against glidepaths towards achieving the Group’s environmental targets, including in relation to climate, renewable energy, water stewardship and recycling;
- reviewing the Group’s ESG agenda, factors contributing to its increasing importance to key stakeholders, performance against ESG metrics and associated governance and controls;
- approving revised terms of reference for the Audit Committee to include responsibilities for engagement and monitoring of external providers conducting assurance over ESG metrics;
- reviewing the perspectives of the Group’s key stakeholders, the Group’s response to stakeholder perspectives, and the effectiveness of engagement mechanisms used;
- assessing the impact of COVID-19 on Group operations and Group business continuity structures and plans to manage the Group’s response;
- approving revisions to the Group’s Standards of Business Conduct and Supplier Code of Conduct, to take effect from 1 January 2022;
- approving the annual Modern Slavery Act statement and annual Conflict Minerals Report;
- reviewing updates on compliance matters, including allegations of misconduct, reports from Speak Up channels and investigations, and the Group’s Delivery with Integrity programme initiatives.

Ethos, Culture, People

The Board shapes and oversees the Group’s culture and ethos. Setting the ‘tone from the top’ is an important part of the Board’s role.

Activities in 2021

- determining the independence of Non-Executive Directors prior to proposing them for re-appointment at the Company’s AGM;
- reviewing the composition of the Audit and Remuneration Committees, on the recommendation of the Nominations Committee;
- approving changes to Management Board composition, on the recommendation of the Nominations Committee;
- reviewing proposed changes to the Directors’ Remuneration Policy, shareholder perspectives on new policy proposals, responses to shareholder engagement, and adopting the new Directors’ Remuneration Policy for shareholder approval at the 2022 AGM;
- approving revisions to Non-Executive Director fees;
- reviewing the outcomes of the annual Board evaluation in 2021;
- monitoring corporate culture and its alignment with the Group’s purpose, ethos and strategy;
- reviewing the Group’s talent strategy, employer brand, diversity and inclusion agenda, and progress against objectives;
- reviewing approach to talent capability development, with a focus on capabilities needed for Group transformation;
- considering feedback from the Group’s workforce engagement mechanisms;
- reviewing the effectiveness of Speak Up channels; understanding the evolving impact of COVID-19 on the Group’s workforce and reviewing strategies for securing safe on-site environments, effective connectivity for remote working, and safeguarding welfare;
- reviewing health and safety performance for the preceding year, targets for the coming year and action plans; and
- reviewing the funding positions relating to the Group’s retirement benefit schemes.
Our Directors value engagement with our shareholders and wider stakeholders to understand their views and inform the Board’s decision-making, strategy development and risk assessment.

Shareholder and Investor Engagement
The Board is committed to open and transparent dialogue with shareholders and investors to ensure their views are understood and considered. The Chairman and Executive Directors’ annual engagement programme is discussed below.

The Senior Independent Director and other Non-Executive Directors are also available to meet with major shareholders on request.

Annual investor relations programme
A global engagement programme is conducted annually with shareholders, investors, potential investors and analysts. This is led by the Chairman and Executive Directors, supported by the Investor Relations team. The Executive Directors presented our Full and Half-Year results and pre-close statements with investor Q&A calls. Presentations and transcripts are published on bat.com.

In total we hosted 678 investor meetings in 2021 facilitated by virtual ways of working, covering 71% of our shareholder base with broad geographic coverage across the US, the UK, South Africa, Europe and other markets.

Investor interaction encompassed a broad range of event formats, including our virtual attendance at 11 investor conferences, 14 investor roadshows and four salesforce briefings. We launched our new IR website in February 2021 (see Spotlight on shareholder communication on page 107) enabling us to further leverage our digital interaction with investors.

We significantly increased our engagement on ESG topics (see Spotlight on ESG below), interacting with ESG-focused teams within our investment community through conference presentations and an ESG roadshow. This engagement also enabled investors to interact with members of our executive management team.

In February 2021, Jack Bowles and Tadeu Marroco presented for the first time at the Consumer Analyst Group of New York (CAGNY) conference via a live webcast and Q&A to over 150 investors. These presentations focused on our strengths and capabilities across brand-building, digital, ESG, science and R&D and articulated our commitment to deliver value for our stakeholders, driven by our A Better Tomorrow™ purpose.

ESG Engagement
We continue to build on our strong ESG foundations, with 2021 marking the 20th anniversary of our first Social Report in 2001. We increased our ESG engagement with investors through our investor relations programme and we also hosted more than 40 ESG-specific meetings with over 100 different investment institutions over the year.

We participated in two dedicated ESG investor conferences where Dr David O'Reilly, Director, Scientific Research, hosted meetings with investors, supported by the IR team.

At the Deutsche Bank Consumer Conference in June 2021, Kingsley Wheaton, Chief Marketing Officer, joined Dr O’Reilly to communicate our purpose of building A Better Tomorrow™ and reducing the health impact of our business.
How the Board considers shareholder and investor views

The Chairman, the Executive Directors and Remuneration Committee Chair regularly update the Board on their dialogue with shareholders and investors. The Board also receives updates from the Head of Investor Relations and our brokers on key issues raised by shareholders and on stock performance. Shareholder and investor perspectives considered by the Board in 2021 included transformation, New Categories strategy and performance, ESG targets, deleveraging, capital allocation and key regulatory developments. The Board takes shareholder feedback into account in decision-making and developing Group strategy (discussed further on this page and on pages 110 and 128 to 132).

Annual General Meeting (AGM)

Our AGM is an opportunity for further shareholder engagement, for the Chairman to set out progress, and for the Board to answer questions. Our 2021 AGM was held whilst the UK Government's COVID-19 'Stay at Home' measures were in force, prohibiting public gatherings of more than two people. Given those restrictions, our 2021 AGM was convened with a minimum quorum of two shareholders in accordance with the Company’s Articles of Association. Shareholders were given the opportunity to submit questions about AGM business in advance of the meeting and responses to the queries received were published at bat.com/agm.

Looking ahead, we plan to hold our 2022 AGM in person, subject to UK Government guidelines applicable at that time. Details of our 2022 AGM are set out on page 379.

For disclosures required by paragraph 7.2.6 of the Disclosure Guidance and Transparency Rules and the Companies Act 2006, see the Other Information section

Shareholder communication

We launched our refreshed investor website in February 2021 alongside our results for FY 2020, taking into account investor feedback. As part of the refresh, the design was fully updated, improving user experience and making content easier to navigate.

We also added new content areas, including:
- Our investment case and our approach to ESG, and
- Shareholder FAQ and regular consensus sharing.

A new Investor News Hub pulls our press releases, news and features together in one place for investors. An automated news alert service is available to keep investors up to date. We are increasing our investor reach with live broadcasts of events, including results and conferences on our website, with playback slides and transcript available online. During 2021, the refreshed site has seen an 18% increase in traffic with over 47,000 visits.
Wider Stakeholder Engagement

A broad range of stakeholders are important to the Group at local, regional and functional levels. Key stakeholders are essential to our ability to generate long-term, sustainable value and we identify them by applying an established stakeholder engagement framework, which takes into account strategic objectives and risks to the Group.

Our key stakeholders are referenced in our business model on page 18, with an overview of their importance, what engagement is not at Board level. Following its review, the Board remains satisfied there is well-established and effective engagement with the Group’s key stakeholders, which enables the Board to understand their perspectives. The Board will continue to monitor the ongoing effectiveness of stakeholder engagement.

Where the Board does not engage directly with our stakeholders, it is kept updated so Directors maintain an effective understanding of what matters to them and can draw on these perspectives, including in Board decision-making and strategy development. An overview of how the Board engaged with wider stakeholders and maintained its understanding of their interests during the year follows below, with further information on page 72 and on page 165 in relation to workforce engagement on remuneration matters.

Key priorities from workforce feedback

- Transformation
  - Focus areas are implementation of business simplification and change management.
- Simplier, faster, stronger organisation
  - Initiatives in response to feedback include: functional briefings on our Quest programme, live global webcast on the 2020/21 staff Year results with Q&A; the “Technology Inspiring a Modern Enterprise” global virtual awareness week; and a series of global webinars to develop digital capabilities.
- Innovation
  - Focus areas are New Categories strategy, footprint expansion and development of product knowledge.
- Staying Connected
  - Focus areas are maintaining active staff engagement and staff wellbeing during the pandemic.

2023: Directors’ engagement forums

<table>
<thead>
<tr>
<th>Events with Directors</th>
<th>Events with Directors</th>
<th>Events with Directors</th>
<th>Events with Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>AmS&amp;BA</td>
<td>Centre</td>
<td>ENA</td>
</tr>
<tr>
<td>8</td>
<td>6</td>
<td>8</td>
<td>7</td>
</tr>
</tbody>
</table>

* Total virtual face-to-face market visits or other forums by location/region/centre function that one or more Directors attended in 2021.

The Board keeps up to date with the current views of our workforce through a combination of engagement methods across multiple channels at different levels of our organisation. These include town halls, works councils, webcasts, our “Your Voice” global employee survey, and direct engagement through Directors’ market and site visits (discussed on page 72). Given the spread, scale and diversity of the Group’s workforce, the Board considers it effective to use this blend of established channels, augmented by structured reporting.

These engagement channels, combined with Group-wide reporting structures to capture workforce feedback, cover all Group company employees and individuals contracted on a fixed-term basis to undertake permanent roles. Focus and action areas reviewed by the Board are then cascaded to our workforce.

Engagement across our organisation remained a top priority in 2021, as COVID-19 continued to affect our organisation and ways of working. The Board reviewed our workforce engagement channels across the Group in 2021 and consolidated feedback from them. The overarching themes were transformation, innovation, and staying connected (particularly in the pandemic context), highlighted below.

Our Board’s usual programme of market and site visits allows Directors to engage directly with people across our organisation, but continued to be curtailed in 2021 due to COVID-19 restrictions.

However, our Executive Directors led a series of virtual market visits and other forums to connect regularly with regional, local and functional teams (highlighted to left), and featured on our internal global news channel “BATV”. The Chairman delivered a personal video greeting to staff worldwide on his appointment and featured in our internal eZine.

Our Executive Directors also presented global, functional and market webcasts including discussions on our purpose, ethos, strategy, performance and business outlook in real time with Q&A.

The Board was briefed on London HQ return to site plans, staff perspectives on the positives and negatives, and how safeguarding measures would ensure a COVID-secure return for staff working on site.

The Board noted that staff felt well supported during the pandemic, and the need to balance the advantages of more flexible working practices going forward, with recognition of on-site working as a powerful catalyst for collaborative and cohesive teamwork.

UK Companies Act: Employee engagement

This section summarises the Directors’ approach to engaging with the Group’s workforce, including employees of UK Group companies, and how the Directors have regard to their interests. Further information is provided on pages 20 to 21, 70 to 73, and pages 163 to 165 in relation to remuneration matters. Further details regarding the effect of that regard are provided on page 110.
Our consumers are at the core of everything we do. Consumer-led innovation and product science are central to achieving our purpose of building A Better Tomorrow™. We believe that our multi-category approach is the most effective way to appeal to the diverse preferences of adult consumers worldwide.

The Board is regularly briefed by the Executive Directors and senior management on product performance across all portfolio categories and how product offerings continue to evolve to satisfy adult consumer preferences. In 2021, the Board was updated on how we are responding to consumer views on safety and quality of New Categories products, and our contribution to developing voluntary industry standards in various markets.

The Board was also briefed on how we understand our consumers’ shift to digital and e-commerce channels, and our development of mobile e-commerce and subscription tools.

Through its strategy sessions in 2021, the Board reviewed how we are actioning our wealth of consumer insights to support delivery of relevant product pipelines for a step-change in New Categories performance.

Whilst retailer, wholesaler and distributor relationships are managed at local market and business unit levels, the Board is briefed regularly on the Group’s route-to-market strategies and developments in the global retail environment.

In 2021, focus areas for Board updates included our response to retail customer feedback on the accelerating shift to e-commerce, including new tools for digital engagement roll-out across 40 markets, and how markets were adapting to maintain their engagement with customers, as COVID-19 impacts continue and beyond.

The Audit Committee also reviews the Group’s Youth Access Prevention action plans annually, including for New Categories digital channels.

Our relationships with suppliers and contracted farmers are managed day-to-day by the Group’s Operations function and at local market level. The Board periodically reviews the Group’s supply chain strategies, supplier footprint and progress of sustainable agriculture and farmer livelihoods programmes.

In 2021, the Board was regularly updated on the impact of COVID-19 on our operations and supply chain, mitigation plans to avoid supply chain disruption, and initiatives to support suppliers.

The Board reviewed the Group’s New Categories supplier network and geographic sourcing footprint, supply chain resilience and business continuity. The review focussed on sources of uncertainty and managing external impacts, through increased automation and efficiency improvements in collaboration with our suppliers.

The Board reviewed the annual Modern Slavery Statement, including commitments to ensure that operations are free from exploitation of labour and modern slavery, and the due diligence and monitoring programmes underpinning those commitments.

The Board approved the revised Supplier Code of Conduct (discussed on page 110). The Board also discussed the Company’s annual Conflict Minerals Report which details due diligence undertaken to determine the origin of minerals at risk of being sourced in conditions of conflict.

We believe tobacco harm reduction can only be solved collaboratively, and that only through collaborative effort can effective regulation be developed to deliver public health objectives and also enable real consumer choice.

The Board is briefed on scientific engagement with regulators, public health bodies, and scientific communities. In 2021, this included updates covering engagement with the US FDA on vapour products, and the progress of US subsidiary Kentucky BioProcessing towards developing proprietary vaccine technology.

At every regular Board meeting, the Board reviews a report from our Legal & External Affairs Director covering evolving product regulation, regulatory engagement, developments in excise tax, anti-illicit trade initiatives, litigation and compliance.

For example, in 2021, these reports included briefings on developments in the US FDA’s approach to regulating menthol and flavours. The Board was also kept up to date on evolving product regulation and excise tax regimes, with focus on developments in the US and the EU, at its strategy sessions and through regular briefings from the Chief Executive.

The Board was briefed on investor and wider stakeholder expectations on sustainability policies, programmes and performance, including on alignment with the TCFD reporting framework and progress towards net-zero carbon emissions. It also considered the Group’s range of responses to stakeholder feedback on the environmental impact of our products. Examples included our work to enable Vuse’s certification as the first carbon neutral global vapour brand, our reduction of single-use plastics in our New Categories products, and take-back schemes for New Categories.

The Audit Committee regularly reviews the Group’s ESG performance against key metrics, and is briefed annually on our investment in community and charitable initiatives.

In 2021, the Audit Committee was briefed on enhanced due diligence and governance guidance for end markets and central functions when making charitable contributions and providing in-kind support under the revised Group Community Investment Framework.

The Audit Committee is also updated on engagement with tax authorities on material Group tax matters.

The Non-Executive Directors regularly attend the Corporate Audit Committee and Regional Audit & CSR Committees, where societal and community perspectives at regional and local levels are discussed. The Audit Committee also reviews feedback from these Committees.

UK Companies Act: Business relationships

This section summarises how the Directors have regard to the need to foster business relationships with customers, suppliers and other external stakeholders. Further information is provided on pages 20 to 21. Information regarding the effect of that regard is provided on page 110.
Principal Decisions Made by the Board

Outlined below are some of the principal decisions made by the Board over the year, highlighting how the Board considered relevant factors including key stakeholder perspectives, the environment, corporate reputation, and the long-term impact of decisions.

Capital Allocation to Build A Better Tomorrow™
In approving the 2022 budget, the Board weighed a variety of imperatives for a multi-year, balanced capital allocation plan.

The budget emphasises New Categories investment and builds on the Group’s investment in Organigram Holdings Inc. and portfolio investments by Bloomroom Ventures to develop an ecosystem of capabilities, technologies and insights. This investment enables our strategy for long-term sustainability in nicotine and beyond.

The budget is also designed to secure mid-term, high single digit EPS growth, achieve our shareholders’ del everage expectations to maintain financial flexibility, and prioritise dividend distribution, whilst enabling commercial delivery across all categories in line with our guidance.

Our capital allocation anticipates developing our portfolios in nicotine and beyond to meet evolving consumer preferences, underpinned by robust product stewardship, scientific research and collaborative innovation to meet those needs, and considers the environmental impact of our operations and the complexity of navigating external fiscal and regulatory environments.

Amongst other factors, the 2022 budget also takes into account workforce remuneration and commercial arrangements with suppliers and customers.

Revised Standards of Business Conduct and Supplier Code of Conduct
The Board approved revised Standards of Business Conduct (SoBC) and a revised Supplier Code of Conduct, applicable from 1 January 2022. These revised policies are aligned with our strategy and ethos and take account of evolving external requirements and expectations of all our stakeholders for high standards of integrity in our business conduct.

Our revised SoBC emphasises that a key driver to delivering our corporate purpose is our ethos, which guides our culture and behaviours across the Group and enables an organisation future-fit for sustainable growth.

Updates to these policies were informed by feedback from our staff and business partners, international standards such as the ILO Declaration on Fundamental Principles and Rights at Work and OECD Guidelines for Multinational Enterprises, and external benchmarking. Continuous development of these policies demonstrates our commitment – within our organisation and in collaboration with our suppliers – to deliver results with high standards of integrity across our value chain.

Revised Standards of Business Conduct and Supplier Code of Conduct

<table>
<thead>
<tr>
<th>Key stakeholder perspectives taken into account</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholders and investors</td>
</tr>
</tbody>
</table>

Capital Allocation to Build A Better Tomorrow™

Progress Towards Net Zero Emissions
The Board reviewed progress against the glidepath towards achieving the Group’s commitment to net zero value chain carbon emissions by 2050. This encompasses science-based targets across all emission scopes and is discussed on pages 47 and 61.

In setting environmental targets, regard was had to the emphasis placed across our key stakeholders – our shareholders and investors, our people, our consumers, our customers and suppliers, and wider society – on the importance of responding to climate change and maintaining high standards of environmental management, as well as to our broader, long-term sustainable success and corporate reputation.

Costs associated with progressing towards these targets were taken into account, balanced against the clear imperative to continue taking action to address worldwide implications of climate change, demonstrating our commitment to act as a responsible organisation and business partner.

Key stakeholder perspectives taken into account

<table>
<thead>
<tr>
<th>Key stakeholder perspectives taken into account</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholders and investors</td>
</tr>
</tbody>
</table>

We define principal decisions as those decisions and discussions by the Board that are strategic or material to the Group and those of significance to any of our key stakeholders.
Division of Responsibilities

Governance Framework

An overview of our governance framework is set out below. There is a clear and effective division of responsibility established between our Board, its Committees and operational management.

Our Board

Primary Board responsibilities include:

- Assessing and monitoring culture and its alignment with Group purpose, values and strategy
- Ensuring workplace policies and practices align with values and support sustainable success
- Review of Speak Up channels and reports arising
- Board oversight of M&A transactions

Delegation of Authorities: As part of our internal controls framework, the Board delegates certain authorities to executive management through the Group Statement of Delegated Authorities to enable effective delivery of Group strategy (see page 102).

Board Committees

Audit Committee
Monitors the integrity of financial reporting, independence and effectiveness of the external auditors, assurance of ESG metrics, internal controls and risk management.

Nominations Committee
Recommends Board and Management Board appointments; oversees development of executive talent pipeline.

Remuneration Committee
Established the Directors' Remuneration Policy; determines remuneration for the Chairman and executive management.

The Board has three principal Board Committees to which it has delegated certain responsibilities. The roles, membership and activities of these Committees are described in their individual reports in this section.

Each Committee has its own terms of reference, available at bat.com/governance. These are regularly reviewed and updated where necessary, most recently in 2021 in respect of the Audit Committee.

Management Board structure

The Management Board is chaired by the Chief Executive and comprises the Executive Directors and 11 senior Group executives whose names and roles are described on page 102.

Zafrar Khan was appointed as Director, Operations with effect from 1 February 2021. Alan Davy stepped down from the Management Board with effect from 31 January 2021.

The Management Board is responsible for overseeing the implementation of Group strategy and policies set by the Board, and creating the framework for Group subsidiaries’ day-to-day operations.

Management Board responsibilities

Primary responsibilities of the Management Board include:

- Developing Group strategy for the Group’s product portfolio for approval by the Board
- Monitoring Group operating performance
- Ensuring Group, regional and functional strategies and resources are effective and aligned
- Managing the central functions
- Overseeing the management and development of Group talent

111
## Our Approach to Division of Responsibilities

The Board comprises the Non-Executive Chairman, two Executive Directors and seven independent Non-Executive Directors.

This section sets out the roles and division of responsibilities between the Chairman, Executive Directors and Non-Executive Directors.

<table>
<thead>
<tr>
<th>Role</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman</td>
<td>- Leadership of the Board and its overall effectiveness&lt;br&gt;- Promotes constructive debate and effective decision-making&lt;br&gt;- Sets the Board agenda&lt;br&gt;- Facilitates Directors’ contributions&lt;br&gt;- Interfaces with shareholders&lt;br&gt;- Ensures effective shareholder engagement&lt;br&gt;- Representational duties on behalf of the Company</td>
</tr>
<tr>
<td>Chief Executive</td>
<td>- Overall responsibility for Group performance&lt;br&gt;- Leadership of the Group&lt;br&gt;- Enables planning and execution of Group objectives and strategies&lt;br&gt;- Stewardship of Group assets&lt;br&gt;- Drives the cultural tone of the organisation</td>
</tr>
<tr>
<td>Finance and Transformation Director</td>
<td>- Leadership of the Group in respect of financial matters&lt;br&gt;- Enables planning and execution of Group financial objectives and strategies&lt;br&gt;- Leadership of the design and delivery of the Group’s QUEST transformation programme to accelerate delivery of Group strategy</td>
</tr>
<tr>
<td>Senior Independent Director</td>
<td>- Leads review of the Chairman’s performance&lt;br&gt;- Presides at Board meetings in the Chairman’s absence&lt;br&gt;- Chairs the Nominations Committee when Chairman succession considered&lt;br&gt;- Sounding board for the Chairman&lt;br&gt;- Intermediary for other Directors&lt;br&gt;- Available to meet with shareholders</td>
</tr>
<tr>
<td>Non-Executive Directors</td>
<td>- Oversee Group strategy and resource allocation&lt;br&gt;- Monitor Group performance and delivery of Group strategy&lt;br&gt;- Oversee systems of control and risk management&lt;br&gt;- Review management proposals and provide strategic guidance&lt;br&gt;- Scrutinise and hold to account performance against objectives&lt;br&gt;- Bring external judgement, perspective and effective challenge to management</td>
</tr>
</tbody>
</table>

### Board Efficacy

Board meetings during the year continued to be convened virtually due to continuing COVID-19 travel restrictions, with in-person meetings resuming in December 2021. Feedback from the annual Board evaluation confirmed that Board meetings continued to operate well and are considered to be chaired effectively.

The Chairman facilitates constructive Board relations, supporting effective contribution from Non-Executive Directors and promoting a culture of openness and debate. The Chairman seeks a consensus at Board meetings but, if necessary, decisions are taken by majority decision. If any Director has concerns on any issues that cannot be resolved, such concerns are noted in the Board minutes. No such concerns arose in 2021.
Independence
The Board considers all Non-Executive Directors to be independent, as they are free from any business or other relationships that could interfere materially with, or appear to affect, their judgement.

Luc Jobin was determined by the Board to be independent on his appointment as Chairman, as reported in the Company’s Annual Report and Form 20-F for 2020. The Board has determined Holly Keller Koeppel to be independent, having taken into account her service on the board of Reynolds American Inc. (Reynolds American) and pursuant to the Agreement and Plan of Merger with Reynolds American. The Board has also considered the independence requirements outlined in the NYSE’s listing standards and has determined that these are met by the Chairman and all the Non-Executive Directors. The Board considers that it includes an appropriate combination of Executive and Non-Executive Directors.

Commitment
Before appointing prospective Directors, the Board takes into account their other commitments and significant time commitments are disclosed prior to appointment. The letters of appointment for the Chairman and Non-Executive Directors set out their expected time commitment to the Company (see page 116). Any additional external appointments following appointment to the Board require prior approval by the Board in accordance with the UK Corporate Governance Code. The Board assesses the significance of any additional external appointment notified by a Director, supported by the Company Secretary.

During 2021, the Board gave approval to Holly Keller Koeppel’s appointment as a non-executive director of Flutter Entertainment plc from 13 May 2021. This additional appointment was considered by the Board to be significant, but not to impair her ability to serve as a Director of the Company in view of the anticipated time commitment and given that she had stepped down as a non-executive director of Vesuvius plc on 12 May 2021. Including the Company, Holly is currently a non-executive director of three listed companies.

In 2021, the Board considered and gave approval to Darrell Thomas’ appointment as an independent director of Dorman Products Inc. from 30 October 2021. The Board considers this additional appointment to be significant, but did not consider it to impair Darrell’s ability to serve as a Director of the Company as he would hold a total of two listed company mandates (within the voting guidelines of leading corporate governance advisory bodies). Following this appointment, Darrell is currently a non-executive director of two listed companies.

Conflicts of Interests
In relation to Darrell’s appointment as a non-executive director of Scotia Holdings (US) Inc. from 4 February 2022, a potential situational conflict was reviewed and authorised by the Board as another company in the Bank of Nova Scotia group is a supplier to the Group in Colombia (although those supply arrangements are not material and Darrell has no involvement in the operations of that supplier or BAT subsidiary operations in Colombia). The Board determined that these arrangements did not impact Mr Thomas’ independence as a Non-Executive Director of the Company.

The Board has formal procedures for managing conflicts of interest. Directors receive effective support to assist them in meeting their responsibilities under the UK Corporate Governance Code and discharging their directors’ duties, both individually and collectively.

Directors Information and Advice
Directors receive effective support to assist them in meeting their responsibilities under the UK Corporate Governance Code and discharging their directors’ duties, both individually and collectively.

- Directors receive papers for review in good time ahead of each Board and Committee meeting.
- Papers and presentations to the Board and its Committees include discussion of specific stakeholder considerations as applicable.
- The Company Secretary ensures effective information flow within and between the Board and its Committees, and between the Non-Executive Directors and senior management.
- The Company Secretary, in conjunction with external advisers where appropriate, advises the Board on all governance matters.
- All Directors have access to the advice and services of the Company Secretary. The appointment and replacement of the Company Secretary is a matter for the Board.
- A procedure is in place for all Directors to take independent professional advice at the Company’s expense if required.
- Each Board Committee may obtain independent legal or other professional advice, at the Company’s expense, and secure attendance at meetings of external participants if needed.
Board Induction

All Directors receive a thorough and personalised induction on joining the Board, taking into account their skills, experience and scope of appointment.

Luc Jobin completed his induction as Chairman in 2021, discussed below. Darrell Thomas completed his Non-Executive Director’s induction in early 2021, as set out in the Annual Report and Form 20-F for 2020.

Professional Development

Non-Executive Directors receive a full programme of briefings during the year across all areas of the Group’s activities from the Executive Directors, members of the Management Board, the Company Secretary, other senior executives and outside advisors.

During 2021, key briefings for the Board included cyber security, patent portfolios, evolving product regulation, and other regulations impacting the Group’s business and governance arrangements, for example, the UK Financial Conduct Authority’s consultation on the proposed introduction of new regulations to enhance disclosure of the diversity of boards and executive management.

In the context of reviewing the Group’s climate strategy and enhanced sustainability targets, the Board was briefed on the objectives and requirements of the TCFD framework and stakeholder expectations on progress towards net zero carbon emissions across operational supply chains. The Board also recapped on directors’ duties under Section 172 of the UK Companies Act 2006 as part of its annual review of Group stakeholder engagement.

Committees of the Board are kept updated on developments within their respective remits. In 2021, the Audit Committee was updated on regulator and stakeholder expectations in respect of addressing climate risks in annual reporting. UK Government proposals to reform audit and corporate governance arrangements, and in relation to revisions to applicable UK auditing standards and their impact. The Remuneration Committee was regularly updated by its external consultants on UK and U.S. corporate governance developments impacting executive remuneration.

2021: Internal Board Review Process

1. Evaluate
   - Directors evaluate performance and effectiveness of the Board, its Committees (as applicable) and each of the other Directors.

2. Report
   - The Company Secretary collates anonymised feedback and prepares reports for the Board, its Committees and each of the Directors.

3. Review and Action
   - Board Committees review evaluation outcomes, identify any actions and provide feedback to the Board.
   - The Board reviews the evaluation outcomes and identifies action areas.
   - The Chairman provides feedback to the other Directors. The Senior Independent Director provides feedback to the Chairman.

Non-Executive Directors regularly attend meetings of the Group’s Regional Audit and Corporate and Social Responsibility Committees and Corporate Audit Committee to gain a better understanding of the Group’s regions and central functions and the risks faced by the business at market, regional and functional levels. The Chairman meets with each Non-Executive Director individually towards the end of each year, to discuss their individual training and development plans.

Board Review Process

The performance and effectiveness of the Board, its Committees, the Executive and Non-Executive Directors and the Chairman were evaluated internally in 2021, facilitated by the Company Secretary. An external evaluation of the Board, its Committees and the Directors was conducted in 2019, facilitated by Independent Audit Limited.

The Chairman is responsible for the overall evaluation process and each Committee Chair is responsible for the evaluation of the performance and effectiveness of their Committee. The evaluations were conducted through a series of detailed questionnaires and all participants were requested to provide commentary to support their assessments.

All Directors participated in the evaluation process, assessing the Board, the Committees of which they were a member or regularly attended in 2021, and each of the Directors individually. In addition, several members of the Management Board and other senior management participated in elements of the evaluation.

Anonymous reports specifying the findings of the evaluations were prepared by the Company Secretary for the Board and each Committee. The Board and Committees then reviewed and discussed their respective reports and identified action areas for 2022 taking into account the evaluation findings.

The Chairman received reports from the Company Secretary on the performance and effectiveness of all Executive and Non-Executive Directors (other than himself) in 2021 and he provided individual feedback to each Director.

The Senior Independent Director received a report from the Company Secretary on the Chairman’s performance and effectiveness, and led a discussion reviewing the Chairman’s effectiveness with the other Directors (without the Chairman present). The Senior Independent Director then provided feedback to the Chairman.
# 2021 Evaluation: Outcomes and Actions

The Board considers that it, its Committees and its Directors continue to function effectively and that the working relationships between the Board and its Committees continue to be sound.

## Leadership and culture

The Board put their collective skillsets to good use in providing support to the Executive Directors’ drive to simplify the organisation and embed the BAT ethos. The Board continued to be adaptable in the face of COVID-19, and praised management’s consistent approach to prioritising staff welfare in 2021.

The Chairman and two new Non-Executive Directors were welcomed to the Board, refreshing the skillsets and perspectives of an already diverse and experienced team.

Non-Executive Directors were seen to be supportive in the development of strategy and offering appropriate challenge. The candid nature of their discussions with the executive team was highlighted as a good example of the open culture at Board and senior management level.

The organisation’s resilience was clear to the Board in 2021, notwithstanding constraints on spending time in the wider business. The Non-Executive Directors look forward to resuming their usual programme of market and site visits in 2022.

**Key Action for 2022**

- Plan for Non-Executive Director market and site visits.

## Strategy

The Board considered its strategy discussions to be effective, leading to strong strategic objective setting, and notably in driving the ESG and people agendas forward in the year. The Remuneration Committee has been focused on ensuring that strategic objectives are reflected in the Group’s remuneration strategy.

Following up on actions arising from the 2020 Board evaluation to allow additional time for deep dives on strategic objectives and review of major initiatives, during the year the Board’s agenda included a series of in-depth reviews: for example on talent strategy, ESG agenda and the New Categories supply chain.

The Board is keen to build on this into 2022 with further emphasis on the competitive landscape, scenario planning, and emerging issues and trends.

**Key Action for 2022**

- More detail for the Board on the competitive landscape and consumer trends, with more time in the Board agenda for in-depth scenario analysis and planning.

## Composition and succession

The Board regards its composition to be well balanced in terms of skills, experience, geography and gender, with recent appointments demonstrating its effectiveness at bringing the right people around the table.

Following up on actions arising from the 2020 Board evaluation, the Nominations Committee completed its skills profile for future non-executive directors to support succession planning. The Nominations Committee is keen to see more of the executive management pipeline in 2022.

**Key Action for 2022**

- Additional time to be allowed on the Board agenda for executive management succession planning.

## Risk management

The continued focus on business controls and compliance is highly regarded by the Board, and the Board’s monitoring of key risks and oversight of compliance is considered to be effective. The Audit Committee’s oversight of the fundamental reporting environment was considered to be sound, with the Committee staying on top of key projects and activities.

In the context of the Group’s transformational agenda, Directors noted the benefit of understanding the risks and stresses of extensive business change and the pressure points from a people perspective.

Actions arising from the 2020 Board evaluation, to further enhance the Board’s understanding of strategic opportunities and risks presented by evolving technologies, were followed up during the year. For example, the Board reviewed developments in cyber security and the Audit Committee assessed digital transformation risks and the approach to managing risks identified.

**Key Action for 2022**

- Further emphasis in the Board agenda on change management in the context of the Group’s transformational agenda, including from a people perspective.

## Dynamics and information

Board and Committee meetings are considered to be chaired effectively, and well-supported by the Company Secretariat.

The Chairman was recognised for his inclusive style and fostering open discussion. Agendas are seen as well-balanced between business critical items and governance matters.

During the year the Board conducted several in-depth reviews of market analysis and the competitor environment in response to actions identified from the 2020 Board evaluation to emphasise time for these areas in the Board agenda.

**Key Action for 2022**

- Additional pre-read material to be provided for key presentations to enable greater time for discussion in Board meetings.
### Composition, Succession, Evaluation

**Nominations Committee**

- **Role**
  - As set out in the Terms of Reference, the Nominations Committee is responsible for:
    - reviewing the structure, size and composition of the Board and Management Board on a regular basis to ensure both have an appropriate balance of skills, expertise, knowledge and, in relation to the Board, independence;
    - reviewing the succession plans for appointments to the Board, the Management Board and Company Secretary to maintain an appropriate balance of skills and experience and to ensure progressive refreshing of both the Board and the Management Board;
    - making recommendations to the Board on suitable candidates for appointments to the Board, the Management Board and Company Secretary, ensuring that the procedure for those appointments is rigorous, transparent, objective and merit-based and has regard for diversity;
    - assessing the time needed to fulfil the roles of Chairman, Senior Independent Director and Non-Executive Director, and ensuring Non-Executive Directors have sufficient time to fulfil their duties;
    - overseeing the development of a pipeline of diverse, high-performing potential Executive Directors, Management Board members and other senior managers; and
    - implementing the Board Diversity Policy and monitoring progress towards the achievement of its objectives, summarised on page 119.

- **Key Activities in 2021**
  - Making recommendations to the Board in respect of Board Committee appointments, including appointment of Karen Guerra to the Audit Committee from 1 April 2021, as set out on page 120.
  - Making recommendations to the Board to appoint a new Director, Operations with effect from 1 February 2021, as set out at page 111.
  - Analysis of the profile, skills and experience required of future Non-Executive Directors in the context of the Group’s purpose and strategy, to support Board succession planning activities.
  - Making recommendations to the Board in relation to Directors’ annual appointment and re-election at the AGM, discussed further on page 117.
  - Reviewing the Executive Directors’ and Management Board members’ annual performance assessments and assessing the development of candidates for Management Board roles.
  - Overseeing the Group’s diversity and inclusion agenda, its role in promoting an inclusive and high-performing culture and the Group’s talent strategy, and progress in building diverse talent pipelines and creating enablers across the organisation.
  - Reviewing the Committee’s effectiveness in 2021, following the Committee evaluation process, discussed on pages 114 to 115.

- **Terms of Appointment to the Board**
  - Details of the Directors’ terms of appointment to the Board and the Company’s policy on payments for loss of office are contained in the current Directors’ Remuneration Policy, which is set out in full in the Remuneration Report 2018, in the Company’s Annual Report and Form 20-F for 2018 available on bat.com.
  - The Executive Directors have rolling one-year contracts. Non-Executive Directors do not have service contracts with the Company but instead have letters of appointment for one year, with an expected time commitment of 25 to 30 days per year.

### Nominations Committee current members

<table>
<thead>
<tr>
<th>Name</th>
<th>Member since</th>
<th>Attendance</th>
<th>Ad hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luc Jobin (Chair)</td>
<td>2017</td>
<td>2/2</td>
<td>4/4</td>
</tr>
<tr>
<td>Sue Farr</td>
<td>2015</td>
<td>2/2</td>
<td>4/4</td>
</tr>
<tr>
<td>Karen Guerra</td>
<td>2016</td>
<td>2/2</td>
<td>4/4</td>
</tr>
<tr>
<td>Holly Keller Koeppel</td>
<td>2017</td>
<td>2/2</td>
<td>4/4</td>
</tr>
<tr>
<td>Savio Kwan</td>
<td>2014</td>
<td>2/2</td>
<td>4/4</td>
</tr>
<tr>
<td>Dimitri Panayotopoulos</td>
<td>2015</td>
<td>2/2</td>
<td>3/4</td>
</tr>
<tr>
<td>Darrell Thomas</td>
<td>2020</td>
<td>2/2</td>
<td>4/4</td>
</tr>
<tr>
<td>Richard Burrows</td>
<td>2019 – 2021</td>
<td>1/1</td>
<td>2/2</td>
</tr>
<tr>
<td>Jerry Fowden</td>
<td>2019 – 2021</td>
<td>1/1</td>
<td>2/2</td>
</tr>
</tbody>
</table>

**Notes:**

1. Number of meetings in 2021: (a) the Committee held six meetings, four of which were ad hoc; and (b) Dimitri Panayotopoulos did not attend the ad hoc meeting in March, which was convened at short notice, due to prior commitments.
2. Membership: (a) all members of the Committee are independent Non-Executive Directors in accordance with UK Corporate Governance Code 2018 Provisions 10 and 17, applicable US federal securities laws and NYSE listing standards; (b) Richard Burrows ceased to be a member of the Committee on stepping down from the Board at the conclusion of the Company’s AGM on 28 April 2021; and (c) Jerry Fowden ceased to be a member of the Committee on stepping down from the Board with effect from 1 April 2021.
3. Other attendees: the Chief Executive, the Director, Talent, Culture & Inclusion, and Group Head of Talent & Organisation Effectiveness regularly attend meetings by invitation but are not members.

**Terms of Reference**

The Committee’s terms of reference align with the requirements of the Code. No changes were made to the Committee’s terms of reference in 2021.

For the Committee’s terms of reference see bat.com/governance
Balance and Diversity
The Board appreciates the benefits of diversity in all of its forms, within its own membership and at all levels across our organisation. Our Non-Executive Directors come from a broad range of industry and professional backgrounds, with varied experience and expertise aligned to the Group’s strategy. Biographies of the Directors, including a summary of their skills, experience and contribution brought to the Board, are set out on pages 100 to 101. The diversity of our Board is set out on this page and our Board Diversity Policy is discussed on page 119.

Board Succession Planning
The Board considers the length of service of the Board members as a whole and the need for it to refresh its membership progressively over time. The Nominations Committee is responsible for regularly reviewing the composition of the Board and Management Board to ensure both have an appropriate balance of skills, expertise and knowledge. The Committee is also responsible for identifying candidates for Board positions and ensuring that all appointments are made on merit, against objective criteria, and with due regard for our Board Diversity Policy (see page 119). This process includes a full evaluation of candidates’ attributes and how these would augment the Board’s mix of skills, expertise and knowledge and involves interviews with a range of candidates.

In 2021, the Committee assessed the profiles, skills and experience required of future Non-Executive Directors, taking into account the Group’s purpose and strategy. Following this assessment, the Committee developed candidate profile requirements to support Non-Executive Director succession planning. Heidrick & Struggles1 was appointed to support the Committee with future Non-Executive Director search activities in 2021. The Committee will report on the process leading to the appointment of Krishnan ‘Kandy’ Anand as a Non-Executive Director from 14 February 2022 in the Annual Report and Form 20-F for 2022.

Annual General Meeting 2022
With the exception of Marion Helmes, the Company will submit all eligible Directors for re-election and, in the case of Kandy Anand, election for the first time. Prior to making recommendations to the Board in respect of Directors’ submissions for re-election, the Committee carried out an assessment of each Director, including their performance, contribution to the long-term sustainable success of the Company and, in respect of each of the Non-Executive Directors, their continued independence.

In relation to the proposed reappointment of Savio Kwan, who will have served as a Non-Executive Director for just over eight years at the time of the 2022 AGM, the Committee conducted a particularly rigorous review, taking into account relevant considerations including his performance and his attendance record. The Committee concluded that Savio continues to make effective use of his experience, challenges management constructively and maintains independence of thought and approach, and considered it appropriate to recommend to the Board that Savio be submitted for re-election at the 2022 AGM.

The Chairman’s letter accompanying the 2022 AGM Notice confirms that all Non-Executive Directors being proposed for re-election are effective and that they continue to demonstrate commitment to their roles.

Board Retirements
Richard Burrows stepped down as Chairman and from the Board with effect from the conclusion of the Company’s AGM on 28 April 2021. Jerry Fowden stepped down from the Board with effect from 1 April 2021. Marion Helmes will step down from the Board with effect from the conclusion of the Company’s AGM on 28 April 2022.

Notes:
1. Heidrick & Struggles International, Inc. is an independent executive search firm, compliant with the Standard and Enhanced Code of Conduct for Executive Search Firms. Heidrick & Struggles has no connections with the Company or its Directors other than in respect of provision of executive search services.
2. Applying UK Office for National Statistics ethnicity categories of: Asian; Black; Mixed/multiple ethnic groups; Other non-white ethnic group, in alignment with the Parker Review.
Executive Succession Planning
As part of the Committee’s responsibility to oversee the development of a pipeline of diverse, high-performing senior management, it reviews succession plans and talent pools at short-, mid- and long-term time horizons for the Executive Directors, other Management Board members, and certain other members of senior management.

Talent Pipeline Development
The Board regularly reviews Group talent development more broadly, including progress on our talent and culture strategic priorities to:

– attract the best talent, including development of a strong employer brand and engagement with strategic talent pools;
– develop future winning capabilities through accelerating leadership and functional capability development and digital transformation;
– enable an agile and empowered organisation through proactive organisational design effectiveness, leaders who are accountable and empowered, and a strong learning culture; and
– promote an inclusive and high-performing culture through a bold diversity and inclusion agenda, and strong leadership teams.

Our talent and culture strategic priorities are underpinned by our Group diversity and inclusion agenda, discussed on pages 69 to 73.

Progress in 2021 against our objective to develop a pipeline of diverse, high-performing senior managers is set out on page 119.

Diversity and Inclusion Agenda
Our diversity and inclusion agenda focuses on the core areas of driving ownership and accountability, building diverse talent pipelines and creating enablers.

In the context of our talent and culture strategic priorities, the Board oversees and monitors progress of our Group diversity and inclusion agenda. In 2021, this included:

– reviewing progress against the Group’s diversity and inclusion ambitions through to 2025, including to have women in 40% of senior leadership team roles and 45% of management roles, and a 50% spread of distinct nationalities in key leadership team roles;
– the Group’s progress in gaining industry-leading employer certifications in diversity and inclusion and the Group’s ambitions to gain further recognition;
– the roll-out of diversity and inclusion, LGBT+, and race and ethnicity allyship guides, including as part of leadership programmes; and
– implementation of our IGNITE returners programme in multiple markets, which focuses on supporting experienced professionals return to the workplace after a career break.

Our Strategic Report discusses our diversity and inclusion agenda and initiatives further, and provides details on the representation of women and distinct nationalities in our workforce, and in our senior management population, on pages 69 to 73.
Board Diversity Policy

We believe that talent is our competitive advantage and diversity is a critical component of our success, providing better understanding, connectivity and insight to our consumers and our employees. 'We are diverse' is one of the five key principles of our ethos, set out on page 69.

Our commitment to promoting diversity across our organisation is reflected in our Group Standards of Business Conduct, discussed further on pages 56 to 57. We respect and celebrate each other’s differences and value what makes each of us unique. These include our race, ethnicity, cultural and social background, geographical origin, gender, age, any disability, sexual orientation, religion, skills, experience, education and professional background, perspectives and thinking styles.

Objectives and Progress Update

The objectives of our Board Diversity Policy (as applied in 2021) and progress against these objectives in the year are set out below. The Board complies with the recommendations on ethnic diversity made by the Parker Review.

As at 31 December 2021, the representation of women on the Board was 40%, compliant with the recommendations on gender diversity made by the Hampton-Alexander Review.

<table>
<thead>
<tr>
<th>Objective in 2021</th>
<th>Progress in 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Considering all aspects of diversity when reviewing the composition of, and succession planning for, the Board and Management Board.</td>
<td>– The Nominations Committee has regard to diversity in its widest sense, including attributes such as gender, race, ethnicity, cultural and social backgrounds, and other personal attributes, when undertaking these activities.</td>
</tr>
<tr>
<td>Considering a wide pool of candidates across genders for appointment to the Board.</td>
<td>– Executive search firms are engaged to support Board and Management Board succession planning where applicable and are required to provide gender-balanced shortlists of candidates. Succession planning for Executive Directors and Management Board members takes into account potential internal candidates from across the Group and potential external candidates.</td>
</tr>
<tr>
<td>Maintaining at least 30% female Board representation, with the ambition of progressing towards further gender balance.</td>
<td>– The representation of women on the Board was 40% as at 31 December 2021 (2020: 33.3%). Please refer to the note above in relation to representation of women on the Board in 2022.</td>
</tr>
<tr>
<td>Giving preference, where appropriate, to engagement of executive search firms accredited under the Standard and Enhanced Codes of Conduct for Executive Search Firms.</td>
<td>– Non-Executive Director succession planning takes into account the Board’s ambition to further improve gender diversity.</td>
</tr>
<tr>
<td>Oversight of the development of a pipeline of diverse, high-performing potential Executive Directors, Management Board members and other senior managers.</td>
<td>– Where executive search firms are engaged to provide executive search services to support Board succession planning, preference is given to those that are accredited under the Standard and Enhanced Codes of Conduct for Executive Search Firms.</td>
</tr>
</tbody>
</table>

Our Commitment to Furthering Diversity

When Marion Helmes steps down from the Board at conclusion of the 2022 AGM, and following Kandy Anand’s appointment as a Non-Executive Director, the representation of women on the Board will be 30% at conclusion of the 2022 AGM (40% at conclusion of the 2021 AGM).

The Board is fully committed to enhancing its gender balance so that women represent at least 33% of the Board prior to the Company’s following AGM in 2023. The Nominations Committee will be actively progressing its Non-Executive Director succession planning to meet this objective, supported by the Board Diversity Policy.

In view of the UK Financial Conduct Authority (FCA) consultation on enhanced disclosure of the diversity of boards and executive management, the Board also anticipates that a revised Board Diversity Policy will be introduced during 2022, aligned to any new UK Listing Rules requirements implemented by the FCA.
Audit Committee current members

<table>
<thead>
<tr>
<th>Name</th>
<th>Member since</th>
<th>Attended/Eligible to attend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holly Keller Koeppel</td>
<td>2017</td>
<td>5/5, 0/0</td>
</tr>
<tr>
<td>Karen Guerra</td>
<td>2021</td>
<td>4/4, 0/0</td>
</tr>
<tr>
<td>Darrell Thomas</td>
<td>2020</td>
<td>5/5, 0/0</td>
</tr>
<tr>
<td>Luc Jobin</td>
<td>2019 – 2021</td>
<td>2/2, 0/0</td>
</tr>
<tr>
<td>Jerry Fowden</td>
<td>2019 – 2021</td>
<td>1/1, 0/0</td>
</tr>
</tbody>
</table>

Notes:
1. Meetings: (a) the Committee held five meetings in 2021; (b) five meetings of the Committee are scheduled for 2022.
2. Membership: (a) all members of the Committee are independent Non-Executive Directors in accordance with the UK Corporate Governance Code 2018 Provisions 10 and 24 and applicable US federal securities laws and NYSE listing standards. The Board has determined each Committee member to meet the financial literacy requirements applicable under NYSE listing standards. Each member of the Committee has relevant financial experience in accordance with the UK Corporate Governance Code 2018. The Committee members as a whole have competence relevant to the sectors the Group operates in; (b) Holly Keller Koeppel and Darrell Thomas are each designated as an audit committee financial expert in accordance with applicable US federal securities laws and NYSE listing standards; (c) Karen Guerra became a Committee member on 1 April 2021; (d) Luc Jobin ceased to be a Committee member on his appointment as Chairman from conclusion of the Company’s AGM on 28 April 2021; and (e) Jerry Fowden ceased to be a Committee member on stepping down from the Board with effect from 1 April 2021.
3. The Finance and Transformation Director attends all Committee meetings but is not a member. Other Directors may attend by invitation: The Director, Legal & External Affairs and General Counsel; the Group Head of Internal Audit; and the external auditors attend all meetings.
4. The Committee meets alone with the external auditors, and separately with the Group Head of Internal Audit, at the end of every Committee meeting. The Committee also meets periodically with management.

Introduction

On behalf of the Audit Committee, I am pleased to introduce our report for 2021. The report sets out the Committee’s role and responsibilities, and discusses our activities during the year.

Karen Guerra joined the Committee on 1 April 2021 and, later that month, Luc Jobin stepped down from the Committee on his appointment as Chairman. We welcome Karen and extend our thanks to Luc for his service to the Committee since 2019.

We have addressed a series of important topics this year. We assessed climate-related risks and their impact on the Group to ensure robust processes are in place to identify, assess and manage climate risks in alignment with the TCFD framework. We also reviewed the approach to managing cyber security and digital transformation risks across the Group and our role in monitoring cyber security controls is now expressly recognised in the Committee’s revised terms of reference.

We have given detailed consideration to a range of accounting matters during the year, including rigorous assessment of adjusting items. We also introduced a new Group accounting policy on biological assets in view of the Group’s acquisition of a non-controlling interest in Organigram Holdings Inc.

Alongside these activities, we maintained our focus on safeguarding a sound control environment, taking account of the continued impact of COVID-19 on ways of working. We monitored progress on the internal audit plan during the year and are satisfied the blended approach to remote and on-site audits continues to be effective. The internal audit plan approved for 2022 builds on these principles and is designed to be responsive to the evolving nature of Group risks.

We appreciate the expectations of our shareholders and wider stakeholders for transparent, high quality reporting on our ESG metrics and progress on our sustainability agenda. Our Group sustainability reporting is well established, including procedures for reporting ESG metrics and related information. To enhance this, we have extended the scope of external assurance of reported ESG metrics, overseen by the Committee under our revised terms of reference.
Role
As set out in its terms of reference, the Audit Committee monitors and reviews the:

- integrity of the Group’s financial statements and any formal announcements relating to the Company’s performance, considering any significant financial reporting issues, significant judgements and estimates reflected in them, before their submission to the Board;
- consistency of the Group’s accounting policies;
- effectiveness of, and makes recommendations to the Board on, the Group’s accounting, internal accounting and other financial controls, auditing matters and business risk management systems;
- effectiveness of the Group’s internal audit function; and
- independence, performance, effectiveness and objectivity of the Company’s external auditors, making recommendations to the Board as to their reappointment (or for a tender of audit services where appropriate), and approving their terms of engagement and the level of audit, audit-related and non-audit fees.

Revisions to the Audit Committee terms of reference in 2021
Revised Audit Committee terms of reference were adopted by the Board in September 2021 to:

- extend the remit of the Committee to include responsibilities for the engagement of external providers to conduct assurance over defined ESG metrics and related information in annual reporting, monitoring that assurance work, and reviewing its effectiveness, taking into account applicable regulatory and professional requirements; and
- make express reference to the Committee’s role in monitoring cyber security controls as part of the Committee’s oversight of the Group’s internal controls and business risk systems.

Key Activities in 2021
Regular work programme – reviewing:

- the Group’s annual results, half-year results, the application of accounting standards, and the external auditors’ reports where results are audited;
- the Group’s external auditors’ year-end audit, including the key audit matters, critical audit matters, materiality assessments and the Group’s control environment, and confirming the independence of the Group’s external auditors;
- the basis of preparation and accounting judgements;
- the steps taken to validate the Group’s ‘going concern’ assessment at half-year and year-end and agreeing the process and steps taken to determine the Group’s viability statement at year-end;
- adjusting items, applicable accounting treatments and the use of alternative performance measures;
- the annual assessment of goodwill and intangible impairment;
- the accounting applicable to retirement benefits liabilities and assets;
- the Group’s liquidity position, including current facilities and financing needs;
- the internal processes followed for the preparation of the Annual Report and Form 20-F and confirming that the processes appropriately facilitated the preparation of an Annual Report and Form 20-F that is fair, balanced and understandable;
- the Group’s risk register, including prioritisation and categorisation of Group risks, and relevant mitigating factors;
- oversight of management’s activities to ensure ongoing compliance with the US Sarbanes-Oxley Act of 2002 (SOx) (discussed on page 127);
- the Company’s status as a Foreign Private Issuer for the purposes of US securities laws;
- regular reports from the Group Head of Internal Audit on the internal audits of markets, business units, processes and operations, management responses to internal audit findings and action plans put in place to address any issues raised;
- the 2022 internal audit plan and progress against the 2021 plan;
- annual and interim reports on the Group’s ‘Delivery with Integrity’ compliance programme (discussed on pages 56 to 57), and monitoring compliance with the Standards of Business Conduct (SoBC), and monitoring SoBC incident reporting and the effectiveness of ‘Speak Up’ channels prior to review by the Board;
- the Group’s sustainability performance on an annual basis, including performance against the Group’s ESG targets, the Group’s responsible marketing and youth access prevention activities, and the Group’s community investment activities in countries and communities in which the Group operates under the Group Strategic Framework for Community Investment, (discussed on page 54);
- the outcomes of assessments of countries in which Group companies operate identified to have a higher degree of exposure to human rights risks in 2021, including local compliance with Group policies, standards and controls and local measures in place to enhance human rights risk management;
- periodic reports from the Group’s Corporate Audit Committee and Regional Audit and Corporate Social Responsibility Committees;
- the annual report from the Group Head of Security on security risks, losses and fraud arising during the preceding year;
- half-year and year-end reports on political contributions, (discussed on page 127); and
- the Committee’s effectiveness, following the annual evaluation of the Committee (discussed on pages 114 to 115).

Further specific matters considered by the Committee in relation to the financial statements:

- segmental reporting: the Committee reviewed the application of segmental reporting in accordance with IFRS 8 (Operating Segments) and assessed that the Group’s financial reporting segmentation would remain by geography for the 2021 financial statements with revenue disclosures also provided by product category (see note 2 in the Notes on the Accounts);
- revisions to Group accounting policies: the Committee endorsed the introduction of a new Group accounting policy on biological assets in accordance with IAS 41 (Agriculture) to take effect from the acquisition by the Group of a 19.9% equity investment in Organigram Holdings Inc.
- UK-adopted IFRS: following the incorporation of IFRS standards into UK regulations at the end of the transition of the UK’s exit from the EU, the Group’s financial reporting is prepared under UK-adopted international accounting standards from 1 January 2021 onwards.
- Euro Hybrid Bond issuance: the Committee reviewed the accounting treatment applicable to the €2 billion hybrid bond issuance and assessed its classification as equity in accordance with IAS 32 (Financial Instruments) and its impact on the earnings per share calculation (see note 11 in the Notes on the Accounts).
Significant accounting judgements and estimates considered by the Committee in relation to the 2021 financial statements:

The significant accounting judgements and estimates considered in relation to the financial statements for the year ended 31 December 2021 are summarised below.

– the Group’s significant tax exposures: reviewing updates on corporate tax matters and reports from the Group Head of Tax on the status of the Franked Investment Income Group Litigation Order (FI GLO) and issues in various markets, including tax disputes in the Netherlands. The Committee concurred with management’s assessments and disclosures in respect of these (see note 31 in the Notes on the Accounts);

– contingent liabilities, provisions and deposits in connection with ongoing litigation:
  Imperial Tobacco Canada (ITCAN): monitoring the status of the ongoing Canadian Companies’ Creditors Arrangement Act (CCAA) proceedings under which Group subsidiary ITCAN filed for protection in March 2019 following the judgment of the Quebec Court of Appeal in the Quebec Class Action lawsuits. The Committee also reassessed the accounting treatment in respect of all other ongoing tobacco-related litigation to which ITCAN is a defendant and confirmed that it continued to be appropriate to make no provision in respect of that litigation, as it is not possible to reasonably estimate the amount of any potential settlement (see note 31 in the Notes on the Accounts) and that, whilst ITCAN is subject to the CCAA proceedings, it continued to be appropriate to consolidate ITCAN’s financial results in the Group financial statements;
  Fox and Kalamazoo rivers: the Committee reassessed the provision in respect of the Fox River clean-up costs and related legal expenses and confirmed that the provision would continue to be retained at the prior year level (see note 24 in the Notes on the Accounts), although inherent uncertainties remain (see note 31 in the Notes on the Accounts). The Committee reviewed the position in respect of the Kalamazoo River claim and confirmed that a provision should be recognised on the basis set out at note 31 in the Notes on the Accounts;
  Reynolds American Companies: the Committee considered and endorsed management’s approach to accounting for the Master Settlement Agreement and the Engle class-action and progeny cases consistent with the prior year (see note 31 in the Notes on the Accounts); and
  VAT on social contributions in Brazil: the Committee assessed the accounting treatment applicable to claims made by a Group subsidiary in Brazil for refunds of VAT on social contributions made in Brazil (see note 31 in the Notes on the Accounts) and in relation to the disposal of part of the associated contingent asset (see note 5 in the Notes on the Accounts);

– foreign exchange and hyperinflation: as the Group has operations in certain jurisdictions with severe currency restrictions where foreign currency is not readily available, including in hyperinflationary territories such as Venezuela, the Committee assessed management’s approach to applicable accounting treatment and confirmed that methodologies used to determine relevant exchange rates for accounting purposes were appropriate;

– goodwill and intangibles impairment review: the Committee reviewed management’s assessments of the carrying value of intangibles, including goodwill (see note 12 in the Notes on the Accounts), with particular focus on:
  US Business: the Committee considered potential regulatory changes in the US in relation to menthol in cigarettes and assessed that no impairment was required for US business goodwill or intangible assets and that retaining indefinite-life designation for the Newport and Camel brand intangibles was appropriate;
  GTR: despite a delay in returning to normal operations after COVID-19, the Committee concurred with management’s assessment that there was no indication of impairment;

Peru: the Committee reviewed the Group’s business in Peru and concluded that an impairment to goodwill or other intangibles of €54 million was required;

– changes in the Group: the Committee considered the accounting treatment in relation to the Group’s disposal of operations in Iran (concurring with the accounting for the disposal including treatment of costs and foreign exchange) and acquisition of an initial 19.9% equity investment in Organigram Holdings Inc. and concurred with management’s assessment to account for this as an associate (see note 14 in the Notes on the Accounts);

– hybrid bonds: the Committee assessed the issuance of perpetual hybrid bonds, concurring with management’s assessment for such to be classified as equity instead of borrowings; and

– adjusting items: the Committee conducted a rigorous assessment of all adjusting items, including the appropriate application of adjusting items treatment to Quantum programme implementation costs (see note 7 in the Notes on the Accounts) and costs arising from the disposal of the Group’s operations in Iran (see note 6(f) in the Notes on the Accounts).

Risk topics considered by the Committee included:

– risks relating to the continued impact of COVID-19 and the approach to incorporating those risks into existing risks to the Group managed under the Group’s risk register;

– climate change risks and their impact on the Group, to ensure robust processes are in place to manage both physical and transitional climate change risks, and annual reporting on the identification, assessment and management of those risks, in alignment with the TCFD framework;

– risks related to ESG and the approach to incorporating ESG risks into existing risks managed under the Group’s risk register, to ensure appropriate internal standards, strategic plans, governance, monitoring and reporting mechanisms are in place to align with recognised international standards, meet external expectations and identify emerging issues;

– current and emerging risks in the context of the Group’s digital strategy, technology architecture and data management, with particular focus on digital transformation, cyber security, protection of the Group’s information systems and data, and the approach to managing those risks.
those services does not impair auditor independence and objectivity.

The Group has an established AIP, reflecting the requirements of applicable laws, to safeguard the independence and objectivity of the Group’s external auditors and to specify the approval processes for the engagement of the Group’s external auditors to provide audit, audit-related and other non-audit services. The key principle of the AIP is that the Group’s external auditors to provide audit, audit-related and other non-audit services, except in respect of non-audit services falling within the exceptions described above; prohibits the provision of certain types of services by the external auditors, including those with contingent fee arrangements, expert services unrelated to audit and other services prohibited by US securities laws and the Public Company Accounting Oversight Board; specifies requirements in respect of audit partner rotation, including for both the lead and the concurring external audit partners to rotate off the Group audit engagement at least every five years, and not to recommence provision of audit or audit-related services to the Group for a further five years; and provides authority for the Committee to oversee any allegations of improper influence, coercion, manipulation or purposeful misleading in connection with any external audit, and to review any issues arising in the course of engagement with the external auditors.

For further information please refer to the Group Principal Risks on pages 92 to 97 and the Group risk factors on pages 217 to 230

External Auditors

KPMG LLP (KPMG) were appointed as the Company’s auditors with effect from 23 March 2015, following a competitive tender process carried out in 2015. The Committee continually reviews its relationship with the auditors, including consideration as to when it next intends to complete a competitive tender process for the Company’s external audit. The Committee also reviews the quality of the audit and discusses opportunities for improvement with KPMG and management. These are taken into consideration in determining when the Committee next intends to complete a competitive tender process for the external audit.

The Committee continues to monitor this, taking into account the effectiveness and independence of the auditors and the best interests of shareholders, and will ensure that an audit tender is conducted no later than in respect of the 2025 financial year in accordance with applicable law and regulations.

UK Competition and Markets Authority Audit Order

The Company has complied with the Statutory Audit Services Order issued by the UK Competition and Markets Authority for the financial year ended 31 December 2021.

Group Auditor Independence Policy (AIP)

The Group has an established AIP, reflecting the requirements of applicable laws, to safeguard the independence and objectivity of the Group’s external auditors and to specify the approval processes for the engagement of the Group’s external auditors to provide audit, audit-related and other non-audit services. The Committee recognises that using the external auditors to provide services can be beneficial given their detailed knowledge of our business. However, the AIP does not permit the Committee to delegate its responsibilities to the external auditors and the external auditors are only permitted to provide audit, audit-related and non-audit services in accordance with the AIP.

The AIP does not permit the external auditors to maintain a financial, employment or business relationship with any Group company, or provide services to any Group company, which:

- creates a mutual or conflicting interest with any Group company;
- places the external auditors in the position of auditing their own work;
- results in the external auditors acting as a manager or employee of any Group company; or
- places the external auditor in the position of advocate for any Group company.

Audit services are approved in advance by the Committee on the basis of an annual engagement letter and the scope of audit services is agreed by the Committee with the external auditors.

Subject to the restrictions specified in the AIP, the external auditors may also provide certain non-audit services with the prior approval of the Committee. The requirement for the Committee’s pre-approval of non-audit services may be waived only if the aggregate amount of all non-audit services provided is less than 5% of the total amount paid to the external auditors during the reporting year, where those services were not recognised to be non-audit services at the time of engagement, and provided those services are promptly brought to the attention of the Committee and their provision is approved prior to completion of the audit in the relevant reporting year.

The provision of permitted non-audit services must be put to tender if expected spend exceeds limits specified in the AIP, unless a waiver of this requirement, in accordance with the terms of the AIP, is agreed by the Finance and Transformation Director and notified to the Committee.

The AIP:

- requires Committee pre-approval for all audit, audit-related and other non-audit services, except in respect of non-audit services falling within the exceptions described above;
- prohibits the provision of certain types of services by the external auditors, including those with contingent fee arrangements, expert services unrelated to audit and other services prohibited by US securities laws and the Public Company Accounting Oversight Board;
- prohibits the Chief Executive, Finance and Transformation Director, Group Financial Controller and Group Chief Accountant from having been employed by the external auditors in any capacity in connection with the Group audit for two years before initiation of an audit;
- specifies requirements in respect of audit partner rotation, including for both the lead and the concurring external audit partners to rotate off the Group audit engagement at least every five years, and not to recommence provision of audit or audit-related services to the Group for a further five years; and
- provides authority for the Committee to oversee any allegations of improper influence, coercion, manipulation or purposeful misleading in connection with any external audit, and to review any issues arising in the course of engagement with the external auditors.
External audit fees

The Committee reviews a schedule identifying the total fees for all audit and audit-related services, tax services and other non-audit services expected to be undertaken by the external auditors in the following year. Tax services and other non-audit services in excess of the tender thresholds referred to above must be itemised. Updated schedules are also submitted to the Committee at mid-year and year-end, so that it has full visibility of the Group spend on services provided by the Group’s external auditors.

A breakdown of audit, audit-related, tax and other non-audit fees paid to KPMG firms and associates in 2021 is provided in note 6(i) in the Notes on the Accounts and is summarised as follows:

<table>
<thead>
<tr>
<th>Services provided by KPMG firms and associates 2021</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audit services</td>
<td>18.2</td>
<td>18.6</td>
</tr>
<tr>
<td>Audit of defined benefit schemes</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>Audit-related assurance services</td>
<td>8.0</td>
<td>8.5</td>
</tr>
<tr>
<td>Total audit and audit-related services</td>
<td>26.6</td>
<td>27.6</td>
</tr>
<tr>
<td>Other assurance services</td>
<td>0.3</td>
<td>0.5</td>
</tr>
<tr>
<td>Tax advisory services</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tax compliance</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other non-audit services</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total non-audit services</td>
<td>0.3</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Note: In 2021, non-audit fees paid to KPMG amounted to 1.1% of the audit and audit-related assurance fees paid to them (2020: 1.8%). All audit and non-audit services provided by the external auditors in 2021 were pre-approved by the Committee.

External auditor effectiveness

The Committee, on behalf of the Board, is responsible for the relationship with the external auditors. The Committee carries out an annual assessment of the Group’s external auditors, covering qualification, expertise and resources, objectivity and independence, and the effectiveness of the audit process. This assessment takes into account the Committee’s interactions with, and observations of, the external auditors and considers a range of factors, including:

– experience and expertise of the external auditors in their direct communication with, and support to, the Committee;
– their mindset and professional scepticism;
– their effectiveness in completing the agreed external audit plan;
– their approach to handling significant audit and accounting judgements;
– content, quality and robustness of the external auditors’ reports; and
– their provision of non-audit services, as noted above, and other matters that may impact independence.

The Committee’s assessment is also informed by an external audit satisfaction survey completed by members of the Group’s senior management. No material issues were identified during the external auditor assessment in 2021. The Committee is satisfied with the qualification, expertise and resources of its external auditors, and that the objectivity and independence of its external auditors are not in any way impaired by the non-audit services which they provide. The Committee has recommended to the Board the proposed reappointment of KPMG at the 2022 AGM.

Audit Partner Rotation

In accordance with the requirements of the UK Financial Reporting Council (FRC) Ethical Standard and the US SEC independence rules on partner rotation, the previous audit partner’s term concluded at the end of the 2020 year-end audit and the current audit partner’s tenure commenced from the start of the 2021 year-end audit.

FRC review of Half Year report to 30 June 2021

The FRC carried out a review of the Company’s Half Year report to 30 June 2021. The FRC correspondence with the Company regarding the outcomes of that review confirmed there were no questions or queries that required substantive correspondence between the Company and the FRC.

The outcomes of the FRC review of the Company’s Half Year report were reviewed by the Committee and have been taken into account in the preparation of the Annual Report and Accounts for the year ended 31 December 2021.

The review conducted by the FRC was based solely on the Company’s published Half Year report to 30 June 2021. The FRC’s review does not provide any assurance that the Half Year Report is correct in all material respects; the FRC’s role is to consider compliance with reporting requirements, not to verify the information provided.

Risk Management and Internal Control

Overview

The Company maintains its system of risk management and internal control with a view to safeguarding shareholders’ investment and the Company’s assets. It is designed to identify, evaluate and manage risks that may impede the Company’s objectives. It cannot, and is not designed to, eliminate them entirely. The system therefore provides a reasonable, not absolute, assurance against material misstatement or loss. A description of the principal risks that may affect the Group’s business is provided in our Strategic Report on pages 92 to 97. The main features of the risk management processes and system of internal control operated within the Group are described below. These have been in place throughout the year under review and remain in place at date. These do not cover associates of the Group.

Board oversight

During the year, the Board considered the nature and extent of the principal risks that the Group is willing to take to achieve its strategic objectives (its ‘risk appetite’) and its framework for maintaining sound risk management and internal control systems. Risk appetite is reviewed annually by the Board to ensure that it is appropriate. Alongside a robust assessment of the principal risks and uncertainties facing the Group (including those that would threaten its business model, future performance, solvency, liquidity and viability), the Board also considers emerging risks which may challenge the Group’s ability to achieve its strategic objectives in the future. Emerging risks are assessed by the Board to determine the potential impact and likelihood and, where applicable, incorporated into the Group’s risk register with appropriate mitigating activities. Emerging risks are kept under regular review by the Committee, prior to Board assessment.

With the support of the Committee, the Board also conducts an annual review of the effectiveness of the Group’s risk management and internal control systems. This review covers all material controls including financial, operational and compliance controls and risk management systems, with the Committee continuing to have a strong focus on IT systems and controls.
Audit and Corporate Social Responsibility (CSR) Committee framework

The Group’s Regional Audit and CSR Committee framework underpins the Audit Committee. It provides a flexible channel for the structured flow of information through the Group, with committees for each of the three Group regions, for the US business, and for locally-listed Group entities and specific markets where considered appropriate.

The Regional Audit and CSR Committees are supported by Risk and Control Committees established at business unit level, and within certain Group functions where applicable. This framework ensures that significant financial, social, environmental, governance and reputational risks faced by the Group are appropriately managed and that any failings or weaknesses are identified so that remedial action may be taken. The Group’s Regional Audit and CSR Committees are all chaired by an Executive Director, comprise members of the Management Board and regularly attended by one or more Non-Executive Directors.

In addition, the Corporate Audit Committee focuses on the Group’s risks and control environment that fall outside the regional committees’ remit, such as central functions, and global programmes, processes and projects. It comprises members of the Management Board and is chaired by a Regional Director. One or more of the Non-Executive Directors also regularly attend meetings of the Corporate Audit Committee.

External and internal auditors attend meetings of these committees and regularly have private audiences with members of the committees after meetings. Additionally, central, regional and individual market management, along with Internal Audit, support the Board in its role of ensuring a sound control environment.

Risk management

Risk registers, based on a standardised methodology, are used at Group, functional, directly-reporting business unit (DRBU), and individual market levels to identify, assess and monitor the risks (both financial and non-financial) faced by the business at each level. Risks are assessed and prioritised at three levels by reference to their impact (high/medium/low) and likelihood (probable/possible/unlikely).

Mitigation plans are required to be in place to manage the risks identified, and progress against those plans is monitored. The risk registers are reviewed on a regular basis. Functional and regional risk registers are reviewed regularly by the relevant Regional Audit and CSR Committee or the Corporate Audit Committee, as appropriate. DRBU and market risk registers are reviewed as part of local Risk and Controls meetings.

At the Group level, specific responsibility for managing each identified risk is allocated to a member of the Management Board. The Group risk register is reviewed regularly by a committee of senior managers, chaired by the Finance and Transformation Director. In addition, it is reviewed annually by the Board and twice yearly by the Committee. The Board and the Committee review changes in the status of identified risks and assess the changes in impact and likelihood. The Committee also conducts detailed reviews on selected risks, meeting senior managers responsible for managing and mitigating them, so that it can consider those risks at a more granular level.

As reported in the Company’s half-year report to 30 June 2021, the Group no longer maintains ‘market size reduction and consumer downtrading’ as a principal risk, due to the Group’s strategy to deliver long-term sustainable growth with a range of innovation and less harmful products. The Group’s current principal risks otherwise remain broadly unaltered from those maintained as at 31 December 2020.

Internal control

Group operating companies and other business units are annually required to complete a controls self-assessment, called Control Navigator, of the key controls that they are expected to have in place. Its purpose is to enable them to self-assess their internal control environment, assist them in identifying any controls that may need strengthening and support them in implementing and monitoring action plans to address control weaknesses. The Control Navigator assessment is reviewed annually to ensure that it remains relevant to the business and covers all applicable key controls. In addition, at each year-end, Group operating companies and other business units are required to:

- review their system of internal control, confirm whether it remains effective, and report on any specific control deficiencies and the action being taken to address them; and
- review and confirm that policies and procedures to promote compliance with the SoBC are fully embedded and identify any material instances of non-compliance.

The results of these reviews are reported to the relevant Regional Audit and CSR Committees or to the Corporate Audit Committee, and to the Audit Committee, to ensure that appropriate remedial action has been, or will be, taken where necessary. They are also considered by the SOx Steering Committee and the Disclosure Committee in determining management’s opinion on the internal controls over financial reporting (ICFR).

Annual review

The Financial Reporting Council’s ‘Guidance on Risk Management, Internal Control and Related Financial and Business Reporting’ provides guidance in relation to issues of risk and internal control management and related reporting. The processes described above, and the reports that they give rise to, enable the Board and the Committee to monitor risk and internal control management on a continuing basis throughout the year and to review its effectiveness at the year-end. The Board, with advice from the Committee, has completed its annual review of the effectiveness of that system for 2021.

The Board is satisfied that the system of risk and internal control management accords with the UK Corporate Governance Code 2018 and satisfies the requirements for internal controls over financial reporting.
Audit Committee

Continued

Internal Audit function
The Group’s Internal Audit function is responsible for carrying out risk-based audits of Group companies, business units, and global processes. A separate Business Controls Team provides advice and guidance on controls to the Group’s businesses.

The Group’s Internal Audit function works to a rolling 18-month audit plan, prioritising principal risk areas aligned to the Group’s risk register. During 2021, the Internal Audit plan was kept under regular review with the Committee, enabling flexibility to augment the plan to cover additional audit assignments in response to emerging risks where appropriate and ongoing monitoring of the continuing effectiveness of remote audit work.

In 2021, internal audits covered various markets, manufacturing facilities in various locations and a range of other business activities, including business continuity planning, cyber and data security and access controls, IT infrastructure, supply chain compliance, leaf sourcing, business transformation programmes, business to consumer (B2C) e-commerce channels and New Categories youth access prevention procedures. The Committee considered internal audit findings and action plans established to address any issues identified.

The scope of each internal audit is assessed for SOx impact and audit of applicable SOx controls is included where relevant. Reviews of SOx controls and their effectiveness are primarily conducted by the Group’s Business Controls Team and assurance is also undertaken by the Group’s external auditors, see page 127.

The Committee has approved the Internal Audit plan for 2022 and assessed its alignment with the Group’s risk register and coverage of Group risks. The design of the Internal Audit plan for 2022 builds on progress made in 2021, with enhanced use of data analytics, and takes account of the evolving nature of Group risks.

The strategic priorities for Internal Audit underpin the design of the Internal Audit plan for 2022, with continued emphasis on New Categories and innovation in ways of working, whilst maintaining thorough coverage of core business activities, lines of defence and IT controls. The Internal Audit plan for 2022 anticipates the continuation of COVID-19 travel restrictions into 2022, balancing remote fieldwork and use of data analytics with focused site visits.

The Committee reviews the effectiveness of the Group’s internal audit function annually. The Committee considers the Internal Audit function to be effective and to have the necessary resources to enable it to fulfil its mandate.

Financial reporting controls
The Group has in place a series of policies, practices and controls in relation to the financial reporting and consolidation process, which are designed to address key financial reporting risks, including risks arising from changes in the business or accounting standards, and to provide assurance of the completeness and accuracy of the Annual Report and Form 20-F.

A key area of focus is to assess whether the Annual Report and Form 20-F and financial statements are ‘fair, balanced and understandable’ in accordance with the UK Corporate Governance Code, with particular regard to:

- **Fair**: Consistency of reporting between the financial statements and narrative reporting of Group performance and coverage of an overall picture of the Group’s performance;
- **Balanced**: Consistency of narrative reporting of significant accounting judgements and key matters considered by the Committee with disclosures of material judgements and uncertainties noted in the financial statements; appropriate use, prominence and explanation of primary and adjusted performance measures; and
- **Understandable**: Clarity and structure of the Annual Report and Form 20-F and financial statements, appropriate emphasis of key messages, and use of succinct and focused narrative with strong linking throughout the report, to provide shareholders with the information needed to assess the Group’s business, performance, strategy and financial position.

The Group Manual of Accounting Policies and Procedures sets out the Group accounting policies, its treatment of transactions and its internal reporting requirements.

The internal reporting of financial information to prepare the Group’s annual and half-year financial statements is signed off by the heads of finance responsible for the Group’s markets and business units. The heads of finance responsible for the Group’s markets and all senior managers must also confirm annually that all information relevant to the Group audit has been provided to the auditors and that reasonable steps have been taken to ensure full disclosure in response to requests for information from the external auditors.

The Committee Chair participated in the 2021 Annual Report and Form 20-F drafting and review processes, and engaged with the Finance and Transformation Director and the Group Head of Internal Audit during the drafting process.

Extermal assurance of ESG metrics and related information
To further strengthen robust procedures in place for reporting ESG metrics and related information for the Group in the Annual Report and Form 20-F, the scope of external assurance over annual reporting of ESG metrics and related information has been extended, with the work of the external assurance provider overseen by the Committee under its revised terms of reference discussed on page 121.

Following a competitive tender process, KPMG LLP were appointed as the external assurance provider in relation to defined ESG metrics and related information. The Committee approved KPMG’s provision of these services in accordance with the requirements of the Group Auditor Independence Policy. ESG metrics and related information subject to external assurance are identified in the assurance statement set out in our 2021 ESG Report.
SOx compliance oversight

The Group is subject to certain rules and regulations of US securities laws, including the US Securities Exchange Act 1934 and SOx. SOx places specific responsibility on our Chief Executive and the Finance and Transformation Director to certify or disclose information applicable to the financial statements, disclosure controls and procedures (DCP) and ICFR. This includes our Chief Executive and Finance and Transformation Director giving attestations in respect of ICFR effectiveness under §404 of SOx.

The Committee has oversight of processes established to ensure full and ongoing compliance with applicable US securities laws, including SOx. Two committees provided assurance during 2021 with regard to applicable SOx certifications. The Disclosure Committee reviews the Company’s financial statements for appropriate disclosure, design and maintains DCPs, and reports to, and is subject to the oversight of, the Chief Executive and the Finance and Transformation Director.

A sub-committee of the Disclosure Committee, the SOx Steering Committee, provides assurance that ICFR have been designed, and are being operated, implemented, evaluated and disclosed appropriately, in accordance with applicable requirements and subject to the oversight of the Chief Executive and Finance and Transformation Director. The activities of this sub-committee are directly reported to the Disclosure Committee.

The outputs from the Disclosure Committee and SOx Steering Committee were presented to and reviewed by the Committee. No material weaknesses were identified and the Committee is satisfied that, where areas for improvement were identified, processes are in place to ensure that remedial action is taken and progress is monitored.

In 2021, the Committee also reviewed the scope of the external auditors’ SOx procedures, and received reports on their progress with their independent assessment of ICFR across the Group.

Code of Ethics for the Chief Executive and Senior Financial Officers

The Company has adopted a Code of Ethics applicable to the Chief Executive, the Finance and Transformation Director, and other senior financial officers, as required by SOx and applicable US listing standards. No waivers or exceptions to the Code of Ethics were granted in 2021.

Group Standards of Business Conduct (SoBC)

The Committee is responsible for monitoring compliance with the SoBC, and reports on this to the Board. The SoBC requires all staff to act with a high degree of business integrity, comply with applicable laws and regulations, and ensure that standards are never compromised for the sake of results. Every Group company and all staff worldwide, including senior management and the Board, are expected to adhere to the SoBC. The SoBC and the Group’s Delivery with Integrity compliance programme are discussed on pages 56 to 57.

All Group companies have adopted the SoBC or local equivalent. Information on compliance with the SoBC is gathered at a regional and global level and reports of SoBC allegations, including details of the channels through which allegations are reported, are provided on a regular basis to the Regional Audit and CSR Committees, Corporate Audit Committee, and to the Committee. A breakdown of SoBC contacts and SoBC allegations reported across the Group in 2021 is set out on page 57.

The SoBC and information on the total number of SoBC contacts and SoBC allegations reported in 2021 (including established breaches) is available at bat.com/sobc.

Speak Up

The Group maintains Speak Up channels which enable concerns regarding SoBC compliance matters, including concerns about possible improprieties in financial reporting, to be raised in confidence (and anonymously should an individual wish) without fear of reprisal. The SoBC includes the Group’s Speak Up policy, which is supplemented by local procedures throughout the Group that provide staff with further guidance on reporting matters and raising concerns, and the channels through which they can do so. The Board periodically reviews the Group’s Speak Up policy and reports arising from Speak Up channels. The Speak Up policy was revised with effect from 1 January 2022 (as part of the revised SoBC). The Board is satisfied that the Group’s Speak Up policy and procedures enable proportionate and independent investigation of matters raised, and ensure that appropriate follow-up action is taken.

Political contributions

The Group does not make contributions to UK or European Union (EU) political organisations or incur UK or EU political expenditure. The total amount of political contributions made to non-UK and non-EU political parties in 2021 was £4,339,371 (2020: £4,851,616) as follows:

Reynolds American Companies reported political contributions totalling £4,339,371 (US$5,970,975) for the full year 2021 to US political organisations and to non-federal-level political party and candidate committees in accordance with their contributions programme. No corporate contributions were made to federal candidates or party committees and all contributions were made in accordance with applicable laws.

All political contributions made by Reynolds American Companies are assessed and approved in accordance with Reynolds American’s policies and procedures to ensure appropriate oversight and compliance with applicable laws.

In accordance with the US Federal Election Campaign Act, Reynolds American Companies continue to support an employee-operated Political Action Committee (PAC), a non-partisan committee registered with the US Federal Election Commission that facilitates voluntary political donations by eligible employees of Reynolds American Companies. According to US federal finance laws, the PAC is a separate segregated fund and is controlled by a governing board of individual employee-members of the PAC. In 2021, Reynolds American Companies incurred expenses, as authorised by US law, in providing administrative support to the PAC.

No other political contributions were reported.
Remuneration Report

Annual Statement on Remuneration

The following Annual Report on Remuneration has been prepared in accordance with the relevant provisions of the Companies Act 2006 and as prescribed in: The Large and Medium-sized Companies and Group Reports (Accounts and Reports) Regulations 2002 (the UK Directors’ Remuneration Report Regulations).

Introduction

I am pleased to present to you the Directors’ Remuneration Report for the year ended 31 December 2021 which sets out our role and the new Remuneration Policy. This report contains:

– The Annual Remuneration Report, explaining how the current Remuneration Policy has been implemented during 2021; and
– The new Directors’ Remuneration Policy, which will be put forward for a binding vote at the 2022 AGM.

2021 has been a year of further volatility as we have continued to manage the disruption arising from the COVID-19 pandemic across our business. We are incredibly proud of the collective effort made by the Group’s employees and management teams as they have remained focused on delivering growth, serving the needs of our customers and consumers, while managing through continued disruption.

Our response to the pandemic has continued to be guided by our Ethos and our primary focus has been on looking after our people and protecting their health, safety, and wellbeing. Throughout the disruption caused by COVID-19 the Group has continued to focus on providing practical support to employees to navigate through this unprecedented period and has not entered furlough arrangements or made redundancies as a result of the pandemic.

Our Focus in 2021

We have completed the review of the Directors’ Remuneration Policy during 2021, which has focused on opportunities to strengthen alignment with 1) the Group’s strategy and ESG agenda, 2) shareholder and advisory body feedback arising from the AGM in 2021 and 3) an assessment of our position in the marketplace.

Our priority has been to ensure that the Remuneration Policy:

– Creates close, long-term links between the Group’s senior management and our shareholders;
– Enables the Group to attract and retain top quality talent in the global marketplace;
– Directly supports Group strategy delivery and our A Better Tomorrow™ agenda, by rewarding high levels of sustainable long-term performance in both an appropriate and competitive manner; and
– Continues to incorporate best practice policy features.

In summary we are proposing no changes to the headline operation or quantum of our Remuneration Policy. Our overarching objective has been to ensure that the new Remuneration Policy reflects our corporate purpose and our primary ESG ambition, to reduce the health impact of our business. Specifically, we have sought through the new Remuneration Policy to:

– Strengthen focus on revenue growth in New Categories;
– Ensure focus on improving profitability in New Categories; and
– Incentivise the continued financial performance of the Group.

The Committee acknowledges that a significant minority of shareholders have been unable to support recent decisions regarding fixed pay increases for Executive Directors and have sought fuller disclosures as to the Committee’s decision-making process, which has been reflected through voting on the Directors’ Remuneration Reports in 2020 and 2019. This has been a key consideration throughout the Committee’s review process and our report this year is structured differently to provide greater detail on the perspectives of shareholders and how the Committee has responded, which are set out in the following pages.

Shareholder Engagement and New Remuneration Policy

The latter part of 2021 was dedicated to a programme of engagement with shareholders on the proposals which are contained in the new Remuneration Policy. We have engaged with shareholders representing 60% of our issued share capital, together with the Investment Association, Institutional Shareholder Services and Glass Lewis.

Our objective has been to undertake a focused review of the Remuneration Policy, building on the work undertaken in 2018 which introduced a variety of changes to our policy, including alignment of Executive Directors’ pensions arrangements with those of the wider workforce and post-employment sharing requirements. Our current Remuneration Policy was approved at the 2019 AGM with significant support from our shareholders.

Our programme of shareholder engagement has helped to refine proposals and ensure that proposed changes to the Remuneration Policy are targeted and are timely and appropriate for the Group, and

– That the proposals to strengthen the focus on New Categories performance within the short-term incentive plan (STI) and long-term incentive plan (LTI) are timely and appropriate for the Group, and
– There were opportunities to reconsider some aspects of the proposed metrics for both the STI and LTI, such as the balance and weighting between metrics and some specific performance conditions.

The tables on pages 129 and 130 summarise the proposals put forward by the Committee during shareholder engagement, together with the key points of feedback received from shareholders and the adjustments made by the Committee taking into account the feedback received.
Incentive plans – Short-Term Incentive Plan (IEIS): The Group made changes to the IEIS for 2021 following engagement with shareholders and introduced New Categories revenue performance into the plan. Recent discussions with shareholders have focused on opportunities to further strengthen prioritisation of New Categories performance, together with the incentivisation of the continued financial performance of the Group.

The Committee considers that the proposed changes outlined below will strengthen alignment with the Group’s long-term strategy delivery and the interests of shareholders.

Summary of Changes

<table>
<thead>
<tr>
<th>Measure</th>
<th>Original proposal</th>
<th>Final proposal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term incentive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volume Share</td>
<td>15%</td>
<td>10%</td>
</tr>
<tr>
<td>New Categories Revenue</td>
<td>20%</td>
<td>15%</td>
</tr>
<tr>
<td>Adj Profit from Operations</td>
<td>30%</td>
<td>25%</td>
</tr>
<tr>
<td>Deleverage (ex FX)</td>
<td>35%</td>
<td>30%</td>
</tr>
<tr>
<td>Adjusted Cash Generated From Operations</td>
<td></td>
<td>20%</td>
</tr>
<tr>
<td>New Categories Contribution</td>
<td></td>
<td>20%</td>
</tr>
</tbody>
</table>

Proposed change and rationale (I)

The introduction of a new measure ‘New Categories contribution’ with a 20% weighting. This measure will incentivise year-on-year improvement in New Categories profit contribution in line with the Group’s pathway to profitability by 2025. Further details are provided on page 143.

Shareholder feedback

Shareholders have welcomed the introduction of ’New Categories contribution’ to the IEIS as both timely and relevant.

Committee response

The Committee has considered the feedback carefully and understands shareholder views regarding adjusting for restructuring costs, which may be considered as an ongoing cost of doing business for purposes of the performance measure. Consequently, adjusting for restructuring costs has been removed from the performance measure. Litigation settlements are considered unpredictable and outside of management control, accordingly, adjusting for these have been retained as part of this measure.

Shareholder feedback

Shareholders have in general been supportive of the proposed change.

Shareholder feedback

The majority of shareholders have been supportive of the proposed re-weightings, with some specific questions raised to understand the balance of weighting between performance measures.

Committee response

Weightings were maintained as originally proposed during shareholder engagement. The Committee considered it appropriate to retain a slightly higher weighting for the ‘adjusted cash generated from operations’ measure given the Group’s continued need to focus on cash generation to support returns to shareholders and provide flexibility with capital allocation.

The introduction of the ‘New Categories contribution’ measure also further strengthens the focus within the IEIS on financial performance, whereby financial metrics represent 75% of the weighting within the plan.
Incentive plans – Long-Term Incentive Plan: Changes are made with the aim of reflecting our corporate purpose more directly, in particular our commitment to reduce the health impact of our business as part of our A Better Tomorrow™ agenda. These changes take into account shareholder feedback and focus on harm reduction as an imperative to delivering long-term sustainable growth, as follows:

### Summary of Changes

<table>
<thead>
<tr>
<th>2021 measures</th>
<th>Original proposal</th>
<th>Final proposal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term incentive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted revenue growth</td>
<td>20% Adjusted revenue growth</td>
<td>20% Adjusted revenue growth 15%</td>
</tr>
<tr>
<td>EPS (current / constant)</td>
<td>40% EPS (current / constant)</td>
<td>20% EPS (current / constant) 30%</td>
</tr>
<tr>
<td>Cash Conversion</td>
<td>20% Cash Conversion</td>
<td>20% Cash Conversion 20%</td>
</tr>
<tr>
<td>Relative TSR</td>
<td>20% Relative TSR (streamlined comparator group)</td>
<td>20% Relative TSR (streamlined comparator group) 20%</td>
</tr>
<tr>
<td>New Categories revenue growth</td>
<td>20% New Categories revenue growth</td>
<td>20% New Categories revenue growth 15%</td>
</tr>
</tbody>
</table>

**Proposed change and rationale (I)**

The introduction of a new measure ‘New Categories revenue growth’, with a 15% weighting. Our strategic objective is to provide long-term sustainable growth for our shareholders and this performance measure is directly aligned with our transformation ambitions and stated targets and will measure future growth in New Categories. Further details are provided on page 144.

**Shareholder feedback**

Some shareholders have wanted to understand the basis of measurement and the relationship with the ‘New Categories revenue’ metric in the IEIS. When we presented our original proposals, some shareholders requested that the Committee reconsider the relative weight between revenue measures and EPS, such that there is a greater balance between profit delivery and revenue growth.

**Committee response**

The inclusion of New Categories revenue growth in both the IEIS and LTIP is an important step given New Categories growth is a critical part of our long-term strategy and ESG agenda. The IEIS measure will continue to provide focus on in year delivery, while the LTIP measure will focus on cumulative and sustained performance over a three-year period. The Committee understands the views expressed by shareholders and as a result has adjusted the original proposals such that the weighting for the ‘New Categories revenue growth’ and ‘adjusted revenue growth’ measures have been reduced from 20% to 15% and the weighting for the ‘adjusted diluted earnings per share’ measure has been increased from 20% to 30% to increase the overall proportion based on profitability versus the original proposals.

**Proposed change and rationale (II)**

The ‘relative total shareholder return’ (TSR) measure is retained with the current weighting of 20%. The comparator group of companies has undergone a review as the constituents have been in place since 2013, other than the addition of the Altria Group in 2019. A review of comparator companies was believed to be timely and relevant considering changes in the Group’s business over the last eight years, our strategic focus and ambition to become a multi-category, new-category led business.

The review exercise has aimed to deliver a more focused and relevant comparator group comprised of businesses which are adjacent to the Group’s, well correlated and broadly comparable in terms of their size and scale. The final constituents represent the tobacco, soft drinks, alcohol and fast moving consumer goods sectors. Back testing of the comparator group changes for past awards confirmed that these changes would not have impacted vesting under the TSR measure. Further details are provided on page 144.

**Shareholder feedback**

The majority of shareholders have expressed comfort with the proposed comparator group changes and the intent to ensure the TSR comparator group is well calibrated and relevant for the future. A small number of shareholders had requested that additional specific companies were considered for inclusion in the comparator group.

More broadly, the Committee is aware that relative TSR can attract strong and often conflicting opinions, with a small number of shareholders expressing a preference for the removal of the measure from the LTIP.

**Committee response**

The Committee is pleased that the comparator group changes have been met with support and has taken into consideration feedback as to the composition of the group. Consequently, Swedish Match, which was not part of the original proposal, will be included in the new TSR comparator group from 2022. The Committee remains of the view that the relative TSR measure is an important component of the LTIP and helps to maintain alignment with shareholder interests, a view which is shared by the majority of our shareholders.
These changes to performance measures will apply to the IEIS from 2022 and to new awards made under the LTIP from 2022 for the Executive Directors and the Group’s wider management population. Importantly they will ensure that the Group’s transformation ambitions and core financial delivery are appropriately reflected in both the IEIS and LTIP.

Wider Themes from Shareholder Engagement

ESG measures: A small number of shareholders have enquired whether the Committee considers the introduction of broader ESG measures to either the IEIS or the LTIP. The Committee gave consideration to broader ESG measures as part of the policy review process. In view of our primary ESG commitment, to reduce the health impact of our business, and accordingly, the importance of sustainable New Categories growth, the Committee concluded that the proposed changes to IEIS and LTIP would focus on incentivising delivery of our corporate purpose and stated ambitions of delivering £5 billion in revenues in New Categories by 2025, reaching profitability in New Categories over the same time period and the continued transformation of our portfolio. Discussions with shareholders have confirmed there is consensus that this is the right approach for the Group at this time, being both directly linked to Group strategy delivery and quantifiable. The Remuneration Committee will continue to monitor ESG measures and we will continue to drive performance across our comprehensive suite of objectives across all areas of ESG, which are discussed in the Strategic Report.

Returns measures: A discrete group of shareholders have expressed a preference for a returns-type measure within the LTIP. While the Committee concurs that this is an important metric for the business to continue to track, it believes there are other important metrics to focus remuneration on at this time. We expect the Group’s return on capital performance over the near to medium term be driven by organic profit growth which is a key performance metric already represented in the IEIS and LTIP. Further, at this stage of our transformation journey the Committee believes the IEIS and LTIP should be focused on measures more closely linked to the Group’s transformation agenda (such as New Categories revenue growth and category contribution) and key financial performance measures (such as adjusted profit from operations, EPS and cash). The Committee will continue to keep metric formulation and the orientation of our incentive plans under review as our transformation journey progresses.

Executive Director remuneration: A significant minority of shareholders have been unable to support recent decisions regarding fixed pay increases for the Executive Directors and have requested fuller disclosures as to the Committee’s decision-making process in the future. During our engagement, shareholders have provided their feedback on decisions made in 2020 and 2021; while the rationale followed by the Remuneration Committee at the time has been understood, shareholders have explained their expectation of restraint with regard to fixed pay increases in future, with the majority wishing to see an employee average-led approach. The Remuneration Committee has considered the matters raised by shareholders in detail and the approach to be taken in 2022 is set out on page 132.

I would like to thank our shareholders, and wider stakeholders who have worked with us, for their feedback which has helped to maintain an ongoing and transparent dialogue regarding executive remuneration.

Group Performance

The performance measures included in our incentive plans are closely aligned with the Group’s strategy and the metrics as set out in the Strategic Report. The Group has delivered a strong performance in 2021, accelerating growth in New Categories, delivering on its leverage commitment and advancing the ESG agenda while managing the ongoing impacts arising from the COVID-19 pandemic. The performance targets set by the Committee early in the year have remained unchanged throughout the 2021 performance period.

Target setting for 2021 assumed a rate of recovery from lockdown impacts in emerging markets and Global Travel Retail, while expecting ongoing disruption from further lockdowns elsewhere in the Group, together with prolonged travel restrictions and social distancing. A key focus area of target setting was growth in the New Categories business, founded on geographic expansion, growth in the consumer base and achieving leadership of the Vapour category in the US. Target setting also assumed a continuing strong profit performance in developed markets driven by an increase in pricing. The impact of price increases and consequent flow through to revenue and profit growth was expected to be constrained by less favourable geopolitical mix due to the weighting of the post-pandemic volume recovery towards emerging markets. In order to meet profit objectives, ambitious cost savings were also embedded in the targets, anticipated to be delivered from product costs and the continued simplification of the organisation. The Group’s continued emphasis on deleveraging was reflected in a stretch target which was calibrated in anticipation of further strong delivery in operating cash flow conversion as well as the Group delivering against its profit targets.

2021 Short-term Incentive

The Group has delivered combustibles and THP volume share gains of 6 bps over performance in 2020 together with a robust performance with growth in New Categories revenue at constant rates of 50.9% and growth in adjusted profit from operations at constant rates of 5.2%. In addition, there has been continued progress with the deleveraging ambition (excluding foreign exchange) with a full year performance of -0.50x.

These results are reflected in the outcomes for the IEIS, for which the corporate result across the four measures (Group’s share of key markets, New Categories revenue, adjusted profit from operations and deleveraging excluding foreign exchange) was 85.7%.

2019 Long-term Incentive

The Group has delivered a compound annual growth rate in Group revenue of 5.3% at constant rates through the three year 2019 to 2021 period, a compound annual growth rate in adjusted, diluted EPS of 6.8% at constant rates and a corresponding operating cash flow conversion ratio of 101.0% at current rates over the same period.

These results are reflected in the outcomes for the 2019 LTIP award, for which the corporate result across relative total shareholder return (TSR), adjusted diluted EPS, adjusted revenue growth and deleveraging with cash flow conversion ratio, results in a vesting in March 2022 of 49.1%.

The vesting result reflects, through the relative TSR measure, movements in the Group’s share price during the performance period. The Committee applied a downward adjustment at grant to the 2019 LTIP award, whereby the number of shares awarded were calculated on the basis of the Group’s closing share price on 25 February 2019, increased by 15%. This adjustment was made in recognition of the decline in Group share price over the preceding 12 months. Given the share price is below that used to determine the grant, the Committee are comfortable that there has been no windfall gain.
Remuneration Report

Annual Statement on Remuneration

Continued

Following evaluation of the formulaic outcomes for both the 2021 IEIS and 2019 LTIP, the Committee considered the results against the underlying performance of the Group and the experience of our shareholders. The Committee concluded that the outcomes were a fair reflection of performance delivered in what continues to be challenging and volatile market conditions and no adjustments were required. In addition, share price fluctuations are reflected throughout the Executive Directors’ remuneration, in the vesting and holding periods as well as their individual shareholdings. The performance against the key measures that delivered the IEIS and LTIP remuneration outcomes are summarised on pages 138 and 139.

Executive Director Remuneration

The Remuneration Committee has considered in detail the views of shareholders and wider stakeholders with respect to annual salary reviews and the management of executive pay. This topic was discussed at length with shareholders during our engagement on the Remuneration Policy. The Committee has also given due consideration to the total remuneration positioning of the Executive Directors in relation to the wider market, their individual performance, and the level of pay increases for UK employees generally. Pay increases for UK employees are expected to range between 0% and 7.2%, based on performance in the prior year, with the average of employee increases falling within the 2.6% to 3.8% range.

The Remuneration Committee has decided that the salaries of the Chief Executive and the Finance and Transformation Director will be maintained at their current levels, with no further increases to apply in April 2022.

Pay and Transparency

The Remuneration Committee recognises the importance of considering executive compensation in the broader context of the Group’s workforce and the role that large organisations may play in encouraging greater transparency in this respect. Consequently, from 2022 the Group has broadened the scope of its pay equality reporting as follows.

Gender Pay: UK

In March 2022, we will be publishing data relating to UK Gender Pay in line with the statutory requirements. As a result of our continued focus we have seen an improvement in both our mean and median pay gaps by 3 percentage points when compared to 2020 and an improvement in the median bonus gap by 7 percentage points compared to 2020.

These improvements are attributable to increased time at level among senior female employees reflecting our commitment to continue to nurture and retain our female talent in more senior roles. The Group is committed to driving further progress in this area and has a comprehensive set of diversity initiatives in place which are explained further on pages 3 to 5 in our Diversity and Inclusion Report.

Gender Pay: International Business

We will also be publishing in March 2022 voluntary disclosures on gender pay for our international business. We felt it important to complement the statutory reporting for the UK with a broader view of the Group. Our international business gender pay data includes gender pay information from a cross-section of key markets, representing each of the Group’s regions and functions. Further details are included on pages 7 to 10 in our Diversity and Inclusion Report.

Ethnicity Pay: UK

During 2021 we completed a data gathering exercise with the help of UK employees. I am delighted to say that 77% of employees in the UK supported this effort and this has allowed the Group to complete a review of UK ethnicity pay data. Further details are included on page 11 in our Diversity and Inclusion Report.

We will continue to review our approach to ensure the Group provides as much transparency as is practicable in this important area.

Looking Ahead to 2022

The annual report on remuneration details remuneration in 2021 and the decisions made by the Remuneration Committee during this period. The new Remuneration Policy will be put forward for a binding vote at the 2022 AGM.

The Group has delivered a strong performance in 2021 and I believe that our proposed new Remuneration Policy supports Group strategy, drives pay for performance and meets the needs of our stakeholders in a considered way.

I would once again like to thank our shareholders and wider stakeholders for the direct engagement and feedback during this past year on both our remuneration policy and practices. I look forward to continuing this dialogue in 2022.

Dimitri Panayotopoulos
Chairman, Remuneration Committee
10 February 2022
1 Summary of Our Current Directors’ Remuneration Policy

This section provides a summary of the Remuneration Policy for the Executive Directors and the Non-Executive Directors that was approved by shareholders at the AGM on 25 April 2019 and was in place during the year ended 31 December 2021.

The full Directors’ Remuneration Policy is set out in the Remuneration Report 2018 contained in the Annual Report for the year ended 31 December 2018, which is available at bat.com.

As referenced in the Annual Statement on Remuneration on pages 128 to 132, we will be putting forward to a vote the updated Directors’ Remuneration Policy at the AGM on 28 April 2022 and the full detail of the updated policy can be found on pages 152 to 162.

<table>
<thead>
<tr>
<th>Strategic Purpose</th>
<th>Key Features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Salary</strong></td>
<td>To attract and retain high-calibre individuals to deliver the Group’s long-term strategy and to offer market-competitive levels of guaranteed cash to reflect an individual’s skills, experience and role within the Group.</td>
</tr>
<tr>
<td></td>
<td>– Normally paid in 12 equal monthly instalments during the year;</td>
</tr>
<tr>
<td></td>
<td>– Reviewed annually in February (changes effective from April) or subject to ad-hoc review on significant change of responsibilities;</td>
</tr>
<tr>
<td></td>
<td>– Reviewed taking into consideration several factors including individual performance and appropriate market data based on a Pay Comparator Group;</td>
</tr>
<tr>
<td></td>
<td>– Annual increases will generally be in the range of the increases in the base pay of other UK-based employees in the Group and will not exceed 10% per annum; and</td>
</tr>
<tr>
<td></td>
<td>– Recently appointed Executive Directors’ base salaries may exceed the top of the range of the salary increases for UK-based employees where the Remuneration Committee considers it appropriate to reflect the accrual of experience.</td>
</tr>
<tr>
<td><strong>Benefits</strong></td>
<td>To provide market-competitive benefits consistent with the role which:</td>
</tr>
<tr>
<td></td>
<td>– attract and retain high-calibre individuals to deliver the Group’s long-term strategic plans; and</td>
</tr>
<tr>
<td></td>
<td>– recognise that such talent is global in source and that the availability of certain benefits (e.g. relocation, repatriation, taxation compliance advice) will from time to time be necessary to avoid such factors being an inhibitor to accepting the role.</td>
</tr>
<tr>
<td></td>
<td>– The Company offers the following contractual benefits to Executive Directors:</td>
</tr>
<tr>
<td></td>
<td>– A car or car allowance;</td>
</tr>
<tr>
<td></td>
<td>– Use of a car and driver for personal and business use;</td>
</tr>
<tr>
<td></td>
<td>– Employment tax advice;</td>
</tr>
<tr>
<td></td>
<td>– Tax equalisation payments (where appropriate);</td>
</tr>
<tr>
<td></td>
<td>– Private medical insurance, including general practitioner ‘walk in’ medical services;</td>
</tr>
<tr>
<td></td>
<td>– Personal life and accident insurance;</td>
</tr>
<tr>
<td></td>
<td>– Housing, education allowances or similar arrangements as appropriate to family circumstances; and</td>
</tr>
<tr>
<td></td>
<td>– Other benefits may include Executive Directors and their partners’ attendance at hospitality or similar functions, and the provision of benefits which may be treated as benefits for tax purposes, such as the provision of home security and reimbursement of expenses incurred in connection with their duties.</td>
</tr>
<tr>
<td><strong>Pension</strong></td>
<td>To provide competitive post-retirement benefit arrangements which recognise the external environment in the context of attracting and retaining senior high-calibre individuals to deliver the Group’s long-term strategy.</td>
</tr>
<tr>
<td></td>
<td>– Only base salary is pensionable.</td>
</tr>
<tr>
<td></td>
<td>– Defined Contribution (“DC”) benefits – Executive Directors are eligible to receive a pension benefit equivalent to a maximum of 15% of base salary as a contribution into the British American Tobacco UK Pension Plan or, as alternative provision, they can opt for either a cash allowance or accrual in a DC unfunded arrangement. The Company contribution rate is aligned with the benefit available to our wider UK population where the default contribution rate is 15%, comprising of a core 10% contribution rate and an additional 5% contribution on a matching basis to an employee’s pension contribution.</td>
</tr>
</tbody>
</table>
Remuneration Report

Annual Statement on Remuneration

Continued

Short-term incentives (STI)

To incentivise the attainment of corporate targets aligned to the Group’s strategic objectives on an annual basis, with a deferred element to ensure alignment with shareholders’ interests.

– To ensure, overall, a market-competitive remuneration to attract and retain high-calibre individuals to deliver the Group’s long-term strategy.

Opportunity

– Chief Executive – Maximum 250%; on-target 125%.
– Finance and Transformation Director – Maximum 190%; on-target 95%.

Operation

– 50% of the incentive delivered as cash; 50% as deferred shares (DSBS) which vest after three years. Deferred shares attract a dividend equivalent which is delivered in additional quarterly interim dividend equivalent shares.
– The Remuneration Committee sets the performance targets each year at the beginning of the performance period and is able to vary the exact measures and the weighting of them from year to year;
– Performance measures for 2021 can be found on page 137 and for 2022 on page 143;
– The Remuneration Committee has discretion to adjust outcomes in circumstances where it considers it is appropriate to do so to reflect the overall performance of the Company;
– In cases of identified poor individual performance, the corporate result may be reduced by up to 50%; and
– Clawback and malus provisions are in place.

Long-term incentives (LTIP)

To put in place a combination of measures with appropriately stretching targets around the long-term strategy delivery that provides a balance relevant to the Company’s business and market conditions as well as alignment between Executive Directors’ and shareholders’ interests.

– To facilitate the appointment of senior high-calibre individuals required to deliver the Group’s long-term strategy, and to promote the long-term success of the Company.

Opportunity

– Maximum annual award of shares of 500% of salary for all Executive Directors.
– Normal annual grants of 500% of salary for the Chief Executive and 400% of salary for the Finance and Transformation Director.

Operation

– LTIP awards vest only to the extent that:
  – the performance conditions are satisfied at the end of the three-year performance period; and
  – an additional vesting period of two years from the third anniversary of the date of grant has been completed;
– Dividend equivalent shares are awarded at the end of the extended vesting period to the extent that the awards vest;
– The Remuneration Committee sets the performance targets for the applicable performance period each year;
– Vesting levels are based on the achievement of appropriately stretching targets against performance measures aligned to the Group’s long-term strategy;
– Performance measures for the 2019-2021 performance period are detailed on page 138 and for the awards to be granted in 2022 are detailed on page 144;
– The Remuneration Committee has discretion to adjust the level of vesting in circumstances where it considers it is appropriate to do so to reflect the overall performance of the Company; and
– Clawback and malus provisions are in place.

Shareholding requirements

– To strengthen the alignment between the interests of the Executive Directors and those of shareholders by requiring Executive Directors to build up a high level of personal shareholding in the Company.
– To ensure long-term alignment between the interests of the Executive Directors and those of shareholders through the operation of post-employment shareholding requirements.

Executive Directors are required to hold shares in the Company:

– during service as a Director, equal to the value of the same multiple of salary at which LTIP awards are made to that Director (currently, 500% for the Chief Executive and 400% for the Finance and Transformation Director); and
– after ceasing service as a Director, equal to the value of 100% of the shareholding requirement that applied while a Director for a period until the second anniversary of cessation of employment with the Group.

All-employee share plans

Executive Directors are eligible to participate in the Company’s all-employee share schemes which are designed to incentivise employees by giving them an opportunity to build shareholdings in the Company.

– All-employee share schemes are the Partnership Share Scheme, the Sharesave Scheme and the Share Incentive Plan (SIP); and
– Executive Directors are subject to the same limits on participation as other employees, as defined by the applicable statutory provisions.
2 Overview of What Our Executive Directors Earned in 2021 and Why

What our Executive Directors earned in 2021

<table>
<thead>
<tr>
<th>Single figure for Executive Directors</th>
<th>2021</th>
<th>Jack Bowles</th>
<th>2020</th>
<th>Tadeu Marroco</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed Pay</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salary</td>
<td>£'000</td>
<td>1,316</td>
<td>£'000</td>
<td>1,259</td>
<td>£'000</td>
</tr>
<tr>
<td>Taxable benefits</td>
<td></td>
<td>320</td>
<td></td>
<td>508</td>
<td></td>
</tr>
<tr>
<td>Pension</td>
<td></td>
<td>197</td>
<td></td>
<td>189</td>
<td></td>
</tr>
<tr>
<td><strong>Total Fixed Pay</strong></td>
<td></td>
<td>1,833</td>
<td></td>
<td>1,956</td>
<td></td>
</tr>
<tr>
<td><strong>Variable Pay</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-term incentives</td>
<td>£'000</td>
<td>2,820</td>
<td>£'000</td>
<td>2,238</td>
<td>£'000</td>
</tr>
<tr>
<td>Long-term incentives 1,2</td>
<td></td>
<td>2,815</td>
<td></td>
<td>757</td>
<td></td>
</tr>
<tr>
<td>Other emoluments</td>
<td></td>
<td>3</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Total Variable Pay</strong></td>
<td></td>
<td>5,638</td>
<td></td>
<td>2,998</td>
<td></td>
</tr>
<tr>
<td><strong>Total Remuneration</strong></td>
<td></td>
<td>7,471</td>
<td></td>
<td>4,954</td>
<td></td>
</tr>
</tbody>
</table>

Notes:
1. The 2019 LTIP award is due to vest on 28 March 2022 for Jack Bowles (first award made as an Executive Director) and Tadeu Marroco based on completion of the three-year performance period on 31 December 2021. The value shown is based on the average share price for the three-month period ended 31 December 2021 of 2,616p. Given the share price performance since the date of grant of awards, none of the value shown in the table above is attributable to share price appreciation.
2. Long-term incentives shown for 2020: in accordance with the UK Directors’ Remuneration Report Regulations, estimates for the values of the vesting 2018 LTIP awards were given in the Annual Report on Remuneration for the year ended 31 December 2020; these amounts have been re-presented to show the actual market value on the date of vesting in 2021.

Further information in respect of this remuneration can be found in Section 3 on page 136.

How this aligns to performance

Short-term incentives for the performance period ended in 2021

<table>
<thead>
<tr>
<th>Performance summary:</th>
<th>Jack Bowles</th>
<th>Tadeu Marroco</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Executive: corporate performance – 214.3% of salary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finance and Transformation Director: corporate performance – 162.8% of salary</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Group share of Key Markets**
- +6 bps growth over 2020
- +50.9% growth
- +6% CAGR at current rates of exchange
- +45.5% CAGR at constant rates of exchange
- 100.0% achievement
- 100.0% achievement

**Adjusted profit from operations (APFO)**
- at constant rates of exchange +5.2% growth
- at constant rates of exchange +45.5% achievement
- 100.0% achievement
- 100.0% achievement
- 100.0% achievement
- 100.0% achievement

**Deleveraging (excluding foreign exchange)**
- -0.50x at constant rates of exchange
- -0.50x at constant rates of exchange
- -0.50x at constant rates of exchange
- -0.50x at constant rates of exchange
- -0.50x at constant rates of exchange
- -0.50x at constant rates of exchange

**Long-term incentives for the three-year performance period ended in 2021**

<table>
<thead>
<tr>
<th>Vesting at 49.1%</th>
<th>Jack Bowles</th>
<th>Tadeu Marroco</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total shareholder return (TSR)</td>
<td>0% achievement</td>
<td>0% achievement</td>
</tr>
<tr>
<td>17 out of 24 in FMCG comparator group 2019–2021</td>
<td>(0% of award vesting out of possible 20%)</td>
<td>(0% of award vesting out of possible 20%)</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share (EPS) growth 3.5% CAGR at current rates of exchange</td>
<td>0% achievement</td>
<td>0% achievement</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share (EPS) growth 6.8% CAGR at constant rates of exchange</td>
<td>45.5% achievement</td>
<td>45.5% achievement</td>
</tr>
<tr>
<td>Adjusted revenue growth 5.3% CAGR at constant rates of exchange</td>
<td>100.0% achievement</td>
<td>100.0% achievement</td>
</tr>
<tr>
<td>Adjusted operating cash flow conversion ratio 101.0% ratio over the performance period</td>
<td>100.0% achievement</td>
<td>100.0% achievement</td>
</tr>
</tbody>
</table>

**Non-GAAP measures**

Adjusted profit from operations (APFO), deleveraging (excluding foreign exchange), New Categories revenue, adjusted diluted EPS, adjusted revenue and adjusted operating cash flow conversion ratio are non-GAAP measures used by the Remuneration Committee to assess performance. Please refer to pages 302 to 311 for definitions of these measures.
## 3 Executive Directors’ Remuneration for the Year Ended 31 December 2021

### Total remuneration for the year ended 31 December 2021

<table>
<thead>
<tr>
<th></th>
<th>Jack Bowles</th>
<th>Tadeu Marroco</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Salary</strong></td>
<td>€1,316</td>
<td>€1,259</td>
</tr>
<tr>
<td><strong>Taxable benefits</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– car allowance</td>
<td>€20</td>
<td>€20</td>
</tr>
<tr>
<td>– health insurance</td>
<td>€15</td>
<td>€15</td>
</tr>
<tr>
<td>– life insurance</td>
<td>€18</td>
<td>€19</td>
</tr>
<tr>
<td>– tax advice</td>
<td>€49</td>
<td>€65</td>
</tr>
<tr>
<td>– use of Company driver</td>
<td>€65</td>
<td>€85</td>
</tr>
<tr>
<td>– home and personal security</td>
<td>€80</td>
<td>€155</td>
</tr>
<tr>
<td>– tax &amp; social security</td>
<td>€62</td>
<td>€136</td>
</tr>
<tr>
<td>– other expenses related to individual/Company functions</td>
<td>€11</td>
<td>€13</td>
</tr>
<tr>
<td><strong>Short-term incentives</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STI vesting percentage (% of maximum)</td>
<td>85.7%</td>
<td>71.1%</td>
</tr>
<tr>
<td>STI: cash – Group performance cash element</td>
<td>€1,410</td>
<td>€1,119</td>
</tr>
<tr>
<td>STI: DSBS – Group performance deferred element</td>
<td>€1,410</td>
<td>€1,119</td>
</tr>
<tr>
<td><strong>Total short-term incentives (page 137)</strong></td>
<td>€2,820</td>
<td>€2,238</td>
</tr>
<tr>
<td><strong>Long-term incentives</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP vesting percentage (% of maximum)</td>
<td>49.1%</td>
<td>54.2%</td>
</tr>
<tr>
<td>LTIP value to vest</td>
<td>€2,267</td>
<td>€612</td>
</tr>
<tr>
<td>Dividend equivalents</td>
<td>€548</td>
<td>€145</td>
</tr>
<tr>
<td><strong>Total long-term incentives (page 138)</strong></td>
<td>€2,815</td>
<td>€757</td>
</tr>
<tr>
<td><strong>Total pension-related benefits (page 139)</strong></td>
<td>€197</td>
<td>€189</td>
</tr>
<tr>
<td><strong>Other emoluments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share Reward Scheme (value of ordinary shares awarded)</td>
<td>€3</td>
<td>€3</td>
</tr>
<tr>
<td>Sharesave Scheme (face value of discount on options granted)</td>
<td>–</td>
<td>€15</td>
</tr>
<tr>
<td><strong>Total other emoluments</strong></td>
<td>€3</td>
<td>€3</td>
</tr>
<tr>
<td><strong>Total remuneration</strong></td>
<td>€7,471</td>
<td>€4,954</td>
</tr>
</tbody>
</table>

### Notes:

1. Taxable benefits: the figures shown are gross amounts as, in line with the UK market, it is the normal practice for the Company to pay the tax which may be due on any benefits, with the exception of the car or car allowance. The numbers presented above for car or car allowance are inclusive of applicable VAT and income tax.

2. Taxable benefits: the figures shown are gross amounts as, in line with the UK market, it is the normal practice for the Company to pay the tax which may be due on any benefits, with the exception of the car or car allowance. The numbers presented above for car or car allowance are inclusive of applicable VAT and income tax.

3. The amount reported for Jack Bowles for 2020 in the Annual Report on Remuneration for the year ended 31 December 2020 was £220,000. This amount has been restated above to account for credits received in the UK in respect of overseas tax payments made by the Company. The figure reported for 2021 relates to overseas taxes paid by the Company in respect of employment income in order to protect Jack Bowles to his UK tax position in line with the Company policy for the wider workforce.

4. The 2019 LTIP award is due to vest on 28 March 2022 based on completion of the three-year performance period on 31 December 2021. The value shown is based on the average share price for the three-month period ended 31 December 2021 of 2,616p. The LTIP vesting figure above for Jack Bowles reflects the first award made as an Executive Director. The LTIP vesting figure above for Tadeu Marroco reflects an award made prior to being appointed as an Executive Director.

5. LTIP award shown for 2020: the values disclosed in the Annual Report on Remuneration for the year ended 31 December 2020 were estimated values as the award had not vested by the date of that report; these amounts have been re-presented based on the actual market value on the date of vesting of 27 March 2021 of 2,578p.

6. LTIP dividend equivalent payments: the dividend equivalent payment that will attach to the LTIP award that is included in the Single Figure Table is reported. The values for the year ended 31 December 2020 have been restated on this basis. The amount reported for Jack Bowles will be delivered in shares following the end of the two-year additional holding period.
## Short-Term Incentives for the Year Ended 31 December 2021

### STI performance measures, weightings and results for year ended 31 December 2021

<table>
<thead>
<tr>
<th>STI performance measure and target 2021</th>
<th>Description of measure 2021</th>
<th>Actual performance 2021</th>
<th>Payout (maximum)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group’s share of Key Markets (growth over prior year)</td>
<td>The Group’s volume share in its Key Markets accounts for around 80% of cigarettes volume and 90% of THP volume of the Group’s subsidiaries. The Group’s share is calculated from data as independently measured by retail audit agencies and scanner sales to consumers, or from estimated shipment share.</td>
<td>Global volume share in key markets grew by 6 bps.</td>
<td>9.0% (15%)</td>
</tr>
<tr>
<td>Weighting: 15%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold: 0 bps growth over 2020</td>
<td></td>
<td>Strategic Report: Delivering our strategy – A Better Tomorrow™ for Consumers</td>
<td></td>
</tr>
<tr>
<td>Maximum: 10 bps growth over 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Categories revenue (growth over prior year)</td>
<td>New Categories Revenue is the revenue derived from the Vapour, THP and Modern Oral product categories. This measure is assessed at constant rates of exchange.</td>
<td>New Categories revenue grew by 50.9%.</td>
<td>20% (20%)</td>
</tr>
<tr>
<td>Weighting: 20%</td>
<td></td>
<td>Strategic Report: Delivering our strategy – A Better Tomorrow™ for Shareholders</td>
<td></td>
</tr>
<tr>
<td>Threshold: 15% growth over 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum: 30% growth over 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted profit from operations (APFO) (growth over prior year)</td>
<td>APFO is the adjusted profit from operations at constant rates of exchange for the year ended 31 December 2021. Please refer to page 308 for the detailed description of APFO.</td>
<td>APFO growth over the prior year of 5.2%.</td>
<td>21.7% (30%)</td>
</tr>
<tr>
<td>Weighting: 30%</td>
<td></td>
<td>Strategic Report: Delivering our strategy – A Better Tomorrow™ for Shareholders</td>
<td></td>
</tr>
<tr>
<td>Threshold: 3.0% growth over 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum: 8.0% growth over 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deleveraging (excluding foreign exchange)</td>
<td>Deleveraging (excluding foreign exchange) refers to the reduction in Adjusted Net Debt to Adjusted ED/ITDA during the year ended 31 December 2021, assessed at constant rates of exchange.</td>
<td>Deleveraging (excluding foreign exchange) was 0.50x.</td>
<td>35% (35%)</td>
</tr>
<tr>
<td>Weighting: 35%</td>
<td></td>
<td>Strategic Report: Delivering our strategy – A Better Tomorrow™ for Shareholders</td>
<td></td>
</tr>
<tr>
<td>Threshold: 0.10x reduction versus 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum: 0.30x reduction versus 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### STI outcome for year ended 31 December 2021

<table>
<thead>
<tr>
<th></th>
<th>Available STI award as % of base salary</th>
<th>STI award achieved as % of maximum opportunity</th>
<th>STI award achieved as % of base salary</th>
<th>STI award achieved £’000 (Value shown in Single Figure Table)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>250%</td>
<td>85.7%</td>
<td>214.3%</td>
<td>2,820</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>190%</td>
<td>85.7%</td>
<td>162.8%</td>
<td>1,308</td>
</tr>
</tbody>
</table>

Notes:
1. Malus and clawback provisions apply.
2. 50% of the STI award will be paid in cash and 50% as an award under the DSBS. Awards made under the DSBS are in the form of free ordinary shares in the Company that normally vest after three years and no further performance conditions apply in that period. In certain circumstances, such as resigning before the end of the three-year period, participants may forfeit all or some of the shares.
3. The Remuneration Committee did not consider that any discretion to adjust the formulaic outcome need be applied.
### Long-Term Incentives (LTIP) for the Year Ended 31 December 2021

<table>
<thead>
<tr>
<th>LTIP performance measure</th>
<th>Description of measure and target for 2019 LTIP Performance period 1 January 2019 – 31 December 2021</th>
<th>Result achieved</th>
<th>Vesting percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative TSR(^1)</td>
<td>(2019–2021) LTIP target (\text{Relative to a peer group of international FMCG companies})</td>
<td>Ranked 17 out of 24 (out of maximum of 20%)</td>
<td>0%</td>
</tr>
<tr>
<td>EPS growth at current rates of exchange</td>
<td>(2019–2021) LTIP target (\text{Relative to a peer group of international FMCG companies})</td>
<td>3.5% CAGR (out of maximum of 20%)</td>
<td>0%</td>
</tr>
<tr>
<td>EPS growth at constant rates of exchange</td>
<td>(2019–2021) LTIP target (\text{Relative to a peer group of international FMCG companies})</td>
<td>6.8% CAGR (out of maximum of 20%)</td>
<td>9.1%</td>
</tr>
<tr>
<td>Adjusted revenue(^2)</td>
<td>(2019–2021) LTIP target (\text{Adjusted revenue growth measure})</td>
<td>5.3% CAGR (out of maximum of 20%)</td>
<td>20%</td>
</tr>
<tr>
<td>Adjusted Operating cash flow conversion ratio</td>
<td>(2019–2021) LTIP target (\text{Adjusted revenue growth measure})</td>
<td>101.0% ratio (out of maximum of 20%)</td>
<td>20%</td>
</tr>
</tbody>
</table>

**Notes:**

1. **Relative TSR**: the constituents of the FMCG peer group for the 2019-2021 LTIP were: Altria Group, Anheuser-Busch InBev, Campbell Soup, Carlsberg, Coca-Cola, Coty/Parfums, Danone, Diageo, Heineken, Imperial Brands, Japan Tobacco, Johnson & Johnson, Kellogg, Kimberly-Clark, LVMH, Mondelez International, Novo, PepsiCo, Pernod Ricard, Philip Morris International, Procter & Gamble, Reedel Benckiser and Unilever.

2. **The underpin for adjusted revenue growth measure**: the adjusted revenue growth measure can only vest provided the corresponding three-year CAGR of APFO exceeds the CAGR of the threshold performance level for APFO as approved annually in the STI and approved by the Board. The underpin was exceeded with reference to the APFO STI outcomes for 2019, 2020 and 2021.

3. The Remuneration Committee did not consider that any discretion to adjust the formulaic outcome need be applied.
LTIP outcome for year ended 31 December 2021

<table>
<thead>
<tr>
<th></th>
<th>Number of ordinary shares subject to award</th>
<th>Vesting % achieved (based on 2019–2021 performance period)</th>
<th>Number of ordinary shares to vest</th>
<th>Value of ordinary shares to vest £’000</th>
<th>Dividend equivalent payment on vesting £’000</th>
<th>Total value to vest £’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>176,532</td>
<td>49.1%</td>
<td>86,677</td>
<td>2,267</td>
<td>548</td>
<td>2,815</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>36,057</td>
<td>49.8%</td>
<td>17,956</td>
<td>470</td>
<td>114</td>
<td>584</td>
</tr>
</tbody>
</table>

Notes:
1. The value of ordinary shares to vest shown above is based on the average share price for the three-month period ended 31 December 2021 of 2,616p.
2. The dividend equivalent amount shown above that will be delivered on vesting is the value of the dividend equivalents accrued on the proportion of the award that is due to vest. Dividend equivalent will be delivered as shares following the end of the two-year post-vesting holding period for Jack Bowles. Dividend equivalent will be delivered as cash on vesting date for Tadeu Marroco due to LTIP award being made prior to appointment as Executive Director.
3. The number of shares subject to award made to Tadeu Marroco reflect the award opportunities available at the time of the award, prior to being appointed as Executive Director.
4. The vesting percentage for Tadeu Marroco reflects the vesting percentage applicable to awards made prior to being appointed as Executive Director.

Executive Directors’ pension entitlements and accruals for the year ended 31 December 2021

<table>
<thead>
<tr>
<th>Pension values</th>
<th>Defined Contribution (DC) Unapproved Unfunded Retirement Benefit Scheme (UURBS)</th>
<th>British American Tobacco UK Pension Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>1,117</td>
<td>359</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>780</td>
<td>211</td>
</tr>
<tr>
<td>Total</td>
<td>1,897</td>
<td>570</td>
</tr>
</tbody>
</table>

Note:
1. The DC UURBS credit accrued over the year is increased in line with the Company’s Weighted Average Cost of Debt (WACD) over the year. For the year ended 31 December 2021, a WACD of 3.5% has been used.

Jack Bowles
The total Company contribution to the DC arrangements over the period 1 January to 31 December 2021 was £197,526. Of this, £3,033 was paid to the British American Tobacco UK Pension Plan and £194,493 was credited to the DC UURBS. These total amounts are based on a Company contribution rate of 15% of salary per annum.

Tadeu Marroco
The total Company contribution paid to the DC arrangements over the period 1 January to 31 December 2021 was £120,643. Of this, £3,033 was paid to the funded British American Tobacco UK Pension Plan and £117,610 was credited to the DC UURBS. These total amounts are based on a Company contribution rate of 15% of salary per annum.

No excess retirement benefits have been paid to or are receivable by an Executive or former Executive Director.
Remuneration Report

Annual Statement on Remuneration

Continued

Other Information Relating to Chief Executives’ Remuneration for the year Ended 31 December 2021

Chief Executives’ pay – comparative figures 2012 to 2021

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Executives’ ‘single figure’ of total remuneration (£’000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicandro Durante1 (to 1 April 2019)</td>
<td>6,340</td>
<td>6,674</td>
<td>3,617</td>
<td>4,543</td>
<td>8,313</td>
<td>10,244</td>
<td>8,651</td>
<td>3,054</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Jack Bowles (from 1 April 2019)</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>3,512</td>
<td>4,954</td>
<td>7,471</td>
</tr>
<tr>
<td>Annual bonus (STI) paid against maximum opportunity (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicandro Durante1 (to 1 April 2019)</td>
<td>85.0</td>
<td>81.3</td>
<td>73.2</td>
<td>100</td>
<td>100</td>
<td>97.2</td>
<td>100</td>
<td>50.0</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Jack Bowles (from 1 April 2019)</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>96</td>
<td>71.1</td>
<td>85.7</td>
</tr>
<tr>
<td>Long-term incentive (LTIP) paid against maximum opportunity (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicandro Durante1 (to 1 April 2019)</td>
<td>87.1</td>
<td>49.2</td>
<td>0.0</td>
<td>8.7</td>
<td>46.0</td>
<td>96.1</td>
<td>70.5</td>
<td>69.3</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Jack Bowles (from 1 April 2019)</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>69.9</td>
<td>54.2</td>
<td>49.1</td>
</tr>
</tbody>
</table>

Notes:
1. Nicandro Durante retired as Chief Executive on 1 April 2019. Historical data are taken from the Directors’ Remuneration Reports for the relevant years and are recast (as appropriate) on the basis of the ‘single figure’ calculation as prescribed in the UK Directors’ Remuneration Report Regulations. His ‘single figure’ remuneration for the year ended 31 December 2019 has been time-apportioned to reflect the period he was Chief Executive.

Total shareholder return (TSR) performance:1 1 January 2012 to 31 December 2021

Note:
1. Performance and pay chart: this shows the performance of a hypothetical investment of £100 in ordinary shares (as measured by the TSR for the Company) against a broad equity market index (the FTSE 100 Index) over a period of 10 financial years starting from 1 January 2012 through to 31 December 2021 based on 30-trading-day average values. The FTSE 100 has been selected by the Committee as an appropriate comparator group due to BAT’s position within the FTSE. A local currency basis is used for the purposes of the TSR calculation making it consistent with the approach to TSR measurement for the LTIP.
Annual change in remuneration of Directors’ and employees

The following table shows the percentage change in the Directors’ remuneration measured against a comparator group comprising the UK employee population across all UK entities. This comparator group is considered to be the most appropriate group due to the limited number of employees employed under BAT p.l.c. contracts outside of the Director group. In addition, using a more widely-drawn group encompassing the worldwide nature of the Group’s business would also present practical difficulties in collation and a less relevant comparator, given the significant variations in employee pay across the Group, the differing economic conditions and wide variations in gross domestic product per capita.

<table>
<thead>
<tr>
<th></th>
<th>% change in salary/fees</th>
<th>% change in taxable benefits1</th>
<th>% change in STI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020 to 2021</td>
<td>2019 to 2020</td>
<td>2020 to 2021</td>
</tr>
<tr>
<td>Executive Directors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jack Bowles</td>
<td>5%</td>
<td>7%</td>
<td>(37%)</td>
</tr>
<tr>
<td>Tadeu Marroco2</td>
<td>4%</td>
<td>5%</td>
<td>(33%)</td>
</tr>
<tr>
<td>Chairman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Burrows3</td>
<td>2%</td>
<td>3%</td>
<td>8%</td>
</tr>
<tr>
<td>Luc Jobin4</td>
<td>334%</td>
<td>2%</td>
<td>24%</td>
</tr>
<tr>
<td>Non-Executive Directors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sue Farr</td>
<td>1%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td>Dr Marion Helmes</td>
<td>1%</td>
<td>2%</td>
<td>(72%)</td>
</tr>
<tr>
<td>Jerry Fowler5</td>
<td>2%</td>
<td>2%</td>
<td>(98%)</td>
</tr>
<tr>
<td>Holly Koeppel</td>
<td>1%</td>
<td>3%</td>
<td>(99%)</td>
</tr>
<tr>
<td>Savio Kwan</td>
<td>1%</td>
<td>2%</td>
<td>(97%)</td>
</tr>
<tr>
<td>Dimitri Panayotopoulos1</td>
<td>9%</td>
<td>21%</td>
<td>(78%)</td>
</tr>
<tr>
<td>Karen Guerra7</td>
<td>0%</td>
<td>n/a</td>
<td>0%</td>
</tr>
<tr>
<td>Darrell Thomas8</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Average UK-based employee9</td>
<td>6%</td>
<td>3%</td>
<td>(1%)</td>
</tr>
</tbody>
</table>

Notes:

1. Changes in taxable benefit values for 2019 to 2020 and for 2020 to 2021 for Non-Executive Directors were primarily a result of a reduction in travel and subsistence costs associated with business functions due to COVID-related travel restrictions throughout 2020 and 2021. Further details of the taxable benefits figures can be found in the table on page 144.

2. Tadeu Marroco was appointed as an Executive Director from 5 August 2019. For the period 5 August 2019 to 31 December 2019, annualised figures have been used to calculate the year-on-year change.

3. Richard Burrows departed the Company 28 April 2021. For the period 1 January to 28 April 2021, annualised figures have been used to calculate the year-on-year change.

4. Luc Jobin was appointed Chairman from 28 April 2021. The change in fees from 2020 to 2021 is due to the increase in fees received following the appointment.

5. Jerry Fowler was appointed to the Board on 1 September 2019 and left the Company on 31 March 2021. For the period 1 September to 31 December 2019 and 1 January to 31 March 2021, annualised figures have been used to calculate the year-on-year change.

6. Dimitri Panayotopoulos started receiving the Senior Independent Director fee with effect from 1 May 2020.

7. Karen Guerra was appointed to the Board on 14 September 2020. The change in fees from 2020 to 2021 is due to the increase in fees received following the appointment.

8. Darrell Thomas was appointed to the Board on 7 December 2020, receiving no fees or taxable benefits in 2020. Accordingly, no year-on-year change figures have been included.

9. The data for the UK-based employee comparator group are made up as follows as at 1 November 2021: (1) the weighted average base salaries; (2) the average taxable benefits per grade; and (3) the weighted average bonus result based on that population as at that date.
Chief Executive Pay Ratio Disclosure

The below table reflects the Chief Executive pay ratio when compared to employees at the 25th percentile, median and 75th percentile of the Group’s UK workforce for years 2019, 2020 and 2021. The table also includes the salary and total remuneration figures for the employees at each percentile for 2021.

<table>
<thead>
<tr>
<th>Year</th>
<th>Method</th>
<th>25th percentile pay ratio</th>
<th>Median pay ratio</th>
<th>75th percentile pay ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>Option A</td>
<td>144:1</td>
<td>86:1</td>
<td>36:1</td>
</tr>
<tr>
<td>2020</td>
<td>Option A</td>
<td>103:1</td>
<td>66:1</td>
<td>29:1</td>
</tr>
<tr>
<td>2021</td>
<td>Option A</td>
<td>138:1</td>
<td>90:1</td>
<td>37:1</td>
</tr>
</tbody>
</table>

Employees remuneration for 2021

<table>
<thead>
<tr>
<th>25th percentile</th>
<th>Median</th>
<th>75th percentile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salary</td>
<td>£36,010</td>
<td>£55,849</td>
</tr>
<tr>
<td>Total Remuneration</td>
<td>£53,880</td>
<td>£83,438</td>
</tr>
</tbody>
</table>

Notes:
1. Option A uses the total full-time equivalent remuneration for all UK employees for the financial year ended 31 December 2021 and has been used to calculate the ratio as this is viewed to be the most robust and comprehensive means of assessment and is also reflective of shareholder preferences.
2. Total pay and benefits are based on the workforce as at 1 November 2021 and include the annualised income for the earnings period 1 January 2021 to 31 December 2021.
3. Total pay and benefits for the Chief Executive are based on the single figure calculation on page 135.
4. Total pay and benefits for the workforce is calculated as far as possible on the same basis as the Chief Executive single figure calculation. This includes salary, taxable benefits, short-term incentive, long-term incentive, dividends, pension benefits and any other remuneration receivable. For the purposes of this analysis, the following has been assumed:
   - For all employees that are eligible for a car benefit, the applicable car allowance amounts have been used;
   - For all employees that participate in the global International Executive Incentive Scheme or equivalent corporate incentive scheme, incentive pay-outs are calculated based on the same metrics, and
   - For all employees that participate in the UK DC scheme, Company contributions of 15% of salary have been used.
5. For the calculation of the total pay and benefits for employees, employees on international assignment into and out of the UK have been included; however assignment benefits, such as housing support, education support, home leave allowance or relocation costs, have not been included as these are not consistent with the benefits included in the Chief Executive single figure calculation.
6. For hourly paid employees who are not full time, total pay and benefits have been pro-rated based on full-time employee hours.

The figures above show that following the decrease from 2019 to 2020, there has been an increase in the Chief Executive pay ratio across all quartiles from 2020 to 2021.

The increase in pay ratio from 2020 to 2021 is due to the 2019 LTIP award being the first award made to Jack Bowles at Chief Executive award levels.

Fixed remuneration remained aligned with that of the wider UK-based workforce, with salary increasing in line with the wider workforce increase range, pension contribution percentage remaining aligned with the wider workforce at 15% and taxable benefits reducing significantly.

The CEO pay ratio is likely to continue to vary over time, with variances being attributable to the CEO variable pay opportunity which accounts for 80% to 90% of the total remuneration.

The Company believes the median pay ratio for 2021 reflects the diversity of our business footprint and employee population across the UK. The Group’s remuneration policies and practices are founded on a high degree of alignment and consistency, with total remuneration at all levels providing competitive compensation that enables the attraction and retention of talent while also providing equitable differentiated remuneration based on grade, performance and experience. Further details on all-employee rewards at BAT can be found on pages 163 and 164.
4 Executive Directors’ Remuneration for the Upcoming Year

Base salary for 2022

The Remuneration Committee has determined the following salaries for the Executive Directors.

<table>
<thead>
<tr>
<th>Executive Directors – salaries</th>
<th>Base salary from 1 Apr 2022 £</th>
<th>Percentage change</th>
<th>Base salary from 1 Apr 2021 £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>1,325,610</td>
<td>n/a</td>
<td>1,325,610</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>803,400</td>
<td>n/a</td>
<td>803,400</td>
</tr>
</tbody>
</table>

Benefits and pension

No changes have been made to the provision of benefits or pension for 2022.

Short-term incentives for 2022

STI opportunity levels for Executive Directors will be in line with those set out in our Directors’ Remuneration Policy. STI metrics and weightings are as follows:

<table>
<thead>
<tr>
<th>2022 STI metrics &amp; weightings</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume share growth (Incl THP)</td>
<td>10%</td>
</tr>
<tr>
<td>New Categories revenue</td>
<td>15%</td>
</tr>
<tr>
<td>Adjusted profit from operations</td>
<td>25%</td>
</tr>
<tr>
<td>New Categories contribution</td>
<td>20%</td>
</tr>
<tr>
<td>Adjusted cash generated from operations</td>
<td>30%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
</tr>
</tbody>
</table>

Notes:
1. Group share of key markets will include THP performance for all major markets (markets included are Japan, South Korea, Italy, the Czech Republic, Ukraine, Russia, Poland, Greece and Hungary).
2. New Categories Revenue is the revenue derived from the Vapour, THP and Modern Oral product categories. This measure is assessed at constant rates of exchange. Further details of the metric can be found on page 305.
3. New Categories Contribution is the contribution to APFO from Vapour, THP and Modern Oral products. It is stated after deduction of directly attributable costs and allocated cross-category shared costs, before the deduction of administrative overheads and excluding the impact of adjusting items. The measure is assessed at constant rates of exchange.
4. Net cash generated from operating activities, less net finance costs, net capital expenditure, dividends from associates and dividends paid to non-controlling interests and before cash paid/received in respect of litigation. Adjusted CGFO is measured at constant rates of exchange.

Due to the commercial sensitivity of the targets, details for the year ending 31 December 2022 will be disclosed retrospectively in the Annual Report on remuneration for the year ending 31 December 2022.
Remuneration Report
Annual Statement on Remuneration
Continued

Long-term incentives for 2022

The Chief Executive and Finance and Transformation Director will be granted an LTIP award equal to a maximum of 500% of salary and 400% of salary, respectively. The measures and targets for 2022 LTIP awards are set out below.

<table>
<thead>
<tr>
<th>LTIP measures and performance ranges</th>
<th>% of award vesting at maximum</th>
<th>% of award vesting at threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative TSR</td>
<td>20</td>
<td>3</td>
</tr>
<tr>
<td>Median performance vs. FMCG peer group to upper quartile. The current constituents of the FMCG peer group as part of the new remuneration policy will be:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altria Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coca-Cola</td>
<td>30</td>
<td>4.5</td>
</tr>
<tr>
<td>Anheuser-Busch Inbev</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diageo</td>
<td>5%–10% compound annual growth in adjusted diluted EPS over the performance period</td>
<td></td>
</tr>
<tr>
<td>Japanese Tobacco</td>
<td>3%–5% compound annual growth over the performance period</td>
<td></td>
</tr>
<tr>
<td>Philip Morris International</td>
<td>5%–10% compound annual growth in adjusted diluted EPS over the performance period</td>
<td></td>
</tr>
<tr>
<td>Swedish Match</td>
<td>20%–30% compound annual growth over the performance period</td>
<td></td>
</tr>
<tr>
<td>Unilever</td>
<td>Adjusted operating cash flow conversion ratio</td>
<td></td>
</tr>
<tr>
<td>EPS growth (15% current and 15% constant rates of exchange)</td>
<td>15</td>
<td>2.25</td>
</tr>
<tr>
<td>Adjusted revenue growth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth in New Categories revenue</td>
<td>15</td>
<td>2.25</td>
</tr>
<tr>
<td>Adjusted operating cash flow conversion ratio</td>
<td>20</td>
<td>3</td>
</tr>
<tr>
<td>Ratio of 85%–95% over the performance period at current rates of exchange</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>15</td>
</tr>
</tbody>
</table>

5 Chairman and Non-Executive Directors’ Remuneration for the Year Ended 31 December 2021

The following table shows a single figure of remuneration for the Chairman and Non-Executive Directors in respect of qualifying services for the year ended 31 December 2021 together with comparative figures for 2020.

<table>
<thead>
<tr>
<th></th>
<th>2021 £’000</th>
<th>2020 £’000</th>
<th>2021 £’000</th>
<th>2020 £’000</th>
<th>2021 £’000</th>
<th>2020 £’000</th>
<th>2021 £’000</th>
<th>2020 £’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Base fee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairman</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luc Jobin3 (from 28 April 2021)</td>
<td>523</td>
<td>96</td>
<td>9</td>
<td>26</td>
<td>20</td>
<td>16</td>
<td>552</td>
<td>138</td>
</tr>
<tr>
<td>Richard Burrows (up to 28 April 2021)</td>
<td>234</td>
<td>714</td>
<td>–</td>
<td>–</td>
<td>36</td>
<td>77</td>
<td>270</td>
<td>791</td>
</tr>
<tr>
<td><strong>Chairman/Committee membership fees</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Taxable benefits</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total remuneration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-Executive Directors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sue Farr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Guerra</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Marion Helmes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holly Keller Koeppel4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Savio Kean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dimitri Panayotopoulos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darrell Thomas6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jerry Fowden (up to 31 March 2021)</td>
<td>25</td>
<td>96</td>
<td>7</td>
<td>–</td>
<td>3</td>
<td>32</td>
<td>139</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,509</td>
<td>1,443</td>
<td>261</td>
<td>244</td>
<td>58</td>
<td>135</td>
<td>1,829</td>
<td>1,836</td>
</tr>
</tbody>
</table>

Note:
1. Committee memberships: are shown, together with changes during the year, in the reports of the respective committees in the Governance sections of the Directors’ Report.
2. Benefits: the Chairman’s benefits in respect of Richard Burrows in 2021 comprised: health insurance and ‘walk-in’ medical services £15,000 (2020: £16,000); home and personal security in the UK and Ireland £15,000 (2020: £11,000), and commuting flights to London (2020: £2,000); The Chairman’s benefits in respect of Luc Jobin in 2021 comprised: health insurance and ‘walk-in’ medical services £8,000; the use of a Company driver £1,000; and commuting flights to London £3,000. The benefits for the other Non-Executive Directors principally comprised travel-related expenses incurred in connection with individual and/or accompanied attendance at certain business functions and/or events and ‘walk-in’ medical services. The figures shown are grossed-up amounts (as appropriate) as, in line with the UK market, it is the normal position for the Company to pay the tax that may be due on any benefits.
3. Pension: Luc Jobin receives a pension in respect of prior service to Imasco Limited (acquired in 2000 by the Group) and Imperial Tobacco Canada Limited, a subsidiary of BAT. In 2021 the amount was CAD$190,228.00 (£87,399.21) (2020: CAD$150,228.00 (£86,112.85)).
4. Deferred Compensation Plan for Directors of Reynolds American Inc. (DCP): as a former outside director of Reynolds American Inc. Holly Keller Koeppel participated in the DCP under which she elected to defer payment of a portion of her Reynolds American retainers and meeting attendance fees to a Reynolds American stock account. Following the acquisition of Reynolds American by BAT, amounts deferred to a stock account (Deferred Stock Units or DSUs) mirror the performance of, and receive dividend equivalents based on, BAT American Depository Shares (ADSs). The DSUs of Holly Keller Koeppel are disclosed as a note to ‘Summary of Directors’ shareholdings’ below. DSUs deferred under the DCP will be paid in accordance with the terms of the DCP, section 409A of the US Internal Revenue Code of 1986, as amended, and the Director’s existing deferral elections.
5. Darrell Thomas was appointed to the Board on 7 December 2020, with the first fee being paid to him in January 2021.
6. The Non-Executive Directors’ fees structure 2021 is set out in the table overleaf.
Chairman and Non-Executive Directors’ fees and remuneration for the upcoming year

As described in the Annual Report on Remuneration for the year ended 31 December 2020, the Chairman’s fee was £670,000 from 28 April 2021.

The Chairman’s fee and the fees for Non-Executive Directors will be maintained at their current levels, with no increases to apply in May 2022.

6 Directors’ Share Interests

Summary of Directors’ share interests

<table>
<thead>
<tr>
<th>Directors’ Name</th>
<th>Ordinary shares held as at 31 Dec 2021</th>
<th>Unvested awards subject to performance measures and continued employment (LTIP)</th>
<th>Unvested awards subject to continued employment only (DSBS)</th>
<th>Unvested interests (Sharesave)</th>
<th>Total ordinary shares subject to outstanding scheme interests</th>
<th>Total of all interests in ordinary shares as at 31 Dec 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Executive Directors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jack Bowles1,2</td>
<td>239,214</td>
<td>629,975</td>
<td>119,862</td>
<td>–</td>
<td>749,837</td>
<td>989,051</td>
</tr>
<tr>
<td>Tadeu Marroco2,3</td>
<td>78,126</td>
<td>265,012</td>
<td>56,348</td>
<td>890</td>
<td>322,250</td>
<td>400,376</td>
</tr>
<tr>
<td><strong>Non-Executive Directors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sue Farr</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Jerry Fowden (up to 31 March 2021)4</td>
<td>10,000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>10,000</td>
<td>–</td>
</tr>
<tr>
<td>Karen Guerra</td>
<td>5,000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>5,000</td>
<td>–</td>
</tr>
<tr>
<td>Dr Marion Helmes</td>
<td>4,500</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4,500</td>
<td>–</td>
</tr>
<tr>
<td>Holly Keller Koeppel5</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Savio Kwan</td>
<td>8,238</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>8,238</td>
<td>–</td>
</tr>
<tr>
<td>Dimitri Panayiotopoulos</td>
<td>3,300</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3,300</td>
<td>–</td>
</tr>
<tr>
<td>Darrell Thomas4</td>
<td>2,600</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2,600</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes:

1. Jack Bowles: ordinary shares held include 822 held by the trustees of the BAT Share Incentive Plan (SIP).
2. Changes from 31 December 2021: Tadeu Marroco: purchases of five ordinary shares on 5 January 2022 and five ordinary shares on 2 February 2022 under the SIP. There were no changes in the interests of the Chairman and the other Non-Executive Directors.
3. Tadeu Marroco: ordinary shares held include 1,347 held by the trustees of the SIP.
4. American Depositary Shares (ADSs): each of the interests in ordinary shares held by Luc Jobin, Jerry Fowden and Darrell Thomas consists of an equivalent number of BAT ADSs each of which represents one ordinary share in the Company.
5. Deferred Stock Units (DSUs): at the date of this report Holly Keller Koeppel, being a former director of Reynolds American Inc. and a participant in the Deferred Compensation Plan for Directors of Reynolds American (DCP), holds DSUs which were granted prior to becoming a Director of BAT. Each DSU entitles the holder to receive a cash payment upon ceasing to be a Director equal to the value of one BAT ADS. The number of DSUs increases on each dividend date by reference to the value of dividends declared on the ADSs underlying the DSUs. Ms Koeppel currently holds 26,660.09 DSUs (31 December 2020: 25,125.91 DSUs).
Executive Directors’ shareholding guidelines

Executive Directors are encouraged to build up a high level of personal shareholding to ensure a continuing alignment of interests with shareholders. The shareholding guidelines require Executive Directors to hold ordinary shares equal to the value of a percentage of salary as set out in the table below.

<table>
<thead>
<tr>
<th>Name</th>
<th>No. of eligible ordinary shares held at 31 Dec 2021</th>
<th>Value of eligible ordinary shares held at 31 Dec 2021 (£m)</th>
<th>Actual percentage (%) of base salary at 31 Dec 2021</th>
<th>Shareholding requirements (% of base salary 31 Dec 2021)</th>
<th>Compliant with shareholding requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>301,919</td>
<td>8,255</td>
<td>623%</td>
<td>500%</td>
<td>Yes</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>106,653</td>
<td>2,916</td>
<td>363%</td>
<td>400%</td>
<td>See note 2</td>
</tr>
</tbody>
</table>

Executive Directors are required to hold shares equivalent to 100% of current shareholding requirements for two full years following the date of their departure with a sale restriction mechanism in place for this period. More detail on Executive Director shareholding requirements can be found in the Directors Remuneration policy on page 157.

Ben Stevens was compliant with the post-employment shareholding requirement up to the end of the two year post employment shareholding period which ended on 4 August 2021.

Eligibility of shares: (a) unvested ordinary shares under the DSBS, which represent deferral of earned bonus, are eligible and count towards the requirement on a net-of-tax basis; (b) unvested ordinary shares under the LTIP are not eligible and do not count towards the requirement during the performance period, but the estimated notional net number of ordinary shares held during the LTIP Extended Vesting Period are eligible and will count towards the requirement; and (c) ordinary shares held in trust under the all-employee share ownership plan (SIP) are not eligible and do not count towards the shareholding requirement.

Non-Executive Directors are not subject to any formal shareholding requirements although they are encouraged to build a small interest in ordinary shares during, the term of their appointment. As noted in the Directors’ Remuneration policy on page 162, future fees for Non-Executive Directors may be paid in cash or a combination of cash and shares, with the proportion to be paid in shares in a year to be disclosed in the relevant Directors’ Remuneration Reports.

Notes:
1. Value of ordinary shares shown above: this is based on the closing mid-market share price on 31 December 2021 of 2,734p.
2. Tadeu Marroco was appointed as an Executive Director on 5 August 2019, prior to which the shareholding requirement for Mr Marroco was set at a lower percentage of salary with Mr Marroco being compliant with required percentage. Under the Directors’ Remuneration Policy, Executive Directors may generally sell a maximum of up to 50% of any shares vesting (after tax) under the Company’s share plans until the threshold for shareholding requirements has been met and Mr Marroco is compliant with this policy requirement. In line with the Directors’ Remuneration Policy, the shareholding requirement is equal to the value of the same multiple of salary at which LTIP awards are made to that Director, as such the shareholding requirement for Mr Marroco increased to 400% in 2020.
3. Meeting the guidelines: if an Executive Director does not at any time, meet the requirements of the shareholding guidelines, the individual may, generally, only sell a maximum of up to 50% of any ordinary shares vesting (after tax) under the Company share plans until the threshold required under the shareholding guidelines has been met.
4. Waiver of compliance with guidelines: this is permitted with the approval of the Remuneration Committee in circumstances where a restriction on a requested share sale could cause undue hardship. No such applications were received from the Executive Directors during 2021.
Executive Directors’ outstanding scheme interests

<table>
<thead>
<tr>
<th>Plan</th>
<th>Awarded in 2021</th>
<th>Lapsed in 2021</th>
<th>Exercised/released in 2021</th>
<th>@31 Dec 2021</th>
<th>Exercise price (p)</th>
<th>End of performance period</th>
<th>Data from which exercisable or shares released</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP1</td>
<td>43,785</td>
<td>–</td>
<td>20,054</td>
<td>23,731</td>
<td>–</td>
<td>2,802</td>
<td>31 Dec 2021</td>
</tr>
<tr>
<td>LTIP2</td>
<td>176,532</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>176,532</td>
<td>–</td>
<td>31 Dec 21</td>
</tr>
<tr>
<td>DSBS</td>
<td>12,064</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>DSBS</td>
<td>26,192</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>26,192</td>
<td>–</td>
<td>31 Dec 21</td>
</tr>
<tr>
<td>DSBS</td>
<td>53,618</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>53,618</td>
<td>–</td>
<td>31 Dec 22</td>
</tr>
<tr>
<td>DSBS</td>
<td>–</td>
<td>40,052</td>
<td>–</td>
<td>–</td>
<td>40,052</td>
<td>–</td>
<td>31 Dec 23</td>
</tr>
<tr>
<td>Sharesave</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Sharesave</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP1</td>
<td>28,248</td>
<td>–</td>
<td>12,938</td>
<td>15,310</td>
<td>–</td>
<td>2,787</td>
<td>31 Dec 2021</td>
</tr>
<tr>
<td>LTIP2</td>
<td>36,057</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>36,057</td>
<td>–</td>
<td>31 Dec 21</td>
</tr>
<tr>
<td>LTIP3</td>
<td>113,938</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>113,938</td>
<td>–</td>
<td>31 Dec 22</td>
</tr>
<tr>
<td>LTIP3</td>
<td>–</td>
<td>115,017</td>
<td>–</td>
<td>–</td>
<td>115,017</td>
<td>–</td>
<td>31 Dec 23</td>
</tr>
<tr>
<td>DSBS</td>
<td>7,783</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>7,783</td>
<td>–</td>
<td>31 Dec 20</td>
</tr>
<tr>
<td>DSBS</td>
<td>13,233</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>13,233</td>
<td>–</td>
<td>31 Dec 21</td>
</tr>
<tr>
<td>DSBS</td>
<td>24,388</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>24,388</td>
<td>–</td>
<td>31 Dec 22</td>
</tr>
<tr>
<td>DSBS</td>
<td>–</td>
<td>18,727</td>
<td>–</td>
<td>–</td>
<td>18,727</td>
<td>–</td>
<td>31 Dec 23</td>
</tr>
<tr>
<td>Sharesave</td>
<td>266</td>
<td>–</td>
<td>266</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 May 21</td>
</tr>
<tr>
<td>Sharesave</td>
<td>–</td>
<td>433</td>
<td>–</td>
<td>–</td>
<td>433</td>
<td>–</td>
<td>1 May 24</td>
</tr>
<tr>
<td>Sharesave</td>
<td>624</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>624</td>
<td>–</td>
<td>1 May 25</td>
</tr>
</tbody>
</table>

Notes:
1. Details of the performance condition for the LTIP awards granted in 2018 (which vested during 2021), and of achievement against that condition in the period to 31 December 2020, were set out in the Annual Report on Remuneration for the year ended 31 December 2020.
2. Details of the performance condition attached to 2019 LTIP awards, and of achievement against that condition in the period to 31 December 2021, are set out on page 138.
3. Details of the performance condition attached to 2020 and 2021 LTIP awards are set out on page 148.

Further details in relation to scheme interests granted during the year ended 31 December 2021

<table>
<thead>
<tr>
<th>Plan</th>
<th>Ordinary shares awarded</th>
<th>Price per ordinary share awarded (p)</th>
<th>Face value of award (£'000)</th>
<th>Proportion of award vesting for threshold performance (%)</th>
<th>Performance period</th>
<th>Date from which exercisable or shares released</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP2</td>
<td>230,314</td>
<td>2,794</td>
<td>6,435</td>
<td>15</td>
<td>2021-2023</td>
<td>29 Mar 26</td>
</tr>
<tr>
<td>DSBS</td>
<td>40,052</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>29 Mar 24</td>
<td></td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP2</td>
<td>115,017</td>
<td>2,794</td>
<td>3,214</td>
<td>15</td>
<td>2021-2023</td>
<td>29 Mar 26</td>
</tr>
<tr>
<td>DSBS</td>
<td>18,727</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>29 Mar 24</td>
<td></td>
</tr>
</tbody>
</table>

Notes:
1. The price per ordinary share is the price used to determine the number of ordinary shares subject to the awards, which is calculated as the average of the closing mid-market price of an ordinary share over the three dealing days preceding the date of grant.
2. Details of the performance condition attached to these LTIP awards are set out on page 148.
Remuneration Report

Annual Statement on Remuneration

Continued

Further details in relation to performance conditions attaching to outstanding scheme interests

<table>
<thead>
<tr>
<th>LTIP awards granted in 2020</th>
<th>LTIP awards granted in 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 January 2020–31 December 2022</td>
<td>1 January 2021–31 December 2023</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Performance Condition</th>
<th>Weighting</th>
<th>Threshold</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative TSR</td>
<td>20%</td>
<td>At median, 3% of award vests</td>
<td>At upper quartile, 20% of award vests</td>
</tr>
<tr>
<td>EPS growth at current rates of exchange</td>
<td>20%</td>
<td>At 5% CAGR, 3% of award vests</td>
<td>At 10% CAGR, 20% of award vests</td>
</tr>
<tr>
<td>EPS growth at constant rates of exchange</td>
<td>20%</td>
<td>At 5% CAGR, 3% of award vests</td>
<td>At 10% CAGR, 20% of award vests</td>
</tr>
<tr>
<td>Adjusted revenue growth</td>
<td>20%</td>
<td>At 3% CAGR, 3% of award vests</td>
<td>At 5% CAGR, 20% of award vests</td>
</tr>
<tr>
<td>Adjusted operating cash flow conversion ratio</td>
<td>20%</td>
<td>At 85%, 3% of award vests</td>
<td>At 95%, 20% of award vests</td>
</tr>
</tbody>
</table>

7 Other Disclosures

Payments to past directors or for loss of office

There were no payments to past Directors or for loss of office.

Relative importance of spend on pay

To illustrate the relative importance of the remuneration of the Directors in the context of the Group’s finances overall, the Remuneration Committee makes the following disclosure:

<table>
<thead>
<tr>
<th>Item</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remuneration of Group employees1</td>
<td>2,717</td>
<td>2,744</td>
<td>(1%)</td>
</tr>
<tr>
<td>Remuneration of Executive Directors</td>
<td>10</td>
<td>8</td>
<td>25%</td>
</tr>
<tr>
<td>Remuneration of Chairman and Non-Executive Directors</td>
<td>2</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Total dividends2</td>
<td>4,904</td>
<td>4,745</td>
<td>3%</td>
</tr>
</tbody>
</table>

Notes:

1. Total remuneration of Group employees: this represents the total employee remuneration costs for the Group, set out on page 193 within note 3(a) in the Notes on the Accounts.
2. Total dividends: this represents the total dividends paid in 2021. For further details please refer to pages 79, 304 and 351.

Shareholder dilution – options and awards outstanding

Satisfaction of Company share plan awards in accordance with the Investment Association’s Principles of Remuneration

- by the issue of new ordinary shares;
- ordinary shares issued from treasury only up to a maximum of 10% of the Company’s issued share capital in a rolling 10-year period;
- within this 10% limit, the Company can only issue (as newly issued ordinary shares or from treasury) 5% of its issued share capital to satisfy awards under discretionary or executive plans; and
- the rules of the Company’s Deferred Share Bonus Scheme do not allow for the satisfaction of awards by the issue of new ordinary shares.

New ordinary shares issued by the Company during the year ended 31 December 2021

- 26,191 ordinary shares issued by the Company in relation to the Sharesave Scheme;
- a total of 958,857 Sharesave Scheme options over ordinary shares in the Company were outstanding at 31 December 2021, representing 0.04% of the Company’s issued share capital (excluding shares held in treasury); and
- options outstanding under the Sharesave Scheme are exercisable until 1 March 2027 at option prices ranging from 2,076p to 4,056p.
8 The Remuneration Committee and Shareholder Engagement

Remuneration Committee current members

Dimitri Panayotopoulos (Chairman)
Sue Farr
Dr Marion Helmes
Savio Kwan

Role

As set out in the Terms of Reference, the Remuneration Committee is responsible for:

- determining and proposing the Directors' Remuneration Policy (covering salary, benefits, performance-based variable rewards and retirement benefits) for shareholder approval;
- determining, within the terms of the approved Directors' Remuneration Policy, the specific remuneration packages for the Chairman and the Executive Directors, on appointment, on review and, if appropriate, any compensation payment due on termination of appointment;
- the setting of targets applicable for the Company’s performance-based variable reward schemes and determining achievement against those targets, exercising discretion where appropriate and as provided by the applicable scheme rules and the Directors’ Remuneration Policy;
- reviewing Group workforce remuneration and related policies, and the alignment of incentives and rewards with Group culture, taking these into account when setting the policy for Executive Director remuneration, providing feedback to the Board on workforce reward, incentives and conditions applicable across the Group and supporting the Board’s monitoring of the Group’s culture and its alignment with the Group’s purpose, values and strategy;
- setting remuneration for members of the Management Board and the Company Secretary; and
- monitoring and advising the Board on any major changes to the policy on employee benefit structures for the Group.

Remuneration Committee terms of reference

The Committee's terms of reference align with the requirements of the UK Corporate Governance Code 2018. No changes were made to the Remuneration Committee's terms of reference in 2021.

For the Remuneration Committee's terms of reference see: www.bat.com/governance

Attendance at meetings in 2021

<table>
<thead>
<tr>
<th>Name</th>
<th>Member since</th>
<th>Attendance/ Eligible to attend Scheduled</th>
<th>Attendance/ Eligible to attend Ad Hoc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimitri Panayotopoulos(b)</td>
<td>2015</td>
<td>4/4</td>
<td>2/3</td>
</tr>
<tr>
<td>Sue Farr</td>
<td>2016</td>
<td>4/4</td>
<td>3/3</td>
</tr>
<tr>
<td>Karen Guerra(b)</td>
<td>2020 – 2021</td>
<td>1/1</td>
<td>2/2</td>
</tr>
<tr>
<td>Marion Helmes</td>
<td>2019</td>
<td>4/4</td>
<td>3/3</td>
</tr>
<tr>
<td>Savio Kwan</td>
<td>2016</td>
<td>4/4</td>
<td>3/3</td>
</tr>
</tbody>
</table>

Notes:

1. Number of meetings in 2021: (a) the Committee held seven meetings in 2021, three of which were ad hoc; (b) Dimitri Panayotopoulos did not attend the ad hoc meeting in February 2021 due to a scheduled medical appointment. That ad hoc meeting was chaired by a member of the Remuneration Committee in accordance with the Committee’s Terms of Reference.
2. Membership: (a) all members of the Committee are independent Non-Executive Directors in accordance with the UK Corporate Governance Code 2018 Provisions 10 and 32 and applicable NYSE listing standards; and (b) Karen Guerra stepped down from the Committee with effect from 1 April 2021.
3. Other attendees: the Chairman, the Chief Executive, the Director, Talent, Culture and Inclusion, the Group Head of Reward and other senior management, including the Company Secretary, may be consulted and provide advice, guidance and assistance to the Remuneration Committee. They may also attend Committee meetings (or parts thereof) by invitation. Neither the Chairman, any Executive Director nor member of senior management plays any part in determining their own respective remuneration.
4. PwC LLP: Appointed in January 2020 as one of the Remuneration Committee’s remuneration consultants, representatives of PwC LLP attended meetings of the Remuneration Committee in 2021. PwC LLP agrees to the Remuneration Consultants Group (RCG) Code of Conduct which seeks to clarify the scope and conduct of the role of executive remuneration consultants when advising UK listed companies and is one of the founding members of the RCG. The Committee is satisfied that the advice received is independent and objective.
5. Meridian Compensation Partners: Appointed in January 2020 as one of the Remuneration Committee’s remuneration consultants, a representative of Meridian Compensation Partners attended meetings of the Remuneration Committee in 2021.
Remuneration Report

Annual Statement on Remuneration
Continued

Remuneration Committee advisers during 2021

<table>
<thead>
<tr>
<th>Independent external advisers</th>
<th>Services provided to the Remuneration Committee</th>
<th>Fees</th>
<th>Other services provided to the Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>PwC LLP</td>
<td>General advice on remuneration matters including: market trends and comparator group analysis; policy review and shareholder engagement perspectives; and independent measurement of the relative TSR performance conditions.</td>
<td>2021: £165,946</td>
<td>Tax, corporate finance and consulting services to Group companies worldwide excluding the US.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2020: £126,013</td>
<td></td>
</tr>
<tr>
<td>Meridian</td>
<td>General advice on remuneration matters including market trends, shareholder engagement perspectives and comparator group analysis.</td>
<td>2021: $72,974</td>
<td>Consulting services to Group companies in the US.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2020: $49,537</td>
<td></td>
</tr>
<tr>
<td>Herbert Smith Freehills LLP</td>
<td>Advice in respect of share plan regulations is provided to the Company and is available to the Remuneration Committee. Fees relate to advice given to the Company.</td>
<td>2021: £29,000</td>
<td>General corporate legal and tax advice principally in the UK.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2020: £28,000</td>
<td></td>
</tr>
<tr>
<td>KPMG LLP</td>
<td>Specified procedures to assist in the assessment of the calculations of the STI bonus and LTI outcomes and future targets.</td>
<td>2021: £20,000</td>
<td>Audit and tax services and other non-audit services.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2020: £28,000</td>
<td></td>
</tr>
</tbody>
</table>

Notes:
1. PwC LLP also provides other international services and international tax advice such as tax return services including for certain globally mobile directors. The Remuneration Committee advisory team is not involved in any other services PwC provides to the Group.
2. The fees payable to PwC and Meridian are based on annual fixed fees for specified services with anything outside this scope being charged on a time and material basis.

Regular work programme 2021

The Remuneration Committee:

- reviewed salaries for the Executive Directors to take effect from 1 April 2021, taking into account market positioning and the level of salary increases awarded to UK employees. A programme of shareholder engagement on executive remuneration was conducted, led by the Committee Chairman, and the Committee considered feedback from shareholders (discussed at page 131);
- reviewed salaries for members of the Management Board and the Company Secretary from 1 April 2021, taking into account market positioning and the level of salary increases awarded to UK employees;
- assessed the achievement against the targets for the 2020 STI award and set the STI targets for 2021;
- reviewed updates on performance against the 2021 STI target measures and for outstanding LTIP awards;
- assessed the achievement against the performance conditions for the vesting of the 2018 LTIP award, determined the contingent level of LTIP awards for March 2021 and reviewed the associated performance conditions;
- assessed the achievement against the targets for the 2020 Share Reward Scheme and set the targets for the 2021 award;
- reviewed and assessed the target ranges across STI and LTI plans to ensure there is an appropriate level of stretch within the target range to drive performance for the benefit of shareholders;
- reviewed the Annual Statement and the Annual Report on Remuneration for the year ended 31 December 2020 prior to its approval by the Board and subsequent proposal to shareholders at the Company’s AGM on 28 April 2021;
- reviewed the 2021 AGM voting results relating to remuneration resolutions, market trends in the context of that annual general meeting season and corporate governance developments in the UK and the US;
- monitored the continued application of the Company’s shareholding guidelines for the Executive Directors and members of the Management Board; and
- reviewed the Remuneration Committee’s effectiveness following the Board and Committee evaluation process, discussed further on pages 114 to 115.

Directors’ Remuneration Policy

The Committee conducted an in-depth assessment of proposed changes to the current Directors’ Remuneration Policy and an associated programme of shareholder engagement led by the Committee Chairman.

In determining the revised Directors’ Remuneration Policy to be proposed to shareholders at the Company’s AGM on 28 April 2022, the Committee has taken into account shareholder feedback, remuneration and related policies applicable to the wider workforce, the alignment of incentives and rewards with the Group’s culture, the application of the UK Corporate Governance Code and applicable regulations.
Other activities in 2021
The Remuneration Committee
– reviewed the terms of appointment and associated remuneration, and terms of termination of employment, in connection with Management Board changes during the year;
– reviewed elements of the Group’s workforce remuneration strategy and their alignment with Executive Directors’ remuneration and their alignment with the Group’s culture, with specific focus on the reward architecture for management grade employees across the Group;
– approved changes to the methodology for calculating the share of market read for the STI volume share metric in a limited number of markets, based on the local market environment and reporting capabilities; and
– reviewed the UK gender pay report for 2020 for applicable UK Group companies, prior to publication in March 2021.

Voting on Remuneration and Engagement with Shareholders
At the AGM on 28 April 2021, shareholders considered and voted on the 2020 Directors’ Remuneration Report as set out on the table below. No other resolutions in respect of Directors’ remuneration or incentives were considered at the 2021 AGM. Further information regarding shareholder engagement in relation to remuneration matters is set out in the Annual Statement on Remuneration on page 128 and in the discussion of Board engagement with shareholders on pages 106 to 107.

Approval of Directors’ Remuneration Report¹

<table>
<thead>
<tr>
<th>2021 AGM</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage for</td>
<td>61.71</td>
</tr>
<tr>
<td>Votes for (including discretionary)</td>
<td>1,091,216,857</td>
</tr>
<tr>
<td>Percentage against</td>
<td>38.29</td>
</tr>
<tr>
<td>Votes against</td>
<td>676,947,189</td>
</tr>
<tr>
<td>Total votes cast excluding votes withheld</td>
<td>1,768,164,046</td>
</tr>
<tr>
<td>Votes withheld²</td>
<td>16,119,810</td>
</tr>
<tr>
<td>Total votes cast including votes withheld</td>
<td>1,784,283,856</td>
</tr>
</tbody>
</table>

The Directors’ Remuneration Policy was approved by shareholders at the 2019 AGM. A summary of this Policy is on pages 133 to 134.

Approval of Directors’ Remuneration Policy²

<table>
<thead>
<tr>
<th>2019 AGM</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage for</td>
<td>92.63</td>
</tr>
<tr>
<td>Votes for (including discretionary)</td>
<td>1,641,331,721</td>
</tr>
<tr>
<td>Percentage against</td>
<td>7.37</td>
</tr>
<tr>
<td>Votes against</td>
<td>130,661,885</td>
</tr>
<tr>
<td>Total votes cast excluding votes withheld</td>
<td>1,771,993,606</td>
</tr>
<tr>
<td>Votes withheld³</td>
<td>1,820,757</td>
</tr>
<tr>
<td>Total votes cast including votes withheld</td>
<td>1,773,814,363</td>
</tr>
</tbody>
</table>

Notes:
1. Directors’ Remuneration Report: does not include the part of the Remuneration Report containing the Remuneration Policy (see note 2 below).
2. Directors’ Remuneration Policy: was approved by shareholders at the 2019 AGM held on 25 April 2019 and is set out in full in the 2018 Annual Report on Remuneration.
3. Votes withheld: these are not included in the final proxy figures as they are not recognised as a vote in law.

The Directors’ Remuneration Report has been approved by the Board on 10 February 2022 and signed on its behalf by:

Dimitri Panayotopoulos
Chairman, Remuneration Committee
10 February 2022
Malus and clawback

Report as summarised below:

Remuneration Committee starting on page 128 of this Remuneration Report. Those key changes have been further explained in relevant sections of the Policy

workforce and shareholders, to ensure it is aligned to the Company's purpose and values, and promotes the long-term success of the Company.

The Remuneration Committee has worked extensively to develop a policy that closely aligns the Executive Directors to the wider workforce and rewards long-term

sustainable performance. The Remuneration Committee continually reviews the Policy, taking into account any feedback received from engagement with the wider

Risk

risks arising from remuneration that are not proportionate to outcomes.

ensure that we remunerate our Executive Directors in accordance with high standards of governance while mitigating, as far as possible, reputational and other

The combination of performance target setting for the STI and LTI, the inclusion of provisions for discretionary adjustments and malus and clawback provisions

Clarity and simplicity

Our policy provides an overall remuneration package that is transparent for our Executive Directors and shareholders alike; its simple structure has a clear and

strategy and the need to promote the long-term success of the Company; and

– ensure that remuneration arrangements are transparent and promote effective engagement with shareholders and the workforce.

Our remuneration principles and the key elements of the Directors’ Remuneration Policy align with the UK Corporate Governance Code 2018 requirements, as follows:

Predictability and proportionality

There is a clear link between the operation of our short and long-term incentive plan awards and the delivery of our strategy and long-term performance. Variable

remuneration at the Company accounts for between 80%-90% of an Executive Directors' total remuneration, ensuring that poor performance is not rewarded.

therefore there is a straightforward link to the delivery of the Group’s long-term strategy. Principles driving fixed remuneration (salary, benefits, pension) are closely aligned with the

clarity and simplicity

Our policy provides an overall remuneration package that is transparent for our Executive Directors and shareholders alike; its simple structure has a clear and

A summary of key changes

The background and explanation of the proposed key changes from the current remuneration policy are given in the Annual Statement from the Chairman of the

Summary of key changes

The background and explanation of the proposed key changes from the current remuneration policy are given in the Annual Statement from the Chairman of the


<table>
<thead>
<tr>
<th>Policy Element</th>
<th>Change in Policy</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-Term Incentive (STI)</td>
<td>Underlying policy is unchanged, however alternative measures and weightings have been selected for awards to be made in 2022.</td>
<td>155</td>
</tr>
<tr>
<td>performance measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-Term Incentive Plan (LTIP)</td>
<td>Underlying policy is unchanged, however alternative measures and weightings have been selected for awards to be made in 2022.</td>
<td>156</td>
</tr>
<tr>
<td>performance measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malus and clawback</td>
<td>Updated and expanded to reflect market best practice</td>
<td>157</td>
</tr>
</tbody>
</table>

152
## Future Policy Table – Executive Directors

### Base salary

<table>
<thead>
<tr>
<th>How the element supports the Company’s strategic objectives</th>
<th>To attract and retain high-calibre individuals to deliver the Company’s strategic plans and to offer market-competitive levels of guaranteed cash to reflect an individual’s skills, experience and role within the Company.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operation of the element</td>
<td>Base salary is normally paid in 12 equal monthly instalments during the year. Salaries are normally reviewed annually in February (with salary changes effective from April) or subject to an ad hoc review on a significant change of responsibilities.</td>
</tr>
<tr>
<td>2022 Policy: no change in policy</td>
<td>Salaries are reviewed taking into account factors including individual performance as well as appropriate market data including general UK pay trends and a company size and complexity model based on a Pay Comparator Group*.</td>
</tr>
<tr>
<td></td>
<td>The Committee will review and potentially amend the constituents of the Pay Comparator Group from time to time.</td>
</tr>
<tr>
<td></td>
<td>* Current constituents of the pay comparator group are: Accenture, Align Group, ArisGlobal-Research Institute, Astellas, Bayer, Coca-Cola Company, Colgate-Palmolive, Danone, Diageo, GlaxoSmithKline, Heineken, Imperial Brands, Johnson &amp; Johnson, Kraft Heinz, L’Oréal, Microsoft, Mondelēz International, Nestlé, Novartis, PepsiCo, Philip Morris International, Praxair &amp; Gambia, Reed Elsevier, Saint-Gobain, Siemens, Unilever, Vodafone.</td>
</tr>
</tbody>
</table>

### Maximum potential value

| Operation of the element                                   | The salary of a recently appointed Executive Director as he or she progresses in a role may exceed the top of the range of the salary increases for UK-based employees where the Committee considers it appropriate to reflect the accrual of experience. A significant change in responsibilities or material change in role may be reflected in an above average increase (which may exceed 10%) in salary. |
| 2022 Policy: no change in policy                           | Annual increases for Executive Directors’ base salaries in the normal course will generally be in the range of the increases in the base pay of other UK-based employees in the Group and will not exceed 10% per annum. |

### Benefits

<table>
<thead>
<tr>
<th>How the element supports the Company’s strategic objectives</th>
<th>To provide market-competitive benefits consistent with the role which:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>– attract and retain high-calibre individuals to deliver the Company’s strategic plans; and</td>
</tr>
<tr>
<td></td>
<td>– recognise that such talent is global in source and that the availability of certain benefits (e.g. relocation, repatriation, taxation compliance advice) will from time to time be necessary to avoid such factors being an inhibitor to accepting the role.</td>
</tr>
<tr>
<td>Operation of the element</td>
<td>The Company currently offers the following contractual benefits to Executive Directors: a car or car allowance; the use of a car and driver for personal and business use; employment tax advice (including in instances where multi-jurisdictional tax authorities are involved); tax equalisation payments (where appropriate); private medical insurance, including general practitioner ‘walk-in’ medical services; personal life and accident insurance; and housing and education allowances or similar arrangements as appropriate to family circumstances (anticipated to be provided for Executive Directors who relocate internationally).</td>
</tr>
<tr>
<td>2022 Policy: no change in policy</td>
<td>Other benefits may include the Executive Directors’ and their partners’ attendance at hospitality or similar functions, and the provision of services and benefits which may be treated as benefits for tax purposes, such as the provision of home security and the reimbursement of expenses incurred in connection with their duties.</td>
</tr>
<tr>
<td></td>
<td>Other benefits not identified above may be offered if, in the Committee’s view, these are necessary in order to remain aligned with market practice.</td>
</tr>
<tr>
<td></td>
<td>With the exception of the car or car allowance, in line with the UK market and the practice followed for all the Group’s other UK employees, it is also practice to pay the tax that may be due on benefits.</td>
</tr>
<tr>
<td></td>
<td>The Company provides Directors and Officers liability insurance (D&amp;O) and an indemnity to Directors to cover costs and liabilities incurred in the execution of their duties.</td>
</tr>
</tbody>
</table>
## Remuneration Report

### Annual Statement on Remuneration

**Continued**

<table>
<thead>
<tr>
<th><strong>Maximum potential value</strong></th>
<th><strong>2022 Policy:</strong> no change in policy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2022 Policy:</strong> no change in policy</td>
<td>The maximum potential values are based on market practice for individuals of this level of seniority, with any tax on benefits paid by the Company in addition. The maximum annual value (subject to periodic inflation-related increases where applicable) that can be offered for the following benefits is:</td>
</tr>
<tr>
<td>- car allowance: £20,000;</td>
<td></td>
</tr>
<tr>
<td>- use of a car and company driver for personal and business use: cost is dependent on the miles driven in any year;</td>
<td></td>
</tr>
<tr>
<td>- the cost of private medical insurance is dependent on an individual’s circumstances and is provided on a family basis;</td>
<td></td>
</tr>
<tr>
<td>- GP ‘walk-in’ medical services located close to the Group’s headquarters in London: £5,000 per annum;</td>
<td></td>
</tr>
<tr>
<td>- personal life and accident insurance designed to pay out at a multiple of four and five times base salary, respectively;</td>
<td></td>
</tr>
<tr>
<td>- employment tax advice as required, but not exceeding £30,000 and tax equalisation payments as agreed by the Committee from time to time; and</td>
<td></td>
</tr>
<tr>
<td>- housing and education allowances or other similar arrangements, as appropriate to the individual’s family circumstances.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Pensions</strong></th>
<th><strong>How the element supports the Company’s strategic objectives</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How the element supports the Company’s strategic objectives</strong></td>
<td>To provide competitive post-retirement benefit arrangements which are aligned to the wider workforce whilst also recognising the external environment in the context of attracting and retaining senior high calibre individuals to deliver the Group’s long-term strategy.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Operation of the element</strong></th>
<th><strong>2022 Policy:</strong> no change in policy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2022 Policy:</strong> no change in policy</td>
<td>Defined contribution benefits Executive Directors are eligible to receive a pension benefit equivalent to 15% of base salary, which the Committee may determine to provide as a contribution into the British American Tobacco UK Pension Plan (the “Plan”) (or a similar defined contribution arrangement from time to time) or as a gross cash sum paid in lieu thereof. The level of contribution in the Plan is restricted to take into account the annual allowance, and the individual may elect to accumulate any balance in the Defined Contribution Unfunded Unapproved Retirement Benefits Scheme (“DC UURBS”) or receive the balance as a gross cash sum. The DC UURBS closed to new entrants on 31 March 2021.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Operation</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operation</strong></td>
<td>The pension arrangements operate in accordance with the rules of the applicable scheme, including in respect of any benefits payable in the event of death or on early retirement. Details of the Executive Directors’ accrued pension benefits are provided in the Annual Report on Remuneration on page 139.</td>
</tr>
</tbody>
</table>

| **Maximum potential value** | **The maximum annual contribution in the defined contribution section of the Pension Fund is 15% of base salary in alignment with the wider workforce. Excess benefits (whether accrued in the DC UURBS or paid as a cash sum) are subject to this same limit.** |

154
Short-term incentives: International Executive Incentive Scheme (IEIS)

<table>
<thead>
<tr>
<th>How the element supports the Company’s strategic objectives</th>
<th>To incentivise the attainment of corporate targets aligned to the Group’s strategic objectives on an annual basis, with a deferred element to ensure alignment with shareholders’ interests. To ensure, overall, a market-competitive package to attract and retain high-calibre individuals to deliver the Group’s long-term strategy.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Operation of the element 2022 Policy: no change in policy</th>
<th>The IEIS is awarded 50% in cash and 50% in shares through the Deferred Share Bonus Scheme (DSBS). The deferred shares normally vest after three years and attract additional dividend equivalent shares. IEIS cash payments are subject to clawback provisions, and the deferred shares element of the IEIS is subject to updated malus and clawback provisions, as described on page 157.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Performance assessment 2022 Policy: underlying policy is unchanged, however alternative measures / weightings have been selected for awards to be made in 2022</th>
<th>The IEIS is assessed against a range of performance measures. The Committee determines performance measures, weightings and targets annually each year. The Remuneration Committee will review the formulaic outcome of the incentive measures to ensure it reflects the underlying performance of the business and the experience of shareholders over the performance period. The Committee retains the ability to adjust any formulaic outcomes if considered appropriate. Any such adjustments will be fully disclosed in the relevant Directors’ Remuneration Report. In cases of identified poor individual performance, the corporate result may be reduced by up to 50%. Performance measures for 2021 can be found on page 137 and for 2022 on page 143.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Maximum potential value and payment and threshold 2022 Policy: no change in policy</th>
<th>Chief Executive – Maximum 250% of salary; on-target 125% of salary. Other Executive Directors – Maximum 190% of salary; on-target 95% of salary. The payout at threshold is 0% for each performance measure.</th>
</tr>
</thead>
</table>
**Remuneration Report**

**Annual Statement on Remuneration**

**Continued**

**Long-term incentives: Long-Term Incentive Plan (LTIP)**

<table>
<thead>
<tr>
<th>How the element supports the Company’s strategic objectives</th>
<th>To incentivise individuals to deliver the Group’s long-term strategy and promote the long-term success of the Company, and facilitate the appointment and retention of senior high-calibre talent. To put in place a combination of measures with appropriately stretching targets around the long-term plan that provides a balance relevant to the Company’s business and market conditions as well as providing alignment between Executive Directors’ and shareholders’ interests.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Operation of the element 2022 Policy: no change in policy</th>
<th>LTIP awards are annual awards over shares that vest only to the extent that: 1. the performance condition is satisfied at the end of the three-year performance period; and 2. an additional vesting period of two years from the date of the third anniversary of the date of grant has been completed – the LTIP Extended Vesting Period. Participants may receive a dividend equivalent which is delivered in additional shares on vesting at the end of the LTIP Extended Vesting Period to the extent to which awards vest. LTIP awards may be delivered in any form provided under the LTIP rules as approved by shareholders. Awards are subject to updated malus and clawback provisions, as described on page 157.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Performance assessment, measures and weighting 2022 Policy: underlying policy is unchanged, however alternative measures / weightings have been selected and the TSR comparator group has been updated for awards to be made in 2022</th>
<th>The Committee sets performance measures and targets for each LTIP grant. Measures, weightings and performance conditions will be selected based on the strategic priorities for BAT at that time. The performance measures and weightings for the LTIP grant in 2022 will be: 1. Relative total shareholder return (TSR) (20%). 2. Growth in New Categories revenue (15%). 3. Adjusted diluted earnings per share (ESP) growth (30%) at current rates (15%) at constant rates (15%) 4. Adjusted revenue growth (15%). 5. Adjusted operating cash flow conversion ratio (20%). The Remuneration Committee will engage with shareholders in advance if it proposes significant changes to the LTIP performance measures. The Remuneration Committee will review the formulaic outcome of the incentive measures to ensure it reflects the underlying performance of the business and the experience of shareholders over the performance period. The Committee retains the ability to adjust any formulaic outcomes if considered appropriate. Any such adjustments will be fully disclosed in the relevant Directors’ Remuneration report.</th>
</tr>
</thead>
</table>

| Maximum potential value and payment at threshold | Maximum award of shares permitted is 100% of salary for Executive Directors. The payout for threshold performance is 15% of maximum for each measure. |
4. The operation of the remuneration policy for employees below Board level is discussed on pages 163 and 164.

Where the Committee determines that these provisions are to be applied, the participant may be required to repay up to the excess value which was paid or vested. This repayment may also be effected by the number of shares

Malus and Clawback provisions apply to DSBS and LTIP awards at any time before or after the vesting of a share award or at any time after the payment of IEIS cash element where it is determined that the participant:

3. Malus and clawback provisions apply to DSBS awards and the cash portion of the IEIS respectively for the duration of three years from the date of the award and to LTIP awards for the duration of five years from the date of award if: (1) there has been a material

(3) contributed to serious reputational damage of any Group company or one of its business units, in each case prior to the vesting of the relevant award or payment of the bonus.

(1) committed misconduct; (2) caused a material loss for any Group company as a result of (a) reckless, negligent or wilful actions or (b) inappropriate behaviour or behaviour that is not aligned with corporate values; (3) contributed to serious reputational damage of any Group company or one of its business units; in each case prior to the vesting of the relevant award or payment of the bonus.

Where the Committee determines that these provisions are to be applied, the participant may be required to repay up to the excess value which was paid or vested. This repayment may also be effected by the number of shares

subject to the award being reduced and/or by a reduction in other cash or share-based awards held by the participant.

5. The Committee reserves the right to make any remuneration payments where the terms were agreed prior to an individual being appointed an Executive Director of the Company or prior to the approval and implementation of the Remuneration Policy (including, for the avoidance of doubt, pursuant to the current Remuneration Policy). This includes the achievement of the applicable performance conditions for Executive Directors who are eligible to receive share-based awards.

Executive Directors are eligible to participate in the Company’s all-employee share schemes, in the same way as the wider workforce, which are designed to incentivise employees by giving them an opportunity to build shareholdings in the Company.

Additional notes to the Future Policy Table:

1. The Committee reserves the right to make any remuneration payments where the terms were agreed prior to an individual being appointed an Executive Director of the Company or prior to the approval and implementation of the Remuneration Policy (including, for the avoidance of doubt, pursuant to the current Remuneration Policy). This includes the achievement of the applicable performance conditions for Executive Directors who are eligible to receive share-based awards.

Executive Directors are eligible to participate in the Company’s all-employee share schemes, in the same way as the wider workforce, which are designed to incentivise employees by giving them an opportunity to build shareholdings in the Company.

The Company currently operates two all-employee share schemes: the Sharesave Scheme, an HM Revenue & Customs (HMRC) tax-advantaged savings-related share option scheme, and the Share Incentive Plan (SIP) – an HMRC tax-advantaged plan operated by the Company to allow eligible employees to purchase shares in the Company (the Partnership Plan) and to make an annual award of free shares of a level based on performance in the previous financial year (the Share Reward Scheme).

Executive Directors are subject to the same limits on participation as other employees, as defined by the applicable statutory provisions. Currently, these limits are monthly savings under the Sharesave Scheme of £500 per month, and annual share purchases under the Partnership Plan of £1,800 and annual share awards under the Share Reward Scheme of £3,600.

Operation of the element 2022 Policy: no change in policy

Executive Directors are required to hold shares in the Company:

– during service as a Director, equal to the value of the same multiple of salary at which LTIP awards are made to that Director; and

– after ceasing service as a Director during the period until the second anniversary of cessation of employment with the Group, of a value equal to 100% of the shareholding requirement that applied whilst a Director. In order to monitor and enforce the above provisions, former Executive Directors are required to hold their shares in a nominee account in respect of which a sale restriction applies to shares held to comply with the requirements.

Those Executive Directors who do not meet the shareholding requirements may generally sell a maximum of up to 50% of any shares vesting (after tax) until the threshold for the shareholding requirements has been met. The estimated notional net-of-tax number of shares held subject to unvested awards under the DSBS element, and LTIP Awards during the LTIP Extended Vesting Period, will count towards the respective shareholding requirements.

A waiver of compliance with the shareholding requirements is permitted at the discretion of the Committee in circumstances which the Committee considers to be exceptional.

How the element supports the Company’s strategic objectives

To strengthen the alignment between the interests of the Executive Directors and those of the shareholders by requiring Executive Directors to build up a high level of personal shareholding in the Company.

To ensure long-term alignment through the operation of post-employment shareholding requirements.

50% of any shares vesting (after tax) until the threshold for the shareholding requirements has been met. The estimated notional net-of-tax number of shares held subject to unvested awards under the DSBS element, and LTIP Awards during the LTIP Extended Vesting Period, will count towards the respective shareholding requirements.

A waiver of compliance with the shareholding requirements is permitted at the discretion of the Committee in circumstances which the Committee considers to be exceptional.

Executive Directors are required to hold shares in the Company:

– during service as a Director, equal to the value of the same multiple of salary at which LTIP awards are made to that Director; and

– after ceasing service as a Director during the period until the second anniversary of cessation of employment with the Group, of a value equal to 100% of the shareholding requirement that applied whilst a Director. In order to monitor and enforce the above provisions, former Executive Directors are required to hold their shares in a nominee account in respect of which a sale restriction applies to shares held to comply with the requirements.

Those Executive Directors who do not meet the shareholding requirements may generally sell a maximum of up to 50% of any shares vesting (after tax) until the threshold for the shareholding requirements has been met. The estimated notional net-of-tax number of shares held subject to unvested awards under the DSBS element, and LTIP Awards during the LTIP Extended Vesting Period, will count towards the respective shareholding requirements.

A waiver of compliance with the shareholding requirements is permitted at the discretion of the Committee in circumstances which the Committee considers to be exceptional.

Executive Directors are required to hold shares in the Company:

– during service as a Director, equal to the value of the same multiple of salary at which LTIP awards are made to that Director; and

– after ceasing service as a Director during the period until the second anniversary of cessation of employment with the Group, of a value equal to 100% of the shareholding requirement that applied whilst a Director. In order to monitor and enforce the above provisions, former Executive Directors are required to hold their shares in a nominee account in respect of which a sale restriction applies to shares held to comply with the requirements.

Those Executive Directors who do not meet the shareholding requirements may generally sell a maximum of up to 50% of any shares vesting (after tax) until the threshold for the shareholding requirements has been met. The estimated notional net-of-tax number of shares held subject to unvested awards under the DSBS element, and LTIP Awards during the LTIP Extended Vesting Period, will count towards the respective shareholding requirements.

A waiver of compliance with the shareholding requirements is permitted at the discretion of the Committee in circumstances which the Committee considers to be exceptional.

Additional notes to the Future Policy Table:

1. The Committee reserves the right to make any remuneration payments where the terms were agreed prior to an individual being appointed an Executive Director of the Company or prior to the approval and implementation of the Remuneration Policy (including, for the avoidance of doubt, pursuant to the current Remuneration Policy). This includes the achievement of the applicable performance conditions for Executive Directors who are eligible to receive share-based awards.

2. The Company recognises the opportunities and benefits that accrue to the Company and its Executive Directors who undertake non-executive roles. Consequently, an Executive Director may, with the permission of the Board, undertake a single external appointment and the Executive Director may retain the fees from such appointment.

3. Malus and clawback provisions apply to DSBS awards and the cash portion of the IEIS respectively for the duration of three years from the date of the award and to LTIP awards for the duration of five years from the date of award if: (1) there has been a material misrepresentation in relation to the performance of any Group company, relevant business unit and/or the participant; (2) an erroneous calculation was made in assessing the extent to which an award vested or bonus was paid.

(1) committed misconduct; (2) caused a material loss for any Group company as a result of (a) reckless, negligent or wilful actions or (b) inappropriate behaviour or behaviour that is not aligned with corporate values; (3) contributed to serious reputational damage of any Group company or one of its business units, in each case prior to the vesting of the relevant award or payment of the bonus.

Where the Committee determines that these provisions are to be applied, the participant may be required to repay up to the excess value which was paid or vested. This repayment may also be effected by the number of shares

subject to the award being reduced and/or by a reduction in other cash or share-based awards held by the participant.

4. The operation of the remuneration policy for employees below Board level is discussed on pages 163 and 164.
Illustrations of the Application of the Remuneration Policy

The levels of remuneration to be received by Jack Bowles and Tadeu Marroco as Executive Directors for the first complete year in which the Remuneration Policy will apply are shown as the hypothetical values of their remuneration packages under different performance scenarios in the charts below.

Remuneration outcomes for varying levels of performance

The following assumptions have been applied in the chart above.

<table>
<thead>
<tr>
<th></th>
<th>Chief Executive</th>
<th>Finance and Transformation Director</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed remuneration</strong></td>
<td>Salary: £1,325,610 (effective 1 Jan 2022)</td>
<td>Salary: £693,400 (effective 1 Jan 2022)</td>
</tr>
<tr>
<td>Pension: 15% of salary</td>
<td>Benefits: £320,000 (illustrative based on 2021 figure)</td>
<td>Pension: 15% of salary Benefits: £100,000 (illustrative based on 2021 figure)</td>
</tr>
<tr>
<td><strong>STI (IEIS)</strong></td>
<td>250%</td>
<td>190%</td>
</tr>
<tr>
<td><strong>LTI (LTIP)</strong></td>
<td>500%</td>
<td>400%</td>
</tr>
<tr>
<td><strong>Minimum</strong></td>
<td>Fixed remuneration only:</td>
<td>No IEIS payout; no vesting under LTIP</td>
</tr>
<tr>
<td><strong>On-target</strong></td>
<td>Fixed remuneration, plus: 50% IEIS payout; threshold vesting under the LTIP</td>
<td></td>
</tr>
<tr>
<td><strong>Maximum</strong></td>
<td>Fixed remuneration, plus: 100% IEIS payout; 100% vesting under the LTIP</td>
<td></td>
</tr>
<tr>
<td><strong>Maximum plus 50% share price growth</strong></td>
<td>Fixed remuneration, plus: All elements are the same as the maximum but assuming 50% share price appreciation during relevant performance period of LTIP</td>
<td></td>
</tr>
</tbody>
</table>

158
Other Policy Provisions in Relation to Directors’ Pay

Flexibility, judgement and discretion

As the Remuneration Policy needs to be capable of operating over a three-year period, the Committee has built in a degree of flexibility to enable the practical implementation of the Remuneration Policy over that prospective lifetime, including as set out in the Future Policy Table above. The key discretions and areas of flexibility and judgement under the STI (cash and deferred shares) and LTI are summarised as follows:

– to determine performance measures, weightings and targets annually for the STI and to set performance measures and targets for each LTIP grant based on the strategic priorities of BAT at that time.
– to alter performance conditions if events happen which cause the Committee to determine that the performance conditions are no longer a fair measure of the Company’s performance, or to take account of legal changes or to obtain or retain favourable tax, regulatory or exchange control treatment or in the event that it considers it fair and reasonable to do so, provided that the revised target is, in the opinion of the Committee, not materially less challenging than was intended in setting the original condition.
– to exercise available discretions in connection with any termination of employment or change of control or similar event.
– to determine whether awards under the LTIP are delivered as options or under any other form permitted under the LTIP rules as approved by shareholders, and in respect of operational matters not otherwise covered by this Policy, to operate the IEIS, DSBS and LTIP in accordance with their terms.
– to operate the malus and clawback provisions.

Approach to Remuneration of Directors on Recruitment

Principles

In making an Executive Director appointment (whether an internal promotion or external appointee) the Committee will follow these principles.

2022 Policy: no change in policy

– British American Tobacco seeks to appoint senior, high-calibre managers. Many of its competitors for talent are based outside the UK.
– To offer a package (both fixed salary, pension and performance-related remuneration) which is sufficiently competitive (but not excessively so) so that senior, high-calibre candidates can be appointed, and which is designed to promote the long-term success of the Company.
– The Committee will consider the market, including the Pay Comparator Group, and by reference to other companies of equivalent size and complexity to ensure that it does not overpay.
– Consideration will be given to relevant factors, such as the candidate’s skills, knowledge and experience and his or her current package and current location in determining the overall package.
– Internal pay relativities and the terms and conditions of employment of the new and existing Executive Directors will be considered to ensure fairness between Executive Directors.

External appointment to role of Executive Director – additional considerations

2022 Policy: no change in policy

– Maximum incentive opportunities will be set in line with the Policy set out in the policy table.
– The Committee will consider matching up to the maximum of the expected value of lost short or long-term incentive awards in order to facilitate the recruitment of that individual.
– A replacement award would generally take the form of either a one-off award with a vesting period similar to the award given up (and, in the case of a replacement of a performance-based award, appropriate performance conditions) or a cash replacement payment in respect of an award that is within three months of vesting, although in either case the Committee may make other arrangements as it deems to be necessary.
– Where appropriate, a replacement award will also be made subject to malus and clawback provisions.

Relocation

British American Tobacco may provide appropriate relocation support.

2022 Policy: no change in policy

Relocation support of up to £200,000 may be provided in connection with recruitment. Examples of this support may include: shipment of goods; temporary accommodation; assistance to find accommodation; tax support services; and spouse or partner career counselling.

Inbound relocation and shipment expenses are subject to clawback provisions.
Remuneration Report

Annual Statement on Remuneration
Continued

Service Contracts – Executive Directors
The following table describes the provisions of the service contracts of Jack Bowles and Tadeu Marroco. It is currently anticipated that service contracts for newly-appointed Executive Directors will not contain terms differing materially from these provisions (provided that other arrangements may be entered into in connection with the recruitment of Executive Directors, as described in the ‘Approach to remuneration of Directors on recruitment’ section on page 159).

<table>
<thead>
<tr>
<th>Notice period</th>
<th>A period of notice to be given by either the Executive Director or the Company of 12 months.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employed on a permanent contract, terminable by either party on one-year’s notice.</td>
<td>The Company may require the Executive Director to be on garden leave during all or any part of the period of notice (whether given by the Executive Director or the Company).</td>
</tr>
</tbody>
</table>

**Contractual terms – no change in policy**
The contract includes obligations which could give rise to, or impact upon, remuneration and/or payments for loss of office.

The provisions of the Company’s incentive arrangements applicable on a termination of employment are set out separately below.

| The primary obligations under the contract which may give rise to remuneration or payments for loss of office are as follows: |
| The Company may, at its reasonable discretion, make the payment in lieu of notice in phased monthly or quarterly instalments and may determine that it should be reduced in accordance with the duty on the part of the Executive Director to mitigate their loss; and |
| to continue to pay the Executive Director’s salary and contractual benefits during any garden leave period. |

In addition to the contractual rights to a payment on loss of office, the Executive Director may have statutory and/or common law rights to certain additional payments depending on the circumstances of the termination.

**Inspection of service contracts**
Copies may be inspected at the Company’s registered office; these contracts are amended annually following the salary review.

<p>| The dates of the latest service contracts are shown below: |</p>
<table>
<thead>
<tr>
<th>Executive Director</th>
<th>Executive date of current service contract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>11 December 2018 (appointment as an Executive Director commenced 1 January 2019)</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>5 August 2019</td>
</tr>
</tbody>
</table>
Policy on Payment for Loss of Office

Treatment of awards under the share incentive schemes: no change in policy

International Executive Incentive Scheme (IEIS)/Deferred Share Bonus Scheme (DSBS)

Long-Term Incentive Plan (LTIP) All-employee scheme

The release of awards is dependent on 'leaver' status and is at the discretion of the Committee.

Plan   'Good leaver'   Other leaver scenarios
IEIS and DSBS 2022 Policy: no change in policy

'Good leavers' are eligible for a bonus pro-rated for the period of employment during the year. Payments made during a notice period or after cessation may, at the discretion of the Committee, be made in cash only.
Bonuses are assessed based on actual full-year performance and paid at the normal time.
Deferred awards under the DSBS will vest upon termination of employment.

No entitlement to a bonus but the Committee has the discretion to treat ‘other’ leavers in the same manner as ‘good leavers’, this discretion is not exercisable in the case of summary dismissal.
Deferred awards under the DSBS will lapse unless the Committee, in its absolute discretion, decides otherwise.

LTIP 2022 Policy: no change in policy.

Vesting occurs at the end of the LTIP Extended Vesting Period, subject to performance over the normal performance period and, where applicable, pro-rated for the period of employment during the performance period.
Unvested awards, including any awards which are still subject to the LTIP Extended Vesting Period, will lapse unless the Committee, in its absolute discretion, decides otherwise.

All-employee share schemes

Directors are treated in accordance with the scheme rules, in the same manner as applies to all employees.

The Committee retains discretion in deciding ‘good leaver’ status other than in cases of automatic ‘good leavers’ as set out in the applicable provisions of the DSBS and LTIP rules. The discretionary powers are intended to provide flexibility as Executive Directors may leave employment for a broad variety of reasons which may not necessarily fall within the prescribed category of ‘good leaver’. The Committee exercises its discretion by reference to guidelines which set out its agreed relevant factors to assist in the determination of a leaver’s status.

Guidelines

Factors which may indicate that discretion may be exercised to treat as a ‘good leaver’
Resignation intending to cease work altogether.
Resignation intending to take up a different occupation, such as a portfolio career.
Delayed resignation from the Company to accommodate the Company’s plans or the demands of his or her current workload.
Departure at the request of and/or with the agreement of the Company.

Factors which may indicate that discretion may not be exercised
Resignation from the Company to work for a competitor or to undertake a role otherwise acting in conflict with the interests of the Company.
Resignation from the Company notwithstanding the Company’s plans and role demands.
Termination or resignation in any circumstance involving factors such as misconduct or poor performance.

In exercising its discretion, the Committee will also take into account the individual’s overall performance as well as their contribution to the Company during their total period of employment.

Other – no change in policy

– Payment of legal fees incurred by an individual in connection with reviewing a settlement agreement on termination of employment.
– Reimbursement of reasonable relocation costs of up to £200,000 where an Executive Director (and, where relevant, his or her family) had originally relocated to take up the appointment; this may include the shipment of personal goods and winding-up his or her affairs in the UK and the incidental costs incurred in doing so.

In certain circumstances, the Committee may approve new contractual arrangements with departing Executive Directors, potentially including (but not limited to) settlement, confidentiality, restrictive covenants and/or consultancy arrangements. These arrangements would only be entered into where the Committee believes that it is in the best interests of the Company and its shareholders to do so.
## Terms of Appointment for the Chairman and other Non-Executive Directors

Non-Executive Directors, including the Chairman, are appointed as officeholders, not employees. In any given year, the period of appointment runs from the close of the Company’s last AGM to the close of the Company’s next AGM.

The Chairman may terminate his or her appointment on one month’s written notice, and the Company may give a compensation payment in lieu of all or part of such notice. The Chairman may be removed by the Company prior to the expiry of his or her term of appointment by three months’ written notice or a compensation payment in lieu of all or part of such notice.

A Non-Executive Director may terminate his or her appointment at any time in accordance with the Company’s Articles of Association. Alternatively, a Non-Executive Director’s appointment will terminate if: (1) the Board requests that he or she not offer himself or herself for re-election at the next AGM; (2) the Non-Executive Director is not re-elected at the next AGM; (3) the Non-Executive Director is required to vacate office for any reason pursuant to any of the provisions of the Company’s Articles of Association; or (4) the Non-Executive Director is removed as Director or otherwise required to vacate office under any applicable law.

### Chairman and Non-Executive Directors

#### Fees

**2022 Policy:** policy has been updated so fees may be delivered in cash or a combination of cash and shares

The Chairman receives a single all-inclusive fee. Other Non-Executive Directors receive a base fee and may also receive additional fees in respect of committee membership and/or chairmanship.

The Committee considers annually the fee payable to the Chairman and to the other Non-Executive Directors. This process may take into account factors including the breadth and demands of the relevant role as well as comparison with fees paid by the same comparator group of companies used for setting the base salary of Executive Directors. The annual review does not necessarily result in a change to the fees.

Fees may be paid in cash or a combination of cash and shares, with the proportion to be paid in shares in a year to be disclosed in the relevant Directors’ Remuneration Report.

It is anticipated that any future aggregate increase in fees for the Chairman and other Non-Executive Directors will generally be in the range of the increases in the base pay of UK-based employees in the Group and will not exceed 10% per annum during the policy period.1

The Chairman and other Non-Executive Directors do not participate in any discussion on their own respective remuneration.

#### Benefits, travel and related expenses

**2022 Policy:** no change in policy

Non-Executive Directors may be reimbursed for the cost of travel, accommodation and related expenses incurred in connection with their duties and are eligible to use general practitioner ‘walk-in’ services. The Non-Executive Directors and their partners may attend hospitality or similar functions.

Benefits for the Chairman may also include: the use of a Company driver; private medical insurance and personal accident insurance benefits; the provision of home and personal security; and assistance in relation to personal tax matters.

If necessary, the Company will pay for independent professional advice in connection with the performance of duties as Non-Executive Directors.

The Company provides D&O insurance and an indemnity to the Non-Executive Directors to cover costs and liabilities incurred in the execution of their duties.

In instances where any benefits, reimbursements or expenses are classified by HMRC as a benefit to the Non-Executive Directors, it is also the practice of the Company to pay any tax due on any such benefits.

#### Other

**2022 Policy:** no change in policy

There are no formal requirements or guidelines to hold shares in the Company. No Non-Executive Director is eligible to participate in the British American Tobacco share schemes, bonus schemes or incentive plans and no Non-Executive Director may be a member of any Group pension plan.

**Note:**

1. Aggregate fees limit: the total annual fees of the Chairman and other Non-Executive Directors are limited to the overall aggregate annual limit authorised by shareholders with reference to the Company’s Articles of Association (currently £2,500,000).
Principles of Remuneration for Our Wider Workforce

The Group’s remuneration policies and practices are founded on a high degree of alignment and consistency across the organisation. Accordingly, remuneration for senior management is determined considering the remuneration principles that apply to the Executive Directors, and similar principles also form the basis of the remuneration arrangements for the wider workforce.

The reward strategy for all employees is built around the following four strategic pillars and comprises fixed and variable remuneration elements:

- **Competitive yet sustainable**
  - Competitive remuneration, able to attract and retain talent.
  - Agility to meet changing generational needs.
  - Responsible cost structure to support profit delivery.

- **Transparent**
  - Clear and inclusive policies, openly communicated.
  - Individual total reward package statements form part of regular annual cycle.

- **Equitably differentiated**
  - Differentiated on clear and objective criteria – level, performance and experience.
  - Supported by unbiased processes and tools.

- **Aligned to shareholder interests**
  - Competitive employment cost base and incentives that align the interests of employees with those of shareholders.

A globally consistent pay comparator group, derived from the peer group used by the Remuneration Committee for executive pay benchmarking, is utilised across all levels of the organisation for pay benchmarking purposes, with an appropriate level of flexibility provided to the other employing entities.

The approach to annual salary reviews is consistent across the Group, with consideration given to the scope of the role, level of individual experience, responsibility, individual performance and pay levels in the selected peer group.

All middle-to-senior managers are eligible to participate in a short-term incentive plan with the same metrics as Executive Directors. Other employees in corporate functions are eligible to participate in annual bonus plans, which mirror the Executive Directors’ performance objectives. Functional incentive schemes are offered to the Group’s employees in non-corporate positions such as sales force or manufacturing roles. Opportunities and metrics which apply to those schemes may vary by organisational level with functional performance indicators incorporated where appropriate.

Senior managers are eligible to participate in the long-term incentive schemes, namely the Performance Share Plan (PSP) and the Restricted Share Plan (RSP), with opportunities varying across levels with the most senior managers having a bigger portion of their pay delivered under the long-term incentive schemes. Metrics under the PSP are the same as those for Executive Directors.

In the UK, all employees are encouraged to become shareholders by participating in all-employee share plans on the same terms as Executive Directors. Similar all-employee share schemes have been adopted for other jurisdictions with the goal of encouraging broader long-term employee ownership.

Retirement benefits, typically in the form of a pension, are provided based on local market practice. Pension contribution rates for Executive Directors under the defined contribution scheme are aligned with those available to the wider UK employee population. Other benefits provided to the wider employee population reflect local market practice and legislative requirements.

The key difference between Executive Directors’ remuneration and the wider employee population is the increased emphasis on long-term performance in respect of Executive Directors, with a greater percentage of their total remuneration being performance-related and delivered in BAT shares. This includes an additional two-year holding period on vested LTIPs, and post-employment shareholding requirements which do not apply to other employees other than members of the Management Board.

**Fixed remuneration**

**Salary**

- Salary is a key element of total remuneration for all employees.
- Salary ranges for each grade are set by reference to external market data, and individual positioning within the set salary ranges will depend on level of experience, responsibility and individual performance.
- Annual salary reviews typically take place in April each year.

In several markets Collective Labour Agreements (CLAs) exist covering some employees, therefore, some of the above principles may not apply.

**Benefits and recognition**

- Benefits provided to employees reflect local market practice and legislative requirements.
- The benefits architecture for the Group includes core benefits (such as medical insurance and life insurance) and local statutory benefits and may be delivered as a combination of benefits in kind, cash allowance and flexible benefits.
- Additional financial and non-financial rewards can be made for outstanding contributions to the business in exceptional circumstances.

**Pension**

- Retirement benefits are provided to employees based on local market practice.
- Under the UK Defined Contribution arrangements, the Company contributions for all UK employees is 10% of base salary rising to a maximum of 15% on a matching basis. For managers in senior management roles, the total contribution to the British American Tobacco UK Pension Plan (“Plan”) is automatically restricted to £4,000 per annum in line with the UK Government’s Tapered Annual Allowance. The balance of any Company contributions due above this £4,000 limit is paid as a cash allowance or, alternatively, paid into the Defined Contribution Unapproved Unfunded Retirement Benefits Scheme (DC UURBS). The DC UURBS closed to new entrants on 31 March 2021. Employees can choose to opt out of the restriction and have all the Company contribution paid into the Plan.
Remuneration Report

Annual Statement on Remuneration
Continued

Variable remuneration

Short-term incentives

Short-term incentive schemes are designed to reward employees across the business for the delivery of financial, strategic and operational targets. The Group operates various short-term incentive arrangements, as set out below, with participation dependent on role.

International Executive Incentive Scheme (IEIS) – globally aligned scheme for all managers in senior management roles (c. 1,700 employees), including the Executive Directors.

- Incentive opportunities for the IEIS participants are defined globally for each eligible grade.
- A portion of any award receivable is deferred in BAT shares for three years, with the remaining portion paid in cash during the following year.
- Dividend-equivalent payments on all unvested deferred shares are paid quarterly in cash via payroll.

Corporate annual bonus plans – in operation for employees in corporate functions who are not eligible to participate in the IEIS (c. 15,000 employees).

- Designed to mirror the basic construct of the IEIS with opportunity levels set locally.
- Performance metrics aligned to those of the IEIS.

Functional incentive schemes – in operation for employees in non-corporate functions, examples include trade marketing or factory incentive schemes.

- Opportunity levels are set locally and vary by grade.
- Functional performance measures are incorporated into each scheme to ensure line of sight for participants.

Long-term incentives

Long-term incentive schemes are designed to reward and retain our senior talent while aligning the interests of leaders with those of our shareholders. From 2020, we have moved from a single LTI plan to a segmented approach by grade as set out below.

Restricted Share Plan (RSP) – globally aligned discretionary plan for managers at eligible grades in senior management roles (c. 540 employees), excluding the Executive Directors. Aligns scheme participants with the success of the Group through its share price.

- Opportunity levels are defined globally for each eligible grade.
- No performance conditions apply to awards.
- Awards are typically granted in March of each year, and vest in full following the end of the three-year vesting period provided the participant remains an employee of the Group on the vesting date.
- Dividend-equivalent payments are paid on shares vesting.

Performance Share Plan (PSP) – discretionary plan for our most senior managers (c. 160 employees), including the Executive Directors, which rewards their contribution to the long-term global performance of the Company.

- Consistent performance measures across all plan participants with opportunity levels defined globally for each eligible grade.
- Awards vest only to the extent that the performance conditions are satisfied at the end of the three-year performance period.
- Awards are typically granted in March of each year, and vest following the end of a three-year performance period.
- Dividend-equivalent payments are paid on any shares vesting.

All-employee share schemes

- In the UK, all employees are eligible to participate in the Company’s all-employee share schemes (c. 2,500 employees) – the Partnership Share Scheme, the Sharesave Scheme and the Share Incentive Plan – all of which are HMRC-approved plans, which are designed to incentivise employees by giving them an opportunity to build shareholdings in the Company.
Process in setting Executive Directors’ remuneration

The Committee considers the budgeted salary increases for the UK-based employee population, the guidance given to managers on the range of salary increases and other remuneration arrangements and employment conditions for all UK-based employees when determining remuneration for the Executive Directors.

It is expected that future salary increases for the Executive Directors will be in line with the range set out in the salary review guidelines for the general UK employee population, except in exceptional circumstances, such as where a recently appointed Executive Director’s salary is increased to reflect his or her growth in the role over time or where significant additional responsibilities are added to the role.

As a key principle, management provides the Remuneration Committee with visibility of the potential impact of proposed changes to the Executive Directors’ Remuneration Policy on the wider employee population.

Workforce engagement

The Board keeps up to date with the current views of our workforce and provides the workforce with information, including on how executive pay and the pay of the wider workforce are aligned, through a combination of engagement methods across multiple channels at different levels of our organisation. These include town halls, works councils, webcasts, global independently managed Speak Up channels, our biennial ‘Your Voice’ global employee survey, and direct engagement through Directors’ market and site visits where possible.

Feedback from these channels is collected across the Group and are independently analysed to define the priority themes. The consolidated feedback and themes are reviewed by our Board each year, as part of our Workforce Voice in the Boardroom programme. This focuses on ensuring the Board understands the views of our workforce, and reviews details of the key themes identified and how we have responded.

The views of our workforce are a key consideration for the Remuneration Committee when reviewing the reward priorities of the organisation. In 2021 we conducted our latest ‘Your Voice’ global employee survey, with the results of this survey also serving as a factor in shaping the reward agenda of the organisation. Although employees are not specifically consulted on the policy for Directors’ remuneration, there continues to be an ongoing dialogue with employees, through a variety of channels, about the Company’s broader pay practices.

In addition to the Workforce Voice in the Boardroom programme, the Remuneration Committee also receives updates from management on feedback received during the year where relevant to remuneration matters considered by the Remuneration Committee and takes feedback into account as applicable in determining executive remuneration.

The Remuneration Committee is regularly updated on the pay principles and practices in operation across the Group and considers them in relation to the implementation of the Directors’ Remuneration Policy, and in ensuring there is an appropriate degree of alignment throughout the Group.
Governance

Responsibility of Directors

This page is intentionally left blank
This page is intentionally left blank
Financial Statements

This page is intentionally left blank
This page is intentionally left blank
**Financial Statements**

**Report of Independent Registered Public Accounting Firm**

To the Shareholders and Board of Directors of British American Tobacco p.l.c.

**Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting**

We have audited the accompanying Group Balance Sheet of British American Tobacco p.l.c. and subsidiaries (the "Group") as of December 31, 2021 and 2020, the related Group Income Statement, Group Statement of Comprehensive Income, Group Statement of Changes in Equity, and Group Cash Flow Statement for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). We also have audited the Group's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Group as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. Also in our opinion, the Group maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021 based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

**Basis for Opinions**

The Group’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s report on internal control over financial reporting. Our responsibility is to express an opinion on the Group’s consolidated financial statements and an opinion on the Group’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

**Definition and Limitations of Internal Control Over Financial Reporting**

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Critical Audit Matters**

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

176
Impairment analysis of goodwill and trademarks with indefinite lives arising from the 2017 acquisition of Reynolds American Inc. (Reynolds American)

As discussed in Note 12 to the consolidated financial statements, the Group, as at December 31, 2021, has goodwill and trademarks with indefinite lives of £33,021 million and £69,475 million, respectively, arising from the 2017 acquisition of Reynolds American.

We identified the evaluation of the impairment analysis of goodwill and trademarks with indefinite lives arising from the 2017 acquisition of Reynolds American as a critical audit matter. There is a high degree of auditor judgment involved in evaluating: (i) the budgeted revenue and discount rates used in the analysis of the recoverability of trademarks with indefinite lives and goodwill allocated to the Reynolds American cash-generating unit; and (ii) the impact of the proposed menthol ban on the terminal growth rates and discount rates for the Newport and Camel indefinite lived trademarks and the goodwill allocated to the Reynolds American cash-generating unit.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the goodwill and trademarks with indefinite lives impairment testing process including controls related to the development of the budgeted revenue and management’s determination of the applicable discount rates. In addition, we assessed the impairment analysis by:

- assessing and challenging Reynolds American’s budgeted revenue by examining externally derived publicly available data, including, broker and analyst reports, industry reports, media reports, macro-economic assumptions, academic and scientific studies, and regulatory changes;
- challenging the budgeted revenue by comparing the historical projections to actual results to assess the Group’s ability to accurately forecast;
- performing sensitivity analysis on the budgeted revenue to assess its impact on the Group’s determination that the fair values of the Reynolds American goodwill and trademarks with indefinite lives exceed their carrying value;
- specifically for the proposed federal menthol ban, critically evaluating the Group’s assessment of the potential timing of the impact based on the FDA rulemaking process and recent litigations;
- assessing and challenging the impact of the proposed menthol ban on the terminal growth rates used in the value-in-use based assessment of the recoverability of the goodwill allocated to the Reynolds American cash-generating unit and the Newport and Camel indefinite lived brands by comparing management’s projected brand retention rates against actual brand retention rates in similar markets where a menthol ban has been implemented; and
- involving a valuation professional with specialized skills and knowledge, who assisted in independently developing a range of the discount rates using publicly available market data for comparable companies and comparing these rates to those utilized by Reynolds American to assess their reasonableness.

Canadian legal proceedings

As discussed in Note 31 to the consolidated financial statements, the Group’s operating company in Canada, Imperial Tobacco Canada (“Imperial”), has received an unfavorable judgment on the smoking and health class actions certified by the Quebec Superior Court. As a result of this judgment, Imperial has filed for creditor protection under the Companies’ Creditors Arrangement Act (the “CCAA”) and has asked the Ontario Superior Court to stay all pending or contemplated litigation against Imperial in order to resolve all of the outstanding litigation across the country.

We identified the evaluation of the Canadian legal proceedings as a critical audit matter because complex and subjective auditor judgment was required in evaluating the Group’s assessment of the relevant law, historical and pending court rulings, and the Group’s ability to estimate the likelihood and extent of any future economic outflow arising from the ultimate resolution of the Canadian litigation.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the legal exposure process including controls related to the interpretation of relevant law and related court rulings and estimation of the likelihood and extent of any future economic outflow arising from the ultimate resolution of the Canadian litigation. In addition, we assessed the Canadian legal proceedings by:

- reading letters received directly from the Group’s external and internal legal counsel that evaluated the current status of the Canadian legal proceedings. We further inquired of internal legal counsel to evaluate their basis for conclusions in their letter; and
- assessing relevant historical and recent judgments passed by the judicial court authorities in relation to the Canadian litigation and read the related Canadian court rulings in order to challenge Imperial’s interpretation of the Canadian legal proceedings.

/s/ KPMG LLP
We have served as the Group’s auditor since 2015.

London, United Kingdom
February 10, 2022
## Group Income Statement

For the years ended 31 December

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue1</td>
<td>25,684</td>
<td>25,776</td>
<td>25,877</td>
</tr>
<tr>
<td>Raw materials and consumables used</td>
<td>(4,542)</td>
<td>(4,583)</td>
<td>(4,599)</td>
</tr>
<tr>
<td>Changes in inventories of finished goods and work in progress</td>
<td>160</td>
<td>445</td>
<td>162</td>
</tr>
<tr>
<td>Employee benefit costs</td>
<td>(2,717)</td>
<td>(2,744)</td>
<td>(3,221)</td>
</tr>
<tr>
<td>Depreciation, amortisation and impairment costs</td>
<td>(1,076)</td>
<td>(1,450)</td>
<td>(1,512)</td>
</tr>
<tr>
<td>Other operating income</td>
<td>196</td>
<td>188</td>
<td>163</td>
</tr>
<tr>
<td>Loss on reclassification from amortised cost to fair value</td>
<td>(3)</td>
<td>(3)</td>
<td>(3)</td>
</tr>
<tr>
<td>Other operating expenses</td>
<td>(7,468)</td>
<td>(7,667)</td>
<td>(7,851)</td>
</tr>
<tr>
<td><strong>Profit from operations</strong></td>
<td>10,234</td>
<td>9,962</td>
<td>9,016</td>
</tr>
<tr>
<td>Net finance costs</td>
<td>(1,486)</td>
<td>(1,745)</td>
<td>(1,602)</td>
</tr>
<tr>
<td>Share of post-tax results of associates and joint ventures</td>
<td>2, 9</td>
<td>415</td>
<td>498</td>
</tr>
<tr>
<td><strong>Profit before taxation</strong></td>
<td>9,163</td>
<td>8,672</td>
<td>7,912</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>(2,189)</td>
<td>(2,108)</td>
<td>(2,063)</td>
</tr>
<tr>
<td><strong>Profit for the year</strong></td>
<td>6,974</td>
<td>6,564</td>
<td>5,849</td>
</tr>
<tr>
<td>Attributable to:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Owners of the parent</td>
<td>6,801</td>
<td>6,400</td>
<td>5,704</td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>173</td>
<td>164</td>
<td>145</td>
</tr>
<tr>
<td><strong>6,974</strong></td>
<td><strong>6,564</strong></td>
<td><strong>5,849</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Earnings per share**

<table>
<thead>
<tr>
<th>Basic</th>
<th>Diluted</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>296.9p</td>
<td><strong>295.6p</strong></td>
</tr>
<tr>
<td>280.0p</td>
<td>278.9p</td>
</tr>
<tr>
<td>249.7p</td>
<td><strong>249.0p</strong></td>
</tr>
</tbody>
</table>

**Note:**

1. Revenue is net of duty, excise and other taxes of £38,595 million, £39,172 million and £39,826 million for the years ended 31 December 2021, 2020 and 2019, respectively.

The accompanying notes are an integral part of these consolidated financial statements.
### Group Statement of Comprehensive Income

For the years ended 31 December

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profit for the year</strong></td>
<td>6,974</td>
<td>6,564</td>
<td>5,849</td>
</tr>
<tr>
<td><strong>Other comprehensive income/(expense)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Items that may be reclassified subsequently to profit or loss:</td>
<td>509</td>
<td>(2,997)</td>
<td>(3,216)</td>
</tr>
<tr>
<td>Foreign currency translation and hedges of net investments in foreign operations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– differences on exchange from translation of foreign operations</td>
<td>32</td>
<td>(2,597)</td>
<td>(2,967)</td>
</tr>
<tr>
<td>– reclassified and reported in profit for the year</td>
<td>291</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>– net investment hedges – net fair value gains/(losses) on derivatives</td>
<td>75</td>
<td>(16)</td>
<td>21</td>
</tr>
<tr>
<td>– net investment hedges – differences on exchange on borrowings</td>
<td>24</td>
<td>(163)</td>
<td>(18)</td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net fair value gains/(losses)</td>
<td>95</td>
<td>(257)</td>
<td>(246)</td>
</tr>
<tr>
<td>– reclassified and reported in profit for the year</td>
<td>32</td>
<td>90</td>
<td>53</td>
</tr>
<tr>
<td>– tax on net fair value (gains)/losses in respect of cash flow hedges</td>
<td>10(f)</td>
<td>(32)</td>
<td>44</td>
</tr>
<tr>
<td>Investments held at fair value</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net fair value gains</td>
<td>18</td>
<td>9</td>
<td>–</td>
</tr>
<tr>
<td>– associates – share of OCI, net of tax</td>
<td>9</td>
<td>(17)</td>
<td>(98)</td>
</tr>
<tr>
<td>Items that will not be reclassified subsequently to profit or loss:</td>
<td>313</td>
<td>55</td>
<td>(507)</td>
</tr>
<tr>
<td>Retirement benefit schemes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net actuarial gains/(losses)</td>
<td>15</td>
<td>382</td>
<td>105</td>
</tr>
<tr>
<td>– surplus recognition</td>
<td>15</td>
<td>(1)</td>
<td>10</td>
</tr>
<tr>
<td>– tax on actuarial (gains)/losses in respect of subsidiaries</td>
<td>10(f)</td>
<td>(82)</td>
<td>(26)</td>
</tr>
<tr>
<td>Associates – share of OCI, net of tax</td>
<td>9</td>
<td>14</td>
<td>(34)</td>
</tr>
<tr>
<td><strong>Total other comprehensive income/(expense) for the year, net of tax</strong></td>
<td>822</td>
<td>(2,942)</td>
<td>(3,723)</td>
</tr>
<tr>
<td><strong>Total comprehensive income for the year, net of tax</strong></td>
<td>7,796</td>
<td>3,622</td>
<td>2,126</td>
</tr>
<tr>
<td><strong>Attributable to</strong>:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Owners of the parent</td>
<td>7,622</td>
<td>3,474</td>
<td>2,000</td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>174</td>
<td>148</td>
<td>126</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>7,796</td>
<td>3,622</td>
<td>2,126</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
Financial Statements

Group Statement of Changes in Equity

<table>
<thead>
<tr>
<th>Notes</th>
<th>Share capital £m</th>
<th>Share premium, capital redemption and merger reserves £m</th>
<th>Other reserves £m</th>
<th>Retained earnings £m</th>
<th>Total attributable to owners of parent £m</th>
<th>Perpetual hybrid bonds £m</th>
<th>Non-controlling interests £m</th>
<th>Total equity £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at 1 January 2021</td>
<td>614</td>
<td>26,618</td>
<td>(6,600)</td>
<td>42,041</td>
<td>62,673</td>
<td>–</td>
<td>282</td>
<td>62,955</td>
</tr>
<tr>
<td>Total comprehensive income for the year comprising:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit for the year</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>6,801</td>
<td>6,801</td>
<td>–</td>
<td>173</td>
<td>6,974</td>
</tr>
<tr>
<td>Other comprehensive income for the year</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>523</td>
<td>298</td>
<td>821</td>
<td>–</td>
<td>822</td>
</tr>
<tr>
<td>Other changes in equity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges reclassified and reported in total assets</td>
<td>–</td>
<td>–</td>
<td>45</td>
<td>–</td>
<td>45</td>
<td>–</td>
<td>–</td>
<td>45</td>
</tr>
<tr>
<td>Employee share options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– value of employee services</td>
<td>28</td>
<td>–</td>
<td>–</td>
<td>76</td>
<td>76</td>
<td>–</td>
<td>–</td>
<td>76</td>
</tr>
<tr>
<td>– treasury shares used for share option schemes</td>
<td>–</td>
<td>4</td>
<td>–</td>
<td>(4)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Dividends and other appropriations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– ordinary shares</td>
<td>22(f)</td>
<td>–</td>
<td>–</td>
<td>(4,904)</td>
<td>(4,904)</td>
<td>–</td>
<td>–</td>
<td>(4,904)</td>
</tr>
<tr>
<td>– to non-controlling interests</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(162)</td>
<td>(162)</td>
</tr>
<tr>
<td>Purchase of own shares</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– held in employee share ownership trusts</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(82)</td>
<td>(82)</td>
<td>–</td>
<td>–</td>
<td>(82)</td>
</tr>
<tr>
<td>Perpetual hybrid bonds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– proceeds, net of issuance fees</td>
<td>22(d)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1,681</td>
<td>–</td>
<td>1,681</td>
</tr>
<tr>
<td>– tax on issuance fees</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4</td>
<td>–</td>
<td>4</td>
</tr>
<tr>
<td>– coupons paid</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(6)</td>
<td>(6)</td>
<td>–</td>
<td>–</td>
<td>(6)</td>
</tr>
<tr>
<td>– tax on coupons paid</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>Non-controlling interests – acquisitions</td>
<td>27(b)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(5)</td>
<td>(5)</td>
<td>–</td>
</tr>
<tr>
<td>Other movements – non-controlling interests</td>
<td>27(b)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Other movements</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(4)</td>
<td>(4)</td>
<td>–</td>
<td>–</td>
<td>(4)</td>
</tr>
<tr>
<td>Balance at 31 December 2021</td>
<td>614</td>
<td>26,622</td>
<td>(6,032)</td>
<td>44,212</td>
<td>65,416</td>
<td>1,685</td>
<td>300</td>
<td>67,401</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
### Strategic Report

#### Governance Report

#### Financial Statements

#### Other Information

<table>
<thead>
<tr>
<th>Notes</th>
<th>Share capital £m</th>
<th>Share premium, capital redemption and merger reserves £m</th>
<th>Other reserves £m</th>
<th>Retained earnings £m</th>
<th>Total attributable to owners of parent £m</th>
<th>Non-controlling interests £m</th>
<th>Total equity £m</th>
</tr>
</thead>
</table>

## Balance at 1 January 2020

<table>
<thead>
<tr>
<th>Notes</th>
<th>Share capital £m</th>
<th>Share premium, capital redemption and merger reserves £m</th>
<th>Other reserves £m</th>
<th>Retained earnings £m</th>
<th>Total attributable to owners of parent £m</th>
<th>Non-controlling interests £m</th>
<th>Total equity £m</th>
</tr>
</thead>
</table>

## Total comprehensive income for the year comprising:

### Other changes in equity

#### Cash flow hedges reclassified and reported in total assets

#### Employee share options

#### Dividends and other appropriations

#### Dividends and other appropriations

#### Purchase of own shares

#### Other movements non-controlling interests

#### Other movements

### Balance at 31 December 2020

<table>
<thead>
<tr>
<th>Notes</th>
<th>Share capital £m</th>
<th>Share premium, capital redemption and merger reserves £m</th>
<th>Other reserves £m</th>
<th>Retained earnings £m</th>
<th>Total attributable to owners of parent £m</th>
<th>Non-controlling interests £m</th>
<th>Total equity £m</th>
</tr>
</thead>
</table>

The accompanying notes are an integral part of these consolidated financial statements.

181
## Group Balance Sheet

### Assets

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>115,625</td>
<td>115,343</td>
</tr>
<tr>
<td>13</td>
<td>4,953</td>
<td>5,060</td>
</tr>
<tr>
<td>14</td>
<td>1,946</td>
<td>1,796</td>
</tr>
<tr>
<td>15</td>
<td>918</td>
<td>714</td>
</tr>
<tr>
<td>16</td>
<td>611</td>
<td>534</td>
</tr>
<tr>
<td>17</td>
<td>210</td>
<td>242</td>
</tr>
<tr>
<td>18</td>
<td>50</td>
<td>22</td>
</tr>
<tr>
<td>19</td>
<td>243</td>
<td>367</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td><strong>124,078</strong></td>
<td><strong>124,078</strong></td>
</tr>
</tbody>
</table>

### Inventories

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>5,279</td>
<td>5,998</td>
</tr>
<tr>
<td>17</td>
<td>3,951</td>
<td>3,721</td>
</tr>
<tr>
<td>18</td>
<td>456</td>
<td>242</td>
</tr>
<tr>
<td>19</td>
<td>182</td>
<td>430</td>
</tr>
<tr>
<td>21</td>
<td>2,809</td>
<td>3,139</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td><strong>12,612</strong></td>
<td><strong>13,612</strong></td>
</tr>
</tbody>
</table>

### Total assets

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>137,690</td>
<td>137,690</td>
</tr>
</tbody>
</table>

### Equity – capital and reserves

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>22(a)</td>
<td>614</td>
<td>614</td>
</tr>
<tr>
<td>22(b)</td>
<td>26,622</td>
<td>26,618</td>
</tr>
<tr>
<td>22(c)</td>
<td>(6,032)</td>
<td>(6,600)</td>
</tr>
<tr>
<td>22(c)</td>
<td>44,212</td>
<td>42,041</td>
</tr>
<tr>
<td>22(d)</td>
<td>65,416</td>
<td>62,673</td>
</tr>
<tr>
<td>22(e)</td>
<td>1,685</td>
<td>–</td>
</tr>
<tr>
<td>22(e)</td>
<td>300</td>
<td>282</td>
</tr>
<tr>
<td><strong>Total equity</strong></td>
<td><strong>67,401</strong></td>
<td><strong>62,955</strong></td>
</tr>
</tbody>
</table>

### Liabilities

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>35,666</td>
<td>39,927</td>
</tr>
<tr>
<td>15</td>
<td>1,239</td>
<td>1,524</td>
</tr>
<tr>
<td>16</td>
<td>16,462</td>
<td>16,314</td>
</tr>
<tr>
<td>24</td>
<td>392</td>
<td>387</td>
</tr>
<tr>
<td>25</td>
<td>982</td>
<td>1,084</td>
</tr>
<tr>
<td>19</td>
<td>79</td>
<td>41</td>
</tr>
<tr>
<td><strong>Total non-current liabilities</strong></td>
<td><strong>59,257</strong></td>
<td><strong>59,257</strong></td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.

On behalf of the Board

Luc Jobin

Chairman

10 February 2022
## Group Cash Flow Statement

For the years ended 31 December

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit for the year</td>
<td>6,974</td>
<td>6,564</td>
<td>5,849</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>2,189</td>
<td>2,108</td>
<td>2,063</td>
</tr>
<tr>
<td>Share of post-tax results of associates and joint ventures</td>
<td>(415)</td>
<td>(455)</td>
<td>(498)</td>
</tr>
<tr>
<td>Net finance costs</td>
<td>1,486</td>
<td>1,745</td>
<td>1,602</td>
</tr>
<tr>
<td>Profit from operations</td>
<td>10,234</td>
<td>9,962</td>
<td>9,016</td>
</tr>
</tbody>
</table>

### Adjustments for
- depreciation, amortisation and impairment costs
  - 4
  - 1,076   | 1,450   | 1,512   |
- (increase)/decrease in inventories
  - (393)   | 300     | (699)   |
- (increase) in receivables related to the charge in respect of the Quebec Class Actions
  - 24
  - (50)    | 371     | 436     |
- (decrease)/increase in Master Settlement Agreement payable
  - 6
  - (36)    | 369     | (124)   |
- increase/(decrease) in trade and other receivables
  - 183     | (320)   | 730     |
- decrease in net retirement benefit liabilities
  - (104)   | (96)    | (40)    |
- (decrease)/increase in other provisions for liabilities
  - (145)   | –       | 382     |
- other non-cash items
  - (27)    | 430     | 46      |

Cash generated from operating activities | 11,678  | 11,567  | 10,948  |
Dividends received from associates | 353     | 351     | 252     |
Tax paid | (2,314)  | (2,132) | (2,204) |

**Net cash generated from operating activities** | 9,717   | 9,786   | 8,996   |

### Cash flows from investing activities

| Interest received | 33     | 48     | 80     |
| Purchases of property, plant and equipment | (527)   | (511)   | (664)   |
| Proceeds on disposal of property, plant and equipment | 31     | 44     | 34     |
| Purchases of intangibles | (218)   | (244)   | (151)   |
| Purchases of investments | (369)   | (343)   | (191)   |
| Proceeds on disposals of investments | 141     | 184     | 339     |
| Investment in associates and acquisitions of other subsidiaries net of cash acquired | (133)   | 39      | (86)    |
| Disposal of subsidiary, net of cash disposed of | (27)    | (98)    | –       |

**Net cash used in investing activities** | (1,140) | (783)   | (639)   |

### Cash flows from financing activities

| Interest paid on borrowings and financing related activities | (1,479) | (1,737) | (1,601) |
| Interest element of lease liabilities | (23)    | (26)    | (32)    |
| Capital element of lease liabilities | (154)   | (164)   | (154)   |
| Proceeds from increases in and new borrowings | 978     | 9,826   | 4,247   |
| Reductions in and repayments of borrowings | (4,843) | (10,633) | (5,640) |
| Inflows/(outflows) relating to derivative financial instruments | 229     | (283)   | (564)   |
| Purchases of own shares held in employee share ownership trusts | (82)    | (18)    | (117)   |
| Proceeds from the issue of perpetual hybrid bonds, net of issuance costs | 1,681   | –       | –       |
| Coupon paid on perpetual hybrid bonds | (6)     | –       | –       |
| Dividends paid to owners of the parent | (4,904) | (4,745) | (4,598) |
| Capital injection from and purchases of non-controlling interests | 30      | 1       | 17      |
| Dividends paid to non-controlling interests | (150)   | (136)   | (157)   |
| Other | 3       | 2       | 3       |

**Net cash used in financing activities** | (8,749) | (7,897) | (8,593) |

| Net cash flows (used in)/generated from operating, investing and financing activities | (172)   | 1,106   | (236)   |
| Differences on exchange | (253)   | (253)   | (57)    |

**Decrease/increase in net cash and cash equivalents in the year** | (425)   | 853     | (293)   |

**Net cash and cash equivalents at 1 January** | 2,888   | 2,035   | 2,328   |

**Net cash and cash equivalents at 31 December** | 21      | 2,463   | 2,035   |

The accompanying notes are an integral part of these consolidated financial statements.
Financial Statements

Notes on Accounts

1 Accounting Policies

Basis of preparation

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and UK-adopted international accounting standards. UK-adopted international accounting standards differ in certain respects from IFRS as issued by the IASB. The differences have no impact on the Group’s consolidated financial statements for the periods presented.

The consolidated financial statements have been prepared on a going concern basis under the historical cost convention except as described in the accounting policy below on financial instruments. In performing its going concern assessment, management considered forecasts and liquidity requirements within the going concern period. This includes the impact of COVID-19, as well as the payments arising from the Master Settlement Agreement due in the U.S. in 2022 and other known liabilities or future payments (including interim dividends), as they fall due.

The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the date of the financial statements. The key estimates and assumptions are set out in the accounting policies below, together with the related notes to the accounts.

The critical accounting judgements include:

– the identification and quantification of adjusting items, which are separately disclosed as memorandum information, is explained below and the impact of these on the calculation of adjusted earnings per share is described in note 11;
– the determination as to whether to recognise provisions and the exposures to contingent liabilities related to pending litigation or other outstanding claims, as well as other contingent liabilities. The accounting policy on contingent liabilities, which are not provided for, is set out below and the contingent liabilities of the Group are explained in note 31. Judgement is required to assess the probability that a pending claim is probable (more likely than not to succeed), possible or remote;
– the determination as to whether control (subsidiaries), joint control (joint arrangements), or significant influence (associates) exists in relation to the investments held by the Group. This is assessed after taking into account the Group’s ability to appoint Directors to the entity’s Board, its relative shareholding compared with other shareholders, any significant contracts or arrangements with the entity or its other shareholders and other relevant facts and circumstances. The application of these policies to Group subsidiaries in territories including Canada is explained in note 32;
– the review of applicable exchange rates for transactions with and translation of entities in territories where there are restrictions on the free access to foreign currency, or multiple exchange rates; and
– the determination as to whether perpetual hybrid bonds should be classified as equity instead of borrowings (note 22(d)).

The critical accounting estimates include:

– the review of assets, especially indefinite life assets such as goodwill and certain trademarks and similar intangibles. The key assumptions used in respect of the impairment testing are the determination of cash-generating units, the budgeted and forecast cash flows of these units, the long-term growth rate for cash flow projections and the rate used to discount the cash flow projections. These are described in note 12;
– the estimation of and accounting for retirement benefit costs. The determination of the carrying value of assets and liabilities, as well as the charge for the year, and amounts recognised in other comprehensive income, involves judgements made in conjunction with independent actuaries. These involve estimates about uncertain future events based on the environment in different countries, including life expectancy of scheme members, salary and pension increases, inflation, as well as discount rates and asset values at the year-end. The assumptions used by the Group and sensitivity analysis are described in note 15; and
– the estimation of amounts to be recognised in respect of taxation and legal matters, and the estimation of other provisions for liabilities and charges are subject to uncertain future events, may extend over several years and so the amount and/or timing may differ from current assumptions. The accounting policy for taxation is explained below. The recognised deferred tax assets and liabilities, together with a note of unrecognised amounts, are shown in note 16, and a contingent tax asset is explained in note 10(b). Other provisions for liabilities and charges are as set out in note 24.

Such estimates and assumptions are based on historical experience and various other factors that are believed to be reasonable in the circumstances and constitute management’s best judgement at the date of the financial statements. In the future, actual experience may deviate from these estimates and assumptions, which could affect the financial statements as the original estimates and assumptions are modified, as appropriate, in the year in which the circumstances change.

These consolidated financial statements were authorised for issue by the Board of Directors on 10 February 2022.

Basis of consolidation

The consolidated financial information includes the financial statements of British American Tobacco p.l.c. and its subsidiary undertakings, collectively ‘the Group’, together with the Group’s share of the results of its associates and joint arrangements.

A subsidiary is an entity controlled by the Group. The Group controls an entity when it has the power over the entity and has the ability to affect those returns through its power over the entity. Non-controlling interests represent the share of earnings or equity in subsidiaries that is not attributable, directly or indirectly, to shareholders of the Group.
1 Accounting Policies Continued

Associates comprise investments in undertakings, which are not subsidiary undertakings or joint arrangements, where the Group’s interest in the equity capital is long-term and over whose operating and financial policies the Group exercises a significant influence. They are accounted for using the equity method.

Joint arrangements comprise contractual arrangements where two or more parties have joint control and where decisions regarding the relevant activities of the entity require unanimous consent.

Joint operations are jointly-controlled arrangements where the parties to the arrangement have rights to the underlying assets and obligations for the underlying liabilities relating to the arrangement. The Group accounts for its share of the assets, liabilities, income and expenses of any such arrangement.

Joint ventures comprise arrangements where the parties to the arrangement have rights to the net assets of the arrangement. They are accounted for using the equity method.

Foreign currencies and hyperinflationary territories

The functional currency of the Parent Company is sterling and this is also the presentation currency of the Group. The income and cash flow statements of Group undertakings expressed in currencies other than sterling are translated to sterling using exchange rates applicable to the dates of the underlying transactions. Average rates of exchange in each year are used where the average rate approximates the relevant exchange rate at the date of the underlying transactions. Assets and liabilities of Group undertakings are translated at the applicable rates of exchange at the end of each year. In territories where there are restrictions on the free access to foreign currency or multiple exchange rates, the applicable rates of exchange are regularly reviewed.

The differences between retained profits translated at average and closing rates of exchange are taken to reserves, as are differences arising on the retranslation to sterling (using closing rates of exchange) of overseas net assets at the beginning of the year, and are presented as a separate component of equity. They are recognised in the income statement when the gain or loss on disposal of a Group undertaking is recognised.

Foreign currency transactions are initially recognised in the functional currency of each entity in the Group using the exchange rate ruling at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of foreign currency assets and liabilities at year end rates of exchange are recognised in the income statement, except when deferred in equity as qualifying cash flow hedges, on intercompany net investment loans and qualifying net investment hedges. Foreign exchange gains or losses recognised in the income statement are included in profit from operations or net finance costs depending on the underlying transactions that gave rise to these exchange differences.

In addition, for hyperinflationary countries where the effect on the Group results would be significant, the financial statements in local currency are adjusted to reflect the impact of local inflation prior to translation into sterling, in accordance with IAS 29 Financial Reporting in Hyperinflationary Economies. Where applicable, IAS 29 requires all transactions to be indexed, based on the present value of the transaction, foreign exchange gains or losses resulting from the translation of foreign currency assets and liabilities at year end rates of exchange are recognised in the income statement, except when deferred in equity as qualifying cash flow hedges, on intercompany net investment loans and qualifying net investment hedges. Foreign exchange gains or losses recognised in the income statement are included in profit from operations or net finance costs depending on the underlying transactions that gave rise to these exchange differences.

The results and balance sheets of operations in hyperinflationary territories are translated at the period end rate. In the case of Venezuela, the Group uses an estimated exchange rate calculated by reflecting the development of the general price index since the Group last achieved meaningful repatriation of dividends.

Revenue

Revenue principally comprises sales of cigarettes, other tobacco products, and nicotine products, to external customers. Revenue excludes duty, excise and other taxes related to sales in the period and is stated after deducting rebates, returns and other similar discounts and payments to direct and indirect customers. For vast majority of the Group’s sales, revenue is recognised when control of the goods is transferred to a customer at a point in time; this is usually evidenced by a transfer of the significant risks and rewards of ownership upon delivery to the customer, which in terms of timing is not materially different to the date of shipping.

Retirement benefit costs

The Group operates both defined benefit and defined contribution schemes including post-retirement healthcare schemes. For defined benefit schemes, the actuarial cost charged to profit from operations consists of current service cost, net interest on the net defined benefit liability or asset, past service cost and the impact of any settlements.

The net deficit or surplus for each defined benefit pension scheme is calculated in accordance with IAS 19 Employee Benefits and is recorded in equity and is a component of other comprehensive income.

For defined benefit obligations at the balance sheet date less the fair value of the scheme assets adjusted, where appropriate, for any surplus restrictions or the effect of minimum funding requirements. Some benefits are provided through defined contribution schemes and payments to these are charged as an expense as they fall due.

Share-based payments

The Group has equity-settled and cash-settled share-based compensation plans.

Equity-settled share-based payments are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments in cash is expensed over the vesting period, based on the Group’s estimate of awards that will eventually vest. For plans where vesting conditions are based on total shareholder returns, the fair value at date of grant reflects the conditions, whereas earnings per share vesting conditions are reflected in the calculation of awards that will eventually vest over the vesting period.

For cash-settled share-based payments, a liability equal to the portion of the services received is recognised at its current fair value determined at each balance sheet date.

Fair value is measured by the use of the Black-Scholes option pricing model, except where vesting is dependent on market conditions when the Monte Carlo option pricing model is used. The expected life used in the models has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.
Financial Statements

Notes on Accounts

1 Accounting Policies

Research and development

Research expenditure is charged to income in the year in which it is incurred. Development expenditure is charged to income in the year it is incurred, unless it meets the recognition criteria of IAS 38 "Intangible Assets" to be capitalised as an intangible asset.

Taxation

Taxation is chargeable on the profits for the period, together with deferred taxation. The current income tax charge is calculated on the basis of tax laws enacted or substantively enacted at the balance sheet date in the countries where the Group’s subsidiaries, associates and joint arrangements operate and generate taxable income.

Deferred taxation is provided in full using the liability method for temporary differences between the carrying amount of assets and liabilities for financial accounting purposes and the amount used for taxation purposes. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax is determined using the tax rates that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realised or deferred tax liability is settled.

Tax is recognised in the income statement except to the extent that it relates to items recognised in other comprehensive income or directly in equity, in which case it is recognised in the statement of other comprehensive income or the statement of changes in equity.

The Group has exposures in respect of the payment or recovery of a number of taxes. With effect from 1 January 2019, the Group adopted the requirements of IFRIC 23 "Uncertainty over Income Tax Treatments" which requires that, where there is uncertainty as to whether a particular tax treatment will be accepted by the relevant taxation authority, the financial statements reflect the probable outcome with estimated amounts determined based on the most likely amount or expected value, depending on which method is expected to better predict the resolution of the uncertainty. Prior to 1 January 2019, liabilities or assets for these payments or recoveries were recognised in the income statement except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Goodwill

Goodwill arising on acquisitions is capitalised and any impairment of goodwill is recognised immediately in the income statement and is not subsequently reversed. Goodwill in respect of subsidiaries is included in intangible assets. In respect of associates and joint ventures, goodwill is included in the carrying value of the investment in the associated company or joint venture. On disposal of a subsidiary, associate or joint venture, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

Intangible assets other than goodwill

The intangible assets shown on the Group balance sheet consist mainly of trademarks and similar intangibles, including certain intellectual property, acquired by the Group’s subsidiary undertakings and computer software. Acquired trademarks and similar assets are carried at cost less accumulated amortisation and impairment. Trademarks with indefinite lives are not amortised but are reviewed annually for impairment. Other trademarks and similar assets are amortised on a straight-line basis over their remaining useful lives, consistent with the pattern of economic benefits expected to be received, which do not exceed 20 years. Any impairments of trademarks are recognised in the income statement, but increases in trademark values are not recognised.

Computer software is carried at cost less accumulated amortisation and impairment, and, with the exception of global software solutions, is amortised on a straight-line basis over periods ranging from three years to five years. Global software solutions are software assets designed to be implemented on a global basis and used as a standard solution by all of the operating companies in the Group. Prior to 2021, these assets were amortised on a straight-line basis over periods not exceeding 10 years. Since 2021, global software solutions are amortised on a straight-line basis over periods not exceeding 13 years. The revision in useful economic life is a result of ongoing use of global software solutions due to the extension of third-party supplier support. In 2021 and 2022, the estimated impact of this change in accounting estimate is a reduction in annual amortisation expense of £26 million and, in 2023, a reduction in annual amortisation expense of £12 million.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and impairment. Depreciation is calculated on a straight-line basis to write off the assets over their useful economic life. No depreciation is provided on freehold land or assets classified as held-for-sale. Freehold and leasehold property are depreciated at rates between 2.5% and 4% per annum, and plant and equipment at rates between 3% and 25% per annum.

Capitalised interest

Borrowing costs which are directly attributable to the acquisition, construction or production of intangible assets or property, plant and equipment that takes a substantial period of time to get ready for its intended use or sale, are capitalised as part of the cost of the asset.

Leased assets

With effect from 1 January 2019, the Group has applied IFRS 16 "Leases" to contractual arrangements which are, or contain, leases of assets, and consequently recognises right-of-use assets and lease liabilities at the commencement of the leasing arrangement, with the assets included as part of property, plant and equipment in note 13 and the liabilities included as part of borrowings in note 23.

In adopting IFRS 16, the Group applied the modified retrospective approach with no restatement of prior periods, as permitted by the Standard. The Group took advantage of certain practical expedients available under the Standard, including ‘grandfathering’ previously recognised lease arrangements such that contracts were not reassessed at the implementation date as to whether they were, or contained, a lease, and leases previously classified as finance leases under IAS 17 Leases remained capitalised on the adoption of IFRS 16.
1 Accounting Policies Continued

For leasing arrangements entered into after 1 January 2019, the Group has also adopted several practical expedients available under the Standard including not applying the requirements of IFRS 16 to leases of intangible assets, applying the portfolio approach where appropriate to do so, and to not apply the recognition and measurement requirements of IFRS 16 to short-term leases (leases of less than 12 months maximum duration) or leases of low-value assets. Except for property-related leases, non-lease components have not been separated from lease components.

Lease liabilities are initially recognised at an amount equal to the present value of estimated contractual lease payments at the inception of the lease, after taking into account any options to extend the term of the lease. Lease commitments are discounted to present value using the interest rate implicit in the lease if this can be readily determined, or the applicable incremental rate of borrowing, as appropriate. Right-of-use lease assets are initially recognised at an amount equal to the lease liability, adjusted for initial direct costs in relation to the assets, then depreciated over the shorter of the lease term and their estimated useful lives.

Prior to 1 January 2019, the Group applied IAS 17 Leases. Arrangements where the Group had substantially all the risks and rewards of ownership of the leased asset were classified as finance leases and were included as part of property, plant and equipment. Under IAS 17, leases which were not classified as finance leases were classified as operating leases and such arrangements were not capitalised. Rental payments under operating leases were charged to operating profit on a straight-line basis over the lease term.

Impairment of non-financial assets

Assets are reviewed for impairment whenever events indicate that the carrying amount of a cash-generating unit may not be recoverable. In addition, assets that have indefinite useful lives are tested annually for impairment. An impairment loss is recognised to the extent that the carrying value exceeds the higher of the asset’s fair value less costs to sell and its value-in-use.

A cash-generating unit is the smallest identifiable group of assets that generates cash flows which are largely independent of the cash flows from other assets or groups of assets. At the acquisition date, any goodwill acquired is allocated to the relevant cash-generating unit or group of cash-generating units expected to benefit from the acquisition for the purpose of impairment testing of goodwill.

Impairment of financial assets held at amortised cost

Loss allowances on financial assets which are held at amortised cost are recognised on initial recognition of the underlying asset. As permitted by IFRS 9 Financial Instruments, loss allowances on trade receivables arising from the recognition of revenue under IFRS 15 Revenue from Contracts with Customers are initially measured at an amount equal to lifetime expected losses. Allowances in respect of loans and other receivables are initially recognised at an amount equal to 12-month expected credit losses. Allowances are measured at an amount equal to the lifetime expected credit losses where the credit risk on the receivables increases significantly after initial recognition.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is based on the weighted average cost incurred in acquiring inventories and bringing them to their existing location and condition, which will include raw materials, direct labour and overheads, where appropriate. Net realisable value is the estimated selling price less costs to completion and sale. Tobacco inventories which have an operating cycle that exceeds 12 months are classified as current assets, consistent with recognised industry practice.

Biological Assets

The investments in associates and joint ventures shown in the Group balance sheet include biological assets held by Organigram Holdings Inc. In accordance with IAS 41 Agriculture, the Group measures biological assets at fair value less costs to sell up to the point of harvest, at which point this becomes the basis for the cost of finished goods inventories after harvest with subsequent expenditures incurred on these being capitalised, where applicable, in accordance with IAS 2 Inventories. Unrealised fair value gains and losses arising during the growth of biological assets are recognised immediately in the income statement.

Equity instruments

Instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements. Instruments that cannot be settled in the Group’s own equity instruments and that include no contractual obligation to deliver cash or another financial asset are classified as equity. Equity instruments issued by the Group are recognised at the proceeds received, net of issuance costs.

On 27 September 2021, the Group issued two €1 billion perpetual hybrid bonds. As the Group has the unconditional right to avoid transferring cash or another financial asset in relation to these bonds, they are classified as equity instruments in the consolidated financial statements.

Financial instruments

The Group’s business model for managing financial assets is set out in the Group Treasury Manual which notes that the primary objective with regard to the management of cash and investments is to protect against the loss of principal. Additionally, the Group aims: to maximise Group liquidity by concentrating cash at the Centre, to align the maturity profile of external investments with that of the forecast liquidity profile, to wherever practicable, match the interest rate profile of external investments to that of debt maturities or fixings, and to optimise the investment yield within the Group’s investment parameters. The majority of financial assets are held in order to collect contractual cash flows (typically cash and cash equivalents and loans and other receivables), but some assets (typically investments) are held for investment potential.

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the relevant instrument and derecognised when it ceases to be a party to such provisions. Such assets and liabilities are classified as current if they are expected to be realised or settled within 12 months after the balance sheet date. If not, they are classified as non-current. In addition, current liabilities include amounts where the entity does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.
Financial Statements

Notes on Accounts

1 Accounting Policies Continued

The Group early adopted the phase one and phase two Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures regarding Interest Rate Benchmark Reform in 2019 and 2020 respectively. The Amendments provide an exemption for certain hedging relationships directly affected by changes in interest rate benchmarks where the reform gives rise to uncertainties regarding the interest rate designated as a hedged risk, or the timing or amount of interest rate cashflows of either the hedged item or of the hedging instrument, such that without the exemption the relationship might not qualify for hedge accounting. In addition, the Amendments provide a practical expedient for financial assets and financial liabilities that are modified or have existing contractual terms activated that change the basis for determining the contractual cash flows as a result of Interest Rate Benchmark Reform, such that the change to the contractual cash flows is applied prospectively by revising the effective interest rate.

Non-derivative financial assets are classified on initial recognition in accordance with the Group’s business model as investments, loans and receivables, or cash and cash equivalents and accounted for as follows:

- Investments: these are non-derivative financial assets that cannot be classified as loans and other receivables or cash and cash equivalents. Dividend and interest income on these investments are included within finance income when the Group’s right to receive payments is established. This category includes financial assets at fair value through profit and loss and financial assets at fair value through other comprehensive income.

- Loans and other receivables: these are non-derivative financial assets with fixed or determinable payments that are solely payments of principal and interest on the principal amount outstanding, that are primarily held in order to collect contractual cash flows. These balances include trade and other receivables, which are measured at amortised cost, using the effective interest rate method, and stated net of allowances for credit losses, and deposits with banks and other financial institutions which cannot be classified as cash and cash equivalents. In addition, as explained in note 17, certain litigation related deposits are recognised as assets within loans and other receivables where management has determined that these payments represent a resource controlled by the entity as a result of past events. These deposits are held at the fair value of consideration transferred less impairment, if applicable, and have not been discounted.

- Cash and cash equivalents: cash and cash equivalents include cash in hand and deposits held on call, together with other short-term highly liquid investments including investments in certain money market funds. Cash equivalents normally comprise instruments with maturities of three months or less at their date of acquisition. In the cash flow statement, cash and cash equivalents are shown net of bank overdrafts, which are included as current borrowings in the liabilities section on the balance sheet.

Fair values for quoted investments are based on observable market prices. If the securities do not trade on a financial asset market, the fair value is established by using valuation techniques principally involving discounted cash flow analysis.

Non-derivative financial liabilities, including borrowings and trade payables, are stated at amortised cost using the effective interest method. For borrowings, their carrying value includes accrued interest payable, as well as unamortised issue costs. As shown in note 23, certain borrowings are subject to fair value hedges, as defined below.

Derivative financial assets and liabilities are initially recognised, and subsequently measured, at fair value, which includes accrued interest receivable and payable where relevant. Changes in their fair values are recognised as follows:

- for derivatives that are designated as cash flow hedges, the changes in their fair values are recognised directly in other comprehensive income, to the extent that they are effective, with the ineffective portion being recognised in the income statement. Where the hedged item results in a non-financial asset, the accumulated gains and losses, previously recognised in other comprehensive income, are included in the initial carrying value of the asset (basis adjustment) and recognised in the income statement in the same periods as the hedged item. Where the underlying transaction does not result in such an asset, the accumulated gains and losses are reclassified to the income statement in the same periods as the hedged item;

- for derivatives that are designated as fair value hedges, the carrying value of the hedged item is adjusted for the fair value changes attributable to the risk being hedged, with the corresponding entry being made in the income statement. The changes in fair value of these derivatives are also recognised in the income statement;

- for derivatives that are designated as hedges of net investments in foreign operations, the changes in their fair values are recognised directly in other comprehensive income, to the extent that they are effective, with the ineffective portion being recognised in the income statement. Where non-derivatives such as foreign currency borrowings are designated as net investment hedges, the relevant exchange differences are similarly recognised. The accumulated gains and losses are reclassified to the income statement when the foreign operation is disposed of; and

- for derivatives that do not qualify for hedge accounting or are not designated as hedges, the changes in their fair values are recognised in the income statement in the period in which they arise. These are referred to as ‘held-for-trading’.

In order to qualify for hedge accounting, the Group is required to document prospectively the economic relationship between the item being hedged and the hedging instrument. The Group is also required to demonstrate an assessment of the economic relationship between the hedged item and the hedging instrument, which shows that the hedge will be highly effective on an ongoing basis. This effectiveness testing is re-performed periodically to ensure that the hedge has remained, and is expected to remain, highly effective.

Hedge accounting is discontinued when a hedging instrument is derecognised (e.g. through expiry or disposal), or no longer qualifies for hedge accounting. Where the hedged item is a highly probable forecast transaction, the related gains and losses remain in equity until the transaction takes place, when they are reclassified to the income statement in the same manner as for cash flow hedges as described above. When a hedged future transaction is no longer expected to occur, any related gains and losses, previously recognised in other comprehensive income, are immediately reclassified to the income statement.

Derivative fair value changes recognised in the income statement are either reflected in arriving at profit from operations (if the hedged item is similarly reflected) or in finance costs.
**1 Accounting Policies Continued**

**Dividends**
The Company pays interim quarterly dividends, and the Group recognises the interim dividend in the period in which it is paid.

**Segmental analysis**
The Group is organised and managed on the basis of its geographic regions. These are the reportable segments for the Group as they form the focus of the Group’s internal reporting systems and are the basis used by the chief operating decision maker, identified as the Management Board, for assessing performance and allocating resources. The Group is primarily a single product business providing cigarettes and other tobacco products. While the Group has clearly differentiated brands, global segmentation between a wide portfolio of brands is not part of the regular internally reported financial information. The results of New Category products are reported as part of the results of each geographic region, and currently individually and in aggregate represent less than 10% of the Group’s revenue and operating profit in total.

**Segmental analysis**
The prices agreed between Group companies for intra-group sales of materials, manufactured goods, charges for royalties, commissions, services and fees, are based on normal commercial practices which would apply between independent businesses. Royalty income, less related expenditure, is included in the region in which the licensor is based.

**Adjusting items**
Adjusting items are significant items of income or expense in revenue, profit from operations, net finance costs, taxation and the Group’s share of the post-tax results of associates and joint ventures which individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group’s underlying financial performance because of their size, nature or incidence. In identifying and quantifying adjusting items, the Group consistently applies a policy that defines criteria that are required to be met for an item to be classified as adjusting. These items are separately disclosed in the segmental analyses or in the notes to the accounts as appropriate.

**Provisions**
Provisions are recognised when either a legal or constructive obligation as a result of a past event exists at the balance sheet date, it is probable that an outflow of economic resources will be required to settle the obligation and a reasonable estimate can be made of the amount of the obligation.

**Contingent liabilities and contingent assets**
Subsidiaries and associate companies are defendants in tobacco-related and other litigation. Provision for this litigation (including legal costs) is made at such time as an unfavourable outcome becomes probable and the amount can be reasonably estimated.

Contingent assets are possible assets whose existence will only be confirmed by future events not wholly within the control of the entity and are not recognised as assets until the realisation of income is virtually certain. Where a provision has not been recognised, the Group records its external legal fees and other external defence costs for tobacco-related and other litigation as these costs are incurred.

As explained in note 17, certain litigation-related deposits are recognised as assets within loans and other receivables where management has determined that these payments represent a resource controlled by the entity. These deposits are held at the fair value of consideration transferred less impairment, if applicable, and have not been discounted.

**Repurchase of share capital**
When share capital is repurchased, the amount of consideration paid, including directly attributable costs, is recognised as a deduction from equity. Repurchased shares which are not cancelled, or shares purchased for the employee share ownership trusts, are classified as treasury shares and presented as a deduction from total equity.

**Future changes to accounting policies**
A number of interpretations and revisions to existing standards have been issued which will be applicable to the Group financial statements in future years, but are not expected to have a material effect on reported profit or equity or on the disclosures in the financial statements.
### Segmental Analyses

The chief operating decision maker, the Management Board, reviews adjusted profit from operations at constant currencies to evaluate segment performance and allocate resources to the overall business on a geographic region basis. The Management Board also reviews at constant currencies adjusted revenues at current rates of exchange and operating margin. Regional Directors are responsible for delivering the operating and financial results of their Region inclusive of all product categories. Therefore, the results of New Categories (comprising Tobacco Heating Products, Vapour products and Modern Oral products) are reported to the Management Board as part of the results of each geographic region. However, additional information has been provided to disaggregate revenue based on product category to enable investors to better compare the Group’s business performance across periods and by reference to the Group’s investment activity. Interest income, interest expense, share of post-tax results of associates and joint ventures and taxation are centrally managed, and accordingly, such items are not presented by segment as they are excluded from the measure of segment profitability.

The four geographic regions are the reportable segments for the Group as they form the focus of the Group’s internal reporting systems and are the basis used by the Management Board for assessing performance and allocating resources. Transactions between Group subsidiaries are conducted on arm’s length terms in accordance with appropriate transfer pricing rules and Organisation for Economic Cooperation & Development (OECD) principles. The Management Board reviews current and prior year adjusted segmental revenue and adjusted profit from operations at constant rates of exchange. The constant rate comparison provided for reporting segment information is based on a retranslation, at prior year exchange rates, of the current year results of the Group, including intercompany royalties payable in foreign currency to UK entities. However, the Group does not adjust for the normal transactional gains and losses in operations which are generated by movements in exchange rates.

In respect of the U.S. region, all financial statements and financial information provided by or with respect to the U.S. business or RAI (and/or RAI) and its subsidiaries (collectively, the ‘Reynolds Group’) are prepared on the basis of US GAAP and constitute the primary financial statements or financial information of the U.S. business or RAI (and/or the Reynolds Group). Solely for the purpose of consolidation within the results of BAT p.l.c. and the BAT Group, this financial information is then converted to IFRS. To the extent any such financial information provided in these financial statements relates to the U.S. business or RAI (and/or the Reynolds Group), it is provided as an explanation of the U.S. business’s or RAI’s (and/or the Reynolds Group’s) primary US GAAP based financial statements and information.

Effective 1 January 2022, the North African markets of Algeria, Egypt, Libya, Morocco, Sudan and Tunisia, which currently form part of the ENA region, will be moved to the APME region.

The following table shows 2021 revenue and adjusted revenue at current rates, and 2021 adjusted revenue translated using 2020 rates of exchange. The 2020 figures are stated at the 2020 rates of exchange.

#### 2021

<table>
<thead>
<tr>
<th></th>
<th>Revenue</th>
<th>Adjusted Revenue</th>
<th>Translation</th>
<th>Adjusted Revenue</th>
<th>Current rates</th>
<th>Adjusting items</th>
<th>Revenue</th>
<th>Current rates</th>
<th>Adjusting items</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>12,530</td>
<td>(839)</td>
<td>11,691</td>
<td>11,691</td>
<td>11,473</td>
<td>–</td>
<td>11,473</td>
<td>11,473</td>
<td>–</td>
</tr>
<tr>
<td>APME</td>
<td>4,535</td>
<td>(344)</td>
<td>4,191</td>
<td>4,191</td>
<td>4,537</td>
<td>–</td>
<td>4,537</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>AMSSA</td>
<td>4,067</td>
<td>(266)</td>
<td>3,801</td>
<td>3,801</td>
<td>3,772</td>
<td>–</td>
<td>3,772</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ENA</td>
<td>6,429</td>
<td>(428)</td>
<td>6,001</td>
<td>6,001</td>
<td>5,994</td>
<td>–</td>
<td>5,994</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Revenue</td>
<td>27,561</td>
<td>(1,877)</td>
<td>25,684</td>
<td>25,684</td>
<td>25,776</td>
<td>–</td>
<td>25,776</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: adjusting items in revenue are in respect of excise included in goods acquired from a third party under short-term arrangements and then passed on to customers. This is deemed as adjusting due to the distorting nature to revenue and operating margin. From 2020 onwards, such arrangements have been discontinued or are immaterial such that no adjustments have been made in 2020 and 2021.

The following table shows 2020 revenue and adjusted revenue at current rates, and 2020 adjusted revenue translated using 2019 rates of exchange. The 2019 figures are stated at the 2019 rates of exchange.

#### 2020

<table>
<thead>
<tr>
<th></th>
<th>Revenue</th>
<th>Adjusted Revenue</th>
<th>Translation</th>
<th>Adjusted Revenue</th>
<th>Current rates</th>
<th>Adjusting items</th>
<th>Revenue</th>
<th>Current rates</th>
<th>Adjusting items</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>11,536</td>
<td>(63)</td>
<td>11,473</td>
<td>11,473</td>
<td>10,373</td>
<td>–</td>
<td>10,373</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>APME</td>
<td>4,535</td>
<td>(107)</td>
<td>4,537</td>
<td>4,537</td>
<td>5,153</td>
<td>–</td>
<td>5,153</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>AMSSA</td>
<td>4,321</td>
<td>(549)</td>
<td>3,772</td>
<td>3,772</td>
<td>4,261</td>
<td>–</td>
<td>4,261</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ENA</td>
<td>6,169</td>
<td>(175)</td>
<td>5,994</td>
<td>5,994</td>
<td>6,090</td>
<td>50</td>
<td>6,090</td>
<td>50</td>
<td>–</td>
</tr>
<tr>
<td>Revenue</td>
<td>26,870</td>
<td>(894)</td>
<td>25,776</td>
<td>25,776</td>
<td>25,877</td>
<td>50</td>
<td>25,877</td>
<td>50</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: adjusting items in revenue are in respect of excise included in goods acquired from a third party under short-term arrangements and then passed on to customers. This is deemed as adjusting due to the distorting nature to revenue and operating margin.
2 Segmental Analyses Continued

The following table shows 2021 profit from operations and adjusted profit from operations at current rates, and 2021 adjusted profit from operations translated using 2020 rates of exchange. The 2020 figures are stated at the 2020 rates of exchange.

<table>
<thead>
<tr>
<th>Segment</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted* segment result</td>
<td>Adjusted* segment result</td>
</tr>
<tr>
<td></td>
<td>Current rates £m</td>
<td>Current rates £m</td>
</tr>
<tr>
<td></td>
<td>Translation exchange £m</td>
<td>Adjusting* items £m</td>
</tr>
<tr>
<td>U.S.</td>
<td>6,343 (456)</td>
<td>5,887 (321)</td>
</tr>
<tr>
<td>APME</td>
<td>1,833 (116)</td>
<td>1,717 (430)</td>
</tr>
<tr>
<td>AMSSA</td>
<td>1,688 (98)</td>
<td>1,590 (94)</td>
</tr>
<tr>
<td>ENA</td>
<td>2,088 (132)</td>
<td>1,956 (71)</td>
</tr>
<tr>
<td>Profit from operations</td>
<td>11,952 (802)</td>
<td>11,150 (916)</td>
</tr>
<tr>
<td>Net finance costs</td>
<td>(1,486)</td>
<td>(1,746)</td>
</tr>
<tr>
<td>Share of post-tax results of associates and joint ventures</td>
<td>415</td>
<td>455</td>
</tr>
<tr>
<td>Profit before taxation</td>
<td>9,163</td>
<td>8,672</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>(2,189)</td>
<td>(2,108)</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>6,974</td>
<td>6,564</td>
</tr>
</tbody>
</table>

* The adjustments to profit from operations are explained in notes 3, 4, 6(d), 6(f), 6(g) and 7.

The following table shows 2020 profit from operations and adjusted profit from operations at current rates, and 2020 adjusted profit from operations translated using 2019 rates of exchange. The 2019 figures are stated at the 2019 rates of exchange.

<table>
<thead>
<tr>
<th>Segment</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted* segment result</td>
<td>Adjusted* segment result</td>
</tr>
<tr>
<td></td>
<td>Current rates £m</td>
<td>Current rates £m</td>
</tr>
<tr>
<td></td>
<td>Translation exchange £m</td>
<td>Adjusting* items £m</td>
</tr>
<tr>
<td>U.S.</td>
<td>5,816 (32)</td>
<td>5,784 (809)</td>
</tr>
<tr>
<td>APME</td>
<td>1,909 (56)</td>
<td>1,853 (381)</td>
</tr>
<tr>
<td>AMSSA</td>
<td>1,796 (718)</td>
<td>1,618 (65)</td>
</tr>
<tr>
<td>ENA</td>
<td>2,140 (30)</td>
<td>2,110 (148)</td>
</tr>
<tr>
<td>Profit from operations</td>
<td>11,661 (296)</td>
<td>11,365 (1,403)</td>
</tr>
<tr>
<td>Net finance costs</td>
<td>(1,745)</td>
<td>(1,620)</td>
</tr>
<tr>
<td>Share of post-tax results of associates and joint ventures</td>
<td>455</td>
<td>498</td>
</tr>
<tr>
<td>Profit before taxation</td>
<td>8,672</td>
<td>7,912</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>(2,108)</td>
<td>(2,063)</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>6,564</td>
<td>5,849</td>
</tr>
</tbody>
</table>

* The adjustments to profit from operations are explained in notes 4, 6(d), 6(f), 6(g) and 7.
2 Segmental Analyses Continued

Adjusted profit from operations at constant rates of £11,952 million (2020: £11,661 million; 2019: £11,032 million) excludes adjusting depreciation, amortisation and impairment charges as explained in notes 4 and 7. These are excluded from segmental adjusted profit from operations at constant rates as follows:

<table>
<thead>
<tr>
<th></th>
<th>Adjusted depreciation, amortisation and impairment charges</th>
<th>Depreciation, amortisation and impairment charges</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Constant rates £m</td>
<td>Current rates £m</td>
</tr>
<tr>
<td></td>
<td>Translation exchange £m</td>
<td>Adjusting items £m</td>
</tr>
<tr>
<td>U.S.</td>
<td>210 (7)</td>
<td>203  276  479</td>
</tr>
<tr>
<td>APME</td>
<td>154 (8)</td>
<td>146  20  166</td>
</tr>
<tr>
<td>AMSSA</td>
<td>131 (8)</td>
<td>123  56  179</td>
</tr>
<tr>
<td>ENA</td>
<td>266 (14)</td>
<td>252  –  252</td>
</tr>
<tr>
<td></td>
<td>761 (37)</td>
<td>724  352  1,076</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Adjusted depreciation, amortisation and impairment charges</th>
<th>Depreciation, amortisation and impairment charges</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Constant rates £m</td>
<td>Current rates £m</td>
</tr>
<tr>
<td></td>
<td>Translation exchange £m</td>
<td>Adjusting items £m</td>
</tr>
<tr>
<td>U.S.</td>
<td>205 (1)</td>
<td>204  272  476</td>
</tr>
<tr>
<td>APME</td>
<td>170 (3)</td>
<td>167  274  441</td>
</tr>
<tr>
<td>AMSSA</td>
<td>137 (16)</td>
<td>121  34  155</td>
</tr>
<tr>
<td>ENA</td>
<td>266 (7)</td>
<td>259  119  378</td>
</tr>
<tr>
<td></td>
<td>778 (27)</td>
<td>751  699  1,450</td>
</tr>
</tbody>
</table>

Additional information by product category

Although the Group’s operations are managed on a Regional basis, additional information for revenue is provided based on product category as follows:

<table>
<thead>
<tr>
<th>Product Category</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustibles</td>
<td>22,029</td>
<td>22,752</td>
<td>23,001</td>
</tr>
<tr>
<td>New Categories</td>
<td>2,054</td>
<td>1,443</td>
<td>1,255</td>
</tr>
<tr>
<td>Vapour</td>
<td>927</td>
<td>611</td>
<td>401</td>
</tr>
<tr>
<td>THP</td>
<td>853</td>
<td>634</td>
<td>728</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>274</td>
<td>198</td>
<td>126</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,118</td>
<td>1,160</td>
<td>1,081</td>
</tr>
<tr>
<td>Other</td>
<td>483</td>
<td>421</td>
<td>540</td>
</tr>
<tr>
<td>Revenue</td>
<td>25,684</td>
<td>25,776</td>
<td>25,877</td>
</tr>
</tbody>
</table>
2 Segmental Analyses Continued

External revenue and non-current assets other than financial instruments, deferred tax assets and retirement benefit assets are analysed between the UK and all foreign countries at current rates of exchange as follows:

<table>
<thead>
<tr>
<th></th>
<th>United Kingdom</th>
<th>All foreign countries</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Intangible assets</strong></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Intangible assets</td>
<td>481</td>
<td>487</td>
<td>115,144</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Property, plant and equipment</strong></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Property, plant and equipment</td>
<td>339</td>
<td>344</td>
<td>4,614</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Investments in associates and joint ventures</strong></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments in associates and joint ventures</td>
<td>8</td>
<td>8</td>
<td>1,940</td>
</tr>
</tbody>
</table>

The consolidated results of the Reynolds Group operating in the U.S. met the criteria for separate disclosure under the requirements of IFRS 8 Operating Segments. Revenue arising from the operations of the Reynolds Group, inclusive of the sales made to fellow Group companies, in 2021, 2020 and 2019 was £11,707 million, £11,481 million and £10,417 million, respectively. The majority of sales are to customers based in the U.S. Non-current assets attributable to the operations of the Reynolds Group were £106,495 million (2020: £105,549 million).

The main acquisitions comprising the goodwill balance of £43,194 million (2020: £43,319 million), included in intangible assets, are provided in note 12. Included in investments in associates and joint ventures are amounts of £1,759 million (2020: £1,724 million) attributable to the investment in ITC Ltd. Further information is provided in notes 9 and 14.

3 Employee Benefit Costs

<table>
<thead>
<tr>
<th></th>
<th>£m</th>
<th>£m</th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2020</td>
<td>2019</td>
<td></td>
</tr>
<tr>
<td>Wages and salaries</td>
<td>2,315</td>
<td>2,277</td>
<td>2,651</td>
</tr>
<tr>
<td>Social security costs</td>
<td>185</td>
<td>194</td>
<td>223</td>
</tr>
<tr>
<td>Other pension and retirement benefit costs (note 15)</td>
<td>139</td>
<td>182</td>
<td>227</td>
</tr>
<tr>
<td>Share-based payments – equity and cash-settled (note 28)</td>
<td>78</td>
<td>91</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>2,717</td>
<td>2,744</td>
<td>3,221</td>
</tr>
</tbody>
</table>

Included within employee benefits costs are expenses in relation to the Group’s restructuring and integration initiatives of £160 million (2020: £91 million; 2019: £364 million), as explained in note 7.

On 7 October 2021, a partial buy-out was concluded in the U.S. with approximately US$1.9 billion (£1.4 billion) of plan liabilities being removed from the balance sheet, resulting in a settlement gain of £35 million, which is reported in the income statement, and recognised as an adjusting item.

4 Depreciation, Amortisation and Impairment Costs

<table>
<thead>
<tr>
<th></th>
<th>£m</th>
<th>£m</th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2020</td>
<td>2019</td>
<td></td>
</tr>
<tr>
<td>Intangibles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– amortisation and impairment of trademarks and similar intangibles</td>
<td>333</td>
<td>360</td>
<td>508</td>
</tr>
<tr>
<td>– amortisation and impairment of computer software</td>
<td>129</td>
<td>129</td>
<td>108</td>
</tr>
<tr>
<td>– impairment of goodwill</td>
<td>57</td>
<td>209</td>
<td>194</td>
</tr>
<tr>
<td>Property, plant and equipment – depreciation and impairment</td>
<td>557</td>
<td>752</td>
<td>702</td>
</tr>
<tr>
<td></td>
<td>1,076</td>
<td>1,450</td>
<td>1,512</td>
</tr>
</tbody>
</table>

Enumerated below are movements in costs that have impacted depreciation, amortisation and impairment in 2021, 2020 and 2019. These include changes in our underlying business performance, as well as impact of adjusting items, as defined in note 1.
Financial Statements

Notes on Accounts

Continued

4 Depreciation, Amortisation and Impairment Costs Continued

Intangibles – amortisation and impairment of trademarks and similar intangibles

Acquisitions in previous years have resulted in the capitalisation of trademarks and similar intangibles, including those which are amortised over their expected useful lives, which do not exceed 20 years. The amortisation and impairment of these acquired trademarks and similar intangibles are charged to the income statement as adjusting. In 2021, the amortisation and impairment of these acquired trademarks and similar intangibles is £306 million (2020: £339 million; 2019: £481 million). In 2019, the Group incurred an impairment charge of £129 million, which included the partial impairment of the Kodiak brand as a result of declining volumes.

Impairment of goodwill

The impairment of goodwill is charged to the income statement as adjusting, and further information is provided in note 12(e).

During 2021, the Group impaired £3 million of goodwill held in Myanmar as a result of the decision to cease activities in the market. The Group also recognised a goodwill impairment charge of £54 million in 2021 due to continued difficult trading conditions in Peru as a consequence of the COVID-19 pandemic.

During 2019, the Group impaired the goodwill arising from the Bentoel acquisition, amounting to £172 million, goodwill arising from the VapeWild acquisition of £12 million and goodwill arising from the Highendsmoke acquisition of £10 million.

Property, plant and equipment – depreciation and impairment

The following items are included within depreciation and impairment of property, plant and equipment:

– Restructuring and integration related depreciation and impairment costs and reversals were a net credit of £11 million (2020: £151 million net cost; 2019: £63 million net cost) resulting from obsolete machines in relation to downsizing and factory rationalisation as mentioned in note 7; and

– Gains and losses recognised on disposal of property, plant and equipment.

5 Other Operating Income

Other operating income of £196 million (2020: £188 million; 2019: £163 million) comprises income that is associated with the Group’s normal activities, but which falls outside the definition of turnover and includes one-off capital profits on property sales and one-off disposals of fixed assets.

As explained in note 31, the Group recognised £5 million (2020: £58 million; 2019: £86 million) in respect of a tax case in Brazil. In addition, during 2021, £130 million of the unrecongnised contingent asset in respect of historical VAT on social contributions claims was sold to financial institutions for £45 million.

Also, in 2021, R.J. Reynolds Tobacco Company (RJRT) reached an agreement with several Master Settlement Agreement (MSA) states to waive RJRT’s claims under the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&M Brands, Inc. (S&M Brands), under which the states released certain claims against S&M Brands in exchange for receiving a portion of the funds S&M Brands had deposited into escrow accounts in those states pursuant to the states’ escrow statutes. In consideration for waiving claims, RJRT, together with Santa Fe Natural Tobacco Company, received approximately £40 million from the escrow funds paid to those MSA states under their settlement with S&M Brands.

In 2019, as discussed in note 7, certain items of operating income have been incurred as part of the Group’s restructuring and integration activities.
6 Other Operating Expenses

(a) Items included within other operating expenses

The following items are included within other operating expenses:

<table>
<thead>
<tr>
<th>Item</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Master settlement agreement (note 6(b),(d))</td>
<td>2,486</td>
<td>2,783</td>
<td>2,163</td>
</tr>
<tr>
<td>Marketing expenses in operating profit (note 6(c))</td>
<td>1,242</td>
<td>1,096</td>
<td>1,149</td>
</tr>
<tr>
<td>Inventory write-offs (note 20)</td>
<td>215</td>
<td>309</td>
<td>255</td>
</tr>
<tr>
<td>Research and development expenses (excluding employee benefit costs and depreciation) (note 6(e))</td>
<td>141</td>
<td>121</td>
<td>126</td>
</tr>
<tr>
<td>Loss on disposal of BAT Parks (note 6(f))</td>
<td>358</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Excise, VAT and penalties in respect of disputes in Turkey, South Korea and Russia (note 6(g))</td>
<td>26</td>
<td>(40)</td>
<td>202</td>
</tr>
<tr>
<td>Judgment in respect of Quebec class actions (note 6(h))</td>
<td>–</td>
<td>–</td>
<td>436</td>
</tr>
<tr>
<td>Exchange differences</td>
<td>19</td>
<td>(29)</td>
<td>22</td>
</tr>
<tr>
<td>Hedge ineffectiveness within operating profit (5)</td>
<td>–</td>
<td>(3)</td>
<td>(3)</td>
</tr>
<tr>
<td>Expenses relating to short-term leases</td>
<td>–</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Expenses relating to leases of low-value assets</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Gains arising from sale and leaseback transactions</td>
<td>–</td>
<td>(1)</td>
<td>–</td>
</tr>
<tr>
<td>Auditor’s remuneration (note 6(i))</td>
<td>27.1</td>
<td>28.3</td>
<td>25.3</td>
</tr>
</tbody>
</table>

(b) Master Settlement Agreement

In 1998, the major U.S. cigarette manufacturers (including the R.J. Reynolds Tobacco Company, Lorillard and Brown & Williamson, which are now part of the Reynolds Group) entered into the Master Settlement Agreement (MSA) with attorneys general representing most U.S. states and territories. The MSA imposes a perpetual stream of future payment obligations on the major U.S. cigarette manufacturers. The amounts of money that the participating manufacturers are required to annually contribute are based upon, amongst other things, the volume of cigarettes sold and market share (based on cigarette shipments in that year).

During 2012, R.J. Reynolds Tobacco Company, Santa Fe Natural Tobacco Company (SFNTC), various other tobacco manufacturers, 17 states, the District of Columbia and Puerto Rico reached an agreement related to the Non-Participating Manufacturer (NPM) adjustment under the MSA, and three more states joined the agreement in 2013. Under this agreement, R.J. Reynolds Tobacco Company has received credits of more than US$1 billion, in respect of its Non-Participating Manufacturer (NPM) Adjustment claims related to the period from 2003 to 2012. These credits have been applied against the companies’ MSA payments over a period of five years from 2013, subject to, and dependent upon, meeting the various ongoing performance obligations. During 2014, two additional states agreed to settle NPM disputes related to claims for the period 2003 to 2012. R.J. Reynolds Tobacco Company has received US$170 million in credits, which has been applied over a five-year period from 2014. During 2015, another state agreed to settle NPM disputes related to claims for the period 2004 to 2014 and included a method to determine future adjustments from 2015 forward. R.J. Reynolds Tobacco Company has received US$285 million in credits, which was applied over a four-year period from 2016. In 2016, no additional states agreed to settle NPM disputes. During 2017, two more states agreed to settle NPM disputes related to claims for the period 2004 to 2014. It is estimated that R.J. Reynolds Tobacco Company will receive US$61 million in credits, which will be applied over a five-year period from 2017. During 2018, nine more states agreed to settle NPM disputes related to claims for the period 2004 to 2019. With an option through 2022, subject to certain conditions. It is estimated that R.J. Reynolds Tobacco Company will receive US$182 million in credits for settled periods through 2017, which will be applied over a five-year period from 2018. Also in 2018, one additional state agreed to settle NPM disputes related to claims for the period 2004 to 2024, subject to certain conditions. It is estimated that R.J. Reynolds Tobacco Company will receive US$265 million in credits for settled periods through 2017, which will be applied over a five-year period from 2019. In the first quarter of 2020, certain conditions set forth in the 2017 and 2018 agreements were met for those 10 states. In addition, in August 2020, 24 states, the District of Columbia and Puerto Rico agreed to settle NPM disputes related to claims for the period 2018 to 2022. Credits in respect of future years’ payments and the NPM Adjustment claims would be accounted for in the applicable year and will not be treated as adjusting items. Only credits in respect of prior year payments are included as adjusting items.

In 2020, R.J. Reynolds Tobacco Company recognised additional expenses under the state settlement agreements in the States of Mississippi, Florida, Texas and Minnesota. R.J. Reynolds Tobacco Company recognised US$214 million of expense for payment obligations to the State of Florida for the ITG Brands, LLC acquired brands from the date of divestiture, June 12, 2015, as a result of an unfavourable judgment. In addition, R.J. Reynolds Tobacco Company recognised US$264 million related to the resolution of claims against it in the States of Texas, Minnesota and Mississippi for payment obligations to those states for the ITG Brands, LLC acquired brands from the date of divestiture. Finally, R.J. Reynolds Tobacco Company settled certain related claims with Philip Morris USA under the state settlement agreements in the states of Mississippi, Texas and Minnesota for US$8 million. Additional information related to the resolution of these claims is included in notes 6(d) and 31. During 2021, an additional US$17 million expense was recognised in relation to the final resolution of the Texas and Minnesota claims.

6 Other Operating Expenses Continued

(c) Marketing expenses in operating profit

Certain marketing activities, such as discounts or allowances provided to customers, are required to be deducted from revenue as explained in note 1. Other marketing expenses, such as point of sale and promotional materials, media advertising and sponsorship, and consumer research, are reported as operating expenses and have been shown in the table above.

(d) Litigation costs

Litigation costs included within other operating expenses, and reported as an adjusting item, were £54 million (2020: £87 million; 2019: £236 million) predominantly related to other litigation costs including Engle progeny.

In 2020, also included as an adjusting item was a charge of £400 million incurred largely in respect of charges following the development in cases regarding payment obligations under the state settlement agreements with Florida, Texas, Minnesota and Mississippi for brands previously sold to a third party. The Group recognised a charge of £188 million in the period for a final judgment of a case in the Florida court. The Group continues to pursue indemnification remedies in a Delaware court for payments made to Florida as a result of this judgment, as explained in note 31. During 2020, the Group also recognised a provision of £212 million related to the settlement discussions with other manufacturers and the States of Texas, Minnesota and Mississippi for payment obligations related to these brands in prior years. During 2021, an additional £12 million expense was recognised in relation to the final resolution of the Texas and Minnesota claims.

(e) Litigation costs

Litigation costs included within other operating expenses, and reported as an adjusting item, were £54 million (2020: £87 million; 2019: £236 million) predominantly related to other litigation costs including Engle progeny.

In 2020, also included as an adjusting item was a charge of £400 million incurred largely in respect of charges following the development in cases regarding payment obligations under the state settlement agreements with Florida, Texas, Minnesota and Mississippi for brands previously sold to a third party. The Group recognised a charge of £188 million in the period for a final judgment of a case in the Florida court. The Group continues to pursue indemnification remedies in a Delaware court for payments made to Florida as a result of this judgment, as explained in note 31. During 2020, the Group also recognised a provision of £212 million related to the settlement discussions with other manufacturers and the States of Texas, Minnesota and Mississippi for payment obligations related to these brands in prior years. During 2021, an additional £12 million expense was recognised in relation to the final resolution of the Texas and Minnesota claims.

(f) Research and development

Total research and development costs, including employee benefit costs and depreciation, are £304 million (2020: £307 million; 2019: £376 million). Included in the 2019 research and development costs is £65 million of costs primarily related to packages in respect of employee benefit reductions as part of the Group’s 2019 restructuring initiative (Quantum), as discussed in note 7.

(g) Loss on disposal of BAT Pars

On 6 August 2021, the Group disposed of its Iranian subsidiary, B.A.T. Pars Company PJSC (BAT Pars). Included within other operating expenses, and recognised as an adjusting item, is a charge of £358 million comprising £272 million of foreign exchange reclassified from other comprehensive income (note 22(c)(i)) and an impairment charge and associated costs of £88 million. In addition, a credit of £2 million was recognised in relation to a partial unwind of discounting on the deferred proceeds. More information has been provided in note 27(d).

(h) Tax disputes in Turkey, South Korea and Russia

The settlement of tax disputes in Turkey, South Korea and Russia were recognised as adjusting items.

Turkey

As explained in note 31, British American Tobacco Tutun Mamulleri Sanayi ve Ticaret Anonim Sirketi (BAT Tutun) was subject to a series of tax audits mainly on inventory movements for the years 2015, 2016 and 2019. In August 2021, BAT Tutun applied under the relevant tax amnesty law to settle its retrospective tax assessments. Based on the settlement through the tax amnesty procedure, BAT Tutun agreed to pay £47 million in 18 instalments from 1 November 2021 until 31 July 2024. Of the £47 million, £30 million of excise and penalties were recognised and charged to operating profit, £11 million as interest in net finance costs (note 8(b)) and £6 million in taxation.

South Korea

As explained in note 31, on 16 September 2021, Rothmans Far East B.V. Korea Branch Office received £4 million in relation to a VAT case. In line with the treatment of the associated expense incurred in 2016, the cash received was recognised as an adjusting item.

Russia

In August 2019, the Russian tax authority issued a final audit report to JSC British American Tobacco-SpB (BAT SpB) related to the application of legislation introduced in 2017 that prospectively limited the amount of production that could take place prior to excise tax increases, without being subject to higher excise tax rates. The final audit report sought to retrospectively apply the legislation to the years 2015 to 2017. BAT SpB submitted an appeal to the Federal Tax Services (FTS) objecting to the findings. The FTS accepted some of BAT SpB’s arguments and, on 27 January 2020, a final claim was issued by the FTS. As a consequence, the Group recognised a charge of £202 million. The Group also recognised an interest charge of £50 million (note 8(b)).

In 2020, a credit of £40 million was recognised in relation to the 2019 charge discussed above, of which £14 million was offset in the adjusting items included in taxation (note 10(d)).

(h) Quebec class actions

In 2019, a charge of £436 million was incurred in respect of the Quebec class actions, as explained in note 31, and charged as an adjusting item.
6 Other Operating Expenses Continued

(i) Auditor’s remuneration

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total expense for audit services pursuant to legislation:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– fees to KPMG LLP for Parent Company and Group audit</td>
<td>8.7</td>
<td>8.7</td>
<td>6.8</td>
</tr>
<tr>
<td>– fees to KPMG LLP firms and associates for local statutory and Group reporting audits</td>
<td>9.5</td>
<td>9.9</td>
<td>9.0</td>
</tr>
<tr>
<td>Total audit fees expense – KPMG LLP firms and associates</td>
<td>18.2</td>
<td>18.6</td>
<td>15.8</td>
</tr>
<tr>
<td>Audit fees expense to other firms</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Total audit fees expense</td>
<td>18.4</td>
<td>18.8</td>
<td>15.9</td>
</tr>
<tr>
<td>Fees to KPMG LLP firms and associates for other services:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– audit-related assurance services</td>
<td>8.0</td>
<td>8.5</td>
<td>8.5</td>
</tr>
<tr>
<td>– other assurance services</td>
<td>0.3</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>– tax advisory services</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>– tax compliance</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>– audit of defined benefit schemes of the Company</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>– other non-audit services</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>8.7</td>
<td>9.5</td>
<td>9.4</td>
</tr>
</tbody>
</table>

The total auditor’s remuneration to KPMG firms and associates included above are £26.9 million (2020: £28.1 million; 2019: £25.2 million).

Under SEC regulations, the remuneration to KPMG firms and associates of £26.9 million in 2021 (2020: £28.1 million; 2019: £25.1 million) is required to be presented as follows: audit fees £26.2 million (2020: £27.5 million; 2019: £24.7 million), audit-related fees £0.4 million (2020: £0.5 million; 2019: £0.4 million), tax fees £nil (2020: £nil; 2019: £nil) and all other fees £0.3 million (2020: £0.1 million; 2019: £0.1 million). Audit-related fees are in respect of services provided to associated pension schemes. All other fees are in respect of other assurance services, including those provided over information derived from the financial information systems subject to audit or over the controls over those systems.

7 Restructuring and Integration Costs

Restructuring costs reflect the costs incurred as a result of initiatives to improve the effectiveness and the efficiency of the Group as a globally integrated enterprise. These costs represent additional expenses incurred that are not related to the normal business and day-to-day activities. These initiatives include the costs associated with Quantum, being a review of the Group’s organisational structure announced in 2019 to simplify the business and create a more efficient, agile and focused company. In 2019 and 2020, these also included a review of the Group’s manufacturing operations. It is expected that such restructuring programmes (related to Quantum) will be substantially complete by the end of 2022.

The costs of the Group’s initiatives are included in profit from operations under the following headings:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employee benefit costs (note 3)</td>
<td>160</td>
<td>91</td>
<td>364</td>
</tr>
<tr>
<td>Depreciation, amortisation and impairment costs (note 4)</td>
<td>(11)</td>
<td>151</td>
<td>63</td>
</tr>
<tr>
<td>Other operating income (note 5)</td>
<td>–</td>
<td>–</td>
<td>(7)</td>
</tr>
<tr>
<td>Other operating expenses</td>
<td>1</td>
<td>166</td>
<td>145</td>
</tr>
<tr>
<td>Total</td>
<td>150</td>
<td>408</td>
<td>565</td>
</tr>
</tbody>
</table>

The adjusting charge in 2021 relates to the cost of employee packages in respect of Quantum and the ongoing costs associated with initiatives to improve the effectiveness and efficiency of the Group as a globally integrated organisation. In addition, Quantum initiatives in certain countries have resulted in the move to above market business models utilising local distributors as importers. As a consequence, with the cessation of a physical presence in these markets, foreign exchange previously recognised in Other Comprehensive Income for these countries has been reclassified to the income statement and reported within other operating expenses (note 22(c)(i)).

Included under the Quantum initiatives above is a charge of £27 million, including £4 million for foreign exchange reclassified from equity (note 22(c)(ii)), related to the Group’s withdrawal from Myanmar. In addition, as set out in note 4, goodwill in relation to Myanmar was impaired and charged to the income statement. These costs were recognised in 2021 as an adjusting item.
Financial Statements

Notes on Accounts

Continued

7 Restructuring and Integration Costs

Continued

The depreciation, amortisation and impairment costs in 2021 include a credit of £25 million due to a partial reversal of previously estimated impairment following the revision of factory rationalisation initiatives.

Included within other operating expenses is a credit of £59 million representing the release of an accrual on the successful conclusion of the dispute with former shareholders of Reynolds American, as explained in note 31.

The adjusting charges in 2020 and 2019 relate to the ongoing restructuring costs associated with the implementation of revisions to the Group’s operating model, mainly in relation to Quantum, including the cost of packages in respect of permanent headcount reduction and permanent employee benefit reductions in the Group. The costs also cover the downsizing and factory rationalisation activities in the Netherlands and Hungary in 2020, Germany in 2019, and Russia and APME in both 2020 and 2019.

Also, in 2020, as a consequence of a reduction in volumes due to the significant increase in excise in Indonesia, the Group announced a restructuring programme which included the partial closure of the factory operations in Indonesia. As a result of this decision, a £39 million impairment was recognised in respect of machinery. This impairment charge related to some of the machinery in use as well as machinery held for future use which, following the significant changes in consumer preferences, is not expected to be brought in to manufacturing in the future.

Also included in other operating income in 2019 are amounts related to cash and reversal of deferred consideration associated with the acquisition of TDR d.o.o. (TDR) (note 27).

8 Net finance Costs

(a) Net finance costs/(income)

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest expense</td>
<td>£1,436</td>
<td>£1,605</td>
<td>£1,676</td>
</tr>
<tr>
<td>Interest expense on lease liabilities</td>
<td>24</td>
<td>26</td>
<td>32</td>
</tr>
<tr>
<td>Facility fees</td>
<td>33</td>
<td>23</td>
<td>10</td>
</tr>
<tr>
<td>Interest and fair value related to early repurchase of bonds (note 8(b))</td>
<td>–</td>
<td>142</td>
<td>–</td>
</tr>
<tr>
<td>Interest related to adjusting tax payables (note 8(b))</td>
<td>31</td>
<td>11</td>
<td>80</td>
</tr>
<tr>
<td>Fair value changes on derivative financial instruments and hedged items</td>
<td>252</td>
<td>(217)</td>
<td>367</td>
</tr>
<tr>
<td>Fair value change on other financial items (note 8(b))</td>
<td>24</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Exchange differences</td>
<td>(279)</td>
<td>205</td>
<td>(479)</td>
</tr>
<tr>
<td><strong>Finance costs</strong></td>
<td>£1,521</td>
<td>£1,795</td>
<td>£1,602</td>
</tr>
<tr>
<td>Interest under the effective interest method</td>
<td>(35)</td>
<td>(50)</td>
<td>(84)</td>
</tr>
<tr>
<td><strong>Finance income</strong></td>
<td>(35)</td>
<td>(50)</td>
<td>(84)</td>
</tr>
<tr>
<td><strong>Net finance costs</strong></td>
<td>£1,486</td>
<td>£1,745</td>
<td>£1,619</td>
</tr>
</tbody>
</table>

The Group manages foreign exchange gains and losses and fair value changes on a net basis excluding adjusting items, which are explained in note 8(b). The derivatives that generate the fair value changes are explained in note 19.

Facility fees principally relate to the Group’s central banking facilities.

In October 2020, the Group completed a tender offer to repurchase sterling-equivalent £2,653 million of bonds, including £24 million of accrued interest. Following this, in November 2020, the Group also completed a ‘make-whole’ bond redemption exercise of sterling-equivalent £462 million of bonds, including £6 million of accrued interest. Further details on the tender offer and ‘make-whole’ redemption exercise are provided in note 26. Other costs directly associated with the early repurchase of bonds, including the premium paid, were treated as adjusting items, as detailed in note 8(b).

(b) Adjusting items included in net finance costs

Adjusting items are significant items in net finance costs which individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group’s underlying financial performance.

In 2021, as part of the disposal of the Group’s operations in Iran (note 27(d)), a provision of £24 million was charged to net finance costs against non-current investments held at fair value due to the uncertainty around recovery of these funds.

In addition, the Group recognised interest on adjusting tax payables of £31 million (2020: £11 million; 2019: £80 million), which included interest of £20 million (2020: £21 million; 2019: £28 million) in relation to the Franked Investment Income Group Litigation Order (FII GLO) (note 10(b)), an amnesty tax payment in Turkey of £11 million (2020: Eni; 2019: Eni) and Eni (2020: net credit of £10 million; 2019: charge of £50 million) in respect of the excise dispute (note 6(g)) and withholding tax in Russia.

In 2020, the Group incurred additional interest costs of £157 million and fair value gains of £15 million in relation to the early repurchase of bonds.
9 Associates and Joint Ventures

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total £m</td>
<td>Group’s share £m</td>
<td>Total £m</td>
</tr>
<tr>
<td>Revenue</td>
<td>7,668</td>
<td>2,164</td>
<td>7,001</td>
</tr>
<tr>
<td>Profit from operations</td>
<td>1,911</td>
<td>567</td>
<td>2,086</td>
</tr>
<tr>
<td>Net finance costs</td>
<td>13</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Profit on ordinary activities before taxation</td>
<td>1,924</td>
<td>569</td>
<td>2,000</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>(499)</td>
<td>(147)</td>
<td>(421)</td>
</tr>
<tr>
<td>Profit on ordinary activities after taxation</td>
<td>1,425</td>
<td>422</td>
<td>1,579</td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>(22)</td>
<td>(7)</td>
<td>(30)</td>
</tr>
<tr>
<td>Post-tax results of associates and joint ventures</td>
<td>1,403</td>
<td>415</td>
<td>1,549</td>
</tr>
</tbody>
</table>

Enumerated below are movements that have impacted the post-tax results of associates and joint ventures in 2021, 2020 and 2019. The amounts below were reported as adjusting items under the share of profit from associates in the income statement.

(a) Adjusting Items

In 2021, the Group’s interest in ITC Ltd. (ITC) decreased from 29.42% to 29.38% (2020: 29.46% to 29.42%; 2019: 29.57% to 29.46%) as a result of ITC issuing ordinary shares under the ITC Employee Share Option Scheme. The issue of these shares and change in the Group’s share of ITC resulted in a gain of £6 million (2020: £17 million; 2019: £25 million), which is treated as a deemed partial disposal and included in the income statement.

In 2021, due to a challenging operating environment, the investment in Kamaran Industry & Investment Company, one of the Group’s associates in Yemen, was impaired. This resulted in a charge of £18 million to the income statement.

As detailed in note 14, as a result of the liquidation of Tisak d.d., the Group reclassified the foreign exchange previously recognised in other comprehensive income to the income statement. This resulted in a credit of £2 million to the income statement.

Also, in 2021, the Group incurred a £2 million charge in relation to the amortisation of acquired intangibles associated with the acquisition of Organigram in March 2021, as described in note 14.

In 2020, ITC recognised a charge in respect of the cost of leaf tobacco stocks destroyed in a third-party warehouse fire, the Group’s share of which was £4 million.

(b) Other Financial Information

The Group’s share of the results of associates and joint ventures is shown in the table below.

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group’s share £m</td>
<td>Group’s share £m</td>
<td>Group’s share £m</td>
</tr>
<tr>
<td>Profit on ordinary activities after taxation</td>
<td>– attributable to owners of the Parent</td>
<td>415</td>
<td>455</td>
</tr>
<tr>
<td>Other comprehensive income:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Items that may be reclassified to profit and loss</td>
<td>(17)</td>
<td>(98)</td>
<td>(115)</td>
</tr>
<tr>
<td>Items that will not be reclassified to profit and loss</td>
<td>14</td>
<td>(34)</td>
<td>7</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>412</td>
<td>323</td>
<td>390</td>
</tr>
</tbody>
</table>
9 Associates and Joint Ventures Continued

Summarised financial information of the Group’s associates and joint ventures is shown below.

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ITC £m</td>
<td>Others £m</td>
<td>Total £m</td>
</tr>
<tr>
<td>Revenue</td>
<td>5,312</td>
<td>2,356</td>
<td>7,668</td>
</tr>
<tr>
<td>Profit on ordinary activities before taxation</td>
<td>1,931</td>
<td>(7)</td>
<td>1,924</td>
</tr>
<tr>
<td>Post-tax results of associates and joint ventures</td>
<td>1,427</td>
<td>(24)</td>
<td>1,403</td>
</tr>
<tr>
<td>Other comprehensive income</td>
<td>(11)</td>
<td>–</td>
<td>(11)</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>1,416</td>
<td>(24)</td>
<td>1,392</td>
</tr>
<tr>
<td></td>
<td>ITC £m</td>
<td>Others £m</td>
<td>Total £m</td>
</tr>
<tr>
<td>Revenue</td>
<td>4,892</td>
<td>2,109</td>
<td>7,001</td>
</tr>
<tr>
<td>Profit on ordinary activities before taxation</td>
<td>1,930</td>
<td>70</td>
<td>2,000</td>
</tr>
<tr>
<td>Post-tax results of associates and joint ventures</td>
<td>1,495</td>
<td>54</td>
<td>1,549</td>
</tr>
<tr>
<td>Other comprehensive income</td>
<td>(450)</td>
<td>–</td>
<td>(450)</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>1,045</td>
<td>54</td>
<td>1,099</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ITC £m</td>
<td>Others £m</td>
<td>Total £m</td>
</tr>
<tr>
<td>Revenue</td>
<td>5,556</td>
<td>2,025</td>
<td>7,581</td>
</tr>
<tr>
<td>Profit on ordinary activities before taxation</td>
<td>2,322</td>
<td>57</td>
<td>2,379</td>
</tr>
<tr>
<td>Post-tax results of associates and joint ventures</td>
<td>1,646</td>
<td>40</td>
<td>1,686</td>
</tr>
<tr>
<td>Other comprehensive income</td>
<td>(365)</td>
<td>–</td>
<td>(365)</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>1,281</td>
<td>40</td>
<td>1,321</td>
</tr>
</tbody>
</table>
### 10 Taxation on Ordinary Activities

#### (a) Summary of taxation on ordinary activities

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK corporation tax</td>
<td>(25)</td>
<td>38</td>
<td>8</td>
</tr>
<tr>
<td>Comprising:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– current year tax expense</td>
<td>(26)</td>
<td>–</td>
<td>(33)</td>
</tr>
<tr>
<td>– adjustments in respect of prior periods</td>
<td>1</td>
<td>38</td>
<td>41</td>
</tr>
<tr>
<td>Overseas tax</td>
<td>2,401</td>
<td>2,387</td>
<td>2,047</td>
</tr>
<tr>
<td>Comprising:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– current year tax expense</td>
<td>2,418</td>
<td>2,369</td>
<td>2,074</td>
</tr>
<tr>
<td>– adjustments in respect of prior periods</td>
<td>(17)</td>
<td>18</td>
<td>(27)</td>
</tr>
<tr>
<td>Total current tax</td>
<td>2,376</td>
<td>2,425</td>
<td>2,055</td>
</tr>
<tr>
<td>Deferred tax</td>
<td>(187)</td>
<td>(317)</td>
<td>(8)</td>
</tr>
<tr>
<td>Comprising:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– deferred tax relating to origination and reversal of temporary differences</td>
<td>(29)</td>
<td>(184)</td>
<td>55</td>
</tr>
<tr>
<td>– deferred tax relating to changes in tax rates</td>
<td>(158)</td>
<td>(133)</td>
<td>(47)</td>
</tr>
</tbody>
</table>

**Total:** 2,189  2,108  2,063

#### (b) Franked Investment Income Group Litigation Order

The Group is the principal test claimant in an action in the United Kingdom against HM Revenue and Customs (HMRC) in the Franked Investment Income Group Litigation Order (FII GLO). There were 18 corporate groups in the FII GLO as at 31 December 2021. The case concerns the treatment for UK corporate tax purposes of profits earned overseas and distributed to the UK.

The original claim was filed in 2003. The trial of the claim was split broadly into issues of liability and quantification. The main liability issues were heard by the High Court, Court of Appeal and Supreme Court in the UK and the European Court of Justice in the period to November 2012. The detailed technical issues of the quantification mechanics of the claim were heard by the High Court during May and June 2014 and the judgment handed down on 18 December 2014. The High Court determined that in respect of issues concerning the calculation of uneasily charged corporation tax and advance corporation tax, the law of restitution including the defence on change of position and questions concerning the calculation of overpaid interest, the approach of the Group was broadly preferred. The conclusion reached by the High Court would, if upheld, produce an estimated receivable of £1.2 billion for the Group. Appeals on a majority of the issues were made to the Court of Appeal, which heard the arguments in June 2016. The Court of Appeal determined in November 2016 on the majority of issues that the conclusion reached by the High Court should be upheld. The Supreme Court gave permission for a number of issues to be appealed in two separate hearings. The first, in February 2020, concerned the time limit for bringing claims. HMRC sought to challenge existing case law. In November 2020, the Supreme Court handed down its judgment. The Supreme Court agreed to overturn existing case law partially but introduced a new test for determining whether claims of this type are in time. The case has been remitted to the High Court to apply that new test to the facts. The second hearing was heard in December 2020 and concerned issues relating to the type of claims BAT is entitled to bring. The judgment from the second hearing was handed down in July 2021. Applying that judgment reduces the value of the FII claim to approximately £0.3 billion, mainly as the result of the application of simple interest and the limitation to claims for advance corporation tax offset against lawful corporation tax charges, which is subject to the determination of the timing issue by the High Court and any subsequent appeal.

During 2015, HMRC paid to the Group a gross amount of £1,224 million in two separate payments. The payments made by HMRC have been made without any admission of liability and are subject to refund were HMRC to succeed on appeal. The second payment in November 2015 followed the introduction of a new 45% tax on the interest component of restitution claims against HMRC. HMRC held back £261 million from the second payment contending that it represents the new 45% tax on that payment, leading to total cash received by the Group of £963 million. Actions challenging the legality of the withholding of the 45% tax have been lodged by the Group. The First Tier Tribunal found in favour of HMRC in July 2017 and the Group’s appeal to the Upper Tribunal was heard in July 2018 and judgment has not yet been handed down.

The net £0.9 billion held by the Group is higher than the current value of the claim referred to above. Due to the uncertainty of the amounts and eventual outcome, the Group has not recognised any impact in the Income Statement in the current or prior period. The receipt, net of the deduction by HMRC, is held within trade and other payables as disclosed in note 25. Any future recognition as income will be treated as an adjusting item, due to the size of the amount, with interest of £20 million for the 12 months to 31 December 2021 (2020: £21 million; 2019: £28 million) accruing on the balance, which was also treated as an adjusting item.

The final resolution of all issues in the litigation is likely to take a number of years and the Group intends from 2022 onwards to commence annual interim repayments to HMRC of at least £50 million per annum.
10 Taxation on Ordinary Activities  Continued

(c) Factors affecting the taxation charge
The taxation charge differs from the standard 19% (2020: 19%; 2019: 19%) rate of corporation tax in the UK. The major causes of this difference are listed below:

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>%</td>
<td>£m</td>
</tr>
<tr>
<td>Profit before tax</td>
<td>9,163</td>
<td>8,672</td>
</tr>
<tr>
<td>Less: share of post-tax results of associates and joint ventures (see note 9)</td>
<td>(415)</td>
<td>(455)</td>
</tr>
<tr>
<td>Tax at 19% (2020 and 2019: 19%) on the above</td>
<td>8,748</td>
<td>8,217</td>
</tr>
<tr>
<td>Factors affecting the tax rate:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tax at standard rates other than UK corporation tax rate</td>
<td>319</td>
<td>368</td>
</tr>
<tr>
<td>Other national tax charges</td>
<td>184</td>
<td>142</td>
</tr>
<tr>
<td>Permanent differences</td>
<td>87</td>
<td>20</td>
</tr>
<tr>
<td>Overseas withholding taxes</td>
<td>189</td>
<td>155</td>
</tr>
<tr>
<td>Double taxation relief on UK profits</td>
<td>(23)</td>
<td>(22)</td>
</tr>
<tr>
<td>(Utilised)/unutilised tax losses</td>
<td>(10)</td>
<td>5</td>
</tr>
<tr>
<td>Adjustments in respect of prior periods</td>
<td>(43)</td>
<td>18</td>
</tr>
<tr>
<td>Deferred tax relating to changes in tax rates</td>
<td>(158)</td>
<td>(133)</td>
</tr>
<tr>
<td>Additional net deferred tax (credits)/charges</td>
<td>(18)</td>
<td>(6)</td>
</tr>
<tr>
<td></td>
<td>2,189</td>
<td>2,108</td>
</tr>
</tbody>
</table>

(d) Adjusting items included in taxation
In 2021, adjusting items in taxation included a net credit of £91 million mainly relating to the revaluation of deferred tax liabilities arising on trademarks recognised in the Reynolds American acquisition in 2017 due to changes in U.S. state tax rates.

In 2020, adjusting items in taxation included a net credit of £35 million mainly relating to the release of a provision regarding the application of overseas withholding tax, the revaluation of deferred tax liabilities arising on trademarks recognised in the Reynolds American acquisition in 2017 due to changes in U.S. state tax rates and the excise dispute in Russia (note 6(g)).

In 2019, adjusting items in taxation total a credit of £65 million relating primarily to changes in U.S. state tax rates, relating to the revaluation of deferred tax liabilities arising on trademarks recognised in the Reynolds American acquisition in 2017.

(e) Tax on adjusting items
In addition, the tax on adjusting items, separated between the different categories, as per note 11, amounted to £119 million (2020: £287 million; 2019: £373 million). The adjustment to the adjusted earnings per share (note 11) also includes £6 million (2020: £8 million; 2019: £17 million) in respect of the non-controlling interests' share of the adjusting items net of tax.

(f) Tax on items recognised directly in other comprehensive income

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current tax</td>
<td>(4)</td>
<td>(5)</td>
<td>(7)</td>
</tr>
<tr>
<td>Deferred tax</td>
<td>(110)</td>
<td>23</td>
<td>138</td>
</tr>
<tr>
<td>(Charged)/credited to other comprehensive income</td>
<td>(114)</td>
<td>18</td>
<td>131</td>
</tr>
</tbody>
</table>

(g) Tax on items recognised directly in equity
In relation to the perpetual hybrid bonds issued on 27 September 2021 (note 22(d)), tax relief of £5 million has been recognised on the issuance costs and coupon incurred.
11 Earnings Per Share

Earnings used in the basic, diluted and headline earnings per share calculation represent the profit attributable to the ordinary equity shareholders after deducting amounts representing the coupon on perpetual hybrid bonds on a pro-rata basis regardless of whether coupons have been deferred or paid in the period. Below is a reconciliation of the earnings used to calculate earnings per share:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings attributable to owners of the parent</td>
<td>6,801</td>
<td>6,400</td>
<td>5,704</td>
</tr>
<tr>
<td>Coupon on perpetual hybrid bonds</td>
<td>(15)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tax on coupon on perpetual hybrid bonds</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Earnings</strong></td>
<td><strong>6,789</strong></td>
<td><strong>6,400</strong></td>
<td><strong>5,704</strong></td>
</tr>
</tbody>
</table>

Below is a reconciliation from basic to diluted earnings per share:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic earnings per share (ordinary shares of 25p each)</td>
<td>6,789</td>
<td>2,287</td>
<td>296.9</td>
</tr>
<tr>
<td>Share options</td>
<td>-</td>
<td>10</td>
<td>(1.3)</td>
</tr>
<tr>
<td><strong>Share options</strong></td>
<td><strong>6,789</strong></td>
<td><strong>2,297</strong></td>
<td><strong>295.6</strong></td>
</tr>
</tbody>
</table>

Adjusted earnings per share calculation

Earnings have been affected by a number of adjusting items, which are described in notes 3 to 10. Adjusting items are significant items in the profit from operations, net finance costs, taxation and the Group’s share of the post-tax results of associates and joint ventures which individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group’s underlying financial performance. The Group believes that these items are useful to users of the Group financial statements in helping them to understand the underlying business performance. To illustrate the impact of these items, an adjusted earnings per share calculation is shown below.

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic earnings per share</td>
<td>6,789</td>
<td>2,287</td>
<td>296.9</td>
</tr>
<tr>
<td>Effect of restructuring and integration costs</td>
<td>7</td>
<td>150</td>
<td>6.5</td>
</tr>
<tr>
<td>Tax and non-controlling interests on restructuring and integration costs</td>
<td>(39)</td>
<td>(1.7)</td>
<td>(64)</td>
</tr>
<tr>
<td>Effect of amortisation and impairment of goodwill, trademarks and similar intangibles</td>
<td>4</td>
<td>363</td>
<td>15.9</td>
</tr>
<tr>
<td>Tax and non-controlling interests on amortisation and impairment of goodwill, trademarks and similar intangibles</td>
<td>(71)</td>
<td>(3.1)</td>
<td>(77)</td>
</tr>
<tr>
<td>Effect of associates’ adjusting items net of tax</td>
<td>9(a)</td>
<td>12</td>
<td>0.5</td>
</tr>
<tr>
<td>Effect of Quebec class action</td>
<td>6(b)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tax on Quebec class action</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Effect of excise and VAT disputes</td>
<td>6(g)</td>
<td>26</td>
<td>1.1</td>
</tr>
<tr>
<td>Tax on excise and VAT disputes</td>
<td>10(d)</td>
<td>(3)</td>
<td>(0.1)</td>
</tr>
<tr>
<td>Effect of disposal of BAT Pars</td>
<td>6(f)</td>
<td>358</td>
<td>15.7</td>
</tr>
<tr>
<td>Other adjusting items</td>
<td>3.6(d)</td>
<td>19</td>
<td>0.8</td>
</tr>
<tr>
<td>Deferred tax relating to changes in tax rates</td>
<td>10</td>
<td>(98)</td>
<td>(4.3)</td>
</tr>
<tr>
<td>Effect of early repurchase of bonds</td>
<td>8(b)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tax effect of early repurchase of bonds</td>
<td>-</td>
<td>(32)</td>
<td>(1.4)</td>
</tr>
<tr>
<td>Effect of interest on FII GLO settlement and other</td>
<td>8(b)</td>
<td>55</td>
<td>2.4</td>
</tr>
<tr>
<td>Tax effect of interest on FII GLO settlement and other</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Effect of retrospective guidance on WHT</td>
<td>10(d)</td>
<td>-</td>
<td>(42)</td>
</tr>
<tr>
<td><strong>Adjusted earnings per share (basic)</strong></td>
<td>7,556</td>
<td>330.4</td>
<td>333.0</td>
</tr>
</tbody>
</table>

203
### Financial Statements

#### Notes on Accounts

**11 Earnings Per Share Continued**

<table>
<thead>
<tr>
<th>Notes</th>
<th>2021 Earnings £m</th>
<th>Earnings per share pence</th>
<th>2020 Earnings £m</th>
<th>Earnings per share pence</th>
<th>2019 Earnings £m</th>
<th>Earnings per share pence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diluted earnings per share</td>
<td>6,789</td>
<td>295.6</td>
<td>6,400</td>
<td>278.9</td>
<td>5,704</td>
<td>249.0</td>
</tr>
<tr>
<td>Effect of restructuring and integration costs</td>
<td>7</td>
<td>150</td>
<td>6.6</td>
<td>408</td>
<td>17.7</td>
<td>565</td>
</tr>
<tr>
<td>Tax and non-controlling interests on restructuring and integration costs</td>
<td>(39)</td>
<td>(1.7)</td>
<td>(64)</td>
<td>2.8</td>
<td>(101)</td>
<td>4.4</td>
</tr>
<tr>
<td>Effect of amortisation and impairment of goodwill, trademarks and similar intangibles</td>
<td>4</td>
<td>363</td>
<td>15.8</td>
<td>548</td>
<td>23.9</td>
<td>675</td>
</tr>
<tr>
<td>Tax and non-controlling interests on amortisation and impairment of goodwill, trademarks and similar intangibles</td>
<td>$(71)</td>
<td>(3.1)</td>
<td>$(77)</td>
<td>(3.4)</td>
<td>$(115)</td>
<td>(5.0)</td>
</tr>
<tr>
<td>Effect of associates’ adjusting items net of tax</td>
<td>9(a)</td>
<td>12</td>
<td>0.5</td>
<td>13</td>
<td>0.6</td>
<td>25</td>
</tr>
<tr>
<td>Effect of Quebec class action</td>
<td>6(h)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>436</td>
<td>19.0</td>
</tr>
<tr>
<td>Effect of excise and VAT disputes</td>
<td>6(g)</td>
<td>26</td>
<td>1.1</td>
<td>(40)</td>
<td>(1.7)</td>
<td>202</td>
</tr>
<tr>
<td>Tax on excise and VAT disputes</td>
<td>10(d)</td>
<td>3</td>
<td>0.1</td>
<td>14</td>
<td>0.6</td>
<td>16</td>
</tr>
<tr>
<td>Effect of disposal of BAT Pars</td>
<td>6(f)</td>
<td>358</td>
<td>15.6</td>
<td>–</td>
<td>–</td>
<td>236</td>
</tr>
<tr>
<td>Other adjusting items</td>
<td>3.6(d)</td>
<td>19</td>
<td>0.8</td>
<td>487</td>
<td>21.2</td>
<td>236</td>
</tr>
<tr>
<td>Tax effect on other adjusting items</td>
<td>(5)</td>
<td>(0.2)</td>
<td>(104)</td>
<td>(4.5)</td>
<td>(50)</td>
<td>(2.2)</td>
</tr>
<tr>
<td>Deferred tax relating to changes in tax rates</td>
<td>10</td>
<td>(98)</td>
<td>(4.3)</td>
<td>(21)</td>
<td>(0.9)</td>
<td>(49)</td>
</tr>
<tr>
<td>Effect of early repurchase of bonds</td>
<td>8(b)</td>
<td>–</td>
<td>–</td>
<td>142</td>
<td>6.2</td>
<td>–</td>
</tr>
<tr>
<td>Tax effect of early repurchase of bonds</td>
<td>–</td>
<td>–</td>
<td>(32)</td>
<td>(1.4)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Effect of interest on FII GLO settlement and other</td>
<td>8(b)</td>
<td>55</td>
<td>2.4</td>
<td>11</td>
<td>0.5</td>
<td>80</td>
</tr>
<tr>
<td>Tax effect of interest on FII GLO settlement and other</td>
<td>–</td>
<td>–</td>
<td>(4)</td>
<td>(0.2)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Effect of retrospective guidance on WHT</td>
<td>10(d)</td>
<td>–</td>
<td>–</td>
<td>(42)</td>
<td>(1.8)</td>
<td>–</td>
</tr>
<tr>
<td>Adjusted earnings per share (diluted)</td>
<td>7,556</td>
<td>329.0</td>
<td>7,613</td>
<td>331.7</td>
<td>7,418</td>
<td>323.8</td>
</tr>
</tbody>
</table>
### 11 Earnings Per Share Continued

**Headline earnings per share as required by the JSE Limited**

The presentation of headline earnings per share, as an alternative measure of earnings per share, is mandated under the JSE Listing Requirements. It is calculated in accordance with Circular 1/2021 ‘Headline Earnings’, as issued by the South African Institute of Chartered Accountants.

<table>
<thead>
<tr>
<th>Basic</th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings £m</td>
<td>Earnings per share pence</td>
<td>Earnings £m</td>
<td>Earnings per share pence</td>
</tr>
<tr>
<td>Basic earnings per share</td>
<td>6,789</td>
<td>296.9</td>
<td>6,400</td>
</tr>
<tr>
<td>Effect of impairment of intangibles, property, plant and equipment and assets held-for-sale</td>
<td>138</td>
<td>6.0</td>
<td>465</td>
</tr>
<tr>
<td>Tax and non-controlling interests on impairment of intangibles and property, plant and equipment</td>
<td>(42)</td>
<td>(1.8)</td>
<td>(74)</td>
</tr>
<tr>
<td>Effect of (gains)/losses on disposal of property, plant and equipment, held-for-sale assets, partial/full termination of IFRS 16 leases, and sale and leaseback</td>
<td>(10)</td>
<td>(0.4)</td>
<td>(26)</td>
</tr>
<tr>
<td>Tax and non-controlling interests on disposal of property, plant and equipment, held-for-sale assets, partial/full termination of IFRS 16 leases, and sale and leaseback</td>
<td>2</td>
<td>0.1</td>
<td>8</td>
</tr>
<tr>
<td>Effect of impairment of BAT Pars</td>
<td>83</td>
<td>3.6</td>
<td>–</td>
</tr>
<tr>
<td>Tax on impairment of BAT Pars</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Effect of foreign exchange reclassification from reserves to the income statement</td>
<td>– Subsidiaries</td>
<td>291</td>
<td>12.7</td>
</tr>
<tr>
<td>– Associates</td>
<td>(2)</td>
<td>(0.1)</td>
<td>–</td>
</tr>
<tr>
<td>Issue of shares and change in shareholding in associate</td>
<td>(6)</td>
<td>(0.3)</td>
<td>(17)</td>
</tr>
</tbody>
</table>

**Headline earnings per share (basic)**

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings £m</td>
<td>Earnings per share pence</td>
<td>Earnings £m</td>
</tr>
<tr>
<td>Headline earnings per share (basic)</td>
<td>7,243</td>
<td>316.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diluted</th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings £m</td>
<td>Earnings per share pence</td>
<td>Earnings £m</td>
<td>Earnings per share pence</td>
</tr>
<tr>
<td>Diluted earnings per share</td>
<td>6,789</td>
<td>295.6</td>
<td>6,400</td>
</tr>
<tr>
<td>Effect of impairment of intangibles, property, plant and equipment and assets held-for-sale</td>
<td>138</td>
<td>6.0</td>
<td>465</td>
</tr>
<tr>
<td>Tax and non-controlling interests on impairment of intangibles and property, plant and equipment</td>
<td>(42)</td>
<td>(1.8)</td>
<td>(74)</td>
</tr>
<tr>
<td>Effect of (gains)/losses on disposal of property, plant and equipment, held-for-sale assets, partial/full termination of IFRS 16 leases, and sale and leaseback</td>
<td>(10)</td>
<td>(0.4)</td>
<td>(26)</td>
</tr>
<tr>
<td>Tax and non-controlling interests on disposal of property, plant and equipment, held-for-sale assets, partial/full termination of IFRS 16 leases, and sale and leaseback</td>
<td>2</td>
<td>0.1</td>
<td>8</td>
</tr>
<tr>
<td>Effect of impairment of BAT Pars</td>
<td>83</td>
<td>3.6</td>
<td>–</td>
</tr>
<tr>
<td>Tax on impairment of BAT Pars</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Effect of foreign exchange reclassification from reserves to the income statement</td>
<td>– Subsidiaries</td>
<td>291</td>
<td>12.6</td>
</tr>
<tr>
<td>– Associates</td>
<td>(2)</td>
<td>(0.1)</td>
<td>–</td>
</tr>
<tr>
<td>Issue of shares and change in shareholding in associate</td>
<td>(6)</td>
<td>(0.3)</td>
<td>(17)</td>
</tr>
</tbody>
</table>

**Headline earnings per share (diluted)**

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings £m</td>
<td>Earnings per share pence</td>
<td>Earnings £m</td>
</tr>
<tr>
<td>Headline earnings per share (diluted)</td>
<td>7,243</td>
<td>315.3</td>
</tr>
</tbody>
</table>
12 Intangible Assets

(a) Overview of intangible assets

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Goodwill £m</td>
<td>Computer software £m</td>
<td>Trademarks and similar intangibles £m</td>
<td>Assets in the course of development £m</td>
<td>Total £m</td>
</tr>
<tr>
<td>1 January</td>
<td>43,319</td>
<td>1,307</td>
<td>73,598</td>
<td>120</td>
<td>118,344</td>
</tr>
<tr>
<td>Cost</td>
<td>(685)</td>
<td>(2,116)</td>
<td></td>
<td></td>
<td>(3,091)</td>
</tr>
<tr>
<td>Accumulated amortisation and impairment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net book value at 1 January</td>
<td>43,319</td>
<td>422</td>
<td>71,482</td>
<td>120</td>
<td>115,343</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(68)</td>
<td></td>
<td>640</td>
<td></td>
<td>569</td>
</tr>
<tr>
<td>– internal development</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>– acquisitions (note 27)</td>
<td>36</td>
<td>–</td>
<td>39</td>
<td></td>
<td>75</td>
</tr>
<tr>
<td>– separately acquired</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Reallocations</td>
<td>–</td>
<td>116</td>
<td>18</td>
<td>(136)</td>
<td>–</td>
</tr>
<tr>
<td>Amortisation charge</td>
<td>–</td>
<td>(116)</td>
<td>(219)</td>
<td></td>
<td>(435)</td>
</tr>
<tr>
<td>Impairment</td>
<td>(57)</td>
<td>(13)</td>
<td>(14)</td>
<td></td>
<td>(84)</td>
</tr>
</tbody>
</table>

(b) Goodwill

Goodwill of £43,194 million (2020: £43,319 million) is included in intangible assets in the balance sheet of which the following are the significant acquisitions:

- Reynolds American £33,021 million (2020: £32,719 million);
- Rothmans Group £4,408 million (2020: £4,408 million);
- Imperial Tobacco Canada £2,345 million (2020: £2,304 million);
- ETI (Italy) £1,384 million (2020: £1,474 million) and ST (principally Scandinavia) £1,043 million (2020: £1,111 million). The principal allocations of goodwill in the Rothmans’ acquisition are to the cash-generating units of Europe and South Africa, with the remainder mainly relating to operations in APME.

During 2021, the Group recognised a goodwill impairment charge of £57 million (2020: £209 million) as explained in note 12(e)(ix) below.
12 Intangible Assets Continued

(c) Trademarks and similar intangibles

Trademarks and similar intangibles with indefinite lives

The net book value of trademarks and similar intangibles with indefinite lives is £86,475 million (2020: £86,839 million) and relates to the acquisition of Reynolds American. The trademarks acquired, including Newport, Camel, Natural American Spirit, Grizzly and Pall Mall, all of which are part of the Group’s Strategic Portfolio of key brands, form the core focus of the U.S. business and receive significant support in the form of dedicated internal resources, forecasting and, where appropriate, marketing investment. These trademarks have significant market share and positive cashflow growth expectations. There are no regulatory or contractual restrictions on the use of the trademarks, and there are no plans by management to significantly redirect resources elsewhere. Consequently, in the view of management, these trademarks do not have a foreseeable and definite end to their ability to generate future cash flows and hence are not amortised.

Trademarks and similar intangibles with definite lives

The majority of trademarks and similar intangibles with definite lives relate to trademarks acquired in previous years. These trademarks are amortised over their expected useful lives, which do not exceed 20 years. Included in the net book value of trademarks and similar intangibles are trademarks relating to the acquisition of Reynolds American £2,038 million (2020: £2,260 million). In 2020, the Group acquired the formulations, brands, associated know-how and other relevant assets owned by Dryft Sciences, LLC, relating to its white nicotine pouch products. These have been accounted as trademarks with a value of £103 million (see note 27(c)).

Also, in 2020, due to the migration to Vuse and difficult trading conditions in South Africa and the delisting of certain brands in Belize, the Group recognised an impairment charge of £18 million.

(d) Computer software and assets in the course of development

Included in computer software and assets in the course of development are internally developed assets with a carrying value of £517 million (2020: £513 million). The costs of internally developed assets include capitalised expenses of employees working full time on software development projects, third-party consultants and software licence fees from third-party suppliers.

The Group has £2 million of future contractual commitments (2020: £6 million) related to intangible assets.

(e) Impairment testing

(i) Overview

a. Estimation uncertainty

As described in note 1, the critical accounting estimates used in the preparation of the consolidated financial statements include the review of asset values, especially indefinite life assets such as goodwill and certain trademarks and similar intangibles.

There is significant judgement with regard to assumptions and estimates involved in the forecasting of future cash flows, which form the basis of the assessment of the recoverability of these assets, with the effect that the value-in-use of calculations incorporate estimation uncertainty, particularly for certain assets held in relation to the Canadian, U.S., Malaysian, Peruvian and South African markets and the Global Travel Retail (GTR) business.

b. Impact of climate change

The impact of climate change on the future cash flows has been considered for scenarios analysed in terms of future access to tobacco and nicotine. The climate change scenario analyses – conducted in line with TCFD recommendations – undertaken this year did not identify any material financial impact.

(ii) Impairment testing – Trademarks and similar intangibles with indefinite lives (brands)

The trademarks and similar intangibles with indefinite lives (brands) have been tested for impairment on a value-in-use basis. The value-in-use calculations use cash flows based on detailed brand budgets prepared by management using projected sales volumes, revenues and projected brand profitability covering a five-year horizon and, thereafter, grown into perpetuity. Corporate costs are allocated to the brand budgets based on either specific allocations, where appropriate, or based on volumes. The pre-tax discount rates, ranging between 8.71% and 9.94%, and long-term growth rates of between 0.75% and 1%, applied to the brand value-in-use calculations have been determined by local management based on experience, specific market and brand trends and pricing and cost expectations. Following the application of a reasonable range of sensitivities, there was no indication of impairment.

Refer to note 12(e)(v) for further information on the Newport and Camel brand impairment testing. As the trademarks and similar intangibles with indefinite lives relate to the acquisition of Reynolds American, the brand budgets used in the value-in-use calculations have also been incorporated into the budget information used in the impairment testing of the Reynolds American goodwill.

207
Financial Statements

Notes on Accounts

Continued

12 Intangible Assets

(iii) Cash-generating units and information on goodwill impairment testing

In 2021, goodwill was allocated for impairment testing purposes to 17 (2020: 19) individual cash-generating units – one in the U.S. (2020: one), six in APME (2020: six), six in AMSSA (2020: seven) and four in ENA (2020: five).

The number of cash-generating units in AMSSA and ENA reduced by one as a result of the 2020 impairment of goodwill in Twisp and Blue Nile (note 12(e)(iv)).

In 2021, goodwill was allocated for impairment testing purposes to 17 (2020: 19) individual cash-generating units – one in the U.S. (2020: one), six in APME (2020: six), six in AMSSA (2020: seven) and four in ENA (2020: five).

The number of cash-generating units in AMSSA and ENA reduced by one as a result of the 2020 impairment of goodwill in Twisp and Blue Nile (note 12(e)(iv)).

The recoverable amounts of all cash-generating units have been determined on a value-in-use basis. The key assumptions for the recoverable amounts of all units are the budgeted volumes, revenues, operating margins and terminal growth rates, which directly impact the cash flows, and the discount rates used in the calculation. The long-term growth rate is used purely for the impairment testing of goodwill under IAS 36 and does not reflect long-term planning assumptions used by the Group for investment proposals or for any other assessments.

Pre-tax discount rates, as shown above, were used in the impairment testing, based on the Group’s weighted average cost of capital, taking into account the cost of capital and borrowings, to which specific market-related premium adjustments are made. These adjustments are derived from external sources and are based on the spread between bonds (or credit default swaps, or similar indicators) issued by the U.S. or comparable governments and by the relevant local government, adjusted for the Group’s own credit market risk. For ease of use and consistency in application, these results are periodically calibrated into bands based on internationally recognised credit ratings. The long-term growth rates and discount rates have been applied to the budgeted cash flows of each cash-generating unit. These cash flows have been determined by local management based on experience, specific market and brand trends, as well as pricing and cost expectations. These have been endorsed by Group management as part of the consolidated Group’s budget.

(iv) Impairment testing – Goodwill (excluding Reynolds American and Canada)

The value-in-use calculations use cash flows based on detailed financial budgets prepared by management covering a one-year period extrapolated over a 10-year horizon with growth of 3% (2020: 3%) in years 2 to 10 having been assumed as the long-term volume decline is more than offset by pricing to drive revenue growth. A 10-year horizon is considered appropriate based on the Group’s history of profit and cash growth, its well-balanced portfolio of brands and the industry in which it operates. For recent acquisitions and start-up ventures the detailed financial budget is expanded to reflect the medium-term plan of the country or market management spanning five years or beyond.

As a result of difficult trading conditions, the above assumptions were amended to reflect the short- to medium-term plans of the country or area management spanning up to a period of five years for the Malaysian, GTR, South African and Peruvian cash-generating units.

Having recognised an impairment charge in 2020 due to difficult trading conditions in Malaysia (£197 million), including high incidence of illicit trade and downtrading, the Malaysian CGU assessment was amended to reflect the short- to medium-term country plans. As a result of the assessment, in 2021, no further deterioration in performance was identified requiring further impairment consideration. The Group will continue to monitor Malaysia’s performance going forward to identify if any impairment triggers materialise.

During 2021, GTR continued to experience difficult trading conditions as a consequence of the COVID-19 pandemic, as global travel continued to be significantly constrained. As a result, management prepared forecasted cashflows assuming a phased recovery, alongside maintaining the long-term growth rate at 0%. Following the application of a reasonable range of sensitivities, there was no indication of impairment. For the GTR cash-generating unit headroom to reduce to 0%, the forecast cash flows would need to reduce by a further 79% in each forecast year or the pre-tax discount rate would need to increase to 29.7%.

Management believes that the duty-free business will recover and therefore both scenarios are not considered, at this stage, to be reasonably possible.

### Cash-generating unit

<table>
<thead>
<tr>
<th>Cash-generating unit</th>
<th>Carrying amount £m</th>
<th>Pre-tax discount rate %</th>
<th>Carrying amount £m</th>
<th>Pre-tax discount rate %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reynolds American</td>
<td>33,021</td>
<td>8.4</td>
<td>32,719</td>
<td>7.6</td>
</tr>
<tr>
<td>Europe</td>
<td>5,362</td>
<td>6.1</td>
<td>5,639</td>
<td>6.2</td>
</tr>
<tr>
<td>Canada</td>
<td>2,345</td>
<td>19.3</td>
<td>2,304</td>
<td>19.1</td>
</tr>
<tr>
<td>Australia</td>
<td>719</td>
<td>6.8</td>
<td>756</td>
<td>7.9</td>
</tr>
<tr>
<td>South Africa</td>
<td>512</td>
<td>14.6</td>
<td>552</td>
<td>11.5</td>
</tr>
<tr>
<td>Singapore</td>
<td>352</td>
<td>8.2</td>
<td>356</td>
<td>9.6</td>
</tr>
<tr>
<td>GTR</td>
<td>233</td>
<td>7.7</td>
<td>241</td>
<td>6.5</td>
</tr>
<tr>
<td>Malaysia</td>
<td>226</td>
<td>11.2</td>
<td>232</td>
<td>10.3</td>
</tr>
<tr>
<td>Peru</td>
<td>91</td>
<td>10.7</td>
<td>145</td>
<td>9.5</td>
</tr>
<tr>
<td>Other</td>
<td>333</td>
<td>6.8</td>
<td>375</td>
<td>7.8</td>
</tr>
<tr>
<td>Total</td>
<td>43,194</td>
<td></td>
<td>43,319</td>
<td></td>
</tr>
</tbody>
</table>

Included within ‘Other’ above is goodwill arising on various acquisitions that have been allocated to eight cash-generating units which are, individually, insignificant. The pre-tax discount rate represents the weighted average pre-tax discount rate.

12 Intangible Assets

Continued

For recent acquisitions and start-up ventures the detailed financial budget is expanded to reflect the medium-term plan of the country or market management spanning five years or beyond.

As a result of difficult trading conditions, the above assumptions were amended to reflect the short- to medium-term plans of the country or area management spanning up to a period of five years for the Malaysian, GTR, South African and Peruvian cash-generating units.

Having recognised an impairment charge in 2020 due to difficult trading conditions in Malaysia (£197 million), including high incidence of illicit trade and downtrading, the Malaysian CGU assessment was amended to reflect the short- to medium-term country plans. As a result of the assessment, in 2021, no further deterioration in performance was identified requiring further impairment consideration. The Group will continue to monitor Malaysia’s performance going forward to identify if any impairment triggers materialise.

During 2021, GTR continued to experience difficult trading conditions as a consequence of the COVID-19 pandemic, as global travel continued to be significantly constrained. As a result, management prepared forecasted cashflows assuming a phased recovery, alongside maintaining the long-term growth rate at 0%. Following the application of a reasonable range of sensitivities, there was no indication of impairment. For the GTR cash-generating unit headroom to reduce to 0%, the forecast cash flows would need to reduce by a further 79% in each forecast year or the pre-tax discount rate would need to increase to 29.7%.

Management believes that the duty-free business will recover and therefore both scenarios are not considered, at this stage, to be reasonably possible.

208
12 Intangible Assets Continued

South Africa continues to recover from a five-month sales ban in 2020, with the forecasted cashflows prepared to reflect the continued expected recovery. Following the application of a reasonable range of sensitivities, there was no indication of impairment. For the South African cash-generating unit headroom to reduce to £nil, the forecast cash flows would need to reduce by a further 23% in each forecast year or the pre-tax discount rate would need to increase to 18.9%. Management believes that the post-ban recovery will continue in South Africa and therefore both scenarios are not considered by management, at this stage, to be reasonably possible.

In Peru, due to continued difficult trading conditions as a consequence of the COVID-19 pandemic and its impact on the forecasted operating cashflows, the Group had recognised an impairment charge of £54 million in 2021. This partial impairment reduces the carrying value of goodwill to £91 million. Also, in 2021, the Group impaired in full the goodwill of Myanmar resulting in an impairment charge of £3 million.

The table below shows the headroom and the impairment charge that would be recognised if the assumptions used in the value-in-use calculation were changed:

<table>
<thead>
<tr>
<th>Carrying amount of CGU £m</th>
<th>Headroom £m</th>
<th>Increase in discount rate £m</th>
<th>Decrease in cash flows £m</th>
<th>Increase in terminal value £m</th>
<th>Change in headroom/impairment charge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peru1</td>
<td>91</td>
<td>–</td>
<td>(14)</td>
<td>(10)</td>
<td>(11)</td>
</tr>
</tbody>
</table>

Note:
1. Peru: reasonably possible changes in key assumptions that would result in additional impairment would be a 1.6% increase in the pre-tax discount rate, a 10% decrease in forecast cash flows reflecting a permanent loss in volumes arising from the COVID-19 pandemic or a 1% increase in terminal decline.

With the exception of the Peruvian cash-generating unit, following the application of a reasonable range of sensitivities to all the cash-generating units, and after reflecting the impairments above, there was no indication of any further impairment.

In 2020, the Group also impaired in full the goodwill arising from the acquisitions of Twisp in South Africa and Blue Nile in Sudan due to difficult trading conditions in these markets. This resulted in the recognition of impairment charges of £11 million and £1 million, respectively.

(v) Impairment testing – Reynolds American

Goodwill relating to Reynolds American and the Newport and Camel trademarks

On 29 April 2021, the FDA reconfirmed its intention to issue a proposed product standard to ban menthol as a characterising flavour in cigarettes. Management notes that the FDA announcement does not itself constitute a ban on menthol in cigarettes, and any proposed regulation of menthol in cigarettes would need to be introduced through the established U.S. comprehensive rule-making process, the timetable and outcome for which was, and remains, uncertain. Management continues to believe that any ban, given the mechanisms and processes required to be followed in the U.S., is unlikely to be implemented within the next five years. In addition, it is unclear how any such potential U.S. regulation might affect the manufacture and marketing of Group combustible brands containing menthol. The base case scenario used in the impairment model therefore does not include any potential impact of changes in regulation in relation to menthol flavourings in combustibles within the five-year discrete forecast period. Any potential impacts have been captured within the terminal growth rate and discount rates applied.

The Group has a long-standing track record of managing regulatory shifts and, in the event of regulatory change, the Group remains confident in its ability to navigate that environment successfully.

Since 2018, having considered the combination of the risk of implementation and impact of any change in regulations, the Group has not recognised any impairment on either the Newport or Camel brands or the Reynolds American goodwill, as management concluded that there would not be a significant impact to the value-in-use.

The carrying amounts for Reynolds American goodwill, Newport and Camel brands intangibles were £33,021 million, £29,517 million and £12,485 million, respectively (2020: £32,719 million, £29,248 million and £12,371 million). The value-in-use calculations for brands, as described in note 12(a)(ii) above, have been incorporated in the base case scenario used in the Reynolds American goodwill model. The value-in-use calculations have been prepared based on a five-year cash flow forecast which assumes long-term volume decline of cigarettes. This decline is more than offset by pricing. After this forecast, a growth rate of 1% has been assumed for Reynolds American goodwill, 0.75% for Newport and 0.85% for Camel and a pre-tax discount rate of 8.4% (2020: 7.6%), 9.9% (2020: 8.3%) and 9.4% (2020: 8.3%), respectively.

209
12 Intangible Assets Continued

The excess of value-in-use earnings over the carrying values (headroom) of the Reynolds American goodwill and the Newport and Camel brands intangibles would be reduced to nil if the following individual changes, none of which are considered reasonably possible by management, were made to the key assumptions used in the impairment model.

<table>
<thead>
<tr>
<th>Assumptions</th>
<th>Reynolds American goodwill %</th>
<th>Newport %</th>
<th>Camel %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease in revenue by</td>
<td>7.2</td>
<td>15.1</td>
<td>15.2</td>
</tr>
<tr>
<td>Increase in pre-tax discount rate by</td>
<td>1.6</td>
<td>2.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Decrease in terminal value rate by</td>
<td>1.4</td>
<td>5.1</td>
<td>5.6</td>
</tr>
</tbody>
</table>

For Reynolds American goodwill, the change in revenue assumption is based on combustibles revenue in the five-year forecast reducing by 7.2% in each year and assumes that other assumptions are not changed. For Newport and Camel, the change in revenue assumption is based on the revenue in the five-year forecast reducing by 15.1% and 15.2%, respectively in each year and assumes that other assumptions are not changed.

(vi) Impairment testing – Canada

Goodwill relating to Imperial Tobacco Canada Ltd (ITCAN)

In March 2019, ITCAN obtained an Initial Order from the Ontario Superior Court of Justice granting it protection under the Companies’ Creditors Arrangement Act (CCAA). If the CCAA bankruptcy protection were to end, significant liabilities might crystallise. As a consequence, to reflect the risk to future operating cash flows, the value-in-use calculations have been prepared based on a five-year cash flow forecast, after which a growth rate of -2.5% and a pre-tax discount rate of 19.3% (2020: 19.1%) have been assumed. Further information on the Quebec Class Actions and CCAA can be found in note 31.

In addition to the increase in discount rate, a reasonable range of sensitivities was applied to the value-in-use calculation, and there was no indication of impairment.

The excess of value-in-use earnings over the carrying values (headroom) of the ITCAN goodwill would be reduced to nil if the following individual changes, none of which are considered reasonably possible by management, were made to the key assumptions used in the impairment model. The change in revenue assumption is based on combustibles revenue in the five-year forecast reducing by 27.4% in each year and assumes that other assumptions are not changed.

<table>
<thead>
<tr>
<th>Assumptions</th>
<th>Canada goodwill %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease in revenue by</td>
<td>27.4</td>
</tr>
<tr>
<td>Increase in pre-tax discount rate by</td>
<td>14.7</td>
</tr>
</tbody>
</table>

The £2,345 million of goodwill relating to ITCAN on the Group’s balance sheet at 31 December 2021 will continue to be reviewed on a regular basis. Any future impairment charge would result in a non-cash charge to the income statement that will be treated as an adjusting item.
## 13 Property, Plant and Equipment

(a) Overview of property, plant and equipment, including right-of-use assets

<table>
<thead>
<tr>
<th></th>
<th>Freehold property £m</th>
<th>Leasehold property £m</th>
<th>Plant, equipment and other owned £m</th>
<th>Plant, equipment and other leased £m</th>
<th>Assets in the course of construction £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 January</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>1,518</td>
<td>798</td>
<td>5,807</td>
<td>217</td>
<td>764</td>
<td>9,104</td>
</tr>
<tr>
<td>Accumulated depreciation and impairment</td>
<td>(444)</td>
<td>(319)</td>
<td>(2,179)</td>
<td>(110)</td>
<td>(4,044)</td>
<td>(6,642)</td>
</tr>
<tr>
<td><strong>Net book value at 1 January</strong></td>
<td>1,074</td>
<td>483</td>
<td>2,632</td>
<td>197</td>
<td>764</td>
<td>5,050</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(23)</td>
<td>(22)</td>
<td>(135)</td>
<td>(5)</td>
<td>(18)</td>
<td>(203)</td>
</tr>
<tr>
<td>Additions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– right-of-use assets</td>
<td>–</td>
<td>88</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>164</td>
</tr>
<tr>
<td>– separately acquired</td>
<td>–</td>
<td>1</td>
<td>45</td>
<td>–</td>
<td>508</td>
<td>554</td>
</tr>
<tr>
<td>Reallocations</td>
<td>44</td>
<td>51</td>
<td>441</td>
<td>1</td>
<td>(537)</td>
<td>–</td>
</tr>
<tr>
<td>Depreciation</td>
<td>(35)</td>
<td>(110)</td>
<td>(303)</td>
<td>(57)</td>
<td>(505)</td>
<td>–</td>
</tr>
<tr>
<td>Impairment</td>
<td>(4)</td>
<td>(2)</td>
<td>(37)</td>
<td>–</td>
<td>(11)</td>
<td>(54)</td>
</tr>
<tr>
<td>Right-of-use assets – reassessments, modifications and terminations</td>
<td>–</td>
<td>(11)</td>
<td>–</td>
<td>(5)</td>
<td>–</td>
<td>(16)</td>
</tr>
<tr>
<td>Disposals</td>
<td>(7)</td>
<td>(1)</td>
<td>(12)</td>
<td>–</td>
<td>–</td>
<td>(20)</td>
</tr>
<tr>
<td>Net reclassifications as held-for-sale</td>
<td>(16)</td>
<td>–</td>
<td>(11)</td>
<td>–</td>
<td>–</td>
<td>(27)</td>
</tr>
<tr>
<td><strong>31 December</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>1,421</td>
<td>847</td>
<td>5,750</td>
<td>247</td>
<td>706</td>
<td>8,971</td>
</tr>
<tr>
<td>Accumulated depreciation and impairment</td>
<td>(388)</td>
<td>(370)</td>
<td>(3,130)</td>
<td>(130)</td>
<td>(4,018)</td>
<td>(7,218)</td>
</tr>
<tr>
<td><strong>Net book value at 31 December</strong></td>
<td>1,033</td>
<td>417</td>
<td>2,620</td>
<td>117</td>
<td>706</td>
<td>4,953</td>
</tr>
</tbody>
</table>

Refer to notes 4 and 7 for more information on property, plant and equipment impairments. The £27 million (2020: £nil) of assets reclassified as held-for-sale primarily relates to the disposal of the Iranian subsidiary, BAT Pars, as disclosed on note 27(d).

The Group has £30 million of future contractual commitments (2020: £110 million) related to property, plant and equipment.
13 Property, Plant and Equipment Continued

(b) Right-of-use assets
In accordance with IFRS 16 Leases, the right-of-use assets related to leased properties have been included in the asset class ‘Leasehold Property’ (note 13(c)) and other right-of-use assets have been reported under ‘Plant, equipment and other leased’.

The Group leases various offices, warehouses, retail spaces, equipment and vehicles through its subsidiaries across the globe. Arrangements are entered into in the course of ordinary business, and lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions reflecting local commercial practice. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

Assets representing ‘plant, equipment and other’ relate to leases of various assets including tobacco vending machines, industrial equipment and distribution vehicles in Brazil, Japan, Pakistan, Poland, Romania, Switzerland, U.S. and other countries.

(c) Leasehold property
As of 31 December 2021, the Group holds £165 million (2020: £132 million) of leasehold properties acquired and another £312 million (2020: £351 million) of right-of-use leased properties.

Assets representing ‘leasehold property’ relate to leases in respect of offices, retail space, warehouses and manufacturing facilities occupied by Group subsidiaries and include property leases with lease terms of more than five years in Brazil, Bangladesh, Germany, Mexico, Romania, Singapore and Vietnam, amongst other countries. In addition, capitalised expenditure representing leasehold improvements is included in this asset class.

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold property net book value movements for the year ended 31 December 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Net book value at 1 January £m</td>
<td>Differences on exchange £m</td>
</tr>
<tr>
<td>Property acquired (IAS16)</td>
<td>132</td>
<td>(8)</td>
</tr>
<tr>
<td>Right-of-use properties (IFRS16)</td>
<td>351</td>
<td>(14)</td>
</tr>
<tr>
<td></td>
<td>483</td>
<td>(22)</td>
</tr>
</tbody>
</table>

Leasehold property net book value movements for the year ended 31 December 2020

<table>
<thead>
<tr>
<th></th>
<th>2020 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold property net book value movements for the year ended 31 December 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Net book value at 1 January £m</td>
<td>Differences on exchange £m</td>
</tr>
<tr>
<td>Property acquired (IAS16)</td>
<td>135</td>
<td>(6)</td>
</tr>
<tr>
<td>Right-of-use properties (IFRS16)</td>
<td>421</td>
<td>(19)</td>
</tr>
<tr>
<td></td>
<td>556</td>
<td>(25)</td>
</tr>
</tbody>
</table>

* Property acquired (IAS 16 Property, plant and equipment) other net movements represent additions (directly acquired and/or transferred from assets in the course of construction) net of disposals, whereas the right-of-use properties (IFRS 16) other net movements relates to new leases net of reassessments, modifications and terminations as reported in the Property, plant and equipment movement table in note 13(a). Other net movements also includes £nil (2020: £1 million) in relation to acquired companies.

(d) Freehold property
As of 31 December 2021, the Group owns freehold property amounting to £1,033 million (2020: £1,074 million), representing factories, warehouses and office buildings together with adjoining land, mainly in the U.S., UK, Bangladesh, Indonesia and South Korea.

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of freehold land within freehold property on which no depreciation is provided</td>
<td>242</td>
<td>251</td>
</tr>
</tbody>
</table>

212
14 Investments in Associates and Joint Ventures

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 January</td>
<td>1,796</td>
<td>1,860</td>
</tr>
<tr>
<td>Total comprehensive income (note 9)</td>
<td>412</td>
<td>323</td>
</tr>
<tr>
<td>Dividends</td>
<td>(392)</td>
<td>(394)</td>
</tr>
<tr>
<td>Additions (note 27(c))</td>
<td>130</td>
<td>5</td>
</tr>
<tr>
<td>Other equity movements</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>31 December</td>
<td>1,948</td>
<td>1,796</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>1,286</td>
<td>1,021</td>
</tr>
<tr>
<td>Current assets</td>
<td>1,144</td>
<td>1,155</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>(83)</td>
<td>(61)</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>(399)</td>
<td>(319)</td>
</tr>
<tr>
<td></td>
<td>1,948</td>
<td>1,796</td>
</tr>
<tr>
<td>ITC Ltd. (Group’s share of the market value is £7,839 million (2020: £7,574 million))</td>
<td>1,759</td>
<td>1,724</td>
</tr>
<tr>
<td>Other listed associates (Group’s share of the market value is £232 million (2020: £184 million))</td>
<td>154</td>
<td>26</td>
</tr>
<tr>
<td>Unlisted associates</td>
<td>35</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>1,948</td>
<td>1,796</td>
</tr>
</tbody>
</table>

The principal associate undertaking of the Group is ITC Ltd. (ITC). Included within the dividends amount of £392 million (2020: £394 million) are £383 million (2020: £386 million) attributable to dividends declared by ITC.

Organigram Inc.
On 11 March 2021, the Group announced a strategic collaboration agreement with Organigram Inc., a wholly owned subsidiary of publicly traded Organigram Holdings Inc. (collectively, Organigram). Under the terms of the transaction, a Group subsidiary acquired a 19.9% equity stake in Organigram Holdings Inc. (listed on both the Nasdaq and Toronto Stock Exchange under the symbol ‘OGI’) to become its largest shareholder.

The Group’s share of the fair value of net assets acquired included £49 million of intangibles and £30 million of goodwill, representing a strategic premium to enter the legal cannabis market in North America.

The carrying value of the investment at 31 December 2021 is £125 million, which is higher than the value implied by the market price of individual shares at that date. Due to the likelihood of short-term volatility in the share price, third-party valuations were considered which indicate a valuation for the Group’s investment in excess of the current carrying value. Any potential impairment of the investment would be immaterial to the Group. Management will continue to monitor the carrying value, in line with IAS 36, over the course of future periods.

Tisak d.d.
The Group’s investment in Tisak d.d. (Tisak) was acquired as part of the TDR transaction (note 27). During 2016, the Group entered into an agreement with Tisak’s parent Agrokor d.d. (Agrokor) to convert certain outstanding trading balances into long-term loans and an additional shareholding in Tisak. As part of the agreement, Agrokor had the right to reacquire the additional shareholding in Tisak. As a consequence of this, while the Group had legal ownership of the additional shareholding, it did not consider that the shares provided any additional equity interest and continued to account for 26% of the equity of Tisak. In 2017, due to the financial difficulties of Agrokor and Tisak, the Group fully impaired this investment resulting in a charge of £27 million to the income statement in that year that was reported as an adjusting item. In July 2018, Agrokor’s creditors approved a settlement plan proposed by Agrokor’s administrators. The settlement plan has not returned any value to the Group, and Tisak was liquidated on 21 September 2021.
Financial Statements

Notes on Accounts

Continued

14 Investments in Associates and Joint Ventures

Continued

ITC Ltd.

ITC is an Indian conglomerate based in Kolkata and maintains a presence in cigarettes, hotels, paper and packaging, agri-business and other fast-moving goods (e.g. confectionery, branded apparel, personal care, stationery and safety matches). BAT’s interest in ITC is 29.38%.

ITC prepares accounts on a quarterly basis with a 31 March year-end. As permitted by IAS 28 Investments in associates and joint ventures, results up to 30 September 2021 have been used in applying the equity method. This is driven by the availability of information at the half-year, to be consistent with the treatment in the Group’s interim accounts. Any further information available after the date used for reporting purposes is reviewed and any material items adjusted for in the final results. The latest published information available is at 31 December 2021.

15 Retirement Benefit Schemes

The Group operates various funded and unfunded defined benefit schemes, including pension and post-retirement healthcare schemes, and defined contribution pension schemes through its subsidiary undertakings in multiple jurisdictions, with its most significant arrangements being in the U.S., UK, Canada, Germany, Switzerland and the Netherlands. Together, schemes in these territories account for over 90% of the total underlying obligations of the Group’s defined benefit arrangements and over 70% of the defined benefit net costs charged to adjusted profit.

Pension obligations consist mainly of final salary pension schemes which provide benefits to members in the form of a guaranteed level of pension payable for life. The level of benefits provided depends on members’ length of service and their salary in the final years leading up to retirement. In addition, the Group operates several healthcare benefit schemes, of which the most significant are in the U.S. and Canada. The majority of defined benefit schemes allow for the future accrual of benefits. With the exception of arrangements required under local regulations, most of the Group’s arrangements are closed to new entrants.

Benefits provided through defined contribution schemes are charged as an expense as payments fall due. The liabilities arising in respect of defined benefit schemes are determined in accordance with the advice of independent, professionally qualified actuaries, using the projected unit credit method. It is Group policy that all schemes are formally valued at least every three years.

Through its defined benefit pension schemes and healthcare benefit schemes, the Group is exposed to a number of risks, including:

- **Asset volatility**: The scheme liabilities are calculated using discount rates set by reference to bond yields. If scheme assets underperform this yield, e.g. due to stock market volatility, this will create a deficit. However, most funded schemes hold a proportion of assets which are expected to outperform bonds in the long term, and the majority of schemes by value are subject to local regulation regarding funding deficits.

- **Changes in bond yields**: A decrease in corporate bond yields will increase scheme liabilities, although this will be partially offset by an increase in the value of the schemes’ bond holdings, ‘buy-in’ insurance assets or other hedging instruments.

- **Inflation risk**: Some of the Group’s pension obligations are linked to inflation, and higher inflation will lead to higher liabilities, although in most cases, caps on the level of inflationary increases are in place in the scheme rules, while some assets and derivatives provide specific inflation protection.

- **Life expectancy**: The majority of the schemes’ obligations are to provide benefits for the life of the member, so increases in life expectancy will result in an increase in the plans’ liabilities. Assumptions regarding mortality and mortality improvements are regularly reviewed in line with actuarial tables and scheme specific experience.

The Group has an internal body, the Pensions Executive Committee (PEC), that is chaired by the Finance and Transformation Director. The PEC sets and oversees a set of philosophies, policies and practices in respect of post-employment benefits including, but not limited to, design, funding, investment strategy, risk management and governance. It also reviews significant changes to defined benefit schemes in the countries with the most significant liabilities, and defined contribution schemes in the countries with the most significant costs. Significant changes to defined benefit arrangements include scheme closures to future accrual and risk management exercises such as the ‘buy-in’ and ‘buy-out’ transactions referred to below.

A ‘buy-out’ transaction is where a pension scheme derecognises all (or part) of its liabilities, removing it from the balance sheet, by permanently transferring those obligations from the sponsoring employer to a third-party provider and eliminating all further legal or constructive obligation to the pension scheme or to the sponsoring employer. By contrast, with a ‘buy-in’ transaction the scheme liabilities remain on the balance sheet and the sponsoring employer remains responsible for the fulfillment of the pension obligations. However, these obligations are de-risked through the purchase of an insurance product designed to match the underlying cash flows of the pension liability reducing the risks associated with improved longevity and interest and discount rate movements. The Group consequently benefits from the ‘buy-in’ as it reduces the individual scheme’s reliance on the Group for future cash funding requirements.

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>3,889</td>
<td>3,399</td>
</tr>
<tr>
<td>Current assets</td>
<td>3,391</td>
<td>3,513</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>(231)</td>
<td>(194)</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>(1,061)</td>
<td>(858)</td>
</tr>
<tr>
<td></td>
<td>5,988</td>
<td>5,860</td>
</tr>
</tbody>
</table>

Group’s share of ITC Ltd. (2021: 29.38%; 2020: 29.42%)

1,759

1,724

Notes on Accounts Continued
Under the UKPF scheme rules, the Trustee does not have a unilateral power to commence a wind up of UKPF, and the Group has recognised a surplus as an

benefits. Contributions were £21 million in 2020 and £30 million in 2019.

but is committed to pay £18 million in July 2022 and £18 million in July 2023 as contributions towards further de-risking of UKPF’s assets and securing members’

2020. This schedule was subsequently replaced with a new Schedule with an effective date of 30 March 2021, such that the Group made no contributions in 2021

Following the completion of the valuation noted above, the Trustee and the Group agreed a new Schedule of Contributions with an effective date of 5 October

retirement benefit asset of £293 million (2020: £389 million).

The formal triennial actuarial valuation of the UKPF was last carried out with an effective date of 31 March 2020. This showed that UKPF had a surplus of

215 Retirement Benefit Schemes Continued

All of the Group’s arrangements, including funded schemes where formal trusts or equivalents are required, have been developed and are operated in accordance

with local practices and regulations where applicable in the countries concerned. Responsibility for the governance of these schemes, including specific investment

decisions and funding contribution schedules, generally lies with the trustees, or equivalent bodies, of each arrangement. The trustees will usually consist of

representatives appointed by both the sponsoring company and the beneficiaries.

The funded arrangements in the Group have policies on investment management, including strategies over a preferred long-term investment profile, and schemes

in certain territories including Canada and the Netherlands manage their bond portfolios to match the weighted average duration of scheme liabilities. In addition,

as noted below, certain arrangements in the UK and Canada have been de-risked through the purchase of insurance policies. The majority of funded schemes are

subject to local regulations regarding funding requirements. Contributions to defined benefit schemes are determined after consultation with the respective trustees

and actuaries of the individual externally funded schemes, and after taking into account regulatory requirements in each territory. The Group’s contributions to

funded defined benefit schemes in 2022 in total are expected to be £83 million compared to £74 million in 2021.

U.S.

In the U.S., the main funded pension plans are the Reynolds American Retirement Plan (PEP) and the Retirement Income Plan for Certain RAI Affiliates

(Affiliates), and the only funded healthcare scheme is the Brown & Williamson Tobacco Corporation Welfare & Fringe Benefit Plan, all of which are established with

corporate trustees that are required to run the plans in accordance with the plan’s rules and to comply with all relevant legislation, including the Employee


The corporate trustees act as custodians with a committee of local management acting in a fiduciary capacity with regard to investment decisions, risk mitigation

and administration of the arrangements. Contributions to the various funded plans are agreed with the named fiduciary, scheme actuaries and the committee of

local management after taking account of statutory requirements including the Pension Protection Act of 2008, as amended. Through its U.S. subsidiaries, the

Group may make significant contributions, either as required by statutory requirements or at the discretion of the Group, with the aim of maintaining a funding

status of at least 90%, and remaining fully funded in the long term. During 2021, the Group did not contribute to its funded pension and post-retirement plans in the

U.S. and does not expect to do so in 2022.

For funded plans in the U.S., the trustees employ a risk mitigation strategy which seeks to balance pension plan returns with a reasonable level of funded status

volatility. Based on this framework, the asset allocation has two primary components. The first component is the hedging portfolio, which uses extended duration

fixed income holdings (typically U.S. Government and investment grade corporate bonds) and, to a lesser extent, derivatives to match a portion of the interest rate

risk associated with the benefit obligations, thereby reducing expected funded status volatility. The second component is the return-seeking portfolio, which is
designed to enhance portfolio returns. The return-seeking portfolio is broadly diversified across asset classes.

On 7 October 2021, the Group concluded a transaction affecting portions of the membership of the PEP and the Affiliates plans referred to above, allowing the

Group to fully settle portions of its liability by transferring the obligations to the Metropolitan Tower Life Insurance Company in a buy-out. Approximately US$1 billion

(£1.4 billion) of plan liabilities have been removed from the balance sheet, resulting in a settlement gain of £35 million.

At 31 December 2021, the PEP and Affiliates plans referred to above were reporting surpluses under IAS 19 totalling £463 million (2020: £232 million). Under the

rules of these plans, after assuming the gradual settlement of the plan liabilities over the lives of the arrangements, any surplus would be returnable to the Group in

the event of a termination or could otherwise be repurposed for other existing or replacement benefit plans, and accordingly, no surplus restrictions have been

recognised.

United Kingdom

In the U.K., the main pension arrangement is the British American Tobacco UK Pension Fund (UKPF), which is established under trust law and has a corporate

trustee that is required to run the scheme in accordance with the UKPF’s Trust Deed and Rules and to comply with the Pension Scheme Act 1993, Pensions Act

1995, Pensions Act 2004 and all other relevant legislation. With effect from 1 July 2020, UKPF was closed to further accrual of benefits with all active members

becoming deferred members. A past service credit was recognised on the difference between the salary increase assumption for active members and the inflation

assumption for deferred members at the date of the plan amendment and curtailment of benefits.

The formal triennial actuarial valuation of the UKPF was last carried out with an effective date of 31 March 2020. This showed that UKPF had a surplus of

£139 million on a Technical Provisions basis, in accordance with the statutory funding objective. The Trustee also has a Long-Term Funding Target to be fully

funded on a Solvency Liabilities basis by 2026, and on this basis UKPF had a surplus of £7 million at the valuation date. Under IAS 19, this was reported as a net


Following the completion of the valuation noted above, the Trustee and the Group agreed a new Schedule of Contributions with an effective date of 5 October

2020. This schedule was subsequently replaced with a new Schedule with an effective date of 30 March 2021, such that the Group made no contributions in 2021

but is committed to pay £18 million in July 2022 and £18 million in July 2023 as contributions towards further de-risking of UKPF’s assets and securing members’

benefits. Contributions were £21 million in 2020 and £30 million in 2019.

Under the UKPF scheme rules, the Trustee does not have a unilateral power to commence a wind up of UKPF; and the Group has recognised a surplus as an

unconditional right to a refund assuming the gradual settlement of the UKPF liabilities over the life of the scheme with any future surplus returnable to the Group at

the end of the life of the scheme. The funding commitment is not considered onerous and no additional liabilities or surplus restrictions have been recognised.
Financial Statements
Notes on Accounts

15 Retirement Benefit Schemes Continued

As part of its risk management strategy, on 31 May 2019, the UK Trustee entered into a buy-in agreement with Pension Insurance Corporation plc (‘PIC’) to acquire an insurance policy with the intent of matching a specific part of UKPF’s future cash flows arising from the accrued pension liabilities of retired and deferred members and improving the security to the UKPF and its members. On an IAS 19 basis, the subsequent fair value of the insurance policy matches the present value of the liabilities being insured. On 19 May 2021, the Trustee entered into an agreement with PIC to acquire a second buy-in policy which involved the transfer of £383 million of assets held by UKPF to PIC. As a result of these transactions, approximately 84% of the assets held by UKPF (2020: 75%) are represented by the buy-in contracts, covering 91% of UKPF’s liabilities (2020: 83%).

For the residual assets held by UKPF, the current allocation is broadly split as 75% in risk reducing assets and 25% in return seeking assets. The return seeking portfolio is invested in illiquid assets which, in the normal course of events, will wind down naturally over time, with their value being realised as the investments mature. This is consistent with the Trustee’s ultimate target which is to be 100% invested in risk reducing assets or matching assets. Given the strong funding position of UKPF as shown in the 31 March 2020 Actuarial valuation, the Trustee will continue to review the investment strategy and may look to increase the proportion of risk-reducing or matching assets, commensurate with their ultimate target to further reduce UKPF’s exposure to asset volatility.

Other territories
Payments made to pensioners by the operating companies in Germany, net of income on scheme assets, are deemed to be company contributions to the Contractual Trust Arrangements and are anticipated to be around £37 million in 2022 and £33 million per annum for the four years after that. Contributions to pension schemes in Canada, Netherlands and Switzerland in total are anticipated to be around £11 million in 2022 and then also around £11 million per annum for the four years after that.

For schemes in the Netherlands reporting surpluses of £77 million (2020: £26 million), these surpluses have been recognised as an unconditional right to a refund assuming the gradual settlement of the pension liabilities over the life of the scheme, with any future surplus returnable to the Group at the end of the life of the scheme. For schemes in surplus in Canada of £27 million (2020: £19 million), the economic benefit has been calculated as a combination of the expected level of administration expenses which may be charged to the plan assets in accordance with the plan rules, which economically represents a potential surplus refund, and the value of the employer reserve account as defined in legislation, which represents a potential reduction in contributions on an ongoing basis or a surplus refund at the end of the life of the scheme.

On 2 September 2021, the Group through its Canadian subsidiaries entered into a buy-in agreement with five insurers to acquire insurance policies that operate as Contractual Trust Arrangements and are anticipated to be around £37 million in 2022 and £33 million per annum for the four years after that. Contributions to pension schemes in Canada, Netherlands and Switzerland in total are anticipated to be around £11 million in 2022 and then also around £11 million per annum for the four years after that.

For schemes in the Netherlands reporting surpluses of £77 million (2020: £26 million), these surpluses have been recognised as an unconditional right to a refund assuming the gradual settlement of the pension liabilities over the life of the scheme, with any future surplus returnable to the Group at the end of the life of the scheme. For schemes in surplus in Canada of £27 million (2020: £19 million), the economic benefit has been calculated as a combination of the expected level of administration expenses which may be charged to the plan assets in accordance with the plan rules, which economically represents a potential surplus refund, and the value of the employer reserve account as defined in legislation, which represents a potential reduction in contributions on an ongoing basis or a surplus refund at the end of the life of the scheme.

Unfunded arrangements
The majority of benefit payments are from trustee administered funds, however, there are also a number of unfunded schemes where the sponsoring company meets the benefit payment obligation as it falls due, including UK-based Defined Benefit and Defined Contribution Unapproved Unfunded Retirement Benefit Schemes (DB UURBS and DC UURBS respectively). The DC UURBS credits accrued in the year are increased in line with the Company’s Weighted Average Cost of Debt and the scheme is therefore treated as a defined benefit scheme under IAS 19. For unfunded pension schemes in the U.S. and UK, 3% of the liabilities reported at year-end are expected to be settled by the Group within 10 years, 28% between 10 and 20 years, 19% between 20 and 30 years, and 15% thereafter. For unfunded healthcare schemes in the U.S. and Canada, 63% of the liabilities reported at year-end are expected to be settled by the Group within 10 years, 27% between 10 and 20 years, 8% between 20 and 30 years, and 2% thereafter.

The amounts recognised in the balance sheet are determined as follows:

<table>
<thead>
<tr>
<th>Pension schemes</th>
<th>Healthcare schemes</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021 £m</td>
<td>2020 £m</td>
<td>2021 £m</td>
</tr>
<tr>
<td>Present value of funded scheme liabilities</td>
<td>(9,859)</td>
<td>(11,970)</td>
</tr>
<tr>
<td>Fair value of funded scheme assets</td>
<td>10,644</td>
<td>12,403</td>
</tr>
<tr>
<td>Unrecognised funded scheme surpluses</td>
<td>765</td>
<td>433</td>
</tr>
<tr>
<td>(16)</td>
<td>(16)</td>
<td>-</td>
</tr>
<tr>
<td>(769)</td>
<td>417</td>
<td>(53)</td>
</tr>
<tr>
<td>(555)</td>
<td>(602)</td>
<td>(482)</td>
</tr>
<tr>
<td>214</td>
<td>(185)</td>
<td>(535)</td>
</tr>
</tbody>
</table>

The above net (liability)/asset is recognised in the balance sheet as follows:

- retirement benefit scheme liabilities | (702) | (897) | (537) | (627) | (1,239) | (1,524) |
- retirement benefit scheme assets | 916 | 712 | 2 | 2 | 918 | 714 |

214 | (185) | (535) | (625) | (321) | (810) |
15 Retirement Benefit Schemes Continued

The net liabilities of funded pension schemes by territory are as follows:

<table>
<thead>
<tr>
<th>Territory</th>
<th>Liabilities 2021 £m</th>
<th>Liabilities 2020 £m</th>
<th>Assets 2021 £m</th>
<th>Assets 2020 £m</th>
<th>Total 2021 £m</th>
<th>Total 2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>(3,378)</td>
<td>(5,012)</td>
<td>3,748</td>
<td>5,144</td>
<td>370</td>
<td>132</td>
</tr>
<tr>
<td>UK</td>
<td>(3,357)</td>
<td>(3,485)</td>
<td>3,645</td>
<td>3,866</td>
<td>288</td>
<td>381</td>
</tr>
<tr>
<td>Germany</td>
<td>(913)</td>
<td>(1,035)</td>
<td>896</td>
<td>918</td>
<td>(17)</td>
<td>(117)</td>
</tr>
<tr>
<td>Canada</td>
<td>(706)</td>
<td>(756)</td>
<td>724</td>
<td>758</td>
<td>18</td>
<td>2</td>
</tr>
<tr>
<td>Netherlands</td>
<td>(769)</td>
<td>(873)</td>
<td>846</td>
<td>893</td>
<td>77</td>
<td>20</td>
</tr>
<tr>
<td>Switzerland</td>
<td>(317)</td>
<td>(348)</td>
<td>311</td>
<td>312</td>
<td>(6)</td>
<td>(36)</td>
</tr>
<tr>
<td>Rest of Group</td>
<td>(419)</td>
<td>(461)</td>
<td>474</td>
<td>512</td>
<td>55</td>
<td>51</td>
</tr>
<tr>
<td><strong>Funded schemes</strong></td>
<td><strong>(9,859)</strong></td>
<td><strong>(11,970)</strong></td>
<td><strong>10,644</strong></td>
<td><strong>12,403</strong></td>
<td><strong>785</strong></td>
<td><strong>433</strong></td>
</tr>
</tbody>
</table>

Of the Group’s unfunded pension schemes, 57% (2020: 54%) relate to arrangements in the UK and 32% (2020: 32%) relate to arrangements in the U.S., while 85% (2020: 85%) of the Group’s unfunded healthcare arrangements relate to arrangements in the U.S.

The amounts recognised in the income statement are as follows:

<table>
<thead>
<tr>
<th>Scheme Type</th>
<th>Liabilities 2021 £m</th>
<th>Liabilities 2020 £m</th>
<th>Assets 2021 £m</th>
<th>Assets 2020 £m</th>
<th>Total 2021 £m</th>
<th>Total 2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pension schemes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Service cost</td>
<td>60</td>
<td>72</td>
<td>2</td>
<td>2</td>
<td>62</td>
<td>74</td>
</tr>
<tr>
<td>– Past service cost</td>
<td>(29)</td>
<td>(12)</td>
<td>–</td>
<td>–</td>
<td>(29)</td>
<td>(12)</td>
</tr>
<tr>
<td>Interest on scheme liabilities</td>
<td>226</td>
<td>300</td>
<td>19</td>
<td>27</td>
<td>245</td>
<td>327</td>
</tr>
<tr>
<td>– Interest on scheme assets</td>
<td>(226)</td>
<td>(289)</td>
<td>(5)</td>
<td>(7)</td>
<td>(231)</td>
<td>(296)</td>
</tr>
<tr>
<td>– Interest on unfunded funded scheme surpluses</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Defined contribution schemes</td>
<td>32</td>
<td>72</td>
<td>16</td>
<td>22</td>
<td>48</td>
<td>94</td>
</tr>
<tr>
<td><strong>Total amount recognised in the income statement</strong> (note 3)</td>
<td>123</td>
<td>160</td>
<td>16</td>
<td>22</td>
<td>139</td>
<td>182</td>
</tr>
</tbody>
</table>

The above changes are recognised within employee benefit costs in note 3 and include a credit of £23 million in 2021 (2020: charge of £10 million) in respect of settlements, past service costs and defined contribution costs reported as part of the restructuring costs and other adjusting items charged in arriving at profit from operations (note 7). Included in current service cost in 2021 is £15 million (2020: £16 million) of administration costs. Current service cost is stated after netting employee contributions, where applicable.

The movements in scheme liabilities are as follows:

<table>
<thead>
<tr>
<th>Scheme Type</th>
<th>Liabilities 2021 £m</th>
<th>Liabilities 2020 £m</th>
<th>Assets 2021 £m</th>
<th>Assets 2020 £m</th>
<th>Total 2021 £m</th>
<th>Total 2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present value at 1 January</td>
<td>12,572</td>
<td>12,032</td>
<td>798</td>
<td>829</td>
<td>13,370</td>
<td>12,861</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(122)</td>
<td>(106)</td>
<td>5</td>
<td>(23)</td>
<td>(117)</td>
<td>(129)</td>
</tr>
<tr>
<td>Current service cost</td>
<td>60</td>
<td>72</td>
<td>2</td>
<td>2</td>
<td>62</td>
<td>74</td>
</tr>
<tr>
<td>Past service credit and settlements</td>
<td>(1,426)</td>
<td>(58)</td>
<td>–</td>
<td>–</td>
<td>(1,426)</td>
<td>(58)</td>
</tr>
<tr>
<td>Interest on scheme liabilities</td>
<td>226</td>
<td>300</td>
<td>19</td>
<td>27</td>
<td>245</td>
<td>327</td>
</tr>
<tr>
<td>Contributions by scheme members</td>
<td>3</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Benefits paid (705)</td>
<td>(705)</td>
<td>(737)</td>
<td>(55)</td>
<td>(58)</td>
<td>(760)</td>
<td>(765)</td>
</tr>
<tr>
<td>Actuarial losses/gains</td>
<td>– arising from changes in demographic assumptions</td>
<td>147</td>
<td>26</td>
<td>3</td>
<td>(7)</td>
<td>150</td>
</tr>
<tr>
<td>– arising from changes in financial assumptions</td>
<td>(384)</td>
<td>1,032</td>
<td>(18)</td>
<td>59</td>
<td>(412)</td>
<td>1,091</td>
</tr>
<tr>
<td>Experience losses/gains</td>
<td>53</td>
<td>10</td>
<td>(47)</td>
<td>(31)</td>
<td>6</td>
<td>(21)</td>
</tr>
<tr>
<td>Present value at 31 December</td>
<td>10,414</td>
<td>12,572</td>
<td>707</td>
<td>798</td>
<td>11,121</td>
<td>13,370</td>
</tr>
</tbody>
</table>

Changes in financial assumptions principally relate to discount rate movements in both years. Past service and settlements in the table above includes amounts relating to the U.S. buy-out transaction during the year.
### Financial Statements

#### Notes on Accounts

**15 Retirement Benefit Schemes Continued**

Scheme liabilities by scheme membership:

<table>
<thead>
<tr>
<th></th>
<th>Pension schemes</th>
<th>Healthcare schemes</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021 £m</td>
<td>2020 £m</td>
<td>2021 £m</td>
</tr>
<tr>
<td>Active members</td>
<td>1,090</td>
<td>1,305</td>
<td>41</td>
</tr>
<tr>
<td>Deferred members</td>
<td>1,750</td>
<td>1,897</td>
<td>1</td>
</tr>
<tr>
<td>Retired members</td>
<td>7,574</td>
<td>9,370</td>
<td>665</td>
</tr>
<tr>
<td><strong>Present value at 31 December</strong></td>
<td><strong>10,414</strong></td>
<td><strong>12,572</strong></td>
<td><strong>707</strong></td>
</tr>
</tbody>
</table>

Approximately 95% of scheme liabilities in both years relate to guaranteed benefits.

The movements in funded scheme assets are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Pension schemes</th>
<th>Healthcare schemes</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021 £m</td>
<td>2020 £m</td>
<td>2021 £m</td>
</tr>
<tr>
<td>Fair value of scheme assets at 1 January</td>
<td>12,403</td>
<td>11,682</td>
<td>173</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(116)</td>
<td>(117)</td>
<td>–</td>
</tr>
<tr>
<td>Settlements</td>
<td>(1,397)</td>
<td>(45)</td>
<td>–</td>
</tr>
<tr>
<td>Interest on scheme assets</td>
<td>226</td>
<td>289</td>
<td>5</td>
</tr>
<tr>
<td>Company contributions</td>
<td>74</td>
<td>103</td>
<td>–</td>
</tr>
<tr>
<td>Contributions by scheme members</td>
<td>3</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(668)</td>
<td>(696)</td>
<td>(13)</td>
</tr>
<tr>
<td>Actuarial gains</td>
<td>119</td>
<td>1,184</td>
<td>7</td>
</tr>
<tr>
<td><strong>Fair value of scheme assets at 31 December</strong></td>
<td><strong>10,644</strong></td>
<td><strong>12,403</strong></td>
<td><strong>172</strong></td>
</tr>
</tbody>
</table>

The actuarial gains and losses in both years principally relate to movements in the fair values of scheme assets including revaluations on initial recognition and subsequent remeasurement of insurance assets acquired in the buy-in transactions referred to above. Actual returns are stated net of applicable taxes and fund management fees. Past service and settlements in the table above includes amounts relating to the U.S. buy-out transaction during the year.

Scheme assets have been diversified into equities, bonds and other assets and are typically invested via fund investment managers into both pooled and segregated mandates of listed and unlisted equities and bonds.

<table>
<thead>
<tr>
<th></th>
<th>Pension schemes</th>
<th>Healthcare schemes</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021 £m</td>
<td>2020 £m</td>
<td>2021 £m</td>
</tr>
<tr>
<td>Equities – listed</td>
<td>741</td>
<td>1,259</td>
<td>6</td>
</tr>
<tr>
<td>Equities – unlisted</td>
<td>892</td>
<td>992</td>
<td>65</td>
</tr>
<tr>
<td>Bonds – listed</td>
<td>1,929</td>
<td>2,432</td>
<td>5</td>
</tr>
<tr>
<td>Bonds – unlisted</td>
<td>1,924</td>
<td>3,163</td>
<td>72</td>
</tr>
<tr>
<td>Other assets – listed</td>
<td>543</td>
<td>202</td>
<td>15</td>
</tr>
<tr>
<td>Other assets – unlisted</td>
<td>4,615</td>
<td>4,305</td>
<td>9</td>
</tr>
<tr>
<td><strong>Fair value of scheme assets at 31 December</strong></td>
<td><strong>10,644</strong></td>
<td><strong>12,403</strong></td>
<td><strong>172</strong></td>
</tr>
</tbody>
</table>

In the above analysis, investments via equity-based investment funds are shown under listed equities, and investments via bond-based investment funds are shown under listed bonds. Other assets include insurance contracts, cash and other deposits, derivatives and other hedges, recoverable taxes, infrastructure investments and investment property.

In the U.S., pension plan assets are invested using active investment strategies and multiple investment management firms. Managers within each asset class cover a range of investment styles and approaches. Allowable investment types include global equity, fixed income, real assets, private equity and absolute return. The range of allowable investment types utilised for pension assets provides enhanced returns and more widely diversifies the plan.

As noted above, during 2021 and 2019, the UKPF Trustee acquired insurance policies that operate as a UK Fund investment asset in a buy-in transaction. The residual assets now predominantly consist of liability driven investments and absolute return funds as well as a proportion of illiquid investments, such as private equity and infrastructure investments. Insurance policies acquired in buy-in transactions in the UK and Canada are included within ‘other assets-unlisted’ in the table above.
15 Retirement Benefit Schemes Continued

The fair values of listed scheme assets were derived from observable data including quoted market prices and other market data, including market values of individual segregated investments and of pooled investment funds where quoted. The fair value of buy-in insurance products was estimated as the present value of the underlying obligations covered by the insurance policy. The fair values of other unlisted assets were derived from cash flow projections of estimated future income after taking into account the estimated recoverable value of these assets.

The recognition of retirement benefit surpluses on the balance sheet is restricted where the economic benefit, in the form of a potential refund or reduction in future contributions, has a present value which is less than the net assets of the scheme. The movements in the unrecognised scheme surpluses, recognised in other comprehensive income, are as follows:

<table>
<thead>
<tr>
<th>Pension schemes</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
<th>Healthcare schemes</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
<th>Total</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrecognised funded scheme surpluses at 1 January</td>
<td>(16)</td>
<td>(28)</td>
<td>(20)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(16)</td>
<td>(28)</td>
<td>(20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>2</td>
<td>3</td>
<td>(1)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2</td>
<td>3</td>
<td>(1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest on unrecognised funded scheme surpluses</td>
<td>(1)</td>
<td>(1)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(1)</td>
<td>(1)</td>
<td>–</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Movement in year (note 22)</td>
<td>(1)</td>
<td>10</td>
<td>(7)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(1)</td>
<td>10</td>
<td>(7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrecognised funded scheme surpluses at 31 December</td>
<td>(16)</td>
<td>(16)</td>
<td>(28)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(16)</td>
<td>(16)</td>
<td>(28)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The principal actuarial assumptions (weighted to reflect individual scheme differences) used in the following territories are shown below. In both years, discount rates are determined by reference to normal yields on high quality corporate bonds at the balance sheet date.

<table>
<thead>
<tr>
<th>U.S.</th>
<th>UK</th>
<th>Germany</th>
<th>Canada</th>
<th>Netherlands</th>
<th>Switzerland</th>
<th>U.S.</th>
<th>UK</th>
<th>Germany</th>
<th>Canada</th>
<th>Netherlands</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of increase in salaries (%)</td>
<td>3.4</td>
<td>–</td>
<td>2.5</td>
<td>2.5</td>
<td>1.4</td>
<td>1.2</td>
<td>3.4</td>
<td>–</td>
<td>2.5</td>
<td>3.0</td>
<td>2.1</td>
</tr>
<tr>
<td>Rate of increase in pensions in payment (%)</td>
<td>2.5</td>
<td>3.4</td>
<td>1.8</td>
<td>Nil</td>
<td>1.1</td>
<td>Nil</td>
<td>2.5</td>
<td>3.0</td>
<td>1.5</td>
<td>Nil</td>
<td>0.9</td>
</tr>
<tr>
<td>Rate of increase in deferred pensions (%)</td>
<td>0.1</td>
<td>3.0</td>
<td>1.8</td>
<td>Nil</td>
<td>1.1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.2</td>
<td>1.5</td>
<td>Nil</td>
</tr>
<tr>
<td>Discount rate (%)</td>
<td>3.0</td>
<td>1.8</td>
<td>1.3</td>
<td>2.8</td>
<td>1.0</td>
<td>0.2</td>
<td>2.6</td>
<td>1.4</td>
<td>0.9</td>
<td>2.3</td>
<td>0.5</td>
</tr>
<tr>
<td>General inflation (%)</td>
<td>2.5</td>
<td>3.4</td>
<td>1.8</td>
<td>2.0</td>
<td>2.0</td>
<td>1.0</td>
<td>2.5</td>
<td>3.0</td>
<td>1.5</td>
<td>2.0</td>
<td>2.0</td>
</tr>
</tbody>
</table>

The weighted average duration of liabilities (years)

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>UK</td>
</tr>
</tbody>
</table>
| Weighted average duration of liabilities (years) | 12.3 | 16.7 | 13.6 | 11.0 | 17.1 | 13.3 | 11.6 | 17.0 | 14.0 | 11.0 | 16.0 | 13.4 | 219
15 Retirement Benefit Schemes

For healthcare inflation in the U.S., the assumption is 7.0% for 2021 (2020: 6.0%) and in Canada, the assumption is 5.0% for both years.

Mortality assumptions are subject to regular review. The principal schemes used the following tables:

<table>
<thead>
<tr>
<th>Country</th>
<th>Methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>PRI-2012 mortality tables without collar or amount, projected with MP-2021 generational projection (2020: PRI-2012 mortality tables without collar or amount, projected with MP-2020 generational projection)</td>
</tr>
<tr>
<td>UK</td>
<td>S2PA (YOB) with the CMI (2020) improvement model with a 1.25% long-term improvement rate (2020: S2PA (YOB) with the CMI (2019) improvement model with a 1.25% long-term improvement rate)</td>
</tr>
<tr>
<td>Germany</td>
<td>RT Heubeck 2018 G (both years)</td>
</tr>
<tr>
<td>Canada</td>
<td>CPM-2014 Private Table (both years)</td>
</tr>
<tr>
<td>Netherlands</td>
<td>AG Prognosetafel 2020 (both years)</td>
</tr>
<tr>
<td>Switzerland</td>
<td>LPP/BVG 2020 base table with CMI projection factors for mortality improvements with a 1.5% long-term improvement rate (2020: LPP/BVG 2015 base table with CMI projection factors for mortality improvements with a 1.5% long-term improvement rate)</td>
</tr>
</tbody>
</table>

Based on the above, the weighted average life expectancy, in years, for mortality tables used to determine benefit obligations is as follows:

<table>
<thead>
<tr>
<th></th>
<th>U.S.</th>
<th>UK</th>
<th>Germany</th>
<th>Canada</th>
<th>Netherlands</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>31 December 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Member age 65 (current life expectancy)</td>
<td>21.6</td>
<td>23.5</td>
<td>22.9</td>
<td>24.2</td>
<td>20.5</td>
<td>23.9</td>
</tr>
<tr>
<td>Member age 45 (life expectancy at age 65)</td>
<td>22.1</td>
<td>24.0</td>
<td>24.5</td>
<td>25.9</td>
<td>23.2</td>
<td>26.2</td>
</tr>
<tr>
<td>31 December 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Member age 65 (current life expectancy)</td>
<td>20.4</td>
<td>22.4</td>
<td>22.8</td>
<td>24.1</td>
<td>18.3</td>
<td>23.8</td>
</tr>
<tr>
<td>Member age 45 (life expectancy at age 65)</td>
<td>21.9</td>
<td>23.8</td>
<td>24.5</td>
<td>25.9</td>
<td>23.1</td>
<td>26.0</td>
</tr>
</tbody>
</table>

For the remaining territories, typical assumptions are that real salary increases will be from 0% to 8.0% (2020: 0% to 9.0%) per annum and discount rates will be from 0% to 11.0% (2020: 0% to 12.0%) above inflation. Pension increases, where allowed for, are generally assumed to be in line with inflation. Assumptions of life expectancy are in line with best practice in each territory. For countries where there is not a deep market in such corporate bonds, the yield on government bonds is used.

The valuation of retirement benefit schemes involves judgements about uncertain future events. Sensitivities in respect of the key assumptions used to measure the principal pension schemes as at 31 December 2021 are set out below. These sensitivities show the hypothetical impact of a change in each of the listed assumptions in isolation, with the exception of the sensitivity to inflation which incorporates the impact of certain correlating assumptions such as salary increases. While each of these sensitivities holds all other assumptions constant, in practice such assumptions rarely change in isolation, while asset values also change, and the impacts may offset to some extent.

<table>
<thead>
<tr>
<th>Sensitivity</th>
<th>U.S.</th>
<th>UK</th>
<th>Germany</th>
<th>Canada</th>
<th>Netherlands</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average life expectancy – increase/(decrease) of scheme liabilities</td>
<td>271</td>
<td>(267)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rate of inflation – increase/(decrease) of scheme liabilities</td>
<td>182</td>
<td>(175)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discount rate – (decrease)/increase of scheme liabilities</td>
<td>(327)</td>
<td>346</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A one percentage point increase in healthcare inflation would increase healthcare scheme liabilities by £33 million, and a one percentage point decrease would decrease liabilities by £25 million. The income statement effect of this change in assumption is not material.
### 16 Deferred Tax

Net deferred tax (liabilities)/assets comprise:

<table>
<thead>
<tr>
<th></th>
<th>Stock relief</th>
<th>Excess of capital allowances over depreciation</th>
<th>Tax losses</th>
<th>Undistributed earnings of associates and subsidiaries</th>
<th>Retirement benefits</th>
<th>Trademarks</th>
<th>Other temporary differences</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 January 2021</strong></td>
<td>(13)</td>
<td>(189)</td>
<td>58</td>
<td>(231)</td>
<td>246</td>
<td>(16,784)</td>
<td>1,133</td>
<td>(15,789)</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(3)</td>
<td>5</td>
<td>(3)</td>
<td>2</td>
<td>(4)</td>
<td>(149)</td>
<td>4</td>
<td>(148)</td>
</tr>
<tr>
<td>Credited/(charged) to the income statement</td>
<td>12</td>
<td>(16)</td>
<td>34</td>
<td>8</td>
<td>(22)</td>
<td>63</td>
<td>(50)</td>
<td>29</td>
</tr>
<tr>
<td>Charged to other comprehensive income</td>
<td>–</td>
<td>49</td>
<td>–</td>
<td>(3)</td>
<td>91</td>
<td>16</td>
<td>158</td>
<td></td>
</tr>
<tr>
<td><strong>31 December 2021</strong></td>
<td>(4)</td>
<td>(151)</td>
<td>94</td>
<td>(221)</td>
<td>139</td>
<td>(16,779)</td>
<td>1,071</td>
<td>(15,851)</td>
</tr>
<tr>
<td><strong>1 January 2020</strong></td>
<td>(45)</td>
<td>(208)</td>
<td>79</td>
<td>(316)</td>
<td>278</td>
<td>(17,408)</td>
<td>995</td>
<td>(16,413)</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>4</td>
<td>13</td>
<td>(3)</td>
<td>8</td>
<td>–</td>
<td>528</td>
<td>(44)</td>
<td>506</td>
</tr>
<tr>
<td>Credited/(charged) to the income statement</td>
<td>28</td>
<td>(6)</td>
<td>(21)</td>
<td>(18)</td>
<td>(12)</td>
<td>75</td>
<td>138</td>
<td>184</td>
</tr>
<tr>
<td>Charged relating to changes in tax rates</td>
<td>–</td>
<td>12</td>
<td>3</td>
<td>97</td>
<td>–</td>
<td>21</td>
<td>–</td>
<td>133</td>
</tr>
<tr>
<td>(Charged)/credited to other comprehensive income</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(21)</td>
<td>–</td>
<td>–</td>
<td>44</td>
<td>23</td>
</tr>
</tbody>
</table>

31 December 2020

<table>
<thead>
<tr>
<th></th>
<th>Stock relief</th>
<th>Excess of capital allowances over depreciation</th>
<th>Tax losses</th>
<th>Undistributed earnings of associates and subsidiaries</th>
<th>Retirement benefits</th>
<th>Trademarks</th>
<th>Other temporary differences</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>31 December 2020</strong></td>
<td>(13)</td>
<td>(189)</td>
<td>58</td>
<td>(231)</td>
<td>246</td>
<td>(16,784)</td>
<td>1,133</td>
<td>(15,789)</td>
</tr>
</tbody>
</table>
17 Trade and Other Receivables

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade receivables</td>
<td>2,998</td>
<td>2,763</td>
</tr>
<tr>
<td>Loans and other receivables</td>
<td>755</td>
<td>696</td>
</tr>
<tr>
<td>Prepayments and accrued income</td>
<td>408</td>
<td>504</td>
</tr>
<tr>
<td></td>
<td>4,161</td>
<td>3,963</td>
</tr>
<tr>
<td>Current</td>
<td>3,951</td>
<td>3,721</td>
</tr>
<tr>
<td>Non-current</td>
<td>210</td>
<td>242</td>
</tr>
<tr>
<td></td>
<td>4,161</td>
<td>3,963</td>
</tr>
</tbody>
</table>

The majority of receivables are held in order to collect contractual cash flows, in accordance with the Group’s business model for managing financial assets, and hence are measured at amortised cost. In certain countries, however, the Group has entered into factoring arrangements and periodically sells certain trade receivables to banks and other financial institutions, without recourse, for cash. These trade receivables have been derecognised from the statement of financial position to reflect the transfer by the Group of substantially all of the risks and rewards of the receivables, including credit risk. Consequently, the cash inflows have been recognised within operating cash flows. Typically in these arrangements, the Group also acts as a collection agent for the bank. At 31 December 2021, the value of trade receivables derecognised through the factoring arrangements where the Group acts as a collection agent was £362 million (2020: £500 million) and where the Group does not act as a collection agent was £8 million (2020: £25 million). Included in trade receivables above is £110 million (2020: £205 million) of trade debtor balances which were available for factoring under these arrangements. In addition, the Group participates in certain supply chain finance programmes utilised by our customers allowing us to receive payment for invoices earlier than the agreed due date at a discounted value. At 31 December 2021, the value of trade receivables derecognised through these arrangements was £171 million (2020: £131 million).

Included in loans and other receivables are £84 million of litigation related deposits (2020: £78 million). Management has determined that these payments represent a resource controlled by the entity, as a result of past events and from which future economic benefits are expected to flow to the entity either by being recoverable on conclusion of ongoing appeal processes or by reducing amounts potentially payable should the appeal process fail. These deposits are held at the fair value of consideration transferred less impairment, if applicable. The effect of discounting would be immaterial.

Also included in loans and other receivables are deposits that do not meet the definition of cash and cash equivalents as well as loans provided to farmers. The cash flows arising from these transactions are included in investing activities and have been reconciled to the cash flow statement in note 18.

Prepayments and accrued income include £24 million (2020: £8 million) of accrued income primarily in relation to rebates.

Amounts receivable from related parties including associated undertakings are shown in note 30.
### 17 Trade and Other Receivables Continued

Trade and other receivables have been reported in the balance sheet net of allowances as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade receivables – gross</td>
<td>3,035</td>
<td>2,804</td>
</tr>
<tr>
<td>Trade receivables – allowance</td>
<td>(37)</td>
<td>(41)</td>
</tr>
<tr>
<td>Loans and other receivables – gross</td>
<td>755</td>
<td>696</td>
</tr>
<tr>
<td>Loans and other receivables – allowance</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Prepayments and accrued income</td>
<td>408</td>
<td>504</td>
</tr>
<tr>
<td><strong>Net trade and other receivables per balance sheet</strong></td>
<td><strong>4,161</strong></td>
<td><strong>3,963</strong></td>
</tr>
</tbody>
</table>

The movements in the allowance account are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Trade receivables £m</th>
<th>Loans and other receivables £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 January</td>
<td>41</td>
<td>–</td>
<td>41</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(2)</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>Provided in the year</td>
<td>7</td>
<td>7</td>
<td>31</td>
</tr>
<tr>
<td>Released</td>
<td>(9)</td>
<td>(9)</td>
<td>(15)</td>
</tr>
<tr>
<td>31 December</td>
<td>37</td>
<td>37</td>
<td>41</td>
</tr>
</tbody>
</table>

As permitted by IFRS 9, the loss allowance on trade receivables arising from the recognition of revenue under IFRS 15 is initially measured at an amount equal to lifetime expected losses. Allowances in respect of loans and other receivables are initially recognised at an amount equal to 12-month expected credit losses. Allowances are measured at an amount equal to the lifetime expected credit losses where the credit risk on the receivables increases significantly after initial recognition.

The Group holds bank guarantees, other guarantees and credit insurance in respect of some of the past due debtor balances.

Trade and other receivables are predominantly denominated in the functional currencies of subsidiary undertakings apart from the following: U.S. dollar: 2.2% (2020: 2.6%), UK sterling: 0.1% (2020: 0.1%), Euro: 3.6% (2020: 0.4%) and other currencies: 0.9% (2020: 1.7%).

There is no material difference between the above amounts for trade and other receivables and their fair value due to the short-term duration of the majority of trade and other receivables as determined using discounted cash flow analysis. There is no concentration of credit risk with respect to trade receivables as the Group has a large number of internationally dispersed customers.
18 Investments Held at Fair Value

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fair value through P&amp;L</td>
<td>Fair value through OCI</td>
</tr>
<tr>
<td>1 January</td>
<td>255</td>
<td>9</td>
</tr>
<tr>
<td>Difference on exchange</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Additions</td>
<td>327</td>
<td>18</td>
</tr>
<tr>
<td>Disposals</td>
<td>(98)</td>
<td>–</td>
</tr>
<tr>
<td>Provisions</td>
<td>(24)</td>
<td>–</td>
</tr>
<tr>
<td>Fair value movements</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>31 December</td>
<td>469</td>
<td>37</td>
</tr>
<tr>
<td>Current</td>
<td>456</td>
<td>–</td>
</tr>
<tr>
<td>Non-current</td>
<td>13</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>469</td>
<td>37</td>
</tr>
</tbody>
</table>

The Group’s investments principally consist of non-derivative financial assets that cannot be classified as loans and other receivables or cash and cash equivalents, as well as investments made by the Group’s corporate venture capital unit, Blomorrow Ventures.

Investments held at fair value through profit and loss principally consist of government securities, indexed deposits, treasury bills or other treasury products with maturities of more than three months which, if held for less than 12 months, form part of the Group’s definition of net debt. Investments held at fair value through other comprehensive income (OCI) include equity investments in various start-up businesses which are held for their strategic value.

Investments held at fair value through profit and loss above include restricted amounts of £351 million (2020: £115 million) due to investments held by subsidiaries in CCAA protection (note 32), as well as £61 million (2020: £97 million) subject to potential exchange control restrictions.

In 2021, as part of the disposal of the Group’s operations in Iran (note 27(d)), a provision of £24 million (2020: £nil) against non-current investments held at fair value was charged to net finance costs as recoverability of these funds is not certain.

Investments held at fair value are predominantly denominated in the functional currencies of subsidiary undertakings with less than 4% in other currencies (2020: less than 2% in other currencies).

The classification of these investments under the IFRS 13 Fair value measurement fair value hierarchy is given in note 26.

Below is a reconciliation of the fair value investments cash flows to the cash flow statement – investing activities:

<table>
<thead>
<tr>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash outflow from investments held at fair value</td>
<td>345</td>
</tr>
<tr>
<td>Cash outflow from loans and other receivables</td>
<td>24</td>
</tr>
<tr>
<td>Cash outflows from investments per cash flow statement</td>
<td>369</td>
</tr>
<tr>
<td>Cash inflow from investments held at fair value</td>
<td>(98)</td>
</tr>
<tr>
<td>Cash inflow from loans and other receivables</td>
<td>(43)</td>
</tr>
<tr>
<td>Cash inflows from investments per cash flow statement</td>
<td>(141)</td>
</tr>
</tbody>
</table>
19 Derivative Financial Instruments

The fair values of derivatives are determined based on market data (primarily yield curves, implied volatilities and exchange rates) to calculate the present value of all estimated flows associated with each derivative at the balance sheet date. In the absence of sufficient market data, fair values would be based on the quoted market price of similar derivatives. The classification of these derivative assets and liabilities under the IFRS 13 fair value hierarchy is given in note 26.

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets £m</td>
<td>Liabilities £m</td>
</tr>
<tr>
<td>Fair value hedges</td>
<td></td>
</tr>
<tr>
<td>– interest rate swaps</td>
<td>5</td>
</tr>
<tr>
<td>– cross-currency swaps</td>
<td>114</td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td></td>
</tr>
<tr>
<td>– cross-currency swaps</td>
<td>107</td>
</tr>
<tr>
<td>– forward foreign currency contracts</td>
<td>81</td>
</tr>
<tr>
<td>Net investment hedges</td>
<td></td>
</tr>
<tr>
<td>– forward foreign currency contracts</td>
<td>62</td>
</tr>
<tr>
<td>Held-for-trading*</td>
<td></td>
</tr>
<tr>
<td>– interest rate swaps</td>
<td>28</td>
</tr>
<tr>
<td>– forward foreign currency contracts</td>
<td>28</td>
</tr>
<tr>
<td>Total</td>
<td>425</td>
</tr>
<tr>
<td>Current</td>
<td>182</td>
</tr>
<tr>
<td>Non-current</td>
<td>243</td>
</tr>
<tr>
<td>Derivatives</td>
<td></td>
</tr>
<tr>
<td>– in respect of net debt**</td>
<td>273</td>
</tr>
<tr>
<td>– other</td>
<td>152</td>
</tr>
<tr>
<td>Total</td>
<td>425</td>
</tr>
</tbody>
</table>

* Derivatives which do not meet the tests for hedge accounting under IFRS 9 or which are not designated as hedging instruments are referred to as 'held-for-trading'. These derivatives principally consist of interest rate swaps and forward foreign currency contracts which have not been designated as hedges due to their value changes offsetting with other components of net finance costs relating to financial assets and financial liabilities. The Group does not use derivatives for speculative purposes. All derivatives are undertaken for risk management purposes.

** Derivatives in respect of net debt are in a net asset position of £91 million as at 31 December 2021 (2020: net asset position of £346 million). The Group’s net debt is presented in note 23.

For cash flow hedges, the timing of expected cash flows is as follows: assets of £188 million (2020: £251 million) of which £78 million (2020: £98 million) is expected within one year and £107 million (2020: £143 million) beyond five years and liabilities of £70 million (2020: £100 million) of which £33 million (2020: £94 million) is expected within one year and £nil (2020: £nil) beyond five years.

The Group’s cash flow hedges are principally in respect of sales or purchases of inventory and certain debt instruments. A certain number of forward foreign currency contracts were used to manage the currency profile of external borrowings and are reflected in the currency table in note 23. Interest rate swaps have been used to manage the interest rate profile of external borrowings and are reflected in the re-pricing table in note 23.
### 19 Derivative Financial Instruments Continued

The tables below set out the maturities of the Group’s derivative financial instruments on an undiscounted contractual basis, based on spot rates.

The maturity dates of all gross-settled derivative financial instruments are as follows:

<table>
<thead>
<tr>
<th>Within one year</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assets</td>
<td>Liabilities</td>
</tr>
<tr>
<td></td>
<td>Inflow (£m)</td>
<td>Outflow (£m)</td>
</tr>
<tr>
<td>Forward foreign currency contracts</td>
<td>5,743</td>
<td>(4,727)</td>
</tr>
<tr>
<td>Cross-currency swaps</td>
<td>14</td>
<td>(22)</td>
</tr>
<tr>
<td>Between one and two years</td>
<td>807</td>
<td>(779)</td>
</tr>
<tr>
<td>Cross-currency swaps</td>
<td>705</td>
<td>(592)</td>
</tr>
<tr>
<td>Between two and three years</td>
<td>9</td>
<td>(15)</td>
</tr>
<tr>
<td>Cross-currency swaps</td>
<td>9</td>
<td>(15)</td>
</tr>
<tr>
<td>Between three and four years</td>
<td>9</td>
<td>(15)</td>
</tr>
<tr>
<td>Cross-currency swaps</td>
<td>726</td>
<td>(579)</td>
</tr>
<tr>
<td>8,022</td>
<td>(6,744)</td>
<td>13,702</td>
</tr>
</tbody>
</table>

The maturity dates of net-settled derivative financial instruments, which primarily relate to interest rate swaps, are as follows:

<table>
<thead>
<tr>
<th>Within one year</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assets (inflow/outflow) (£m)</td>
<td>Liabilities (outflow/inflow) (£m)</td>
</tr>
<tr>
<td>Within one year</td>
<td>127</td>
<td>225</td>
</tr>
<tr>
<td>Between one and two years</td>
<td>25</td>
<td>19</td>
</tr>
<tr>
<td>Between two and three years</td>
<td>23</td>
<td>11</td>
</tr>
<tr>
<td>Between three and four years</td>
<td>(2)</td>
<td>11</td>
</tr>
<tr>
<td>Between four and five years</td>
<td>–</td>
<td>12</td>
</tr>
<tr>
<td>Beyond five years</td>
<td>–</td>
<td>(17)</td>
</tr>
<tr>
<td>173</td>
<td>261</td>
<td>338</td>
</tr>
</tbody>
</table>
19 Derivative Financial Instruments Continued

The items designated as hedging instruments are as follows:

<table>
<thead>
<tr>
<th>Interest rate risk exposure:</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value hedges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-- interest rate swaps</td>
<td>4,413</td>
<td>757</td>
</tr>
<tr>
<td>-- cross-currency swaps</td>
<td>672</td>
<td>1,428</td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-- cross-currency swaps</td>
<td>1,751</td>
<td>2,822</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Foreign currency risk exposure:</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flow hedges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-- forward foreign currency contracts</td>
<td>3,573</td>
<td>3,279</td>
</tr>
<tr>
<td>Net investment hedges (derivative related)</td>
<td>6,120</td>
<td>5,922</td>
</tr>
<tr>
<td>Net investment hedges (non-derivative related)</td>
<td>368</td>
<td>392</td>
</tr>
</tbody>
</table>

20 Inventories

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Em</td>
<td>Em</td>
</tr>
<tr>
<td>Raw materials and consumables</td>
<td>2,100</td>
</tr>
<tr>
<td>Finished goods and work in progress</td>
<td>3,046</td>
</tr>
<tr>
<td>Goods purchased for resale</td>
<td>133</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>5,279</strong></td>
</tr>
</tbody>
</table>

Inventories pledged as security for liabilities amount to £nil (2020: £2 million). Write-offs taken to other operating expenses in the Group income statement were £215 million (2020: £309 million; 2019: £255 million). In 2020, this included £24 million in relation to the restructuring in Indonesia (refer to note 7) and £47 million as a result of the decision to withdraw glo Sens from Japan. Goods purchased for resale include Group brands produced under third-party contract manufacturing arrangements.
21 Cash and Cash Equivalents

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and bank balances</td>
<td>2,529</td>
<td>2,940</td>
</tr>
<tr>
<td>Cash equivalents</td>
<td>280</td>
<td>199</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,809</strong></td>
<td><strong>3,139</strong></td>
</tr>
</tbody>
</table>

The carrying value of cash and cash equivalents approximates their fair value.

Cash and cash equivalents are denominated in the functional currency of the subsidiary undertaking or other currencies as shown below:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional currency</td>
<td>2,422</td>
<td>2,597</td>
</tr>
<tr>
<td>U.S. dollar</td>
<td>170</td>
<td>197</td>
</tr>
<tr>
<td>Euro</td>
<td>92</td>
<td>170</td>
</tr>
<tr>
<td>Other currencies</td>
<td>125</td>
<td>175</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,809</strong></td>
<td><strong>3,139</strong></td>
</tr>
</tbody>
</table>

In the Group cash flow statement, net cash and cash equivalents are shown after deducting bank overdrafts and accrued interest where applicable, as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents as above</td>
<td>2,809</td>
<td>3,139</td>
</tr>
<tr>
<td>Less overdrafts and accrued interest</td>
<td>(346)</td>
<td>(251)</td>
</tr>
<tr>
<td><strong>Net cash and cash equivalents</strong></td>
<td>2,463</td>
<td>2,888</td>
</tr>
</tbody>
</table>

Cash and cash equivalents also include £42 million (2020: £48 million) of cash that is held as a hedging instrument.

Restricted cash

Cash and cash equivalents include restricted amounts of £1,024 million (2020: £878 million) due to subsidiaries in CCAA protection (note 32), as well as £305 million (2020: £455 million) principally due to exchange control restrictions, including amounts of £92 million (2020: £141 million) where the underlying restrictions are expected to be short-term in nature.

22 Capital and Reserves

(a) Share capital

|                  | Ordinary shares of 25p each Number of shares £m |
|------------------|-----------------------------------------------|----------|
| Allotted and fully paid |                                               |          |
| 1 January 2021    | 2,456,591,597                                 | 614.14   |
| Changes during the year |                                               |          |
| – share option schemes |                                           | 26,191   |
| 31 December 2021  | 2,456,617,788                                 | 614.15   |

Allotted and fully paid

1 January 2020 | 2,456,520,738 | 614.12 |
Changes during the year |                                               |          |
– share option schemes | | 70,859 | 0.02 |
31 December 2020 | 2,456,591,597 | 614.14 |

Allotted and fully paid

1 January 2019 | 2,456,415,884 | 614.09 |
Changes during the year |                                               |          |
– share option schemes | | 104,854 | 0.03 |
31 December 2019 | 2,456,520,738 | 614.12 |
22 Capital and Reserves Continued

Share capital
The Company’s ordinary shares are fully paid and no further contribution of capital may be required by the Company from the shareholders. All ordinary shares rank equally with regard to participation in dividends and to share in the proceeds of the Company’s residual assets upon a winding up of the Company. Shareholders may, by ordinary resolution, declare final dividends, but not in excess of the amount recommended by the Directors. Holders of ordinary shares have no pre-emptive rights.

On a show of hands every shareholder who is present in person at a general meeting is entitled to one vote regardless of the number of shares held by the shareholder, unless a poll is demanded. On a poll, every shareholder who is present in person or by proxy has one vote for every share held by the shareholder. The Company’s Annual General Meeting voting is undertaken by way of a poll.

All rights attached to the Company’s shares held by the Group as treasury shares are suspended until those shares are reissued.

(b) Share premium account, capital redemption reserves and merger reserves comprise:

<table>
<thead>
<tr>
<th>Year</th>
<th>Share premium account £m</th>
<th>Capital redemption reserves £m</th>
<th>Merger reserves £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 December 2021</td>
<td>107</td>
<td>101</td>
<td>26,414</td>
<td>26,622</td>
</tr>
<tr>
<td>31 December 2020</td>
<td>103</td>
<td>101</td>
<td>26,414</td>
<td>26,618</td>
</tr>
<tr>
<td>31 December 2019</td>
<td>84</td>
<td>101</td>
<td>26,414</td>
<td>26,609</td>
</tr>
</tbody>
</table>

Share premium account
The share premium account includes the difference between the value of shares issued and their nominal value. The share premium increase includes £nil (2020: £2 million; 2019: £3 million) in respect of ordinary shares issued under the Company’s share option schemes. A further £4 million (2020: £7 million; 2019: £nil) increase in share premium is related to shares repurchased and not cancelled that have been transferred from the Company to other Group undertakings, to be granted to certain employees on vesting of awards, and represents the excess of transfer price of the share over the original weighted average cost of shares.

Capital redemption account
On the purchase of own shares as part of the share buy-back programme for shares which are cancelled, a transfer is made from retained earnings to the capital redemption reserve equivalent to the nominal value of shares purchased. Purchased shares which are not cancelled are classified as treasury shares and presented as a deduction from total equity.

Merger reserve account
The merger reserve comprises:

a. In 1999, shares were issued for the acquisition of the Rothmans International B.V. Group and the difference between the fair value of shares issued and their nominal value of £3,748 million was credited to merger reserves; and

b. On 25 July 2017, the Group announced the completion of the acquisition of the remaining 57.8% of RAI not already owned by the Group. Shares were issued for the acquisition and the difference between the fair value of shares issued and their nominal value of £22,666 million was credited to merger reserves.
### 22 Capital and Reserves Continued

(c) Equity attributed to owners of the parent – movements in other reserves and retained earnings (which are after deducting treasury shares) comprise:

<table>
<thead>
<tr>
<th></th>
<th>Translation reserve (£)</th>
<th>Hedging reserve (£)</th>
<th>Fair value reserve (£)</th>
<th>Revaluation reserve (£)</th>
<th>Other (£)</th>
<th>Total other reserves (£)</th>
<th>Treasury shares (£)</th>
<th>Other (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 January 2021</strong></td>
<td>(6,830)</td>
<td>(504)</td>
<td>(18)</td>
<td>179</td>
<td>573</td>
<td>(6,600)</td>
<td>(5,150)</td>
<td>47,191</td>
</tr>
<tr>
<td><strong>Comprehensive income and expense</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit for the year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign currency translation and hedges of net investments in foreign operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>differences on exchange from translation of foreign operations</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>reclassified and reported in profit for the year</td>
<td>291</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>net investment hedges – net fair value gains on derivatives</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>net investment hedges – differences on exchange on borrowings</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cash flow hedges</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>net fair value gains</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>reclassified and reported in profit for the year</td>
<td>95</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tax on net fair value gains in respect of cash flow hedges (note 10(f))</td>
<td>(32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investments held at fair value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>net fair value gains</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associates – share of OCI, net of tax (note 9)</td>
<td>(18)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>(17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Retirement benefit schemes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>net actuarial gains (note 15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>surplus recognition (note 15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tax on actuarial gains in respect of subsidiaries (note 10(f))</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Associates – share of OCI, net of tax (note 9)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other changes in equity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges reclassified and reported in total assets</td>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employee share options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>value of employee services</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treasury shares used for share option schemes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividends and other appropriations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ordinary shares</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of own shares</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>held in employee share ownership trusts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perpetual hybrid bonds</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>coupons paid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tax on coupons paid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-controlling interests – acquisitions (note 27(b))</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other movements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>31 December 2021</strong></td>
<td>(6,427)</td>
<td>(363)</td>
<td>6</td>
<td>179</td>
<td>573</td>
<td>(6,032)</td>
<td>(5,122)</td>
<td>49,334</td>
</tr>
</tbody>
</table>
## 22 Capital and Reserves Continued

<table>
<thead>
<tr>
<th></th>
<th>Translation reserve (i) £m</th>
<th>Hedging reserve (i) £m</th>
<th>Fair value reserve (ii) £m</th>
<th>Revaluation reserve (v) £m</th>
<th>Other (vi) £m</th>
<th>Total other reserves £m</th>
<th>Treasury shares (vii) £m</th>
<th>Other £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 January 2020</strong></td>
<td>(3,974)</td>
<td>(346)</td>
<td>13</td>
<td>179</td>
<td>573</td>
<td>(3,555)</td>
<td>(5,261)</td>
<td>45,495</td>
</tr>
<tr>
<td><strong>Comprehensive income and expense</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit for the year</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>6,400</td>
</tr>
<tr>
<td>Foreign currency translation and hedges of net investments in foreign operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– differences on exchange from translation of foreign operations</td>
<td>(2,582)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(2,582)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>– net investment hedges – net fair value losses on derivatives</td>
<td>(16)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(16)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>– net investment hedges – differences on exchange on borrowings</td>
<td>(163)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(163)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net fair value losses</td>
<td>– (256)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(256)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>– reclassified and reported in profit for the year</td>
<td>– 90</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>90</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>– tax on net fair value losses on cash flow hedges</td>
<td>(note 10(f))</td>
<td>– 44</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>44</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Associates – share of OCI, net of tax (note 9)</td>
<td>(95)</td>
<td>(3)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(98)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td><strong>Retirement benefit schemes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net actuarial gains (note 15)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>105</td>
</tr>
<tr>
<td>– surplus recognition (note 15)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>10</td>
</tr>
<tr>
<td>– tax on actuarial gains in respect of subsidiaries (note 10(f))</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(28)</td>
</tr>
<tr>
<td>Associates – share of OCI, net of tax (note 9)</td>
<td>–</td>
<td>– (31)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(31)</td>
<td>–</td>
<td>(3)</td>
</tr>
<tr>
<td><strong>Other changes in equity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges reclassified and reported in total assets</td>
<td>– (33)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(33)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Employee share options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– value of employee services</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>88</td>
</tr>
<tr>
<td>– treasury shares used for share option schemes</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>9 (16)</td>
</tr>
<tr>
<td>Dividends and other appropriations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– ordinary shares</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(4,747)</td>
</tr>
<tr>
<td>Purchase of own shares</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– held in employee share ownership trusts</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(17)</td>
</tr>
<tr>
<td><strong>Other movements</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>31 December 2020</strong></td>
<td>(6,830)</td>
<td>(504)</td>
<td>(18)</td>
<td>179</td>
<td>573</td>
<td>(6,600)</td>
<td>(5,150)</td>
<td>47,191</td>
</tr>
</tbody>
</table>
### 22 Capital and Reserves Continued

<table>
<thead>
<tr>
<th>Translation reserve (i) £m</th>
<th>Hedging reserve (ii) £m</th>
<th>Fair value reserve (iii) £m</th>
<th>Revaluation reserve (iv) £m</th>
<th>Other (v) £m</th>
<th>Total other reserves £m</th>
<th>Treasury shares (vi) £m</th>
<th>Other £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 January 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(914)</td>
<td>(177)</td>
<td>6</td>
<td>179</td>
<td>573</td>
<td>(333)</td>
<td>(5,242)</td>
</tr>
<tr>
<td>Comprehensive income and expense</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit for the year</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>5,704</td>
</tr>
<tr>
<td>Foreign currency translation and hedges of net investments in foreign operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– differences on exchange from translation of foreign operations</td>
<td></td>
<td>(2,948)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>– net investment hedges – net fair value gains on derivatives</td>
<td></td>
<td>21</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>21</td>
<td>–</td>
</tr>
<tr>
<td>– net investment hedges – differences on exchange on borrowings</td>
<td></td>
<td>(18)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(18)</td>
<td>–</td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net fair value losses</td>
<td>–</td>
<td>(246)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(246)</td>
<td>–</td>
</tr>
<tr>
<td>– reclassified and reported in profit for the year</td>
<td></td>
<td>53</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>53</td>
<td>–</td>
</tr>
<tr>
<td>– tax on net fair value losses in respect of cash flow hedges (note 10(f))</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(3,555)</td>
<td>(5,261)</td>
</tr>
<tr>
<td>Associates – share of OCI, net of tax (note 9)</td>
<td></td>
<td>(115)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(115)</td>
<td>–</td>
</tr>
<tr>
<td>Retirement benefit schemes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– net actuarial losses (note 15)</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(582)</td>
</tr>
<tr>
<td>– surplus recognition (note 15)</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(7)</td>
</tr>
<tr>
<td>– tax on actuarial losses in respect of subsidiaries (note 10(f))</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>75</td>
</tr>
<tr>
<td>Associates – share of OCI, net of tax (note 9)</td>
<td></td>
<td>–</td>
<td>7</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>–</td>
</tr>
<tr>
<td>Other changes in equity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges reclassified and reported in total assets</td>
<td></td>
<td>–</td>
<td>(32)</td>
<td>–</td>
<td>(32)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Employee share options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– value of employee services</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>115</td>
</tr>
<tr>
<td>Dividends and other appropriations</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(3,476)</td>
</tr>
<tr>
<td>Purchase of own shares</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– held in employee share ownership trusts</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(117)</td>
<td>–</td>
</tr>
<tr>
<td>Other movements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>–</td>
<td>98</td>
</tr>
<tr>
<td>31 December 2019</td>
<td>(3,974)</td>
<td>(346)</td>
<td>13</td>
<td>179</td>
<td>573</td>
<td>(3,555)</td>
<td>(5,261)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>45,495</td>
</tr>
</tbody>
</table>

i. Translation reserve:
The translation reserve is explained in the accounting policy on foreign currencies in note 1.

In 2021, included within the differences on exchange from translation of foreign operations is £291 million which has been reclassified from reserves to the income statement and recognised in other operating expenses as an adjusting item. The £291 million comprises £272 million in respect of the disposal of BAT Pars (note 27(d)) and £19 million from the Group exiting certain countries. As a result of Quantum initiatives, the Group has withdrawn its operations from Myanmar and, in certain countries, the Group has moved to above market business models utilising local distributors as importers. As a consequence, with the cessation of a physical presence in these markets, foreign exchange previously recognised in other comprehensive income for these countries has been reclassified to the income statement.

As detailed in note 14, as a result of the liquidation of Tisak d.d., the Group reclassified to the income statement the foreign exchange previously recognised in associates other comprehensive income. This resulted in a credit of £2 million to the income statement.
22 Capital and Reserves Continued

ii. Hedging reserve:
The hedging reserve is explained in the accounting policy on financial instruments in note 1.
Of the amounts reclassified from the hedging reserve and reported in profit for the year, a loss of £29 million (2020: £16 million gain; 2019: £12 million gain) and a gain of £6 million (2020: £19 million gain; 2019: £3 million gain) were reported within revenue and raw materials and consumables, respectively, together with a loss of £4 million (2020: £2 million loss; 2019: £11 million gain) reported in other operating expenses, and a gain of £59 million (2020: £57 million gain; 2019: £27 million gain) reported within net finance costs.
The Group hedges certain foreign currency denominated borrowings with cross-currency interest rate swaps. As permitted by IFRS 9 Financial Instruments, the foreign currency basis spreads have been separated from the hedging instrument and are recognised in reserves as a 'cost of hedging' and are reclassified to the income statement in the same period in which profit and loss is affected by the hedged expected cashflows as a component of the associated interest expense. The basis spreads are disclosed within hedging reserves as they are not material. Included within the balance of hedging reserves at 31 December 2021 is an accumulated gain of £4 million (2020: £9 million; 2019: £14 million) in respect of the cost of hedging.

iii. Fair value reserve:
The fair value reserve is explained in the accounting policy on financial instruments in note 1. Fair value gains and losses arising from investments held at fair value through other comprehensive income are recognised in this reserve.

iv. Revaluation reserve:
The revaluation reserve relates to the acquisition of the cigarette and snus business of ST in 2008.

v. Other reserves:
Other reserves comprise:

(a) £483 million which arose in 1998 from merger accounting in a Scheme of Arrangement and Reconstruction whereby British American Tobacco p.l.c. acquired the entire share capital of B.A.T Industries p.l.c. and the share capital of that company’s principal financial services subsidiaries was distributed, so effectively demerging them; and
(b) In the 1999 Rothmans transaction, convertible redeemable preference shares were issued as part of the consideration. The discount on these shares was amortised by crediting other reserves and charging retained earnings. The £90 million balance in other reserves comprises the accumulated balance in respect of the preference shares converted during 2004.

vi. Treasury shares:
Total equity attributable to owners of the parent is stated after deducting the cost of treasury shares which include £4,823 million (2020: £4,836 million; 2019: £4,845 million) for shares repurchased and not cancelled and £299 million (2020: £314 million; 2019: £416 million) in respect of the cost of own shares held in employee share ownership trusts. The reduction in the shares repurchased and not cancelled is primarily due to shares reissued to satisfy the vesting of U.S. share options.
The previous share buy-back programme was suspended from 30 July 2014. As at 31 December 2021, treasury shares include 6,269,959 (2020: 6,053,158; 2019: 6,275,677) shares held in trust and 161,930,217 (2020: 162,347,246; 2019: 162,845,590) shares repurchased and not cancelled as part of the Company’s share buy-back programme. From March 2020, the company has utilised shares acquired in the share buy-back programme to satisfy share-based payment awards made to certain employees. On 10 February 2022, the Board approved a proposed £2 billion share repurchase programme for 2022.

(d) Perpetual hybrid bonds
On 27 September 2021, the Group issued two £1 billion perpetual hybrid bonds amounting to £1,703 million, which have been classified as equity. Issuance costs of these bonds, amounting to £26 million (222 million), have been recognised within equity.
These bonds include redemption options exercisable at the Group’s discretion from September 2026 to December 2026 (the 3% perpetual hybrid bond) and June 2029 to September 2029 (the 3.75% perpetual hybrid bond), on specified dates thereafter, or in the event of specific circumstances (such as a change in IFRS or tax regime) as set out in the individual terms of each issue.
The coupons associated with these perpetual hybrid bonds are fixed at 3% until 2026 and 3.75% until 2029, respectively, and would reset to rates determined by the contractual terms of each instrument on certain dates thereafter. The bonds are perpetual in nature and do not have maturity dates for the repayment of principal. The contractual terms of these perpetual hybrid bonds allow the Group to defer coupon payments, however certain contingent events could trigger mandatory payments of such deferred coupons, including the payment of dividends on and the repurchase of ordinary shares, subject to certain exceptions in each case. The full terms and conditions of such events can be found in the prospectus dated 27 September 2021 which is available under the debt facilities section of the Group’s debt microsite (bat.com/debt). As the Group has the unconditional right to avoid transferring cash or another financial asset in relation to these bonds, they are classified as equity instruments in the consolidated financial statements.
During the year, the Group did not defer any eligible coupon payments and in December 2021 paid a coupon of £6 million on the 3% December 2026 bond which has been recognised within equity. The fair value of these bonds at 31 December 2021 is £1,651 million.

(e) Non-controlling interests
Movements in non-controlling interests primarily relate to profit for the year and dividends (reported as a movement in retained earnings) and differences on exchange arising from the translation into sterling (reported as a movement in other reserves). Information on subsidiaries with material non-controlling interests is provided in note 32.
Notes on Accounts

22 Capital and Reserves Continued

(f) Dividends and other appropriations

The interim quarterly dividend payment for the year ended 31 December 2020 of 215.6p per ordinary share (31 December 2019: 210.4p per ordinary share) was payable in four equal instalments: amounts payable in May 2021 of £1,241 million (May 2020: £1,185 million), August 2021 of £1,228 million (August 2020: £1,206 million), November 2021 of £1,232 million (November 2020: £1,206 million) and £1,236 million in February 2022 (February 2021: £1,203 million) respectively. The total dividends recognised as an appropriation from reserves in 2021 was £4,904 million (2020: £4,747 million).

The Board has declared an interim dividend of 217.8p per ordinary share of 25p for the year ended 31 December 2021, payable in four equal quarterly instalments of 54.45p per ordinary share in May 2022, August 2022, November 2022 and February 2023. These payments will be recognised as appropriations from reserves in 2022 and 2023. The total amount payable is estimated to be £5,003 million based on the number of shares outstanding at the date of these accounts.

23 Borrowings

<table>
<thead>
<tr>
<th>Currency</th>
<th>Maturity dates</th>
<th>Interest rates</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eurobonds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euro*</td>
<td></td>
<td></td>
<td>7,316</td>
<td>8,875</td>
</tr>
<tr>
<td>UK sterling</td>
<td>2022 to 2055</td>
<td>2.1% to 7.3%</td>
<td>4,086</td>
<td>4,590</td>
</tr>
<tr>
<td>Swiss franc</td>
<td>2026</td>
<td>1.4%</td>
<td>203</td>
<td>540</td>
</tr>
<tr>
<td>Bonds issued pursuant to Rules under the U.S. Securities Act (as amended)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. dollar</td>
<td>2022 to 2050</td>
<td>1.7% to 8.1%</td>
<td>25,625</td>
<td>25,461</td>
</tr>
<tr>
<td>U.S. dollar</td>
<td>2022</td>
<td>USD 3m LIBOR + 88bps</td>
<td>554</td>
<td>548</td>
</tr>
<tr>
<td>Bonds and notes</td>
<td></td>
<td></td>
<td>37,784</td>
<td>40,998</td>
</tr>
<tr>
<td>Commercial paper</td>
<td></td>
<td></td>
<td>269</td>
<td></td>
</tr>
<tr>
<td>Other loans</td>
<td></td>
<td></td>
<td>500</td>
<td>1,929</td>
</tr>
<tr>
<td>Bank loans</td>
<td></td>
<td></td>
<td>313</td>
<td>317</td>
</tr>
<tr>
<td>Bank overdrafts</td>
<td></td>
<td></td>
<td>346</td>
<td>249</td>
</tr>
<tr>
<td>Lease liabilities</td>
<td></td>
<td></td>
<td>446</td>
<td>475</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>39,658</td>
<td>43,968</td>
</tr>
</tbody>
</table>

* As at 31 December 2021, there were no outstanding floating Eurobonds in euro currency (2020: £384 million, 3M EURIBOR + 50bps).

Perpetual hybrid bonds issued by the Group have been classified as equity (note 22(d)) and therefore excluded from borrowings. Other loans comprise £500 million (2020: £nil) relating to a bilateral facility and £nil (2020: £1,929 million) relating to a term loan. Commercial paper is issued at competitive rates to meet short-term borrowing requirements as and when needed.

Current borrowings per the balance sheet include interest payable of £460 million at 31 December 2021 (2020: £499 million).

Included within borrowings are £9,197 million (2020: £5,356 million) of borrowings subject to fair value hedges where their amortised cost has been increased by £101 million (2020: £173 million).

The fair value of borrowings is estimated to be £40,557 million (2020: £47,029 million) of which £38,683 million (2020: £44,059 million) has been calculated using quoted market prices and is within level 1 of the fair value hierarchy and £1,874 million (2020: £2,970 million) has been calculated based on discounted cash flow analysis and is within level 3 of the fair value hierarchy.

Amounts secured on Group assets including property, plant and equipment, inventory and receivables as at 31 December 2021 are £10 million (2020: £21 million).

The majority of lease liabilities are also secured against the associated assets. Borrowings are repayable as follows:

<table>
<thead>
<tr>
<th>Per balance sheet</th>
<th>Contractual gross maturities</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021 £m</td>
</tr>
<tr>
<td>Within one year</td>
<td></td>
</tr>
<tr>
<td>3,992</td>
<td>4,041</td>
</tr>
<tr>
<td>Between one and two years</td>
<td></td>
</tr>
<tr>
<td>2,464</td>
<td>4,049</td>
</tr>
<tr>
<td>Between two and three years</td>
<td></td>
</tr>
<tr>
<td>3,953</td>
<td>2,587</td>
</tr>
<tr>
<td>Between three and four years</td>
<td></td>
</tr>
<tr>
<td>4,090</td>
<td>3,854</td>
</tr>
<tr>
<td>Between four and five years</td>
<td></td>
</tr>
<tr>
<td>2,739</td>
<td>4,108</td>
</tr>
<tr>
<td>Beyond five years</td>
<td></td>
</tr>
<tr>
<td>22,500</td>
<td>25,329</td>
</tr>
<tr>
<td></td>
<td>39,658</td>
</tr>
</tbody>
</table>

The contractual gross maturities in each year include the borrowings maturing in that year together with forecast interest payments on all borrowings which are outstanding for all or part of that year.
23 Borrowings Continued

Borrowings are denominated in the functional currency of the subsidiary undertaking or other currencies as shown below:

<table>
<thead>
<tr>
<th>Functional currency</th>
<th>U.S. dollar £m</th>
<th>UK sterling £m</th>
<th>Euro £m</th>
<th>Other currencies £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 December 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total borrowings</td>
<td>30,363</td>
<td>2,837</td>
<td>453</td>
<td>5,775</td>
<td>230</td>
</tr>
<tr>
<td>Effect of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– cross-currency swaps</td>
<td>2,219</td>
<td>– (450)</td>
<td>(1,973)</td>
<td>– (204)</td>
<td></td>
</tr>
<tr>
<td>– forward foreign currency contracts</td>
<td>(24)</td>
<td>(464)</td>
<td>58</td>
<td>432</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>32,558</td>
<td>2,373</td>
<td>3</td>
<td>3,860</td>
<td>662</td>
</tr>
<tr>
<td>31 December 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total borrowings</td>
<td>32,000</td>
<td>2,700</td>
<td>452</td>
<td>8,221</td>
<td>595</td>
</tr>
<tr>
<td>Effect of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– cross-currency swaps</td>
<td>3,795</td>
<td>– (450)</td>
<td>(3,536)</td>
<td>(265)</td>
<td>(456)</td>
</tr>
<tr>
<td>– forward foreign currency contracts</td>
<td>593</td>
<td>(460)</td>
<td>–</td>
<td>394</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>36,388</td>
<td>2,240</td>
<td>2</td>
<td>4,165</td>
<td>724</td>
</tr>
</tbody>
</table>

The exposure to interest rate changes when borrowings are re-priced is as follows:

<table>
<thead>
<tr>
<th>Within 1 year £m</th>
<th>Between 1-2 years £m</th>
<th>Between 2-3 years £m</th>
<th>Between 3-4 years £m</th>
<th>Between 4-5 years £m</th>
<th>Beyond 5 years £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 December 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total borrowings</td>
<td>3,999</td>
<td>2,477</td>
<td>3,853</td>
<td>4,090</td>
<td>2,739</td>
<td>22,500</td>
</tr>
<tr>
<td>Effect of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– interest rate swaps</td>
<td>4,192</td>
<td>– (500)</td>
<td>(1,107)</td>
<td>– (2,585)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>– cross-currency swaps</td>
<td>566</td>
<td>– (552)</td>
<td>– (19)</td>
<td>– (99)</td>
<td>(204)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8,757</td>
<td>1,825</td>
<td>3,353</td>
<td>2,964</td>
<td>2,739</td>
<td>19,816</td>
</tr>
<tr>
<td>31 December 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total borrowings</td>
<td>6,519</td>
<td>1,568</td>
<td>2,594</td>
<td>3,855</td>
<td>4,108</td>
<td>25,324</td>
</tr>
<tr>
<td>Effect of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– interest rate swaps</td>
<td>219</td>
<td>– (219)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>– cross-currency swaps</td>
<td>454</td>
<td>– (744)</td>
<td>– (23)</td>
<td>– (143)</td>
<td>(456)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7,192</td>
<td>1,349</td>
<td>1,850</td>
<td>3,855</td>
<td>4,085</td>
<td>25,181</td>
</tr>
</tbody>
</table>

Lease liabilities are repayable as follows:

<table>
<thead>
<tr>
<th>Per balance sheet</th>
<th>Contractual gross maturities</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021 £m</td>
<td>2020 £m</td>
</tr>
<tr>
<td>Within one year</td>
<td>126</td>
</tr>
<tr>
<td>Between one and two years</td>
<td>93</td>
</tr>
<tr>
<td>Between two and three years</td>
<td>66</td>
</tr>
<tr>
<td>Between three and four years</td>
<td>49</td>
</tr>
<tr>
<td>Between four and five years</td>
<td>38</td>
</tr>
<tr>
<td>Beyond five years</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>446</td>
</tr>
</tbody>
</table>

For more information on leasing arrangements, refer to note 13(b).

As at 31 December 2021, the Group’s undrawn committed borrowing facilities (note 26) amount to £7,850 million (2020: £9,366 million) with £4,850 million maturing within one year (2020: £6,366 million maturing within one year), £150 million maturing between three and four years and with £2,850 million maturing between four and five years (2020: £3,000 million maturing between four to five years).
23 Borrowings Continued

The Group’s composition and movements in net debt are presented below along with a reconciliation to the financing activities in the Group Cash Flow Statement:

<table>
<thead>
<tr>
<th>Borrowings (excluding lease liabilities)*</th>
<th>£m</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening balance</td>
<td>43,493</td>
<td>44,787</td>
<td></td>
</tr>
<tr>
<td>Subsidiaries acquired</td>
<td>–</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cash flow</td>
<td>(3,768)</td>
<td>(1,049)</td>
<td></td>
</tr>
<tr>
<td>Foreign exchange</td>
<td>(387)</td>
<td>(24)</td>
<td></td>
</tr>
<tr>
<td>Fair value, accrued interest and other</td>
<td>(126)</td>
<td>(195)</td>
<td></td>
</tr>
<tr>
<td>Closing balance</td>
<td>39,212</td>
<td>43,493</td>
<td></td>
</tr>
</tbody>
</table>

* Borrowings as at 31 December 2021 include £754 million (2020: £790 million) in respect of the purchase price adjustments relating to the acquisition of Reynolds American.

Fair value, accrued interest and other movements in lease liabilities in 2021 mainly comprise additions of £147 million (2020: £85 million) (net of reassessments, modifications and terminations), see note 13(a). The movement of £7 million (2020: £20 million) in current investments held at fair value represents the fair value gains for these investments.

<table>
<thead>
<tr>
<th>Cash flows per net debt statement</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-financing cash flows included in net debt</td>
<td>33</td>
<td>11,292</td>
</tr>
<tr>
<td>Interest paid</td>
<td>(1,479)</td>
<td>(1,737)</td>
</tr>
<tr>
<td>Remaining cash flows relating to derivative financial instruments</td>
<td>251</td>
<td>(43)</td>
</tr>
<tr>
<td>Purchases of own shares held in employee share ownership trusts</td>
<td>(82)</td>
<td>(18)</td>
</tr>
<tr>
<td>Proceeds from issue of perpetual hybrid bonds</td>
<td>1,681</td>
<td>–</td>
</tr>
<tr>
<td>Dividends paid to owners of the parent</td>
<td>(4,904)</td>
<td>(4,745)</td>
</tr>
<tr>
<td>Capital injection from and purchase of non-controlling interests</td>
<td>1</td>
<td>17</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

Net cash used in financing activities per cash flow statement (6,749) (7,897)
24 Provisions for Liabilities

<table>
<thead>
<tr>
<th></th>
<th>Restructuring of existing businesses £m</th>
<th>Employee-related benefits £m</th>
<th>Fox River £m</th>
<th>Other provisions £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 January 2021</td>
<td>241</td>
<td>38</td>
<td>70</td>
<td>636</td>
<td>985</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>(13)</td>
<td>(3)</td>
<td></td>
<td>(23)</td>
<td>(39)</td>
</tr>
<tr>
<td>Provided in respect of the year (*)</td>
<td>32</td>
<td>27</td>
<td></td>
<td>199</td>
<td>258</td>
</tr>
<tr>
<td>Utilised during the year</td>
<td>(81)</td>
<td>(21)</td>
<td>(8)</td>
<td>(241)</td>
<td>(351)</td>
</tr>
<tr>
<td>– in respect of MSA litigation (Texas, Minnesota, Mississippi)</td>
<td>–</td>
<td>–</td>
<td></td>
<td>(199)</td>
<td>(199)</td>
</tr>
<tr>
<td>– in respect of other</td>
<td>(81)</td>
<td>(21)</td>
<td>(8)</td>
<td>(42)</td>
<td>(152)</td>
</tr>
<tr>
<td>31 December 2021</td>
<td>179</td>
<td>41</td>
<td>62</td>
<td>571</td>
<td>853</td>
</tr>
</tbody>
</table>

Analysed on the balance sheet as

– current                123                                    14                          8              316                461
– non-current             56                                     27                          54             255                392

179                                    41                          62           571                853

<table>
<thead>
<tr>
<th></th>
<th>Restructuring of existing businesses £m</th>
<th>Employee-related benefits £m</th>
<th>Fox River £m</th>
<th>Other provisions £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 January 2020</td>
<td>298</td>
<td>28</td>
<td>73</td>
<td>659</td>
<td>1,088</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>5</td>
<td>(2)</td>
<td></td>
<td>(57)</td>
<td>(54)</td>
</tr>
<tr>
<td>Subsidiaries acquired</td>
<td>–</td>
<td>–</td>
<td></td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Provided in respect of the year (*)</td>
<td>60</td>
<td>19</td>
<td></td>
<td>312</td>
<td>391</td>
</tr>
<tr>
<td>– in respect of MSA litigation (Texas, Minnesota, Mississippi)</td>
<td>–</td>
<td>–</td>
<td></td>
<td>212</td>
<td>212</td>
</tr>
<tr>
<td>– in respect of other</td>
<td>60</td>
<td>19</td>
<td></td>
<td>100</td>
<td>179</td>
</tr>
<tr>
<td>Utilised during the year</td>
<td>(122)</td>
<td>(7)</td>
<td>(3)</td>
<td>(284)</td>
<td>(416)</td>
</tr>
<tr>
<td>– in respect of excise dispute in Russia</td>
<td>–</td>
<td>–</td>
<td></td>
<td>(226)</td>
<td>(226)</td>
</tr>
<tr>
<td>– in respect of other</td>
<td>(122)</td>
<td>(7)</td>
<td>(3)</td>
<td>(58)</td>
<td>(190)</td>
</tr>
<tr>
<td>31 December 2020</td>
<td>241</td>
<td>38</td>
<td>70</td>
<td>636</td>
<td>985</td>
</tr>
</tbody>
</table>

Analysed on the balance sheet as

– current                165                                    23                          1              409                598
– non-current             76                                     15                          69             227                387

241                                    38                          70           636                985

* Amounts provided above are shown net of reversals of unused provisions which include reversals of £20 million (2020: £72 million) for restructuring of existing businesses, £1 million (2020: £4 million) for employee benefits and £147 million (2020: £125 million) for other provisions, of which £34 million (2020: £4 million) was reclassified to trade and other payables.

The restructuring provisions relate to the restructuring and integration costs incurred and are reported as adjusting items. The principal restructuring activities in 2021 and 2020 are as described in note 7 and primarily include the cost of employee packages and long-term social plans associated with redundancy programmes from previous years. Provisions associated with redundancy packages are determined based on termination packages offered in each country. The long-term social plans primarily relate to social plans in Germany, which span over several years and are based on actuarial calculations. These are discounted to present value using Central Bank rates. We do not consider the effect of discounting to be material. While some elements of the non-current provisions of £56 million will unwind over several years, as termination payments are made over extended periods in some countries, it is estimated that approximately 97% of these non-current provisions will unwind within five years.

Employee-related benefits mainly relate to employee benefits other than post-employment benefits. The principal components of these provisions are gratuity and termination awards, jubilee payments due after a certain service period and expected payments associated with long-term disability. The majority of these provisions are calculated by actuaries. It is estimated that approximately 84% of the non-current provisions of £27 million will unwind within five years.

A provision of £274 million was made in 2011 for a potential claim under a 1998 settlement agreement entered into by a Group subsidiary in respect of the clean-up of sediment in the Fox River. On 30 September 2014, the Group, NCR, Appvion and Windward Prospects entered into a funding agreement; the details of this agreement are explained in note 31. This agreement led to payments of £2 million in 2021 (2020: £2 million). In addition, the Group incurred legal costs of £6 million (2020: £1 million), which were also charged against the provision. It is expected that the non-current provision will unwind within five years.
24 Provisions for Liabilities Continued

Other provisions comprise balances set up in the ordinary course of general business that cannot be classified within the other categories, such as sales returns and onerous contracts, together with amounts in respect of supplier, excise and other disputes. The nature of the amounts provided in respect of disputes is such that the extent and timing of cash flows are difficult to estimate and the ultimate liability may vary from the amounts provided. Other provisions also include a provision for interest of £150 million in relation to the Franked Investment Income Group Litigation Order (FII GLO), as mentioned in notes 8(b) and 10(b). The provision is calculated based on the UK central bank base rate plus 2% and has been charged to net finance costs. As there is uncertainty over the potential timing of the utilisation, as explained in note 10(b), the provision has been reported as a non-current provision.

In 2020, the Group recognised a provision of US$272 million (£212 million) in relation to the ITG Brands, LLC MSA litigation agreements with the States of Texas, Minnesota and Mississippi which was utilised in 2021. Further details are provided in note 31.

On 1 March 2019, the Quebec Court of Appeal in Montreal upheld the Superior Court’s decision of May 2015 (reducing ITCAN’s share of the judgment due to a change in interest computation to a maximum of CAD$9.2 billion). The Court of Appeal also upheld the previously stated requirements for the defendants to deposit CAD$1.1 billion into an escrow account. The Board of Directors of ITCAN reassessed the recoverability of the litigation related deposit and, accordingly, the Group recognised a charge against the income statement of CAD$758 million (£436 million) in 2019, reflecting the amount of the judgment that is considered to be probable and estimable in line with IAS 37 Provisions, Contingent Liabilities and Contingent Assets. Consequently, the Group utilised the litigation related deposit which was shown as a receivable at 31 December 2018 (within trade and other receivables) against the current estimate of the liability and both the provision and litigation related deposit were reduced accordingly. Further details are provided in note 31.

In 2019, the Group recognised a provision of £252 million in relation to the Russia excise dispute. The provision was utilised in January 2020, when the tax claim was paid.

25 Trade and Other Payables

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade payables</td>
<td>3,923</td>
<td>3,722</td>
</tr>
<tr>
<td>Duty, excise and other taxes</td>
<td>3,148</td>
<td>3,410</td>
</tr>
<tr>
<td>Accrued charges and deferred income</td>
<td>2,095</td>
<td>2,228</td>
</tr>
<tr>
<td>FII GLO (note 10(b))</td>
<td>963</td>
<td>963</td>
</tr>
<tr>
<td>Social security and other taxation</td>
<td>55</td>
<td>53</td>
</tr>
<tr>
<td>Sundry payables</td>
<td>375</td>
<td>381</td>
</tr>
<tr>
<td></td>
<td>10,559</td>
<td>10,757</td>
</tr>
</tbody>
</table>

As explained in note 17, the Group acts as a collection agent for banks and other financial institutions in certain debt factoring arrangements. The cash collected in respect of these arrangements that has not yet been remitted amounts to £137 million (2020: £128 million) and is included in sundry payables.

In addition, the Group has certain Supply Chain Financing (SCF) or ‘reverse factoring’ arrangements in place. The principal purpose of these arrangements is to provide the supplier with the option to access liquidity earlier through the sale of its receivables due from the Group to a bank or other financial institution prior to their due date. Management has determined that the Group’s payables to these suppliers have neither been extinguished nor have the liabilities been significantly modified by these arrangements. The value of amounts payable, invoice due dates and other terms and conditions applicable, from the Group’s perspective, remain unaltered, with only the ultimate payee being changed. At 31 December 2021, the value of amounts payable under the SCF programmes was £251 million (2020: £48 million). The cash outflows in respect of these arrangements have been recognised within operating cash flows. Included in this amount is £156 million of leaf payables where the standard payment terms with the vendor is 150 days, consistent with credit terms normally available in certain markets.

Accrued charges and deferred income include £1 million of deferred income (2020: £nil) and £58 million (2020: £55 million) in respect of interest payable mainly related to tax matters. FII GLO of £963 million relates to receipts in 2015, in respect of the Franked Investment Income Government Litigation Order (note 10(b)). Amounts payable to related parties including associated undertakings are shown in note 30.

There is no material difference between the above amounts for trade and other payables and their fair value due to the short-term duration of the majority of trade and other payables, as determined using discounted cash flow analysis.

Trade and other payables are predominantly denominated in the functional currencies of subsidiary undertakings with less than 6% in other currencies (2020: less than 5% in other currencies).
26 Financial Instruments and Risk Management

Management of financial risks

One of the principal responsibilities of Treasury is to manage the financial risks arising from the Group's underlying operations. Specifically, Treasury manages, within an overall policy framework set by the Group’s Main Board and Corporate Finance Committee (CFC), the Group's exposure to funding and liquidity, interest rate, foreign exchange and counterparty risks. The Group’s treasury position is monitored by the CFC which meets regularly throughout the year and is chaired by the Group Finance Director. The approach is one of risk reduction within an overall framework of delivering total shareholder return.

The Group defines capital as net debt (note 23) and equity (note 22). There are no externally imposed capital requirements for the Group. Group policies include a set of financing principles that provide a framework within which the Group’s capital base is managed and, in particular, the policies on dividends (as a percentage of long-term sustainable earnings) and share buy-back are decided. The key objectives of the financing principles is to appropriately balance the interests of equity and debt holders in driving an efficient financing mix for the Group. The Group’s average cost of debt in 2021 is 3.5% (2020: 3.6%).

The Group manages its financial risks in line with the classification of its financial assets and liabilities in the Group’s balance sheet and related notes. The Group’s management of specific risks is dealt with as follows:

Liquidity risk

It is the policy of the Group to maximise financial flexibility and minimise refinancing risk by issuing debt with a range of maturities, generally matching the projected cash flows of the Group and obtaining this financing from a wide range of sources. The Group has a target average centrally managed debt maturity of at least five years with no more than 20% of centrally managed debt maturing in a single rolling year. As at 31 December 2021, the average centrally managed debt maturity was 10.1 years (2020: 9.9 years) and the highest proportion of centrally managed debt maturing in a single rolling year was 18.6% (2020: 16.4%). Perpetual hybrid bonds are treated as equity (note 22 (d)) and therefore not included within the debt maturity analysis.

The Group utilises cash pooling and zero balancing bank account structures at the centre, to minimise the required debt issuance and to optimise the yield within the Group. The key objectives of Treasury in respect of cash and cash equivalents are to protect their principal value, to concentrate cash at the centre, to minimise the required debt issuance and to optimise the yield earned. The amount of debt issued by the Group is determined by forecasting the net debt requirement after the mobilisation of cash.

The Group defines capital as net debt (note 23) and equity (note 22). There are no externally imposed capital requirements for the Group. Group policies include a set of financing principles that provide a framework within which the Group’s capital base is managed and, in particular, the policies on dividends (as a percentage of long-term sustainable earnings) and share buy-back are decided. The key objectives of the financing principles is to appropriately balance the interests of equity and debt holders in driving an efficient financing mix for the Group. The Group’s average cost of debt in 2021 is 3.5% (2020: 3.6%).

As part of its short-term capital management, the Group invests in a range of cash and cash equivalents, including money market funds, which are regarded as highly liquid and are not exposed to significant changes in fair value. These are kept under continuous review as described in the credit risk section below. At 31 December 2021, the Group does not have any investments in money market funds (2020: £nil).

As part of its working capital management, in certain countries, the Group has entered into factoring arrangements and supply chain financing arrangements. These are explained in further detail in note 17 and note 25.

Subsidiary companies are funded by share capital and retained earnings, loans from the central finance companies on commercial terms, or through local borrowings by the subsidiaries in appropriate currencies to predominantly fund short- to medium-term working capital requirements.

Available facilities in current year:

It is Group policy that short-term sources of funds (including drawings under both the Group US$4 billion U.S. commercial paper (U.S. CP) programme and the Group £3 billion euro commercial paper (ECP) programme) are backed by undrawn committed lines of credit and cash. Commercial paper is issued by B.A.T. International Finance p.l.c., B.A.T. Netherlands Finance B.V. and B.A.T Capital Corporation and guaranteed by British American Tobacco p.l.c. At 31 December 2021, commercial paper of £269 million was outstanding (2020: £nil). Cashflows relating to commercial paper that have maturity periods of three months or less are presented on a net basis in the Group’s cash flow statement.

At 31 December 2021, the Group had access to a £5.85 billion revolving credit facility. This facility was undrawn at 31 December 2021. In 2021, the Group exercised the first of the one-year extension options on both tranches of the revolving credit facility with the second one-year extension subsequently exercised in February 2022. Effective March 2022, therefore, the £2.85 billion 364-day tranche will be extended to March 2023 at the reduced amount of £2.7 billion and £2.5 billion of the five-year tranche will be extended from March 2026 to March 2027 (with £3.0 billion of this tranche remaining available until March 2025 and £2.85 billion remaining available from March 2025 to March 2026).

During 2021, the Group extended short-term bilateral facilities totalling £2.5 billion until March or April 2022, some with extension options to extend for further periods. As at 31 December 2021, £500 million was drawn on a short-term basis. Of such short-term bilateral facilities, in December 2021, the Group amended and extended a total of £500 million until December 2022 and subsequent to year end, the Group amended and extended a further £500 million until January 2023 and effective April 2022, an additional £350 million was agreed to be extended until October 2022 and £500 million until April 2023. Cashflows relating to bilateral facilities that have maturity periods of three months or less are presented on a net basis in the Group’s cash flow statement.

As part of its short-term capital management, the Group invests in a range of cash and cash equivalents, including money market funds, which are regarded as highly liquid and are not exposed to significant changes in fair value. These are kept under continuous review as described in the credit risk section below. At 31 December 2021, the Group does not have any investments in money market funds (2020: £nil).

As part of its working capital management, in certain countries, the Group has entered into factoring arrangements and supply chain financing arrangements. These are explained in further detail in note 17 and note 25.

Subsidiary companies are funded by share capital and retained earnings, loans from the central finance companies on commercial terms, or through local borrowings by the subsidiaries in appropriate currencies to predominantly fund short- to medium-term working capital requirements.

Available facilities in current year:

It is Group policy that short-term sources of funds (including drawings under both the Group US$4 billion U.S. commercial paper (U.S. CP) programme and the Group £3 billion euro commercial paper (ECP) programme) are backed by undrawn committed lines of credit and cash. Commercial paper is issued by B.A.T. International Finance p.l.c., B.A.T. Netherlands Finance B.V. and B.A.T Capital Corporation and guaranteed by British American Tobacco p.l.c. At 31 December 2021, commercial paper of £269 million was outstanding (2020: £nil). Cashflows relating to commercial paper that have maturity periods of three months or less are presented on a net basis in the Group’s cash flow statement.

At 31 December 2021, the Group had access to a £5.85 billion revolving credit facility. This facility was undrawn at 31 December 2021. In 2021, the Group exercised the first of the one-year extension options on both tranches of the revolving credit facility with the second one-year extension subsequently exercised in February 2022. Effective March 2022, therefore, the £2.85 billion 364-day tranche will be extended to March 2023 at the reduced amount of £2.7 billion and £2.5 billion of the five-year tranche will be extended from March 2026 to March 2027 (with £3.0 billion of this tranche remaining available until March 2025 and £2.85 billion remaining available from March 2025 to March 2026).

During 2021, the Group extended short-term bilateral facilities totalling £2.5 billion until March or April 2022, some with extension options to extend for further periods. As at 31 December 2021, £500 million was drawn on a short-term basis. Of such short-term bilateral facilities, in December 2021, the Group amended and extended a total of £500 million until December 2022 and subsequent to year end, the Group amended and extended a further £500 million until January 2023 and effective April 2022, an additional £350 million was agreed to be extended until October 2022 and £500 million until April 2023. Cashflows relating to bilateral facilities that have maturity periods of three months or less are presented on a net basis in the Group’s cash flow statement.
26 Financial Instruments and Risk Management Continued

Issuance, drawdowns and repayments in current year:

- In February 2021, the Group repaid a £600 million bond at maturity;
- In June 2021, the Group repaid £500 million of the £1,929 million term loan that has a maturity date in January 2022; the remaining £1,429 million was repaid in September 2021;
- In July, August, September and November 2021, the Group repaid £500 million, £1,100 million, CHF 400 million and £600 million of bonds at maturity, respectively; and
- The Group issued perpetual hybrid bonds totalling £2 billion in September 2021. Please refer to note 22(0) for further details.

Available facilities in prior year:

In March 2020, the Group refinanced its £6 billion revolving credit facility consisting of a £3 billion 364-day tranche (with two one-year extension options and a one-year term-out option), and a £3 billion five-year tranche (with two one-year extension options). The facility no longer contains a financial covenant. As at 31 December 2020, the facility was undrawn.

In March and April 2020, the Group arranged short-term bilateral facilities with core relationship banks for a total amount of approximately £4.8 billion, strengthening the Group’s liquidity position and further mitigating liquidity risks during the COVID-19 crisis. The bilateral facilities have since been reduced to a total amount of approximately £3.4 billion. At 31 December 2020, these facilities were undrawn.

Issuance, drawdowns and repayments in prior year:

- In April 2020, the Group accessed the U.S. dollar market under its SEC Shelf Programme, raising a total of US$2.4 billion across three tranches. Additionally, the Group accessed the European market under its EMTN programme, raising a total of €1.7 billion across two tranches;
- In May and June 2020, the Group repaid US$750 million and US$770.8 million bonds at maturity, respectively. Additionally, in June 2020, the Group raised £500 million in the sterling market under its EMTN Programme;
- In July 2020, the Group repaid a £600 million bond and a £1.9 billion term loan at maturity, and in August 2020, the Group repaid a US$1 billion bond at maturity;
- In September 2020, the Group accessed the U.S. dollar market under its SEC Shelf Programme, raising a total of US$36.25 billion across five tranches. The Group also made a tender offer to repurchase portions of seven series of bonds prior to their maturities. The tender offer was completed in October 2020, totalling US$3.2 billion under five series of bonds, £70 million and €100 million under two separate series of bonds, all of which would have otherwise matured in 2021 and 2022; and
- In October 2020, the Group exercised the make whole redemption provision to fully redeem the remaining amounts outstanding following the tender offer on three series of bonds that would have otherwise matured in 2022. In November 2020, the balance outstanding on these bonds was repurchased, totalling US$597.6 million.

Currency risk

The Group is subject to exposure on the translation of the net assets of foreign currency subsidiaries and associates into its reporting currency, sterling. The Group’s primary balance sheet translation exposures are to the U.S. dollar, Canadian dollar, euro, Danish krone, Swiss franc, South African rand, Russian rouble, Brazilian real, Australian dollar, Malaysian ringgit, Singaporean dollar and Indian rupee. These exposures are kept under continuous review. The Group’s policy on borrowings is to broadly match the currency of these borrowings with the currency of cash flows arising from the Group’s underlying operations. Within this overall policy, the Group aims to minimise all balance sheet translation exposure where it is practicable and cost-effective to do so through matching currency assets with currency borrowings. The main objective of these policies is to protect shareholder value by increasing certainty and minimising volatility in earnings per share. At 31 December 2021, the currency profile of the Group’s gross debt, after taking into account derivative contracts, was 68% U.S. dollar (2020: 63%), 13% euro (2020: 13%), 13% sterling (2020: 19%) and 6% other currencies (2020: 5% other currencies).

The Group faces currency exposures arising from the translation of profits earned in foreign currency subsidiaries and associates and joint arrangements; these exposures are not normally hedged. Exposures also arise from:

(i) foreign currency denominated trading transactions undertaken by subsidiaries. These exposures comprise committed and highly probable forecast sales and purchases, which are offset wherever possible. The remaining exposures are hedged within the Treasury policies and procedures with forward foreign exchange contracts and options, which are designated as hedges of the foreign exchange risk of the identified future transactions; and
(ii) forecast dividend flows from subsidiaries to the centre. To ensure cash flow certainty, the Group enters into forward foreign exchange contracts which are designated as net investment hedges of the foreign exchange risk arising from the investments in these subsidiaries.

IFRS 7 requires a sensitivity analysis that shows the impact on the income statement and on items recognised directly in other comprehensive income of hypothetical changes of exchange rates in respect of non-functional currency financial assets and liabilities held across the Group. All other variables are held constant although, in practice, market rates rarely change in isolation. Financial assets and liabilities held in the functional currency of the Group’s subsidiaries, as well as non-financial assets and liabilities and translation risk, are not included in the analysis. The Group considers a 10% strengthening or weakening of the functional currency against the non-functional currency of its subsidiaries as a reasonably possible change. The impact is calculated with reference to the financial asset or liability held as at the year-end, unless this is unrepresentative of the position during the year.
26 Financial Instruments and Risk Management Continued

A 10% strengthening of functional currencies against non-functional currencies would result in pre-tax profit being £53 million higher (2020: £37 million higher; 2019: £22 million lower). A 10% weakening of functional currencies against non-functional currencies would result in pre-tax profit being £55 million higher (2020: £74 million higher; 2019: £20 million higher) and items recognised directly in other comprehensive income being £177 million lower (2020: £70 million lower; 2019: £27 million higher).

The exchange sensitivities on items recognised directly in other comprehensive income relate to hedging of certain net asset currency positions in the Group, as well as on cash flow hedges in respect of future transactions, but do not include sensitivities in respect of exchange on non-financial assets or liabilities.

Interest rate risk

The objectives of the Group’s interest rate risk management policy are to lessen the impact of adverse interest rate movements on the earnings, cash flow and economic value of the Group. Additional objectives are to minimise the cost of hedging and the associated counterparty risk.

During 2020, the Group financial covenant, being gross interest cover, was removed from the centrally managed banking facilities. In order to manage its interest rate risk, the Group maintains both floating rate and fixed rate debt. The Group sets targets (within overall guidelines) for the desired ratio of floating to fixed rate debt on a net basis (at least 50% fixed on a net basis in the short to medium term) as a result of regular reviews of market conditions and strategy by the Corporate Finance Committee and the board of the main central finance company. At 31 December 2021, the relevant ratios of floating to fixed rate borrowings were 10:90 (2020: 7:93) on a net basis. Underlying borrowings are arranged on both a fixed rate and a floating rate basis and, where appropriate, the Group uses derivatives, primarily interest rate swaps to vary the fixed and floating mix, or forward starting swaps to manage the refinancing risk. The interest rate profile of liquid assets is taken into account in determining the net interest rate exposure.

IFRS 7 requires a sensitivity analysis that shows the impact on the income statement and on items recognised directly in other comprehensive income of hypothetical changes of interest rates in respect of financial assets and liabilities of the Group. All other variables are held constant although, in practice, market rates rarely change in isolation. For the purposes of this sensitivity analysis, financial assets and liabilities with fixed interest rates are not included. The Group considers a 100 basis point change in interest rates a reasonably possible change except where rates are less than 100 basis points. In these instances, it is assumed that the interest rates increase by 100 basis points and decrease to zero for the purpose of performing the sensitivity analysis. The impact is calculated with reference to the financial asset or liability held as at the year-end, unless this is unrepresentative of the position during the year.

A 100 basis point increase in interest rates would result in pre-tax profit being £44 million higher (2020: £31 million lower; 2019: £143 million lower). A 100 basis point decrease in interest rates, or less where applicable, would result in pre-tax profit being £47 million higher (2020: £26 million higher; 2019: £158 million higher). The effect of these interest rate changes on items recognised directly in other comprehensive income is not material in either year.

In accordance with the UK Financial Conduct Authority’s announcement on 27 July 2017, and following the decision taken by global regulators in 2018 to replace Interbank Offered Rates with alternative nearly risk-free rates, such benchmark rates are expected to be largely discontinued after 2021. The IASB addressed the effects of interest rate benchmark reform on financial reporting, with two phases of Amendments to IFRS 9 Financial Instruments (and other Standards) which the Group adopted in its Year End 2019 and 2020 accounts, respectively, as explained in the accounting policies (note 1). The impact on the Group’s profit or equity from the application of these amendments was not material.

In January 2021, the Group confirmed adherence to the ISDA 2020 IBOR Fallbacks Protocol as published by the International Swaps and Derivatives Association, Inc. (ISDA) on 23 October 2020 (the Protocol), ensuring that appropriate fallback rates can apply to derivatives in the event of LIBOR discontinuation.

As at 31 December 2021, the Group has a floating rate bond with a nominal value US$750 million (£534 million) (2020: US$750 million (£549 million)) that is due to mature in August 2022 before USD LIBOR ceases. £1,929 million of floating rate borrowings outstanding at 31 December 2020 were repaid during the year. In addition, the Group has bilateral facilities totalling £2.5 billion of which £350 million was drawn down at 31 December 2021. The contractual language on these facilities was updated during 2021 such that all drawings are based on SONIA with effect from the end of November 2021. The Group’s syndicated revolving credit facility (undrawn at 31 December 2021 and 2020) has historically had references to USD LIBOR, EURIBOR and GBP LIBOR. This facility includes market standard LIBOR replacement language, and with effect from June 2021 the agreement has adopted SOFR and SONIA as the alternative benchmark rates in respect of USD LIBOR and GBP LIBOR, respectively.

Following announcements by the respective regulators, EURIBOR and USD LIBOR are now expected to continue for the foreseeable future, with USD LIBOR rates potentially discontinued after June 2023. The Group has a total of nine derivatives that may be impacted by an interest rate benchmark reform of which two are free-standing derivatives (EUR interest rate swaps) maturing in January 2023 with nominal values of £750 million (£530 million). The remaining four impacted derivatives (cross currency interest rate swaps) maturing in January 2022 (US$300 million £221 million) in fair value hedge relationship with nominal value US$300 million (£221 million) maturing in June 2022 (before USD LIBOR cessation) and therefore no further exposure arises.

The remaining four impacted derivatives (cross currency interest rate swaps) with nominal values totalling £600 million (£472 million) maturing in October 2020 are in fair value hedge relationships on which the follow-on index for the ongoing LIBOR interest rates. The Group is party to the ISDA fallback protocol and in January 2022, it automatically replaced the GBP LIBOR with an economically equivalent interest rate derivatives referencing SONIA on their reset date. The Group has updated the respective hedge documentation accordingly since the uncertainty regarding the transition for these four derivatives has ceased. The hedge relationship on these derivatives will continue with any resulting ineffectiveness likely to be immaterial.
The Group therefore believes that any outstanding contracts on 1 January 2022 with interest rates based on LIBOR or similar benchmarks will adequately provide for alternate calculations of interest in the event that they are unavailable.

Credit risk
The Group has no significant concentrations of customer credit risk. Subsidiaries have policies in place requiring appropriate credit checks on potential customers before sales commence. The process for monitoring and managing credit risk once sales to customers have been made varies depending on local practice in the countries concerned.

Certain territories have bank guarantees, other guarantees or credit insurance provided in the Group’s favour in respect of Group trade receivables, the issuance and terms of which are dependent on local practices in the countries concerned. All derivatives are subject to ISDA agreements or equivalent documentation.

Cash deposits and other financial instruments give rise to credit risk on the amounts due from the related counterparties. Generally, the Group aims to transact with counterparties with strong investment grade credit ratings. However, the Group recognises that due to the need to operate over a large geographic footprint, this will not always be possible. Counterparty credit risk is managed on a global basis by limiting the aggregate amount and duration of exposure to any one counterparty, taking into account its credit rating. The credit ratings of all counterparties are reviewed regularly.

The Group ensures that it has sufficient counterparty credit capacity of requisite quality to undertake all anticipated transactions throughout its geographic footprint, while at the same time ensuring that there is no geographic concentration in the location of counterparties.

With the following exceptions, the maximum exposure to the credit risk of financial assets at the balance sheet date is reflected by the carrying values included in the Group’s balance sheet. The Group has entered into short-term risk participation agreements in relation to certain leaf supply arrangements and the maximum exposure under these would be £89 million (2020: £88 million). In addition, the Group has entered into a guarantee arrangement to support a short-term bank credit facility with distribution and supply chain partner. The maximum exposure under the arrangement would be £1 million (2020: £36 million).

Price risk
The Group is exposed to price risk on investments held by the Group, which are included in investments held at fair value on the consolidated balance sheet, but the quantum of such is not material.

Hedge accounting
In order to qualify for hedge accounting, the Group is required to document prospectively the economic relationship between the item being hedged and the hedging instrument. The Group is also required to demonstrate an assessment of the economic relationship between the hedged item and the hedging instrument, which shows that the hedge will be highly effective on an ongoing basis. This effectiveness testing is repeated periodically to ensure that the hedge has remained, and is expected to remain, highly effective. The prospective effectiveness testing determines that an economic relationship between the hedged item and the hedging instrument exists.

In accordance with the Group Treasury Policy, the exact hedge ratios and profile of a hedge relationship will depend on several factors, including the desired degree of certainty and reduced volatility of net interest costs and market conditions, trends and expectations in the relevant markets. The sources of ineffectiveness include spot and forward differences, impact of time value and timing differences between periods in the hedged item and hedging instrument.

The Group’s risk management strategy has been explained in further detail under the interest rate risk and currency risk sections of this note.

Fair value estimation
The fair values of financial assets and liabilities with maturities of less than one year, other than derivatives, are assumed to approximate their book values. For other financial instruments which are measured at fair value in the balance sheet, the basis for fair values is described below.
26 Financial Instruments and Risk Management Continued

Fair value hierarchy

The following table presents the Group's financial assets and liabilities that are measured at fair value in accordance with IFRS 13 classification hierarchy:

<table>
<thead>
<tr>
<th></th>
<th>Level 1 £m</th>
<th>Level 2 £m</th>
<th>Level 3 £m</th>
<th>Total £m</th>
<th>Level 1 £m</th>
<th>Level 2 £m</th>
<th>Level 3 £m</th>
<th>Total £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets at fair value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment held at fair value (note 18)</td>
<td>405</td>
<td>–</td>
<td>101</td>
<td>506</td>
<td>171</td>
<td>–</td>
<td>93</td>
<td>264</td>
</tr>
<tr>
<td>Derivatives relating to</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– interest rate swaps (note 19)</td>
<td>–</td>
<td>33</td>
<td>–</td>
<td>33</td>
<td>–</td>
<td>65</td>
<td>–</td>
<td>65</td>
</tr>
<tr>
<td>– cross-currency swaps (note 19)</td>
<td>–</td>
<td>221</td>
<td>–</td>
<td>221</td>
<td>–</td>
<td>444</td>
<td>–</td>
<td>444</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>405</td>
<td>425</td>
<td>101</td>
<td>931</td>
<td>171</td>
<td>797</td>
<td>93</td>
<td>1,061</td>
</tr>
<tr>
<td><strong>Liabilities at fair value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivatives relating to</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– interest rate swaps (note 19)</td>
<td>–</td>
<td>36</td>
<td>–</td>
<td>36</td>
<td>–</td>
<td>53</td>
<td>–</td>
<td>53</td>
</tr>
<tr>
<td>– cross-currency swaps (note 19)</td>
<td>–</td>
<td>35</td>
<td>–</td>
<td>35</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>– forward foreign currency contracts (note 19)</td>
<td>–</td>
<td>243</td>
<td>–</td>
<td>243</td>
<td>–</td>
<td>266</td>
<td>–</td>
<td>266</td>
</tr>
</tbody>
</table>

Level 2 financial instruments are not traded in an active market, but the fair values are based on quoted market prices, broker/dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The Group’s level 2 financial instruments include OTC derivatives.

Netting arrangements of derivative financial instruments

The gross fair value of derivative financial instruments as presented in the Group balance sheet, together with the Group’s rights of offset associated with recognised financial assets and recognised financial liabilities subject to enforceable master netting arrangements and similar agreements, is summarised as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount presented in the Group balance sheet* £m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial assets</td>
<td>425</td>
<td>(184)</td>
</tr>
<tr>
<td>Financial liabilities</td>
<td>(314)</td>
<td>184</td>
</tr>
<tr>
<td>Total</td>
<td>111</td>
<td>(111)</td>
</tr>
</tbody>
</table>

* No financial instruments have been offset in the Group balance sheet.

The Group is subject to master netting arrangements in force with financial counterparties with whom the Group trades derivatives. The master netting arrangements determine the proceedings should either party default on their obligations. In case of any event of default, the non-defaulting party will calculate the sum of the replacement cost of outstanding transactions and amounts owed to it by the defaulting party. If that sum exceeds the amounts owed by the defaulting party, the defaulting party will pay the balance to the non-defaulting party. If the sum is less than the amounts owed by the defaulting party, the non-defaulting party will pay the balance to the defaulting party.
# 26 Financial Instruments and Risk Management

The hedged items by risk category are presented below:

<table>
<thead>
<tr>
<th>Carrying amount of the hedged item £m</th>
<th>Accumulated amount of fair value hedge adjustments on the hedged item included in the carrying amount of the hedged item £m</th>
<th>Line item in the statement of financial position where the hedged item is included</th>
<th>Changes in fair value used for calculating hedge ineffectiveness £m</th>
<th>Cash flow hedge reserve (gross of tax) £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fair value hedges</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest rate risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– borrowings (liabilities)</td>
<td>9,197</td>
<td>101</td>
<td>Borrowings</td>
<td>87</td>
</tr>
<tr>
<td><strong>Cash flow hedges</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest rate risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– borrowings (liabilities)</td>
<td>2,132</td>
<td></td>
<td>Borrowings</td>
<td>(69)</td>
</tr>
<tr>
<td><strong>Cash flow hedges</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest rate risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– borrowings (liabilities)</td>
<td>2,816</td>
<td></td>
<td>Borrowings</td>
<td>155</td>
</tr>
</tbody>
</table>

£368 million (2020: £392 million) of the Group’s borrowings are designated as net investment hedge instruments of the Group’s net investments in foreign operations. In line with the Group’s risk management policies, the net investment hedge relationships are reviewed periodically. A number of these relationships had matured in 2019. The change in the value used for calculating hedge ineffectiveness for hedged items designated under net investment hedge relationships is £24 million (2020: £21 million).

As at 31 December 2021, the accumulated balance of the cash flow hedge reserve was a loss of £363 million (2020: loss of £504 million) including an accumulated loss of £538 million (2020: loss of £628 million) in relation to interest rate exposure and foreign currency exposure arising from borrowings held by the Group, and an accumulated gain of £116 million (2020: gain of £139 million) in relation to deferred tax arising from cash flow hedges. The remainder related to the Group’s foreign currency exposure on forecasted transactions and cost of hedging (note 22(c)(ii)).
27 Changes in the Group

(a) Acquisitions

The Group acquired certain businesses and other tobacco assets as noted below. The financial impact of the transactions to the Group were immaterial individually and in aggregate. Except as noted, there were no material differences between the fair value and book values of net assets acquired in business combinations.

On 12 November 2020, the Group acquired 100% of the share capital in Eastern Tobacco Company for Trading, formerly known as Raffles Mohammed Sudji Led Establishment for Trading when acting as BAT’s distributor in Saudi Arabia (KSA), for £50 million (SAR 246 million). Goodwill of £36 million, representing anticipated synergies, and trademarks and similar intangibles of £39 million, as well as £36 million of cash and cash equivalents, were recognised on acquisition.

On 8 April 2019, the Group via its U.S. subsidiary R.J. Reynolds Vapor Company (RJR Vapor), acquired a 45% stake in VapeWild Holdings LLC, a vertically integrated vapour manufacturer and retailer for US$40 million. This was followed by a further acquisition of 15% on 24 June 2019 for US$8 million, giving the Group a 60% interest for US$46 million (€36 million). The Group consolidated VapeWild as a subsidiary from the date of the first investment. Goodwill of £11 million, representing a strategic premium to enter this segment of the U.S. vapour market, and trademarks and similar intangibles of £39 million were recognised on acquisition. Following the announcements with regard to flavours in vapour in the U.S., goodwill was impaired in full in 2019. The business was subsequently discontinued and liquidation proceedings commenced in December 2020.

On 21 December 2017, the Group signed an agreement to acquire 100% of the share capital of Twisp Proprietary Limited, a South African e-cigarette/nicotine vapour company with a market share of circa 70% within South Africa and a leading presence in shopping malls via its branded kiosks outlets. Completion of the proposed acquisition was conditional upon South African anti-trust clearance, which was given in the second half of 2019 and BAT acquired control on 30 September 2019 for a purchase price of £25 million of which £6 million was deferred and contingent upon future performance in the market. Goodwill of £12 million, representing a strategic premium to enter this segment of the South African vapour market, and trademarks and similar intangibles of £15 million were recognised on acquisition. Due to difficult trading conditions, the goodwill and intangibles were fully impaired in 2020 and deferred consideration adjusted by £3 million. The final payment of deferred consideration of £3 million was paid in 2021.

On 5 May 2017, the Group acquired certain tobacco assets, including a distribution company, Express Logistic and Distribution EOOD (ELD), from Bulgartabac Holding AD in Bulgaria. The assets acquired, including brands and other intangibles of £117 million, were purchased for a total consideration of £110 million, of which £8 million was contingent upon full performance in the market. €14 million of this was paid during 2015 and €13 million of this was paid during 2019. Subsequently, ELD was disposed of in 2019 at carrying value.

On 4 January 2017, the Group completed the acquisition of 100% of Winnington Holding AB, a Swedish manufacturer of ‘white’ snus, for a purchase price of £25 million. Goodwill of £8 million and brands as part of the consideration payable was £45 million of which £8 million was contingent on achievement of certain post-acquisition targets. Subsequent payments in respect of this were £1 million in 2016, £5 million in 2017, £1 million in 2018 and £1 million in 2019.

On 30 September 2015, the Group acquired TDR and other tobacco and retail assets from Adris Grupa d.d. (Adris) for a total enterprise value of €550 million. Part of the consideration was contingent upon certain targets being met post-acquisition, and €5 million of this was paid in January 2017. In 2019, the Group reached an agreement with Adris regarding the level of contingent consideration such that any remaining amounts would not be paid by the Group and the Group received £3 million in full and final settlement of all claims between Adris and the Group. Consequently, £9 million of cash and deferred consideration was recognised as other income (note 7).

(b) Non-controlling interests

In 2021, the Group made a capital contribution to Brascuba Cigarritos S.A. at a cost of £5 million (2020: £17 million; 2019: £20 million). This contribution was in proportion to a capital contribution made by the non-controlling interest to the company and as such, the Group’s shareholding remains unchanged.

In addition, in 2021, as part of a Voluntary Tender Offer for the non-controlling interests of the Group’s Indonesian subsidiary, the Group acquired 0.2% additional shares at a cost of £4 million as explained in note 30.

Also in 2021, the Group acquired a further 2.7% in Hrvatski Duhani d.d. Tobacco Leaf Processing at a cost of £1 million.

(c) Other transactions

(i) Organigram

On 11 March 2021, the Group announced a strategic collaboration agreement with Organigram Holdings Inc. (collectively, Organigram). Under the terms of the transaction, a Group subsidiary acquired a 19.9% equity stake in Organigram Holdings Inc. (listed on both the Nasdaq and Toronto Stock Exchange under the symbol ‘OGI’) to become its largest shareholder, with the ability to appoint two directors to Organigram Holdings Inc.’s board of directors and representation on its investment committee. At closing, one BAT nominee, Mr. Jeyan Heper, was added to the board. A second nominee and a replacement for Mr. Heper, who resigned on 31 October 2021, are expected to be proposed in due course. The Group accounts for the investment as an associate.

The Group’s investment provides a significant injection of capital for Organigram that will enable them to expand and accelerate their R&D and product development activities and support business expansion. The Group’s investment of £129 million has been allocated against the Group’s share of Organigram’s net assets, including the recognition of £49 million of intangibles, and goodwill of £30 million, which represents a strategic premium to enter the legal cannabis market in North America.

During 2021, Organigram acquired all of the issued and outstanding shares of The Edibles & Infusions Corporation (EIC) for an initial consideration of CAD$22 million, payable in shares.
27 Changes in the Group Continued

Organic assets also acquired all of the issued and outstanding shares of Laurentian Organic Inc. for consideration of CAD$36 million, payable in cash and shares. The impact of these transactions on the Group was not material. As a result of these transactions, the Group’s shareholding was reduced to 18.8%. Potential additional shares are payable on both transactions upon the acquired businesses achieving certain earnout milestones. The transactions and results of these changes are immaterial to the Group and organic measures, excluding the results of these acquisitions, are not presented.

(ii) Other acquisitions

During 2021, the Group increased its ownership of a wholesale producer and distributor operating in the agriculture sector based in Uzbekistan, FE "Sanfruit" JSC to 42.61%, for £1 million. During 2020, the ownership was increased to 38.63%, for £5 million.

On 20 October 2020, the Group acquired the formulations, brands, associated know-how and other relevant assets owned by Drift Sciences, LLC (DSL) relating to its white nicotine pouch products for consideration of up to US$150 million payable in accordance with the achievement of certain milestones. The transaction has been accounted for as an asset acquisition, rather than as a business combination, as the intellectual property and associated assets acquired do not represent an integrated set of activities required by IFRS for business combination accounting. Consequently, the consideration payable has been assigned to the acquired assets by relative fair value. On 10 January 2019, the Group acquired a minority stake in AYR Limited, a vapour technology company based in the UK, for £8 million, with the potential to increase this in the future. The investment terms also provide for the Group and AYR to agree a commercial collaboration agreement under which the Group and AYR will jointly develop future vaping products.

(d) Disposals

On 26 June 2021, the Group agreed to dispose of its Iranian subsidiary, B.A.T. Pars Company PJSC (BAT Pars) to DTM ME FZE LLC. Accordingly, BAT Pars was derecognised as held-for-sale at that date and £152 million of assets, primarily comprised £38 million of cash and cash equivalents, £38 million of inventory and £14 million of property, plant and equipment, were transferred to held-for-sale assets. Also, £24 million of liabilities, primarily comprised £10 million of trade creditors and £8 million of corporation tax payable, were transferred to held-for-sale liabilities. Subsequently an impairment charge and associated costs of £8 million was recognised in the income statement and treated as an adjusting item.

Completion took place on 6 August 2021. The value of the consideration, in Euros, is subject to the finalisation of the completion accounts process, as well as various other matters, with payment deferred until September 2022. Discounted estimated proceeds of £45 million have been recognised as a current receivable. At 31 December 2021, a credit of £2 million was recognised in operating profit in relation to a partial unwind of discounting on the deferred proceeds. In addition, £272 million in respect of foreign exchange previously recognised in other comprehensive income has been reclassified to the income statement. The financial impact of this has also been treated as an adjusting item.

The held-for-sale impairment charge of £83 million and the foreign exchange reclassification of £272 million which were charged to the income statement have been included as non-cash items in the cash flow statement. In compliance with IAS 7 Statement of cash flows, the £98 million of cash and cash equivalents held at the date of disposal have been reported as a cash outflow under investing activities.

In addition, £24 million of related investments held at fair value were provided against as a charge to net finance costs given uncertainties regarding recovery of these funds.

28 Share-based Payments

The Group operates a number of share-based payment arrangements of which the two principal ones are:

Long-Term Incentive Plan (LTIP)

Awards granted from 2020 under the Long-Term Incentive Plan are the Performance Share Plan and the Restricted Share Plan with the following conditions:

Performance Share Plan (PSP): nil-cost options released three years from date of grant. Payment is subject to performance conditions based on earnings per share (40% of grant), operating cash flow (20% of grant), total shareholder return (20% of grant) and net turnover (20% of grant) in 2021, 2020 and 2019. Total shareholder return combines the share price and dividend performance of the Company by reference to one comparator group. Participants are not entitled to dividends prior to the exercise of the options. A cash equivalent dividend accrues through the vesting period and is paid on vesting. Both equity and cash-settled PSP awards are granted in March each year.

Restricted Share Plan (RSP): Nil-cost options released three years from date of grant and may be subject to forfeit if a participant leaves employment before the end of the three-year holding period. Participants are not entitled to dividends prior to the exercise of the options. A cash equivalent dividend accrues through the vesting period and is paid on vesting. Both equity- and cash-settled RSP awards are granted in March.

Awards granted in 2019 are nil-cost options exercisable after three years from date of grant with a contractual life of 10 years. The performance conditions and the dividend entitlement attached to these awards are identical to the PSP award mentioned above. Both equity and cash-settled LTIP awards were granted in March.

Following the acquisition of Reynolds American on 25 July 2017, underlying Reynolds American shares for LTIPs were replaced with BAT American Depositary Shares (ADS). LTIP awards for ADSs are measured against the performance conditions of Reynolds American at the maximum of 150% at the vesting date. Equity-settled LTIPs were granted by Reynolds American in March each year with options exercisable after three years from the date of grant with the payment made no later than 90 days from date of vesting. Participants are not entitled to dividends prior to exercise of the options.

Deferred Share Bonus Scheme (DSBS)

Free ordinary shares released three years from date of grant and may be subject to forfeit if a participant leaves employment before the end of the three-year holding period. Participants receive a separate payment equivalent to a proportion of the dividend payment during the holding period. Both equity- and cash-settled deferred shares are granted in March each year.

The Group also has a number of other arrangements which are not material for the Group and these are as follows:
28 Share-based Payments Continued

Sharesave Scheme (SAYE)
Options granted in March each year from 2011 onwards (previously, November until 2009, and no options were granted during 2010) by invitation at a 20% discount to the market price. Options to this equity-settled scheme are exercisable at the end of a three-year or five-year savings contract. Participants are not entitled to dividends prior to the exercise of the options. The maximum amount that can be saved by a participant in this way is £6,000 in any tax year.

Share Reward Scheme (SRS) and International Share Reward Scheme (ISRS)
Free shares granted in April each year (maximum £3,600 in any year) under the equity-settled schemes are subject to a three-year holding period. Participants receive dividends during the holding period which are reinvested to buy further shares.

Partnership Share Scheme
Open to all eligible employees, where employees can allocate part of their pre-tax salary to purchase shares in British American Tobacco p.l.c. The maximum amount that can be allocated in this way to any individual is £1,800 in any tax year. The shares purchased are held in a UK-based trust and are normally capable of transfer to participants tax-free after a five-year holding period.

Share-based payment expense
The amounts recognised in the income statement in respect of share-based payments were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Equity-settled £m</td>
<td>Cash-settled £m</td>
<td>Equity-settled £m</td>
</tr>
<tr>
<td>LTIP (note (a))</td>
<td>30</td>
<td>36</td>
<td>58</td>
</tr>
<tr>
<td>DSBS (note (b))</td>
<td>39</td>
<td>2</td>
<td>44</td>
</tr>
<tr>
<td>Other schemes</td>
<td>7</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Total recognised in the income statement (note 3)</td>
<td>76</td>
<td>2</td>
<td>88</td>
</tr>
</tbody>
</table>

Share-based payment liability
The Group issues to certain employees cash-settled share-based payments that require the Group to pay the intrinsic value of these share-based payments to the employee at the date of exercise. The Group has recorded liabilities in respect of vested and unvested grants at the end of 2021 and 2020:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vested £m</td>
<td>Unvested £m</td>
</tr>
<tr>
<td>LTIP</td>
<td>0.1</td>
<td>1.1</td>
</tr>
<tr>
<td>DSBS</td>
<td>0.1</td>
<td>6.4</td>
</tr>
<tr>
<td>Total liability</td>
<td>0.2</td>
<td>7.5</td>
</tr>
</tbody>
</table>

(a) Long-Term incentive Plan
Details of the movements for the equity- and cash-settled LTIP scheme during the years ended 31 December 2021 and 31 December 2020, were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Equity-settled Number of options in thousands</td>
<td>Cash-settled Number of options in thousands</td>
</tr>
<tr>
<td>Outstanding at start of year</td>
<td>10,000</td>
<td>274</td>
</tr>
<tr>
<td>Granted during the period</td>
<td>3,440</td>
<td>81</td>
</tr>
<tr>
<td>Exercised during the period</td>
<td>(1,639)</td>
<td>(48)</td>
</tr>
<tr>
<td>Forfeited during the period</td>
<td>(1,910)</td>
<td>(64)</td>
</tr>
<tr>
<td>Outstanding at end of year</td>
<td>9,891</td>
<td>243</td>
</tr>
<tr>
<td>Exercisable at end of year</td>
<td>611</td>
<td>29</td>
</tr>
</tbody>
</table>

As at 31 December 2021, the Group has 9,891,000 shares (2020: 10,000,000 shares) outstanding which includes 2,650,364 shares (2020: 2,876,738 shares) which are related to Reynolds American LTIP awards from which nil shares (2020: nil shares) are exercisable at the end of the year.

The weighted average British American Tobacco p.l.c. share price at the date of exercise for share options exercised during the period was £27.67 (2020: £29.37; 2019: £28.31) for equity-settled and £27.59 (2020: £28.68; 2019: £30.87) for cash-settled options.

The weighted average British American Tobacco p.l.c. share price for ADS on the New York Stock Exchange at the date of exercise for share options exercised during the period relating to equity-settled Reynolds American LTIP awards was US$35.93 (2020: US$40.04; 2019: US$36.35).
28 Share-based Payments Continued

The outstanding shares for the year ended 31 December 2021 had a weighted average remaining contractual life of 3.7 years (2020: 8.1 years; 2019: 8.2 years) for the equity-settled scheme, 1.70 years for Reynolds American equity-settled scheme (2020: 1.72 years; 2019: 1.93 years) and 4.1 years (2020: 8.1 years; 2019: 8.3 years) for the cash-settled share-based payment arrangements.

(b) Deferred Share Bonus Scheme

Details of the movements for the equity- and cash-settled DSBS scheme during the years ended 31 December 2021 and 31 December 2020, were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Equity-settled</td>
<td>Cash-settled</td>
</tr>
<tr>
<td></td>
<td>Number of options in thousands</td>
<td>Number of options in thousands</td>
</tr>
<tr>
<td>Outstanding at start of year</td>
<td>4,141</td>
<td>200</td>
</tr>
<tr>
<td>Granted during the period</td>
<td>1,562</td>
<td>179</td>
</tr>
<tr>
<td>Exercised during the period</td>
<td>(1,497)</td>
<td>(142)</td>
</tr>
<tr>
<td>Forfeited during the period</td>
<td>(65)</td>
<td>(14)</td>
</tr>
<tr>
<td>Outstanding at end of year</td>
<td>4,141</td>
<td>223</td>
</tr>
<tr>
<td>Exercisable at end of year</td>
<td>–</td>
<td>1</td>
</tr>
</tbody>
</table>

The weighted average British American Tobacco p.l.c. share price at the date of exercise for share options exercised during the financial year was £27.58 (2020: £28.08; 2019: £28.40) for equity-settled and £27.70 (2020: £28.06; 2019: £30.06) for cash-settled options.

The outstanding shares for the year ended 31 December 2021 had a weighted average remaining contractual life of 1.3 years (2020: 1.4 years; 2019: 1.5 years) for the equity-settled scheme and 1.3 years (2020: 1.4 years; 2019: 1.5 years) for the cash-settled scheme.

Valuation assumptions

Assumptions used in the Black-Scholes models to determine the fair value of share options at grant date were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LTIP</td>
<td>DSBS</td>
</tr>
<tr>
<td>Expected volatility (%)</td>
<td>27.0</td>
<td>27.0</td>
</tr>
<tr>
<td>Average expected term to exercise (years)*</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Risk-free rate (%)</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Expected dividend yield (%)</td>
<td>7.7</td>
<td>7.7</td>
</tr>
<tr>
<td>Share price at date of grant (£)</td>
<td>27.94</td>
<td>27.94</td>
</tr>
<tr>
<td>Fair value at grant date (£)*</td>
<td>19.87 / 22.20</td>
<td>22.20</td>
</tr>
<tr>
<td>Fair value at grant date (£)* – Management Board</td>
<td>17.35 / 22.20</td>
<td>22.20</td>
</tr>
</tbody>
</table>

* Where two figures have been quoted for the Long-Term Incentive Plan, the numbers relate to PSP and RSP awards, respectively.

Market condition features were incorporated into the Monte-Carlo models for the total shareholder return elements of the LTIP, in determining fair value at grant date. Assumptions used in these models were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LTIP</td>
<td>DSBS</td>
</tr>
<tr>
<td>Average share price volatility FMCG comparator group (%)</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>Average correlation FMCG comparator group (%)</td>
<td>29</td>
<td>31</td>
</tr>
</tbody>
</table>

Fair values determined from the Black-Scholes and Monte-Carlo models use assumptions revised at the end of each reporting period for cash-settled share-based payment arrangements. The expected British American Tobacco p.l.c. share price volatility was determined taking account of the return index (the share price index plus the dividend reinvested) over a five-year period. The FMCG share price volatility and correlation was also determined over the same periods. The average expected term to exercise used in the models has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions and behavioural conditions, forfeiture and historical experience.

The risk-free rate has been determined from market yield curves for government gilts with outstanding terms equal to the average expected term to exercise for each relevant grant. The expected dividend yield was determined by calculating the yield from the last two declared dividends divided by the grant share price.

In addition to these valuation assumptions, LTIP awards, excluding RSP, contain earnings per share performance conditions. As these are non-market performance conditions they are not included in the determination of fair value of share options at the grant date, however, they are used to estimate the number of awards expected to vest. This pay-out calculation is based on expectations published in analysts’ forecasts.

248
29 Group Employees
The average number of persons employed by the Group and its associates during the year, including Directors, was 82,868 (2020: 89,182).

<table>
<thead>
<tr>
<th></th>
<th>2021 Number</th>
<th>2020 Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>4,789</td>
<td>4,914</td>
</tr>
<tr>
<td>APME</td>
<td>10,488</td>
<td>12,703</td>
</tr>
<tr>
<td>AMSSA</td>
<td>16,799</td>
<td>17,869</td>
</tr>
<tr>
<td>ENA</td>
<td>22,289</td>
<td>23,957</td>
</tr>
<tr>
<td>Subsidiary undertakings</td>
<td>54,365</td>
<td>59,443</td>
</tr>
<tr>
<td>Associates</td>
<td>28,503</td>
<td>29,739</td>
</tr>
<tr>
<td></td>
<td>82,868</td>
<td>89,182</td>
</tr>
</tbody>
</table>

Included within the employee numbers for ENA are certain employees in the UK in respect of central functions. Some of the costs of these employees are allocated or charged to the various regions and markets in the Group.

30 Related Party Disclosures
The Group has a number of transactions and relationships with related parties, as defined in IAS 24 Related Party Disclosures, all of which are undertaken in the normal course of business. Transactions with CTBAT International Limited (a joint operation) are not included in these disclosures as the results are immaterial to the Group.

Intercompany transactions and balances are eliminated on consolidation and therefore are not disclosed.

Transactions and balances with associates relate mainly to the sale and purchase of cigarettes and tobacco leaf. The Group’s share of dividends from associates, included in other net income in the table below, was £392 million (2020: £394 million; 2019: £239 million).

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– revenue</td>
<td>524</td>
<td>495</td>
<td>511</td>
</tr>
<tr>
<td>– purchases</td>
<td>(123)</td>
<td>(80)</td>
<td>(79)</td>
</tr>
<tr>
<td>– other net income</td>
<td>387</td>
<td>388</td>
<td>248</td>
</tr>
<tr>
<td>Amounts receivable at 31 December</td>
<td>48</td>
<td>33</td>
<td>42</td>
</tr>
<tr>
<td>Amounts payable at 31 December</td>
<td>(3)</td>
<td>(5)</td>
<td>(2)</td>
</tr>
</tbody>
</table>

On 5 October 2021, PT Bentoel Internasional Investama Tbk (Bentoel) announced its intention to delist from the Indonesia Stock Exchange and go private by conducting a Voluntary Tender Offer (VTO). As part of this, in two phases in November and December 2021, the Group acquired an additional 0.2% of shares in Bentoel from independent shareholders at a cost of £4 million and terminated the total return swap (as explained in note 32).

As set out in note 27, in March 2021, the Group acquired a 19.9% equity stake in Organigram. The Group and Organigram also entered into a Product Development Collaboration Agreement following which a Centre of Excellence has been established to focus on developing the next generation of cannabis products with an initial focus on cannabidiol (CBD). The Centre of Excellence is located at Organigram’s indoor facility in New Brunswick, Canada, which holds the Health Canada licences required to conduct R&D activities with cannabis products. Both the Group and Organigram are contributing scientists, researchers, and product developers to the Centre of Excellence, which is governed and supervised by a steering committee consisting of an equal number of senior members from each company. Both partners share a commitment to continue to maintain the highest regulatory and ethical standards. Furthermore, as part of the transaction, the Group and Organigram have agreed to grant each other a royalty-free licence to certain intellectual property to enable the development of new and potentially disruptive, novel products. Both parties have the ability to independently commercialise any products developed as a result of the collaboration under their own brands.

During 2021, the Group increased its ownership of a wholesale producer and distributor operating in the agriculture sector based in Uzbekistan, FE “Samfruit” JSC to 42.81%, for £1 million. In 2020 the Group increased its ownership to 38.63% for £5 million.

During 2021, the Group made a capital contribution in Brascuba Cigarillos S.A. at a cost of £6 million (2020: £17 million; 2019: £20 million). There was a capital reduction in CTBAT International Limited of approximately US$171 million with funds remitted prorate to investors in 2021.

Also in 2021, the Group acquired a further 2.7% in Hrvatski Duhani d.d. Tobacco Leaf Processing at a cost of £1 million.

During 2019, the Group acquired 60% of VapeWild Holdings LLC and a minority stake in AYR Limited. Please refer to note 27 for the VapeWild Holdings LLC business that was discontinued and liquidated in 2020.
30 Related Party Disclosures Continued

The key management personnel of British American Tobacco consist of the members of the Board of Directors of British American Tobacco p.l.c. and the members of the Management Board. No such person had any material interest during the year in a contract of significance (other than a service contract) with the Company or any subsidiary company. The term key management personnel in this context includes their close family members.

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
</tbody>
</table>

The total compensation for key management personnel, including Directors, was:

- salaries and other short-term employee benefits 18 17 26
- post-employment benefits 1 2 4
- share-based payments 16 13 23

<table>
<thead>
<tr>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
</tbody>
</table>

The following table, which is not part of IAS 24 disclosures, shows the aggregate emoluments of the Directors of the Company.

<table>
<thead>
<tr>
<th>Executive Directors</th>
<th>Chairman</th>
<th>Non-Executive Directors</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021 £’000</td>
<td>2020 £’000</td>
<td>2019 £’000</td>
<td>2021 £’000</td>
</tr>
<tr>
<td>Salary; fees; benefits; incentives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- salary</td>
<td>2,119</td>
<td>2,026</td>
<td>2,356</td>
</tr>
<tr>
<td>- fees</td>
<td>727</td>
<td>714</td>
<td>695</td>
</tr>
<tr>
<td>- taxable benefits</td>
<td>420</td>
<td>744</td>
<td>608</td>
</tr>
<tr>
<td>- short-term incentives</td>
<td>4,128</td>
<td>3,274</td>
<td>4,791</td>
</tr>
<tr>
<td>- long-term incentives</td>
<td>3,399</td>
<td>1,294</td>
<td>4,420</td>
</tr>
<tr>
<td>Sub-total</td>
<td>10,066</td>
<td>7,338</td>
<td>12,175</td>
</tr>
<tr>
<td>Pension; other emoluments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- pension</td>
<td>318</td>
<td>304</td>
<td>686</td>
</tr>
<tr>
<td>- other emoluments</td>
<td>6</td>
<td>20</td>
<td>47</td>
</tr>
<tr>
<td>Sub-total</td>
<td>324</td>
<td>324</td>
<td>733</td>
</tr>
<tr>
<td>Total emoluments</td>
<td>10,390</td>
<td>7,662</td>
<td>12,908</td>
</tr>
</tbody>
</table>

Aggregate gains on LTIP shares exercised in the year

<table>
<thead>
<tr>
<th>Award</th>
<th>Exercised LTIP shares</th>
<th>Exercise date</th>
<th>Price per share (£)</th>
<th>Aggregate gain (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tadeu Marroco</td>
<td>26 March 2018</td>
<td>15,310</td>
<td>29 March 2021</td>
<td>28.27</td>
</tr>
</tbody>
</table>

LTIP – Value of awards 2018

<table>
<thead>
<tr>
<th>Shares</th>
<th>Price per share (£)</th>
<th>Face value (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Bowles</td>
<td>43,785</td>
<td>38.94</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td>26,248</td>
<td>38.94</td>
</tr>
</tbody>
</table>

Note: 1. For information only as awards are made as nil-cost options.

In 2021, no Sharesave were exercised by Executive Directors.
31 Contingent Liabilities and Financial Commitments

1. The Group is subject to contingencies pursuant to requirements that it complies with relevant laws, regulations and standards.

2. Failure to comply could result in restrictions in operations, damages, fines, increased tax, increased cost of compliance, interest charges, reputational damage or other sanctions. These matters are inherently difficult to quantify. In cases where the Group has an obligation as a result of a past event existing at the balance sheet date, if it is probable that an outflow of economic resources will be required to settle the obligation and if the amount of the obligation can be reliably estimated, a provision will be recognised based on best estimates and management judgement.

3. There are, however, contingent liabilities in respect of litigation, taxes in some countries and guarantees for which no provisions have been made.

General Litigation Overview

4. There are a number of legal and regulatory actions, proceedings and claims against Group companies related to tobacco and New Category products that are pending in a number of jurisdictions. These proceedings include, among other things, claims for personal injury (both individual claims and class actions) and claims for economic loss arising from the treatment of smoking- and health-related diseases (such as medical recoupment claims brought by local governments).

5. The plaintiffs in these cases seek recovery on a variety of legal theories, including negligence, strict liability in tort, design defect, failure to warn, fraud, misrepresentation, violations of unfair and deceptive trade practices statutes, conspiracy, public nuisance, medical monitoring and violations of competition and antitrust laws. The plaintiffs seek various forms of relief, including compensatory and, where available, punitive damages, treble or multiple damages and statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, attorneys’ fees, and injunctive and other equitable relief.

6. Although alleged damages often are not determinable from a complaint, and the law governing the pleading and calculation of damages varies from jurisdiction to jurisdiction, compensatory and punitive damages have been specifically pleaded in a number of cases, sometimes in amounts ranging into the hundreds of millions and even hundreds of billions of sterling.

7. With the exception of the Engle progeny cases described below, the Group continues to win the majority of tobacco-related litigation claims that reach trial, and a very high percentage of the tobacco-related litigation claims brought against them, including Engle progeny cases, continue to be dismissed at or before trial. Based on their experience in tobacco-related litigation and the strength of the defences available to them in such litigation, the Group’s companies believe that their successful defence of tobacco-related litigation in the past will continue in the future.

8. Group companies generally do not settle claims. However, Group companies may enter into settlement discussions in some cases, if they believe it is in their best interests to do so. Exceptions to this general approach include, but are not limited to, actions taken pursuant to ‘offer of judgment’ statutes and Filter Cases, as defined below. An ‘offer of judgment,’ if rejected by the plaintiff, preserves the Group’s right to recover attorneys’ fees under certain statutes in the event of a verdict favourable to the Group. Such offers are sometimes made through court-ordered mediations. Other settlements by Group companies include the State Settlement Agreements (as defined in paragraph 41 below), the funding by various tobacco companies of a US$5.2 billion (approximately £3.8 billion) trust fund contemplated by the Master Settlement Agreement (as described in paragraph 41 below) to benefit tobacco growers, the original Bron flight attendant case, and most of the Engle progeny cases pending in U.S. federal court, after the initial dock of over 4,000 such cases was reduced to approximately 400 cases. The Group believes that the circumstances surrounding these claims are readily distinguishable from the current categories of tobacco-related litigation claims involving Group companies.

9. Although the Group intends to defend all pending cases vigorously, and believes that the Group’s companies have valid bases for appeals of adverse verdicts and valid defences to all actions, and that an outflow of resources related to any individual case is not considered probable, litigation is subject to many uncertainties, and, generally, it is not possible to predict the outcome of any particular litigation pending against Group companies, or to reasonably estimate the amount or range of any possible loss. Furthermore, a number of political, legislative, regulatory and other developments relating to the tobacco industry and cigarette smoking have received wide media attention. These developments may negatively affect the outcomes of tobacco-related legal actions and encourage the commencement of additional similar litigation. Therefore, the Group does not provide estimates of the financial effect of the contingent liabilities represented by such litigation, as such estimates are not practicable.

10. The following table lists the categories of the tobacco-related actions pending against Group companies as of 31 December 2021 and the increase or decrease from the number of cases pending against Group companies as of 31 December 2020. Details of the quantum of past judgments awarded against Group companies, the majority of which are under appeal, are also identified along with any settlements reached during the relevant period. Given the volume and more active nature of the Engle progeny cases and the Filter Cases in the U.S. described below, and the fluctuation in the number of such cases and amounts awarded from year to year, the Group presents judgment or settlement figures for these cases on a three-year basis. Where no quantum is identified, either no judgment has been awarded against a Group company, or where a verdict has been reached no quantification of damages has been given, or no settlement has been entered into. Further details on the judgments, damages quantification and settlements are included within the case narratives below. For a discussion of the non-tobacco related litigation pending against the Group, see note 31, paragraph 83, et seq.
### 31 Contingent Liabilities and Financial Commitments

<table>
<thead>
<tr>
<th>Case Type</th>
<th>Case Numbers as at 31 December 2021</th>
<th>Case Numbers as at 31 December 2020 (note 1)</th>
<th>Change in Number Increase/(decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S. tobacco-related actions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical reimbursement cases (note 2)</td>
<td>2</td>
<td>2</td>
<td>No change</td>
</tr>
<tr>
<td>Class actions (note 3)</td>
<td>20</td>
<td>20</td>
<td>No change</td>
</tr>
<tr>
<td>Individual smoking and health cases (note 4)</td>
<td>222</td>
<td>169</td>
<td>33</td>
</tr>
<tr>
<td>Engle Progeny Cases (note 5)</td>
<td>1,071</td>
<td>1,400</td>
<td>(329)</td>
</tr>
<tr>
<td>Broin II Cases (note 6)</td>
<td>1,200</td>
<td>1,227</td>
<td>(27)</td>
</tr>
<tr>
<td>Filter Cases (note 7)</td>
<td>46</td>
<td>48</td>
<td>(2)</td>
</tr>
<tr>
<td>State Settlement Agreements – Enforcement and Validity (note 8)</td>
<td>2</td>
<td>4</td>
<td>(2)</td>
</tr>
<tr>
<td><strong>Non-U.S. tobacco-related actions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical reimbursement cases</td>
<td>19</td>
<td>19</td>
<td>No change</td>
</tr>
<tr>
<td>Class actions (note 9)</td>
<td>12</td>
<td>12</td>
<td>No change</td>
</tr>
<tr>
<td>Individual smoking and health cases (note 10)</td>
<td>52</td>
<td>68</td>
<td>(16)</td>
</tr>
</tbody>
</table>

(Note 1) This includes cases to which the Reynolds American Inc. (Reynolds American) group companies were a party at such date.

(Note 2) This category of cases includes the Department of Justice action. See note 31, paragraphs 20-24.

(Note 3) See note 31, paragraphs 25-38.

(Note 4) This category of cases includes smoking and health cases alleging personal injuries caused by tobacco use or exposure brought by or on behalf of individual plaintiffs based on theories of negligence, strict liability, breach of express or implied warranty and violations of state deceptive trade practices or consumer protection statutes. The plaintiffs seek to recover compensatory damages, attorneys' fees and costs and punitive damages. Out of the 222 active individual smoking and health cases, six judgments have been returned in the plaintiffs' favour, awarding damages totaling approximately US$150.5 million (approximately £110.8 million), which are pending post-trial in trial courts or on appeal. For a further description of these cases, see note 31, paragraphs 39-40.

(Note 5) In July 1998, trial began in Engle v. R.J. Reynolds Tobacco Co., a then-certified class action filed in Circuit Court, Miami-Dade County, Florida, against U.S. cigarette manufacturers, including R. J. Reynolds Tobacco Co. (RJRT) (individually, and as successor by merger to Lorillard Tobacco Company (Lorillard Tobacco)) and Brown & Williamson Holdings, Inc. (formerly Brown & Williamson Tobacco Corporation) (B&W). In July 2000, the jury in Phase II awarded the class a total of approximately US$145 billion (approximately £107.1 billion) in punitive damages, apportioned US$36.3 billion (approximately £26.8 billion) to RJRT, US$17.6 billion (approximately £13 billion) to B&W, and US$16.3 billion (approximately £12 billion) to Lorillard Tobacco. This decision was appealed and ultimately resulted in the Florida Supreme Court in December 2006 decertifying the class and allowing judgments entered for only two of the three Engle class representatives to stand and setting aside the punitive damages award. Putative Engle class members were permitted to file individual lawsuits, deemed 'Engle progeny cases', against the Engle defendants, within one year of the Supreme Court's decision (subsequently extended to 11 January 2008). Between the period 1 January 2019 and 31 December 2021, 21 judgments have been returned in the plaintiffs' favour, awarding damages totaling approximately US$225 million (approximately £166.1 million). Certain of these judgments have been appealed by RJRT and in certain other cases, RJRT still had time to appeal, as of 31 December 2021. For a further description of the Engle progeny cases, see note 31, paragraphs 29-38 seq.

(Note 6) Brook v. Philip Morris, Inc. was a class action filed in Circuit Court in Miami-Dade County, Florida in 1991 and brought on behalf of flight attendants alleged to have suffered from diseases or ailments caused by exposure to Environmental Tobacco Smoke (ETS) in airplane cabins. Group companies and other cigarette manufacturer defendants settled Brook, agreeing to pay a total of US$300 million (approximately £221.5 million) to fund research on the detection and cure of tobacco-related diseases and US$49 million (approximately £36.2 million) in plaintiffs’ counsel’s fees and expenses. Group companies’ share of these payments totalled US$174 million (approximately £128.5 million). Brook II cases refer to individual cases by class members. There have been no Brook II trials since 2007. For a further description of the Brook II cases, see note 16 to paragraph 40.

(Note 7) Includes claims brought against Lorillard Tobacco and Lorillard Inc. by individuals who seek damages resulting from their alleged exposure to asbestos fibres that were incorporated into filter material used in one brand of cigarettes manufactured by a predecessor to Lorillard Tobacco for a limited period of time ending more than 50 years ago. Since 1 January 2019, Lorillard Tobacco and RJRT have paid, or have reached agreement to pay, a total of approximately US$25.9 million (approximately £19.1 million) in settlements to resolve 102 Filter Cases. See note 17 to paragraph 40.

(Note 8) Group companies’ expenses and payments under the State Settlement Agreements for 2021 amounted to approximately US$3.4 billion (approximately £2.5 billion) in respect of settlement expenses and US$3.7 billion (approximately £2.7 billion) in respect of settlement cash payments. See note 31, paragraph 43. The pending cases referred to above relate to the enforcement, validity or interpretation of the State Settlement Agreements in which RJRT, B&W or Lorillard Tobacco is a party. See note 31, paragraphs 41-54.
31 Contingent Liabilities and Financial Commitments Continued

(Note 9) Outside the United States, there are 12 class actions being brought against Group companies as of 31 December 2021. These include class actions in the following jurisdictions: Canada (11) and Venezuela (1). For a description of the Group companies’ class actions, see note 31, paragraphs 70-81. Pursuant to the judgment in 2015 in the two Quebec class actions, the plaintiffs were awarded damages and interest in the amount of CAD$15.6 billion, most of which were on a joint and several basis (approximately £9.1 billion), of which the Group companies’ share was CAD$10.4 billion (approximately £6.1 billion). On 1 March 2019, the Quebec Court of Appeal handed down a judgment which largely upheld and endorsed the lower court’s previous decision in the Quebec Class Actions, as further described below.

The share of the judgment for Imperial Tobacco Canada Limited (‘Imperial’), the Group’s operating company in Canada, was reduced to approximately CAD$9.2 billion (approximately £5.4 billion). For a further description of the Quebec Class Actions, see paragraph 76. All of the class actions in Canada are currently stayed pursuant to a court order. See paragraph 58.

(Note 10) As at 31 December 2021, the jurisdictions with the most active individual cases against Group companies were, in descending order: Brazil (23), Italy (11), Canada (5), Argentina (5), Chile (4) and Ireland (2). There were a further two jurisdictions with one active case only. Out of these 52 cases, one case in Argentina (Balíassare) returned a first instance judgment on 28 December 2020, in the amount of ARS 685,976 (approximately £5,000) in compensatory damages and ARS 2,500,000 (approximately £18,000) in punitive damages (plus interest), in the plaintiffs’ favour as of 31 December 2021. BAT Argentina filed a notice of appeal of the judgment on 3 February 2021.

11. Certain terms and phrases used in this note 31 may require some explanation.

a. ‘Judgment’ or ‘final judgment’ refers to the final decision of the court resolving the dispute and determining the rights and obligations of the parties. At the trial court level, for example, a final judgment generally is entered by the court after a jury verdict and after post-verdict motions have been decided. In most cases, the losing party may appeal a verdict only after a final judgment has been entered by the trial court.

b. ‘Damages’ refers to the amount of money sought by a plaintiff in a complaint, or awarded to a party by a jury or, in some cases, by a judge. ‘Compensatory damages’ are awarded to compensate the prevailing party for actual losses suffered, if liability is proved. In cases in which there is a finding that a defendant has acted wilfully, maliciously or fraudulently, generally based on a higher burden of proof than is required for a finding of liability for compensatory damages, a plaintiff also may be awarded ‘punitive damages’. Although damages may be awarded at the trial court stage, a losing party may be protected from paying any damages until all appellate motions have been exhausted by posting a supersedeas bond. The amount of such a bond is governed by the law of the relevant jurisdiction and generally is set at the amount of damages plus some measure of statutory interest, modified at the discretion of the appropriate court or subject to limits set by a court or statute.

c. ‘Settlement’ refers to certain types of cases in which cigarette manufacturers, including RJRT, B&W and Lorillard Tobacco, have agreed to resolve disputes with certain plaintiffs without resolving the cases through trial.

d. All sums set out in note 31 have been converted to GBP and US$ using the following exchange rates: GBP 1 to US$ 1.3545, GBP 1 to CAD 1.7109, GBP 1 to EURO 1.1910, GBP 1 to BRL 7.5443, GBP 1 to AOA 763.1513, GBP 1 to NUG 711,7127, GBP 1 to HKR 1610.1000, GBP 1 to HKY 8.9537, GBP 1 to JPY 155.9717, GBP 1 to QAR 4.9316, GBP 1 to SAR 5.0852 and GBP 1 to ARS 139.0908.

U.S. Tobacco Litigation

12. Group companies, notably RJRT (individually and as successor by merger to Lorillard Tobacco) and B&W as well as other leading cigarette manufacturers, are defendants in a number of product liability cases. In a number of these cases, the amounts of compensatory and punitive damages sought are significant.

13. The total number of U.S. tobacco product liability cases pending at 31 December 2021 involving RJRT, B&W and/or Lorillard Tobacco was approximately 2,573. As at 31 December 2021, British American Tobacco (Investments) Limited (‘Investments’) has been served as a co-defendant in one of those cases (2016:1). No other UK-based Group company has been served as a co-defendant in any U.S. tobacco product liability case pending as at 31 December 2021.

14. Since many of these pending cases seek unspecified damages, it is not possible to quantify the total amounts being claimed, but the aggregate amounts involved in such litigation are significant, possibly totalling billions of U.S. dollars. The cases fall into four broad categories: medical reimbursement cases; class actions; individual cases; and other claims.

15. RJRT (individually and as successor to Lorillard Tobacco), American Snuff Co., Santa Fe Natural Tobacco Company, Inc. (SFNTC), R.J. Reynolds Vapor Company (RJR Vapor), Reynolds American, Lorillard Inc., other Reynolds American affiliates and indemnitees, including but not limited to B&W (collectively, the Reynolds Defendants), believe that they have valid defences to the tobacco-related litigation claims against them, as well as valid bases for appeal of adverse verdicts against them. The Reynolds Defendants have, through their counsel, filed pleadings and memoranda in pending tobacco-related litigation that set forth and discuss a number of grounds and defences that they and their counsel believe have a valid basis in law and fact.

16. Scheduled trials. Trial schedules are subject to change, and many cases are dismissed before trial. In the U.S., there are 57 cases, exclusive of Engle progeny cases, scheduled for trial as of 31 December 2021 through 31 December 2022, for the Reynolds Defendants: 39 individual smoking and health cases, 15 Filter Cases, and 3 non-smoking and health cases. There are also approximately 151 Engle progeny cases against RJRT (individually and as successor to Lorillard Tobacco) and B&W scheduled for trial through 31 December 2022. It is not known how many of these cases will actually be tried.

17. Trial results. From 1 January 2019 through 31 December 2021, 53 trials occurred in individual smoking and health, Engle progeny, and Filter Cases in which the Reynolds Defendants were defendants, including five where mistrials were declared. Verdicts in favour of the Reynolds Defendants and, in some cases, other defendants, were returned in 15 cases, tried in Florida (11), Oregon (1), and Massachusetts (3). Verdicts in favour of the plaintiffs were returned in 24 cases, which were tried in Florida (21), Massachusetts (2) and New Mexico (1). Six of the cases (four in Florida, one in New York, and one in Connecticut) were dismissed during trial. Two cases were punitive damages retrials. One case in Massachusetts is awaiting a decision.

253
Financial Statements
Notes on Accounts
Continued

31 Contingent Liabilities and Financial Commitments Continued

(a) Medical Reimbursement Cases

18. These civil actions seek to recover amounts spent by government entities and other third-party providers on healthcare and welfare costs claimed to result from illnesses associated with smoking.

19. At 31 December 2021, one U.S. medical reimbursement suit (Crow Creek Sioux Tribe v. American Tobacco Co.) was pending against RJRT, B&W and Lorillard Tobacco in a Native American tribal court in South Dakota. The plaintiffs seek to recover actual and punitive damages, restitution, funding of a clinical cessation programme, funding of a corrective public education programme, and disgorgement of unjust profits from sales to minors. No other medical reimbursement suits are pending against these companies by county or other political subdivisions of the states.

U.S. Department of Justice Action

20. On 22 September 1999, the U.S. Department of Justice brought an action in the U.S. District Court for the District of Columbia against various industry members, including RJRT, B&W, Lorillard Tobacco, B.A.T Industries p.l.c. (Industries) and Investments (United States v. Philip Morris USA Inc.). The U.S. Department of Justice initially sought (1) recovery of federal funds expended in providing health care to smokers who developed alleged smoking-related diseases pursuant to the Medical Care Recovery Act and Medicare Secondary Payer provisions of the Social Security Act and (2) equitable relief under the civil provisions of the Racketeer Influenced and Corrupt Organizations Act (RICO), including disgorgement of roughly US$280 billion (approximately £206.7 billion) in profits the government contended were earned as a result from illnesses associated with smoking.

21. Industries was dismissed for lack of personal jurisdiction on 28 September 2000. In addition, Investments was a defendant at the trial, but intervening changes in controlling law post-trial led to a 28 March 2011 court ruling that the court’s Final Judgment and Remedial Order no longer applied to Investments prospectively, and for this reason, Investments would not have to comply with any of the remaining injunctive remedies being sought by the government. As the government did not appeal the 28 March 2011 ruling, this means that Investments is no longer in the case and is not subject to any injunctive relief that the court is expected to order against the remaining defendants. As the case continued as against RJRT and Lorillard Tobacco with respect to injunctive relief and related matters, the following is noted:

22. The non-jury trial of the RICO portion of the claim began on 21 September 2004 and ended on 9 June 2005. On 17 August 2006, the federal district court issued its Final Judgment and Remedial Order, which found certain defendants, including RJRT, B&W, Lorillard Tobacco and Investments, had violated RICO, but did not impose any direct financial penalties. The district court instead enjoined the defendants from committing future racketeering acts, participating in certain trade organisations, making misrepresentations concerning smoking and health and youth marketing, and using certain brand descriptors such as ‘low tar’, ‘light’, ‘ultra-light’, ‘mild’ and ‘natural’. The district court also ordered the defendants to issue ‘corrective communications’ on five subjects, including smoking and health and addiction, and to comply with further undertakings, including maintaining websites of historical corporate documents and disseminating certain marketing information on a confidential basis to the government. In addition, the district court placed restrictions on the defendants’ ability to dispose of certain assets for use in the United States, unless the transferee agrees to abide by the terms of the district court’s order, and ordered certain defendants to reimburse the U.S. Department of Justice its taxable costs incurred in connection with the case.

23. Defendants, including RJRT, B&W, Lorillard Tobacco and Investments, appealed, and the U.S. government cross-appealed to the DC Circuit. On 22 May 2009, the DC Circuit affirmed the federal district court’s RICO liability judgment, but vacated the order and remanded for further factual findings and clarification as to whether liability should be imposed against B&W, based on changes in the nature of B&W’s business operations (including the extent of B&W’s control over tobacco operations). The court also remanded on three other discrete issues relating to the injunctive remedies, including for the district court ‘to reformulate’ the injunction on the use of low-tar descriptors ‘to exempt foreign activities that have no substantial, direct, and foreseeable domestic effects’, and for the district court to evaluate whether corrective communications could be required at point-of-sale displays (which requirement the DC Circuit vacated). On 28 June 2010, the U.S. Supreme Court denied the parties’ petitions for further review.

24. On 22 December 2010, the district court dismissed B&W from the litigation. In November 2012, the trial court entered an order setting forth the text of the corrective statements and directed the parties to engage in discussions with the Special Master to implement them. After various proceedings and appeals, the federal district court in October 2017 ordered RJRT and the other U.S. tobacco company defendants to fund the publishing of compelled public statements in various U.S. media outlets, including in newspapers, on television, on the companies’ websites, and in onserts on cigarette packages. The compelled public statements in newspapers and on television were completed in 2018 and in package onserts were completed in mid-2020. Also, the compelled public statements now appear on RJRT websites. The district court is considering mandating the display of the compelled public statements at retail point of sale; an evidentiary hearing is scheduled to begin on 13 June 2022.

254
31 Contingent Liabilities and Financial Commitments Continued

(b) Class Actions

25. At 31 December 2021, RJRT, B&W and Lorillard Tobacco were named as defendants in two separate actions attempting to assert claims on behalf of classes of persons allegedly injured or financially impacted by their smoking, one asserting claims of violation of the Americans With Disabilities Act of 1990, and SFNTC was named in 16 separate cases relating to the use of the words ‘natural,’ ‘100% additive-free,’ or ‘organic’ in Natural American Spirit brand宣传材料 and promotional materials. If the classes are or remain certified, separate trials may be needed to assess individual plaintiffs’ damages. Among the pending class actions, 16 specified the amount of the claim in the complaint and alleged that the plaintiffs were seeking in excess of US$5 million (approximately £3.7 million) and one that alleged that the plaintiffs were seeking less than US$75,000 (approximately £55,370) per class member plus unspecified punitive damages.

No Additive/Natural/Organic Claim Cases

26. A total of 16 pending putative class actions were filed in nine U.S. federal district courts against SFNTC, a subsidiary of Reynolds American, which cases generally allege, in various combinations, violations of state deceptive and unfair trade practice statutes, and claim state common law fraud, negligent misrepresentation, and unjust enrichment based on the use of descriptors such as ‘natural,’ organic and ‘100% additive-free’ in the marketing, labelling, advertising, and promotion of SFNTC’s Natural American Spirit brand cigarettes. In these actions, the plaintiffs allege that the use of these terms suggests that Natural American Spirit brand cigarettes are less harmful than other cigarettes and, for that reason, violated state consumer protection statutes or amounted to fraud or a negligent or intentional misrepresentation. The actions seek various categories of recovery, including economic damages, injunctive relief (including medical monitoring and cessation programmes), interest, restitution, disgorgement, treble and punitive damages, and attorneys’ fees and costs. In April 2016, in response to a motion by the various plaintiffs, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated these cases for pre-trial purposes before a federal court in New Mexico. On 21 December 2017, that court granted the defendants’ motion to dismiss in part, dismissing a number of claims with prejudice, and denied it in part. The district court conducted a five-day hearing on the motion for class certification and on the motion challenging the admissibility of expert opinion testimony in December 2020. The parties filed post-hearing briefs in January 2021 and filed proposed findings of fact and conclusions of law in February 2021. A decision is pending.

Other Putative Class Actions

27. Jones v American Tobacco Co. is a putative class action filed in December 1998 in the Circuit Court, Jackson County, Missouri. The action was brought by a plaintiff on behalf of a putative class of Missouri tobacco product users and purchasers against various defendants, including RJRT, B&W and Lorillard Tobacco alleging that the plaintiffs’ use of the defendants’ tobacco products has caused them to become addicted to nicotine, and seeking an unspecified amount of compensatory and punitive damages. There is currently no activity in this case.

28. Young v American Tobacco Co. is a case filed in November 1997 in the Circuit Court, Orleans Parish, Louisiana against various U.S. cigarette manufacturers, including RJRT and B&W, and parent companies of such manufacturers. This putative ETS class action was brought on behalf of a putative class of Louisiana residents who, though not themselves cigarette smokers, have been exposed to second-hand smoke from cigarettes manufactured by the defendants, and who allegedly suffered injury as a result of that exposure, and seeks an unspecified amount of compensatory and punitive damages. In March 2016, the court entered an order staying the case, including all discovery, pending the completion of an ongoing smoking cessation programme ordered by the court in a now-concluded Louisiana state court certified class action, Scott v American Tobacco Co.

Engle Class Action and Engle Progeny Cases (Florida)

29. In July 1998, trial began in Engle v R. J. Reynolds Tobacco Co., a then-certified class action filed in Circuit Court, Miami-Dade County, Florida, against U.S. cigarette manufacturers, including RJRT, B&W and Lorillard Tobacco. The then-certified class consisted of Florida citizens and residents, and their survivors, who suffered from smoking-related diseases that first manifested between 5 May 1990, and 21 November 1996, and were caused by an addiction to cigarettes. In July 1999, the jury in this Phase I found against RJRT, B&W, Lorillard Tobacco and the other defendants on common issues relating to the defendants’ conduct, general causation, the addictiveness of cigarettes, and entitlement to punitive damages.

30. In July 2000, the jury in the Phase II awarded the class a total of approximately US$145 billion (approximately £107.1 billion) in punitive damages, apportioned US$36.3 billion (approximately £26.8 billion) to RJRT, US$17.6 billion (approximately £13 billion) to B&W, and US$16.3 billion (approximately £12 billion) to Lorillard Tobacco. The three class representatives in the Engle class action were awarded US$13 million (approximately £9.6 million) in compensatory damages.

31. This decision was appealed and ultimately resulted in the Florida Supreme Court in December 2006 declassifying the class and allowing judgments entered for only two of the three Engle class representatives to stand and setting aside the punitive damages award. The court preserved certain of the jury’s Phase I findings, including that cigarettes cause certain diseases, nicotine is addictive, and defendants placed defective cigarettes on the market, breached duties of care, concealed health-related information and conspired. Putative Engle class members were permitted to file individual lawsuits, deemed ‘Engle progeny cases’, against the Engle defendants, within one year of the Supreme Court’s decision (subsequently extended to 11 January 2008).

32. During 2015, RJRT and Lorillard Tobacco, together with Philip Morris USA Inc. (PM USA), settled virtually all of the Engle progeny cases then pending against them in federal district court. The total amount of the settlement was US$100 million (approximately £73.8 million) divided as follows: RJRT US$42.5 million (approximately £31.4 million); PM USA US$42.5 million (approximately £31.4 million); and Lorillard Tobacco US$15 million (approximately £11.1 million). The settlement covered more than 400 federal Engle progeny cases but did not cover 12 federal progeny cases previously tried to verdict and then pending on post-trial motions or appeal, and two federal progeny cases filed by different lawyers from the ones who negotiated the settlement for the plaintiffs.
Financial Statements

Notes on Accounts

Continued

31 Contingent Liabilities and Financial Commitments

33. As at 31 December 2021, there were approximately 1,071 Engle progeny cases pending in which RJRT, B&W and/or Lorillard Tobacco have all been named as defendants and served. These cases include claims by or on behalf of 1,304 plaintiffs. In addition, as of 31 December 2021, RJRT was aware of four additional Engle progeny cases that have been filed but not served. The number of pending cases fluctuates for a variety of reasons, including voluntary and involuntary dismissals. Voluntary dismissals include cases in which a plaintiff accepts an offer of judgment from RJRT, Lorillard Tobacco and/or RJRT's affiliates and indemnitees. An offer of judgment, if rejected by the plaintiff, preserves RJRT's and Lorillard Tobacco's right to recover attorneys' fees under Florida law in the event of a verdict favourable to RJRT or Lorillard Tobacco, or affiliates of such entities. Such offers are sometimes made through court-ordered mediations.

34. 41 trials occurred in Engle progeny cases in Florida state and federal courts against RJRT, B&W and/or Lorillard Tobacco from 1 January 2019 through 31 December 2021, and additional state court trials are scheduled for 2022.

35. The following chart identifies the number of trials in Engle progeny cases as at 31 December 2021 and additional information about the adverse judgments entered:

<table>
<thead>
<tr>
<th>Number of trials resulting in plaintiffs’ verdicts</th>
<th>Total damages awarded in final judgments against RJRT</th>
</tr>
</thead>
<tbody>
<tr>
<td>21**</td>
<td>US$224,990,000 (approximately £168 million)</td>
</tr>
</tbody>
</table>

** Number of adverse judgments appealed by RJRT on the 41 trials resulting in plaintiffs’ verdicts 1 January 2019 to 31 December 2021 (note 11):

<table>
<thead>
<tr>
<th>Number of adverse judgments appealed by RJRT</th>
<th>Amount of overall damages comprising 'compensatory damages' (approximately)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 (note 12)</td>
<td>US$65,440,000 (of overall US$224,990,000) (approximately £48 million of £168 million)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of adverse judgments appealed by RJRT</th>
<th>Amount of overall damages comprising 'punitive damages' (approximately)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>US$159,550,000 (of overall US$224,990,000) (approximately £118 million of £166 million)</td>
</tr>
</tbody>
</table>

36. By statute, Florida applies a US$200 million (approximately £153.8 million) bond cap to all Engle progeny cases in the aggregate. Individual bond caps for any given Engle progeny case vary depending on the number of judgments in effect at a given time. Judicial attempts by several plaintiffs in the Engle progeny cases to challenge the bond cap as violating the Florida Constitution have failed. In addition, bills have been introduced in sessions of the Florida legislature that would eliminate the Engle progeny bond cap, but those bills have not been enacted as of 31 December 2021.

37. In 2021, RJRT or Lorillard Tobacco paid judgments in five Engle progeny cases. Those payments totalled US$15.14 million (approximately £11.2 million) in compensatory or punitive damages. Additional costs were paid in respect of attorneys’ fees and statutory interest.

38. Appeals of individual Engle progeny cases as at 31 December 2021 include 15 adverse judgments appealed by RJRT.

<table>
<thead>
<tr>
<th>Number of adverse judgments appealed by RJRT</th>
<th>Number of adverse judgments, in which RJRT still has time to file an appeal</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 (note 13)</td>
<td>3 (note 12)</td>
</tr>
</tbody>
</table>

Note 11: The 21 trials include two cases that were tried twice (Gloger v. R.J. Reynolds Tobacco Co. and Bessent-Dixon v. R.J. Reynolds Tobacco Co.) and one case (Robert Miller v. R.J. Reynolds Tobacco Co.) where plaintiff moved for a new trial following a plaintiff’s verdict where the jury awarded no compensatory or punitive damages, and an adverse judgment has not yet been entered. Plaintiff’s motion for new trial on compensatory damages was granted and RJRT appealed.

Note 12: Of the 13 adverse verdicts appealed by RJRT as a result of judgments arising in the period 1 January 2019 to 31 December 2021:

a. 5 appeals remain undecided in the District Courts of Appeal; and
b. 7 appeals were decided and/or closed in the District Court of Appeals. Of these 7 appeals, 6 were affirmed in favour of plaintiff (review of by the Florida Supreme Court has been sought in 3 of the 7 cases), and 1 was reversed for a new trial; and

Note 13: Of the 15 adverse judgments appealed by RJRT (during the period 1 January 2019 to 31 December 2021):

a. 5 appeals remain undecided in the District Courts of Appeal; and
b. 9 appeals were decided and/or closed in the District Courts of Appeal, and 1 appeal was reversed by the Eleventh Circuit. Of these appeals, 5 were affirmed in favour of plaintiff, 3 in which review of Florida Supreme Court was sought, 1 was voluntarily dismissed and judgment paid, 1 in which the Eleventh Circuit reversed the district court’s denial of Defendants’ motion for judgment in accordance with the verdict, and 3 were reversed for a new trial; and
c. does not include four cases that were appealed prior to the relevant time period but which remain pending before the Florida Supreme Court.

256
31 Contingent Liabilities and Financial Commitments

Continued

(c) Individual Cases

39. As of 31 December 2021, 222 individual cases were pending in the United States against RJRT, B&W and/or Lorillard Tobacco. This category of cases includes smoking and health cases alleging personal injuries caused by tobacco use or exposure brought by or on behalf of individual plaintiffs based on theories of negligence, strict liability, breach of express or implied warranty, and violations of state deceptive trade practices or consumer protection statutes. The plaintiffs seek to recover compensatory damages, attorneys’ fees and costs, and punitive damages. The category does not include the Engle progeny cases, Broin II cases, and Filter Cases discussed above and below. One of the individual cases is brought by or on behalf of an individual or his/her survivors alleging personal injury as a result of exposure to ETS.

40. The following chart identifies the number of individual cases pending as of 31 December 2021 as against the number pending as of 31 December 2020, along with the number of Engle progeny cases, Broin II cases, and Filter Cases, which are discussed further below.

<table>
<thead>
<tr>
<th>Case Type</th>
<th>U.S. Case Numbers 31 December 2021</th>
<th>U.S. Case Numbers 31 December 2020</th>
<th>Change in Number</th>
<th>Increase/Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Smoking and Health Cases</td>
<td>222</td>
<td>189</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td>Engle Progeny Cases (Number of Plaintiffs)</td>
<td>1,071 (1,304)</td>
<td>1,400 (1,725)</td>
<td>(329)</td>
<td>(27)</td>
</tr>
<tr>
<td>Broin II Cases (note 16)</td>
<td>1,200</td>
<td>1,227</td>
<td>(27)</td>
<td></td>
</tr>
<tr>
<td>Filter Cases (note 17)</td>
<td>46</td>
<td>48</td>
<td>(2)</td>
<td></td>
</tr>
</tbody>
</table>

(Note 14) Out of the 222 pending individual smoking and health cases, six have received adverse verdicts or judgments in the court of first instance or on appeal, and the total amount of those verdicts or judgments is approximately US$150.1 million (approximately £110.8 million).

(Note 15) The number of Engle progeny cases will fluctuate as cases are dismissed or if any of the dismissed cases are appealed. Please see earlier table in paragraph 35.

(Note 16) Broin v. Philip Morris, Inc. was a class action filed in Circuit Court in Miami-Dade County, Florida in 1991 and brought on behalf of flight attendants alleged to have suffered from diseases or ailments caused by exposure to ETS in airplane cabins. In October 1997, RJRT, B&W, Lorillard Tobacco and other cigarette manufacturer defendants settled Broin, agreeing to pay a total of US$300 million (approximately £221.5 million) in three annual US$100 million (approximately £73.3 million) installments, allocated among the companies by market share, to fund research on the early detection and cure of diseases associated with tobacco smoke. It also required those companies to pay a total of US$49 million (approximately £36.2 million) for the plaintiffs’ counsel’s fees and expenses. RJRT’s portion of these payments was approximately US$86 million (approximately £63.5 million); B&W’s was approximately US$57 million (approximately £42.1 million); and Lorillard Tobacco’s was approximately US$31 million (approximately £22.9 million). The settlement agreement, among other things, limits the types of claims class members may bring and eliminates claims for punitive damages. The settlement agreement also provides that, in individual cases by class members that are referred to as Broin II lawsuits, the defendants will bear the burden of proof with respect to whether ETS can cause certain specifically enumerated diseases, referred to as ‘specific causation’. With respect to all other liability issues, including whether an individual plaintiff’s disease was caused by his or her exposure to ETS in airplane cabins, referred to as ‘general causation’, individual plaintiffs will bear the burden of proof. On 7 September 1999, the Florida Supreme Court approved the settlement. There have been no Broin II trials since 2007. There have been periodic efforts to activate cases and the Group expects this to continue over time.

(Note 17) Includes claims brought against Lorillard Tobacco and Lorillard Inc. by individuals who seek damages resulting from their alleged exposure to asbestos fibres that were incorporated into filter material used in one brand of cigarettes manufactured by a predecessor to Lorillard Tobacco for a limited period of time ending more than 50 years ago. Pursuant to the terms of a 1952 agreement between P. Lorillard Company and H&V Specialties Co., Inc. (the manufacturer of the filter material), Lorillard Tobacco is required to indemnify Hollingsworth & Vose for legal fees, expenses, judgments and resolutions in cases and claims alleging injury from finished products sold by P. Lorillard Company that contained the filter material. As of 31 December 2021, Lorillard Tobacco and/or Lorillard Inc. was a defendant in 46 Filter Cases. Since 1 January 2019, Lorillard Tobacco and RJRT have paid, or have reached agreement to pay, a total of approximately US$25.9 million (approximately £19.1 million) in settlements to resolve 102 Filter Cases.

(d) State Settlement Agreements

41. In November 1998, the major U.S. cigarette manufacturers, including RJRT, B&W and Lorillard Tobacco, entered into the Master Settlement Agreement (MSA) with attorneys general representing 46 U.S. states, the District of Columbia and certain U.S. territories and possessions. These cigarette manufacturers previously settled four other cases, brought on behalf of Mississippi, Florida, Texas and Minnesota, by separate agreements with each state (collectively and with the MSA, the ‘State Settlement Agreements’).

42. These State Settlement Agreements settled all health care cost recovery actions brought by, or on behalf of, the settling jurisdictions; released the defending major U.S. cigarette manufacturers from various additional present and potential future claims; imposed future payment obligations in perpetuity on RJRT, B&W, Lorillard Tobacco and other major U.S. cigarette manufacturers; and placed significant restrictions on their ability to market and sell cigarettes and smokeless tobacco products. In accordance with the MSA, various tobacco companies agreed to fund a US$5.2 billion (approximately £3.8 billion) trust fund to be used to address the possible adverse economic impact of the MSA on tobacco growers.

287
31 Contingent Liabilities and Financial Commitments

43. RJRT and SFNTC are subject to the substantial payment obligations under the State Settlement Agreements. Payments under the State Settlement Agreements are subject to various adjustments for, among other things, the volume of cigarettes sold, relative market share, operating profit and inflation. Reynolds American’s operating subsidiaries’ expenses and payments under the State Settlement Agreements for 2018, 2019, 2020 and 2021 and the projected expenses and payments for 2022 and onwards are set forth below (in millions of U.S. dollars)*:

<table>
<thead>
<tr>
<th>Settlement expenses</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022 and thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Settlement cash payments</td>
<td>$2,741</td>
<td>$2,762</td>
<td>$3,572</td>
<td>$3,420</td>
<td></td>
</tr>
<tr>
<td>Projected settlement expenses</td>
<td>$&gt;3,300</td>
<td>$&gt;3,200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Projected settlement cash payments</td>
<td>$&gt;3,100</td>
<td>$&gt;3,200</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Subject to adjustments for changes in sales volume, inflation, operating profit and other factors. Payments are allocated among the companies on the basis of relative market share or other methods.

44. The State Settlement Agreements have materially adversely affected RJRT’s shipment volumes. Reynolds American believes that these settlement obligations may materially adversely affect the results of operations, cash flows or financial position of Reynolds American and RJRT in future periods. The degree of the adverse impact will depend, among other things, on the rate of decline in U.S. cigarette sales in the premium and value categories, RJRT’s share of the domestic premium and value cigarette categories, and the effect of any resulting cost advantage of manufacturers not subject to the State Settlement Agreements.

45. In addition, the MSA includes an adjustment that potentially reduces the annual payment obligations of RJRT, Lorillard Tobacco and the other signatories to the MSA, known as ‘Participating Manufacturers’ (PMs). Certain requirements, collectively referred to as the ‘Adjustment Requirements’, must be satisfied before the Non-Participating Manufacturers (NPM) Adjustment for a given year is available: (i) an Independent Auditor must determine that the PMs have experienced a market share loss, beyond a triggering threshold, to those manufacturers that do not participate in the MSA (such non-participating manufacturers being referred to as NPMs); and (ii) in a binding arbitration proceeding, a firm of independent economic consultants must find that the disadvantages of the MSA were a significant factor contributing to the loss of market share. This finding is known as a significant factor determination.

46. When the Adjustment Requirements are satisfied, the MSA provides that the NPM Adjustment applies to reduce the annual payment obligation of the PMs. RJRT and Lorillard Tobacco are or were involved in NPM Adjustment proceedings concerning the years 2003 to 2019. In 2012, RJRT, Lorillard Tobacco, and SFNTC entered into an agreement (the Term Sheet) with certain settling states that resolved accrued and potential NPM adjustments for the years 2003 through 2012 and, as a result, RJRT and SFNTC collectively received, or are to receive, more than US$3.1 billion (approximately £812.1 million) in credits that, in substantial part, were applied to MSA payments in 2014 through 2017. After an arbitration panel ruled in September 2013 that six states had not diligently enforced their qualifying statutes in the year 2003, additional states joined the Term Sheet. RJRT executed the NPM Adjustment Settlement Agreement on 25 September 2017 (which incorporated the Term Sheet). Since the NPM Adjustment Settlement Agreement was executed, an additional 10 states have joined. NPM proceedings are ongoing and could result in further reductions of the companies’ MSA-related payments.

47. RJRT and Lorillard Tobacco are or were involved in NPM Adjustment proceedings concerning the years 2003 to 2019. In 2012, RJRT, Lorillard Tobacco, and SFNTC entered into an agreement (the Term Sheet) with certain settling states that resolved accrued and potential NPM adjustments for the years 2003 through 2012 and, as a result, RJRT and SFNTC collectively received, or are to receive, more than US$3.1 billion (approximately £812.1 million) in credits that, in substantial part, were applied to MSA payments in 2014 through 2017. After an arbitration panel ruled in September 2013 that six states had not diligently enforced their qualifying statutes in the year 2003, additional states joined the Term Sheet. RJRT executed the NPM Adjustment Settlement Agreement on 25 September 2017 (which incorporated the Term Sheet). Since the NPM Adjustment Settlement Agreement was executed, an additional 10 states have joined. NPM proceedings are ongoing and could result in further reductions of the companies’ MSA-related payments.

48. On 18 January 2017, the State of Florida filed a motion to join Imperial Tobacco Group, PLC (ITG) as a defendant and to enforce the Florida State Settlement Agreement, which motion was sought payment under the Florida State Settlement Agreement of approximately US$45 million (approximately £33.2 million) with respect to the four brands (Winston, Salem, Kool and Maverick) that were sold to ITG in the divestiture of certain assets, on 12 June 2015, by subsidiaries or affiliates of Reynolds American and Lorillard, together with the transfer of certain employees and certain liabilities, to a wholly owned subsidiary of Imperial Brands plc (the Divestiture), referred to as the ‘Acquired Brands’. The motion also claimed future annual losses of approximately US$30 million per year (approximately £22.1 million) absent the court’s enforcement of the Florida State Settlement Agreement. The State’s motion sought, among other things, an order declaring that RJRT and ITG are in breach of the Florida Settlement Agreement and are required, jointly and severally, to make annual payments to the State under the Florida State Settlement Agreement with respect to the Acquired Brands. In addition, on 18 January 2017, PM USA filed a motion to enforce the Florida State Settlement Agreement, asserting among other things that RJRT and ITG breached that agreement by failing to make settlement payments as to the Acquired Brands, which PM USA asserts has improperly shifted settlement payment obligations to PM USA. On 27 January 2017, RJRT sought leave to file a supplemental pleading for breach by ITG of its obligations regarding jonder into the Florida State Settlement Agreement. The Florida court, on 30 March 2017, ruled that ITG should be joined into the enforcement action.
31 Contingent Liabilities and Financial Commitments

49. After a bench trial, on 27 December 2017 the court entered an order holding that RJRT (not ITG) is liable for annual settlement payments for the Acquired Brands, finding that ITG did not assume liability for annual settlement payments under the terms of the asset purchase agreement relating to the Divestiture and RJRT remained liable for payments under the Florida State Settlement Agreement as to the Acquired Brands. In January 2018, the auditor of the Florida State Settlement Agreement adjusted the final 2017 invoice for the annual payment and amended the 2015 and 2016 invoices for the respective annual payment and the net operating profit penalties for each of 2015, 2016 and 2017 under the Florida Settlement Agreement, based on the auditor’s interpretation of the court’s order. The adjusted invoices reflected amounts due to both the State of Florida and PM USA. In total, the estimated additional amounts due were US$99 million (approximately £73.1 million) with US$84 million (approximately £62.1 million) to the State of Florida and US$15 million (approximately £11.8 million) to PM USA. RJRT advised the auditor that it disputed these amounts, and therefore no further amounts were due or would be paid for those years pending the final resolution of RJRT’s appeal of the court’s order. On 23 January 2018, RJRT filed a notice of appeal, and on 25 January 2018, RJRT filed an amended notice of appeal, and PM USA filed a notice of appeal as to the court’s ruling as to ITG. On 26 January 2018, the State moved for recovery of its attorneys’ fees and costs from RJRT. The State and PM USA filed a joint motion for the entry of final judgment on 1 February 2018. The court declined to enter a final judgment until after resolution of the dispute between RJRT and PM USA regarding PM USA’s assertion that settlement payment obligations have been improperly shifted to PM USA. On 15 August 2018, the court entered a final judgment in the action (the Final Judgment). As a result of the Final Judgment, PM USA’s challenge to RJRT’s accounting assumptions related to the Acquired Brands was rendered moot, subject to reinstatement if ITG joins the Florida State Settlement Agreement or if judgment is reversed. On 29 August 2018, RJRT filed a notice of appeal on the Final Judgment. On 7 September 2018, PM USA filed a notice of appeal with respect to the court’s ruling as to ITG. On 12 September 2018, RJRT filed a motion to consolidate RJRT’s appeal with the appeal filed by PM USA, which was granted on 1 October 2018. Appellate briefs were filed in December 2018. On 18 February 2019, an intermediate appellate panel was scheduled for 7 April 2020, was conducted through video conference on 9 June 2020. On 29 July 2020, Florida’s Fourth District Court of Appeal affirmed the Final Judgment. On 12 August 2020, RJRT filed a motion for rehearing or for certification to the Florida Supreme Court of the 29 July 2020 decision. On 30 November 2020, RJRT posted an additional bond in the amount of US$84,102,984.75 (approximately £62.1 million), over the US$103,694,155.08 (approximately £76.6 million) bond initially posted, to cover additional disputed amounts plus two years of statutory interest. The total amount RJRT bonded for its appeal was US$137,797,139.63 (approximately £136.6 million). RJRT’s motion for rehearing or certification to the Florida Supreme Court was denied on 18 September 2020 and its motion for review was denied by the Florida Supreme Court on 15 October 2020. RJRT satisfied the Final Judgment (approximately US$192,869,589.86 (approximately £142,400,000)) and paid approximately US$5.2 million (approximately £4.2 million) of Florida’s attorneys’ fees. RJRT’s appellate bonds were released to RJRT by order dated 5 November 2020. RJRT is seeking indemnification from ITG in the Delaware action, as described below.

50. On 17 February 2017, ITG filed an action in the Court of Chancery of the State of Delaware seeking declaratory relief against Reynolds American and RJRT. In its complaint, ITG asked the court to declare various matters related to its rights and obligations under the asset purchase agreement (and related documents) relating to the Divestiture with respect to the subject of the Florida enforcement litigation. On 24 March 2017, Reynolds American and RJRT answered the ITG complaint and counterclaimed. Cross-motions for partial judgment on the pleadings were filed focusing on whether ITG’s obligation to use “reasonable best efforts” to join the Florida State Settlement Agreement continued after the 12 June 2015 closing. On 30 November 2017, following argument, the Delaware court ruled in favour of RJRT, holding that ITG’s obligation to use its reasonable best efforts to join the Florida Settlement Agreement did not terminate due to the closing of the asset purchase agreement relating to the Divestiture. On 4 January 2019, RJRT filed another motion for partial judgment on the pleadings seeking to resolve two contract-interpretation questions under the asset purchase agreement: first, to the extent RJRT is held liable for settlement payments based on post-closing sales of the Acquired Brands, ITG assumed this liability, and second, that the asset purchase agreement does not entitle ITG to a unique protection from an equity-fee law that does not yet exist in a Previously Settled State. Argument on RJRT’s motion for partial judgment was heard on 4 June 2019. On 23 September 2019, the Delaware Chancery Court declined to resolve, at that time, the first issue, whether ITG had assumed any liability imposed on RJRT for making settlement payments on ITG’s brands. The court concluded that both sides had presented reasonable interpretations of the asset purchase agreement, which was therefore ambiguous, so the court would receive any parol evidence that may exist to help interpret the intent of the asset purchase agreement on assumed liabilities. The court granted RJRT’s motion on the second issue and ruled that ITG could not refuse to join the Florida State Settlement Agreement unless a joinder exempted it from a future equity-fee statute. On 11 October 2019, ITG filed in the Chancery Court a motion to seek interlocutory appeal in the Delaware Supreme Court on the second issue, which was denied on 31 October 2019. On 31 October 2019, ITG filed a notice of interlocutory appeal directly to the Delaware Supreme Court, which was denied on 7 November 2019. Following the settlement of the Minnesota and Texas enforcement litigations, as described below, claims in the Delaware litigation with respect to those states were voluntarily dismissed by orders entered, respectively, on 7 April 2021 and 2 June 2021. On 20 August 2021, Reynolds American and RJRT amended their cross-motions for partial judgment on the pleadings to account for those settlements, as well as the resolution of the Florida enforcement litigation, including, among other things, a claim for indemnification for the Final Judgment in Florida. Discovery is ongoing and scheduled to end in early 2022. A hearing on summary judgment motions is scheduled to follow, and trial is scheduled to begin on 8 September 2022.

51. On 26 March 2018, the State of Minnesota filed a motion against RJRT to enforce the Minnesota State Settlement Agreement, which motion sought payments under the Minnesota State Settlement Agreement of approximately US$40 million (approximately £29.5 million) with respect to the Acquired Brands. The motion also claimed future annual losses of approximately US$15 million (approximately £11.1 million) absent the court’s enforcement of the Minnesota State Settlement Agreement.
31 Contingent Liabilities and Financial Commitments Continued

The State of Minnesota also filed a separate complaint against ITG, which complained the same payments. The State’s motion against RJRT and complaint against ITG sought, among other things, an order declaring that RJRT and ITG were in breach of the Minnesota State Settlement Agreement and were jointly and severally liable to make annual payments to the State of Minnesota under the Minnesota State Settlement Agreement with respect to the Acquired Brands. In addition, on 28 March 2018, PM USA filed a motion to enforce the Minnesota State Settlement Agreement, asserting, among other things, that RJRT and ITG breached the Minnesota State Settlement Agreement by failing to make settlement payments as to the Acquired Brands, which PM USA asserted had improperly shifted settlement payment obligations to PM USA. On 27 March 2018, the Minnesota court consolidated the motions to enforce and separate complaint against ITG into one proceeding captioned In re Petition of the State of Minnesota for an Order Compelling Payments of Settlement Proceeds Related to ITG Brands LLC, Court File No. 62-CV-18-1912. On 11 June 2018, the court held a scheduling conference in the case and by order dated 21 June 2018, set a discovery schedule for the case, under which discovery is complete. A hearing on the motions to enforce to determine if RJRT and/ or ITG are liable to make payments on the Acquired Brands was held on 26 June 2019. On 24 September 2019, the Minnesota District Court issued an Order and Memorandum, holding RJRT liable for settlement payments on the Acquired Brands, and determining the issue of whether RJT is a ‘successor or assign’ of RJRT under the Minnesota State Settlement Agreement is unresolved, reasoning ITG’s status depends on whether it satisfied its post-closing obligation to expend its reasonable best efforts to join the Minnesota State Settlement Agreement. On 23 December 2018, ITG filed a motion in the Minnesota District Court seeking certification of an appeal of certain questions arising from the 24 September 2019 order. On 21 January 2020, a hearing was held on ITG’s motion seeking certification of an appeal. On 19 February 2020, the Minnesota District Court entered an Order and Memorandum denying ITG’s motion for certification. A multi-day hearing to determine whether ITG is liable for settlement payments was completed on 9 September 2020. The parties filed post-hearing briefs on 13 November 2020. A status conference was held on 3 March 2021, at which the judge indicated a hearing on the nature of settlement discussions by 15 March 2021. On 15 March 2021, the parties resolved all claims and an order of dismissal was entered by the Minnesota district court on 17 March 2021.

52. On 28 January 2019, the State of Texas filed motions in the original Texas health care reimbursement case, brought against the tobacco industry that led to the Texas State Settlement Agreement, to join ITG as a defendant and to enforce the Texas State Settlement Agreement against RJRT and ITG, seeking payment under the Texas State Settlement Agreement of past and present claims of approximately US$260.4 million (approximately £192.2 million) with respect to the Acquired Brands that were sold to ITG in the Divestiture. The motion also claimed future annual losses of an unspecified amount absent the court’s enforcement of the Texas State Settlement Agreement. The State’s motion sought, among other things, an order declaring that RJRT, or in the alternative, ITG, is in breach of the Texas Settlement Agreement and is required to make annual payments to the State under the Texas State Settlement Agreement with respect to the Acquired Brands. In addition, on 29 January 2019, PM USA filed a motion to enforce the Texas State Settlement Agreement, asserting among other things that RJRT and ITG breached that agreement by failing to make settlement payments as to the Acquired Brands, which PM USA asserts has improperly shifted settlement payment obligations to PM USA. After completion of discovery, a hearing on the motions to enforce was held on 30 October 2019. On 25 February 2020, the Court entered a Memorandum Opinion and Order holding that RJRT remains liable for settlement payments on the Acquired Brands under the Texas Settlement Agreement. The Court further held that, although ITG is unambiguously an assign within the meaning of the Texas Settlement Agreement, a final determination of the scope of ITG’s obligations under the asset purchase agreement is to be determined in the litigation pending before the Delaware Court. Pursuant to the Court’s direction, on 9 March 2020 the parties submitted a status report indicating the remaining issues before the Court include RJRT’s position that the Court should subtract the equity fee payments made on the Acquired Brands by ITG’s distributors from the settlement payments due by RJRT after including the Acquired Brands in calculating damages, whether a final judgment should be entered in favour of ITG, whether a partial final judgment should be entered against RJRT and the State’s request for an award of attorneys’ fees and costs against RJRT and/ or ITG. On 5 May 2020 the Court entered final judgment (later clarified in a 14 August 2020 amended judgment) on the State’s motion, ordering RJRT to pay all settlement amounts due on the Acquired Brands under the Texas Settlement Agreement; granting RJRT a full dollar-for-dollar set-off for all equity fee payments made on the Acquired Brands by ITG or its distributors, but holding RJRT liable for any equity fee payments that are lawfully refunded; and ordering the case closed, to be reopened after ITG’s liability under the asset purchase agreement is determined by the Delaware Court. ITG’s equity fee payments to Texas for the Acquired Brands currently equal approximately 90% of the annual Texas settlement payments for those brands. Thus, the settlement payments for those Acquired Brands exceed ITG’s equity fee payments by approximately US$3 million (approximately £2.2 million) per year. As such, RJRT would owe approximately US$3 million (approximately £2.2 million) a year after an equity fee basis. Due to how the profit penalty is allocated, RJRT will pay approximately US$10 million (approximately £7.4 million) less in 2019 in Texas profit penalty than it would have paid had ITG joined, with that trend continuing in future years. However, because ITG made equity fee payments at a substantially lower rate before 2019, and because of how the profit penalty was calculated before now, RJRT owed approximately US$260.4 million (before interest) (approximately £192.2 million) in past payments under the judgment through 2020. On 3 and 4 June 2020, respectively, RJRT and ITG filed notices of appeal of the 5 May 2020 judgment. In August 2020, RJRT filed a notice of appeal, and in September 2020, the State and ITG filed notices of appeal from the portion of the judgment denying the motion to remove the equity fee set-off. RJRT moved to dismiss ITG’s appeal for lack of jurisdiction, which was ordered by the Fifth Circuit Court of Appeals to be argued with ITG’s appeal. On 2 November 2020 RJRT filed its appellate brief. On 19 January 2021 the parties filed responses. On 27 May 2021, the parties entered into a settlement agreement resolving all claims. On 27 May 2021, the parties filed a stipulation dismissing the claims and on 28 May 2021, the Fifth Circuit dismissed the parties’ appeals.
31 Contingent Liabilities and Financial Commitments Continued

53. In June 2015, ITG joined the Mississippi Settlement Agreement. On 26 December 2016, PM USA filed a Motion to Enforce Settlement Agreement against RJRT and ITG alleging RJRT and ITG failed to act in good faith in calculating the base-year net operating profits for the Acquired Brands, claiming damages of approximately US$8 million (approximately £4.4 million) through 2017. On 21 February 2019, the Chancery Court of Jackson County, Mississippi held a scheduling conference and issued a discovery schedule order. A hearing on PM USA’s Motion to Enforce Settlement Agreement originally scheduled for 3-6 May 2021 was adjourned on consent of the parties to 11-12 August 2021. On 8 June 2021, PM USA and RJRT entered into a settlement agreement resolving the outstanding payment calculation issues. On 11 June 2021, the Mississippi Chancery Court entered an order withdrawing PM USA’s motion to enforce. On 3 December 2019, the State of Mississippi filed a Notice of Violation and Motion to Enforce the Settlement Agreement in the Chancery Court of Jackson County, Mississippi against RJRT, PM USA and ITG, seeking a declaration that the base year 1997 net operating profit to be used in calculating the Net Operating Profit Adjustment was not affected by the change in the federal corporate tax rate in 2018 from 35% to 21%, and an order requiring RJRT to pay the approximately US$5 million (approximately £3.7 million) difference in its 2018 payment because of this issue. Determination of this issue may affect RJRT’s annual payment thereafter. A hearing on Mississippi’s Motion to Enforce Settlement Agreement occurred on 6-7 October 2021.

54. In January 2021, RJRT reached an agreement with several MSA states to waive RJRT’s claims under the MSA in connection with a settlement between those MSA states and a non-participating manufacturer, S&M Brands, Inc. (S&M Brands), under which the states released certain claims against S&M Brands in exchange for receiving a portion of the funds S&M Brands had deposited into escrow accounts in those states pursuant to the states’ escrow statutes. In consideration for waiving claims, RJRT, together with SFNTC, received approximately $55.4 million from the escrow funds paid to those MSA states under their settlement with S&M Brands.

Tobacco-Related Litigation Outside the U.S.

55. As at 31 December 2021:

- a. medical reimbursement actions are being brought in Angola, Brazil, Canada, Nigeria and South Korea;
- b. class actions are being brought in Canada and Venezuela; and
- c. active tobacco product liability claims against the Group’s companies existed in 12 markets outside the U.S. The only markets with five or more claims were Argentina, Brazil, Canada, Nigeria and Italy.

(a) Medical reimbursement cases

Angola

56. In or about November 2016, BAT Angola affiliate Sociedade Unificada de Tabaco de Angola SA filed with a collective action filed in the Provincial Court of Luanda, 2nd Civil Section, by the consumer association Associação Angolana dos Direitos do Consumidor (AADIC). The lawsuit seeks damages of AOA 800,000,000 (approximately £1,900,000) allegedly incurred by the Angolan Instituto Nacional do Controle do Cancro (INCC) for the cost of treating tobacco-related disease, non-material damages allegedly suffered by certain individual smokers on the rolls of INCC, and the mandating of certain cigarette package warnings. SUT filed its answer to the claim on or about 5 December 2016. The case remains pending.

Argentina

57. In 2007, the non-governmental organisation the Argentina Tort Law Association (ATLA) and Emma Mendoza Voguet brought a reimbursement action against Nobleza Piccaro S.A. I.C.Y.F. (Nobleza) and Massalin Particulares. The case is being heard in the Contencioso Administrative Court. The parties filed conclusive briefs on 20 May 2019. On 11 May 2021, the Court dismissed the case on the basis of plaintiffs’ lack of legal standing to bring the suit. Plaintiffs did not appeal within the applicable deadline and accordingly the judgment dismissing the case has become final.

Canada

58. On 1 March 2019, the Quebec Court of Appeal handed down a judgment which largely upheld and endorsed the lower court’s previous decision in two Quebec class actions (the Quebec Class Actions), as further described below. The share of the judgment for Imperial, the Group’s operating company in Canada, is approximately CAD $9.2 billion (approximately £5.4 billion). As a result of this judgment, there were attempts by the Quebec plaintiffs to obtain payment out of the CAD $756 million (approximately £443 million) on deposit with the court. JTI-MacDonald Corp (a co-defendant in the cases) filed for creditor protection under the Companies’ Creditors Arrangement Act (the CCAA) on 8 March 2019. A court order to stay all tobacco litigation in Canada against all defendants (including RJRT and its affiliate R.J. Reynolds Tobacco International Inc. (collectively, the RJR Companies)) until 4 April 2019 was obtained, and the need for a mediation process to resolve all the outstanding litigation across the country was recognised. On 12 March 2019 Imperial filed for creditor protection under the CCAA. In its application Imperial asked the Ontario Superior Court to stay all pending or contemplated litigation against Imperial, certain of its subsidiaries and all other Group companies that were defendants in the Canadian tobacco litigation, including British American Tobacco p.l.c. (the Company), Investments, Industries and Carreras Rothmans Limited (collectively, the UK Companies). On 22 March 2019, Rothmans, Benson & Hedges Inc. also filed for CCAA protection and obtained a stay of proceedings (together with the other two stays, the Stays). The Stays are currently in place until 31 March 2022. While the Stays are in place, no steps are to be taken in connection with the Canadian tobacco litigation with respect to any of the defendants.

59. The below represents the state of the referenced litigation as at the advent of the Stays.

60. Following the implementation of legislation enabling provincial governments to recover health-care costs directly from tobacco manufacturers, 10 actions for recovery of health-care costs arising from the treatment of smoking- and health-related diseases have been brought. These proceedings name various Group companies as defendants, including the UK Companies and Imperial as well as the RJR Companies. Pursuant to the terms of the 1999 sale of RJR’s international tobacco business to Japan Tobacco Incorporated (JTI), JTI has agreed to indemnify RJRT for all liabilities and obligations (including litigation costs) arising in respect of the Canadian recoupment actions. Subject to a reservation of rights, JTI has assumed the defence of the RJR Companies in these actions.

61. The 10 cases were proceeding in British Columbia, New Brunswick, Newfoundland and Labrador, Ontario, Quebec, Manitoba, Alberta, Saskatchewan, Nova Scotia and Prince Edward Island. The enabling legislation is in force in all 10 provinces. In addition, legislation has received Royal Assent in two of the three territories in Canada, but has yet to be proclaimed into force.
31 Contingent Liabilities and Financial Commitments

<table>
<thead>
<tr>
<th>Canadian province</th>
<th>Act pursuant to which Claim was brought</th>
<th>Companies named as Defendants</th>
<th>Current stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>British Columbia</td>
<td>Tobacco Damages and Health Care Costs Recovery Act 2000</td>
<td>Imperial, Investments, Industries, Carreras Rothsman Limited and the RJR Companies and other former Rothmans Group companies have been named as defendants and served.</td>
<td>The defences of Imperial, Investments, Industries, Carreras Rothsman Limited and the RJR Companies have been filed, and document production and discoveries were ongoing. On 13 February 2017 the Province estimated a range of damages between CAD $11.1 billion (approximately £6.5 billion) and CAD $23.2 billion (approximately £13.6 billion), including expected future costs. Following a motion to set a trial date, the New Brunswick Court of Queen’s Bench ordered that the trial commence on 4 November 2019. On 7 March 2019, the New Brunswick Court of Queen’s Bench released a decision which requires the Province to produce a substantial amount of additional documentation and data to the defendants. As a result, the original trial date of 4 November 2019 would have been delayed. No new trial date has been set.</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>Tobacco Damages and Health Care Costs Recovery Act 2006</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>The defences of Imperial, the UK Companies and the RJR Companies have been filed and document production and discoveries are substantially complete. The most recent expert report filed by the Province estimated a range of damages between CAD $11.1 billion (approximately £6.5 billion) and CAD $23.2 billion (approximately £13.6 billion) in 2016/2017 dollars for the period 1954 – 2060, and the Province amended the damages sought in its Statement of Claim to CAD $330 billion (approximately £192.9 billion). On 31 January 2019, the Province delivered a further expert report claiming an additional amount between CAD $9.4 billion (approximately £5.5 billion) and CAD $10.9 billion in damages (approximately £6.4 billion) in respect of ETS. No trial date has been set.</td>
</tr>
<tr>
<td>Ontario</td>
<td>Tobacco Damages and Health Care Costs Recovery Act 2009</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>The defences of Imperial, the UK Companies and the RJR Companies have been filed. The parties completed significant document production in the summer of 2017 and discoveries commenced in the autumn of 2018. On 15 June 2018, the Province delivered an expert report quantifying its damages in the range of CAD $280 billion (approximately £163.7 billion) – CAD $630 billion (approximately £388.2 billion) in 2016/2017 dollars. On 31 January 2019, the Province amended the damages sought in its Statement of Claim to CAD $330 billion (approximately £192.9 billion). On 31 January 2019, the Province delivered a further expert report claiming an additional amount between CAD $9.4 billion (approximately £5.5 billion) and CAD $10.9 billion in damages (approximately £6.4 billion) in respect of ETS. No trial date has been set.</td>
</tr>
<tr>
<td>Newfoundland and Labrador</td>
<td>Tobacco Health Care Costs Recovery Act 2001</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>The case is at an early case management stage. The defences of Imperial, the UK Companies and the RJR Companies have been filed and the Province began its document production in March 2018. Damages have not been quantified by the Province. No trial date has been set.</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>Tobacco Damages and Health Care Costs Recovery Act 2007</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>This case is at an early case management stage. The defences of Imperial, the UK Companies and the RJR Companies have been filed and the Province has delivered a test shipment of documents. Damages have not been quantified by the Province. No trial date has been set.</td>
</tr>
<tr>
<td>Manitoba</td>
<td>Tobacco Damages Health Care Costs Recovery Act 2006</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>This case is at an early case management stage. The defences of Imperial, the UK Companies and the RJR Companies have been filed and document production commenced. Damages have not been quantified by the Province. No trial date has been set.</td>
</tr>
<tr>
<td>Alberta</td>
<td>Crown’s Right of Recovery Act 2009</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>This case is at an early case management stage. The defences of Imperial, the UK Companies and the RJR Companies have been filed and the Province commenced its document production. The Province has stated its claim to be worth CAD $10 billion (approximately £5.8 billion). No trial date has been set.</td>
</tr>
</tbody>
</table>
31 Contingent Liabilities and Financial Commitments Continued

<table>
<thead>
<tr>
<th>Canadian province</th>
<th>Act pursuant to which Claim was brought</th>
<th>Companies named as Defendants</th>
<th>Current stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quebec</td>
<td>Tobacco Related Damages and Health Care Costs Recovery Act 2009</td>
<td>Imperial, Investments, Industries, the RJR Companies and Carreras Rothmans Limited have been named as defendants and served.</td>
<td>The case is at an early case management stage. The defences of Imperial, Investments, Industries, Carreras Rothmans Limited and the RJR Companies have been filed. Motions over admissibility of documents and damages discovery have been filed but not heard. The Province is seeking CAD$60 billion (approximately £35.1 billion). No trial date has been set.</td>
</tr>
<tr>
<td>Prince Edward Island</td>
<td>Tobacco Damages and Health Care Costs Recovery Act 2009</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>This case is at an early case management stage. The defences of Imperial, the UK Companies and the RJR Companies have been filed and the next step was expected to be document production, which the parties deferred for the time being. Damages have not been quantified by the Province. No trial date has been set.</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>Tobacco Health Care Costs Recovery Act 2005</td>
<td>Imperial, the UK Companies and the RJR Companies have been named as defendants and served.</td>
<td>This case is at an early case management stage. The defences of Imperial, the UK Companies and the RJR Companies have been filed. The Province provided a test document production in March 2018. Damages have not been quantified by the Province. No trial date has been set.</td>
</tr>
</tbody>
</table>

Nigeria

62. British American Tobacco (Nigeria) Limited (BAT Nigeria), the Company and Investments have been named as defendants in a medical reimbursement action by the federal government of Nigeria, filed on 6 November 2007 in the Federal High Court, and in similar actions filed by the Nigerian states of Kano (9 May 2007), Oyo (30 May 2007), Lagos (13 March 2008), Ogun (26 February 2008), and Gombe (17 October 2008) commenced in their respective High Courts. In the five cases that remain active, the plaintiffs seek a total of approximately 10.6 trillion Nigerian naira (approximately £14.9 billion) in damages, including special, anticipatory and punitive damages, restitution and disgorgement of profits, as well as declaratory and injunctive relief.

63. The suits claim that the state and federal government plaintiffs incurred costs related to the treatment of smoking-related illnesses resulting from allegedly tortious conduct by the defendants in the manufacture, marketing, and sale of tobacco products in Nigeria, and assert that the plaintiffs are entitled to reimbursement for such costs. The plaintiffs assert causes of action for negligence, negligent design, fraud and deceit, fraudulent concealment, breach of express and implied warranty, public nuisance, conspiracy, strict liability, indemnity, restitution, unjust enrichment, voluntary assumption of a special undertaking, and performance of another’s duty to the public.

64. The Company and Investments have made a number of challenges to the jurisdiction of the Nigerian courts. Such challenges are still pending (on appeal) against the federal government and the states of Lagos, Kano, Gombe and Ogun. The underlying cases are stayed or adjourned pending the final outcome of these jurisdictional challenges. In the state of Oyo, on 13 November 2015, and 24 February 2017, respectively, the Company’s and Investments’ jurisdictional challenges were successful in the Court of Appeal and the issuance of the writ of summons was set aside.

South Korea

65. In April 2014, Korea’s National Health Insurance Service (NHIS) filed a healthcare recoupment action against KT&G (a Korean tobacco company), PM Korea and BAT Korea (including BAT Korea Manufacturing). The NHIS is seeking damages of roughly 54 billion Korean Won (approximately £33.5 million) in respect of health care costs allegedly incurred by the NHIS treating patients with lung (small cell and squamous cell) and laryngeal (squamous cell) cancer between 2003 and 2012. Court hearings in the case, which constitute the trial, commenced in September 2014. On 20 November 2020, the court issued a judgment in favour of the defendants and dismissing all of the plaintiff’s claims. The NHIS filed an appeal of the judgment on 11 December 2020. Appellate proceedings commenced in June 2021 and remain ongoing.
**Financial Statements**

**Notes on Accounts Continued**

31 Contingent Liabilities and Financial Commitments Contained

**Brazil**

66. On 21 May 2019, the Federal Attorney’s Office (AGU) in Brazil filed an action in the Federal Court of Rio Grande do Sul against the Company, the BAT Group’s Brazilian subsidiary Souza Cruz LTDA (Souza Cruz), Philip Morris International, Philip Morris Brazil Indústria e Comércio LTDA and Philip Morris BrS/A, asserting claims for medical reimbursement for funds allegedly expended by the federal government as public health care expenses to treat 26 tobacco-related diseases over the last five years and that will be expended in perpetuity during future years, including diseases allegedly caused both by cigarette smoking and exposure to ETS. The action includes a claim for moral damages allegedly suffered by Brazilian society to be paid into a public welfare fund. The action is for an unspecified amount of monetary compensation, as the AGU seeks a bifurcated action in which liability would be determined in the first phase followed by an evidentiary phase to ascertain damages.

67. On 19 July 2019, the trial court ordered that service of the action on the Company be effected via service on Souza Cruz. On 6 August 2019, Souza Cruz refused to receive service on behalf of the Company due to Souza Cruz’s lack of power to receive the summons on behalf of the Company and such refusal was attached to the case files on 9 August 2019. On 7 August 2019, Souza Cruz was served with the complaint by the AGU and Souza Cruz’s acknowledgement of service was attached to the case files on 12 August 2019.

68. On 19 August 2019, Souza Cruz filed an interlocutory appeal challenging the 19 July 2019 trial court order permitting the AGU to effect service on the Company by serving Souza Cruz and requesting a stay of the proceedings until the appeal is decided. Souza Cruz also appealed the fact that several documents attached to the AGU’s complaint are in English, without proper translation, and it appealed the very short term of 30 days for the defendants to prepare their defences.

69. On 20 August 2019, Souza Cruz informed the trial court about the appeal and the trial court entered an order, which ordered the closure of the online system preventing the parties from submitting any petition so that no prejudice would be caused to the defendants and permitted the AGU, within 15 days of its notification, to respond to the argument that the service of a foreign defendant via its Brazilian subsidiary constituted proper service, denied the request for additional time to file defences, denied the request to have the foreign language documents attached to the initial complaint fully translated into Portuguese, and ordered that defences be filed within 30 business days. On 18 February 2020, Souza Cruz filed an interlocutory appeal (including a request to stay the deadline to file defences). On 12 March 2020, the court denied the request for a stay. On 11 May 2020, the court denied the interlocutory appeal.

Soouza Cruz and the Company submitted on 8 August 2020 requests for clarification of this appellate decision. The court granted the Company’s request to intervene, and rejected Souza Cruz and the Company’s request for clarification of the appellate decision, which decision became final on 12 May 2020. On 19 May 2020, a notice was sent to the Public Prosecutor’s Office (MPF) regarding the AGU’s request that the MPF join the action as a plaintiff. The MPF, in its response filed 10 July 2020, rejected the AGU’s request, and declined to join the action as party, but will act as an ‘inspector of the law’, which enables MPF to express its opinion on matters in the case. The court to date has not opened up the term for the AGU to reply to the defences presented. On 19 February 2021, the Associação de Controle do Tabagismo, Promoção da Saúde (ACT) filed a petition seeking to intervene in the case as amicus curiae, which petition remains pending. On 12 March 2021 and 26 March 2021, respectively, Souza Cruz and PMB filed petitions requesting that ACT’s powers be limited should ACT be admitted as amicus curiae. On 19 May 2021, ACT filed a brief in further support of its amicus curiae petition. On 8 August 2021, the Company responded to ACT’s request to intervene as amicus curiae, arguing that ACT’s request should be rejected or in the alternative that the scope of ACT’s intervention rights should be limited. On 31 August 2021, ACT responded to the Company’s submission. A court ruling on ACT’s petition is pending.

(b) Class Actions

**Canada**

70. As noted above, on 1 March 2019 the Quebec Court of Appeal handed down a judgment which largely upheld and endorsed the lower court’s previous decision in two Quebec Class Actions, as further described below. Imperial’s share of the judgment is approximately CAD $9.2 billion (approximately £4.4 billion). As a result of this judgment, there were attempts by the Quebec plaintiffs to obtain payment out of the CAD $758 million (approximately £443 million) on deposit with the court. JTI-MacDonnell, the BAT Group’s Canadian subsidiary, filed a petition requesting the court to order that the deposit be paid to the Quebec plaintiffs. The Quebec beneficiaries of the judgment challenged the petition, asserting that the funds were held as security that the Quebec plaintiffs would fulfill their obligations to the Quebec beneficiaries of the judgment. On 29 April 2021, the Quebec plaintiffs were granted a judgment which largely upheld and endorsed the lower court’s previous decision in the Quebec Class Action lawsuit against Imperial, certain of its subsidiaries and all other Group companies that were defendants in the Canadian tobacco litigation, including the UK Companies. On 22 March 2019, Rothmans, Benson & Hedges Inc. also filed for CCAA protection and obtained a stay of the ongoing litigation, including the UK Companies. On 22 March 2019, Benson & Hedges Inc. also filed for CCAA protection and obtained a stay of the proceedings (together with the other two stays, the Stays). The Stays are currently in place until 31 March 2022. While the Stays are in place, no steps are to be taken in connection with the Canadian tobacco litigation with respect to any of the defendants.

71. The below represents the state of the referenced litigation as at the advent of the Stays.

72. There are 11 class actions being brought in Canada against Group companies.
31 Contingent Liabilities and Financial Commitments Continued

73. Knight Class Action: the Supreme Court of British Columbia certified a class of all consumers who purchased Imperial cigarettes in British Columbia bearing ‘light’ or ‘mild’ descriptors since 1974. The plaintiff is seeking compensation for amounts spent on ‘light and mild’ products and a disgorgement of profits from Imperial on the basis that the marketing of light and mild cigarettes was deceptive because it conveyed a false and misleading message that those cigarettes are less harmful than regular cigarettes.

74. On appeal, the appellate court confirmed the certification of the class, but limited any financial liability, if proven, to 1997 onward. Imperial’s third-party claim against the federal government was dismissed by the Supreme Court of Canada. The federal government is seeking a cost order of CAD$55 million (approximately £2.9 million) from Imperial relating to its now dismissed third-party claim. After being dormant for several years, the plaintiff delivered a Notice of Intention to Proceed, and Imperial delivered an application to dismiss the action for delay. The application was heard on 23 June 2017 and was dismissed on 23 August 2017. Notice to class members of certification was provided on 14 February 2018. As at the date of the Stays, the next steps were expected to include discovery-related ones.

75. Growers’ Class Action: in December 2009, Imperial was served with a proposed class action filed by Ontario tobacco farmers and the Ontario Flue-Cured Tobacco Growers’ Marketing Board. The plaintiffs allege that Imperial and the Canadian subsidiaries of Philip Morris International and JTI failed to pay the agreed domestic contract price to the growers used in products manufactured for the export market and which were ultimately smuggled back into Canada. JTI has sought indemnification pursuant to the JTI Indemnities (discussed below at paragraphs 137-138). The plaintiffs seek damages in the amount of CAD$50 million (approximately £29.2 million). Various preliminary challenges have been heard, the last being a motion for summary judgment on a limitation period. The motion was dismissed and ultimately, leave to appeal to the Ontario Court of Appeal was dismissed in November 2016. In December 2017, the plaintiffs proposed that the action proceed by way of individual actions as opposed to a class action. As at the date of the Stays, the claim was in abeyance pending further action from the Court of Appeal.

76. Quebec Class Actions: there are currently two class actions in Quebec. On 21 February 2005, the Quebec Superior Court granted certification in two class actions against Imperial and two other domestic manufacturers. The court certified two classes, with the class definitions being revised in two class actions against Imperial and two other domestic manufacturers.

The group also includes the heirs of members who meet the criteria described above. Pursuant to the judgment, the plaintiffs were awarded damages and interest against Imperial and the Canadian subsidiaries of Philip Morris International and JTI in the amount of CAD$15.6 billion (approximately £9.1 billion), most of which was on a joint and several basis, of which Imperial’s share was CAD$10.4 billion (approximately £6.1 billion). An appeal of the judgment was filed on 28 June 2015. The court also awarded provisional execution pending appeal of CAD$1,131 million (approximately £661.1 million), of which Imperial’s share was approximately CAD$742 million (approximately £433.7 million). This order was subsequently overturned by the Court of Appeal. Following the cancellation of the order for provisional execution, the plaintiffs filed a motion against Imperial and one other manufacturer seeking security in the amount of CAD $5 billion (approximately £2.9 billion) to guarantee, in whole or in part, the payment of costs of the appeal and the judgment. On 27 October 2015, the Court of Appeal ordered the parties to post security in the amount of CAD$584 million (approximately £33.7 million), of which Imperial’s share was CAD$375 million (approximately £21.4 million). The security was paid in seven equal quarterly instalments of just over CAD$108 million (approximately £63.1 million) between 31 December 2015 and 30 June 2017. The appeal was heard in November 2016. On 1 March 2019, the trial judgment was upheld by an unanimous decision of the five-member panel of the Court of Appeal, with one exception being an amendment to the original interest calculation applied to certain portions of the judgment. The interest adjustment has resulted in the reduction of the total maximum award in the two cases to CAD $13.7 billion (approximately £8 billion) as of 1 March 2019, with Imperial’s share being reduced to approximately CAD $9.2 billion (approximately £5.4 billion). The Court of Appeal also upheld the payment of the initial deposits into the defendants’ solicitors’ trusts account within 60 days, totaling approximately CAD $1.3 billion (approximately £660.5 million), of which Imperial’s share was recalculated by the Court of Appeal as CAD $759 million (approximately £443.6 million). Imperial has already paid CAD $758 million (approximately £443 million) into court as security for the judgment.

77. Other Canadian Smoking and Health Class Actions: seven putative class actions described below, have been filed against various Canadian and non-Canadian tobacco-related entities, including the UK Companies, Imperial and the RJR Companies, in various Canadian provinces. In these cases, none of which have quantified their asserted damages, the plaintiffs allege claims based on fraud, fraudulent concealment, breach of warranty of merchantability, and of fitness for a particular purpose, failure to warn, design defects, negligence, breach of a ‘special duty’ to children and adolescents, conspiracy, concert of action, unjust enrichment, market share liability and violations of various trade practices and competition statutes. Pursuant to the terms of the 1999 sale of RJR’s international tobacco business, and in order to settle claims related to a reservation of rights, Imperial and the defence of the RJR Companies in these seven actions (Semple, Kurika, Adams, Dorion, Bourassa, McDermid and Jacklin, discussed below).
31 Contingent Liabilities and Financial Commitments Continued

78. In June 2009, four smoking and health class actions were filed in Nova Scotia (Semple), Manitoba (Kunika), Saskatchewan (Adams) and Alberta (Goriun) against various Canadian and non-Canadian tobacco-related entities, including the UK Companies, Imperial and the RJR Companies. In Saskatchewan, the Company, Carreras Rothmans Limited and Ryesekks p.l.c. have been released from Adams, and the RJR Companies have been admitted to certification motion materials and no dates for certification motions were set.

79. In June 2010, two further smoking and health class actions were filed in British Columbia against various Canadian and non-Canadian tobacco-related entities, including Imperial, the UK Companies and the RJR Companies. The Bourassa claim is allegedly on behalf of all individuals who have suffered chronic respiratory disease and the McDemid claim proposes a class based on heart disease. Both claims state that they have been brought on behalf of those who have smoked a minimum of 25,000 cigarettes. The UK Companies, Imperial, the RJR Companies and other defendants objected to jurisdiction. Subsequently, the Company, Carreras Rothmans Limited and Ryesekks p.l.c. were released from Bourassa and McDemid. Imperial, Industries, Investments and the RJR Companies remain as defendants in both actions. The plaintiffs did not serve their certification motion materials and no dates for certification motions were set.

80. In June 2012, a smoking and health class action was filed in Ontario (Jaccin) against various Canadian and non-Canadian tobacco-related entities, including the UK Companies, Imperial and the RJR Companies. The claim has been in abeyance.

Venezuela

81. In April 2008, the Venezuelan Federation of Associations of Users and Consumers (FEVACU) and Wolfang Cardozo Espinol and Giorgio Di Muro Di Nunno, acting as individuals, filed a class action against the UK Companies, Imperial, the RJR Companies and other defendants to recover compensatory and punitive damages for tobacco-related illnesses in Venezuela. The class action seeks recoveries of damages for future expenses of treating smoking-related illnesses in Venezuela. Both C.A. Cigarrera Bigott Sui.s.s., a Group subsidiary, and ASUELECTRIC, represented by its president Giorgio Di Muro Di Nunno (who had previously filed as an individual), filed motions to dismiss the class action. On 16 October 2008, the Commercial Court of the Supreme Court of Justice held, the Municipal Court of Zagreb has appointed the court financial and pretrial obligations absent further order from the court.

82. As at 31 December 2021, four smoking and health class actions were filed in Nova Scotia (Semple), Manitoba (Kunika), Saskatchewan (Adams) and Alberta (Goriun) against various Canadian and non-Canadian tobacco-related entities, including the UK Companies, Imperial and the RJR Companies. In Saskatchewan, the Company, Carreras Rothmans Limited and Ryesekks p.l.c. have been released from Adams, and the RJR Companies have been admitted to certification motion materials and no dates for certification motions were set.

(c) Individual Tobacco-Related Personal Injury Claims

83. On 22 July 2020, Nicholas Bernston filed a personal injury action in the Northern District of Oklahoma against JUUL, Altria Client Services, LLC, RJR Vapor, Reynolds American, and others. The complaint seeks damages for personal injuries (including pneumonia and acute respiratory failure) allegedly resulting from vaping on several theories, including strict liability, negligence, and breach of implied warranty of merchantability. On 24 July 2020, JUUL notified the JPML that this case could be a potential tag-along in the JUUL MDL. On 5 August 2020, the Judicial Panel on Multidistrict Litigation entered a conditional transfer order transferring the case to the Northern District of California. That order became effective on 12 August 2020, and this case now is a member case in the JUUL multidistrict litigation (MDL). On 13 October 2020, RJR Vapor and Reynolds American moved to dismiss the complaint or, in the alternative, for a stay or a suggestion of remand to the Northern District of Oklahoma. On 16 October 2020, the MDL court issued an order staying those motions to dismiss. The case will remain pending against Reynolds American and RJR Vapor, but they will not be subject to discovery or other pretrial obligations absent further order from the court.

Croatian Distributor Dispute

84. BAT Hrvatska d.o.o (t/k/a Cigarrera Bigott) and British American Tobacco Investments (Central and Eastern Europe) Limited are named as defendants in a claim by Mr Perica received on 22 August 2017 and brought before the commercial court of Zagreb, Croatia. Mr Perica seeks damages of HRK 408,000,000 (approximately £45.6 million) relating to a BAT Standard Distribution Agreement dating from 2005. BAT Hrvatska d.o.o and British American Tobacco Investments (Central and Eastern Europe) Ltd filed a reply to the statement of claim on 6 October 2017. A hearing had been scheduled to take place on 10 May 2018, but it was postponed due to a change of the judge hearing the case. The Commercial Court in Zagreb declared they do not have jurisdiction and that the competent court to hear this case is the Municipal Court in Zagreb. TDR d.o.o. is also named as the defendant in a claim by Mr Perica received on 30 April 2018 and brought before the commercial court of Zagreb, Croatia. Mr Perica seeks 408,000,000 (approximately £45.6 million) claiming that BAT Hrvatska d.o.o. transferred a business unit to TDR d.o.o, thus making them liable. The defendants filed motions to dismiss the case. On 5 August 2020, the Judicial Panel on Multidistrict Litigation entered a conditional transfer order transferring the case to the Northern District of Oklahoma against JUUL, Altria Client Services, LLC, RJR Vapor, Reynolds American, and others. The complaint seeks damages for personal injuries (including pneumonia and acute respiratory failure) allegedly resulting from vaping on several theories, including strict liability, negligence, and breach of implied warranty of merchantability. On 24 July 2020, JUUL notified the JPML that this case could be a potential tag-along in the JUUL MDL. On 5 August 2020, the Judicial Panel on Multidistrict Litigation entered a conditional transfer order transferring the case to the Northern District of California. That order became effective on 12 August 2020, and this case now is a member case in the JUUL multidistrict litigation (MDL). On 13 October 2020, RJR Vapor and Reynolds American moved to dismiss the complaint or, in the alternative, for a stay or a suggestion of remand to the Northern District of Oklahoma. On 16 October 2020, the MDL court issued an order staying those motions to dismiss. The case will remain pending against Reynolds American and RJR Vapor, but they will not be subject to discovery or other pretrial obligations absent further order from the court.
31 Contingent Liabilities and Financial Commitments Continued

BAT/Reynolds American Inc. Shareholder Litigation
85. Following the Company’s acquisition of the remaining 57.8% of Reynolds American in July 2017, pursuant to North Carolina law, Nicoventures Trading Limited (Nicoventures) and Investments filed a complaint against Reynolds American in the U.S. District Court for the Eastern District of Virginia for alleged infringement of six patents based on the importation and sale of the glo device and the NeoStiks consumable. Nicoventures claimed in the court filing, to the amount of 100 million Yen (approximately £641,000). The PMI affiliate has also filed a request for injunction with respect to the glo device. BAT Japan denies infringement and is challenging the validity of the two PMI affiliate’s Japanese patents.

86. Certain Group companies are party to a number of patent litigation cases and procedural challenges concerning the validity of patents owned by or licensed to them and/or the alleged infringement of third-parties’ patents.

87. On 22 June 2018, Nicoventures Trading Limited (Nicoventures) and Investments filed a Complaint for Judicial Appraisal in state court in North Carolina against 20 dissenting shareholders holding an aggregate of approximately 6.52 million shares filed a notice of appeal to the North Carolina Supreme Court. On 17 December 2019, the North Carolina Supreme Court issued an opinion affirming the Business Court’s decision, and on 21 January 2022 the dissenters’ deadline to seek further review expired, meaning that this matter is now concluded.

Patents Litigation
88. On 9 April 2020, an affiliate of Philip Morris International (PMI) filed a Complaint for Judicial Appraisal in state court in North Carolina against RJR Vapor on 6 March 2019 and 2 July 2019, each complaint in the U.S. District Court for the Middle District of North Carolina against the vapour products Vuse Vibe and Vuse Alto, and the tin used in the modern oral product Velo. Nine patents in total were asserted: two against Vibe, four against Alto and three against Velo. On 5 January 2021, Altria filed an Amended Complaint adding Modoral Brands Inc. as a defendant with respect to the Velo product claims. The plaintiffs have sought damages but have not to date sought preliminary or permanent injunctions. RJR Vapor has responded to the complaint. The parties conducted a one-day mediation session in August 2021, but were unable to resolve the dispute. A claim construction hearing was held on 28 April 2021, and the court issued its claim construction ruling on 12 May 2021. Fact discovery, expert discovery, and summary judgment briefings are completed. No date has been set for a summary judgment hearing, and no trial date has been set.

89. On 4 September 2020, RAI Strategic Holdings, Inc. and RJR Vapor commenced an action in the U.S. District Court for the Eastern District of Virginia against Altria Client Services LLC, Philip Morris USA, Inc., Altria Group, Inc., Philip Morris International, Inc., and Philip Morris Products S.A. (collectively, Philip Morris) for infringement of six patents based on the importation and commercialization within the United States of IQOS. On 8 May 2020 and 12 June 2020, Philip Morris filed Inter Partes Review (IPR) petitions in the U.S. Patent Office challenging the validity of each of the six patents asserted. On 29 June 2020, Philip Morris asserted counterclaims alleging that RJR Vapor infringes five patents. On 24 November 2020, the court issued a claim construction order that determined that each disputed term would have its plain and ordinary meaning. On 4 December 2020, the magistrate judge issued an order staying RJR Vapor and Philip Morris’s patent claims pending a decision by the U.S. Patent Office regarding whether to proceed with the IPRs. At the time of the stay, fact and expert discovery was ongoing and was scheduled to conclude 26 January 2021. The court lifted the stay, and the parties have substantially completed discovery. On 6 August 2021, the court denied all summary judgment motions. Trial on the Altria and Philip Morris patents was scheduled to have begun on 4 April 2022, but the court postponed the trial and set a new trial date of 6 June 2022; the RJR Vapor offensive patent case remains stayed pending (i) an appeal by Philip Morris to the Federal Circuit in relation an exclusion order granted against Philip Morris by the International Trade Commission based on the relevant patents, and (ii) the decisions in IPRs commenced by Philip Morris against the relevant patents at the U.S. Patent Office.

90. On 28 May 2020 Altria Client Services LLC and U.S. Smokeless Tobacco Company LLC commenced proceedings against RJR Vapor before the U.S. District Court for the Middle District of North Carolina against the vapour products Vuse Vibe and Vuse Alto, and the tin used in the modern oral product Velo. Nine patents in total were asserted: two against Vibe, four against Alto and three against Velo. On 5 January 2021, Altria filed an Amended Complaint adding Modoral Brands Inc. as a defendant with respect to the Velo product claims. The plaintiffs have sought damages but have not to date sought preliminary or permanent injunctions. RJR Vapor has responded to the complaint. The parties conducted a one-day mediation session in August 2021, but were unable to resolve the dispute. A claim construction hearing was held on 28 April 2021, and the court issued its claim construction ruling on 12 May 2021. Fact discovery, expert discovery, and summary judgment briefings are completed. No date has been set for a summary judgment hearing, and no trial date has been set.

91. On 27 April 2020, the court issued its final judgment upholding Reynolds American’s proposed valuation of £59.64 per share and concluding that no further payment is due to the dissenters for their shares. Dissenting shareholders holding an aggregate of approximately 6.52 million shares filed a notice of appeal to the North Carolina Supreme Court. On 12 June 2020, Nicoventures and Investments filed their defence to the counterclaim. The trial of this action took place between 18-25 May 2021. On 14 July 2021 the England and Wales High Court (Patents Court) handed down its judgment finding that all four divisional patents were invalid for lack of an inventive step and consequently, that PMP’s counterclaim failed. On 2 November 2021, PMP filed a request for permission to appeal.

92. On 17 January 2019, BAT commenced proceedings against Philip Morris for revocation against the relevant patents at the U.S. Patent Office challenging the validity of each of the six patents. On 4 December 2020, the court lifted the stay, and the parties have substantially completed discovery. No date has been set for a summary judgment hearing, and no trial date has been set.
92. On 27 November 2020 Philip Morris filed a complaint before the Regional Court Mannheim in Germany against British American Tobacco (Germany) GmbH (BAT Germany) alleging that the sale, offer for sale and importation of Vype ePod products infringes a patent. Philip Morris is seeking an injunction, a recall of product from commercial customers and a declaratory judgment for damages. The trials of this action took place on 15 June 2021 and 9 November 2021. A decision on the matter was promulgated on 30 November 2021. The decision dismissed the complaint in its entirety. On 28 December 2021, Philip Morris lodged an appeal against this decision before the Higher Regional Court Karlsruhe.

93. On 11 December 2020 Philip Morris filed a complaint before the Regional Court Düsseldorf in Germany against BAT Germany alleging that the sale, offer for sale and importation of the glo TABAK HEATER and neo STICK products infringe a patent. Philip Morris is seeking an injunction, a recall of product from commercial customers and a declaratory judgment for damages. The trial of this action took place on 30 November 2021. The court promulgated its decision on 21 December 2021 and decided that the above-mentioned products infringe the patent. The decision is not final and was appealed by BAT Germany on 21 December 2021 to the Higher Regional Court Düsseldorf. On 31 December 2021, BAT Germany also lodged a formal request with the appeal court to suspend the injunction order against the neo STICK products. On 24 January 2022, the appeal court granted this request, subject to providing a security and indicating that the neo STICK products are only suitable for new glo TABAK HEATER devices.

94. On 14 December 2020, Modoral Brands Inc. (Modoral) filed a complaint in the U.S. District Court for the District of Delaware against Pinkerton Tobacco Co., LP, Swedish Match North America LLC, and NYZ AB (collectively, “Pinkerton”) alleging trade secret misappropriation of Modoral’s Velo product. The complaint includes claims for trade secret misappropriation, manufacture, use, and/or sale of Modoral’s Velo product does not infringe U.S. Patent No. 9,161,908 (the ‘908 Patent) or any of Swedish Match’s trade secrets. On 3 June 2021, the case was transferred to the U.S. District Court for the Central District of California. On 13 July 2021, Swedish Match and Helix Innovations GmbH filed counterclaims against Modoral for infringement of the ‘908 patent and misappropriation of trade secrets arising out of the manufacture, use, and sale of Modoral’s Velo product. On 15 December 2021, the court entered a Markman Order finding that the ‘908 patent distinguishes a nicotine complex from the claimed ‘nicotine salt’, andSpirolidol does not functionally exclude the nicotine polacrilex complex used in the accused Velo product from the claimed invention because it “is not a nicotine salt”. Swedish Match agreed to a joint stipulation and request for entry of judgment of non-infringement for all of the asserted claims of the ‘908 patent, which the Court granted on 19 January 2022. Modoral filed a motion to stay Swedish Match’s remaining trade secret misappropriation claims in light of Swedish Match’s intent to appeal the Markman Order to the Federal Circuit. Modoral also filed a Rule 54(b) motion for partial final judgment of the infringement claims. Both motions are scheduled for argument on 4 March 2022.

95. On 19 April 2017, Sociedade Agrícola de Tabacos, Limitada (SAT) (a BAT Group company in Mozambique) filed a complaint to the National Inspectorate for Economic Activities (INAE), the government body under the Ministry of Industry and Trade, regarding alleged infringements of its registered trademark (GT) by GS Tobacco SA (GST). INAE subsequently seized the allegedly infringing products (GS cigarettes) and fined and ordered GST to discontinue manufacturing products that could infringe SAT’s intellectual property rights. Following INAE’s decision, in July 2017 and March 2018, SAT sought damages via the Judicial Court of Nampula, from GST in the amount of and equivalent to €573,000 as well as a permanent restraint order in connection with the manufacturing and selling of the allegedly infringing products. The Judicial Court of Nampula granted the order on an interim basis on 7 August 2017. After hearing the parties, on 5 September 2017, the court found that no alleged infringement by GST had occurred and removed the interim restraint order, this decision was appealed by SAT and is currently pending a decision. GST filed an application for review against the initial decision directly to the Minister of Trade and Industry, which reversed the decision of INAE. On 31 December 2018, SAT was notified of GST’s counterclaim against SAT at the Judicial Court of Nampula for damages allegedly sustained as a result of SAT’s complaint to INAE (and INAE’s decision). GST is seeking damages in the amount equivalent to €190 million. On 31 January 2019 SAT filed a formal response to the counterclaim. GST was notified on 28 February 2019 to file a response to our formal response to the counterclaim and the judge scheduled the preliminary hearing for 14 March 2019. This hearing was adjourned and was held on 2 April 2019, when the court heard arguments on the validity of SAT’s counterclaim. On 2 September 2019, SAT received notification of an order which provided that (i) SAT’s claim had been dismissed by the court; and (ii) the GST counterclaim would proceed to trial.

96. In December 2020, the Company and British American Tobacco (GLP) Limited (GLP) were named as defendants in a claim made in the English High Court by around 7,500 Malawian tobacco farmers and their family members. The claim also names Imperial Brands plc and five affiliates as defendants. The farmers claim they were subjected to unlawful and exploitative working conditions on tobacco farms from which it is alleged that the defendants indirectly acquired tobacco. They seek unspecified damages (including aggravated and exemplary damages) for the torts of negligence and conversion and unquantified personal and proprietary remedies for restitution of unjust enrichment. They also seek an injunction to restrain the commission of further torts of conversion or negligence by the defendants. The defendants had an application to strike out the claims dismissed in a judgment dated 25 June 2021. In January 2022, the Company and GLP were served with a similar claim by around a further 3,500 claimants. The Company and GLP intend vigorously to defend the claims.
At that hearing, the Court of First Instance set a timetable for the parties to file written submissions setting out their arguments with regard to the legal status of the BAT entities in Bahrain and UAE. A further hearing was held on 2 February 2022. The court is seeking further information from the BAT entities in Bahrain and UAE ahead of a further hearing on 23 February 2022.

Asbestos Litigation

99. On 15 January 2021, plaintiffs in an individual asbestos personal injury action (Rentko), originally filed 5 October 2020 in the New York City Asbestos Litigation court, filed an amended complaint, which named as defendants the Company, BATUS Holdings, Inc., British American Tobacco (Brands) Inc., and RJRT, along with various other defendants. The amended complaint was served 20 January 2021 on BATUS Holdings, Inc. and British American Tobacco (Brands) Inc., and served 22 January 2021 on RJRT. The amended complaint alleges that one of the plaintiffs was exposed to the defendants' asbestos and asbestos-contaminated talcum powder products, which allegedly caused her to develop mesothelioma, and asserts claims against the defendants for negligence, breach of warranty, product liability, negligent misrepresentation, fraudulent concealment, and civil conspiracy. A further amended complaint was filed on 27 January 2021, which named Reynolds American as a defendant as an alleged successor in interest to the Company, and which was served on Reynolds American on 5 February 2021. Plaintiffs seek unspecified compensatory and punitive damages jointly and severally against the defendants. Reynolds American and RJRT moved to dismiss the amended complaint on 26 March 2021. A notice of discontinuance was filed on 31 March 2021 discontinuing the litigation without prejudice as against the Company, BATUS Holdings, Inc. and British American Tobacco (Brands) Inc. A stipulation of discontinuance was filed on 6 April 2021 discontinuing the litigation without prejudice as against Reynolds American and RJRT.

100. On 23 April 2021, plaintiff in an asbestos personal injury action (Smoltino), originally filed 25 August 2020 in the New York City Asbestos Litigation court, filed an amended complaint, which named as defendants the Company, BATUS Holdings, Inc., British American Tobacco (Brands) Inc., Reynolds American and RJRT, along with various other defendants. The amended complaint was served on BATUS Holdings, Inc., British American Tobacco (Brands) Inc. and RJRT on 23 April 2021 and served on Reynolds American on 26 April 2021. The amended complaint alleged that plaintiff's decedent was exposed to the defendants' asbestos and asbestos-contaminated talcum powder products, which allegedly caused her to develop mesothelioma, and asserted claims against the defendants for negligence, breach of warranty, product liability, negligent misrepresentation, fraudulent concealment, wrongful death and civil conspiracy. Plaintiff seeks unspecified compensatory and punitive damages jointly and severally against the defendants. A notice of discontinuance was filed on 19 May 2021 discontinuing the litigation without prejudice as against the Company, BATUS Holdings, Inc. and British American Tobacco (Brands) Inc. Reynolds American and RJRT moved to dismiss the amended complaint on 10 May 2021. A stipulation of discontinuance was filed on 24 May 2021 discontinuing the litigation without prejudice as against Reynolds American and RJRT.
31 Contingent Liabilities and Financial Commitments

101. On 11 May 2021, plaintiff in an asbestos personal injury action (Gilbride) filed a complaint in the Superior Court of New Jersey Law Division – Middlesex County, which named as defendants R. J. Reynolds Tobacco Company, individually and as successor-by-merger to British American Cosmetics, along with various other defendants. The complaint was served on RJRT on 26 May 2021. The complaint alleged that plaintiff was exposed to asbestos-containing cosmetic talcum powder products sold and supplied by the Defendants (and/or their predecessors in interest), which allegedly caused her to develop mesothelioma, and asserted claims under state law, including for negligence, breach of warranty, strict liability in tort, marketing an ultra-hazardous product, failure to warn, product liability, negligent misrepresentation, fraudulent concealment, and civil conspiracy. Plaintiff seeks unspecified compensatory and punitive damages jointly and severally against the defendants. A stipulation for voluntary dismissal was filed with the court on 7 July 2021.

Fox River

Background to environmental liabilities arising out of contamination of the Fox River:

102. In Wisconsin, the authorities have identified potentially responsible parties (PRPs) to fund the clean-up of river sediments in the lower Fox River. The pollution was caused by discharges of Polychlorinated Biphenyls (PCBs) from paper mills and other facilities operating close to the river. Among the PRPs is NCR Corporation (NCR).

103. In NCR’s Form 10-K Annual Report for the year ended 31 December 2014, the total clean-up costs for the Fox River were estimated at US$825 million (approximately £609.1 million). This estimate is subject to uncertainties and does not include natural resource damages (NRDs). Total NRDs may range from US$0 to US$246 million (approximately £0 to £181.6 million).

104. Industries’ involvement with the environmental liabilities arises out of indemnity arrangements which it became party to due to a series of transactions that took place from the late-1970s onwards and subsequent litigation brought by NCR against Industries and Appvion Inc. (Appvion) (a former Group subsidiary) in relation to those arrangements which was ultimately settled. U.S. authorities have never identified Industries as a PRP.

105. There has been a substantial amount of litigation in the United States involving NCR and Appvion regarding the responsibility for the costs of the clean-up operations. The U.S. Government also brought enforcement proceedings against NCR and Appvion to ensure compliance with regulations relating to the Fox River clean-up. This litigation has been settled through agreements with other PRPs and a form of settlement known as a Consent Decree with the U.S. Government, approved by the District Court of Wisconsin on 23 August 2017.

106. The principal terms of that Consent Decree, in summary, are as follows:

a. NCR is obliged to perform and fund all of the remaining Fox River remediation work by itself.

b. The U.S. Government enforcement proceedings were settled, with NCR having no liability to meet the U.S. Government’s claim for costs that it incurred in relation to the clean-up to date, a secondary responsibility to meet certain future costs, and no liability to the U.S. Government for NRDs.

c. NCR ceased to pursue its contribution claims against other PRPs and in return received contribution protection preventing other PRPs from pursuing their contribution claims against NCR and existing claims for contribution being dismissed by order of the Court. NCR does, however, have the right to reinstate its contribution claims if the other PRPs decide to continue to pursue certain contractual claims against NCR.

d. Appvion also agreed to cease pursuance of claims against the other PRPs, subject to retention of the right to reinstate its claims if the other PRPs decide to continue to pursue certain claims against Appvion.

107. A Consent Decree between the U.S. Government, P.H. Glatfelter and Georgia Pacific settling the allocation of costs on the Fox River was approved by the District Court in the Eastern District of Wisconsin on 14 March 2019. This Consent Decree concludes all existing litigation on the Fox River, following P.H. Glatfelter’s withdrawal of its appeal against the issuance of the Consent Decree as a term of the settlement.

108. In NCR’s Form 10-K Annual Report for the year ended 31 December 2020, NCR disclosed that, in November 2019, an arbitral tribunal had awarded approximately US$10 million (approximately £7.4 million) to a remediation general contractor engaged by the LLC formed by NCR and Appvion to perform the clean-up operation of the Fox River. NCR further stated that its indemnitors and co-obligors were responsible for the majority of the award, with its own share being approximately 25% of the award.

109. NCR has taken the position that, under the terms of a 1998 Settlement Agreement between it, Appvion and Industries, and a 2005 arbitration award, Industries and Appvion generally had a joint and several obligation to bear 60% of the Fox River environmental remediation costs imposed on NCR and of any amounts NCR has to pay in respect of other PRPs’ contribution claims. BAT has not acknowledged any such liability to NCR and has defences to such claims. Further, under the terms of the Funding Agreement (described below), any dispute between Industries and NCR as to the final amount of any NCR claim against Industries in respect of the Fox River (if any) can only be determined at the later of (i) the completion of Fox River remediation works or (ii) the final resolution and exhaustion of all possible appeals in proceedings brought against Sequana, PricewaterhouseCoopers LLP (PwC) and other former advisers.

110. Until May 2012, Appvion and Windward Prospects Limited (Windward) (another former Group subsidiary) had paid a 60% share of the clean-up costs incurred by NCR. Industries was never required to contribute. Around that time, Appvion refused to continue to pay clean-up costs, leading to NCR demanding that Industries pay a 60% share of those costs.

111. Industries commenced proceedings against Windward and Appvion in December 2011 seeking indemnification in respect of any liability it might have to NCR (the English Indemnity Proceedings) pursuant to a 1990 de- merger agreement between those parties.
114. The Windward Dividend Claim and BAT section 423 Claim were heard.

112. On 30 September 2014, Industries entered into a Funding Agreement with Windward, Appvion, NCR and BTI 2014 LLC (BTI) (a wholly owned subsidiary of Industries). Pursuant to the Funding Agreement, the English Insolvency Proceedings and a counterclaim Appvion had brought in those proceedings, as well as an NCR-Appvion arbitration concerning Appvion’s indemnity to NCR, were discontinued as part of an overall agreement between the parties providing a framework through which they would together fund the ongoing costs of the Fox River clean-up. Under the agreement, NCR has agreed to accept funding by Industries at the lower level of 50% of the ongoing clean-up related costs of the Fox River (rather than the 60% referred to above). This remains subject to an ability to litigate at a later stage the extent of Industries’ liability (if any) in relation to Fox River clean-up related costs (including in respect of the 50% of costs that Industries has paid under the Funding Agreement to date). In addition, Windward has contributed US$10 million (approximately £7.4 million) of funding and Appvion has contributed US$25 million (approximately £18.5 million) for Fox River and agreed to contribute US$25 million (approximately £18.5 million) for the Kalamazoo River (see further below). Appvion entered Chapter 11 bankruptcy protection on 1 October 2017.

113. The parties also agreed to cooperate in order to maximise recoveries from certain claims made against third parties, including (i) a claim commenced by Windward in the High Court of England & Wales (the High Court) against Sequana and the former Windward directors (the Windward Dividend Claim). That claim was assigned to BTI under the Funding Agreement, and relates to dividend payments made by Windward to Sequana of around €443 million (approximately £372 million) in 2008 and €135 million (approximately £113.4 million) in 2009 (the Dividend Payments) and (ii) a claim commenced by Industries directly against Sequana to recover the value of the Dividend Payments alleging that the dividends were paid for the purpose of putting assets beyond the reach of Windward’s creditors (including Industries) (the BAT section 423 Claim) (together the Sequana Proceedings).

114. The Windward Dividend Claim and BAT section 423 Claim were heard together in the High Court, with judgment handed down on 11 July 2016. The court upheld the BAT section 423 Claim and, by way of a consequential judgment handed down on 10 February 2017, ordered that Sequana pay to BTI an amount up to the full value of the 2009 Dividend plus interest, which equates to around US$185 million (approximately £136.6 million). The Court dismissed the Windward Dividend Claim.

115. The parties pursued cross appeals on the judgment, during which time Sequana was granted a stay in respect of the above payments. That stay was lifted in May 2017, three months after Sequana had entered into an insolvency process in France seeking court protection (the Sauvegarde). The court upheld the BAT section 423 Claim and, by way of a consequential judgment handed down on 10 February 2017, ordered that Sequana pay to BTI an amount up to the full value of the 2009 Dividend plus interest, which equates to around US$185 million (approximately £136.6 million). The Court dismissed the Windward Dividend Claim.

116. On 6 February 2019 the Court of Appeal gave judgment upholding the High Court’s findings, with one material change to the method of calculating the damages awarded. Sequana therefore remains liable to pay approximately US$185 million (approximately £136.6 million). Because of Sequana’s ongoing insolvency process, execution of that judgment is stayed. The Court of Appeal dismissed BTI’s appeal in relation to the Windward Dividend Claim. The Court of Appeal also dismissed Sequana’s application for permission to appeal the High Court’s costs order in favour of Industries. Sequana therefore remains liable to pay around £10 million in costs to Industries.

117. All parties to the appeal sought permission from the Court of Appeal for a further appeal to the UK Supreme Court. On 31 July 2019, BTI was granted permission to appeal to the Supreme Court. On the same day, the Supreme Court refused Sequana permission to appeal. The hearing of BTI’s appeal took place before the UK Supreme Court on 4 and 5 May 2021 and the judgment is awaited.

118. BTI has brought claims against certain of Windward’s former advisers, including Windward’s auditors at the time of the dividend payments, PricewaterhouseCoopers LLP (PwC) (which claims were also assigned to BTI under the Funding Agreement). The claim had been stayed pending the outcome of the Sequana Proceedings. Once that stay was lifted, PwC applied to strike-out BTI’s claim. A hearing of this application took place in October 2019. On 15 November 2019, the court dismissed PwC’s application. The court granted PwC permission to appeal in respect of part of its dismissal of the application and the hearing of that appeal was heard by the Court of Appeal on 27 and 28 October 2020. On 11 January 2021, the Court of Appeal handed down judgment dismissing PwC’s appeal. The Court of Appeal also refused PwC’s application for permission to appeal to the Supreme Court and made an order requiring PwC to file its Defence within two months of 11 January 2021. This deadline was subsequently extended. PwC subsequently applied directly to the Supreme Court for permission to appeal the Court of Appeal’s decision. PwC’s application for permission to appeal to the Supreme Court has yet to be determined. In the meantime, BTI’s claim against PwC is progressing in the High Court. PwC served its Defence on 22 April 2021 and filed it with the Court on 26 April 2021. A Case Management Conference has been listed in a window between 2 March 2022 and 4 March 2022 (inclusive).

119. An agreed stay is in place in respect of BTI’s separate assigned claim against Freshfields Bruckhaus Deringer.

120. The sums Industries has paid under the Funding Agreement are subject to the reservation as set out in paragraph 112 above and ongoing adjustment. Clean-up costs can only be estimated in advance of the work being carried out and certain sums payable are the subject of ongoing U.S. litigation. In 2019, Industries paid £32 million in respect of clean-up costs. In 2020, Industries paid £2 million in respect of clean-up costs. In 2021, Industries paid a further £1.8 million in respect of clean-up costs. Industries is potentially liable for further costs associated with the clean-up. Industries has a provision of £92.3 million which represents the current best estimate of its exposure – see note 24.
127. It is anticipated that NCR will look to Industries to pay 60% of any sums in respect of the Kalamazoo River in Michigan, in relation to remediation costs caused by PCBs released into that river.

128. Industries also anticipates that NCR may seek to recover from Appvion (subject to a cap of US$25 million (approximately £18.5 million)) for ‘Future Sites’ under the Funding Agreement. The basis of the recovery would be the same as any demand NCR may make on Industries. Appvion entered Chapter 11 bankruptcy protection on 1 October 2017. The effect of the Chapter 11 proceedings on Appvion’s liability for Future Sites payments under the Funding Agreement is currently uncertain.

129. As detailed above, Industries is taking active steps to protect its interests, including seeking to procure the repayment of the Windward dividends, pursuing the other valuable claims that are now within its control, and working with the other parties to the Funding Agreement to maximise recoveries from third parties with a view to ensuring that amounts funded towards clean-up related costs are later recouped under the agreed repayment mechanisms under the Funding Agreement.

Other environmental matters

130. Reynolds American and its subsidiaries are subject to federal, state and local environmental laws and regulations concerning the discharge, storage, handling and disposal of hazardous or toxic substances. Such laws and regulations provide for significant fines, penalties and liabilities, sometimes without regard to whether the defendant was aware of, or was responsible for, the release or presence of hazardous or toxic substances. In addition, third parties may make claims against owners or operators of properties for personal injuries and property damage associated with releases of hazardous or toxic substances. In the past, RJRT has been named a PRP with third parties under CERCLA with respect to several superfund sites. Reynolds American and its subsidiaries are not aware of any current environmental matters that are expected to have a material adverse effect on the business, results of operations or financial position of Reynolds American or its subsidiaries.

Criminal investigations

131. From time to time, the Group investigates, and becomes aware of, allegations of misconduct against Group companies. The Group cooperates with the authorities’ investigations, where appropriate, including with the DOJ and OFAC in the United States, which are conducting an investigation into suspicions of breach of sanctions.

132. Potential fines, penalties or other consequences cannot currently be determined. It may well exceed the amounts which are payable on the face of the Consent Decree.
31 Contingent Liabilities and Financial Commitments

Continued

Closed litigation matters

<table>
<thead>
<tr>
<th>Matter</th>
<th>Jurisdiction</th>
<th>Companies named as Defendants</th>
<th>Description</th>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vuse Litigation (Illinois School Districts)</td>
<td>U.S.</td>
<td>Reynolds American, RJR Vapor, the Company, Lorillard LLC and LOEC Inc.</td>
<td>Public Nuisance</td>
<td>Voluntary dismissal by plaintiff</td>
</tr>
<tr>
<td>Brazil Associação de Defesa da Saúde do Fumante class action</td>
<td>Brazil</td>
<td>Souza Cruz</td>
<td>Class action</td>
<td>Superior Court of Justice</td>
</tr>
<tr>
<td>UK Serious Fraud Office (SFO) investigation</td>
<td>UK</td>
<td>The Company, its subsidiaries, and associated persons</td>
<td>Investigation</td>
<td>SFO's announcement that the investigation had been closed</td>
</tr>
<tr>
<td>Perry</td>
<td>U.S.</td>
<td>Investments</td>
<td>Individual case</td>
<td>Dormant/closed</td>
</tr>
<tr>
<td>Antimonopoly Committee of Ukraine</td>
<td>Ukraine</td>
<td>British American Tobacco Sales &amp; Marketing Ukraine Limited Liability Company</td>
<td>Competition investigation</td>
<td>Judgment of Supreme Court of Ukraine</td>
</tr>
</tbody>
</table>

General Litigation Conclusion

134. While it is impossible to be certain of the outcome of any particular case or of the amount of any possible adverse verdict, the Group believes that the defences of the Group's companies to all these various claims are meritorious on both the law and the facts, and a vigorous defence is being made everywhere.

135. As indicated above, on 1 March 2019 the Quebec Court of Appeal released its appeal judgment. The trial judgment was largely upheld by a unanimous decision of the five-member panel including the requirement that the defendants deposit the initial deposits in their solicitors' trust accounts within 60 days. This is the only executory aspect of the judgment. In these circumstances we are of the view that it is more likely than not that there will be an outlay and it is reasonably estimable at CAD $758 million (approximately £443 million), the amount of the initial deposit paid into court. If further adverse judgments are entered against any of the Group’s companies in any case, avenues of appeal will be pursued. Such appeals could require the appellants to post appeal bonds or substitute security (as has been necessary in Quebec) in amounts which could in some cases equal or exceed the amount of the judgment. At least in the aggregate, and despite the quality of defences available to the Group, it is not impossible that the Group’s results of operations or cash flows in any particular period could be materially adversely affected by the impact of a significant increase in litigation, difficulties in obtaining the bonding required to stay execution of judgments on appeal, or any final outcome of any particular litigation.

136. Having regard to all these matters, with the exception of the Quebec Class Actions, Fox River and certain Engle progeny cases identified above, the Group does not consider it appropriate to make any provision in respect of any pending litigation because the likelihood of any resulting material loss, on an individual case basis, is not considered probable and/or the amount of any such loss cannot be reasonably estimated. Notwithstanding the negative decision in the Quebec Class Actions, the Group does not believe that the ultimate outcome of this litigation will significantly impair the Group’s financial condition. If the facts and circumstances change and result in further unfavourable outcomes in the pending litigation, then there could be a material impact on the financial statements of the Group.

Other contingencies

137. **JTI Indemnities.** By a purchase agreement dated 9 March 1999, amended and restated as of 11 May 1999, referred to as the 1999 Purchase Agreement, R.J. Reynolds Tobacco Holdings, Inc. (RJR) and RJRT sold their international tobacco business to JTI. Under the 1999 Purchase Agreement, RJR and RJRT retained certain liabilities relating to the international tobacco business sold to JTI, and agreed to indemnify JTI against: (i) any liabilities, costs and expenses arising out of the imposition or assessment of any tax with respect to the international tobacco business arising prior to the sale, other than as reflected on the closing balance sheet; (ii) any liabilities, costs and expenses that JTI or any of its affiliates, including the acquired entities, may incur after the sale with respect to any of RJR’s or RJRT’s employee benefit and welfare plans; and (iii) any liabilities, costs and expenses incurred by JTI or any of its affiliates arising out of certain activities of Northern Brands.

138. RJRT has received claims for indemnification from JTI, and several of these have been resolved. Although RJR and RJRT recognise that, under certain circumstances, they may have other unresolved indemnification obligations to JTI under the 1999 Purchase Agreement, RJR and RJRT disagree what circumstances described in such claims give rise to any indemnification obligations by RJR and RJRT and the nature and extent of any such obligation. RJR and RJRT have conveyed their position to JTI, and the parties have agreed to resolve their differences at a later date.
139. ITG Indemnity. In the Divestiture, Reynolds American agreed to defend and indemnify, subject to certain conditions and limitations, ITG in connection with claims relating to the purchase or use of one or more of the Winston, Kool, Salem or Maverick cigarette brands on or before 12 June 2015, as well as in actions filed before 13 June 2023, relating to the purchase or use of one or more of the Winston, Kool, Salem or Maverick cigarette brands. In the purchase agreement relating to the Divestiture, ITG agreed to defend and indemnify, subject to certain conditions and limitations, Reynolds American and its affiliates in connection with claims relating to the purchase or use of one or more of the Winston, Kool, Salem or Maverick cigarette brands after 12 June 2015. ITG has tendered a number of actions to Reynolds American under the terms of this indemnity, and Reynolds American has, subject to a reservation of rights, agreed to defend and indemnify ITG pursuant to the terms of the indemnity. Reynolds American has tendered an action to ITG under the terms of this indemnity, and ITG has, subject to a reservation of rights, agreed to defend and indemnify Reynolds American and its affiliates pursuant to the terms of the indemnity. These claims are substantially similar in nature and extent to claims asserted directly against RJRT in similar actions.

140. Loews Indemnity. In 2008, Loews Corporation (Loews), entered into an agreement with Lorillard Inc., Lorillard Tobacco, and certain of its affiliates, which agreement is referred to as the ‘Separation Agreement’. In the Separation Agreement, Lorillard agreed to indemnify Loews and its officers, directors, employees and agents against all costs and expenses arising out of third-party claims (including, without limitation, attorneys’ fees, interest, penalties and costs of investigation or preparation of defence), judgments, fines, losses, claims, damages, liabilities, taxes, demands, assessments, and amounts paid in settlement based on, arising out of or resulting from, among other things, Lorillard’s ownership of or the operation of Lorillard’s assets and properties, and its operation or conduct of its businesses at any time prior to or following the separation of Lorillard and Loews (including with respect to any product liability claims). Loews is a defendant in three pending product liability actions, each of which is a putative class action. Pursuant to the Separation Agreement, Lorillard is required to indemnify Loews for the amount of any losses and any legal or other fees with respect to each such action. Following the closing of the Lorillard merger, RJRT assumed Lorillard’s obligations under the Separation Agreement as was required under the Separation Agreement.

141. SFRTI Indemnity. In connection with the 13 January 2016 sale by Reynolds American of the international rights to the Natural American Spirit brand name and associated trademarks, along with SFR Tobacco International GmbH (SFRTI) and other international companies that distributed and marketed the brand outside the United States, to JT International Holding BV (‘JTI Holding’), each of SFNTC, R. J. Reynolds Global Products, Inc., and R. J. Reynolds Tobacco B.V. agreed to indemnify, JTI Holding against, among other things, any liabilities, costs, and expenses relating to actions (i) commenced on or before (a) 13 January 2019, to the extent relating to alleged personal injuries, and (b) in all other cases, 13 January 2021; (ii) brought by (a) a governmental authority to enforce legislation implemented by an EU Directive, or (b) a consumer association; and (iii) arising out of any statement or claim (a) made on or before 13 January 2016, (b) by any company sold to JTI Holding in the transaction, (c) concerning Natural American Spirit brand products consumed or intended to be consumed outside of the United States and (d) that the Natural American Spirit brand product is natural, organic, or additive-free. Under the terms of this indemnity, JTI has requested indemnification from Santa Fe Natural Tobacco Company Germany GmbH (SFNTCG) in connection with an audit of SFNTCG relating to transfer pricing for the tax years 2007 to 2010 and 2012 to 2015. SFNTCG contests the audit results. The amount in dispute is approximately €1 million plus interest (approximately £1.7 million).

142. Indemnification of Distributors and Retailers. RJRT, Lorillard Tobacco, SFNTC, American Snuff Co. and RJR Vapor have entered into agreements to indemnify certain distributors and retailers from liability and related defence costs arising out of the sale or distribution of their products. Additionally, SFNTC has entered into an agreement to indemnify a supplier from liability and related defence costs arising out of the sale or use of SFNTC’s products. The cost has been, and is expected to be, insignificant. RJRT, SFNTC, American Snuff Co. and RJR Vapor believe that the indemnified claims are substantially similar in nature and extent to the claims that they are already exposed to by virtue of their having manufactured those products.

143. Except as otherwise noted above, Reynolds American is not able to estimate the maximum potential of future payments, if any, related to these indemnification obligations.

144. Competition Investigations. There are instances where Group companies are cooperating with relevant national competition authorities in relation to ongoing competition law investigations and/or engaged in legal proceedings at the appellate level, including (amongst others) in the Netherlands.

Tax disputes
The Group has exposures in respect of the payment or recovery of a number of taxes. The Group is and has been subject to a number of tax audits covering, amongst others, excise tax, value added taxes, sales taxes, corporate taxes, withholding taxes and payroll taxes.

The estimated costs of known tax obligations have been provided in these accounts in accordance with the Group’s accounting policies. In some countries, tax law requires that full or part payment of disputed tax assessments be made pending resolution of the dispute. To the extent that such payments exceed the estimated obligation, they would not be recognised as an expense. While the amounts that may be payable or receivable in relation to tax disputes could be material to the results or cash flows of the Group in the period in which they are recognised, the Board does not expect these amounts to have a material effect on the Group’s financial condition.
31 Contingent Liabilities and Financial Commitments Continued

The following matters are in or may proceed to litigation:

Corporate taxes

Brazil

The Brazilian Federal Tax Authority has filed claims against Souza Cruz seeking to reassess the profits of overseas subsidiaries to cover VAT and social contribution tax. The reassessments are for the years 2004 until and including 2012 for a total amount of BRL 1,813 million (£240 million) to cover tax, interest and penalties.

Souza Cruz appealed all reassessments. Regarding the first assessments (2004-2006), Souza Cruz’s appeals were rejected by the ultimate Administrative Court after which Souza Cruz filed two lawsuits with the Judicial Court to appeal the reassessments. The judgment in respect of the reassessment of corporate income tax has been decided in favour of Souza Cruz by the first level of the Judicial Court and Souza Cruz is waiting to see whether the Brazilian Tax Authorities will appeal the judgment. The lawsuit appealing the social contribution tax is pending judgment in the first level of the Judicial Court. The appeal against the second assessments (2007 and 2008) was upheld at the second tier tribunal and was closed. In 2015, a further reassessment for the same period (2007 and 2008) was raised after the five-year statute of limitation which has been appealed against.

Souza Cruz received further reassessments in 2014 for the 2009 calendar year and in 2015 an assessment for the 2010 calendar year. Souza Cruz appealed both the reassessments in full. In December 2016, assessments were received for the calendar years 2011 and 2012 which have also been appealed.

Netherlands

The Dutch tax authority has issued a number of assessments on various issues across the years 2003-2016 in relation to various intra-group transactions. The assessments amount to an aggregate net liability across these periods of €1,146 million covering tax, interest and penalties. The Group has appealed against the assessments in full.

The Group believes that its companies have meritorious defences in law and fact in each of the above matters and intends to pursue each dispute through the judicial system as necessary. The Group does not consider it appropriate to make provision for these amounts nor for any potential further amounts which may be assessed in relation to these matters in subsequent years.

Indirect and other taxes

Bangladesh

On 25 July 2018, the Appellate Division of the Supreme Court of Bangladesh has reversed the decision of the High Court Division against British American Tobacco Bangladesh Company Limited (BATB) in respect of the retrospective demands for VAT and Supplementary Duty amounting to approximately £154 million. On 3 February 2020, the certified Court Order was received. The Government filed a Review Petition on 25 March 2020 in the Appellate Division of the Supreme Court of Bangladesh against the judgment. On 9 December 2021, the review petitions were heard and the Appellate Division of the Supreme Court of Bangladesh dismissed the review petitions filed by the National Board of Revenue (NBR) which resulted in BATB winning the cases against the NBR.

In addition, in 2017, NBR passed a discriminatory special order fixing BDT 27 for local brands and BDT 35 for foreign brand cigarettes. After NBR passed the special order, it was highlighted to the Government that it was against the principles of foreign direct investment and against WTO practice. Subsequently, the Finance Minister directed that no action should be taken in this regard until the different issues raised were finalised. Later in 2018, the special order itself was repealed. AKTC (a local Bangladesh tobacco manufacturer) filed a case against NBR to get a direction from the Court to implement the special order and reserve low segment for local industries. The judgment in the AKTC case was passed by the High Court Division verbally on 21 September 2020. The judgment revived the discriminatory regime of VAT and Supplementary Duty (SD) between local and international/imported brands for the fiscal year 2017 – 2018. In light of the judgment, the Large Taxpayers’ Unit (LTU) of National Board of Revenue by a notice asked BATB to show cause as to why BATB believed it should not be liable to pay £210 million as unpaid VAT and SD. Challenging the judgment, BATB filed and moved an appeal (known as the Civil Miscellaneous Petition for Leave to Appeal) before the Appellate Division of the Supreme Court of Bangladesh. On a preliminary hearing on 4 October 2020, the Appellate Division Judge in Chamber stayed operation of the judgment for eight weeks as an interim measure. Since the judgment has been stayed, the operation of the show cause notice shall also be deemed to have been stayed. BATB has formally notified LTU of this on 12 October 2020. In the meantime, the judgment will remain stayed.

On 20 December 2020, BATB filed a Civil Petition for Leave to Appeal as directed by the Appellate Division Judge in Chamber. The judgment passed by the High Court Division will continue to remain stayed while the appeal remains pending at the Appellate Division of the Supreme Court of Bangladesh. So far, the appeal has not been listed for hearing.

Egypt

British American Tobacco Egypt LLC (BAT Egypt) is subject to two ongoing civil cases concerning the imposition of sales tax on low-price category brands brought by the Egyptian tax authority for £88 million. Management believes that the tax claims are unfounded and has appealed the tax claims. These cases are under review by the Council of State. During hearings in August 2020, the courts decided, in both cases, to transfer the files to court appointed experts.

One case (pertaining to the period from May 2008 to February 2009) was referred to a court-appointed expert who filed a report in January 2022. A hearing date has not yet been set. In the other case (pertaining to the period from March 2009 to June 2010), the expert has concluded his report and filed it with the court. In May 2021, a judgment was issued which acquitted BAT Egypt from paying £210 million as unpaid VAT and SD. An appeal has been submitted to the Supreme Administrative Court to extend the acquittal to the rest of the disputed period. The appeal process is expected to take approximately two years.
31 Contingent Liabilities and Financial Commitments
Continued

South Korea
In 2016, the Board of Audit and Inspection of Korea (BAI) concluded its tax assessment in relation to the 2014 year-end tobacco inventory, and imposed additional national excise, local excise, VAT taxes and penalties. This resulted in the recognition of a KRW 80.7 billion (approximately £50 million) charge by Group subsidiaries, BAT Korea Ltd., Rothmans Far East B.V. Korea Branch Office and BAT Korea Manufacturing Ltd. Management deems the tax and penalties to be unfounded and has appealed to the tax tribunal against the assessment. On grounds of materiality and the likelihood of the tax and penalties being reversed in future, the Group classified the tax and penalties charge as an adjusting item in 2016.

On 23 August 2019, the trial court ruled in favour of Rothmans Far East B.V. Korea Branch Office on KRW 6.7 billion (approximately £4 million), the VAT portion of the assessment; appeals on the other elements of the assessment are still pending at Appeals Court. The Korean government appealed the ruling on 16 September 2019. On 16 April 2021 the Court of Appeals affirmed the ruling of the Trial Court. The government immediately appealed to the Supreme Court and the Supreme Court also affirmed the ruling of the Appeals Court on 28 August 2021. On 16 September 2021, Rothmans Far East B.V. Korea Branch Office duly received the amount litigated (VAT portion) including statutory interests (note 6).

Turkey
In Turkey, British American Tobacco Tutun Mamulleri Sanayi ve Ticaret Anonim Sirketi (BAT Tutun) was subject to a series of tax audits mainly on inventory movements for the years 2015, 2016 and 2019. The final audit reports sought retrospective payment of additional tax with interest and penalties mostly based on alleged illegitimate intra-group forestalling relating to finished goods giving rise to further excise tax. In 2020 and 2021, BAT Tutun received a total tax assessment amounting to TRY 2.7 billion (approximately £151 million), of which, TRY 2.1 billion (approximately £120 million) related to tax and penalties and TRY 0.6 billion (approximately £31 million) related to late payment interest. In August 2021, BAT Tutun applied under the relevant tax amnesty law to settle its retrospective tax assessments. Based on the settlement through the tax amnesty procedure, BAT Tutun agreed to pay £47 million in 18 instalments from 1 November 2021 until 31 July 2024.

Brazil
On 15 March 2017, the Brazilian Supreme Court ruled that for all taxpayers VAT (ICMS) should not be included in the calculation of social contribution taxes (PIS/Cofins) which are levied based on revenue. On 13 May 2021, the Supreme Court modulated the effects of the first decision handed down in 2017, stating that the taxpayers who filed a lawsuit by 15 March 2017 will be able to recover credits from the past five years.

The Group’s Brazilian subsidiary, Souza Cruz, had filed an individual lawsuit to establish that it had overpaid taxes to the government. Based on favourable court decisions in 2020 and 2019 the Group has recognised £5 million in 2021 (2020: £58 million; 2019: £86 million) in other income representing management’s best estimate of the amounts likely to be recovered at this time with the potential for further amounts in future periods.

If the ruling were to be enacted retrospectively for a period of five years, the potential asset is estimated to be around £480 million. During 2021, £130 million of the unrecognised contingent asset was sold to financial institutions for £45 million.

Commitments in relation to service contracts, non-capitalised leases
The total future minimum payments under non-cancellable service contracts based on when payments fall due:

<table>
<thead>
<tr>
<th></th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service contracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within one year</td>
<td>41</td>
<td>63</td>
</tr>
<tr>
<td>Between one and five years</td>
<td>81</td>
<td>17</td>
</tr>
<tr>
<td>Beyond five years</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>127</td>
<td>86</td>
</tr>
</tbody>
</table>

Financial commitments arising from short-term leases and leases of low-value assets that are not capitalised under IFRS 16 Leases are £7 million (2020: £6 million) for property and £19 million (2020: £3 million) for plant, equipment and other assets.
32 Interests in Subsidiaries
Subsidiaries with material non-controlling interests

Until 2020, non-controlling interests principally arise from the Group’s listed investment in Malaysia (British American Tobacco (Malaysia) Berhad). But due to difficult trading conditions, as mentioned in note 12, the non-controlling interest in Malaysia is no longer material to the Group and is not disclosed anymore.

In 2021, non-controlling interests principally arise from the Group’s listed investment in Bangladesh (British American Tobacco Bangladesh Company Limited) where the Group held 72.91% in 2021, 2020 and 2019. Summarised financial information for Bangladesh is shown below as required by IFRS 12 Disclosure of interest in other entities. No adjustments have been made to the information below for the elimination of intercompany transactions and balances with the rest of the Group.

<table>
<thead>
<tr>
<th>Summarised financial information</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>640</td>
<td>553</td>
<td>527</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>127</td>
<td>101</td>
<td>86</td>
</tr>
<tr>
<td>– Attributable to non-controlling interests</td>
<td>34</td>
<td>27</td>
<td>23</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>127</td>
<td>91</td>
<td>70</td>
</tr>
<tr>
<td>– Attributable to non-controlling interests</td>
<td>34</td>
<td>25</td>
<td>19</td>
</tr>
<tr>
<td>Dividends paid to non-controlling interests</td>
<td>(28)</td>
<td>(31)</td>
<td>(8)</td>
</tr>
</tbody>
</table>

Summary net assets:

<table>
<thead>
<tr>
<th>Summarised financial information</th>
<th>2021 £m</th>
<th>2020 £m</th>
<th>2019 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>303</td>
<td>271</td>
<td>287</td>
</tr>
<tr>
<td>Current assets</td>
<td>345</td>
<td>271</td>
<td>241</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>70</td>
<td>58</td>
<td>65</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>262</td>
<td>190</td>
<td>144</td>
</tr>
<tr>
<td>Total equity at the end of the year</td>
<td>316</td>
<td>294</td>
<td>319</td>
</tr>
<tr>
<td>– Attributable to non-controlling interests</td>
<td>86</td>
<td>80</td>
<td>86</td>
</tr>
<tr>
<td>Net cash generated from operating activities</td>
<td>52</td>
<td>137</td>
<td>140</td>
</tr>
<tr>
<td>Net cash used in investing activities</td>
<td>(26)</td>
<td>(11)</td>
<td>(51)</td>
</tr>
<tr>
<td>Net cash used in financing activities</td>
<td>(55)</td>
<td>(111)</td>
<td>(75)</td>
</tr>
<tr>
<td>Differences on exchange</td>
<td>–</td>
<td>(1)</td>
<td>(1)</td>
</tr>
</tbody>
</table>

(Decrease)/increase in net cash and cash equivalents | (29)    | 14      | 13      |

Net cash and cash equivalents at 1 January        | 30      | 16      | 3       |

Net cash and cash equivalents at 31 December      | 1       | 30      | 16      |

Subsidiaries subject to restrictions:

As a result of the Group’s Canadian subsidiary, Imperial Tobacco Canada (ITCAN), entering CCAA protection, the assets of ITCAN are subject to restrictions. The table below summarises the assets and liabilities of ITCAN:

<table>
<thead>
<tr>
<th>Summarised financial information</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>2,403</td>
<td>2,354</td>
</tr>
<tr>
<td>Current assets</td>
<td>1,630</td>
<td>1,251</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>(109)</td>
<td>(132)</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>(479)</td>
<td>(528)</td>
</tr>
</tbody>
</table>

3,445                                           | 2,845   |

Under the terms of CCAA, the court has appointed FTI Consulting Canada Inc. to act as a monitor. This monitor has no operational input and is not involved in the management of the business. The Group considers that ITCAN continues to meet the requirements of IFRS 10 Consolidated Financial Statements, and, until such requirements are not met, the Group will continue to consolidate the results of ITCAN.
32 Interests in Subsidiaries Continued

Whilst the Group continues to control the operations of its Canadian subsidiary, there are restrictions over the ability to access or use certain assets including the ability to remit dividends. Included in non-current assets for 2021 and 2020 is goodwill of £2.3 billion subject to impairment reviews (note 12). Included in current liabilities are trade and other payables of £341 million (2020: £284 million), the majority of which are amounts payable in respect of duties and excise. A breakdown of current assets has been provided below.

<table>
<thead>
<tr>
<th>2021 (£m)</th>
<th>2020 (£m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents *</td>
<td>1,114</td>
</tr>
<tr>
<td>Inventory</td>
<td>126</td>
</tr>
<tr>
<td>Investments held at fair value</td>
<td>351</td>
</tr>
<tr>
<td>Other</td>
<td>39</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,630</strong></td>
</tr>
</tbody>
</table>

* Cash and cash equivalents above include £1,024 million (2020: £878 million) of restricted cash and cash equivalents. The Group defines restricted cash and cash equivalents as where there are significant restrictions on its ability to access or use the assets and settle the liabilities of the Group, but excludes cash and cash equivalents where there are also outstanding local currency borrowings or where there is an outstanding excise liability. In addition, dividends payable would also be excluded from restricted cash and cash equivalents if the dividend has been approved by the necessary regulatory channels.

Refer to note 31 for information on the Quebec Class Actions.

Other shareholdings

At 31 December 2021, the Group holds almost 100% (2020: 92%) of the equity shares of PT Bentoel Internasional Investama Tbk (Bentoel). In 2011, the Group sold 984 million shares, representing approximately 14% of Bentoel’s share capital, for the purposes of fulfilling certain obligations pursuant to Bapepam-LK (Indonesia) takeover regulations. The Group simultaneously entered into a total return swap on 971 million of the shares. In June 2016, the Group and other investors participated in a rights issue by Bentoel, with the Group increasing its stake in Bentoel to 92%. Simultaneously, the Group amended the total return swap to take account of an additional 1,684 million shares with the shares subject to the total return swap representing 7% of Bentoel's issued capital. While the Group did not have legal ownership of these shares, it retained the risks and rewards associated with them which resulted in the Group continuing to recognise an effective interest in 99% of Bentoel’s net assets and results. As explained in note 30, on 5 October 2021, Bentoel announced its intention to delist from the Indonesia Stock Exchange and go private by conducting a Voluntary Tender Offer (VTO). As part of this process, the Group terminated the total return swap, with legal ownership of the shares being reacquired by the Group. The process is on-going and is expected to conclude in the early part of 2022, with no material impact to the Group.

Refer to note 14 for information on the Group’s 42% investment in Tisak d.d.

33 Summarised Financial Information

The following summarised financial information is required by the rules of the Securities and Exchange Commission and has been prepared as a requirement of the Regulation S-X 3-10 in respect of the guarantees of:

The financial information relates to the guarantees of:

- US$12.35 billion of outstanding bonds issued by B.A.T Capital Corporation (BATCAP) in connection with the acquisition of Reynolds American Inc. (Reynolds American), including registered bonds issued in exchange for the initially issued bonds (the 2017 Bonds);
- US$10.65 billion of outstanding bonds issued by BAT pursuant to the Shelf Registration Statement on Form F-3 filed on July 17, 2019, pursuant to which BATCAP or BATIF may issue an indefinite amount of debt securities; and
- US$11.50 billion of outstanding bonds issued by BAT pursuant to the Shelf Registration Statement on Form F-3 filed on July 17, 2019, pursuant to which BATCAP or BATIF may issue an indefinite amount of debt securities.

As of July 28, 2020, all relevant Group entities suspended their reporting obligations with respect to the US$7.7 billion (2020: US$7.7 billion) of Reynolds American unsecured notes and US$40.9 million (2020: US$40.9 million) of Lorillard unsecured notes. As such, no summarised financial information is provided with respect to these securities.

As described below, Reynolds American is a subsidiary guarantor of all outstanding series of BATCAP and BATIF bonds. Under the terms of the indentures governing such notes, any subsidiary guarantor (including Reynolds American) other than BATCAP or BATIF, as applicable, BATNF and BATHTN, will automatically and unconditionally be released from all obligations under its guarantee, and such guarantee shall thereupon terminate and be discharged and of no further force or effect, in the event that (1) its guarantee of all then outstanding notes issued under the Group’s EMTN Programme is released or (2) at substantially the same time its guarantee of the debt securities is terminated, such subsidiary guarantor is released from all obligations in respect of indebtedness for borrowed money for which such subsidiary guarantor is an obligor (as a guarantor or borrower). Under the EMTN Programme, Reynolds American’s guarantee is released if at any time the aggregate amount of indebtedness for borrowed money, subject to certain exceptions, for which Reynolds American is an obligor does not exceed 10% of the outstanding long-term debt of BAT as reflected in the balance sheet included in BAT’s most recent publicly released interim or annual consolidated financial statements.
### 33 Summarised Financial Information Continued

Reynolds American’s guarantee may be released notwithstanding Reynolds American guaranteeing other indebtedness, provided Reynolds American’s guarantee of outstanding notes issued under the EMTN Programme is released. If Reynolds American’s guarantee is released, BAT is not required to replace such guarantee, and the debt securities will have the benefit of fewer subsidiary guarantees for the remaining maturity of the debt securities.

**Note:** The following summarised financial information report the unconsolidated contribution of each applicable company to the Group’s consolidated results and not the separate financial statements for each applicable company as local financial statements are prepared in accordance with local legislative requirements and may differ from the financial information provided below. In particular, in respect of the U.S. region, all financial statements and financial information provided by or with respect to the U.S. business or RAI (and/or RAI and its subsidiaries (collectively, the Reynolds Group)) are prepared on the basis of US GAAP and constitute the primary financial statements or financial information of the U.S. business or RAI (and/or the Reynolds Group). Solely for the purpose of consolidation within the results of BAT p.l.c. and the BAT Group, this financial information is then converted to IFRS. To the extent any such financial information provided in these financial statements relates to the U.S. business or RAI (and/or the Reynolds Group), it is provided as an explanation of the U.S. business’s or RAI’s (and/or the Reynolds Group’s) primary US GAAP based financial statements and information.

The subsidiaries disclosed below are wholly-owned and the guarantees provided are full and unconditional, and joint and several:

a. British American Tobacco p.l.c. (as the parent guarantor), referred to as ‘BAT p.l.c.’ in the financials below;

b. B.A.T Capital Corporation (as an issuer or a subsidiary guarantor, as the case may be), referred to as ‘BATCAP’ in the financials below;

c. B.A.T. International Finance p.l.c. (as an issuer or a subsidiary guarantor, as the case may be), referred to as ‘BATIF’ in the financials below;

d. B.A.T. Netherlands Finance B.V. (as a subsidiary guarantor), referred to as ‘BATNF’ in the financials below;

e. Reynolds American Inc. (as a subsidiary guarantor), referred to as ‘RAI’ in the financials below; and

f. British American Tobacco Holdings (The Netherlands) B.V. (as a subsidiary guarantor of the 2017 Bonds only), referred to as ‘BATHTN’ in the financials below.

In accordance with Regulation S-X 13-01, information in respect of investments in subsidiaries that are not issuers or guarantors has been excluded from non-current assets as shown in the balance sheet table below. The ‘BATHTN’ column in the summarised financial information is only applicable in the context of the 2017 Bonds. British American Tobacco Holdings (The Netherlands) B.V. (BATHTN) is not an issuer nor guarantor of any of the other securities referenced in this note. None of the issuers or other guarantors has material balances with or an investment in BATHTN. Investments in subsidiaries represents share capital acquired in relation to or issued by subsidiary undertakings.

<table>
<thead>
<tr>
<th>Summarised Financial Information</th>
<th>BAT p.l.c. £m</th>
<th>BATCAP £m</th>
<th>BATIF £m</th>
<th>BATNF £m</th>
<th>RAI £m</th>
<th>BATHTN £m</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income Statement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(Loss)/profit from operations</td>
<td>(111)</td>
<td>(1)</td>
<td>(2)</td>
<td>–</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td>Dividend income</td>
<td>6,200</td>
<td>–</td>
<td>–</td>
<td>4,827</td>
<td>164</td>
<td>–</td>
</tr>
<tr>
<td>Net finance income/(costs)</td>
<td>170</td>
<td>(43)</td>
<td>63</td>
<td>1</td>
<td>(421)</td>
<td>–</td>
</tr>
<tr>
<td>Profit/(loss) before taxation</td>
<td>6,259</td>
<td>(44)</td>
<td>61</td>
<td>1</td>
<td>4,409</td>
<td>164</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>5</td>
<td>19</td>
<td>1</td>
<td>–</td>
<td>97</td>
<td>–</td>
</tr>
<tr>
<td>Profit/(loss) for the year</td>
<td>6,264</td>
<td>(25)</td>
<td>62</td>
<td>1</td>
<td>4,506</td>
<td>164</td>
</tr>
<tr>
<td><strong>Intercompany Transactions – Income Statement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transactions with non-issuer/non-guarantor subsidiaries (expense)/income</td>
<td>(111)</td>
<td>(1)</td>
<td>(2)</td>
<td>–</td>
<td>36</td>
<td>–</td>
</tr>
<tr>
<td>Transactions with non-issuer/non-guarantor subsidiaries net finance (cost)/income</td>
<td>(2)</td>
<td>709</td>
<td>370</td>
<td>–</td>
<td>28</td>
<td>–</td>
</tr>
<tr>
<td>Dividend income from non-issuer/non-guarantor subsidiaries</td>
<td>6,200</td>
<td>–</td>
<td>–</td>
<td>4,827</td>
<td>164</td>
<td>–</td>
</tr>
</tbody>
</table>

279
33 Summarised Financial Information
Continued

Income Statement

<table>
<thead>
<tr>
<th>BAT p.l.c.</th>
<th>BATCAP</th>
<th>BATIF</th>
<th>BATNF</th>
<th>RAI</th>
<th>BATHTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Revenue</td>
<td>(112)</td>
<td>(1)</td>
<td>(2)</td>
<td>(5)</td>
<td>–</td>
</tr>
<tr>
<td>Loss from operations</td>
<td>(112)</td>
<td>(1)</td>
<td>(2)</td>
<td>(5)</td>
<td>–</td>
</tr>
<tr>
<td>Dividend income</td>
<td>5,050</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4,845</td>
</tr>
<tr>
<td>Net finance income/(costs)</td>
<td>131</td>
<td>417</td>
<td>174</td>
<td>–</td>
<td>(758)</td>
</tr>
<tr>
<td>Profit before taxation</td>
<td>5,069</td>
<td>416</td>
<td>172</td>
<td>–</td>
<td>4,082</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>(14)</td>
<td>(101)</td>
<td>4</td>
<td>–</td>
<td>170</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>5,055</td>
<td>315</td>
<td>176</td>
<td>–</td>
<td>4,252</td>
</tr>
</tbody>
</table>

Intercompany Transactions – Income Statement

Transactions with non-issuer/non-guarantor subsidiaries (expense)/income | (118)  | (1)   | 4     | –   | 22     |
Transactions with non-issuer/non-guarantor subsidiaries net finance income | 5,050  | –     | –     | –   | 4,845   |
Dividend income from non-issuer/non-guarantor subsidiaries | 5,050  | –     | –     | –   | 4,845   |

Balance Sheet

<table>
<thead>
<tr>
<th>BAT p.l.c.</th>
<th>BATCAP</th>
<th>BATIF</th>
<th>BATNF</th>
<th>RAI</th>
<th>BATHTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>1,916</td>
<td>18,192</td>
<td>4,986</td>
<td>1,417</td>
<td>357</td>
</tr>
<tr>
<td>Current assets</td>
<td>8,443</td>
<td>3,583</td>
<td>35,772</td>
<td>21</td>
<td>1,033</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>9</td>
<td>17,024</td>
<td>13,667</td>
<td>1,417</td>
<td>8,778</td>
</tr>
<tr>
<td>Non-current borrowings</td>
<td>–</td>
<td>16,965</td>
<td>13,560</td>
<td>1,417</td>
<td>8,719</td>
</tr>
<tr>
<td>Other non-current liabilities</td>
<td>9</td>
<td>59</td>
<td>107</td>
<td>–</td>
<td>59</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>1,607</td>
<td>4,633</td>
<td>25,451</td>
<td>20</td>
<td>862</td>
</tr>
<tr>
<td>Current borrowings</td>
<td>1,580</td>
<td>4,602</td>
<td>25,081</td>
<td>20</td>
<td>263</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>27</td>
<td>31</td>
<td>370</td>
<td>–</td>
<td>619</td>
</tr>
</tbody>
</table>

Intercompany Transactions – Balance Sheet

Amounts due from non-issuer/non-guarantor subsidiaries | 8,405  | 25,999| 38,539| –   | 620   |
Amounts due to non-issuer/non-guarantor subsidiaries | 3      | 3,139 | 20,422| –   | 62    |
Investment in subsidiaries (that are not issuers or guarantors) | 27,234 | –     | 718   | –   | 23,643|

**Summarised Financial Information**

As at 31 December 2020

<table>
<thead>
<tr>
<th>BAT p.l.c.</th>
<th>BATCAP</th>
<th>BATIF</th>
<th>BATNF</th>
<th>RAI</th>
<th>BATHTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>236</td>
<td>18,981</td>
<td>10,332</td>
<td>1,509</td>
<td>402</td>
</tr>
<tr>
<td>Current assets</td>
<td>7,070</td>
<td>3,404</td>
<td>30,601</td>
<td>22</td>
<td>268</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>1,580</td>
<td>17,867</td>
<td>15,326</td>
<td>1,509</td>
<td>8,885</td>
</tr>
<tr>
<td>Non-current borrowings</td>
<td>1,571</td>
<td>17,867</td>
<td>15,243</td>
<td>1,509</td>
<td>8,823</td>
</tr>
<tr>
<td>Other non-current liabilities</td>
<td>9</td>
<td>83</td>
<td>–</td>
<td>–</td>
<td>62</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>232</td>
<td>4,444</td>
<td>24,038</td>
<td>22</td>
<td>972</td>
</tr>
<tr>
<td>Current borrowings</td>
<td>4,439</td>
<td>23,478</td>
<td>22</td>
<td>220</td>
<td>1</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>43</td>
<td>115</td>
<td>560</td>
<td>–</td>
<td>772</td>
</tr>
</tbody>
</table>

**Summarised Financial Information**

As at 31 December 2021

<table>
<thead>
<tr>
<th>BAT p.l.c.</th>
<th>BATCAP</th>
<th>BATIF</th>
<th>BATNF</th>
<th>RAI</th>
<th>BATHTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>236</td>
<td>18,981</td>
<td>10,332</td>
<td>1,509</td>
<td>402</td>
</tr>
<tr>
<td>Current assets</td>
<td>7,070</td>
<td>3,404</td>
<td>30,601</td>
<td>22</td>
<td>268</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>1,580</td>
<td>17,867</td>
<td>15,326</td>
<td>1,509</td>
<td>8,885</td>
</tr>
<tr>
<td>Non-current borrowings</td>
<td>1,571</td>
<td>17,867</td>
<td>15,243</td>
<td>1,509</td>
<td>8,823</td>
</tr>
<tr>
<td>Other non-current liabilities</td>
<td>9</td>
<td>83</td>
<td>–</td>
<td>–</td>
<td>62</td>
</tr>
<tr>
<td>Current liabilities</td>
<td>232</td>
<td>4,444</td>
<td>24,038</td>
<td>22</td>
<td>972</td>
</tr>
<tr>
<td>Current borrowings</td>
<td>4,439</td>
<td>23,478</td>
<td>22</td>
<td>220</td>
<td>1</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>43</td>
<td>115</td>
<td>560</td>
<td>–</td>
<td>772</td>
</tr>
</tbody>
</table>
Perpetual hybrid bonds

BAT p.l.c. has issued two €1 billion of perpetual hybrid bonds which have been classified as equity as there is no contractual obligation to either repay the principal or make payments of interest (note 22(d)).

BAT p.l.c.’s unconsolidated contribution to the Group’s consolidated equity results is shown below:

<table>
<thead>
<tr>
<th>BAT p.l.c.</th>
<th>2021 £m</th>
<th>2020 £m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Share capital</td>
<td>614</td>
<td>614</td>
</tr>
<tr>
<td>Share premium</td>
<td>107</td>
<td>103</td>
</tr>
<tr>
<td>Perpetual hybrid bonds</td>
<td>1,685</td>
<td>–</td>
</tr>
<tr>
<td>Other equity</td>
<td>33,571</td>
<td>32,191</td>
</tr>
<tr>
<td>Total equity</td>
<td>35,977</td>
<td>32,908</td>
</tr>
</tbody>
</table>
This disclosure is made in accordance with Section 409 of the Companies Act 2006 and The Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, as amended by The Companies, Partnerships and Groups (Accounts and Reports) Regulations 2015. A full list of subsidiary undertakings, associates and joint ventures and joint operations as defined by IFRS (showing the country of incorporation, effective percentage of equity shares held and full registered office addresses) as at 31 December 2021 is disclosed below.

The subsidiary undertakings that are held directly by British American Tobacco p.l.c. (the ultimate Parent Company) are indicated thus*; all others are held by sub-holding companies.

Unless otherwise stated, the equity shares held are in the form of ordinary shares or common stock, except for those indicated thus#, which include preference shares. The effective percentage of equity shares held in subsidiary undertakings is 100% unless otherwise stated. Further, where the effective percentage of equity shares held by the sub-holding company is different from that held by British American Tobacco p.l.c., the percentage of equity shares held by British American Tobacco p.l.c. is indicated thus^ and is shown after the percentage interest held by the sub-holding company.

The results of a number of these subsidiary undertakings principally affect the financial statements of the Group. These principal subsidiary undertakings are highlighted in grey and are considered to be the main corporate entities in those countries which, in aggregate, contributed 85% of the Group revenue and 100% of profit from operations.

### Subsidiary Undertakings

<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Entity Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>Rruga e Kavajes, Ish Kombinati Ushqimor, Tirana, Albania</td>
<td>British American Tobacco – Albania SH.P.K.</td>
</tr>
<tr>
<td>Algeria</td>
<td>Zone d’activité El Omran, Route de Ouled Fayet, Ilot 789: Lot 04, Cheraga, Alger, Algérie</td>
<td>British American Tobacco (Algérie) S.P.A. (51%)</td>
</tr>
<tr>
<td>Angola</td>
<td>Viana Park, Polo Industrial, Viana, Luanda, Angola</td>
<td>British American Tobacco – B.A.T. Angola, Limitada1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sociedade Geral de Distribuição e Comércio, Limitada</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sociedade Industrial Tabacos Angola LDA (77.60%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sociedade Unificada Tabacos Angola LDA (76.39%)</td>
</tr>
<tr>
<td>Argentina</td>
<td>San Martín 140, Floor 14, City of Buenos Aires, Argentina</td>
<td>British American Tobacco Argentina S.A.I.C.y F. (99.98%)</td>
</tr>
<tr>
<td>Australia</td>
<td>196 William Street, Woolloomooloo, NSW 2011, Australia</td>
<td>British American Tobacco South East Asia Pty Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>British American Tobacco Australasia Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>British American Tobacco Australia Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>British American Tobacco Australia Overseas Pty Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>British American Tobacco Australia Services Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rothmans Asia Pacific Limited#</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Benson &amp; Hedges Company Pty. Limited</td>
</tr>
<tr>
<td></td>
<td></td>
<td>W.D. &amp; H.O. Wills Holdings Limited</td>
</tr>
<tr>
<td>Austria</td>
<td>Dr. Karl Lueger Platz 5, 1010, Wien, Austria</td>
<td>British American Tobacco (Austria) GmbH</td>
</tr>
<tr>
<td>Bahrain</td>
<td>Flat 2115, Building 2504, Road 2832, Block 428 Al Seef Area, Kingdom of Bahrain</td>
<td>British American Tobacco Middle East W.L.L</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>New DOHS Road, Mohakhali, Dhaka 1206, Bangladesh</td>
<td>British American Tobacco Bangladesh Company Limited (72.91%)</td>
</tr>
<tr>
<td>Barbados</td>
<td>Chancery Chambers, Chancery House, High Street, Bridgetown, Barbados</td>
<td>Southward Insurance Ltd.</td>
</tr>
<tr>
<td>Belarus</td>
<td>7B Piasa 3 Kuprevicha Str., Minsk, 220141, Belarus</td>
<td>British-American Tobacco Trading Company Foreign Trade Unitary Enterprise</td>
</tr>
<tr>
<td>Belgium</td>
<td>Globe House, 4 Temple Place, London, WC2R 2PG, United Kingdom</td>
<td>British American Tobacco Holdtris Belgium N.V.</td>
</tr>
<tr>
<td></td>
<td>Nieuwe Gentsesteenweg 21, 1702 Goet-Gistel, Belgium</td>
<td>British American Tobacco Belgium N.V.</td>
</tr>
<tr>
<td>Benin</td>
<td>Colonou, Lot Numbero H19, Quartiers Les Cocotiers, 01 BP 2520, Benin</td>
<td>British American Tobacco Benin SA</td>
</tr>
<tr>
<td>Bolivia</td>
<td>Av. Ballivan entre calles 11 y 1x No. 555, Edificio El Doral, Piso 19, Oficina E, Zona de Catedral, La Paz, Bolivia</td>
<td>BAT Bolivia S.R.L.</td>
</tr>
</tbody>
</table>
Financial Statements

Group Companies and Undertakings

Continued

Croatia
Skrakovci cvea 27, 10000 Zagreb, Croatia
Kolose d.d. (93.42%)
Ivanka Lukić 2a, 70000 Zagreb, Croatia
BAT HRVATSKA d.o.o. u likvidaciji
Osijek V. Novča 1, 52210 Nový, Croatia
TDR d.o.o.
Osijek 2, 33000 Virovitica, Croatia
Hrvatski Buhan d.d. Tobacco Leaf Processing (89.55%) (85.25%)^5

Cuba
Parcela nº 2 a noroeste do terminal de contêineres de Mariel, a 2,2 km do vértice nº 4, Município de Mariel, Província de Artemisa, na República de Cuba.

Brasilcuba Cigarmilos S.A. (50%)

Cyprus
Protides Business Centre, 5th Floor, 8 Stasinou Avenue, Nicosia, CY-1060, Cyprus
B.A.T (Cyprus) Limited
Rothmans (Middle East) Limited

Czech Republic
Karolinská 654/2, Prague 8 – Karlín, 186 00, Czech Republic
British American Tobacco (Czech Republic), s.r.o.

Denmark
Sejlstræde 50, 1777 Copenhagen, Denmark
British American Tobacco Denmark A/S (House of Prince A/S)
Preis (1892) Denmark A/S

Djibouti
Rue de Magadiscio, Lot No. 133, Djibouti City, Djibouti
British American Tobacco Djibouti SARL

Egypt
Administrative unit no.1, 6th Floor, Building 52B, Sector A, Downtown Mall Kalyaneya, 5th settlement, New Cairo, Egypt
BETCO for General Services and Marketing LLC
BETCO for Trade and Distribution LLC
British American Tobacco Egypt LLC
British American Tobacco North Africa LLC

Eritrea
PO. Box 749, 62 Fei Kei Street, Amerana, Eritrea
British American Tobacco (Eritrea) Share Company^5

Estonia
Tonnimõte 7-10, 10145 Tallinn, Estonia
British American Tobacco Estonia AS

Fiji
Lady Maria Road, Nabua, Suva, Fiji
British American Tobacco (Fiji) Marketing Pte Limited
Central Manufacturing Company Pte Limited
Rothmans of Pall Mall (Fiji) Pte Limited

Finland
cio Retail 24, Olantiuoma 7, 02200 Espoo, Finland
British American Tobacco Finland Oy

France
111 Avenue Victor Hugo, Paris, 75016, France
Carreras France SAS
Tour Légende, 20 place de la Défense, CS 80289, 92030 Paris La Défense Cedex, France
British American Tobacco France SAS

Germany
Altenfelder Str. 20354 Hamburg, Germany
BTRG Gesellschaft fur Beteiligungen mbH
British American Tobacco (Germany) GmbH
British American Tobacco (Industrie) GmbH
Schulterblatt Strasse, 23, 01458 Elstendorf/Ostsee, Germany
Quantus Beteiligungs – und Beratungsgesellschaft mbH

Ghana
4th Floor, Volta Place, Airport Residence Area, Patrice Lumumba Street, Accra, Ghana
British American Tobacco Ghana Limited (97.09%)

Greece
27, Ag. Thoma Street, Maroussi, 151 24, Greece
British American Tobacco Hellas S.A.

Guernsey
St. Martin’s House, Le Bordage, St. Peter’s Port, GY1 4AU, Guernsey
Belair Insurance Company Limited

Guyana
Lot 122 Parade Street, Kingston, Georgetown, Guyana
Demerara Tobacco Company Limited (10.25%)

Honduras
Boulevard del Sur, Zona El Cacao, San Pedro Sula, Depart.de Cortés, Honduras
Tabacalera Hondureña S.A. (83.64%)

Hong Kong
TDP One Pacific Place, Bl Quennanway, Hong Kong
British American Tobacco China Investments Limited
LEHMAN, LEE & XU CORPORATE SERVICES, Suite 3313, Tower One, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Raymonds Asia-Pacific Limited
Level 30, Three Pacific Place, 1 Queen’s Road East, Wanchai, Hong Kong
British American Tobacco Asia-Pacific Region Limited
Level 24, Suites 2407 - 09, 3 Pacific Place, 1 Queen’s Road East, Wanchai, Hong Kong

BAY Global Travel Retail Limited

Hungary
11124 Budapest, Csoörz utca 49-51. 3. em., Hungary
BAY Pécsi Dohánytúra Karlóttat Petélossegő Szállás
## Group Companies and Undertakings

Continued

<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mali</td>
<td>DJELIBOUGOU-Immeuble BASSARO- BP 2065, Bamako -Mali</td>
<td>British American Tobacco (Mali) Sarl</td>
</tr>
<tr>
<td>Malta</td>
<td>PM Building, Level 2, Bone Street, Zone 1, Central Business District, Birkerka, CBO 1060, Malta.</td>
<td>British American Tobacco (Malta) Limited</td>
</tr>
<tr>
<td></td>
<td>Central Cigarette Company Limited</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rothmans of Paf Mal (Malta) Limited</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Francisco I Madero 2750 Poniente, Colonia Centro, Monterrey, Nuevo León, C.P. 64000, Mexico.</td>
<td>British American Tobacco Mexico – Mexico S.A. de C.V.</td>
</tr>
<tr>
<td></td>
<td>BAT DBS Mexico S.A. de C.V.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British American Tobacco Mexico Comercial, S.A. de C.V.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British American Tobacco Mexico, S.A. de C.V.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British American Tobacco Servicios S.A. de C.V.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cigarrera La Moderna, S.A. de C.V.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prados Los Sauces Sin numero, Colonia Los Sauces, C.P. 63197, Tepic, Nayarit, Mexico</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Procesadora de Tabacos de Mexico, S.A. de C.V. (93%)</td>
<td></td>
</tr>
<tr>
<td>Moldova, Republic of</td>
<td>65, Stephen cel Mare Str., of. 416, Chisinau, MD2001, Republic of Moldova</td>
<td>British American Tobacco – Moldova SRL</td>
</tr>
<tr>
<td>Mozambique</td>
<td>2289 Avenida de Angola, Maputo, Mozambique</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British American Tobacco Mozambique Limitada (95%)</td>
<td></td>
</tr>
<tr>
<td>Myanmar</td>
<td>Min Aye Yar Street, Plot No. (55, 56), Survey Ward No. (14) Shwe Than Lwin Industrial Zone, Hlaing Tharar Township Yangon Region, Myanmar</td>
<td>British American Tobacco Myanmar Limited (95%)</td>
</tr>
<tr>
<td></td>
<td>British American Tobacco Myanmar Services Limited (95%)</td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>24 Orban Street, Klein Windhoek, Namibia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Twisp (Pty) Limited</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shop 48, Second Floor Old Power Station Complex, Armstrong Street, Windhoek, Namibia</td>
<td>British American Tobacco Namibia (Pty) Limited</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Handelsweg 54 A, 1181 ZA, Amstelveen, Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British Properties B.V.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.A. T. Netherlands Finance B.V.</td>
<td></td>
</tr>
<tr>
<td>British American Tobacco European Operations Centre B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Exports B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Holdings (Australia) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Holdings (Malaysia) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Holdings (South Africa) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Holdings (The Netherlands) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Holdings (Venezuela) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco Holdings (Vietnam) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco International (Holdings) B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Michigan B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Phoenix B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Portland B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Seattle B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Toronto B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Vancouver B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Washington B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Williamsport B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British American Tobacco – Youngstown B.V.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Netherlands

Handelsweg 54 A, 1181 ZA, Amstelveen, Netherlands
British Properties B.V.
S.A. T. Netherlands Finance B.V.
British American Tobacco European Operations Centre B.V.
British American Tobacco Exports B.V.
British American Tobacco Holdings (Australia) B.V.
British American Tobacco Holdings (Malaysia) B.V.
British American Tobacco Holdings (South Africa) B.V.
British American Tobacco Holdings (The Netherlands) B.V.
British American Tobacco Holdings (Venezuela) B.V.
British American Tobacco Holdings (Vietnam) B.V.
British American Tobacco International (Holdings) B.V.

Molensteegh Invest B.V.
Special (1980) B.V.
Rothmans Far East B.V.
Rothmans International Holdings B.V.
Rothmans Tobacco Investments B.V.
Rothmans UK Holdings B.V.

New Zealand

2 Wait Street, Parnell, Auckland, 1052, New Zealand

BAT (New Zealand) Limited

BAT Holdings (New Zealand) Limited

Mint Advisory Limited, Suite 6, 8 Yrua Street, St Heliers, Auckland, 1071, New Zealand

New Zealand (UK Finance) Limited

Nigeria

1, Tobacco Road, Iluoye Local Government Area, Ibadan, Oyo State, Nigeria

British American Tobacco (Nigeria) Limited

2 Olumegbon Road, Ikoyi, Lagos, Nigeria

British American Tobacco Marketing Nigeria Limited
Group Companies and Undertakings
Continued

Serbia
Bulevar Milutina Mirkovice 12, Beograd, 11070, Serbia
British American Tobacco South Eastern Europe d.o.o. Beograd
Kralja Stefana Provencanog 209, Vranje, 17500, Serbia
British American Tobacco Vranje a.d. Vranja

Singapore
15 Senoko Loop, Singapore, 758168
British American Tobacco Sales & Marketing Singapore Pte. Ltd.
Shenton Way, #03-00 OUE Downtown, Singapore 068809

Slovenia
Bravni-carjeva ulica 13, 1000 Ljubljana, Slovenia
British American Tobacco d.o.o.

Solomon Islands
Kukum Highway, Honiara, Honiara, Solomon Islands

South Africa
Waterway House South, 3 Dock Road, V&A Waterfront, Cape Town, Western Cape 8002, South Africa
Agrega EEMEA (Pty) Ltd
Amalgamated Tobacco Corporation (South Africa) (Pty) Ltd
American Cigarette Company (Overseas) (Pty) Ltd
American Shared Services Africa Middle East (Pty) Ltd
British American Tobacco (SA) (Pty) Ltd
British American Tobacco Holdings South Africa (Pty) Ltd
British American Tobacco Properties South Africa (Pty) Ltd.
British American Tobacco Services South Africa (Pty) Ltd.
British American Tobacco South Africa (Pty) Ltd
British American Tobacco East and Southern Africa (Pty) Ltd
Brown & Williamson Tobacco Corporation (Pty) Ltd
Business Venture Investments No 216 (Pty) Ltd
Carlton Cigarette Company (Pty) Ltd
John Chapman (Pty) Ltd
John Player & Sons (Pty) Ltd
Kentucky Tobacco Corporation (Pty) Ltd
Marlins of London (Pty) Ltd
Rennbrandt Tobacco Corporation (Overseas) (Pty) Ltd
Riggo Tobacco Corporation of New York (Pty) Ltd
Rothmans of Pall Mall London (Pty) Ltd
St Regis Tobacco Corporation (Pty) Ltd
Thomas Bear’s Son and Company (Pty) Ltd
Tobacco Research and Development Institute (Pty) Ltd
Twee (Pty) Ltd
W & W Tobacco (Pty) Ltd
Westminster Tobacco Company (Cape Town and London) (Pty) Ltd
Winfield Tobacco Corporation (Pty) Ltd
Winston Tobacco Corporation (Pty) Ltd

Spain
Torreco Espacio, Paseo de la Castellana, 2590, 28046 Madrid, Spain
British American Tobacco Española, S.A.

Sri Lanka
178 Shinnal Ramanathan Mawatha, Colombo, 15, Sri Lanka
Ceylon Tobacco Company Pte. (84.13%)

Sudan
Byblos Tower, Al-Muk Nemer Street, Postal Code 11111, P.O. Box 1381, Khartoum, Sudan
Blue Nile Cigarette Company Limited

Swaziland
211 King Mswati III Avenue West, Matsapha Industrial Site, Matsapha, eSwatini
British American Tobacco Swaziland (Pty) Limited

Sweden
Hyllie Boulevard 32, 215 32 Malmö, Sweden
Niconorun AB
Stenvaldsgatan 23, 213 76 Malmö, Sweden
Winfell AB

Switzerland
c/o British American Tobacco Switzerland S.A., Route de France 17, 2926 Boncourt, Switzerland
American Cigarette Company (Overseas) Limited
British American Tobacco Switzerland SA
BAT Switzerland Vending SA
Rothmans of Pall Mall Limited
Route de France 17, 2926 Boncourt, Switzerland
Nicoventures Communications (Switzerland) SA
GBL Simulacra S.A., Route de la Gâline 107, c/o GBL Simulacra AG 1752 Villars-sur-Glâne, Switzerland
Intertab SA (50%),
c/o Bright Law AG, Bundesplatz, 6302 Zug, Switzerland
British American Tobacco International Limited (In Liquidation)

Tanzania
Acacia Estate Building, Kinondoni Road, P.O Box 288, Dar es Salaam, Tanzania
BAT Distribution Tanzania Limited
British American Tobacco Tanzania Limited (In Liquidation)
International Cigarette Distributors Limited (99%) (In Liquidation)

Turkey
Oncu Maslak Is Merkezi, Eski Büyükdere Caddesi, Kat 9-10, Maslak, Sanyal, Istanbul
British American Tobacco Tütün Mamulleri Sanayi ve Ticaret Anonim Sirketi
Uganda
10th Floor, Lofts Towers, Plot 16 Mackinnon Road, Nakasero, Kampala, Uganda
British American Tobacco Uganda Limited (90%)

Ukraine
15/15 Bolshennovka St, Kyiv, 01014 Ukraine
LLC 'British American Tobacco Sales and Marketing Ukraine'
21 Nezalezhnosti Str, Chernihiv Oblast, Prylucky, 17502, Ukraine
PJSC 'B.A.T – Prylucky Tobacco Company'

United Arab Emirates
Jumeriah Business Centre 3, 37th Floor, Jumeriah Lake Towers, Dubai, P.O. Box 337222, United Arab Emirates
British American Tobacco GCC DMCC
British American Tobacco ME DMCC
Unit # 2620, DMCC Business Center, Level # 1, Jewellery & Gemplex 3
21 Nezalezhnosti Str, Chernihiv Oblast, Prylucky, 17502, Ukraine
PJSC 'A/T B.A.T. – Prylucky Tobacco Company'

United Kingdom
212-218 Upper Newtownards Road, Belfast, BT4 3ET, Northern Ireland
Murray, Sons & Company, Limited
7 More London, Riverside, London, SE1 2RT, United Kingdom
Kyesekiks P.L.C. (50%) (In Liquidation)
Building 7, Chiswick Business Park, 566 Chiswick High Road, London, W4 5YG, United Kingdom
British American Tobacco UK Limited

10 Molines Limited

Globe House, 1 Water Street, London, WC2R 3LA, United Kingdom
Advanced Technologies (Cambridge) Limited
Allen & Ginter (UK) Limited
B.A.T (U.K. and Export) Limited
B.A.T Far East Holding Limited
B.A.T Far East Leaf Limited
B.A.T Services Limited
B.A.T Uzbekistan (Investments) Limited
B.A.T Vietnam Limited
B.A.T (Westminster House) Limited
B.A.T. China Limited

BATUS Limited

Big Ben Tobacco Company Limited
British American Shared Services (GSD) Limited
British American Shared Services Limited
British American Tobacco (AIT) Limited

British American Tobacco (GLP) Limited
British American Tobacco (Investments) Limited
British American Tobacco (Philippines) Limited
British American Tobacco (Serbia) Limited
British American Tobacco (South America) Limited
British American Tobacco China Holdings Limited
British American Tobacco Exports Limited
British American Tobacco Georgia Limited
British American Tobacco Global Travel Retail Limited
British American Tobacco International Holdings (UK) Limited
British American Tobacco Investments (Central & Eastern Europe) Limited
British American Tobacco Italy Investments Limited
British American Tobacco Italy Limited
British American Tobacco Korea (Investments) Limited
British American Tobacco Malaysia (Investments) Limited
British American Tobacco Peru Holdings Limited
British American Tobacco UK Pension Fund Trustee Limited®
British-American Tobacco (Mauritius) p.l.c.
Carreras Rothmans Limited®
Chelwood Trading & Investment Company Limited
East African Tobacco Company (U.K.) Limited
Kibo Holdings Limited
Lord Extra Limited
Middletion Investment Company Limited
Nicovations Limited
Nicoventions Holdings Limited
Nicoventions Retail (UK) Limited
Nicoventions Trading Limited
Powhattian Limited
Precis (2396) Limited
Ridirectors Limited
Rothmans Exports Limited
Rothmans International Limited
Rothmans International Services Limited
Rothmans International Tobacco (UK) Limited
Rothmans of Pall Mall (Overseas) Limited
Rothmans Trading Limited
Ryservs (1995) Limited
Ryservs (No.3) Limited
Tobacco Exporters International Limited
Tobacco Marketing Consultants Limited
Venezuela Property Company Limited
Westminster Trading & Investment Company Limited
Westminster Tobacco Company Limited
Globe House, 2 Milford Lane, London, WC2R 3LN, United Kingdom
World Investment Company Limited
Financial Statements

Group Companies and Undertakings

Continued

Globe House, 4 Temple Place, London, WC2R 2PG, United Kingdom
Amalgamated Tobacco Company Limited
American Cigarette Company (Overseas) Limited
Ardath Tobacco Company Limited
B.A.T Additional Retirement Benefit Scheme Trustee Limited
B.A.T Industries p.l.c.
B.A.T. International Finance p.l.c.*
B.A.T. Operating Finance Limited
BATLaw Limited
BATMark Limited*
Benson & Hedges (Overseas) Limited
British American Global Shared Services Limited
British American (1998) Limited*
British American Tobacco (2009) Limited
British American Tobacco (2009 PCA) Limited
British American Tobacco (Corby) Limited
British American Tobacco (2012) Limited
British American Tobacco (Brands) Limited
British American Tobacco (Brands) (Export) Limited
British American Tobacco (Brands) (Investor) Limited
British American Tobacco (Brands) (USA) Limited
British American Tobacco (Brands) (USA) Inc.
British American Tobacco (Brands) (USA) LLC
British American Tobacco (Brands) Inc.
British American Tobacco (Brands) Limited
British American Tobacco Healthcare Trustee Limited
British American Tobacco Taiwan Logistics Limited
Brown & Williamson Tobacco Corporation (Export) Limited
Btomorrow Ventures Limited
Carreras Limited
Courteigh of London Limited
Durhill Tobacco of London Limited
John Sinclair Limited
London Securities Limited
Moorigate Tobacco Co. Limited
Peter Jackson (Overseas) Limited
Precis (1789) Limited
Precis (1814) Limited
Kohlmanns International Enterprises Limited
Kohlmanns of Pall Mall Limited
Senior Service (Overseas) Limited
South Western Nominees Limited
The London Tobacco Company Limited
Tobacco Insurance Company Limited
Weston (2009) Limited
Weston Investment Company Limited

United States
CSC-Lawyers Incorporating Service, 2710 Gateway Oaks Drive, Suite 150N, Sacramento CA 95833-3505, United States
Genstar Capital Corporation
291 Little Falls Drive, Wilmington, DE 19808, United States
B.A.T. Capital Corporation
BATUS Holdings Inc.
BATUS Japan, Inc.
BATUS Retail Services, Inc.
British American Tobacco (Brands), Inc.
Brown & Williamson Holdings, Inc.
BTD Investments Inc.
Btomorrow Innovation Hub Inc.
BTI 2014 LLC
Imasco Holdings Group, Inc.
Imasco Holdings, Inc.
TLC (USA) Limited
Louisville Corporate Services, Inc.
Nicoventures U.S. Limited
Farmers Bank Building, Suite 1402, 301 N. Market Street, Wilmington, DE 19801, United States
Reynolds Finance Company
300 Airways Drive, Owensboro, KY 42301, United States
KBio, Inc.
401 N. Main Street, Winston-Salem, NC 27101, United States
Conwood Holdings, Inc.
EXP Homes, LLC
Lorillard Licensing Company LLC
Lorillard, LLC
Modoral Brands Inc.
Northern Brands International, Inc.
RCI Reynolds Global Products, Inc.
RCI Reynolds Tobacco Company
RCI Reynolds Tobacco International, Inc.
RCI Reynolds Vapor Company
RCI Reynolds Tobacco Co.
RCI Reynolds Tobacco Holdings, Inc.
RAI Innovations Company
RAI International, Inc.
RAI Services Company
RAI Strategic Holdings, Inc.
Reynolds American Inc.
Reynolds Brands Inc.
Reynolds Marketing Services Company
Reynolds Technologies, Inc.
KJR Realty Relocation Services, Inc.
KJR Vapor Co., LLC
Roswell LLC
S.P. Imports, Inc.
Spot You More, Inc.
Vuse Stores LLC
Associated Undertakings and Joint Ventures

Canada
35 English Drive, Moncton, New Brunswick, E1E 3X3, Canada
Organigram Holdings Inc. (16.8%)

France
88 Avenue des Ternes, 75017, Paris, France
A6ome SAS (24%)

India
H-8800 Hódiméozsвязь, Erzelséti út 58, Hungary
Országos Dhanybóbfellsétítő Kftálló Felelossegös Tarsaság (49%)

Vietnam
20/F Mplaza Saigon, 39 Le Duan Street, Ben Nghe Ward, District 1, Ho Chi Minh City, Vietnam
British American Tobacco – Vinataba (JV) (70%)

Zambia
Plot No. PH1 IND & 53 & 54, LS-MFEZ, Chifwema Road, Lusaka, Zambia
British American Tobacco (Zambia) plc (78.08%)

Hong Kong
29/F, Oxford House, 979 King’s Road, Tai Kok Tsui, Quarry Bay, Hong Kong
CTBAT International Co. Limited (50%)

Notes:
1. Ownership held in the class of US Dollar 100 (100%)/(6.33%) and US Dollar 49,900 (100%).
2. Ownership held in the class of Series F and 2nd Preferred shares.
3. Ownership held in the class of A shares (55%) and class of B shares (100%).
4. Ownership held in class of A shares and B shares.
5. Ownership held solely in class of preference shares.
6. Ownership held in class of Investment stock (98.98%) and Ordinary shares (98.35%).
7. Ownership held in the class of Charter Capital Contribution Units.
8. Company limited by guarantee.
9. 8 March year-end.
10. 31 March year-end.
This page is intentionally left blank
This page is intentionally left blank
Other Information

Additional Disclosures

<table>
<thead>
<tr>
<th>Additional Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information on the Group</td>
</tr>
<tr>
<td>Selected Financial Information</td>
</tr>
<tr>
<td>Non-Financial Measures</td>
</tr>
<tr>
<td>Non-GAAP Measures</td>
</tr>
<tr>
<td>Governance</td>
</tr>
<tr>
<td>Additional Disclosures on Liquidity and Capital Resources</td>
</tr>
<tr>
<td>Summary of Group Risk Factors</td>
</tr>
<tr>
<td>Group Risk Factors</td>
</tr>
<tr>
<td>Regulation of the Group’s Business</td>
</tr>
<tr>
<td>Disclosure Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Accountability Act of 2012 (ITRA)</td>
</tr>
<tr>
<td>Mineral Contracts</td>
</tr>
<tr>
<td>Property, Plant and Equipment</td>
</tr>
<tr>
<td>Revenues from Customers</td>
</tr>
<tr>
<td>Raw Materials</td>
</tr>
<tr>
<td>U.S. Corporate Governance Practices</td>
</tr>
<tr>
<td>Controls and Procedures</td>
</tr>
<tr>
<td>Statements Regarding Competitive Position</td>
</tr>
<tr>
<td>Directors’ Report Information</td>
</tr>
<tr>
<td>Cautionary Statement</td>
</tr>
</tbody>
</table>

Shareholder Information

<table>
<thead>
<tr>
<th>Shareholder Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dividends</td>
</tr>
<tr>
<td>Shareholder Taxation Information</td>
</tr>
<tr>
<td>Share Capital and Security Ownership</td>
</tr>
<tr>
<td>Articles of Association</td>
</tr>
<tr>
<td>Purchase of Shares</td>
</tr>
<tr>
<td>Group Employee Trust</td>
</tr>
<tr>
<td>American Depositary Shares</td>
</tr>
<tr>
<td>Shareholding Administration and Services</td>
</tr>
<tr>
<td>Exhibits</td>
</tr>
</tbody>
</table>

Other Information

<table>
<thead>
<tr>
<th>Other Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glossary</td>
</tr>
<tr>
<td>Cross Reference to Form 20-F</td>
</tr>
</tbody>
</table>
Information on the Group

Overview
British American Tobacco p.l.c. is the parent holding company of the Group, a leading consumer-centric, multi-category consumer goods company that provides tobacco and nicotine products to millions of consumers around the world. According to the Group’s internal estimates, the BAT Group is a market leader by volume in more than 50 countries, producing the cigarette chosen by one in eight of the world’s one billion smokers.

The Group, excluding the Group’s associated undertakings, is organised into four regions:
- the United States (U.S. – Reynolds American Inc.);
- Asia-Pacific and the Middle East (APME);
- Americas and Sub-Saharan Africa (AmSSA); and
- Europe and North Africa (ENA).

The Group’s range of combustible products covers all segments, from value-for-money to premium with a portfolio of international, regional and local brands, and designs in key global jurisdictions.

The Group manages a globally-integrated supply chain and its products are distributed to retail outlets worldwide.

History and development of BAT
The Group has had a significant global presence in the tobacco industry for over 100 years. BAT Ltd. was incorporated in 1902, when the Imperial Tobacco Company and the American Tobacco Company agreed to form a joint venture company, BAT Ltd. Inherited companies and quickly expanded into major markets, including India and Ceylon, Egypt, Malaya, Northern Europe and East Africa. In 1927, BAT Ltd. expanded into the U.S. market through its acquisition of B&W.

During the 1960s, 1970s and 1980s, the Group diversified its business under the umbrella of B.A.T Industries p.l.c., with acquisitions in the paper, cosmetics, retail and financial services industries, among others. Various business reorganisations followed as the business was eventually refocused on the Group’s core cigarette, cigars and tobacco products businesses with BAT becoming a separately listed entity on the LSE in 1998.

The following is a summary of the significant mergers, acquisitions and disposals undertaken since 1998:
- 1999 - global merger with Rothmans International;
- 2000 - acquisition of Imperial Tobacco Canada;
- 2003 - acquisition of Ente Tabachè Italiani S.p.A., Italy’s state-owned tobacco company, Tabacalera Nacional in Peru and Duvsanska Industria Vranje in Serbia;
- 2004 - the U.S. assets, liabilities and operations, other than certain specified assets and liabilities, of BAT’s wholly-owned subsidiary, B&W, were combined with RJR Tobacco Company to form Reynolds American Inc. As a result of the B&W business combination, B&W acquired beneficial ownership of approximately 42% of the Reynolds American Inc. shares;
- 2008 - acquisition of Tekel, the Turkish state-owned tobacco company and the cigarette and snus business of Skandinavisk Tobakskompani A/S;
- 2009 - acquisition of an effective 95% interest in Bentoel in Indonesia;
- 2011 - acquisition of Protobacco in Colombia;
- 2012 - acquisition of CN Creative Limited in the UK;
- 2013 - entered into joint operations in China;
- 2015 - acquisition of the shares not already owned by the Group in Souza Cruz in Brazil, the acquisition of the CHIC Group in Poland, the acquisition of TDR d.o.o., a cigarette manufacturer in Central Europe. Also in 2015, the Group increased its investment in Reynolds American Inc. by US$4.7 billion to maintain the Group’s approximate 42% equity position following Reynolds American Inc.’s purchase of Lorillard Inc.;
- 2016 - acquisition of Ten Motives in the UK;
- 2017 - acquisition of the remaining 57.8% of Reynolds American Inc. the Group did not already own. Following completion of the acquisition, Reynolds American Inc. became an indirect, wholly-owned subsidiary of BAT and is no longer a publicly-held corporation. In 2017, the Group also acquired certain tobacco assets from Bulgartabac Holding AD in Bulgaria and Fabrika Duhana Sarajevo (FDS) in Bosnia, acquired Winnington Holdings AB in Sweden and acquired certain assets from Must Have Limited in the UK, including the electronic cigarette brand VAP;
- 2018 - acquisition of Quantum Beteiligungs-und Beratungsgesellschaft mbH in Germany;
- 2019 - acquisition of the Twisp Propriety Limited in South African and 60% of VapeWild Holdings LLC in the US;
- 2020 - acquisition of the nicotine pouch product assets of Dryft Sciences, LLC (Dryft) in the U.S. and the acquisition of Eastern Tobacco Company for Trading in Saudi Arabia;
- 2021 - entered into a strategic collaboration agreement with Organigram Inc., a wholly-owned subsidiary of publicly-traded Organigram Holdings Inc., as part of which a Group subsidiary acquired a 19.9% equity stake in Organigram Holdings Inc., being a company focused on research and product development activities of next generation adult cannabis products, with an initial focus on cannabinoid; and
- 2021 - disposed of BAT Pars Company PJSC, the Group’s Iranian subsidiary.

British American Tobacco p.l.c. was incorporated in July 1997 under the laws of England and Wales as a public limited company and is domiciled in the United Kingdom.

Seasonality
The Group’s business segments are not significantly affected by seasonality although in certain markets cigarette consumption trends rise during summer months due to longer daylight time and tourism.

Patents and trademarks
Our trademarks, which include the brand names under which our products are sold, are key assets which we consider, in the aggregate, to be important to the business as a whole. As well as protecting our brand names by way of trademark registration, we also protect our innovations by means of patents and designs in key global jurisdictions.

Board oversight of M&A transactions
The Company’s Board has strategic oversight of significant M&A transactions (determined by value or strategic nature of transaction), which are referred to it for noting under the Group Statement of Delegated Authorities (SoDA).

Other M&A transactions are referred for strategic oversight to the Management Board or other applicable senior forum or persons, under the Group SoDA. Those referral requirements under the Group SoDA apply alongside any requirement for corporate approval of M&A transactions by or within a Group company.
## Selected Financial Information

This information set out below has been derived from, in part, the audited consolidated financial statements of the Group commencing on page 178. This selected financial information should be read in conjunction with the consolidated financial statements and the Strategic Report.

### Income statement data

<table>
<thead>
<tr>
<th></th>
<th>As of and for the Year Ended 31 December</th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td>25,684</td>
<td>25,776</td>
<td>25,877</td>
<td>24,492</td>
<td>19,564</td>
</tr>
<tr>
<td><strong>Raw materials and consumables used</strong></td>
<td></td>
<td>(4,542)</td>
<td>(4,583)</td>
<td>(4,599)</td>
<td>(4,664)</td>
<td>(4,520)</td>
</tr>
<tr>
<td><strong>Changes in inventories of finished goods and work in progress</strong></td>
<td></td>
<td>160</td>
<td>445</td>
<td>162</td>
<td>114</td>
<td>(513)</td>
</tr>
<tr>
<td><strong>Employee benefit costs</strong></td>
<td></td>
<td>(2,717)</td>
<td>(2,744)</td>
<td>(3,221)</td>
<td>(3,005)</td>
<td>(2,679)</td>
</tr>
<tr>
<td><strong>Depreciation, amortisation and impairment costs</strong></td>
<td></td>
<td>(1,076)</td>
<td>(1,450)</td>
<td>(1,512)</td>
<td>(1,038)</td>
<td>(902)</td>
</tr>
<tr>
<td><strong>Other operating income</strong></td>
<td></td>
<td>196</td>
<td>188</td>
<td>163</td>
<td>931</td>
<td>6,412</td>
</tr>
<tr>
<td><strong>Loss on reclassification from amortised cost to fair value</strong></td>
<td></td>
<td>(3)</td>
<td>(3)</td>
<td>(3)</td>
<td>(3)</td>
<td>–</td>
</tr>
<tr>
<td><strong>Other operating expenses</strong></td>
<td></td>
<td>(7,468)</td>
<td>(7,667)</td>
<td>(7,851)</td>
<td>(6,668)</td>
<td>(4,682)</td>
</tr>
<tr>
<td><strong>Profit from operations</strong></td>
<td></td>
<td>10,234</td>
<td>9,962</td>
<td>9,016</td>
<td>9,313</td>
<td>6,412</td>
</tr>
<tr>
<td><strong>Net finance costs</strong></td>
<td></td>
<td>(1,486)</td>
<td>(1,745)</td>
<td>(1,602)</td>
<td>(1,381)</td>
<td>(1,094)</td>
</tr>
<tr>
<td><strong>Share of post-tax results of associates and joint ventures</strong></td>
<td></td>
<td>415</td>
<td>455</td>
<td>498</td>
<td>419</td>
<td>24,209</td>
</tr>
<tr>
<td><strong>Profit before taxation</strong></td>
<td></td>
<td>9,163</td>
<td>8,672</td>
<td>7,912</td>
<td>8,351</td>
<td>29,527</td>
</tr>
<tr>
<td><strong>Taxation on ordinary activities</strong></td>
<td></td>
<td>(2,189)</td>
<td>(2,108)</td>
<td>(2,063)</td>
<td>(2,141)</td>
<td>8,129</td>
</tr>
<tr>
<td><strong>Profit for the year</strong></td>
<td></td>
<td>(6,974)</td>
<td>6,564</td>
<td>5,849</td>
<td>6,210</td>
<td>37,656</td>
</tr>
</tbody>
</table>

### Per share data

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic weighted average number of ordinary shares, in millions</strong></td>
<td>Basic</td>
<td>2,287</td>
<td>2,286</td>
<td>2,284</td>
<td>2,285</td>
<td>2,044</td>
</tr>
<tr>
<td><strong>Diluted weighted average number of ordinary shares, in millions</strong></td>
<td>Diluted</td>
<td>2,297</td>
<td>2,295</td>
<td>2,291</td>
<td>2,292</td>
<td>2,051</td>
</tr>
<tr>
<td><strong>Earnings per share-basic (pence)</strong></td>
<td>Basic</td>
<td>286.9p</td>
<td>280.0p</td>
<td>249.7p</td>
<td>264.0p</td>
<td>1,833.9p</td>
</tr>
<tr>
<td><strong>Earnings per share-diluted (pence)</strong></td>
<td>Diluted</td>
<td>295.6p</td>
<td>278.9p</td>
<td>249.0p</td>
<td>263.2p</td>
<td>1,827.6p</td>
</tr>
<tr>
<td><strong>Dividends per share (pence)</strong></td>
<td></td>
<td>217.8p</td>
<td>215.6p</td>
<td>210.4p</td>
<td>203.0p</td>
<td>195.2p</td>
</tr>
<tr>
<td><strong>Dividends per share (US dollars)</strong></td>
<td></td>
<td>$2.94</td>
<td>$2.99</td>
<td>$2.69</td>
<td>$2.71</td>
<td>$2.54</td>
</tr>
</tbody>
</table>

### Balance sheet data

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-current assets</strong></td>
<td></td>
<td>124,558</td>
<td>124,078</td>
<td>127,731</td>
<td>133,687</td>
<td>127,088</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td>12,807</td>
<td>13,612</td>
<td>13,274</td>
<td>12,655</td>
<td>13,966</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td></td>
<td>137,365</td>
<td>137,690</td>
<td>141,005</td>
<td>146,342</td>
<td>141,054</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td></td>
<td>54,820</td>
<td>59,257</td>
<td>58,022</td>
<td>64,325</td>
<td>64,468</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td>15,144</td>
<td>15,478</td>
<td>18,823</td>
<td>16,329</td>
<td>15,605</td>
</tr>
<tr>
<td><strong>Total borrowings</strong></td>
<td></td>
<td>39,658</td>
<td>43,968</td>
<td>45,366</td>
<td>47,509</td>
<td>49,450</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Share capital</strong></td>
<td></td>
<td>614</td>
<td>614</td>
<td>614</td>
<td>614</td>
<td>614</td>
</tr>
<tr>
<td><strong>Total equity</strong></td>
<td></td>
<td>67,401</td>
<td>62,955</td>
<td>64,160</td>
<td>65,688</td>
<td>60,981</td>
</tr>
</tbody>
</table>

### Cash flow data

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net cash generated from operating activities</strong></td>
<td></td>
<td>9,717</td>
<td>9,786</td>
<td>8,996</td>
<td>10,295</td>
<td>5,347</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td></td>
<td>(1,140)</td>
<td>(763)</td>
<td>(639)</td>
<td>(1,021)</td>
<td>(18,544)</td>
</tr>
<tr>
<td><strong>Net cash used in/generated from financing activities</strong></td>
<td></td>
<td>(6,579)</td>
<td>(8,023)</td>
<td>(8,593)</td>
<td>(9,527)</td>
<td>14,831</td>
</tr>
</tbody>
</table>

Notes:
1. All of the information above is in respect of continuing operations, revised for the fully retrospective adoption of IFRS 15.
2. Revenue is net of duty, excise and other taxes of £38,595 million, £39,172 million, £39,826 million, £38,553 million and £37,780 million for the years ended 31 December 2021, 2020, 2019, 2018, and 2017, respectively.
3. In February 2022, the BAT Directors declared an interim dividend of 217.8 pence per share for the year ended 31 December 2021, payable in four equal instalments of 54.45 pence per ordinary share. The interim dividend will be paid in BAT share certificates in May 2022, August 2022, November 2022 and February 2023. The equivalent quarterly dividends receivable by holders of ADSs in US dollars will be calculated based on the exchange rate on the applicable payment date.
Other Information

Non-Financial Measures

Volume

Volume is defined as the number of units sold. Units may vary between categories. This can be summarised for the principal metrics as follows:

- Factory made cigarettes (FMC) – sticks, regardless of weight or dimensions;
- Roll-Your-Own/Make-Your-Own – kilos, converted to a stick equivalent based upon 0.8 grams (per stick equivalent) for Roll-Your-Own and between 0.5 and 0.7 grams (per stick equivalent) for Make-Your-Own;
- Traditional oral – pouches (being 1:1 conversion to stick equivalent) and kilos, converted to a stick equivalent based upon 2.8 grams (per stick equivalent) for Moist Snuff, 2.0 grams (per stick equivalent) for Dry Snuff and 7.1 grams (per stick equivalent) for other oral;
- Modern Oral – pouches, being 1:1 conversion to stick equivalent;
- Tobacco Heat sticks – sticks, being 1:1 conversion to stick equivalent; and
- Vapour - pods and 10 millilitre bottles. There is no conversion to a stick equivalent.

Volume is recognised in line with IFRS 15 Revenue from Contracts with Customers, based upon transfer of control. It is assumed that there is no material difference, in line with the Group’s recognition of revenue, between the transfer of control and shipment date.

Volume is used by management and investors to assess the relative performance of the Group and its brands within categories, given volume is a principal determinant of revenue.

Volume Share

Volume share is the number of units bought by consumers of a specific brand or combination of brands, as a proportion of the total units bought by consumers in the industry, category or other sub-categorisation.

Sub-categories include, but are not limited to, the total nicotine category, modern oral, vapour, traditional oral, total oral or cigarette. Except when referencing particular markets, volume share is based on our key markets (representing around 85% of the Group’s cigarette and THP volume).

Where possible, the Group utilises data provided by third-party organisations, including AC Nielsen, based upon retail audit of sales to consumers. In certain markets, where such data is not available, other measures are employed which assess volume share based upon other movements within the supply chain, such as sales to retailers. This may depend on the provision of data to the industry by the customers including distributors/wholesalers.

Volume share is used by management to assess the relative performance to the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates. This measure is also useful to understand the Group’s performance when seeking to grow scale within a market or category from which future financial returns can be realised. The Group’s management believes that this measure is useful to investors to understand the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates.

Volume share in each year compares the average volume share in the year with the average volume share in the prior year. This is a more robust measure of performance, removing short-term volatility that may arise at a point in time.

However, in certain circumstances, related to periods of introduction to a market, in order to illustrate the latest performance, data may be provided as at the end of the period rather than the average in that period. In these instances the Group states these are at a specific date (for instance, December 2021).

Value Share

Value share is the retail value of units bought by consumers of a particular brand or combination of brands, as a proportion of the total retail value of units bought by consumers in the industry, category or other sub-categorisation in discussion. Except when referencing particular markets, value share is based on our key markets (representing around 90% of the Group’s cigarette and THP value).

Where possible, the Group utilises data provided by third-party organisations, including AC Nielsen, based upon retail audit of sales to consumers. In certain markets, where such data is not available, other measures are employed which assess value share based upon other movements within the supply chain, such as sales to retailers. This may depend on the provision of data to the industry by the customers including distributors/wholesalers.

Value share is used by management to assess the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates, specifically indicating the Group’s ability to realise value relative to the market. The measure is particularly useful when the Group’s products and/or the relevant category in the market in which they are sold has developed or achieved scale from which value can be realised. The Group’s management believes that this measure is useful to investors to apprehend the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates, specifically indicating the Group’s ability to realise value relative to the market.

Value share in each year compares the average value share in the year with the average value share in the prior period. This is a more robust measure of performance, removing short-term volatility that may arise at a point in time. However, in certain circumstances, related to periods of introduction to a market, in order to illustrate the latest performance, data may be provided that is as at the end of the period rather than the average in that period. In these instances the Group states these are at a specific date (for instance, December 2021).
Price Mix
Price mix is a term used by management and investors to explain the movement in revenue between periods. Revenue is affected by the volume (how many units are sold) and the value (how much is each unit sold for). Price mix is used to explain the value component of the sales as the Group sells each unit for a value (price) but may also achieve a movement in revenue due to the relative proportions of higher value volume sold compared to lower value volume sold (mix).

This term is used to explain the Group’s relative performance between periods only. It is calculated as the difference between the movement in revenue (between periods) and volume (between periods). For instance, the growth in combustibles revenue (excluding translational foreign exchange movements) of 4.0% in 2021, with a decline in combustibles volume of 0.3% in 2021, leads to a price mix of 4.3% in 2021. No assumptions underlie this metric as it utilises the Group’s own data.

Non-Combustible Consumers
The number of consumers of Non-Combustible products is defined as the estimated number of Legal Age (minimum 18 years) consumers of the Group’s Non-Combustible products. In markets where regular consumer tracking is in place, this estimate is obtained from adult consumer tracking studies conducted by third parties (including Kantar). In markets where regular consumer tracking is not in place, the number of consumers of Non-Combustible products is derived from volume sales of consumables and devices in such markets, using consumption patterns obtained from other similar markets with consumer tracking (utilising studies conducted by third parties including Kantar).

The number of Non-Combustible products consumers is used by management to assess the number of consumers regularly using the Group’s New Categories products as the increase in Non-Combustible products is a key pillar of the Group’s ESG Ambition and is integral to the sustainability of our business.

The Group’s management believes that this measure is useful to investors given the Group’s ESG ambition and alignment to the sustainability of the business with respect to the Non-Combustibles portfolio.

Total weight of unnecessary single use plastics in our packaging
This measure covers packaging for all Group products. We use the definition developed by the UK Plastics Pact for unnecessary single-use plastics: “items where consumption could be avoided through elimination, reuse or replacement and items that, post-consumption, commonly do not enter recycling and composting systems, or where they do, are not recycled due to their format, composition or size”. We began reporting on this metric in 2020, so 2019 data is not available.

% of operations sites at zero waste to landfill
Operations sites refers to all BAT-owned cigarette manufacturing factories, sites manufacturing other tobacco products, Snus, Modern Oral and liquids and green leaf threshing (GLT) tobacco processing sites. We began reporting on this metric in 2020, so 2019 data is not available.

% of farms monitored for child labour; % of farms with incidents of child labour identified; Number of child labour incidents identified; % reported as resolved by end of the growing season
Data for these measures are collected for our contracted farmers by BAT field technicians (FTs) based on farmer and worker interviews and observations during monthly farm visits. These are recorded and tracked in our FSM system. All child labour data refers to hazardous child labour as defined by the ILO Convention No. 182 on Minimum Age and ILO Convention No. 138 on the Worst Forms of Child Labour. For child labour incidents identified, our leaf operations and third-party suppliers work with the farmer to implement a remediation plan that considers the individual circumstances. Wherever possible, this plan involves local community or school support. Remediation is verified in follow-up visits to the farm. If there is a repeat instance, a formal written warning is given to the farmer. In a small number of cases, where there is persistent non-compliance, the farmer’s contract is not renewed for the next growing season.
To supplement the presentation of the Group’s results of operations and financial condition in accordance with IFRS, we also present several non-GAAP measures used by management to monitor the Group’s performance. The Group’s management regularly reviews the measures used to assess and present the financial performance of the Group and, as relevant, its geographic segments.

Changes to Non-GAAP measures in 2021
As reported in 2020, Change in Revenue from Strategic Portfolio at constant rates of exchange ceased to be a KPI and has accordingly been removed as a non-GAAP measure. This was replaced as a KPI by Revenue from New Categories at constant rates of exchange, which has already been provided as a non-GAAP measure in previous reports.

Adjusted Revenue
Definition – revenue before the impact of adjusting items.
To supplement BAT’s revenue presented in accordance with IFRS, the Group’s Management Board, as the chief operating decision-maker, reviews adjusted revenue to evaluate the underlying business performance of the Group and its geographic segments. The Group’s Management Board defines adjusted revenue as revenue before the impact of adjusting items (specifically the excise on bought-in goods that the Group acquired and sold which, for the period 2017 to 2019, has been recorded in accordance with IFRS as a cost of sale and within revenue, with a dilutive effect on operating margin).

In 2021 and 2020, as the short-term arrangements ceased or were immaterial, the goods are manufactured by the Group, and the excise, in accordance with Group policy, is not included in cost of sales or revenue. In 2019, this excise included in revenue led to a reduction in revenue and improvement in operating margin that did not represent the underlying performance of the Group. As such, the excise on bought-in goods in 2019 met the Group’s definition of an adjusting item, as defined in note 1 in the Notes on the Accounts.

The Group’s Management Board also believes that adjusted revenue provides information that enables investors to better compare the Group’s business performance across periods. Adjusted revenue has limitations as an analytical tool. The most directly comparable IFRS measure to adjusted revenue is revenue. Adjusted revenue is not a presentation made in accordance with IFRS, and is not a measure of financial condition or liquidity and should not be considered as an alternative to revenue as determined in accordance with IFRS. Adjusted revenue is not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider this performance measure in isolation from, or as a substitute analysis for, BAT’s results as determined in accordance with IFRS.

The table below reconciles the Group’s revenue to adjusted revenue for the periods presented and to adjusted revenue at constant rates based on a re-translation of adjusted revenue for each year at the previous year’s exchange rates. Refer to note 2 in the Notes on the Accounts for further discussion of the segmental results and for the reconciliation of adjusted revenue at current and constant rates of exchange to segmental revenue and to Group revenue for the years ended 31 December 2021, 2020 and 2019.

<table>
<thead>
<tr>
<th>For the year ended 31 December (£m)</th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>25,684</td>
<td>25,776</td>
<td>25,877</td>
</tr>
<tr>
<td>Less: Excise on goods bought-in on short-term arrangements</td>
<td>–</td>
<td>–</td>
<td>(50)</td>
</tr>
<tr>
<td>Adjusted revenue</td>
<td>25,684</td>
<td>25,776</td>
<td>25,827</td>
</tr>
<tr>
<td>Impact of translational foreign exchange</td>
<td>1,877</td>
<td>894</td>
<td>(144)</td>
</tr>
<tr>
<td>2021 adjusted revenue re-translated at 2020 exchange rates</td>
<td>27,561</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020 adjusted revenue re-translated at 2019 exchange rates</td>
<td></td>
<td>26,670</td>
<td></td>
</tr>
<tr>
<td>2019 adjusted revenue re-translated at 2018 exchange rates</td>
<td></td>
<td>25,683</td>
<td></td>
</tr>
<tr>
<td>Change in adjusted revenue at prior year’s exchange rates (constant rates)</td>
<td>+6.9%</td>
<td>+3.3%</td>
<td>+5.6%</td>
</tr>
</tbody>
</table>
Adjusted Revenue by Product Category or Geographic Segment – Including Revenue From New Categories

Definition – revenue by product category, before the impact of adjusting items and at the prior year’s prevailing exchange rate, derived from the principal product categories of Combustibles, New Categories (being comprised of revenue from Vapour, THP and Modern Oral), and Traditional Oral, including by the geographic segments of the United States, Europe and North Africa, Americas and Sub-Saharan Africa and Asia-Pacific and Middle East.

To supplement BAT’s revenue presented in accordance with IFRS, the Group’s Management Board, as the chief operating decision-maker, reviews adjusted revenue growth from the principal product categories of combustibles, New Categories and Traditional Oral, including from the geographic segments of the United States, Europe and North Africa, Americas and Sub-Saharan Africa and Asia-Pacific and Middle East, to evaluate the underlying business performance of the Group reflecting the focus of the Group’s investment activity. The Group’s Management Board assesses adjusted revenue by product category, including by geographic segment, at constant rates of exchange, as revenue before the impact of adjusting items and translated to the Group’s reporting currency at the prior period’s prevailing exchange rate, derived from the Group’s combustible portfolio (including but not limited to Kent, Dunhill, Lucky Strike, Pall Mall, Rothmans, Camel (U.S.), Newport (U.S.), Natural American Spirit (U.S.)), the Group’s New Category portfolio (being Vapour, THP and Modern Oral) and the Group’s Traditional Oral portfolio and the Group’s operations in the United States, Europe and North Africa, Americas and Sub-Saharan Africa and Asia-Pacific and Middle East.

The Group’s Management Board also believes that the adjusted revenue performance by product category, including by geographic segment provides information that enables investors to better compare the Group’s business performance across periods and by reference to the Group’s investment activity. Adjusted revenue by product category, including by geographic segment have limitations as analytical tools. The most directly comparable IFRS measure to adjusted revenue by product category, including by geographic segment, is revenue. Adjusted revenue by product category, including by geographic segment, are not presentations made in accordance with IFRS, are not measures of financial condition or liquidity and should not be considered as alternatives to revenue as determined in accordance with IFRS. Adjusted revenue by product category, including by geographic segment, are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider these performance measures in isolation from, or as a substitute analysis for, BAT’s results as determined in accordance with IFRS.

Reconciliation of revenue by product category to adjusted revenue by product category at constant rates of exchange – 2021- 2020

<table>
<thead>
<tr>
<th>Product Category</th>
<th>2021 Reported £m</th>
<th>Adjusting Items £m</th>
<th>Impact of Exchange £m</th>
<th>Adjusted £m</th>
<th>Impact of Exchange £m</th>
<th>Adjusted at constant vs 2020 £m</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustible</td>
<td>22,029</td>
<td>-3.2%</td>
<td>22,029</td>
<td>1,640</td>
<td>23,669</td>
<td>44.0%</td>
<td></td>
</tr>
<tr>
<td>Vapour</td>
<td>927</td>
<td>+51.8%</td>
<td>927</td>
<td>46</td>
<td>973</td>
<td>+59.3%</td>
<td></td>
</tr>
<tr>
<td>THP</td>
<td>853</td>
<td>+34.4%</td>
<td>853</td>
<td>74</td>
<td>927</td>
<td>+46.1%</td>
<td></td>
</tr>
<tr>
<td>Modern Oral</td>
<td>274</td>
<td>+38.8%</td>
<td>274</td>
<td>4</td>
<td>278</td>
<td>+46.0%</td>
<td></td>
</tr>
<tr>
<td>Total New Categories</td>
<td>2,054</td>
<td>+44.2%</td>
<td>2,054</td>
<td>124</td>
<td>2,178</td>
<td>+50.9%</td>
<td></td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,118</td>
<td>-3.6%</td>
<td>1,118</td>
<td>77</td>
<td>1,195</td>
<td>+3.0%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>483</td>
<td>+15.1%</td>
<td>483</td>
<td>36</td>
<td>519</td>
<td>+25.1%</td>
<td></td>
</tr>
<tr>
<td>Total Revenue</td>
<td>25,684</td>
<td>-0.4%</td>
<td>25,684</td>
<td>1,877</td>
<td>27,561</td>
<td>+6.9%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product Category</th>
<th>2020 Reported £m</th>
<th>Adjusting Items £m</th>
<th>Impact of Exchange £m</th>
<th>Adjusted £m</th>
<th>Impact of Exchange £m</th>
<th>Adjusted at constant vs 2020 £m</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustible</td>
<td>22,752</td>
<td>-1.1%</td>
<td>22,752</td>
<td>842</td>
<td>23,594</td>
<td>+2.8%</td>
<td></td>
</tr>
<tr>
<td>Vapour</td>
<td>611</td>
<td>+52.3%</td>
<td>611</td>
<td>4</td>
<td>615</td>
<td>+53.4%</td>
<td></td>
</tr>
<tr>
<td>THP</td>
<td>634</td>
<td>-12.9%</td>
<td>634</td>
<td>2</td>
<td>636</td>
<td>-12.7%</td>
<td></td>
</tr>
<tr>
<td>Modern Oral</td>
<td>198</td>
<td>+57.1%</td>
<td>198</td>
<td>198</td>
<td>198</td>
<td>+57.1%</td>
<td></td>
</tr>
<tr>
<td>Total New Categories</td>
<td>1,443</td>
<td>+14.9%</td>
<td>1,443</td>
<td>6</td>
<td>1,449</td>
<td>+15.4%</td>
<td></td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,160</td>
<td>+7.2%</td>
<td>1,160</td>
<td>5</td>
<td>1,165</td>
<td>+7.7%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>421</td>
<td>-21.7%</td>
<td>421</td>
<td>41</td>
<td>462</td>
<td>-14.4%</td>
<td></td>
</tr>
<tr>
<td>Total Revenue</td>
<td>25,776</td>
<td>-0.4%</td>
<td>25,776</td>
<td>894</td>
<td>26,670</td>
<td>+3.3%</td>
<td></td>
</tr>
</tbody>
</table>

Reconciliation of revenue by product category to adjusted revenue by product category at constant rates of exchange – 2020- 2019

<table>
<thead>
<tr>
<th>Product Category</th>
<th>2020 Reported £m</th>
<th>Adjusting Items £m</th>
<th>Impact of Exchange £m</th>
<th>Adjusted £m</th>
<th>Impact of Exchange £m</th>
<th>Adjusted at constant vs 2019 £m</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combustible</td>
<td>22,752</td>
<td>-1.1%</td>
<td>22,752</td>
<td>842</td>
<td>23,594</td>
<td>+2.8%</td>
<td></td>
</tr>
<tr>
<td>Vapour</td>
<td>611</td>
<td>+52.3%</td>
<td>611</td>
<td>4</td>
<td>615</td>
<td>+53.4%</td>
<td></td>
</tr>
<tr>
<td>THP</td>
<td>634</td>
<td>-12.9%</td>
<td>634</td>
<td>2</td>
<td>636</td>
<td>-12.7%</td>
<td></td>
</tr>
<tr>
<td>Modern Oral</td>
<td>198</td>
<td>+57.1%</td>
<td>198</td>
<td>198</td>
<td>198</td>
<td>+57.1%</td>
<td></td>
</tr>
<tr>
<td>Total New Categories</td>
<td>1,443</td>
<td>+14.9%</td>
<td>1,443</td>
<td>6</td>
<td>1,449</td>
<td>+15.4%</td>
<td></td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,160</td>
<td>+7.2%</td>
<td>1,160</td>
<td>5</td>
<td>1,165</td>
<td>+7.7%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>421</td>
<td>-21.7%</td>
<td>421</td>
<td>41</td>
<td>462</td>
<td>-14.4%</td>
<td></td>
</tr>
<tr>
<td>Total Revenue</td>
<td>25,776</td>
<td>-0.4%</td>
<td>25,776</td>
<td>894</td>
<td>26,670</td>
<td>+3.3%</td>
<td></td>
</tr>
</tbody>
</table>
Reconciliation of revenue by product category to adjusted revenue by product category at constant rates of exchange

<table>
<thead>
<tr>
<th></th>
<th>2021 Reported</th>
<th>2021 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>2020 Reported</th>
<th>2020 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td><strong>U.S.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combustible</td>
<td>10,015</td>
<td>+0.9%</td>
<td>–</td>
<td>10,015</td>
<td>719</td>
<td>+8.1%</td>
<td>10,734</td>
<td>+56.9%</td>
</tr>
<tr>
<td>Vapour</td>
<td>561</td>
<td>+46.4%</td>
<td>–</td>
<td>561</td>
<td>40</td>
<td>+1.3%</td>
<td>601</td>
<td>+56.9%</td>
</tr>
<tr>
<td>THP</td>
<td>1</td>
<td>-21.8%</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>-1.6%</td>
<td>2</td>
<td>-80.1%</td>
</tr>
<tr>
<td>New Categories</td>
<td>564</td>
<td>+43.0%</td>
<td>–</td>
<td>564</td>
<td>40</td>
<td>+1.3%</td>
<td>604</td>
<td>+53.3%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,077</td>
<td>-4.3%</td>
<td>–</td>
<td>1,077</td>
<td>78</td>
<td>-2.6%</td>
<td>1,155</td>
<td>+2.6%</td>
</tr>
<tr>
<td>Other</td>
<td>35</td>
<td>+26.9%</td>
<td>–</td>
<td>35</td>
<td>2</td>
<td>+36.0%</td>
<td>37</td>
<td>+36.0%</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>11,691</td>
<td>+1.9%</td>
<td>–</td>
<td>11,691</td>
<td>839</td>
<td>+9.2%</td>
<td>12,530</td>
<td>+9.2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2020 Reported</th>
<th>2020 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>2019 Reported</th>
<th>2019 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combustible</td>
<td>9,926</td>
<td>+9.3%</td>
<td>–</td>
<td>9,926</td>
<td>54</td>
<td>+9.9%</td>
<td>10,078</td>
<td>+9.9%</td>
</tr>
<tr>
<td>Vapour</td>
<td>383</td>
<td>+65.1%</td>
<td>–</td>
<td>383</td>
<td>2</td>
<td>+86.1%</td>
<td>401</td>
<td>+86.1%</td>
</tr>
<tr>
<td>THP</td>
<td>1</td>
<td>+0.0%</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>+0.5%</td>
<td>2</td>
<td>+0.5%</td>
</tr>
<tr>
<td>New Categories</td>
<td>394</td>
<td>+81.9%</td>
<td>–</td>
<td>394</td>
<td>2</td>
<td>+82.9%</td>
<td>401</td>
<td>+82.9%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,126</td>
<td>+7.0%</td>
<td>–</td>
<td>1,126</td>
<td>5</td>
<td>+7.6%</td>
<td>1,131</td>
<td>+7.6%</td>
</tr>
<tr>
<td>Other</td>
<td>27</td>
<td>+4.6%</td>
<td>–</td>
<td>27</td>
<td>2</td>
<td>+5.1%</td>
<td>31</td>
<td>+5.1%</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>11,473</td>
<td>+10.6%</td>
<td>–</td>
<td>11,473</td>
<td>63</td>
<td>+11.2%</td>
<td>11,536</td>
<td>+11.2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2021 Reported</th>
<th>2021 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>2020 Reported</th>
<th>2020 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMSSA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combustible</td>
<td>3,435</td>
<td>-2.8%</td>
<td>–</td>
<td>3,435</td>
<td>244</td>
<td>+4.1%</td>
<td>3,679</td>
<td>+4.1%</td>
</tr>
<tr>
<td>Vapour</td>
<td>141</td>
<td>+115%</td>
<td>–</td>
<td>141</td>
<td>1</td>
<td>+115%</td>
<td>141</td>
<td>+115%</td>
</tr>
<tr>
<td>THP</td>
<td>–</td>
<td>-100%</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>-100%</td>
<td>–</td>
<td>-100%</td>
</tr>
<tr>
<td>New Categories</td>
<td>141</td>
<td>+114%</td>
<td>–</td>
<td>141</td>
<td>1</td>
<td>+114%</td>
<td>141</td>
<td>+114%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>1,126</td>
<td>+7.0%</td>
<td>–</td>
<td>1,126</td>
<td>5</td>
<td>+7.6%</td>
<td>1,131</td>
<td>+7.6%</td>
</tr>
<tr>
<td>Other</td>
<td>27</td>
<td>+4.6%</td>
<td>–</td>
<td>27</td>
<td>2</td>
<td>+5.1%</td>
<td>31</td>
<td>+5.1%</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>3,801</td>
<td>+0.8%</td>
<td>–</td>
<td>3,801</td>
<td>266</td>
<td>+7.8%</td>
<td>4,067</td>
<td>+7.8%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2020 Reported</th>
<th>2020 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>2019 Reported</th>
<th>2019 Adjusting</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMSSA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combustible</td>
<td>3,535</td>
<td>-11.4%</td>
<td>–</td>
<td>3,535</td>
<td>508</td>
<td>+1.3%</td>
<td>4,043</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Vapour</td>
<td>65</td>
<td>+52.8%</td>
<td>–</td>
<td>65</td>
<td>3</td>
<td>+58.6%</td>
<td>68</td>
<td>+58.6%</td>
</tr>
<tr>
<td>THP</td>
<td>–</td>
<td>-49.8%</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>-47.3%</td>
<td>–</td>
<td>-47.3%</td>
</tr>
<tr>
<td>New Categories</td>
<td>66</td>
<td>+51.3%</td>
<td>–</td>
<td>66</td>
<td>2</td>
<td>+57.1%</td>
<td>68</td>
<td>+57.1%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>171</td>
<td>-24.3%</td>
<td>–</td>
<td>171</td>
<td>39</td>
<td>-7.2%</td>
<td>210</td>
<td>-7.2%</td>
</tr>
<tr>
<td>Other</td>
<td>3,772</td>
<td>-11.5%</td>
<td>–</td>
<td>3,772</td>
<td>549</td>
<td>+1.4%</td>
<td>4,321</td>
<td>+1.4%</td>
</tr>
</tbody>
</table>

306
<table>
<thead>
<tr>
<th>APME</th>
<th>Reported</th>
<th>vs 2020</th>
<th>Adjusting items</th>
<th>Adjusted</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>Adjusted at constant vs 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£m</td>
<td>%</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Combustible</td>
<td>3,935</td>
<td>-10.3%</td>
<td>-</td>
<td>3,935</td>
<td>113</td>
<td>4,048</td>
<td>-7.7%</td>
</tr>
<tr>
<td>Vapour</td>
<td>15</td>
<td>+255%</td>
<td>-</td>
<td>15</td>
<td>-</td>
<td>15</td>
<td>+260%</td>
</tr>
<tr>
<td>THP</td>
<td>497</td>
<td>-26.0%</td>
<td>-</td>
<td>497</td>
<td>(7)</td>
<td>490</td>
<td>-27.1%</td>
</tr>
<tr>
<td>New Categories</td>
<td>514</td>
<td>-24.0%</td>
<td>-</td>
<td>514</td>
<td>(7)</td>
<td>507</td>
<td>-25.0%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>88</td>
<td>-1.3%</td>
<td>-</td>
<td>88</td>
<td>1</td>
<td>89</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Revenue</td>
<td>4,537</td>
<td>-11.9%</td>
<td>-</td>
<td>4,537</td>
<td>107</td>
<td>4,644</td>
<td>-9.9%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ENA</th>
<th>Reported</th>
<th>vs 2019</th>
<th>Adjusting items</th>
<th>Adjusted</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>Adjusted at constant vs 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£m</td>
<td>%</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Combustible</td>
<td>5,024</td>
<td>-6.2%</td>
<td>-</td>
<td>5,024</td>
<td>390</td>
<td>5,414</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Vapour</td>
<td>207</td>
<td>+40.2%</td>
<td>-</td>
<td>207</td>
<td>5</td>
<td>212</td>
<td>+43.8%</td>
</tr>
<tr>
<td>THP</td>
<td>341</td>
<td>+150%</td>
<td>-</td>
<td>341</td>
<td>23</td>
<td>364</td>
<td>+167%</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>266</td>
<td>+43.9%</td>
<td>-</td>
<td>266</td>
<td>3</td>
<td>269</td>
<td>+45.6%</td>
</tr>
<tr>
<td>New Categories</td>
<td>814</td>
<td>+73.6%</td>
<td>-</td>
<td>814</td>
<td>31</td>
<td>845</td>
<td>+80.3%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>41</td>
<td>+18.2%</td>
<td>-</td>
<td>41</td>
<td>(1)</td>
<td>40</td>
<td>+18.1%</td>
</tr>
<tr>
<td>Other</td>
<td>122</td>
<td>-8.9%</td>
<td>-</td>
<td>122</td>
<td>8</td>
<td>130</td>
<td>-4.9%</td>
</tr>
<tr>
<td>Revenue</td>
<td>6,001</td>
<td>+0.1%</td>
<td>-</td>
<td>6,001</td>
<td>428</td>
<td>6,429</td>
<td>+7.3%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ENA</th>
<th>Reported</th>
<th>vs 2019</th>
<th>Adjusting items</th>
<th>Adjusted</th>
<th>Impact of exchange</th>
<th>Adjusted at constant</th>
<th>Adjusted at constant vs 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>£m</td>
<td>%</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
<td>£m</td>
</tr>
<tr>
<td>Combustible</td>
<td>5,356</td>
<td>-3.4%</td>
<td>-</td>
<td>5,356</td>
<td>167</td>
<td>5,523</td>
<td>+0.5%</td>
</tr>
<tr>
<td>Vapour</td>
<td>148</td>
<td>+0.4%</td>
<td>-</td>
<td>148</td>
<td>(1)</td>
<td>147</td>
<td>+0.2%</td>
</tr>
<tr>
<td>THP</td>
<td>136</td>
<td>+143%</td>
<td>-</td>
<td>136</td>
<td>9</td>
<td>145</td>
<td>+159%</td>
</tr>
<tr>
<td>Modern Oral</td>
<td>185</td>
<td>+58.5%</td>
<td>-</td>
<td>185</td>
<td>1</td>
<td>186</td>
<td>+59.3%</td>
</tr>
<tr>
<td>New Categories</td>
<td>469</td>
<td>+46.7%</td>
<td>-</td>
<td>469</td>
<td>9</td>
<td>478</td>
<td>+49.6%</td>
</tr>
<tr>
<td>Traditional Oral</td>
<td>34</td>
<td>+16.2%</td>
<td>-</td>
<td>34</td>
<td>-</td>
<td>34</td>
<td>+14.2%</td>
</tr>
<tr>
<td>Other</td>
<td>135</td>
<td>-31.6%</td>
<td>-</td>
<td>135</td>
<td>(1)</td>
<td>134</td>
<td>-31.7%</td>
</tr>
<tr>
<td>Revenue</td>
<td>5,994</td>
<td>-1.8%</td>
<td>-</td>
<td>5,994</td>
<td>175</td>
<td>6,169</td>
<td>+2.1%</td>
</tr>
</tbody>
</table>
## Adjusted Profit From Operations and Adjusted Operating Margin

### Definition – profit from operations before the impact of adjusting items and adjusted profit from operations as a percentage of adjusted revenue.

To supplement BAT’s results from operations presented in accordance with IFRS, the Group’s Management Board, as the chief operating decision-maker, reviews adjusted profit from operations to evaluate the underlying business performance of the Group and its geographic segments, to allocate resources to the overall business and to communicate financial performance to investors. The Group also presents adjusted operating margin, which is defined as adjusted profit from operations as a percentage of adjusted revenue, as defined previously. Adjusted profit from operations and adjusted operating margin are not measures defined by IFRS. The most directly comparable IFRS measure to adjusted profit from operations is profit from operations.

Adjusting items, as identified in accordance with the Group’s accounting policies, represent certain items of income and expense which the Group considers distinctive based on their size, nature or incidence. In identifying and quantifying adjusting items, the Group consistently applies a policy that defines criteria that are required to be met for an item to be classified as adjusting and provides details of items that are specifically excluded from being classified as adjusting items. Adjusting items in profit from operations include restructuring and integration costs, amortisation of trademarks and similar intangibles, impairment of goodwill and charges in respect of certain litigation.

The definition of adjusting items is explained in note 1 in the Notes on the Accounts.

The Group’s Management Board believes that these additional measures are useful to investors and are used by the Group’s Management Board as described above, because they exclude the impact of adjusting items which have less bearing on the routine ongoing operating activities of the Group, thereby enhancing users’ understanding of underlying business performance. The Group’s Management Board also believes that adjusted profit from operations provides information that enables investors to better compare the Group’s business performance across periods. Additionally, the Group’s Management Board believes that similar measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the Group, many of which present an adjusted operating profit-related performance measure when reporting their results. Adjusted profit from operations and adjusted operating margin have limitations as analytical tools. They are not presentations made in accordance with IFRS, are not measures of financial condition or liquidity and should not be considered as alternatives to profit for the year, profit from operations or operating margin as determined in accordance with IFRS. Adjusted profit from operations and adjusted operating margin are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider these performance measures in isolation from, or as a substitute analysis for, BAT’s results of operations as determined in accordance with IFRS.

The table below reconciles the Group’s profit from operations to adjusted profit from operations, and to adjusted profit from operations at constant rates based on a re-translation of adjusted profit from operations for each year, at the previous year’s exchange rates, and provides adjusted operating margin for the periods presented. Refer to note 2 in the Notes on the Accounts for further discussion of the segmental results and for the reconciliation of adjusted profit from operations at current and constant rates of exchange to segmental profit from operations and to Group profit for the years ended 31 December 2021, 2020 and 2019.

### Table: Adjusted Profit From Operations and Adjusted Operating Margin

<table>
<thead>
<tr>
<th>For the year ended 31 December (£m)</th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profit from operations</strong></td>
<td>10,234</td>
<td>9,962</td>
<td>9,016</td>
</tr>
<tr>
<td><strong>Add:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring and integration costs</td>
<td>150</td>
<td>408</td>
<td>481</td>
</tr>
<tr>
<td>Amortisation and impairment of trademarks and similar intangibles</td>
<td>306</td>
<td>339</td>
<td>481</td>
</tr>
<tr>
<td>Impairment of goodwill</td>
<td>57</td>
<td>209</td>
<td>194</td>
</tr>
<tr>
<td>(Income)/charge in respect of an excise tax dispute in Russia</td>
<td>– (40)</td>
<td>202</td>
<td></td>
</tr>
<tr>
<td>Charge in respect of Canada class action</td>
<td>–</td>
<td>–</td>
<td>436</td>
</tr>
<tr>
<td>Charge in respect of MSA liabilities related to brands sold to a third party</td>
<td>–</td>
<td>400</td>
<td>–</td>
</tr>
<tr>
<td>Credit in respect of the partial buy-out of the pension fund in the U.S.</td>
<td>(39)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Charge in respect of the sale of the Group’s operations in Iran</td>
<td>358</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other, including litigation</td>
<td>80</td>
<td>87</td>
<td>236</td>
</tr>
<tr>
<td><strong>Adjusted profit from operations</strong></td>
<td>11,150</td>
<td>11,365</td>
<td>11,130</td>
</tr>
</tbody>
</table>

### Operating margin

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating margin</td>
<td>39.8%</td>
<td>38.6%</td>
<td>34.8%</td>
</tr>
<tr>
<td>Adjusted operating margin*</td>
<td>43.4%</td>
<td>44.1%</td>
<td>43.1%</td>
</tr>
</tbody>
</table>

### Impact of translational foreign exchange

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>802</td>
<td>296</td>
</tr>
</tbody>
</table>

### 2021 adjusted profit from operations re-translated at 2020 exchange rates

<table>
<thead>
<tr>
<th></th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>11,952</td>
</tr>
</tbody>
</table>

### 2020 adjusted profit from operations re-translated at 2019 exchange rates

<table>
<thead>
<tr>
<th></th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>11,661</td>
</tr>
</tbody>
</table>

### 2019 adjusted profit from operations re-translated at 2018 exchange rates

<table>
<thead>
<tr>
<th></th>
<th>£m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>11,032</td>
</tr>
</tbody>
</table>

### Change in adjusted profit from operations at prior year’s exchange rates (constant rates)

<table>
<thead>
<tr>
<th></th>
<th>+5.2%</th>
<th>+4.8%</th>
<th>+6.6%</th>
</tr>
</thead>
</table>

* Adjusted profit from operations as a percentage of adjusted revenue.
Adjusted Share of Post-Tax Results of Associates and Joint Ventures

Definition – share of post-tax results of associates and joint ventures before the impact of adjusting items.

To supplement BAT’s performance presented in accordance with IFRS, the Group’s share of post-tax results of associates and joint ventures is also presented before adjusting items (as defined in note 1 in the Notes on the Accounts). The Group’s Management Board believes that adjusted share of post-tax results of associates and joint ventures provides information that enables investors to better compare the Group’s business performance across periods. The Group’s Management Board uses adjusted share of post-tax results from associates and joint ventures as part of the total assessment of the underlying performance of all the Group’s business interests. Adjusted share of post-tax results of associates and joint ventures has limitations as an analytical tool. It is not a presentation made in accordance with IFRS, is not a measure of financial condition or liquidity, and should not be considered as an alternative to the Group’s share of post-tax results of associates and joint ventures as determined in accordance with IFRS. Adjusted share of post-tax results of associates and joint ventures is not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider this performance measure in isolation from, or as a substitute analysis for, BAT’s results of operations as determined in accordance with IFRS.

The most directly comparable IFRS measure to adjusted share of post-tax results of associates and joint ventures is share of post-tax results of associates and joint ventures.

For the year ended 31 December (£m)

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group’s share of post-tax results of associates and joint ventures</td>
<td>415</td>
<td>455</td>
<td>498</td>
</tr>
<tr>
<td>Issue of shares and changes in shareholding</td>
<td>(6)</td>
<td>(17)</td>
<td>(25)</td>
</tr>
<tr>
<td>Impairment of the Group’s associate in Yemen</td>
<td>18</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Other</td>
<td>–</td>
<td>4</td>
<td>–</td>
</tr>
<tr>
<td>Adjusted Group’s share of post-tax results of associates and joint ventures</td>
<td>427</td>
<td>442</td>
<td>473</td>
</tr>
</tbody>
</table>

Underlying Tax Rate

Definition – Tax rate incurred before the impact of adjusting items and to adjust for the inclusion of the Group’s share of post-tax results of associates and joint ventures within the Group’s pre-tax results.

BAT management monitors the Group’s underlying tax rate to assess the tax rate applicable to the Group’s underlying operations, excluding the Group’s share of post-tax results of associates and joint ventures in BAT’s pre-tax results and adjusting items (as defined in note 1 in the Notes on the Accounts). Underlying tax rate is not a measure defined by IFRS. The table below provides the calculation of the Group’s effective tax rate as determined in accordance with IFRS with underlying tax rate for the periods presented. The Group’s Management Board believes that this additional measure is useful to investors, and is used by BAT management as described above, because it excludes the contribution from the Group’s associates, recognised after tax but within the Group’s pre-tax profits, and adjusting items, thereby enhancing users’ understanding of underlying business performance.

Underlying tax rate has limitations as an analytical tool. It is not a presentation made in accordance with IFRS and should not be considered as an alternative to the effective tax rate as determined in accordance with IFRS. Underlying tax rate is not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider this measure in isolation from, or as a substitute analysis for, the Group’s effective tax rate as determined in accordance with IFRS. The table below provides the calculation of the Group’s underlying tax rate for the periods presented.

For the year ended 31 December (£m)

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit before taxation</td>
<td>9,163</td>
<td>8,672</td>
<td>7,912</td>
</tr>
<tr>
<td>Less: Share of post-tax results of associates and joint ventures</td>
<td>(415)</td>
<td>(455)</td>
<td>(498)</td>
</tr>
<tr>
<td>Adjusting items within profit from operations</td>
<td>916</td>
<td>1,403</td>
<td>2,114</td>
</tr>
<tr>
<td>Adjusting items within finance costs</td>
<td>55</td>
<td>153</td>
<td>80</td>
</tr>
<tr>
<td>Adjusted profit before taxation, excluding associates and joint ventures</td>
<td>9,719</td>
<td>9,773</td>
<td>9,608</td>
</tr>
<tr>
<td>Taxation on ordinary activities</td>
<td>(2,189)</td>
<td>(2,108)</td>
<td>(2,063)</td>
</tr>
<tr>
<td>Adjusting items in taxation</td>
<td>(91)</td>
<td>(35)</td>
<td>(65)</td>
</tr>
<tr>
<td>Taxation on adjusting items</td>
<td>(119)</td>
<td>(287)</td>
<td>(373)</td>
</tr>
<tr>
<td>Adjusted taxation</td>
<td>(2,399)</td>
<td>(2,430)</td>
<td>(2,501)</td>
</tr>
<tr>
<td>Effective tax rate</td>
<td>23.9%</td>
<td>24.3%</td>
<td>26.1%</td>
</tr>
<tr>
<td>Underlying tax rate</td>
<td>24.7%</td>
<td>24.9%</td>
<td>26.6%</td>
</tr>
</tbody>
</table>
Non-GAAP Measures
Continued

Adjusted Diluted Earnings Per Share
Definition – diluted earnings per share before the impact of adjusting items.
BAT management monitors adjusted diluted earnings per share, a measure which removes the impact of adjusting items, (as defined in note 1 in the Notes on the Accounts), from diluted earnings per share. Adjusted diluted earnings per share is used by management within the Group’s incentive schemes, as reported within the Remuneration Report beginning on page 128 and reported in note 11 in the Notes on the Accounts. The Group’s Management Board believes that this additional measure is useful to investors, and is used by BAT management as described above, as an indicator of diluted earnings per share before adjusting items. Adjusted diluted earnings per share has limitations as an analytical tool and should not be used in isolation from, or as a substitute for, diluted earnings per share as determined in accordance with IFRS. The most directly comparable IFRS measure to adjusted diluted earnings per share is diluted earnings per share and a reconciliation is provided in note 11 in the Notes on the Accounts. The definition of adjusting items is provided in note 1 in the Notes on the Accounts.

Operating Cash Flow Conversion Ratio
Definition – net cash generated from operating activities before the impact of adjusting items and dividends from associates and excluding trading loans to third parties, pension short fall funding, taxes paid and net capital expenditure, as a proportion of adjusted profit from operations.
Net Debt
Definition – total borrowings, including related derivatives, less cash and cash equivalents and current investments held at fair value.

The Group uses net debt to assess its financial capacity. Net debt is not a measure defined by IFRS. The most directly comparable IFRS measure to net debt is total borrowings. The Group’s Management Board believes that this additional measure, which is used internally to assess the Group’s financial capacity, is useful to the users of the financial statements in helping them to see how business financing has changed over the year. Net debt has limitations as an analytical tool. It is not a presentation made in accordance with IFRS and should not be considered as an alternative to total borrowings or total liabilities determined in accordance with IFRS. Net debt is not necessarily comparable to similarly titled measures used by other companies. In addition, it does not exclude restricted cash (as set out in note 21 in the Notes on the Accounts) in the calculation. As a result, you should not consider this measure in isolation from, or as a substitute analysis for, the Group’s measures of financial position or liquidity as determined in accordance with IFRS. A reconciliation of borrowings to net debt is provided in note 23 in the Notes on the Accounts.
Other Information

Non-GAAP Measures

Continued

Adjusted Net Debt to Adjusted Earnings Before Interest, Tax, Depreciation and Amortisation (Adjusted EBITDA)

Definition – net debt excluding the impact of the revaluation of Reynolds American Inc. acquired debt arising as part of the purchase price allocation process, as a proportion of profit for the year (earnings) before net finance costs/income, taxation on ordinary activities, depreciation, amortisation, impairment costs, the Group’s share of post-tax results of associates and joint ventures, and other adjusting items.
Results on a Constant Translational Currency Basis

Movements in foreign exchange rates have impacted the Group’s financial results. The Group’s Management Board reviews certain of its results, including adjusted revenue, revenue growth from New Categories, adjusted profit from operations and adjusted diluted earnings per share, at constant rates of exchange. The Group calculates these financial measures at constant rates of exchange based on a re-translation, at prior year exchange rates, of the current year’s results of the Group and, where applicable, its geographic segments. The Group does not adjust for the normal transactional gains and losses in profit from operations that are generated by exchange movements. Although the Group does not believe that these measures are a substitute for IFRS measures, the Group’s Management Board does believe that such results excluding the impact of currency fluctuations year-on-year provide additional useful information to investors regarding the Group’s operating performance on a local currency basis.

Accordingly, the constant rates of exchange financial measures appearing in the discussion of the Group results of operations (beginning on page 74) should be read in conjunction with the information provided in note 2 in the Notes on the Accounts.

In 2021, 2020 and 2019, results were affected by translational exchange rate movements. In 2021, at the prevailing exchange rates, adjusted revenue declined by 0.4%, revenue growth from New Categories increased 42.4% and adjusted profit from operations declined by 1.9% versus 2020. At constant rates of exchange, adjusted revenue would have increased by 6.9%, revenue from New Categories would have increased by 50.9% and adjusted profit from operations would have increased by 5.2%. This lower growth rate at prevailing exchange rates reflects the negative translational impact as a result of the relative strengthening of the pound sterling. In 2020, at the prevailing exchange rates, adjusted revenue declined by 0.4%, adjusted profit from operations increased by 2.1%, adjusted revenue from the strategic portfolio increased by 4.0% and adjusted revenue from New Categories increased by 14.9% versus 2019. At constant rates of exchange, adjusted revenue would have increased by 3.3%, adjusted profit from operations would have increased by 7.0% and adjusted revenue from New Categories would have increased by 15.4%. This lower growth rate at prevailing exchange rates reflects the negative translational impact as a result of the relative strengthening of the pound sterling.

In 2021, 2020 and 2019, adjusted diluted earnings per share was affected by translational exchange rate movements. In 2021, the adjusted diluted earnings per share of 329.0p, a decrease of 0.8%, would, when translated at 2020 exchange rates, have been 353.5p, an increase of 6.6%. This lower growth rate, in 2021, at prevailing exchange rates, reflects the negative translational impact as a result of the relative strength of the pound sterling. In 2020, the adjusted diluted earnings per share of 331.7p, an increase of 2.4%, would, when translated at 2019 exchange rates, have been 341.4p, an increase of 5.5%. This lower growth rate, in 2020, at prevailing exchange rates, reflects the negative translational impact as a result of the relative strength of the pound sterling.
Employees

As at 31 December 2021, the number of persons employed by the Group was 52,050 worldwide. The Group believes that its labour relations are good.

Certain temporary employees are included in the below figures. The number of such temporary employees is approximately 241 in 2021 and largely relates to seasonal workers within operations.

The following table sets forth the number of Group employees by region in 2021, 2020 and 2019.

<table>
<thead>
<tr>
<th>Region (number of employees worldwide)</th>
<th>As of 31 December</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021</td>
</tr>
<tr>
<td>U.S.</td>
<td>4,405</td>
</tr>
<tr>
<td>APME</td>
<td>9,747</td>
</tr>
<tr>
<td>AmSSA</td>
<td>15,565</td>
</tr>
<tr>
<td>ENA¹</td>
<td>22,333</td>
</tr>
<tr>
<td><strong>Total employees</strong></td>
<td><strong>52,050</strong></td>
</tr>
</tbody>
</table>

Note:

1. Included within the employee numbers for ENA are certain employees in different locations in respect of central functions. Some of the costs of these employees are allocated or charged to the various regions and markets in the Group.
Additional Disclosures on Liquidity and Capital Resources

The Group’s cash inflows derive principally from its operating activities. They are supplemented when required by cash flows from financing activities, typically to support general corporate requirements but also, from time to time, to support acquisitions. The principal sources of liquidity for the Group are cash flows generated from the operating business and proceeds from issuances of debt securities described below under ‘capital resources’.

The Board reviews and agrees the overall treasury policies and procedures, delegating appropriate oversight to the Finance and Transformation Director and the treasury function. The treasury policies include a set of financing principles and key performance indicators. The Group’s treasury position is monitored by a Corporate Finance Committee chaired by the Finance and Transformation Director. Treasury operations are subject to periodic independent reviews and audits, both internal and external.

In 2021, 2020 and 2019, all contractual borrowing covenants were met and none are expected to inhibit the Group’s operations or funding plans. In 2020, the Group’s financial covenant (interest cover) was removed from the terms of the revolving credit facility and syndicated term loan.

Capital Expenditure

Gross capital expenditures include purchases of property, plant and equipment and purchases of certain intangibles. The Group’s gross capital expenditures for 2021, 2020 and 2019 were £664 million, £648 million and £807 million, respectively, representing investment in the Group’s global operational infrastructure (including, but not limited to, the manufacturing network, trade marketing and IT systems). The Group expects gross capital expenditures in 2022 of approximately £750 million, representing the ongoing investment in the Group’s operational infrastructure, including the continued investment into New Categories. This is expected to be funded by the Group’s cash flows and existing facilities.

Hedging Instruments

As discussed in note 23 in the Notes on the Accounts, the Group hedges its exposure to interest rate movements and currency movements. BAT’s cash flow hedges are principally in respect of sales or purchases of inventory and certain debt instruments. A certain number of forward foreign currency contracts were used to manage the currency profile of external borrowings. Interest rate swaps have been used to manage the interest rate profile of external borrowings, while cross-currency swaps have been used to manage the currency profile of external borrowings.

Capital Resources

Policy

The Group utilises cash pooling and zero balancing bank account structures in addition to intercompany loans and borrowings to ensure that there is the maximum mobilisation of cash within the Group. The key objectives of treasury in respect of cash and cash equivalents are to protect the principal value of the Group’s cash and cash equivalents, to concentrate cash at the centre to minimise the required long-term debt issuance, including perpetual hybrid debt treated as an equity instrument, and to optimise the yield earned. The amount of debt the Group issues is determined by forecasting the net debt requirement after the mobilisation of cash. Subsidiary companies are funded by share capital and retained earnings, loans from the central finance companies on commercial terms or through local borrowings by the subsidiaries in appropriate currencies. All contractual borrowing covenants have been met and none are expected to inhibit the Group’s operations or funding plans.

Borrowings

The following table sets out the Group’s long- and short-term borrowings as of the dates indicated:

<table>
<thead>
<tr>
<th>Currency</th>
<th>Maturity dates</th>
<th>Interest rates at 31 December 2021</th>
<th>As of 31 December (£m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eurobonds²</td>
<td>2022 to 2045</td>
<td>0.9% to 3.1%</td>
<td>7,316</td>
</tr>
<tr>
<td>Euro</td>
<td>2021</td>
<td>3m EURIBOR +50bps</td>
<td>8,875</td>
</tr>
<tr>
<td>UK pound sterling</td>
<td>2022 to 2055</td>
<td>2.1% to 7.3%</td>
<td>4,086</td>
</tr>
<tr>
<td>Swiss franc</td>
<td>2026</td>
<td>1.4%</td>
<td>203</td>
</tr>
<tr>
<td>Bonds issued pursuant to rules under the</td>
<td></td>
<td></td>
<td>230</td>
</tr>
<tr>
<td>U.S. Securities Act (as amended)²</td>
<td>2022 to 2050</td>
<td>1.7% to 8.1%</td>
<td>25,425</td>
</tr>
<tr>
<td>US dollar</td>
<td>2022</td>
<td>USD 3m LIBOR + 81bps</td>
<td>25,461</td>
</tr>
<tr>
<td>Commercial Paper²</td>
<td>2022</td>
<td>1.7% to 8.1%</td>
<td>554</td>
</tr>
<tr>
<td>Other loans</td>
<td></td>
<td>2.1%</td>
<td>548</td>
</tr>
<tr>
<td>Bank loans</td>
<td></td>
<td>1.7%</td>
<td>1,056</td>
</tr>
<tr>
<td>Bank overdrafts</td>
<td></td>
<td>1.7%</td>
<td>500</td>
</tr>
<tr>
<td>Finance leases</td>
<td></td>
<td>1.7%</td>
<td>1,929</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>28,958</td>
</tr>
</tbody>
</table>

Notes:
1. The financial data above has been extracted from the Group’s consolidated financial statements.
2. The issuers of these debt securities are B.A.T. International Finance p.l.c., B.A.T Capital Corporation, Reynolds American Inc., or R.J. Reynolds Tobacco Company, as applicable. British American Tobacco p.l.c. is the ultimate guarantor in each case.

Perpetual hybrid bonds issued by the Company have been classified as equity and therefore excluded from borrowings.
Off-Balance Sheet Arrangements and Contractual Obligations

The Group has no significant off-balance sheet arrangements. The Group has contractual obligations to make future payments on debt agreements. In the normal course of business, the Group enters into contractual arrangements where the Group commits to future purchases of services from unaffiliated parties and related parties.

The Group’s undiscounted contractual obligations as of 31 December 2021 were as follows:

<table>
<thead>
<tr>
<th>Payments due by period (£m)</th>
<th>Total</th>
<th>Less than 1 Year</th>
<th>1–3 Years</th>
<th>3–5 Years</th>
<th>Thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term notes and other borrowings, exclusive of interest¹</td>
<td>38,752</td>
<td>3,406</td>
<td>6,178</td>
<td>6,742</td>
<td>22,426</td>
</tr>
<tr>
<td>Interest payments related to long-term notes¹</td>
<td>460</td>
<td>460</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Lease liabilities</td>
<td>446</td>
<td>126</td>
<td>159</td>
<td>87</td>
<td>74</td>
</tr>
<tr>
<td>Purchase obligations²</td>
<td>1,160</td>
<td>943</td>
<td>207</td>
<td>10</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total cash obligations</strong></td>
<td>40,818</td>
<td>4,935</td>
<td>6,544</td>
<td>6,839</td>
<td>22,500</td>
</tr>
</tbody>
</table>

Notes:

1. For more information about the Group’s long-term debt, see note 23 in the Notes on the Accounts.
2. Purchase obligations primarily include commitments to acquire tobacco leaf. Purchase orders for the purchase of other raw materials and other goods and services are not included in the table, as the Group’s operating subsidiaries are not able to determine the aggregate amount of such purchase orders that represent contractual obligations, as purchase orders typically represent authorisations to purchase rather than binding agreements.

The table above does not include any amounts that the Group may pay to fund its retirement benefit plans as the timing and amount of any such future funding are unknown and dependent on, among other things, the future performance of defined benefit pension plan assets, interest rate assumptions and other factors. The net retirement benefit scheme liabilities totalled £321 million as of 31 December 2021, which is net of pension assets of £10,816 million. The Group expects to be required to contribute £83 million to its defined benefit plans during 2022. See note 15 in the Notes on the Accounts for further information.

The above table also excludes any amounts in relation to service contracts which are disclosed in note 31 in the Notes on the Accounts.
Summary of Group Risk Factors

The following is a summary of some of the risks and uncertainties, the occurrence of any one of which, alone or in combination with other events or circumstances, may materially adversely affect the Group’s results of operations and financial condition. You should read this summary together with the ‘Group Principal Risks’ section on pages 84 to 88 and the more detailed description of each risk factor contained below.

Business execution and supply chain risks

- Competition from illicit trade.
- Geopolitical tensions that have the potential to disrupt the Group’s business in multiple markets.
- Disruption to the Group’s data and information technology systems, including by cyber attack or the malicious manipulation or disclosure of confidential or sensitive information.
- Failure to meet current or future New Categories demand.
- Failure of a financial counterparty.
- Exposure to unavailability of, and price volatility, in raw materials and increased costs of employment.
- Failure to retain key personnel or to attract and retain skilled talent.
- Disruption to the supply chain and distribution channels.
- Failure to deliver digital innovation and drive digital transformation.
- Exposure to product contamination.
- Inability to obtain adequate supplies of tobacco leaf.
- Failure to successfully design, implement and sustain an integrated operating model.
- Failure to manage the Group’s climate change risk.

Legal, regulatory and compliance risks

- Exposure to, the enactment of, proposals for, or rumours of regulation that significantly impairs the Group’s ability to communicate, differentiate, market or launch its products and/or the lack of appropriate regulation for New Categories.
- Adverse implications of proposed EU legislation on single-use plastics that will result in on-pack environmental warnings and financial implications relating to the Extended Producer Responsibility (EPR).
- Exposure to litigation on tobacco, nicotine, New Categories and other issues.
- Significant and/or unexpected increases or structural changes in tobacco and nicotine-related taxes.
- Failure to comply with health and safety and environmental laws.
- Exposure to unfavourable tax rulings.
- Unexpected legislative changes to corporate income tax laws.
- Exposure to potential liability under competition or antitrust laws.
- Failure to establish and maintain adequate controls and procedures to comply with applicable securities, corporate governance and compliance regulations.
- Loss of confidential information, including through manipulation of data by employees and system failure.
- Failure to comply with product regulations due to uncertainty surrounding the proper interpretation and application of those regulations.
- Failure to uphold high standards of ESG management.
- Failure to manage the Group’s climate change risk.
- Use and disclosure of personal data.
- Failure to comply with product regulations due to uncertainty surrounding the proper interpretation and application of those regulations.
- Failure to uphold New Categories marketing practices.

Economic and financial risks

- Foreign exchange rate exposures.
- Inability to obtain price increases and exposure to risks from excessive price increases and value chain erosion.
- Effects of declining consumption of legitimate tobacco products and a tough competitive environment.
- Funding, liquidity and interest rate risks.
- Failure to achieve growth through mergers, acquisitions and joint ventures.
- Unforeseen underperformance in key global markets.
- Increases in net liabilities under the Group’s retirement benefit schemes.

Product pipeline, commercialisation and Intellectual Property risks

- Inability to predict consumers’ changing behaviours and launch innovative products that offer adult tobacco and nicotine consumers meaningful value-added differentiation.
- Exposure to risks associated with intellectual property rights, including the failure to identify, protect and prevent infringement of the Group’s intellectual property rights and potential infringement of, or the failure to retain licences to use, third-party intellectual property rights.
Other Information

Group Risk Factors

Business Execution and Supply Chain Risks

Risk: Competition from illicit trade.

Description
Illicit trade, illegal products and tobacco trafficking in the form of counterfeit products, smuggled genuine products (product diversion), and locally manufactured products, which do not comply with applicable regulations and/or in which applicable taxes are evaded, represent a significant and growing threat to the legitimate tobacco industry and New Categories products. Factors such as increasing levels of taxation, price increases, economic downturn, lack of law enforcement, appropriate penalties and weak border control are encouraging more adult tobacco and New Categories consumers to switch to illegal cheaper tobacco and New Categories products and are providing greater rewards for counterfeiters and smugglers. Regulatory restrictions such as plain packaging or graphic health warnings, display bans, flavour or ingredient restrictions and increased compliance costs further disadvantage legitimate industry participants by providing competitive advantages to illicit manufacturers and distributors of illicit tobacco and New Categories products.

In addition, third parties may seek to divert product when there is an arbitrage opportunity for them between lower and higher excise countries.

Impact
Illicit trade has an adverse effect on the Group’s overall sales volume and may restrict the ability to increase selling prices. Illicit trade can also damage brand equity and reputation, which could undermine the Group’s investment in Trade Marketing and Distribution. Operational costs (e.g. track and trace costs) can increase and the product may become commoditised.

These factors in turn could reduce profits and have an adverse effect on the Group’s results of operations and financial conditions and cause the Group to fail to deliver on its strategic growth plans. Further, counterfeit products (especially New Categories) and other illicit products could harm consumers, damaging goodwill and/or the category (with lower volumes and reduced profits), and potentially leading to misplaced claims against BAT and further regulation and also lead to a failure to deliver our corporate harm reduction objective. In addition, as the Group has contractual and legislative obligations to prevent the diversion of our products into illicit channels, actual and perceived breaches of the obligations to prevent product diversion into illicit channels can lead to substantial fines in the forms of seizure payments and legislative penalties (including financial penalties), as well as the risk of reputational damage (including negative perceptions of our governance and our ESG credentials) from Group products being found in illicit channels.

Risk: Geopolitical tensions that have the potential to disrupt the Group’s business in multiple markets.

Description
The Group’s operations and financial condition are influenced by the economic and political situations in the markets and regions in which it has operations, which are often unpredictable and outside of its control. Some markets in which the Group operates face the threat of civil unrest and can be subject to frequent changes in regime. In others, there is a risk of terrorism, conflict, global health crisis, war, organised crime or other criminal activity. The Group is also exposed to economic policy changes in jurisdictions in which it operates. In addition, some markets maintain trade barriers or adopt policies that favour domestic producers, preventing or restricting the Group’s sales.

Impact
Deterioration of socio-economic or political conditions could lead to injury or loss of life, restricted mobility, loss of assets and/or denial of access to BAT sites that reduce the Group’s access to particular markets or may disrupt the Group’s operations, such as supply chain, or manufacturing or distribution capabilities. Such disruption may result in increased taxes and/or other costs due to the need for more complex supply chain and security arrangements, to build new facilities or to maintain inefficient facilities, or in a reduction of the Group’s sales volume. Further, there may be reputational damage, including negative perceptions of our governance and protection of our people and our ESG credentials.

Risk: Disruption to the Group’s data and information technology systems, including by cyber attack or the malicious manipulation or disclosure of confidential or sensitive information.

Description
The Group increasingly relies on data and information technology systems for its daily business operations, internal communications, controls, reporting and relations with customers and suppliers. Some of these systems are managed by third-party service providers. A significant disruption of the Group’s systems, including those managed by third-party service providers, due to computer viruses, cyber threats, malicious intrusions or unintended or malicious behaviour by employees, contractors or services providers could affect the Group’s communications and operations. Computer viruses and cyber attacks are becoming more sophisticated and coordinated. In addition, such disruption may compromise the integrity of information and result in the inappropriate disclosure of confidential information, or may lead to false or misleading statements being made about the Group.
Risk: Disruption to the Group’s data and information technology systems, including by cyber attack or the malicious manipulation or disclosure of confidential or sensitive information continued.

**Impact**

Any disruption to technology systems related to the Group’s operations could adversely affect its business and result in financial and reputational losses. Any delays or failure to rapidly detect or respond to attempts to gain unauthorised access to the Group’s information technology systems through a cyber attack can lead to a loss of access to systems or information being corrupted or lost, resulting in significantly increased costs for remediation and reputational consequences.

Security breaches and the loss of data or operational capacity may disrupt relationships throughout the supply chain, expose the Group or our consumers to a risk of loss or misuse of information, which could further expose the Group to liability, impact the Group’s reputation and lead to increased costs.

The disclosure of trade secrets or other commercially sensitive information may provide competitors with a competitive advantage resulting in competitive or operational damage to the Group. The disclosure of confidential and sensitive information about the Group’s employees, customers, consumers, suppliers or other third parties could compromise data privacy and expose the Group to liability.

Failure to effectively prevent or respond to a major breach or cyber attack may also subject the Group to significant reputational damage.

---

Risk: Failure to meet current or future New Categories demand.

**Description**

The New Categories supply chain is a multi-tiered and complex environment with reliance on multiple factors, such as third-party suppliers’ ability to upscale production in order to meet demand while maintaining product quality, dependency on single suppliers at various points in the chain and the Group’s ability to build adequate consumables production capacity in line with product demand. The geographical spread of suppliers and customers exposes the Group to political and economic conflicts such as Brexit and trade wars which may compromise the New Categories supply chain. Given the developing nature of the New Categories portfolio, there is also an enhanced risk that some products may not meet product quality and safety standards or may be subject to regulatory changes, leading to product recalls, which we have experienced in the past, or bans of certain ingredients or products. In addition, the New Categories supply chain may be vulnerable to changes in local legislation related to liquid nicotine that could increase import duties. Furthermore, the New Categories supply chain includes the development of sensitive trade secrets jointly with external design partners, which carries the risk of exposure of innovations to competitors.

**Impact**

Vulnerabilities in the New Categories supply chain may impact the Group’s ability to maintain supply and meet the current and future demand requirements across the New Categories portfolio, potentially resulting in significant reputational harm and financial impact that may negatively affect the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans. Over-forecasting may also lead to write-off and negatively impact working capital. The design of New Categories devices may also prevent the scaling of commercial manufacturing, which will either restrict supply or increase the costs of production.

Further, there may be loss of investors’ confidence in ESG performance, including failure to deliver our corporate purpose of harm reduction.

In addition, changes in local legislation related to liquid nicotine import duties may increase New Categories production costs, which may increase end market pricing and reduce demand. Furthermore, the exposure of sensitive trade secrets can lead to competitive disadvantages and further negatively impact the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

---

Risk: Failure of a financial counterparty.

**Description**

The Group relies on transactions with a variety of financial counterparties to manage the Group’s business and financial risks. In the event that any of these counterparties fails, payments due from such counterparties, such as under hedging or insurance contracts, may not be recovered. In addition, failure of a transnational banking party may lead to the loss of cash balances and disruption to payment systems involving such counterparty.

**Impact**

The inability to recover payments due from one or more failed financial counterparties or the loss of cash balances may cause significant financial loss and have an adverse impact on the Group’s results of operations, financial condition and financial risk profile. In addition, the loss of cash balances or a disruption to payment systems may cause disruption to the Group’s ongoing operations and ability to pay its creditors and suppliers.
Risk: Exposure to unavailability of, and price volatility, in raw materials and increased costs of employment.

Description
The availability and price of various commodities required in the manufacture of the Group’s products fluctuate. Raw materials and other inputs used in the Group’s business, such as wood pulp and energy, are commodities that are subject to price volatility caused by numerous factors, including political influence, market fluctuations and natural disasters.

Similarly, the Group is exposed to the risk of an increase above inflation in employment costs, including due to governmental action to introduce or increase minimum wages. Employment and health care law changes may also increase the cost of provided health care and other employment benefits expenses.

Impact
Restricted availability and price volatility of commodities may result in supply shortages and unexpected increases in costs for raw materials and packaging for the Group’s products, which may affect the Group’s results of operations and financial condition.

Similarly, the Group’s profitability may be affected by increases in overall employment costs.

The Group may not be able to increase prices to offset increased costs without suffering reduced sales volume and revenue. In the absence of compensating for increased costs through pricing, significant increases in raw material, packaging and employment costs above inflation will impact product margins, leading to lower profits and negatively affecting the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

Risk: Failure to retain key personnel or to attract and retain skilled talent.

Description
The Group relies on a number of highly experienced employees with detailed knowledge of the tobacco industry, other areas of focus for the Group (including New Categories and Beyond Nicotine) and the Group’s business. Similarly, the Group is dependent on its ability to identify, attract, develop and retain such qualified personnel in the future. The Group is also dependent on external hires to ensure that there are the right new business critical capabilities and knowledge to accelerate transformation. BAT anticipates that this trend will continue and therefore the ability to continue to build awareness, increase reach and ultimately attract the new target audience remains a primary focus.

The shift in career development expectations from new hires are leading to shorter tenures. Although the Group is increasing its effort on retaining critical capabilities and knowledge, following any departure of new external hires, there can be no assurance that this effort will be successful. Furthermore, broader economic and ESG trends may impact the Group’s ability to retain key employees and may increase competition for highly talented employees, potentially resulting in the loss of experienced employees.

Impact
If the Group is unable to retain its existing key employees or to attract and retain skilled talent in the future, critical positions may be left vacant, which could adversely impact the delivery of strategic objectives, which could ultimately impact the Group’s results of operations, financial condition and achieving its ESG related ambitions.

High voluntary employee turnover may also reduce organisational performance and productivity, which may have a further adverse impact on the Group’s results of operations and financial condition.

Risk: Disruption to the supply chain and distribution channels.

Description
The Group has an increasingly global approach to managing its supply chain and distribution channels and is exposed to the risk of disruption to any aspect of the Group’s supply chain, to suppliers’ operations or to distribution channels, and the deterioration in the financial condition of a trading partner. This is especially so in our New Categories Supply Chain which is a multi-tiered and complex environment.

Such disruption may be caused by a cyber event, global health crisis, major fire, violent weather conditions or other natural disasters that affect manufacturing or other facilities of the Group’s operating subsidiaries or those of their suppliers and distributors. In certain geographic areas where the Group operates, insurance coverage may not be obtainable on commercially reasonable terms, if at all. Coverage may be subject to limitations or the Group may be unable to recover damages from its insurers.

Disruption may also be caused by spread of infectious disease (such as the COVID-19 pandemic) or by a deterioration/shortage in labour or union relations, disputes or work stoppages or other labour-related developments within the Group or its suppliers and distributors. In some markets, distribution of the Group’s products is through third-party monopoly channels, often licensed by governments. The Group may be unable to renew these third-party supplier and distribution agreements on satisfactory terms for numerous reasons, including government regulations or ESG considerations.

Furthermore, there are some product categories for which the Group does not have spare production capacity or where substitution between different production plants is very difficult. Consolidation of global suppliers and certain distributors that control large geographies may reduce the Group’s availability of alternatives and negatively impact the Group’s negotiating power with key suppliers and distributors.

These risks are particularly relevant in jurisdictions where the Group’s manufacturing facilities are more concentrated or for certain product categories where production is more centralised.
Risk: Disruption to the supply chain and distribution channels continued.

Impact

Any disruption to the Group’s supply chain and distribution channels could have an adverse effect on the results of operations and financial conditions of the Group through failures to meet shipment demand, contract disputes, increased costs, loss of market share and inability to reinvest into New Category and support harm reduction agenda and cause the Group to fail to deliver on its strategic growth plans.

Risk: Failure to deliver digital innovation and drive digital transformation.

Description

The Group’s strategy in areas of further growth and increasing profitability depends to a large extent on digital transformation and innovation. Digital transformation and innovation are key drivers of the Group’s ethos and Quest, which includes new and modern categories of products, increased interaction with customers, data-driven decision making and cost optimisation efforts driven by automated and modernised processes. Examples of the Group’s ambitions that depend on digital transformation include:

− the ability to leverage our data assets to generate insights and foresights as a key driver of revenue growth;
− the expansion and flexibility of technology solutions to streamline the market realisation of new products and marketing campaigns; and
− the ability to build new solutions and the flexibility to react to market disruptions.

The Group must effectively implement new ways of working and supporting technologies to fully develop the digital agenda defined by the Board (e.g. digital channels, data and analytics, automation, etc.).

The Group may see stalled progress in the pace of digital transformation and hampered strategy goals realisation if the necessary information and digital technology is not ready to support the business implementation of global functional transformations (e.g. direct relationship with consumers, integrated planning, demand forecasting and revenue growth management). The unavailability of the necessary digital technology may be due to missing technology capabilities, lack of scalability or poor data quality. Shortage of skills and ineffective ways of working may slow down the pace of the Group’s digital transformation and hamper its value realisation processes. In addition, sub-optimal design of the global digital platforms implemented by BAT may lead to the fragmentation and under-utilisation of such platforms and slow down the Group’s digital transformation.

Impact

The Group’s multi-category strategy requires dealing with different consumer needs and behaviours as well as complying with various regulations, which increasingly requires the expansion and flexibility of technology solutions. This may lead to the fragmentation and under-utilisation of existing and future technology solutions. Similarly, increased control and centralisation of the technology solutions and delivery mechanisms may slow down the effective delivery of the Group’s digital transformation and innovation.

The Group’s inability to adapt to the ever-changing digital space and fully exploit the value expected from digital transformation may have an adverse impact on its competitive edge, market share and profitability, and may prevent the Group from reaching its medium and long-term financial targets.

Risk: Exposure to product contamination.

Description

The Group may experience product contamination, whether by accident or deliberate malicious intent, during supply chain or manufacturing processes, or may otherwise fail to comply with the Group’s quality standards. The Group may also receive threats of malicious tampering.

Impact

Product contamination or threats of contamination may expose the Group to significant costs associated with recalling products from the market or temporarily ceasing production. In addition, adult tobacco consumers may lose confidence in the specific brand affected by the contamination, resulting in reputational damage and a loss of sales volume and market share. The Group could be subject to liability and costs associated with civil and criminal actions as well as regulatory sanctions brought in connection with a contamination of the Group’s products. Each of these results may in turn have an adverse effect on the Group’s results of operations, financial condition and reputation and cause the Group to fail to deliver on its strategic growth plans.
### Group Risk Factors

#### Business Execution and Supply Chain Risks

**Risk: Inability to obtain adequate supplies of tobacco leaf.**

**Description**

The Group purchases significant volumes of packed leaf each year. Tobacco leaf supplies are impacted by a variety of factors, including weather conditions, drought, flood and other natural disasters, growing conditions, diseases causing crop failure, climate change and local planting decisions. Tobacco production in certain countries is also subject to a variety of controls, including regulation affecting farming and production control programmes, and competition for land use from other agriculture products. Such controls and competition can further constrain the production of tobacco leaf, raising prices and reducing supply.

Human rights issues may arise in connection with our tobacco leaf supply chain. Due to the large number of casual and temporary workers, the use of family labour in small-scale farming and high levels of rural poverty, the agricultural sector as a whole is vulnerable to human rights issues. The Group recognises that child labour is a risk to our tobacco leaf supply chain. The aforementioned issues could also threaten the next generation of farmers as young people move away from the rural areas to the cities.

**Impact**

Restricted availability of tobacco leaf may impact the quality of the Group’s products to a level that may prevent the Group accessing sufficient tobacco leaf that meets volume, quality and the Group’s ESG compliance impacting the Group’s ability to deliver on consumer needs. Accordingly, the reduction of tobacco leaf supply may impact supply and demand of the Group’s products and have a negative impact on results of operations. The Group’s commitment to ESG may result in higher tobacco leaf prices. Higher tobacco leaf prices may also increase the Group’s costs for raw materials and have an adverse effect on its results of operations and financial condition. The Group may also experience reputation damage from failing to manage human rights issues in our leaf supply chain, which may impact availability of suppliers willing to do business with us.

**Risk: Failure to successfully design, implement and sustain an integrated operating model.**

**Description**

The Group aims to improve profitability and productivity through supply chain improvements and the implementation of an integrated operating model and organisational structure, including standardisation of processes, centralised back-office services and a common IT platform. The Group undertakes transformation initiatives periodically which aim to simplify the organisation and facilitate growth. The Group’s efforts to achieve these goals are driven and enabled through use of our TaO (central SAP ERP system) global template – a standardised process used by all BAT entities globally with the use of a central SAP instance common for BAT subsidiaries (excluding Reynolds American Inc. and its subsidiaries). These processes include, among others, core back-office global processes, procurement, warehouse management, accounting and controlling.

**Impact**

Failure by the Group to successfully design, implement and sustain the integrated operating model, organisational structure and transformation initiatives could lead to the failure to realise anticipated benefits, increased costs, disruption to operations, decreased trading performance, disgruntled employees, loss of institutional knowledge and reduced market share. These results could in turn reduce profitability and funds available for investment by the Group in long-term growth opportunities. Lack of adherence to the TaO template, as well as template degradation over time, may result in the failure to maintain achieved productivity gains and capture additional productivity gains which may in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

**Risk: Failure to uphold the high standard of ESG management.**

**Description**

Stakeholder expectations of Group’s ESG performance are continually evolving. The Group may fail to have the appropriate internal standards, strategic plans and governance, monitoring and reporting mechanisms in place to ensure it can identify emerging issues, meet external expectations and align with recognised international standards.

**Impact**

Failure to uphold high standards of ESG management or provide transparent and consistent reporting could seriously impact Group reputation and reduce investor confidence. In addition, poor performance across any aspect of ESG, such as a failure to address climate change or human rights impacts across the Group’s business and supply chain, could result in increased regulation, difficulty in attracting and retaining talent, criminal or civil prosecution, or decreases in consumer demand for our products. As well as resulting in our failure to deliver our ESG targets.
Risk: Failure to manage the Group’s climate change risk

Description
The Group is currently exposed to violent weather conditions or other natural disasters in locations across the Group, further climate changes may lead to acute risks such as more frequent and severe weather events or chronic risks such as events relating to longer-term shifts in climate patterns and higher temperatures, which, among other things, could lead to reductions in the supply and quality of tobacco leaf and other supplies and cause other disruptions in our supply chains.

The Group will also experience transitional risks associated to low carbon economy. The TCFD was introduced by the Financial Sustainability Board (FSB) for companies, investors and other financial stakeholders to disclose climate-related financial risk. As climate change legislation is evolving rapidly, companies are required to adapt quickly to identify, assess, monitor and mitigate climate change related transitional risks, failure to adapt could lead to BAT scoring lower in sustainability benchmarking indices, such as CDP and DJSI.

As consumer behaviours and expectations evolve, the Group may fail to adapt its product portfolio and marketing strategy in response to stakeholders’ increasing environmental expectations. Factors such as emerging climate-change, product sustainability and circularity related aspects of the products may result in the potential rejection of the Group’s products as well as reputational risk in relation to business performance and sustainability in comparison to peers.

Impact
Any disruption to the Group’s supply chain (including agricultural supply chain) and distribution channels could have an adverse effect on the results of operations and financial conditions of the Group through failures to meet shipment demand, contract disputes, increased costs, reduced production capacity and loss of market share.

Consumer behaviours and expectations related to environmental issues and the Group’s sustainability credentials are rapidly starting to influence their purchasing choices which may lead to consumers seeking alternative sustainable products. The inability to timely develop and roll out sustainable innovations or products in line with consumer demand, including any failure to predict changes in consumer and societal behaviour and expectations and to fill gaps in the product portfolio, as well as the risk of poor product quality, could lead to missed opportunities, under- or over-supply, loss of competitive advantage, loss of market share, unrecoverable costs and/or the erosion of the Group’s consumer base or brand equity. There are also further financial implications from having to fund Extended Producer Responsibility schemes.

Lower ESG rating by investors, investor-owned platforms or other commonly used indices (e.g. CDP, DJSI) may impact perceived business resilience, sustainability and share price. Investors are becoming increasingly interested in the environmental sustainability of listed companies and their resilience in overall ESG matters is influencing their investment decisions.

Employees are also becoming increasingly aware of the climate change impact and have higher expectations of the effect that the Group has on the environment which has bearings on employee retention and the Group’s attractiveness to future employees.

Non-compliance with the TCFD could reduce BAT’s ability to attract investors and result in reputational damage and potentially other sanctions.

Description
The Group continues to closely monitor the development and disruption of the present coronavirus (the “COVID-19 pandemic”) and current and further waves seen in some countries across the Group. The consequences of COVID-19 may include significant logistical challenges for staff and their ability to perform their duties, potential loss of lives or significant level of illness in the workforce, inability to deliver revenue stream and market share targets impacting profits and cash flows, disruption to supply chain and third parties unable to deliver contractual goods and services. In addition, some countries in which the Group operates have adopted regulations restricting the ability to manufacture, distribute, market and sell products.

Impact

The COVID-19 pandemic’s impact on the Group’s results of operations and financial condition is uncertain and cannot be predicted as the pandemic evolves. The long-term impacts of the COVID-19 pandemic to the Group’s business will depend on a range of factors which we are not able to accurately predict, including the duration and scope of the pandemic, the geographies impacted, the impact of the pandemic on economic activity and the nature and severity of measures adopted by governments. These factors include, but are not limited to:

- Reductions or volatility in consumer demand for one or more of our products due to illness, retail closures, quarantine or other travel restrictions, health consciousness (quitting use of tobacco and nicotine products), government restrictions, the deterioration of socio-economic conditions, economic hardship and consumer-downtrading (switching to a cheaper brand), which may impact the Group’s market share.
- Disruptions to the Group’s operations, such as its supply chain, or manufacturing or distribution capabilities, which may result in increased costs due to the need for more complex supply chain arrangements, to expand existing facilities or to maintain inefficient facilities, a reduction of the Group’s sales volumes or an increase in bad debts from customers.
- Disruption to the Group’s operations resulting from a significant number of the Group’s employees, including employees performing key functions, working remotely for extended periods of time or becoming ill, which may reduce the employees’ efficiency and productivity and cause product development delays, hamper new product innovation and have other adverse effects on the Group’s business.
- Significant volatility in financial markets (including exchange rate volatility) and measures adopted by governments and central banks that further restrict liquidity, which may limit the Group’s access to funds, lead to shortages of cash and cash equivalents needed to operate the Group’s business, and impact the Group’s ability to refinance its existing debt.
- Regulations restricting the ability to manufacture, distribute, market and sell products, and potentially increasing illicit trade.
- Governments seeking to increase revenues through increased corporate taxes and excise in combustible and/or New Category products, increasing the cost and prices of our products – which could reduce volumes and margins, and/or increase illicit trade.

All of these factors may have material adverse effects on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

324
Legal, Regulatory and Compliance Risks

Risk: Exposure to, the enactment of, proposals for, or rumours of regulation that significantly impairs the Group’s ability to communicate, differentiate, market or launch its products and/or the lack of appropriate regulation for New Categories.

Description

Tobacco control measures are in place in nearly all markets in which we operate and specific regulations for non-tobacco nicotine products and Beyond Nicotine products (including CBD) are gaining momentum. Such restrictions are introduced by legislation, regulations and/or voluntary agreements. Most tobacco and nicotine control measures can be categorised as follows:

- Category Bans: including regulations that ban the sale, import, possession, or use of certain product categories, entirely (e.g. New Categories);
- Place: including regulations restricting consumption in private and public spaces (e.g. public place smoking or vaping bans, including restaurants and bars);
- Product: including regulations on the use of or testing for ingredients, product design and attributes (e.g. tar/ nicotine / carbon monoxide ceilings) /flavours bans (including menthol); product safety (e.g. reduced cigarette ignition propensity standards); product disclosure (e.g. ingredients and emissions) and environmental impact (e.g. Extended Producer Responsibility (EPR) requirements for cigarette filters);
- Packaging and labelling: including regulations on health warnings and other government-mandated messages; restrictions on the use of certain descriptors and brand names; requirements on pack shape, size, weight and colour; and mandatory plain packaging;
- Advertising, promotion and sponsorship: including partial or total bans on advertising, promotions and sponsorship, and online and direct engagement communication;
- Purchase: including regulations on where the products are sold, such as type of outlet (e.g. supermarkets and vending machines), radius or distance restrictions (e.g. 300 meters from a school), online sales bans, regulation regarding how they are sold and displayed (e.g. above the counter or under the counter) and minimum purchase age and increases thereof; and
- Price: including regulations that have implications on prices and margins (e.g. excise taxes, minimum prices and import/export duties).

The Group believes that further tobacco control and nicotine regulation is expected over the medium term in many of the Group’s markets. Irresponsible behaviour or marketing practices of competitors (for example where there is a lack of appropriate regulation) or actions contrary to the regulations in certain markets, may cause reputational harm to the industry as a whole and may result in additional regulation or bans. Further, there is pressure on governments from international organisations and agencies, tobacco control NGOs, vanguard regulators and the private sector (including philanthropists, pharmaceutical and security technology companies and social justice groups) to pursue regulatory policies and implement tobacco or nicotine product-related regulation which is not science or evidence based and is aimed at increasing the complexity and cost burden on the tobacco or nicotine industry, limiting the commercial viability of tobacco and nicotine products or prohibiting the products completely. Regulators may be lacking in understanding of New Categories products and their role in tobacco harm reduction due to their novelty. These factors can lead to a lack of adequate or existing regulatory regimes or clear and appropriate product classifications.

In addition, the Group may fail to implement the right level of control measures or to maintain adequate standards of compliance with regulatory measures. For example, the Group’s marketing activities may fail to comply with the relevant law and regulations or with the Group’s International Marketing Principles.

Insufficient information, instruction and training in the relevant areas and a lack of knowledge of the existence and/or requirements of relevant regulations including tobacoo and/or nicotine product-related regulation which is not science or evidence based and is aimed at increasing the complexity and cost burden on the tobacco or nicotine industry, limiting the commercial viability of tobacco and nicotine products or prohibiting the products completely. Regulators may be lacking in understanding of New Categories products and their role in tobacco harm reduction due to their novelty. These factors can lead to a lack of adequate or existing regulatory regimes or clear and appropriate product classifications.

There may also be negative and disproportionate societal responses to consumer abuse or misuse of tobacco and/or nicotine products (e.g. in New Categories) or to certain categories of products.

Traditional Tobacco Products

With respect to tobacco and combustible products, many of the measures outlined in the FCTC have been or are in the process of being implemented through national legislation in many markets in which the Group operates, including recommendations for plain packaging and flavour bans (e.g. menthol bans – in effect in the European Union since 20 May 2020). In April 2021, the U.S. Food and Drug Administration (“FDA”) announced that it will issue proposed product standards to ban menthol as a characterising flavour in cigarettes in the U.S. In December 2021, a regulatory agenda released in the U.S. confirmed the FDA’s plans to publish a Notice of Proposed Rulemaking for a menthol cigarette ban in April 2022. Further, various national or international regulatory regimes may seek to require the reduction of nicotine levels in tobacco products.

In March 2018, the FDA published its Advanced Notice of Proposed Rulemaking titled “Tobacco Product Standard for Nicotine Level of Lumber Cigarettes” and invited interested parties to submit comments on, among other issues, maximum nicotine limits and whether any maximum nicotine level should apply to combustible tobacco products. In October 2019, the FDA withdrew the Advanced Notice of Proposed Rulemaking without explanation.

In the U.S., manufacturers of all tobacco products deemed to be under the authority of the FDA as of 2016 (which includes vapour and Modern Oral products that contain or can be used with tobacco-derived nicotine) must submit information to the FDA seeking formal marketing authorisation of such products.

In 2021, New Zealand published its Smokefree 2025 Action Plan, considering the implementation of drastic measures, such as a ban on tobacco sales to those born after a certain date and very low nicotine cigarettes.

Finally, the FCTC COP10 and the EU Tobacco Product Directive 2, post-implementation review which is currently ongoing, are likely to result in calls for further regulation for tobacco products.
Other Information

Group Risk Factors

Continued

Legal, Regulatory and Compliance Risks

Continued

Risk: Exposure to, the enactment of, proposals for, or rumours of regulation that significantly impairs the Group's ability to communicate, differentiate, market or launch its products and/or the lack of appropriate regulation for New Categories. continued.

New Categories

With respect to New Categories, regulation is still evolving and frameworks for regulation and taxation vary from country to country. Some regulators have applied or are considering applying combustible tobacco products' restrictive regulatory framework to New Categories. Some jurisdictions have banned or are considering banning certain New Category products altogether.

Following reports of individuals experiencing acute respiratory injury in suspected association with vaping certain e-liquids (EVALI) and reports regarding vaping youth usage in the U.S., stricter regulatory views gained momentum and were publicly supported by the World Health Organization (WHO) which continues to call on countries to ban or regulate novel nicotine products as tobacco. The U.S., the EU and Canada are playing a leading role across all identified regulatory risks, including: bans on flavours, sales channel bans, advertising restrictions and nicotine limits, among others.

The U.S. is expected to issue additional decisions on the marketing authorisation of BAT and competitor vapour products in the near-term, which could result in further restrictions on our ability to offer flavoured vapour products, including menthol.

The FDA granted marketing authorisation for the Vuse Solo device and its tobacco (“original”) flavour in October 2021, but denied authorisation for Vuse Solo flavours other than menthol (which were not on the market). That denial is being appealed with the FDA. The FDA has not issued a decision on the authorisation of the Vuse Solo menthol flavour, which remains on the market pending FDA decision. There can be no assurance that the Vuse Solo menthol authorisation will be granted, or that the other flavours appeal will succeed. Additionally, the continued marketing authorisation of Vuse Solo original flavour is contingent on continued compliance with regulatory requirements; the marketing authorisation may be suspended or withdrawn if the FDA determines that the continued marketing of the product is no longer appropriate for the protection of the public health. The FDA has not issued marketing authorisations for Vuse Alto and its associated flavours, including menthol, with FDA decisions still pending. Although the Vuse Alto menthol and tobacco flavoured products remain on the market pending FDA decisions there can be no assurance that these authorisations (or the other Vuse Alto flavours) will be granted. Similarly, the Group’s Velo products remain on the market in the U.S., again pending FDA decisions on their marketing authorisations, and there can be no assurance these will be granted. If the FDA denies a marketing authorisation then the relevant product(s) would need to be withdrawn from the market (unless a court intervenes or the FDA).

With respect to Modern Oral and other New Categories, regulatory frameworks currently follow divergent approaches. In certain markets, where there is an absence of adequate regulation, actions of irresponsible competitors may cause reputational harm to the category and result in outright bans or adverse regulation, as has been the case with Modern Oral in Russia with allegations regarding youth usage. In markets where there is a likelihood of tobacco, pharmaceutical or food regulatory classification, the category can be at risk of severe regulation or total ban.

The Group believes that Tobacco Heated Products are likely to be regulated as traditional tobacco products, driven by the decision of WHO’s 7th Conference of Parties to the Framework Convention on Tobacco Control, and Reports from the WHO submitted to the COP9 for Noting, to apply tobacco control regulations to these products including recommendations for plain packaging and flavour bans.

Beyond Nicotine

As the Group also looks to Beyond Nicotine products including CBD (in connection with its investment in Organigram), it may be subject to additional regulation and these products might not be scalable on a global basis given varying degrees of regulation.

Please refer to pages 340 to 344 for details of tobacco and nicotine regulatory regimes under which the Group’s businesses operate.
Risk: Exposure to, the enactment of, proposals for, or rumours of regulation that significantly impairs the Group’s ability to communicate, differentiate, market or launch its products and/or the lack of appropriate regulation for New Categories, continued.

Impact

Existing and future regulatory measures impacting one or more New Categories and/or Beyond Nicotine traditional tobacco products could adversely affect volume, revenue and profits, as a result of: restrictions on the Group’s ability to sell and differentiate its products or brands, leverage price, innovate, make scientific claims, compete in future product categories and make new market entries; regulations (e.g. pharma or food) or total bans of tobacco and/or New Categories products in certain markets; reduced margins due to increased operating costs; impediments to building or maintaining brand equity; and restrictions on the Group’s ability to deliver, market and sell existing or new products responding to consumers’ preferences. In addition, new (and changes to existing) regulation could lead to greater complexity, as well as higher production and compliance costs.

As an example, through the acquisition of Reynolds American Inc., the Group acquired the Newport brand, the leading menthol cigarette brand in the U.S., the Group’s largest single market. The sales of Newport, together with the other menthol brands of the Group’s operating subsidiaries, represent a significant portion of the Group’s total net sales. Any action by the FDA or any other governmental authority banning or materially restricting the use of menthol in tobacco products could have a significant negative impact on sales volumes which would, in turn, have an adverse effect on the results of operations and financial position of the Group.

Regulations can also have an adverse impact on the Group’s ability to compete within the legitimate tobacco, nicotine or New Categories industry and with illicit traders or legal operators exploiting legal and regulatory loopholes. Regulations could also lead to reduced consumer acceptability of new product specifications, leading to consumers seeking alternatives in illicit markets.

Unclear or inadequate regulations can lead to legal uncertainty, impacting the Group’s position in the marketplace.

In the specific case of New Categories, our corporate harm reduction ambition, including of revenue of £5 billion by 2025 and 50 million New Categories consumers of non-combustible products by 2030 could be at risk if stricter regulatory views are imposed at a global scale, or if appropriate regulation is lacking or there is a lack of acceptance of tobacco harm reduction as a tobacco control policy (preventing a balanced regulatory framework for New Categories). Any action by the FDA or any government authority restricting the use of New Category products could also have an adverse effect on the operation and financial position of the Group and the possible failure of the Group’s harm reduction objective and loss of confidence in the Group’s ESG performance.

As a reflection of the real or perceived impact of stricter regulation in our business, the Group’s share price has also experienced, and could in the future experience, shocks upon the announcement, rumour of or enactment of restrictive regulation. All these effects may have an adverse effect on the Group’s results of operations and financial conditions and cause the Group to fail to deliver on its strategic growth plans.

In addition, considering the significant number of regulations that may apply to the Group’s businesses across the world, the Group is and may in the future be subject to claims for breach of such regulations. Government authorities (such as the FDA), organisations or even individuals may allege that our marketing activities do not comply with the relevant laws and regulations, or with our International Marketing Principles. As such, the Group could be subject to liability and costs associated with civil and criminal actions as well as regulatory sanctions, fines and penalties brought in connection with these allegations. Even when proven untrue, there are often financial costs and reputational impacts in defending against such claims and allegations (including potential adverse impact on the treatment by the FDA of the Group’s PMTAs in the U.S.). Each of these results may in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.
Legal, Regulatory and Compliance Risks Continued

Risk: Adverse implications of EU legislation on single-use plastics that will result in on-pack environmental warnings and financial implications relating to the Extended Producer Responsibility (EPR).

**Description**

The EU adopted a Directive on single-use plastics in July 2019 which, among other products, targets tobacco products with filters containing plastic. The Cellulose Acetate in our filters is defined as a single-use plastic under the Directive and, as such, the Directive will have an impact on the Group’s cigarettes, filters for other tobacco products and consumables for THPs.

Under the Directive, the Group will be subject to (and in some cases already is subject to) Extended Producer Responsibility (“EPR”) schemes, requiring the Group to cover the costs of collecting, transporting, treating and cleaning-up of filters containing plastic. The Directive also imposes on tobacco manufacturers the obligation to finance consumer awareness campaigns and to place environmental markings on packs of products with filters containing plastic.

Prior to the anticipated implementation deadline for EPR schemes on 5 January 2023, the European Commission is expected to issue guidelines on the criteria for the costs of cleaning up litter in the first half of 2022. In addition, in December 2020 the European Commission adopted and published an implementing Act harmonising specifications for required product markings with a compliance deadline of July 2021. When transposing the Directive into national law, EU member states could decide to expand the scope of EPR systems under their respective national laws, which may expose the Group to additional regulations and financial obligations. This is the case in France, where EPR implementation has already occurred with an expansion of the scope to include non-plastic filters for RYO products. Although Sweden’s government has abandoned plans to extend its national EPR system to Snus and modern oral pouches, other markets are still at risk of extension, such as in Spain (tobacco manufacturers would be mandated to financially contribute to the cost of cleaning of parts of the general sewage system), the Czech Republic (tobacco manufacturers would be mandated to contribute to the cost of managing household waste costs), and Poland and Romania (manufacturers’ financial contribution would also cover paper filters, although they are not plastic items). Proposed regulations are still being discussed in these countries.

It is noted that there is a growing level of scrutiny on the use of single-use plastic across the world and a number of other markets in which the Group operates are considering ways to restrict (or ban) the use of filters made of plastic and/or introduce EPR schemes covering other plastic elements in our products beyond filters for traditional products and/or New Categories products.

**Impact**

The financial implications of existing and future EPR schemes will increase administrative burdens and operating costs and may have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans. If significant space is appropriated on the packaging of some of the Group’s products, this may also be an impediment to maintaining or building brand equity of the Group’s products which may, in turn, have a negative impact on the Group’s sales volume.

Risk: Exposure to litigation on tobacco, nicotine, New Categories and other issues.

**Description**

The Group is involved in litigation related to its tobacco and nicotine products, including legal, regulatory and patent actions, proceedings and claims, brought against it in a number of jurisdictions. Claims brought against the Group may be based on personal injury (both individual claims and class actions), economic loss arising from the treatment of smoking and health-related diseases (such as medical recoupment claims brought by local governments), patent infringement (please refer to the risk factor under “Product pipeline, commercialisation and Intellectual Property risks, Exposure to risks associated with intellectual property rights, including the failure to identify, protect and prevent infringement of the Group’s intellectual property rights and potential infringement of, or the failure to retain licences to use, third-party intellectual property rights” below), negligence, strict tort liability, design defect, failure to warn, fraud, misrepresentation, deceptive/unfair trade practices, conspiracy, medical monitoring and violations of antitrust/racketeering laws.

Certain actions, such as those in the U.S. and Canada, involve claims in the tens or hundreds of billions of pounds sterling. The Group is also involved in proceedings that are not directly related to its tobacco and nicotine products, including proceedings based on environmental pollution claims.

Additional legal and regulatory actions, proceedings and claims may be brought against the Group in the future.

328
Risk: Exposure to litigation on tobacco, nicotine, New Categories and other issues continued.

Impact
The Group’s consolidated results of operations and financial position could be materially affected by any unfavourable outcome of certain pending or future litigation. The Group could be exposed to substantial liability, which may take the form of ongoing payments. Whether successful or not, the costs of the Group’s involvement in litigation could materially increase due to costs associated with bringing proceedings and defending claims, which may also cause operational and strategic disruption by diverting management time away from business matters. Liabilities and costs in connection with litigation could result in bankruptcy of one or more Group entities, which, in turn, could cause a material reduction in the Group’s sales volume and profits. Any negative publicity resulting from these claims may also adversely affect the Group’s reputation.

The occurrence of any of the above effects could in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.

Risk: Significant and/or unexpected increases or structural changes in tobacco and nicotine-related taxes.

Description
Tobacco and nicotine products are subject to high levels of taxation, including excise taxes, sales taxes, import duties and levies in most markets in which the Group operates. In many of these markets, taxes are generally increasing, but the rate of increase varies between markets and between different types of tobacco and nicotine products. Increases in, or the introduction of new, tobacco and nicotine-related taxes may be caused by a number of factors, including fiscal pressures, health policy objectives and increased lobbying pressure from anti-tobacco advocates.

With respect to New Categories, although a common framework for regulation and taxation has yet to emerge, the manufacture, sale, packaging and advertising of such products are increasingly being regulated and taxed.

Impact
Significant or unexpected increases in, or the introduction of new, tobacco-related taxes or minimum retail selling prices, changes in relative tax rates for different tobacco and nicotine products or adjustments to excise have in the past resulted, and may in the future result in, the need for the Group to absorb such tax increases due to limits in its ability to increase prices, an alteration in the sales mix in favour of value-for-money brands or products, or growth in illicit trade, each of which could impact pricing, sales volume and profit for the Group’s products. Significant or unexpected increases of tobacco-related taxes could also impact BAT’s ability to deliver the corporate purpose of harm reduction.

Risk: Failure to comply with health and safety and environmental laws.

Description
The Group is subject to a variety of laws, regulations and operational standards relating to health and safety and the environment.

The Group may fail to assess certain risks and implement the right level of control measures or to maintain adequate standards of health and safety or environmental compliance, which could cause injury, ill health, disability or loss of life to employees, contractors or members of the public, or harm to the natural environment and local communities in which the Group operates. As a result of the outcomes of the recent COP26, further future regulation is anticipated as governments look to meet their climate change ambitions.

Insufficient information, instruction and training in the relevant areas and a lack of knowledge of the existence and/or requirements of relevant regulations, or a failure to monitor, assess and implement the requirements of new or modified legislation, may increase these risks.

Impact
Any failure by the Group to comply with applicable health and safety or environmental laws, or the exposure to the consequences of a perceived failure, could result in business disruption, reputational damage, difficulties in recruiting and retaining staff, increased insurance costs, consequential losses, the obligation to install or upgrade costly pollution control equipment, loss of value of the Group’s assets, remedial costs and damages, fines and penalties as well as civil or criminal liability. Each of these results could in turn adversely impact the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.
Legal, Regulatory and Compliance Risks Continued

Risk: Exposure to unfavourable tax rulings.

Description
The Group is subject to tax laws in a variety of jurisdictions. The Group's interpretation and application of the tax laws could differ from those of the relevant tax authority, which may subject the Group to claims for breach of such laws, including for late or incorrect filings or for misinterpretation of rules. Tax authorities in a variety of jurisdictions, such as the Netherlands and Russia, have assessed, and may in the future assess, the Group for historical tax claims, including interest and penalties, arising from disputed areas of tax law. The Group is currently party to tax disputes in a number of jurisdictions, some of which involve claims for amounts in the hundreds of millions of pounds sterling.

Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.

Impact
The Group's failure to comply with the relevant tax authority's interpretation and application of the tax laws could result in significant financial and legal penalties, including the payment of additional taxes, fines and interest in the event of an unfavourable ruling by a tax authority in a disputed area, as well as the payment of dispute costs. Disruption to the business could occur as a result of management's time being diverted away from business matters. Each of these results could negatively affect the Group's results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

Risk: Unexpected legislative changes to corporate income tax laws.

Description
The Group is subject to corporate income tax laws in the jurisdictions in which it operates. These laws frequently change on a prospective or retroactive basis.

Impact
Legislative changes to corporate income tax laws and regulations may have an adverse impact on the Group's corporate income tax liabilities and may lead to a material increase of the Group's overall tax rate. This could, in turn, negatively affect the Group's results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

Risk: Exposure to potential liability under competition or antitrust laws.

Description
According to the Group's internal estimates, the Group is a market leader by volume and/or value in certain categories in a number of countries in which it operates and/or is one of a small number of tobacco and/or New Categories companies in certain other markets in which it operates. The Group has had antitrust infringement decisions against it in the past and is subject to ongoing investigations (please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group). The Group may fail to comply with competition or antitrust laws and may be subject to investigation and/or litigation for alleged abuse of its position in markets in which it has significant market share or for alleged collusion/anti-competitive arrangements with other market participants. Competition / antitrust laws continue to evolve globally with increasingly aggressive enforcement.

Impact
Failure by the Group to comply with competition or antitrust laws and investigations (and/or litigation) for violation of such laws may result in significant legal liability, fines, penalties and/or damages actions; criminal sanctions against the Group, its officers and employees; increased costs, prohibitions on conduct of the Group's business; forced changes in business practices, forced divestment of brands and businesses (or parts of businesses) to competitors or other buyers; director disqualifications; commercial agreements being held void; and operational and strategic disruption (including by diverting management time away from business matters). The Group may face increased public scrutiny and the investigation or imposition of sanctions by antitrust regulation agencies and/or courts for violations of competition regimes which may subject the Group to reputational damage and loss of goodwill, including negative perceptions of the Group's governance and our ESG credentials.

The occurrence of any of the above effects could in turn have an adverse effect on the Group's results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.
Risk: Failure to establish and maintain adequate controls and procedures to comply with applicable securities, corporate governance and compliance regulations.

Description
The Group’s operations are subject to a range of rules and regulations around the world. These include U.S. securities, corporate governance and compliance laws and regulations such as the Sarbanes-Oxley Act of 2002 and the U.S. Foreign Corrupt Practices Act of 1977, which applies to the Group’s worldwide activities. While the Group continuously seeks to improve its systems of internal controls and to remedy any weaknesses identified, there can be no assurance that the policies and procedures will be followed at all times or effectively detect and prevent violations of applicable laws. In addition, the Group is subject to increasingly stringent reporting obligations under UK corporate reporting regulations.

Impact
The increased scope and complexity of applicable regulations to which the Group is subject may lead to higher costs for compliance. Failure to comply with laws and regulations may result in significant legal liability, fines, penalties, and/or damages actions, criminal sanctions against the Group, its officers and employees, and damage to the Group’s reputation. Non-compliance with such regulations could also lead to a loss of the Group’s listing on one or more stock exchanges or a loss of investor confidence with a subsequent reduction in share price.

Risk: Loss of confidential information, including through manipulation of data by employees and system failure.

Description
Unintended or inappropriate behaviour by employees, contractors, service providers and others using or managing the Group’s confidential information especially given the increased use of third parties (including sensitive or confidential information of third parties) or personal data (including sensitive consumer personal data) may affect the Group’s communications and operations which may result in the unauthorised disclosure of such information. Increased remote working has and may increase this risk.

In addition, flaws in our IT systems and/or those of our suppliers, a lack of infrastructure or application resilience, slow or insufficient disaster recovery service levels or the installation of new systems may increase the possibility that data, including confidential, personal or other sensitive information, stored or communicated by IT systems may be corrupted, lost or disclosed. There may be malicious ‘bad actor’ activity (e.g. cyber attack) or ‘insider threat’ (e.g. activists or disgruntled employees).

Impact
The loss of confidential information may result in civil or criminal legal liability and prosecution by enforcement bodies and/or claims from third parties, which may subject the Group to the imposition of material fines, damages and/or penalties and the costs associated with defending these claims. It could also lead to a competitive disadvantage through the loss of trade secrets. There could also be potential exposure from extortion attempts and costs from business continuity situations.

Inappropriate disclosure of confidential information or violation of the GDPR or other privacy laws (please refer to the risk factor under “Loss or misuse of personal data through a failure to comply with the European General Data Protection Regulation, the UK Data Protection Act 2018, e-Privacy Laws and other privacy legislation governing the processing of personal data” below) may also result in significant reputational harm and public scrutiny which could create negative perceptions of the Group’s governance and our ESG credentials, a loss of investor confidence (including a possible share price impact) and reduced third-party reliance on the Group’s information technology systems or other data handling practices. In addition, restoration and remediation of disclosed confidential information or personal data may be costly, difficult or even impossible. The occurrence of any of the above effects could in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.
Legal, Regulatory and Compliance Risks  Continued

Risk: Failure to comply with product regulations due to uncertainty surrounding the proper interpretation and application of those regulations.

**Description**

The interpretation and application of regulations concerning the Group’s products, such as the Tobacco and Related Products Directive (TPD2), may be subject to debate and uncertainty. This includes uncertainty over product classifications and restrictions on advertising. In particular with respect to the developing category of New Categories, which has grown in size and complexity in a relatively short period of time, a consensus framework for the interpretation and application of existing regulation, such as the rules concerning nicotine-containing liquids used in vapour products, has yet to emerge.

The continuously changing and evolving landscape of regulation concerning the Group’s products contributes to the uncertainty surrounding interpretation and application and creates a risk that the Group may misinterpret or fail to comply with developing regulations in the various jurisdictions in which it operates, or becomes subject to enforcement actions from regulators. With the continuous changing of product cycle plans and expansion to new markets and innovations, there is a risk that such changes and launches fail to comply with the relevant regulations, including pre-approval and/or pre-registration requirements. For example, some governments have intentionally banned or are seeking to ban novel tobacco products and products containing nicotine, while others would need to amend their existing legislation to permit their sale. Even in countries where the sale of such products is currently permitted, some governments have adopted, or are seeking to adopt, bans on New Categories or restrictions on certain flavours.

**Impact**

The significant number of emerging regulations and the uncertainty surrounding their interpretation and application may subject the Group to claims for breach of such regulations. Financial costs of such enforcement actions include financial penalties, product recalls and litigation costs, and entail a significant risk of adverse publicity and damage to the Group’s reputation and goodwill.

Risk: Failure to uphold high standards of corporate behaviour, including through unintended or malicious breach of anti-bribery and anti-corruption and other anti-financial crime laws.

**Description**

The Group is subject to various anti-corruption laws and regulations and other anti-financial crime laws including but not limited to failure to prevent facilitation of tax evasion, money laundering and terrorist financing (Anti-Corruption Laws). All employees of BAT, its subsidiaries and joint ventures which it controls are expected to uphold a high standard of corporate behaviour and comply with the Group Standards of Business Conduct (SoBC) which includes a requirement to comply with Anti-Corruption Laws. Employees, associates, suppliers, distributors and agents are prohibited from engaging in improper conduct to obtain or retain business or to improperly influence (directly or indirectly) a person working in an official capacity to decide in the Group’s favour. The Group’s employees, contractors and service providers may fail to comply with our SoBC and/or may violate applicable Anti-Corruption Laws.

From time-to-time, the Group investigates, and becomes aware of governmental authorities’ investigations into, and allegations of misconduct against Group companies. The Group cooperates with the authorities’ investigations, where appropriate, including with the DOJ and OFAC in the United States, which are conducting an investigation into suspicions of breach of sanctions. Potential fines, penalties or other consequences cannot currently be assessed. As the investigations are ongoing, it is not possible to identify the timescale in which these matters might be resolved. Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.

**Impact**

Failure of the Group to comply with Anti-Corruption Laws or to deploy and maintain robust internal policies, procedures and controls could result in significant fines and penalties (reducing the Group’s ability to reinvest in the future), a share price impact, criminal and/or civil sanctions against the Group and its officers and employees, increased costs, prohibitions or other limitations or requirements (e.g. compliance requirements) on the conduct of the Group’s business and reputational harm (including negative perceptions of the Group’s governance and our ESG credentials), it may subject the Group to claims for breach of such regulations and it could in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans. Even when proven untrue, there are often financial costs, time demands and reputational impacts associated with investigating and defending against such claims.

332
Risk: Imposition of sanctions under sanctions regimes or similar international, regional or national measures.

Description

National, international and supra-national sanctions regimes or similar international, regional or national measures are complex and dynamic and may affect territories in which the Group operates or third parties with which it may have commercial relationships. There may be unintended or malicious breaches of sanctions due to inappropriate or negligent behaviour by BAT employees, contractors, customers, suppliers or service providers.

In particular, the Group has operations in a number of territories that are subject to various sanctions, including Cuba and Belarus. Operations in these territories expose the Group to the risk of significant financial costs and disruption in operations that may be difficult or impossible to predict or avoid or the activities could become commercially and/or operationally unviable. Sanctions can be imposed quickly (as happened recently in Belarus) with the possibility of further territories the Group operates in becoming subject to sanctions at short notice.

National, international and supra-national sanctions regimes may also affect third parties with which the Group has commercial relationships (including possible risk aversion to being associated with a sanctioned territory) and could lead to supply and payment chain disruptions.

From time-to-time, the Group investigates, and becomes aware of governmental authorities’ investigations into, allegations of misconduct against Group companies. The Group cooperates with the authorities’ investigations, where appropriate, including with the DOJ and OFAC in the United States, which are conducting an investigation into suspicions of breach of sanctions. Potential fines, penalties or other consequences cannot currently be assessed. As the investigations are ongoing, it is not possible to identify the timescale in which these matters might be resolved.

Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.

Impact

As a result of the limitations imposed by sanctions, it may become commercially and/or operationally unviable for the Group and/or its critical business partners to operate in certain territories or execute transactions related to them and the Group may be required to exit existing operations in such territories. The Group may also experience difficulty in sourcing materials or importing products, repatriating currency from a sanctioned country and finding financial institutions willing to transact with it, any of which may expose the Group to increased costs. In addition, the costs of complying with sanctions may increase as a result of new, or changes to existing, sanctions regimes.

Any failure to comply with sanctions regimes or similar international, regional, or national or supra-national measures may result in significant legal liability, fines (reducing the Group’s ability to reinvest in the future) and/or penalties, criminal and/or civil sanctions against the Group, its officers and employees, damage to commercial or banking relationships and reputational harm. Reputational harm (including negative perceptions of the Group’s governance and our ESG credentials) may result regardless of whether the Group complies with imposed sanctions.

The occurrence of any of the above effects could in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.
Other Information

Group Risk Factors

Legal, Regulatory and Compliance Risks

Risk: Loss or misuse of personal data through a failure to comply with the European General Data Protection Regulation, the UK Data Protection Act 2018, e-Privacy Laws and other privacy legislation governing the processing of personal data.

Description

Personal data is a subset of data (which is likely to be confidential) which attracts different risks and treatment under applicable law. Breaches of data privacy laws include misuse of information which may not be confidential in nature. These include, for example, unsolicited marketing calls to a publicly available number, or using an individual’s personal data in a way which was not authorised or in a way that the individual did not reasonably expect such technologies as online tracking or monitoring.

Various privacy laws, including the European General Data Protection Regulation (“GDPR”), UK Data Protection Act 2018 (“UKDPA”) and e-Privacy Directive (“e-Privacy Laws”) / EU Regulatory guidances, govern the way in which organisations (comprising employees, contractors, service providers and other authorised persons) handle individuals’ personal data including how such organisations, including the Group, track or monitor their online behaviour. Unintended or malicious breaches of data privacy laws may occur through inappropriate or negligent behaviour by BAT employees, contractors, service providers or others. In particular:

– in the event of:
  – an unauthorised disclosure of personal data as a result of a bad actor (e.g. cyber attack); or
  – flaws in our IT systems, or application resilience, slow or insufficient disaster recovery service levels or the installation failure of a new system (which result in personal data stored or communicated by IT systems being corrupted, lost or disclosed).
  – Depending on the risk to the individuals concerned, such personal data breaches (including mass personal data unavailability) must be reported to the local data protection supervisory authority which could subject Group companies to not only regulatory scrutiny but also individual claims or even class action suits; and
  – ePrivacy Laws state that any misuse of consumer personal data or lack of transparency provided to consumers on how we use their data or track their online behaviours are subject to regulatory scrutiny.

Legal requirements relating to the collection, storage, handling, and transfer of personal data continue to evolve. Following the entry into force of the GDPR in May 2018, other jurisdictions in which the Group operates have enacted similar local legislation such as the California Consumer Privacy Act U.S. and the “LGPD” in Brazil which further increases the risks surrounding the processing of personal data especially in the consumer space. As part of the Group’s digital transformation initiative, it has an enhanced focus on consumer data, especially regarding New Categories, which increases these risks.

Impact

Failure to comply with existing or future e-Privacy Laws and privacy legislation governing the processing of personal data may adversely impact the Group’s results of operations and financial condition.

Loss or misuse of personal data may result in civil or criminal legal liability and prosecution by enforcement bodies, which may subject the Group to the imposition of material fines (currently up to 4% of Group worldwide turnover in the context of GDPR) and/or penalties and/or claims and costs associated with defending these claims (which could include class action suits brought by consumers). The Group’s officers and employees may also be subject to personal criminal sanctions.

Reputational damage could also potentially cause significant harm to the Group, including negative perceptions of the Group’s governance and our ESG credentials.

Relevant data protection supervisory authority could also order certain Group legal entities to cease processing activities, which could result in a significant impact.

The occurrence of any of the above effects could in turn have an adverse effect on the Group’s results of operations and financial condition.

Risk: Failure to uphold New Categories marketing practices.

Description

The regulatory landscape is constantly evolving with marketing practices being different in key New Categories markets. The Group’s marketing activities may be alleged to be non-compliant laws and regulations, or with the International Marketing Principles (“IMPs”) on the marketing and sale of tobacco products to consumers such as age verification measures with allegations of this in the media. Online activities can also be wrongly considered to be aimed at consumers in a country where such activities are not permitted.

Impact

The Group is and may in the future be subject to claims for breach of marketing practices. In particular, national authorities (such as the FDA), organisations or even individuals may allege that our marketing activities do not comply with the relevant laws and regulations, or with our IMPS. As such, the Group could be subject to liability and costs as well as regulatory sanctions, fines and penalties brought in connection with these allegations. Even when proven untrue, there are often financial costs and reputational impacts in defending against such claims and allegations.

Future breaches may lead to a loss of investor confidence in ESG performance and inability to meet our responsible marketing focus area if our IMPS are not followed, impacting our corporate purpose of delivering harm reduction.
Economic and Financial Risks

**Risk: Foreign exchange rate exposures.**

**Description**

The Group’s reporting currency is the pound sterling. The Group is exposed to the risk of fluctuations in exchange rates affecting the translation of net assets and earned profits of overseas subsidiaries into the Group’s reporting currency. These translational exposures are not normally hedged.

Exposures also arise from the foreign currency denominated trading transactions undertaken by subsidiaries and dividend flows. Where not offset by opposing flows, these exposures are generally hedged according to internal policies, but hedging of exposure to certain currencies might not be possible due to exchange controls, limited currency availability or prohibitive costs, and errors in hedging may occur. Fiscal policy divergence in relation to interest rates between key markets may also increase these risks.

**Impact**

During periods of exchange rate volatility, the impact of exchange rates on the Group’s results of operations and financial condition can be significant. Fluctuations in exchange rates of key currencies against the pound sterling may result in volatility in the Group’s reported earnings per share, cash flow and balance sheet. Furthermore, the dividend paid by the Group may be impacted if the payout ratio is not adjusted. Differences in translation between earnings and net debt may also affect key ratios used by credit rating agencies, which may have an adverse effect on the Group’s credit ratings.

In addition, volatility and/or increased costs in the Group’s business due to transactional foreign exchange rate exposures may adversely affect operating margins and profitability and attempts to increase prices to offset such increases could adversely impact sales volumes.

**Risk: Inability to obtain price increases and exposure to risks from excessive price increases and value chain erosion.**

**Description**

Annual price increases by the Group are among the key drivers in increasing market profitability. However, the Group has in the past been, and may in the future be, unable to obtain such price increases as a result of increased regulation; increased competition from illicit trade; stretched consumer affordability arising from deteriorating political and economic conditions and rising prices; sharp increases or changes in excise structures; and competitors’ pricing.

As the New Category market continues to develop, the Group may face erosion in the value chain for New Categories through lower market prices, excise taxes, high retail trade margins or high production costs that make New Categories less competitive versus combustible tobacco products. As an example, excise on Tobacco Heated Products in Japan is increasing and will align closer to FMC following a five year (2018-2022) phased excise plan.

In addition, the Group faces the risk that price increases it has conducted in the past, and may conduct in the future, may be excessive and not find adequate adult tobacco consumer acceptance.

**Impact**

If the Group is unable to obtain price increases or is adversely affected by impacts of excessive price increases, it may be unable to achieve its strategic growth metrics, have fewer funds to invest in growth opportunities, and, in the case of excessive price increases, be faced with quicker reductions in sales volumes than anticipated due to accelerated market decline, down-trading (switching to a cheaper brand) and increased illicit trade. These in turn impact the Group’s market share, results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

In addition, erosion in the value chain for New Categories could have a negative impact on the Group’s sales volume or pricing for these products. High excise could dampen demand for New Categories or result in lower profit margins. Lower market prices, high retail trade margins or increases in production costs could also negatively impact profit margins or lead to uncompetitive pricing.
In addition, the Group’s ability to finance strategic opportunities or respond to threats may be impacted by limited access to funds, which may result in an erosion of shareholder value reflected in an underperforming share price, and/or underperforming bond prices and higher yields. In the case of funding or liquidity constraints, the Group may also suffer reputational damage due to its perceived failure to manage the financial risk profile of its strategic growth plans. These conditions could also lead to underperforming bond prices and increased yields. All these factors may have material adverse effects on the Group’s results of operations and financial conditions and cause the Group to fail to deliver on its strategy.

The Group is also exposed to increases in interest rates in connection with both existing floating rate debt and future debt refinancings. The current economic environment, with historically low interest rates, increases the likelihood of higher interest rates in the future. The phaseout of LIBOR and uncertainty regarding the appropriate benchmark replacement similarly increases uncertainty with respect to the interest rates applicable to the Group’s floating rate debt. Furthermore, broader ESG trends may impact the Group’s access to funding.

Any future decline in the demand for tobacco products could have an adverse effect on the Group’s results of operations and financial conditions and cause the Group to fail to deliver on its strategic growth plans. The phaseout of LIBOR may result in the Group being subject to higher or uncertain interest rates with respect to future floating rate debt. The Group may also require the use of new capital markets to refinance its existing debt. Inability to fund the business under the Group’s capital structure, failure to access funding and foreign exchange or increases in interest rates may also have an adverse effect on the Group’s credit rating, which would in turn result in further increased funding costs and may require the Group to issue equity or seek new sources of capital. Non-compliance with the Group’s covenants under certain credit facilities could lead to an acceleration of its debt. The phaseout of LIBOR may result in the Group being subject to higher or uncertain interest rates with respect to future floating rate debt. All these factors may have material adverse effects on the Group’s results of operations and financial conditions and cause the Group to fail to deliver on its strategic growth plans. These conditions could also lead to underperforming bond prices and increased yields.
Risk: Failure to achieve growth through mergers, acquisitions and joint ventures.

Description
The Group’s growth strategy includes a combination of organic growth as well as mergers, acquisitions and joint ventures. The Group may be unable to acquire attractive businesses on favourable terms and may inappropriately value or otherwise fail to identify or capitalise on growth opportunities. The Group may not be able to deliver strategic objectives and revenue improvements from business combinations, successfully integrate businesses it acquires or establishes, or obtain appropriate regulatory approvals for business combinations. Risks from integration of businesses also include the risk that the integration may divert the Group’s focus and resources from its other strategic goals. Additionally, the Group could be exposed to financial, legal or reputational risks if it fails to appropriately consider any compliance, antitrust or ESG aspects of a transaction. Further, the Group has certain uncapped indemnification obligations in connection with divestitures and could incur similar obligations in the future.

Impact
Any of the foregoing risks could result in increased costs, decreased revenues or a loss of opportunities and have an adverse effect on the Group’s results of operations and financial condition, and in the case of a breach of compliance or antitrust regulation, could lead to reputational damage, fines and potentially criminal sanctions. The Group may become liable for claims arising in respect of conduct prior to any merger or acquisition of businesses if deemed to be a successor to the liabilities of the acquired company or indemnification claims relating to divestitures, and any resulting adverse judgment against the Group may adversely affect its results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities applicable to the Group.

Risk: Unforeseen underperformance in key global markets.

Description
A substantial majority of the Group’s profit from operations is based on its operations in certain key markets, including the US. A number of these markets are declining for a variety of factors, including price increases, restrictions on advertising and promotions, smoking prevention campaigns, increased pressure from anti-tobacco groups, migration to smokeless products and private businesses adopting policies that prohibit or restrict, or are intended to discourage, smoking and tobacco use. Economic and political factors affecting the Group’s key markets include the prevailing economic climate, governmental austerity measures, levels of employment, inflation, governmental action to increase minimum wages, employment costs, interest rates, raw material costs, consumer confidence and consumer pricing.

Impact
Any change to the economic and political factors in any of the key markets in which the Group operates could affect consumer behaviour and have an impact on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

Risk: Increases in net liabilities under the Group’s retirement benefit schemes.

Description
The Group currently maintains and contributes to defined benefit pension plans and other post-retirement benefit plans that cover various categories of employees and retirees worldwide. The Group’s obligations to make contributions under these arrangements may increase in the case of increases in pension liabilities, decreases in asset returns, salary increases, inflation, decreases in long-term interest rates, increases in life expectancies, changes in population trends and other actuarial assumptions.

Impact
Higher contributions to the Group’s retirement benefit schemes could have an adverse impact on the Group’s results of operations, financial condition and ability to raise funds and cause the Group to fail to deliver on its strategic growth plans.
Product Pipeline, Commercialisation and Intellectual Property Risks

Risk: Inability to predict consumers’ changing behaviours and launch innovative products that offer adult tobacco and nicotine consumers meaningful value-added differentiation.

**Description**

The Group focuses its research and development activities on both creating new products, including New Category and Beyond Nicotine products, whilst maintaining and improving the quality of its existing products. In a competitive market, the Group believes that innovation is key to growth. The Group considers that one of its key challenges in the medium and long term is to provide adult tobacco and nicotine consumers with high-quality products that take into account their changing preferences and expectations, including those in relation to ESG, while complying with evolving regulation.

The Group continues to develop and roll-out its New Category portfolio which requires significant investment. The Group may be unsuccessful in developing and launching innovative products or maintaining and improving the quality of existing products across Combustibles, New Categories and Beyond Nicotine that offer consumers meaningful value-added differentiation. The Group may fail to keep pace with innovation in its sector or changes in consumer expectations and is also exposed to the risk of an inability to build a strong enough brand equity through social media and other technological tools to compete with its competitors. There are potential bans and restrictions in key markets when using social media to advertise and communicate. Competitors may be more successful in predicting changing consumer behaviour, developing and rolling out consumer-relevant products and may be able to do so more quickly and at a lower cost.

In addition, the Group devotes considerable resources to the research and development of innovative products that may have the potential to reduce the risks of smoking-related diseases. The complex nature of research and development programmes necessary to satisfy emerging regulatory and scientific requirements creates a substantial risk that these programmes will fail to demonstrate health-related claims regarding New Categories and Beyond Nicotine or to achieve adult tobacco consumer, regulatory and scientific acceptance.

Furthermore, the regulatory environment impacting non-combustible tobacco products, vapour products and other non-tobacco nicotine products and Beyond Nicotine, including classification of products for regulatory and excise purposes, is still developing and it cannot be predicted whether regulations will permit the marketing of such products in any given market in the future. Categorisation as medicines, for example, and restrictions on advertising could stifle innovation, increase complexity and costs and significantly undermine the commercial viability of these products.

Alternatively, categorisation of any New Categories, as tobacco products for instance, could result in the application of onerous regulation, which could further stifle uptake.

**Impact**

The inability to timely develop and roll out innovations or products in line with consumer demand, including any failure to predict changes in adult tobacco consumer and societal behaviour and expectations and to fill gaps in the product portfolio, as well as the risk of poor product quality, could lead to missed opportunities, under- or over-supply, loss of competitive advantage, unrecoverable costs and/or the erosion of the Group’s consumer base or brand equity.

Restrictions on packaging and labelling or on promotion and advertising could impact the Group’s ability to communicate its innovations and product differences to adult tobacco consumers, leading to unsuccessful product launches. An inability to provide robust scientific results sufficient to substantiate health-related product claims poses a significant threat to the ability to launch innovative products and comply with emerging regulatory and legal regimes.

The occurrence of any of the above effects could in turn have an adverse effect on the Group’s results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.

In addition, there may be loss of investors’ confidence in ESG performance, including failure to deliver our corporate purpose of harm reduction.
Risk: Exposure to risks associated with intellectual property rights, including the failure to identify, protect and prevent infringement of the Group's intellectual property rights and potential infringement of, or the failure to retain licences to use, third-party intellectual property rights.

Description
The Group relies on trademarks, patents, registered designs, copyrights, domain names and trade secrets. The brand names under which the Group's products are sold are key assets of its business. The protection and maintenance of these brand names and of the reputation of these brands is important to the Group’s success. Protection of intellectual property rights is also important in connection with the Group’s innovative products, including New Categories.

The Group is exposed to the risk of infringements of its intellectual property rights by third parties due to limitations in judicial protection, failure to identify, protect and register its innovations and/or inadequate enforceability of these rights in some markets in which the Group operates.

The Group currently is involved in various patent infringement litigation proceedings in several countries related to the Group’s New Category inventions and products. This litigation involves both claims by the Group that competitors are infringing the Group’s patents and claims by competitors that the Group is infringing competitors’ patents. Please refer to note 31 in the Notes on the Accounts for details of contingent liabilities relating to patent litigation applicable to the Group.

Some brands and trademarks under which the Group’s products are sold are licensed for a fixed period of time in certain markets. If any of these licences are terminated or not renewed after the end of the applicable term, the Group would no longer have the right to use, and to sell products under, those brand(s) and trademark(s).

In addition, as third party rights are not always identifiable, the Group may be subject to claims for infringement of third party intellectual property rights.

Impact
Any erosion in the value of the Group’s brands or innovations, or failure to obtain or maintain adequate protection of intellectual property rights for any reason, or the loss of brands, trademarks or other intellectual property rights under licence to Group companies, may have a material adverse effect on the Group’s market share, results of operations and financial condition. Any inability to appropriately protect the Group’s products and key innovations will also limit its growth and affect competitiveness and return on innovation investment.

Any infringement of third-party intellectual property rights could result in interim or final injunctions, product recalls, legal liability and the payment of damages, any of which may disrupt operations, negatively impact the Group’s reputation and have an adverse effect on its results of operations and financial condition and cause the Group to fail to deliver on its strategic growth plans.
Overview
The Group’s businesses operate under increasingly stringent regulatory regimes worldwide. The tobacco industry is one of the most highly regulated in the world, with manufacturers required to comply with a variety of different regulatory regimes across the globe. The Group continues to respond to these regimes and engages with governments and other regulatory bodies to find solutions to changing regulatory landscapes. Restrictions on the manufacture, sale, marketing and packaging of tobacco and non-tobacco nicotine products are in place in nearly all countries and markets.

Regulation can typically be categorised as follows:

Place: including regulations restricting smoking in private, public and work places (e.g. public place smoking bans);

Product: including regulations on the use of ingredients, product design and attributes (e.g. ceilings regarding tar, nicotine and carbon monoxide yields, as well as restrictions on flavours); product safety regulations (e.g. the EU’s General Product Safety Directive (2001/95/EC), electrical safety regulations and reduced ignition propensity standards for cigarettes); regulatory product disclosure requirements (e.g. in relation to ingredients and emissions); and bans of entire product categories (e.g. bans on the manufacture, import, export, sale, and advertisement of novel tobacco products or non-tobacco nicotine products);

Packaging and labelling: including regulations on health warnings and other government-mandated messages (e.g. in respect of content, positioning, size and rotation); restrictions on the use of certain descriptors and brand names; requirements on pack shape, size, weight and colour and mandatory plain packaging;

Sponsorship, promotion and advertising: including partial or total bans on tobacco and/or non-tobacco nicotine product advertising, marketing, promotions and sponsorship and restrictions on brand sharing and stretching (the latter refers to the creation of an association between a tobacco product and a non-tobacco product by the use of tobacco branding on the non-tobacco product);

Purchase: including regulations on the manner in which tobacco products and non-tobacco nicotine products are sold, such as type of outlet (e.g. supermarkets and vending machines) and how they are sold (e.g. above-the-counter versus beneath-the-counter);

Price: including regulations which have implications for the prices that manufacturers can charge for their tobacco products and non-tobacco nicotine products (e.g. excise taxes and minimum prices); and

Responsibility: including regulations introducing Extended Producer Responsibility schemes on cigarette manufacturers to cover the cost to clean up tobacco and/or non-tobacco nicotine product advertising, marketing, promotions and sponsorships and restrictions on brand sharing and stretching (the latter refers to the creation of an association between a tobacco product and a non-tobacco product by the use of tobacco branding on the non-tobacco product);

Other developments in regulation have been driven by tobacco control activities undertaken outside the FCTC process. For example, the EU Tobacco Products Directive (2001/37/EC), referred to as TPD1, was adopted by the EU in May 2001 for transposition into EU member states’ laws by September 2002. TPD1 included provisions that set maximum tar, nicotine and carbon monoxide yields, introduced larger health warnings and banned descriptors such as ‘light’ and ‘mild’.

A revised TPD1, the EU Tobacco and Related Products Directive (2014/40/EU), referred to as TPD2, was adopted in April 2014 for transposition into EU member states’ laws by May 2016. Provisions of TPD2 include: larger combined pictorial and textual health warnings covering 65% of the two main pack surfaces (front and back) for cigarettes; restrictions on pack shape and size, including minimum pack sizes of 20 sticks for cigarettes and 30g for roll-your-own and make-your-own tobacco; increased ingredients reporting; ‘tracking and tracing’ requirements; and for e-cigarettes: nicotine limits, pre-market notification, ingredients reporting and advertising bans. Among other things, TPD2 bans the sale of cigarettes and roll-your-own tobacco with a characterising flavour. Menthol-flavoured cigarettes were exempted from the ban until May 2020, which has since been applied also to menthol cigarettes. (See ‘The U.S. for information pertaining to the regulation of menthol in that market’).

Regulation of the Group’s Business
To date, the FCTC has been ratified by 182 countries, not including the U.S. The FCTC has led to increased efforts by tobacco-control advocates and public health organisations to reduce the supply of, and demand for, tobacco products, and to encourage governments to further regulate the tobacco industry. As national regulations increasingly reflect global influences, the scope of areas regulated will likely further expand. The guidelines on advertising, promotion and sponsorship, for example, seek to broaden the definition of tobacco advertising to include product display, the use of vending machines as well as the design of the pack itself. Where adopted by contracting parties, a number of the measures referred to in the guidelines may result in either additional costs for the tobacco industry or restrictions on a manufacturer’s ability to differentiate its products and communicate those differences to adult smokers. The World Health Organization and other public health organisations have recently focused their efforts on attempting to widen the scope of the FCTC to include Reduced Risk Products (RRPs), mostly indirectly by adopting decisions and working groups concerning these products. Given that these organisations are reluctant to acknowledge the harm reduction properties of RRPs, this approach risks to result in a further push for stricter regulations of RRPs or the application of existing tobacco regulations to RRPs. All engagement efforts of the tobacco industry are being closely monitored by these organisations and often (incorrectly) labelled as unlawful industry interference. In turn, this has an impact on the willingness of Parties to engage with the industry, which limits the opportunity of the industry to mitigate these risks.

The biannual session of the Conference of the Parties to the FCTC took place in November 2021 (COP9). Due to the virtual nature of the meetings most substantive discussions have however been postponed to COP10, which will take place in 2023 in Panama.

EU Tobacco and Related Products Directive (2014/40/EU)
Other developments in regulation have been driven by tobacco control activities undertaken outside the FCTC process. For example, the EU Tobacco Products Directive (2001/37/EC), referred to as TPD1, was adopted by the EU in May 2001 for transposition into EU member states’ laws by September 2002. TPD1 included provisions that set maximum tar, nicotine and carbon monoxide yields, introduced larger health warnings and banned descriptors such as ‘light’ and ‘mild’.

A revised TPD1, the EU Tobacco and Related Products Directive (2014/40/EU), referred to as TPD2, was adopted in April 2014 for transposition into EU member states’ law by May 2016. Provisions of TPD2 include: larger combined pictorial and textual health warnings covering 65% of the two main pack surfaces (front and back) for cigarettes; restrictions on pack shape and size, including minimum pack sizes of 20 sticks for cigarettes and 30g for roll-your-own and make-your-own tobacco; increased ingredients reporting; ‘tracking and tracing’ requirements; and for e-cigarettes: nicotine limits, pre-market notification, ingredients reporting and advertising bans. Among other things, TPD2 bans the sale of cigarettes and roll-your-own tobacco with a characterising flavour. Menthol-flavoured cigarettes were exempted from the ban until May 2020, which has since been applied also to menthol cigarettes. (See ‘The U.S. for information pertaining to the regulation of menthol in that market’).
Regulation of Ingredients, Including Flavoured Tobacco Products

A number of countries have restricted, and others are seeking to restrict or ban, the use of certain flavours or ingredients in cigarettes and other tobacco products, on the basis that such products are alleged to appeal disproportionately to minors, act as a catalyst for young people taking up smoking and/or increase the attractiveness of use of the relevant product. To the extent flavours are permitted, this is often restricted to tobacco and/or menthol products only.

Such restrictions have been enacted in markets including the U.S., Canada, Australia, Turkey and Iran. An ingredients ban in Brazil, which would ban the use of certain ingredients with flavouring or aromatic properties, including menthol, is not currently in force due to ongoing legal challenges. TPD2 similarly bans in the EU the manufacture and sale of cigarettes and roll-your-own tobacco with a characterising flavour other than tobacco. A number of the above regulations are subject to ongoing legal challenges (See ‘The U.S.’ for information pertaining to the regulation of menthol in that market).

Currently, European regulators are increasingly seeking to restrict, and even ban, the use of flavours or ingredients in vapour products and other RRPs (see “Reduced Risk-Products”). For example, Hungary, Finland, the Netherlands, Denmark, Sweden and Norway have adopted, or are considering to adopt, bills banning flavours in vapour products. This is partially based on a scientific opinion on e-cigarettes commissioned by the EU (the SCHEER report), which was published on 16 April 2021 and which alleges that flavours have a relevant contribution for attractiveness of use of electronic cigarettes. Legal challenges are expected to be filed against these new regulations, which will be supported by credible and contrary scientific evidence.

Further legislation on ingredients, both for FMCs and RRPs, is to be expected. The Conference of Parties to the FCTC has tasked a working group to further elaborate the partial guidelines on the regulation of the contents of tobacco products and tobacco product disclosures. The substantive discussions by the Conference of Parties to the FCTC on this report have been postponed to COP10 (see ‘World Health Organization Framework Convention on Tobacco Control’). Furthermore, certain industry players have avoided the menthol characterising flavour ban that came into force in the EU on 20 May 2020 by introducing several low menthol/WS3 products. This has resulted in several legal challenges in various EU countries.

Restrictions on Smoking in Private, Public and Workplaces

The Group operates in a number of markets which have in place restrictions on smoking in certain private, public and workplace environments, including restaurants, bars and nightclubs. While these restrictions vary in scope and severity, the use of certain flavoured tobacco products, such as menthol and menthol cigarettes, is often restricted or banned in many jurisdictions around the world. The use of flavoured tobacco products, on the basis that such products are alleged to appeal disproportionately to minors, act as a catalyst for young people taking up smoking and/or increase the attractiveness of use of the relevant product. To the extent such products are permitted, this is often restricted to tobacco and/or menthol products only.

Such restrictions have been enacted in markets including the U.S., Canada, Australia, Turkey and Iran. An ingredients ban in Brazil, which would ban the use of certain ingredients with flavouring or aromatic properties, including menthol, is not currently in force due to ongoing legal challenges. TPD2 similarly bans in the EU the manufacture and sale of cigarettes and roll-your-own tobacco with a characterising flavour other than tobacco. A number of the above regulations are subject to ongoing legal challenges (See “The U.S.” for information pertaining to the regulation of menthol in that market).

Currently, European regulators are increasingly seeking to restrict, and even ban, the use of flavours or ingredients in vapour products and other RRPs (see “Reduced Risk-Products”). For example, Hungary, Finland, the Netherlands, Denmark, Sweden and Norway have adopted, or are considering to adopt, bills banning flavours in vapour products. This is partially based on a scientific opinion on e-cigarettes commissioned by the EU (the SCHEER report), which was published on 16 April 2021 and which alleges that flavours have a relevant contribution for attractiveness of use of electronic cigarettes. Legal challenges are expected to be filed against these new regulations, which will be supported by credible and contrary scientific evidence.

Further legislation on ingredients, both for FMCs and RRPs, is to be expected. The Conference of Parties to the FCTC has tasked a working group to further elaborate the partial guidelines on the regulation of the contents of tobacco products and tobacco product disclosures. The substantive discussions by the Conference of Parties to the FCTC on this report have been postponed to COP10 (see “World Health Organization Framework Convention on Tobacco Control”). Furthermore, certain industry players have avoided the menthol characterising flavour ban that came into force in the EU on 20 May 2020 by introducing several low menthol/WS3 products. This has resulted in several legal challenges in various EU countries.
Plain and Standardised Packaging
Plain (or ‘standardised’) packaging generally refers to a ban on the use of trademarks, logos and colours on packaging other than the use of a single colour and the presentation of brand name and variant in a specified font and location(s). The presentation of individual cigarettes may be similarly restricted. Plain packaging is high on the agenda of tobacco control groups, and the non-binding FCTC guidelines recommend that contracting parties consider introducing plain packaging. To date, 22 countries (including Australia, Belgium, Canada, Denmark, France, Ireland, New Zealand, the Netherlands, Saudi Arabia, Singapore, Turkey, and the UK) have adopted plain packaging legislation, with the measure being implemented in 18 of those countries. Countries, territories and states that are currently considering adopting plain packaging legislation include, but are not limited to Argentina, India, Ecuador, Panama, Brazil, Chile, Spain and South Africa. Others, such as South Korea, Ukraine and Colombia, are considering implementing increased graphic health warnings. Also RRPs are increasingly facing plain packaging regulations (see ‘Reduced Risk Products’), such as in Denmark where a bill was adopted on 15 December 2020, which introduces plain packaging for vapour products and THPs.

Product Display Bans at Point of Sale and Licensing Regimes
Product display bans at point of sale and licensing regimes have become relatively commonplace and have been implemented for several years in a number of countries both at national and state levels, including in Norway, Iceland, Finland, New Zealand, Thailand, Canada, Australia, and the UK. The Danish bill (referenced above) also introduces a product display ban for RRPs. A large number of countries, such as Hungary, Finland and Spain, have also sought to restrict the supply of tobacco products, including through the adoption of licensing regimes limiting the number of retail outlets from which it is possible to purchase tobacco products and/or by prohibiting the sale of tobacco products within a certain distance of specified public places.

Illicit Trade
The illegal market for tobacco products is an increasingly important issue for governments and the industry across the world. Euromonitor International estimates that approximately 400 billion cigarettes per year are smuggled, manufactured illegally or counterfeited. A number of governments, regulators and organisations have or are considering adopting regulation to support anti-illicit trade activities. Among other forms, such regulation may comprise mandatory ‘tracking and tracing’ requirements enabling regulators to identify the point at which any seized product left the legal supply chain, security features to combat counterfeiting and inspection and authentication obligations in respect of seized product. The TPDo, for example, requires that all unit packets of tobacco are marked with a unique and removable identifier, which when scanned provides various information about that product’s route-to-market.

In November 2012, the FCTC adopted the Protocol to Eliminate Illicit Trade in Tobacco-Products which includes a raft of supply chain control measures, including the implementation of ‘tracking and tracing’ technologies. The Protocol entered into force on 25 September 2016 and was considered at the first session of the Meeting of the Parties to the Protocol in October 2018. As at 1 January 2021, 62 parties have ratified the Protocol. The second session of the Meeting of the Parties to the Protocol took place in November 2021.

Reduced Risk Products (“RRPs”)
More recently, significant debate has been generated regarding the appropriate regulation of vapour products, including regulation of the nicotine liquids used in them. As the nascent vapour category has grown in size and complexity in a relatively short period of time, a consensus framework for regulation and taxation has yet to emerge. The TPDo, for example, establishes frameworks for the regulation of novel tobacco products and e-cigarettes, introducing nicotine limits, health warnings requirements, advertising bans and pre-market notification and post-market disclosure obligations. The Conference of the Parties to the FCTC is also contemplating to redefine the scope of the FCTC to include novel tobacco products and products containing nicotine.

In countries where the sale of vapour products is permitted, governments are seeking to more strictly regulate these products, including by adopting or seeking to adopt bans on vaping in public places, bans or restrictions on flavours or other restrictions such as plain packaging and retail display and advertising bans. Conversely, some governments have intentionally banned or are seeking to ban novel tobacco products and products containing nicotine, such as Hong Kong, while others would amend their existing legislation in order to permit their sale. For example, in Australia nicotine is currently classified as poison, meaning that the importation of vapour products or nicotine refill liquids is illegal in every state and territory, as is the possession and use of these products. While Australia’s Therapeutic Goods Administration re-classified nicotine as a prescription-only medication as of 1 October 2021, the effect will be that a doctor’s prescription will be required to legally access nicotine vapour products and liquid nicotine. Recent reports in North America of individuals experiencing acute respiratory injury in suspected association with vaping certain e-liquids (EVALI) and youth usage have led to an increase in scrutiny of vapour products, especially at State and Provincial levels in the U.S. and Canada.

Also, other RRPs, such as nicotine pouches and THPs, are facing increasing scrutiny by regulators. In countries such as Belgium, Germany, the Netherlands, modern oral products have sought to be classified as food stuff or medicinal products to ban these products from the market. In Germany and Hungary, THPs have faced being classified in the same way as traditional tobacco products, with the potential consequence of facing the same restrictions or excise categories. These might be temporary measures until the countries have amended their existing tobacco legislation to include these products under its scope.

The U.S.
Through the RAI subsidiaries, the Group is subject to U.S. federal, state, and local laws and regulations. The Family Smoking Prevention and Tobacco Control Act (FSPTCA), which was enacted in 2009, grants the U.S. Food & Drug Administration (FDA) broad authority over the manufacture, sale, marketing and packaging of tobacco products but at the outset limited the agency’s authority to cigarettes, smokeless tobacco products, cigarette tobacco and roll-your-own tobacco products. Key elements of the FSPTCA include: filing of facility registrations, product listing, constituent testing and ingredient information; obtaining FDA clearance for all new products and product modifications; banning all characterising flavours other than tobacco or menthol in cigarettes; establishing ‘user fees’ to fund the FDA’s regulation of tobacco products; increasing the health warning size on cigarette packs with the option to introduce pictorial health warnings; implementing good manufacturing practices; revising the labelling and advertising requirements for smokeless tobacco products; and requiring the study of menthol. The U.S. Congress did limit the FDA’s authority in two areas, prohibiting it from:

- banning categories of tobacco products; and
- requiring the reduction of nicotine yields of a tobacco product to zero.
On 10 May 2016, the FDA issued a final regulation, referred to as the Deeming Rule, deeming all remaining products that are ‘made or derived from tobacco’ to be subject to FDA regulatory authority under the FSPTCA. The Final Rule became effective as of 8 August 2016, though each requirement of the Final Rule had its own compliance date. Such ‘deemed’ tobacco products subject to the FSPTCA include, among others, electronic nicotine delivery systems (including e-cigarettes, e-hookahs, e-cigars, vape pens, advanced refillable personal vapourisers, electronic pipes and e-liquids mixed in vape shops), certain dissolvable tobacco products, cigars and pipe tobacco.

The ‘grandfathered’ date under the Final Rule for newly deemed products remained the same as the ‘grandfathered’ date for those tobacco products already subject to the FSPTCA – 15 February 2007. Any tobacco product that was not legally marketed as of 15 February 2007 is considered a new tobacco product subject to premarket review by the FDA. The FDA has recognised that few, if any, e-cigarettes were on the market as of 15 February 2007, but thousands of such products (including R. J. Reynolds Vapor Company’s Vuse products) subsequently have entered into commerce. To address this issue, the FDA established a compliance policy regarding the premarket review requirements for all newly deemed tobacco products that are not grandfathered products but were on the market as of 8 August 2016. The FDA allowed such products to remain on the market so long as the manufacturer filed the appropriate Premarket Tobacco Product Application (PMTA) by a specific deadline.

The Final Rule established staggered initial compliance periods based on the expected complexity of the applications to be submitted. On 28 July 2017, as part of the FDA’s announcement of a comprehensive regulatory plan for nicotine and tobacco, the FDA extended the deadline for submission of PMTAs for newly deemed products by several years (for e-cigarettes, the new deadline was August 2022). However, as a result of legal action, in July 2019 a federal court ultimately brought forward the filing deadline for non-combustible products to 12 May 2020. In October 2019, R. J. Reynolds Vapor Company filed PMTAs for Vuse Solo. Based upon requirements of the FSPTCA that must be addressed in PMTAs, and the FDA’s Guidance related to vapour but reversed its previous compliance policy that allowed products to remain on the market pending the submission of PMTAs for newly deemed products by several years (for e-cigarettes, the new deadline was August 2022). This led to the requirement that the FDA’s Guidance regarding the type of evidence required for such applications, the costs of preparing a PMTA are significant.

In January 2020, the FDA reinforced the filing deadline of 12 May 2020 in its Guidance related to vapour but reversed its previous compliance policy that allowed products to remain on the market pending the submission of a PMTA. The Guidance announced the agency’s intent to enforce (as of February 2020) the PMTA requirements on certain products as follows: 1) Flavoured, cartridge-based vapour products except for tobacco- or menthol-flavoured products; 2) All other vapour products for which the manufacturer failed to take (or is failing to take) adequate measures to prevent minors’ access; 3) Any vapour products that targets or whose marketing is likely to promote use by minors; and 4) Any vapour product that is offered for sale in the U.S. after 12 May 2020, and for which the manufacturer has not submitted a premarket application. Flavoured disposable vapour products and flavoured open systems with or without a nicotine threshold would only get an extension if the manufacturer has failed to take adequate measures to prevent minors’ access, 2) product that targets or whose marketing is likely to promote use by minors, or 3) fails to file a PMTA by 12 May 2020.

In April 2020, the federal court extended the PMTA deadline by 120 days to 9 September 2020 to address the FDA’s concerns regarding delays caused by the COVID-19 pandemic. R. J. Reynolds Vapor Company filed PMTAs for the remaining Vuse products (Vibe, Ciro, and Alto) and the Velo products (pouch and lozenges) by the September 2020 deadline. Certain additional data from ongoing research relevant to the Alto and Velo applications were submitted as amendments to the PMTAs during the FDA review process. The FDA granted marketing authorisation for the Vuse Solo device and its tobacco (‘original’) flavour in October 2021, but denied authorisation for Vuse Solo flavours other than menthol (which were not on the market). That denial is being appealed with the FDA. The FDA has not issued a decision on the authorisation of the Vuse Solo menthol flavour, which remains on the market pending FDA decision. There can be no assurance that the Vuse Solo menthol authorisation will be granted, or that the other flavours appeal will succeed.

Additionally, the continued marketing authorisation of Vuse Solo original flavour is contingent on continued compliance with regulatory requirements; the marketing authorisation may be suspended or withdrawn if the FDA determines that the continued marketing of the product is no longer appropriate for the protection of the public health. The FDA has not issued marketing authorisations for Vuse Alto and its associated flavours, including menthol, with FDA decisions still pending. Although the Vuse Alto menthol and tobacco flavoured products remain on the market pending FDA decisions there can be no assurance that these authorisations (or the other Vuse Alto flavours) will be granted. Similarly, the Group’s Velo products remain on the market in the U.S., again pending FDA decisions on their marketing authorisations and there can be no assurance these will be granted. If the FDA denies a marketing authorisation then the relevant product(s) would need to be withdrawn from the market (unless a court intervenes).

### Comprehensive plan for tobacco and nicotine regulation

On 28 July 2017, the FDA announced its intent to develop a comprehensive plan for tobacco and nicotine regulation that recognises the continuum of risk for nicotine delivery. As part of that plan, the FDA planned to publish an Advance Notice of Proposed Rulemaking (ANPRM) to seek public input regarding the potential health benefits and possible adverse effects of lowering the level of nicotine in combustible cigarettes.

The ANPRM would request comments from interested stakeholders regarding the potential impact of a nicotine product standard on, among other things:

1. the likelihood that existing users of tobacco products will stop using cigarettes;
2. the likelihood that those who do not use tobacco products will start using such products; and
3. the illicit trade of cigarettes containing nicotine at levels higher than a non-addictive nicotine threshold.

In addition, the Center for Tobacco Products (CTP), which was established within the FDA in 2009, will coordinate with the FDA Center for Drug Evaluation and Research regarding medicinal nicotine and other therapeutic products as part of an agency-wide nicotine framework. As part of the comprehensive plan, the FDA also announced its intent to issue ANPRMs requesting public stakeholder input on the impact of flavours (including menthol) in increased initiation among young and young adults as well as assisting adult smokers to switch to potentially less harmful forms of nicotine delivery, and the patterns of use and public health impact of premium cigars.
This follows on from the FDA’s decision to issue its own preliminary scientific evaluation regarding menthol cigarettes in 2013, which concluded that menthol cigarettes adversely affect initiation, addiction and cessation compared to non-menthol cigarettes. In 2018, the FDA took several steps to further this plan. Firstly, in January 2018, the FDA held a public hearing to obtain input from a broad group of stakeholders on ways to streamline the regulatory process for the issuance of therapeutic claims for nicotine products. Secondly, in March 2018, the agency issued three ANPRMs, seeking information on (1) the lowering of nicotine levels to non-addictive or minimally addictive levels, (2) the impact of flavours (including menthol) on increased initiation among youth and young adults as well as assisting adult smokers to switch to potentially less harmful forms of nicotine delivery; and (3) the patterns of use and public health impact of premium cigars. In April 2021, the FDA announced that it will issue proposed product standards to ban menthol as a characterising flavour in cigarettes in the U.S. In December 2021, a regulatory agenda released in the U.S. confirmed the FDA’s plans to publish a Notice of Proposed Rulemaking for a menthol cigarette ban in April 2022.

Additional regulation
In addition to the ANPRMs on reduced nicotine products and flavours, the FDA, in April 2019, issued a proposed rule on the format and content of reports to demonstrate substantial equivalence. This follows on the FDA’s previous statements regarding the development of foundational rules so as to provide clarity and predictability to the tobacco product submission process, including not only substantial equivalence applications but new product applications as well as MRTP applications. In September 2019, FDA published a proposed rule on the format and content of PMTAs. The final foundational rules for substantial equivalence and PMTAs were published on 5 October 2021 and became effective on 4 November 2021. Notably, in each rule, FDA changed the term “grandfathered tobacco product” to “Pre-Existing Tobacco Product,” indicating that the latter term more appropriately describes those products that were commercially marketed in the U.S. as of 15 February 2007. The FDA has not yet promulgated its proposed rule on MRTP applications, though the most recent FDA semi-annual regulatory agenda — which details the regulatory activities that the FDA expects to undertake in the foreseeable future — targeted November 2021 for the issuance of a proposed rule.

Under the FSPTCA, for a manufacturer to launch a new tobacco product or modify an existing tobacco product after 22 March 2011, the manufacturer must obtain an order from the FDA allowing the new or modified product to be marketed. Similarly, a manufacturer that introduced a cigarette or smokeless tobacco product between 15 February 2007 and 22 March 2011 is required to file a substantial equivalence report with the FDA demonstrating either (1) that the new or modified product had the same characteristics as a product commercially available as at 15 February 2007, referred to as a predicate product, or (2) if the new or modified product had different characteristics than the predicate product, that it did not raise different questions of public health. A product subject to such report is referred to as a provisional product. A manufacturer may continue to market a provisional product unless and until the FDA issues an order that the provisional product is not substantially equivalent (NSE), in which case the FDA could then require the manufacturer to remove the provisional product from the market. Many of the RAI subsidiaries’ cigarette and smokeless tobacco products currently on the market are provisional products.

In January 2017, the FDA issued its first proposed product standard just prior to President Trump’s inauguration whereby the agency would require the reduction, over a three-year period, of the levels of N-nitrosonornicotine (NNN) contained in smokeless tobacco products.

Since issuing this proposal, the agency has simply stated that it is evaluating submitted comments. The FDA’s semi-annual regulatory agenda has not listed the NNN proposal since its publication. Thus, it is not known whether or when this proposed rule will be finalised, and, if adopted, whether the final rule will be the same as or similar to the proposed rule. On 18 December 2017, the FDA accepted for review MRTP applications for six Camel Snus smokeless tobacco products. In 2018, the FDA began its review of these applications, which included facility inspections and a public meeting held 13-14 September 2018 before the Tobacco Product Scientific Advisory Committee to obtain its review and recommendation. The FDA is completing its independent review of the applications with no announced deadline for completion.

On 18 March 2020, FDA issued a rule mandating the incorporation on cigarettes packages of graphic health warnings. The rule requires eleven new textual warnings, each accompanied by a specific graphic image, on the top 50% of the front and back of all cigarette packages, on the left 50% of the front and back of cigarette cartons, and the top 20% of all cigarette advertising, beginning 18 June 2021. On 3 April 2020, RAI subsidiaries R. J. Reynolds Tobacco Company and Santa Fe Natural Tobacco Company, in conjunction with several cigarette manufacturers and retailers, filed a lawsuit seeking to permanently enjoin implementation of the rule. The court has on multiple occasions entered orders delaying the implementation of the rule, which currently is delayed until 9 January 2023. All briefing and oral argument in the case has been completed, and the parties await a ruling from the court as to whether the final rule will be enjoined permanently. Irrespective of the court’s decision, once issued it is expected to be appealed to the federal court of appeals. If the industry challenge is unsuccessful, the RAI companies are prepared to implement the rule’s requirements by the January 2023 deadline, having created compliant packaging and obtained approval from the FDA for the required warning rotation plans.

Cigarettes and other tobacco products are subject to substantial taxes in the U.S. All states and the District of Columbia currently impose cigarette excise taxes. Certain city and county governments, such as those of New York, Philadelphia and Chicago, also impose substantial excise taxes on cigarettes sold in those jurisdictions. Also, all states and the District of Columbia currently subject smokeless tobacco products to excise taxes. Various states and the District of Columbia impose a tax on vapour products, such as e-cigarettes, and many other states have proposed taxes on vapour products. Currently, there is no federal tax on vapour products.

State and local governments also consider and implement other legislation and regulation regarding the sale of tobacco products. Measures include, among others, limiting or prohibiting the sale of flavoured tobacco products, restricting where tobacco products may be sold and increasing the minimum age to purchase tobacco products. The Group believes that, as a responsible business, it can contribute through information, ideas and practical steps, to help regulators address the key issues regarding its products, including underage access, illicit trade, product information, product design, involuntary exposure to smoke and the development of potentially less harmful products, while maintaining a competitive market that accommodates the significant percentage of adults who choose to be tobacco consumers. The Group is committed to working with national governments and multilateral organisations and welcomes opportunities to participate in good faith to achieve sensible and balanced regulation of traditional tobacco and potentially reduced-risk products.
Disclosure Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRA)

Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 added Section 13(r) to the Exchange Act. Section 13(r) requires an issuer to disclose in its annual or quarterly reports, as applicable, whether it or any of its affiliates knowingly engaged in certain activities, transactions or dealings relating to Iran or with designated natural persons or entities sanctioned under programmes relating to terrorism or the proliferation of weapons of mass destruction. Disclosure is required even where the activities, transactions or dealings are conducted outside the U.S. by non-U.S. affiliates in compliance with applicable law, and whether or not the activities are sanctionable under U.S. law.

As of the date of this report, BAT is not aware of any activity, transaction or dealing by the Group or any of its affiliates during the financial year ended 31 December 2021 that is disclosable under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act, except as set forth below. This information is to the best of BAT’s knowledge.

Until 6 August 2021, BAT had a local operation in Iran, established on 18 October 2003, through its wholly-owned non-U.S. subsidiary, B.A.T. Pars Company (Private Joint Stock) (BAT Pars). BAT Pars produced its products, which include Kent, Pall Mall and Montana brands, in its own factory in Eshtehard, which is in the Alborz province of Iran. As at 6 August 2021, BAT Pars distributed its product via 54 sub-agents with national and provincial distribution licences, who sell products to wholesalers and retailers with the support of BAT Pars’ sales representatives. BAT Pars had 326 direct employees and an additional 1,192 contract workers supplied by a private company.

On 25 June 2021, the Group agreed to dispose of BAT Pars to DTM ME FZE LLC. Consideration is subject to the completion accounts process, with payment deferred until September 2022. The transaction was subject to the approval by State Centre of Tobacco Planning and Supervision of the Ministry of Industry of Iran and was successfully completed on 6 August 2021.

Concerning the business of BAT Pars during its period of ownership within the Group, various elements such as income tax, payroll, social security, other taxes, excise, monopoly fees, duties and other fees, including for utilities, licences and judicial fees to commence litigation, were payable to the Government of Iran and affiliated entities regarding BAT Pars’ operation. BAT Pars maintained bank accounts in Iran with various banks to facilitate its operations in the country and to make any required payments, as described above, to the Government of Iran and affiliated entities regarding its operations.

During the year ended 31 December 2021, BAT did not have any gross revenues or net profits derived from transactions with the Government of Iran or affiliated entities.

BAT maintains policies and procedures designed to ensure that its former activities in Iran and elsewhere comply in all material aspects with the applicable and relevant trade sanctions laws and regulations, including U.S. and other international trade sanctions and/or embargoes. BAT’s sanctions policies and procedures have been designed to be as robust as possible. However, there can be no absolute assurance that these policies and procedures will be effective. Were they to be ineffective, penalties or sanctions could be imposed against BAT, which could be material. Following completion of the disposal of BAT Pars, the above-described activities in Iran have ceased.
Other Information

Material Contracts

The Master Settlement Agreement & State Settlement Agreements

In 1998, the major U.S. cigarette manufacturers (including R.J. Reynolds Tobacco Company, Lorillard and Brown & Williamson, businesses which are now part of Reynolds American) entered into the Master Settlement Agreement ("MSA") with attorneys general representing most U.S. states and territories. The MSA imposes a perpetual stream of future payment obligations on the major US cigarette manufacturers. The amounts of money that the participating manufacturers are required to annually contribute are based upon, among other things, the volume of cigarettes sold and market share (based on cigarette shipments in that year).

During 2012, R.J. Reynolds Tobacco Company, various other tobacco manufacturers, 17 states, the District of Columbia and Puerto Rico reached a final agreement related to Reynolds American’s 2003 MSA activities, and three more states joined the agreement in 2013. Under this agreement, R.J. Reynolds Tobacco Company has received credits of more than US$1 billion in respect of its Non-Participating Manufacturer ("NPM") Adjustment claims related to the period from 2003 to 2012. These credits have been applied against the company’s MSA payments over a period of five years from 2013, subject to, and dependent upon, meeting the various ongoing performance obligations. During 2014, two additional states agreed to settle NPM disputes related to claims for the period 2003 to 2012. R.J. Reynolds Tobacco Company received US$170 million in credits, which have been applied over a five-year period from 2014. During 2015, another state agreed to settle NPM disputes related to claims for the period 2004 to 2014. R.J. Reynolds Tobacco Company received US$285 million in credits, which have been applied over a four-year period from 2016. During 2016, no additional states agreed to settle NPM disputes. During 2017, two more states agreed to settle NPM disputes related to claims for the period 2004 to 2014. It is estimated that R.J. Reynolds Tobacco Company will receive US$61 million in credits, which will be applied over a five-year period from 2017. During 2018, nine more states agreed to settle NPM disputes related to claims for the period 2004 to 2019, with an option through 2022, subject to certain conditions. It is estimated that R.J. Reynolds Tobacco Company will receive US$182 million in credits for settled periods through 2017, which will be applied over a five-year period from 2018. Also in 2018, a 10th additional state agreed to settle NPM disputes related to claims for the period 2004 to 2024, subject to certain conditions. It is estimated that R.J. Reynolds Tobacco Company will receive US$206 million in credits for settled periods through 2017, which will be applied over a five-year period from 2019. In the first quarter of 2020, certain conditions set forth in the 2018 agreements were met for those 10 states. In addition, in August 2020, 24 states, the District of Columbia and Puerto Rico agreed to settle NPM disputes related to claims for the period 2016-2022. Credits in respect of future years’ payments and the NPM Adjustment claims would be accounted for in the applicable year and will not be treated as adjusting items. Only credits in respect of prior year payments are included as adjusting items.

The BAT Group is subject to substantial payment obligations under the MSA and the state settlement agreements with the states of Mississippi, Florida, Texas and Minnesota (such settlement agreements, collectively “State Settlement Agreements”). Reynolds American Inc.’s operating subsidiaries’ expenses and payments under the MSA and the State Settlement Agreements for 2021 amounted to US$3,420 million in respect of settlement expenses and US$3,744 million in respect of settlement cash payments. Reynolds American Inc.’s operating subsidiaries’ expenses and payments under the MSA and the State Settlement Agreements for 2020 amounted to US$3,572 million in respect of settlement expenses and US$2,848 million in respect of settlement cash payments. Reynolds American Inc.’s operating subsidiaries’ expenses and payments under the MSA and the State Settlement Agreements for 2019 amounted to US$2,762 million in respect of settlement expenses and US$2,918 million in respect of settlement cash payments.

R.J. Reynolds Tobacco Company divested certain brands to Imperial Tobacco Group (ITG) in 2015. In 2020, R.J. Reynolds Tobacco Company recognised additional expenses, included above, under the state settlement agreements in the states of Mississippi, Florida, Texas and Minnesota related to these divested brands. R.J. Reynolds Tobacco Company recognised US$241 million of expense for payment obligations to the state of Florida for the ITG acquired brands from the date of divestiture, 12 June 2015, as a result of an unfavourable judgment. In addition, R.J. Reynolds Tobacco Company recognised US$204 million related to the resolution of claims against 4 in the states of Texas, Minnesota and Mississippi for payment obligations to those states for the ITG acquired brands from the date of divestiture. Finally, R.J. Reynolds Tobacco Company settled certain related claims with Phillip Morris USA under the state settlement agreements in the states of Mississippi, Texas and Minnesota for US$8 million.

Reynolds American Inc.: Transfer of Pension Obligations

On October 7 2021, Reynolds American Inc. entered into a ‘buy out’ transaction with Metropolitan Tower Life Insurance Company to transfer $1.9 billion of pension obligations (and eliminating all further legal or constructive obligation to the pension scheme or to the sponsoring employer) through the purchase of annuities for retirees receiving benefit payments of less than a threshold amount per month. The transaction was funded with plan assets (see note 15 in the Notes on the Accounts on page 215).
Change of Control Provisions as at 31 December 2021

Significant agreements

<table>
<thead>
<tr>
<th>Nature of agreement</th>
<th>Key provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>The revolving credit facilities agreement, effective 12 March 2020, entered into between the Company, B.A.T. International Finance p.l.c., B.A.T. Netherlands Finance B.V. and B.A.T. Capital Corporation (as borrowers and, in the case of the Company, as a guarantor) and HSBC Bank plc (as agent) and certain financial institutions (as lenders), pursuant to which the lenders agreed to make available to the borrowers £5.85 billion for general corporate purposes (the Facility).</td>
<td>– should a borrower (other than the Company) cease to be a direct or indirect subsidiary of the Company, such borrower shall immediately repay any outstanding advances made to it and shall cease to be a borrower under the Facility; and – where there is a change of control in respect of the Company, the lenders can require all amounts outstanding under the Facility to be repaid.</td>
</tr>
<tr>
<td>In March and December 2021, the Group extended short-term bilateral facilities with core relationship banks for a total amount of £2.5 billion. B.A.T. International Finance p.l.c. is the borrower under these facilities and the Company as the guarantor. As at 31 December 2021, £500 million was drawn on a short-term basis.</td>
<td>– should the borrower cease to be a direct or indirect subsidiary of the Company, the borrower shall immediately repay any outstanding advances made to it under these facilities; and – where there is a change of control in respect of the Company, the lenders can require all amounts outstanding under these facilities to be repaid.</td>
</tr>
<tr>
<td>Packaging Materials Agreement dated 8 April 2015, between Souza Cruz S.A. and Amcor Group GmbH for the production and supply of packaging for a value of R$1.5 billion.</td>
<td>– either party may terminate the agreement in the event of any direct or indirect acquisition of at least 25% of the voting shares of the supplier and/or its affiliates by directly or indirectly a competitor of Souza Cruz S.A., importer or distributor.</td>
</tr>
<tr>
<td>Global Framework Agreement dated 1 January 2014, between British American Tobacco (Investments) Limited and Papierfabrik Wattens GmbH &amp; Co for the supply of direct materials, cigarette and plug-wrap paper.</td>
<td>– Either party may terminate the agreement in the event of a change of control of the other party (or certain of its affiliated companies) in specified circumstances and which, in relation to British American Tobacco (Investments) Limited, would trigger a right for the other party to terminate the agreement on a change of control of British American Tobacco (Investments) Limited (or any holding company), where the new controlling entity is a customer or competitor of the other party.</td>
</tr>
<tr>
<td>On 25 July 2017, the Company acceded as a guarantor under the indenture of its indirect, wholly-owned subsidiary Reynolds American Inc. The securities issued under the indenture include approximately US$7.7 billion aggregate principal amount of unsecured Reynolds American Inc debt securities.</td>
<td>– with respect to each series of debt securities issued under the indenture, upon a change of control event, combined with a credit ratings downgrade of the series to below investment-grade level (such downgrade occurring on any date from the date of the public notice of an arrangement that could result in a change of control event until the end of the 60-day period following public notice of the occurrence of a change of control event), Reynolds American Inc. is obligated to make an offer to repurchase all debt securities from each holder of debt securities. As a guarantor under the indenture, the Company guarantees such payments.</td>
</tr>
<tr>
<td>Rules of the long-term incentive plans 2007 and 2016 (“LTIPs”).</td>
<td>– in the event of a change of control of the Company as a result of a takeover, reconstruction or winding-up of the Company (not being an internal reorganisation), LTIP awards will become exercisable for a limited period based on the period of time that has elapsed since the date of the award and the achievement of the performance conditions at that date, unless the Remuneration Committee determines this not to be appropriate in the circumstances; and – the rules of the LTIPs allow (as an alternative to early release) that participants may, if permitted, exchange their LTIP awards for new awards of shares in the acquiring company on a comparable basis.</td>
</tr>
</tbody>
</table>
Other Information

Property, Plant and Equipment

The Group uses a combination of in-house and contract manufacturers to manufacture its products.

BAT-owned manufacturing facilities

<table>
<thead>
<tr>
<th></th>
<th>United States</th>
<th>APME</th>
<th>AmSSA</th>
<th>ENA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fully integrated cigarette manufacturing</td>
<td>2</td>
<td>14</td>
<td>15</td>
<td>11</td>
<td>42</td>
</tr>
<tr>
<td>Sites processing tobacco only</td>
<td>1</td>
<td>6</td>
<td>9</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>Site manufacturing other tobacco products, Snus, Modern Oral and Liquids</td>
<td>3</td>
<td>–</td>
<td>–</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>R&amp;D facilities and Product Centres</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>7</strong></td>
<td><strong>21</strong></td>
<td><strong>27</strong></td>
<td><strong>20</strong></td>
<td><strong>75</strong></td>
</tr>
</tbody>
</table>

Note:

1. As of 31 December 2021.

The plants and properties owned or leased and operated by the Group’s subsidiaries are maintained in good condition and are believed to be suitable and adequate for the Group’s present needs.

The technology employed in the Group’s factories is sophisticated, especially in the area of cigarette-making and packing where throughputs can reach between 500 and 1,000 packs per minute. The Group can produce many different pack formats (e.g., the number of cigarettes per packet) and configurations (e.g., bevel edge, round corner, international) to suit marketing and consumer requirements. New technology machines are sourced from the leading machinery suppliers to the industry. Close cooperation with these organisations helps the Group support its marketing strategy by driving its product innovations, which are brought to the market on a regular basis. The Group utilises quality standards, processes and procedures covering the entire end-to-end value chain to help to ensure quality products are provided to its customers and adult tobacco consumers according to the Group’s requirements and end market regulatory requirements.

The Group has several improvement initiatives which it is currently managing. For example, the Group is continuing to realise the benefits of its Integrated Work System Programme launched in 2014, which is centrally led with an aim to improve the performance of the Group’s factories globally by focusing on manufacturing standards, continuous improvement, assessment and benchmarking, and organisational development. The Group also utilises a survey process in the factories with an aim to improve factory productivity and reduce costs in the manufacturing environment. This process, known as ‘Bulls Eye’, has been in existence for a number of years and highlights productivity opportunities by benchmarking.

In 2021, the Group manufactured cigarettes in 42 cigarette factories in 40 countries. These plants and properties are owned or leased and operated by the Group’s subsidiaries. The Group’s factory outputs and establishments vary significantly in size and production capacity. Also in 2021, the Group used third-party manufacturers to manufacture the components required, including the devices, related to New Categories. The Group also used third-party manufacturers to supplement the Group’s own production facilities in the US and Poland to bottle the liquids used in the vapour products.

For more information on property, plant and equipment, see note 13 in the Notes on the Accounts.

Raw Materials

While the Group does not own tobacco farms or directly employ farmers, it sources tobacco leaf directly from over 75,000 contracted farmers and through third-party suppliers mainly in developing countries and emerging markets. In respect of farmers we contract, we continually strive to improve farmer sustainability and viability with a focus on improved quality and resistance of seed, tailored mechanisation to reduce costs of production and increased yield, with similar expectation on our third-party suppliers in respect of their farmer contracts. We review our contracts on an annual basis considering Group requirements over the medium term (2-3 years) to promote the stability of demand and supply on production volumes. The Group also purchases a small amount of tobacco leaf from India where the tobacco is bought over an auction floor. The price of tobacco in US dollars varies from year-to-year driven by domestic inflationary pressures, economic and political factors as well as climatic conditions which impact supply, demand and quality of tobacco grown.

While COVID-19 impacted tobacco supply chains across most markets and required process enhancements to minimise transmission risks within communities, prices and availability of tobacco were not significantly impacted. The Group believes there is an adequate supply of tobacco leaf in the world markets to satisfy its current and anticipated production requirements.

We also source a number of other materials required as part of our production requirements, covering areas that include wrapping materials and filters for our combustibles business and liquids and batteries for our New Categories products. We work closely with our suppliers to ensure a robust supply chain, with contingency sourcing in place. Contracts and sourcing agreements are reviewed regularly, to ensure competitive trading terms while recognising that prices may be impacted by external factors that affect our third-party supply partners. COVID-19 has led to some short-term disruption in the supply of certain materials (due to local lockdowns and travel restrictions), yet this has been proactively managed to mitigate the impact.
US Corporate Governance Practices

Principles

In the U.S., ADSs of the Company are listed on the New York Stock Exchange (NYSE). The significant differences between the Company’s corporate governance practices and requirements by UK listing standards for U.S. companies are discussed below.

The Company has applied a robust set of board governance principles, which reflect the UK Corporate Governance Code 2018 and its principles-based approach to corporate governance. NYSE rules require U.S. companies to adopt and disclose on their websites corporate governance guidelines. The Company complies with UK requirements, including a statement in this report of how the Company has applied the principles of the UK Corporate Governance Code 2018 and how the Company has complied with the provisions of the UK Corporate Governance Code 2018.

Independence

The Company's Board governance principles require that all Non-Executive Directors be determined by the Board to be independent in character and judgement and free from any business or other relationships that could interfere materially with, or appear to affect, their judgement. The Board also has formal procedures for managing conflicts of interest. The Board has determined that, in its judgement, all of the Non-Executive Directors are independent. In doing so, the Board has taken into consideration the independence requirements outlined in the NYSE’s listing standards and considers these to be met by the Chairman and all of its Non-Executive Directors.

Committees

The Committee has a number of Board Committees that are broadly comparable in purpose and composition to those required by NYSE rules for domestic U.S. companies. For instance, the Committee has a Nominations Committee and a Remuneration Committee.

The Company also has an Audit Committee, which NYSE rules require for both US companies and foreign private issuers. These Committees are composed solely of Non-Executive Directors and, in the case of the Nominations Committee, the Chairman whom the Board has determined to be independent in the manner described above.

Each Board Committee has its own terms of reference, which prescribe the composition, main tasks and requirements of each of the Committees (see the Board Committee reports on pages 116, 120 and 128).

Under U.S. securities law and the listing standards of the NYSE, the Company is required to have an audit committee that satisfies the requirements of Rule 10A-3 under the Exchange Act and Section 303A.06 of the NYSE Listed Company Manual. The Committee has determined that it has a functioning Audit Committee that meets the requirements.

The Committee has also adopted a code of ethics for its Chief Executive, Finance and Transformation Director, Group Financial Controller and Group Chief Accountant as required by the provisions of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules issued by the SEC. The Committee has also adopted a code of ethics as required by the provisions of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules issued by the SEC. No waivers or exceptions to the Code of Ethics were granted in 2021. The Code of Ethics includes requirements in relation to confidentiality, conflicts of interest and corporate opportunities, and is available at bat.com/sobc.

The Committee has also adopted a code of ethics for its Chief Executive, Finance and Transformation Director, Group Financial Controller and Group Chief Accountant as required by the provisions of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules issued by the SEC. No waivers or exceptions to the Code of Ethics were granted in 2021. The Code of Ethics includes requirements in relation to confidentiality, conflicts of interest and corporate opportunities, and is available at bat.com/sobc.

Shareholder Approval of Equity Compensation Plans

The NYSE rules for U.S. companies require that shareholders must be given the opportunity to vote on all equity-compensation plans and material revisions to those plans. The Company complies with UK requirements that are similar to the NYSE rules. The Board, however, does not explicitly take into consideration the NYSE’s detailed definition of what are considered ‘material revisions’.

Codes of Business Conduct and Ethics

The NYSE rules require US companies to adopt and disclose a code of business conduct and ethics for all directors, officers and employees and promptly disclose any waivers of the code for directors or executive officers. The Group Standards of Business Conduct (the “SoBC”) described on pages 56 and 57 apply to all staff in the Group, including senior management and the Board, and satisfy the NYSE requirements. All Group companies have adopted the SoBC (or localised versions). The SoBC also set out the Group’s whistleblowing policy, enabling staff, in confidence and anonymously, to raise concerns without fear of reprisal, including concerns regarding questionable accounting or auditing matters. The SoBC is available at bat.com/sobc.

The Company has also adopted a code of ethics for its Chief Executive, Finance and Transformation Director, Group Financial Controller and Group Chief Accountant as required by the provisions of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules issued by the SEC. No waivers or exceptions to the Code of Ethics were granted in 2021. The Code of Ethics includes requirements in relation to confidentiality, conflicts of interest and corporate opportunities, and obligations for those senior financial officers to act with honesty and integrity in the performance of their duties and to promote full, fair, accurate, timely and understandable disclosures in all reports and other documents submitted to the SEC, the UK Financial Conduct Authority, and any other regulatory agency.

The Company considers that these codes and policies address the matters specified in the UK Corporate Governance Code 2018.

Independent Director Contact

Interested parties may communicate directly with the independent directors, individually or as a group, by sending written correspondence addressed to the independent director(s) to the attention of the Company Secretary at the following address: c/o Paul McCrory, Company Secretary, British American Tobacco p.l.c., Globe House, 4 Temple Place, London WC2R 2PG.
Other Information

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures
The Group maintains ‘disclosure controls and procedures’ (as such term is defined in Exchange Act Rule 13a-15(e)), that are designed to ensure that information required to be disclosed in reports the Group files or submits under the Exchange Act is recorded, processed, summarised and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive and Finance and Transformation Director, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, our management, including the Chief Executive and Finance and Transformation Director, recognise that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Group have been detected. The Group’s disclosure controls and procedures have been designed to meet, and management believes that they meet, reasonable assurance standards.

Management, with the participation of the Chief Executive and Finance and Transformation Director, has evaluated the effectiveness of the Group disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b) as of the end of the period covered by this annual report. Based on that evaluation, the Chief Executive and Finance and Transformation Director have concluded that the Group disclosure controls and procedures were effective at a reasonable assurance level.

Management's report on internal control over financial reporting
Management, under the oversight of the Chief Executive and the Finance and Transformation Director, is responsible for establishing and maintaining adequate internal control over financial reporting for the Group. The Group’s internal control over financial reporting consists of processes which are designed to: provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Group's financial statements for external reporting purposes in accordance with IFRS as issued by the IASB and UK-adopted international accounting standards; provide reasonable assurance that receipts and expenditure are made only in accordance with the authorisation of management; and provide reasonable assurance regarding the prevention or timely detection of any unauthorised acquisition, use or disposal of assets that could have a material effect on the consolidated financial statements.

As required by Section 404 of the Sarbanes-Oxley Act of 2002, management has assessed the effectiveness of the internal control over financial reporting (as defined in Rules 13(a)-13(f) and 15(d)-15(f) under the US Securities Exchange Act of 1934) based on the updated Internal Control-Integrated Framework issued by the Committee of Sponsoring Organisations of the Treadway Commission (COSO) (2013). Based on that assessment, management has determined that the Group’s internal control over financial reporting was effective as at 31 December 2021.

Any internal control framework, no matter how well designed, has inherent limitations, including the possibility of human error and the circumvention or overriding of controls and procedures and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate.

KPMG LLP, an independent registered public accounting firm, who also audit the Group's consolidated financial statements, has audited the effectiveness of the Group’s internal control over financial reporting as at 31 December 2021, which is included in this document.

Changes in internal control over financial reporting
During the period covered by this report, there were no changes in the Group’s internal control over financial reporting that have materially affected or are reasonably likely to materially affect the effectiveness of internal control over financial reporting.

Statements Regarding Competitive Position

Statements referring to the competitive position of BAT and its subsidiaries are based on the Group’s belief and best estimates. In certain cases, such statements and figures rely on a range of sources, including investment analyst reports, independent market surveys, and the Group’s own internal assessments of market share.
Directors’ Report Information

This Other Information section of the British American Tobacco Annual Report and Form 20-F, which includes Additional Disclosures and Shareholder Information, forms part of, and includes certain disclosures which are required by law to be included in, the Directors’ Report.

Strategic Report Disclosures

Section 414C(11) of the Companies Act 2006 allows the Board to include in the Strategic Report information that it considers to be of strategic importance that would otherwise need to be disclosed in the Directors’ Report. The Board has chosen to take advantage of this provision and accordingly, the information set out below, which would otherwise be required to be contained in the Directors’ Report, has been included in the Strategic Report.

Information required in the Directors’ Report | Section in the Strategic Report
--- | ---
Information on dividends | Financial review
Certain risk information about the use of financial instruments | Financial review
An indication of likely future developments in the business of the Group | A strategy for accelerated growth
An indication of the activities of the Group in the field of research and development | Accelerating the Enterprise of the Future
Tobacco Harm Reduction Through World-class Science

A statement describing the Group’s policy regarding the hiring, continuing employment and training, career development and promotion of disabled persons | People and Culture
Details of employee engagement: information, consultation, regard to employee interests, share scheme participation and the achievement of a common awareness of the financial and economic factors affecting the performance of the Group | Engaging with our stakeholders
Details of business relationships: Directors’ regard to business relationships with customers, suppliers and other external stakeholders | Engaging with our stakeholders
Disclosures concerning greenhouse gas emissions and energy consumption | Excellence in Environmental Management

Shareholder Information Disclosures

Information required in the Directors’ Report | Section in Other Information
--- | ---
Change of control provisions | Material contracts
Information on dividends | Dividends
Share capital – structure and voting rights; restrictions on transfers of shares | Articles of Association
Directors – appointment and retirement | Articles of Association
Amendment of Articles of Association | Articles of Association
Branch outside of the UK - Representative Office in South Africa | Inside page of the back cover
Major shareholders | Share capital and security ownership
Directors – share issuance and buy-back powers | Share capital and security ownership
Purchases of shares

Listing Rules (LRs) Disclosures

For the purpose of LR 9.8.4R the applicable information required to be disclosed by LR 9.8.4 R | Section in Other Information
--- | ---
Section (12) – shareholder waivers of dividends | Group Employee Trust
Section (13) – shareholder waivers of future dividends | Group Employee Trust

Directors: Interests and Indemnities

Interests – details of Directors’ remuneration and emoluments, and their interests in the Company’s shares (including share options and deferred shares) as at 31 December 2021 are given in the Remuneration Report; and
– no Director had any material interest in a contract of significance (other than a service contract) with the Company or any subsidiary company during the year.

Insurance – appropriate cover provided in the event of legal action against the Company’s Directors.

Indemnities – provision of indemnities to Directors in accordance with the Company’s Articles of Association and to the maximum extent permitted by law; and
– as at the date of this report, such indemnities are in force covering any costs, charges, expenses or liabilities that they may incur in or about the execution of their duties to the Company or to any entity which is an associated company (as defined in Section 256 of the Companies Act 2006), or as a result of duties performed by them on behalf of the Company or any such associated company.

Directors' Report Approval and Signature

The Directors’ Report comprises the information on pages 68 to 122 and pages 299 to 379. The Directors’ Report was approved by the Board of Directors on 10 February 2022 and signed on its behalf by PaulMcCorry, Company Secretary.
Other Information

Cautionary Statement

This document contains certain forward-looking statements, including “forward-looking” statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “outlook,” “target” and similar expressions. These include statements regarding our intentions, beliefs or current expectations concerning, amongst other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the economic and business circumstances occurring from time to time in the countries and markets in which the Group operates, including the projected future financial and operating impacts of the COVID-19 pandemic.

In particular, these forward-looking statements include, among other statements, statements regarding the Group’s future financial performance, planned product launches and future regulatory developments, as well as: (i) certain statements in the Overview section (pages 2 to 11, including the Chairman’s Introduction, Chief Executive’s Review and Finance and Transformation Director’s Overview; (ii) certain statements in the Strategic Management section (pages 12 to 32), including Our Global Business section; (iii) certain statements in the Financial Review section (pages 75 to 83), including the Treasury and Cash Flow section and going concern discussions; and (iv) certain statements in the Other Information section (pages 299 to 382), including the Additional Disclosures and Shareholder Information sections.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this document are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated.

Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are uncertainties related to the following: the impact of competition from illicit trade; the impact of adverse domestic or international legislation and regulation; the inability to develop, commercialise and deliver the Group’s New Categories strategy; adverse litigation and dispute outcomes and the effect of such outcomes on the Group’s financial condition; the impact of significant increases or structural changes in tobacco, nicotine and New Categories related taxes; translational and transactional foreign exchange rate exposure; changes or differences in domestic or international economic or political conditions; the ability to maintain credit ratings and to fund the business under the current capital structure; the impact of serious injury, illness or death in the workplace; adverse decisions by domestic or international regulatory bodies; and changes in the market position, businesses, financial condition, results of operations or prospects of the Group. Further details on the principal risks that may affect the Group can be found in the ‘Group Principal Risks’ section of the Strategic Report on pages 92 to 97 of this document. A summary of all the risk factors (including the principal risks) which are monitored by the Board through the Group’s risk register is set out in the Additional Disclosures section under the heading ‘Group Risk Factors’ on pages 317 to 339.

Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

No statement in this document is intended to be a profit forecast and no statement in this document should be interpreted to mean that earnings per share of BAT for the current or future financial years would necessarily match or exceed the historical published earnings per share of BAT.
Share Prices and Listing

Premium Listing – London Stock Exchange (LSE)
The primary market for BAT’s ordinary shares is the LSE (Share Code: BATS; ISIN: GB0002875804). BAT’s ordinary shares have been listed on the LSE main market since 8 September 1998 and are a constituent element of the FTSE 100 Index.

Secondary Listing – Johannesburg Stock Exchange (JSE Limited), South Africa
BAT’s ordinary shares have a secondary listing and are traded in South African rand on the Main Board of the JSE in South Africa (Abbreviated name: BATS; Trading code: BTI). BAT’s ordinary shares have been listed on the JSE since 28 October 2008 and are a constituent element of the JSE Top 40 Index.

American Depositary Shares (ADSs) – New York Stock Exchange (NYSE)
BAT ordinary shares trade in the form of BAT ADSs in the United States under the symbol BTI (CUSIP Number: 110448107). The BAT ADSs have been listed on the NYSE since 25 July 2017 as a Sponsored Level III ADS programme for which Citibank, N.A. is the depositary (the ‘Depositary’) and transfer agent. Each ADS represents one ordinary share. ADSs are evidenced by American Depositary Receipts (ADRs).

Share Prices
The high and low prices at which the Company’s ordinary shares and ADSs are recorded as having traded during the year on each of the LSE, JSE and NYSE are as follows:

<table>
<thead>
<tr>
<th></th>
<th>High</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSE</td>
<td>£29.14</td>
<td>£24.85</td>
</tr>
<tr>
<td>JSE</td>
<td>R590.95</td>
<td>R513.00</td>
</tr>
<tr>
<td>NYSE</td>
<td>US$40.51</td>
<td>US$33.65</td>
</tr>
</tbody>
</table>
Other Information

Dividends

Policy
The Group’s policy is to pay dividends of 65% of long-term sustainable earnings, calculated with reference to adjusted diluted earnings per share, as defined on page 308, and reconciled from earnings per share in note 11 in the Notes on the Accounts. Please see page 79 of this Annual Report and Form 20-F 2021 for further discussion on the Group’s dividend.

Currencies and Exchange Rates
Details of foreign exchange rates are set out in the Financial Review section of the Strategic Report on page 83 of this Annual Report and Form 20-F 2021. There are currently no UK foreign exchange controls or restrictions on remittance of dividends on the ordinary shares other than restrictions applicable to certain countries and persons subject to UK economic sanctions.

American Depositary Shares – Dividends
The following table shows the dividends paid by British American Tobacco p.l.c. in the years ended 31 December 2019 to 31 December 2021 inclusive.

<table>
<thead>
<tr>
<th>Announcement Year</th>
<th>Payment</th>
<th>Dividend Period</th>
<th>Dividend Per BAT Ordinary Share</th>
<th>Dividend Per BAT ADS</th>
<th>ADS ratio 1:1</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>May</td>
<td>Quarterly Interim 2019</td>
<td>0.5075</td>
<td>0.6596590</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>August</td>
<td>Quarterly Interim 2019</td>
<td>0.5075</td>
<td>0.6155970</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>November</td>
<td>Quarterly Interim 2019</td>
<td>0.5075</td>
<td>0.6521370</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>February</td>
<td>Quarterly Interim 2019</td>
<td>0.5075</td>
<td>0.6571610</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>2.0300</td>
<td>2.5845940</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>May</td>
<td>Quarterly Interim 2020</td>
<td>0.526</td>
<td>0.6424030</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>August</td>
<td>Quarterly Interim 2020</td>
<td>0.526</td>
<td>0.6889020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>November</td>
<td>Quarterly Interim 2020</td>
<td>0.526</td>
<td>0.6895860</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>February</td>
<td>Quarterly Interim 2020</td>
<td>0.526</td>
<td>0.7178320</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>2.164</td>
<td>2.738723</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>May</td>
<td>Quarterly Interim 2021</td>
<td>0.539</td>
<td>0.7576180</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>August</td>
<td>Quarterly Interim 2021</td>
<td>0.539</td>
<td>0.7345300</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>November</td>
<td>Quarterly Interim 2021</td>
<td>0.539</td>
<td>0.7217210</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>February</td>
<td>Quarterly Interim 2021</td>
<td>0.539</td>
<td>0.7298860</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>2.156</td>
<td>2.943755</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note:
1. Holders of BAT ADSs: dividends are receivable in US dollars based on the £ sterling/US dollar exchange rate on the applicable ADS payment date, being three business days after the payment date for the BAT ordinary shares.

354
Quarterly Dividends for the Year Ended 31 December 2021

The Group pays quarterly dividends. The Board has declared an interim dividend of 217.8p per ordinary share of 25p which is payable in four equal quarterly instalments of 54.45p per ordinary share in May 2022, August 2022, November 2022 and February 2023. This represents an increase of 1.0% on 2020 (2020: 215.6p per share), and a payout ratio, on 2021 adjusted diluted earnings per share, of 66.2%.

The quarterly dividends will be paid to shareholders registered on either the UK main register or the South Africa branch register and to ADS holders, each on the applicable record dates set out under the heading 'Key dates' below.

Holders of American Depositary Shares (ADSs)
For holders of ADSs listed on the NYSE, the record dates and payment dates are set out below. The equivalent quarterly dividends receivable by holders of ADSs in US dollars will be calculated based on the exchange rate on the applicable payment date.

South Africa branch register
In accordance with the JSE Listing Requirements, the finalisation information relating to shareholders registered on the South Africa branch register (comprising the amount of the dividend in South African rand, the exchange rate and the associated conversion date) will be published on the dates stated below, together with South Africa dividends tax information.

The quarterly dividends are regarded as 'foreign dividends' for the purposes of the South Africa Dividends Tax. For the purposes of South Africa Dividends Tax reporting, the source of income for the payment of the quarterly dividends is the United Kingdom.

Key dates
In compliance with the requirements of the LSE, the NYSE and Strate, the electronic settlement and custody system used by the JSE, the following are the salient dates for the quarterly dividend payments. All dates are 2022 unless otherwise stated.

<table>
<thead>
<tr>
<th>Event</th>
<th>Payment No. 1</th>
<th>Payment No. 2</th>
<th>Payment No. 3</th>
<th>Payment No. 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary announcement (includes declaration data required for JSE purposes)</td>
<td>11 February</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publication of finalisation information (JSE)</td>
<td>14 March</td>
<td>28 June</td>
<td>20 September</td>
<td>12 December</td>
</tr>
<tr>
<td>No removal requests (in either direction) permitted between the UK main register and the South Africa branch register</td>
<td>28 March</td>
<td>11 July</td>
<td>3 October</td>
<td>27 December</td>
</tr>
<tr>
<td>Last day to trade (LDT) cum-dividend (JSE)</td>
<td>22 March</td>
<td>5 July</td>
<td>27 September</td>
<td>20 December</td>
</tr>
<tr>
<td>No transfers permitted between the UK main register and the South Africa branch register</td>
<td>28 March-</td>
<td>11 July-</td>
<td>28 September-</td>
<td>21 December-</td>
</tr>
<tr>
<td>No shares to be dematerialised or rematerialised on the South Africa branch register</td>
<td>(inclusive)</td>
<td>(inclusive)</td>
<td>(inclusive)</td>
<td>(inclusive)</td>
</tr>
<tr>
<td>Shares commence trading ex-dividend (LSE)</td>
<td>23 March</td>
<td>6 July</td>
<td>21 December</td>
<td></td>
</tr>
<tr>
<td>Shares commence trading ex-dividend (NYSE)</td>
<td></td>
<td>23 March-</td>
<td></td>
<td>21 December-</td>
</tr>
<tr>
<td>(inclusive)</td>
<td></td>
<td>(inclusive)</td>
<td></td>
<td>(inclusive)</td>
</tr>
<tr>
<td>Record date (LSE, JSE and NYSE)</td>
<td>24 March</td>
<td>7 July</td>
<td>29 September</td>
<td>22 December</td>
</tr>
<tr>
<td>Last date for receipt of Dividend Reinvestment Plan (DRIP) elections (LSE)</td>
<td>24 March</td>
<td>7 July</td>
<td>29 September</td>
<td>22 December</td>
</tr>
<tr>
<td>Payment date (LSE and JSE)</td>
<td>25 March</td>
<td>8 July</td>
<td>30 September</td>
<td>23 December</td>
</tr>
<tr>
<td>Record date (LSE, JSE and NYSE)</td>
<td></td>
<td>25 March</td>
<td>8 July</td>
<td>23 December</td>
</tr>
<tr>
<td>Last date for receipt of Dividend Reinvestment Plan (DRIP) elections (LSE)</td>
<td></td>
<td>8 April</td>
<td>27 July</td>
<td>20 October</td>
</tr>
<tr>
<td>Payment date (LSE and JSE)</td>
<td></td>
<td>4 May</td>
<td>17 August</td>
<td>10 November</td>
</tr>
<tr>
<td>ADS payment date (NYSE)</td>
<td></td>
<td>9 May</td>
<td>22 August</td>
<td>15 November</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 February 2023</td>
</tr>
</tbody>
</table>
The following discussion summarises material US federal income tax consequences and UK taxation consequences to US holders of owning and disposing of ordinary shares or ADSs, this information is accurate as at 8 March 2022. This discussion does not address any tax consequences arising under the laws of any state, local or foreign jurisdiction or under any US federal laws other than those pertaining to income tax. This discussion is based upon the US Internal Revenue Code of 1986 (the ‘US Tax Code’), the Treasury regulations promulgated under the US Tax Code and court and administrative rulings and decisions, all as in effect on the date hereof. These laws may change, possibly retroactively, and any change could affect the accuracy of the statements and conclusions set forth in this discussion.

This discussion addresses only those US holders of ordinary shares or ADSs who hold such equity interests as capital assets within the meaning of Section 1221 of the US Tax Code. Further, this discussion does not address all aspects of US federal income taxation that may be relevant to US holders in light of their particular circumstances or that may be applicable to them if they are subject to special treatment under the US federal income tax laws, including, without limitation:

- a bank or other financial institution;
- a tax-exempt organisation;
- an S corporation or other pass-through entity and an investor therein;
- an insurance company;
- a mutual fund;
- a regulated investment company or real estate investment trust;
- a dealer or broker in stocks and securities, or currencies;
- a trader in securities that elects mark-to-market treatment;
- a US holder subject to the alternative minimum tax provisions of the US Tax Code;
- a US holder that received ordinary shares or ADSs through the exercise of an employee stock option, pursuant to a tax qualified retirement plan or otherwise as compensation;
- a US holder that is a tax-qualified retirement plan or a participant or beneficiary under such a plan;
- a person that is not a US holder (as defined below);
- a person that has a functional currency other than the US dollar;
- a person required to recognise any item of gross income as a result of such income being recognised on an applicable financial statement;
- a US holder of ordinary shares or ADSs that holds such equity interest as part of a hedge, straddle, constructive sale, conversion or other integrated transaction;
- a US holder that owns (directly, indirectly or constructively) 10% or more of ordinary shares or ADSs by vote or by value; or
- a US expatriate.

The determination of the actual tax consequences to a US holder will depend on the US holder’s specific situation. US holders of ordinary shares or ADSs should consult their own tax advisers as to the tax consequences of owning and disposing of ordinary shares or ADSs, in each case, including the applicability and effect of the alternative minimum tax and any state, local, foreign or other tax laws and of changes in those laws.

For purposes of this discussion, the term US holder means a beneficial owner of ordinary shares or ADSs (as the case may be) that:

- is for US federal income tax purposes: (i) an individual citizen or resident of the United States; (ii) a corporation, including any entity treated as a corporation for US federal income tax purposes, created or organised in or under the laws of the United States, any state thereof or the District of Columbia; (iii) a trust if a US court is able to exercise primary supervision over the trust’s administration and one or more US persons are authorised to control all substantial decisions of the trust or it has a valid election in effect under applicable Treasury regulations to be treated as a US person; or (iv) an estate that is subject to US federal income tax on its income regardless of its source; and
- is not resident in the UK for UK tax purposes.

The US federal income tax consequences to a partner in an entity or arrangement treated as a partnership for US federal income tax purposes that holds ordinary shares or ADSs generally will depend on the status of the partner and the activities of the partnership. Partners in a partnership holding any such equity interest should consult their own tax advisers.

Material US Federal Income Tax Consequences Relating to the Ownership and Disposition of Ordinary Shares or ADSs

The following is a discussion of the material US federal income tax consequences of the ownership and disposition by US holders of ordinary shares or ADSs. This discussion assumes that BAT is not, and will not become, a passive foreign investment company for US federal income tax purposes, as described below.

ADSs

A US holder of ADSs, for US federal income tax purposes, generally will be treated as the owner of the underlying ordinary shares that are represented by such ADSs. Accordingly, deposits or withdrawals of ordinary shares for or from ADSs will not be subject to US federal income tax.

Taxation of Dividends

The gross amount of distributions on the ordinary shares or ADSs will be taxable as dividends to the extent paid out of BAT’s current or accumulated earnings and profits, as determined under US federal income tax principles. Such income will be includable in a US holder’s gross income as ordinary income on the day actually or constructively received by the US holder. Such dividends will be treated as foreign source income and will not be eligible for the dividends received deduction allowed to corporations under the US Tax Code.
With respect to non-corporate US investors, certain dividends received from a qualified foreign corporation may be subject to reduced rates of taxation. A qualified foreign corporation includes a foreign corporation that is eligible for the benefits of a comprehensive income tax treaty with the United States that the Treasury determines to be satisfactory for these purposes and that includes an exchange of information provision. The Treasury has determined that the treaty between the United States and the United Kingdom meets these requirements, and BAT believes that it is eligible for the benefits of the treaty. However, non-corporate holders that do not meet a minimum holding period requirement during which they are not protected from the risk of loss or that elect to treat the dividend income as ‘investment income’ pursuant to Section 163(d)(4) of the US Tax Code will not be eligible for the reduced rates of taxation. In addition, the rate reduction will not apply to dividends if the recipient of the dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. US holders should consult their own tax advisers regarding the application of these rules to their particular circumstances.

The amount of any dividend paid by BAT in £ sterling (including any such amount in respect of ADSs that is converted into US dollars by the depositary bank) will equal the US dollar value of the £ sterling actually or constructively received, calculated by reference to the exchange rate in effect on the date the dividend is so received by the US holder, regardless of whether the £ sterling are converted into US dollars. If the £ sterling received as a dividend are converted into US dollars on the date received, the US holder generally will not be required to recognise foreign currency exchange gain or loss in respect of the dividend income. If the £ sterling received as a dividend are not converted into US dollars on the date of receipt, the US holder will have a basis in £ sterling equal to their US dollar value on the date of receipt. Any gain or loss realised on a subsequent conversion or other disposition of £ sterling will be treated as US source ordinary income or loss. US holders of ADSs should consult their own tax advisers regarding the application of these rules to the amount of any dividend paid by BAT in £ sterling that is converted into US dollars by the depositary bank.

To the extent that the amount of any distribution exceeds BAT’s current and accumulated earnings and profits for a taxable year, as determined under US federal income tax principles, the distribution will first be treated as a tax-free return of capital, causing a reduction in the US holder’s adjusted basis of the ordinary shares or ADSs, and to the extent the amount of the distribution exceeds the US holder’s tax basis, the excess will be taxed as capital gain recognised on a sale or exchange, as described below. BAT does not expect to determine earnings and profits in accordance with US federal income tax principles. Therefore, notwithstanding the foregoing, US holders should expect that distributions generally will be reported as dividend income for US information reporting purposes.

Distributions by BAT of ordinary shares (which may be distributed by the depositary bank to a holder of ADSs in the form of ADSs) to a US holder that is made as part of a pro rata distribution to all holders of ordinary shares and ADSs in respect of their ordinary shares or ADSs, and for which there is no option to receive other property (not including ADSs), generally will not be subject to US federal income tax. The basis of any new ordinary shares (or ADSs representing new ordinary shares) so received will be determined by allocating the US holder’s basis in the previously held ordinary shares or ADSs, based on their relative fair market values on the date of distribution.

Passive foreign investment company

A passive foreign investment company ("PFIC"), is any foreign corporation if, after the application of certain "look-through" rules: (1) at least 75% of its gross income is "passive income" as that term is defined in the relevant provisions of the US Tax Code; or (2) at least 50% of the average value of its assets produce "passive income." The determination as to PFIC status made in a tax year is based on the assets, income and operations of the foreign corporation for that tax year. If BAT determines it to be a PFIC, US holders could be subject to additional US federal income taxes on gain recognised with respect to the ordinary shares or ADSs.

Taxation of capital gains

Upon a sale, exchange or other taxable disposition of ordinary shares or ADSs, a US holder will generally recognise capital gain or loss for US federal income tax purposes in an amount equal to the difference between the US dollar value of the amount realised on the disposition and the US holder’s adjusted tax basis in the ordinary shares or ADSs as determined in US dollars. Such gain or loss generally will be US source gain or loss, and will be long-term capital gain or loss if the US holder has held the ordinary shares or ADSs for more than one year. Certain non-corporate US holders may be eligible for preferential rates of US federal income tax in respect of long-term capital gains. The deductibility of capital losses is subject to limitations.

The amount realised on a sale, exchange or other taxable disposition of ordinary shares for an amount in foreign currency will be the US dollar value of that amount on the date of sale or disposition. On the settlement date, the US holder will recognise US source foreign currency exchange gain or loss (taxable as ordinary income or loss) equal to the difference (if any) between the US dollar value of the amount received based on the exchange rates in effect on the date of sale, exchange or other disposition and the settlement date. However, in the case of ordinary shares traded on an established securities market that are sold by a cash-basis US holder (or an accrual-basis US holder that so elects), the amount realised will be based on the exchange rate in effect on the settlement date for the sale, and no foreign currency exchange gain or loss will be recognised at that time.

A US holder’s tax basis in ordinary shares or ADSs will generally equal the US dollar cost of the ordinary shares or ADSs. The US dollar cost of ordinary shares purchased with foreign currency will generally be the US dollar value of the purchase price on the date of purchase, or the settlement date for the purchase in the case of ordinary shares traded on an established securities market that are purchased by a cash-basis US holder (or an accrual-basis US holder that so elects).
Information with respect to foreign financial assets

Individuals and certain entities that own "specified foreign financial assets" with an aggregate value in excess of US$50,000 are generally required to file information reports with respect to such assets with their US federal income tax returns. Depending on the individual's circumstances, higher threshold amounts may apply. Specified foreign financial assets include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained by financial institutions: (1) stocks and securities issued by non-US persons; (2) financial instruments and contracts held for investment that have non-US issuers or counterparties; and (3) interests in non-US entities. If a US holder is subject to this information reporting regime, the failure to file information reports may subject the US holder to penalties. US holders are urged to consult their own tax advisers regarding their obligations to file information reports with respect to ordinary shares or ADSs.

Medicare net investment tax

Certain persons who are individuals (other than non-resident aliens), estates or trusts are required to pay an additional 3.8% tax on the lesser of (1) their "net investment income" (in the case of individuals) or "undistributed net investment income" (in the case of estates and trusts) which includes dividend income in respect of, and gain recognised on the disposition of, ordinary shares or ADSs for the relevant taxable year; and (2) the excess of their modified adjusted gross income (in the case of individuals) or adjusted gross income (in the case of estates and trusts) for the taxable year over specified dollar amounts. US holders are urged to consult their own tax advisers regarding the applicability of this provision to their ownership of ordinary shares or ADSs.

Credits or deductions for UK taxes

As indicated under 'Material UK tax consequences' below, dividends in respect of, and gains on the disposition of, ordinary shares or ADSs may be subject to UK taxation in certain circumstances. A US holder may be eligible to claim a credit or deduction in respect of UK taxes attributable to such income or gain for purposes of computing the US holder's US federal income tax liability, subject to certain limitations. The US foreign tax credit rules are complex, and US holders should consult their own tax advisers regarding the availability of US foreign tax credits and the application of the US foreign tax credit rules to their particular situation.

Information reporting and backup withholding

Information reporting and backup withholding may apply to dividend payments and proceeds from the sale, exchange or other taxable disposition of ordinary shares or ADSs. Backup withholding will not apply, however, to a US holder that: (1) furnishes a correct taxpayer identification number (TIN), certifies that such holder is not subject to backup withholding on Internal Revenue Service Form W-9 (or appropriate successor form) and otherwise complies with all applicable requirements of the backup withholding rules; or (2) provides proof that such holder is otherwise exempt from backup withholding. Backup withholding is not an additional tax, and any amounts withheld under the backup withholding rules may be refunded or credited against a holder's US federal income tax liability, if any, provided that such holder furnishes the required information to the Internal Revenue Service in a timely manner. The Internal Revenue Service may impose a penalty upon any taxpayer that fails to provide the correct TIN.

This summary of material US federal income tax consequences is not tax advice. The determination of the actual tax consequences for a US holder will depend on the US holder's specific situation. US holders of ordinary shares or ADSs, in each case, should consult their own tax advisers as to the tax consequences of owning and disposing of ordinary shares or ADSs, including the applicability and effect of the alternative minimum tax and any state, local, foreign or other tax laws and of changes in those laws.

Material UK Tax Consequences

The following paragraphs summarise material aspects of the UK tax treatment of US holders of ordinary shares or ADSs and do not purport to be either a complete analysis of all tax considerations relating to holding ordinary shares or ADSs or an analysis of the tax position of BAT. They are based on current UK legislation and what is understood to be current HMRC practice, both of which are subject to change, possibly with retrospective effect.

The comments are intended as a general guide and (otherwise than where expressly stated to the contrary) apply only to US holders of ordinary shares or ADSs (other than under a personal equity plan or individual savings account) and who are the absolute beneficial owners of such shares. These comments do not deal with certain types of shareholders such as charities, dealers in securities, persons holding or acquiring shares in the course of a trade, persons who have or could be treated for tax purposes as having acquired their ordinary shares or ADSs by reason of their employment, collective investment schemes, persons subject to UK tax on the remittance basis and insurance companies. You are encouraged to consult an appropriate independent professional tax adviser with respect to your tax position.

Tax on chargeable gains as a result of disposals of ordinary shares or ADSs

Subject to the below, US holders will not generally be subject to UK tax on chargeable gains on a disposal of ordinary shares or ADSs provided that they do not carry on a trade, profession or vocation in the United Kingdom through a branch, agency or permanent establishment in connection with which the ordinary shares or ADSs are held. A US holder who is an individual, who has ceased to be resident for tax purposes in the United Kingdom for a period of less than five years and who disposes of ordinary shares or ADSs during that period may be liable for UK tax on capital gains (in the absence of any available exemptions or reliefs). If applicable, the tax charge will arise in the tax year that the individual returns to the United Kingdom.
Tax on dividends

BAT is not required to withhold UK tax at source from dividends paid on ordinary shares or ADSs.

US holders will not generally be subject to UK tax on dividends received from BAT provided that they do not carry on a trade, profession or vocation in the United Kingdom through a branch, agency or permanent establishment in connection with which the ordinary shares or ADSs are held.

Stamp duty and stamp duty reserve tax (SDRT)

Based on current published HMRC practice and recent case law, transfers of ADSs should not be subject to SDRT or stamp duty. The transfer of an underlying ordinary share to the ADS holder in exchange for the cancellation of an ADS should also not give rise to a stamp duty or SDRT charge.

Transfers of ordinary shares outside of the depositary bank, including the repurchase of ordinary shares by BAT, will generally be subject to stamp duty or SDRT at the rate of 0.5% of the amount or value of the consideration given, except as described above in connection with the cancellation of an ADS. If ordinary shares are redeposited into a clearance service or depositary system, the redeposit will attract stamp duty or SDRT at the higher rate of 1.5%.

The purchaser or the transferee of the ordinary shares or ADSs will generally be responsible for paying any stamp duty or SDRT payable. Where stamp duty or SDRT is payable, it is payable regardless of the residence position of the purchaser.

Inheritance tax

A gift or settlement of ordinary shares or ADSs by, or on the death of, an individual shareholder may give rise to a liability to UK inheritance tax even if the shareholder is not a resident of, or domiciled in, the United Kingdom.

A charge to inheritance tax may arise in certain circumstances where ordinary shares or ADSs are held by close companies and trustees of settlements.

However, pursuant to the Estate and Gift Tax Treaty 1980 (the “Treaty”) entered into between the United Kingdom and the United States, a gift or settlement of ordinary shares or ADSs by shareholders who are domiciled in the United States for the purposes of the Treaty may be exempt from any liability to UK inheritance tax.
Share Capital

### Ordinary Shares

At 31 December 2021, there was a total of 2,456,617,788 ordinary shares in issue held by 108,467 shareholders. These shareholdings are analysed as follows:

#### (a) by listing as at 31 December 2021:

<table>
<thead>
<tr>
<th>Register</th>
<th>Total number of shares</th>
<th>Number of holders</th>
<th>% of issued share capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>2,201,910,356</td>
<td>35,134</td>
<td>89.63</td>
</tr>
<tr>
<td>South Africa</td>
<td>254,707,432</td>
<td>69,124</td>
<td>10.37</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,456,617,788</strong></td>
<td><strong>104,258</strong></td>
<td><strong>100.00</strong></td>
</tr>
</tbody>
</table>

#### (b) by size of shareholding as at 31 December 2021:

<table>
<thead>
<tr>
<th>Size of Shareholding</th>
<th>Number of Holders</th>
<th>% of Ordinary Share Capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–1,999</td>
<td>30,072</td>
<td>0.58</td>
</tr>
<tr>
<td>2,000–9,999</td>
<td>3,650</td>
<td>0.63</td>
</tr>
<tr>
<td>10,000–19,999</td>
<td>1,011</td>
<td>2.38</td>
</tr>
<tr>
<td>20,000–49,999</td>
<td>138</td>
<td>2.04</td>
</tr>
<tr>
<td>500,000 and over</td>
<td>262</td>
<td>87.01</td>
</tr>
<tr>
<td>Treasury shares (UK)</td>
<td>1</td>
<td>7.36</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>35,134</strong></td>
<td><strong>100.00</strong></td>
</tr>
</tbody>
</table>

### South Africa Register

<table>
<thead>
<tr>
<th>Size of Shareholding</th>
<th>Number of Holders</th>
<th>% of SA Ordinary Share Capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–1,999</td>
<td>63,837</td>
<td>6.44</td>
</tr>
<tr>
<td>2,000–9,999</td>
<td>3,557</td>
<td>5.69</td>
</tr>
<tr>
<td>10,000–19,999</td>
<td>1,592</td>
<td>25.43</td>
</tr>
<tr>
<td>20,000–49,999</td>
<td>78</td>
<td>9.89</td>
</tr>
<tr>
<td>500,000 and over</td>
<td>60</td>
<td>52.55</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>69,124</strong></td>
<td><strong>100.00</strong></td>
</tr>
</tbody>
</table>

Security Ownership

- **American Depositary Shares (ADSs)**
  - At 31 December 2021, there was a total of 347,266,515 ADSs outstanding held by 8,909 registered holders. The ADS register is analysed by size of shareholding as at 31 December 2021 as follows:
  
<table>
<thead>
<tr>
<th>Size of Shareholding</th>
<th>Number of Holders</th>
<th>% of Total ADSs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–1,999</td>
<td>8,721</td>
<td>0.69</td>
</tr>
<tr>
<td>2,000–9,999</td>
<td>166</td>
<td>0.22</td>
</tr>
<tr>
<td>10,000–19,999</td>
<td>20</td>
<td>0.16</td>
</tr>
<tr>
<td>200,000–499,999</td>
<td>1</td>
<td>0.09</td>
</tr>
<tr>
<td>500,000 and over</td>
<td>1</td>
<td>98.84</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>8,909</strong></td>
<td><strong>100.00</strong></td>
</tr>
</tbody>
</table>

- **Security Ownership – Major Shareholders**
  - As at 8 February 2022, based on information received from Citibank, there were 35,086 record holders of ordinary shares listed on the LSE (including Citibank as the depositary bank for the ADSs) and 2,196,967,436 of such ordinary shares outstanding. As at that date, to BAT’s knowledge, 299 record holders, representing 0.01% of the ordinary shares listed on the LSE, had a registered address in the US. As at 6 February 2022, there were 723 record holders of ordinary shares listed on the JSE (including PLC Nominees (Proprietary) Limited as the nominee for the dematerialised ordinary shares listed on the JSE) and 259,652,752 of such ordinary shares outstanding. As at such date, to BAT’s knowledge, no record holders of the ordinary shares listed on the JSE had a registered address in the US. As at 8 February 2022, based on information received from Citibank, there were 8,883 record holders of ADSs and 259,359,198 ADSs outstanding. As at that date, based on information received from Citibank, 9,820 record holders, representing 99.94% of ADSs representing ordinary shares, had a registered address in the US.

- **Security Ownership – Major Shareholders**
  - At 31 December 2021, the following substantial interests (3% or more) in the Company’s ordinary share capital (voting securities) had been notified to the Company in accordance with Section 5.1.2 of the Disclosure Guidance and Transparency Rules (DTRs).

<table>
<thead>
<tr>
<th>Name</th>
<th>Number of ordinary shares</th>
<th>% of issued share capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Capital Group Companies, Inc. 2</td>
<td>251,653,679</td>
<td>10.96</td>
</tr>
<tr>
<td>Spring Mountain Investments Ltd. 3</td>
<td>187,023,731</td>
<td>8.15</td>
</tr>
<tr>
<td>BlackRock, Inc.</td>
<td>132,891,526</td>
<td>5.79</td>
</tr>
</tbody>
</table>

**Notes:**
1. One registered holder of ADSs represents 513,342 underlying shareholders.
2. Includes 18,902,551 ordinary shares represented by ADRs.
3. Includes 5,807,274 ordinary shares represented by ADRs.
On 25 January 2022, The Capital Group Companies, Inc. notified the Company that, on 24 January 2022, its interest in ordinary shares had decreased by 234,956,959 (10.89% of issued share capital), including 14,025,662 ordinary shares represented by ADRs. Its total voting rights interest decreased to a total of 253,782,074 ordinary shares consisting of 249,908,259 ordinary shares and 3,972,871 of equivalent financial instruments (rights to recall lent shares of Common Stock and rights to recall ADRs which represents 11.06% of the Company’s outstanding shares).

On 26 January 2022, The Capital Group Companies, Inc. notified the Company that on 25 January 2022, its interest in ordinary shares had increased to 253,762,060 (11.06% of issued share capital) including 13,652,301 ordinary shares represented by ADRs. Its total voting rights interest increased to a total of 258,127,131 voting rights consisting of 253,762,060 ordinary shares and 4,360,071 of equivalent financial instruments (rights to recall lent shares of Common Stock and rights to recall ADRs which represents 11.25% of the Company’s outstanding shares).

All shares held by the significant shareholders represent the Company’s ordinary shares. These significant shareholders have no special voting rights compared with other holders of the Company’s ordinary shares.

**Additional Significant Shareholding Disclosure**

>>Portfolio Services Ltd filed with the SEC an amendment to Schedule 13G under the Exchange Act on 10 February 2022 disclosing that as of 31 December 2021 it and Kenneth B. Dart, who is the beneficial owner of all of the outstanding shares of Portfolio Services Ltd., beneficially owned 187,023,731 ordinary shares representing 8.2% of the Company’s ordinary shares outstanding as of 31 December 2021. Portfolio Services Ltd filed with the SEC an amendment to Schedule 13G under the Exchange Act on 22 January 2021 disclosing that as of 31 December 2020 Kenneth B. Dart, who is the beneficial owner of all the outstanding shares of Portfolio Services Ltd., beneficially owned 114,819,555 ordinary shares representing 5.0% of the Company’s ordinary shares outstanding as of 31 December 2020.

BlackRock, Inc. filed with the SEC an amendment to Schedule 13G under the Exchange Act on 29 January 2021 disclosing that as of 31 December 2020 it beneficially owned 178,392,857 ordinary shares representing 7.8% of the Company’s ordinary shares outstanding as of 31 December 2020. BlackRock, Inc. filed with the SEC an amendment to Schedule 13G under the Exchange Act on 7 February 2020 disclosing that as of 31 December 2019 it beneficially owned 170,313,722 ordinary shares representing 7.4% of the Company’s ordinary shares outstanding as of 31 December 2020.

BlackRock, Inc. filed the SEC an amendment to Schedule 13G under the Exchange Act on 2 February 2021 disclosing that as of 31 December 2020 it beneficially owned 184,921,039 ordinary shares representing 8.1% of the Company’s ordinary shares outstanding as of 31 December 2020. BlackRock, Inc. filed with the SEC a statement on Schedule 13G under the Exchange Act on 29 January 2021 disclosing that as of 31 December 2020 it beneficially owned 178,392,857 ordinary shares representing 7.8% of the Company’s ordinary shares outstanding as of 31 December 2020. BlackRock, Inc. filed with the SEC an amendment to Schedule 13G under the Exchange Act on 3 February 2022 disclosing that as of 31 December 2021 it beneficially owned 114,819,555 ordinary shares representing 5.0% of the Company’s ordinary shares outstanding as of 31 December 2020.

Capital International Investors, a division of Capital Research and Management Company, filed with the SEC an amendment to Schedule 13G under the Exchange Act on 11 February 2022 disclosing that as of 31 December 2021 it beneficially owned 110,680,543 ordinary shares representing 4.8% of the Company’s ordinary shares outstanding as of 31 December 2020. Capital International Investors, a division of Capital Research and Management Company, filed with the SEC an amendment to Schedule 13G under the Exchange Act on 16 February 2021 disclosing that as of 31 December 2020 it beneficially owned 42,749,672 ordinary shares representing 1.9% of the Company’s ordinary shares outstanding as of 31 December 2020. Capital International Investors, a division of Capital Research and Management Company, filed with the SEC a statement on Schedule 13G under the Exchange Act on 16 February 2021, disclosing that as of 31 December 2020 it beneficially owned 122,341,746 ordinary shares representing 5.3% of the Company’s ordinary shares outstanding as of 31 December 2020. Capital Research Global Investors, a division of Capital Research and Management Company, filed with the SEC an amendment to Schedule 13G under the Exchange Act on 10 February 2021 disclosing that as of 31 December 2020 it beneficially owned 120,909,021 ordinary shares representing 5.2% of the Company’s ordinary shares outstanding as of 31 December 2019.

The Capital Group Companies, Inc. notified the Company on: 8 March 2019 that its interest had increased above 11% to 253,390,697 ordinary shares on 7 March 2019; 11 April 2019 that its interest had decreased below 11% to 252,158,534 ordinary shares on 10 April 2019; 15 April 2019 that its interest had increased above 11% to 252,776,218 ordinary shares on 11 April 2019; 16 April 2019 that its interest had decreased below 11% to 251,780,072 ordinary shares on 15 April 2019; 19 November 2019 that its interest had increased above 11% to 253,543,406 ordinary shares on 18 November 2019; 6 January 2020 that its interest had increased above 12% to 275,376,579 ordinary shares on 3 January 2020; 26 March 2020 that its interest had decreased below 12% to 274,639,101 ordinary shares on 25 March 2020; 8 April that its interest had increased above 12% to 276,318,394 ordinary shares on 7 April 2020; 22 July 2020 that its interest had decreased below 12% to 243,800,405 ordinary shares on 20 July 2020; 6 August 2020 that its interest had decreased below 11% to 248,222,696 ordinary shares on 4 August 2020; 1 October 2020 that its interest had increased above 11% to 256,821,304 ordinary shares on 9 September 2020; 28 March 2021 that its interest had decreased to 252,372,160 ordinary shares on 26 March 2021; 20 April 2021 that its interest had increased above 11% to 253,881,408 ordinary shares on 11 April 2021; and 15 October 2021 that its interest had decreased below 11% to 251,829,230 ordinary shares on 14 October 2021.

Spring Mountain Investments Ltd notified the Company on: 22 October 2020 that its interest had increased above the notifiable threshold of 3% to 69,295,724 ordinary shares on 20 October 2020; 11 December 2020 that its interest had increased above 4% to 92,462,558 ordinary shares on 9 December 2020; 14 January 2021 that its interest had increased above 5% to 119,596,737 ordinary shares on 12 January 2021; 19 February 2021 that its interest had increased above 6% to 138,342,092 ordinary shares on 23 February 2021; 22 April 2021 that its interest had increased above 7% to 161,977,731 ordinary shares on 20 April 2021; 17 August 2021 that its interest had increased above 8% to 184,360,731 ordinary shares on 16 August 2021; and 12 November 2021 that its interest had increased to 187,023,731 ordinary shares on 11 November 2021.

To the extent known by BAT, BAT is not directly or indirectly owned or controlled by another corporation, any foreign government or by any other natural or legal person, severally or jointly. BAT is not aware of any arrangements, the operation of which may at a subsequent date result in a change of control of the Group.
### Share Capital and Security Ownership Continued

#### Security Ownership of the Board of Directors and the Management Board

The following table presents information regarding the total amount of ordinary shares beneficially owned (outright, by their family or by connected persons) by each current Director of BAT, each member of the Management Board and all Directors and the Management Board as a group, as of 9 February 2022. Unless otherwise indicated, the address for each Director and member of the Management Board listed is: c/o British American Tobacco p.l.c., Globe House, 4 Temple Place, London, WC2R 2PG, United Kingdom. The address for Michael Dijanosic is Level 30, Three Pacific Place, 1 Queen’s Road East, Hong Kong. The address for Guy Meldrum is 401 North Main Street, Winston-Salem, NC 27101, United States of America.

<table>
<thead>
<tr>
<th>Directors</th>
<th>Number of Ordinary Shares</th>
<th>Percentage of Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luc Jobin</td>
<td>90,236</td>
<td>0.0039</td>
</tr>
<tr>
<td>Jack Bowles</td>
<td>239,214</td>
<td>0.0104</td>
</tr>
<tr>
<td>Tadeu Marrococ</td>
<td>78,133</td>
<td>0.0034</td>
</tr>
<tr>
<td>Sue Farr</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Karen Guerra</td>
<td>5,000</td>
<td>0.0002</td>
</tr>
<tr>
<td>Dr Marion Heimes</td>
<td>4,500</td>
<td>0.0002</td>
</tr>
<tr>
<td>Holly Keller Kooppeiti</td>
<td>4,238</td>
<td>0.0004</td>
</tr>
<tr>
<td>Savio Kwang</td>
<td>3,300</td>
<td>0.0001</td>
</tr>
<tr>
<td>Dimitri Panayotopoulos</td>
<td>3,007</td>
<td>0.0001</td>
</tr>
<tr>
<td>Darrell Thomas</td>
<td>2,600</td>
<td>0.0001</td>
</tr>
<tr>
<td>Johan Vandermeulen</td>
<td>18,294</td>
<td>0.0008</td>
</tr>
<tr>
<td>Michael Dijanosic</td>
<td>150,447</td>
<td>0.0066</td>
</tr>
<tr>
<td>Luciano Comini</td>
<td>30,523</td>
<td>0.0013</td>
</tr>
<tr>
<td>Marina Bellini</td>
<td>30,253</td>
<td>0.0013</td>
</tr>
<tr>
<td>Luc Jobin</td>
<td>2,551</td>
<td>0.0001</td>
</tr>
<tr>
<td>Marina Bellini</td>
<td>2,551</td>
<td>0.0001</td>
</tr>
<tr>
<td>Luciano Comini</td>
<td>2,551</td>
<td>0.0001</td>
</tr>
<tr>
<td>Michael Dijanosic</td>
<td>2,551</td>
<td>0.0001</td>
</tr>
<tr>
<td>Johan Vandermeulen</td>
<td>2,551</td>
<td>0.0001</td>
</tr>
<tr>
<td>Kingsley Wheaton</td>
<td>2,551</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

#### Management Board

<table>
<thead>
<tr>
<th>Directors</th>
<th>Number of Ordinary Shares</th>
<th>Percentage of Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jerome Abelmani</td>
<td>102,664</td>
<td>0.0045</td>
</tr>
<tr>
<td>Marina Bellini</td>
<td>52,551</td>
<td>0.0022</td>
</tr>
<tr>
<td>Luciano Comini</td>
<td>30,253</td>
<td>0.0013</td>
</tr>
<tr>
<td>Michael Dijanosic</td>
<td>28,876</td>
<td>0.0013</td>
</tr>
<tr>
<td>Zafar Khan</td>
<td>415</td>
<td>0.0002</td>
</tr>
<tr>
<td>Hae In Kim</td>
<td>18,294</td>
<td>0.0008</td>
</tr>
<tr>
<td>Paul Lageweg</td>
<td>150,447</td>
<td>0.0066</td>
</tr>
<tr>
<td>Guy Meldrum</td>
<td>25,299</td>
<td>0.0011</td>
</tr>
<tr>
<td>David O'Reilly</td>
<td>77,822</td>
<td>0.0034</td>
</tr>
<tr>
<td>Johan Vandermeulen</td>
<td>77,506</td>
<td>0.0034</td>
</tr>
<tr>
<td>Kingsley Wheaton</td>
<td>61,992</td>
<td>0.0027</td>
</tr>
</tbody>
</table>

#### Notes:

1. The ordinary shares beneficially owned by Mr Jobin and Mr Thomas are represented by ADSs, each of which represents one ordinary share.

2. The number of ordinary shares beneficially owned by the Executive Directors include ordinary shares awarded and required to be held for a period of at least three years in a UK-based trust under the SIP. Ordinary shares cannot be sold or transferred out of the trust until the end of the three-year holding period. The amounts next to the corresponding Executive Director include the following ordinary shares held in the trust under the SIP: (a) 622 ordinary shares for Mr Bowles, of which 451 have been held for less than three years; (b) 1,347 ordinary shares for Mr Marrococ, of which 528 have been held for less than three years; in all cases, the beneficial owner of ordinary shares under the SIP may direct the trust to exercise its voting rights in accordance with the instructions. See footnote (1) to the table below under the heading “Outstanding Share-based Awards and Options-based Awards of the Board of Directors.”

3. The number of ordinary shares beneficially owned by the Executive Directors include the following number of awards of restricted ordinary shares granted under the DSBS that are scheduled to vest within 60 days of 9 February 2022: (a) 28,152 ordinary shares for Mr Bowles; (b) 13,233 ordinary shares for Mr Marrococ. Until awards of ordinary shares under the DSBS vest, they are held in trust and the recipient of such award does not have the ability to transfer, sell or otherwise dispose of the ordinary shares. See footnote (4) to the table below under the heading “Outstanding Share-based Awards and Options-based Awards of the Board of Directors.”

4. The number of ordinary shares beneficially owned by Mr Marrococ includes 36,057 options granted under the LTIP that are scheduled to vest and may be exercised within 60 days of 9 February 2022. Each option is convertible into one ordinary share upon exercise. See footnote (1) to the table below under the heading “Outstanding Share-based Awards and Options-based Awards of the Board of Directors and the Management Board” for additional details regarding the LTIP.

5. Ms Koeppel, being a former director of Reynolds American Inc. and a participant in the Deferred Compensation Plan for Directors of Reynolds American Inc. ("DCP"), holds DSUs which were granted prior to becoming a Director of BAT. Each DSU entitles the holder to receive a cash payment upon ceasing to be a Director equal to the value of one BAT ADS. The number of DSUs increases on each dividend date by reference to the value of dividends declared on the ADSs underlying the DSUs. Mr Kooppeiti currently holds 20,658,296 DSUs.

6. All Directors and the Management Board as a group (21 persons)
8. The number of ordinary shares beneficially owned by the members of the Management Board include the following number of awards of restricted ordinary shares granted under the DSBS that are scheduled to vest within 60 days of 9 February 2022: (a) 13,785 ordinary shares for Mr Abelman; (b) 5,084 ordinary shares for Mr Comin; (c) 2,881 ordinary shares for Mr Conn; (d) 3,785 ordinary shares for Mr Khan; (e) 3,785 ordinary shares for Ms Kim; (f) 5,265 ordinary shares for Mr Lageweg; (g) 5,051 ordinary shares for Mr Meldrum; (h) 11,028 ordinary shares for Dr O'Reilly; (i) 2,827 ordinary shares for Mr Panayotopoulos; (j) 13,785 ordinary shares for Mr Wheaton; and (k) 5,525 ordinary shares for Ms Bellini. Until awards of ordinary shares under the DSBS vest, they are held in trust and the recipient of such award does not have the ability to transfer, sell or direct the voting of the applicable ordinary shares. See footnote (4) to the table below under the heading ‘Outstanding Share-based Awards and Options-based Awards of the Board of Directors and the Management Board’ for additional details regarding the DSBS.

9. The number of ordinary shares beneficially owned by Mr Lageweg includes 109,558 ADSs, each of which represents one ordinary share.

10. The information in this column is based on 2,294,690,625 ordinary shares outstanding (excluding treasury shares) as of 9 February 2022. Any securities not outstanding subject to options, warrants, rights or conversion privileges that give the beneficial owner the right to acquire the securities within 60 days are deemed to be outstanding for the purpose of computing the percentage of outstanding securities of the class owned by such person but are not deemed to be outstanding for the purpose of computing the percentage of the class by any other person.

Outstanding Share-Based Awards and Options-Based Awards of the Board of Directors and the Management Board

The following table presents information regarding the options and the restricted share awards held by the Directors and the Management Board as of 9 February 2022. The following Directors (being the Chairman and the Non-Executive Directors) have not been granted share-based Awards or Options-based Awards over ordinary shares: Mr Jobin, Ms Farr, Ms Guerra, Dr Helmes, Ms Koeppel, Mr Kwan, Mr Panayotopoulos and Mr Thomas.

<table>
<thead>
<tr>
<th>Directors</th>
<th>Number of Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Grant £</th>
<th>Number of Shares Awarded</th>
<th>Exerciseable (LTIP/Sharesave)</th>
<th>Vesting (DSBS/SIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LTIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jack Bowles</td>
<td>176,532</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2024 – 27 Mar 2029</td>
<td></td>
</tr>
<tr>
<td></td>
<td>223,129</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2025 – 29 Mar 2030</td>
<td></td>
</tr>
<tr>
<td></td>
<td>230,314</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2026 – 28 Mar 2031</td>
<td></td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td>629,975</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DSBS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>53,618</td>
<td>30 Mar 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>40,052</td>
<td>29 Mar 2024</td>
<td></td>
</tr>
<tr>
<td><strong>SIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2019</td>
<td>–</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 May 2019</td>
<td>–</td>
<td>–</td>
<td>6</td>
<td>8 May 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 Aug 2019</td>
<td>–</td>
<td>–</td>
<td>8</td>
<td>8 Aug 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>14 Nov 2019</td>
<td>–</td>
<td>–</td>
<td>9</td>
<td>14 Nov 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>6 Feb 2020</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>6 Feb 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2020</td>
<td>–</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>13 May 2020</td>
<td>–</td>
<td>–</td>
<td>9</td>
<td>13 May 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>19 Aug 2020</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>19 Aug 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 Nov 2020</td>
<td>–</td>
<td>–</td>
<td>12</td>
<td>12 Nov 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>5 Feb 2021</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>5 Feb 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 May 2021</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>12 May 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>20 Aug 2021</td>
<td>–</td>
<td>–</td>
<td>16</td>
<td>20 Aug 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>11 Nov 2021</td>
<td>–</td>
<td>–</td>
<td>16</td>
<td>11 Nov 2024</td>
<td></td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td>120,313</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Other Information
Share Capital and Security Ownership
Continued

<table>
<thead>
<tr>
<th>Number of Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Grant £</th>
<th>Number of Shares Awarded</th>
<th>Vesting (LTIP/Sharesave)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTIP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36,057</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td>113,938</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2025 – 29 Mar 2030</td>
</tr>
<tr>
<td>115,017</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2026 – 28 Mar 2031</td>
</tr>
<tr>
<td>Sharesave2</td>
<td>624</td>
<td>30 Mar 2020</td>
<td>24.01</td>
<td>26.35</td>
<td>1 May 2025 – 31 Oct 2025</td>
</tr>
<tr>
<td>Total Options3</td>
<td>265,636</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DSBS4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– 30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>24,388</td>
<td>30 Mar 2023</td>
<td></td>
</tr>
<tr>
<td>– 29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>18,727</td>
<td>29 Mar 2024</td>
<td></td>
</tr>
<tr>
<td>SIP5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– 1 Apr 2019</td>
<td>–</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
<td></td>
</tr>
<tr>
<td>– 8 May 2019</td>
<td>–</td>
<td>–</td>
<td>11</td>
<td>8 May 2022</td>
<td></td>
</tr>
<tr>
<td>– 8 Aug 2019</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>8 Aug 2022</td>
<td></td>
</tr>
<tr>
<td>– 14 Nov 2019</td>
<td>–</td>
<td>–</td>
<td>14</td>
<td>14 Nov 2022</td>
<td></td>
</tr>
<tr>
<td>– 6 Feb 2020</td>
<td>–</td>
<td>–</td>
<td>12</td>
<td>6 Feb 2023</td>
<td></td>
</tr>
<tr>
<td>– 1 Apr 2020</td>
<td>–</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
<td></td>
</tr>
<tr>
<td>– 13 May 2020</td>
<td>–</td>
<td>–</td>
<td>14</td>
<td>13 May 2023</td>
<td></td>
</tr>
<tr>
<td>– 19 Aug 2020</td>
<td>–</td>
<td>–</td>
<td>21</td>
<td>19 Aug 2023</td>
<td></td>
</tr>
<tr>
<td>– 12 Nov 2020</td>
<td>–</td>
<td>–</td>
<td>20</td>
<td>12 Nov 2023</td>
<td></td>
</tr>
<tr>
<td>– 5 Feb 2021</td>
<td>–</td>
<td>–</td>
<td>21</td>
<td>5 Feb 2024</td>
<td></td>
</tr>
<tr>
<td>– 1 Apr 2021</td>
<td>–</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
<td></td>
</tr>
<tr>
<td>– 14 May 2021</td>
<td>–</td>
<td>–</td>
<td>22</td>
<td>14 May 2024</td>
<td></td>
</tr>
<tr>
<td>– 20 Aug 2021</td>
<td>–</td>
<td>–</td>
<td>25</td>
<td>20 Aug 2024</td>
<td></td>
</tr>
<tr>
<td>– 11 Nov 2021</td>
<td>–</td>
<td>–</td>
<td>27</td>
<td>11 Nov 2024</td>
<td></td>
</tr>
<tr>
<td>Total Restricted Share Awards6</td>
<td>56,877</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

364
### Management Board

#### Jerome Abelman

<table>
<thead>
<tr>
<th></th>
<th>Number of Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Grant of Option £</th>
<th>Number of Shares Awarded</th>
<th>Exercisable (LTIP/Sharesave)</th>
<th>Vesting (DSBS/SIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LTIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>37,560</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40,676</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023 – 29 Mar 2030</td>
<td></td>
</tr>
<tr>
<td></td>
<td>38,715</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024 – 28 Mar 2031</td>
<td></td>
</tr>
<tr>
<td><strong>Restricted Share Plan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10,653</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10,139</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024</td>
<td></td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>137,743</td>
<td></td>
</tr>
<tr>
<td><strong>DSBS4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>15,824</td>
<td>30 Mar 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>11,114</td>
<td>29 Mar 2024</td>
<td></td>
</tr>
<tr>
<td><strong>SIP5</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2019</td>
<td>–</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 May 2019</td>
<td>–</td>
<td>–</td>
<td>9</td>
<td>8 May 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 Aug 2019</td>
<td>–</td>
<td>–</td>
<td>10</td>
<td>8 Aug 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>14 Nov 2019</td>
<td>–</td>
<td>–</td>
<td>11</td>
<td>14 Nov 2022</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>6 Feb 2020</td>
<td>–</td>
<td>–</td>
<td>10</td>
<td>6 Feb 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2020</td>
<td>–</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>13 May 2020</td>
<td>–</td>
<td>–</td>
<td>12</td>
<td>13 May 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>19 Aug 2020</td>
<td>–</td>
<td>–</td>
<td>18</td>
<td>19 Aug 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 Nov 2020</td>
<td>–</td>
<td>–</td>
<td>17</td>
<td>12 Nov 2023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>5 Feb 2021</td>
<td>–</td>
<td>–</td>
<td>18</td>
<td>5 Feb 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 May 2021</td>
<td>–</td>
<td>–</td>
<td>18</td>
<td>12 May 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>20 Aug 2021</td>
<td>–</td>
<td>–</td>
<td>22</td>
<td>20 Aug 2024</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>11 Nov 2021</td>
<td>–</td>
<td>–</td>
<td>24</td>
<td>11 Nov 2024</td>
<td></td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>41,221</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

365
### Share Capital and Security Ownership

#### Continued

<table>
<thead>
<tr>
<th>Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Grant £</th>
<th>Number of Shares Awarded</th>
<th>Exercisable (LTI/SIP) Vesting (DSBS/SIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marina Bellini</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LTIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29,296</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td>31,105</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023 – 29 Mar 2030</td>
</tr>
<tr>
<td>39,835</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024 – 28 Mar 2031</td>
</tr>
<tr>
<td><strong>Restricted Share Plan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8,146</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td>10,433</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Sharesave</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td>119,600</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DSBS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>12,101</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>10,711</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>SIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>1 Apr 2019</td>
<td>–</td>
<td>–</td>
<td>99</td>
<td>1 Apr 2022</td>
</tr>
<tr>
<td>–</td>
<td>8 Aug 2019</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>8 Aug 2022</td>
</tr>
<tr>
<td>–</td>
<td>14 Nov 2019</td>
<td>–</td>
<td>–</td>
<td>3</td>
<td>14 Nov 2022</td>
</tr>
<tr>
<td>–</td>
<td>6 Feb 2020</td>
<td>–</td>
<td>–</td>
<td>2</td>
<td>6 Feb 2023</td>
</tr>
<tr>
<td>–</td>
<td>1 Apr 2020</td>
<td>–</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
</tr>
<tr>
<td>–</td>
<td>13 May 2020</td>
<td>–</td>
<td>–</td>
<td>2</td>
<td>13 May 2023</td>
</tr>
<tr>
<td>–</td>
<td>19 Aug 2020</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>19 Aug 2023</td>
</tr>
<tr>
<td>–</td>
<td>12 Nov 2020</td>
<td>–</td>
<td>–</td>
<td>6</td>
<td>12 Nov 2023</td>
</tr>
<tr>
<td>–</td>
<td>5 Feb 2021</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>5 Feb 2024</td>
</tr>
<tr>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
</tr>
<tr>
<td>–</td>
<td>12 May 2021</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>14 May 2024</td>
</tr>
<tr>
<td>–</td>
<td>20 Aug 2021</td>
<td>–</td>
<td>–</td>
<td>10</td>
<td>20 Aug 2024</td>
</tr>
<tr>
<td>–</td>
<td>11 Nov 2021</td>
<td>–</td>
<td>–</td>
<td>10</td>
<td>11 Nov 2024</td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td>28,708</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of Options Held</td>
<td>Date of Grant/Award</td>
<td>Options Exercise Price</td>
<td>Market Price at Date of Grant of Option</td>
<td>Number of Shares Awarded</td>
<td>Exercisable (LTIP/Sharesave) Vesting (DSBS/SIP)</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>-----------------------------------------</td>
<td>--------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Luciano Comin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP1</td>
<td>31,550</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td></td>
<td>5,299</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>25.52</td>
<td>30 Mar 2023 – 29 Mar 2030</td>
</tr>
<tr>
<td></td>
<td>36,077</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>29 Mar 2024 – 28 Mar 2031</td>
</tr>
<tr>
<td>Restricted Share Plan7</td>
<td>8,773</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>9,448</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Options3</strong></td>
<td>91,147</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DSBS4</td>
<td>–</td>
<td>28 Mar 2019</td>
<td>–</td>
<td>5,084</td>
<td>28 Mar 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>13,032</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>10,059</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td>SIP5</td>
<td>–</td>
<td>8 May 2019</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 Aug 2019</td>
<td>–</td>
<td>9</td>
<td>8 May 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>14 Nov 2019</td>
<td>–</td>
<td>12</td>
<td>14 Nov 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>6 Feb 2020</td>
<td>–</td>
<td>10</td>
<td>6 Feb 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2020</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>13 May 2020</td>
<td>–</td>
<td>13</td>
<td>13 May 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>19 Aug 2020</td>
<td>–</td>
<td>18</td>
<td>19 Aug 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 Nov 2020</td>
<td>–</td>
<td>17</td>
<td>12 Nov 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>5 Feb 2021</td>
<td>–</td>
<td>18</td>
<td>5 Feb 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 May 2021</td>
<td>–</td>
<td>19</td>
<td>14 May 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>20 Aug 2021</td>
<td>–</td>
<td>22</td>
<td>20 Aug 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>11 Nov 2021</td>
<td>–</td>
<td>24</td>
<td>11 Nov 2024</td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28,677</td>
</tr>
<tr>
<td><strong>Michael Dijanovic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP1</td>
<td>8,299</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td></td>
<td>7,739</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>30 Mar 2023 – 29 Mar 2030</td>
</tr>
<tr>
<td></td>
<td>31,567</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>29 Mar 2024 – 28 Mar 2031</td>
</tr>
<tr>
<td>Restricted Share Plan7</td>
<td>2,149</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>8,267</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Options3</strong></td>
<td>58,021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>2,746</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>4,873</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td>SIP5</td>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>30</td>
<td>1 Apr 2024</td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10,476</td>
</tr>
</tbody>
</table>
### Share Capital and Security Ownership

#### Continued

<table>
<thead>
<tr>
<th>Number of Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Option £</th>
<th>Number of Shares Awarded</th>
<th>Exercisable (LTIP/Sharesave) Vesting (DSBS/SIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zafar Khan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LTIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8,862</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td></td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td>8,855</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>25.52</td>
<td></td>
<td>30 Mar 2023 – 29 Mar 2030</td>
</tr>
<tr>
<td>31,567</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td></td>
<td>29 Mar 2024 – 28 Mar 2031</td>
</tr>
<tr>
<td><strong>Restricted Share Plan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,459</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td></td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td>8,043</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td></td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td><strong>59,786</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DSBS</strong></td>
<td>28 Mar 2019</td>
<td>–</td>
<td>2,981</td>
<td></td>
<td>28 Mar 2022</td>
</tr>
<tr>
<td>30 Mar 2020</td>
<td>–</td>
<td>3,062</td>
<td>30 Mar 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 Mar 2021</td>
<td>–</td>
<td>2,992</td>
<td>29 Mar 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SIP</strong></td>
<td>1 Apr 2019</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
<td></td>
</tr>
<tr>
<td>1 Apr 2021</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 Aug 2021</td>
<td>–</td>
<td>1</td>
<td>20 Aug 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Nov 2021</td>
<td>–</td>
<td>2</td>
<td>11 Nov 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td></td>
<td></td>
<td><strong>9,242</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hae In Kim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LTIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30,048</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td></td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td>2,802</td>
<td>6 Apr 2020</td>
<td>0.00</td>
<td>29.50</td>
<td></td>
<td>6 Apr 2023 – 5 Apr 2030</td>
</tr>
<tr>
<td>35,325</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td></td>
<td>29 Mar 2024 – 28 Mar 2031</td>
</tr>
<tr>
<td><strong>Restricted Share Plan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8,355</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td></td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td>9,251</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td></td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td><strong>85,781</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DSBS</strong></td>
<td>28 Mar 2019</td>
<td>–</td>
<td>3,798</td>
<td></td>
<td>28 Mar 2022</td>
</tr>
<tr>
<td>30 Mar 2020</td>
<td>–</td>
<td>12,411</td>
<td>30 Mar 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 Mar 2021</td>
<td>–</td>
<td>9,789</td>
<td>29 Mar 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SIP</strong></td>
<td>1 Apr 2019</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
<td></td>
</tr>
<tr>
<td>8 May 2019</td>
<td>–</td>
<td>1</td>
<td>8 May 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Aug 2019</td>
<td>–</td>
<td>3</td>
<td>8 Aug 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 Nov 2019</td>
<td>–</td>
<td>4</td>
<td>14 Nov 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Feb 2020</td>
<td>–</td>
<td>3</td>
<td>6 Feb 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Apr 2020</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 May 2020</td>
<td>–</td>
<td>3</td>
<td>13 May 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 Aug 2020</td>
<td>–</td>
<td>7</td>
<td>19 Aug 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Nov 2020</td>
<td>–</td>
<td>6</td>
<td>12 Nov 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Feb 2021</td>
<td>–</td>
<td>6</td>
<td>5 Feb 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Apr 2021</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 May 2021</td>
<td>–</td>
<td>7</td>
<td>14 May 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 Aug 2021</td>
<td>–</td>
<td>9</td>
<td>20 Aug 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Nov 2021</td>
<td>–</td>
<td>9</td>
<td>11 Nov 2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td></td>
<td></td>
<td><strong>26,385</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total

**368**
<table>
<thead>
<tr>
<th>Name</th>
<th>LTIP</th>
<th>Restricted Share Plan</th>
<th>Sharesave</th>
<th>Total Options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paul Lageweg</strong></td>
<td></td>
<td></td>
<td></td>
<td>115,485</td>
</tr>
<tr>
<td>LTIP1</td>
<td>29,296</td>
<td>31,105</td>
<td>36,159</td>
<td>8,146</td>
</tr>
<tr>
<td>Options Exercise Price £</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Market Price at Date of Grant of Option £</td>
<td>33.28</td>
<td>26.33</td>
<td>27.94</td>
<td>26.33</td>
</tr>
<tr>
<td>Number of Shares Awarded</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vesting (LTIP/Sharesave)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Guy Meldrum</strong></td>
<td></td>
<td></td>
<td></td>
<td>100,966</td>
</tr>
<tr>
<td>LTIP1</td>
<td>31,550</td>
<td>43,593</td>
<td>8,773</td>
<td>8,773</td>
</tr>
<tr>
<td>Options Exercise Price £</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Market Price at Date of Grant of Option £</td>
<td>33.28</td>
<td>26.33</td>
<td>27.94</td>
<td>26.33</td>
</tr>
<tr>
<td>Number of Shares Awarded</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vesting (LTIP/Sharesave)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Share Capital and Security Ownership

#### Continued

<table>
<thead>
<tr>
<th>Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Option £</th>
<th>Number of Shares Awarded</th>
<th>Exercisable (LTIP/Sharesave)</th>
<th>Vesting (DSBS/SIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dr David O'Reilly</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30,048</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
<td></td>
</tr>
<tr>
<td>12,354</td>
<td>2 Apr 2020</td>
<td>0.00</td>
<td>25.52</td>
<td>–</td>
<td>2 Apr 2023 – 1 Apr 2030</td>
<td></td>
</tr>
<tr>
<td>31,282</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024 – 28 Mar 2031</td>
<td></td>
</tr>
<tr>
<td>Restricted Share Plan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8,522</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023</td>
<td></td>
</tr>
<tr>
<td>8,152</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024</td>
<td></td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td>90,398</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DSBS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>12,659</td>
<td>30 Mar 2023</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>8,958</td>
<td>29 Mar 2024</td>
<td></td>
</tr>
<tr>
<td>SIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>1 Apr 2019</td>
<td>–</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>8 May 2019</td>
<td>–</td>
<td>–</td>
<td>31</td>
<td>8 May 2022</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>8 Aug 2019</td>
<td>–</td>
<td>–</td>
<td>32</td>
<td>8 Aug 2022</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>14 Nov 2019</td>
<td>–</td>
<td>–</td>
<td>33</td>
<td>14 Nov 2022</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>6 Feb 2020</td>
<td>–</td>
<td>–</td>
<td>29</td>
<td>6 Feb 2023</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>1 Apr 2020</td>
<td>–</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>13 May 2020</td>
<td>–</td>
<td>–</td>
<td>34</td>
<td>13 May 2023</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>19 Aug 2020</td>
<td>–</td>
<td>–</td>
<td>44</td>
<td>19 Aug 2023</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>12 Nov 2020</td>
<td>–</td>
<td>–</td>
<td>42</td>
<td>12 Nov 2023</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>5 Feb 2021</td>
<td>–</td>
<td>–</td>
<td>43</td>
<td>5 Feb 2024</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>12 May 2021</td>
<td>–</td>
<td>–</td>
<td>44</td>
<td>14 May 2024</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>20 Aug 2021</td>
<td>–</td>
<td>–</td>
<td>48</td>
<td>20 Aug 2024</td>
<td></td>
</tr>
<tr>
<td>–</td>
<td>11 Nov 2021</td>
<td>–</td>
<td>–</td>
<td>51</td>
<td>11 Nov 2024</td>
<td></td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td>33,405</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total: 370**
### Johan Vandermeulen

<table>
<thead>
<tr>
<th>Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Grant of Option £</th>
<th>Number of Shares Awarded</th>
<th>Vesting (LTIP/Sharesave)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTIP</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td></td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023 – 29 Mar 2030</td>
</tr>
<tr>
<td></td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>28 Mar 2024 – 28 Mar 2031</td>
<td></td>
</tr>
<tr>
<td>Restricted Share Plan</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>143,587</strong></td>
</tr>
<tr>
<td><strong>DSBS</strong></td>
<td>28 Mar 2019</td>
<td>–</td>
<td>–</td>
<td>13,785</td>
<td>28 Mar 2022</td>
</tr>
<tr>
<td></td>
<td>30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>16,290</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>11,615</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td>42,182</td>
<td></td>
<td></td>
<td>371</td>
<td></td>
</tr>
</tbody>
</table>
### Other Information

#### Share Capital and Security Ownership

<table>
<thead>
<tr>
<th>Kingsley Wheaton</th>
<th>Number of Options Held</th>
<th>Date of Grant/Award</th>
<th>Options Exercise Price £</th>
<th>Market Price at Date of Grant of Option £</th>
<th>Number of Shares Awarded</th>
<th>Exercisable (LTIP/Sharesave) Vesting (DSBS/SIP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTIP1</td>
<td>43,194</td>
<td>28 Mar 2019</td>
<td>0.00</td>
<td>33.28</td>
<td>–</td>
<td>28 Mar 2022 – 27 Mar 2029</td>
</tr>
<tr>
<td></td>
<td>46,777</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023 – 29 Mar 2030</td>
</tr>
<tr>
<td></td>
<td>48,578</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024 – 28 Mar 2031</td>
</tr>
<tr>
<td>Restricted Share Plan7</td>
<td>12,251</td>
<td>30 Mar 2020</td>
<td>0.00</td>
<td>26.33</td>
<td>–</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td>Sharesave7</td>
<td>12,722</td>
<td>29 Mar 2021</td>
<td>0.00</td>
<td>27.94</td>
<td>–</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td><strong>Total Options</strong></td>
<td><strong>164,831</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>30 Mar 2020</td>
<td>–</td>
<td>–</td>
<td>18,198</td>
<td>30 Mar 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>29 Mar 2021</td>
<td>–</td>
<td>–</td>
<td>13,454</td>
<td>29 Mar 2024</td>
</tr>
<tr>
<td>SIP5</td>
<td>–</td>
<td>1 Apr 2019</td>
<td>–</td>
<td>–</td>
<td>112</td>
<td>1 Apr 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 May 2019</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>8 May 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>8 Aug 2019</td>
<td>–</td>
<td>–</td>
<td>14</td>
<td>8 Aug 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>14 Nov 2019</td>
<td>–</td>
<td>–</td>
<td>16</td>
<td>14 Nov 2022</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>6 Feb 2020</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>6 Feb 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2020</td>
<td>–</td>
<td>–</td>
<td>125</td>
<td>1 Apr 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>13 May 2020</td>
<td>–</td>
<td>–</td>
<td>15</td>
<td>13 May 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>19 Aug 2020</td>
<td>–</td>
<td>–</td>
<td>22</td>
<td>19 Aug 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 Nov 2020</td>
<td>–</td>
<td>–</td>
<td>20</td>
<td>12 Nov 2023</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>5 Feb 2021</td>
<td>–</td>
<td>–</td>
<td>22</td>
<td>5 Feb 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>1 Apr 2021</td>
<td>–</td>
<td>–</td>
<td>92</td>
<td>1 Apr 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>12 May 2021</td>
<td>–</td>
<td>–</td>
<td>21</td>
<td>14 May 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>20 Aug 2021</td>
<td>–</td>
<td>–</td>
<td>24</td>
<td>20 Aug 2024</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>11 Nov 2021</td>
<td>–</td>
<td>–</td>
<td>26</td>
<td>11 Nov 2024</td>
</tr>
<tr>
<td><strong>Total Restricted Share Awards</strong></td>
<td><strong>45,972</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

1. LTIP: grants or awards of ordinary shares under the LTIP are for nil consideration. The number of options shown is the maximum that may be exercised subject to the completion of the applicable performance period and conditions under the rules of the LTIP. The number of options which may vest and become exercisable may be less than the number of ordinary shares shown in the table.

2. Sharesave Scheme: grants of options under the Sharesave Scheme are: (a) normally granted at a discount of 20% to the market price of ordinary shares at the time of invitation, as permitted by the rules of the Sharesave Scheme; and (b) are exercisable at the end of a three-year or five-year savings contract up to a monthly limit of £500.

3. Each of the LTIP and Sharesave Scheme contains provisions which permit the Board of Directors or a duly authorised committee of the Board of Directors to establish further plans for the benefit of overseas employees based on the relevant share plan but modified as necessary or desirable to take account of overseas tax, exchange control or applicable securities laws. Any new ordinary shares issued under such plans would not count towards any applicable plan limits under the LTIP or the Sharesave Scheme.

4. DSBS: a portion of annual bonus is deferred into a grant of ordinary shares which vests after a three year period. No further performance conditions apply in that period. Participants have no ownership over the shares until vesting and the shares carry no rights to vote in that period. Dividend equivalent payments are paid quarterly during the vesting period.

5. SIP: the SIP is an all-employee plan which includes the SRS under which eligible employees receive an award of ordinary shares (Free Shares) in April of each year in which the plan operates in respect of performance in the previous financial year. The Free Shares are held in a UK-based trust from the date of the award for a minimum period of three years. During that time the SIP participant is entitled to receive dividends on those ordinary shares which are re-invested by such trust to buy further ordinary shares (Dividend Shares), on behalf of the SIP participant. The Dividend Shares are also held in the trust from the date of acquisition for a minimum period of three years. During the three-year holding periods, the SIP participant may not remove the Free Shares or the Dividend Shares from the trust, but may direct the trust to exercise its voting rights in accordance with his or her instructions. In addition to the Free Shares and Dividend Shares, participants in the SIP are also eligible to purchase additional ordinary shares from their pre-tax salary up to an annual statutory limit (Partnership Shares). The SIP also provides that BAT has the right to offer additional ordinary shares to a participant at no cost for each Partnership Share the participant purchases, in a ratio of two such ordinary shares for each Partnership Share purchased (Matching Shares). BAT does not currently provide any Matching Shares.

6. BAT has established similar plans to the SIP for non-UK employees and specific plans for employees in Germany, Belgium and the Netherlands. Each of these plans has been modified to take account of overseas tax, exchange control and applicable securities laws.

7. Restricted Share Plan: grant of ordinary shares which vests after a three year period. No performance conditions apply in that period. Participants have no ownership over the shares until vesting and the shares carry no rights to vote in that period. Dividend equivalent payments are paid on shares vested.
Articles of Association

The Company is incorporated under the name of British American Tobacco p.l.c. and is registered in England and Wales under registered number 3407696. Under the Companies Act 2006 (the "Companies Act"), the Company's objects are unrestricted. The following descriptions summarise certain provisions of the Company's current Articles of Association (the "Articles") (as adopted by special resolution at the AGM on 28 April 2010), applicable English and Welsh law and the Companies Act. This summary is qualified in its entirety by reference to the Companies Act and the Articles, available on bat.com. The Articles may be altered or added to, or completely new articles may be adopted, by a special resolution of the shareholders of the Company, subject to the provisions of the Companies Act.

Share capital – structure

Ordinary shares

– all of the Company’s ordinary shares are fully paid
– no further contribution of capital may be required by the Company from the holders of such shares

Alteration of share capital – the Company by ordinary resolution may:

– consolidate and divide all or any of its shares into shares of a larger amount than its existing shares
– divide or sub-divide any of its shares into shares of smaller amount than its existing shares
– determine that, as between the shares resulting from such a sub-division, any of them may have any preference or advantage as compared with the others

Alteration of share capital – the Company, subject to the provisions of the Companies Act, may:

– reduce its share capital, its capital redemption reserve and any share premium account in any way
– purchase its own shares, including redeemable shares, and may hold such shares as treasury shares or cancel them

Dividend rights

– shareholders may, by ordinary resolution, declare dividends but not in excess of the amount recommended by the Directors
– the Directors may pay interim dividends out of distributable profits
– no dividend shall be paid otherwise than out of the profits available for distribution as specified under the provisions of the Companies Act

– the Directors may, with the authority of an ordinary resolution of the shareholders, pay scrip dividends or satisfy the payment of a dividend by the distribution of specific assets
– unclaimed dividends for a period of 12 years may be forfeited and cease to be owed by the Company
– specific provisions enable the Directors to elect to pay dividends by bank or electronic transfer only

Dividend rights

– shareholders may, by ordinary resolution, declare dividends but not in excess of the amount recommended by the Directors

– the Directors may pay interim dividends out of distributable profits
– no dividend shall be paid otherwise than out of the profits available for distribution as specified under the provisions of the Companies Act
– the Directors may, with the authority of an ordinary resolution of the shareholders, pay scrip dividends or satisfy the payment of a dividend by the distribution of specific assets
– unclaimed dividends for a period of 12 years may be forfeited and cease to be owed by the Company
– specific provisions enable the Directors to elect to pay dividends by bank or electronic transfer only

Share capital – voting rights

Voting at general meetings

– by a show of hands, unless a poll is demanded, and on a show of hands, every shareholder who is present in person at a general meeting has one vote regardless of the number of shares held by that shareholder

– every proxy appointed by a shareholder and present at a general meeting has one vote except that if the proxy has been duly appointed by more than one shareholder entitled to vote on the resolution and is instructed by one or more of those shareholders to vote for the resolution and by one or more others to vote against it, or is instructed by one or more of those shareholders to vote in one way and is given discretion as to how to vote by one or more others (and wishes to use that discretion to vote in the other way), he has one vote for and one vote against the resolution

– on a poll, every shareholder who is present in person or by proxy has one vote for every share held by the shareholder
– a shareholder (or his duly appointed proxy) entitled to more than one vote need not use all his votes or cast all the votes he uses in the same way
– a poll may be demanded by any of the following:
  (1) the Chairman of the meeting;
  (2) the Directors;
  (3) not less than five shareholders having the right to vote at the meeting;
  (4) a shareholder or shareholders representing not less than one-tenth of the total voting rights of all shareholders having the right to vote at the meeting (excluding any voting rights attached to treasury shares); or
  (5) a shareholder or shareholders holding shares which confer a right to vote on the resolution at the meeting being shares on which an aggregate sum has been paid up equal to not less than one-tenth of the total sum paid up on all shares conferring that right (excluding any voting rights attached to treasury shares).

Matters transacted at general meetings

– ordinary resolutions can include resolutions for the appointment, reappointment and removal of Directors, the receiving of the Annual Report, the declaration of final dividends, the appointment and reappointment of the external auditor, the authority for the Company to purchase its own shares and the grant of authority to allot shares
– an ordinary resolution is passed when a simple majority of the votes cast at a meeting vote in favour of the resolution
– special resolutions can include resolutions amending the Company’s Articles and resolutions relating to certain matters concerning a winding-up of the Company
– a special resolution is passed when not less than three-quarters of the votes cast at a meeting vote in favour of the resolution
– quorum for a meeting of the Company is a minimum of two shareholders present in person or by proxy or by a duly authorised representative(s) of a corporation which is a shareholder and entitled to vote
– convening a meeting: the Company may specify a time not more than 48 hours before the time of the meeting (excluding any part of a day that is not a working day) by which a person must be entered on the register of members in order to have the right to attend or vote at the meeting

373
Articles of Association

Share capital – pre-emptive rights and new issues of shares

- holders of ordinary shares have no pre-emptive rights under the Articles – the ability of the Directors to cause the Company to issue shares, securities convertible into shares or rights to shares, otherwise than pursuant to an employee share scheme, is restricted
- under the Companies Act, the directors of a company are, with certain exceptions, unable to allot any equity securities without express authorisation, which may be given in a company’s articles of association or given by its shareholders in a general meeting, but which in either event cannot last for more than five years
- under the Companies Act, a company may also not allot shares for cash (otherwise than pursuant to an employee share scheme) without first making an offer to existing shareholders to allot such shares to them on the same or more favourable terms in proportion to their respective shareholdings, unless this requirement is waived by a special resolution of the shareholders

Restrictions on transfers of shares

- Directors can, in their absolute discretion, refuse to register the transfer of a share in certificated form which is not fully paid, provided that such a refusal would not prevent dealings in shares in certificated form which are not fully paid from taking place on a proper basis
- the Directors may also refuse to register a transfer of a share in certificated form (whether fully paid or not) unless the instrument of transfer: (1) is lodged, duly stamped, and is deposited at the registered office of the Company or such other place as the Directors may appoint and is accompanied by a certificate for the shares to which it relates and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer; (2) is in respect of only one class of share; and (3) is in favour of not more than four transferees
- for uncertificated shares, transfers shall be registered only in accordance with the terms of the Uncertificated Securities Regulations 2001 so that Directors may refuse to register a transfer which would require shares to be held jointly by more than four persons
- if the Directors refuse to register a share transfer, they must give the transferee notice of this refusal as soon as practicable and in any event within two months of the instrument of transfer being lodged with the Company

Repurchase of shares

- subject to authorisation by shareholder resolution, the Company may purchase its own shares in accordance with the Companies Act
- any shares which have been bought back may be held as treasury shares or, if not so held, must be cancelled immediately upon completion of the purchase, thereby reducing the amount of the Company’s issued share capital

Directors

Appointment and retirement

- a Board of Directors of not fewer than five Directors and not subject to any maximum (unless otherwise determined by ordinary resolution of shareholders)
- Directors and the Company (by ordinary resolution) may appoint a person who is willing to act as a Director
- the Articles govern the minimum number of Directors who must be subject to retirement at each AGM and who may seek re-election
- notwithstanding the Articles, all of the Directors of the Company will be subject to re-election at the forthcoming AGM to be held on 28 April 2022 in accordance with the UK Corporate Governance Code
- fees for Non-Executive Directors and the Chairman are determined by the Directors but cannot currently exceed in aggregate an annual sum of £2,500,000, unless determined otherwise by ordinary resolution of the shareholders
- the remuneration of the Executive Directors is determined by the Remuneration Committee, which comprises independent Non-Executive Directors

Disclosure of interests

- the Articles require disclosure, subject to certain limited exceptions, of Directors’ interests in transactions that may result in a conflict of interest, including those which may arise as a result of the Director’s office or employment or persons connected with such Director, and identify procedures to resolve such conflicts of interest

Meetings and voting

- the quorum for a meeting of Directors is two Directors
- the Articles place a general prohibition on a Director voting at a Board meeting on any matter in which he has an interest other than by virtue of his interest in shares in the Company
- the Articles restrict a Director’s ability to vote on any resolution concerning a matter in which such Director has a material interest, unless such Director’s interest arises only because the resolution relates to the giving of guarantees; the provision of indemnities; insurance proposals; retirement benefits; and other specified transactions or arrangements with a company in which the Director may have an indirect interest

Borrowing powers

- the Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking, property, assets (present and future) and uncalled capital
- the Directors may also issue debentures, debenture stock and other securities
### Additional disclosures

<table>
<thead>
<tr>
<th>Disclosure of ownership of shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>– there are no provisions in the Articles whereby persons acquiring, holding or disposing of a certain percentage of the Company's ordinary shares are required to make disclosure of their ownership percentage, although there are such requirements under statute and regulation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Director retirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>– there is no requirement for a Director to retire on reaching any age</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sinking funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>– there is no sinking fund provision in the Articles applicable to the Company's ordinary shares</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Limitations on voting and shareholding</th>
</tr>
</thead>
<tbody>
<tr>
<td>– there are no limitations under the Articles restricting the right of non-resident or foreign owners to hold or vote ordinary shares in the Company</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distribution of assets on a winding up</th>
</tr>
</thead>
<tbody>
<tr>
<td>– If the Company is wound up, the liquidator may, with the sanction of a special resolution and any other sanction required by law, divide among the members in specie the whole or any part of the assets of the Company and may, for that purpose, value any assets and determine how the division shall be carried out as between the members or different classes of members</td>
</tr>
<tr>
<td>– the liquidator may, with the like sanction, vest the whole or any part of the assets in trustees upon such trusts for the benefit of the members as he may with the like sanction determine, but no member shall be compelled to accept any assets upon which there is a liability</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anti-takeover devices and change of control</th>
</tr>
</thead>
<tbody>
<tr>
<td>– there are no provisions in the Articles that would have the effect of delaying, deferring or preventing a takeover, or change of control, of the Company</td>
</tr>
<tr>
<td>– under English law, the Company's Directors have a fiduciary duty to take only those actions that are in the interests of the Company and any anti-takeover devices employed by the Directors in the future, if any, must accordingly be in the interests of the Company</td>
</tr>
<tr>
<td>– the Company is also subject to the City Code on Takeovers and Mergers (the &quot;City Code&quot;), which governs the conduct of mergers and takeovers in the UK. Any takeover of the Company would have to be in accordance with the City Code</td>
</tr>
</tbody>
</table>
Other Information

Purchase of Shares

Renewal of Authority for Company to Purchase Own Shares

Current authority to purchase shares

– this authority (granted at the 2021 AGM) will expire at the 2022 AGM; and
– renewed authority to purchase the Company’s ordinary shares in order that the appropriate mechanisms are in place to enable the share buy-back programme to be reinstated at any time and authority would be exercised when, in the opinion of the Directors, the exercise of the authority would result in an increase in the Company’s earnings per share and would be in the interest of its shareholders generally.

Proposed authority to purchase shares

– the minimum price that may be paid for such shares is 25p, and the maximum price is the higher of: (i) an amount equal to 105% of the average of the middle-market prices shown in the quotation for an ordinary share as derived from the LSE Daily Official List for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased; and (ii) the higher of the price of the last independent trade and the highest current independent bid for an ordinary share in the Company on the trading venues where the market purchases by the Company will be carried out;
– in the absence of the necessary practical arrangements, the proposed authority has not been extended to enable BAT to purchase its own ordinary shares on the JSE in South Africa or the NYSE in the form of ADSs; and
– further details are set out in the Notice of Annual General Meeting 2022 which is made available to all shareholders and is published on bat.com.

Treasury shares

– in accordance with the Company’s policy, any repurchased shares are expected to be held as treasury shares; at 31 December 2021, the number of treasury shares was 161,930,217 (2020: 162,347,246); no dividends are paid on treasury shares; treasury shares have no voting rights; and treasury shares may be resold at a later date.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

At the AGM on 28 April 2021, authorisation was given to the Company to repurchase up to 229.4 million ordinary shares for the period until the next AGM in 2022. This authorisation is renewed annually at the AGM. No ordinary shares were repurchased by the Company during 2021. The following table provides details of ordinary share purchases made by the trustees of employee share ownership plans (“ESOPs”) and other purchases of ordinary shares and ADSs made to satisfy the commitments to deliver shares under certain employee share-based payment plans.

<table>
<thead>
<tr>
<th>Date</th>
<th>Total number of ordinary shares purchased by ESOPs or certain employee share-based plans</th>
<th>Average price paid per ordinary share £</th>
<th>Total number of ADSs purchased by ESOPs or certain employee share-based plans</th>
<th>Average price paid per ADS US$</th>
<th>Total number of ordinary shares purchased as part of a publicly announced plan</th>
<th>Maximum number of shares that may yet be purchased as part of a publicly announced plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 January</td>
<td>3,046</td>
<td>28.118500</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3 February</td>
<td>3,187</td>
<td>27.188100</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3 February</td>
<td>21,151</td>
<td>27.127600</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3 March</td>
<td>3,407</td>
<td>25.497000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>31 March</td>
<td>1,783,215</td>
<td>27.709844</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 April</td>
<td>322,326</td>
<td>27.239586</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 April</td>
<td>177,289</td>
<td>27.320552</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 April</td>
<td>7,041</td>
<td>27.290000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 April</td>
<td>8,292</td>
<td>27.320552</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7 April</td>
<td>3,270</td>
<td>27.772500</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7 April</td>
<td>7,487</td>
<td>27.982000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7 April</td>
<td>2,770</td>
<td>27.605000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>28 April</td>
<td>80,120</td>
<td>27.046770</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>5 May</td>
<td>3,440</td>
<td>27.176900</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>12 May</td>
<td>20,286</td>
<td>28.130600</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3 June</td>
<td>3,482</td>
<td>27.226300</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7 July</td>
<td>3,221</td>
<td>28.091500</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4 August</td>
<td>3,208</td>
<td>27.060000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>20 August</td>
<td>23,208</td>
<td>27.142953</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 September</td>
<td>177,693</td>
<td>27.286770</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 September</td>
<td>2,752</td>
<td>27.151700</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6 October</td>
<td>3,925</td>
<td>25.149800</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4 November</td>
<td>3,415</td>
<td>25.220000</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 November</td>
<td>23,881</td>
<td>25.912700</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 December</td>
<td>3,255</td>
<td>25.643500</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>2,694,364</td>
<td>27.853777</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes:

1. There was no publicly announced plan for BAT to purchase its own ordinary shares or ADSs during the year ended 31 December 2021.
2. All the purchases of ordinary shares were made on open market transactions.
Group Employee Trust

The British American Tobacco Group Employee Trust (BATGET)

Function
- used to satisfy the vesting and exercise of awards of ordinary shares under the BAT Deferred Share Bonus Scheme and Long-Term Incentive Plans; and
- a committee of senior management reporting to the Board’s Share Schemes Committee monitors the number of ordinary shares held in BATGET to satisfy outstanding awards.

Funding
- funded by interest-free loan facilities from the Company totalling £1 billion;
- this enables BATGET to facilitate the purchase of ordinary shares to satisfy the future vesting or exercise of options and awards;
- loan to BATGET: £300.00 million at 31 December 2021 (2020: £795.02 million);
- the loan is either repaid from the proceeds of the exercise of options or, in the case of ordinary shares acquired by BATGET to satisfy the vesting and exercise of awards, the Company will subsequently waive the loan provided over the life of the awards; and
- if any options lapse, ordinary shares may be sold by BATGET to cover the loan repayment.

Ordinary shares held in BATGET

<table>
<thead>
<tr>
<th></th>
<th>1 Jan 2021</th>
<th>31 Dec 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of ordinary shares</td>
<td>5,787,154</td>
<td>5,995,678</td>
</tr>
<tr>
<td>Market value of ordinary shares</td>
<td>£156.7m</td>
<td>£163.9m</td>
</tr>
<tr>
<td>% of issued share capital of Company</td>
<td>0.24</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Dividends paid in 2021
- BATGET currently waives dividends on the ordinary shares held by it, and

Voting rights
- the trustee does not exercise any voting rights while ordinary shares are held in BATGET; and
- share scheme participants may exercise the voting rights attaching to those ordinary shares once the ordinary shares have been transferred out of BATGET.

Notes:
1. Company share-based payment arrangements: details of the material equity share-based and cash-settled share-based arrangements are set out in note 28 in the Notes on the Accounts.
2. The values of ordinary shares shown are based on the closing mid-market share price on 31 December 2021: 2,733p (31 December 2020: 2,708p).
3. In addition to the ordinary shares held in BATGET, the trust held the following American Depositary Shares (ADSs) which relate to the vesting and exercise of certain employee stock awards formerly granted by Reynolds American Inc. over Reynolds American Inc. common stock and which were assumed by BAT to be satisfied by the delivery of ADSs following the merger with Reynolds American Inc. on 25 July 2017.

American Depositary Shares

<table>
<thead>
<tr>
<th></th>
<th>1 Jan 2021</th>
<th>31 Dec 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of ADSs</td>
<td>15,197</td>
<td>15,197</td>
</tr>
<tr>
<td>Market value of ADSs(a)</td>
<td>US$0.6m</td>
<td>US$0.6m</td>
</tr>
<tr>
<td>% of issued share capital</td>
<td>0.0006</td>
<td>0.0006</td>
</tr>
</tbody>
</table>

Note:
(a) The value of the ADSs shown is based on the closing price of ADSs on 31 December 2021 of US$37.41
American Depositary Shares

Fees and Charges Payable by ADS Holders

Citibank, N.A. (Citibank) was appointed as the depositary bank (the "Depositary") for BAT's ADS programme pursuant to the Amended and Restated Deposit Agreement dated 1 December 2008 and amended as of 14 February 2017 and 14 June 2017 between BAT, the Depositary and the owners and holders of ADSs (the "Deposit Agreement"). Citibank was reappointed as the Depositary pursuant to the Second Amended and Restated Deposit Agreement dated 26 November 2018 (the "Restated Deposit Agreement").

The Restated Deposit Agreement provides that ADS holders may be required to pay various fees to the Depositary, and the Depositary may refuse to provide any service for which a fee is assessed until the applicable fee has been paid.

<table>
<thead>
<tr>
<th>Service</th>
<th>Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issuance of ADSs upon deposit of ordinary shares (excluding issuances as</td>
<td>Up to US$0.05 per ADS issued¹</td>
</tr>
<tr>
<td>a result of distributions of shares described below)</td>
<td></td>
</tr>
<tr>
<td>Cancellation of ADSs</td>
<td>Up to US$0.05 per ADS surrendered¹</td>
</tr>
<tr>
<td>Distribution of cash dividends or other cash distributions (i.e., sale</td>
<td>Up to US$0.05 per ADS held²</td>
</tr>
<tr>
<td>of rights and other entitlements)</td>
<td></td>
</tr>
<tr>
<td>Distribution of ADSs pursuant to: (1) stock dividends or other free stock</td>
<td>Up to US$0.05 per ADS held</td>
</tr>
<tr>
<td>distributions; or (2) exercise of rights to purchase additional BAT ADSs</td>
<td></td>
</tr>
<tr>
<td>(i.e., spinoff shares)</td>
<td></td>
</tr>
<tr>
<td>Distribution of securities other than ADSs or rights to purchase</td>
<td>Up to US$0.05 per ADS held</td>
</tr>
<tr>
<td>additional ADSs</td>
<td></td>
</tr>
<tr>
<td>Depositary bank services</td>
<td>Up to US$0.05 per ADS held</td>
</tr>
</tbody>
</table>

Notes:

1. Under the terms of a separate agreement between BAT and the Depositary, the Depositary has agreed to waive the fees that would otherwise be payable in connection with the issuance of ADSs upon deposit of ordinary shares and the cancellation of ADSs and corresponding withdrawal of ordinary shares, in each case by BAT or any of its affiliates, officers, directors or employees. The terms of this separate agreement may be amended at any time by BAT and the Depositary.

2. While under the Restated Deposit Agreement cash dividends paid in respect of ADSs are subject to a fee of up to US$0.05 per ADS payable to the Depositary, under the terms of the separate agreement between BAT and the Depositary referred to above, such dividends are instead subject to a fee of up to US$0.02 per ADS per year (a fee of US$0.005 per dividend based on the distribution of four quarterly cash dividends per year). Under the separate agreement, this dividend fee may not be varied by the Depositary without the consent of BAT.

Contact details for Citibank Shareholder Services are on page 377.

In addition, ADS holders may be required under the Restated Deposit Agreement to pay the Depositary: (a) taxes (including applicable interest and penalties) and other governmental charges; (b) registration fees; (c) certain cable, telex and facsimile transmission and delivery expenses; (d) the expenses and charges incurred by the Depositary in the conversion of foreign currency; (e) such fees and expenses as are incurred by the Depositary in connection with compliance with applicable exchange control regulations and other regulatory requirements; and (f) the fees and expenses incurred by the Depositary, the custodian or any nominee in connection with the servicing or delivery of deposited securities. The Depositary may: (a) withhold dividends or other distributions or sell for the account of any ADS holder any or all of the shares underlying the ADSs in order to satisfy any tax or governmental charge; and (b) deduct from any cash distribution the applicable fees and charges of, and expenses incurred by, the Depositary and any taxes, duties or other governmental charges on account.

Fees and Payments Made by the Depositary to BAT

Under the terms of the contractual arrangements set out in the separate agreement between BAT and the Depositary referred to above, BAT received a total of approximately US$6.1 million from the Depositary, comprising fees charged in respect of dividends and a contribution to BAT's ADS programme administration costs for the year ended 31 December 2021.

In 2021, these programme administration costs principally included those associated with AGM proxy mailings, exchange listing and regulatory fees, foreign private issuer analysis, legal fees, share registration fees and other expenses incurred by BAT in relation to the ADS programme.

Under these contractual arrangements, the Depositary has also agreed to waive certain standard fees associated with the administration of the ADS programme.
Shareholding Administration and Services

Ordinary Shareholder Enquiries

United Kingdom Registrar
Computershare Investor Services PLC
The Pavilions, Bridgwater Road, Bristol BS99 6Z
Tel: 0800 408 0094 or +44 370 889 3159
Online: www.investorcentre.co.uk/contactus

South African Registrar
Computershare Investor Services Proprietary Limited
Private Bag X9000, Saxonwold, 2132, South Africa
Tel: 0861 150 634, +27 11 870 8216
Email: web.queries@computershare.co.za

American Depository Shares Enquiries
All enquiries regarding ADS holder accounts and payment of dividends should be addressed to:
Citibank Shareholder Services
PO Box 43077, Providence, Rhode Island 02940-3077, USA
Tel: +1 888 985 2055 (toll-free) or +1 781 575 4555
Email: citibank@shareholders-online.com
Website: www.citi.com/it

Manage Your Shareholding Online
Computershare Investor Services PLC (Computershare) operates an online service, Investor Centre, for holders of shares on the Company’s UK share register. Investor Centre allows shareholders to manage their shareholding online, enabling shareholders to:
- update personal details and provide address changes;
- update dividend bank mandate instructions and review dividend payment history;
- register for the Dividend Reinvestment Plan (“DRIP”); and
- register to receive Company communications electronically.

To register for Investor Centre, go to www.computershare.com/uk/investor/brit. Shareholders with any queries regarding their holding should contact Computershare using the above contact details.

Share dealing
Computershare also offers a share dealing service to existing shareholders. For full details on how to trade British American Tobacco shares traded on the London Stock Exchange, go to www.computershare.com/dealing/uk. Please note that this service is only available in certain countries.

Dividends

Comprehensive information on dividend payments is available on pages 352 and 353.

DRIP
We offer a DRIP to our UK shareholders. The DRIP allows eligible shareholders to use their cash dividends to acquire additional shares in the Company. The DRIP shares are purchased by Computershare through a low-cost dealing arrangement. Contact Computershare in the UK for details and exclusions of this service.

Taxation of dividends
See pages 354 and 357 for details on dividend taxation. A fact sheet detailing historical UK capital gains tax information is available at bat.com/cgt. Alternatively, contact the British American Tobacco Company Secretarial Department on +44 20 7645 1000.

Share Fraud
The practice of share fraud (also known as ‘boiler room’ scams) unfortunately continues with many companies’ shareholders receiving unsolicited phone calls or mail from people offering to sell them what often turn out to be worthless or high risk shares in US or UK investments, or to buy shares at an inflated price in return for an upfront payment.

If you suspect that you have been approached by fraudsters, please tell the FCA using the share fraud reporting form at www.fca.org.uk/scams, where you can find out more about investment scams. You can also call the FCA Consumer Helpline on 0800 111 6768. If you have lost money to investment fraud, you should report it to Action Fraud on 0300 123 2040 or online at www.actionfraud.police.uk.

Documents on Display and Publications
This Annual Report and Form 20-F 2021 is available online at bat.com/annualreport. Copies of current and past Annual Reports are available on request from:
British American Tobacco Publications
Unit 80, London Industrial Park, Roding Road, London E6 6LS
Tel: +44 20 7511 7797 Email: bat@team365.co.uk

 ADS holders can contact Citibank Shareholder Services in the United States using the contact details shown opposite.

Highlights from the current and past Annual Reports can be produced in alternative formats such as Braille, audio tape and large print.

Our Website
Comprehensive information about British American Tobacco is available from our website: bat.com. Within the Investors section you will find valuation and charting tools, dividend and share price data and you can download shareholder publications and subscribe for email alert services. You can also download our Investor Relations app to access all the latest financial information on your iPad, iPhone or Android device.

Calendar 2022

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 April</td>
<td>Annual General Meeting</td>
</tr>
<tr>
<td>27 July</td>
<td>Half-Year Report</td>
</tr>
</tbody>
</table>

Notes:
- BAT provides for the vote on each resolution to be by poll rather than by a show of hands. This provides for greater transparency and allows the votes of all shareholders to be counted, including those cast by proxy. The voting results will be released on the same day in accordance with regulatory requirements and made available on bat.com.
The following documents are filed in the SEC EDGAR system, as part of this Annual Report on Form 20-F, and can be viewed on the SEC’s website, www.sec.gov:

<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Articles of Association of British American Tobacco p.l.c.</td>
</tr>
<tr>
<td>2.1</td>
<td>Second Amendment and Restated Deposit Agreement dated as of 25 November 1998.</td>
</tr>
<tr>
<td>2.2</td>
<td>Indenture dated as of 15 April 2017 between British American Tobacco p.l.c. and certain of its subsidiaries as guarantors, and Wilmington Trust, National Association as Trustee.</td>
</tr>
<tr>
<td>2.3</td>
<td>Indenture dated as of 28 September 2019 between British American Tobacco p.l.c. and certain of its subsidiaries as guarantors, and Wilmington Trust, National Association as Trustee.</td>
</tr>
<tr>
<td>2.4</td>
<td>Indenture dated as of 6 September 2019 and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee, authorization agreement transfer agent calculation agent and initial paying agent.</td>
</tr>
<tr>
<td>2.5</td>
<td>Supplemental Indenture No. 1, dated as of 6 September 1998, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.6</td>
<td>Supplemental Indenture No. 2, dated as of 6 September 1998, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.7</td>
<td>Supplemental Indenture No. 3, dated as of 6 September 1998, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.8</td>
<td>Supplemental Indenture No. 4, dated as of 6 September 1998, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.9</td>
<td>Supplemental Indenture No. 5, dated as of 2 April 2010, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.10</td>
<td>Supplemental Indenture No. 6, dated as of 2 April 2010, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.11</td>
<td>Supplemental Indenture No. 7, dated as of 29 September 2020, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.12</td>
<td>Supplemental Indenture No. 8, dated as of 29 September 2020, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.13</td>
<td>Supplemental Indenture No. 9, dated as of 29 September 2020, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.14</td>
<td>Supplemental Indenture No. 10, dated as of 29 September 2020, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.15</td>
<td>Supplemental Indenture No. 11, dated as of 29 September 2020, by and among B.A.T. Capital Corporation, the Guarantors party thereto and Citibank, N.A., as trustee.</td>
</tr>
<tr>
<td>2.16</td>
<td>Indenture, dated as of 29 September 2020, by and among B.A.T. International Finance B.V., the Guarantors party thereto and Citibank, N.A., as trustee, authorization agreement transfer agent calculation agent and initial paying agent.</td>
</tr>
<tr>
<td>2.17</td>
<td>Supplemental Indenture No. 1, dated as of 28 September 2018, among British American Tobacco p.l.c. and certain of its subsidiaries as guarantors, and Wilmington Trust, National Association as Trustee.</td>
</tr>
<tr>
<td>2.18</td>
<td>Supplemental Indenture No. 2, dated as of 28 September 2018, among British American Tobacco p.l.c. and certain of its subsidiaries as guarantors, and Wilmington Trust, National Association as Trustee.</td>
</tr>
<tr>
<td>2.19</td>
<td>Description of Securities registered under Section 12 of the Exchange Act.</td>
</tr>
<tr>
<td>4.1</td>
<td>Rules of the British American Tobacco 2007 Long-Term Incentive Plan.</td>
</tr>
<tr>
<td>4.2</td>
<td>Rules of the British American Tobacco 2016 Long-Term Incentive Plan.</td>
</tr>
<tr>
<td>4.3</td>
<td>British American Tobacco p.l.c. Deferred Annual Share Bonus Scheme.</td>
</tr>
<tr>
<td>4.5</td>
<td>British American Tobacco p.l.c. 2019 Deferred Annual Share Bonus Scheme.</td>
</tr>
<tr>
<td>4.6</td>
<td>Deferred Compensation Plan for Directors of Reynolds American Inc. (Amended and Restated Effective 30 November 2007).</td>
</tr>
<tr>
<td>4.8</td>
<td>Service Contract between British American Tobacco p.l.c. and Jack Bowles, dated as of 11 December 2018.</td>
</tr>
<tr>
<td>4.9</td>
<td>Service Contract between British American Tobacco p.l.c. and Taiwo Maroko, dated as of 27 February 2019.</td>
</tr>
<tr>
<td>4.10</td>
<td>Master Settlement Agreement dated as of the MLA, dated 23 November 1998.</td>
</tr>
<tr>
<td>4.13</td>
<td>Settlement Agreement and Release as to: The State of Minnesota v. Philip Morris, Inc. and among the State of Minnesota Blue Cross and Blue Shield of Minnesota and the various tobacco company defendants named therein, dated as of 25 May 1997.</td>
</tr>
</tbody>
</table>

380
Interactive Data Files (formatted in XBRL (Extensible Business Reporting Language) and furnished electronically).

Instruments to the SEC on request.

The total amount of securities authorized under each such instrument does not exceed 10% of the total consolidated assets of BAT and its subsidiaries.

Certified under Section 906 of the Sarbanes-Oxley Act of 2002.

Guarantor Subsidiaries of the Registrant (included as part of Exhibit 2.1).

Interactive Data Files (formatted in XBRL (Extensible Business Reporting Language) and furnished electronically).

Notes:

1. Incorporated by reference to Exhibit 3.1 to BAT’s Registration Statement on Form F-4 (Reg. No. 333-217939) filed on 12 May 2017.

2. Incorporated by reference to Exhibit 4.1 to BAT’s Registration Statement on Form S-8 (Reg. No. 333-237186) filed on 16 March 2020.

3. Incorporated by reference to Exhibit 4.2 to BAT’s Annual Report on Form 20-F for the year ended 31 December 2019 filed on 26 March 2020.


5. Incorporated by reference to Exhibit 4.8 to British American Tobacco p.l.c.’s Form 6-K filed on 2 April 2020.


7. Incorporated by reference to Exhibit 4.6 to British American Tobacco p.l.c.’s Form 6-K filed on 2 April 2020.

8. Incorporated by reference to Exhibit 4.5 to British American Tobacco p.l.c.’s Form 6-K filed on 2 April 2020.


10. Incorporated by reference to Exhibit 4.3 to British American Tobacco p.l.c.’s Form 6-K filed on 2 April 2020.

11. Incorporated by reference to Exhibit 4.2 to British American Tobacco p.l.c.’s Form 6-K filed on 2 April 2020.

12. Incorporated by reference to Exhibit 4.1 to British American Tobacco p.l.c.’s Form 6-K filed on 2 April 2020.


15. Incorporated by reference to Exhibit 4.8 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.


17. Incorporated by reference to Exhibit 4.6 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.


22. Incorporated by reference to Exhibit 4.1 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.


27. Incorporated by reference to Exhibit 4.6 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.


30. Incorporated by reference to Exhibit 4.3 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.


32. Incorporated by reference to Exhibit 4.1 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.

33. Incorporated by reference to Exhibit 4.2 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.

34. Incorporated by reference to Exhibit 4.1 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.

35. Incorporated by reference to Exhibit 4.2 to British American Tobacco p.l.c.’s Form 6-K filed on 24 September 2020.
Glossary

ADR  American Depositary Receipt
ADS  American Depositary Share – 1 ADS is equivalent to 1 BAT ordinary share
AGM  Annual General Meeting
AmSSA  Americas (excluding US) and Sub-Saharan Africa
APFO  Adjusted profit from operations
APME  Asia-Pacific and Middle East
BATGET  British American Tobacco Group Employee Trust
bps  Basis points
CC  Constant currency
CGFO  Cash generated from operations
CO2e  Carbon dioxide equivalent
Code  UK Corporate Governance Code, July 2018 version
CSR  Corporate Social Responsibility
DSBS  Deferred share bonus scheme
EMTN  European Medium Term Notes
ENA  Europe and North Africa
EPS  Earnings per share
ESG  Environmental, Social and Governance
EU  European Union
FII GLO  Franked Investment Income Group Litigation Order
FTC  Framework Convention on Tobacco Control
FMCG  Fast Moving Consumer Goods
GAAP  Generally Accepted Accounting Practice
GD  Global Drive Brands, being Kent, Dunhill, Pall Mall, Lucky Strike and Rothmans
GDPR  EU General Data Protection Regulation
GDSB  Global Drive and Key Strategic Brands, being the GDBs, plus Shuang Xi and State Express 555
GJ  Gigajoules (of energy use)
IASB  International Accounting Standards Board
IIFS  International Executive Incentive Scheme
IFRS  International Financial Reporting Standards as issued by the IASB and as adopted by the EU
ISA  International Standards on Auditing
JSE  Johannesburg Stock Exchange
KPI  Key performance indicator
LIBOR  London Interbank Offered Rate
LSE  London Stock Exchange
LR  Listing Rules
LTIP  Long-Term Incentive Plan
MCE  Million cigarettes equivalent
MSA  Master Settlement Agreement
NGP  Next Generation Product
NRT  Nicotine Replacement Therapy
NTO  Net turnover or revenue
NYSE  New York Stock Exchange
OCF  Operating cash flow
OECD  Organisation for Economic Co-operation and Development
OTP  Other tobacco products, including but not limited to roll-your-own, make-your-own and cigars
Parker Report  The Parker Review Committee’s final report on ethnic diversity in UK boards published on 12 October 2017
PACOB  Public Company Accounting Oversight Board
Reynolds American  Reynolds American Inc.
Reynolds American Companies  Reynolds American Inc. and its subsidiary companies
SAFL  Sustainable Agriculture and Farmer Livelihoods
SEC  United States Securities and Exchange Commission
SIP  Share incentive plan
SSBC  Group Standards of Business Conduct
SOx  United States Sarbanes-Oxley Act of 2002
SRS  Share reward scheme
TaO  Programme to implement the new operating model, including one instance of SAP
TCFD  Taskforce on Climate-related Financial Disclosures
TDR  Tobacco and Related Products Directive (directive 2014/40/EU)
TDP1  European Tobacco Products Directive (directive 2001/37/EC)
TDP2  European Tobacco and Related Products Directive (directive 2014/40/EU)
TSR  Total shareholder return
US  United States of America
UURBS  Unfunded unapproved retirement benefit scheme
WHO  World Health Organization
### Cross-Reference to Form 20-F

<table>
<thead>
<tr>
<th>Item</th>
<th>Form 20-F caption</th>
<th>Location in this document</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Identity of Directors, Senior Management and Advisers</td>
<td>N/A</td>
</tr>
<tr>
<td>2</td>
<td>Offer Statistics and Expected Timetable</td>
<td>N/A</td>
</tr>
<tr>
<td>3</td>
<td>Key Information</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>92-97, 317-339 &gt;&gt;, Developments in Ukraine page &gt;&gt;</td>
</tr>
<tr>
<td>4</td>
<td>Information on the Company</td>
<td>3, 77, 81, 211-214, 245-246, 300, 315, 379</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>280-289, 298</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>211-212, 348</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>4a</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>A</td>
<td>80-81, 183, 229-239, 315-316, 336</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>3-5, 11-13, 16-19, 31, 50-51, 76, 198, 300</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>2-73, 75-97, 340-344 &gt;&gt;, Developments in Ukraine page &gt;&gt;</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>N/A</td>
</tr>
<tr>
<td>6</td>
<td>Directors, Senior Management and Employees</td>
<td>100-102, 113</td>
</tr>
<tr>
<td></td>
<td>A</td>
<td>128-185, 214-220, 250, 360-372</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>100-102, 116-128, 133-134, 149-151, 250, 351, 374-375</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>249, 314</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>73, 163-165, 246-248, 361-372, 377</td>
</tr>
<tr>
<td>7</td>
<td>Major Shareholders and Related Party Transactions</td>
<td>360-361</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>249-250</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>8</td>
<td>Financial Information</td>
<td>79, 85, 122, 178-281, 318-339, 354-355</td>
</tr>
<tr>
<td></td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>353</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>N/A</td>
</tr>
<tr>
<td>9</td>
<td>The Offer and Listing</td>
<td>353</td>
</tr>
<tr>
<td></td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>215, 276, 346-347</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>354</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>356-359</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>G</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>H</td>
<td>379</td>
</tr>
<tr>
<td></td>
<td>I</td>
<td>N/A</td>
</tr>
<tr>
<td>10</td>
<td>Additional Information</td>
<td>239-244</td>
</tr>
</tbody>
</table>
### Cross-Reference to Form 20-F

#### Continued

<table>
<thead>
<tr>
<th>Item</th>
<th>Form 20-F caption</th>
<th>Location in this document</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Description of Securities Other Than Equity Securities</td>
<td>A Debt securities: N/A</td>
</tr>
<tr>
<td></td>
<td>B Warrants and rights: N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C Other securities: N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D American Depositary Shares</td>
<td>378</td>
</tr>
<tr>
<td>13</td>
<td>Defaults, Dividend Arrearages and Delinquencies: N/A</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Material Modifications to the Rights of Security Holders and Use of Proceeds: N/A</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Controls and Procedures</td>
<td>350</td>
</tr>
<tr>
<td>16A</td>
<td>Audit Committee Financial Expert</td>
<td>120, 349</td>
</tr>
<tr>
<td>16B</td>
<td>Code of Ethics</td>
<td>127, 349</td>
</tr>
<tr>
<td>16C</td>
<td>Principal Accountant Fees and Services</td>
<td>123-124, 197</td>
</tr>
<tr>
<td>16D</td>
<td>Exemptions from the Listing Standards for Audit Committees</td>
<td>N/A</td>
</tr>
<tr>
<td>16E</td>
<td>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</td>
<td>376</td>
</tr>
<tr>
<td>16F</td>
<td>Change in Registrant’s Certifying Accountant</td>
<td>N/A</td>
</tr>
<tr>
<td>16G</td>
<td>Corporate Governance</td>
<td>349</td>
</tr>
<tr>
<td>16H</td>
<td>Mine Safety Disclosure</td>
<td>N/A</td>
</tr>
<tr>
<td>16I</td>
<td>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</td>
<td>N/A</td>
</tr>
<tr>
<td>17</td>
<td>Financial Statements</td>
<td>N/A</td>
</tr>
<tr>
<td>18</td>
<td>Financial Statements</td>
<td>176-281</td>
</tr>
<tr>
<td>19</td>
<td>Exhibits</td>
<td>380-381</td>
</tr>
</tbody>
</table>
Registered office
Globe House, 4 Temple Place, London WC2R 3PG
tel: +44 20 7845 1000, facsimile: +44 20 7240 0855
Incorporated in England and Wales No. 3427696

Representative Office in South Africa
Watermans House South, No 1 Dock Road, V&A Waterfront, Cape Town 8000, South Africa
PO Box 638, Cape Town 8000, South Africa
tel: +27 21 003 8712

Secretary
Paul McCrory

Investor relations
Enquiries should be directed to Mike Nightingale, Victoria Buxton, William Houston or John Horney
tel: +44 20 7845 1180

Press office
Enquiries should be directed to Anna Vickerstaff
tel: +44 20 7845 2388
email: press_office@bat.com

Auditors
KPMG LLP
15 Canada Square, Canary Wharf, London E14 5GL

References in this publication to British American Tobacco “BAT”, “we”, “us”, and “our” mean, denoting applicable to refer to British American Tobacco p.l.c., (the Company) (No. 3004350) and when denoting tobacco business activity refer to British American Tobacco Group operating companies, collectively or individually as the case may be.

Design and production: Redlight Yellow www.redlightyellow.com
Printed in the UK by Clowes Printers Ltd on FSC 100% recycled paper made entirely from post-consumer waste. All our products are Elemental Chlorine Free. The manufacturing process had the BSI/BAA and EMAS (Eco Management and Audit Scheme) certificates for environmental management.
Developments related to Ukraine

Subsequent to the approval of the Annual Report 2021 by the Board of the Company on 10 February 2022 and the date of British American Tobacco p.l.c.’s consolidated financial statements for the years ended 31 December 2021, 2020 and 2019, management are monitoring the military conflict involving Russia and Ukraine. In 2021, Russia and Ukraine accounted for 3% of Group revenue and a slightly lower proportion of adjusted profit from operations. Our primary focus is on the safety and wellbeing of our employees, with the Group employing approximately 3,500 people in total across the two countries. The Group manufactures cigarettes and glo consumables domestically in both Russia and Ukraine. Whilst it is too early to determine the impact on the Group’s operations, we will continue to monitor and revisit our contingency plans in light of developments, including in response to any further sanctions.

Please refer to page 333 for the identified risk in relation to the imposition of sanctions. Following the developments in Ukraine, this risk will be extended to include Russia and disputed territories.
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

Date: 8 March 2022

British American Tobacco p.l.c.
(Registrant)

By: /s/ Paul McCrory
    Paul McCrory
    Company Secretary
THIRTY-THIRD SUPPLEMENTAL TRUST DEED

18 MARCH 2021

B.A.T. INTERNATIONAL FINANCE p.l.c.

and

B.A.T CAPITAL CORPORATION

and

B.A.T. NETHERLANDS FINANCE B.V.

and

BRITISH AMERICAN TOBACCO p.l.c.

and

THE LAW DEBENTURE TRUST CORPORATION p.l.c.

further modifying and restating the Trust Deed dated 6 July 1998 (as previously modified and restated) relating to the U.S.$3,000,000,000 (now £25,000,000,000) Euro Medium Term Note Programme

ALLEN & OVERY

Allen & Overy LLP
THIS THIRTY-THIRD SUPPLEMENTAL TRUST DEED is made on 18 March 2021

BETWEEN:

(1) B.A.T. INTERNATIONAL FINANCE p.l.c. (a public limited company with company number 1060930) whose registered office is at Globe House, 4 Temple Place, London WC2R 2PG (BATIF);

(2) B.A.T. NETHERLANDS FINANCE B.V. (a company incorporated with limited liability under the laws of The Netherlands and registered with the Trade Register of the Chamber of Commerce under No. 60533536) whose registered office is at Handelsweg 53A, 1181 ZA Amstelveen, The Netherlands (BATNF);

(3) B.A.T CAPITAL CORPORATION, (a company incorporated with limited liability in the State of Delaware, United States of America) whose registered office is at 103 Foulk Road, Suite 120, Wilmington, Delaware 19803, United States of America (BATCAP and, together with BATNF and BATIF each in their capacities as Issuer, the Issuers and each an Issuer);

(4) BRITISH AMERICAN TOBACCO p.l.c. (a public limited company with company number 3407696) whose registered office is at Globe House, 4 Temple Place, London WC2R 2PG (British American Tobacco and, together with BATCAP, BATIF and BATNF in their capacities as guarantors of Notes issued by the other Issuers, the Guarantors and each a Guarantor); and

(5) THE LAW DEBENTURE TRUST CORPORATION p.l.c. (company number 1675231) whose registered office is at 8th Floor, 100 Bishopsgate, London EC2N 4AG (the Trustee, which expression, where the context so admits, includes any successor or other trustee for the time being of this Thirty-Third Supplemental Trust Deed) as trustee for the Noteholders and the Couponholders.

WHEREAS:

(A) This Thirty-Third Supplemental Trust Deed is supplemental to:

(i) the Trust Deed dated 6 July 1998 (hereinafter called the Principal Trust Deed) made between BATIF, BATCAP, British American Tobacco, B.A.T Finance B.V. (BATFIN), B.A.T. Industries p.l.c. (BAT Industries), British American Tobacco Mexico, S.A. de C.V. (BAT Mexico) and the Trustee relating to the U.S.$3,000,000,000,000 (now £25,000,000,000) Euro Medium Term Note Programme (the Programme) established by BATIF, BATCAP and originally BATFIN;

(ii) the First Supplemental Trust Deed dated 22 March 1999 (hereinafter called the First Supplemental Trust Deed) made between the same parties as are parties to the Principal Trust Deed and modifying the provisions of the Principal Trust Deed;

(iii) the Second Supplemental Trust Deed dated 19 January 2000 (hereinafter called the Second Supplemental Trust Deed) made between the same parties as are parties to the Principal Trust Deed and BAT(CI) Finance Limited (BATCIF) and effecting the substitution of BATCIF in place of BATIF as principal debtor in respect of certain Notes issued by BATIF pursuant to the Programme;

(iv) the Third Supplemental Trust Deed dated 15 August 2000 (hereinafter called the Third Supplemental Trust Deed) made between the same parties as are parties to the Principal Trust Deed and BATCIF and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);
(v) the Fourth Supplemental Trust Deed dated 3 July 2002 (hereinafter called the Fourth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF), BATFIN and BATCIF and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(vi) the Fifth Supplemental Trust Deed dated 16 April 2003 (hereinafter called the Fifth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATFIN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(vii) the Sixth Supplemental Trust Deed dated 26 May 2005 (hereinafter called the Sixth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATFIN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(viii) the Seventh Supplemental Trust Deed dated 21 June 2005 (hereinafter called the Seventh Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATHTN, BATFIN, BAT Industries and BAT Mexico and effecting the substitution of BATHTN in place of BATIF as principal debtor in respect of the Series 25 EUR 1,000,000,000 Floating Rate Guaranteed Notes due 2006 issued by BATIF pursuant to the Programme;

(ix) the Eighth Supplemental Trust Deed dated 30 November 2005 (hereinafter called the Eighth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(x) the Ninth Supplemental Trust Deed dated 30 November 2007 (hereinafter called the Ninth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(xi) the Tenth Supplemental Trust Deed dated 1 December 2008 (hereinafter called the Tenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(xii) the Eleventh Supplemental Trust Deed dated 4 March 2010 (hereinafter called the Eleventh Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATHTN and effecting the substitution of BATHTN in place of BATIF as principal debtor in respect of the Series 22 €1,000,000,000 5.125 per cent. Guaranteed Notes due 2013 issued by BATIF pursuant to the Programme;

(xiii) the Twelfth Supplemental Trust Deed dated 1 December 2010 (hereinafter called the Twelfth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);
(xiv) the Thirteenth Supplemental Trust Deed dated 25 May 2011 (hereinafter called the Thirteenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF and BATHTN and substituting BATHTN in place of BATIF as the principal debtor in respect of the Series 36 €650,000,000 4.875 per cent. Guaranteed Notes due 2021 issued by BATIF pursuant to the Programme;

(xv) the Fourteenth Supplemental Trust Deed dated 9 December 2011 (hereinafter called the Fourteenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF and BATCAP) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(xvi) the Fifteenth Supplemental Trust Deed dated 11 December 2012 (hereinafter called the Fifteenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF and BATCAP) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(xvii) the Sixteenth Supplemental Trust Deed dated 12 December 2013 (hereinafter called the Sixteenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATNF and BATCAP) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(xviii) the Seventeenth Supplemental Trust Deed dated 16 May 2014 (hereinafter called the Seventeenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);

(xix) the Eighteenth Supplemental Trust Deed dated 4 September 2014 (hereinafter called the Eighteenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and modifying the provisions of the Principal Trust Deed (as previously modified and restated) in respect of the Series 47 CHF 400,000,000 0.625 per cent. Guaranteed Notes due 2021 issued by BATIF pursuant to the Programme;

(xx) the Nineteenth Supplemental Trust Deed dated 4 September 2014 (hereinafter called the Nineteenth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and modifying the provisions of the Principal Trust Deed (as previously modified and restated) in respect of the Series 48 CHF 250,000,000 1.375 per cent. Guaranteed Notes due 2026 issued by BATIF pursuant to the Programme;

(xxi) the Twentieth Supplemental Trust Deed dated 4 September 2014 (hereinafter called the Twentieth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and modifying the provisions of the Principal Trust Deed (as previously modified and restated) in respect of the Series 46 CHF 350,000,000 Floating Rate Guaranteed Notes due 2016 issued by BATIF pursuant to the Programme;

(xxii) the Twenty-First Supplemental Trust Deed dated 8 December 2014 (hereinafter called the Twenty-First Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and substituting BATNF in place
of BATHTN as the principal debtor in respect of the Series 30 £325,000,000 5.500 per cent. Guaranteed Notes due 2016, the Series 36 €650,000,000 4.875 per cent. Guaranteed Notes due 2021 and the Series 37 €600,000,000 4.000 per cent. Guaranteed Notes due 2020, each issued by BATHTN pursuant to the Programme;

(xxiii) the Twenty-Second Supplemental Trust Deed dated 8 December 2014 (hereinafter called the Twenty-Second Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and substituting BATNF in place of BATHTN as the principal debtor in respect of the Series 40 €750,000,000 2.375 per cent. Guaranteed Notes due 2023 and the Series 44 €600,000,000 3.125 per cent. Guaranteed Notes due 2029, each issued by BATHTN pursuant to the Programme;

(xxiv) the Twenty-Third Supplemental Trust Deed dated 8 December 2014 (hereinafter called the Twenty-Third Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and effecting the addition of BATNF as a guarantor in respect of the Series 26 £500,000,000 6.375 per cent. Guaranteed Notes due 2019, the Series 32 €1,250,000,000 5.375 per cent. Guaranteed Notes due 2017, the Series 33 £500,000,000 7.250 per cent. Guaranteed Notes due 2024, the Series 34 £1,250,000,000 5.875 per cent. Guaranteed Notes due 2015, the Series 35 £250,000,000 6.000 per cent. Guaranteed Notes due 2022, the Series 37 £500,000,000 6.000 per cent. Guaranteed Notes due 2034, the Series 38 €275,000,000 5.750 per cent. Guaranteed Notes due 2040 and the Series 39 €600,000,000 3.625 per cent. Guaranteed Notes due 2021, each issued by BATIF pursuant to the Programme;

(xxv) the Twenty-Fourth Supplemental Trust Deed dated 8 December 2014 (hereinafter called the Twenty-Fourth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and effecting the addition of BATNF as a guarantor in respect of the Series 41 US$300,000,000 1.125 per cent. Guaranteed Notes due 2016, the Series 42 €650,000,000 2.750 per cent. Guaranteed Notes due 2025, the Series 43 £650,000,000 4.000 per cent. Guaranteed Notes due 2026, and the Series 45 €400,000,000 Floating Rate Guaranteed Notes due 2018, each issued by BATIF pursuant to the Programme;

(xxvi) the Twenty-Fifth Supplemental Trust Deed dated 12 April 2016 (hereinafter called the Twenty-Fifth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and effecting the addition of BATNF as a guarantor in respect of the Series 41 US$300,000,000 1.125 per cent. Guaranteed Notes due 2016, the Series 42 €650,000,000 2.750 per cent. Guaranteed Notes due 2025, the Series 43 £650,000,000 4.000 per cent. Guaranteed Notes due 2026, and the Series 45 €400,000,000 Floating Rate Guaranteed Notes due 2018, each issued by BATIF pursuant to the Programme;

(xxvii) the Twenty-Sixth Supplemental Trust Deed dated 12 April 2016 (hereinafter called the Twenty-Sixth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and substituting BATIF in place of BATNF as the principal debtor in respect of the Series 36 €650,000,000 4.875 per cent. Guaranteed Notes due 2021 and the Series 37 €600,000,000 4.000 per cent. Guaranteed Notes due 2020, each issued by BATNF pursuant to the Programme;

(xxviii) the Twenty-Seventh Supplemental Trust Deed dated 12 April 2016 (hereinafter called the Twenty-Seventh Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN substituting BATIF in place of BATNF as the principal debtor in respect of the Series 40 €750,000,000 2.375 per cent. Guaranteed Notes due 2023 and the Series 44 €600,000,000 3.125 per cent. Guaranteed Notes due 2029, each issued by BATNF pursuant to the Programme;

(xxix) the Twenty-Seventh Supplemental Trust Deed dated 20 May 2016 (hereinafter called the Twenty-Seventh Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed (other than BATCAP) and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated);
the Twenty-Eighth Supplemental Trust Deed dated 31 May 2017 (hereinafter called the Twenty-Eighth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated); 

the Twenty-Ninth Supplemental Trust Deed dated 12 February 2018 (hereinafter called the Twenty-Ninth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and effecting the addition of BATCAP as a guarantor in respect of the Series 40 €750,000,000 2.375 per cent. Guaranteed Notes due 2023, the Series 42 €650,000,000 2.750 per cent. Guaranteed Notes due 2025, the Series 43 €650,000,000 4.000 per cent. Guaranteed Notes due 2026, the Series 44 €600,000,000 3.125 per cent. Guaranteed Notes due 2029, the Series 45 €400,000,000 Floating Rate Guaranteed Notes due 2018, the Series 47 CHF400,000,000 0.625 per cent. Guaranteed Notes due 2021, the Series 48 CHF250,000,000 1.375 per cent. Guaranteed Notes due 2026, the Series 49 €800,000,000 0.375 per cent. Guaranteed Notes due 2019, the Series 50 €800,000,000 0.875 per cent. Guaranteed Notes due 2023, the Series 51 €800,000,000 1.250 per cent. Guaranteed Notes due 2027, the Series 52 €600,000,000 2.000 per cent. Guaranteed Notes due 2045, the Series 53 €600,000,000 1.000 per cent. Guaranteed Notes due 2022, the Series 54 CHF350,000,000 4.000 per cent. Guaranteed Notes due 2055, the Series 55 £500,000,000 1.750 per cent. Guaranteed Notes due 2021, the Series 56 £650,000,000 2.250 per cent. Guaranteed Notes due 2052, and the Series 57 US$650,000,000 1.625 per cent. Guaranteed Notes due 2019, each issued by BATIF pursuant to the Programme; 

the Thirty-First Supplemental Trust Deed dated 25 May 2018 (hereinafter called the Thirtieth Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and BATHTN and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated); 

the Thirty-First Supplemental Trust Deed dated 1 May 2019 (hereinafter called the Thirty-First Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated); and 

the Thirty-Second Supplemental Trust Deed dated 31 March 2020 (hereinafter called the Third-Second Supplemental Trust Deed) made between the same parties as are parties to this Thirty-Third Supplemental Trust Deed and modifying and restating the provisions of the Principal Trust Deed (as previously modified and restated) (and together with the Principal Trust Deed, the First Supplemental Trust Deed, the Second Supplemental Trust Deed, the Third Supplemental Trust Deed, the Fourth Supplemental Trust Deed, the Fifth Supplemental Trust Deed, the Sixth Supplemental Trust Deed, the Seventh Supplemental Trust Deed, the Eighth Supplemental Trust Deed, the Ninth Supplemental Trust Deed, the Tenth Supplemental Trust Deed, the Eleventh Supplemental Trust Deed, the Twelfth Supplemental Trust Deed, the Thirteenth Supplemental Trust Deed, the Fourteenth Supplemental Trust Deed, the Fifteenth Supplemental Trust Deed, the Sixteenth Supplemental Trust Deed, the Seventeenth Supplemental Trust Deed, the Eighteenth Supplemental Trust Deed, the Nineteenth Supplemental Trust Deed, the Twentieth Supplemental Trust Deed, the Twenty-First Supplemental Trust Deed, the Twenty-Second Supplemental Trust Deed, the Twenty-Third Supplemental Trust Deed, the Twenty-Fourth Supplemental Trust Deed, the Twenty-Fifth Supplemental Trust Deed, the Twenty-Sixth Supplemental Trust Deed, the Twenty-Seventh Supplemental Trust Deed, the Twenty-Eighth Supplemental Trust Deed, the Twenty-Ninth Supplemental Trust Deed, the Thirtieth Supplemental Trust Deed, the Thirty-First Supplemental Trust Deed and the Thirty-Second Supplemental Trust Deed, the Subsisting Trust Deeds).
On 18 March 2021 the Issuers published a modified and updated Prospectus relating to the Programme (the **Base Prospectus**).

The Issuers have requested the Trustee to concur in making further modifications to the Principal Trust Deed (as previously modified and restated) to reflect the relevant modifications referred to in Recital (B) above.

**NOW THIS THIRTY-THIRD SUPPLEMENTAL TRUST DEED WITNESSETH AND IT IS HEREBY DECLARED** as follows:

1. Subject as hereinafter provided and unless there is something in the subject matter or context inconsistent therewith, all words and expressions defined in the Subsisting Trust Deeds shall have the same meanings in this Thirty-Third Supplemental Trust Deed.

2. **Save:**

   (a) in relation to all Series of Notes issued during the period up to and including the day last preceding the date of this Thirty-Third Supplemental Trust Deed;

   (b) in relation to any Notes issued on or after the date of this Thirty-Third Supplemental Trust Deed so as to be consolidated and form a single series with the Notes of any Series issued during the period up to and including the day last preceding the date of this Thirty-Third Supplemental Trust Deed; and

   (c) for the purpose (where necessary) of construing the provisions of this Thirty-Third Supplemental Trust Deed,

   with effect on and from the date of this Thirty-Third Supplemental Trust Deed:

   (i) the Principal Trust Deed (as previously modified, restated and supplemented) is hereby modified and restated in such manner as would result in the Principal Trust Deed being in the form set out in the Schedule hereto; and

   (ii) the provisions of the Principal Trust Deed (as previously modified, restated and supplemented) insofar as the same still have effect shall cease to have effect and in lieu thereof the provisions of the Principal Trust Deed as so further modified (and being in the form set out in the Schedule hereto) shall have effect.

3. The Subsisting Trust Deeds and this Thirty-Third Supplemental Trust Deed shall henceforth be read and construed together as one trust deed.

4. A memorandum of this Thirty-Third Supplemental Trust Deed shall be endorsed by the Trustee on the original of the Principal Trust Deed and by BATIF, BATNF, BATCAP and the Guarantors on their respective duplicates thereof.

5. This Thirty-Third Supplemental Trust Deed and any non-contractual obligations arising out of or in connection with it are governed by, and shall be construed in accordance with, English law.

6. Each of the parties hereto irrevocably agrees that the courts of England are to have jurisdiction to settle any disputes which may arise out of or in connection with this Thirty-Third Supplemental Trust Deed (including a dispute relating to any non-contractual obligations arising out of or in connection with it) and that accordingly any suit, action or proceedings arising out of or in connection with these presents (together referred to as **Proceedings**) may be brought in the courts of England, including any Proceedings relating to any non-contractual obligations arising out of or in
connection with this Thirty-Third Supplemental Trust Deed. Each of the parties hereto irrevocably and unconditionally waives and agrees not to raise any objection which it may have now or subsequently to the laying of the venue of any Proceedings in the courts of England and any claim that any Proceedings have been brought in an inconvenient forum and further irrevocably and unconditionally agrees that a judgment in any Proceedings brought in the courts of England shall be conclusive and binding upon it and may be enforced in the courts of any other jurisdiction. Nothing in this Clause shall limit any right to take Proceedings against any of the parties hereto in any other court of competent jurisdiction (outside the Contracting States, as defined in Section 1(3) of the Civil Jurisdiction and Judgments Act 1982), nor shall the taking of Proceedings in one or more jurisdictions preclude the taking of Proceedings in any other jurisdiction, whether concurrently or not.

7. Each of BATNF and BATCAP irrevocably and unconditionally appoints British American Tobacco at its registered office at Globe House, 4 Temple Place, London WC2R 2PG and in the event of its ceasing so to act will appoint such other person as the Trustee may approve and as BATNF or BATCAP, as the case may be, may nominate in writing to the Trustee for the purpose to accept service of process on its behalf in England in respect of any Proceedings. Each of BATNF and BATCAP:
   (a) agrees to procure that, so long as any Notes issued by it remain liable to prescription, there shall be in force an appointment of such a person approved by the Trustee with an office in London with authority to accept service as aforesaid;
   (b) agrees that failure by any such person to give notice of such service of process to BATNF or BATCAP, as the case may be, shall not impair the validity of such service or of any judgment based thereon; and
   (c) agrees that nothing in this Thirty-Third Supplemental Trust Deed shall affect the right to serve process in any other manner permitted by law.

8. This Thirty-Third Supplemental Trust Deed may be executed and delivered in any number of counterparts, all of which, taken together, shall constitute one and the same deed and any party to this Thirty-Third Supplemental Trust Deed may enter into the same by executing and delivering a counterpart.

9. A person who is not a party to this Thirty-Third Supplemental Trust Deed has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Thirty-Third Supplemental Trust Deed, but this does not affect any right or remedy of a third party which exists or is available apart from that Act.

IN WITNESS whereof this Thirty-Third Supplemental Trust Deed has been executed as a deed by each of the parties hereto and delivered on the date first stated above.

7
SCHEDULE 1

FORM OF MODIFIED AND RESTATED PRINCIPAL TRUST DEED

Dated 6 July 1998 and modified and restated on 18 March 2021

TRUST DEED

DATED 6 JULY 1998 AND MODIFIED AND RESTATED ON 18 MARCH 2021

B.A.T. INTERNATIONAL FINANCE p.l.c.

and

B.A.T CAPITAL CORPORATION

and

B.A.T. NETHERLANDS FINANCE B.V.

and

BRITISH AMERICAN TOBACCO p.l.c.

and

THE LAW DEBENTURE TRUST CORPORATION p.l.c.

relating to a

£25,000,000,000

Euro Medium Term Note Programme

8
CONTENTS

Clause                                           Page
1.   Interpretation                              11
2.   Amount and Issue of the Notes              19
3.   Form of the Notes                           22
4.   Stamp Duties and Taxes                     23
5.   Guarantee and Indemnity                    24
6.   Application of Moneys and Partial Payments 28
7.   Investment by the Trustee                  28
8.   Covenants                                  29
9.   Remuneration and Indemnification of the Trustee 31
11.  Trustee Liable for Negligence              36
12.  Waiver and Proof of Default                37
13.  Trustee Contracting with the Issuer and the Guarantors 37
14.  Modification and Substitution              38
15.  Appointment, Retirement and Removal of the Trustee 40
16.  Holder of Definitive Note Assumed to be Couponholder 40
17.  Currency Indemnity                         41
18.  Communications                             41
19.  Governing Law                              43
20.  Submission to Jurisdiction                  43
21.  Waiver of trial by jury                    43
22.  Counterparts                               43
23.  Contracts (Rights of Third Parties) Act 1999 44

Schedule
1.   Terms and Conditions of the Notes           45
2.   Forms of Global and Definitive Notes, Coupons and Talons 79
   Part 1   Form of Global Note                  80
   Part 2   Form of Definitive Note              88
   Part 3   Form of Coupon                       92
   Part 4   Form of Talon                        94
3.   Provisions for Meetings of Noteholders      97

Signatories                                   105
BETWEEN:

(1) **B.A.T. INTERNATIONAL FINANCE p.l.c.** (company number 1060930) whose registered office is at Globe House, 4 Temple Place, London WC2R 2PG (BATIF);

(2) **B.A.T. NETHERLANDS FINANCE B.V.** (a company incorporated with limited liability under the laws of The Netherlands and registered with the Trade Register of the Chamber of Commerce under No. 60533536) whose registered office is at Handelsweg 53A, 1181 ZA Amstelveen, The Netherlands (BATNF);

(3) **B.A.T CAPITAL CORPORATION** (a company incorporated with limited liability in the State of Delaware, United States of America) whose registered office is at 103 Foulk Road, Suite 120, Wilmington, Delaware 19803, United States of America (BATCAP and, together with BATIF and BATNF each in their capacities as Issuer, the Issuers and each an Issuer);

(4) **BRITISH AMERICAN TOBACCO p.l.c.** (company number 3407696) whose registered office is at Globe House, as aforesaid (British American Tobacco and, together with, in their capacities as guarantors of Notes issued by the other Issuers, BATIF, BATCAP and BATNF, the Guarantors and each a Guarantor); and

(5) **THE LAW DEBENTURE TRUST CORPORATION p.l.c.** (company number 1675231) whose registered office is at 8th Floor, 100 Bishopsgate, London EC2N 4AG (the Trustee, which expression, where the context so admits, includes any successor or other trustee for the time being of this Trust Deed) as trustee for the Noteholders and the Couponholders (each as defined below).

WHEREAS:


(C) The Trustee has agreed to act as trustee of this Trust Deed for the benefit of the Noteholders and the Couponholders upon and subject to the terms and conditions of this Trust Deed.

(D) References hereafter in this Trust Deed to the Issuer and the Guarantors are to the Issuer and the Guarantors specified in the applicable Final Terms (as defined below) in relation to a particular Series of the Notes.

THIS DEED WITNESSES AND IT IS DECLARED as follows:

1. INTERPRETATION

1.1 Definitions

The following expressions have the following meanings:

Agency Agreement means the agreement dated 6 July 1998, as amended and/or supplemented and/or restated from time to time, appointing the Agent and the other Paying Agents in relation to all or any Series of the Notes and any other agreement for the time being in force appointing another Agent or further or other Paying Agents in relation to all or any Series of the Notes, or in connection with their duties, the terms of which have previously been approved in writing by the Trustee, together with any agreement for the time being in force amending or modifying with the prior written approval of the Trustee any of the aforesaid agreements;

Agent means, in relation to all or any Series of the Notes, Citibank, N.A., London Branch at its office at Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB, England, or, if applicable, any Successor agent in relation thereto;

Appointee means any attorney, manager, agent, delegate, nominee, receiver, custodian or other person appointed by the Trustee under this Trust Deed;

Auditors means the auditors for the time being of the relevant Issuer or a Guarantor (as the case may be), or, if they are unable or unwilling to carry out any action requested of them pursuant to the provisions of this Trust Deed, such other firm of accountants as may be selected for the purpose by the relevant Issuer or the relevant Guarantor (as the case may be) which, for the avoidance of doubt in the case of the auditors of the relevant Issuer so being unable or unwilling, may be the auditors of the ultimate Holding Company of the Group, in either such case, as approved by the Trustee (such approval not to be unreasonably withheld) and, failing such selection by the relevant Issuer or the relevant Guarantor (as the case may be) as may be nominated in writing by the Trustee for the purpose;

Borrowed Moneys Indebtedness has the meaning ascribed thereto in Condition 9(a);
Calculation Agent means, in relation to all or any Series of the Notes, the person appointed as such from time to time pursuant to the provisions of the Agency Agreement or, if applicable, any Successor calculation agent in relation thereto;

CGN means a Global Note in respect of which the applicable Final Terms indicates is not in New Global Note form;

Clearstream, Luxembourg means Clearstream Banking SA;

Conditions means, in relation to the Notes of any Series, the terms and conditions endorsed on or incorporated by reference into the Note or Notes constituting such Series, such terms and conditions being in or substantially in the form set out in Schedule 1 or in such other form, having regard to the terms of issue of the Notes of the relevant Series, as may be agreed between the relevant Issuer, the relevant Guarantor(s), the Agent, the Trustee and the relevant Dealer(s) as supplemented by the Final Terms applicable to the Notes of the relevant Series, in each case as from time to time modified in accordance with the provisions of this Trust Deed;

Coupon means an interest coupon appertaining to a Definitive Note (other than a Zero Coupon Note), such coupon being:

(a) if appertaining to a Fixed Rate Note, in the form or substantially in the form set out in Part 3 (Part A) of Schedule 2 or in such other form, having regard to the terms of issue of the Notes of the relevant Series, as may be agreed between the relevant Issuer, the relevant Guarantor(s), the Agent, the Trustee and the relevant Dealer(s); or

(b) if appertaining to a Floating Rate Note, in the form or substantially in the form set out in Part 3 (Part B) of Schedule 2 or in such other form, having regard to the terms of issue of the Notes of the relevant Series, as may be agreed between the relevant Issuer, the relevant Guarantor(s), the Agent, the Trustee and the relevant Dealer(s),

and includes, where applicable, the Talon(s) appertaining thereto and any replacements for Coupons and Talons issued pursuant to Condition 10;

Couponholders means the several persons who are for the time being holders of the Coupons and includes, where applicable, the Talonholders;

Dealers means Banco Bilbao Vizcaya Argentaria, S.A., Banco Santander, S.A., Bank of China Limited, London Branch, Barclays Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Europe AG, Citigroup Global Markets Limited, Commerzbank Aktiengesellschaft, Deutsche Bank AG, London Branch, Goldman Sachs Bank Europe SE, HSBC Bank plc, Lloyds Bank Corporate Markets plc, Lloyds Bank Corporate Markets Wertpapierhandelsbank GmbH, Merrill Lynch International, Mizuho International plc, Mizuho Securities Europe GmbH, NatWest Markets Plc, SMBC Nikko Capital Markets Europe GmbH, SMBC Nikko Capital Markets Limited, Société Générale, Standard Chartered Bank, UniCredit Bank AG, Wells Fargo Securities International Limited and Wells Fargo Securities Europe S.A. and any other entity appointed as a Dealer and notice of whose appointment has been given to the Agent and the Trustee in accordance with the provisions of the Programme Agreement but excluding any entity whose appointment has been terminated in accordance with the provisions of the Programme Agreement and notice of which termination has been given to the Agent and the Trustee in accordance with the provisions of the Programme Agreement and references to a relevant Dealer or relevant Dealers mean, in relation to any Tranche or Series of Notes, the Dealer or Dealers with whom the relevant Issuer has agreed the issue of the Notes of such Tranche or Series and Dealer means any one of them;
Definitive Note means a Note in definitive form issued or, as the case may require, to be issued by the relevant Issuer in accordance with the provisions of the Programme Agreement or any other agreement between the relevant Issuer and the relevant Dealer(s), the Agency Agreement and this Trust Deed in exchange for a Global Note (all as indicated in the applicable Final Terms), such Note in definitive form being in the form or substantially in the form set out in Part 2 of Schedule 2 with such modifications (if any) as may be agreed between the relevant Issuer, the relevant Guarantor(s), the Agent, the Trustee and the relevant Dealer(s) and having the Conditions endorsed thereon or, if permitted by the relevant Stock Exchange, incorporating the Conditions by reference (where applicable to this Trust Deed) as indicated in the applicable Final Terms and having the relevant information supplementing, replacing or modifying the Conditions appearing in the applicable Final Terms endorsed thereon or attached thereto and (except in the case of a Zero Coupon Note) having Coupons and, where appropriate, Talons attached thereto on issue;

Early Redemption Amount has the meaning ascribed thereto in Condition 6(f);

Euroclear means Euroclear Bank SA/NV;

Eurosystem means the central banking system for the euro;

Event of Default means an event described in Condition 9(a) and which, if so required by that Condition, has been certified by the Trustee to be, in its opinion, materially prejudicial to the interests of the holders of the Notes of the relevant Series;

Extraordinary Resolution has the meaning set out in Schedule 3;

Final Terms has the meaning set out in the Programme Agreement;

Fixed Rate Note means a Note on which interest is calculated at a fixed rate payable in arrear on a fixed date or fixed dates in each year and on redemption or on such other dates as may be agreed between the relevant Issuer and the relevant Dealer(s) (as indicated in the applicable Final Terms);

Floating Rate Note means a Note on which interest is calculated at a floating rate payable one-, two-, three-, six- or twelve-monthly or in respect of such other period or on such date(s) as may be agreed between the relevant Issuer and the relevant Dealer(s) (as indicated in the applicable Final Terms);

FSMA means the Financial Services and Markets Act 2000 of the United Kingdom;

Global Note means a global note in the form or substantially in the form set out in Part 1 of Schedule 2 with such modifications (if any) as may be agreed between the relevant Issuer, the Agent, the Trustee and the relevant Dealer(s), together with the copy of the applicable Final Terms annexed thereto, comprising some or all of the Notes of the same Series, issued by the relevant Issuer pursuant to the Programme Agreement or any other agreement between the relevant Issuer and the relevant Dealer(s), the Agency Agreement and this Trust Deed on issue;

Group has the meaning ascribed thereto in Condition 9(a);

Guarantee means the guarantee and indemnity of the Guarantors in Clause 5;

Holding Company means a holding company within the meaning of Section 1159 of the Companies Act 2006;
Interest Commencement Date means, in the case of interest-bearing Notes, the date specified in the applicable Final Terms from (and including) which such Notes bear interest, which may or may not be the Issue Date;

Interest Payment Date means, in relation to any Floating Rate Note, either:
(a) the date which falls the number of months or other period specified as the Specified Period in the applicable Final Terms after the preceding Interest Payment Date or the Interest Commencement Date (in the case of the first Interest Payment Date); or
(b) such date or dates as are indicated in the applicable Final Terms;

Issue Date means, in respect of any Note, the date of issue and purchase of such Note pursuant to and in accordance with the Programme Agreement or any other agreement between the relevant Issuer and the relevant Dealer(s), being in the case of any Definitive Note the same date as the date of issue of the Global Note which initially represented such Note;

Issue Price means the price, generally expressed as a percentage of the nominal amount of the Notes, at which the Notes will be issued;

London Business Day has the meaning set out in Condition 4(b)(v);

London Stock Exchange means the London Stock Exchange plc or such other body to which its functions and business have been transferred;

Maturity Date means the date on which a Note is expressed to be redeemable;

month means calendar month;

NGN means a Global Note in respect of which the applicable Final Terms indicates is in New Global Note form;

Note means a note issued pursuant to the Programme and denominated in such currency or currencies as may be agreed between the relevant Issuer and the relevant Dealer(s) which:
(a) has such maturity as may be agreed between the relevant Issuer and the relevant Dealer(s), subject to such minimum or maximum maturity as may be allowed or required from time to time by the relevant central bank (or equivalent body) or any laws or regulations applicable to the relevant Issuer or the relevant currency; and
(b) has such denomination as may be agreed between the relevant Issuer and the relevant Dealer(s), subject to such minimum denomination as may be allowed or required from time to time by the relevant central bank (or equivalent body) or any laws or regulations applicable to the relevant currency, which will be at least €1,000 (or its equivalent in other currencies) in any event, provided that (i) in the case of any Notes which are to be admitted to trading on the London Stock Exchange’s main market or offered to the public in the United Kingdom in circumstances which require the publication of a prospectus under the Prospectus Regulation (EU) (2017/1129) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, the minimum specified denomination shall be €100,000 (or the equivalent of such amounts in another currency as at the date of issue of the Notes); and (ii) unless otherwise permitted by then current laws and regulations, Notes (including Notes denominated in sterling) in respect of which the issue proceeds are received by the relevant Issuer in the United Kingdom and which have a maturity of less than one year will have a minimum redemption value of £100,000 (or its equivalent in other currencies),
issued or to be issued by the relevant Issuer pursuant to the Programme Agreement or any other agreement between the relevant Issuer and the relevant Dealer(s), the Agency Agreement and this Trust Deed and which shall initially be represented by, and comprised in, a Global Note which may (in accordance with the terms of such Global Note) be exchanged for Definitive Notes (as indicated in the applicable Final Terms) and includes any replacements for a Note issued pursuant to Condition 10;

Noteholders means the several persons who are for the time being bearers of outstanding Notes save that, in respect of the Notes of any Series, for so long as such Notes or any part thereof are represented by a Global Note deposited with a common depositary (in the case of a CGN) or common safekeeper (in the case of a NGN) for Euroclear and Clearstream, Luxembourg, each person who is for the time being shown in the records of Euroclear or Clearstream, Luxembourg (other than Clearstream, Luxembourg, if Clearstream, Luxembourg shall be an accountholder of Euroclear and Euroclear shall be an accountholder of Clearstream, Luxembourg) as the holder of a particular nominal amount of the Notes of such Series shall be deemed to be the holder of such nominal amount of such Notes (and the holder of the relevant Global Note shall be deemed not to be the holder for all purposes of this Trust Deed other than with respect to the payment of principal or interest on such nominal amount of such Notes, the rights to which shall be vested, as against the relevant Issuer and the Guarantors, solely in such common depositary (in the case of a CGN) or common safekeeper (in the case of a NGN) and for which purpose such common depositary (in the case of a CGN) or common safekeeper (in the case of a NGN) shall be deemed to be the holder of such nominal amount of such Notes in accordance with and subject to the terms of the relevant Global Note and the provisions of this Trust Deed and the expressions Noteholder, holder and holder of Notes and related expressions shall be construed accordingly;

notice means, in respect of a notice to be given to Noteholders, a notice validly given pursuant to Condition 13;

Official List has the meaning ascribed thereto in Section 103 of the FSMA;

outstanding means, in relation to the Notes of all or any Series, all the Notes of such Series issued other than:

(a) those Notes which have been redeemed pursuant to this Trust Deed;
(b) those Notes in respect of which the date for redemption in accordance with the Conditions has occurred and the redemption moneys (including all interest payable thereon) have been duly paid to the Trustee or to the Agent in the manner provided in the Agency Agreement (and where appropriate notice to that effect has been given to the relative Noteholders in accordance with Condition 13) and remain available for payment against presentation of the relevant Notes and/or Coupons;
(c) those Notes which have been purchased and cancelled in accordance with Conditions 6(g) and 6(h);
(d) those Notes which have become void under Condition 8;
(e) those mutilated or defaced Notes which have been surrendered and cancelled and in respect of which replacements have been issued pursuant to Condition 10;
(f) (for the purpose only of ascertaining the nominal amount of the Notes outstanding and without prejudice to the status for any other purpose of the relevant Notes) those Notes which are alleged to have been lost, stolen or destroyed and in respect of which replacements have been issued pursuant to Condition 10; and

g) any Global Note to the extent that it shall have been exchanged for Definitive Notes in each case pursuant to its provisions, the provisions of this Trust Deed and the Agency Agreement;

PROVIDED THAT for each of the following purposes, namely:

(i) the right to attend and vote at any meeting of the holders of the Notes of any Series;

(ii) the determination of how many and which Notes of any Series are for the time being outstanding for the purposes of Conditions 9(a), 9(b) and 14 and Schedule 3;

(iii) any discretion, power or authority (whether contained in this Trust Deed or vested by operation of law) which the Trustee is required, expressly or impliedly, to exercise in or by reference to the interests of the holders of the Notes of any Series; and

(iv) the determination by the Trustee whether any event, circumstance, matter or thing is, in its opinion, materially prejudicial to the interests of the holders of the Notes of any Series,

those Notes of the relevant Series (if any) which are for the time being held by or on behalf of the relevant Issuer, the Guarantors or any other subsidiary of the relevant Issuer or the Guarantors, in each case as beneficial owner, shall (unless and until ceasing to be so held) be deemed not to remain outstanding;

**Paying Agents** means, in relation to all or any Series of the Notes, the several institutions (including, where the context permits, the Agent) at their respective specified offices initially appointed as paying agents in relation to such Notes pursuant to the Agency Agreement and/or, if applicable, any Successor paying agents in relation thereto;

**Potential Event of Default** means an event or circumstance which would with the giving of notice, lapse of time, issue of a certificate and/or fulfilment of any other requirement provided for in Condition 9(a) become an Event of Default;

**Programme** means the Euro Medium Term Note Programme established by, or otherwise contemplated in, the Programme Agreement;

**Programme Agreement** means the agreement of even date herewith between the parties hereto (other than the Trustee) and the Dealers named therein concerning the purchase of Notes to be issued pursuant to the Programme as amended and/or supplemented and/or restated from time to time;

**Put Notice** means a notice in the form set out in Schedule 2 to the Agency Agreement;

**Reference Banks** means the several banks initially appointed as reference banks in relation to the Notes of any relevant Series and/or, if applicable, any Successor reference banks in relation thereto such banks being, in the case of a determination of LIBOR, the principal London office of four major banks in the London inter-bank market and, in the case of a determination of EURIBOR, the principal Euro-zone office of four major banks in the Euro-zone inter-bank market, in each case selected by the Agent or as specified in the applicable Final Terms;

**Relevant Date** has the meaning ascribed thereto in Condition 7(f);
repay, redeem and pay shall each include both the others and cognate expressions shall be construed accordingly;

**Series** means a Tranche of Notes together with any further Tranche or Tranches of Notes which are (a) expressed to be consolidated and form a single series and (b) identical in all respects (including as to listing) except for their respective Issue Dates, Interest Commencement Dates and/or Issue Prices and the expressions *Notes of the relevant Series, holders of Notes of the relevant Series* and related expressions shall be construed accordingly;

**specified office** means, in relation to a Paying Agent, the office identified with its name at the end of the Conditions or any other office approved by the Trustee and notified to the Noteholders pursuant to Clause 8(j);

**Stock Exchange** means, in relation to the Notes of any Series, the stock exchange or exchanges on which such Notes may from time to time be listed, and references in this Trust Deed to the **relevant Stock Exchange** shall, in relation to the Notes of any Series, be references to the Stock Exchange on which such Notes are, from time to time, or are intended to be, listed;

**subsidiary** means a subsidiary within the meaning of Section 1159 of the Companies Act 2006 of Great Britain;

**Successor** means, in relation to the Agent, any other Paying Agent, the Reference Banks and the Calculation Agent, any successor to any one or more of them in relation to the Notes which shall become such pursuant to the provisions of this Trust Deed and/or the Agency Agreement (as the case may be) and/or such other or further agent, paying agent, reference banks or calculation agent (as the case may be) in relation to the Notes as may (with the prior approval of, and on terms previously approved by, the Trustee in writing) from time to time be appointed as such, and/or, if applicable, such other or further specified offices (in the former case being within the same city as those for which they are substituted) as may from time to time be nominated, in each case by the relevant Issuer and the Guarantors and (except in the case of the initial appointments and specified offices made under and specified in the Conditions and/or the Agency Agreement, as the case may be) notice of whose appointment or, as the case may be, nomination has been given to the Noteholders pursuant to Clause 8(j);

**successor in business** means a company which has acquired as a going concern all or substantially all of the undertaking, assets and liabilities of the relevant Issuer or any Guarantor, as the case may be;

**Talonholders** means the several persons who are for the time being holders of the Talons;

**Talons** means the talons (if any) appertaining to, and exchangeable in accordance with the provisions therein contained for further Coupons appertaining to, the Definitive Notes (other than the Zero Coupon Notes), such talons being in the form or substantially in the form set out in Part 4 of Schedule 2 or in such other form as may be agreed between the relevant Issuer, the Agent, the Trustee and the relevant Dealer(s) and includes any replacements for Talons issued pursuant to Condition 10;

**this Deed** means this trust deed and the Schedules (or, in respect of any reference to the provisions thereof, the same as may be from time to time modified in accordance with the provisions hereof);

**this Trust Deed** means this Deed and any trust deed supplemental hereto and the schedules (if any) thereto and the Notes, the Coupons, the Talons, the Conditions and, unless the context otherwise requires, the Final Terms, all as from time to time modified in accordance with the provisions herein or therein contained;
Tranche means all Notes which are identical in all respects (including as to listing);
trust corporation means a trust corporation (as defined in the Law of Property Act 1925) or a corporation entitled to act as a trustee pursuant to applicable foreign legislation relating to trustees;
Trustee Acts means the Trustee Act 1925 and the Trustee Act 2000; and
Zero Coupon Note means a Note on which no interest is payable.

1.2 Construction of Certain References
(a) All references in this Trust Deed to costs, charges, remuneration or expenses include any value added, turnover or similar tax charged in respect thereof.
(b) All references in this Trust Deed to principal and/or principal amount and/or interest in respect of the Notes or to any moneys payable by the relevant Issuer and/or the Guarantors under this Trust Deed shall, unless the context otherwise requires, be construed in accordance with Condition 5(f).
(c) All references in this Trust Deed to any statute or any provision of any statute shall be deemed to be references to that statute as from time to time modified, extended, amended, superseded or re-enacted or to any statutory instrument, order or regulation made thereunder or under any such modification or re-enactment.
(d) All references in this Trust Deed to any action, remedy or method of proceeding for the enforcement of the rights of creditors shall be deemed to include, in respect of any jurisdiction other than England, references to such action, remedy or method of proceeding for the enforcement of the rights of creditors available or appropriate in such jurisdiction as shall most nearly approximate to such action, remedy or method of proceeding described or referred to in this Trust Deed.
(e) All references in this Trust Deed to Euroclear and/or Clearstream, Luxembourg shall, whenever the context so permits (but not in the case of any NGN), be deemed to include references to any additional or alternative clearing system as is approved by the relevant Issuer, the Agent and the Trustee. In the case of NGNs, such alternative clearing system must also be authorised to hold such Notes as eligible collateral for Eurosystem monetary policy and intra-day credit operations.
(f) All references in this Trust Deed to the relevant currency shall be construed as references to the currency in which payments in respect of the Notes and/or Coupons of the relevant Series are to be made as indicated in the applicable Final Terms.
(g) All references in this Trust Deed to a Directive include any relevant implementing measure of each Member State of the European Economic Area which has implemented such Directive.
(h) As used herein, in relation to any Notes which have a listing or are listed (i) on the London Stock Exchange, listing and listed shall be construed to mean that such Notes have been admitted to the Official List and admitted to trading on the main market of the London Stock Exchange and (ii) on any Stock Exchange within the European Economic Area, listing and listed shall be construed to mean that Notes have been admitted to trading on a market within that jurisdiction which is a regulated market for the purposes of Directive 2014/65/EU of the European Parliament and of the Council on Markets in Financial Instruments. All references in this Trust Deed to listing and listed shall include references to quotation and quoted respectively.
(i) All references in this Trust Deed to the records of Euroclear and Clearstream, Luxembourg shall be to the records that each of Euroclear and Clearstream, Luxembourg holds for its customers which reflect the amount of such customers' interest in the Notes.

(j) All references in these presents involving compliance by the Trustee with a test of reasonableness shall be deemed to include a reference to a requirement that such reasonableness shall be determined by reference solely to the interest of the Noteholders.

1.3 Headings

Headings shall be ignored in construing this Trust Deed.

1.4 Schedules

The Schedules are part of this Trust Deed and have effect accordingly.

1.5 Defined terms

Words and expressions defined in this Trust Deed or the Agency Agreement or used in the applicable Final Terms shall have the same meanings where used herein unless the context otherwise requires or unless otherwise stated and provided that, in the event of inconsistency between the Agency Agreement and this Trust Deed, this Trust Deed shall prevail and, in the event of inconsistency between the Agency Agreement or this Trust Deed and the applicable Final Terms, the applicable Final Terms shall prevail.

2. AMOUNT AND ISSUE OF THE NOTES

2.1 Amount of the Notes, Final Terms and Legal Opinions

The Notes will be issued in Series in an aggregate nominal amount from time to time outstanding not exceeding the Programme Limit from time to time and for the purpose of determining such aggregate nominal amount Clause 3.5 of the Programme Agreement shall apply.

By not later than 3.00 p.m. (London time) on the London Business Day preceding each proposed Issue Date, the relevant Issuer shall deliver or cause to be delivered to the Trustee a copy of the applicable Final Terms and shall notify the Trustee in writing without delay of the relevant Issue Date and the nominal amount of the Notes to be issued. Upon the issue of the relevant Notes, such Notes shall become constituted by this Trust Deed without further formality.

Before the first issue of Notes occurring after each anniversary of this Deed and on such other occasions as the Trustee acting reasonably so requests (on the basis that the Trustee considers it necessary in view of a change (or proposed change) in applicable law or regulations (or the interpretation or application thereof) affecting the relevant Issuer or, as the case may be, the Guarantors, this Trust Deed, the Programme Agreement or the Agency Agreement, or the Trustee has other grounds), the relevant Issuer or, as the case may be, the Guarantors will procure that further legal opinion(s) (relating, if applicable, to any such change or proposed change (or interpretation or application)) in such form and with such content as the Trustee may require from the legal advisers specified in the Programme Agreement or such other legal advisers as the Trustee may require is/are delivered to the Trustee. Whenever such a request is made with respect to any Notes to be issued, the receipt of such opinion in a form satisfactory to the Trustee shall be a further condition precedent to the issue of those Notes.
2.2 Covenant to repay principal and to pay interest

The relevant Issuer covenants with the Trustee that it will, as and when the Notes of any Series or any of them becomes due to be redeemed in accordance with the Conditions, unconditionally pay or procure to be paid to or to the order of the Trustee in the relevant currency in immediately available funds the principal amount in respect of the Notes of such Series becoming due for redemption on that date and (except in the case of Zero Coupon Notes) shall (subject to the provisions of the Conditions) in the meantime and until redemption in full of the Notes of such Series (both before and after any judgment or other order of a court of competent jurisdiction) unconditionally pay or procure to be paid to or to the order of the Trustee as aforesaid interest (which shall accrue from day to day) on the nominal amount of the Notes outstanding of such Series at rates and/or in amounts calculated from time to time in accordance with, or specified in, and on the dates provided for in, the Conditions (subject to Clause 2.4) PROVIDED THAT:

(a) every payment of principal or interest or other sum due in respect of the Notes made to or to the order of the Agent in the manner provided in the Agency Agreement shall be in satisfaction pro tanto of the relative covenant by the relevant Issuer in this Clause contained in relation to the Notes of such Series, except to the extent that there is a default in the subsequent payment thereof in accordance with the Conditions to the relevant Noteholders or Couponholders (as the case may be);

(b) in the case of any payment of principal made to the Trustee or the Agent after the due date or on or after accelerated maturity following an Event of Default, interest shall (subject, where applicable, as provided in the Conditions) continue to accrue on the nominal amount of the relevant Notes (except in the case of Zero Coupon Notes to which the provisions of Condition 6(i) shall apply) (both before and after any judgment or other order of a court of competent jurisdiction) at the rates aforesaid (or, if higher, the rate of interest on judgment debts for the time being provided by English law) up to and including the date which the Trustee determines to be the date on and after which payment is to be made in respect thereof as stated in a notice given to the holders of such Notes (such date to be not later than seven days after the day on which the whole of such principal amount, together with an amount equal to the interest which has accrued and is to accrue pursuant to this proviso up to and including that date, has been received by the Trustee or the Agent); and

(c) in any case where payment of the whole or any part of the principal amount of any Note is improperly withheld or refused upon due presentation thereof (other than in circumstances contemplated by (b) above), interest shall accrue on the nominal amount of such Note (except in the case of Zero Coupon Notes to which the provisions of Condition 6(i) shall apply) payment of which has been so withheld or refused (both before and after any judgment or other order of a court of competent jurisdiction) at the rates aforesaid (or, if higher, the rate of interest on judgment debts for the time being provided by English law) from the date of such withholding or refusal until the date on which, upon further presentation of the relevant Note, payment of the full amount (including interest as aforesaid) in the relevant currency payable in respect of such Note is made or (if earlier) the seventh day after notice is given to the relevant Noteholder(s) (whether individually or in accordance with Condition 13) that the full amount (including interest as aforesaid) in the relevant currency in respect of such Note is available for payment, provided that, upon further presentation thereof being duly made, such payment is made.

The Trustee will hold the benefit of this covenant on trust for the Noteholders and the Couponholders and itself in accordance with this Trust Deed.

20
2.3 Trustee’s requirements regarding Paying Agents

At any time after an Event of Default or a Potential Event of Default shall have occurred, the Trustee may:

(a) by notice in writing to the relevant Issuer, the Guarantors, the Agent and any other Paying Agent require the Agent and any other Paying Agent, until notified by the Trustee to the contrary, so far as permitted by applicable law:

(i) to act as Paying Agents of the Trustee under this Trust Deed and the Notes on the terms of the Agency Agreement (with consequential amendments as necessary and except that the Trustee’s liability for the indemnification, remuneration and expenses of the Paying Agents will be limited to the amounts for the time being held by the Trustee in respect of the Notes on the terms of this Trust Deed) and thereafter to hold all Notes and Coupons and all moneys, documents and records held by them in respect of Notes and Coupons to the order of the Trustee; or

(ii) to deliver all Notes and Coupons and all moneys, documents and records held by them in respect of the Notes and Coupons to the Trustee or as the Trustee directs in such notice; and

(b) by notice in writing to the relevant Issuer and the Guarantors require them to make all subsequent payments in respect of the Notes and Coupons to or to the order of the Trustee and not to the Agent.

2.4 Rate and amount of interest

If the Floating Rate Notes of any Series become immediately due and repayable under Condition 9(a), the rate and/or amount of interest payable in respect of them will be calculated at the same intervals as if such Notes had not become due and repayable, the first of which will commence on the expiry of the Interest Period during which the Notes of the relevant Series become so due and repayable mutatis mutandis in accordance with the provisions of Condition 4(b) except that the rates of interest need not be published.

2.5 Currency of payments

All payments in respect of, under and in connection with this Trust Deed and the Notes of any Series to the relevant Noteholders and Couponholders shall be made in the relevant currency.

2.6 Further Notes

The relevant Issuer shall be at liberty from time to time (but subject always to the provisions of this Trust Deed) without the consent of the Noteholders or the Couponholders, to create and issue further Notes ranking pari passu in all respects (or in all respects save for the date from which interest thereon accrues and the amount of the first payment of interest on such further Notes) and so that the same shall be consolidated and form a single series with the outstanding Notes of a particular Series.

2.7 Separate Series

The Notes of each Series shall form a separate Series of Notes and accordingly, unless for any purpose the Trustee in its absolute discretion shall otherwise determine, the provisions of this Clause and of Clauses 3 to 14 (both inclusive), 15.3, 16, 17 and Schedule 3 shall apply mutatis mutandis separately and independently to the Notes of each Series and in such Clauses and Schedule the expressions Notes, Noteholders, Coupons, Couponholders, Talons and Talonholders shall be construed accordingly.
3. FORM OF THE NOTES

3.1 Global Notes

(a) The Notes of each Tranche will initially be represented by a single Global Note. Each Global Note shall be exchangeable for Definitive Notes together with, where applicable, (except in the case of Zero Coupon Notes) Coupons and, where applicable, Talons attached, in accordance with the provisions of such Global Note.

All Global Notes shall be prepared, completed and delivered to a common depositary (in the case of a CGN) or a common safekeeper (in the case of a NGN) for Euroclear and Clearstream, Luxembourg in accordance with the provisions of the Programme Agreement or (in the case of a CGN) to another appropriate depositary in accordance with any other agreement between the relevant Issuer and the relevant Dealer(s) and, in each case, the Agency Agreement and this Trust Deed.

(b) Each Global Note shall be printed or typed in the form or substantially in the form set out in Part 1 of Schedule 2 and may be a facsimile. Each Global Note shall have annexed thereto a copy of the applicable Final Terms and shall be signed manually or in facsimile by two directors or one director and the secretary or assistant secretary of the relevant Issuer, and shall be authenticated by or on behalf of the Agent and shall, in the case of a Eurosystem-eligible NGN or in the case of a Non-eligible NGN in respect of which effectuation is to be applicable, be effectuated by the common safekeeper acting on the instructions of the Agent. Each Global Note so executed and authenticated (and if applicable effectuated) shall be a binding and valid obligation of the Issuer and title thereto shall pass by delivery.

3.2 Definitive Notes

(a) The Definitive Notes, the Coupons and the Talons shall be to bearer in the respective forms or substantially in the respective forms set out in Part 2, Part 3 and Part 4, respectively, of Schedule 2. The Definitive Notes, the Coupons and the Talons shall be serially numbered and, if listed or quoted, shall be security printed in accordance with the requirements (if any) from time to time of the relevant Stock Exchange and the relevant Conditions shall be incorporated by reference (where applicable to this Trust Deed) into such Definitive Notes if permitted by the relevant Stock Exchange (if any), or, if not so permitted, the Definitive Notes shall be endorsed with or have attached thereto the relevant Conditions, and, in either such case, the Definitive Notes shall have endorsed therein or attached thereto a copy of the applicable Final Terms (or the relevant provisions thereof). Title to the Definitive Notes, the Coupons and the Talons shall pass by delivery.

(b) The Definitive Notes shall be signed manually or in facsimile by two directors or one director and the secretary or assistant secretary of the relevant Issuer, and shall be authenticated by or on behalf of the Agent. The Definitive Notes so executed and authenticated, and the Coupons and Talons, upon execution, and upon execution and authentication of the Definitive Notes, shall be binding and valid obligations of the Issuer. The Coupons and the Talons shall be signed manually or in facsimile by two directors or one director and the secretary or assistant secretary of the relevant Issuer. No Definitive Note and none of the Coupons or Talons appertaining to such Definitive Note shall be binding or valid until such Definitive Note shall have been executed and authenticated and the Coupons or Talons shall have been executed, in each case as aforesaid.

22
3.3 Facsimile Signatures
The relevant Issuer may use the facsimile signature of any person who at the date such signature is affixed to a Note is duly authorised by the relevant Issuer or a director or a secretary of the relevant Issuer notwithstanding that at the time of issue of any of the Notes he may have ceased for any reason to be so authorised or to hold such office.

3.4 Persons to be treated as Noteholders
Except as ordered by a court of competent jurisdiction or as required by law, the relevant Issuer, the Guarantors, the Trustee, the Agent and any other Paying Agent (notwithstanding any notice to the contrary and whether or not it is overdue and notwithstanding any notation of ownership or writing thereon or notice of any previous loss or theft thereof) may (a) for the purpose of making payment thereon or on account thereof deem and treat the bearer of any Global Note, Definitive Note, Coupon or Talon and of all rights thereunder free from all encumbrances, and shall not be required to obtain proof of such ownership or as to the identity of the bearer and (b) for all other purposes deem and treat:
(a) the bearer of any Definitive Note, Coupon or Talon; and
(b) each person for the time being shown in the records of Euroclear or Clearstream, Luxembourg as having a particular nominal amount of Notes credited to his securities account,
as the absolute owner thereof free from all encumbrances and shall not be required to obtain proof of such ownership or as to the identity of the bearer of any Global Note, Definitive Note, Coupon or Talon.

4. STAMP DUTIES AND TAXES
4.1 Stamp Duties
The relevant Issuer will pay any stamp, issue, documentary or other taxes and duties, including interest and penalties, payable in the United Kingdom, The Netherlands, Belgium and Luxembourg in respect of the creation, issue and offering of the Notes and the Coupons and the execution or delivery of this Trust Deed. The relevant Issuer will also indemnify the Trustee, the Noteholders and the Couponholders from and against all stamp, issue, documentary or other taxes paid by any of them in any jurisdiction in connection with any action taken by or on behalf of the Trustee or, as the case may be, the Noteholders or the Couponholders to enforce the relevant Issuer’s or any Guarantor’s obligations under this Trust Deed.

4.2 Change of Taxing Jurisdiction
If the relevant Issuer or a Guarantor becomes subject generally to the taxing jurisdiction of a territory or an authority of or in that territory having power to tax other than or in addition to the United Kingdom (in the case of BATIF and British American Tobacco) or The Netherlands (in the case of BATNF) or the United States (in the case of BATCAP) or any such authority or in such territory then such Issuer or, as the case may be, the relevant Guarantor will (unless the Trustee otherwise agrees) give the Trustee an undertaking satisfactory to the Trustee in terms corresponding to the terms of Condition 7 with the substitution for, or (as the case may require) the addition to, the references in that Condition to the United Kingdom (in the case of BATIF and British American Tobacco), The Netherlands (in the case of BATNF) or the United States (in the case of BATCAP) of references to that other or additional territory or authority to whose taxing jurisdiction such Issuer or the relevant Guarantor has become so subject. In such event this Trust Deed and the Notes will be read accordingly.
5. GUARANTEE AND INDEMNITY

5.1 Guarantee
The Guarantors, jointly and severally, unconditionally and irrevocably guarantee that, if the relevant Issuer does not pay any sum payable by it under this Trust Deed by the time and on the date specified for such payment (whether on the normal due date, on acceleration or otherwise), the Guarantors will pay that sum to or to the order of the Trustee, in the manner provided in Clause 2.2 (or if in respect of sums due under Clause 9, in London in pounds sterling in immediately available funds) before close of business on that date in the city to which payment is so to be made. Clause 2.2(a), (b) and (c) will apply (with consequential amendments as necessary) to such payments other than those in respect of sums due under Clause 9. All payments under this Trust Deed by the Guarantors will be made subject to the provisions of Clause 4.2, Condition 7 and Subclause 5.9 of this Clause.

5.2 Guarantor(s) as Principal Debtor
As between the Guarantors and the Trustee, the Noteholders and the Couponholders but without affecting the relevant Issuer’s obligations, each of the Guarantors will be liable under this Clause as if it were the sole principal debtor and not merely a surety. Accordingly, it will not be discharged, nor will its liability be affected, by anything which would not discharge it or affect its liability if it were the sole principal debtor (including (a) any time, indulgence, waiver or consent at any time given to the relevant Issuer or any other person, (b) any amendment to any other provisions of this Trust Deed or to the Conditions or to any security or other guarantee or indemnity, (c) the making or absence of any demand on the relevant Issuer or any other person for payment, (d) the enforcement or absence of enforcement of this Trust Deed or of any security or other guarantee or indemnity, (e) the taking, existence or release of any security, guarantee or indemnity, (f) the dissolution, amalgamation, reconstruction or reorganisation of the relevant Issuer or any other person or (g) the illegality, invalidity or unenforceability of or any defect in any provision of this Trust Deed or any of the relevant Issuer’s obligations under any of them).

5.3 Guarantor’s Obligations Continuing
Each of the Guarantors’ obligations under this Trust Deed are and will remain in full force and effect by way of continuing security until no sum remains payable under this Trust Deed. Furthermore, the obligations of the Guarantors are additional to, and not instead of, any security or other guarantee or indemnity at any time existing in favour of any person, whether from the Guarantors or otherwise and may be enforced without first having recourse to the relevant Issuer, any other person, any security or any other guarantee or indemnity. Each of the Guarantors irrevocably waives (a) any right which it has whether by virtue of the droit de discussion or otherwise to require that recourse be had to the assets of the relevant Issuer before any claim is enforced against it and (b) all notices and demands of any kind.

5.4 Exercise of Guarantor’s Rights
So long as any sum remains due and outstanding under this Trust Deed:

(a) any right of a Guarantor, by reason of the performance of any of its obligations under this Clause, to be indemnified by the relevant Issuer or to take the benefit of or to enforce any security or other guarantee or indemnity will be exercised and enforced by such Guarantor only in such manner and on such terms as the Trustee may require or approve; and
(b) any amount received or recovered by a Guarantor (a) as a result of any exercise of any such right or (b) in the dissolution, amalgamation, reconstruction or reorganisation of the relevant Issuer will be immediately paid to the Trustee and the Trustee will hold it on the trusts set out in Clause 6.1.

5.5 Suspense Account
Any amount received or recovered by the Trustee (otherwise than as a result of a payment by the relevant Issuer to the Trustee in accordance with Clause 2) in respect of any sum payable by the relevant Issuer under this Trust Deed may be placed in a suspense account and kept there for so long as the Trustee thinks fit.

5.6 Avoidance of Payments
If any payment received by the Trustee or any Noteholder or Couponholder pursuant to the provisions of this Trust Deed is, on the subsequent bankruptcy or insolvency of the relevant Issuer, avoided under any laws related to bankruptcy or insolvency, such payment will not be considered as having discharged or diminished the liability of the Guarantors and this Guarantee will continue to apply as if such payment had at all times remained owing by the relevant Issuer.

5.7 Debts of Issuer
If any moneys become payable by the Guarantors under this Guarantee, the relevant Issuer will not (except in the event of the liquidation of the relevant Issuer), so long as any such moneys remain unpaid, pay any moneys for the time being due from the relevant Issuer to any of the Guarantors.

5.8 Indemnity
As separate, independent and alternative stipulations, each of the Guarantors unconditionally and irrevocably agrees (a) that any sum which, although expressed to be payable by the relevant Issuer under this Trust Deed, is for any reason (whether or not now existing and whether or not now known or becoming known to the relevant Issuer, the Guarantors, the Trustee or any Noteholder or Couponholder) not recoverable from a Guarantor on the basis of a guarantee will nevertheless be recoverable from it as if it were the sole principal debtor and will be paid by it to the Trustee on demand and (b) as a primary obligation to indemnify the Trustee, each Noteholder and each Couponholder against any loss suffered by it as a result of (i) any sum expressed to be payable by the relevant Issuer under this Trust Deed not being paid on the date and otherwise in the manner specified in this Trust Deed or (ii) any payment obligation of the relevant Issuer under this Trust Deed being or becoming void, voidable or unenforceable for any reason (whether or not now existing and whether or not now known or becoming known to the Trustee, any Noteholder or any Couponholder), the amount of that loss being the amount expressed to be payable by the relevant Issuer in respect of the relevant sum.

5.9 Taxes
(a) All payments of principal and interest by the Guarantors will be made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges (together, Taxes) of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of the United Kingdom (in the case of BATIF and British American Tobacco), The Netherlands (in the case of BATNF) and the United States (in the case of BATCAP) or any political subdivision thereof or any authority thereof or therein having power to levy the same unless such withholding or deduction is required by law. In that event, the relevant Guarantor shall (subject as provided below) pay such amounts (the Additional Amounts) as will result in the receipt by the Noteholders and the Couponholders of such amounts as would have been received by them had no such Taxes been required to be withheld or deducted.
(b) No Additional Amounts will be payable by BATIF or British American Tobacco in respect of Notes or Coupons:

(i) presented for payment by or on behalf of a Noteholder or Couponholder who is liable for such withheld or deducted Taxes by reason of his having some connection with the United Kingdom other than the mere holding of a Note or Coupon; or

(ii) to, or to a third party on behalf of, a holder if such withholding or deduction may be avoided by complying with any statutory requirement or by making a declaration of non-residence or other similar claim for exemption to any authority of or in the United Kingdom, unless such holder proves that he is not entitled so to comply or to make such declaration or claim; or

(iii) presented for payment in the United Kingdom; or

(iv) presented for payment more than 30 days after the Relevant Date except to the extent that a Noteholder or Couponholder would have been entitled to payment of such Additional Amounts if he had presented his Note or Coupon for payment on the thirtieth day after the Relevant Date.

(c) No Additional Amounts will be payable by BATNF in respect of Notes or Coupons:

(i) presented for payment by or on behalf of a Noteholder or Couponholder who is liable for such withheld or deducted Taxes by reason of his having some connection with The Netherlands other than the mere holding of a Note or Coupon; or

(ii) to, or to a third party on behalf of, a holder if such withholding or deduction may be avoided by complying with any statutory requirement or by making a declaration of non-residence or other similar claim for exemption to any authority of or in The Netherlands, unless such holder proves that he is not entitled so to comply or to make such declaration or claim; or

(iii) presented for payment in The Netherlands; or

(iv) presented for payment more than 30 days after the Relevant Date except to the extent that a Noteholder or Couponholder would have been entitled to payment of such Additional Amounts if he had presented his Note or Coupon for payment on the thirtieth day after the Relevant Date; or

(v) to, or to another party on behalf of, a holder if such Additional Amounts are payable for or on account of any Taxes imposed or to be withheld in The Netherlands pursuant to the Dutch Withholding Tax Act 2021 (Wet bronbelasting 2021).

(d) In relation to BATCAP, the obligations set out in subclause 5.9(a) above shall not apply to:

(i) any such Taxes which would not have been so imposed but for (i) the existence of any present or former connection between the holder (or between a fiduciary, settlor, beneficiary, member or shareholder of or possessor of a power over such holder, if such holder is an estate, a trust, a partnership or a corporation) and the United States, including, without limitation, such holder (or such fiduciary, settlor, beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof, or being or having been engaged in a trade or business therein or being or having been present therein, or having or having had a permanent establishment therein, or (ii) such holder’s present or former status
as a personal holding company, passive foreign investment company, controlled foreign corporation or private foundation or other tax-exempt organisation (in each case, for United States federal income tax purposes), or as a corporation which accumulates earnings to avoid United States federal income taxes; or

(ii) any such Taxes which would not have been so imposed but for the presentation of a Note or Coupon for payment more than 30 days after the Relevant Date except to the extent that a Noteholder or Couponholder would have been entitled to payment of such Additional Amounts if he had presented his Note or Coupon for payment on the thirtieth day after the Relevant Date; or

(iii) any estate, inheritance, gift, sales, transfer or personal property Taxes or any similar Taxes; or

(iv) any such Taxes which would not have been imposed but for the failure to comply with certification, information, documentation or other reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder of a Note or Coupon, if such compliance is required by statute, by regulation of the United States Treasury Department or by an applicable income tax treaty to which the United States is a party as a precondition to relief or exemption from such Taxes; or

(v) any such Taxes which are payable otherwise than by deduction or withholding from payments in respect of a Note or Coupon; or

(vi) any such Taxes imposed on interest received by a 10 per cent. shareholder of the Issuer within the meaning of Section 871(h)(3)(B) or Section 881(c)(3)(B) of the United States Internal Revenue Code of 1986, as amended (the Code) (or any amended or successor provisions); or

(vii) any such Taxes imposed by reason of a holder of a Note or Coupon being or having been a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business, as described in Section 881(c)(3)(A) of the Code (or any amended or successor provisions); or

(viii) any backup withholding imposed pursuant to Section 3406 of the Code (or any amended or successor provisions); or

(ix) any such Taxes imposed pursuant to Section 871(h)(6) or 881(c)(6) of the Code (or any amended or successor provisions); and

(x) any combination of clauses (i) to (ix) above;

nor will any Additional Amounts be paid in respect of a Note or Coupon to any holder who is not a United States Alien or to any United States Alien who is a fiduciary or partnership or person other than the sole beneficial owner of any such payment, to the extent that a beneficiary or settlor with respect to such fiduciary, a member of such a partnership or the beneficial owner would not have been entitled to the Additional Amounts had such beneficiary, settlor, member or beneficial owner been the holder of such Note or Coupon. The term “United States Alien” means any person who, for United States federal income tax purposes, is a foreign corporation, a non-resident alien individual, a non-resident alien fiduciary of a foreign estate or trust or a foreign partnership any partner of which is for United States federal income tax purposes a foreign corporation, a non-resident alien individual, a non-resident alien fiduciary of a foreign estate or trust or any such foreign partnership.

27
6. APPLICATION OF MONEYS AND PARTIAL PAYMENTS

6.1 Declaration of Trust

All moneys received by the Trustee under this Trust Deed from the relevant Issuer or, as the case may be, the Guarantors (including any moneys which represent principal or interest in respect of Notes or Coupons which have become void under Condition 8) shall, unless and to the extent attributable, in the opinion of the Trustee, to a particular Series of the Notes, be apportioned pari passu and rateably between each Series of the Notes, and all moneys received by the Trustee under this Trust Deed from the relevant Issuer or, as the case may be, the Guarantors to the extent attributable in the opinion of the Trustee to a particular Series of the Notes or which are apportioned to such Series as aforesaid, be held by the Trustee upon trust to apply them (subject to Clause 5.5 and Clause 7):

FIRST in payment or satisfaction of all amounts then due and unpaid under these presents to the Trustee and/or any Appointee;
SECONDLY in or towards payment pari passu and rateably of all principal and interest then due and unpaid in respect of the Notes of that Series;
THIRDLY in or towards payment pari passu and rateably of all principal and interest then due and unpaid in respect of the Notes of each other Series; and
FOURTHLY in payment of the balance (if any) to the relevant Issuer (without prejudice to, or liability in respect of, any question as to how such payment to the relevant Issuer shall be dealt with as between the relevant Issuer and any other person) or, in the event that any moneys were received from any Guarantor, to the extent of such moneys, to such Guarantor.

Without prejudice to this Subclause 6.1, if the Trustee holds any moneys which represent principal or interest in respect of Notes which have become void or in respect of which claims have been prescribed under Condition 8, the Trustee will hold such moneys on the above trusts.

6.2 Partial Payments

Upon any payment under Subclause 6.1 (other than payment in full against surrender of a Note or Coupon) the Note or Coupon in respect of which such payment is made shall be produced to the Trustee or the Paying Agent by or through whom such payment is made and (except in the case of a NGN) the Trustee shall or shall cause such Paying Agent to enface thereon a memorandum of the amount and the date of payment but the Trustee may in any particular case dispense with such production and enfacement upon such indemnity being given as it shall think sufficient.

7. INVESTMENT BY THE TRUSTEE

7.1 No provision of these presents shall (a) confer on the Trustee any right to exercise any investment discretion in relation to the assets subject to the trust constituted by these presents and, to the extent permitted by law, Section 3 of the Trustee Act 2000 shall not apply to the duties of the Trustee in relation to the trusts constituted by these presents and (b) require the Trustee to do anything which may cause the Trustee to be considered a sponsor of a covered fund under Section 619 of the Dodd- Frank Wall Street Reform and Consumer Protection Act and any regulations promulgated thereunder.

7.2 The Trustee may deposit moneys in respect of the Notes or Coupons in its name in an account at such bank or other financial institution as the Trustee may, in its absolute discretion, think fit. If that bank or financial institution is the Trustee or a subsidiary, holding or associated company of the Trustee, the Trustee need only account for an amount of interest equal to the amount of interest which would, at then current rates, be payable by it on such a deposit to an independent customer.
7.3 The parties acknowledge and agree that in the event that any deposits in respect of the Notes or Coupons are held by a bank or a financial institution in the name of the Trustee and the interest rate in respect of certain currencies is a negative value such that the application thereof would result in amounts being debited from funds held by such bank or financial institution ("negative interest"), the Trustee shall not be liable to make up any shortfall or be liable for any loss.

7.4 The Trustee may at its discretion accumulate such deposits and the resulting interest and other income derived thereon. The accumulated deposits shall be applied under Clause 6. All interest and other income deriving from such deposits shall be applied first in payment or satisfaction of all amounts then due and unpaid under Clause 9 to the Trustee and/or any Appointee and otherwise held for the benefit of and paid to the Noteholders of such Series or the holders of the related Coupons, as the case may be.

8. COVENANTS

So long as any of the Notes of any Series remains outstanding, the relevant Issuer and the Guarantors will each:

(a) **Books of Account**: keep, and use reasonable endeavours to procure that each of their respective subsidiaries keeps, proper books of account and, at any time after an Event of Default or Potential Event of Default has occurred or if the Trustee reasonably believes that such an event has occurred, so far as permitted by applicable law, allow, and procure that each of their respective subsidiaries will allow, the Trustee and anyone appointed by it to whom the relevant Issuer, the Guarantors and/or the relevant subsidiary has no reasonable objection, access to its books of account at all reasonable times during normal business hours;

(b) **Notice of Events of Default**: notify the Trustee in writing immediately on becoming aware of the occurrence of any Event of Default or Potential Event of Default;

(c) **Information**: so far as permitted by applicable law, give the Trustee such information as it reasonably requires to perform its functions pursuant to this Trust Deed;

(d) **Financial Statements etc**: send to the Trustee at the time of their issue and in the case of annual financial statements in any event within 180 days of the end of each financial year three copies (in English) of every balance sheet, profit and loss account, report or other notice, statement or circular issued, or which legally or contractually should be issued, to the members or creditors (or any class of them) of the relevant Issuer or the Guarantors or any Holding Company thereof, as the case may be, generally in its or their capacity as such;

(e) **Certificates of Directors**: send to the Trustee, within 30 days of its annual audited financial statements being made available to its members, and also within 30 days of any request by the Trustee, a certificate of the relevant Issuer or, as the case may be, each Guarantor signed by any two of its Directors or any one of its Directors and its Secretary or Assistant Secretary that, having made all reasonable enquiries, to the best of the knowledge, information and belief of the relevant Issuer or, as the case may be, the relevant Guarantor as at a date (the **Certification Date**) not more than five days before the date of the certificate no Event of Default or Potential Event of Default or other breach of this Trust Deed existed or had occurred since the Certification Date of the last such certificate or, if none, the date of this Deed or, if such an event exists or had occurred, giving details of it;
(f) Notices to Bondholders: send, or procure that the Agent sends, to the Trustee at least 48 hours prior to publication the form of each notice to be given to Noteholders and, once given, two copies of each such notice, such notice to be in a form approved in writing by the Trustee (such approval, unless expressed to do so not to constitute approval for the purposes of Section 21 of the FSMA of a communication within the meaning of Section 21 of the FSMA);

(g) Further Acts: so far as permitted by applicable law, do such further things as may be necessary in the opinion of the Trustee to give effect to this Trust Deed;

(h) Notice of late payment: forthwith upon request by the Trustee give notice to the Noteholders of any unconditional payment to the Agent or the Trustee of any sum due in respect of the Notes or Coupons made after the due date for such payment;

(i) Listing: use all reasonable endeavours to maintain the quotation or listing of the Notes on the Stock Exchange but, if it is unable to do so, having used such endeavours, or if the obtaining or maintenance of such quotation or listing is agreed by the Trustee to be unduly onerous and the Trustee is satisfied that the interests of the Noteholders would not be thereby materially prejudiced, instead use all reasonable endeavours to obtain and maintain a quotation or listing of the Notes on another stock exchange approved in writing by the Trustee;

(j) Change in Agents: give at least 14 days’ prior notice to the Noteholders of any future appointment, resignation or removal of any Agent, Calculation Agent, Reference Bank or other Paying Agent or of any change by any Paying Agent or Reference Bank of its specified office and not make any such appointment or removal without the Trustee’s written approval;

(k) Notes held by Issuer etc: send to the Trustee as soon as practicable after being so requested by the Trustee a certificate of the relevant Issuer or, as the case may be, each Guarantor signed by any two of its Directors or any one of its Directors and its Secretary or Assistant Secretary stating the number and nominal amount of Notes held at the date of such certificate by or on behalf of the relevant Issuer or, as the case may be, each Guarantor or their respective subsidiaries;

(l) Payment of interest in the United States: if, in accordance with the provisions of the Conditions, interest in respect of the Notes becomes payable at the specified office of any Paying Agent in the United States of America promptly give notice thereof to the relative Noteholders in accordance with Condition 13;

(m) Euroclear and Clearstream, Luxembourg: use all reasonable endeavours to procure that Euroclear and/or Clearstream, Luxembourg (as the case may be) issue(s) any record, certificate or other document requested by the Trustee under Clause 10.18 or otherwise as soon as practicable after such request;

(n) Drawings: give prior written notice to the Trustee of any proposed redemption pursuant to Conditions 6(b) or 6(c) and, if it shall have given notice to the Noteholders of its intention to redeem any Notes pursuant to Condition 6(c), duly proceed to make drawings (if appropriate) and to redeem Notes accordingly;

(o) Programme Agreement: promptly provide the Trustee with copies of all supplements and/or amendments and/or restatements of the Programme Agreement;
Holding Company: in the event that any company, the share capital of which is or is to be listed on the London Stock Exchange, becomes the ultimate Holding Company of British American Tobacco, procure that such Holding Company shall become a guarantor under this Trust Deed, jointly and severally with the Guarantors, with effect from the later of (i) the date on which such company becomes the ultimate Holding Company of British American Tobacco and (ii) the date on which the share capital of such Holding Company is listed on the London Stock Exchange and, in such event, the term “Guarantors” herein shall be deemed to include such Holding Company.

9. REMUNERATION AND INDEMNIFICATION OF THE TRUSTEE

9.1 Normal Remuneration

So long as the Notes remain outstanding the relevant Issuer will pay the Trustee as remuneration for its services as Trustee such sum on such dates in each case as they may from time to time agree. Such remuneration will accrue from day to day from the date of this Deed or as otherwise agreed between the relevant Issuer, and the Trustee from time to time and shall be payable on such dates as they may from time to time agree. Such remuneration shall accrue from day to day and be payable (in priority to payments to Noteholders and Couponholders) up to and including the date when, all the Notes having become due for redemption, the moneys payable in respect thereof have been paid to the Agent or the Trustee. However, if any payment to a Noteholder or Couponholder of moneys due in respect of any Note or Coupon is improperly withheld or refused, such remuneration will again accrue as from the date of such withholding or refusal until payment to such Noteholder or Couponholder is duly made.

9.2 Extra Remuneration

If an Event of Default or a Potential Event of Default shall have occurred the relevant Issuer hereby agrees that the Trustee shall be entitled to be paid additional remuneration, which may be calculated at its normal hourly rates in force from time to time. In any other case, if the Trustee finds it expedient or necessary or is requested by the relevant Issuer to undertake duties which they both agree to be of an exceptional nature or otherwise outside the scope of the Trustee’s normal duties under this Trust Deed, the relevant Issuer will pay such additional remuneration as they may agree (which may be calculated by reference to the Trustee’s normal hourly rates in force from time to time) or, in the event of the Trustee and the relevant Issuer failing to agree as to any of the matters in this Subclause (or as to such sums referred to in Subclause 9.1), as determined by an investment bank or other person (acting as an expert and not as an arbitrator) selected by the Trustee and approved by the relevant Issuer or, failing such approval, nominated by the President for the time being of The Law Society of England and Wales. The expenses involved in such nomination and such investment bank’s or other person’s fee will be payable by the relevant Issuer. The determination of such investment bank or other person will be conclusive and binding on the relevant Issuer, the Guarantors, the Trustee, the Noteholders and the Couponholders.

9.3 Expenses

The relevant Issuer will also on demand by the Trustee pay or discharge all liabilities and expenses reasonably incurred by the Trustee in the preparation and execution of this Trust Deed and the performance of its functions under this Trust Deed including, but not limited to, legal and travelling expenses and any stamp, documentary or other taxes or duties paid by the Trustee in connection with any legal proceedings reasonably brought or contemplated by the Trustee against the relevant Issuer or any Guarantor to enforce any provision of, or resolving any doubt concerning, or for any other purpose in relation to this Trust Deed.

31
9.4 Indemnity
Subject to section 750 of the Companies Act 2006 (if applicable), the relevant Issuer will indemnify the Trustee in respect of all liabilities and expenses properly incurred by it or by anyone appointed by it or to whom any of its functions hereunder may be delegated by it in the carrying out of its functions hereunder and against any loss, liability, cost, claim, action, demand or expense (including, but not limited to, all costs, charges and expenses paid or incurred in disputing or defending any of the foregoing) which any of them may incur or which may be made against any of them arising out of or in relation to or in connection with, its appointment or the exercise of its functions hereunder.

9.5 Rate of Interest
All amounts due and payable pursuant to Subclauses 9.3 and 9.4 shall be payable by the relevant Issuer on the date specified in a demand in writing by the Trustee. The rate of interest applicable to such payments shall be a rate equivalent to 2 per cent. per annum over the base rate of National Westminster Bank PLC for such time as such amount remains unpaid and interest shall accrue:

(a) in the case of payments made by the Trustee before the date of such written demand from the date on which the payment was made or such later date as specified in such written demand; or
(b) in the case of payments made by the Trustee on or after the date of the written demand, from the date specified in such written demand, which date shall not be a date earlier than the date such payments are made.

All remuneration payable to the Trustee shall carry interest at the rate specified in this clause 9.5 from the date thereof.

9.6 Continuing Effect
Subclauses 9.3 and 9.4 will continue in full force and effect as regards the Trustee even if it no longer is Trustee.

9.7 Apportionment
The Trustee shall be entitled in its absolute discretion to determine in respect of which Series of Notes any liabilities, costs, charges and expenses incurred under this Trust Deed have been incurred or to allocate any such liabilities, costs, charges and expenses between the Notes of more than one Series.

9.8 No withholding or deduction
All payments to be made by the relevant Issuer to the Trustee under clause 9 of this Trust Deed shall be made free and clear of, and without withholding or deduction for, any taxes, duties, assessments or governmental charges of whatever nature imposed, levied, collected, withheld or assessed by or within any relevant jurisdiction or any authority therein or thereof having power to tax, unless such withholding or deduction is required by law. In that event, the relevant Issuer shall pay such additional amounts as will, after such deduction or withholding has been made, leave the Trustee with the full amount which would have been received by it had no such withholding or deduction been required.
10. PROVISIONS SUPPLEMENTAL TO THE TRUSTEE ACTS

10.1 Advice
The Trustee may act on the opinion or advice of, or information obtained from, any expert and will not be responsible to anyone for any loss occasioned by so acting. Any such opinion, advice or information may be sent or obtained by letter, fax or email and the Trustee will not be liable to anyone for acting in good faith on any opinion, advice or information purporting to be conveyed by such means even if it contains some error or is not authentic.

10.2 Trustee to Assume Performance
The Trustee need not notify anyone of the execution of this Trust Deed or do anything to find out if an Event of Default or Potential Event of Default has occurred. Until it has actual knowledge or express notice to the contrary, the Trustee may assume that no such event has occurred and that the relevant Issuer and the Guarantors are performing all their obligations under this Trust Deed.

10.3 Resolutions of Noteholders
The Trustee will not be responsible for having acted in good faith on a resolution in writing or any resolution purporting to have been passed at a meeting of Noteholders in respect of which minutes have been made and signed or any Extraordinary Resolution passed by way of electronic consents received through the relevant Clearing System(s) in accordance with this Trust Deed even if it is later found that there was a defect in the constitution of the meeting or the passing of the resolution, (in the case of a resolution in writing) that not all the holders had signed the resolution or (in the case of an Extraordinary Resolution passed by electronic consents received through the relevant Clearing System(s)) it was not approved by the requisite number of Noteholders or that the resolution was not valid or binding on the Noteholders or the Couponholders.

10.4 Certificate signed by Directors
If the Trustee, in the exercise of its functions, requires to be satisfied or to have information as to any fact or the expediency of any act, it may call for and accept as sufficient evidence of that fact or the expediency of that act a certificate signed by any two Directors or any one Director and the Secretary or Assistant Secretary of the relevant Issuer or any Guarantor (as the case may be) as to that fact or to the effect that, in their opinion, that act is expedient and the Trustee need not call for further evidence and will not be responsible for any loss occasioned by acting on such a certificate.

10.5 Deposit of Documents
The Trustee may deposit this Trust Deed and any other documents with any bank or entity whose business includes the safe custody of documents or with any lawyer or firm of lawyers believed by it to be of good repute and may pay all sums due in respect thereof.

10.6 Discretion
The Trustee will have absolute and uncontrolled discretion as to the exercise of its functions and will not be responsible for any loss, liability, cost, claim, action, demand, expense or inconvenience which may result from their exercise or non-exercise.
10.7 Agents
Whenever it considers it expedient in the interests of the Noteholders, the Trustee may, in the conduct of its trust business, instead of acting personally, employ and pay an agent selected by it, whether or not a lawyer or other professional person, to transact or conduct, or concur in transacting or conducting, any business and to do or concur in doing all acts required to be done by the Trustee (including the receipt and payment of money). If the Trustee exercises reasonable care in selecting such agent, the Trustee will not be responsible to anyone for any misconduct or omission by any such agent so employed by it or be bound to supervise the proceedings or acts of any such agent.

10.8 Delegation
Whenever it considers it expedient in the interests of the Noteholders, the Trustee may delegate to any person on any terms (including power to sub-delegate) all or any of its functions. If the Trustee exercises reasonable care in selecting such delegate, it will not have any obligation to supervise such delegate or be responsible for any loss, liability, cost, claim, action, demand or expense incurred by reason of any misconduct or default by any such delegate or sub-delegate.

10.9 Nominee/Custodian
The Trustee may appoint and pay a custodian or nominee on any terms in relation to assets of the trusts constituted by these presents. If the Trustee exercises reasonable care in selecting such custodian or nominee, it will not have any obligation to supervise such custodian or nominee and shall not be responsible to anyone for any loss, liability, cost, claim, action, demand or expense incurred as a result of any misconduct or default by the custodian or nominee.

10.10 Forged Bonds
The Trustee will not be liable to the relevant Issuer or any Guarantor or any Noteholder or Couponholder by reason of having accepted as valid or not having rejected any Note or Coupon purporting to be such and later found to be forged or not authentic.

10.11 Confidentiality
Unless ordered to do so by a court of competent jurisdiction the Trustee shall not be required to disclose to any Noteholder or Couponholder any confidential, financial or other information made available to the Trustee by the relevant Issuer or any Guarantor or any other person.

10.12 Determinations Conclusive
As between itself and the Noteholders and Couponholders the Trustee may determine all questions and doubts arising in relation to any of the provisions of this Trust Deed. Such determinations, whether made upon such a question actually raised or implied in the acts or proceedings of the Trustee, will be conclusive and shall bind the Trustee, the Noteholders and the Couponholders.

10.13 Currency Conversion
Where it is necessary or desirable to convert any sum from one currency to another, it will (unless otherwise provided hereby or required by law) be converted at such rate or rates, in accordance with such method and as at such date as may reasonably be specified by the Trustee but having regard to current rates of exchange, if available. Any rate, method and date so specified will be binding on the relevant Issuer, the Guarantors, the Noteholders and the Couponholders.

10.14 Events of Default
The Trustee may determine whether or not an Event of Default or Potential Event of Default is in its opinion capable of remedy and/or materially prejudicial to the interests of the Noteholders. Any such determination will be conclusive and binding on the relevant Issuer, the Guarantors, the Noteholders and the Couponholders.
10.15 Payment for and Delivery of Notes
The Trustee will not be responsible for the receipt or application by the relevant Issuer of the proceeds of the issue of the Notes, any exchange of Notes or the delivery of Notes to the persons entitled to them.

10.16 Notes held by the Issuer etc
In the absence of knowledge or express notice to the contrary, the Trustee may assume without enquiry (other than requesting a certificate under Clause 8(k)) that no Notes are for the time being held by or on behalf of the relevant Issuer, the Guarantors or their respective subsidiaries.

10.17 Interests of Noteholders as a class
In connection with the exercise by it of any of its trusts, powers, authorities or discretions under this Trust Deed (including, without limitation, any modification, waiver, authorisation or determination), the Trustee shall have regard to the general interests of the Noteholders as a class but shall not have regard to any interests arising from circumstances particular to individual Noteholders or Couponholders (whatever their number) and, in particular but without limitation, shall not have regard to the consequences of such exercise for individual Noteholders or Couponholders (whatever their number) resulting from their being for any purpose domiciled or resident in, or otherwise connected with, or subject to the jurisdiction of, any particular territory or any political sub-division thereof and the Trustee shall not be entitled to require, nor shall any Noteholder or Couponholder be entitled to claim, from the relevant Issuer, the Guarantors, the Trustee or any other person any indemnification or payment in respect of any tax consequence of any such exercise upon individual Noteholders or Couponholders except to the extent already provided for in Condition 7 and/or any undertaking given in addition thereto or in substitution therefor under this Trust Deed.

10.18 Certificate of Euroclear or Clearstream, Luxembourg
The Trustee may call for and rely on any record and/or document and/or evidence and/or information and/or certification to be issued or given by Euroclear or Clearstream, Luxembourg (a) as to the nominal amount of Notes represented by a Global Note standing to the account of any person and/or (b) in relation to any determination of the nominal amount of Notes represented by a NGN. Any such certificate or other document shall, in the absence of manifest error, be conclusive and binding for all purposes. Any such certificate or other document may comprise any form of statement or print out of electronic records provided by the relevant clearing system (including Euroclear’s Easy-Way or Clearstream, Luxembourg’s Creation Online system) in accordance with its usual procedures. The Trustee shall not be liable to any person by reason of having accepted as valid or not having rejected any record and/or document and/or evidence and/or information and/or certification to such effect purporting to be issued or given by Euroclear or Clearstream, Luxembourg and subsequently found to be forged or not authentic.

10.19 Trustee not bound to act
Save as otherwise expressly provided in this Trust Deed, the Trustee shall have absolute and uncontrolled discretion as to the exercise of the discretions hereby vested in the Trustee, but, whenever the Trustee is under the provisions of this Trust Deed bound to act at the request or direction of the Noteholders, the Trustee shall nevertheless not be so bound unless first indemnified and/or secured and/or prefunded to its satisfaction against all proceedings, claims and demands to which it may render itself liable and all costs, charges, expenses and liabilities which it may incur by so doing, including the cost of its management’s time and/or other internal resources, calculated using its normal hourly rates in force from time to time.

35
10.20 Illegality
No provision of this Trust Deed shall require the Trustee to do anything which may in its opinion be illegal or contrary to applicable law or regulation.

10.21 Trustee’s own funds
Nothing contained in this Trust Deed shall require the Trustee to expend or risk its own funds or otherwise incur any financial liability in the performance of its duties or the exercise of any right, power, authority or discretion hereunder if it has grounds for believing the repayment of such funds or adequate indemnity against, or security for, such risk or liability is not assured to it.

10.22 Trustee entitled to evaluate risk
When determining whether an indemnity or any security is satisfactory to it, the Trustee shall be entitled to evaluate its risk in given circumstances by considering the worst-case scenario and, for this purpose, it may take into account, without limitation, the potential costs of defending or commencing proceedings in England or elsewhere and the risk however remote, of any award of damages against it in England or elsewhere.

10.23 Noteholder indemnities
The Trustee shall be entitled to require that any indemnity or security given to it by the Noteholders or any of them be given on a joint and several basis and be supported by evidence satisfactory to it as to the financial standing and creditworthiness of each counterparty and/or as to the value of the security and an opinion as to the capacity, power and authority of each counterparty and/or the validity and effectiveness of the security.

10.24 Consents and Approvals
Any consent or approval given by the Trustee for the purposes of these presents may be given on such terms and subject to such conditions (if any) as the Trustee thinks fit and notwithstanding anything to the contrary in these presents may be given retrospectively. The Trustee may give any consent or approval, exercise any power, authority or discretion or take any similar action (whether or not such consent, approval, power, authority, discretion or action is specifically referred to in these presents) if it is satisfied that the interests of the Noteholders will not be materially prejudiced thereby. For the avoidance of doubt, the Trustee shall not have any duty to the Noteholders in relation to such matters other than that which is contained in the preceding sentence.

11. TRUSTEE LIABLE FOR NEGLIGENCE
11.1 The duty of care contained in Section 1 of the Trustee Act 2000 shall not apply to this Trust Deed. However, subject to Section 750 of the Companies Act 2006 (if applicable), if the Trustee fails to show the degree of care and diligence required of it as trustee, nothing in this Trust Deed shall relieve or indemnify it for, from or against any liability which would otherwise attach to it in respect of any gross negligence, willful default or fraud of which it may be guilty. Where there are any inconsistencies between the Trustee Acts and the provisions of these presents, the provisions of these presents shall, to the extent allowed by law, prevail and, in the case of any such inconsistency with the Trustee Act 2000, the provisions of this Trust Deed shall take effect as a restriction or exclusion for the purposes of that Act.

36
11.2 Notwithstanding any provision of these presents to the contrary, the Trustee shall not in any event be liable for:

(a) loss of profit, loss of business, loss of goodwill, loss of opportunity, whether direct or indirect; and

(b) special, indirect, punitive or consequential loss or damage of any kind whatsoever,

whether or not foreseeable, even if the Trustee has been advised of the likelihood of such loss or damage, unless the claim for loss or damage is made in respect of fraud on the part of the Trustee.

12. WAIVER AND PROOF OF DEFAULT

12.1 Waiver

The Trustee may, without the consent of the Noteholders or the Couponholders and without prejudice to its rights in respect of any subsequent breach, from time to time and at any time, if in its opinion the interests of the Noteholders will not be materially prejudiced thereby, on such terms as seem expedient to it, waive or authorise any breach or proposed breach by the relevant Issuer or any Guarantor of this Trust Deed or the Conditions or determine that any Event of Default or Potential Event of Default will not be treated as such provided that the Trustee will not do so in contravention of an express direction given by an Extraordinary Resolution or a request made pursuant to Condition 9(a). No such direction or request will affect a previous waiver, authorisation or determination. Any such waiver, authorisation or determination will be binding on the Noteholders and the Couponholders and, if the Trustee so requires, will be notified to the Noteholders as soon as practicable.

12.2 Proof of Default

Proof that the relevant Issuer or any Guarantor has failed to pay a sum due to the holder of any Note or Coupon will (unless the contrary be proved) be sufficient evidence that it has made the same default as regards all other Notes or Coupons which are then payable.

13. TRUSTEE CONTRACTING WITH THE ISSUER AND THE GUARANTORS

Neither the Trustee nor any director or officer or holding company, subsidiary or associated company of a corporation acting as a trustee under this Trust Deed shall by reason of its or his fiduciary position be in any way precluded from:

(a) entering into or being interested in any contract or financial or other transaction or arrangement with the relevant Issuer or any of the Guarantors or any person or body corporate associated with the relevant Issuer or any of the Guarantors (including without limitation any contract, transaction or arrangement of a banking or insurance nature or any contract, transaction or arrangement in relation to the making of loans or the provision of financial facilities or financial advice to, or the purchase, placing or underwriting of or the subscribing or procuring subscriptions for or otherwise acquiring, holding or dealing with, or acting as paying agent in respect of, the Notes or any other notes, bonds, stocks, shares, debenture stock, debentures or other securities of, any Issuer or any person or body corporate associated as aforesaid); or
accepting or holding the trusteeship of any other trust deed constituting or securing any other securities issued by or relating to the relevant Issuer or any of the Guarantors or any such person or body corporate so associated or any other office of profit under the relevant Issuer or any of the Guarantors or any such person or body corporate so associated, and shall be entitled to exercise and enforce its rights, comply with its obligations and perform its duties under or in relation to any such contract, transaction or arrangement as is referred to in (a) above or, as the case may be, any such trusteeship or office of profit as is referred to in (b) above without regard to the interests of the Noteholders and notwithstanding that the same may be contrary or prejudicial to the interests of the Noteholders and shall not be responsible for any liability or expense occasioned to the Noteholders thereby and shall be entitled to retain and shall not be in any way liable to account for any profit made or share of brokerage or commission or remuneration or other amount or benefit received thereby or in connection therewith. Where any holding company, subsidiary or associated company of the Trustee or any director or officer of the Trustee acting other than in his capacity as such a director or officer has any information, the Trustee shall not thereby be deemed also to have knowledge of such information and, unless it shall have actual knowledge of such information, shall not be responsible for any loss suffered by Noteholders resulting from the Trustee’s failing to take such information into account in acting or refraining from acting under or in relation to this Trust Deed.

14. MODIFICATION AND SUBSTITUTION

14.1 Modification
The Trustee may without the consent or sanction of the Noteholders or the Couponholders at any time and from time to time concur with the relevant Issuer in making any modification (a) to this Trust Deed which in the opinion of the Trustee it may be proper to make PROVIDED THAT the Trustee is of the opinion that such modification will not be materially prejudicial to the interests of the Noteholders or (b) to this Trust Deed if in the opinion of the Trustee such modification is of a formal, minor or technical nature, to correct a manifest error or to comply with mandatory provisions of applicable law.

In addition, the Trustee shall be obliged to concur with the relevant Issuer in effecting any Benchmark Amendments in the circumstances and as otherwise set out in Condition 4(b)(ii)(C)(4) without the consent of the Noteholders or Couponholders. Any such modification may be made on such terms and subject to such conditions (if any) as the Trustee may determine, shall be binding upon the Noteholders and the Couponholders and, unless the Trustee agrees otherwise, shall be notified by the relevant Issuer to the Noteholders in accordance with Condition 13 as soon as practicable thereafter.

14.2 Substitution
(a) Substitute Issuer
The Trustee may, without the consent of the Noteholders or the Couponholders, agree to the substitution of any Guarantor or its successor in business or Holding Company or any other subsidiary of any Guarantor or its successor in business or Holding Company (the Substituted Obligor) in place of the relevant Issuer (or of any previous substitute under this Subclause) as the principal debtor under this Trust Deed provided that:

(i) amendments to this Trust Deed are made or a trust deed is executed or some other form of undertaking is given by the Substituted Obligor to the Trustee, in any such case, in form and manner satisfactory to the Trustee, agreeing to be bound by the terms of this Trust Deed with any consequential amendments which the Trustee may deem appropriate as fully as if the Substituted Obligor had been named in this Trust Deed and on the Notes and Coupons as the principal debtor in place of the relevant Issuer;
(ii) where the Substituted Obligor is subject generally to the taxing jurisdiction of any territory or any authority of or in that territory having power to tax (the Substituted Territory) other than the territory to the taxing jurisdiction of which (or to any such authority of or in which) the relevant Issuer is subject generally (the Issuer’s Territory), the Substituted Obligor will (unless the Trustee otherwise agrees) give to the Trustee an undertaking in form and manner satisfactory to the Trustee in terms corresponding to the terms of Condition 7 with the substitution for the references in that Condition to the relevant jurisdiction specified in such Condition of references to the Substituted Territory and in such event this Trust Deed, the Notes and the Coupons (including, but without limitation, Clause 4.2) will be read accordingly;

(iii) if any two of the Directors of the Substituted Obligor certify that it will be solvent immediately after such substitution, the Trustee need not have regard to the financial condition, profits or prospects of the Substituted Obligor or compare them with those of the relevant Issuer or any Guarantor; and

(iv) the obligations of the Substituted Obligor under this Trust Deed are guaranteed by the Guarantors or their successors in business or Holding Companies (or where a Guarantor or its successor in business or Holding Company is the Substituted Obligor by the other Guarantors or their successors in business or Holding Companies) in the same terms (with consequential amendments as necessary) as the Guarantee in form and manner satisfactory to the Trustee.

(b) Release of Substituted Issuer

Any such agreement by the Trustee pursuant to this Subclause 14.2 will, if so expressed, operate to release the relevant Issuer (or any such previous substitute) from any or all of its obligations under this Trust Deed. Not later than 14 days after the execution of any such documents and after compliance with such requirements, notice of the substitution will be given to the Noteholders.

(c) Completion of Substitution

Upon the execution of such documents and compliance with such requirements, the Substituted Obligor will be deemed to be named in this Trust Deed and on the Notes and Coupons as the principal debtor in place of the relevant Issuer (or of any previous substitute under this Subclause 15.2) and this Trust Deed will be deemed to be modified in such manner as shall be necessary to give effect to the substitution.

(d) Substitute Guarantor

The Trustee may similarly, without the consent of the Noteholders or the Couponholders, agree to the substitution of any Guarantor’s successor in business or Holding Company in place of any Guarantor, mutatis mutandis so far as applicable (except that the references to Condition 7 in paragraph 14.2(a)(ii) shall be construed as references to Clause 5.9 and paragraph 14.2(a)(v) shall not be so applicable) upon the terms and subject to the conditions hereinbefore provided, with such modifications or additions as the Trustee may agree or require.

(e) In the case of any proposed substitution pursuant to this Clause 14.2, the Trustee may, without the consent of the Noteholders or the Couponholders, agree to a change in law governing the Notes, the Coupons and/or this Trust Deed, provided that such change would not, in the opinion of the Trustee, be materially prejudicial to the interests of the Noteholders.
15. APPOINTMENT, RETIREMENT AND REMOVAL OF THE TRUSTEE

15.1 Appointment
The Issuer has the power of appointing new trustees but no trustee may be so appointed unless previously approved by an Extraordinary Resolution. A trust corporation will at all times be a Trustee and may be the sole Trustee. Any appointment of a new Trustee will be notified by the relevant Issuer to the Noteholders as soon as practicable.

15.2 Retirement and Removal
Any Trustee may retire at any time on giving at least three months’ written notice to the relevant Issuer and the Guarantors without giving any reason or being responsible for any costs occasioned by such retirement and the Noteholders may by Extraordinary Resolution remove any Trustee provided that the retirement or removal of a sole trust corporation will not be effective until a trust corporation is appointed as successor Trustee. If a sole trust corporation gives notice of retirement or an Extraordinary Resolution is passed for its removal, the relevant Issuer and the Guarantors will use all reasonable endeavours to procure that another trust corporation be appointed as Trustee.

15.3 Co-Trustees
The Trustee may, despite Subclause 15.1, by written notice to the relevant Issuer and the Guarantors (unless it is not, in the opinion of the Trustee, reasonably practicable to do so) appoint anyone to act as an additional Trustee jointly with the Trustee:

(a) if the Trustee considers the appointment to be in the interests of the Noteholders and/or the Couponholders;
(b) to conform with a legal requirement, restriction or condition in any jurisdiction in which a particular act is to be performed; or
(c) to obtain a judgment or to enforce a judgment or any provision of this Trust Deed in any jurisdiction.

Subject to the provisions of this Trust Deed the Trustee may confer on any person so appointed such functions as it thinks fit. The Trustee may by written notice to the relevant Issuer and the Guarantors remove that person. At the Trustee’s request, the relevant Issuer and the Guarantors will forthwith do all things as may be required to perfect such appointment or removal and each of them irrevocably appoints the Trustee as its attorney in its name and on its behalf to do so other than the payment of the costs of such appointee, if any, which will be agreed between the appointee and the Issuers and the Guarantors and otherwise subject to Clause 9.

15.4 Competence of a Majority of Trustees
If there are more than two Trustees the majority of them will be competent to perform the Trustee’s functions provided the majority includes a trust corporation.

16. HOLDER OF DEFINITIVE NOTE ASSUMED TO BE COUPONHOLDER

16.1 Wherever in this Trust Deed the Trustee is required or entitled to exercise a power, trust, authority or discretion under this Trust Deed, except as ordered by a court of competent jurisdiction or as required by applicable law, the Trustee shall, notwithstanding that it may have express notice to the contrary, assume that each Noteholder is the holder of all Coupons appertaining to each Definitive Note of which he is the holder.
NO NOTICE TO COUPONHOLDERS

16.2 No notices need be given to Couponholders. They will be deemed to have notice of the contents of any notice given to Noteholders. Even if it has express notice to the contrary, in exercising any of its functions by reference to the interests of the Noteholders, the Trustee will assume that the holder of each Note is the holder of all Coupons relating to it.

17. CURRENCY INDEMNITY

17.1 Currency of Account and Payment

The currency in which the Notes are denominated (the Contractual Currency) is the currency of account and payment for all sums payable by the relevant Issuer or a Guarantor under or in connection with this Trust Deed in respect of such Notes and the relative Coupons, including damages.

17.2 Extent of discharge

An amount received or recovered in a currency other than the Contractual Currency (whether as a result of, or of the enforcement of, a judgment or order of a court of any jurisdiction, in the winding-up or dissolution of the relevant Issuer or a Guarantor or otherwise), by the Trustee or any Noteholder or Couponholder in respect of any sum expressed to be due to it from the relevant Issuer or a Guarantor will only discharge the relevant Issuer and the relevant Guarantor to the extent of the Contractual Currency amount which the recipient is able to purchase with the amount so received or recovered in that other currency on the date of that receipt or recovery (or, if it is not practicable to make that purchase on that date, on the first date on which it is practicable to do so).

17.3 Indemnity

If the relevant Contractual Currency amount is less than the Contractual Currency amount expressed to be due to the recipient under this Trust Deed, the Notes or the Coupons, the relevant Issuer will indemnify the Trustee, any Noteholder or Couponholder against any loss sustained by any of those parties as a result. In any event, the relevant Issuer will indemnify the recipient against the cost of making any such purchase.

17.4 Indemnity separate

This indemnity constitutes a separate and independent obligation from the other obligations in this Trust Deed, will give rise to a separate and independent cause of action, will apply irrespective of any indulgence granted by the Trustee and/or any Noteholder or Couponholder and will continue in full force and effect despite any judgment, order, claim or proof for a liquidated amount in respect of any sum due under this Trust Deed, the Notes and/or the Coupons or any other judgment or order.

18. COMMUNICATIONS

Any communication shall be by letter or fax:

(a) in the case of BATIF, to it (with a copy to British American Tobacco) at:

Globe House
4 Temple Place
London WC2R 2PG
Tel No.   020 7845 1000
Email   Corporate_Finance_Financial_Risk@bat.com
Attention   The Group Treasurer

(b) in the case of BATNF, to it (with a copy to British American Tobacco) at:
Handelsweg 53A
1181 ZA Amstelveen
The Netherlands

Tel No.   +31 20 5406 911
Email   judith_bollen@bat.com
Attention   The Board of Directors

(c) in the case of BATCAP, to it (with a copy to British American Tobacco) at:
103 Foulk Road, Suite 120 Wilmington
Delaware 19803
United States of America

Tel No.   +1 302 691 6323
Email   Brian.Harrison@cscgfm.com
Attention   Secretary

(d) in the case of British American Tobacco, to it at:
Globe House
4 Temple Place
London WC2R 2PG

Tel No.   020 7845 1000
Email   Corporate_Finance_Financial_Risk@bat.com
Attention   The Group Treasurer

(e) and in the case of the Trustee, to it at:
8th Floor
100 Bishopsgate
London EC2N 4AG

Fax No.   0207 606 0643
Email   Trust.Support@lawdeb.com,
Attention   The Manager, Trust Management

Communications will take effect, in the case of delivery, when delivered or, in the case of email or fax, when received. Communications not by letter shall be confirmed by letter but failure to send or receive that letter shall not invalidate the original communication (provided always that in relation to any communication sent by email to the Trustee, such communication shall only be deemed delivered upon written confirmation by the Trustee and, for the avoidance of doubt, an automatically generated “read” or “received” receipt shall not constitute such confirmation).
19. GOVERNING LAW
This Trust Deed and any non-contractual obligations arising out of or in connection with it is governed by, and shall be construed in accordance with, English law.

20. SUBMISSION TO JURISDICTION
20.1 Each of the parties hereto irrevocably agrees that the courts of England are to have jurisdiction to settle any disputes which may arise out of or in connection with this Trust Deed (including a dispute relating to any non-contractual obligations arising out of or in connection with it) and that accordingly any suit, action or proceedings arising out of or in connection with this Trust Deed (together referred to as Proceedings) may be brought in the courts of England, including any Proceedings relating to any non-contractual obligations arising out of or in connection with this Trust Deed. Each of the parties hereto irrevocably and unconditionally waives and agrees not to raise any objection which it may have now or subsequently to the laying of the venue of any Proceedings in the courts of England and any claim that any Proceedings have been brought in an inconvenient forum and further irrevocably and unconditionally agrees that a judgment in any Proceedings brought in the courts of England shall be conclusive and binding upon it and may be enforced in the courts of any other jurisdiction. Nothing in this Clause shall limit any right to take Proceedings against any of the parties hereto in any other court of competent jurisdiction (outside the Contracting States, as defined in Section 1(3) of the Civil Jurisdiction and Judgments Act 1982), nor shall the taking of Proceedings in one or more jurisdictions preclude the taking of Proceedings in any other jurisdiction, whether concurrently or not.

20.2 Each of BATCAP and BATNF irrevocably and unconditionally appoints British American Tobacco at its registered office at Globe House, 4 Temple Place, London WC2R 2PG and in the event of its ceasing so to act will appoint such other person as the Trustee may approve and as BATCAP or BATNF, as the case may be, may nominate in writing to the Trustee for the purpose to accept service of process on its behalf in England in respect of any Proceedings. Each of BATCAP and BATNF:
   (a) agrees to procure that, so long as any of the Notes issued by it remains liable to prescription, there shall be in force an appointment of such a person approved by the Trustee with an office in London with authority to accept service as aforesaid;
   (b) agrees that failure by any such person to give notice of such service of process to BATCAP or BATNF, as the case may be, shall not impair the validity of such service or of any judgment based thereon; and
   (c) agrees that nothing in this Trust Deed shall affect the right to serve process in any other manner permitted by law.

21. WAIVER OF TRIAL BY JURY
Each party waives any right it may have to a jury trial or any claim or cause of action in connection with this Deed or any transaction contemplated by this Deed. This Deed may be filed as a written consent to trial by court.

22. COUNTERPARTS
This Deed and any trust deed supplemental hereto may be executed and delivered in any number of counterparts, all of which, taken together, shall constitute one and the same deed and any party to this Deed or any trust deed supplemental hereto may enter into the same by executing and delivering a counterpart.
23. **CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999**

A person who is not a party to this Trust Deed or any trust deed supplemental hereto has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Trust Deed or any trust deed supplemental hereto, but this does not affect any right or remedy of a third party which exists or is available apart from that Act.

**IN WITNESS whereof this Deed has been executed as a deed by BATCAP, BATIF, BATNF, British American Tobacco and the Trustee and delivered on the date first stated on page 1.**
SCHEDULE 1

TERMS AND CONDITIONS OF THE NOTES

This Note is one of a Series (as defined below) of Notes issued by B.A.T. International Finance p.l.c. ("BATIF"), B.A.T. Netherlands Finance B.V. ("BATNF") or B.A.T Capital Corporation ("BATCAP") as indicated in the applicable Final Terms (each in its capacity as the issuer of the Notes, the "Issuers" and, together with the other in its capacity as issuer of other notes, the "Issuers") constituted by a Trust Deed (such Trust Deed as modified and/or supplemented and/or restated from time to time, the "Trust Deed") dated 6 July 1998 made between, inter alios, each of BATIF, BATNF and BATCAP as an Issuer, and where it is not the Issuer of the Notes, as guarantor of notes issued by the other Issuers, British American Tobacco p.l.c. ("British American Tobacco") as a guarantor and The Law Debenture Trust Corporation p.l.c. (the "Trustee", which expression shall include any successor as trustee). Each of BATIF, BATNF, BATCAP and British American Tobacco in its capacity as a guarantor is herein referred to as a "Guarantor" and all together in such capacities are herein referred to as the "Guarantors". The Issuer and the Guarantors in relation to the Notes are specified in the applicable Final Terms (as defined below) and such expressions shall be construed accordingly.

References herein to the "Notes" shall be references to the Notes of this Series and shall mean:

(i) in relation to any Notes represented by a global Note (a "Global Note"), units of each Specified Denomination in the Specified Currency;
(ii) any Global Note; and
(iii) any definitive Notes issued in exchange for a Global Note.

The Notes and the Coupons (as defined below) have the benefit of an amended and restated Agency Agreement (such Agency Agreement as amended and/or supplemented and/or restated from time to time, the "Agency Agreement") dated 18 March 2021 and made between the same parties as are parties to the Trust Deed, Citibank, N.A., London Branch as issuing and principal paying agent and agent bank (the "Agent", which expression shall include any successor agent) and the other paying agent named therein (together with the Agent, the "Paying Agents", which expression shall include any additional or successor paying agent).

Interest bearing definitive Notes (unless otherwise indicated in the applicable Final Terms) have interest coupons ("Coupons") and, if indicated in the applicable Final Terms, talons for further Coupons ("Talons") attached on issue. Any reference herein to Coupons or coupons shall, unless the context otherwise requires, be deemed to include a reference to Talons or talons. Global Notes do not have Coupons or Talons attached on issue.

The final terms for this Note (or the relevant provisions thereof) are set out in Part A of the Final Terms attached to or endorsed on this Note which supplement these Terms and Conditions and may specify other terms and conditions which shall, to the extent so specified or to the extent inconsistent with these Terms and Conditions, complete these Terms and Conditions for the purposes of this Note. References to the “applicable Final Terms” are to Part A of the Final Terms (or the relevant provisions thereof) attached to or endorsed on this Note.

The Trustee acts for the benefit of the holders for the time being of the Notes (the "Noteholders", which expression shall, in relation to any Notes represented by a Global Note, be construed as provided below) and the holders of the Coupons (the "Couponholders", which expression shall, unless the context otherwise requires, include the holders of the Talons), in accordance with the provisions of the Trust Deed.

As used herein, "Tranche" means Notes which are identical in all respects (including as to listing and admission to trading) and "Series" means a Tranche of Notes together with any further Tranche or Tranches of Notes which are (i) expressed to be consolidated and form a single series with an existing Tranche of Notes; and (ii) identical in all respects (including as to listing and admission to trading) except for their respective Issue Dates, Interest Commencement Dates and/or Issue Prices.

45
Copies of the Trust Deed, the Agency Agreement and the applicable Final Terms are available for inspection during normal business hours at the registered office for the time being of the Trustee (being at the date of this Base Prospectus at Fifth Floor, 100 Bishopsgate, London EC2N 4AG) and at the specified office of each of the Paying Agents. The Noteholders and the Couponholders are deemed to have notice of, and are entitled to the benefit of, all the provisions of the Trust Deed, the Agency Agreement and the applicable Final Terms which are applicable to them. The statements in these Terms and Conditions include summaries of, and are subject to, the detailed provisions of and definitions contained in the Trust Deed.

Words and expressions defined in the Trust Deed or the Agency Agreement or used in the applicable Final Terms shall have the same meanings where used in these Terms and Conditions unless the context otherwise requires or unless otherwise stated and provided that, in the event of inconsistency between the Agency Agreement and the Trust Deed, the Trust Deed will prevail and, in the event of inconsistency between the Agency Agreement or the Trust Deed and the applicable Final Terms, the applicable Final Terms will prevail.

In the Conditions, “euro” means the currency introduced at the start of the third stage of European economic and monetary union pursuant to the Treaty on the Functioning of the European Union, as amended.

1 Form, Denomination and Title

The Notes are in bearer form and, in the case of definitive Notes, serially numbered, in the Specified Currency and the Specified Denomination(s) specified in the applicable Final Terms. Notes of one Specified Denomination may not be exchanged for Notes of another Specified Denomination.

This Note may be a Fixed Rate Note, a Floating Rate Note, a Zero Coupon Note or a combination of any of the foregoing, depending upon the Interest Basis shown in the applicable Final Terms. Notes of one Specified Denomination may not be exchanged for Notes of another Specified Denomination.

Definitive Notes are issued with Coupons attached, unless they are Zero Coupon Notes in which case references to Coupons and Couponholders in these Terms and Conditions, the Trust Deed and the Agency Agreement are not applicable.

Subject as set out below, title to the Notes and Coupons will pass by delivery. The Issuer, the Guarantors and any Paying Agent will (except as otherwise required by law) deem and treat the bearer of any Note or Coupon as the absolute owner thereof (whether or not overdue and notwithstanding any notice of ownership or writing thereon or notice of any previous loss or theft thereof) for all purposes but, in the case of any Global Note, without prejudice to the provisions set out in the next succeeding paragraph.

For so long as any of the Notes is represented by a Global Note held on behalf of Euroclear Bank SA/NV (“Euroclear”) and/or Clearstream Banking S.A. ("Clearstream, Luxembourg"), each person (other than Euroclear or Clearstream, Luxembourg) who is for the time being shown in the records of Euroclear or of Clearstream, Luxembourg as the holder of a particular nominal amount of such Notes (in which regard any certificate or other document issued by Euroclear or Clearstream, Luxembourg who is for the time being shown in the records of Euroclear or of Clearstream, Luxembourg as the holder of a particular nominal amount of such Notes (in which regard any certificate or other document issued by Euroclear or Clearstream, Luxembourg as to the nominal amount of such Notes standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall be treated by the Issuer, the Guarantors and the Paying Agents as the holder of such nominal amount of such Notes for all purposes, other than with respect to the payment of principal or interest on such nominal amount of such Notes, for which purpose the bearer of the relevant Global Note shall be treated by the Issuer, the Guarantors and any Paying Agent as the holder of such nominal amount of such Notes in accordance with and subject to the terms of the relevant Global Note and the expressions “Noteholder” and “holder of Notes” and related expressions shall be construed accordingly.

Notes which are represented by a Global Note will be transferable only in accordance with the rules and procedures for the time being of Euroclear and Clearstream, Luxembourg, as the case may be. References to Euroclear and/or Clearstream, Luxembourg shall, whenever the context so permits, be deemed to include a reference to any additional or alternative clearing system specified in the applicable Final Terms, or as may otherwise be approved by the Issuer, the Guarantors, the Agent and the Trustee.
2  Status of the Notes and the Guarantee
   
   (a)  Status of the Notes
   
The Notes and Coupons constitute direct, unconditional and (subject to the provisions of Condition 3) unsecured obligations of the Issuer and rank and will rank pari passu and without any preference among themselves and (subject as aforesaid and save to the extent that laws affecting creditors’ rights generally in a bankruptcy or winding up may give preference to any of such other obligations) equally with all other present and future unsecured and unsubordinated obligations of the Issuer from time to time outstanding.

(b)  Status of the Guarantee
   
The payment of principal of, and interest on, the Notes together with all other amounts payable by the Issuer under or pursuant to the Trust Deed has been unconditionally and irrevocably and jointly and severally guaranteed in the Trust Deed by the Guarantors (other than the Issuer).
   
The obligations of each Guarantor under its guarantee constitute direct, unconditional and (subject to the provisions of Condition 3) unsecured obligations of the relevant Guarantor and (subject as aforesaid and save to the extent that laws affecting creditors’ rights generally in a bankruptcy or winding up may give preference to any of such other obligations) rank and will rank equally with all other unsecured and unsubordinated obligations of the relevant Guarantor from time to time outstanding.
   
The Trust Deed contains a covenant on the part of the Issuers and the Guarantors in the event that any other company, the share capital of which is or is to be admitted to the official list of the Financial Conduct Authority under Part VI of the Financial Services and Markets Act 2000 (the “Official List”) and admitted to trading on the London Stock Exchange plc’s main market (the “Market”), becomes the ultimate Holding Company of British American Tobacco, to procure that such other Holding Company shall become a guarantor under the Trust Deed, jointly and severally with the Guarantors, with effect from the later of (i) the date on which such other company becomes the ultimate Holding Company of British American Tobacco and (ii) the date on which the share capital of such other Holding Company is admitted to the Official List and admitted to trading on the Market. In such event, the term “Guarantors” herein shall be deemed to include such other Holding Company.

3  Negative Pledge
   
   So long as any of the Notes remains outstanding (as defined in the Trust Deed) neither the Issuer nor any Guarantor will secure or allow to be secured any Quoted Borrowing or any payment under any guarantee by any of them of any Quoted Borrowing by any mortgage, charge, pledge or lien (other than arising by operation of law) upon any of its undertaking or assets, whether present or future, unless at the same time the same mortgage, charge, pledge or lien is extended, or security which is in the opinion of the Trustee not materially less beneficial to the Noteholders than the security given as aforesaid or which shall be approved by Extraordinary Resolution (as defined in the Trust Deed) of the Noteholders is extended, or (as the case may be) created, in favour of the Trustee to secure equally and rateably the principal of, and interest on, and all other payments (if any) in respect of the Notes and under the Trust Deed.
   
   For the purposes of this Condition 3, “Quoted Borrowing” means any indebtedness which (a) is represented by notes, debentures or other securities issued otherwise than to constitute or represent advances made by banks and/or other lending institutions; (b) is denominated, or confers any right to payment of principal and/or interest, in or by reference to any currency other than the currency of the country in which the issuer of the indebtedness has its principal place of business or is denominated, or confers any right to payment of principal and/or interest, in or by reference to the currency of such country but is placed or offered for...
subscription or sale by or on behalf of, or by agreement with, the issuer of such indebtedness as to over 20 per cent. outside such country; and
(c) at its date of issue, or is intended by the issuer of such indebtedness to become, quoted, listed, traded or dealt in on any stock exchange or
other organised and regulated securities market in any part of the world.

4 Interest

(a) Interest on Fixed Rate Notes

The applicable Final Terms contains provisions applicable to the determination of fixed rate interest and must be read in conjunction with
this Condition 4(a) for full information on the manner in which interest is calculated on Fixed Rate Notes. In particular, the applicable
Final Terms will specify, as applicable, the Interest Commencement Date, the Rate(s) of Interest, the Interest Payment Date(s), the
Maturity Date, the Fixed Coupon Amount, any applicable Broken Amount, the Calculation Amount, the Day Count Fraction and any
applicable Determination Date.

Each Fixed Rate Note bears interest from (and including) the Interest Commencement Date at the rate(s) per annum equal to the Rate(s) of
Interest payable in arrear on the Interest Payment Date(s) in each year up to (and including) the Maturity Date.

If the Notes are in definitive form, except as otherwise provided in the applicable Final Terms, the amount of interest payable on each
Interest Payment Date will amount to the Fixed Coupon Amount (if any) specified in the applicable Final Terms. Payments of interest on
any Interest Payment Date will, if so specified in the applicable Final Terms, amount to the Broken Amount so specified.

Except in the case of Notes in definitive form where an applicable Fixed Coupon Amount or Broken Amount is specified in the applicable
Final Terms, interest shall be calculated in respect of any period by applying the Rate of Interest to:

(A) in the case of Fixed Rate Notes which are represented by a Global Note, the aggregate outstanding amount of the Fixed Rate Notes
represented by such Global Note; or

(B) in the case of Fixed Rate Notes in definitive form, the Calculation Amount; and in each case, multiplying such sum by the applicable
Day Count Fraction.

The resultant figure (including after application of any Fixed Coupon Amount or Broken Amount to the Calculation Amount in the case of
Fixed Rate Notes in definitive form) shall be rounded to the nearest sub-unit of the relevant Specified Currency, half of any such sub-unit
being rounded upwards or otherwise in accordance with applicable market convention.

Where the Specified Denomination of a Fixed Rate Note in definitive form is a multiple of the Calculation Amount, the amount of interest
payable in respect of such Fixed Rate Note shall be the product of the amount (determined in the manner provided above) for the
Calculation Amount and the amount by which the Calculation Amount is multiplied to reach the Specified Denomination, without any
further rounding.

“Day Count Fraction” means in respect of the calculation of an amount of interest in accordance with Condition 4(a):

(i) if “Actual/Actual (ICMA)” is specified in the applicable Final Terms:

(A) in the case of Notes where the number of days in the relevant period from (and including) the most recent Interest Payment
Date or, if none, the Interest Commencement Date) to (but excluding) the relevant payment date (the “Accrual Period”) is
equal to or shorter than the Determination Period during which the Accrual Period ends, the number of days in such Accrual Period
divided by the product of (1) the number of days in such Determination Period and (2) the number of Determination Dates that would occur in one calendar year; or
(B) in the case of Notes where the Accrual Period is longer than the Determination Period commencing on the last Interest Payment Date (or, if none, the Interest Commencement Date), the sum of:

1. the number of days in such Accrual Period falling in the Determination Period in which the Accrual Period begins divided by the product of (x) the number of days in such Determination Period and (y) the number of Determination Periods normally ending in one calendar year; and
2. the number of days in such Accrual Period falling in the next Determination Period divided by the product of (x) the number of days in such Determination Period and (y) the number of Determination Periods normally ending in one calendar year;

(ii) if “30/360” is specified in the applicable Final Terms, the number of days in the period from (and including) the most recent Interest Payment Date (or, if none, the Interest Commencement Date) to (but excluding) the relevant payment date (such number of days being calculated on the basis of 12 30-day months) divided by 360; and

(iii) if “Actual/365 (Fixed)” is specified in the applicable Final Terms, the actual number of days in the period from (and including) the most recent Interest Payment Date (or, if none, the Interest Commencement Date) to (but excluding) the relevant payment date divided by 365.

In these Terms and Conditions:

“Determination Period” means the period from (and including) a Determination Date to (but excluding) the next Determination Date.

“sub-unit” means, with respect to any currency other than Euro, the lowest amount of such currency that is available as legal tender in the country of such currency and, with respect to Euro, means one cent.

(b) Interest on Floating Rate Notes

The applicable Final Terms contains provisions applicable to the determination of floating rate interest and must be read in conjunction with this Condition 4(b) for full information on the manner in which interest is calculated on Floating Rate Notes. In particular, the applicable Final Terms will identify, as applicable, any Specified Interest Payment Dates, any Specified Period, the Interest Commencement Date, the Business Day Convention, any Additional Business Centres, whether ISDA Determination or Screen Rate Determination applies to the calculation of interest, the party who will calculate the amount of interest due if it is not the Agent, the Margin, any maximum or minimum interest rates and the Day Count Fraction. Where ISDA Determination applies to the calculation of interest, the applicable Final Terms will also specify the applicable Floating Rate Option, Designated Maturity and Reset Date. Where Screen Rate Determination applies to the calculation of interest, the applicable Final Terms will also specify the applicable Reference Rate, Interest Determination Date(s) and Relevant Screen Page.

(i) Interest Payment Dates

Each Floating Rate Note bears interest from (and including) the Interest Commencement Date and such interest will be payable in arrear on either:

A) the Specified Interest Payment Date(s) in each year specified in the applicable Final Terms; or

B) if no Specified Interest Payment Date(s) is/are specified in the applicable Final Terms, each date (each such date, together with each Specified Interest Payment Date, an “Interest Payment Date”) which falls the number of months or other period specified as the Specified Period in the applicable Final Terms after the preceding Interest Payment Date or, in the case of the first Interest Payment Date, after the Interest Commencement Date.
Such interest will be payable in respect of each “Interest Period” (which expression shall, in these Terms and Conditions, mean the period from (and including) an Interest Payment Date (or the Interest Commencement Date) to (but excluding) the next (or first) Interest Payment Date) or the relevant payment date if the Floating Rate Notes become payable on a date other than an Interest Payment Date.

If a Business Day Convention is specified in the applicable Final Terms and (x) if there is no numerically corresponding day on the calendar month in which an Interest Payment Date should occur or (y) if any Interest Payment Date would otherwise fall on a day which is not a Business Day, then, if the Business Day Convention specified is:

(1) in any case where Specified Periods are specified in accordance with Condition 4(b)(i)(B) above, the Floating Rate Convention, such Interest Payment Date (i) in the case of (x) above, shall be the last day that is a Business Day in the relevant month and the provisions of (B) below shall apply mutatis mutandis or (ii) in the case of (y) above, shall be postponed to the next day which is a Business Day unless it would thereby fall into the next calendar month, in which event (A) such Interest Payment Date shall be brought forward to the immediately preceding Business Day and (B) each subsequent Interest Payment Date shall be the last Business Day in the month in which the Specified Period falls after the preceding applicable Interest Payment Date occurred; or

(2) the Following Business Day Convention, such Interest Payment Date shall be postponed to the next day which is a Business Day; or

(3) the Modified Following Business Day Convention, such Interest Payment Date shall be postponed to the next day which is a Business Day unless it would thereby fall into the next calendar month, in which event such Interest Payment Date shall be brought forward to the immediately preceding Business Day; or

(4) the Preceding Business Day Convention, such Interest Payment Date shall be brought forward to the immediately preceding Business Day.

In this Condition, “Business Day” means a day (other than a Saturday or a Sunday) which is both:

(A) a day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealings in foreign exchange and foreign currency deposits) in London and each Additional Business Centre (if any) specified in the applicable Final Terms; and

(B) either (1) in relation to any sum payable in a Specified Currency other than euro, a day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealings in foreign exchange and foreign currency deposits) in the principal financial centre of the country of the relevant Specified Currency (if other than London and any Additional Business Centre and which, if the Specified Currency is Australian dollars or New Zealand dollars, shall be Sydney and Auckland, respectively) or (2) in relation to any sum payable in Euro, a day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer (known as TARGET2) System which was launched on 19 November 2007, or any successor thereto (the “TARGET System”) is operating.

50
(ii) Rate of Interest

The Rate of Interest payable from time to time in respect of Floating Rate Notes will be determined in the manner specified in the applicable Final Terms and the provisions below relating to either ISDA Determination or Screen Rate Determination shall apply, depending upon which is specified in the applicable Final Terms.

(A) ISDA Determination for Floating Rate Notes

Where ISDA Determination is specified in the applicable Final Terms as the manner in which the Rate of Interest is to be determined, the Rate of Interest for each Interest Period will be the relevant ISDA Rate plus or minus (as indicated in the applicable Final Terms) the Margin (if any). For the purposes of this sub-paragraph (A), “ISDA Rate” for an Interest Period means a rate equal to the Floating Rate that would be determined by the Agent under an interest rate swap transaction if the Agent were acting as Calculation Agent for that swap transaction under the terms of an agreement incorporating the 2006 ISDA Definitions, as amended and updated as at the Issue Date of the first Tranche of the Notes and as published by the International Swaps and Derivatives Association, Inc. (the “ISDA Definitions”) and under which:

(1) the Floating Rate Option is as specified in the applicable Final Terms;
(2) the Designated Maturity is a period specified in the applicable Final Terms; and
(3) the relevant Reset Date is either (i) if the applicable Floating Rate Option is based on the London inter-bank offered rate (“LIBOR”) or on the euro-zone interbank offered rate (“EURIBOR”) for a currency, the first day of that Interest Period or (ii) in any other case, as specified in the applicable Final Terms.

For the purposes of this sub-paragraph (A), (i) “Floating Rate”, “Calculation Agent”, “Floating Rate Option”, “Designated Maturity”, “Reset Date” and “euro-zone” have the meanings given to those terms in the ISDA Definitions and (ii) the definition of “Banking Day” in the ISDA Definitions shall be amended to insert after the words “are open for” in the second line thereof the word “general”.

(B) Screen Rate Determination for Floating Rate Notes

(1) Where Screen Rate Determination is specified in the applicable Final Terms as the manner in which the Rate of Interest is to be determined, the Rate of Interest for each Interest Period will, subject as provided below, be either:

(I) the offered quotation; or
(II) the arithmetic mean (rounded if necessary to the fifth decimal place, with 0.00005 being rounded upwards) of the offered quotations,

(expressed as a percentage rate per annum) for the Reference Rate(s) which appears or appear, as the case may be, on the Relevant Screen Page as at 11.00 a.m. (London time, in the case of LIBOR, or Brussels time, in the case of EURIBOR) on the Interest Determination Date in question plus or minus (as indicated in the applicable Final Terms) the Margin (if any), all as determined by the Agent. If five or more of such offered quotations are available on the Relevant Screen Page, the highest (or, if there is more than one such highest quotation, one only of such quotations) and the lowest (or, if there is more than one such lowest quotation, one only of such quotations) shall be disregarded by the Agent for the purpose of determining the arithmetic mean (rounded as provided above) of such offered quotations;

(2) If the Relevant Screen Page is not available or, if in the case of sub-paragraph (B)(1)(I) above, no such offered quotation appears or, in the case of sub-paragraph (B)(1)(II) above, fewer than three such offered quotations appear, in each case as at the time specified in the preceding paragraph the Agent shall
request each of the several banks initially appointed as reference banks in relation to the Notes of any relevant Series and/or, if applicable, any Successor reference banks in relation thereto such banks being, in the case of a determination of LIBOR, the principal London office of four major banks in the London inter-bank market and, in the case of a determination of EURIBOR, the principal euro-zone office of four major banks in the euro-zone inter-bank market, in each case selected by the Issuer or as specified in the applicable Final Terms (each a “Reference Bank”, and together the “Reference Banks”) to provide the Agent with its offered quotation (expressed as a percentage rate per annum) for the Reference Rate at approximately 11.00 a.m. (London time, in the case of LIBOR, or Brussels time, in the case of EURIBOR) on the Interest Determination Date in question. If two or more of the Reference Banks provide the Agent with such offered quotations, the Rate of Interest for such Interest Period shall be the arithmetic mean (rounded if necessary to the fifth decimal place with 0.000005 being rounded upwards) of such offered quotations plus or minus (as appropriate) the Margin (if any), all as determined by the Agent; and

(3) If on any Interest Determination Date one only or none of the Reference Banks provides the Agent with such offered quotations as provided in the preceding paragraph, the Rate of Interest for the relevant Interest Period shall be the rate per annum which the Agent determines as being the arithmetic mean (rounded if necessary to the fifth decimal place, with 0.000005 being rounded upwards) of the rates, as communicated to (and at the request of) the Agent by the Reference Banks or any two or more of them, at which such banks were offered, at approximately 11.00 a.m. (London time, in the case of LIBOR, or Brussels time, in the case of EURIBOR) on the relevant Interest Determination Date, deposits in the Specified Currency for a period equal to that which would have been used for the Reference Rate by leading banks in the London inter-bank market (if the Reference Rate is LIBOR) or the euro-zone inter-bank market (if the Reference Rate is EURIBOR) plus or minus (as appropriate) the Margin (if any) or, if fewer than two of the Reference Banks provide the Agent with such offered rates, the offered rate for deposits in the Specified Currency for a period equal to that which would have been used for the Reference Rate, or the arithmetic mean (rounded as provided above) of the offered rates for deposits in the Specified Currency for a period equal to that which would have been used for the Reference Rate, at which, at approximately 11.00 a.m. (London time, in the case of LIBOR, or Brussels time, in the case of EURIBOR) on the relevant Interest Determination Date, any one or more banks (which bank or banks is or are in the opinion of the relevant Issuer suitable for such purpose) informs the Agent it is quoting to leading banks in the London inter-bank market (if the Reference Rate is LIBOR) or the euro-zone inter-bank market (if the Reference Rate is EURIBOR) plus or minus (as appropriate) the Margin (if any), provided that, if the Rate of Interest cannot be determined in accordance with the foregoing provisions of this paragraph, the Rate of Interest shall be determined as at the last preceding Interest Determination Date (though substituting, where a different Margin is to be applied to the relevant Interest Period from that which applied to the last preceding Interest Period, the Margin relating to the relevant Interest Period, in place of the Margin relating to that last preceding Interest Period).
(C) Benchmark Discontinuation

(1) Independent Adviser

Notwithstanding Conditions 4(b)(ii)(B)(2) and (3), if the Issuer determines that a Benchmark Event occurs in relation to an Original Reference Rate when any Rate of Interest (or any component part thereof) remains to be determined by reference to such Original Reference Rate, the Issuer shall use its reasonable endeavours to appoint an Independent Adviser, as soon as reasonably practicable, to advise the Issuer in determining a Successor Rate, failing which an Alternative Rate (in accordance with Condition 4(b)(ii)(C)(2)) and, in either case, an Adjustment Spread (in accordance with and subject to Condition 4(b)(ii)(C)(3)) and any Benchmark Amendments (in accordance with Condition 4(b)(ii)(C)(4)).

In advising the Issuer, the Independent Adviser appointed pursuant to this Condition 4(b)(ii)(C) shall act in good faith as an expert. In the absence of bad faith or fraud, the Independent Adviser shall have no liability whatsoever to the Issuer, the Trustee, the Paying Agents, the Noteholders or the Couponholders for any determination made by it or for any advice given to the Issuer in connection with any determination made by the Issuer pursuant to this Condition 4(b)(ii)(C).

If, following the occurrence of a Benchmark Event (i) the Issuer is unable to appoint an Independent Adviser; or (ii) the Issuer fails to determine a Successor Rate or, failing which, an Alternative Rate in accordance with this Condition 4(b)(ii)(C), in each case prior to the relevant Interest Determination Date, the Rate of Interest applicable to the next succeeding Interest Period shall be equal to the Rate of Interest last determined in relation to the Notes in respect of the immediately preceding Interest Period. If there has not been a first Interest Payment Date, the Rate of Interest shall be the initial Rate of Interest. Where a different Margin or Maximum or Minimum Rate of Interest is to be applied to the relevant Interest Period from that which applied to the last preceding Interest Period, the Margin or Maximum or Minimum Rate of Interest relating to the relevant Interest Period shall be substituted in place of the Margin or Maximum or Minimum Rate of Interest relating to that last preceding Interest Period. For the avoidance of doubt, this paragraph shall apply to the determination of the Rate of Interest applicable to the next succeeding Interest Period only and any subsequent Interest Periods are subject to the subsequent operation of, and to adjustment as provided in, this Condition 4(b)(ii)(C).

(2) Successor Rate or Alternative Rate

If the Issuer, following consultation with the Independent Adviser, determines that:

(I) there is a Successor Rate, then such Successor Rate and (subject to Condition 4(b)(ii)(C)(3)) the applicable Adjustment Spread shall subsequently be used in place of the Original Reference Rate to determine the Rate of Interest (or the relevant component part thereof) for all relevant future payments of interest on the Notes (subject to the subsequent operation of this Condition 4(b)(ii)(C)); or

(II) there is no Successor Rate but that there is an Alternative Rate, then such Alternative Rate and (subject to Condition 4(b)(ii)(C)(3)) the applicable Adjustment Spread shall subsequently be used in place of the Original Reference Rate to determine the Rate of Interest (or the relevant component part thereof) for all relevant future payments of interest on the Notes (subject to the subsequent operation of this Condition 4(b)(ii)(C)).
(3) Adjustment Spread

The Adjustment Spread (or the formula or methodology for determining the Adjustment Spread) shall be applied (subject to the proviso in the following sentence) to the Successor Rate or the Alternative Rate (as the case may be). If the Issuer, following consultation with the Independent Adviser and acting in good faith and in a commercially reasonable manner, is unable to determine the quantum of, or a formula or methodology for determining, such Adjustment Spread, then the Successor Rate or Alternative Reference Rate (as applicable) will apply without an Adjustment Spread.

(4) Benchmark Amendments

If any Successor Rate or Alternative Rate and, in either case (subject to Condition 4(b)(ii)(C)(3)), the applicable Adjustment Spread is determined in accordance with this Condition 4(b)(ii)(C) and the Issuer, following consultation with the Independent Adviser and acting in good faith and in a commercially reasonable manner, determines (a) that amendments to these Conditions, the Agency Agreement and/or the Trust Deed are necessary to ensure the proper operation of such Successor Rate or Alternative Rate and/or (in either case) the applicable Adjustment Spread (such amendments, the “Benchmark Amendments”) and (b) the terms of the Benchmark Amendments, then the Issuer shall, subject to giving notice thereof in accordance with Condition 4(b)(ii)(C)(5), without any requirement for the consent or approval of Noteholders, vary these Conditions, the Agency Agreement and/or the Trust Deed to give effect to such Benchmark Amendments with effect from the date specified in such notice.

At the request of the Issuer, but subject to receipt by the Trustee of a certificate signed by one director of the Issuer pursuant to Condition 4(b)(ii)(C)(5), the Trustee shall (at the request and expense of the Issuer), without any requirement for the consent or approval of the Noteholders, be obliged to concur with the Issuer in effecting any Benchmark Amendments (including, inter alia, by the execution of a supplement to or document amending the Trust Deed and/or the Agency Agreement) and the Trustee shall not be liable to any party for any consequence thereof, provided that the Trustee shall not be obliged so to concur if in the opinion of the Trustee doing so would impose more onerous obligations upon it or expose it to any additional duties, responsibilities or liabilities or reduce or amend the rights and/or the protective provisions afforded to the Trustee in these Conditions, the Agency Agreement or the Trust Deed (including, for the avoidance of doubt, any supplemental trust deed or supplemental agency agreement) in any way.

In connection with any such variation in accordance with this Condition 4(b)(ii)(C)(4), the Issuer shall comply with the rules of any stock exchange on which the Notes are for the time being listed or admitted to trading.

(5) Notices, etc.

Any Successor Rate, Alternative Rate, Adjustment Spread and the specific terms of any Benchmark Amendments determined under this Condition 4(b)(ii)(C) will be notified promptly by the Issuer to the Trustee, the Agent and, in accordance with Condition 13, the Noteholders. Such notice shall be irrevocable and shall specify the effective date of the Benchmark Amendments, if any.

No later than notifying the Trustee of the same, the Issuer shall deliver to the Trustee a certificate signed by one director of the Issuer:
(I) confirming (a) that a Benchmark Event has occurred, (b) the Successor Rate or, as the case may be, the Alternative Rate, (c) the applicable Adjustment Spread and (d) the specific terms of the Benchmark Amendments (if any), in each case as determined in accordance with the provisions of this Condition 4(b)(ii)(C); and

(II) certifying that the Benchmark Amendments (if any) are necessary to ensure the proper operation of such Successor Rate or Alternative Rate and (in either case) the applicable Adjustment Spread.

The Trustee shall be entitled to rely on such certificate (without liability to any person) as sufficient evidence thereof. The Successor Rate or Alternative Rate and the Adjustment Spread and the Benchmark Amendments (if any) specified in such certificate will (in the absence of manifest error or bad faith in the determination of the Successor Rate or Alternative Rate and the Adjustment Spread and the Benchmark Amendments (if any) and without prejudice to the Trustee’s ability to rely on such certificate as aforesaid) be binding on the Issuer, the Trustee, the Agents, the Noteholders and the Couponholders.

(6) Survival of Original Reference Rate

Without prejudice to the obligations of the Issuer under Condition 4(b)(ii)(C)(1), (2), (3) and (4), the Original Reference Rate and the fallback provisions provided for in Condition 4(b)(ii)(B) and Clause 9.2 of the Agency Agreement will continue to apply unless and until the Issuer determines that a Benchmark Event has occurred and the Trustee and the Agents have been notified of the Successor Rate or the Alternative Rate (as the case may be) and the Adjustment Spread (if applicable) and any Benchmark Amendments in accordance with this Condition 4(b)(ii)(C).

(7) Definitions

As used in this Condition 4(b)(ii)(C):

“Adjustment Spread” means either (a) a spread (which may be positive, negative or zero), or (b) a formula or methodology for calculating a spread, in each case to be applied (subject to Condition 4(b)(ii)(C)(3)) to the Successor Rate or the Alternative Rate (as the case may be) and is the spread, formula or methodology which:

(I) in the case of a Successor Rate, is formally recommended in relation to the replacement of the Original Reference Rate with the Successor Rate by any Relevant Nominating Body;

(II) if no such recommendation has been made, or in the case of an Alternative Rate, the Issuer, following consultation with the Independent Adviser, determines, is customarily applied to the relevant Successor Rate or the Alternative Rate (as the case may be) in international debt capital markets transactions to produce an industry-accepted replacement rate for the Original Reference Rate;

(III) if neither (I) nor (II) above applies, the Issuer, following consultation with the Independent Adviser, determines, is recognised or acknowledged as being the industry standard for over-the-counter derivative transactions which reference the Original Reference Rate, where such rate has been replaced by the Successor Rate or the Alternative Rate (as the case may be).
“Alternative Rate” means an alternative benchmark or screen rate which the Issuer, following consultation with the Independent Adviser, determines in accordance with Condition 4(b)(ii)(C)(2) is customarily applied in international debt capital markets transactions for the purposes of determining rates of interest (or the relevant component part thereof) for an interest period of comparable duration and in the same Specified Currency as the Notes or, if the Issuer (following consultation with the Independent Adviser) determines that there is no such rate, such other rate as the Issuer, following consultation with the Independent Adviser and acting in good faith and in a commercially reasonable manner, determines in its discretion is most comparable to the relevant Original Reference Rate.

“Benchmark Amendments” has the meaning given to it in Condition 4(b)(ii)(C)(4).

“Benchmark Event” means:

(i) the Original Reference Rate ceasing to be published for a period of at least five Business Days or ceasing to exist; or

(ii) a public statement by the administrator of the Original Reference Rate that it has ceased or that it will cease publishing the Original Reference Rate permanently or indefinitely (in circumstances where no successor administrator has been appointed that will continue publication of the Original Reference Rate); or

(iii) a public statement by the supervisor of the administrator of the Original Reference Rate that the Original Reference Rate has been or will be permanently or indefinitely discontinued; or

(iv) a public statement by the supervisor of the administrator of the Original Reference Rate as a consequence of which the Original Reference Rate will be prohibited from being used either generally, or in respect of the Notes; or

(v) a public statement by the supervisor of the administrator of the relevant Original Reference Rate that, in the view of such supervisor, such Original Reference Rate is no longer representative of an underlying market; or

(vi) it has become unlawful for any Agent or the Issuer to calculate any payments due to be made to any Noteholder using the Original Reference Rate,

provided that the Benchmark Event shall be deemed to occur (a) in the case of sub-paragraphs (II) and (III) above, on the date of the cessation of publication of the Original Reference Rate or the discontinuation of the Original Reference Rate, as the case may be, (b) in the case of sub-paragraph (IV) above, on the date of the prohibition of use of the Original Reference Rate and (c) in the case of sub-paragraph (V) above, on the date with effect from which the Original Reference Rate will no longer be (or will be deemed by the relevant supervisor to no longer be) representative of its relevant underlying market and which is specified in the relevant public statement, and, in each case, not the date of the relevant public statement.

“Independent Adviser” means an independent financial institution of international repute or an independent financial adviser, in each case, with appropriate expertise in capital markets appointed by the Issuer at its own expense under Condition 4(b)(ii)(C)(1) and notified in writing to the Trustee.
“Original Reference Rate” means the originally-specified benchmark or screen rate (as applicable) used to determine the Rate of Interest (or any component part thereof) on the Notes.

“Relevant Nominating Body” means, in respect of a benchmark or screen rate (as applicable):

(i) the central bank for the currency to which the benchmark or screen rate (as applicable) relates, or any central bank or other supervisory authority which is responsible for supervising the administrator of the benchmark or screen rate (as applicable); or

(ii) any working group or committee sponsored by, chaired or co-chaired by or constituted at the request of (a) the central bank for the currency to which the benchmark or screen rate (as applicable) relates, (b) any central bank or other supervisory authority which is responsible for supervising the administrator of the benchmark or screen rate (as applicable), (c) a group of the aforementioned central banks or other supervisory authorities or (d) the Financial Stability Board or any part thereof.

“Successor Rate” means a successor to or replacement of the Original Reference Rate which is formally recommended by any Relevant Nominating Body.

(D) Linear Interpolation

Where Linear Interpolation is specified as applicable in respect of an Interest Period in the applicable Final Terms, the Rate of Interest for such Interest Period shall be calculated by the Agent by straight line linear interpolation by reference to two rates based on the relevant Reference Rate (where Screen Rate Determination is specified as applicable in the applicable Final Terms) or the relevant Floating Rate Option (where ISDA Determination is specified as applicable in the applicable Final Terms), one of which shall be determined as if the Applicable Maturity were the period of time for which rates are available next shorter than the length of the relevant Interest Period and the other of which shall be determined as if the Applicable Maturity were the period of time for which rates are available next longer than the length of the relevant Interest Period, provided however, that if there is no rate available for the period of time next shorter or, as the case may be, next longer, then the Agent shall determine such rate at such time and by reference to such sources as it determines appropriate.

“Applicable Maturity” means: (a) in relation to Screen Rate Determination, the period of time designated in the Reference Rate, and (b) in relation to ISDA Determination, the Designated Maturity.

(iii) Minimum Rate of Interest and/or Maximum Rate of Interest

If the applicable Final Terms specifies a Minimum Rate of Interest for any Interest Period, then, in the event that the Rate of Interest in respect of such Interest Period determined in accordance with the provisions of paragraph (ii) above is less than such Minimum Rate of Interest, the Rate of Interest for such Interest Period shall be such Minimum Rate of Interest.

If the applicable Final Terms specifies a Maximum Rate of Interest for any Interest Period, then, in the event that the Rate of Interest in respect of such Interest Period determined in accordance with the provisions of paragraph (ii) above is greater than such Maximum Rate of Interest, the Rate of Interest for such Interest Period shall be such Maximum Rate of Interest.

57
Determination of Rate of Interest and calculation of Interest Amounts

The Agent will at or as soon as practicable after each time at which the Rate of Interest is to be determined, determine the Rate of Interest for the relevant Interest Period.

The Agent will calculate the amount of interest (the "Interest Amount") payable on the Floating Rate Notes for the relevant Interest Period by applying the Rate of Interest to:

(A) in the case of Floating Rate Notes which are represented by a Global Note, the aggregate outstanding nominal amount of the Notes represented by such Global Note; or

(B) in the case of Floating Rate Notes in definitive form, the Calculation Amount;

and, in each case, multiplying such sum by the applicable Day Count Fraction, and rounding the resultant figure to the nearest sub-unit of the relevant Specified Currency, half of any such sub-unit being rounded upwards or otherwise in accordance with applicable market convention.

Where the Specified Denomination of a Floating Rate Note in definitive form is a multiple of the Calculation Amount, the Interest Amount payable in respect of such Note shall be the product of the amount (determined in the manner provided above) for the Calculation Amount and the amount by which the Calculation Amount is multiplied to reach the Specified Denomination, without any further rounding.

"Day Count Fraction" means, in respect of the calculation of an amount of interest for any Interest Period:

(A) if "Actual/Actual" or "Actual/Actual (ISDA)" is specified in the applicable Final Terms, the actual number of days in the Interest Period divided by 365 (or, if any portion of that Interest Period falls in a leap year, the sum of (A) the actual number of days in that portion of the Interest Period falling in a leap year divided by 366 and (B) the actual number of days in that portion of the Interest Period falling in a non-leap year divided by 365);

(B) if "Actual/365 (Fixed)" is specified in the applicable Final Terms, the actual number of days in the Interest Period divided by 365;

(C) if "Actual/360" is specified in the applicable Final Terms, the actual number of days in the Interest Period divided by 360;

(D) if "30/360", "360/360" or "Bond Basis" is specified in the applicable Final Terms, the number of days in the Interest Period divided by 360, calculated on a formula basis as follows:

\[
\text{Day Count Fraction} = \frac{[360 \times (Y2 - Y1)] + [30 \times (M2 - M1)] + (D2 - D1)}{360}
\]

where:

"Y1" is the year, expressed as a number, in which the first day of the Interest Period falls;

"Y2" is the year, expressed as a number, in which the day immediately following the last day included in the Interest Period falls;

"M1" is the calendar month, expressed as a number, in which the first day of the Interest Period falls;

"M2" is the calendar month, expressed as number, in which the day immediately following the last day included in the Interest Period falls;

"D1" is the first calendar day, expressed as a number, of the Interest Period, unless such number would be 31, in which case D1 will be 30; and

58
“D2” is the calendar day, expressed as a number, immediately following the last day included in the Interest Period, unless such number would be 31 and D1 is greater than 29, in which case D2 will be 30;

(E) if “30E/360” or “Eurobond Basis” is specified in the applicable Final Terms, the number of days in the Interest Period divided by 360, calculated on a formula basis as follows:

\[
\text{Day Count Fraction} = \frac{360 \times (Y2 - Y1) + 30 \times (M2 - M1) + (D2 - D1)}{360}
\]

where:

“Y1” is the year, expressed as a number, in which the first day of the Interest Period falls;

“Y2” is the year, expressed as a number, in which the day immediately following the last day included in the Interest Period falls;

“M1” is the calendar month, expressed as a number, in which the first day of the Interest Period falls;

“M2” is the calendar month, expressed as a number, in which the day immediately following the last day included in the Interest Period falls;

“D1” is the first calendar day, expressed as a number, of the Interest Period, unless such number would be 31, in which case D1 will be 30; and

“D2” is the calendar day, expressed as a number, immediately following the last day included in the Interest Period, unless such number would be 31, in which case D2 will be 30

(F) if “30E/360 (ISDA)” is specified hereon, the number of days in the Interest Period divided by 360, calculated on a formula basis as follows:

\[
\text{Day Count Fraction} = \frac{360 \times (Y2 - Y1) + 30 \times (M2 - M1) + (D2 - D1)}{360}
\]

where:

“Y1” is the year, expressed as a number, in which the first day of the Interest Period falls;

“Y2” is the year, expressed as a number, in which the day immediately following the last day included in the Interest Period falls;

“M1” is the calendar month, expressed as a number, in which the first day of the Interest Period falls;

“M2” is the calendar month, expressed as a number, in which the day immediately following the last day included in the Interest Period falls;

“D1” is the first calendar day, expressed as a number, of the Interest Period, unless (i) that day is the last day of February or (ii) such number would be 31, in which case D1 will be 30; and

“D2” is the calendar day, expressed as a number, immediately following the last day included in the Interest Period, unless (i) that day is the last day of February but not the Maturity Date or (ii) such number would be 31, in which case D2 will be 30; and

59
(G) if “Actual/365 (Sterling)” is specified in the applicable Final Terms, the actual number of days in the Interest Period divided by 365 or, in the case of an Interest Payment Date falling in a leap year, 366.

(v) Notification of Rate of Interest and Interest Amounts
The Agent will cause the Rate of Interest and each Interest Amount for each Interest Period and the relevant Interest Payment Date to be notified to the Issuer and any stock exchange or other relevant authority on which the relevant Floating Rate Notes are for the time being listed or by which they have been admitted to trading (if the rules of that stock exchange or other relevant authority so require) and notice thereof to be published in accordance with Condition 13 as soon as possible after their determination but in no event later than (a) the commencement of the relevant Interest Period, if determined prior to such time, in the case of notification to such stock exchange of a Rate of Interest and Interest Amount, or (b) in all other cases, the fourth London Business Day thereafter. Each Interest Amount and Interest Payment Date so notified may subsequently be amended (or appropriate alternative arrangements made by way of adjustment) without prior notice in the event of an extension or shortening of the Interest Period. Any such amendment will be promptly notified to each stock exchange or other relevant authority on which the relevant Floating Rate Notes are for the time being listed or by which they have been admitted to trading (if the rules of that stock exchange or other relevant authority so require) and to the Noteholders in accordance with Condition 13. For the purposes of this paragraph, the expression “London Business Day” means a day (other than a Saturday or a Sunday) on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealings in foreign exchange and foreign currency deposits) in London.

(vi) Certificates to be final
All certificates, communications, opinions, determinations, calculations, quotations and decisions given for the purpose of the provisions of this Condition 4(b), by the Agent shall (in the absence of manifest error) be binding on the Issuer, the Guarantors, the Agent, the other Paying Agents, the Trustee and all other Holders and Couponholders and (in the absence as aforesaid) no liability to the Issuer, the Guarantors, the Trustee, the Noteholders or the Couponholders shall attach to the Agent in connection with the exercise or non-exercise by it of its powers, duties and discretions pursuant to such provisions.

(c) Accrual of interest
Each Note (or in the case of the redemption of part only of a Note, that part only of such Note) will cease to bear interest (if any) from the date for its redemption unless, upon due presentation thereof, payment of principal is improperly withheld or refused. In such event, interest will continue to accrue as provided in the Trust Deed.

5 Payments
(a) Method of payment
Subject as provided below:

(i) payments in a Specified Currency other than euro will be made by credit or transfer to an account in the relevant Specified Currency maintained by the payee with, or, at the option of the payee, by a cheque in such Specified Currency drawn on a bank in the principal financial centre of the country of such Specified Currency (which, if the Specified Currency is Australian dollars or New Zealand dollars, shall be Sydney and Auckland, respectively); and
(ii) payments in euro will be made by credit or transfer to a euro account (or any other account to which euro may be credited or transferred) specified by the payee or, at the option of the payee, by a euro cheque. Payments will be subject in all cases to any fiscal or other laws and regulations applicable thereto in the place of payment, but without prejudice to the provisions of Condition 7.

(b) Presentation of definitive Notes and Coupons

Payments of principal in respect of definitive Notes will (subject as provided below) be made in the manner provided in paragraph (a) above only against presentation and surrender (or, in the case of part payment of any sum due, endorsement) of definitive Notes, and payments of interest in respect of definitive Notes will (subject as provided below) be made as aforesaid only against presentation and surrender (or, in the case of part payment of any sum due, endorsement) of Coupons, in each case at the specified office of any Paying Agent outside the United States (which expression, as used herein, means the United States of America (including the States and the District of Columbia, its territories, its possessions and other areas subject to its jurisdiction)).

Fixed Rate Notes in definitive form should be presented for payment together with all unmatured Coupons appertaining thereto (which expression shall for this purpose include Coupons falling to be issued on exchange of matured Talons), failing which the amount of any missing unmatured Coupon (or, in the case of payment not being made in full, the same proportion of the amount of such missing unmatured Coupon as the sum so paid bears to the sum due) will be deducted from the sum due for payment. Each amount of principal so deducted will be paid in the manner mentioned above against surrender of the relative missing Coupon at any time before the expiry of ten years after the Relevant Date (as defined in Condition 7) in respect of such principal (whether or not such Coupon would otherwise have become void under Condition 8) or, if later, five years from the date on which such Coupon would otherwise have become due, but in no event thereafter.

Where any definitive Note that provides that the relative unmatured Coupons are to become void upon the due date for redemption of those Notes is presented for redemption without all unmatured Coupons, and where any definitive Note is presented for redemption without any unexchanged Talon relating to it, redemption shall be made only against the provision of such indemnity as the Issuer may require.

Upon any Fixed Rate Note in definitive form becoming due and repayable prior to its Maturity Date, all unmatured Talons (if any) appertaining thereto will become void and no further Coupons will be issued in respect thereof.

Upon the date on which any Floating Rate Note in definitive form becomes due and repayable, unmatured Coupons and Talons (if any) relating thereto (whether or not attached) shall become void and no payment or, as the case may be, exchange for further Coupons shall be made in respect thereof.

If the due date for redemption of any definitive Note is not an Interest Payment Date, interest (if any) accrued in respect of such Note from (and including) the preceding Interest Payment Date or, as the case may be, the Interest Commencement Date shall be payable only against surrender of the relevant definitive Note.

(c) Payments in respect of Global Notes

Payments of principal and interest (if any) in respect of Notes represented by any Global Note will (subject as provided below) be made in the manner specified above in relation to definitive Notes and otherwise in the manner specified in the relevant Global Note against presentation or surrender, as the case may be, of such Global Note at the specified office of any Paying Agent outside the United States. A record of each payment made against presentation or surrender of any Global Note, distinguishing between any payment of principal and any payment of interest, will be made on such Global Note by the Paying Agent to which it was presented and such record shall be prima facie evidence that the payment in question has been made.
(d) General provisions applicable to payments

The holder of a Global Note shall be the only person entitled to receive payments in respect of Notes represented by such Global Note and the Issuer or, as the case may be, any Guarantor will be discharged by payment to, or to the order of, the holder of such Global Note in respect of each amount so paid. Each of the persons shown in the records of Euroclear or Clearstream, Luxembourg as the beneficial holder of a particular nominal amount of Notes represented by such Global Note must look solely to Euroclear or Clearstream, Luxembourg, as the case may be, for his share of each payment so made by the Issuer or, as the case may be, any Guarantor to, or to the order of, the holder of such Global Note.

Notwithstanding the provisions of paragraph (a) above, if any amount of principal and/or interest in respect of Notes is payable in US dollars, such US dollar payments of principal and/or interest in respect of such Notes will be made at the specified office of a Paying Agent in the United States if:

(i) the Issuer has appointed Paying Agents with specified offices outside the United States with the reasonable expectation that such Paying Agents would be able to make payment in US dollars at such specified offices outside the United States of the full amount of principal and interest on the Notes in the manner provided above when due;

(ii) payment of the full amount of such principal and interest at all such specified offices outside the United States is illegal or effectively precluded by exchange controls or other similar restrictions on the full payment or receipt of principal and interest in US dollars; and

(iii) such payment is then permitted under United States law without involving, in the opinion of the Issuer and the Guarantors, adverse tax consequences to the Issuer or the Guarantors.

(e) Payment Day

If the date for payment of any amount in respect of any Note or Coupon is not a Payment Day, the holder thereof shall not be entitled to payment until the next following Payment Day in the relevant place and shall not be entitled to further interest or other payment in respect of such delay. For these purposes, “Payment Day” means any day (other than a Saturday or a Sunday) which (subject to Condition 8) is:

(i) a day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealings in foreign exchange and foreign currency deposits) in:

   (A) in the case of definitive Notes only, the relevant place of presentation;
   
   (B) each Additional Financial Centre (if any) specified in the applicable Final Terms; and

(ii) either (1) in relation to any sum payable in a Specified Currency other than euro, a day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealings in foreign exchange and foreign currency deposits) in the principal financial centre of the country of the relevant Specified Currency (which, if the Specified Currency is Australian dollars or New Zealand dollars, shall be Sydney and Auckland, respectively) or (2) in relation to any sum payable in euro, a day on which the TARGET System is operating.

(f) Interpretation of principal and interest

Any reference in these Terms and Conditions to principal in respect of the Notes shall be deemed to include, as applicable:
(i) any additional amounts which may be payable with respect to principal under Condition 7 or pursuant to any undertaking or covenant to pay additional amounts given in addition thereto, or in substitution therefor, pursuant to the Trust Deed;

(ii) the Final Redemption Amount of the Notes;

(iii) the Early Redemption Amount of the Notes;

(iv) the Optional Redemption Amount(s) (if any) of the Notes;

(v) the Clean-Up Redemption Amount (if any) of the Notes; and

(vi) any premium and any other amounts (other than interest) which may be payable by the Issuer under or in respect of the Notes.

Any reference in these Terms and Conditions to interest in respect of the Notes shall be deemed to include, as applicable, any additional amounts which may be payable with respect to interest under Condition 7 or pursuant to any undertaking or covenant to pay additional amounts given in addition thereto, or in substitution therefor, pursuant to the Trust Deed.

6 Redemption and Purchase

(a) Redemption at maturity

Unless previously redeemed or purchased and cancelled as specified below, each Note will be redeemed by the Issuer at its Final Redemption Amount specified in, or determined in the manner specified in, the applicable Final Terms in the relevant Specified Currency on the Maturity Date.

(b) Redemption for tax reasons

(i) Where the Issuer is BATIF

(A) The provisions of this paragraph shall only apply where the Issuer is BATIF.

(B) The Notes may be redeemed in whole but not in part, at the option of the Issuer, at any time or, if the Notes are Floating Rate Notes, on any Interest Payment Date, upon not more than 30 nor less than 10 days prior notice given in accordance with Condition 13 (which notice will be irrevocable), at their Early Redemption Amount referred to in paragraph (f) below, together, if applicable, with interest accrued to (but excluding) the date fixed for redemption, if the Issuer satisfies the Trustee that, as a result of any amendment to, or change in, the laws or regulations of the United Kingdom or any political subdivision or taxing authority thereof or therein affecting taxation, or any amendment to or change in an official application or interpretation of such laws or regulations, which amendment or change becomes effective on or after the Issue Date of the first Tranche of the Notes, the Issuer will become obliged to pay any Additional Amounts pursuant to Condition 7(a) on the next succeeding Interest Payment Date in respect of the Notes; provided, however, that (1) no such notice of redemption will be given earlier than 90 days prior to the earliest date on which the Issuer would be obliged to pay such Additional Amounts were a payment in respect of the Notes then due and (2) at the time such notice of redemption is given, such obligation to pay such Additional Amounts remains in effect. Immediately prior to the publication of any notice of redemption pursuant to this paragraph (b)(i), the Issuer will deliver to the Trustee a certificate stating that the Issuer is entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to the right of the Issuer so to redeem have occurred, and the Trustee shall be entitled to accept such certificate as sufficient evidence of the satisfaction of the same in which event it shall be conclusive and binding on the Noteholders and the Couponholders. Upon the expiry of any notice of redemption pursuant to this paragraph (b)(i), the Issuer shall be bound to redeem the Notes as provided herein.
(ii) Where the Issuer is BATCAP

(A) The provisions of this paragraph shall only apply where the Issuer is BATCAP.

(B) The Notes may be redeemed in whole but not in part, at the option of the Issuer, at any time or, if the Notes are Floating Rate Notes, on any Interest Payment Date, upon not more than 30 nor less than 10 days’ (or, in each case, such other number of days as specified in the applicable Final Terms) prior notice given in accordance with Condition 13 (which notice will be irrevocable), at their Early Redemption Amount referred to in paragraph (f) below, together, if applicable, with interest accrued to (but excluding) the date fixed for redemption, if the Issuer satisfies the Trustee that, as a result of any amendment to, or change in, the laws or regulations of the United States or any political subdivision or taxing authority thereof or therein affecting taxation, or any amendment to or change in an official application or interpretation of such laws or regulations, which amendment or change becomes effective on or after the Issue Date of the first Tranche of the Notes, the Issuer will become obliged to pay any Additional Amounts pursuant to Condition 7(b) on the next succeeding Interest Payment Date in respect of the Notes; provided, however, that (1) no such notice of redemption will be given earlier than 90 days prior to the earliest date on which the Issuer would be obliged to pay such Additional Amounts in respect of the Notes if the conditions specified in paragraphs (c) and (j) of Condition 13 are satisfied and (2) at the time such notice of redemption is given, such obligation to pay such Additional Amounts remains in effect. Immediately prior to the publication of any notice of redemption pursuant to this paragraph (b)(ii), the Issuer will deliver to the Trustee a certificate stating that the Issuer is entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to the right of the Issuer so to redeem have occurred, and the Trustee shall be entitled to accept such certificate as sufficient evidence of the satisfaction of the same in which event it shall be conclusive and binding on the Noteholders and the Couponholders. Upon the expiry of any notice of redemption pursuant to this paragraph (b)(ii), the Issuer shall be bound to redeem the Notes as provided herein.

(iii) Where the Issuer is BATNF

(A) The provisions of this paragraph shall only apply where the Issuer is BATNF.

(B) The Notes may be redeemed in whole but not in part, at the option of the Issuer, at any time or, if the Notes are Floating Rate Notes, on any Interest Payment Date, upon not more than 30 nor less than 10 days’ (or, in each case, such other number of days as specified in the applicable Final Terms) prior notice given in accordance with Condition 13 (which notice will be irrevocable), at their Early Redemption Amount referred to in paragraph (f) below, together, if applicable, with interest accrued to (but excluding) the date fixed for redemption, if, as a result of any amendment to, or change in, the laws or regulations of The Netherlands or any political subdivision or taxing authority thereof or therein affecting taxation, or any amendment to or change in an official application or interpretation of such laws or regulations, which amendment or change becomes effective on or after the Issue Date of the first Tranche of the Notes, the Issuer will become obliged to pay any Additional Amounts pursuant to Condition 7(c) on the next succeeding Interest Payment Date in respect of the Notes; provided, however, that (1) no such notice of redemption will be given earlier than 90 days prior to the earliest date on which the Issuer would be obliged to pay such Additional Amounts were a payment in respect of the Notes then due and (2) at the time such notice of redemption is given, such obligation to pay such Additional Amounts remains in effect. Immediately prior to
the publication of any notice of redemption pursuant to this paragraph (b)(iii) the Issuer will deliver to the Trustee a certificate stating that the Issuer is entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to the right of the Issuer so to redeem have occurred, and the Trustee shall be entitled to accept such certificate as sufficient evidence of the satisfaction of the same in which event it shall be conclusive and binding on the Noteholders and the Couponholders. Upon the expiry of any notice of redemption pursuant to this paragraph (b)(iii), the Issuer shall be bound to redeem the Notes as provided herein.

(c) Redemption at the option of the Issuer (Issuer Call)

This Condition 6(c) applies to Notes which are subject to redemption prior to the Maturity Date at the option of the Issuer (other than for taxation reasons), such option being referred to as an “Issuer Call”. The applicable Final Terms contains provisions applicable to any Issuer Call and must be read in conjunction with this Condition 6(c) for full information on any Issuer Call. In particular, the applicable Final Terms will identify, as applicable, the Optional Redemption Date(s), the Optional Redemption Amount (or, if applicable, that the Optional Redemption Amount(s) applicable to any Optional Redemption Date will be the Make-whole Amount), any minimum or maximum amount of Notes which can be redeemed and the applicable notice periods.

If Issuer Call is specified in the applicable Final Terms, the Issuer may (save in respect of any Notes in respect of which a Put Notice has been given pursuant to Condition 6(e)), having given:

(i) not less than 10 nor more than 30 days’ (or, in each case, such other number of days as specified in the applicable Final Terms) notice to the Noteholders in accordance with Condition 13; and

(ii) not less than 10 days (or such shorter notice as such party shall accept) before the giving of the notice referred to in (i), notice to the Agent and the Trustee,

(which notices shall be irrevocable (other than in the circumstances set out below) and shall specify the date fixed for redemption) redeem all or some only of the Notes then outstanding on any Optional Redemption Date and at the Optional Redemption Amount(s) applicable to such Optional Redemption Date together, if appropriate, with interest accrued to (but excluding) the relevant Optional Redemption Date.

Any such notice of redemption may, at the Issuer’s discretion, be subject to one or more conditions precedent, in which case such notice shall state that, in the Issuer’s discretion, the Optional Redemption Date may be delayed until such time as any or all such conditions shall be satisfied (or waived by the Issuer in its sole discretion), or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied (or waived by the Issuer in its sole discretion) by the Optional Redemption Date, or by the Optional Redemption Date so delayed. In the case of a partial redemption of Notes, the Notes to be redeemed (“Redeemed Notes”) will be selected individually by lot, in the case of Redeemed Notes represented by definitive Notes, and in accordance with the rules of Euroclear and/or Clearstream, Luxembourg (to be reflected in the records of Euroclear and Clearstream, Luxembourg as either a pool factor or a reduction in nominal amount, at their discretion), in the case of Redeemed Notes represented by a Global Note, not more than 30 days prior to the date fixed for redemption (such date of selection being hereinafter called the “Selection Date”).

Any such partial redemption must be of a nominal amount not less than the Minimum Redemption Amount and not more than the Maximum Redemption Amount, in each case as specified in the applicable Final Terms. In the case of Redeemed Notes represented by definitive Notes, a list of the serial numbers of such Redeemed Notes will be published in accordance with Condition 13 not less than 14 days prior to the date fixed for redemption. No exchange of the relevant Global Note will be permitted during the period from (and including) the Selection Date to (and including) the date fixed for redemption pursuant to this paragraph (c) and notice to that effect shall be given by the Issuer to the Noteholders in accordance with Condition 13 at least five days prior to the Selection Date.
If, in respect of any Optional Redemption Date, Make-whole Amount is specified in the applicable Final Terms as the Optional Redemption Amount, the Optional Redemption Amount per Note shall be equal to the higher of the following:

(i) the nominal amount of the relevant Note; and

(ii) the nominal amount of the relevant Note multiplied by the price (as reported in writing to the Issuer and the Trustee by the Determination Agent) expressed as a percentage (rounded to five decimal places, with 0.000005 being rounded upwards) at which the Gross Redemption Yield on the Notes on the Determination Date specified in the applicable Final Terms is equal to (A) the Gross Redemption Yield at the Quotation Time specified in the applicable Final Terms on the Determination Date of the Reference Bond specified in the applicable Final Terms (or, where the Determination Agent advises the Issuer and the Trustee that, for reasons of illiquidity or otherwise, such Reference Bond is not appropriate for such purpose, such other government stock as the Determination Agent may recommend) plus (B) any applicable Redemption Margin specified in the applicable Final Terms.

Any notice of redemption given under Condition 6(e) will override any notice of redemption given (whether previously, on the same date or subsequently) under this Condition 6(e).

In this Condition:

“Determination Agent” means the Agent (or any successor financial adviser appointed by the Issuer for the purpose of determining the Make-whole Amount); and

“Gross Redemption Yield” means a yield calculated in accordance with generally accepted market practice at such time, as advised to the Issuer and the Trustee by the Determination Agent.

(d) Clean-Up Call Option

If Clean-Up Call is specified in the applicable Final Terms and 80 per cent. or more in nominal amount of the Notes originally issued (which shall for this purpose include any further Notes issued pursuant to Condition 15) have been redeemed or purchased and cancelled, the Issuer may, having given:

(i) not less than 10 nor more than 30 days’ (or, in each case, such other number of days as specified in the applicable Final Terms) notice to the Noteholders in accordance with Condition 13; and

(ii) not less than 10 days (or such shorter notice as such party shall accept) before the giving of the notice referred to in (i), notice to the Agent and the Trustee,

(which notice shall be irrevocable and shall specify the date fixed for redemption) redeem or, at the Issuer’s option, purchase (or procure the purchase of) on any Interest Payment Date (if the relevant Note is a Floating Rate Note) or at any time (if the relevant Note is not a Floating Rate Note), all but not some only of the Notes then outstanding at the Clean-Up Redemption Amount specified in the applicable Final Terms together with interest accrued (if any) to (but excluding) the date fixed for redemption.

(e) Redemption at the option of the Noteholders (Investor Put)

This Condition 6(e) applies to Notes which are subject to redemption prior to the Maturity Date at the option of the Noteholder, such option being referred to as an “Investor Put”. The applicable Final Terms contains provisions applicable to any Investor Put and must be read in conjunction with this Condition 6(e) for full information on any Investor Put. In particular, the applicable Final Terms will identify the Optional Redemption Date(s), the Optional Redemption Amount and the applicable notice periods.
If Investor Put is specified in the applicable Final Terms, upon the holder of any Note giving to the Issuer in accordance with Condition 13 not less than 10 nor more than 30 days’ (or, in each case, such other number of days as specified in the applicable Final Terms) notice (which notice shall be irrevocable) the Issuer will, upon the expiry of such notice, redeem, subject to, and in accordance with, the terms specified in the applicable Final Terms, in whole (but not in part), such Note on the Optional Redemption Date and at the Optional Redemption Amount together, if appropriate, with interest accrued to (but excluding) the Optional Redemption Date.

To exercise the right to require redemption of a Note the holder of this Note must, if the relevant Note is in definitive form and held outside Euroclear and Clearstream, Luxembourg, deliver at the specified office of any Paying Agent at any time during normal business hours of such Paying Agent falling within the notice period a duly completed and signed notice of exercise in the form (for the time being current) obtainable from any specified office of any Paying Agent (a “Put Notice”) and in which the holder must specify a bank account (or, if payment is required to be made by cheque, an address) to which payment is to be made under this Condition accompanied by the relevant Note or evidence satisfactory to the Paying Agent concerned that such Note will, following delivery of the Put Notice, be held to its order or under its control. If a Note is represented by a Global Note or is in definitive form and held through Euroclear or Clearstream, Luxembourg, to exercise the right to require redemption of such Note the holder must, within the notice period, give notice to the Agent of such exercise in accordance with the standard procedures of Euroclear and Clearstream, Luxembourg (which may include notice being given on his instruction by Euroclear or Clearstream, Luxembourg or any common depositary or common safekeeper, as the case may be, for them to the Agent by electronic means) in a form acceptable to Euroclear and Clearstream, Luxembourg from time to time and, if the relevant Note is represented by a Global Note, at the same time present or procure the presentation of the relevant Global Note to the Agent for notation accordingly.

(f) Early Redemption Amounts
For the purpose of paragraph (b) above and Condition 9, the Notes will be redeemed at the Early Redemption Amount calculated as follows:

(i) in the case of Notes with a Final Redemption Amount equal to the Issue Price, at the Final Redemption Amount thereof;
(ii) in the case of Notes (other than Zero Coupon Notes) with a Final Redemption Amount which is or may be less or greater than the Issue Price, at the amount specified in the applicable Final Terms or, if no such amount or manner is so specified in the applicable Final Terms, at their nominal amount; or
(iii) in the case of Zero Coupon Notes, at their Early Redemption Amount equal to the sum of:
    (A) the Reference Price; and
    (B) the product of the Accrual Yield (compounded annually) being applied to the Reference Price from (and including) the Issue Date of the first Tranche of the Notes to (but excluding) the date fixed for redemption or (as the case may be) the date upon which such Notes become due and repayable.

Where such calculation is to be made for a period which is not a whole number of years, it shall be made (i) in the case of a Zero Coupon Note payable in a Specified Currency other than Sterling, on the basis of a 360-day year consisting of 12 months of 30 days each or (ii) in the case of a Zero Coupon Note payable in Sterling, on the basis of the actual number of days elapsed divided by 365 (or, if any of the days elapsed falls in a leap year, the sum of (x) the number of those days falling in a leap year divided by 366 and (y) the number of those days falling in a non-leap year divided by 365).

(g) Purchases
The Issuer, the Guarantors or any other subsidiary (as defined in the Trust Deed) of the Issuer or any Guarantor may at any time purchase Notes (provided that, in the case of definitive Notes, all unmatured Coupons and Talons appertaining thereto are purchased therewith) at any price in the open market or otherwise. If purchases are made by tender, tenders must be available to all Noteholders alike. Such Notes may be held, reissued, resold or, at the option of the Issuer or the relevant Guarantor, surrendered to any Paying Agent for cancellation.
(h) Cancellation

All Notes which are redeemed will forthwith be cancelled (together with all unmatured Coupons and Talons attached thereto or surrendered therewith at the time of redemption). All Notes so cancelled and any Notes purchased and cancelled pursuant to paragraph (g) above (together with all unmatured Coupons and Talons cancelled therewith) shall be forwarded to the Agent and cannot be reissued or resold.

(i) Late payment on Zero Coupon Notes

If the amount payable in respect of any Zero Coupon Note upon redemption of such Zero Coupon Note pursuant to paragraph (a), (b), (c), (d) or (e) above or upon its becoming due and repayable as provided in Condition 9 is improperly withheld or refused, the amount due and repayable in respect of such Zero Coupon Note shall be the amount calculated as provided in paragraph (f)(iii) above as though the references therein to the date fixed for the redemption or the date upon which such Zero Coupon Note becomes due and payable were replaced by references to the date which is the earlier of:

(i) the date on which all amounts due in respect of such Zero Coupon Note have been paid; and

(ii) five days after the date on which the full amount of the moneys payable in respect of such Zero Coupon Note has been received by the Agent or the Trustee and notice to that effect has been given to the Noteholders in accordance with Condition 13.

7 Taxation

(a) Where the Issuer is BATIF

(1) The provisions of this paragraph shall only apply where the Issuer is BATIF.

(2) All payments of principal and interest by the Issuer or any Guarantor will be made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges (together, “Taxes”) of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of the United Kingdom or any political subdivision thereof or any authority thereof or therein having power to levy the same unless such withholding or deduction is required by law. In that event, the Issuer or the relevant Guarantor (as the case may be) shall pay such amounts (the “Additional Amounts”) as will result in the receipt by the Noteholders and the Couponholders of such amounts as would have been received by them had no such Taxes been required to be withheld or deducted; provided that no such Additional Amounts will be payable in respect of Notes or Coupons:

(i) presented for payment by or on behalf of a Noteholder or Couponholder who is liable for such withheld or deducted Taxes by reason of his having some connection with the United Kingdom other than the mere holding of a Note or Coupon; or

(ii) to, or to a third party on behalf of, a holder if such withholding or deduction may be avoided by complying with any statutory requirement or by making a declaration of non-residence or other similar claim for exemption to any authority of or in the United Kingdom, unless such holder proves that he is not entitled so to comply or to make such declaration or claim; or

(iii) presented for payment in the United Kingdom; or

68
(iv) presented for payment more than 30 days after the Relevant Date except to the extent that a Noteholder or Couponholder would have been entitled to payment of such Additional Amounts if he had presented his Note or Coupon for payment on the thirtieth day after the Relevant Date.

(b) Where the Issuer is BATCAP

1. The provisions of this paragraph shall only apply where the Issuer is BATCAP.

2. All payments of principal and interest by the Issuer or any Guarantor will be made without withholding or deduction for or on account of any Taxes of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of the United States or any political subdivision thereof or any authority thereof or therein having power to levy the same unless such withholding or deduction is required by law. In that event, the Issuer or the relevant Guarantor (as the case may be) shall pay such Additional Amounts as will result in the receipt by the Noteholders and the Couponholders of such amounts as would have been received by them had no such Taxes been required to be withheld or deducted; provided that the foregoing obligations shall not apply to:

(i) any such Taxes which would not have been imposed but for (i) the existence of any present or former connection between the holder (or between a fiduciary, settlor, beneficiary, member or shareholder of or possessor of a power over such holder, if such holder is an estate, a trust, a partnership or a corporation) and the United States, including, without limitation, such holder (or such fiduciary, settlor, beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof, or being or having been engaged in a trade or business therein or being or having been present therein, or having or having had a permanent establishment therein, or (ii) such holder’s present or former status as a personal holding company, passive foreign investment company, controlled foreign corporation or private foundation or other tax-exempt organisation (in each case, for United States federal income tax purposes), or as a corporation which accumulates earnings to avoid United States federal income taxes;

(ii) any such Taxes which would not have been so imposed but for the presentation of a Note or Coupon for payment more than 30 days after the Relevant Date except to the extent that a Noteholder or Couponholder would have been entitled to payment of such Additional Amounts if he had presented his Note or Coupon for payment on the thirtieth day after the Relevant Date;

(iii) any estate, inheritance, gift, sales, transfer or personal property Taxes or any similar Taxes;

(iv) any such Taxes which would not have been imposed but for the failure to comply with certification, information, documentation or other reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder of a Note or Coupon, if such compliance is required by statute, by regulation of the United States Treasury Department or by an applicable income tax treaty to which the United States is a party as a precondition to relief or exemption from such Taxes;

(v) any such Taxes which are payable otherwise than by deduction or withholding from payments in respect of a Note or Coupon;

(vi) any such Taxes imposed on interest received by a ten per cent. shareholder of the Issuer within the meaning of Section 871(h) (3)(B) or Section 881(c)(3)(B) of the United States Internal Revenue Code of 1986, as amended (the “Code”) (or any amended or successor provisions);
(vii) any such Taxes imposed by reason of a holder of a Note or Coupon being or having been a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business, as described in Section 881(c)(3)(A) of the Code (or any amended or successor provisions);
(viii) any backup withholding imposed pursuant to Section 3406 of the Code (or any amended or successor provisions);
(ix) any such Taxes imposed pursuant to Section 871(h)(6) or 881(c)(6) of the Code (or any amended or successor provisions);
(x) any combination of clauses (i) to (ix) above;

nor will any Additional Amounts be paid in respect of a Note or Coupon to any holder who is not a United States Alien or to any United States Alien who is a fiduciary or partnership or person other than the sole beneficial owner of any such payment, to the extent that a beneficiary or settlor with respect to such fiduciary, a member of such a partnership or the beneficial owner would not have been entitled to the Additional Amounts had such beneficiary, settlor, member or beneficial owner been the holder of such Note or Coupon. The term “United States Alien” means any person who, for United States federal income tax purposes, is a foreign corporation, a non-resident alien individual, a non-resident alien fiduciary of a foreign estate or trust or a foreign partnership any partner of which is for United States federal income tax purposes a foreign corporation, a non-resident alien individual, a non-resident alien fiduciary of a foreign estate or trust or any such foreign partnership.

(c) Where the Issuer is BATNF

(1) The provisions of this paragraph shall only apply where the Issuer is BATNF.
(2) All payments of principal and interest by the Issuer or any Guarantor will be made without withholding or deduction for or on account of any Taxes of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of The Netherlands or any political subdivision thereof or any authority thereof or therein having power to levy the same unless such withholding or deduction is required by law. In that event, the Issuer or the relevant Guarantor (as the case may be) shall pay such Additional Amounts as will result in the receipt by the Noteholders and the Couponholders of such amounts as would have been received by them had no such Taxes been required to be withheld or deducted; provided that no such Additional Amounts will be payable in respect of Notes or Coupons:

(i) presented for payment by or on behalf of a Noteholder or Couponholder who is liable for such withheld or deducted Taxes by reason of his having some connection with The Netherlands other than the mere holding of a Note or Coupon; or
(ii) to, or to a third party on behalf of, a holder if such withholding or deduction may be avoided by complying with any statutory requirement or by making a declaration of non-residence or other similar claim for exemption to any authority of or in The Netherlands, unless such holder proves that he is not entitled so to comply or to make such declaration or claim; or
(iii) presented for payment in The Netherlands; or
(iv) presented for payment more than 30 days after the Relevant Date except to the extent that a Noteholder or Couponholder would have been entitled to payment of such Additional Amounts if he had presented his Note or Coupon for payment on the thirtieth day after the Relevant Date; or

70
(v) to, or to another party on behalf of, a holder if such Additional Amounts are payable for or on account of any Taxes imposed or to be withheld in The Netherlands pursuant to the Dutch Withholding Tax Act 2021 (Wet bronbelasting 2021).

(d) The Trust Deed contains provisions (mutatis mutandis) to those contained in paragraphs (a), (b) and (c) above in relation to the relevant taxing jurisdiction of each Guarantor.

(e) Notwithstanding any other provision of these Terms and Conditions, any amounts to be paid on any Note or Coupon by or on behalf of the relevant Issuer will be paid net of any deduction or withholding imposed under Sections 1471 through 1474 of the Code (or any amended or successor provisions), including any regulations thereunder or official interpretations thereof, or required pursuant to an agreement described in Section 1471(b) of the Code or an intergovernmental agreement between the United States and another jurisdiction facilitating the implementation of any of the foregoing (or any fiscal or regulatory legislation, rules or practices implementing such an intergovernmental agreement) (any such withholding or deduction, a "FATCA Withholding"). Neither the relevant Issuer nor any Guarantor nor any other person will be required to pay any Additional Amounts in respect of FATCA Withholding.

(f) For the purpose of this Condition 7, "Relevant Date" means, in respect of any payment, the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurs the later.

8 Prescription

The Notes and Coupons will become void unless presented for payment within a period of ten years (in the case of principal) and five years (in the case of interest) after the Relevant Date (as defined in Condition 7) thereof.

There shall not be included in any Coupon sheet issued on exchange of a Talon any Coupon the claim for payment in respect of which would be void pursuant to this Condition or Condition 5(b) or any Talon which would be void pursuant to Condition 5(b).

9 Events of Default

(a) The Trustee at its discretion may, and if so requested in writing by Noteholders holding at least one-quarter in nominal amount of the Notes then outstanding or if so directed by an Extraordinary Resolution shall (subject in each case to being indemnified to its satisfaction), (provided that, except in the case of the happening of any of the events mentioned in paragraph (i) below, the Trustee shall have certified in writing to the Issuer that, in its opinion, such event is materially prejudicial to the interests of the Noteholders) give notice to the Issuer that the Notes are, and they shall thereupon immediately become, due and payable at their Early Redemption Amount referred to in Condition 6(f), together with accrued interest as provided in the Trust Deed, if any of the following events occurs and is continuing (each, an "Event of Default"):

(i) default is made for a period of seven days or more in the payment on the due date of any principal on the Notes or any of them or for a period of 14 days or more in the payment of any interest due in respect of the Notes or any of them; or

(ii) default is made by the Issuer or any Guarantor in the performance or observance of any covenant or provision binding on it under or pursuant to the Trust Deed or the Notes (other than a covenant for the payment of principal or interest due on or in respect of the Notes) and (except where the Trustee considers such default to be incapable of remedy when no notice as is referred to below is required, and for this purpose, something shall remain capable of remedy notwithstanding that it was required to have been previously done) such default continues on the thirtieth day after service by the Trustee to the Issuer or, as the case may be, the relevant Guarantor of written notice requiring the same to be remedied (or such later date as the Trustee may permit); or
(iii) any other Borrowed Moneys Indebtedness (as defined below) of either the Issuer or any Guarantor becomes due and repayable by reason of any event of default (howsoever described) prior to its stated date of payment or any other Borrowed Moneys Indebtedness of either the Issuer or any Guarantor is not paid within the longer of seven days of its due date or any applicable grace period therefor (and for such purpose there shall be deemed to be a grace period of not less than seven days in respect of any obligation under any guarantee or indemnity or otherwise as surety), provided that no such event shall constitute an Event of Default unless the Borrowed Moneys Indebtedness either (a) in any particular case amounts to at least £50,000,000 or the equivalent thereof in any other currency, or (b) when aggregated with other Borrowed Moneys Indebtedness then so due and repayable or not so paid amounts to at least £200,000,000 or the equivalent thereof in any other currency; or

(iv) where the Issuer or any Guarantor is incorporated in England and Wales:

(A) an order is made or an effective resolution is passed for the winding-up of the Issuer or a relevant Guarantor, or any similar action is taken in any other jurisdiction; or

(B) a distress or execution or other legal process is levied or enforced against or an encumbrancer takes possession of or a receiver, administrative receiver or other similar officer is appointed of the whole or a part of its assets which is substantial in relation to the Group (as defined below) taken as a whole and is not discharged, stayed, removed or paid out within 45 days after such execution or appointment; or

(C) an administration order is made in relation to the Issuer or a relevant Guarantor which is not discharged, stayed or removed within 45 days of such order being made; or

(v) where the Issuer or the relevant Guarantor is BATCAP:

(A) a decree or order by a court having jurisdiction is entered adjudging BATCAP a bankrupt or insolvent, or approving as properly filed a petition seeking reorganisation of BATCAP under the United States Bankruptcy Code or any other similar federal or state applicable law, and such decree or order is continued undischarged and unstayed for a period of 45 days; or

(B) a decree or order of a court having jurisdiction for the appointment of a receiver or liquidator or trustee or assignee in bankruptcy or insolvency of BATCAP is entered in respect of the whole of its property or a part thereof, which is substantial in relation to the Group taken as a whole, or for the winding-up or liquidation of its affairs, and such decree or order is continued and undischarged and unstayed for a period of 45 days; or

(C) BATCAP institutes proceedings to be adjudicated a voluntary bankrupt, or consents to the filing of a bankruptcy proceeding against it, or files a petition or answer or consent seeking reorganisation under the United States Bankruptcy Code or any other similar federal or state applicable law, or consents to the filing of any such petition, or consents to the appointment of a receiver or liquidator or trustee or assignee in bankruptcy or insolvency of BATCAP or of the whole of its property or a part thereof (which part is substantial in relation to the Group taken as a whole) or consents to the winding-up or liquidation of its affairs;

(the terms used in this sub-paragraph (v) shall be construed as they would be in the context of a proceeding instituted and conducted pursuant to the United States Bankruptcy Code or any other similar Federal or state applicable law); or

72
(vi) where the Issuer or the relevant Guarantor is BATNF:

(A) an order is made or an effective resolution is passed for the winding-up of BATNF or any similar action is taken in any other jurisdiction, including, without limitation, an application being made by BATNF for a ‘surseance van betaling’ (within the meaning of The Netherlands Bankruptcy Code (Faillissementswet)); or

(B) a distress or execution or other legal process is levied or enforced against or an encumbrancer takes possession of or a receiver, administrative receiver or other similar officer is appointed of the whole or a part of its assets which is substantial in relation to the Group taken as a whole and is not discharged, stayed, removed or paid out within 45 days after such execution or appointment; or

(C) an administration order is made in relation to BATNF which is not discharged, stayed or removed within 45 days of such order being made; or

(vii) either the Issuer or any Guarantor:

(A) admits in writing its inability to pay its debts generally as they fall due or makes or enters into a general assignment or composition with or for the benefit of its creditors generally; or

(B) stops or threatens to stop payment of its obligations generally or ceases or threatens to cease to carry on its business (except in either case for the purposes of amalgamation, reconstruction or corporate reorganisation, the terms of which shall have been previously approved by the Trustee in writing or by an Extraordinary Resolution of the Noteholders); or

(viii) for any reason whatsoever any guarantee ceases to be binding on and enforceable against the relevant Guarantor other than with the prior written consent of the Trustee or the sanction of an Extraordinary Resolution of the Noteholders.

For this purpose, “Borrowed Moneys Indebtedness” means, in relation to any person, any obligation (whether incurred as principal or as surety) for the payment or repayment of money, whether present or future, actual or contingent comprising or constituted by:

(A) any liability to repay the principal of or to pay interest on borrowed money or deposits; or

(B) any liability (i) under or pursuant to any (a) letter of credit, (b) acceptance credit facility or (c) note purchase facility; or (ii) in relation to (a) any foreign currency transaction or (b) any liability in respect of any purchase price for property or services payment of which is deferred for a period in excess of 180 days after the later of taking possession or becoming the legal owner thereof; or (iii) with regard to any guarantee or indemnity in respect of repayment of obligations as referred to in (i) and (ii) above or of any other borrowed money,

provided that nothing in Condition 9(a)(iv), (v), (vi) or (vii) shall apply to any matter or event resulting from or in connection with a disposal or divestiture of all or part of the interests in financial services businesses of the Group or any reconstruction, amalgamation or corporate reorganisation (or any similar action in any other jurisdiction), the terms of which shall have been approved by the Trustee in writing or by an Extraordinary Resolution of the Noteholders.

For the purposes of these Terms and Conditions, “Group” means British American Tobacco and its Subsidiaries together with its or their ultimate Holding Company (if any) (as defined in the Trust Deed) and any such ultimate Holding Company’s Subsidiaries.

(b) At any time after the Notes become due and repayable pursuant to paragraph (a) of this Condition the Trustee may, at its discretion and without further notice, institute such proceedings against the Issuer and/or any Guarantor as it may think fit to enforce payment of the Notes, but it shall not be bound to
take any such proceedings unless (i) it shall have been so directed by an Extraordinary Resolution or so requested in writing by Noteholders holding at least one-quarter in principal amount of the Notes outstanding and (ii) it shall have been indemnified to its satisfaction. No Noteholder or Couponholder may proceed directly against the Issuer or any relevant Guarantor unless the Trustee, having become bound to proceed, fails to do so within a reasonable period and such failure is continuing.

10 Replacement of Notes, Coupons and Talons

Should any Note Coupon or Talon be lost, stolen, mutilated, defaced or destroyed, it may be replaced at the specified office of the Agent upon payment by the claimant of such costs and expenses as may be incurred in connection therewith and on such terms as to evidence and indemnity the Issuer may reasonably require. Mutilated or defaced Notes Coupons or Talons must be surrendered before replacements will be issued.

11 Agents

The names of the initial Paying Agents and their initial specified offices are set out below.

The Issuer is entitled to vary or terminate the appointment of any Paying Agent and/or appoint additional or other Paying Agents and/or approve any change in the specified office through which any Paying Agent acts, provided that:

(i) there will at all times be an Agent;

(ii) so long as the Notes are listed on any stock exchange or admitted to trading by any other relevant authority, there will at all times be a Paying Agent with a specified office in such place as may be required by the rules and regulations of the relevant stock exchange or any other relevant authority; and

(iii) there will at all times be a Paying Agent with a specified office in a city approved by the Trustee in Western Europe outside the United Kingdom and The Netherlands.

In addition, the Issuer and the Guarantors shall forthwith appoint a Paying Agent having a specified office in New York City in the circumstances described in Condition 5(d). Any variation, termination, appointment or change shall only take effect (other than in the case of insolvency, when it shall be of immediate effect) after not less than 30 nor more than 45 days’ prior notice thereof shall have been given to the Noteholders in accordance with Condition 13.

In acting under the Agency Agreement, the Agents act solely as agents of the Issuer and the Guarantors and, in certain circumstances specified therein, of the Trustee and do not assume any obligation to, or relationship of agency or trust with, any Noteholders or Couponholders.

12 Exchange of Talons

On and after the Interest Payment Date on which the final Coupon comprised in any Coupon sheet matures, the Talon (if any) forming part of such Coupon sheet may be surrendered at the specified office of the Agent or any other Paying Agent in exchange for a further Coupon sheet including (if such further Coupon sheet does not include Coupons to (and including) the final date for the payment of interest due in respect of the Note to which it appertains) a further Talon, subject to the provisions of Condition 8.

13 Notices

All notices regarding the Notes will be deemed to be validly given if published in a leading English language daily newspaper of general circulation in London. It is expected that such publication will be made in the Financial Times in London. The Issuer shall also ensure that notices are duly published in a manner which complies with the rules and regulations of any stock exchange or any other relevant authority on which the Notes are for the time being listed or by which they have been admitted to trading. Any such notice will be deemed to have been given on the date of the first publication or, where required to be published in more than one newspaper, on the date of the first publication in all required newspapers.
Until such time as any definitive Notes are issued, there may, so long as any Global Notes representing the Notes are held in their entirety on behalf of Euroclear and/or Clearstream, Luxembourg, be substituted for such publication in such newspaper the delivery of the relevant notice to Euroclear and/or Clearstream, Luxembourg for communication by them to the holders of the Notes and, in addition, for so long as any Notes are listed on a stock exchange or are admitted to trading by another relevant authority and the rules of that stock exchange or other relevant authority so require, such notice will be published in a daily newspaper of general circulation in the place or places required by that stock exchange or other relevant authority. Any such notice shall be deemed to have been given to the holders of the Notes on the fourth day after the day on which the said notice was given to Euroclear and/or Clearstream, Luxembourg.

Notices to be given by any Noteholder shall be in writing and given by lodging the same, together with the relative Note or Notes, with the Agent. Whilst any of the Notes are represented by a Global Note, such notice may be given by any holder of a Note to the Agent through Euroclear and/or Clearstream, Luxembourg, as the case may be, in such manner as the Agent and Euroclear and/or Clearstream, Luxembourg, as the case may be, may approve for this purpose.

14 Meetings of Noteholders, Modification and Waiver

The Trust Deed contains provisions for convening meetings (including by way of audio or video conference call) of the Noteholders to consider any matter affecting their interests, including the sanctioning by an Extraordinary Resolution of a modification of the Notes, the Coupons or any of the provisions of the Trust Deed. Such a meeting may be convened by the Issuer, any Guarantor or the Trustee and shall (subject to being indemnified and/or secured and/or pre-funded to its satisfaction) be convened by the Trustee upon a request by Noteholders holding not less than ten per cent. in nominal amount of the Notes for the time being remaining outstanding. The quorum at any such meeting for passing an Extraordinary Resolution is one or more persons holding or representing not less than a clear majority in nominal amount of the Notes for the time being outstanding, or at any adjourned meeting one or more persons being or representing Noteholders whatever the nominal amount of the Notes so held or represented, except that at any meeting the business of which includes the modification of certain provisions of the Notes or Coupons or the Trust Deed (including modifying the date of maturity of the Notes or any date for payment of interest thereon, reducing or cancelling the amount of principal or the rate of interest payable in respect of the Notes or altering the currency of payment of the Notes or Coupons) the quorum shall be one or more persons holding or representing not less than three-fourths in nominal amount of the Notes for the time being outstanding, or at any adjourned such meeting one or more persons holding or representing not less than one-fourth in nominal amount of the Notes for the time being outstanding. An Extraordinary Resolution passed at any meeting of the Noteholders shall be binding on all the Noteholders, whether or not they are present at the meeting, and on all Couponholders. Notwithstanding the foregoing, a resolution by way of electronic consents or in writing signed by persons holding or representing not less than 75 per cent. of the nominal amount of the Notes for the time being outstanding shall for all purposes be as valid and effective as an Extraordinary Resolution passed at a meeting of the Noteholders duly convened and held in accordance with the provisions contained in the Trust Deed.

The Trustee may agree, without the consent of the Noteholders or Couponholders, to any modification of, or to the waiver or authorisation of any breach or proposed breach of, any of those Terms and Conditions or any of the provisions of the Trust Deed, or determine, without any such consent as aforesaid, that any Event of Default or Potential Event of Default (as defined in the Trust Deed) shall not be treated as such, which in any such case is not, in the opinion of the Trustee, materially prejudicial to the interests of the Noteholders or may agree, without any such consent as aforesaid, to any modification which is of a formal, minor or technical nature, to correct a manifest error or to comply with mandatory provisions of applicable law. In addition, the Trustee shall be obliged to concur with the Issuer in effecting any Benchmark Amendments in the circumstances and as otherwise set out in Condition 4(b)(C)(4) without the consent of the Noteholders or the Couponholders.

75
The Trustee may also agree without the consent of the Noteholders or Couponholders, to the substitution (i) in place of the Issuer as the principal debtor under the Notes and the Trust Deed of any Guarantor or any successor in business or Holding Company of any Guarantor or any other subsidiary of any Guarantor, such successor in business or such Holding Company provided that all payments in respect of the Notes continue to be unconditionally and irrevocably guaranteed by each Guarantor or the successor in business or Holding Company of each Guarantor in the manner provided in the Trust Deed (or, where a Guarantor or its successor in business or Holding Company is the new principal debtor, by the other Guarantors or their successors in business or Holding Companies); or (ii) in place of any Guarantor as guarantor of the Notes under the Trust Deed, of any successor in business or Holding Company of any Guarantor. In the case of any proposed substitution, the Trustee may agree, without the consent of the Noteholders or Couponholders, to a change of the law governing the Notes, the Coupons and/or the Trust Deed, provided that such change would not, in the opinion of the Trustee, be materially prejudicial to the interests of the Noteholders.

Any such modification, waiver, authorisation, determination or substitution shall be binding on the Noteholders and the Couponholders and, unless the Trustee otherwise agrees, any such modification or substitution shall be notified to the Noteholders in accordance with Condition 13 as soon as practicable thereafter.

In connection with the exercise by it of any of its trusts, powers, authorities and discretions (including, without limitation, any modification, waiver, authorisation or determination), the Trustee shall have regard to the general interests of the Noteholders as a class but shall not have regard to any interests arising from circumstances particular to individual Noteholders or Couponholders (whatever their number) and, in particular but without limitation, shall not have regard to the consequences of any such exercise for individual Noteholders or Couponholders (whatever their number) resulting from their being for any purpose domiciled or resident in, or otherwise connected with, or subject to the jurisdiction of, any particular territory or any political sub-division thereof and the Trustee shall not be entitled to require, nor shall any Noteholder or Couponholder be entitled to claim, from the Issuer, any Guarantor, the Trustee or any other person any indemnification or payment in respect of any tax consequence of any such exercise upon individual Noteholders or Couponholders except to the extent already provided for in Condition 7 and/or any undertaking given in addition to, or in substitution for, Condition 7 pursuant to the Trust Deed.

15 Further Issues

The Issuer shall be at liberty from time to time without the consent of the Noteholders or the Couponholders to create and issue further notes having terms and conditions the same as the Notes or the same in all respects save for the amount and date of the first payment of interest thereon and so that the same shall be consolidated and form a single Series with the outstanding Notes. The Trust Deed contains provisions for convening a single meeting of the Noteholders and the holders of notes of other Series where the Trustee so decides.

16 Indemnification of the Trustee and its Contracting with the Issuer and the Guarantors

The Trust Deed contains provisions for the indemnification, the prefunding and/or the provision of security for the Trustee and for its relief from responsibility, including provisions relieving it from taking action unless indemnified and/or secured and/or prefunded to its satisfaction.

The Trust Deed also contains provisions pursuant to which the Trustee is entitled, inter alia, (i) to enter into business transactions with the Issuer and/or any Guarantor and/or any Subsidiaries of any of them and to act as trustee for the holders of any other securities issued or guaranteed by, or relating to, the Issuer and/or any Guarantor and/or any Subsidiaries of any of them, (ii) to exercise and enforce its rights, comply with its obligations and perform its duties under or in relation to any such transactions or, as the case may be, any such trusteeship without regard to the interests of, or consequences for, the Noteholders or Couponholders, and (iii) to retain and not be liable to account for any profit made or any other amount or benefit received thereby or in connection therewith.
17 Contracts (Rights of Third Parties) Act 1999

No person shall have any right to enforce any term or condition of this Note under the Contracts (Rights of Third Parties) Act 1999 but this does not affect any right or remedy of any person which exists or is available apart from that Act.

18 Governing Law and Submission to Jurisdiction

(a) The Trust Deed, the Notes and the Coupons, and any non-contractual obligations arising out of or in connection with them, are governed by, and shall be construed in accordance with, English law.

(b) Each of the parties to the Trust Deed has in the Trust Deed irrevocably agreed that the courts of England are to have jurisdiction to settle any disputes which may arise out of or in connection with the Trust Deed, the Notes and/or the Coupons (including any dispute relating to any non-contractual obligations arising out of or in connection with them) and that accordingly any suit, action or proceedings (together referred to as “Proceedings”) arising out of or in connection with the Trust Deed, the Notes and the Coupons (including any proceedings relating to any non-contractual obligations arising out of or in connection with them) may be brought in such courts.

(c) Each of the parties to the Trust Deed has in the Trust Deed irrevocably and unconditionally waived any objection which it may have now or hereafter to the laying of the venue of any such Proceedings in any such court and any claim that any such Proceedings have been brought in an inconvenient forum and further irrevocably and unconditionally agreed that a judgment in any such Proceedings brought in the English courts shall be conclusive and binding upon it and may be enforced in the courts of any other jurisdiction.

(d) Nothing contained in this Condition shall limit any right to take Proceedings against any of the parties to the Trust Deed in any other court of competent jurisdiction (outside the Contracting States, as defined in Section 1(3) of the Civil Jurisdiction and Judgments Act 1982, as amended), nor shall the taking of Proceedings in one or more jurisdictions preclude the taking of Proceedings in any other jurisdiction, whether concurrently or not.

(e) Each of BATNF and BATCAP has in the Trust Deed appointed British American Tobacco at its registered office for the time being (being at the date of this Base Prospectus at Globe House, 4 Temple Place, London WC2R 2PG) as its agent for service of process, and undertaken that, in the event of British American Tobacco ceasing to act or ceasing to be registered in England, each of BATNF and BATCAP will appoint another person as its agent for service of process in England in respect of any Proceedings.

(f) Nothing herein shall affect the right to serve proceedings in any other manner permitted by law.
AGENT
Citibank, N.A., London Branch
Citigroup Centre
Canada Square
Canary Wharf
London E14 5LB

OTHER PAYING AGENT
Citibank Europe PLC
1 North Wall Quay
Dublin 1
Ireland

78
SCHEDULE 2

FORMS OF GLOBAL AND DEFINITIVE NOTES, COUPONS AND TALONS

79
PART 1

FORM OF GLOBAL NOTE

ANY UNITED STATES PERSON WHO HOLDS DEFINITIVE NOTES AND COUPONS AND/OR TALONS IN RESPECT OF THIS
OBLIGATION WILL BE SUBJECT TO LIMITATIONS UNDER THE UNITED STATES INCOME TAX LAWS, INCLUDING THE
LIMITATIONS PROVIDED IN SECTIONS 165(j) AND 1287(a) OF THE INTERNAL REVENUE CODE.

THE NOTES COVERED HEREBY HAVE NOT BEEN AND ARE NOT REQUIRED TO BE REGISTERED UNDER THE U.S. SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE
OR OTHER JURISDICTION OF THE UNITED STATES. THE NOTES MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT
SUBJECT TO, SUCH REGISTRATION.

THE NOTES ARE BEING OFFERED AND SOLD OUTSIDE THE UNITED STATES IN COMPLIANCE WITH REGULATION S
PROMULGATED UNDER THE SECURITIES ACT. THE NOTES MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS (I) AS PART OF THEIR
DISTRIBUTION AT ANY TIME, OR (II) UNTIL 40 DAYS AFTER THE COMPLETION OF THE DISTRIBUTION OF ALL NOTES OF
THE TRANCHE OF WHICH THOSE NOTES ARE A PART, AS DETERMINED AND CERTIFIED TO THE DEALERS OR, IN THE CASE
OF NOTES ISSUED ON A SYNDICATED BASIS, THE LEAD MANAGER, BY THE AGENT, EXCEPT IN EITHER CASE IN
ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. TERMS USED ABOVE HAVE THE MEANINGS GIVEN TO
THEM BY REGULATION S.

[B.A.T. INTERNATIONAL FINANCE p.l.c.
(incorporated with limited liability in England and Wales)\(^1\)]

B.A.T. NETHERLANDS FINANCE B.V.
(incorporated with limited liability in The Netherlands)\(^1\)

B.A.T CAPITAL CORPORATION
(incorporated with limited liability in the State of Delaware, United States of America)\(^2\)

unconditionally and irrevocably guaranteed by

BRITISH AMERICAN TOBACCO p.l.c., \(^3\)

(each a Guarantor and together the Guarantors)

GLOBAL NOTE

\(^1\) Applicable to Notes in bearer form with a maturity of more than one year.
\(^2\) Delete whichever are not applicable.
\(^3\) Insert names of the other Guarantors.
This Note is a Global Note in respect of a duly authorised issue of Notes of the Issuer (the "Notes") of the Nominal Amount, Specified Currency(ies) and Specified Denomination(s) as are specified in the Final Terms applicable to the Notes (the "Final Terms"), a copy of which is annexed hereto. References herein to the Conditions shall be to the Terms and Conditions of the Notes as set out in Schedule 1 to the Trust Deed (as defined below) as supplemented, replaced and modified by the Final Terms but, in the event of any conflict between the provisions of the said Conditions and the information in the Final Terms, the Final Terms will prevail. Words and expressions defined in the Conditions shall bear the same meanings when used in this Global Note. This Global Note is issued subject to, and with the benefit of, the Conditions and a Trust Deed (such Trust Deed as modified and/or supplemented and/or restated from time to time, the "Trust Deed") dated 6 July 1998.

The Issuer, subject to and in accordance with the Conditions and the Trust Deed, promises to pay to the bearer hereof on the Maturity Date and/or on such earlier date(s) as all or any of the Notes represented by this Global Note may become due and repayable in accordance with the Conditions and the Trust Deed, the amount payable under the Conditions in respect of such Notes on each such date and to pay interest (if any) on the nominal amount of the Notes from time to time represented by this Global Note calculated and payable as provided in the Conditions and the Trust Deed together with any other sums payable under the Conditions and the Trust Deed, upon presentation and, at maturity, surrender of this Global Note to or to the order of the Agent or any other Paying Agent located outside the United States, its territories and possessions (except as provided in the Conditions) from time to time appointed by the Issuer in respect of the Notes.

If the Final Terms indicates that this Global Note is intended to be a New Global Note, the nominal amount of Notes represented by this Global Note shall be the aggregate amount from time to time entered in the records of both Euroclear Bank SA/NV ("Euroclear") and Clearstream Banking SA ("Clearstream, Luxembourg" and together with Euroclear, the "relevant Clearing Systems"). The records of the relevant Clearing Systems (which expression in this Global Note means the records that each relevant Clearing System holds for its customers which reflect the amount of each such customer’s interest in the Notes) shall be conclusive evidence of the nominal amount of Notes represented by this Global Note and, for these purposes a statement issued by a relevant Clearing System (which statement shall be made available to the bearer upon request) stating the nominal amount of Notes represented by this Global Note at any time shall be conclusive evidence of the records of the relevant Clearing System at that time.

If the Final Terms indicates that this Global Note is not intended to be a New Global Note, the nominal amount of the Notes represented by this Global Note shall be the amount stated in the applicable Final Terms or, if lower, the nominal amount most recently entered by or on behalf of the Issuer in the relevant column in Part II or III of Schedule One hereto or in Schedule Two hereto.

On any redemption of, or payment of interest being made in respect of, or purchase and cancellation of, any of the Notes represented by this Global Note the Issuer shall procure that:

(a) if the Final Terms indicates that this Global Note is intended to be a New Global Note, details of such redemption, payment or purchase and cancellation (as the case may be) shall be entered pro rata in the records of the relevant Clearing Systems, and, upon any such entry being made, the nominal amount of the Notes recorded in the records of the relevant Clearing Systems and represented by this Global Note shall be reduced by the aggregate nominal amount of the Notes so redeemed or purchased and cancelled; or

(b) if the Final Terms indicates that this Global Note is not intended to be a New Global Note, details of such redemption, payment, purchase and cancellation (as the case may be) shall be entered by or on behalf of the Issuer in Schedule One hereto and the relevant space in Schedule One hereto recording any such redemption, payment, purchase and cancellation (as the case may be) shall be signed by or on behalf of the Issuer. Upon any such redemption or purchase and cancellation the nominal amount of this Global Note and the Notes represented by this Global Note shall be reduced by the nominal amount of such Notes so redeemed or purchased and cancelled.

81
Payments due in respect of Notes for the time being represented by this Global Note shall be made to the bearer of this Global Note and each payment so made will discharge the Issuer’s obligations in respect thereof. Any failure to make entries referred to above shall not affect such discharge.

This Global Note may be exchanged (free of charge) in whole, but not in part, for Definitive Notes and (if applicable) Coupons and/or Talons in or substantially in the forms set out in Part 2, Part 3 and Part 4 of Schedule 2 to the Trust Deed (on the basis that all the appropriate details have been included on the face of such Definitive Notes and (if applicable) Coupons and/or Talons and the relevant information supplementing, replacing or modifying the Conditions appearing in the Final Terms has been endorsed on or attached to such Definitive Notes) only upon the occurrence of an Exchange Event.

An **Exchange Event** means:

(i) both Euroclear and Clearstream, Luxembourg have terminated their businesses without a successor clearing organisation being available; or

(ii) the relevant Issuer has requested the issuance of definitive Notes upon a change in tax law that would be adverse to such Issuer but for the issuance of definitive Notes in bearer form.

Upon the occurrence of an Exchange Event:

(A) the Issuer will promptly give notice to Noteholders in accordance with Condition 13 upon the occurrence of such Exchange Event; and

(B) Euroclear and/or Clearstream, Luxembourg (acting on the instructions of any holder of an interest in this Global Note) or the Trustee may give notice to the Agent requesting exchange and, in the event of the occurrence of an Exchange Event as described in (ii) above, the Issuer may also give notice to the Agent requesting exchange. Any such exchange shall occur on a date specified in the notice not later than 60 days after the date of receipt of the first relevant notice by the Agent.

The first notice requesting exchange in accordance with the above provisions shall give rise to the issue of Definitive Notes for the total nominal amount of Notes represented by this Global Note.

Any such exchange as aforesaid may be made on any day (other than a Saturday or Sunday) on which banks are open for general business in London.

The aggregate nominal amount of Definitive Notes issued upon an exchange of this Global Note will be equal to the aggregate nominal amount of this Global Note. Upon exchange of this Global Note for Definitive Notes, the Agent shall cancel it or procure that it is cancelled.

Until the exchange of the whole of this Global Note as aforesaid, the bearer hereof shall (subject as provided in the next paragraph) in all respects be entitled to the same benefits as if he were the bearer of Definitive Notes and the relative Coupons and/or Talons (if any) in the form(s) set out in Part 2, Part 3 and Part 4 (as applicable) of Schedule 2 to the Trust Deed.

Each person (other than Euroclear or Clearstream, Luxembourg) who is for the time being shown in the records of Euroclear or Clearstream, Luxembourg as the holder of a particular nominal amount of the Notes represented by this Global Note (in which regard any certificate or other document issued by Euroclear or Clearstream, Luxembourg as to the nominal amount of such Notes standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall be treated by the Issuer, the Guarantors, the Trustee, the Agent and any other Paying Agent as the holder of such nominal amount of such Notes for all purposes other than with respect to the payment of principal and interest on such nominal amount of such Notes, the right to which shall be vested, as against the Issuer, solely in the bearer of this Global Note in accordance with and subject to the terms of this Global Note and the Trust Deed.

82
This Global Note and any non-contractual obligations arising out of or in connection with it is governed by, and shall be construed in accordance with, English law.

No rights are conferred on any person under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Global Note, but this does not affect any right or remedy of any person which exists or is available apart from that Act.

This Global Note shall not be valid unless (i) authenticated by Citibank, N.A., London Branch as Agent and (ii) if the Final Terms indicates that this Global Note is intended to be a New Global Note and Euroclear or Clearstream, Luxembourg has been appointed as the common safekeeper, effectuated by such common safekeeper.

This Global Note is transferable only to a successor clearing organisation that is subject to the same terms, in accordance with the rules and procedures for the time being of Euroclear or Clearstream, Luxembourg, as the case may be.

IN WITNESS whereof the Issuer has caused this Global Note to be signed manually or in facsimile by two persons duly authorised on its behalf.
Issued as of [ ].

B.A.T. INTERNATIONAL FINANCE p.l.c./
B.A.T. NETHERLANDS FINANCE B.V./
B.A.T CAPITAL CORPORATION

By: ________________________________
    Director

______________________________
    Director/Secretary

Authenticated by
Citibank, N.A., London Branch
as Agent.

By: ________________________________
    Authorised Officer

5 Effectuated without recourse,
Warranty or liability by
as common safekeeper

By: ________________________________

4 Delete whichever are not applicable.
5 This should only be completed where the Final Terms indicates that this Global Note is intended to be a New Global Note in respect of which effectuation is applicable.
Schedule One

PART I

INTEREST PAYMENTS

<table>
<thead>
<tr>
<th>Date made</th>
<th>Interest Payment Date</th>
<th>Total amount of interest payable</th>
<th>Amount of interest paid</th>
<th>Confirmation of payment by or on behalf of the Issuer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6 Schedule One should only be completed where the Final Terms indicates that this Global Note is not intended to be a New Global Note.

85
## PART II
### REDEMPTIONS

<table>
<thead>
<tr>
<th>Date made</th>
<th>Total amount of principal payable</th>
<th>Amount of principal paid</th>
<th>Remaining nominal amount of this Global Note following such redemption(^7)</th>
<th>Confirmation of redemption by or on behalf of the Issuer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^7\) See most recent entry in Part II or III or Schedule Two in order to determine this amount.
<table>
<thead>
<tr>
<th>Date made</th>
<th>Part of nominal amount of this Global Note purchased and cancelled</th>
<th>Remaining nominal amount of this Global Note following such purchase and cancellation</th>
<th>Confirmation of purchase and cancellation by or on behalf of the Issuer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8 See most recent entry in Part II or III or Schedule Two in order to determine this amount.
PART 2
FORM OF DEFINITIVE NOTE

THE NOTES COVERED HEREBY HAVE NOT BEEN AND ARE NOT REQUIRED TO BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. THE NOTES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION.

THE NOTES ARE BEING OFFERED AND SOLD OUTSIDE THE UNITED STATES IN COMPLIANCE WITH REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE NOTES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS (I) AS PART OF THEIR DISTRIBUTION AT ANY TIME, OR (II) UNTIL 40 DAYS AFTER THE COMPLETION OF THE DISTRIBUTION OF ALL NOTES OF THE TRANCHE OF WHICH THOSE NOTES ARE A PART, AS DETERMINED AND CERTIFIED TO THE DEALERS OR, IN THE CASE OF NOTES ISSUED ON A SYNDICATED BASIS, THE LEAD MANAGER, BY THE AGENT, EXCEPT IN EITHER CASE IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. TERMS USED ABOVE HAVE THE MEANINGS GIVEN TO THEM BY REGULATION S.

[ANY UNITED STATES PERSON WHO HOLDS THIS OBLIGATION WILL BE SUBJECT TO LIMITATIONS UNDER THE UNITED STATES INCOME TAX LAWS, INCLUDING THE LIMITATIONS PROVIDED IN SECTIONS 165(j) AND 1287(a) OF THE INTERNAL REVENUE CODE.]

B.A.T. INTERNATIONAL FINANCE p.l.c.
(incorporated with limited liability in England and Wales)

B.A.T. NETHERLANDS FINANCE B.V.
(incorporated with limited liability in The Netherlands)

B.A.T CAPITAL CORPORATION
(incorporated with limited liability in the State of Delaware, United States of America)

unconditionally and irrevocably guaranteed by

BRITISH AMERICAN TOBACCO p.l.c.

(each a Guarantor and together the Guarantors)

[Specified Currency and Nominal Amount of Tranche]

NOTES DUE
[Year of Maturity]

1 Applicable to Notes in bearer form with a maturity of more than one year.
2 Delete whichever are not applicable.
3 Insert names of the other Guarantors.
This Note is one of a Series of Notes of [Specified Currency(ies) and Specified Denomination(s)] each of the Issuer (Notes). References herein to the Conditions shall be to the Terms and Conditions [endorsed hereon/set out in Schedule 1 to the Trust Deed (as defined below) which shall be incorporated by reference herein and have effect as if set out herein] as supplemented, replaced and modified by the relevant information (appearing in the Final Terms (the Final Terms)) endorsed hereon but, in the event of any conflict between the provisions of the said Conditions and such information in the Final Terms, such information will prevail. Words and expressions defined in the Conditions shall bear the same meanings when used in this Note. This Note is issued subject to, and with the benefit of, the Conditions and a Trust Deed (such Trust Deed as modified and/or supplemented and/or restated from time to time, the Trust Deed) dated 6 July 1998.

The Issuer, subject to and in accordance with the Conditions and the Trust Deed, promises to pay to the bearer hereof on the Maturity Date or on such earlier date as this Note may become due and repayable in accordance with the Conditions and the Trust Deed, the amount payable on redemption of this Note and to pay interest (if any) on the nominal amount of this Note calculated and payable as provided in the Conditions and the Trust Deed together with any other sums payable under the Conditions and the Trust Deed.

This Note shall not be valid unless authenticated by Citibank, N.A., London Branch as Agent. IN WITNESS whereof this Note has been executed on behalf of the Issuer.

Issued as of [             ].

B.A.T. INTERNATIONAL FINANCE p.l.c./
B.A.T. NETHERLANDS FINANCE B.V./
B.A.T CAPITAL CORPORATION

By: __________________________
    Director

______________________________
    Director/Secretary

Authenticated by
Citibank, N.A., London Branch
as Agent.

By: __________________________
    Authorised Officer

4 Delete whichever are not applicable.
[Conditions]

[Conditions to be as set out in Schedule 1 to this Trust Deed or such other form as may be agreed between the Issuer, the Agent, the Trustee and the relevant Dealer(s), but shall not be endorsed if not required by the relevant Stock Exchange]
Final Terms

[Here to be set out the text of the relevant information supplementing, replacing or modifying the Conditions which appears in the Final Terms relating to the Notes]
PART 3
FORM OF COUPON

On the front:

B.A.T. INTERNATIONAL FINANCE p.l.c./
B.A.T. NETHERLANDS FINANCE B.V./
B.A.T CAPITAL CORPORATION1

[Specified Currency and Nominal Amount of Tranche]
NOTES DUE
[Year of Maturity]
Series No. [ ]

[Coupon appertaining to a Note in the denomination of [Specified Currency and Specified Denomination]].2

(Part A)

[For Fixed Rate Notes:

This Coupon is payable to bearer, separately negotiable and subject to the Terms and Conditions of the said Notes.

Coupon for [ ] due on [ ][ ]

(Part B)

[For Floating Rate Notes:

Coupon for the amount due in accordance with the Terms and Conditions endorsed on, attached to or incorporated by reference into the said Notes on [the Interest Payment Date falling in [ ][ ][ ]]

This Coupon is payable to bearer, separately negotiable and subject to such Terms and Conditions, under which it may become void before its due date.]

1 Delete whichever are not applicable.
2 Delete where the Notes are all of the same denomination.
ANY UNITED STATES PERSON WHO HOLDS THIS OBLIGATION WILL BE SUBJECT TO LIMITATIONS UNDER THE UNITED STATES INCOME TAX LAWS, INCLUDING THE LIMITATIONS PROVIDED IN SECTIONS 165(j) AND 1287(a) OF THE INTERNAL REVENUE CODE.\(^3\)

[B.A.T. INTERNATIONAL FINANCE p.l.c./B.A.T. NETHERLANDS FINANCE B.V./B.A.T CAPITAL CORPORATION \(^4\)]

By:

\[
\begin{align*}
\text{Director} \\
\text{Director/Secretary}\^{5}\n\end{align*}
\]

\(^3\) Applicable to Notes in bearer form with a maturity of more than one year.
\(^4\) Delete whichever is not applicable.
\(^5\) Delete if not applicable.
PART 4

FORM OF TALON

On the front:

B.A.T. INTERNATIONAL FINANCE p.l.c./
B.A.T. NETHERLANDS FINANCE B.V./
B.A.T. CAPITAL CORPORATION

[Specified Currency and Nominal Amount of Tranche]
NOTES DUE
[Year of Maturity]

Series No. [ ]

[Talon appertaining to a Note in the denomination of [Specified Currency and Specified Denomination]]

On and after [ ] further Coupons [and a further Talon] appertaining to the Note to which this Talon appertains will be issued at the specified office of any of the Paying Agents set out on the reverse hereof (and/or any other or further Paying Agents and/or specified offices as may from time to time be duly appointed and notified to the Noteholders) upon production and surrender of this Talon.

This Talon may, in certain circumstances, become void under the Terms and Conditions endorsed on the Note to which this Talon appertains.

THE NOTES COVERED HEREBY HAVE NOT BEEN AND ARE NOT REQUIRED TO BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. THE NOTES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION.

THE NOTES ARE BEING OFFERED AND SOLD OUTSIDE THE UNITED STATES IN COMPLIANCE WITH REGULATION S PROMULGATED UNDER THE SECURITIES ACT. THE NOTES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS (I) AS PART OF THEIR DISTRIBUTION AT ANY TIME, OR (II) UNTIL 40 DAYS AFTER THE COMPLETION OF THE DISTRIBUTION OF ALL NOTES OF THE TRANCHE OF WHICH THOSE NOTES ARE A PART, AS DETERMINED AND CERTIFIED TO THE DEALERS OR, IN THE CASE OF NOTES ISSUED ON A SYNDICATED BASIS, THE LEAD MANAGER, BY THE AGENT, EXCEPT IN EITHER CASE IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. TERMS USED ABOVE HAVE THE MEANINGS GIVEN TO THEM BY REGULATION S.

[ANY UNITED STATES PERSON WHO HOLDS THIS OBLIGATION WILL BE SUBJECT TO LIMITATIONS UNDER THE UNITED STATES INCOME TAX LAWS, INCLUDING THE LIMITATIONS PROVIDED IN SECTIONS 165(j) AND 1287(a) OF THE INTERNAL REVENUE CODE.]

1 Delete whichever are not applicable.
2 Delete where the Notes are all of the same denomination.
3 Not required on last Coupon sheet.
B.A.T. INTERNATIONAL FINANCE p.l.c./B.A.T. NETHERLANDS FINANCE B.V./B.A.T CAPITAL CORPORATION

By:

Director

Director/Secretary

4 Applicable to Notes in bearer form with a maturity of more than one year.
5 Delete whichever is not applicable.
6 Delete if not applicable.
On the back of Coupons and Talons:

AGENT
Citibank, N.A., London Branch
Citigroup Centre
Canada Square
Canary Wharf
London E14 5LB

OTHER PAYING AGENT
Citibank Europe PLC
1 North Wall Quay
Dublin 1
Ireland

96
SCHEDULE 3

PROVISIONS FOR MEETINGS OF NOTHELDERS

1. The following expressions have the following meanings:

(a) **voting certificate** means a certificate in English issued by a Paying Agent and dated in which it is stated:
   (i) that on that date Notes (whether in definitive form or represented by a Global Note and not being Notes in respect of which a block voting instruction has been issued and is outstanding in respect of the meeting specified in such voting certificate or any adjournment of it) were deposited with that Paying Agent (or held to its order at a bank or other depositary) or blocked in an account with a clearing system and that no such Notes will cease to be so deposited or held or blocked until the earlier of:
      (A) the conclusion of the meeting specified in such certificate or, if later, any adjournment of it; and
      (B) the surrender of the certificate to the Paying Agent which issued it; and
   (ii) that its bearer is entitled to attend and vote at such meeting or any adjournment of it in respect of the Notes represented by such certificate;

(b) **block voting instruction** means a document in English issued by a Paying Agent and dated in which:
   (i) it is certified that Notes (whether in definitive form or represented by a Global Note and not being Notes in respect of which a voting certificate has been issued and is outstanding in respect of the meeting specified in such block voting instruction or any adjournment of it) have been deposited with that Paying Agent (or to its order at a bank or other depositary) or blocked in an account with a clearing system and that no such Notes will cease to be so deposited or held or blocked until the earlier of:
      (A) the conclusion of the meeting specified in such document or, if later, any adjournment of it; and
      (B) the surrender, not less than 48 hours before the time fixed for such meeting or adjournment, of the receipt for each such deposited Note which is to be released to the Paying Agent which issued it or (as the case may be) the Notes ceasing with the agreement of the Paying Agent to be held to its order or under its control or so blocked and the notification of the necessary amendment to the block voting instruction by such Paying Agent to the Issuer;
   (ii) it is certified that each holder of such Notes or a duly authorised agent on his behalf has instructed that Paying Agent that the votes attributable to his Notes so deposited or held or blocked should be cast in a particular way in relation to each resolution to be put to such meeting or any adjourned such meeting and that all such instructions are, during the period of 48 hours before the time fixed for such meeting or adjourned meeting, neither revocable nor subject to amendment;
(iii) the aggregate nominal amount of the Notes so deposited or held or blocked are listed, distinguishing with regard to each resolution between those in respect of which instructions have been so given (A) to vote for, and (B) to vote against, the resolution; and

(iv) a person named in such document (a proxy) is authorised and instructed by that Paying Agent to vote in respect of the Notes so listed in accordance with the instructions referred to in (iii) above as set out in such document.

(c) **Extraordinary Resolution** means:

(i) a resolution passed at a duly convened meeting of Noteholders held in accordance with this Trust Deed by a majority of not less than 75 per cent. of the votes cast;

(ii) a resolution in writing executed by or on behalf of the persons holding or representing not less than 75 per cent. of the nominal amount of the Notes for the time being outstanding who would have been entitled to vote if it had been proposed at a meeting at which they were present and may consist of several instruments in like form each executed by or on behalf of one or more Noteholders; or

(iii) consent given by way of electronic consents through the relevant Clearing System(s) (in a form satisfactory to the Trustee) by or on behalf of the holders of not less than 75 per cent. of the nominal amount of the Notes for the time being outstanding.

2. A holder of a Note (whether in definitive form or represented by a Global Note) may obtain a voting certificate from a Paying Agent or require a Paying Agent to issue a block voting instruction by depositing his Note with such Paying Agent or (to the satisfaction of such Paying Agent) by such Note being held to its order or under its control or being blocked in an account with a clearing system, in each case not later than 48 hours before the time fixed for the relevant meeting. Voting certificates and block voting instructions shall be valid until the relevant Notes cease to be deposited or held or blocked pursuant to paragraph 1 and until then the holder of a voting certificate or (as the case may be) the proxy named in a block voting instruction shall, for all purposes in connection with any meeting or adjourned meeting of Noteholders, be deemed to be the holder of the Notes to which that voting certificate or block voting instruction relates and the Paying Agent with which (or to the order of which) such Notes have been deposited, held or blocked shall be deemed for such purposes not to be the holder of those Notes.

3. The Issuer, the Guarantors or the Trustee may at any time convene a meeting of Noteholders. If it receives a written request by Noteholders holding at least 10 per cent. of the nominal amount of the Notes for the time being outstanding and is indemnified and/or secured and/or prefunded to its satisfaction against all costs and expenses, the Trustee shall convene a meeting of Noteholders. Whenever any party shall take steps to convene any such meeting it shall give notice to the others of the day, time and place of such meeting and the nature of the business to be transacted thereat as soon as is practicable. Every meeting shall be held at a time and place approved by the Trustee (which need not be a physical place and instead may be held by way of audio or video conference call).

4. At least 21 days’ notice (exclusive of the day on which the notice is given and of the day of the meeting) shall be given to the Noteholders. A copy of the notice shall be given by the party convening the meeting to the other parties. The notice shall specify the day, time and place of meeting, be given in the manner provided in the Conditions and shall specify, unless the Trustee otherwise agrees, the nature of the resolutions to be proposed and shall include a statement to the effect that Notes may be deposited with or held to the order of or under the control of any Paying Agent or blocked in an account with a clearing system for the purpose of obtaining voting certificates or appointing proxies but not thereafter until 48 hours before the time fixed for the relevant meeting.
5. A person (who may, but need not, be a Noteholder) nominated in writing by the Trustee may act as chairman of a meeting but if no such nomination is made or if the person nominated is not present within 15 minutes after the time fixed for the meeting the Noteholders present shall choose one of their number to be chairman, failing which the Issuer may appoint a chairman. The chairman of an adjourned meeting need not be the same person as the chairman of the original meeting.

6. A meeting that has been validly convened in accordance with paragraph 3 above, may be cancelled by the person who convened such meeting by giving at least 7 days’ notice (exclusive of the day on which the notice is given and the day of the meeting) to the Noteholders. Any meeting cancelled in accordance with this paragraph 6 shall be deemed not to have been convened.

7. At a meeting one or more persons present in person holding Definitive Notes or voting certificates or being proxies and holding or representing in the aggregate not less than 10 per cent. of the nominal amount of the Notes for the time being outstanding shall (except for the purpose of passing an Extraordinary Resolution) form a quorum for the transaction of business and no business (other than the choosing of a chairman) shall be transacted unless the requisite quorum be present at the commencement of business. The quorum at a meeting for passing an Extraordinary Resolution shall (subject as provided below) be one or more persons present in person holding Definitive Notes or voting certificates or being proxies and holding or representing in the aggregate a clear majority in nominal amount of the Notes for the time being outstanding provided that the quorum at a meeting the business of which includes consideration of proposals specified in the proviso to paragraph 20 shall be one or more persons present holding Definitive Notes or voting certificates or being proxies and holding or representing in the aggregate not less than three-fourths in nominal amount of the Notes for the time being outstanding.

8. If within 15 minutes from the time fixed for a meeting a quorum is not present the meeting shall, if convened upon the requisition of Noteholders or if the Issuer and the Trustee agree, be dissolved. In any other case it shall stand adjourned to such date, not less than 14 nor more than 42 days later, and to such place as the chairman may decide. At such adjourned meeting one or more persons present in person holding Definitive Notes or voting certificates or being proxies (whatever the nominal amount of the Notes so held or represented) shall form a quorum and may pass any resolution and decide upon all matters which could properly have been dealt with at the meeting from which the adjournment took place had a quorum been present at such meeting provided that at an adjourned meeting at which an Extraordinary Resolution is to be proposed for the purpose of effecting any of the modifications specified in the proviso to paragraph 20 the quorum shall be one or more persons so present holding Definitive Notes or voting certificates or being proxies and holding or representing in the aggregate not less than one-fourth in nominal amount of the Notes for the time being outstanding.

9. The chairman may with the consent of (and shall if directed by) a meeting adjourn the meeting from time to time and from place to place but no business shall be transacted at an adjourned meeting which might not lawfully have been transacted at the meeting from which the adjournment took place.

10. At least 10 days’ notice of a meeting adjourned through want of a quorum shall be given in the same manner as for an original meeting and such notice shall state the quorum required at the adjourned meeting. No notice need, however, otherwise be given of an adjourned meeting.

11. Each question submitted to a meeting shall be decided in the first instance by a show of hands and in case of equality of votes the chairman shall both on a show of hands and on a poll have a casting vote in addition to the vote or votes (if any) which he may have as a Noteholder or as a holder of a voting certificate or as a proxy.
12. Unless a poll is (before or on the declaration of the result of the show of hands) demanded at any meeting by the chairman, the Issuer, the Guarantor(s), the Trustee or by one or more persons holding one or more Definitive Notes or voting certificates or being proxies and holding or representing in the aggregate not less than two per cent. in nominal amount of the Notes for the time being outstanding, a declaration by the chairman that a resolution has been carried or carried by a particular majority or lost or not carried by any particular majority shall be conclusive evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against such resolution.

13. If a poll is demanded, it shall be taken in such manner and (subject as provided below) either at once or after such adjournment as the chairman directs and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was demanded as at the date of the taking of the poll. The demand for a poll shall not prevent the continuation of the meeting for the transaction of any business other than the question on which the poll has been demanded.

14. A poll demanded on the election of a chairman or on a question of adjournment shall be taken at the meeting without adjournment.

15. The Issuer, the Guarantors and the Trustee (through their respective representatives) and their respective financial and legal advisers may attend and speak at any meeting of Noteholders. No one else may attend or speak at a meeting of Noteholders or have any of the powers exercisable by Noteholders in such meeting or join in requesting or convening such meeting, unless he is the holder of a Definitive Note or a voting certificate or is a proxy.

16. Subject as provided in paragraph 15 hereof at any meeting:

(a) on a show of hands every person who is present in person and produces a Definitive Note or voting certificate or is a proxy shall have one vote; and

(b) on a poll every person who is so present shall have one vote in respect of each £1 or such other amount as the Trustee may in its absolute discretion stipulate (or, in the case of meetings of holders of Notes denominated in another currency, such amount in such other currency as the Trustee in its absolute discretion may stipulate) in nominal amount of the Definitive Notes so produced or represented by the voting certificate so produced or in respect of which he is a proxy.

Without prejudice to the obligations of the proxies named in any block voting instruction any person entitled to more than one vote need not use all his votes or cast all the votes to which he is entitled in the same way.

17. A proxy need not be a Noteholder.

18. Each block voting instruction shall be deposited at such place as the Trustee shall designate or approve, at least 24 hours before the time appointed for holding the meeting or adjourned meeting at which the proxy named in the block voting instruction proposes to vote and in default the block voting instruction shall not be treated as valid unless the chairman of the meeting decides otherwise before the meeting or adjourned meeting proceeds to business. A notarially certified copy of each block voting instruction shall if required by the Trustee be produced by the proxy at the meeting or adjourned meeting but the Trustee shall not thereby be obliged to investigate or be concerned with the validity of, or the authority of, the proxy named in a block voting instruction.
19. A vote cast in accordance with the terms of a block voting instruction shall be valid even if the block voting instruction or any of the Noteholders’ instructions pursuant to which it was executed has been previously revoked or amended, unless written intimation of such revocation or amendment is received from the relevant Paying Agent by the Issuer or the Trustee at its registered office (or at such other place as the Trustee shall designate or approve) or by the chairman of the meeting in each case at least 24 hours before the time fixed for the meeting or adjourned meeting at which the block voting instruction is used.

20. A meeting of Noteholders shall, subject to the Conditions, in addition to the powers given above, but without prejudice to any powers conferred on other persons by this Trust Deed, have power exercisable by Extraordinary Resolution:

(a) to sanction any proposal by the Issuer, any of the Guarantors or the Trustee for any modification, abrogation, variation or compromise of, or arrangement in respect of, the rights of the Noteholders and/or the Couponholders against the Issuer or any of the Guarantors whether or not these rights arise under this Trust Deed;

(b) to sanction the exchange or substitution for the Notes of, or the conversion of the Notes into, shares, bonds, or other obligations or securities of the Issuer, any of the Guarantors or any other entity;

(c) to assent to any modification of this Trust Deed which shall be proposed by the Issuer, any of the Guarantors or the Trustee;

(d) to authorise anyone to concur in and do anything necessary to carry out and give effect to an Extraordinary Resolution;

(e) to give any authority, direction or sanction required to be given by Extraordinary Resolution;

(f) to appoint any persons (whether Noteholders or not) as a committee or committees to represent the interests of the Noteholders and to confer upon them any powers or discretions which the Noteholders could themselves exercise by Extraordinary Resolution;

(g) to approve a proposed new Trustee and to remove a Trustee;

(h) to approve the substitution of any entity for the Issuer or any of the Guarantors (or any previous substitute) as principal debtor or guarantor under this Trust Deed; and

(i) to discharge or exonerate the Trustee and/or any Appointee from any liability in respect of any act or omission for which it may become responsible under this Trust Deed;

provided that the special quorum provisions contained in the proviso to paragraph 7 and, in the case of an adjourned meeting, in the proviso to paragraph 8 shall apply to any Extraordinary Resolution in relation to any of the matters specified in paragraph 20(b) or (h) or for the purpose of making any modification to this Trust Deed (each of which shall only be capable of being effected after having been approved by an Extraordinary Resolution) which would have the effect of:

(i) changing the date of maturity of the Notes or the dates on which interest is payable in respect of the Notes; or

(ii) reducing or cancelling the amount of principal of, or the rate of interest payable in respect of, the Notes; or

(iii) changing the currency of payment of the Notes or Coupons; or

101
(iv) modifying the provisions hereof relating to the quorum required at meetings of the Noteholders or the majority required to pass (whether at such meeting or by writing) an Extraordinary Resolution; or
(v) amending this proviso.

21. Any procedural resolution passed at a meeting of Noteholders duly convened and held in accordance with this Trust Deed and an Extraordinary Resolution duly passed in accordance with this Trust Deed shall be binding on all the Noteholders, whether or not present at the meeting, and on all the Couponholders and each of them shall be bound to give effect to it accordingly. The passing of such a resolution shall be conclusive evidence that the circumstances of such resolution justify the passing of it. The Issuer shall give notice of the passing of an Extraordinary Resolution to Noteholders as soon as practicable after it has been passed but failure to do so shall not invalidate the resolution.

22. Minutes shall be made of all resolutions and proceedings at every meeting and, if purporting to be signed by the chairman of that meeting or of the next succeeding meeting of Noteholders, shall be conclusive evidence of the matters in them. Until the contrary is proved every meeting for which minutes have been so made and signed shall be deemed to have been duly convened and held and all resolutions passed or proceedings transacted at it to have been duly passed and transacted.

23. Subject to the following sentence, a Written Resolution may be contained in one document or in several documents in like form, each signed by or on behalf of one or more such Noteholders.

For so long as the Notes are in the form of a Global Note held on behalf of one or more of Euroclear, Clearstream, Luxembourg or another clearing system, then, in respect of any resolution proposed by the relevant Issuer or the Trustee:

(a) where the terms of the resolution proposed by the Issuer, the Guarantor or the Trustee (as the case may be) have been notified to the Noteholders through the relevant clearing system(s) as provided in sub-paragraphs (i) and/or (ii) below, each of the Issuer, the Guarantor and the Trustee shall be entitled to rely upon approval of such resolution given by way of electronic consents communicated through the electronic communications systems of the relevant clearing system(s) to the Principal Paying Agent or another specified agent and/or the Trustee in accordance with their operating rules and procedures by or on behalf of the holders of not less than 75 per cent. in nominal amount of the Notes outstanding (the Required Proportion) (Electronic Consent) by close of business on the Relevant Date. Any resolution passed in such manner shall be binding on all Noteholders and Couponholders, even if the relevant consent or instruction proves to be defective. None of the Issuer, the Guarantor or the Trustee shall be liable or responsible to anyone for such reliance.

(i) When a proposal for a resolution to be passed as an Electronic Consent has been made, at least 10 days’ notice (exclusive of the day on which the notice is given and of the day on which affirmative consents will be counted) shall be given to the Noteholders through the relevant clearing system(s). The notice shall specify, in sufficient detail to enable Noteholders to give their consents in relation to the proposed resolution, the method by which their consents may be given (including, where applicable, blocking of their accounts in the relevant clearing system(s) and the time and date (the Relevant Date) by which they must be received in order for such consents to be validly given, in each case subject to and in accordance with the operating rules and procedures of the relevant clearing system(s).
If, on the Relevant Date on which the consents in respect of an Electronic Consent are first counted, such consents do not represent the Required Proportion, the resolution shall, if the party proposing such resolution (the Proposer) so determines, be deemed to be defeated. Such determination shall be notified in writing to the other party or parties to this Trust Deed. Alternatively, the Proposer may give a further notice to Noteholders that the resolution will be proposed again on such date and for such period as shall be agreed with the Trustee (unless the Trustee is the Proposer). Such notice must inform Noteholders that insufficient consents were received in relation to the original resolution and the information specified in sub-paragraph (i) above. For the purpose of such further notice, references to “Relevant Date” shall be construed accordingly.

For the avoidance of doubt, an Electronic Consent may only be used in relation to a resolution proposed by the Issuer, the Guarantor or the Trustee which is not then the subject of a meeting that has been validly convened in accordance with paragraph 3 above, unless that meeting is or shall be cancelled or dissolved; and

Alternatively, the Proposer may give a further notice to Noteholders that the resolution will be proposed again on such date and for such period as shall be agreed with the Trustee (unless the Trustee is the Proposer). Such notice must inform Noteholders that insufficient consents were received in relation to the original resolution and the information specified in sub-paragraph (i) above. For the purpose of such further notice, references to “Relevant Date” shall be construed accordingly.

For the avoidance of doubt, an Electronic Consent may only be used in relation to a resolution proposed by the Issuer, the Guarantor or the Trustee which is not then the subject of a meeting that has been validly convened in accordance with paragraph 3 above, unless that meeting is or shall be cancelled or dissolved; and

Alternatively, the Proposer may give a further notice to Noteholders that the resolution will be proposed again on such date and for such period as shall be agreed with the Trustee (unless the Trustee is the Proposer). Such notice must inform Noteholders that insufficient consents were received in relation to the original resolution and the information specified in sub-paragraph (i) above. For the purpose of such further notice, references to “Relevant Date” shall be construed accordingly.

For the avoidance of doubt, an Electronic Consent may only be used in relation to a resolution proposed by the Issuer, the Guarantor or the Trustee which is not then the subject of a meeting that has been validly convened in accordance with paragraph 3 above, unless that meeting is or shall be cancelled or dissolved; and

Alternatively, the Proposer may give a further notice to Noteholders that the resolution will be proposed again on such date and for such period as shall be agreed with the Trustee (unless the Trustee is the Proposer). Such notice must inform Noteholders that insufficient consents were received in relation to the original resolution and the information specified in sub-paragraph (i) above. For the purpose of such further notice, references to “Relevant Date” shall be construed accordingly.

For the avoidance of doubt, an Electronic Consent may only be used in relation to a resolution proposed by the Issuer, the Guarantor or the Trustee which is not then the subject of a meeting that has been validly convened in accordance with paragraph 3 above, unless that meeting is or shall be cancelled or dissolved; and

Alternatively, the Proposer may give a further notice to Noteholders that the resolution will be proposed again on such date and for such period as shall be agreed with the Trustee (unless the Trustee is the Proposer). Such notice must inform Noteholders that insufficient consents were received in relation to the original resolution and the information specified in sub-paragraph (i) above. For the purpose of such further notice, references to “Relevant Date” shall be construed accordingly.
(ii) a resolution which in the opinion of the Trustee affects the Notes of more than one Series but does not give rise to a conflict of interests between the holders of Notes of any of the Series so affected shall be deemed to have been duly passed if passed at a single meeting (or by a single resolution in writing or by a single resolution passed by way of consents received through the relevant Clearing System(s)) of the holders of the Notes of all the Series so affected;

(iii) a resolution which in the opinion of the Trustee affects the Notes of more than one Series and gives or may give rise to a conflict of interests between the holders of the Notes of one Series or group of Series so affected shall be deemed to have been duly passed only if passed at separate meetings (or by separate resolutions in writing or by separate resolutions passed by way of consents received through the relevant Clearing System(s)) of the holders of the Notes of each Series or group of Series so affected; and

(iv) to all such meetings as aforesaid all the preceding provisions of this Schedule shall mutatis mutandis apply as though references therein to Notes and Noteholders were references to the Notes of the Series or group of Series in question and to the holders of such Notes respectively.

(b) If the Issuer shall have issued and have outstanding Notes which are not denominated in pounds sterling in the case of any meeting of holders of Notes of more than one currency the principal amount of such Notes shall (i) for the purposes of paragraph 3 above be the equivalent in pounds sterling at the spot rate of a bank nominated by the Trustee for the conversion of the relevant currency or currencies into pounds sterling on the seventh dealing day prior to the day on which the requisition in writing is received by the Issuer and (ii) for the purposes of paragraphs 7, 8 and 16 above (whether in respect of the meeting or any adjourned such meeting or any poll resulting therefrom) be the equivalent at such spot rate on the seventh dealing day prior to the day of such meeting. In such circumstances, on any poll each person present shall have one vote for each £1 (or such other pounds sterling amount as the Trustee may in its absolute discretion stipulate) in principal amount of the Notes (converted as above) which he holds or represents.

25. Subject to all other provisions of this Trust Deed, the Trustee may, without the consent of the Noteholders or the Couponholders, prescribe such further regulations regarding the holding of meetings and attendance and voting at them as the Trustee may in its sole discretion determine including (without limitation) such regulations and requirements as the Trustee thinks reasonable (a) to satisfy itself that the persons who purport to make any requisition in accordance with this Trust Deed are entitled to do so; (b) as to the form of voting certificates or block voting instructions so as to satisfy itself that persons who purport to attend or vote at a meeting are entitled to do so; (c) as to the attendance and voting by persons beneficially entitled to interests in the Global Note without the need for them to hold Definitive Notes; (d) where the Trustee has determined that a resolution may properly be put to a meeting of the holders of the Notes of more than one Series issued in different denominations and/or different currencies, as to the weighting of the votes attributable to each such series; (e) so as to satisfy itself that persons who have purported to sign a resolution in writing to constitute an Extraordinary Resolution were in fact Noteholders and holders of different Notes; and (f) as to the holding of meetings by audio or video conference call in circumstances where it may be impractical or inadvisable to hold physical meetings.

104
EXECUTED as a DEED by
B.A.T. INTERNATIONAL FINANCE p.l.c.
acting by
and

EXECUTED as a DEED by
B.A.T CAPITAL CORPORATION
acting by
and

EXECUTED as a DEED by
B.A.T. NETHERLANDS FINANCE B.V.
acting by
and

EXECUTED as a DEED by
BRITISH AMERICAN TOBACCO p.l.c.
acting by

THE COMMON SEAL of
THE LAW DEBENTURE TRUST
CORPORATION p.l.c.
was affixed to this DEED
in the presence of:

Director

Authorised Signatory
6 JULY 1998 AND MODIFIED AND RESTATED ON
18 MARCH 2021

B.A.T. INTERNATIONAL FINANCE p.l.c.
and
B.A.T. NETHERLANDS FINANCE B.V.
and
B.A.T CAPITAL CORPORATION
and
BRITISH AMERICAN TOBACCO p.l.c.
and
THE LAW DEBENTURE TRUST CORPORATION
p.l.c.

relating to a
£25,000,000,000
Euro Medium Term Note Programme

TRUST DEED

ALLEN & OVERY

Allen & Overy LLP
SIGNATORIES TO THE THIRTY-THIRD SUPPLEMENTAL TRUST DEED

EXECUTED as a DEED by

B.A.T. INTERNATIONAL FINANCE p.l.c.

acting by __________________________

and __________________________

EXECUTED as a DEED by

B.A.T. NETHERLANDS FINANCE B.V.

acting by __________________________

and __________________________

EXECUTED as a DEED by

B.A.T CAPITAL CORPORATION

acting by __________________________

and __________________________

EXECUTED as a DEED by

BRITISH AMERICAN TOBACCO p.l.c.

acting by __________________________

and __________________________

_BAT Signature Page to Thirty-Third Supplemental Trust Deed_
SIGNATORIES TO THE THIRTY-THIRD SUPPLEMENTAL TRUST DEED

EXECUTED as a DEED by

B.A.T. INTERNATIONAL FINANCE p.l.c.
acting by ____________________________
and ____________________________

EXECUTED as a DEED by

B.A.T. NETHERLANDS FINANCE B.V.
acting by ____________________________
and ____________________________

EXECUTED as a DEED by

B.A.T CAPITAL CORPORATION
acting by ____________________________
and ____________________________

EXECUTED as a DEED by

BRITISH AMERICAN TOBACCO p.l.c.
acting by ____________________________
and ____________________________

BAT Signature Page to Thirty-Third Supplemental Trust Deed
SIGNATORIES TO THE THIRTY-THIRD SUPPLEMENTAL TRUST DEED

EXECUTED as a DEED by

B.A.T. INTERNATIONAL FINANCE p.l.c.
acting by ________________________
and ________________________

EXECUTED as a DEED by

B.A.T. NETHERLANDS FINANCE B.V.
acting by ________________________
and ________________________

EXECUTED as a DEED by

B.A.T CAPITAL CORPORATION
acting by ________________________
and ________________________

EXECUTED as a DEED by

BRITISH AMERICAN TOBACCO p.l.c.
acting by ________________________
and ________________________

BAT Signature Page to Thirty-Third Supplemental Trust Deed
EXECUTED as a DEED by

B.A.T. INTERNATIONAL FINANCE p.l.c.
acting by ____________________________
and ____________________________

EXECUTED as a DEED by

B.A.T. NETHERLANDS FINANCE B.V.
acting by ____________________________
and ____________________________

EXECUTED as a DEED by

B.A.T CAPITAL CORPORATION
acting by T.J. Hazlett, Director
and B.T. Harrison, Secretary

EXECUTED as a DEED by

BRITISH AMERICAN TOBACCO p.l.c.
acting by ____________________________
and ____________________________

BAT Signature Page to Thirty-Third Supplemental Trust Deed
SIGNATORIES TO THE THIRTY-THIRD SUPPLEMENTAL TRUST DEED

EXECUTED as a DEED by

B.A.T. INTERNATIONAL FINANCE p.l.c.
acting by ______________________
and ______________________

EXECUTED as a DEED by

B.A.T. NETHERLANDS FINANCE B.V.
acting by ______________________
and ______________________

EXECUTED as a DEED by

B.A.T CAPITAL CORPORATION
acting by ______________________
and ______________________

EXECUTED as a DEED by

BRITISH AMERICAN TOBACCO p.l.c.
acting by ______________________
and ______________________
EXECUTED as a DEED by

THE LAW DEBENTURE TRUST

CORPORATION p.l.c. in the presence of:

Director:

Secretary, representing Law Debenture Corporate Services Ltd:

Trustee Signature Page to Thirty-Third Supplemental Trust Deed
As of December 31, 2021, British American Tobacco p.l.c. ("BAT", the "Company", "we", "us" and "our") had the following series of securities registered pursuant to Section 12(b) of the Exchange Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Depositary Shares (evidenced by American Depositary Receipts) each representing one ordinary share</td>
<td>BTI</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>Ordinary shares, nominal value 25 pence per share</td>
<td>BTI</td>
<td>New York Stock Exchange*</td>
</tr>
<tr>
<td>2.259% Notes due 2028</td>
<td>BTI28</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.726% Notes due 2031</td>
<td>BTI31</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>3.734% Notes due 2040</td>
<td>BTI40</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>3.984% Notes due 2050</td>
<td>BTI50A</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.668% Notes due 2026</td>
<td>BTI26A</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>4.700% Notes due 2027</td>
<td>BTI27A</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>4.906% Notes due 2030</td>
<td>BTI30</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>5.282% Notes due 2050</td>
<td>BTI50</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.789% Notes due 2024</td>
<td>BTI24</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>3.215% Notes due 2026</td>
<td>BTI26</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>3.462% Notes due 2029</td>
<td>BTI29</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>4.758% Notes due 2049</td>
<td>BTI49</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.764% Notes due 2022</td>
<td>BTI22</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>3.222% Notes due 2024</td>
<td>BTI24A</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>3.557% Notes due 2027</td>
<td>BTI27</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>4.390% Notes due 2037</td>
<td>BTI37</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>4.540% Notes due 2047</td>
<td>BTI47</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>Floating Rate Notes due 2022</td>
<td>BTI22A</td>
<td>New York Stock Exchange</td>
</tr>
</tbody>
</table>

* Listed, not for trading, but only in connection with the listing of the applicable Registrant’s American Depositary Shares issued in respect thereof.

BAT is the issuer of the ordinary shares and the ordinary shares represented by the American Depositary Shares, as described below. The rest of the securities registered pursuant to Section 12(b) of the Exchange Act described herein were issued by either B.A.T. International Finance p.l.c. ("BATIF") or B.A.T Capital Corporation ("BATCAP"), wholly-owned finance subsidiaries of BAT. BAT is a guarantor and co-registrant of the securities issued by each of BATIF and BATCAP described herein.
BAT’s ordinary shares and American Depositary Shares are described below under “Description of BAT Ordinary Shares and American Depositary Shares”. BATIF’s 1.668% Notes due 2026 are described below under “Description of the Notes Issued Under the BATIF Indenture”. BATCAP’s 2.259% Notes due 2028, 2.726% Notes due 2031, 3.734% Notes due 2040, 3.984% Notes due 2050, 4.700% Notes due 2027, 4.906% Notes due 2030, 5.282% Notes due 2050, 2.789% Notes due 2024, 3.215% Notes due 2026, 3.462% Notes due 2029 and 4.758% Notes due 2049 are described below under “Description of the Notes Issued Under the 2019 BATCAP Indenture”. BATCAP’s 2.764% Notes due 2022, 3.222% Notes due 2024, 3.557% Notes due 2027, 4.390% Notes due 2037, 4.540% Notes due 2047, and Floating Rate Notes due 2022 are described below under “Description of the Notes Issued Under the 2017 BATCAP Indenture”.

Capital terms used but not defined herein have the meanings given to them in BAT’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021. Terms that are defined below retain such definitions solely for purposes of the relevant description of securities.

A. Guarantor Subsidiaries of the Registrant

BATCAP, B.A.T. Netherlands Finance B.V. (“BATNF”) and, unless its guarantee is released in accordance with the BATIF Indenture (as defined below), Reynolds American Inc. (“RAI”), each of which is an indirect 100% owned subsidiary of BAT, have fully and unconditionally guaranteed (along with BAT) BATIF’s obligations under the following senior unsecured notes issued by BATIF, which is a direct 100% owned subsidiary of BAT, under the BATIF Indenture:

- 1.668% Notes due 2026.

BATIF, BATNF and, unless its guarantee is released in accordance with the 2019 BATCAP Indenture (as defined below), RAI have fully and unconditionally guaranteed (along with BAT) BATCAP’s obligations under the following senior unsecured notes issued by BATCAP, under the 2019 BATCAP Indenture:

- 2.259% Notes due 2028;
- 2.726% Notes due 2031;
- 3.734% Notes due 2040;
- 3.984% Notes due 2050;
- 4.700% Notes due 2027;
- 4.906% Notes due 2030;
- 5.282% Notes due 2050;
- 2.789% Notes due 2024;
- 3.215% Notes due 2026;
- 3.462% Notes due 2029; and
BATIF, BATNF, British American Tobacco Holdings (The Netherlands) B.V. (“BATHTN”), which is an indirect 100% owned subsidiary of BAT, and, unless its guarantee is released in accordance with the 2017 BATCAP Indenture (as defined below), RAI have fully and unconditionally guaranteed (along with BAT) BATCAP’s obligations under the following senior unsecured notes issued by BATCAP, under the 2017 BATCAP Indenture:

- 4.758% Notes due 2049.
- 2.764% Notes due 2022;
- 3.222% Notes due 2024;
- 3.557% Notes due 2027;
- 4.390% Notes due 2037;
- 4.540% Notes due 2047; and
- Floating Rate Notes due 2022.

B. Description of BAT Ordinary Shares and American Depositary Shares

DESCRIPTION OF BAT ORDINARY SHARES

The following is a summary of the material terms of (1) the BAT ordinary shares as set forth in the BAT articles of association; (2) English law insofar as it applies to the BAT ordinary shares; and (3) the BAT articles of association, which were adopted pursuant to a special resolution (as defined below) on April 28, 2010. Please note that this is only a summary, and may not contain all of the relevant information.

BAT Articles of Association

BAT is registered in England and Wales under the UK Companies Act 2006 with company registration number 3407696. BAT’s purposes and objects are not restricted.

Share Capital

As at December 31, 2021, the issued and fully paid share capital of BAT was 2,456,617,788 ordinary shares, each with a nominal value of 25 pence. Of this number, 161,930,217 ordinary shares were registered as treasury shares. There are no acquisition rights or obligations in relation to the issue of BAT ordinary shares in the capital of BAT or an undertaking to increase the capital of BAT. There are no convertible securities, exchangeable securities or securities with warrants in BAT.

BAT ordinary shares are fully paid and, accordingly, no further contribution of capital may be required by BAT from the holders of BAT ordinary shares.
Further Issuances of Share Capital and Preemptive Rights

Pursuant to the UK Companies Act 2006, BAT’s directors are, with certain exceptions, not permitted to allot any equity securities without express authorization from BAT’s shareholders. Further, under the UK Companies Act 2006, BAT may not issue shares for cash (other than pursuant to an employee share scheme) without first making an offer to existing shareholders to allot such shares to them on the same or more favorable terms in proportion to their respective shareholdings, unless this requirement is waived by a special resolution of the shareholders. See “—Voting Rights” for an explanation of the requirements for approval of a special resolution.

Subject to receipt of authorization from BAT’s shareholders, the directors may issue shares with such rights or restrictions, including shares that are redeemable at the option of BAT or the shareholder, as the directors or BAT by ordinary resolution may determine. See “—Voting Rights” for an explanation of the requirements for approval of an ordinary resolution.

Throughout this section, references to shares of BAT refer to any shares that may be issued out of the capital of BAT, including BAT ordinary shares.

Changes to the Share Capital

Shareholder approval by ordinary resolution is required for BAT to:

- consolidate and divide all or any of its share capital into shares of larger nominal amount than its existing shares;
- sub-divide its shares, or any of them, into shares of smaller nominal amount than its existing shares; and
- determine that, as between the shares resulting from such a sub-division, any of the shares may have any preference or advantage as compared with the others.

The UK Companies Act 2006 contains the procedural requirements for a reduction of capital. The reduction of capital must be approved by shareholders by special resolution, and must be approved by a court. The decision to approve the reduction is at the court’s discretion, and it will consider whether (a) the reduction is for a discernible purpose, (b) all shareholders are treated equally, (c) the reduction has been properly explained to shareholders and (d) the company’s creditors are safeguarded. Subject to these requirements, BAT may reduce its share capital, its capital redemption reserve and any share premium account in any way.

Repurchase of Shares

Once approved by BAT shareholders by ordinary resolution and subject to certain procedural requirements of the UK Companies Act 2006, BAT may repurchase its own shares, including any BAT ordinary shares and any redeemable shares that may be issued. Any shares which have been repurchased may be held as treasury shares or, if not so held, must be canceled immediately upon the completion of the purchase, thereby reducing the amount of BAT’s issued share capital.

4
Dividends

BAT shareholders may by ordinary resolution declare dividends in accordance with the respective rights of the shareholders but no dividends shall exceed the amount recommended by the directors. No dividend shall be paid other than out of profits available for distribution as specified in the UK Companies Act 2006. The directors may pay interim dividends or dividends payable at a fixed rate, if it appears to them that they are justified by the profits of BAT available for distribution. If the directors act in good faith, they shall not incur any liability to the holders of shares conferring preferred rights for any loss they may suffer by the lawful payment of an interim dividend on any shares having deferred or non-preferred rights, including the BAT ordinary shares.

BAT ordinary shares carry the right to receive dividends and distributions that have been declared by BAT on a pro rata basis but have no other right to share in the profits of BAT and are not entitled to any fixed income. BAT may issue shares that rank prior to the BAT ordinary shares in respect of payment of dividends.

BAT shareholders may, at a general meeting declaring a dividend, upon the recommendation of the directors and by ordinary resolution, direct that the payment of all or any part of the dividend be satisfied by the distribution of specific assets and, where any difficulty arises in regard to the distribution, the directors may settle the same as they think fit.

The directors may, with the approval of BAT shareholders by ordinary resolution, offer any holders of BAT ordinary shares the right to elect to receive BAT ordinary shares, credited as fully paid, instead of cash in respect of the whole (or some part, to be determined by the directors) of any dividend. BAT or the directors may fix a date as the record date by reference to which a dividend will be declared or paid or a distribution, allotment or issue made, and that date may be before, on or after the date on which the dividend, distribution, allotment or issue is declared.

No dividend or other money payable in respect of a share shall bear interest against BAT, unless otherwise provided by the rights attached to the share. Dividends or other distributions paid in respect of BAT ordinary shares do not bear interest.

The directors may elect to pay dividends solely by means of electronic transfer, or such other method as the directors deem appropriate and which method may be different for different holders or groups of holders of shares, to an account nominated in writing by the holder of the shares. Amounts due to shareholders who provide no, or invalid, account details may be held in an account in BAT’s name until such shareholders nominate a valid account.

BAT may cease sending dividend payments in respect of any shares if these payments have been returned undelivered to, or left uncashed by, the shareholder on at least two consecutive occasions or, if following one such occasion, reasonably inquiries have failed to establish a shareholder’s new address. BAT must recommence sending payments for dividends payable on that share if the person(s) entitled so request and have supplied in writing a new address or account to be used for that purpose.
Any dividend which has remained unclaimed for 12 years from the date when it became due for payment will, if the directors so resolve, be forfeited and cease to remain owing by BAT.

Voting Rights
All BAT ordinary shares have equal voting rights and are entitled to attend and vote at all general meetings of BAT. BAT may issue, subject to the restrictions discussed above under the caption “—Share Capital—Further Issuances of Share Capital and Preemptive Rights” shares with preferential voting rights. This section assumes that all shares have equal voting rights and that no preferential shares are issued.

Under English law, resolutions to be voted on by shareholders at a general meeting can be either an ordinary resolution, which means that the resolution must be passed by a simple majority of shareholders or holders of a simple majority of the shares (depending on whether the vote is by a show of hands or by a poll) present in person or by proxy and entitled to vote at the general meeting, or a special resolution, which means that the resolution must be passed by a majority of not less than 75% of the shareholders or holders of 75% of the shares (depending on whether the vote is by a show of hands or by a poll) present in person or by proxy and entitled to vote at the general meeting. For a resolution to be regarded as a special resolution, the notice of the general meeting must specify the intention to propose the resolution as a special resolution.

A resolution put to the vote of a general meeting must be decided on a show of hands unless either the notice of the meeting specifies that a poll will be called on such resolution or a poll is (before the resolution is put to the vote on a show of hands or immediately after the result of a show of hands on that resolution is declared) demanded by:

•  the chairman of the meeting;
•  a majority of the directors present at the meeting;
•  not less than five shareholders having the right to vote at the meeting;
•  a shareholder or shareholders representing not less than one-tenth of the total voting rights of all the shareholders having the right to vote at the meeting (excluding any voting rights attached to any shares in BAT held as treasury shares); or
•  a shareholder or shareholders holding shares conferring a right to vote on the resolution on which an aggregate sum has been paid up equal to not less than one-tenth of the total sum paid up on all the shares conferring that right (excluding any shares in BAT conferring a right to vote at the meeting which are held as treasury shares).

On a show of hands, every shareholder who is present in person has one vote regardless of the number of shares held by such shareholder. Every proxy duly appointed by one or more shareholders entitled to vote on the resolution and present has one vote, except that if the proxy has been duly appointed by more than one shareholder entitled to vote and is instructed by one or
more of those shareholders to vote for the resolution and by one or more others to vote against it, or is instructed by one or more of those shareholders to vote in one way and is given discretion as to how to vote by one or more others (and wishes to use that discretion to vote in the other way) he has one vote for and one vote against the resolution.

On a poll every shareholder present in person or by duly appointed proxy has one vote for every share held by the shareholder. A shareholder or his, her or its duly appointed proxy entitled to more than one vote need not use all his, her or its votes or cast all the votes he, she or it uses the same way.

For the purposes of determining which persons are entitled to attend or vote at a general meeting, BAT may specify in the notice convening the meeting a time, not more than 48 hours before the time fixed for the meeting (not including any part of a day that is not a working day), by which a person must be entered on the register in order to have the right to attend or vote at the meeting.

In the case of joint holders, the most senior of the joint holders who tenders a vote shall be accepted to the exclusion of the votes of the other joint holders, and seniority shall be determined by the order in which the names of the holders stand in the register of shareholders.

If any shares are issued by BAT that are not fully paid, holders of those shares will not be permitted to vote at any general meeting or at any separate meeting of the holders of that class of shares, either in person or by proxy, unless all amounts presently payable by such holder in respect of that share have been paid.

There are no limitations under BAT’s articles of association restricting the right of non-UK resident or foreign owners to hold or vote ordinary shares in BAT.

Transfer of the Shares

A share in certificated form may be transferred by an instrument of transfer which may be in any usual form or in any other form approved by the directors, executed by or on behalf of the transferor and, where the share is not fully paid, by or on behalf of the transferee. A share in uncertificated form may be transferred by means of the relevant system concerned. The transfer may not be in favor of more than four transferees.

In their absolute discretion, the directors may refuse to register the transfer of a share in certificated form which is not fully paid provided that if the share is listed on the Official List of the Financial Conduct Authority such refusal does not prevent dealings in the shares from taking place on an open and proper basis. The directors may also refuse to register a transfer of a share in certificated form (whether fully paid or not) unless the instrument of transfer:

- is lodged, duly stamped, at the registered office of BAT or such other place as the directors may appoint and is accompanied by the certificate for the share to which it relates and such other evidence as the directors may reasonably require to show the right of the transferor to make the transfer;

- is in respect of only one class of share; and
• is not in favor of more than four transferees.

The directors may refuse to register a transfer of a share in uncertificated form to a person who is to hold it thereafter in certificated form in any case where BAT is entitled to refuse to register the transfer under the Uncertificated Securities Regulations 2001.

If the directors refuse to register a transfer of a share, they shall as soon as practicable and in any event within two months after the date on which the transfer was lodged with BAT (in the case of a transfer of a share in certificated form) or the date on which the operator-instruction was received by BAT (in the case of a transfer of a share in uncertificated form which will be held thereafter in certificated form) send to the transferee notice of the refusal together with reasons for the refusal. The directors shall send to the transferee such further information about the reasons for the refusal to the transferee as the transferee may reasonably request.

No fee shall be charged for the registration of any instrument of transfer or other document or instruction relating to or affecting the title to any share.

For uncertificated shares, transfers shall be registered only in accordance with the terms of the Uncertificated Securities Regulations 2001.

**Distribution of Assets on a Winding-up**

If BAT is wound up, the liquidator may, with the sanction of a special resolution and any other sanction required by law, divide among the shareholders in specie the whole or any part of the assets of BAT and may, for that purpose, value any assets and determine how the division shall be carried out as between the shareholders or different classes of shareholders. The liquidator may, with the like sanction, vest the whole or any part of the assets in trustees upon such trusts for the benefit of the shareholders as he may with the like sanction determine, but no shareholder shall be compelled to accept any assets upon which there is a liability.

**Disclosure of Shareholding Ownership**

There are no provisions in BAT’s articles of association whereby persons acquiring, holding or disposing of a certain percentage of BAT’s ordinary shares are required to make disclosure of their ownership percentage, although there are such requirements under statute and regulation.

**Untraced Shareholders**

BAT is entitled to sell at the best price reasonably obtainable any share held by a shareholder, or any share to which a person is entitled by transmission of the title of such share if:

- for a period of 12 years, no payment for amounts payable in respect of the share sent and payable in a manner authorized by the articles of association has been cashed or effected and no communication has been received by BAT from the shareholder or person concerned;
• during that period BAT has paid at least three cash dividends (whether interim or final) and no such dividend has been claimed by the shareholder or person concerned;
• BAT has, after the expiration of that period, by advertisement in a national newspaper published in the United Kingdom and in a newspaper circulating in the area of the registered address or last known address of the shareholder or person concerned, given notice of its intention to sell such share, and the advertisements, if not published on the same day, shall have been published within 30 days of each other; and

BAT will be indebted to the former shareholder or other person previously entitled to the share for an amount equal to the net proceeds of the sale, but no trust or duty to account shall arise and no interest shall be payable in respect of the proceeds of sale.
• BAT has not, during the further period of three months following the date of publication of the advertisements (or, if published on different dates, the later or latest of them) and prior to the sale of the share, received any communication from the shareholder or person concerned.

If, on three consecutive occasions, notices, documents or information sent or supplied to a shareholder have been returned undelivered, the shareholder shall not be entitled to receive any subsequent notice, document or information until he has supplied to BAT (or its agent) a new registered address, or a postal address within the United Kingdom or the Republic of South Africa, or shall have informed BAT of an electronic address.

Variation of Rights
If at any time the capital of BAT is divided into different classes of shares, the rights attached to any class may be varied, either while BAT is a going concern or during or in contemplation of a winding up in such manner (if any) as may be provided by those rights (depending on the drafting of those rights, they may be more significant than is required by law) or if there are no such provisions either with the consent in writing of the holders of three-quarters in nominal value of the issued shares of that class (not including any treasury shares), or with the approval of shareholders by a special resolution passed at a separate meeting of the holders of such shares, but not otherwise.

To every such separate meeting the provisions of the articles of association relating to general meetings shall apply, except that the quorum for any such meeting shall be two persons together holding or representing by proxy at least one-third in nominal value of the issued shares of the class in question (excluding treasury shares). At an adjourned meeting, the quorum shall be one person holding shares of the class in question (excluding treasury shares) or his, her or its proxy.

Unless otherwise expressly provided by the rights attached to any class of shares, those rights shall be deemed not to be varied by the purchase by BAT of any of its own shares or the holding of such shares in treasury.
Change of Control and Takeovers

BAT is subject to the City Code on Takeovers and Mergers, which governs the conduct of mergers and takeovers in the UK.

An English public limited company such as BAT may be acquired in a number of ways, including by means of a scheme of arrangement (as defined below) between the company and its shareholders or by means of a takeover offer.

A scheme of arrangement is a statutory procedure under the UK Companies Act 2006 pursuant to which the English courts may approve an arrangement between an English company and some or all of its shareholders. In a scheme of arrangement, the company would make an initial application to the court to convene a meeting or meetings of its shareholders at which a majority in number of shareholders representing 75% of the voting rights of the shareholders present and voting either in person or by proxy at the meeting must agree to the arrangement by which they will sell their shares in exchange for the consideration being offered by the bidder. If the shareholders so agree, the company will return to court to request the court to sanction the arrangement. Upon such a scheme of arrangement becoming effective in accordance with its terms and the UK Companies Act 2006, it will bind the company and such shareholders.

A takeover offer is an offer to acquire all of the outstanding shares of a company (other than shares which at the date of the offer are already held by the bidder). Under the City Code on Takeovers and Mergers and in order to squeeze out dissenting shareholders, the offer must be made on identical terms to all holders of shares to which the offer relates. If the bidder, by virtue of acceptances of the offer, acquires or contracts to acquire not less than 90% in value of the shares to which the offer relates representing not less than 90% of the voting rights owned by the shares, the UK Companies Act 2006 allows the bidder to give notice to any non-accepting shareholder that the bidder intends to acquire his, her or its shares through a compulsory acquisition (also referred to as a squeeze out), and the shares of such nonaccepting shareholders will be acquired by the bidder six weeks later on the same terms as the offer, unless the shareholder objects to the English court and the court enters an order that the bidder is not entitled to acquire the shares or specifying terms of the acquisition different from those of the offer.

The UK Companies Act 2006 permits a scheme of arrangement or takeover offer to be made relating only to a particular class or classes of a company’s shares.

As BAT is a UK premium listed company, if it were subject to a takeover bid and the takeover were structured as a contractual takeover offer, under the UK Listing Rules a bidder would have to, by virtue of its shareholdings and acceptances of its takeover offer, acquire or agree to acquire shares carrying 75% of the voting rights of BAT before it could cancel BAT’s listing on the Main Market of the LSE.

Where the takeover is by way of a scheme of arrangement, the UK Listing Rules do not impose any additional rules as regards shareholder approval or the level of acceptances required before BAT could be delisted, as the scheme procedure provides sufficient protection for shareholders.
There are no provisions in BAT’s articles of association that would have the effect of delaying, deferring or preventing a takeover, or change of control, of BAT.

Under English law, BAT’s directors have a fiduciary duty to take only those actions that are in the interests of BAT and any anti-takeover devices employed by the directors in the future, if any, must accordingly be in the interests of BAT.

However, under the City Code on Takeovers and Mergers, if an acquisition of BAT ordinary shares increases the aggregate holding of an acquirer and persons acting in concert with the acquirer (i.e., persons who, pursuant to an agreement or understanding, cooperate to obtain or consolidate control of a company or to frustrate the successful outcome of an offer for a company) to shares carrying 30% or more of the voting rights in BAT, the acquirer and, depending on the circumstances, its concert parties, would be required (except with the consent of the Panel on Takeovers and Mergers) to make a cash offer for the outstanding BAT ordinary shares at a price not less than the highest price paid for the BAT ordinary shares by the acquirer or its concert parties during the previous 12 months. This requirement would also be triggered by any acquisition of shares by a person holding (together with its concert parties) shares carrying between 30 and 50% of the voting rights in BAT if the effect of such acquisition were to increase that person’s percentage of the voting rights.

General Meetings
An annual general meeting of shareholders must be held every year within a period of six months of the day following BAT’s financial year end (which is December 31), at such place or places, date and time as may be decided by the directors.

Ability to Call General Meetings
The directors may call general meetings. If there are not sufficient directors to form a quorum in order to call a general meeting, any director may call a general meeting. If there is no director, any shareholder of BAT may call a general meeting.

The directors are required to call a general meeting if requested by shareholders representing at least 5% of the paid-up capital of BAT as carries the right of voting at general meetings (excluding any paid-up capital held as treasury shares). Such meeting must be called within 21 days from the date on which the directors become subject to the requirement, and held on a date not more than 28 days after the date of the notice calling the meeting. A meeting called upon the request of shareholders may only deal with the business stated in the request by shareholders, or as proposed by the directors. If the directors fail to call the general meeting requested by the shareholders, the shareholders who requested the meeting, or any of them representing more than one half of the total voting rights of all of them, may themselves call a general meeting. Such meeting must be called for a date not more than three months after the date on which the directors become subject to the requirement to call a meeting. Any reasonable expenses incurred by the shareholders requesting the meeting by reason of the failure of the directors duly to call a meeting must be reimbursed by the company.
Notice of General Meetings

Pursuant to the UK Companies Act 2006, an annual general meeting and all other general meetings of BAT must be called by at least 21 clear days’ written notice (the “clear days” rule is set out in section 360 of the UK Companies Act 2006 and excludes the day of the meeting and the day that the notice is given). However, the UK Companies Act 2006 allows for this period of notice for meetings other than annual general meetings to be reduced to 14 clear days’ notice provided that: (1) the company allows its shareholders to make proxy appointments via a website (such as one hosted by its share registrars); and (2) shareholders must pass a special resolution at the annual general meeting every year approving the shortening of the notice period to 14 days.

A special resolution enabling BAT to hold general meetings (other than annual general meetings) on 14 clear days’ notice was approved at the last annual general meeting held on April 25, 2019.

The notice shall specify the place, the date and the time of meeting and the general nature of the business to be transacted, and in the case of an annual general meeting shall specify the meeting as such. Where BAT has given an electronic address in any notice of meeting, any document or information relating to proceedings at the meeting may be sent by electronic means to that address, subject to any conditions or limitations specified in the relevant notice of meeting. Subject to the provisions of the articles of association described above under “—Untraced shareholders” and to any rights or restrictions attached to any shares, notices shall be given to all shareholders, to all persons entitled to a share in consequence of the death or bankruptcy of a shareholder and to the BAT directors and to the BAT Group’s auditors. Any notice to be given to a shareholder may be given by reference to the register of shareholders as it stands at any time within the period of 21 days before the notice is given; and no change in the register after that time shall invalidate the giving of the notice.

A shareholder whose registered address is not within the United Kingdom or the Republic of South Africa shall be entitled to receive any notice, document or information from BAT if he, she or it gives BAT an address (not being an electronic address) within the United Kingdom or the Republic of South Africa at which notices, documents or information may be sent or if the directors are satisfied that the sending or supplying of such notices, documents or information by BAT to such address outside of the United Kingdom or the Republic of South Africa would not result in BAT breaching any applicable law (whether in the United Kingdom, Republic of South Africa, or elsewhere) or result, directly or indirectly, in BAT being required to comply with additional filing or other regulatory requirements in the United Kingdom, the Republic of South Africa, or any other jurisdiction.

Where, by reason of any suspension or curtailment of postal services, BAT is unable effectively to give notice of a general meeting, the directors may decide that the only persons to whom notice of the affected general meeting must be sent are: the directors; BAT’s auditors; those shareholders to whom notice to convene the general meeting can validly be sent by electronic means and those shareholders to whom notification as to the availability of the notice of meeting on a website can validly be sent by electronic means. In any case, BAT shall also: (a) advertise the general meeting in at least two national newspapers published in the United Kingdom; and (b) send or supply a confirmatory copy of the notice to shareholders in accordance with its articles of association if at least seven clear days before the meeting the posting of notices again becomes practicable.
Quorum
No business shall be transacted at any general meeting unless a quorum is present. Two persons entitled to vote upon the business to be transacted, each being a shareholder or a proxy for a shareholder or a duly authorized representative of the corporation which is a shareholder (including for this purpose two persons who are proxies or corporate representatives of the same shareholder), shall be a quorum.

Attendance at General Meetings
All shareholders may attend, speak and vote at BAT general meetings (including annual general meetings). A shareholder is entitled to appoint another person as his, her or its proxy to exercise all or any of his, her or its rights to attend and to speak and vote at a meeting of BAT. The appointment of a proxy shall be deemed also to confer authority to demand or join in demanding a poll. Delivery of an appointment of proxy shall not preclude a shareholder from attending and voting at the meeting or at any adjournment of it. A proxy need not be a shareholder. A shareholder may appoint more than one proxy in relation to a meeting, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by him, her or it. An appointment of proxy shall be in writing in any usual form or in any other form which the directors may approve and shall be executed by or on behalf of the appointor which in the case of a corporation may be either under its common seal or under the hand of a duly authorized officer or attorney or other person duly authorized for that purpose. Subject to the provisions of the UK Companies Act 2006, any corporation (other than BAT itself) which is a shareholder of BAT may, by resolution of its directors or other governing body, authorize such person(s) to act as its representative(s) at any meeting of BAT, or at any separate meeting of the holders of any class of shares. BAT may require such person(s) to produce a certified copy of the resolution before permitting him, her or it to exercise his, her or its powers. The directors may (and shall if and to the extent that BAT is required to do so by the UK Companies Act 2006) allow an appointment of proxy to be sent or supplied in electronic form subject to any conditions or limitations as the directors may specify.

The directors or the chairman of the meeting may direct that any person wishing to attend any general meeting should submit to and comply with such searches or other security arrangements as they or he or she consider appropriate in the circumstances. The directors or the chairman of the meeting may in their or his or her absolute discretion refuse entry to, or eject from, any general meeting any person who refuses to submit to a search or otherwise comply with such security arrangements.

The directors or chairman of the meeting may take such action, give such direction or put in place such arrangements as they or he or she consider appropriate to secure the safety of the people attending the meeting and to promote the orderly conduct of the business of the meeting. Any decision of the chairman of the meeting on matters of procedure or matters arising incidentally from the business of the meeting, and any determination by the chairman of the meeting as to whether a matter is of such a nature, shall be final.

13
The directors may make arrangements for simultaneous attendance and participation by electronic means allowing persons not present together at the same place to attend, speak and vote at the meeting (including the use of satellite meeting places). The arrangements for simultaneous attendance and participation at any place at which persons are participating using electronic means may include arrangements for controlling or regulating the level of attendance at any particular venue provided that such arrangements shall operate so that all shareholders and proxies wishing to attend the meeting are able to attend at one or other of the venues.

DESCRIPTION OF BAT AMERICAN DEPOSITARY SHARES

Citibank, N.A. is the depositary bank for the BAT ADSs. Citibank’s depositary offices are located at 388 Greenwich Street, New York, New York 10013. American Depositary Shares are frequently referred to as ADSs and represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as “American Depositary Receipts” or “ADRs.” The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A., London Branch, located at Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB England.

BAT has appointed Citibank as depositary bank pursuant to the deposit agreement. A copy of the deposit agreement and each amendment thereto is on file with the SEC under cover of a Registration Statement on Form F-6EF. A copy of the deposit agreement and each amendment thereto may be obtained from the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and from the SEC’s website at www.sec.gov. Please refer to Registration Number 333-221983 when retrieving such copy.

The following summarizes the material terms of the BAT ADSs and the material rights of owners of BAT ADSs. This summary does not purport to be complete and may not contain all of the important information about the BAT ADSs. The rights and obligations of an owner of BAT ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of BAT ADSs but that may not be contained in the deposit agreement.

Each BAT ADS represents the right to receive, and to exercise the beneficial ownership interests in, one BAT ordinary share that is on deposit with the depositary bank and/or custodian. A BAT ADS also represents the right to receive, and to exercise the beneficial interests in, any other property (including cash) received by the depositary bank or the custodian on behalf of the owners of BAT ADSs but that has not been distributed to the owners of BAT ADSs because of legal restrictions or practical considerations. The BAT ordinary shares deposited with the depositary bank and/or the custodian and any and all other securities, property and cash held by the depositary bank and/or custodian in respect thereof are referred to as the deposited securities. BAT and the depositary bank may agree to change the ADS-to-BAT ordinary share ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary bank services fees payable by BAT ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited securities for the benefit of the holders (i.e., the persons in whose name the BAT ADSs are registered on the books of the depositary bank) and beneficial owners of BAT ADSs. The deposited securities do not constitute the proprietary assets.
of the depositary bank, the custodian or their nominees. Beneficial ownership in the deposited securities will under the terms of the deposit agreement be vested in the beneficial owners of the BAT ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited securities represented by the BAT ADSs for the benefit of the holders and beneficial owners of the corresponding BAT ADSs. A beneficial owner of BAT ADSs may or may not be the holder of BAT ADSs. Beneficial owners of BAT ADSs will be able to receive any benefit in, and to exercise beneficial ownership interests in, the deposited securities only through the registered holders of the BAT ADSs, the registered holders of the BAT ADSs (on behalf of the applicable BAT ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding BAT ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. The depositary bank and BAT may deem and treat the registered holder of an ADS as the absolute owner of such ADS for all purposes and neither the depositary bank nor BAT will have any obligation or be subject to any liability under the deposit agreement or any ADR to any holder or beneficial owner of ADSs unless, in the case of a holder of ADSs, such holder is the registered holder or, in the case of a beneficial owner, such beneficial owner or its representative is the registered holder.

Owners of BAT ADSs become party to the deposit agreement and therefore are bound to its terms and to the terms of any ADR that represents such BAT ADSs. The deposit agreement and the ADRs specify the rights and obligations of BAT as well as the rights and obligations of owners of BAT ADSs and those of the depositary bank. BAT ADS holders appoint the depositary bank to act on their behalf in certain circumstances.

In addition, applicable laws and regulations may require BAT ADS holders to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. BAT ADS holders are solely responsible for complying with such reporting requirements and obtaining such approvals. None of the depositary bank, the custodian, BAT or any of their respective agents or affiliates shall be required to take any actions whatsoever on behalf of BAT ADS holders to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.

BAT will not treat an owner of BAT ADSs as one of its shareholders, and BAT ADS holders will not have direct shareholder rights. The depositary bank will hold the shareholder rights attached to the BAT ordinary shares underlying the BAT ADSs. Owners of BAT ADSs will be able to exercise the shareholder rights for the BAT ordinary shares represented by the BAT ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement a BAT ADS owner must arrange for the cancellation of their BAT ADSs and become a direct shareholder of BAT.

An Owner of BAT ADSs may hold its BAT ADSs either by means of an ADR registered in its name, through a brokerage or safekeeping account, or through an account established by the depositary bank in its name reflecting the registration of uncertificated BAT ADSs directly on the books of the depositary bank (commonly referred to as the direct registration system or DRS). The direct registration system reflects the uncertificated (book-entry) registration of ownership of BAT ADSs by the depositary bank. Under the direct registration system, ownership of BAT ADSs is evidenced by periodic statements issued by the depositary bank to the holders.
of the BAT ADSs. The direct registration system includes automated transfers between the depositary bank and the Depositary Trust Company, referred to as DTC. If a BAT ADS holder decides to hold BAT ADSs through a brokerage or safekeeping account, the holder must rely on the procedures of the broker or bank to assert its rights as BAT ADS owner. Banks and brokers typically hold securities such as the BAT ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit a BAT ADS holder’s ability to exercise its rights as an owner of BAT ADSs. All BAT ADSs held through DTC will be registered in the name of a nominee of DTC.

The registration of the BAT ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable BAT ordinary shares with the beneficial ownership rights and interests in such BAT ordinary shares being at all times vested with the beneficial owners of the BAT ADSs representing the BAT ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited securities, in each case only on behalf of the holders and beneficial owners of the BAT ADSs representing the deposited securities.

**Dividends and Distributions**

Holders of BAT ADSs generally have the right to receive the distributions, including dividends, BAT makes on the deposited securities. Receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of BAT ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of BAT ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses.

**Distributions of Cash**

Whenever BAT makes a cash distribution, including any cash dividend, on any deposited securities, it will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the laws and regulations of England and Wales.

The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of any deposited securities. For further information regarding the conversion of funds into U.S. dollars, see “—Foreign Currency Conversion”.

The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of BAT ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States.
Distributions of BAT Ordinary Shares

Whenever BAT makes a free distribution, including any dividend, of BAT ordinary shares on the deposited securities, it will deposit the applicable number of BAT ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will either distribute to holders new BAT ADSs representing the BAT ordinary shares deposited or modify the ADS-to-BAT ordinary share ratio, in which case each BAT ADS held will represent rights and interests in the additional BAT ordinary shares so deposited. Only whole new BAT ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution.

The distribution of new BAT ADSs or the modification of the ADS-to-BAT ordinary share ratio upon a distribution of BAT ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new BAT ordinary shares so distributed.

No such distribution of new BAT ADSs will be made if it would violate a law (e.g., the U.S. securities laws). If the depositary bank does not distribute new BAT ADSs as described above, it may sell the BAT ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.

Distributions of Rights

Whenever BAT intends to distribute to the holders of BAT ordinary shares rights to subscribe for additional BAT ordinary shares, it will give prior notice to the depositary bank and will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional BAT ADSs to holders.

The depositary bank will establish procedures to distribute rights to subscribe for additional BAT ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of BAT ADSs, and if BAT provides all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). BAT ADS holders may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new BAT ADSs upon the exercise of their rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new BAT ordinary shares other than in the form of BAT ADSs.

The depositary bank will not distribute the rights to BAT ADS holders if:

• BAT does not timely request that the rights be distributed to BAT ADS holders;
• BAT requests that the rights not be distributed to BAT ADS holders;
• BAT fails to deliver satisfactory documents to the depositary bank; or
• it is not reasonably practicable to distribute the rights.
The depositary bank, upon consultation with BAT, will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale, net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement, will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse.

**Elective Distributions**

Whenever BAT intends to make a distribution, including any dividend, on BAT ordinary shares payable at the election of shareholders either in cash or in additional BAT ordinary shares, it will give prior notice thereof to the depositary bank and will indicate whether it wishes the elective distribution to be made available to BAT ADS holders. In such case, BAT will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable.

The depositary bank will make the election available to BAT ADS holders only if it is reasonably practicable and if BAT has provided all of the documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable BAT ADS holders to elect to receive either cash or additional BAT ADSs, in each case as described in the deposit agreement.

If the election is not made available to BAT ADS holders, they will receive either cash or additional BAT ADSs, depending on what a shareholder in England and Wales would receive upon failing to make an election, as more fully described in the deposit agreement.

**Other Distributions**

Whenever BAT intends to distribute to the holders of BAT ordinary shares property other than cash, BAT ordinary shares or rights to subscribe for additional BAT ordinary shares, it will notify the depositary bank in advance and will indicate whether it wishes such distribution to be made to BAT ADS holders. If so, BAT will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable.

If it is reasonably practicable to distribute such property to BAT ADS holders and if BAT provides to the depositary bank all of the documentation contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable.

The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received.

The depositary bank will not distribute the property to BAT ADS holders and will sell the property if:

- BAT does not request that the property be distributed to BAT ADS holders or if BAT requests that the property not be distributed to BAT ADS holders;
- BAT does not deliver satisfactory documents to the depositary bank; or
• the depositary bank determines that all or a portion of the distribution to BAT ADS holders is not reasonably practicable.

The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.

Redemption
Whenever BAT decides to redeem any of the deposited securities held by the custodian, it will notify the depositary bank in advance. If it is practicable and if BAT provides all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders.

The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price for deposited securities. The depositary bank will convert any redemption funds received in a currency other than U.S. dollars into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their BAT ADSs to the depositary bank. BAT ADS holders may have to pay fees, expenses, taxes and other governmental charges upon the redemption of their BAT ADSs. If less than all BAT ADSs are being redeemed, the BAT ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary bank may determine.

Changes Affecting Deposited Securities
The deposited securities represented by BAT ADSs may change from time to time. For example, there may be a change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of such deposited securities or a recapitalization, reorganization, merger, consolidation or sale of assets of BAT.

If any such change were to occur, BAT ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the deposited securities. In such circumstances, the depositary bank may, with BAT’s approval and if BAT requests, deliver new BAT ADSs, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form F-6, call for the exchange of existing BAT ADSs for new BAT ADSs and take any other actions that are appropriate to reflect as to the BAT ADSs the change affecting the BAT ordinary shares. If the depositary bank may not lawfully distribute such property, the depositary bank may, with BAT’s approval and if BAT requests, sell such property and distribute the net proceeds as in the case of a cash distribution.

Issuance of BAT ADSs upon Deposit of BAT Ordinary Shares
The depositary bank may create BAT ADSs on behalf of a BAT ADS holder if it or its broker deposits BAT ordinary shares with the custodian. The depositary bank will deliver these BAT ADSs to the person indicated by the BAT ADS holder only after any applicable issuance fees and any charges and taxes payable for the transfer of the BAT ordinary shares to the custodian are paid. A BAT ADS holder’s ability to deposit BAT ordinary shares and receive BAT ADSs may be limited by U.S. and England and Wales legal considerations applicable at the time of deposit.
The issuance of BAT ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the BAT ordinary shares have been duly transferred to the custodian. The depositary bank will only issue BAT ADSs in whole numbers.

When BAT ADS holders make a deposit of BAT ordinary shares, they will be responsible for transferring good and valid title to the depositary bank. As such, they will be deemed to represent and warrant that:

- the BAT ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained;
- all preemptive (and similar) rights, if any, with respect to such BAT ordinary shares have been validly waived or exercised;
- they are duly authorized to deposit the BAT ordinary shares;
- the BAT ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the BAT ADSs issuable upon such deposit will not be, “restricted securities” (as defined in the deposit agreement); and
- the BAT ordinary shares presented for deposit have not been stripped of any rights or entitlements.

If any of the representations or warranties are incorrect in any way, BAT and the depositary bank may, at the holder’s cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations.

Transfer, Combination and Split Up of ADRs

ADR holders will be entitled to transfer, combine or split up their ADRs and the BAT ADSs evidenced thereby. For transfers of ADRs, they will have to surrender the ADRs to be transferred to the depositary bank and also must:

- ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
- provide any transfer stamps required by the State of New York or the United States; and
- pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement and applicable law, upon the transfer of ADRs.

To have ADRs either combined or split up, BAT ADS holders must surrender the ADRs in question to the depositary bank with a request to have them combined or split up, and they must pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement and applicable law, upon a combination or split up of ADRs.
The depositary bank may require a holder to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will transfer, combine or split up ADRs and the BAT ADSs evidenced thereby.

BAT may restrict transfers of BAT ordinary shares where such transfer might result in ownership of BAT ordinary shares exceeding limits imposed by applicable law or the articles of association of BAT. BAT may also restrict, in such manner as it deems appropriate, transfers of BAT ADSs where such transfer may result in the total number of BAT ordinary shares represented by BAT ADSs owned by a single holder or beneficial owner to exceed any such limits. BAT may, in its sole discretion but subject to applicable law, instruct the depositary bank to take action with respect to the ownership interest of any holder or beneficial owner in excess of such limits, including the imposition of restrictions on the transfer of BAT ADSs, the removal or limitation of voting rights or mandatory sale or disposition on behalf of a holder or beneficial owner of the BAT ordinary shares represented by the BAT ADSs held by such holder or beneficial owner in excess of such limitations, if and to the extent such disposition is permitted by applicable law and the articles of association of BAT.

Withdrawal of Deposited Securities upon Cancellation of BAT ADSs

Holders will be entitled to present their BAT ADSs to the depositary bank for cancellation and then receive the corresponding number of underlying deposited securities at the custodian’s offices. The ability to withdraw the deposited securities held in respect of the BAT ADSs may be limited by U.S. and England and Wales legal considerations applicable at the time of withdrawal. In order to withdraw the deposited securities represented by BAT ADSs, holders will be required to pay to the depositary bank the fees for cancellation of BAT ADSs and any charges and taxes payable upon the transfer of the deposited securities. BAT ADS holders assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the BAT ADSs will not have any rights under the deposit agreement.

If holders hold BAT ADSs registered in their name, the depositary bank may ask them to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel their BAT ADSs. The withdrawal of the deposited securities represented by BAT ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept BAT ADSs for cancellation that represent a whole number of deposited securities.

BAT ADS holders will have the right to withdraw the deposited securities represented by their BAT ADSs at any time except for:

- temporary delays that may arise because (1) the transfer books for the BAT ordinary shares or BAT ADSs are closed, or (2) the deposit of BAT ordinary shares in connection with voting at a shareholders' meeting or a payment of dividends;
• obligations to pay fees, taxes and similar charges; and
• restrictions imposed because of laws or regulations applicable to BAT ADSs or the withdrawal of the deposited securities.

The deposit agreement may not be modified to impair the right to withdraw the securities represented by BAT ADSs except to comply with mandatory provisions of law.

Voting Rights

Holders generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the BAT ordinary shares represented by their BAT ADSs. For more information on the voting rights of holders of BAT ordinary shares see “Description of BAT Ordinary Shares — Voting Rights”.

At BAT’s request, the depositary bank will distribute to BAT ADS holders any notice of shareholders’ meeting (or solicitation of consent or proxy) timely received from BAT together with information explaining how to instruct the depositary bank to exercise the voting rights of the deposited securities. In lieu of distributing such materials, the depositary bank may distribute to holders of BAT ADSs instructions on how to retrieve such materials upon request.

If the depositary bank timely receives voting instructions from a holder of BAT ADSs, it will, to the extent practicable and permitted under applicable law, the deposit agreement and the BAT articles of association, endeavor to vote the deposited securities (in person or by proxy) represented by the holder’s BAT ADSs in accordance with such voting instructions as follows:

• in the event of voting by show of hands, the depositary bank will vote or cause the custodian to vote all BAT ordinary shares held on deposit at that time in accordance with the voting instructions received from a majority of holders of BAT ADSs who provide timely voting instructions; or

Deposited securities for which no voting instructions have been received will not be voted. The ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the deposited securities. BAT cannot assure holders that they will receive voting materials in time to enable them to return voting instructions to the depositary bank in a timely manner.

• in the event of voting by poll, the depositary bank will vote or cause the custodian to vote the BAT ordinary shares held on deposit in accordance with the voting instructions received from the holders of BAT ADSs giving instructions.

Fees and Charges

BAT ADS holders will be required to pay the following fees to the depositary bank under the terms of the deposit agreement:

22
Service | Fees
---|---
• Issuance of BAT ADSs upon deposit of BAT ordinary shares (excluding issuances as a result of distributions of shares described below) | Up to U.S. $0.05 per BAT ADS issued(1)
• Cancellation of BAT ADSs | Up to U.S. $0.05 per BAT ADS surrendered(1)
• Distribution of cash dividends or other cash distributions (i.e., sale of rights and other entitlements) | Up to U.S. $0.05 per BAT ADS held(2)
• Distribution of BAT ADSs pursuant to (1) stock dividends or other free stock distributions, or (2) exercise of rights to purchase additional BAT ADSs | Up to U.S. $0.05 per BAT ADS held
• Depositary bank services | Up to U.S. $0.05 per BAT ADS held

(1) Under the terms of a separate agreement between BAT and the depositary bank, the depositary bank has agreed to waive the fees that would otherwise be payable in connection with the issuance of BAT ADSs upon deposit of BAT ordinary shares and the cancellation of BAT ADSs and corresponding withdrawal of BAT ordinary shares, in each case by BAT or any of its affiliates, officers, directors or employees. The terms of this separate agreement may be amended at any time by BAT and the depositary bank.

(2) While under the deposit agreement cash dividends paid in respect of BAT ADSs are subject to a fee of up to $0.05 per BAT ADS payable to the depositary bank, under the terms of the separate agreement between BAT and the depositary bank referred to above, such dividends are instead subject to a fee of up to $0.02 per BAT ADS per year (a fee of $0.01 per dividend based on the distribution of an interim and a final cash dividend per year or a fee of $0.005 per dividend based on the current distribution of four quarterly cash dividends per year). Under such separate agreement, this dividend fee may not be varied by the depositary bank without the consent of BAT.

BAT ADS holders will also be responsible to pay certain charges such as:

• taxes (including applicable interest and penalties) and other governmental charges;
• the registration fees as may from time to time be in effect for the registration of BAT ordinary shares or other deposited securities on the share register and applicable to transfers of BAT ordinary shares or other deposited securities to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively;
• certain cable, telex and facsimile transmission and delivery expenses;
the expenses and charges incurred by the depositary bank in the conversion of foreign currency;

the fees and expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to BAT ordinary shares, or other deposited securities, BAT ADSs and ADRs; and

the fees and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the servicing or delivery of deposited securities.

ADS fees and charges payable upon (1) the issuance of BAT ADSs, and (2) the cancellation of BAT ADSs are charged to the person to whom the BAT ADSs are issued (in the case of BAT ADS issuances) and to the person whose BAT ADSs are canceled (in the case of BAT ADS cancellations). In the case of BAT ADSs issued by the depositary bank into DTC, the BAT ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the BAT ADSs being issued or the DTC participant(s) holding the BAT ADSs being canceled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the depositary bank services fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (1) distributions other than cash and (2) the depositary bank services fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of BAT ADSs. For BAT ADSs held through DTC, the ADS fees and charges for distributions other than cash and the depositary bank services fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold BAT ADSs.

In the event of refusal to pay the depositary bank’s fees and charges, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank’s fees and charges from any distribution to be made to the BAT ADS holder. Note that the fees and charges holders may be required to pay may vary over time and may be changed by BAT and by the depositary bank (as described in “—Amendments and Termination” below). Prior notice of such changes will be provided. The depositary bank may reimburse BAT for certain expenses incurred by it in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as BAT and the depositary bank agree from time to time.
Amendments and Termination

BAT may agree with the depositary bank to modify the deposit agreement at any time without consent of BAT ADS holders. BAT must give holders 30 days’ prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. BAT will not consider to be materially prejudicial to holders’ substantial rights any modifications or supplements that are reasonably necessary for the BAT ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges they are required to pay. In addition, BAT may not be able to provide holders with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law.

BAT ADS holders will be bound by the modifications to the deposit agreement if they continue to hold their ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent holders from withdrawing the deposited securities represented by their BAT ADSs (except as permitted by law).

BAT has the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, BAT ADS holders’ rights under the deposit agreement will be unaffected.

After termination, the depositary bank will continue to collect distributions received (but will not distribute any such property until a holder requests the cancellation of BAT ADSs) and may sell deposited securities. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of BAT ADSs in a non-interest bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of BAT ADSs still outstanding (after deduction of applicable fees, taxes and expenses).

Books of Depositary

The depositary bank will maintain BAT ADS holder records at its depositary office. BAT ADS holders may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the BAT ADSs and the deposit agreement.

The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of BAT ADSs. These facilities may be closed from time to time, to the extent not prohibited by law.

Limitations on Obligations and Liabilities

The deposit agreement limits the obligations of BAT and the depositary bank’s obligations to BAT ADS holders. In particular:

- BAT and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement and to do so without negligence or bad faith;
• the depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement;
• the depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to you on BAT’s behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in BAT ordinary shares, for the validity or worth of the BAT ordinary shares, for any tax consequences that result from the ownership of BAT ADSs, for the creditworthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any notices from BAT or for BAT’s failure to give notice;
• BAT and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement;
• BAT and the depositary bank disclaim any liability if BAT or the depositary bank are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of the BAT articles of association, or any provision of or governing the deposited securities, or by reason of any act of God or war or other circumstances beyond their control;
• BAT and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in the BAT articles of association or in any provisions of or governing deposited securities;
• BAT and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of BAT ADSs or authorized representatives thereof, or any other person believed by either BAT or the depositary bank in good faith to be competent to give such advice or information;
• BAT and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of deposited securities but is not, under the terms of the deposit agreement, made available to BAT ADS holders;
• BAT and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties;
• BAT and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement; and
• no disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.

Taxes
BAT ADS holders are responsible for the taxes and other governmental charges payable on the BAT ADSs and other deposited securities represented by the BAT ADSs. BAT, the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. Holders will be liable for any deficiency if the sale proceeds do not cover the taxes that are due.

The depositary bank may refuse to issue BAT ADSs, to deliver, transfer, split and combine ADRs or to release deposited securities until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on behalf of a BAT ADS holder. However, holders may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal obligations. BAT ADS holders are required to indemnify BAT, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for them.

Foreign Currency Conversion
The depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. BAT ADS holders may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements.

If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion:

• convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical;
• distribute the foreign currency to holders for whom the distribution is lawful and practical; or
• hold the foreign currency (without liability for interest) for the applicable holders.

Governing Law
The deposit agreement and the ADRs are governed by the laws of the State of New York. The rights of holders of BAT ordinary shares (including BAT ordinary shares represented by BAT ADSs) are governed by the laws of England and Wales and the BAT articles of association. For further information regarding the material terms of the BAT ordinary shares, see “Description of BAT Ordinary Shares”.

27
C. Description of the Notes Issued Under the BATIF Indenture

The following is a summary of the material provisions of the BATIF Indenture (as described below), the applicable supplemental indenture and the BATIF Notes. Any capitalized term used herein but not defined shall have the meaning assigned to such term in the BATIF Indenture, the applicable supplemental indenture or under “—Certain Definitions”. The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all of the provisions of the BATIF Indenture, the applicable supplemental indenture and those terms made a part of the BATIF Indenture and/or applicable supplemental indenture by reference to the Trust Indenture Act of 1939, as amended (the “TIA”).

GENERAL

The 1.668% Notes due 2026 (the “BATIF Notes”) were issued by B.A.T. International Finance p.l.c. (“BATIF” or the “Issuer”).

The BATIF Notes will mature on March 25, 2026.

The BATIF Notes were issued in registered form and treated as a single series of debt securities and were issued under a supplemental indenture to the indenture dated as of September 25, 2020 (as amended or supplemented from time to time, the “BATIF Indenture”) by and among BATIF, as Issuer, British American Tobacco p.l.c. (“BAT” or the “Parent”), B.A.T Capital Corporation (“BATCAP”), B.A.T. Netherlands Finance B.V. (“BATNF”) and, unless its guarantee is released in accordance with the BATIF Indenture, Reynolds American Inc. (“RAI”), each as a guarantor, Citibank, N.A., as trustee (the “Trustee”), registrar, transfer agent, calculation agent and initial paying agent (in such several capacities under the BATIF Indenture, the “Registrar”, “Transfer Agent”, “Calculation Agent”, and “Paying Agent”, respectively).

Each guarantee in respect of the BATIF Notes is referred to herein as a “Guarantee” and each entity that provides a Guarantee is referred to herein as a “Guarantor”. In this “Description of the Notes Issued Under the BATIF Indenture”, the terms “holder”, “Noteholder” and other similar terms refer to a “registered holder” of BATIF Notes, and not to a beneficial owner of a book-entry interest in any BATIF Notes.

PRINCIPAL, MATURITY AND INTEREST

The obligations of the Issuer under the BATIF Notes and BATIF Indenture are fully and unconditionally guaranteed on a joint and several, and senior and unsecured basis by each of the Parent, BATCAP, BATNF and, unless its guarantee is released in accordance with the BATIF Indenture, RAI.

The BATIF Notes were initially issued in an aggregate principal amount of $1,500,000,000, with a maturity date of March 25, 2026. The BATIF Notes bear interest per annum at a rate of 1.668%.
The BATIF Notes will bear interest from the date of the initial issuance of such BATIF Notes or from the most recent interest payment date to which interest has been paid or provided for, payable semi-annually in arrears on March 25 and September 25 of each year, commencing on March 25, 2021 (each, an “Interest Payment Date”) until the maturity date, unless previously purchased and cancelled or redeemed by the Issuer, to the person in whose name any BATIF Note is registered at the close of business on the 15th calendar day preceding each Interest Payment Date, whether or not such day is a Business Day (each, a “Record Date”) notwithstanding any transfer or exchange of such BATIF Notes subsequent to the Record Date and prior to such Interest Payment Date, except that, if and to the extent the Issuer shall default in the payment of the interest due on such Interest Payment Date, and the applicable grace period shall have expired, such defaulted interest may at the option of the Issuer be paid to the persons in whose names the outstanding BATIF Notes are registered at the close of business on a subsequent Record Date (which shall not be less than five Business Days prior to the date of payment of such defaulted interest) established by notice sent by or on behalf of the Issuer to the holders of BATIF Notes, not less than 15 days preceding such subsequent Record Date. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months, or in the case of an incomplete month, the number of days elapsed. If the date on which any interest payment or principal payment is to be made is not a Business Day, such payment will be made on the next day which is a Business Day, without any further interest or other amounts being paid or payable in connection therewith. A “Business Day” refers to any day which is not, in London or New York City, or any other place of payment, a Saturday, Sunday, legal holiday or a day on which banking institutions are authorized or obligated by law or regulation to close.

Form and Denomination
The BATIF Notes were issued in fully registered form and only in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof, and were issued initially as global notes representing the BATIF Notes (collectively, the “BATIF Global Notes”). The BATIF Global Notes were (i) registered in the name of the Depository or the nominee of such Depository, in each case for the credit to an account of a member of, or direct or indirect participant in, the Depository; and (ii) delivered to Citibank, N.A. as custodian for such Depository.

Further Issues
The aggregate principal amount of notes (including the BATIF Notes) issuable under the BATIF Indenture (the “Notes”) is unlimited. The Issuer may, from time to time, without notice to or the consent of the holders of the BATIF Notes, issue Notes of a new series or “reopen” any series of the Notes (including the BATIF Notes) and create and issue additional notes having substantially identical terms and conditions as the then-outstanding Notes of a series (including the BATIF Notes) (or in all respects except as to issue date, issue price, denomination, rate of interest, maturity date and the date from which interest, if any, shall accrue and except as may otherwise be provided in or pursuant to an officer’s certificate or any supplemental indenture relating thereto) so that the additional Notes are consolidated and form a single series of Notes with the outstanding Notes of such series, as the case may be; provided that if the additional Notes are not fungible with the outstanding Notes of the relevant series for United States Federal income tax purposes, the additional Notes will have separate CUSIPs, ISINs, or other identifying numbers.
Status of the BATIF Notes and Guarantees

The BATIF Notes are unsecured and unsubordinated obligations of the Issuer and rank pari passu in right of payment among themselves and with all other direct, unsecured and unsubordinated obligations of the Issuer (except those obligations preferred by statute or operation of law). Each Guarantor fully and unconditionally guarantees, on a senior, unsecured basis, the due and punctual payment (and not collectability) of the principal of and interest on the BATIF Notes (and the payment of additional amounts described under “—Additional Amounts” below) and other obligations under the BATIF Indenture when and as the same shall become due and payable, whether at stated maturity, by declaration of acceleration, call for redemption or otherwise. Each Guarantee is an unsecured and unsubordinated obligation of the respective Guarantor and rank pari passu in right of payment with all other direct, unsecured and unsubordinated obligations of such Guarantor (except those obligations preferred by statute or operation of law). The Issuer and each Guarantor are subject to a negative pledge with respect to certain types of indebtedness, which are discussed below under “—Covenants of the Issuer and the Guarantors—Negative Pledge”.

Guarantees

Release

The BATIF Indenture and the applicable supplemental indenture provide that, without the consent of the Trustee or the Noteholders, any Guarantor that is a subsidiary of the Parent (a “Subsidiary Guarantor”), other than BATCAP and BATNF, will automatically and unconditionally be released from all obligations under its Guarantee, and such Guarantee shall thereupon terminate and be discharged and of no further force or effect, in the event that (1) its guarantee of all then outstanding notes issued under the EMTN Programme is released or (2) at substantially the same time its Guarantee is terminated, the Subsidiary Guarantor is released from all obligations in respect of indebtedness for borrowed money for which such Subsidiary Guarantor is an obligor (as a guarantor or borrower). For purposes of this paragraph, the amount of a Subsidiary Guarantor’s indebtedness for borrowed money shall not include (A) the Notes (including the BATIF Notes) issued pursuant to the BATIF Indenture, (B) any other debt the terms of which permit the termination of such Subsidiary Guarantor’s guarantee of such debt under similar circumstances, as long as such Subsidiary Guarantor’s obligations in respect of such other debt are terminated at substantially the same time as its Guarantee of the Notes (including the BATIF Notes), (C) any debt that is being refinanced at substantially the same time that the Guarantee of the Notes (including the BATIF Notes) is being released, provided that any obligations of the relevant Subsidiary Guarantor in respect of the debt that is incurred in the refinancing shall be included in the calculation of the relevant Subsidiary Guarantor’s indebtedness for borrowed money and (D) for the avoidance of doubt, any debt in respect of which such Subsidiary Guarantor is an obligor (as a guarantor or borrower) (i) between or among the Parent and any subsidiary or subsidiaries thereof or (ii) between or among any subsidiaries of the Parent.
As of the date of this summary, RAI is the only Subsidiary Guarantor to which the above provision is relevant. Under the EMTN Programme, a Subsidiary Guarantor’s guarantee is released if at any time the aggregate amount of indebtedness for borrowed money for which the Subsidiary Guarantor is an obligor does not exceed 10% of the outstanding long-term debt of BAT as reflected in the balance sheet included in BAT’s most recent publicly released interim or annual consolidated financial statements, as evidenced by a certificate to such effect addressed to the trustee under the EMTN Programme and signed by a director of BAT.

Additional Amounts

The Issuer or, if applicable, each Guarantor will make payments of, or in respect of, principal, premium (if any) and interest on the BATIF Notes, or any payment pursuant to the applicable Guarantee, as the case may be, without withholding or deduction for or on account of any present or future tax, levy, impost or other similar governmental charge (“Taxes”) imposed, assessed, levied or collected by or for the account of the United Kingdom, The Netherlands (in the case of a payment by BATNF) or the United States (in the case of a payment by BATCAP or RAI), including in each case any political subdivision thereof or any authority thereof having the power to tax (a “Relevant Taxing Jurisdiction”), unless such withholding or deduction is required by law.

If the Issuer or, if applicable, any such Guarantor is required by a Relevant Taxing Jurisdiction to so withhold or deduct such Taxes, the Issuer or, if applicable, such Guarantor will pay to the Holder such additional amounts (“Additional Amounts”) as will result in the receipt by the Holder of such amounts as would have been received by it if no such withholding or deduction of Taxes had been required; provided, however, that amounts with respect to any United States Tax shall be payable only to Holders that are not United States persons (within the meaning of the Code) and provided further, that neither the Issuer nor such Guarantor shall be required to pay any Additional Amounts for or on account of:

(a) any Taxes that would not have been so imposed, assessed, levied or collected but for the Holder or beneficial owner of the applicable Note or Guarantee (or a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such Holder, if such Holder is an estate, trust, partnership or corporation) being or having been a domiciliary, national or resident of, or engaging or having been engaged in a trade or business, maintaining or having maintained a permanent establishment or being or having been physically present in, a Relevant Taxing Jurisdiction or otherwise having or having had some connection with a Relevant Taxing Jurisdiction other than the holding or ownership of, or the collection of principal of, and premium (if any) or interest on, a Note or the enforcement of the applicable Guarantee, as the case may be;

(b) any Taxes that would not have been so imposed, assessed, levied or collected but for the fact that, where presentation is required in order to receive payment, the applicable Note or Guarantee was presented more than 30 days after the date on which such payment became due and payable or was provided for, whichever is later, except to the extent that the Holder or beneficial owner thereof would have been entitled to Additional Amounts had the applicable Note or Guarantee been presented for payment on any day during such 30-day period;

(c) any estate, inheritance, gift, sales, transfer, personal property or similar Taxes;
(d) any Taxes that are payable otherwise than by withholding or deduction from payments on or in respect of the applicable Note or Guarantee;

(e) any Taxes that would not have been so imposed, assessed, levied or collected but for the failure by the Holder or the beneficial owner of the applicable Note or Guarantee to (i) provide any certification, identification, information, documents or other evidence concerning the nationality, residence or identity of the Holder or the beneficial owner or its connection with a Relevant Taxing Jurisdiction; or (ii) make any valid or timely declaration or claim or satisfy any other reporting, information or procedural requirements relating to such matters if, in either case, compliance is required by statute, regulation, relevant income tax treaty or administrative practice of a Relevant Taxing Jurisdiction as a condition to relief or exemption from such Taxes;

(f) any Taxes imposed by reason of the Holder or the beneficial owner of the applicable Note or Guarantee being or having been considered a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business, as described in Section 881(c)(3)(A) of the Code (or any amended or successor provisions);

(g) any Taxes imposed on interest received by a 10-percent shareholder of the Issuer or any Guarantor within the meaning of Section 871(h)(3)(B) or Section 881(c)(3)(B) of the Code (or any amended or successor provisions);

(h) any backup withholding imposed pursuant to Section 3406 of the Code (or any amended or successor provisions);

(i) any Taxes imposed pursuant to Section 871(h)(6) or Section 881(c)(6) of the Code (or any amended or successor provisions);

(j) any Taxes imposed by reason of the Holder or the beneficial owner of the applicable Note or Guarantee being or having been a personal holding company, passive foreign investment company or controlled foreign corporation for U.S. Federal income tax purposes or a corporation that has accumulated earnings to avoid U.S. Federal income tax;

(k) any Taxes imposed or withheld pursuant to Sections 1471 through 1474 of the Code (or any amended or successor provisions), any U.S. Treasury regulations promulgated thereunder, any official interpretations thereof or any agreements entered into in connection with the implementation thereof (“FATCA Withholding”); or

(l) any combination of the Taxes described in clauses (a) through (k) above.

In addition, Additional Amounts will not be paid with respect to any payment of the principal of, or premium (if any) or interest on, any BATIF Note or any payment pursuant to the applicable Guarantee to any Holder that is a fiduciary, a partnership, a limited liability company or any person other than the sole beneficial owner of such payment to the extent a beneficiary or settlor.
with respect to such fiduciary, a member of such partnership, an interest holder in such limited liability company or a beneficial owner that would not have been entitled to such amounts had such beneficiary, settlor, member, interest holder or beneficial owner been the Holder of the applicable BATIF Note or Guarantee.

Unless otherwise stated, references in any context to the payment of principal of, and premium (if any) or interest on, any BATIF Note, or any payment pursuant to a Guarantee, will be deemed to include payment of Additional Amounts to the extent that, in such context, Additional Amounts are, were or would be payable in respect thereof.

In addition to the exceptions and limitations described above, neither the Issuer nor any Guarantor shall be required to pay any Additional Amounts for or on account of any taxes imposed or to be withheld pursuant to the Dutch Withholding Tax Act 2021 (Wet bronbelasting 2021).

Redemption

The BATIF Notes are subject to optional redemption by the Issuer as described below under “—Optional Redemption”. The BATIF Notes are subject to optional redemption by the Issuer in the event of certain changes in tax laws applicable to payments in respect of the BATIF Notes as described below under “—Redemption for Tax Reasons”.

Optional Redemption

The Issuer may redeem the BATIF Notes, in whole or in part, at the Issuer’s option, at any time and from time to time before the Par Call Date (as defined below), at a redemption price equal to the greater of (x) 100% of the principal amount of the BATIF Notes to be redeemed and (y) as determined by the Independent Investment Banker (as defined below), the sum of the present values of the applicable Remaining Scheduled Payments (as defined below) discounted to the date of redemption (the “Redemption Date”) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months or, in the case of an incomplete month, the number of days elapsed) at the Treasury Rate (as defined below) plus 25 basis points, together with accrued and unpaid interest on the principal amount of the BATIF Notes to be redeemed, but excluding, the Redemption Date.

If the Issuer elects to redeem a series of the BATIF Notes on or after the Par Call Date, the Issuer will pay an amount equal to 100% of the principal amount of the BATIF Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption.

In connection with such optional redemption the following defined terms apply:

- Comparable Treasury Issue means the United States Treasury security selected by the Independent Investment Banker that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the BATIF Notes to the Par Call Date.
Comparable Treasury Price means, with respect to any Redemption Date, (A) the average of the Reference Treasury Dealer Quotations for that Redemption Date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations or (B) if the Independent Investment Banker for the BATIF Notes obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such Quotations.

Independent Investment Banker means one of the Reference Treasury Dealers (as defined below) appointed by the Issuer to act as the “Independent Investment Banker”.

Par Call Date means February 25, 2026 (one month prior to the maturity date of the BATIF Notes).

Reference Treasury Dealer means each of BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, NatWest Markets Securities Inc., SG Americas Securities, LLC and Wells Fargo Securities, LLC and their respective successors and two other nationally recognized investment banking firms that are Primary Treasury Dealers specified from time to time by the Issuer; provided, however, that if any of the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury Dealer”), the Issuer shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer.

Reference Treasury Dealer Quotation means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day immediately preceding that Redemption Date.

Remaining Scheduled Payments means, with respect to each BATIF Note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due from and including the related Redemption Date, but for such redemption, to but excluding the Par Call Date; provided, however, that if that Redemption Date is not an Interest Payment Date with respect to such BATIF Notes, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to that Redemption Date.

Treasury Rate means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent yield to maturity (computed as of the third Business Day immediately preceding that Redemption Date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that Redemption Date.
Notice of any optional redemption will be given in accordance with the BATIF Indenture at least 10 days but not more than 30 days before the Redemption Date to each holder of the BATIF Notes to be redeemed. Any redemption may, at the Issuer’s sole discretion, be subject to the satisfaction of one or more conditions precedent. In the event of a conditional redemption, the notice of conditional redemption shall reflect and specify the conditions to the redemption. Once the notice of redemption is delivered, BATIF Notes called for redemption shall, subject to the satisfaction of any applicable conditions, become irrevocably due and payable on the Redemption Date.

If less than all the BATIF Notes are to be redeemed, in the case of a redemption at the Issuer’s option as discussed in this section, the BATIF Notes to be redeemed shall be selected in accordance with applicable procedures of DTC.

Upon presentation of any BATIF Note redeemed in part only, the Issuer will execute and upon receipt of a written direction from the Issuer, the Paying Agent will authenticate and deliver (or cause to be transferred by book-entry) to, or on, the order of the holder thereof, at the expense of the Issuer, a new BATIF Note of authorized denominations in principal amount equal to the unredeemed portion of the BATIF Note so presented.

The redemption price shall be calculated by the Independent Investment Banker and the Issuer, and the Trustee and any agent shall be entitled to rely on such calculation.

**Redemption for Tax Reasons**

Each series of Notes (including the BATIF Notes) is also redeemable by the Issuer, in whole but not in part, at 100% of the principal amount of such Notes plus any accrued and unpaid interest (including any Additional Amounts) to the applicable date fixed for such redemption pursuant to the terms of the BATIF Indenture or such series of Notes (the “Redemption Date”) at the Issuer’s option at any time prior to their maturity if, due to a Change in Tax Law (as defined below): (i) the Issuer or any Guarantor, in accordance with the terms of the applicable Notes or applicable Guarantee, has, or would, become obligated to pay any Additional Amounts to the Holders of the Notes of that series; (ii) in the case of any Guarantor, (A) the Parent would be unable, for reasons outside its control, to procure payment by the Issuer or any other Guarantor or (B) the procuring of such payment by the Issuer and each such other Guarantor would be subject to withholding Taxes imposed by a Relevant Taxing Jurisdiction; and (iii) such obligation cannot otherwise be avoided by such Guarantor, the Parent or the Issuer, taking reasonable measures available to it. In such case, the Issuer may redeem the applicable Notes upon not less than 30 nor more than 60 days’ notice as provided in “—Notice” below, at 100% of the principal amount of such Notes plus accrued and unpaid interest to the Redemption Date (including Additional Amounts); provided that (a) no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which the Issuer or such Guarantor, as the case may be, would be obligated to pay any such Additional Amounts in respect of the applicable Notes or applicable Guarantee, as applicable, then due; and (b) at the time such notice is given, such obligation to pay such Additional Amounts remains in effect. The Issuer’s right to redeem the applicable Notes shall continue as long as the Issuer or any Guarantor is obligated to pay such Additional Amounts, notwithstanding that the Issuer or such Guarantor, as the case may be, shall have made payments of Additional Amounts. Prior to the giving of any such notice of redemption, the Issuer must
deliver to the Trustee: (i) an officer’s certificate stating that the Issuer is entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to the right of the Issuer to so redeem have occurred; and (ii) an opinion of independent counsel or an independent accountant of recognized standing, selected by the Issuer or any Guarantor, as applicable, with respect to tax matters of the Relevant Taxing Jurisdiction to the effect that the Issuer or such Guarantor has, or would, become obligated to pay such Additional Amounts as a result of such Change in Tax Law.

For the purposes hereof, “Change in Tax Law” shall mean: (i) any changes in, or amendment to, any law of a Relevant Taxing Jurisdiction (including any regulations or rulings promulgated thereunder and including, for this purpose, any treaty entered into by the Relevant Taxing Jurisdiction) or any amendment to or change in the application or official interpretation (including judicial or administrative interpretation) of such law, which change or amendment becomes effective or, in the case of an official interpretation, is announced, on or after the first date of issuance of Notes of such series; or (ii) if the Issuer or any Guarantor consolidates, merges, amalgamates or combines with, or transfers or leases its assets substantially as an entirety to, any person that is incorporated or tax resident under the laws of any jurisdiction other than a Relevant Taxing Jurisdiction (a “successor”) and as a consequence thereof such person becomes the successor obligor to the Issuer or such Guarantor in respect of Additional Amounts that may become payable (in which case, for purposes of this redemption provision, all references to the Issuer or such Guarantor shall be deemed to be and include references to such person), any change in, or amendment to, any law of the jurisdiction of organization or tax residence of such successor, or the jurisdiction through which payments will be made by the successor, or any political subdivision or taxing authority thereof or thereon for purposes of taxation (including any regulations or rulings promulgated thereunder and including, for this purpose, any treaty entered into by such jurisdiction) or any amendment to or change in the application or official interpretation (including judicial or administrative interpretation) of such law, which change or amendment becomes effective or, in the case of an official interpretation, is announced, on or after the date of such consolidation, merger, amalgamation, combination or other transaction.

General

On or before any Redemption Date (as defined above), the Issuer shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued and unpaid interest on the BATIF Notes to be redeemed on such date.

On and after any Redemption Date, interest will cease to accrue on the BATIF Notes or any portion thereof called for redemption.

Maturity

Unless previously purchased or redeemed by the Issuer, and cancelled, the principal amount of each respective series of BATIF Notes shall mature on March 25, 2026, in an amount equal to their principal amount, with accrued and unpaid interest to, but excluding, such date.
Covenants of the Issuer and the Guarantors

Reacquisition

There is no restriction on the ability of the Issuer to purchase or repurchase Notes (including the BATIF Notes), provided, that any Notes so repurchased shall be cancelled and not reissued.

Sinking Fund

There is no provision for a sinking fund for any of the Notes (including the BATIF Notes).

Certain Definitions

Set forth below is a summary of certain of the defined terms used in the BATIF Notes, the BATIF Indenture and the applicable supplemental indenture. You should refer to the BATIF Notes, the BATIF Indenture and applicable supplemental indenture for the full definition of all defined terms as well as any other terms used herein for which no definition is provided.

“Dollar” or “$” means United States dollars, or such other money of the United States that at the time of payment is legal tender for payment of public and private debts.

“EMTN Programme” means the Euro Medium Term Note Programme to which BATCAP, BATIF and BATNF are parties as the issuers under the programme and notes issued thereunder are guaranteed by the Parent, each of the issuers thereunder (except when it is the relevant issuer) and RAI, as amended from time to time.

“Original Issue Discount Note” means any Note that is issued with “original issue discount” within the meaning of Section 1273(a) of the Code and Treasury Regulations promulgated thereunder and any other Note designated by the Company as issued with original issue discount for United States federal income tax purposes.

“Person” means any individual, corporation, partnership, joint venture, association, limited liability company, joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.

“Quoted Borrowing” means any indebtedness which: (i) is represented by notes, debentures or other securities issued otherwise than to constitute or represent advances made by banks and/or other lending institutions; (ii) is denominated, or confers any right to payment of principal and/or interest, in or by reference to any currency other than the currency of the country in which the issuer of the indebtedness has its principal place of business or is denominated, or confers any right to payment of principal and/or interest, in or by reference to the currency of such country but is sold or subscribed by or on behalf of, or by agreement with, the issuer of such indebtedness as to over 20% outside such country; and (iii) at its date of issue is, or is intended by the issuer of such indebtedness to become, quoted, listed, traded or dealt in on any stock exchange or other organized and regulated securities market in any part of the world.

37
**Covenants of the Issuer and the Guarantors**

**Negative Pledge**

The BATIF Indenture provides that so long as any of the Notes (including the BATIF Notes) remains outstanding, neither the Issuer nor any Guarantor will secure or allow to be secured any Quoted Borrowing issued by the Issuer or any Guarantor or any payment under any guarantee by any of them of any such Quoted Borrowing by any mortgage, charge, pledge or lien (other than arising by operation of law) upon any of its undertaking or assets, whether present or future, unless at the same time the same mortgage, charge, pledge or lien is extended, or security which is not materially less beneficial to the holders of the Notes than the security given as aforesaid or which shall be approved by consent of the holders of not less than 75% in aggregate principal amount of the Notes at the time outstanding is extended or created (as the case may be), to secure equally and ratably the principal of, and interest on, and all other payments (if any) in respect of the Notes.

**Limitation on Mergers, Consolidations, Amalgamations and Combinations**

Under the BATIF Indenture, so long as any of the Notes (including the BATIF Notes) remains outstanding thereunder, neither the Issuer nor any Guarantor may consolidate with or merge into any other person or sell, convey, transfer or lease its properties and assets as an entirety or substantially as an entirety to any person (other than any sale or conveyance by way of a lease in the ordinary course of business), unless: (i) in the case of the Issuer, any successor person assumes the Issuer’s obligations on the Notes (including the BATIF Notes) and under the BATIF Indenture and, in the case of any Guarantor, any successor person assumes such Guarantor’s obligations on the Guarantee and under the BATIF Indenture; (ii) immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; (iii) such successor person is organized under the laws of the United States or any State thereof, the United Kingdom, The Netherlands or any other country that is a member of the Organization for Economic Cooperation and Development as of the date of such succession; (iv) such successor person agrees to pay any Additional Amounts with respect to any withholding or deduction of Taxes or any payment on the Notes (including the BATIF Notes) or Guarantees (as applicable) imposed by the jurisdiction (other than the United States, unless otherwise required by clause (i) of this paragraph) in which such successor person is incorporated or otherwise a resident for tax purposes subject to the exceptions described under “—Additional Amounts” (for the avoidance of doubt, solely to the extent such successor person is the Issuer, changes will be made to the BATIF Indenture as are necessary to obligate the Issuer to pay such Additional Amount); and (v) if as a result of such consolidation or merger or such sale, conveyance, transfer or lease, properties or assets of the Issuer or any Guarantor would become subject to a mortgage, pledge, security interest, lien or similar encumbrance to secure payment of any indebtedness for borrowed money of the Issuer or any Guarantor which would not be permitted by the Notes of a series or under the BATIF Indenture, the Issuer or any Guarantor or such successor person, as the case may be, shall take such steps as shall be necessary to effectively secure the Notes of such series equally and ratably with (or prior to) all indebtedness for borrowed money secured thereby.

38
The limitation on mergers, consolidations, amalgamations and combinations described in this section "—Limitation on Mergers, Consolidations, Amalgamations and Combinations" shall not apply to any consolidation, merger, amalgamation or combination in which the Issuer or any Guarantor is the surviving corporation except that, in such case, the provisions of (ii) and (v) above shall apply such that: (x) immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; and (y) if as a result of such consolidation or merger or such sale, conveyance, transfer or lease, properties or assets of the Issuer or any Guarantor would become subject to a mortgage, pledge, security interest, lien or similar encumbrance to secure payment of any indebtedness for borrowed money of the Issuer or any Guarantor which would not be permitted by the Notes or under the BATIF Indenture, the Issuer or any Guarantor, as the case may be, shall take such steps as shall be necessary to effectively secure the Notes equally and ratably with (or prior to) all indebtedness for borrowed money secured thereby.

The BATIF Indenture does not contain covenants or other provisions to afford protection to holders of the Notes in the event of a highly leveraged transaction or a change in control of the Issuer or any Guarantor except as provided above.

Upon certain mergers or consolidations involving the Issuer or any Guarantor, or upon certain sales or conveyances of all or substantially all of the assets of the Issuer or any Guarantor, the obligations of the Issuer or such Guarantor, under the applicable Notes or the applicable Guarantee, shall be assumed by the person formed by such merger or consolidation or which shall have acquired such assets and upon such assumptions such person shall succeed to and be substituted for the Issuer or such Guarantor, as the case may be, and then the Issuer or such Guarantor will (except in the case of a lease) be relieved of all obligations and covenants under the BATIF Indenture, the Notes and the applicable Guarantee, as the case may be. The terms “Issuer” and “Guarantor”, as used in the Notes and the BATIF Indenture, also refer to any such successors or assigns so substituted.

Although there is a limited body of case law interpreting the phrase “entirety or substantially as an entirety”, there is no precise established definition of the phrase under applicable law. Accordingly, in certain circumstances, there may be a degree of uncertainty as to whether a particular transaction would involve a disposition of “entirety or substantially as an entirety” of the Issuer’s assets and its subsidiaries taken as a whole.

Events of Default

Each of the following events shall be an “Event of Default” with respect to any series of the Notes (including the BATIF Notes):

(i) **Non-Payment**: default is made in the payment of: (a) any installment of interest (excluding Additional Amounts) upon any applicable Note as and when the same shall become due and payable, and there is a continuance of such default for a period of 14 days or more; (b) applicable Additional Amounts as and when the same shall become due and payable, and there is a continuance of such default for a period of 14 days; or (c) all or any part of the principal or premium, if any, of any applicable Note as and when the same shall become due and payable either at maturity, upon any redemption, by declaration or otherwise, and there is a continuance of such default for a period of three days;
(ii) Breach of Other Obligations: the Issuer or any Guarantor does not perform or comply with any one or more of its other obligations under the applicable Notes or the BATIF Indenture (other than those described in paragraph (i) above) which is not remedied within 30 days (unless a longer period is specified in the BATIF Indenture) after written notice of such default shall have been given to the Issuer by the Trustee or to the Issuer and the Trustee by the holders of at least 25% of the outstanding principal amount of the Notes;

(iii) Cross-Default: (a) any other present or future indebtedness for borrowed money of the Issuer or any Guarantor, other than the Notes issued by the Issuer, becomes due and payable prior to its stated maturity by reason of any default or event of default in respect thereof by the Issuer or any Guarantor and remains unpaid; or (b) any such indebtedness for borrowed money is not paid when due or, as the case may be, within any applicable grace period; or (c) the Issuer or any Guarantor fails to pay when due and called upon (after the expiry of any applicable grace period) any amount payable by it under any present or future guarantee for, or indemnity in respect of, any indebtedness for borrowed money and which remains unpaid; provided that (x) payment of the indebtedness for borrowed money is not being contested in good faith and in accordance with legal advice or (y) the aggregate amount of the indebtedness for borrowed money, guarantees and indemnities in respect of which one or more of the events mentioned above in clauses (a), (b) and (c) of this paragraph (iii) has or have occurred and is or are continuing, equals or exceeds £750 million or its equivalent in any other currency of the indebtedness for borrowed money or, if greater, 1.25% of the Total Equity of the Parent, as set out in the "Total Equity" line item in the most recent consolidated group balance sheet of the Parent and its subsidiaries in the Parent’s most recent annual report;

(iv) Cessation of Guarantees: any Guarantee ceases to be in full force and effect (except as contemplated by the terms of the BATIF Indenture, including as described above under "—Guarantees—Release") or any Guarantor denies or disaffirms in writing its obligations under the BATIF Indenture or Guarantee;

(v) Enforcement Proceedings: a distress or execution or other legal process is levied or enforced against or an encumbrancer takes possession of or a receiver, administrative receiver or other similar officer is appointed of the whole or a part of the assets of the Issuer or any Guarantor which is substantial in relation to the BAT Group taken as a whole and is not discharged, stayed, removed or paid out within 45 days after such execution or appointment;
(vi) **Security Enforced:** any mortgage, charge, pledge, lien or other encumbrance, present or future, created or assumed by the Issuer or any Guarantor becomes enforceable against all or substantially all of the assets of the Issuer or any Guarantor, and any step is taken to enforce it (including the taking of possession or the appointment of a receiver, administrative receiver, manager or other similar person) and is not discharged within 45 days;

(vii) **Insolvency:** the Issuer or any Guarantor is insolvent or bankrupt or unable to pay its debts (in respect of companies incorporated in England and Wales, within the meaning of Section 123(1)(b) or (c) or Section 123(2) of the UK Insolvency Act 1986), stops, suspends or threatens to stop or suspend payment of all or a material part of its debts, proposes or makes a general assignment or an arrangement or composition (otherwise than for the purposes of reconstruction, amalgamation, reorganization, merger or consolidation or other similar arrangement) with or for the benefit of its creditors in respect of any of such debts or a moratorium is agreed or declared in respect of or affecting all or a material part of the debts of the Issuer;

(viii) **Winding-up:** an order is made or an effective resolution passed for the winding-up or dissolution or administration of the Issuer or any Guarantor, or the Issuer or any Guarantor shall apply or petition for a winding-up or administration order in respect of itself or ceases or threatens to cease to carry on all or substantially all of its business or operations, in each case except for the purpose of and followed by a reconstruction, amalgamation, reorganization, merger or consolidation or other similar arrangement; or

(ix) **Analogous Events:** any event occurs that under the laws of any relevant jurisdiction has an analogous effect to any of the events referred to in any of the foregoing paragraphs (vii) and (viii).

The BATIF Indenture provides that if an Event of Default occurs and is continuing with respect to the Notes of any series then outstanding, then and in each and every such case (other than certain Events of Default specified in paragraphs (vii), (viii) and (ix) above with respect to the Issuer or any Guarantor), unless the principal of all the Notes of such series shall have already become due and payable, the holders of not less than 25% in aggregate principal amount of the Notes of such affected series then outstanding, by notice in writing to the Issuer, each Guarantor and the Trustee, may declare the entire principal amount of all Notes of such series and interest accrued and unpaid thereon, if any, to be due and payable immediately, and upon any such declaration the same shall become immediately due and payable, without any further declaration or other act on the part of any holder. If certain Events of Default described in paragraph (vii), (viii) or (ix) above occur with respect to the Issuer or any Guarantor and are continuing with respect to a series of Notes, the principal amount of and accrued and unpaid interest on all the Notes of such series issued pursuant to the BATIF Indenture shall become immediately due and payable, without any declaration or other act on the part of the Trustee or any holder. Under certain circumstances, the holders of a majority in aggregate principal amount of the then outstanding Notes of such series, by written notice to the Issuer, each Guarantor and the Trustee, may waive defaults and rescind and annul declarations of acceleration and its consequences, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent default or shall impart any right consequent thereon.

41
The holders of a majority in aggregate principal amount of any series of Notes then outstanding will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to the Notes of such series, subject to certain limitations to be specified in the BATIF Indenture, including providing to the Trustee indemnity satisfactory to it.

An Event of Default with respect to any series of Notes would not necessarily constitute an event of default with respect to the other series of Notes.

The BATIF Indenture provides that notwithstanding the foregoing provisions described under “—Events of Default”, if the principal of, premium (if any) or interest on or Additional Amounts with respect to any Note is payable in a currency or currencies other than Dollars and such currency or currencies are not available to the Issuer or any Guarantor for making payment thereof due to the imposition of exchange controls or other circumstances beyond the control of the Issuer or such Guarantor (a “Conversion Event”), the Issuer and the Guarantor will be entitled to satisfy its obligations to Holders of the Notes by making such payment in Dollars in an amount equal to the Dollar equivalent of the amount payable in such other currency, as determined by the Issuer or the Guarantor making such payment; as the case may be, based on the Exchange Rate on the date of such payment, or, if such rate is not then available, on the basis of the most recently available Exchange Rate. Notwithstanding the foregoing provisions, any payment made under such circumstances in Dollars where the required payment is in a currency other than Dollars will not constitute an Event of Default under the BATIF Indenture.

Promptly after the occurrence of a Conversion Event, the Issuer or the relevant Guarantor shall give written notice thereof to the Trustee and to the Paying Agent; and the Trustee, promptly after receipt of such notice, shall give notice thereof in the manner provided in the BATIF Indenture to the Holders of the relevant series of Notes. Promptly after the making of any payment in Dollars as a result of a Conversion Event, the Issuer or the Guarantor making such payment, as the case may be, shall give notice in the manner provided in the BATIF Indenture to the Holders, setting forth the applicable Exchange Rate and describing the calculation of such payments.

No holder of the Notes of a series will have any right to institute any action or proceeding at law or in equity or in bankruptcy or otherwise upon or under or with respect to the BATIF Indenture, or for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy under the BATIF Indenture (except suits for the enforcement of payment of overdue principal or interest) unless (1) the holder of a Note gives to the Trustee written notice of a continuing Event of Default, (2) the holders of at least 25% in principal amount of the outstanding Notes of such series have made a written request to the Trustee to institute such proceeding as Trustee, (3) the holder or holders of Notes offer, and if requested, provide to the Trustee indemnity satisfactory to the Trustee against any loss, liability or expense, (4) the Trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity and (5) during such 60-day period the holders of a majority in aggregate principal amount of the outstanding Notes of such series have not given the Trustee a direction inconsistent with the request. The holder of a Note may not use the BATIF Indenture to prejudice the rights of another holder of a Note or to obtain a preference or priority over another holder of a Note (it being understood that the Trustee does not have an affirmative duty to ascertain whether or not such actions or forbearances are unduly prejudicial to such holders).
Satisfaction and Discharge

The BATIF Indenture provides that BAT may, subject to satisfying certain conditions, discharge certain obligations to the holders of Notes of any series of Notes that have not already been delivered to the Trustee for cancellation and that either have become due and payable or will become due and payable within one year (or scheduled for redemption within one year) by depositing with the Trustee or Paying Agent, in trust, funds in an amount sufficient to pay the entire indebtedness on such series of Notes in respect of principal and premium, if any, and interest, if any, to the date of such deposit (if such Notes have become due and payable) or to the maturity thereof or redemption date, as the case may be, along with an officer’s certificate and an opinion of counsel stating that all conditions precedent relating to the satisfaction and discharge of the BATIF Indenture have been complied with.

Legal Defeasance and Covenant Defeasance

The BATIF Indenture provides that the Issuer will have the option either (a) to be deemed (together with each Guarantor) to have paid and discharged the entire indebtedness represented by, and obligations under, a series of Notes and the applicable Guarantees and to have satisfied all the obligations under the BATIF Indenture relating to the series of Notes (except for certain obligations, including those relating to the defeasance trust and obligations to register the transfer or exchange of Notes, to replace mutilated, destroyed, lost or stolen Notes and to maintain paying agencies) on the 91st day after the applicable conditions described below have been satisfied or (b) to cease (together with each Guarantor) to be under any obligation to comply with the covenants described above under “—Covenants of the Issuer and the Guarantors—Negative Pledge”, “—Covenants of the Issuer and the Guarantors—Limitation on Mergers, Consolidations, Amalgamations and Combinations”, and non-compliance with such covenants and the occurrence of all events described above under “—Events of Default” will not give rise to any Event of Default under the BATIF Indenture, at any time after the applicable conditions described below have been satisfied.

In order to exercise either defeasance option, the Issuer must (i) deposit with the Trustee, irrevocably in money or Government Obligations (as defined in the BATIF Indenture), funds sufficient in the opinion of a certified public accounting firm of national reputation for the payment of principal of and interest on the applicable outstanding Notes of any series to and including the Redemption Date irrevocably designated by the Issuer on or prior to the date of deposit of such money or Government Obligations, and must (ii) comply with certain other conditions, including delivering to the Trustee an opinion of U.S. counsel to the effect that beneficial owners of the applicable Notes will not recognize income, gain or loss for United States Federal income tax purposes as a result of the exercise of such option and will be subject to United States Federal income tax on the same amount and in the same manner and at the same time as would have been the case if such option had not been exercised and, in the case of clause (a) in the previous paragraph, which opinion must state that such opinion is based on a ruling received from or published by the United States Internal Revenue Service or on a change in the applicable U.S. Federal income tax laws after the date of issuance of the relevant Notes.
Modification and Waiver

Without Consent of Noteholders

The BATIF Indenture contains provisions permitting the Issuer, the Guarantors and the Trustee, without the consent of the holders of any of the applicable Notes at any time outstanding, from time to time and at any time, to enter into a supplemental indenture amending or supplementing such BATIF Indenture, the Notes or the Guarantees in order to:

• convey, transfer, assign, mortgage or pledge to the holders of the applicable Notes or any person acting on their behalf as security for the applicable Notes any property or assets;
• evidence the succession of another person to the Issuer or any Guarantor, as the case may be, or successive successions, and the assumption by the successor person(s) of the covenants, agreements and obligations of the Issuer or any Guarantor, as the case may be, pursuant to the BATIF Indenture;
• evidence and provide for the acceptance of appointment of a successor or successors to the Trustee and/or the Paying Agent, Transfer Agent, Calculation Agent and Registrar, as applicable;
• add to the covenants of, or the restrictions, conditions or provisions applicable to, the Issuer and any Guarantor, as the case may be, such further covenants, restrictions, conditions or provisions as the Issuer and any Guarantor, as the case may be, shall consider to be for the protection of the holders of the applicable Notes issued pursuant to the BATIF Indenture, including to eliminate one or both prongs of the release provision under “—Guarantees—Release”, and to make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default under the BATIF Indenture permitting the enforcement of all or any of the several remedies provided in the BATIF Indenture; provided that, in respect of any such additional covenant, restriction, condition or provision, such supplemental indenture may provide for a particular period of grace after default (which may be shorter or longer than that allowed in the case of other defaults) or may limit the remedies available to the Trustee upon such an Event of Default;
• modify the restrictions on, and procedures for, resale and other transfers of the applicable Notes pursuant to law, regulation or practice relating to the resale or transfer of restricted securities generally;
• cure any ambiguity or to correct or supplement any provision contained in the BATIF Indenture, the Notes, or the Guarantees which may be defective or inconsistent with any other provision contained therein or to make such other provision in regard to matters or questions arising under the BATIF Indenture, the Notes or the Guarantees as the Issuer, any Guarantor or the Trustee may deem necessary or desirable and which will not, in the opinion of the Issuer, adversely affect the interests of the holders of the applicable Notes in any material respect.
issue an unlimited aggregate principal amount of Notes under the BATIF Indenture or to “reopen” the applicable series of Notes and create additional notes having substantially identical terms and conditions as the applicable Notes (or in all respects except as to issue price, denomination, rate of interest, Maturity Date and the date from which interest, if any, shall accrue, and except as may otherwise be provided in or pursuant to such officer’s certificate or supplemental indenture relating thereto) so that the additional notes are consolidated and form a single series with the outstanding applicable Notes; and

- evidence the addition of any new Guarantor of the Notes and the BATIF Indenture, or the release of any Guarantor from its obligations with respect to the Notes and the BATIF Indenture, pursuant to the terms of the BATIF Indenture.

With Consent of Noteholders

The BATIF Indenture contains provisions permitting the Issuer, each Guarantor and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of all series of the Notes affected by such supplemental indenture (voting as one class) at the time outstanding under the BATIF Indenture (including consents obtained in connection with a tender offer or exchange offer for the applicable Notes), from time to time and at any time, to enter into a supplemental indenture for the purpose of amending, waiving or otherwise modifying the provisions of the BATIF Indenture, the Notes and the Guarantees, or adding any provisions to or changing in any manner or eliminating any of the provisions of the applicable Notes or of modifying in any manner the rights of the holders of the applicable Notes; provided, that no such supplemental indenture may, without the consent of the holder of each of the Notes so affected:

- change the stated maturity of the applicable Note of, or the date for payment of any principal of, or installment of interest on, any applicable Note, or reduce the amount of principal of an Original Issue Discount Note that would be due and payable upon a declaration of acceleration of the maturity thereof pursuant to the provisions of the BATIF Indenture; or

- reduce the principal amount of or the rate or amount of interest on any applicable Note or Additional Amounts payable with respect thereto or reduce the amount payable thereon in the event of redemption or default or change the method for determining the interest rate thereon; or

- change the currency of payment of principal of or interest on any applicable Note or Additional Amounts payable with respect thereto; or change the obligation of the Issuer or any Guarantor, as the case may be, to pay Additional Amounts (except as otherwise permitted by such applicable Note); or

- impair the right to institute suit for the enforcement of any such payment on or with respect to any applicable Note; or
• reduce the percentage of the aggregate principal amount of the applicable Notes outstanding the consent of whose holders is required for any such supplemental indenture; or

• reduce the aggregate principal amount of any applicable Note outstanding necessary to modify or amend the BATIF Indenture or any such Note or to waive any future compliance or past default or reduce the quorum requirements or the percentage of aggregate principal amount of any applicable Notes outstanding required for the adoption of any action at any meeting of holders of such Notes or to reduce the percentage of the aggregate principal amount of such Notes outstanding necessary to rescind or annul any declaration of the principal of, or all accrued and unpaid interest on, any Note to be due and payable,

provided that no consent of any holder of any applicable Note shall be necessary to permit the Trustee, the Issuer and each Guarantor to execute supplemental indentures as described under “—Without Consent of Noteholders” above.

Any modifications, amendments or waivers to the BATIF Indenture or to the conditions of the applicable Notes will be conclusive and binding on all holders of the applicable Notes, whether or not they have consented to such action or were present at the meeting at which such action was taken, and on all future holders of the applicable Notes, whether or not notation of such modifications, amendments or waivers is made upon such Notes. Any instrument given by or on behalf of any holder of such a Note in connection with any consent to any such modification, amendment or waiver will be irrevocable once given and will be conclusive and binding on all subsequent registered holders of such Note.

**Prescription**

Under New York’s statute of limitations, any legal action upon the Notes in respect of interest or principal must be commenced within six years after the payment thereof is due.

**Notice**

Notices to holders of Notes will be given by first-class mail postage prepaid to the last addresses of such holders as they appear in the Notes register; provided, no such mailing will be required so long as any Global Notes representing the Notes are held in their entirety on behalf of the Depositary or a clearing system, or any of its participants, as there may be substituted for the mailing of notice to holders of Notes described above the delivery of the relevant. Such notices will be deemed to have been given on the date of such mailing; notices to the Depositary or a clearing system, and (if applicable) its participants, for communication by them to the entitled accountholders. Any such notice shall be deemed to have been given on the day on which the said notice was given to the Depositary or a clearing system, and (if applicable) its participants.

**Listing**

The BATIF Notes are listed on the New York Stock Exchange.

46
Consent to Service
Each of the Issuer and the non-U.S. Guarantors has initially designated BATCAP as its authorized agent for service of process in any legal suit, action or proceeding arising out of or relating to the performance of its obligations under the BATIF Indenture, the supplemental indenture and the BATIF Notes brought in any state or federal court in the Borough of Manhattan, the City of New York, and the Guarantors will irrevocably submit (but for these purposes only) to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding.

Governing Law
The BATIF Indenture, the Notes and the Guarantees are, and any applicable supplemental indentures shall be, governed by and construed in accordance with the laws of the State of New York, without regard to principles of conflicts of laws thereof.

Regarding the Trustee and Agents
Citibank, N.A. is the trustee under the BATIF Indenture. Citibank, N.A. is appointed by the Issuer to act as registrar, transfer agent, calculation agent and initial paying agent for the BATIF Notes. The Issuer can change the registrar, transfer agent, calculation agent or paying agent without prior notice to the holders of the BATIF Notes. The address of Citibank, N.A., as paying agent, is Citibank, N.A., Agency & Trust, 388 Greenwich Street, New York, NY 10013. From time to time, Citibank, N.A. and its respective affiliates perform various other services for the BAT Group and its affiliates (including acting as a lender under one or more of the BAT Group’s lending facilities from time to time).

The BATIF Indenture contains limitations on the rights of the trustee, if it becomes a creditor of the Issuer or any Guarantor, to obtain payment of claims in some cases, or to realize on property received in respect of any of these claims as security or otherwise. The Trustee is permitted to engage in other transactions. However, if the Trustee acquires any conflicting interest (as defined in the TIA), it must either eliminate its conflict within 90 days or resign.

The BATIF Indenture provides that except during the continuance of an Event of Default, the Trustee will perform only such duties as are specifically set forth in such BATIF Indenture. During the continuance of an Event of Default of which the Trustee has received written notice, the Trustee will exercise such of the rights and powers vested in it under the BATIF Indenture, and use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs.

D. Description of the Notes Issued Under the 2019 BATCAP Indenture
The following is a summary of the material provisions of the 2019 BATCAP Indenture (as described below), the applicable supplemental indentures and the Notes. Any capitalized term used herein but not defined shall have the meaning assigned to such term in the 2019 BATCAP Indenture, the applicable supplemental indenture or under “—Certain Definitions”. The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all of the provisions of the 2019 BATCAP Indenture, the applicable supplemental indentures and those terms made a part of the 2019 BATCAP Indenture and/or applicable supplemental indentures by reference to the Trust Indenture Act of 1939, as amended (the “TIA”).
GENERAL
The 2.259% Notes due 2028 (the “2028 Notes”), the 2.726% Notes due 2031 (the “2031 Notes”), the 3.734% Notes due 2040 (the “2040 Notes”), the 3.984% Notes due 2050 (the “2050 3.984% Notes”), the 4.700% Notes due 2027 (the “2027 4.700% Notes”), the 4.906% Notes due 2030 (the “2030 Notes”), the 5.282% Notes due 2050 (the “2050 5.282% Notes”), the 2.789% Notes due 2024 (the “2024 Notes”), the 3.215% Notes due 2026 (the “2026 Notes”), the 3.462% Notes due 2029 (the “2029 Notes”) and the 4.758% Notes due 2049 (the “2049 Notes”) and, together with the 2028 Notes, the 2031 Notes, the 2040 Notes, the 2050 3.984% Notes, the 2027 4.700% Notes, the 2030 Notes, the 2050 5.282% Notes, 2024 Notes, the 2026 Notes and the 2029 Notes, the “BATCAP Notes”) were issued by B.A.T Capital Corporation (“BATCAP” or the “Issuer”).

In this “Description of the Notes Issued Under the 2019 BATCAP Indenture”, we refer to each series of the BATCAP Notes as a “series” of BATCAP Notes.

The 2028 Notes will mature on March 25, 2028. The 2031 Notes will mature on March 25, 2031. The 2040 Notes will mature on September 25, 2040. The 2050 3.984% Notes will mature on September 25, 2050. The 2027 4.700% Notes will mature on April 2, 2027. The 2030 Notes will mature on April 2, 2030. The 2050 5.282% Notes will mature on April 2, 2050. The 2024 Notes will mature on September 6, 2024. The 2026 Notes will mature on September 6, 2026. The 2029 Notes will mature on September 6, 2029. The 2049 Notes will mature on September 6, 2049.

The BATCAP Notes were issued in registered form and treated as eleven separate series of debt securities and were each issued under a separate supplemental indenture to the indenture dated as of September 6, 2019 (as amended or supplemented from time to time, the “2019 BATCAP Indenture”) by and among BATCAP, as Issuer, British American Tobacco p.l.c. (“BAT” or the “Parent”), B.A.T. International Finance p.l.c. (“BATIF”), B.A.T. Netherlands Finance B.V. (“BATNF”) and, unless its guarantee is released in accordance with the 2019 BATCAP Indenture, Reynolds American Inc. (“RAI”), each as a guarantor, Citibank, N.A., as trustee (the “Trustee”), registrar, transfer agent, calculation agent and initial paying agent (in such several capacities under the 2019 BATCAP Indenture, the “Registrar”, “Transfer Agent”, “Calculation Agent”, and “Paying Agent”, respectively).

Each guarantee in respect of the BATCAP Notes is referred to herein as a “Guarantee” and each entity that provides a Guarantee is referred to herein as a “Guarantor”. In this “Description of the Notes Issued Under the 2019 BATCAP Indenture”, the terms “holder”, “Noteholder” and other similar terms refer to a “registered holder” of Notes, and not to a beneficial owner of a book-entry interest in any BATCAP Notes.

PRINCIPAL, MATURITY AND INTEREST
The obligations of the Issuer under the BATCAP Notes and 2019 BATCAP Indenture are fully and unconditionally guaranteed on a joint and several and senior and unsecured basis by each of the Parent, BATIF, BATNF and, unless its guarantee is released in accordance with the 2019 BATCAP Indenture, RAI.
The BATCAP Notes were initially issued in the following aggregate principal amounts, with maturity dates as follows:

<table>
<thead>
<tr>
<th>Series of BATCAP Notes</th>
<th>Aggregate principal amount</th>
<th>Maturity date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2028 Notes</td>
<td>$ 1,750,000,000</td>
<td>March 25, 2028</td>
</tr>
<tr>
<td>2031 Notes</td>
<td>$ 1,250,000,000</td>
<td>March 25, 2031</td>
</tr>
<tr>
<td>2040 Notes</td>
<td>$ 750,000,000</td>
<td>September 25, 2040</td>
</tr>
<tr>
<td>2050 3.984% Notes</td>
<td>$ 1,000,000,000</td>
<td>September 25, 2050</td>
</tr>
<tr>
<td>2027 4.700% Notes</td>
<td>$ 900,000,000</td>
<td>April 2, 2027</td>
</tr>
<tr>
<td>2030 Notes</td>
<td>$ 1,000,000,000</td>
<td>April 2, 2030</td>
</tr>
<tr>
<td>2050 5.282% Notes</td>
<td>$ 500,000,000</td>
<td>April 2, 2050</td>
</tr>
<tr>
<td>2024 Notes</td>
<td>$ 1,000,000,000</td>
<td>September 6, 2024</td>
</tr>
<tr>
<td>2026 Notes</td>
<td>$ 1,000,000,000</td>
<td>September 6, 2026</td>
</tr>
<tr>
<td>2029 Notes</td>
<td>$ 500,000,000</td>
<td>September 6, 2029</td>
</tr>
<tr>
<td>2049 Notes</td>
<td>$ 1,000,000,000</td>
<td>September 6, 2049</td>
</tr>
</tbody>
</table>

Interest

The Notes bear interest per annum as follows:

<table>
<thead>
<tr>
<th>Series of BATCAP Notes</th>
<th>Interest rate per annum</th>
</tr>
</thead>
<tbody>
<tr>
<td>2028 Notes</td>
<td>2.259%</td>
</tr>
<tr>
<td>2031 Notes</td>
<td>2.726%</td>
</tr>
<tr>
<td>2040 Notes</td>
<td>3.734%</td>
</tr>
<tr>
<td>2050 3.984% Notes</td>
<td>3.984%</td>
</tr>
<tr>
<td>2027 4.700% Notes</td>
<td>4.700%</td>
</tr>
<tr>
<td>2030 Notes</td>
<td>4.906%</td>
</tr>
<tr>
<td>2050 5.282% Notes</td>
<td>5.282%</td>
</tr>
<tr>
<td>2024 Notes</td>
<td>2.789%</td>
</tr>
<tr>
<td>2026 Notes</td>
<td>3.215%</td>
</tr>
<tr>
<td>2029 Notes</td>
<td>3.462%</td>
</tr>
<tr>
<td>2049 Notes</td>
<td>4.758%</td>
</tr>
</tbody>
</table>

The 2028 Notes, the 2031 Notes, the 2040 Notes and the 2050 3.984% Notes will bear interest from the date of the initial issuance of such 2028 Notes, 2031 Notes, 2040 Notes and 2050 3.984% Notes or from the most recent interest payment date to which interest has been paid or provided for, payable semi-annually in arrears on March 25 and September 25 of each year, commencing on March 25, 2021 (each, an “Interest Payment Date”) until each series’ respective maturity date, unless previously purchased and cancelled or redeemed by the Issuer, to the person in whose name any 2028 Notes, 2031 Notes, 2040 Notes and 2050 3.984% Notes are registered at the close of business on the 15th calendar day preceding each Interest Payment Date, whether or not such day is a Business Day (each, a “Record Date”) notwithstanding any transfer or exchange of such 2028 Notes, 2031 Notes, 2040 Notes and 2050 3.984% Notes subsequent to the Record Date and prior to such Interest Payment Date, except that, if and to the
extent the Issuer shall default in the payment of the interest due on such Interest Payment Date, and the applicable grace period shall have expired, such defaulted interest may at the option of the Issuer be paid to the persons in whose names the outstanding 2028 Notes, 2031 Notes, 2040 Notes and 2050 3.984% Notes are registered at the close of business on a subsequent Record Date (which shall not be less than five Business Days prior to the date of payment of such defaulted interest) established by notice sent by or on behalf of the Issuer to the holders of 2028 Notes, 2031 Notes, 2040 Notes and 2050 3.984% Notes, not less than 15 days preceding such subsequent Record Date. The 2027 4.700% Notes, the 2030 Notes and the 2050 5.282% Notes bear interest from the most recent interest payment date to which interest has been paid or provided for, payable semi-annually in arrears on April 2 and October 2 of each year (each, also an “Interest Payment Date”), until each series’ respective maturity date, unless previously purchased and cancelled or redeemed by the Issuer, to the person in whose name any 2027 4.700% Notes, 2030 Notes and 2050 5.282% Notes are registered at the close of business on the 15th calendar day preceding each Interest Payment Date, whether or not such day is a Business Day (each, also a “Record Date”) notwithstanding any transfer or exchange of such 2027 4.700% Notes, 2030 Notes and 2050 5.282% Notes subsequent to the Record Date and prior to such Interest Payment Date, except that, if and to the extent the Issuer shall default in the payment of the interest due on such Interest Payment Date, and the applicable grace period shall have expired, such defaulted interest may at the option of the Issuer be paid to the persons in whose names the outstanding 2027 4.700% Notes, 2030 Notes and 2050 5.282% Notes are registered at the close of business on a subsequent Record Date (which shall not be less than five Business Days prior to the date of payment of such defaulted interest) established by notice sent by or on behalf of the Issuer to the holders of 2027 4.700% Notes, 2030 Notes and 2050 5.282% Notes, not less than 15 days preceding such subsequent Record Date. The 2024 Notes, the 2026 Notes, the 2029 Notes and the 2049 Notes bear interest from the most recent interest payment date to which interest has been paid or provided for, payable semi-annually in arrears on March 6 and September 6 of each year (each, also an “Interest Payment Date”) until each series’ respective maturity date, unless previously purchased and cancelled or redeemed by the Issuer, to the person in whose name any 2024 Notes, 2026 Notes, 2029 Notes and 2049 Notes are registered at the close of business on the 15th calendar day preceding each Interest Payment Date, whether or not such day is a Business Day (each, also a “Record Date”) notwithstanding any transfer or exchange of such 2024 Notes, 2026 Notes, 2029 Notes and 2049 Notes subsequent to the Record Date and prior to such Interest Payment Date, except that, if and to the extent the Issuer shall default in the payment of the interest due on such Interest Payment Date, and the applicable grace period shall have expired, such defaulted interest may at the option of the Issuer be paid to the persons in whose names the outstanding 2024 Notes, 2026 Notes, 2029 Notes and 2049 Notes are registered at the close of business on a subsequent Record Date (which shall not be less than five Business Days prior to the date of payment of such defaulted interest) established by notice sent by or on behalf of the Issuer to the holders of 2024 Notes, 2026 Notes, 2029 Notes and 2049 Notes, not less than 15 days preceding such subsequent Record Date. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months, or in the case of an incomplete month, the number of days elapsed. If the date on which any interest payment or principal payment is to be made is not a Business Day, such payment will be made on the next day which is a Business Day, without any further interest or other amounts being paid or payable in connection therewith. A “Business Day” refers to any day which is not, in London or New York City, or any other place of payment, a Saturday, Sunday, legal holiday or a day on which banking institutions are authorized or obligated by law or regulation to close.
Form and Denomination

The BATCAP Notes of each series were issued in fully registered form and only in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof, and were issued initially as global notes representing the BATCAP Notes of each series (collectively, the “Global Notes”). The Global Notes were (i) registered in the name of the Depository or the nominee of such Depository, in each case for the credit to an account of a member of, or direct or indirect participant in, the Depository; and (ii) delivered to Citibank, N.A. as custodian for such Depository.

Further Issues

The aggregate principal amount of notes (including each series of BATCAP Notes) issueable under the 2019 BATCAP Indenture (the “Notes”) is unlimited. The Issuer may, from time to time, without notice to or the consent of the holders of the Notes, issue Notes of a new series or “reopen” any series of the Notes (including any series of BATCAP Notes) and create and issue additional Notes having substantially identical terms and conditions as the then-outstanding Notes of a series (or in all respects except as to issue date, issue price, denomination, rate of interest, maturity date and the date from which interest, if any, shall accrue and except as may otherwise be provided in or pursuant to an officer’s certificate or any supplemental indenture relating thereto) so that the additional Notes are consolidated and form a single series of Notes with the outstanding Notes of such series, as the case may be, provided that if the additional Notes are not fungible with the outstanding Notes of the relevant series for United States Federal income tax purposes, the additional Notes will have separate CUSIPs, ISINs, or other identifying numbers.

Status of the Notes and Guarantees

The BATCAP Notes are unsecured and unsubordinated obligations of the Issuer and rank pari passu in right of payment among themselves and with all other direct, unsecured and unsubordinated obligations of the Issuer (except those obligations preferred by statute or operation of law). Each Guarantor fully and unconditionally guarantees, on a senior, unsecured basis, the due and punctual payment (and not collectability) of the principal of and interest on the BATCAP Notes (and the payment of additional amounts described under “—Additional Amounts” below) and other obligations under the 2019 BATCAP Indenture when and as the same shall become due and payable, whether at stated maturity, by declaration of acceleration, call for redemption or otherwise. Each Guarantee is an unsecured and unsubordinated obligation of the respective Guarantor and rank pari passu in right of payment with all other direct, unsecured and unsubordinated obligations of such Guarantor (except those obligations preferred by statute or operation of law). The Issuer and each Guarantor are subject to a negative pledge with respect to certain types of indebtedness, which are discussed in “—Covenants of the Issuer and the Guarantors—Negative Pledge”.

51
Guarantees

Release

The 2019 BATCAP Indenture and the applicable supplemental indentures provide, that, without the consent of the Trustee or the Noteholders, any Guarantor that is a subsidiary of the Parent (a “Subsidiary Guarantor”), other than BATIF and BATNF, will automatically and unconditionally be released from all obligations under its Guarantee, and such Guarantee shall thereupon terminate and be discharged and of no further force or effect, in the event that (1) its guarantee of all then outstanding notes issued under the EMTN Programme is released or (2) at substantially the same time its Guarantee of the Notes is terminated, the Subsidiary Guarantor is released from all obligations in respect of indebtedness for borrowed money for which such Subsidiary Guarantor is an obligor (as a guarantor or borrower). For purposes of this paragraph, the amount of a Subsidiary Guarantor’s indebtedness for borrowed money shall not include (A) the Notes issued pursuant to the 2019 BATCAP Indenture (including the BATCAP Notes), (B) any other debt the terms of which permit the termination of such Subsidiary Guarantor’s guarantee of such debt under similar circumstances, as long as such Subsidiary Guarantor’s obligations in respect of such other debt are terminated at substantially the same time as its Guarantee of the Notes (including the BATCAP Notes), (C) any debt that is being refinanced at substantially the same time that the Guarantee of the Notes (including the BATCAP Notes) is being released, provided that any obligations of the relevant Subsidiary Guarantor in respect of the debt that is incurred in the refinancing shall be included in the calculation of the relevant Subsidiary Guarantor’s indebtedness for borrowed money and (D) for the avoidance of doubt, any debt in respect of which such Subsidiary Guarantor is an obligor (as a guarantor or borrower) (i) between or among the Parent and any subsidiary or subsidiaries thereof or (ii) between or among any subsidiaries of the Parent.

As of the date of this summary, RAI is the only Subsidiary Guarantor to which the above provision is relevant. Under the EMTN Programme, RAI’s guarantee is released if at any time the aggregate amount of indebtedness for borrowed money for which the Subsidiary Guarantor is an obligor does not exceed 10% of the outstanding long-term debt of BAT as reflected in the balance sheet included in BAT’s most recent publicly released interim or annual consolidated financial statements, as evidenced by a certificate to such effect addressed to the trustee under the EMTN Programme and signed by a director of BAT.

Additional Amounts

Each of the Parent, BATIF and BATNF will make payments pursuant to the applicable Guarantee without withholding or deduction for or on account of any present or future tax, levy, impost or other similar governmental charge ("Taxes") imposed, assessed, levied or collected by or for the account of the United Kingdom (in the case of a payment by the Parent or BATIF) or The Netherlands (in the case of a payment by BATNF), including in each case any political subdivision thereof or any authority thereof having the power to tax (a “Relevant Taxing Jurisdiction”), unless such withholding or deduction is required by law.

52
If any such Guarantor is required by a Relevant Taxing Jurisdiction to so withhold or deduct such Taxes, such Guarantor will pay to the holder such additional amounts ("Additional Amounts") as will result in the receipt by the holder of such amounts as would have been received by it if no such withholding or deduction of Taxes had been required; provided, however, that no Guarantor shall be required to pay any Additional Amounts for or on account of:

(a) any Taxes that would not have been so imposed, assessed, levied or collected but for the Holder or beneficial owner of the applicable Note or Guarantee (or a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such Holder, if such Holder is an estate, trust, partnership or corporation) being or having been a domiciliary, national or resident of, or engaging or having been engaged in a trade or business or maintaining or having maintained a permanent establishment or being or having been physically present in, a Relevant Taxing Jurisdiction or otherwise having or having had some connection with a Relevant Taxing Jurisdiction other than the holding or ownership of, or the collection of principal of, and premium (if any) or interest on, a Note or the enforcement of the applicable Note or Guarantee, as the case may be;

(b) any Taxes that would not have been so imposed, assessed, levied or collected but for the fact that, where presentation is required in order to receive payment, the applicable Note or Guarantee was presented more than 30 days after the date on which such payment became due and payable or was provided for, whichever is later, except to the extent that the Holder or beneficial owner thereof would have been entitled to Additional Amounts had the applicable Note or Guarantee been presented for payment on any day during such 30-day period;

(c) any estate, inheritance, gift, sales, transfer, personal property or similar Taxes;

(d) any Taxes that are payable otherwise than by withholding or deduction from payments on or in respect of the applicable Note or Guarantee;

(e) any Taxes that would not have been so imposed, assessed, levied or collected but for the failure by the Holder or the beneficial owner of the applicable Guarantee to (i) provide any certification, identification, information, documents or other evidence concerning the nationality, residence or identity of the Holder or the beneficial owner or its connection with a Relevant Taxing Jurisdiction; or (ii) make any valid or timely declaration or claim or satisfy any other reporting, information or procedural requirements relating to such matters if, in either case, compliance is required by statute, regulation, relevant income tax treaty or administrative practice of a Relevant Taxing Jurisdiction as a condition to relief or exemption from such Taxes;

(f) any Taxes imposed or withheld pursuant to Sections 1471 through 1474 of the Code (or any amended or successor provisions), any U.S. Treasury regulations promulgated thereunder, any official interpretations thereof or any agreements entered into in connection with the implementation thereof ("FATCA Withholding"), or
any combination of the Taxes described in clauses (a) through (f) above.

In addition, in the case of the 2024 Notes, the 2026 Notes, the 2029 Notes, and the 2049 Notes, no Guarantor shall be required to pay any Additional Amounts for or on account of any taxes imposed or to be withheld pursuant to the Dutch Withholding Tax Act 2021 (Wet bronbelasting 2021). In addition, Additional Amounts will not be paid with respect to any payment of the principal of, or premium (if any) or interest on, any Note or any payment pursuant to the applicable Guarantee to any Holder that is a fiduciary, a partnership, a limited liability company or any person other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary, a member of such partnership, an interest holder in such limited liability company or a beneficial owner that would not have been entitled to such amounts had such beneficiary, settlor, member, interest holder or beneficial owner been the Holder of the applicable Note or Guarantee.

Unless otherwise stated, references in any context to the payment of principal of, and premium (if any) or interest on, any Note, or to any payment pursuant to a Guarantee will be deemed to include payment of Additional Amounts to the extent that, in such context, Additional Amounts are, were or would be payable in respect thereof.

Redemption

The Notes are subject to optional redemption by the Issuer as described below under “—Optional Redemption”. The Notes are also subject to optional redemption by the Issuer in the event of certain changes in tax laws applicable to payments in respect of the Notes as described below under “—Redemption for Tax Reasons”.

Optional Redemption

The Issuer may redeem the BATCAP Notes, in whole or in part, at the Issuer’s option, at any time and from time to time before the applicable Par Call Date (as defined below), at a redemption price equal to the greater of (x) 100% of the principal amount of the series of BATCAP Notes to be redeemed and (y) as determined by the Independent Investment Banker (as defined below), the sum of the present values of the applicable Remaining Scheduled Payments (as defined below) discounted to the date of redemption (the “Redemption Date”) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months or, in the case of an incomplete month, the number of days elapsed) at the Treasury Rate (as defined below) plus, in the case of each respective series of BATCAP Notes as follows:

<table>
<thead>
<tr>
<th>Series</th>
<th>Basis Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>2028 Notes</td>
<td>30</td>
</tr>
<tr>
<td>2031 Notes</td>
<td>35</td>
</tr>
<tr>
<td>2040 Notes</td>
<td>35</td>
</tr>
<tr>
<td>2050 3.984% Notes</td>
<td>40</td>
</tr>
<tr>
<td>2027 4.700% Notes</td>
<td>50</td>
</tr>
<tr>
<td>2030 Notes</td>
<td>50</td>
</tr>
<tr>
<td>2050 5.282% Notes</td>
<td>50</td>
</tr>
<tr>
<td>2024 Notes</td>
<td>25</td>
</tr>
<tr>
<td>2026 Notes</td>
<td>30</td>
</tr>
<tr>
<td>2029 Notes</td>
<td>30</td>
</tr>
<tr>
<td>2049 Notes</td>
<td>45</td>
</tr>
</tbody>
</table>
together with, in each case, accrued and unpaid interest on the principal amount of the BATCAP Notes to be redeemed to, but excluding, the Redemption Date.

If the Issuer elects to redeem a series of the BATCAP Notes on or after the applicable Par Call Date, the Issuer will pay an amount equal to 100% of the principal amount of the BATCAP Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption.

In connection with such optional redemption the following defined terms apply:

• **Comparable Treasury Issue** means the United States Treasury security selected by the Independent Investment Banker that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the applicable BATCAP Notes to the relevant Par Call Date.

• **Comparable Treasury Price** means, with respect to any Redemption Date, (A) the average of the Reference Treasury Dealer Quotations for that Redemption Date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations or (B) if the Independent Investment Banker for the applicable BATCAP Notes obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such Quotations.

• **Independent Investment Banker** means one of the Reference Treasury Dealers (as defined below) appointed by the Issuer to act as the “Independent Investment Banker”.

• **Par Call Date** means (i) January 25, 2028, with respect to any 2028 Notes (two months prior to the maturity date of the 2028 Notes), (ii) December 25, 2030, with respect to any 2031 Notes (three months prior to the maturity date of the 2031 Notes), (iii) March 25, 2040, with respect to any 2040 Notes (six months prior to the maturity date of the 2040 Notes) and (iv) March 25, 2050, with respect to any 2050 3.984% Notes (six months prior to the maturity date of the 2050 3.984% Notes), (v) February 2, 2027 with respect to any 2027 4.700% Notes (two months prior to the maturity date of the 2027 4.700% Notes), (vi) January 2, 2030 with respect to any 2030 Notes (three months prior to the maturity date of the 2030 Notes) and (vii) October 2, 2049 with respect to any 2050 5.282% Notes (six months prior to the maturity date of the 2050 5.282% Notes) (viii) August 6, 2024 with respect to any 2024 Notes (one month prior to the maturity date of the 2024 Notes), (ix) July 6, 2026 with respect to any 2026 Notes (two months prior to the maturity date of the 2026 Notes), (x) June 6, 2029 with respect to any 2029 Notes (three months prior to the maturity date of the 2029 Notes) and (xi) March 6, 2049 with respect to any 2049 Notes (six months prior to the maturity date of the 2049 Notes).
• **Reference Treasury Dealer** means, in case of the 2028 Notes, the 2031 Notes, the 2040 Notes and the 2050 3.984% Notes, each of BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, Wells Fargo Securities, LLC, NatWest Markets Securities Inc. and SG Americas Securities, LLC and their respective successors and two other nationally recognized investment banking firms that are Primary Treasury Dealers specified from time to time by the Issuer, in case of the 2027 4.700% Notes, the 2030 Notes and the 2050 5.282% Notes, each of Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc. and Mizuho Securities USA LLC and their respective successors and two other nationally recognized investment banking firms that are Primary Treasury Dealers specified from time to time by the Issuer, and in case of the 2024 Notes, the 2026 Notes, the 2029 Notes, and the 2049 Notes, each of BofA Securities, Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and HSBC Securities (USA) Inc. and their respective successors and two other nationally recognized investment banking firms that are Primary Treasury Dealers specified from time to time by the Issuer; *provided, however*; that if any of the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury Dealer”), the Issuer shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer.

• **Reference Treasury Dealer Quotation** means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day immediately preceding that Redemption Date.

• **Remaining Scheduled Payments** means, with respect to each BATCAP Note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due from and including the related Redemption Date, but for such redemption, to but excluding the relevant Par Call Date; *provided, however*; that if that Redemption Date is not an Interest Payment Date with respect to such BATCAP Notes, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to that Redemption Date.

• **Treasury Rate** means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent yield to maturity (computed as of the third Business Day immediately preceding that Redemption Date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that Redemption Date.
Notice of any optional redemption will be given in accordance with the 2019 BATCAP Indenture at least 10 days but not more than 30 days before the Redemption Date to each holder of the Notes to be redeemed. Any redemption may, at the Issuer’s sole discretion, be subject to the satisfaction of one or more conditions precedent. In the event of a conditional redemption, the notice of conditional redemption shall reflect and specify the conditions to the redemption. Once the notice of redemption is delivered, BATCAP Notes called for redemption shall, subject to the satisfaction of any applicable conditions, become irrevocably due and payable on the Redemption Date.

If less than all the BATCAP Notes of a series are to be redeemed, in the case of a redemption at the Issuer’s option as discussed in this section, the BATCAP Notes to be redeemed shall be selected in accordance with applicable procedures of DTC.

Upon presentation of any BATCAP Note redeemed in part only, the Issuer will execute and upon receipt of a written direction from the Issuer, the Paying Agent will authenticate and deliver (or cause to be transferred by book-entry) to, or on, the order of the holder thereof, at the expense of the Issuer, a new BATCAP Note of authorized denominations in principal amount equal to the unredeemed portion of the BATCAP Note so presented.

The redemption price shall be calculated by the Independent Investment Banker and the Issuer, and the Trustee and any agent shall be entitled to rely on such calculation.

**Redemption for Tax Reasons**

Each series of Notes (including each series of BATCAP Notes) is also redeemable by the Issuer, in whole but not in part, at 100% of the principal amount of such Notes plus any accrued and unpaid interest (including any Additional Amounts) to the applicable date fixed for such redemption pursuant to the terms of the 2019 BATCAP Indenture or such series of Notes (the “Redemption Date”) at the Issuer’s option at any time prior to their maturity if, due to a Change in Tax Law (as defined below): (i) the Issuer or any Guarantor, in accordance with the terms of the applicable Notes or applicable Guarantee, has, or would, become obligated to pay any Additional Amounts to the Holders of the Notes of that series; (ii) in the case of any Guarantor, (A) the Parent would be unable, for reasons outside its control, to procure payment by the Issuer or any other Guarantor or (B) the procuring of such payment by the Issuer and each such other Guarantor would be subject to withholding Taxes imposed by a Relevant Taxing Jurisdiction; and (iii) such obligation cannot otherwise be avoided by such Guarantor, the Parent or the Issuer, taking reasonable measures available to it. In such case, the Issuer may redeem the applicable Notes upon not less than 30 nor more than 60 days’ notice as provided in “—Notice” below, at 100% of the principal amount of such Notes plus accrued and unpaid interest to the Redemption Date (including Additional Amounts); provided that (a) no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which the Issuer or such Guarantor, as the case may be, would be obligated to pay any such Additional Amounts in respect of the applicable Notes or applicable Guarantee, as applicable, then due; and (b) at the time such notice is given, such obligation to pay such Additional Amounts remains in effect. The Issuer’s right to redeem the applicable Notes shall continue as long as the Issuer or any Guarantor is obligated to pay such Additional Amounts, notwithstanding that the Issuer or such Guarantor, as the case may be, shall have made payments of Additional Amounts. Prior to the giving of any such notice of redemption, the Issuer must deliver to the Trustee: (i) an officer’s certificate stating that the Issuer is entitled to effect such redemption and setting forth a statement of facts showing that the
conditions precedent to the right of the Issuer to so redeem have occurred; and (ii) an opinion of independent counsel or an independent accountant of recognized standing, selected by the Issuer or any Guarantor, as applicable, with respect to tax matters of the Relevant Taxing Jurisdiction to the effect that the Issuer or such Guarantor has, or would, become obligated to pay such Additional Amounts as a result of such Change in Tax Law.

For the purposes hereof, “Change in Tax Law” shall mean: (i) any changes in, or amendment to, any law of a Relevant Taxing Jurisdiction (including any regulations or rulings promulgated thereunder and including, for this purpose, any treaty entered into by the Relevant Taxing Jurisdiction) or any amendment to or change in the application or official interpretation (including judicial or administrative interpretation) of such law, which change or amendment becomes effective or, in the case of an official interpretation, is announced, on or after the first date of issuance of Notes of such series; or (ii) if the Issuer or any Guarantor consolidates, merges, amalgamates or combines with, or transfers or leases its assets substantially as an entirety to, any person that is incorporated or tax resident under the laws of any jurisdiction other than a Relevant Taxing Jurisdiction (a “successor”) and as a consequence thereof such person becomes the successor obligor to the Issuer or such Guarantor in respect of Additional Amounts that may become payable (in which case, for purposes of this redemption provision, all references to the Issuer or such Guarantor shall be deemed to be and include references to such person), any change in, or amendment to, any law of the jurisdiction of organization or tax residence of such successor, or the jurisdiction through which payments will be made by the successor, or any political subdivision or taxing authority thereof or thereon for purposes of taxation (including any regulations or rulings promulgated thereunder and including, for this purpose, any treaty entered into by such jurisdiction) or any amendment to or change in the application or official interpretation (including judicial or administrative interpretation) of such law, which change or amendment becomes effective or, in the case of an official interpretation, is announced, on or after the date of such consolidation, merger, amalgamation, combination or other transaction.

**General**

On or before any Redemption Date (as defined above), the Issuer shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued and unpaid interest on the BATCAP Notes to be redeemed on such date.

On and after any Redemption Date, interest will cease to accrue on the BATCAP Notes or any portion thereof called for redemption.

**Maturity**

Unless previously purchased or redeemed by the Issuer, and cancelled, the principal amount of each respective series of BATCAP Notes shall mature on:

<table>
<thead>
<tr>
<th>Series of BATCAP Notes</th>
<th>Maturity date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2028 Notes</td>
<td>March 25, 2028</td>
</tr>
<tr>
<td>2031 Notes</td>
<td>March 25, 2031</td>
</tr>
<tr>
<td>2040 Notes</td>
<td>September 25, 2040</td>
</tr>
</tbody>
</table>

58
Series of BATCAP Notes | Maturity date
---|---
2050 3.984% Notes | September 25, 2050
2027 4.700% Notes | April 2, 2027
2030 Notes | April 2, 2030
2050 5.282% Notes | April 2, 2050
2024 Notes | September 6, 2024
2026 Notes | September 6, 2026
2029 Notes | September 6, 2029
2049 Notes | September 6, 2049

in an amount equal, in each case, to their principal amount, with accrued and unpaid interest to, but excluding, such date.

**Covenants of the Issuer and the Guarantors**

**Reacquisition**

There is no restriction on the ability of the Issuer to purchase or repurchase BATCAP Notes, provided, that any BATCAP Notes so repurchased shall be cancelled and not reissued.

**Sinking Fund**

There is no provision for a sinking fund for any of the Notes.

**Certain Definitions**

Set forth below is a summary of certain of the defined terms used in the BATCAP Notes, the 2019 BATCAP Indenture and the applicable supplemental indentures. You should refer to the BATCAP Notes, the 2019 BATCAP Indenture and applicable supplemental indentures for the full definition of all defined terms as well as any other terms used herein for which no definition is provided.

“Dollar” or “$” means United States dollars, or such other money of the United States that at the time of payment is legal tender for payment of public and private debts.

“EMTN Programme” means the Euro Medium Term Note Programme to which BATCAP, BATIF and BATNF are parties as the issuers under the programme and notes issued thereunder are guaranteed by the Parent, each of the issuers thereunder (except when it is the relevant issuer) and RAI, as amended from time to time.

“Original Issue Discount Note” means any Note that is issued with “original issue discount” within the meaning of Section 1273(a) of the Code and Treasury Regulations promulgated thereunder and any other Note designated by the Company as issued with original issue discount for United States federal income tax purposes.
“Person” means any individual, corporation, partnership, joint venture, association, limited liability company, joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.

“Quoted Borrowing” means any indebtedness which: (i) is represented by notes, debentures or other securities issued otherwise than to constitute or represent advances made by banks and/or other lending institutions; (ii) is denominated, or confers any right to payment of principal and/or interest, in or by reference to any currency other than the currency of the country in which the issuer of the indebtedness has its principal place of business or is denominated, or confers any right to payment of principal and/or interest, in or by reference to the currency of such country but is sold or subscribed by or on behalf of, or by agreement with, the issuer of such indebtedness as to over 20% outside such country; and (iii) at its date of issue is, or is intended by the issuer of such indebtedness to become, quoted, listed, traded or dealt in on any stock exchange or other organized and regulated securities market in any part of the world.

Covenants of the Issuer and the Guarantors

Negative Pledge

The 2019 BATCAP Indenture provides that so long as any of the Notes (including any of the BATCAP Notes) remains outstanding, neither the Issuer nor any Guarantor will secure or allow to be secured any Quoted Borrowing issued by the Issuer or any Guarantor or any payment under any guarantee by any of them of any such Quoted Borrowing by any mortgage, charge, pledge or lien (other than arising by operation of law) upon any of its undertaking or assets, whether present or future, unless at the same time the same mortgage, charge, pledge or lien is extended, or security which is not materially less beneficial to the holders of the Notes than the security given as aforesaid or which shall be approved by consent of the holders of not less than 75% in aggregate principal amount of the Notes at the time outstanding is extended or created (as the case may be), to secure equally and ratably the principal of, and interest on, and all other payments (if any) in respect of the Notes.

Limitation on Mergers, Consolidations, Amalgamations and Combinations

Under the 2019 BATCAP Indenture, so long as any of the Notes (including any of the BATCAP Notes) remains outstanding thereunder, neither the Issuer nor any Guarantor may consolidate with or merge into any other person or sell, convey, transfer or lease its properties and assets as an entirety or substantially as an entirety to any person (other than any sale or conveyance by way of a lease in the ordinary course of business), unless: (i) in the case of the Issuer, any successor person assumes the Issuer’s obligations on the Notes (including the BATCAP Notes) and under the 2019 BATCAP Indenture and, in the case of any Guarantor, any successor person assumes such Guarantor’s obligations on the Guarantee and under the 2019 BATCAP Indenture; (ii) immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; (iii) such successor person is organized under the laws of the United States or any State thereof, the United Kingdom, The Netherlands or any other country that is a member of the Organization for Economic Cooperation and Development as of the date of such succession; (iv) such successor person agrees to pay any Additional Amounts with respect to any withholding or
deduction of Taxes or any payment on the Notes (including the BATCAP Notes) or Guarantees (as applicable) imposed by the jurisdiction (other than
the United States, unless otherwise required by clause (i) of this paragraph) in which such successor person is incorporated or otherwise a resident for
tax purposes subject to the exceptions described under “—Additional Amounts” (for the avoidance of doubt, solely to the extent such successor person is
the Issuer, changes will be made to the 2019 BATCAP Indenture as are necessary to obligate the Issuer to pay such Additional Amount); and (v) if as a
result of such consolidation or merger or such sale, conveyance, transfer or lease, properties or assets of the Issuer or any Guarantor would become
subject to a mortgage, pledge, security interest, lien or similar encumbrance to secure payment of any indebtedness for borrowed money of the Issuer or
any Guarantor which would not be permitted by the Notes of a series or under the 2019 BATCAP Indenture, the Issuer or any Guarantor or such
successor person, as the case may be, shall take such steps as shall be necessary to effectively secure the Notes of such series equally and ratably with
(or prior to) all indebtedness for borrowed money secured thereby.

The limitation on mergers, consolidations, amalgamations and combinations described in this section “—Limitation on Mergers, Consolidations,
Amalgamations and Combinations” shall not apply to any consolidation, merger, amalgamation or combination in which the Issuer or any Guarantor is
the surviving corporation except that, in such case, the provisions of (ii) and (v) above shall apply such that: (x) immediately after giving effect to such
transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and
be continuing; and (y) if as a result of such consolidation or merger or such sale, conveyance, transfer or lease, properties or assets of the Issuer or any
Guarantor would become subject to a mortgage, pledge, security interest, lien or similar encumbrance to secure payment of any indebtedness for
borrowed money of the Issuer or any Guarantor which would not be permitted by the Notes or under the 2019 BATCAP Indenture, the Issuer or any
Guarantor, as the case may be, shall take such steps as shall be necessary to effectively secure the Notes equally and ratably with (or prior to) all
indebtedness for borrowed money secured thereby.

The 2019 BATCAP Indenture does not contain covenants or other provisions to afford protection to holders of the Notes in the event of a highly
leveraged transaction or a change in control of the Issuer or any Guarantor except as provided above.

Upon certain mergers or consolidations involving the Issuer or any Guarantor, or upon certain sales or conveyances of all or substantially all of the
assets of the Issuer or any Guarantor, the obligations of the Issuer or such Guarantor, under the applicable Notes or the applicable Guarantee, shall be
assumed by the person formed by such merger or consolidation or which shall have acquired such assets and upon such assumptions such person shall
succeed to and be substituted for the Issuer or such Guarantor, as the case may be, and then the Issuer or such Guarantor will (except in the case of a
lease) be relieved of all obligations and covenants under the 2019 BATCAP Indenture, the Notes and the applicable Guarantee, as the case may be. The
terms “Issuer” and “Guarantor”, as used in the Notes and the 2019 BATCAP Indenture, also refer to any such successors or assigns so substituted.

Although there is a limited body of case law interpreting the phrase “entirety or substantially as an entirety”, there is no precise established definition of
the phrase under applicable law.

61
Accordingly, in certain circumstances, there may be a degree of uncertainty as to whether a particular transaction would involve a disposition of “entirety or substantially as an entirety” of the Issuer’s assets and its subsidiaries taken as a whole.

**Events of Default**

Each of the following events shall be an “Event of Default” with respect to any series of the Notes (including any series of the BATCAP Notes):

(i) **Non-Payment**: default is made in the payment of: (a) any installment of interest (excluding Additional Amounts) upon any applicable Note as and when the same shall become due and payable, and there is a continuance of such default for a period of 14 days or more; (b) applicable Additional Amounts as and when the same shall become due and payable, and there is a continuance of such default for a period of 14 days; or (c) all or any part of the principal or premium, if any, of any applicable Note as and when the same shall become due and payable either at maturity, upon any redemption, by declaration or otherwise, and there is a continuance of such default for a period of three days;

(ii) **Breach of Other Obligations**: the Issuer or any Guarantor does not perform or comply with any one or more of its other obligations under the applicable Notes or the 2019 BATCAP Indenture (other than those described in paragraph (i) above) which is not remedied within 30 days (unless a longer period is specified in the 2019 BATCAP Indenture) after written notice of such default shall have been given to the Issuer by the Trustee or to the Issuer and the Trustee by the holders of at least 25% of the outstanding principal amount of the Notes;

(iii) **Cross-Default**: (a) any other present or future indebtedness for borrowed money of the Issuer or any Guarantor, other than the Notes issued by the Issuer, becomes due and payable prior to its stated maturity by reason of any default or event of default in respect thereof by the Issuer or any Guarantor and remains unpaid; or (b) any such indebtedness for borrowed money is not paid when due or, as the case may be, within any applicable grace period; or (c) the Issuer or any Guarantor fails to pay when due and called upon (after the expiry of any applicable grace period) any amount payable by it under any present or future guarantee for, or indemnity in respect of, any indebtedness for borrowed money and which remains unpaid; provided that (x) payment of the indebtedness for borrowed money is not being contested in good faith and in accordance with legal advice or (y) the aggregate amount of the indebtedness for borrowed money, guarantees and indemnities in respect of which one or more of the events mentioned above in clauses (a), (b) and (c) of this paragraph (ii) has or have occurred and is or are continuing, equals or exceeds £750 million or its equivalent in any other currency of the indebtedness for borrowed money or, if greater, 1.25% of the Total Equity of the Parent, as set out in the “Total Equity” line item in the most recent consolidated group balance sheet of the Parent and its subsidiaries in the Parent’s most recent annual report;

62
(iv) **Cessation of Guarantees:** any Guarantee ceases to be in full force and effect (except as contemplated by the terms of the 2019 BATCAP Indenture, including as described above under “—Guarantees—Release”) or any Guarantor denies or disaffirms in writing its obligations under the 2019 BATCAP Indenture or Guarantee;

(v) **Enforcement Proceedings:** a distress or execution or other legal process is levied or enforced against or an encumbrancer takes possession of or a receiver, administrative receiver or other similar officer is appointed of the whole or a part of the assets of the Issuer or any Guarantor which is substantial in relation to the BAT Group taken as a whole and is not discharged, stayed, removed or paid out within 45 days after such execution or appointment;

(vi) **Security Enforced:** any mortgage, charge, pledge, lien or other encumbrance, present or future, created or assumed by the Issuer or any Guarantor becomes enforceable against all or substantially all of the assets of the Issuer or any Guarantor, and any step is taken to enforce it (including the taking of possession or the appointment of a receiver, administrative receiver, manager or other similar person) and is not discharged within 45 days;

(vii) **Insolvency:** the Issuer or any Guarantor is insolvent or bankrupt or unable to pay its debts (in respect of companies incorporated in England and Wales, within the meaning of Section 123(1)(b) or (e) or Section 123(2) of the UK Insolvency Act 1986), stops, suspends or threatens to stop or suspend payment of all or a material part of its debts, proposes or makes a general assignment or an arrangement or composition (otherwise than for the purposes of reconstruction, amalgamation, reorganization, merger or consolidation or other similar arrangement) with or for the benefit of its creditors in respect of any of such debts or a moratorium is agreed or declared in respect of or affecting all or a material part of the debts of the Issuer;

(viii) **Winding-up:** an order is made or an effective resolution passed for the winding-up or dissolution or administration of the Issuer or any Guarantor, or the Issuer or any Guarantor shall apply or petition for a winding-up or administration order in respect of itself or ceases or threatens to cease to carry on all or substantially all of its business or operations, in each case except for the purpose of and followed by a reconstruction, amalgamation, reorganization, merger or consolidation or other similar arrangement; or

(ix) **Analogous Events:** any event occurs that under the laws of any relevant jurisdiction has an analogous effect to any of the events referred to in any of the foregoing paragraphs (vii) and (viii).

The 2019 BATCAP Indenture provides that if an Event of Default occurs and is continuing with respect to the Notes of any series then outstanding, then and in each and every such case (other than certain Events of Default specified in paragraphs (vii), (viii) and (ix) above with respect to the Issuer or any Guarantor), unless the principal of all the Notes of such series shall have
already become due and payable, the holders of not less than 25% in aggregate principal amount of the Notes of such affected series then outstanding, by notice in writing to the Issuer, each Guarantor and the Trustee, may declare the entire principal amount of all Notes of such series and interest accrued and unpaid thereon, if any, to be due and payable immediately, and upon any such declaration the same shall become immediately due and payable, without any further declaration or other act on the part of any holder. If certain Events of Default described in paragraph (vii), (viii) or (ix) above occur with respect to the Issuer or any Guarantor and are continuing with respect to a series of Notes, the principal amount of and accrued and unpaid interest on all the Notes of such series issued pursuant to the 2019 BATCAP Indenture shall become immediately due and payable, without any declaration or other act on the part of the Trustee or any holder. Under certain circumstances, the holders of a majority in aggregate principal amount of the then outstanding Notes of such series, by written notice to the Issuer, each Guarantor and the Trustee, may waive defaults and rescind and annul declarations of acceleration and its consequences, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent default or shall impart any right consequent thereon.

The holders of a majority in aggregate principal amount of any series of Notes then outstanding will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to the Notes of such series, subject to certain limitations to be specified in the 2019 BATCAP Indenture, including providing to the Trustee indemnity satisfactory to it.

An Event of Default with respect to any series of Notes would not necessarily constitute an event of default with respect to the other series of Notes. The 2019 BATCAP Indenture provides that notwithstanding the foregoing provisions described under “—Events of Default”, if the principal of, premium (if any) or interest on or Additional Amounts with respect to any Note is payable in a currency or currencies other than Dollars and such currency or currencies are not available to the Issuer or any Guarantor for making payment thereof due to the imposition of exchange controls or other circumstances beyond the control of the Issuer or such Guarantor (a “Conversion Event”), the Issuer and the Guarantor will be entitled to satisfy its obligations to Holders of the Notes by making such payment in Dollars in an amount equal to the Dollar equivalent of the amount payable in such other currency, as determined by the Issuer or the Guarantor making such payment, as the case may be, based on the Exchange Rate on the date of such payment, or, if such rate is not then available, on the basis of the most recently available Exchange Rate. Notwithstanding the foregoing provisions, any payment made under such circumstances in Dollars where the required payment is in a currency other than Dollars will not constitute an Event of Default under the 2019 BATCAP Indenture. Promptly after the occurrence of a Conversion Event, the Issuer or the relevant Guarantor shall give written notice thereof to the Trustee and to the Paying Agent; and the Trustee, promptly after receipt of such notice, shall give notice thereof in the manner provided in the 2019 BATCAP Indenture to the Holders of the relevant series of Notes. Promptly after the making of any payment in Dollars as a result of a Conversion Event, the Issuer or the Guarantor making such payment, as the case may be, shall give notice in the manner provided in the 2019 BATCAP Indenture to the Holders, setting forth the applicable Exchange Rate and describing the calculation of such payments.
No holder of the Notes of a series will have any right to institute any action or proceeding at law or in equity or in bankruptcy or otherwise upon or under or with respect to the 2019 BATCAP Indenture, or for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy under the 2019 BATCAP Indenture (except suits for the enforcement of payment of overdue principal or interest) unless (1) the holder of a Note gives to the Trustee written notice of a continuing Event of Default, (2) the holders of at least 25% in principal amount of the outstanding Notes of such series have made a written request to the Trustee to institute such proceeding as Trustee, (3) the holder or holders of Notes offer, and if requested, provide to the Trustee indemnity satisfactory to the Trustee against any loss, liability or expense, (4) the Trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity and (5) during such 60-day period the holders of a majority in aggregate principal amount of the outstanding Notes of such series have not given the Trustee a direction inconsistent with the request. The holder of a Note may not use the 2019 BATCAP Indenture to prejudice the rights of another holder of a Note or to obtain a preference or priority over another holder of a Note (it being understood that the Trustee does not have an affirmative duty to ascertain whether or not such actions or forbearances are unduly prejudicial to such holders).

Satisfaction and Discharge

The 2019 BATCAP Indenture provides that BAT may, subject to satisfying certain conditions, discharge certain obligations to the holders of Notes of any series of Notes that have not already been delivered to the Trustee for cancellation and that either have become due and payable or will become due and payable within one year (or scheduled for redemption within one year) by depositing with the Trustee or Paying Agent, in trust, funds in an amount sufficient to pay the entire indebtedness on such series of Notes in respect of principal and premium, if any, and interest, if any, to the date of such deposit (if such Notes have become due and payable) or to the maturity thereof or redemption date, as the case may be, along with an officer’s certificate and an opinion of counsel stating that all conditions precedent relating to the satisfaction and discharge of the 2019 BATCAP Indenture have been complied with.

Legal Defeasance and Covenant Defeasance

The 2019 BATCAP Indenture provides that the Issuer will have the option either (a) to be deemed (together with each Guarantor) to have paid and discharged the entire indebtedness represented by, and obligations under, a series of Notes and the applicable Guarantees and to have satisfied all the obligations under the 2019 BATCAP Indenture relating to the series of Notes (except for certain obligations, including those relating to the defeasance trust and obligations to register the transfer or exchange of Notes, to replace mutilated, destroyed, lost or stolen Notes and to maintain paying agencies) on the 91st day after the applicable conditions described below have been satisfied or (b) to cease (together with each Guarantor) to be under any obligation to comply with the covenants described above under “—Covenants of the Issuer and the Guarantors—Negative Pledge”, “—Covenants of the Issuer and the Guarantors—Limitation on Mergers, Consolidations, Amalgamations and Combinations”, and non-compliance with such covenants and the occurrence of all events described above under “—Events of Default” will not give rise to any Event of Default under the 2019 BATCAP Indenture, at any time after the applicable conditions described below have been satisfied.
In order to exercise either defeasance option, the Issuer must (i) deposit with the Trustee, irrevocably in money or Government Obligations (as defined in the 2019 BATCAP Indenture), funds sufficient in the opinion of a certified public accounting firm of national reputation for the payment of principal and interest on the applicable outstanding Notes of any series to and including the Redemption Date irrevocably designated by the Issuer on or prior to the date of deposit of such money or Government Obligations, and must (ii) comply with certain other conditions, including delivering to the Trustee an opinion of U.S. counsel to the effect that beneficial owners of the applicable Notes will not recognize income, gain or loss for United States Federal income tax purposes as a result of the exercise of such option and will be subject to United States Federal income tax on the same amount and in the same manner and at the same time as would have been the case if such option had not been exercised and, in the case of clause (a) in the previous paragraph, which opinion must state that such opinion is based on a ruling received from or published by the United States Internal Revenue Service or on a change in the applicable U.S. Federal income tax laws after the date of issuance of the relevant Notes.

Modification and Waiver

Without Consent of Noteholders

The 2019 BATCAP Indenture contains provisions permitting the Issuer, the Guarantors and the Trustee, without the consent of the holders of any of the applicable Notes at any time outstanding, from time to time and at any time, to enter into a supplemental indenture amending or supplementing such 2019 BATCAP Indenture, the Notes or the Guarantees in order to:

• convey, transfer, assign, mortgage or pledge to the holders of the applicable Notes or any person acting on their behalf as security for the applicable Notes any property or assets;

• evidence the succession of another person to the Issuer or any Guarantor, as the case may be, or successive successions, and the assumption by the successor person(s) of the covenants, agreements and obligations of the Issuer or any Guarantor, as the case may be, pursuant to the 2019 BATCAP Indenture;

• evidence and provide for the acceptance of appointment of a successor or successors to the Trustee and/or the Paying Agent, Transfer Agent, Calculation Agent and Registrar, as applicable;

• add to the covenants of, or the restrictions, conditions or provisions applicable to, the Issuer and any Guarantor, as the case may be, such further covenants, restrictions, conditions or provisions as the Issuer and any Guarantor, as the case may be, shall consider to be for the protection of the holders of the applicable Notes issued pursuant to the 2019 BATCAP Indenture, including to eliminate one or both prongs of the release provision under “—Guarantees—Release”, and to make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default under the 2019 BATCAP Indenture permitting the enforcement of all or any of the several remedies provided in the 2019 BATCAP Indenture; provided that, in
respect of any such additional covenant, restriction, condition or provision, such supplemental indenture may provide for a particular period of grace after default (which may be shorter or longer than that allowed in the case of other defaults) or may limit the remedies available to the Trustee upon such an Event of Default;

• modify the restrictions on, and procedures for, resale and other transfers of the applicable Notes pursuant to law, regulation or practice relating to the resale or transfer of restricted securities generally;

• cure any ambiguity or to correct or supplement any provision contained in the 2019 BATCAP Indenture, the Notes, or the Guarantees which may be defective or inconsistent with any other provision contained therein or to make such other provision in regard to matters or questions arising under the 2019 BATCAP Indenture, the Notes or the Guarantees as the Issuer, any Guarantor or the Trustee may deem necessary or desirable and which will not, in the opinion of the Issuer, adversely affect the interests of the holders of the applicable Notes in any material respect;

• issue an unlimited aggregate principal amount of Notes under the 2019 BATCAP Indenture or to “reopen” the applicable series of Notes and create and issue additional notes having substantially identical terms and conditions as the applicable Notes (or in all respects except as to issue price, denomination, rate of interest, Maturity Date and the date from which interest, if any, shall accrue, and except as may otherwise be provided in or pursuant to such officer’s certificate or supplemental indenture relating thereto) so that the additional notes are consolidated and form a single series with the outstanding applicable Notes; and

• evidence the addition of any new Guarantor of the Notes and the 2019 BATCAP Indenture, or the release of any Guarantor from its obligations with respect to the Notes and the 2019 BATCAP Indenture, pursuant to the terms of the 2019 BATCAP Indenture.

With Consent of Noteholders

The 2019 BATCAP Indenture contains provisions permitting the Issuer, each Guarantor and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of all series of the Notes affected by such supplemental indenture (voting as one class) at the time outstanding under the 2019 BATCAP Indenture (including consents obtained in connection with a tender offer or exchange offer for the applicable Notes), from time to time and at any time, to enter into a supplemental indenture for the purpose of amending, waiving or otherwise modifying the provisions of the 2019 BATCAP Indenture, the Notes and the Guarantees, or adding any provisions to or changing in any manner or eliminating any of the provisions of the applicable Notes or of modifying in any manner the rights of the holders of the applicable Notes; provided, that no such supplemental indenture may, without the consent of the holder of each of the Notes so affected:

67
• change the stated maturity of the applicable Note of, or the date for payment of any principal of, or installment of interest on, any applicable Note, or reduce the amount of principal of an Original Issue Discount Note that would be due and payable upon a declaration of acceleration of the maturity thereof pursuant to the provisions of the 2019 BATCAP Indenture; or
• reduce the principal amount of or the rate or amount of interest on any applicable Note or Additional Amounts payable with respect thereto or reduce the amount payable thereon in the event of redemption or default or change the method for determining the interest rate thereon; or
• change the currency of payment of principal of or interest on any applicable Note or Additional Amounts payable with respect thereto; or change the obligation of the Issuer or any Guarantor, as the case may be, to pay Additional Amounts (except as otherwise permitted by such applicable Note); or
• impair the right to institute suit for the enforcement of any such payment on or with respect to any applicable Note; or
• reduce the percentage of the aggregate principal amount of the applicable Notes outstanding the consent of whose holders is required for any such supplemental indenture; or
• reduce the aggregate principal amount of any applicable Note outstanding necessary to modify or amend the 2019 BATCAP Indenture or any such Note or to waive any future compliance or past default or reduce the quorum requirements or the percentage of aggregate principal amount of any applicable Notes outstanding required for the adoption of any action at any meeting of holders of such Notes or to reduce the percentage of the aggregate principal amount of such Notes outstanding necessary to rescind or annul any declaration of the principal of, or all accrued and unpaid interest on, any Note to be due and payable,

provided that no consent of any holder of any applicable Note shall be necessary to permit the Trustee, the Issuer and each Guarantor to execute supplemental indentures as described under “—Without Consent of Noteholders” above.

Any modifications, amendments or waivers to the 2019 BATCAP Indenture or to the conditions of the applicable Notes will be conclusive and binding on all holders of the applicable Notes, whether or not they have consented to such action or were present at the meeting at which such action was taken, and on all future holders of the applicable Notes, whether or not notation of such modifications, amendments or waivers is made upon such Notes. Any instrument given by or on behalf of any holder of such a Note in connection with any consent to any such modification, amendment or waiver will be irrevocable once given and will be conclusive and binding on all subsequent registered holders of such Note.
Prescription
Under New York’s statute of limitations, any legal action upon the Notes in respect of interest or principal must be commenced within six years after the payment thereof is due.

Notice
Notices to holders of Notes will be given by first-class mail postage prepaid to the last addresses of such holders as they appear in the Notes register; provided, no such mailing will be required so long as any Global Notes representing the Notes are held in their entirety on behalf of the Depositary or a clearing system, or any of its participants, as there may be substituted for the mailing of notice to holders of Notes described above the delivery of the relevant. Such notices will be deemed to have been given on the date of such mailing; notices to the Depositary or a clearing system, and (if applicable) its participants, for communication by them to the entitled account holders. Any such notice shall be deemed to have been given on the day on which the said notice was given to the Depositary or a clearing system, and (if applicable) its participants.

Listing
The BATCAP Notes are listed on the New York Stock Exchange.

Consent to Service
Each of the non-U.S. Guarantors has initially designated BATCAP as its authorized agent for service of process in any legal suit, action or proceeding arising out of or relating to the performance of its obligations under the 2019 BATCAP Indenture, the supplemental indentures and the Notes brought in any state or federal court in the Borough of Manhattan, the City of New York, and the Guarantors will irrevocably submit (but for these purposes only) to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding.

Governing Law
The 2019 BATCAP Indenture, the Notes and the Guarantees are, and any applicable supplemental indentures shall be, governed by and construed in accordance with the laws of the State of New York, without regard to principles of conflicts of laws thereof.

Regarding the Trustee and Agents
Citibank, N.A. is the trustee under the 2019 BATCAP Indenture. Citibank, N.A. is appointed by the Issuer to act as registrar, transfer agent, calculation agent and initial paying agent for the Notes. The address of Citibank, N.A., as paying agent, is Citibank, N.A., Agency & Trust, 388 Greenwich Street, New York, NY 10013. From time to time, Citibank, N.A. and its respective affiliates perform various other services for the BAT Group and its affiliates (including acting as a lender under one or more of the BAT Group’s lending facilities from time to time).

The 2019 BATCAP Indenture contains limitations on the rights of the trustee, if it becomes a creditor of Issuer or any Guarantor, to obtain payment of claims in some cases, or to realize on property received in respect of any of these claims as security or otherwise. The Trustee is permitted to engage in other transactions. However, if the Trustee acquires any conflicting interest (as defined in the TIA), it must either eliminate its conflict within 90 days or resign.
E. Description of the Notes Issued Under the 2017 BATCAP Indenture

The following is a summary of the material provisions of the 2017 BATCAP Indenture (as described below) and the Notes. Any capitalized term used herein but not defined shall have the meaning assigned to such term in the 2017 BATCAP Indenture or under “—Certain Definitions”. The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all of the provisions of the 2017 BATCAP Indenture and those terms made a part of the 2017 BATCAP Indenture by reference to the Trust Indenture Act of 1939, as amended (the “TIA”).

GENERAL

The 2.764% Notes due 2022 (the “2.764% Notes”), the 3.222% Notes due 2024 (the “3.222% Notes”), the 3.557% Notes due 2027 (the “3.557% Notes”), the 4.390% Notes due 2037 (the “4.390% Notes”), the 4.540% Notes due 2047 (the “4.540% Notes” and, together with the 2.764% Notes, the 3.222% Notes, the 3.557% Notes and the 4.390% Notes, the “Fixed Rate Notes”) and the floating rate notes due 2022 (the “Floating Rate Notes”) were issued by B.A.T Capital Corporation (“BATCAP” or the “Issuer”).

In this “Description of the Notes Issued Under the 2017 BATCAP Indenture”, we refer to each series of the Fixed Rate Notes and Floating Rate Notes as a “series” of Notes.

The 2.764% Notes will mature on August 15, 2022. The 3.222% Notes will mature on August 15, 2024. The 3.557% Notes will mature on August 15, 2027. The 4.390% Notes will mature on August 15, 2037. The 4.540% Notes will mature on August 15, 2047. The Floating Rate Notes will mature on August 15, 2022.

The Notes were issued in registered form and treated as eight separate series of debt securities under an indenture dated as of August 15, 2015 (as supplemented by the supplemental indenture no. 1, dated as of September 28, 2018, and as further amended or supplemented from time to time, the “2017 BATCAP Indenture”). The 2017 BATCAP Indenture is by and among BATCAP, as Issuer, British American Tobacco p.l.c. (“BAT” or the “Parent Guarantor”), B.A.T. International Finance p.l.c. (“BATIF”), British American Tobacco Holdings (The Netherlands) B.V. (“BATHTN”), B.A.T. Netherlands Finance B.V. (“BATNF” and, together with BATHTN, the “Dutch Guarantors”), and, unless its guarantee is released in accordance with the 2017 BATCAP Indenture, Reynolds American Inc. (“RAI”), each as a guarantor.

Each entity that provides a guarantee in respect of the Notes is referred to herein as a “Guarantor”. In this “Description of the Notes Issued Under the 2017 BATCAP Indenture”, the terms “holder”, “Noteholder” and other similar terms refer to a “registered holder” of Notes, and not to a beneficial owner of a book-entry interest in any Notes.

**PRINCIPAL, MATURITY AND INTEREST**

The obligations of the Issuer under the Notes and 2017 BATCAP Indenture are fully and unconditionally guaranteed on a senior and unsecured basis by each of the Parent Guarantor, the Dutch Guarantors, BATIF and RAI.

The Notes were initially issued in the following aggregate principal amounts, with maturity dates as follows:

<table>
<thead>
<tr>
<th>Series of Notes</th>
<th>Aggregate principal amount</th>
<th>Maturity date</th>
</tr>
</thead>
<tbody>
<tr>
<td>64% Notes</td>
<td>$ 2,250,000,000</td>
<td>August 15, 2022</td>
</tr>
<tr>
<td>3.222% Notes</td>
<td>$ 2,500,000,000</td>
<td>August 15, 2024</td>
</tr>
<tr>
<td>3.557% Notes</td>
<td>$ 3,500,000,000</td>
<td>August 15, 2027</td>
</tr>
<tr>
<td>4.390% Notes</td>
<td>$ 2,500,000,000</td>
<td>August 15, 2037</td>
</tr>
<tr>
<td>4.540% Notes</td>
<td>$ 2,500,000,000</td>
<td>August 15, 2047</td>
</tr>
<tr>
<td>Floating Rate Notes</td>
<td>$ 750,000,000</td>
<td>August 15, 2022</td>
</tr>
</tbody>
</table>

**Fixed Rate Notes**

The Fixed Rate Notes bear interest per annum and have maturity dates as follows:

<table>
<thead>
<tr>
<th>Series of Fixed Rate Notes</th>
<th>Interest rate per annum</th>
<th>Maturity date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.764% Notes</td>
<td>2.764%</td>
<td>August 15, 2022</td>
</tr>
<tr>
<td>3.222% Notes</td>
<td>3.222%</td>
<td>August 15, 2024</td>
</tr>
<tr>
<td>3.557% Notes</td>
<td>3.557%</td>
<td>August 15, 2027</td>
</tr>
<tr>
<td>4.390% Notes</td>
<td>4.390%</td>
<td>August 15, 2037</td>
</tr>
<tr>
<td>4.540% Notes</td>
<td>4.540%</td>
<td>August 15, 2047</td>
</tr>
</tbody>
</table>

The 2.764% Notes, the 3.222% Notes, the 3.557% Notes, the 4.390% Notes and the 4.540% Notes bear interest from the most recent interest payment date to which interest has been paid or provided, payable semi-annually in arrear on February 15 and August 15 of each year (each, an “Interest Payment Date”) until their respective maturity date, unless previously purchased or
redeemed by BATCAP, to the person in whose name any, 2.764% Note, 3.222% Note, 3.557% Note, 4.390% Note or 4.540% Note, as applicable, is registered at the close of business on the 15th calendar day preceding each Interest Payment Date, whether or not such day is a Business Day (each, a “Record Date”) notwithstanding any transfer or exchange of such Notes subsequent to the Record Date and prior to such Interest Payment Date, except that, if and to the extent BATCAP shall default in the payment of the interest due on such Interest Payment Date, and the applicable grace period shall have expired, such defaulted interest may at the option of BATCAP be paid to the persons in whose names the outstanding Notes are registered at the close of business on a subsequent Record Date (which shall not be less than five Business Days prior to the date of payment of such defaulted interest) established by notice sent by or on behalf of the Issuer to the holders (which term means registered holders) of the 2.764% Notes, 3.222% Notes, 3.557% Notes, 4.390% Notes or 4.540% Notes, as applicable, not less than 15 days preceding such subsequent Record Date. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months, or in the case of an incomplete month, the number of days elapsed. If the date on which any interest payment or principal payment is to be made is not a Business Day, such payment will be made on the next day which is a Business Day, without any further interest or other amounts being paid or payable in connection therewith. A “Business Day” refers to any day which is not, in London or New York City, or any other place of payment, a Saturday, Sunday, legal holiday or a day on which banking institutions are authorized or obligated by law or regulation to close.

Floating Rate Notes
Interest on the Floating Rate Notes is payable quarterly in arrear on February 15, May 15, August 15 and November 15 of each year, commencing on February 15, 2019. Interest will be paid to the person in whose name such Note is registered at the close of business on the second Business Day that precedes the related interest payment date. The Floating Rate Notes bear interest at a rate per annum equal to LIBOR plus 0.88% which will be reset as described below.

If any interest payment date (other than a redemption date or other maturity date) for the Floating Rate Notes would fall on a day that is not a Business Day, the interest payment date will be postponed to the next succeeding business day, except that if that Business Day falls in the next succeeding calendar month, the interest payment date will be the immediately preceding Business Day, in each case with interest accruing to but excluding the date of payment. If a redemption date or other maturity date for the Floating Rate Notes would fall on a day that is not a Business Day, the payment of interest and principal will be made on the next succeeding Business Day, and no interest will accrue or be payable unless the Issuer fails to make payment on such next succeeding Business Day.

The rate of interest on the Floating Rate Notes will be reset quarterly on February 15, May 15, August 15 and November 15 of each year (collectively, the “Interest Reset Dates” and each, an “Interest Reset Date”). If any Interest Reset Date would fall on a day that is not a Business Day, the Interest Reset Date will be postponed to the next succeeding Business Day, except that if that Business Day falls in the next succeeding calendar month, the Interest Reset Date will be the immediately preceding Business Day.
The Calculation Agent for the Floating Rate Notes is the Paying Agent, or its successor appointed by the Issuer. The Calculation Agent will determine
the interest rate for each Interest Reset Date by reference to LIBOR on the second London banking day preceding the applicable Interest Reset Date,
which is referred to herein as an “Interest Determination Date”.

Promptly upon such determination, the Calculation Agent will notify the Issuer and the Trustee of the new interest rate. Upon the request of the holder of
any Floating Rate Note, the Calculation Agent will provide the interest rate then in effect and, if determined, the interest rate that will become effective
on the next Interest Reset Date.

“London banking day” means any day on which dealings in U.S. dollars are transacted in the London interbank market. “LIBOR” will be determined by
the Calculation Agent in accordance with the following provisions:

- With respect to any Interest Determination Date, LIBOR will be the rate (expressed as a percentage per annum) for deposits in U.S. dollars
having a maturity of three months commencing on the related Interest Reset Date that appears on Reuters Page LIBOR01 as of 11:00 a.m.
(London time) on that Interest Determination Date. If no such rate appears, then LIBOR, in respect of that Interest Determination Date will
be determined in accordance with the following provisions.

- With respect to an Interest Determination Date on which no rate appears on Reuters Page LIBOR01, the Calculation Agent will request the
principal London offices of each of four major reference banks in the London interbank market (which may include affiliates of the initial
purchasers of the Unregistered Notes), as selected by the Issuer, to provide its offered quotation (expressed as a percentage per annum) for
deposits in U.S. dollars for the period of three months, commencing on the related Interest Reset Date, to prime banks in the London
interbank market at approximately 11:00 a.m. (London time) on that Interest Determination Date and in a principal amount that is
representative for a single transaction in U.S. dollars in that market at that time. If at least two quotations are provided, then LIBOR on that
Interest Determination Date will be the arithmetic mean of those quotations.

- If fewer than two quotations are provided, then LIBOR on the Interest Determination Date will be the arithmetic mean of the rates quoted
at approximately 11:00 a.m. (New York City time) on the Interest Determination Date by three major banks in New York City (which may
include affiliates of the initial purchasers of the Unregistered Notes) selected by the Issuer for loans in U.S. dollars to leading European
banks, for a period of three months, commencing on the related Interest Reset Date, and in a principal amount that is representative for a
single transaction in U.S. dollars in that market at that time. If at least two such rates are so provided, LIBOR on the Interest Determination
Date will be the arithmetic mean of such rates.
• If fewer than two such rates are so provided, LIBOR on the Interest Determination Date will be LIBOR in effect with respect to the
immediately preceding Interest Determination Date. “Reuters Page LIBOR01” means the display that appears on Reuters (or any successor
service) on page LIBOR01 (or any page as may replace such page on such service) for the purpose of displaying London interbank offered
rates of major banks for U.S. dollars.

Interest on the Floating Rate Notes is calculated on the basis of a 360-day year and the actual number of days elapsed.

All percentages resulting from any calculation of any interest rate for the Floating Rate Notes will be rounded, if necessary, to the nearest one hundred
thousandth of a percentage point, with five one-millionths of a percentage point rounded upward (e.g., 5.876545% (or .05876545) would be rounded to
5.87655% (or .0587655)), and all dollar amounts would be rounded to the nearest cent with one-half cent being rounded upward.

The interest rate on the Floating Rate Notes will in no event be higher than the maximum rate permitted by applicable law and in no event be less than
0.00%.

All calculations made by the Calculation Agent for the purposes of calculating interest on the Floating Rate Notes will be conclusive and binding on the
holders and the Issuer, absent manifest error.

FORM AND DENOMINATION

The Notes were issued in fully registered form and only in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. The
Notes were issued as Global Notes.

FURTHER ISSUES

The aggregate principal amount of Notes issuable under the 2017 BATCAP Indenture is unlimited. The Issuer may, from time to time, without notice to
or the consent of the holders of the Notes, “reopen” any series of the Notes and create and issue additional notes having identical terms and conditions as
the 2.764% Notes, the 3.222% Notes, the 3.557% Notes, the 4.390% Notes, the 4.540% Notes, and the Floating Rate Notes, as the case may be (or in all
respects except for the issue date, issue price, the payment of interest accruing prior to the issue date of such additional notes and/or the first payment of
interest following the issue date of such additional notes) so that the additional notes are consolidated and form a single series of Notes with the Notes,
as the case may be (a “Further Issue”), provided that if the additional notes are not fungible with the Notes for United States federal income tax
purposes, the additional notes will have separate CUSIPs, ISINs, or other identifying numbers.

STATUS OF THE NOTES AND GUARANTEES

The Notes are unsecured and unsubordinated obligations of the Issuer and rank pari passu in right of payment among themselves and with all other
direct, unsecured and unsubordinated obligations of the Issuer (except those obligations preferred by statute or operation of law). Each Guarantor fully
and unconditionally guaranteed, on a senior, unsecured basis, the due and

74
punctual payment (and not collectability) of the principal of and interest on the Notes (and the payment of additional amounts described under “—
Payment of Additional Amounts” below) and other obligations under the 2017 BATCAP Indenture when and as the same shall become due and payable,
whether at stated maturity, by declaration of acceleration, call for redemption or otherwise. Each Guarantee is an unsecured and unsubordinated
obligation of the respective Guarantor and ranks _pari passu_ in right of payment with all other direct, unsecured and unsubordinated obligations of such
Guarantor (except those obligations preferred by statute or operation of law). The Issuer and each Guarantor are subject to a negative pledge with
respect to certain types of indebtedness, which are discussed in “—Covenants of the Issuer and the Guarantors—Negative Pledge” below.

GUARANTEES

Release

The 2017 BATCAP Indenture provides that, without the consent of the Trustee or the Noteholders, a Guarantor that is a subsidiary of the Parent
Guarantor (a “Subsidiary Guarantor”), other than BATIF and the Dutch Guarantors, will automatically and unconditionally be released from all
obligations under its Guarantee, and such Guarantee shall thereupon terminate and be discharged and of no further force or effect, in the event that (1) its
guarantee of all then outstanding notes issued under the EMTN Programme is released or (2) at substantially the same time its Guarantee of the Notes is
terminated, the Subsidiary Guarantor is released from all obligations in respect of indebtedness for borrowed money for which such Subsidiary
Guarantor is an obligor (as a guarantor or borrower). For purposes of this paragraph, the amount of a Subsidiary Guarantor’s indebtedness for borrowed
money shall not include (A) the Notes issued pursuant to the 2017 BATCAP Indenture, (B) any other debt the terms of which permit the termination of
such Subsidiary Guarantor’s guarantee of such debt under similar circumstances, as long as such Subsidiary Guarantor’s obligations in respect of such
other debt are terminated at substantially the same time as its guarantee of the Notes, (C) any debt that is being refinanced at substantially the same time
that the guarantee of the Notes is being released, provided that any obligations of the relevant Subsidiary Guarantor in respect of the debt that is incurred
in the refinancing shall be included in the calculation of the relevant Subsidiary Guarantor’s indebtedness for borrowed money and (D) for the avoidance
of doubt, any debt in respect of which such Subsidiary Guarantor is an obligor (as a guarantor or borrower) (i) between or among the Parent Guarantor
and any subsidiary or subsidiaries thereof or (ii) between or among any subsidiaries of the Parent Guarantor.

As of the date of this summary, RAI is the only Subsidiary Guarantor to which the above provision is relevant. Under the EMTN Programme, a
Subsidiary Guarantor’s guarantee is released if at any time the aggregate amount of indebtedness for borrowed money for which the Subsidiary
Guarantor is an obligor does not exceed 10% of the outstanding long term debt of BAT as reflected in the balance sheet included in BAT’s most recent
publicly released interim or annual consolidated financial statements, as evidenced by a certificate to such effect addressed to the trustee under the
EMTN Programme and signed by a director of BAT.
ADDITIONAL AMOUNTS

The Issuer or, if applicable, each Guarantor, will make payments of, or in respect of, principal, premium (if any) and interest on the Notes, or any payment pursuant to the applicable Guarantee, as the case may be, without withholding or deduction for or on account of any present or future tax, levy, impost or other similar governmental charge whatsoever imposed, assessed, levied or collected (“Taxes”) by or for the account of the United States, the United Kingdom (in the case of a payment by the Parent Guarantor or BATIF), The Netherlands (in the case of a payment by a Dutch Guarantor) or any other jurisdiction through which payment is made by or on behalf of the Issuer or, if applicable, such Guarantor (or any political subdivision thereof or any authority thereof having the power to tax) (a “Relevant Taxing Jurisdiction”), unless such withholding or deduction is required by law.

If the Issuer or, if applicable, any Guarantor, is required by a Relevant Taxing Jurisdiction to so withhold or deduct such Taxes, the Issuer or, if applicable, such Guarantor, will pay to the holder of a Note such additional amounts (“Additional Amounts”) as may be necessary so that the net amount received by such holder will not be less than the amount such holder would have received if such Taxes had not been withheld or deducted; provided, however, that amounts with respect to any United States Tax shall be payable only to holders that are not United States persons (within the meaning of the Code); and provided further, that neither the Issuer nor such Guarantor shall be required to pay any Additional Amounts for or on account of:

(i) any Taxes that would not have been so imposed, assessed, levied or collected but for the fact that the holder or beneficial owner of the applicable Note or Guarantee (or a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such holder, if such holder is an estate, trust, partnership or corporation) is or has been a domiciliary, national or resident of, or engaging or having been engaged in a trade or business or maintaining or having maintained a permanent establishment or being or having been physically present in, a Relevant Taxing Jurisdiction or otherwise having or having had some connection with a Relevant Taxing Jurisdiction other than the holding or ownership of, or the collection of principal of, and premium (if any) or interest on, a Note or the enforcement of the applicable Guarantee, as the case may be;

(ii) any Taxes that would not have been so imposed, assessed, levied or collected but for the fact that, where presentation is required in order to receive payment, the applicable Note or Guarantee was presented more than 30 days after the date on which such payment became due and payable or was provided for, whichever is later, except to the extent that the holder or beneficial owner thereof would have been entitled to Additional Amounts had the applicable Note or Guarantee been presented for payment on any day during such 30-day period;

(iii) any estate, inheritance, gift, sales, transfer, personal property or similar Taxes;

(iv) any Taxes that are payable otherwise than by withholding or deduction from payments on or in respect of the applicable Note or Guarantee;
(v) any Taxes that would not have been so imposed, assessed, levied or collected but for the failure by the holder or the beneficial owner of the applicable Note or Guarantee to (A) provide any certification, identification, information, documents or other evidence concerning the nationality, residence or identity of the holder or the beneficial owner or its connection with the Relevant Taxing Jurisdiction or (B) make any valid or timely declaration or claim or satisfy any other reporting, information or procedural requirements relating to such matters if, in either case, compliance is required by statute, regulation, relevant income tax treaty or administrative practice of the Relevant Taxing Jurisdiction as a condition to relief or exemption from such Taxes;

(vi) any Taxes imposed by reason of the holder or the beneficial owner of the applicable Note or Guarantee being or having been considered a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business, as described in Section 881(c)(3)(A) of the Code (or any amended or successor provisions);

(vii) any Taxes imposed on interest received by a 10-percent shareholder of the Issuer within the meaning of Section 871(h)(3)(B) or Section 881(c)(3)(B) of the Code (or any amended or successor provisions);

(viii) any backup withholding imposed pursuant to Section 3406 of the Code (or any amended or successor provisions);

(ix) any Taxes imposed pursuant to Section 871(h)(6) or Section 881(c)(6) of the Code (or any amended or successor provisions);

(x) any Taxes imposed by reason of the holder or the beneficial owner of the applicable Note or Guarantee being or having been a personal holding company, passive foreign investment company or controlled foreign corporation for U.S. federal income tax purposes or a corporation that has accumulated earnings to avoid U.S. federal income tax;

(xi) any Taxes imposed or withheld pursuant to Sections 1471 through 1474 of the Code (or any amended or successor provisions), any Treasury regulations promulgated thereunder, any official interpretations thereof or any agreements entered into in connection with the implementation thereof; or

(xii) any combination of the Taxes described in (i) through (xi) above.

In addition, Additional Amounts will not be paid with respect to any payment of the principal of, or any premium or interest on, any of the applicable Notes or Guarantees to any holder that is a fiduciary, a partnership, a limited liability company or any person other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary, a member of such partnership, an interest holder in such limited liability company or a benefici2
Unless otherwise stated, references in any context to the payment of principal of, and any premium or interest on, any Note, or any payment pursuant to the Guarantees, will be deemed to include payment of Additional Amounts to the extent that, in such context, Additional Amounts are, were or would be payable in respect thereof.

**REDEMPTION**

The Fixed Rate Notes and the Floating Rate Notes are subject to optional redemption by the Issuer as described below under “—Optional Redemption”.

Both the Fixed Rate Notes and the Floating Rate Notes will be subject to optional redemption by the Issuer in the event of certain changes in tax laws applicable to payments in respect of the Notes as described below under “—Redemption for Tax Reasons”.

**Optional Redemption**

The Issuer may redeem the Fixed Rate Notes, in whole or in part, at the Issuer’s option, at any time and from time to time before the applicable Par Call Date, for all series of Fixed Rate Notes at a redemption price equal to the greater of (x) 100% of the principal amount of the Fixed Rate Notes to be redeemed and (y) as determined by the Independent Investment Banker (as defined below), the sum of the present values of the applicable Remaining Scheduled Payments (as defined below) discounted to the date of redemption (the “Redemption Date”) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months or, in the case of an incomplete month, the number of days elapsed) at the Treasury Rate (as defined below) plus, in the case of each respective series of Fixed Rate Notes as follows:

<table>
<thead>
<tr>
<th>Notes</th>
<th>Basis Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.764% Notes</td>
<td>15 basis points</td>
</tr>
<tr>
<td>3.222% Notes</td>
<td>20 basis points</td>
</tr>
<tr>
<td>3.557% Notes</td>
<td>20 basis points</td>
</tr>
<tr>
<td>4.390% Notes</td>
<td>25 basis points</td>
</tr>
<tr>
<td>4.540% Notes</td>
<td>30 basis points</td>
</tr>
</tbody>
</table>

Together with, in each case, accrued and unpaid interest on the principal amount of the Fixed Rate Notes to be redeemed to, but excluding, the Redemption Date.

If the Issuer elects to redeem the 2.764% Notes, 3.222% Notes, 3.557% Notes, 4.390% Notes, 4.540% Notes or the Floating Rate Notes on or after the applicable Par Call Date (as defined below), the Issuer will pay an amount equal to 100% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption.

In connection with such optional redemption the following defined terms apply:

- **Comparable Treasury Issue** means the United States Treasury security selected by the Independent Investment Banker that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to, the remaining term of the 2.764% Notes, 3.222% Notes, 3.557% Notes, 4.390% Notes or the 4.540% Notes, as the case may be, to the relevant Par Call Date.
Comparable Treasury Price means, with respect to any Redemption Date, (A) the average of the Reference Treasury Dealer Quotations for that Redemption Date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations or (B) if the Independent Investment Banker for the applicable Fixed Rate Notes obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such Quotations.

Independent Investment Banker means one of the Reference Treasury Dealers (as defined below) appointed by the Issuer to act as the “Independent Investment Banker”.

Par Call Date means (i) July 15, 2022 with respect to any 2.764% Notes (one month prior to the maturity date of the 2.764% Notes), (ii) June 15, 2024 with respect to any 3.222% Notes (two months prior to the maturity date of the 3.222% Notes), (iii) May 15, 2027 with respect to any 3.557% Notes (three months prior to the maturity date of the 3.557% Notes), (iv) February 15, 2037 with respect to any 4.390% Notes (six months prior to the maturity date of the 4.390% Notes), (v) February 15, 2047 with respect to any 4.540% Notes (six months prior to the maturity date of the 4.540% Notes) and (vi) July 15, 2022 with respect to any Floating Rate Notes (one month prior to the maturity date of the Floating Rate Notes).

Reference Treasury Dealer means each of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and HSBC Securities (USA) Inc. and their respective successors and two other nationally recognized investment banking firms that are Primary Treasury Dealers specified from time to time by the Issuer; provided, however, that if any of the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury Dealer”), the Issuer shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer.

Reference Treasury Dealer Quotation means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day immediately preceding that Redemption Date.

Remaining Scheduled Payments means, with respect to each Fixed Rate Note to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due from and including the related Redemption Date, but for such redemption, to but excluding the relevant Par Call Date; provided, however, that if that Redemption Date is not an Interest Payment Date with respect to such Fixed Rate Notes, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to that Redemption Date.

79
• **Treasury Rate** means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent yield to maturity (computed as of the third Business Day immediately preceding that Redemption Date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that Redemption Date.

Notice of any optional redemption will be given in accordance with “—Notice” below at least 10 days but not more than 30 days before the Redemption Date to each holder of the Fixed Rate Notes to be redeemed.

If less than all the Fixed Rate Notes are to be redeemed, in the case of a redemption at the Issuer’s option as discussed in this section, the Fixed Rate Notes to be redeemed shall be selected in accordance with applicable procedures of DTC.

**Redemption for Tax Reasons**

Each series of Notes is also redeemable by the Issuer, in whole but not in part, at 100% of the principal amount of such Notes plus any accrued and unpaid interest to the applicable Redemption Date (including any Additional Amounts) at the Issuer’s option at any time prior to their maturity if, due to a Change in Tax Law (as defined below): (i) the Issuer or a Guarantor, in accordance with the terms of the applicable Notes or applicable Guarantee, has, or would, become obligated to pay any Additional Amounts to the holders or beneficial owners of the Notes of that series; (ii) in the case of a Guarantor, (A) the Parent Guarantor would be unable, for reasons outside its control, to procure payment by the Issuer or any other Guarantor or (B) the procuring of such payment by the Issuer and each such other Guarantor would be subject to withholding taxes imposed by a Relevant Taxing Jurisdiction; and (iii) such obligation cannot otherwise be avoided by such Guarantor, the Parent Guarantor or the Issuer, taking reasonable measures available to it. In such case, the Issuer may redeem the applicable Notes upon not less than 30 nor more than 60 days’ notice as provided in “—Notice” below, at 100% of the principal amount of such Notes plus accrued and unpaid interest to the Redemption Date (including Additional Amounts); provided, that, (a) no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which the Issuer or such Guarantor, as the case may be, would be obligated to pay any such Additional Amounts in respect of the applicable Notes or applicable Guarantee, as applicable, then due and (b) at the time such notice is given, such obligation to pay such Additional Amounts remains in effect. The Issuer’s right to redeem the applicable Notes shall continue as long as the Issuer or a Guarantor is obligated to pay such Additional Amounts, notwithstanding that the Issuer or such Guarantor, as the case may be, shall have made payments of Additional Amounts. Prior to the giving of any such notice of redemption, the Issuer must deliver to the Trustee: (i) an officer’s certificate stating that the Issuer is entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to the right of the Issuer so to redeem have occurred; and (ii) an opinion of

80

80
independent counsel or an independent accountant of recognized standing, selected by the Issuer or any Guarantor, as applicable, with respect to tax matters of the Relevant Taxing Jurisdiction to the effect that the Issuer or such Guarantor has, or would, become obligated to pay such Additional Amounts as a result of such Change in Tax Law.

For the purposes hereof, “Change in Tax Law” shall mean: (i) any changes in, or amendment to, any law of a Relevant Taxing Jurisdiction (including any regulations or rulings promulgated thereunder and including, for this purpose, any treaty entered into by the Relevant Taxing Jurisdiction) or any amendment to or change in the application or official interpretation (including judicial or administrative interpretation) of such law, which change or amendment becomes effective or, in the case of an official interpretation, is announced, on or after August 15, 2017; or (ii) if the Issuer or a Guarantor consolidates, merges, amalgamates or combines with, or transfers or leases its assets substantially as an entirety to, any person that is incorporated or tax resident under the laws of any jurisdiction other than a Relevant Taxing Jurisdiction (a “successor”) and as a consequence thereof such person becomes the successor obligor to the Issuer or such Guarantor in respect of Additional Amounts that may become payable (in which case, for purposes of this redemption provision, all references to the Issuer or such Guarantor shall be deemed to be and include references to such person), any change in, or amendment to, any law of the jurisdiction of organization or tax residence of such successor, or the jurisdiction through which payments will be made by the successor, or any political subdivision or taxing authority thereof or thereon for purposes of taxation (including any regulations or rulings promulgated thereunder and including, for this purpose, any treaty entered into by such jurisdiction) or any amendment to or change in the application or official interpretation (including judicial or administrative interpretation) of such law, which change or amendment becomes effective or, in the case of an official interpretation, is announced, on or after the date of such consolidation, merger, amalgamation, combination or other transaction.

General

Upon presentation of any Fixed Rate Note redeemed in part only, the Issuer will execute and the Paying Agent will authenticate and deliver (or cause to be transferred by book-entry) to, or on, the order of the holder thereof, at the expense of the Issuer, a new Fixed Rate Note or Fixed Rate Notes, of authorized denominations, in principal amount equal to the unredeemed portion of the Note so presented.

On or before any Redemption Date (as defined above), the Issuer shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued and unpaid interest on the Notes to be redeemed on such date. The redemption price shall be calculated by the Independent Investment Banker and the Issuer, and the Trustee and any agent shall be entitled to rely on such calculation.

On and after any Redemption Date, interest will cease to accrue on the Notes or any portion thereof called for redemption.

81
Maturity

Unless previously purchased or redeemed by the Issuer, and cancelled, the principal amount of each respective series of Notes shall mature on:

<table>
<thead>
<tr>
<th>Series of Notes</th>
<th>Maturity date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.764% Notes</td>
<td>August 15, 2022</td>
</tr>
<tr>
<td>3.222% Notes</td>
<td>August 15, 2024</td>
</tr>
<tr>
<td>3.557% Notes</td>
<td>August 15, 2027</td>
</tr>
<tr>
<td>4.390% Notes</td>
<td>August 15, 2037</td>
</tr>
<tr>
<td>4.540% Notes</td>
<td>August 15, 2047</td>
</tr>
<tr>
<td>Floating Rate Notes</td>
<td>August 15, 2022</td>
</tr>
</tbody>
</table>

in an amount equal, in each case, to their principal amount, with accrued and unpaid interest to such date.

Reacquisition

There is no restriction on the ability of the Issuer to purchase or repurchase Notes, provided, that any Notes so repurchased shall be cancelled and not reissued.

Sinking Fund

There is no provision for a sinking fund for any of the Notes.

Certain Definitions

Set forth below is a summary of certain of the defined terms used in the Notes and the 2017 BATCAP Indenture. You should refer to the Notes and the 2017 BATCAP Indenture for the full definition of all defined terms as well as any other terms used herein for which no definition is provided.

“EMTN Programme” means the Euro Medium Term Note Programme to which BATIF, BATCAP, BATHTN and BATNF are parties as the issuers under the programme and notes issued thereunder are guaranteed by the Parent Guarantor, each of the issuers thereunder (except when it is the relevant issuer) and RAI, as amended from time to time.

“Person” means any individual, corporation, partnership, joint venture, association, limited liability company, joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.

“Quoted Borrowing” means any indebtedness which: (a) is represented by notes, debentures or other securities issued otherwise than to constitute or represent advances made by banks and/or other lending institutions; (b) is denominated, or confers any right to payment of principal and/or interest, in or by reference to any currency other than the currency of the country in which the issuer of the indebtedness has its principal place of business or is denominated, or confers any right to payment of principal and/or interest, in or by reference to the currency of such country but is placed or offered for subscription or sale by or on behalf of, or by agreement with, the issuer of such indebtedness as to over 20% outside such country; and (c) at its date of issue is, or is intended by the issuer of such indebtedness to become, quoted, listed, traded or dealt in on any stock exchange or other organized and regulated securities market in any part of the world.
COVENANTS OF THE ISSUER AND THE GUARANTORS

Negative Pledge

The 2017 BATCAP Indenture provides that so long as any of the applicable Notes remains outstanding, neither the Issuer nor any Guarantor will secure or allow to be secured any Quoted Borrowing or any payment under any guarantee by any of them of any Quoted Borrowing by any mortgage, charge, pledge or lien (other than arising by operation of law) upon any of its undertaking or assets, whether present or future, unless at the same time the same mortgage, charge, pledge or lien is extended, or security which is not materially less beneficial to the holders of the applicable Notes than the security given as aforesaid or which shall be approved by consent of the holders of not less than 75% in aggregate principal amount of the applicable Notes at the time outstanding is extended or created (as the case may be), to secure equally and ratably the principal of, and interest on, and all other payments (if any) in respect of the applicable Notes.

Limitation on Mergers, Consolidations, Amalgamations and Combinations

So long as any of the applicable Notes remain outstanding, neither the Issuer nor any Guarantor may consolidate with or merge into any other person or sell, convey, transfer or lease its properties and assets as an entirety or substantially as an entirety to any person (other than any sale or conveyance by way of a lease in the ordinary course of business), unless: (i) in the case of the Issuer, any successor person assumes the Issuer’s obligations on the applicable Notes and under the 2017 BATCAP Indenture and, in the case of any Guarantor, any successor person assumes such Guarantor’s obligations on the applicable Guarantee and under the 2017 BATCAP Indenture; (ii) immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; (iii) such successor person is organized under the laws of the United States, the United Kingdom, The Netherlands or any other country that is a member of the Organization for Economic Cooperation and Development as of the date of such succession; (iv) such successor person agrees to pay any Additional Amounts imposed by the jurisdiction in which such successor person is incorporated or otherwise a resident for tax purposes or through which payments are made and resulting therefrom or otherwise; and (v) if as a result of such consolidation or merger or such sale, conveyance, transfer or lease, properties or assets of the Issuer or any Guarantor would become subject to a mortgage, pledge, security interest, lien or similar encumbrance to secure payment of any indebtedness for borrowed money of the Issuer or a Guarantor which would not be permitted by the applicable Notes or under the 2017 BATCAP Indenture, the Issuer or any Guarantor or such successor person, as the case may be, shall take such steps as shall be necessary to effectively secure the Notes equally and ratably with (or prior to) all indebtedness for borrowed money secured thereby.
The limitation on mergers, consolidations, amalgamations and combinations described in this section “—Limitation on Mergers, Consolidations, Amalgamations and Combinations” shall not apply to any consolidation, merger, amalgamation or combination in which the Issuer or applicable Guarantor is the surviving corporation except that, in such case, the provisions of (ii) and (v) above shall apply such that: (x) immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; and (y) if as a result of such consolidation or merger or such sale, conveyance, transfer or lease, properties or assets of the Issuer or any Guarantor would become subject to a mortgage, pledge, security interest, lien or similar encumbrance to secure payment of any indebtedness for borrowed money of the Issuer or a Guarantor which would not be permitted by the applicable Notes or under the 2017 BATCAP Indenture, the Issuer or any Guarantor, as the case may be, shall take such steps as shall be necessary to effectively secure the Notes equally and ratably with (or prior to) all indebtedness for borrowed money secured thereby.

The 2017 BATCAP Indenture does not contain covenants or other provisions to afford protection to holders of the Notes in the event of a highly leveraged transaction or a change in control of the Issuer or any Guarantor except as provided above.

Upon certain mergers or consolidations involving the Issuer or a Guarantor, or upon certain sales or conveyances of the properties of the Issuer or a Guarantor, the obligations of the Issuer or such Guarantor, under the applicable Notes or the applicable Guarantee, shall be assumed by the person formed by such merger or consolidation or which shall have acquired such property and upon such assumptions such person shall succeed to and be substituted for the Issuer or such Guarantor, as the case may be, and then the Issuer or such Guarantor will be relieved from all obligations under the Notes and the applicable Guarantee, as the case may be. The terms “Issuer” and “Guarantor”, as used in the Notes and the 2017 BATCAP Indenture, also refer to any such successors or assigns so substituted.

Although there is a limited body of case law interpreting the phrase “entirety or substantially as an entirety”, there is no precise established definition of the phrase under applicable law. Accordingly, in certain circumstances, there may be a degree of uncertainty as to whether a particular transaction would involve a disposition of “entirety or substantially as an entirety” of the Issuer’s assets and its subsidiaries taken as a whole.

EVENTS OF DEFAULT
The following will be Events of Default (each an “Event of Default”) with respect to the applicable Notes:

(i) Non-Payment: default is made in the payment of: (a) any installment of interest (excluding Additional Amounts) upon any applicable Note as and when the same shall become due and payable, and continuance of such default for a period of 14 days or more; (b) applicable Additional Amounts as and when the same shall become due and payable, and continuance of such default for a period of 14 days; or (c) all or any part of the principal or premium, if any, of any applicable Note as and when the same shall become due and payable either at maturity, upon any redemption, by declaration or otherwise, and continuance of such default for three days;
(ii) Breach of Other Obligations: the Issuer or any Guarantor does not perform or comply with any one or more of its other obligations under the applicable Notes or the 2017 BATCAP Indenture (other than those described in paragraph (i) above) which is not remedied within 30 days after written notice of such default shall have been given to the Issuer by the Trustee or to the Issuer and the Trustee by the holders of at least 25% of the outstanding principal amount of the Notes;

(iii) Cross-Default: (a) any other present or future indebtedness for borrowed money of the Issuer or any Guarantor, other than the Notes issued by the Issuer, becomes due and payable prior to its stated maturity by reason of any default or event of default in respect thereof by the Issuer or any Guarantor and remains unpaid; or (b) any such indebtedness for borrowed money is not paid when due or, as the case may be, within any applicable grace period; or (c) the Issuer or any Guarantor fails to pay when due and called upon (after the expiry of any applicable grace period) any amount payable by it under any present or future guarantee for, or indemnity in respect of, any indebtedness for borrowed money and which remains unpaid; provided that (x) payment of the indebtedness for borrowed money is not being contested in good faith and in accordance with legal advice or (y) the aggregate amount of the indebtedness for borrowed money, guarantees and indemnities in respect of which one or more of the events mentioned above in (a), (b) and (c) has or have occurred and is or are continuing, equals or exceeds £750 million or its equivalent in any other currency of the indebtedness for borrowed money or, if greater, 1.25% of the Total Equity of the Parent Guarantor, as set out in the “Total Equity” line item in the most recent consolidated group balance sheet of the Parent Guarantor and its subsidiaries in the Parent Guarantor’s most recent Annual Report;

(iv) Cessation of Guarantees: any Guarantee ceases to be in full force and effect (except as contemplated by the terms of the 2017 BATCAP Indenture) or any Guarantor denies or disaffirms in writing its obligations under the 2017 BATCAP Indenture or Guarantee;

(v) Enforcement Proceedings: a distress or execution or other legal process is levied or enforced against or an encumbrancer takes possession of or a receiver, administrative receiver or other similar officer is appointed of the whole or a part of the assets of the Issuer or any Guarantor which is substantial in relation to the BAT Group taken as a whole and is not discharged, stayed, removed or paid out within 45 days after such execution or appointment;

(vi) Security Enforced: any mortgage, charge, pledge, lien or other encumbrance, present or future, created or assumed by the Issuer or any Guarantor becomes enforceable and any step is taken to enforce it (including the taking of possession or the appointment of a receiver, administrative receiver, manager or other similar person) against all or substantially all of the assets of the Issuer or any Guarantor and is not discharged within 45 days;
(vii) Insolvency: the Issuer or any Guarantor is insolvent or bankrupt or unable to pay its debts (in respect of companies incorporated in England and Wales, within the meaning of Sections 123(1)(b) or (c) or Section 123(2) of the UK Insolvency Act 1986), stops, suspends or threatens to stop or suspend payment of all or a material part of its debts, proposes or makes a general assignment or an arrangement or composition (otherwise than for the purposes of reconstruction, amalgamation, reorganization, merger or consolidation or other similar arrangement) with or for the benefit of its creditors in respect of any of such debts or a moratorium is agreed or declared in respect of or affecting all or a material part of the debts of the Issuer;

(viii) Winding-up: an order is made or an effective resolution passed for the winding-up or dissolution or administration of the Issuer or any Guarantor, or the Issuer or any Guarantor shall apply or petition for a winding-up or administration order in respect of itself or ceases or threatens to cease to carry on all or substantially all of its business or operations, in each case except for the purpose of and followed by a reconstruction, amalgamation, reorganization, merger or consolidation or other similar arrangement; or

(ix) Analogous Events: any event occurs that under the laws of any relevant jurisdiction has an analogous effect to any of the events referred to in any of the foregoing paragraphs (vii) and (viii).

The 2017 BATCAP Indenture provides that if an Event of Default occurs and is continuing with respect to the Notes of a series, then and in each and every such case (other than certain Events of Default specified in paragraphs (vii), (viii) and (ix) above with respect to the Issuer or any Guarantor), unless the principal of all the applicable Notes shall have already become due and payable, the holders of not less than 25% in aggregate principal amount of the applicable Notes then outstanding, by notice in writing to the Issuer, each Guarantor and the Trustee, may declare the entire principal amount of all applicable Notes issued pursuant to the 2017 BATCAP Indenture and interest accrued and unpaid thereon, if any, to be due and payable immediately, and upon any such declaration the same shall become immediately due and payable, without any further declaration or other act on the part of any holder. If certain Events of Default described in paragraph (vii), (viii) or (ix) above occur with respect to the Issuer and are continuing, the principal amount of and accrued and unpaid interest on all the applicable Notes issued pursuant to the 2017 BATCAP Indenture shall become immediately due and payable, without any declaration or other act on the part of the Trustee or any holder. Under certain circumstances, the holders of a majority in aggregate principal amount of the applicable Notes then outstanding, by written notice to the Issuer, each Guarantor and the Trustee, may waive defaults and rescind and annul declarations of acceleration and its consequences, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent default or shall impart any right consequent thereon.

The holders of a majority in aggregate principal amount of the applicable Notes then outstanding will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, subject to certain limitations to be specified in the 2017 BATCAP Indenture, including providing to the Trustee indemnity satisfactory to it.
An Event of Default with respect to any series of Notes would not necessarily constitute an event of default with respect to the other series of Notes.

The 2017 BATCAP Indenture also provides that no holder of any Notes governed by the 2017 BATCAP Indenture may institute any action or proceeding at law or in equity or in bankruptcy or otherwise upon or under or with respect to the 2017 BATCAP Indenture, or for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy under the 2017 BATCAP Indenture (except suits for the enforcement of payment of overdue principal or interest) unless (1) the holder of a Note gives to the Trustee written notice of a continuing Event of Default, (2) the holders of at least 25% in principal amount of the then outstanding Notes make a written request to the Trustee to pursue the remedy, (3) the holder or holders of Notes offer, and if requested, provide to the Trustee indemnity reasonably satisfactory to the Trustee against any loss, liability or expense, (4) the Trustee does not comply with the request within 60 days after receipt of the request and the offer and, if requested, the provision of indemnity and (5) during such 60-day period the holders of a majority in principal amount of the then outstanding Notes do not give the Trustee a direction inconsistent with the request. The holder of a Note may not use the 2017 BATCAP Indenture to prejudice the rights of another holder of a Note or to obtain a preference or priority over another holder of a Note (it being understood that the Trustee does not have an affirmative duty to ascertain whether or not such actions or forbearances are unduly prejudicial to such holders).

SATISFACTION AND DISCHARGE

The 2017 BATCAP Indenture provides that BAT may, subject to satisfying certain conditions, discharge certain obligations to the holders of Notes of any series of Notes that have not already been delivered to the Trustee for cancellation and that either have become due and payable or will become due and payable within one year (or scheduled for redemption within one year) by depositing with the Trustee or Paying Agent, in trust, funds in an amount sufficient to pay the entire indebtedness on such series of Notes in respect of principal and premium, if any, and interest, if any, to the date of such deposit (if such Notes have become due and payable) or to the maturity thereof or redemption date, as the case may be, along with an officer’s certificate and an opinion of counsel stating that all conditions precedent relating to the satisfaction and discharge of the 2017 BATCAP Indenture have been complied with.

LEGAL DEFEASANCE AND COVENANT DEFEASANCE

The 2017 BATCAP Indenture provides that the Issuer will have the option either (a) to be deemed (together with each Guarantor) to have paid and discharged the entire indebtedness represented by, and obligations under, a series of Notes and the applicable Guarantees and to have satisfied all the obligations under the 2017 BATCAP Indenture relating to the series of Notes (except for certain obligations, including those relating to the defeasance trust and obligations to register the transfer or exchange of Notes, to replace mutilated, destroyed, lost or stolen Notes and to maintain paying agencies) on the 91st day after the applicable conditions described below have been satisfied or (b) to cease (together with each Guarantor) to be under...
any obligation to comply with the covenant described above under “—Covenants of the Issuer and the Guarantors—Negative Pledge” and the condition relating to the absence of any events of default under “—Covenants of the Issuer and the Guarantors—Limitation on Mergers, Consolidations, Amalgamations and Combinations” under the 2017 BATCAP Indenture, and non-compliance with such covenants and the occurrence of all events described above under “—Events of Default” will not give rise to any Event of Default under the 2017 BATCAP Indenture, at any time after the applicable conditions described below have been satisfied.

In order to exercise either defeasance option, the Issuer must (i) deposit with the Trustee or Paying Agent, irrevocably in money or Government Obligations (as defined in the 2017 BATCAP Indenture) funds sufficient in the opinion of a certified public accounting firm of national reputation for the payment of principal of and interest on the applicable outstanding Notes of any series to and including the Redemption Date irrevocably designated by the Issuer on or prior to the date of deposit of such money or Government Obligations, and must (ii) comply with certain other conditions, including delivering to the Trustee an opinion of U.S. counsel to the effect that beneficial owners of the applicable Notes will not recognize income, gain or loss for United States federal income tax purposes as a result of the exercise of such option and will be subject to United States federal income tax on the same amount and in the same manner and at the same time as would have been the case if such option had not been exercised and, in the case of clause (a) in the previous paragraph, which opinion must state that such opinion is based on a ruling received from or published by the United States Internal Revenue Service or on a change of law after August 15, 2017.

MODIFICATION AND WAIVER

Without Consent of Noteholders

The 2017 BATCAP Indenture contains provisions permitting the Issuer, each Guarantor and the Trustee, without the consent of the holders of any of the applicable Notes at any time outstanding under such 2017 BATCAP Indenture, from time to time and at any time, to enter into a supplemental indenture amending or supplementing such 2017 BATCAP Indenture, the Notes or the Guarantees in order to:

- convey, transfer, assign, mortgage or pledge to the holders of the applicable Notes or any person acting on their behalf as security for the applicable Notes any property or assets;
- evidence the succession of another person to the Issuer or any Guarantor, as the case may be, or successive successions, and the assumption by the successor person(s) of the covenants, agreements and obligations of the Issuer or any Guarantor, as the case may be, pursuant to the 2017 BATCAP Indenture;
- evidence and provide for the acceptance of appointment of a successor or successors to the Trustee and/or the Paying Agent, Transfer Agent, Calculation Agent and Registrar, as applicable;

88
• add to the covenants of, or the restrictions, conditions or provisions applicable to, the Issuer and any Guarantor, as the case may be, such further covenants, restrictions, conditions or provisions as the Issuer and any Guarantor, as the case may be, shall consider to be for the protection of the holders of the applicable Notes issued pursuant to the 2017 BATCAP Indenture, including to eliminate one or both prongs of the release provision under “—Guarantees—Release”, and to make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default under the 2017 BATCAP Indenture permitting the enforcement of all or any of the several remedies provided in the 2017 BATCAP Indenture; provided that, in respect of any such additional covenant, restriction, condition or provision, such supplemental indenture may provide for a particular period of grace after default (which may be shorter or longer than that allowed in the case of other defaults) or may limit the remedies available to the Trustee upon such an Event of Default;

• if required by the requirements of the SEC, comply with any requirements of the SEC in connection with the qualification of the 2017 BATCAP Indenture under the TIA;

• modify the restrictions on, and procedures for, resale and other transfers of the applicable Notes pursuant to law, regulation or practice relating to the resale or transfer of restricted securities generally;

• cure any ambiguity or to correct or supplement any provision contained in the 2017 BATCAP Indenture, the Notes, or the Guarantees which may be defective or inconsistent with any other provision contained therein or to make such other provision in regard to matters or questions arising under the 2017 BATCAP Indenture, the Notes or the Guarantees as the Issuer, any Guarantor or the Trustee may deem necessary or desirable and which will not, in the opinion of the Issuer or any Guarantor, adversely affect the interests of the holders of the applicable Notes in any material respect;

• issue an unlimited aggregate principal amount of Notes under the 2017 BATCAP Indenture or to “reopen” the applicable series of Notes and create and issue additional notes having identical terms and conditions as the applicable Notes (or in all respects except for the issue date, issue price, payment of interest accruing prior to the issue date of such additional notes and/or the first payment of interest following the issue date of such additional notes) so that the additional notes are consolidated and form a single series with the outstanding applicable Notes; and

• evidence the addition of any new Guarantor of the Notes and the 2017 BATCAP Indenture, or the release of any Guarantor from its obligations with respect to the Notes and the 2017 BATCAP Indenture, in either case pursuant to the terms of the 2017 BATCAP Indenture.
With Consent of Noteholders

The 2017 BATCAP Indenture contains provisions permitting the Issuer, each Guarantor and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of all series of the Notes affected by such supplemental indenture (voting as one class) at the time outstanding under the 2017 BATCAP Indenture (including consents obtained in connection with a tender offer or exchange offer for the applicable Notes), from time to time and at any time, to enter into a supplemental indenture for the purpose of amending, waiving or otherwise modifying the provisions of the 2017 BATCAP Indenture, the Notes and the Guarantees, or adding any provisions to or changing in any manner or eliminating any of the provisions of the applicable Notes or of modifying in any manner the rights of the holders of the applicable Notes; provided, that no such supplemental indenture may, without the consent of the holder of each of the Notes so affected:

- change the stated maturity of the applicable Note of, or the date for payment of any principal of, or installment of interest on, any applicable Note; or
- reduce the principal amount of or the rate or amount of interest on any applicable Note or Additional Amounts payable with respect thereto or reduce the amount payable thereon in the event of redemption or default or change the method for determining the interest rate thereon; or
- change the currency of payment of principal of or interest on any applicable Note or Additional Amounts payable with respect thereto; or change the obligation of the Issuer or any Guarantor, as the case may be, to pay Additional Amounts (except as otherwise permitted by such applicable Note); or
- impair the right to institute suit for the enforcement of any such payment on or with respect to any applicable Note; or
- reduce the percentage of the aggregate principal amount of the applicable Notes outstanding the consent of whose holders is required for any such supplemental indenture; or
- reduce the aggregate principal amount of any applicable Note outstanding necessary to modify or amend the 2017 BATCAP Indenture or any such Note or to waive any future compliance or past default or reduce the quorum requirements or the percentage of aggregate principal amount of any applicable Notes outstanding required for the adoption of any action at any meeting of holders of such Notes or to reduce the percentage of the aggregate principal amount of such Notes outstanding necessary to rescind or annul any declaration of the principal of all accrued and unpaid interest on any Note to be due and payable,

provided, that no consent of any holder of any applicable Note shall be necessary to permit the Trustee, the Issuer and each of the Guarantors to execute supplemental indenture as described under “Without Consent of Noteholders” above.

90
Any modifications, amendments or waivers to the 2017 BATCAP Indenture or to the conditions of the applicable Notes will be conclusive and binding on all holders of the applicable Notes, whether or not they have consented to such action or were present at the meeting at which such action was taken, and on all future holders of the applicable Notes, whether or not notation of such modifications, amendments or waivers is made upon such Notes. Any instrument given by or on behalf of any holder of such a Note in connection with any consent to any such modification, amendment or waiver will be irrevocable once given and will be conclusive and binding on all subsequent registered holders of such Note.

PRESCRIPTION
Under New York’s statute of limitations, any legal action upon the Notes in respect of interest or principal must be commenced within six years after the payment thereof is due.

NOTICE
Notices to holders of Notes will be given by first-class mail postage prepaid to the last addresses of such holders as they appear in the Notes register; provided, no such mailing shall be required if Notes are held through DTC, as such notice shall be given in accordance with applicable procedures of DTC. Such notices will be deemed to have been given on the date of such publication or mailing.

So long as any Global Notes representing the Notes are held in their entirety on behalf of a clearing system, or any of its participants, there may be substituted for the publication and mailing of notice to holders of Notes described above the delivery of the relevant notices to the clearing system, and its participants, for communication by them to the entitled accountholders. Any such notice shall be deemed to have been given on the day on which the said notice was given to the clearing system, and its participants.

LISTING
The Notes are listed on the New York Stock Exchange.

CONSENT TO SERVICE
Each of the non-U.S. Guarantors has initially designated BATCAP as their authorized agent for service of process in any legal suit, action or proceeding arising out of or relating to the performance of its obligations under the 2017 BATCAP Indenture and the Notes brought in any state or federal court in the Borough of Manhattan, the City of New York, and will irrevocably submit (but for those purposes only) to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding.

GOVERNING LAW
The 2017 BATCAP Indenture, Notes and Guarantees shall be governed by and construed in accordance with the laws of the State of New York, without regard to principles of conflicts of laws thereof.
REGARDING THE TRUSTEE AND AGENTS

Wilmington Trust, National Association is the trustee under the 2017 BATCAP Indenture. Citibank, N.A., London Branch has been appointed by the Issuer to act as registrar, transfer agent, calculation agent and paying agent for the Notes. Citibank, N.A., New York Branch replaced Citibank, N.A., London Branch as paying agent, registrar, transfer agent and calculation agent on October 16, 2018. From time to time, Citibank, N.A., London Branch, Citibank, N.A., New York Branch and their respective affiliates perform various other services for the BAT and its affiliates. The 2017 BATCAP Indenture contains limitations on the rights of the trustee, if it becomes a creditor of the Issuer or any Guarantor, to obtain payment of claims in some cases, or to realize on property received in respect of any of these claims as security or otherwise. The Trustee is permitted to engage in other transactions. However, if the Trustee acquires any conflicting interest (as defined in the TIA), it must either eliminate its conflict within 90 days, apply to the SEC for permission to continue or resign.

The 2017 BATCAP Indenture provides that except during the continuance of an Event of Default, the Trustee will perform only such duties as are specifically set forth in such 2017 BATCAP Indenture. During the continuance of an Event of Default of which the Trustee has received written notice, the Trustee will exercise such of the rights and powers vested in it under the 2017 BATCAP Indenture, and use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs.
BRITISH AMERICAN TOBACCO P.L.C.

RULES

of the

BRITISH AMERICAN TOBACCO

2016 LONG TERM INCENTIVE PLAN

Adopted pursuant to shareholders’ approval obtained on 27 April 2016
and amended by the Board on 10 December 2018
and amended by the Board on 3 June 2019
and amended by the Board on 25 February 2020
and amended by the Board on 19 February 2021
and amended by the Board on 8 February 2022

Herbert Smith Freehills LLP

HSF Ref: 30889176
1. INTERPRETATION AND CONSTRUCTION 3
2. PLAN LIMITS 5
3. AWARDS 6
4. AWARDS ARE NON-TRANSFERABLE 8
5. PERFORMANCE CONDITION 8
6. ADDITIONAL TERMS SPECIFIC TO FORFEITABLE SHARE AWARDS 8
7. VESTING 9
8. CESSATION OF OFFICE OR EMPLOYMENT 10
9. CORPORATE ACTIONS 12
10. OPTIONS 14
11. DIVIDEND EQUIVALENT 15
12. CASH ALTERNATIVE – OPTIONS AND CONDITIONAL AWARDS 15
13. TAX LIABILITY 16
14. VESTED SHARE ACCOUNTS 16
15. CLAW-BACK 17
16. VARIATION OF CAPITAL 18
17. ADMINISTRATION 18
18. AMENDMENTS 19
19. DATA PROTECTION 19
20. GENERAL 20

APPENDIX 1: OPERATION OF CLAW-BACK 22
1. INTERPRETATION 24
2. APPLICATION 24
3. PERFORMANCE AND SERVICE CONDITION 24
4. APPLICATION OF PARAGRAPH 5 AND 6 25
5. AWARDS (I) WHERE THE “WAIT AND SEE” APPROACH SHALL APPLY (INCLUDING ALL AWARDS SUBJECT TO AN EXTENDED VESTING PERIOD), (II) DESCRIBED IN PARAGRAPHS 3.1 AND 3.2 OF ADDENDUM I TO THE PLAN OR (III) THAT OTHERWISE ARE NOT EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL 25
6. AWARDS WITHOUT AN EXTENDED VESTING PERIOD AND WHERE THE “WAIT AND SEE” APPROACH DOES NOT APPLY AND THAT ARE OTHERWISE EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL 26
7. DIVIDEND EQUIVALENTS 26
8. CASH ALTERNATIVE 26
9. CODE § 409A EXEMPTION AND COMPLIANCE 26
10. COOPERATION 27
11. SETTLEMENT
ADDENDUM I: AWARDS GRANTED TO RAI PARTICIPANTS (PRIOR TO 2020)
1. APPLICATION
2. MODIFICATION
3. TERMS
4. SETTLEMENT
ADDENDUM II: AWARDS GRANTED TO RAI PARTICIPANTS (FROM 2020)
1. APPLICATION
2. MODIFICATION
3. TERMS
4. SETTLEMENT
SCHEDULE 1: PERFORMANCE CONDITIONS
RULES OF THE BRITISH AMERICAN TOBACCO P.L.C. LONG TERM INCENTIVE PLAN

1. INTERPRETATION AND CONSTRUCTION

1.1 For the purposes of the Plan, the following terms shall have the meaning indicated below unless the context clearly indicates otherwise:

“Award” means one of a Conditional Award, a Forfeitable Share Award or an Option;

“Board” means the board of directors of the Company or a committee duly authorised by the board of directors or, following any Corporate Action, the Board or duly authorised committee as constituted immediately prior to the Corporate Action;

“Claw-back” means a recovery of value by the Company from a Participant in accordance with the provisions of Rule 15 (Claw-back) and Appendix 1 (Operation of Claw-back);

“Company” means British American Tobacco p.l.c. (registered in England and Wales under No. 3407696);

“Conditional Award” means a right to receive a transfer of Shares following vesting of the Award;

“Control” has the meaning given by Section 995 of the Income Tax Act 2007;

“Corporate Action” means any of the events referred to in:

(A) Rules 9.1 to 9.5 (but excluding a Reorganisation as defined in Rule 9.8); or
(B) if the Board determines that Awards will vest pursuant to such Rule, Rule 9.6;

“Cross-Border Merger” means a merger pursuant to the implementation in any relevant jurisdiction of Directive 2005/56/EC (on cross-border mergers of limited liability companies);

“Dealing Day” means any day on which the London Stock Exchange is open for trading;

“Dealing Restriction” means any restriction on the dealing in shares, whether direct or indirect, pursuant to any law, regulation, code or enactment in England and Wales and/or the jurisdiction in which the Participant is resident, or any share dealing code of the Company;

“Eligible Employee” means an employee (including an executive director) of any Group Company;

“Employees’ Share Scheme” has the meaning given by Section 1166 of the Companies Act 2006;

“Financial Year” means the financial year of the Company within the meaning of Section 390 of the Companies Act 2006;

“Forfeitable Share Award” means a beneficial interest in Shares, legal title to which is held by the Nominee subject to the restrictions set out in Rule 6 (Additional terms applicable to Forfeitable Share Awards) until, and which shall be transferred to the Participant following, the vesting of the Award;

“Grant Date” means the date on which a Conditional Award or Option is granted, or the date on which the Board determines that a Forfeitable Share Award shall be granted;

“Group” means the Company and any company which from time to time is a subsidiary of the Company, within the meaning of section 1159 of the Companies Act 2006 (each a “Group Company”);

“Market Value” means, in relation to a Share on any day, the mid-closing price of a Share on such day (as derived from the Daily Official List of the London Stock Exchange);

“Nominee” means any person appointed by the Company from time to time to hold legal title to the Shares subject to a Forfeitable Share Award on behalf of the Participant in accordance with these Rules (which may be the trustee of a Trust acting as a nominee);
“Normal Vesting Date” means:

(A) subject to (B):

(i) where the Board determines that an extended vesting period shall apply, the fifth anniversary of the Grant Date, or otherwise,

(ii) the third anniversary of the Grant Date or any later date determined by the Board; or

(B) in respect of an Award granted in respect of the recruitment of an Eligible Employee, any other date (which may be prior to the third anniversary of the Grant Date) as determined by the Board prior to the Grant Date;

“Option” means a right to acquire Shares, which may be exercised by the Participant following the vesting of the Award during any period permitted for exercise;

“Option Price” shall be nil, or such other amount as the Board may determine (provided that the Board may reduce or waive such amount at any time);

“Participant” means an Eligible Employee who has received an Award to the extent it has not been released and has not lapsed (or, following his death, his Personal Representatives);

“Performance Condition” means the performance condition to which an Award is subject, which may consist of one or more performance elements, being as set out in a Schedule to the Plan (as substituted or amended by the Board from time to time);

“Performance Period” means the period of three Financial Years beginning with the Financial Year in which the Grant Date falls, or such other period as is determined by the Board prior to the Grant Date in accordance with Rule 5;

“Personal Representatives” means, following his death, the Participant’s personal representatives, or a person fulfilling a similar function in any jurisdiction;

“Plan” means this British American Tobacco 2016 Long Term Incentive Plan, as amended from time to time;

“Quarter Day” means 31 March, 30 June, 30 September or 31 December;

“Rule” means a rule of this Plan;

“Share” means a fully paid ordinary share in the capital of the Company;

“Treasury Shares” means Shares to which Sections 724 to 732 of the Companies Act 2006 apply;

“Trust” means any employee benefit trust from time to time established by the Company;

“U.S. Taxpayer” has the meaning given in Rule 3.11 (U.S. Taxpayers); and

“vesting” means:

(A) Shares subject to a Conditional Award becoming due to be transferred to the Participant;

(B) Shares subject to a Forfeitable Share Award ceasing to be subject to the restrictions set out in Rule 6 (Additional terms applicable to Forfeitable Share Awards), and legal title to such Shares becoming due to be transferred to the Participant; or

(C) an Option becoming exercisable,

(and “vest” shall be construed accordingly).

1.2 In this Plan unless the context requires otherwise:

1.2.1 the headings are inserted for convenience only and do not affect the interpretation of any Rule;
1.2.2 a reference to a statute or statutory provision includes a reference:
(A) to that statute or statutory provision as from time to time consolidated, modified, re-enacted or replaced by any statute or statutory provision;
(B) to any repealed statute or statutory provision which it re-enacts (with or without modification); and
(C) to any subordinate legislation made under it;
1.2.3 words in the singular include the plural, and vice versa;
1.2.4 a reference to the masculine shall be treated as a reference to the feminine and vice versa;
1.2.5 a reference to a person shall include a reference to a body corporate; and
1.2.6 a reference to writing or written form shall include any legible format capable of being reproduced on paper, irrespective of the medium used.
1.3 In this Plan:
1.3.1 a reference to the “transfer of Shares” (or similar) shall include both the issue and allotment of Shares and the transfer of Treasury Shares; and
1.3.2 a provision obliging, or permitting, any company to do any thing shall be read as obliging, or permitting, such company to do that thing, or procure that thing to be done; and
1.3.3 the use of the word “including” shall mean including without limitation and without prejudice to the generality of the foregoing.

2. PLAN LIMITS
2.1 Pursuant to the Plan:
2.1.1 subject to Rule 2.2, the Board may not grant a Conditional Award or Option; and
2.1.2 Shares may not be issued for the purpose of a Forfeitable Share Award, if the number of Shares subject to such proposed Award (the “Relevant Shares”) would cause either of the limits in Rules 2.3 or 2.4 to be breached.
2.2 Rule 2.1 shall not apply in respect of a Conditional Award or Option granted on terms that it shall not be capable of being satisfied by the issue of Shares.

5 per cent limit: discretionary Employees’ Share Scheme
2.3 The number of Relevant Shares, when added to the aggregate of:
2.3.1 the number of Shares subject to outstanding options or awards granted within the previous 10 years under the Plan or any other discretionary Employees’ Share Scheme adopted by the Company which may be satisfied by the issue of Shares; and
2.3.2 the number of Shares actually issued within the previous 10 years under the Plan, under any other discretionary Employees’ Share Scheme or to a Trust (but excluding any of those Shares that were used to satisfy an option or award granted more than 10 years previously, and without double counting any Shares which the Board has determined are to be used to satisfy options or awards counted under Rule 2.3.1 above), may not exceed such number as represents 5 per cent of the Company’s issued share capital immediately prior to such proposed grant or issue.
The number of Relevant Shares, when added to the aggregate of:

2.4.1 the number of Shares subject to outstanding options or awards granted within the previous 10 years under the Plan or any other Employees’ Share Scheme adopted by the Company which may be satisfied by the issue of Shares; and

2.4.2 the number of Shares actually issued within the previous 10 years under the Plan, under any other Employees’ Share Scheme or to a Trust (but excluding any of those Shares: that were used to satisfy an option or award granted more than 10 years previously, and without double counting any Shares which the Board has determined are to be used to satisfy options or awards counted under Rule 2.4.1 above),

may not exceed such number as represents 10 per cent of the Company’s issued share capital immediately prior to such proposed grant or issue.

References in this Rule 2 to the issue of Shares shall include the transfer of Treasury Shares, but only until such time as the guidelines issued by institutional investor bodies cease to provide that they should be so included.

Awards may be granted to Eligible Employees selected by the Board.

Timing of grants

3.2 An Award may only be granted:

3.2.1 during the period of 42 days commencing on the date on which the Plan is approved by shareholders of the Company in general meeting;

3.2.2 during the period of 42 days commencing on the Dealing Day immediately following the day on which the Company announces its results for the preceding financial year, half-year or other period;

3.2.3 in respect of an Award to be granted in respect of the recruitment of an Eligible Employee, as soon as reasonably practicable after the Eligible Employee commences holding office or employment with any Group Company; and/or

3.2.4 at such time at which the Board determines that exceptional circumstances exist which justify the grant of the Award, or, in any such case, if the grant of Awards during such period or at such time would be contrary to any Dealing Restriction, as soon as reasonably practicable after such restriction ceases to apply.

An Award granted in breach of this limit shall immediately lapse in respect of the number of Shares which cause this limit to be breached. Awards which have been released or have lapsed, or which are granted in connection with the recruitment of an Eligible Employee in lieu of incentive awards granted by the individual’s former employer which are forfeited, and any right to receive Shares as a dividend equivalent, shall be ignored for this purpose.
In this Rule 3.3, the “Relevant Value” of a Share subject to an Award means either (as determined by the Board): (i) the Market Value of a Share on the Dealing Day immediately preceding the Grant Date; or (ii) the average of the Market Values of a Share over such number of Dealing Days preceding the Grant Date as the Board may determine (all being within the period of 30 days preceding the Grant Date and, where the Award is granted within the period in Rule 3.2.2, being on or after the date of the results announcement).

3.4 Where an Eligible Employee’s gross annual basic salary is denominated in a currency other than pounds sterling, for the purposes of Rule 3.3 above such gross annual basic salary shall be converted into pounds sterling on such basis as the Board may reasonably determine.

Method of grant

3.5 An Award shall be granted by the Board.

3.6 A Conditional Award or an Option shall be granted by deed.

3.7 The Company shall procure that the Shares subject to a Forfeitable Share Award shall, on or as soon as reasonably practicable following the Grant Date, be issued to or acquired by a Nominee, and shall thereafter be held on behalf of the Participant until the date on which the Forfeitable Share Award vests or such earlier date as the Forfeitable Share Award lapses.

3.8 No payment for the grant of an Award shall be made by the Participant.

3.9 A Participant may within 30 days of the Grant Date release an Award (in full but not in part) by written notice to the Company. Where a Participant does not release an Award within such period, the Participant shall be deemed to have accepted the Award on the terms set out in the Rules. Alternatively, it may be a term of the grant of an Award that the Participant shall be required to accept the terms of the Award within such period following grant as may be determined by the Board and, where the Board specifies such period, the Award shall lapse at the end of such period if the terms of the Award have not been accepted by the Participant.

Award notification

3.10 As soon as practicable following the Grant Date the Company shall notify a Participant of the grant of an Award. Such notification shall specify:

3.10.1 whether the Award takes the form of a Conditional Award, a Forfeitable Share Award or an Option;
3.10.2 the Grant Date;
3.10.3 the Normal Vesting Date;
3.10.4 the number of Shares in respect of which the Award is granted;
3.10.5 in relation to an Option, the Option Price (if any);
3.10.6 the full terms of the Performance Condition and the Performance Period;
3.10.7 if applicable, that the dividend equivalent provisions of Rule 11 (Dividend equivalent) shall apply; and
3.10.8 that the Award is subject to the claw-back provisions of Rule 15 (Claw-back) and Appendix 1 (Operation of Claw-back).

U.S. Taxpayers

3.11 The provisions of Appendix 2 (Awards Granted to U.S. Taxpayers) shall apply to a Conditional Award or an Option that is held by any Participant while he or she is subject to taxation under the U.S. Internal Revenue Code of 1986, as amended (a “U.S. Taxpayer”). References to Code §409A are to §409A of the U.S. Internal Revenue Code of 1986, as amended.
4. **AWARDS ARE NON-TRANSFERABLE**

4.1 A Participant may not transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, any part of his interest in an Award. An Award shall (unless the Board determines otherwise) lapse on the Participant doing so (whether voluntarily or involuntarily), being deprived of the beneficial ownership of an Award by operation of law, or becoming bankrupt.

4.2 Rule 4.1 does not restrict the transmission of an Award to the Participant’s Personal Representatives following his death.

5. **PERFORMANCE CONDITION**

5.1 An Award shall be granted subject to the Performance Condition.

5.2 Subject to Rule 5.3, each element of the Performance Condition shall be assessed over a period of not less than three years, ending no later than the Normal Vesting Date.

5.3 An Award granted in respect of the recruitment of an Eligible Employee may be granted on terms that the Performance Condition shall be assessed over such shorter period as the Board may determine prior to the grant of the Award.

5.4 If events happen following the Grant Date which cause the Board to determine that any element of the Performance Condition is no longer a fair measure of the Company’s performance, the Board may alter the terms of such element as it determines to be appropriate but not so that the revised target is, in the opinion of the Board, materially less challenging than was intended in setting the original Performance Condition.

5.5 The Performance Condition may not be retested.

6. **ADDITIONAL TERMS SPECIFIC TO FORFEITABLE SHARE AWARDS**

6.1 The Participant shall be (subject to the Award lapsing) the beneficial owner of the Shares subject to a Forfeitable Share Award. For the avoidance of doubt, such beneficial interest shall be subject to the restriction in Rule 4.1 (*Awards are non-transferable*).

6.2 Until a Forfeitable Share Award vests, the Nominee shall refuse to act on any instruction from the Participant to (and subject to Rule 6.3, shall not) transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, legal title to the Shares subject to the Award or any interest therein, or enter into any agreement or accept any offer to do any such thing.

6.3 The Nominee shall take such action as is necessary to give effect to Rules 9.8 (*Roll-over of Award*), 13.1 (*Tax Liability*), 15 (*Claw-back*), 16 (*Variation of capital*) and Appendix 1 (*Operation of Claw-back*) and without further instruction from the Participant (and for the avoidance of doubt nothing in this Rule 6 shall prevent Shares subject to a Forfeitable Share Award becoming subject to a Corporate Action pursuant to Rule 9.3 (*Scheme of compromise or arrangement*)).

**Voting rights on forfeitable Shares**

6.4 Unless the Board determines otherwise, the Participant shall be entitled to direct the Nominee to vote the Shares subject to a Forfeitable Share Award, provided that the Nominee shall not be bound to seek directions from the Participant to vote and in the absence of any such direction shall not vote.
6.5 Unless the Board determines otherwise, the Participant shall be entitled to receive any dividends paid in respect of Shares subject to a Forfeitable Share Award (and if the Board so determines the Nominee shall waive the right to receive any dividends in respect of such Shares).

Lapse of Forfeitable Share Award

6.6 Where a Forfeitable Share Award lapses, the Participant shall cease to be beneficially entitled to the Shares subject to the Award, and the beneficial interest in such Shares shall, unless the Board directs otherwise, revert to a Trust specified by the Board for nil or nominal consideration.

7. VESTING

Normal vesting

7.1 An Award shall vest on the Normal Vesting Date.

Vesting subject to Dealing Restrictions

7.2 A Conditional Award or a Forfeitable Share Award shall not vest unless, and vesting shall be delayed until, the Board is satisfied that at that time:

7.2.1 such vesting;
7.2.2 the transfer of Shares to the Participant and the sale of Shares pursuant to Rule 13 (Tax Liability); and
7.2.3 any action needed to be taken by the Company to give effect to such vesting is not contrary to any Dealing Restriction.

Extent of vesting determined by the Performance Condition

7.3 The extent to which an Award shall be capable of vesting (if at all) shall be determined by reference to the Performance Condition. At the end of the period over which the Performance Condition is assessed, the Award shall lapse to the extent that the Performance Condition is not met.

7.4 Where an Award vests (pursuant to Rule 7.7 (International Transfers), Rule 8 (Cessation of office or employment) or 9 (Corporate Actions)) prior to the end of the period over which any element of the Performance Condition is assessed, such element shall be assessed based on performance to the last Quarter Day prior to the date on which the Award vests using such information (not limited to published accounts) as the Board shall determine.

Effect of vesting

7.5 The effect of the vesting of an Award is that:

7.5.1 the Shares in respect of which a Conditional Award vests shall be transferred to the Participant as soon as is reasonably practicable (which may include transferring the Shares on more than one consecutive Dealing Day on such basis as the Board may determine);
7.5.2 the Shares in respect of which a Forfeitable Share Award vests shall cease to be subject to the restrictions set out in Rule 6 (Additional terms applicable to Forfeitable Share Awards), and legal title to such Shares shall be transferred to the Participant as soon as is reasonably practicable; and
7.5.3 an Option shall, to the extent that it vests, become exercisable in accordance with Rule 10 (Options).
7.5A Shares shall not cease to be subject to the restrictions set out in Rule 6 (Additional terms applicable to Forfeitable Share Awards) until such time as it is practicable for a number of Shares in respect of such vesting to be sold in accordance with Rule 13.1.1 (Tax Liability) (such that a proportion of such Shares may cease to be subject to such restrictions on each Dealing Day within a period of consecutive Dealing Days (and on such basis) as the Board may determine), unless the Participant has in advance made other arrangements to pay the amount of the Tax Liability arising in respect of such vesting to the Company or the Board determines otherwise.

Disciplinary proceedings

7.6 Unless the Board determines otherwise, an Award shall not vest while a Participant is subject to an investigation process and/or formal disciplinary process (or similar), or where a Participant has been served with notice that such a process may be instigated without such notice having been rescinded, and vesting shall (subject to the Award lapsing to any extent prior to or as a result of the conclusion of such process pursuant to Rule 8 (Cessation of office or employment) or 15 (Claw-back)) be delayed until the conclusion of such process.

International transfers

7.7 Where a Participant, whilst continuing to hold an office or employment with a Group Company, is to be transferred to work in another country, and as a result the Board considers that following such transfer either he or a Group Company is likely to suffer a tax disadvantage in respect of an Award or, due to securities or exchange control laws, the Participant is likely to be restricted in his ability to receive Shares pursuant to an Award, to exercise an Option and/or to hold or deal in Shares, the Board may decide that an Award shall vest on such date as it may determine, in which case:

7.7.1 the proportion of the Award which may vest shall be limited (unless the Board determines otherwise) to a pro rata proportion on the basis of the number of months (rounded up to the nearest whole month) which have elapsed from the first day of the Performance Period to such vesting date, as compared to the number of whole months within the Performance Period. Any remainder of the Award shall lapse; and

7.7.2 an Option may be exercised during such period as may be determined by the Board ending no later than the date on which the Participant’s transfer takes effect.

8. CESSATION OF OFFICE OR EMPLOYMENT

Cessation where Awards lapse

8.1 An Award shall lapse:

8.1.1 on the Participant ceasing to hold office or employment with any Group Company; or

8.1.2 if the Participant gives or receives notice of such cessation, on such earlier date as may be determined by the Board, save in each case where Rule 8.2 or Rule 8.6 applies.

Reasons for cessation where Awards remain capable of vesting

8.2 An Award shall not lapse pursuant to Rule 8.1 where the reason for the cessation or notice is:

8.2.1 disability, ill-health or injury (as evidenced to the satisfaction of the Board);

8.2.2 redundancy (within the meaning of the Employment Rights Act 1996);
8.2.3 the transfer of the Participant’s employment in connection with the disposal of a business or undertaking, or a part- business or part-
undertaking;
8.2.4 the company with which the Participant holds office or employment ceasing to be a Group Company; or
8.2.5 any other reason, if the Board so determines.
Where the Board exercises its discretion under Rule 8.2.5 the Board may impose additional conditions on the Award (including as to when the
Award may vest).

Cessation prior to the Normal Vesting Date
8.3 Where prior to the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons
specified in Rule 8.2:
8.3.1 an Award shall not vest at the date of such cessation, but shall continue to be capable of vesting (in which case an Option may be
exercised during the period of six months, or such other period as may be determined by the Board, from such date on which the Award
may vest, and shall lapse at the expiry of such period); or
8.3.2 the Board may determine that the Award shall instead vest on or at any time following the date of cessation (in which case an Option
may be exercised during the period of six months, or such other period as may be determined by the Board, from such vesting date, and
shall lapse at the expiry of such period).
For the avoidance of doubt, the Board may make the determination in Rule 8.3.2 on a standing basis (subject to revocation of such determination
at any time) in respect of all Awards to be granted to a specified Eligible Employee or Eligible Employees.
8.4 Where prior to the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons
specified in Rule 8.2, unless the Board determines otherwise:
8.4.1 if the date of such cessation falls within the first six months of the Performance Period, the Award shall lapse in full on the date of such
cessation; or
8.4.2 where Rule 8.4.1 does not apply, the proportion of the Award which may vest (under any Rule) shall be limited to a pro rata proportion
on the basis of the number of months (rounded up to the nearest whole month) which have elapsed from the first day of the Performance
Period to the date of cessation, as compared to the number of whole months within the Performance Period. Any remainder of the
Award shall lapse.
Exercise period in the event of cessation on or after the Normal Vesting Date
8.5 Where on or after the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons
specified in Rule 8.2, an Option shall lapse at the expiry of the period of six months, or such other period as may be determined by the Board,
from the date of cessation.
Death
8.6 An Award shall vest on the Participant’s death. An Option may be exercised (by the Participant’s Personal Representatives) during a period of
one year from the date of the Participant’s death and shall lapse at the expiry of such period. Where a Participant dies during an exercise period
pursuant to either Rule 8.3 or 8.5 an Option shall not lapse as a result of such Rule until the expiry of the twelve month period in this Rule 8.6.
Cessation following a Corporate Action

8.7 Where a Participant ceases to hold office or employment with any Group Company following a Corporate Action within the relevant exercise period referred to in Rule 9 (Corporate Actions), an Option shall not lapse pursuant to this Rule 8 until the expiry of the relevant exercise period in Rule 9 (Corporate Actions). This Rule 8.7 shall not apply where the cessation is by way of (or occurs where there are circumstances which the Board determines would have justified) summary dismissal or service of notice of termination of office or employment on the grounds of misconduct.

Meaning of cessation of office or employment

8.8 No provision of this Rule 8 shall apply in respect of any cessation of office or employment if immediately following the cessation the Participant holds an office or employment with any Group Company, or in respect of any notice of cessation if arrangements are in place that mean immediately following the notice becoming effective the Participant will hold an office or employment with any Group Company.

9. CORPORATE ACTIONS

General offers

9.1 Awards shall vest:

9.1.1 upon a person obtaining Control of the Company as a result of making a general offer to acquire Shares;
9.1.2 upon a person, having obtained Control of the Company, making a general offer to acquire Shares; or
9.1.3 if a person makes a general offer to acquire Shares that would result in that person obtaining Control of the Company and the Board so determines, on the date which the Board determines to be the last practicable date prior to the date on which it expects such person to obtain Control of the Company,

in each case being a general offer to acquire all of the Shares (other than Shares held by the person making the offer and any person connected to that person).

Options may be exercised during the period of six months from the date of any such event (but if not exercised, Options shall not lapse at the expiry of such period).

Compulsory acquisition

9.2 Awards shall vest upon a person becoming entitled to acquire Shares under Sections 979 to 982 of the Companies Act 2006.

Options may be exercised during a period of one month from the date on which that person first becomes so entitled, and shall lapse at the expiry of such period.

Scheme of compromise or arrangement

9.3 Awards shall vest upon a Court sanctioning a compromise or arrangement which, on becoming effective, would result in:

9.3.1 any person obtaining Control of the Company;
9.3.2 the undertaking, property and liabilities of the Company being transferred to another existing or new company; or
9.3.3 the undertaking, property and liabilities of the Company being divided among and transferred to two or more companies, whether existing or new.

Options may be exercised during a period of six months from the date of a Court sanctioning such a compromise or arrangement (or, if earlier, to the day prior to the date on which a transfer as described in Rule 9.3.2 or Rule 9.3.3 is to become effective), and shall lapse at the expiry of such period.
Merger

9.4 Awards shall vest upon a competent authority approving a Cross-Border Merger, pursuant to which the Company shall cease to exist. Options may be exercised during the period from the date of a competent authority approving a Cross-Border Merger until the day prior to the date on which the Cross-Border Merger is to become effective, and shall lapse at the expiry of such period.

Voluntary winding-up

9.5 Awards shall vest in the event of a notice being given of a resolution for the voluntary winding-up of the Company. Options may be exercised during a period of two months from the date of such a notice being given and shall lapse at the expiry of such period.

Demerger or special dividend

9.6 If the Board so determines, Awards may vest following the announcement of a demerger of a substantial part of the Group’s business, a special dividend or a similar event affecting the value of Shares to a material extent on such date specified by the Board. Where the Board makes such determination, Options may be exercised during a period of two months (or such other period as the Board may determine) from the date specified by the Board and, unless the Board determines otherwise, shall lapse at the expiry of such period.

Extent of vesting on a Corporate Action

9.7 Where an Award vests (and, in the case of an Option, is exercised) pursuant to any of Rules 9.1 to 9.6, the proportion of the Award which may vest shall be limited (unless the Board determines otherwise) to a pro rata proportion on the basis of the number of months (rounded up to the nearest whole month) which have elapsed from the first day of the Performance Period to the date of the Corporate Action, as compared to the number of whole months within the Performance Period. Any remainder of the Award shall lapse.

Roll-over of Award on a Reorganisation or takeover

9.8 Unless the Board determines otherwise, an Award shall not vest pursuant to this Rule 9 if, as a result of any event that would otherwise be a Corporate Action, a company will obtain Control of the Company or will obtain substantially all of the assets of the Company (the “Acquiring Company”), and either:

9.8.1 the Acquiring Company will immediately following such event have (either directly or indirectly) substantially the same shareholders and approximate shareholdings as those of the Company prior to such event (a “Reorganisation”); or

9.8.2 the Board, with the agreement of the Acquiring Company, determines that the Award shall not vest as a result of such event and so notifies the Participant prior to the occurrence of the date on which the Award would otherwise vest.

In such case:

9.8.3 the existing Option or Conditional Award (the “Old Award”) shall lapse on the occurrence of the relevant event, provided that the New Parent Company shall grant a replacement right to receive shares (the “New Award”) over such number of shares in the New Parent Company which are of equivalent value to the number of Shares in respect of which the Old Award was outstanding. The New Award shall be granted on the terms of the Plan, but as if the New Award had been granted at the same time as the Old Award and shall continue to be subject to the Performance Condition (but subject to Rule 5.4 (Performance Condition));

9.8.4 where the event is an event specified in Rule 9.1.1 or Rule 9.1.2 (notwithstanding that the Award shall not vest pursuant to such Rule) the Nominee shall action the acceptance of the general offer in respect of the Shares subject to the Forfeitable Share Award; and/or
9.8.5 the proceeds from the relevant event received by the Nominee in respect of the Shares subject to the Forfeitable Share Award, whether in cash or securities (and the Nominee shall accept, on behalf of the Participant, any offer of securities in preference to the receipt of cash), shall continue to be held on behalf of the Participant subject to the terms of the Plan, provided that a proportion of such proceeds as is of equal value to the amount of any Tax Liability arising in respect of the Award at such time shall vest and shall be dealt with in accordance with Rule 13.1.1 (Tax Liability) (and references in the Plan to the Shares subject to the Forfeitable Share Award shall be read as being to the proceeds that continue to be held on behalf of the Participant).

For the purposes of this Rule 9.8:

9.8.6 the “New Parent Company” shall be the Acquiring Company, or, if different the company that is the ultimate parent company of the Acquiring Company within the meaning of section 1159 of the Companies Act 2006; and

9.8.7 the terms of the Plan shall following the date of the relevant event be construed as if:

(A) the reference to “British American Tobacco p.l.c.” in the definition of “Company” in Rule 1 (Interpretation and construction) were a reference to the company which is the New Parent Company, and

(B) save where the New Parent Company is listed, Rule 18.2 (Amendments) were omitted.

Compulsory winding-up

9.9 An Award shall lapse on the passing of an effective resolution, or the making of a Court order, for the compulsory winding-up of the Company.

Concert parties

9.10 For the purposes of this Rule 9, a person shall be deemed to have Control of the Company where he and any others acting in concert with him together have Control of the Company.

10. OPTIONS

10.1 An Option may be exercised, in full or in any number of parts, by the delivery to the Company (or such other person nominated by the Company) of a valid notice of exercise in such form as the Board may prescribe together with payment of the Option Price for the Shares in respect of which the Option is exercised (if any).

10.2 An Option shall lapse on the tenth anniversary of the Grant Date (or such earlier date as the Board may determine prior to the Grant Date).

10.3 Any Shares in respect of which the Option is exercised shall be transferred to the Participant as soon as reasonably practicable (which may include transferring the Shares on more than one consecutive Dealing Days on such basis as the Board may determine).

10.4 An Option may not be exercised unless the Board is satisfied that at such time:

10.4.1 such exercise,

10.4.2 the transfer of Shares to the Participant and the sale of Shares pursuant to Rule 13; and

10.4.3 any action needed to be taken by the Company to give effect to such exercise,

is not contrary to any Dealing Restriction. Where the exercise, transfer or dealing in Shares is contrary to any Dealing Restriction on the last Dealing Day in any of the periods referred to in Rules 8.3, 8.5 or 8.6 (Rule 8 being in relation to cessation of office or employment) or Rules 9.1 to 9.3 or 9.6 (Rule 9 being in relation to Corporate Actions), such period shall be extended to the end of the first Dealing Day thereafter on which the Board is satisfied that the exercise, transfer and dealing in Shares is not contrary to any Dealing Restriction.
10.5 An Option shall lapse on the earliest date provided under any Rule (save only as expressly provided in Rules 8.6 (Death) and 8.7 (Cessation following a Corporate Action)).

11. DIVIDEND EQUIVALENT

11.1 If at any time prior to the Normal Vesting Date the Board so determines, on or following the date on which an Award vests the Company may:

11.1.1 make a cash payment to the Participant equal to the amount of any dividends that the Participant would have received in respect of the number of Shares in respect of which the Award vests had the Participant been the full legal and beneficial owner of such Shares during the period from the Grant Date to the date the Award vests; or

11.1.2 transfer to the Participant such number of additional Shares as have an aggregate Market Value on the date on which the Award vests equal to the amount determined in accordance with Rule 11.1.1 above.

11.2 A cash payment under Rule 11.1 may be made in a currency other than pounds sterling, in which case the amount of such payment shall be converted into such other currency on such basis as is determined by the Board.

11.3 Rule 11.1 shall not apply in respect of a Forfeitable Share Award unless the Board determines pursuant to Rule 6.5 (Dividend rights on forfeitable Shares) that the Participant shall not be entitled to receive dividends paid in respect of the Shares subject to the Forfeitable Share Award.

12. CASH ALTERNATIVE – OPTIONS AND CONDITIONAL AWARDS

12.1 This Rule 12 shall not apply in respect of any Award granted to a Participant resident in any jurisdiction where the grant of an Award which provides for a cash alternative would be unlawful, fall outside any applicable exemption under securities, exchange control or similar regulations, or would cause adverse tax or social security (or similar) contribution consequences for the Company or the Participant (in each case as determined by the Board) or where the Board determines prior to the Grant Date that this Rule 12 shall not apply.

12.2 The Board may determine prior to the Grant Date that a Conditional Award or Option shall only be satisfied in cash, in which case the Award shall not be a right to acquire Shares, and the vesting of the Conditional Award or exercise of the Option shall be satisfied in full by the payment of a cash equivalent amount, in substitution for the transfer of Shares.

12.3 Where the Board has made no determination pursuant to Rule 12.1 or 12.2 in respect of any Conditional Award or Option, the Board may determine at any time prior to the transfer of Shares pursuant to such Award that the vesting of the Conditional Award or the exercise of the Option (or a part thereof) shall be satisfied by the payment of a cash equivalent amount, in substitution for the transfer of Shares.

12.4 A "cash equivalent amount" shall be calculated as the number of Shares which would otherwise be transferred in respect of the relevant vesting or exercise but which are being substituted for the cash equivalent amount, multiplied by an amount equal to the relevant value less, in the case of an Option, the Option Price (if any), where the "relevant value" is the Market Value of a Share on the date on which the Award vests or, in the case of an Option, is exercised (or, in either case, where only a part of the Award is to be satisfied with payment of a cash equivalent amount, is the Market Value of a Share on the date on which Shares are transferred to the Participant pursuant to the Award).

12.5 A cash equivalent amount shall be paid as soon as reasonably practicable following the relevant vesting or exercise.
12.6 A cash equivalent amount may be paid in a currency other than pounds sterling, in which case the cash equivalent amount shall be converted into such other currency on such basis as is determined by the Board.

13. TAX LIABILITY

13.1 When any Tax Liability arises in respect of an Award, the Participant authorises any Group Company:

13.1.1 to retain and sell legal title to such number of the Shares which would otherwise have been transferred to the Participant on vesting or exercise of the Award, or any part thereof, (notwithstanding that beneficial title shall pass) as may be sold for aggregate proceeds equal to the Group Company’s estimate of the amount of the Tax Liability;

13.1.2 to deduct an amount equal to the Group Company’s estimate of the Tax Liability from any cash payment made under the Plan; and/or

13.1.3 where the amount realised under Rule 13.1.1 or deducted under Rule 13.1.2 is insufficient to cover the full amount of the Tax Liability, to deduct any further amount as is necessary through payroll, and in each case to apply such amount in paying the amount of the Tax Liability to the relevant revenue authority or in reimbursing the relevant Group Company for any such payment, provided that, where the amount realised under Rule 13.1.1 or deducted under Rule 13.1.2 is greater than the actual Tax Liability, the Group Company shall repay the excess to the Participant as soon as reasonably practicable.

The Group Company shall be entitled to make the estimates referred to in this Rule 13.1 on the basis of the highest rates of tax and/or social security applicable at the relevant time in the jurisdiction in which the Group Company is liable to account for the Tax Liability, notwithstanding that the Tax Liability may not arise at such rates.

13.2 “Tax Liability” shall mean any amount of tax and/or social security (or similar) contributions which any Group Company becomes liable to pay on behalf of the Participant to the revenue authorities in any jurisdiction, together with all or such proportion (if any) of employer’s social security contributions which would otherwise be payable by any Group Company as is determined to be recoverable from the Participant (to the extent permitted by law) by the Board, or which the Participant has agreed to pay or which are subject to recovery pursuant to an election to which paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992 applies.

14. VESTED SHARE ACCOUNTS

14.1 Legal title to any Shares which are due to be transferred to the Participant pursuant to the Plan may be transferred to a person (the “Vested Share Account Provider”) appointed by the Company from time to time to hold legal title to such Shares on behalf of the Participant.

14.2 The Vested Share Account Provider shall receive and hold Shares on behalf of the Participant in accordance with such terms and conditions as are agreed by the Company from time to time, and by participating in the Plan the Participant irrevocably agrees to those terms and conditions (which shall be available to the Participant on request to the Company).

14.3 The transfer of any Shares to the Vested Share Account Provider shall satisfy any obligation of the Company under the Plan to transfer Shares to the Participant (and references in the Plan to Shares (or legal title thereof) having been transferred to the Participant shall be read accordingly).

14.4 The terms and conditions referred to in Rule 14.2 above may include terms that the Participant shall not be entitled to transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, some or all of the Shares if to do so would be in breach of the Participant’s obligations under the Company’s shareholding requirements as they apply to such Participant.

16
15. **CLAW-BACK**

**Claw-back events**

15.1 The Board may at any time prior to the fifth anniversary of the Grant Date of an Award determine that a Claw-back shall apply in respect of the Award, if the Board determines that:

15.1.1 there has been a material misrepresentation in relation to the performance of any Group Company, relevant business unit and/or the Participant on the basis of which the extent to which the Award will be capable of vesting, or vested, was determined (which may include, but shall not be limited to: (i) a misstatement of the financial results and/or health of any Group Company; (ii) an erroneous calculation in relation to any Group Company’s results or other performance benchmark; (iii) errors in any Group Company’s financial statements; or (iv) discrepancies in the financial accounts, and, for the avoidance of doubt, notwithstanding that such misrepresentation may not arise from fraud or reckless behaviour); or

15.1.2 an erroneous calculation was made in assessing the extent to which the Award is to be capable of vesting, or vested, and, in either case, the Award is capable of vesting, or vested, in respect of a greater number of Shares than would have been the case had there not been such a misrepresentation or had such error not been made; or

15.1.3 there has been a significant failure within any Group Company which has a material impact on the value of the Group (taken as a whole), including but not limited to circumstances where the Company or any other Group Company has entered into an involuntary administration or insolvency process or there has been a significant reduction in, or cessation of, the ability of any material Group Company (or group of Group Companies) to continue normal operations.

15.2 The Board may at any time (whether before or after vesting) determine that a Claw-back shall apply in respect of an Award where the Participant is found to have:

15.2.1 committed at any time prior to the vesting of the Award, including prior to grant, an act or omission which justifies, or in the opinion of the Board would have justified, summary dismissal or service of notice of termination of office or employment on the grounds of misconduct;

15.2.2 engaged in at any time prior to the vesting of the Award, including prior to grant:

   (A) reckless, negligent or wilful action or inaction; or
   (B) inappropriate behaviour or behaviour that is not aligned with any employee policy or handbook or Group values, and in either case the Board determines that such circumstances have contributed to a material loss for any Group Company; or

15.2.3 contributed at any time prior to the vesting of the Award, including prior to grant, to circumstances which give rise to a sufficiently negative impact on the reputation of any Group Company or business unit (or would have if such circumstances had been made public).

15.3 Rules 15.1.3, 15.2.2 and 15.2.3 shall only apply to awards granted on or after 1 January 2022.
Applying Claw-back

15.4 A Claw-back shall be applied in accordance with the provisions of Appendix 1 (Operation of Claw-back).

Lapse of Awards to give effect to claw-back of other awards

15.5 By participating in the Plan, the Participant acknowledges that the Board may lapse any Award to such extent as it determines to be necessary (including in full) in order to give effect to a claw-back under the terms of the Plan or any other Employees’ Share Scheme or bonus scheme operated from time to time by any Group Company.

No Claw-back following Corporate Action

15.6 No Claw-back shall be capable of being applied at any time following any Corporate Action, save where the determination that the Claw-back shall apply was made prior to such event (and, for the avoidance of doubt, a Corporate Action does not include a Reorganisation).

16. VARIATION OF CAPITAL

16.1 If in respect of Shares subject to a Forfeitable Share Award the Nominee receives on behalf of a Participant any rights to acquire securities, the Nominee shall sell such rights nil paid to the extent necessary to take up the remaining rights.

16.2 In the event of any variation of the share capital of the Company, or in the event of the demerger of a substantial part of the Group’s business, a special dividend or similar event affecting the value of Shares to a material extent (which shall not include the payment of any ordinary dividend):

16.2.1 the Board may make such adjustments to Conditional Awards and Options as it may determine to be appropriate; and

16.2.2 any proceeds from such an event received by a Nominee in respect of any Shares subject to a Forfeitable Share Award, whether in cash or securities, (including where the Nominee takes up rights pursuant to Rule 16.1) shall be held by the Nominee on the same terms as the Forfeitable Share Award to which they relate, and references to the Shares subject to a Forfeitable Share Award shall be read to include such proceeds.

16.3 For the avoidance of doubt Rule 16.2 shall not apply in respect of any Awards pursuant to which legal title to Shares has been transferred prior to the date of the relevant event (such that the recipient of such legal title shall participate in such event as a holder of Shares) including pursuant to the vesting of an Award under Rule 9.6 (Demerger or special dividend).

17. ADMINISTRATION

17.1 Any notice or other communication under or in connection with this Plan may be given by the Company (or its agents) to a Participant personally, by email or by post, or by a Participant to the Company or any Group Company either personally or by post to the Secretary of the Company. Items sent by post shall be pre-paid and shall be deemed to have been received 48 hours after posting. Items sent by email shall be deemed to have been received immediately.

17.2 A Participant shall not be entitled to:

17.2.1 receive copies of accounts or notices sent to holders of Shares;

17.2.2 subject to Rule 6.4 (Voting rights on forfeitable Shares) in respect of a Forfeitable Share Award, exercise voting rights; or

17.2.3 subject to Rule 6.5 (Dividends rights on forfeitable Shares) in respect of a Forfeitable Share Award, receive dividends, in respect of Shares subject to an Award legal title to which has not been transferred to the Participant.
17.3 Any discretion (including the power to make any determination) of the Board under or in connection with the Plan may be exercised by the Board in its absolute discretion.

17.4 Any exercise of discretion (including the making of any determination) by the Board under or in connection with the Plan shall be final and binding.

17.5 Any disputes regarding the interpretation of the Rules or the terms of any Award shall be determined by the Board (upon such advice as the Board determines to be necessary) and any decision in relation thereto shall be final and binding.

18. AMENDMENTS

18.1 Subject to Rules 18.2 and 18.4, the Board may at any time add to or alter the Plan or any Award made thereunder in any respect.

18.2 Subject to Rule 18.3, no addition or alteration to the advantage of present or future Participants relating to eligibility, the limits on participation, the overall limits on the issue of Shares or the transfer of Treasury Shares, the basis for determining a Participant’s entitlement to, or the terms of, Shares or cash provided pursuant to the Plan and the provisions for adjustments on a variation of share capital shall be made without the prior approval by ordinary resolution of the shareholders of the Company in general meeting.

18.3 Rule 18.2 shall not apply to any alteration to or substitution of the Performance Condition or to any alteration or addition which is necessary or desirable in order to comply with or take account of the provisions of any proposed or existing legislation, law or other regulatory requirements or to take advantage of any changes in legislation, law or other regulatory requirements, or to obtain or maintain favourable taxation, exchange control or regulatory treatment of any Group Company or any Participant or to make minor amendments to benefit the administration of the Plan.

18.4 No alteration or addition shall be made under Rule 18.1 which would abrogate or adversely affect the subsisting rights of a Participant unless it is made:

18.4.1 with the consent in writing of the Participant;

18.4.2 with the consent in writing of such number of Participants as hold Awards under the Plan in relation to 75 per cent. of the Shares subject to all Awards under the Plan; or

18.4.3 by a resolution at a meeting of Participants passed by not less than 75 per cent. of the Participants who attend and vote either in person or by proxy,

and for the purpose of Rule 18.4.2 or 18.4.3 the Participants shall be treated as the holders of a separate class of share capital and the provisions of the Articles of Association of the Company relating to class meetings shall apply mutatis mutandis.

18.5 The Board may, in respect of Eligible Employees who are or who may become subject to taxation outside the United Kingdom on their remuneration, establish such plans or sub-plans based on the Plan but subject to such modifications as the Board determines to be necessary or desirable to take account of or to mitigate or to comply with relevant overseas taxation, securities or exchange control laws, provided that the terms of awards made under such plans or sub-plans are not overall more favourable than the terms of Awards made under the Plan and provided that awards made, and Shares issued, pursuant to such plans or sub-plans shall count towards the limits set out in Rules 2 (Plan limits) and 3.3 (Individual limit).
purposes of the legitimate interests of the Company and each other Group Company in incentivising their officers and employees and operating the Plan; (ii) such processing being necessary for the purposes of any relevant data controller in respect of such personal data complying with its legal obligations; and (iii) such processing being necessary for the performance of the contractual obligations arising under the Plan. The collection and processing of such personal data for such purposes is a contractual requirement of participation in the Plan.

19.2 The purposes for which personal data shall be processed as referred to in this Rule 19 shall be in order to allow the Company and any other relevant Group Companies to incentivise their officers and employees and to operate the Plan and to fulfil its or their obligations to the Participant under the Plan, and for other purposes relating to or which may become related to the Participant’s office or employment, the operation of the Plan or the business of the Group or to comply with legal obligations. Such processing will principally be for, but will not be limited to, personnel, administrative, financial, regulatory or payroll purposes as well as for the purposes of introducing and administering the Plan.

19.3 The personal data to be processed as referred to in this Rule 19 may be disclosed or transferred to, and/or processed by:

19.3.1 any professional advisors of any Group Company, HM Revenue & Customs or any other revenue, regulatory or governmental authorities;

19.3.2 a trustee of a Trust; any registrars, brokers, payroll provider or appointed in connection with any employee share or incentive plans operated by any Group Company; or any person appointed (whether by the Participant or any Group Company) to act as nominee on behalf of (or provide a similar service to) the Participant;

19.3.3 subject to appropriate confidentiality undertakings), any prospective purchasers of, and/or any person who obtains control of or acquires, the Company or the whole or part of the business of the Group; or

19.3.4 any Group Company and officers, employees or agents of such Group Company.

19.4 Further information in relation to the processing of personal data referred to in this Rule 19, including the details and identity of the data controller and of the Participant’s rights in respect of such personal data, is available in the Employee Data Protection Policy (or otherwise on request to the Company Secretary).

19.5 To the extent that the processing of personal data of a Participant referred to in this Rule 19 is subject to the laws or regulations of any jurisdiction that is not an EU member state and under which the legal grounds for processing described in Rule 19.1 do not provide a sufficient legal basis under such other laws or regulations for the processing referred to in Rule 19.1 to 19.3, by such processing for the purposes of such other laws or regulations (but shall not be deemed to consent to such processing for the purposes of EU Regulation 2016/679).

19.6 In this Rule 19, “personal data” and “data controller” each have the meaning given in EU Regulation 2016/679 and “Employee Data Protection Policy” means such privacy policy or similar operated by any Group Company in relation to the processing of personal data as amended from time to time and as is applicable to the Participant.

20. GENERAL

20.1 In the event of any discrepancy between these Rules in English and (i) any copy of these Rules translated into any other language; or (ii) any communications, notices or materials issued in connection with this Plan, these Rules in English shall prevail.

20.2 The Plan shall terminate on the 10th anniversary of the approval of the Plan by the shareholders of the Company in general meeting, or at any earlier time by resolution of the Board or an ordinary resolution of the shareholders in general meeting. Such termination shall be without prejudice to the subsisting rights of Participants.
20.3 Save as otherwise provided under the Plan:

20.3.1 Shares issued and allotted pursuant to the Plan will rank pari passu in all respects with the Shares then in issue at the date of such allotment, except that they will not rank for any rights attaching to Shares by reference to a record date preceding the date of allotment; and

20.3.2 Shares to be transferred pursuant to the Plan will be transferred free of all liens, charges and encumbrances and together with all rights attaching thereto, except they will not rank for any rights attaching to Shares by reference to a record date preceding the date of transfer.

20.4 If and so long as the Shares are admitted to listing and/or for trading on any stock exchange or market, the Company shall apply for any Shares issued and allotted pursuant to the Plan to be so admitted as soon as practicable.

20.5 Any transfer of Shares under the Plan is subject to such consent, if any, of any authorities in any jurisdiction as may be required, and the Participant shall be responsible for complying with the requirements to obtain or obviate the necessity for such consents.

20.6 The terms of any individual’s office or employment with any past or present Group Company, and the rights and obligations of the individual thereunder, shall not be affected by his participation in the Plan and the Plan shall not form part of any contract of employment between the individual and any such company.

20.7 An Eligible Employee shall have no right to receive an Award under the Plan and participation in the Plan and the grant of any Award is at the discretion of the Company.

20.8 Participation in the Plan by, or the grant of any Award under it to, a Participant in any year does not create any right to or expectation of participation in the Plan or the grant of any Award in any future year, even if the Participant has previously participated in the Plan (or any similar plan) over a long period of time and/or if participation in the Plan and/or an Award under it (or any similar plan) has been granted (including repeatedly) without the relevant Group Company specifically expressing the voluntary and discretionary nature at the time of each such participation or Award.

20.9 By participating in the Plan, the Participant waives all and any rights to compensation or damages in consequence of the termination of his office or employment with any past or present Group Company for any reason whatsoever, whether lawfully or otherwise, insofar as those rights arise or may arise from his ceasing to have rights under the Plan (including ceasing to be entitled to exercise any Option) as a result of such termination, or from the loss or diminution in value of such rights or entitlements, including by reason of the operation of the terms of the Plan, any determination by the Board pursuant to a discretion contained in the Plan or the provisions of any statute or law relating to taxation.

20.10 Benefits under the Plan shall not form part of a Participant’s remuneration for any purpose and shall not be pensionable.

20.11 The invalidity or non-enforceability of any provision or Rule of the Plan shall not affect the validity or enforceability of the remaining provisions and Rules of the Plan which shall continue in full force and effect.

20.12 These Rules shall be governed by and construed in accordance with English Law.

20.13 The English courts shall have exclusive jurisdiction to determine any dispute which may arise out of, or in connection with, the Plan.
APPENDIX 1: OPERATION OF CLAW-BACK

Claw-back prior to the transfer of Shares in respect of an Award (or “malus”)

1. Where the Board determines (pursuant to Rule 15 (Claw-back)) that a Claw-back shall apply in respect of an Award prior to legal title to Shares having been transferred to the Participant pursuant to the Award (whether before or after vesting), the Claw-back shall be applied by the Board reducing the number of Shares in respect of which the Award may vest or, in the case of an Option, be exercised (or after vesting by reducing the number of Shares legal title to which may be transferred pursuant to the Award) by up to the number of Shares determined by the Board to be the excess number of Shares in respect of which the Award was granted and/or is outstanding (and the Award shall lapse to the extent so reduced, which may be in full).

Claw-back following the transfer of Shares in respect of an Award

2. Where the Board determines (pursuant to Rule 15 (Claw-back)) that a Claw-back shall apply in respect of an Award following legal title to Shares having been transferred to the Participant pursuant to the Award (a “Post-Transfer Claw-back”), the Board shall determine:
   a. the excess number of Shares in respect of which the Award vested (the “Excess Shares”); and
   b. the aggregate Market Value of such Excess Shares (as determined by the Board) on the date on which the Award vested or, in the case of an Option, the date the Option was exercised (the “Equivalent Value”).

3. In the case of a Post-Transfer Claw-back:
   a. any dividends received in respect of the Shares subject to a Forfeitable Share Award pursuant to Rule 6.5 (Dividend rights on forfeitable Shares); and/or
   b. any cash payment made or additional Shares transferred pursuant to Rule 11 (Dividend equivalent) in respect of such Award shall be subject to the Claw-back to the extent that the Board determines that such cash payment or Shares relate to the Excess Shares.

4. A Post-Transfer Claw-back may be effected in such manner as may be determined by the Board, and notified to the Participant, including by any one or more of the following:
   a. by reducing the number of Shares and/or amount of cash in respect of which an Outstanding Award vests or may vest (or has vested, but in respect of which no Shares have yet been transferred or cash payment made), whether before or after the assessment of performance conditions in respect of such Outstanding Award, by the number of Excess Shares and/or the Equivalent Value (and such Outstanding Award shall lapse to the extent so reduced);
   b. by setting-off against any amounts payable by any Group Company to the Participant an amount up to the Equivalent Value (including from any bonus payment which may otherwise become payable to the Participant); and/or
   c. by requiring the Participant to immediately transfer to the Company a number of Shares equal to the Excess Shares or a cash amount equal to the Equivalent Value (which shall be an immediately payable debt due to the Company), provided that the Board may reduce the number of Excess Shares or the amount of the Equivalent Value subject to the Claw-back in order to take account of any Tax Liability (as defined in Rule 13 (Tax Liability)) which arose on the Excess Shares (howsoever delivered to the Participant).

5. For the avoidance of doubt, nothing in Rule 15 (Clawback) or this Appendix shall in any way restrict a Participant from being able to transfer or otherwise deal in Shares acquired on vesting or exercise of an Award.
6. In paragraph 4 above:

“Outstanding Award” means any other Award under the Plan, any award or option under any other Employees’ Share Scheme operated from time to time by any Group Company (other than any award or options granted under any arrangement which satisfies the provisions of Schedules 2 or 3, or (unless the terms of such arrangement state that shares acquired thereunder are subject to claw-back) 4 or 5, of the Income Tax (Earnings and Pensions) Act 2003), or any bonus award under any bonus scheme operated from time to time by any Group Company, in each case which is either held by the Participant at the time of a determination that a Claw-back shall be applied or which are granted to the Participant following such a determination; and

“vests” shall include shares or cash subject to an award becoming due to be transferred or paid, and in the case of an option, the option becoming exercisable.
APPENDIX 2: AWARDS GRANTED TO U.S. TAXPAYERS

1. INTERPRETATION

1.1 This Appendix shall form part of the Rules of the Plan.

1.2 In this Appendix a reference to a “Paragraph” is to a paragraph of this Appendix.

1.3 Capitalized terms used in this Appendix that are not otherwise defined in this Appendix shall have the meanings set forth in the Plan.

2. APPLICATION

2.1 The provisions of this Appendix shall apply to a Conditional Award or an Option that is held by any Participant while he or she is a U.S. Taxpayer. For the avoidance of doubt, any references to an Award in this Appendix shall be to a Conditional Award or an Option (and not to a Forfeitable Share Award).

2.2 To the extent that any provision of Paragraphs 4 to 10 is inconsistent with any Rule of the Plan, such provision of this Appendix shall take precedence. Paragraph 3 is included to aid interpretation.

3. PERFORMANCE AND SERVICE CONDITION

Rule 5 – Performance Condition

3.1 All Awards to which this Appendix applies shall be subject to a Performance Condition, each element of which shall be assessed over the Performance Period (or, if applicable, the period described in Rule 7.4).

Rule 8 – Cessation of Office or Employment

3.2 All Awards to which this Appendix applies are subject to a service condition which applies until the Award’s Normal Vesting Date or any earlier vesting date.

Paragraph 5 – Awards where the “wait and see approach” shall apply (including all Awards subject to an extended vesting period); vesting date

3.3 Notwithstanding the date on which a Conditional Award that is subject to Paragraph 5 vests, the Shares in respect of which such Award vests shall not be transferred to the U.S. Taxpayer until the Normal Vesting Date (subject to any earlier date specified in Paragraph 5.5). Shares in respect of an Option that is subject to Paragraph 5 shall be deemed to be exercised on the date on which such Option vests pursuant to the Plan, as amended by this Appendix.

Rule 8 and Paragraph 6 – Cessation of Office or Employment; Award without extended vesting period and where the Committee does not determine that the “wait and see” approach shall apply

3.4 An Award that is subject to Paragraph 6 will be subject to a service condition until the date on which it vests, and (a) Shares in respect of a Conditional Award will be transferred to the U.S. Taxpayer no later than the 15th day of the third month following the end of the calendar year in which the Award is no longer subject to a substantial risk of forfeiture (within the meaning of Code § 409A) and (b) Shares in respect of an Option shall be deemed to be exercised on the date on which such Option vests.

Rules 7, 8 and 9 – Vesting, Cessation of Office or Employment and Corporate Actions

3.5 Where an Award vests prior to the Normal Vesting Date, the extent of vesting shall be determined by such applicable Rule.

Lapse

3.6 Awards to which this Appendix applies shall lapse at any time specified in the Rules or this Appendix.
4. APPLICATION OF PARAGRAPH 5 AND 6

An Award to which this Appendix applies shall be subject to Paragraph 5 or 6, but shall only be capable of being subject to one of Paragraph 5 or Paragraph 6, and which such Paragraph the Award is subject to shall be determined without any involvement of the U.S. Taxpayer and shall not be capable of change for any reason.

5. AWARDS (I) WHERE THE “WAIT AND SEE” APPROACH SHALL APPLY (INCLUDING ALL AWARDS SUBJECT TO AN EXTENDED VESTING PERIOD), (II) DESCRIBED IN PARAGRAPHS 3.1 AND 3.2 OF ADDENDUM I TO THE PLAN OR (III) THAT OTHERWISE ARE NOT EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL

5.1 An Award shall be subject to this Paragraph 5 if:

5.1.1 the Normal Vesting Date of an Award is more than one year after the end of the Performance Period;

5.1.2 on the Grant Date the U.S. Taxpayer is a director of the Company or a member of the Management Board of the Company (unless determined otherwise by the Committee prior to the Grant Date);

5.1.3 such Award is otherwise not exempt from Code § 409A by reason of complying with the short-term deferral exemption from Code § 409A; and/or

5.1.4 it is so determined by the Committee prior to the Grant Date (including pursuant to Paragraph 3.2 of Addendum I to the Plan).

5.2 An Award which is subject to this Paragraph 5 shall vest on the earliest of:

5.2.1 the Normal Vesting Date;

5.2.2 any date on which the Award vests pursuant to Rule 9 (subject to Paragraph 5.3);

5.2.3 the U.S. Taxpayer’s death; or

5.2.4 any earlier vesting date determined by the Board pursuant to Rule 7.7 or Rule 8.2 (including pursuant to Paragraph 3.1 of Addendum I to the Plan).

5.3 An Award subject to this Paragraph 5:

5.3.1 may only vest under Rule 9 if the event falling within Rule 9 which would give rise to such vesting constitutes a “change in control event” as described in U.S. Treasury Regulations or other guidance issued pursuant to Code § 409A; and

5.3.2 to the extent it does not vest by such time, shall lapse on any date on which an Option would lapse pursuant to Rule 9.2 to 9.6.

5.4 An Award subject to this Paragraph 5 that is an Option shall be deemed to be automatically exercised to the fullest extent permitted by the Rules on the date on which it vests pursuant to the Plan, as amended by this Appendix, and such Shares shall become due to be transferred to the U.S. Taxpayer within 60 days (90 days if such Option vests pursuant to Paragraph 5.2.3) of such date of automatic exercise.
5.5 Any Shares in respect of which a Conditional Award which is subject to this Paragraph 5 vests shall become due to be transferred to the U.S. Taxpayer within 60 days (90 days in the case of Paragraph 5.5.2(ii) below) of the earlier of:

5.5.1 the Normal Vesting Date; or
5.5.2 if applicable, (i) the date set forth in Paragraph 5.2.2; (ii) the date set forth in Paragraph 5.2.3 or (iii) any applicable date described in Paragraph 5.2.4,

and shall be transferred within such period (and, for the avoidance of doubt, not prior to such period).

6. AWARDS WITHOUT AN EXTENDED VESTING PERIOD AND WHERE THE “WAIT AND SEE” APPROACH DOES NOT APPLY AND THAT ARE OTHERWISE EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL

6.1 An Award shall be subject to this Paragraph 6 if the Award is not subject to Paragraph 5.

6.2 An Award which is subject to this Paragraph 6 shall, subject to Rule 7.6, vest on the earliest of:

6.2.1 the Normal Vesting Date;
6.2.2 any date on which the Award vests pursuant to Rule 9;
6.2.3 the Participant’s death;
6.2.4 any earlier vesting date determined by the Board pursuant to Rule 7.7; and
6.2.5 the date on which the U.S. Taxpayer ceases to hold office or employment with any Group Company for any of the reasons specified in Rule 8.2 (for the avoidance of doubt subject to Rule 8.8).

6.3 An Award subject to this Paragraph 6 that is an Option shall be deemed to be automatically exercised to the fullest extent permitted by the Rules on the date on which it vests pursuant to this Plan, as amended by this Appendix, and such Shares shall become due to be transferred to the U.S. Taxpayer no later than the 15th day of March in the calendar year immediately following the calendar year in which the Award is no longer subject to a substantial risk of forfeiture (within the meaning of Code § 409A).

6.4 Any Shares in respect of which a Conditional Award which is subject to this Paragraph 6 vests shall be transferred to the U.S. Taxpayer no later than the 15th day of March in the calendar year immediately following the calendar year in which the Award is no longer subject to a substantial risk of forfeiture (within the meaning of Code § 409A).

6.5 Rule 8.3.1 shall not apply to an Award which is subject to this Paragraph 6.

7. DIVIDEND EQUIVALENTS

Any payment to which a U.S. Taxpayer may become entitled under Rule 11 with respect to an Award shall be paid to the U.S. Taxpayer at the same time as the transfer of Shares under Paragraph 5.4, 5.5, 6.3 or 6.4, as applicable.

8. CASH ALTERNATIVE

8.1 If Shares cannot be delivered in accordance with Paragraph 5.4, 5.5, 6.3 or 6.4, as applicable, because of a Dealing Restriction, such Award shall instead be satisfied by the payment of a cash equivalent amount pursuant to Rule 12 (as such Rule is amended by Paragraph 8.2).

8.2 Any cash payment to which a U.S. Taxpayer may become entitled under Rule 12 with respect to an Award shall be paid to the U.S. Taxpayer at the same time as the transfer of Shares would have occurred under Paragraph 5.4, 5.5, 6.3 or 6.4, as applicable.

9. CODE § 409A EXEMPTION AND COMPLIANCE

9.1 Awards subject to Paragraph 6 are intended to be exempt from Code § 409A to the maximum extent possible under the exemption for “short-term deferrals” specified in the Treasury Regulations, and the provisions of this Appendix and the Plan, as it applies to such Award, shall be construed, interpreted and applied accordingly. Without limiting the foregoing, the Board shall not exercise any discretion that is otherwise afforded to it under the Plan in a manner that is inconsistent with such treatment. For the avoidance of doubt, any Award subject to Paragraph 6 shall, in all events, be paid within the short-term deferral period specified in Treasury Regulation § 1.409A-1(b)(4).
9.2 To the extent that any Award to which this Appendix applies is subject to Code § 409A, the provisions of this Appendix and the Plan, as it applies to such Award, shall be construed, interpreted and applied in such a way as to comply with the applicable provisions of Code § 409A to the maximum extent possible. If an Award is subject to Code § 409A, then: (i) any payment or transfer of Shares on account of a change in control shall be made only if the change in control qualifies as a “change in control event,” as defined for purposes of Code § 409A; (ii) any provision in the Plan that is inconsistent with the requirements of Code § 409A shall not apply to such Award; (iii) the Board shall exercise discretion otherwise afforded to it under the Plan (including under Appendix 1 to the Plan) only to the extent that such exercise of discretion is consistent with the requirements of Code § 409A; and (iv) the U.S. Taxpayer shall not have the right to designate any payment date with respect to such Award.

9.3 In the event that a U.S. Taxpayer is deemed to be a “specified employee” on the date of his or her “separation from service,” as defined for purposes of Code § 409A (other than by reason of death), determined pursuant to identification methodology adopted by a Group Company in compliance with Code § 409A, and if any portion of the Shares or other payments to be received by such U.S. Taxpayer in respect of an Award would constitute a “deferral of compensation” subject to Code § 409A, Shares or amounts that would otherwise be delivered or payable pursuant to this Plan, as amended by this Appendix, during the six (6) month period immediately following the date of such U.S. Taxpayer’s separation from service shall instead be delivered or paid either (i) during the period commencing on the date that is six (6) months and one (1) day following the date of such U.S. Taxpayer’s separation from service and ending fifteen (15) days following the first business day of the seventh month after the date of such separation from service, provided that the U.S. Taxpayer shall not have the right to designate the delivery or payment date, or (ii) if earlier, as soon as practicable (and in any event within ninety (90) days) after the U.S. Taxpayer’s death.

9.4 Each Award hereunder shall constitute a separate payment within the meaning of Treasury Regulation §1.409A-2(b)(2).

10. COOPERATION
In the event that the terms of this Plan would subject any U.S. Taxpayer to taxes or penalties under Code § 409A (“409A Penalties”), the Committee, the Company and such U.S. Taxpayer shall cooperate diligently to amend the terms of the Plan and the U.S. Taxpayer’s Award agreement to avoid such 409A Penalties, to the extent possible, provided that in no event shall any Group Company be responsible for any 409A Penalties that arise in connection with any amounts payable in respect of any Award granted under this Plan.

11. SETTLEMENT
No Award subject to paragraph 5 of this Appendix shall be settled with Shares from a trust.
ADDENDUM I: AWARDS GRANTED TO RAI PARTICIPANTS (PRIOR TO 2020)

1. APPLICATION

1.1 This Addendum applies to Participants who are employees of Reynolds American Inc. or a subsidiary of Reynolds American Inc. (collectively, “RAI” and such Participants, “RAI Participants”).

1.2 This Addendum sets out certain additional terms which apply in respect of Awards granted under the Plan to RAI Participants prior to 2020.

1.3 References in this Addendum to a “Rule” is to the Rule of the Plan. Capitalized terms used in this Addendum shall, save where otherwise defined herein, have the meaning given in the Rules. To the extent that any provision of this Addendum is inconsistent with any Rule of the Plan, such provision of this Addendum shall take precedence.

2. MODIFICATION

2.1 The Board may at any time, and without notice to any person, add or alter or discontinue the terms of this Addendum in any respect without prior notice to any Participant.

3. TERMS

Retirement

3.1 Pursuant to Rule 8.2.5 (Reasons for cessation where Award remain capable of vesting) it has been determined that Rule 8.1 (Cessation where Awards lapse) shall not apply in respect of a RAI Participant who ceases to hold office or employment with any Group Company (within the meaning of Rule 8.8 (Meaning of cessation of office or employment)) in circumstances where the RAI Participant meets the criteria set out below (provided that this provision shall not apply where, in the opinion of the Board, the RAI Participant has committed an act or omission which justifies, or in the opinion of the Board would have justified, summary dismissal of service or notice of cessation of employment on the grounds of misconduct). The criteria referred to are: a RAI Participant’s voluntary termination of his or her employment with RAI (i) on or after his or her 65th birthday, (ii) on or after his or her 55th birthday with 10 or more years of service with RAI, or (iii) on or after his or her 50th birthday with 20 or more years of service with RAI. RAI shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence, including the form and timing of the RAI Participant’s notice of the RAI Participant’s intent to retire.

3.2 Notwithstanding anything in the Plan or Appendix 2 to the Plan to the contrary, a Conditional Award or an Option granted to a RAI Participant who is on the Grant Date, or who may become during the applicable Performance Period, eligible for the application of the preceding paragraph, shall be subject to the terms of Paragraph 5 of Appendix 2 to the Plan.

Disability

3.3 With respect to RAI Participants, the reference to “disability” in Rule 8.2 (Reasons for cessation where Awards remain capable of vesting) shall mean that the RAI Participant has become eligible for and is in receipt of benefits under RAI’s Long-Term Disability Plan. RAI shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence.

4. SETTLEMENT

4.1 Awards granted to RAI Participants may, at the discretion of the Board, be satisfied by the transfer of British American Tobacco p.l.c. American Depositary Shares, and references in the Plan (including any Appendix, Schedule or Addendum thereto) to “Shares” shall be read accordingly.

4.2 No Award subject to this Addendum shall be settled with Shares from a trust.
ADDENDUM II: AWARDS GRANTED TO RAI PARTICIPANTS (FROM 2020)

1. APPLICATION

1.1 This Addendum applies to Participants who are employees of Reynolds American Inc. or a subsidiary of Reynolds American Inc. (collectively, “RAI” and such Participants, “RAI Participants”).

1.2 This Addendum sets out certain additional terms which currently apply in respect of Awards granted under the Plan to RAI Participants from 2020.

1.3 References in this Addendum to a “Rule” is to the Rule of the Plan. Capitalized terms used in this Addendum shall, save where otherwise defined herein, have the meaning given in the Rules. To the extent that any provision of this Addendum is inconsistent with any Rule of the Plan, such provision of this Addendum shall take precedence.

2. MODIFICATION

2.1 The Board may at any time, and without notice to any person, add or alter or discontinue the terms of this Addendum in any respect without prior notice to any Participant.

3. TERMS

Disability

3.1 With respect to RAI Participants, the reference to “disability” in Rule 8.2 (Reasons for cessation where Awards remain capable of vesting) shall mean that the RAI Participant has become eligible for and is in receipt of benefits under RAI’s Long-Term Disability Plan. RAI shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence.

4. SETTLEMENT

4.1 Awards granted to RAI Participants may, at the discretion of the Board, be satisfied by the transfer of British American Tobacco p.l.c. American Depositary Shares, and references in the Plan (including any Appendix, Schedule or Addendum thereto) to “Shares” shall be read accordingly.

4.2 No Award subject to this Addendum shall be settled with Shares from a trust.
SCHEDULE 1: PERFORMANCE CONDITIONS

SCHEDULE 1A

PERFORMANCE CONDITION APPLICABLE TO AWARDS GRANTED IN 2016, 2017, 2018, 2019, 2020 and 2021

TO PARTICIPANTS OTHER THAN EXECUTIVE DIRECTORS

1. Subject to the Rules, the extent to which the Shares in respect of which an Award is granted (the “Award Shares”) may vest shall be determined:
   a. as to 40% of the Award Shares, by reference to the performance target based on Earnings per Share specified in paragraph 3 below if satisfied
   b. as to 20% of the Award Shares, by reference to the performance target based on Total Shareholder Return specified in paragraph 4 below;
   c. as to 20% of the Award Shares, by reference to the performance target based on the Operating Cash Flow Conversion Ratio specified in paragraph 5 below; and
   d. as to 20% of the Award Shares, by reference to the performance target based on Net Turnover specified in paragraph 6 below.

2. The Performance Period for
   a. Awards granted in 2016 shall commence on 1 January 2016 and end on 31 December 2018;
   b. Awards granted in 2017 shall commence on 1 January 2017 and end on 31 December 2019;
   c. Awards granted in 2018 shall commence on 1 January 2018 and end on 31 December 2020;
   d. Awards granted in 2019 shall commence on 1 January 2019 and end on 31 December 2021;
   e. Awards granted in 2020 shall commence on 1 January 2020 and end on 31 December 2022; and
   f. Awards granted in 2021 shall commence on 1 January 2021 and end on 31 December 2023.

3. Earnings per Share
   a. The performance target in this paragraph 3 (the “EPS Target”) shall consist of two equal, independent elements such that the number of Award Shares which vest pursuant to this EPS Target shall be the aggregate of the number of Award Shares which vest pursuant to each element.
   b. Each element of the EPS Target operates by calculating the compound annual growth in adjusted diluted earnings per share (unless the Board determines that an alternative definition of earnings per share is more appropriate) for the Company, in the case of the first element measured at current rates of exchange, and in the case of the second element measured at constant rates of exchange.
EPS Target: current rates of exchange
c. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at current rates of exchange, as follows:

\[
\begin{array}{c|c|c}
\text{Compound annual growth rate in} & \text{% of the Award Shares which may vest} \\
\text{adjusted diluted EPS (measured at current rates of exchange) over} & \text{pursuant to this element of the EPS Target} \\
\text{the Performance Period} & \text{as follows:} \\
10\% \text{ pa or greater} & 20\% \\
Between 10\% \text{ pa and 5\% pa} & \text{Pro-rata between 20\% and 4\%} \\
5\% \text{ pa} & 4\% \\
Less than 5\% \text{ pa} & 0\% \\
\end{array}
\]

EPS Target: constant rates of exchange
d. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at constant rates of exchange, as follows:

\[
\begin{array}{c|c|c}
\text{Compound annual growth rate in} & \text{% of the Award Shares which may vest} \\
\text{adjusted diluted EPS (measured at constant rates of exchange) over} & \text{pursuant to this element of the EPS Target} \\
\text{the Performance Period} & \text{as follows:} \\
10\% \text{ pa or greater} & 20\% \\
Between 10\% \text{ pa and 5\% pa} & \text{Pro-rata between 20\% and 4\%} \\
5\% \text{ pa} & 4\% \\
Less than 5\% \text{ pa} & 0\% \\
\end{array}
\]

e. For the purposes of paragraphs 3.c and 3.d above, compound annual growth in adjusted diluted earnings per share over the Performance Period (expressed as a percentage) is calculated as follows:

\[
\left[ \left\{ \left( \frac{E^3}{E^0} \right)^{\frac{1}{3}} \right\} - 1 \right] \times 100
\]

Where:

- \(E^0\) = adjusted diluted earnings per share of the Company in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and
- \(E^3\) = adjusted diluted earnings per share of the Company in the final Financial Year of the Performance Period (being “Year 3”), measured at:
  i. current rates of exchange for the purposes of paragraph 3.c; and
  ii. constant rates of exchange for the purposes of paragraph 3.d, for which purpose the value of \(E^0\) and \(E^3\) shall be taken as index values, with the value for \(E^0\) being the base index value (representing adjusted diluted earnings per share in Year 0), with the purpose of such index being to reflect changes over the Performance Period in adjusted diluted earnings per share of the Company as measured on a constant currency basis, and \(E^3\) being taken as the value of such index for Year 3,
4. **TSR Target**

a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 4 (the “TSR Target”) depends upon the Company’s Total Shareholder Return over the Performance Period relative to the Total Shareholder Return of the Comparator Group:

<table>
<thead>
<tr>
<th>Ranked position of the Company’s TSR against the relevant comparator companies</th>
<th>% of the Award Shares which vest pursuant to this TSR Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper quartile or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between upper quartile and median</td>
<td>Pro-rata between 20% and 4%</td>
</tr>
<tr>
<td>Median</td>
<td>4%</td>
</tr>
<tr>
<td>Below median</td>
<td>0%</td>
</tr>
</tbody>
</table>

b. For the purpose of this TSR Target:

i. The Comparator Group shall comprise the following companies:

- [Altria Group]
- Anheuser-Busch InBev
- Campbell Soup Company
- Carlsberg A/S
- Coca-Cola
- Colgate-Palmolive
- Danone
- Diageo
- [Heineken](1)
- [Imperial Brands](1)
- [Japan Tobacco](1)
- Johnson & Johnson
- Kellogg
- [Kimberley-Clark](1)
- LVMH
- [Mondelēz International](1)
- [Nestlé](1)
- PepsiCo Inc
- Philip Morris International
- Procter & Gamble
- Reckitt Benckiser
- [SABMiller](2)
- Unilever

ii. The Total Shareholder Return of the Company and each of the relevant comparator companies over the relevant Performance Period (expressed as a percentage) shall be computed as follows:

\[
\left\{ \left( \frac{\text{TSR}_2}{\text{TSR}_1} \right)^{4/3} \right\} - 1
\]

1 Included only for Awards granted from 2019
2 Included only for Awards granted in 2016
Where:

\[ \text{TSR}_0 = \text{the average return index of the relevant companies as calculated by Datastream (or other such data provider as determined by the Board) (excluding Saturdays and Sundays) in the three months preceding the beginning of the Performance Period; and} \]

\[ \text{TSR}_3 = \text{the average return index (calculated in the same manner as for } \text{TSR}_0 \text{) in the 3 months preceding the end of the Performance Period.} \]

iii. Unless the Board determines otherwise, the Total Shareholder Return for the Company and each of the relevant comparator companies shall be calculated on a local currency basis.

iv. The Company and the companies in the Comparator Group shall be ranked by the resulting Total Shareholder Return figures, with the company with the highest figure having the highest ranking, and median and upper quartile performance shall be determined on such basis as the Board, acting reasonably, may specify from time to time.

5. Operating Cash Flow Conversion Ratio Target

a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 5 (the “Operating Cash Flow Conversion Ratio Target”) depends upon the Company’s average Operating Cash Flow as a percentage of Adjusted Operating Profit over the Performance Period:

<table>
<thead>
<tr>
<th>Average Operating Cash Flow Conversion Ratio over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to the Operating Cash Flow Conversion Ratio Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between 95% and 85%</td>
<td>Pro-rata between 20% and 4%</td>
</tr>
<tr>
<td>85%</td>
<td>4%</td>
</tr>
<tr>
<td>Less than 85% of Adjusted Operating Profit</td>
<td>0%</td>
</tr>
</tbody>
</table>

b. For the purpose of this Operating Cash Flow Conversion Ratio Target:

i. the “Average Operating Cash Flow Conversion Ratio” is the aggregate of the Operating Cash Flow Conversion Ratios for each Financial Year in the Performance Period, divided by the number of Financial Years in the Performance Period; and

ii. the “Operating Cash Flow Conversion Ratio” for a Financial Year (expressed as a percentage) is calculated as follows:

\[ \left( \frac{\text{Operating Cash Flow}}{\text{Adjusted Operating Profit}} \right) \times 100 \]

Where:

“Operating Cash Flow” in respect of a Financial Year is the adjusted profit from operations (excluding associates) plus depreciation, amortisation and impairment, plus other non-cash items, less the increase / (decrease) in working capital, less net capital expenditure, in each case for such Financial Year. All of these items are excluding costs and movements relating to restructuring and integration in the Financial Year; and
“Adjusted Operating Profit” in respect of a Financial Year is derived by excluding the adjusting items from the profit from operations for such Financial Year. Adjusting items include restructuring and integration costs, amortisation and impairment of trademarks and similar intangibles, a gain on deemed partial disposal of a trademark and a payment and release of a provision relating to non-tobacco litigation.

For the purpose of this Operating Cash Flow Conversion Ratio Target, Operating Cash Flow and Adjusted Operating Profit are calculated at current rates of exchange, unless the Board determines otherwise.

6. Net Turnover Target

a. The performance target in this paragraph 6 (the “NTO Target”) operates by calculating the compound annual growth in the Net Turnover of the Company, measured at constant rates of exchange on an organic basis.

b. The percentage of the Award Shares which may vest pursuant to this NTO Target depends upon the compound annual growth in Net Turnover over the Performance Period as follows:

<table>
<thead>
<tr>
<th>Compound annual growth of Net Turnover over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this NTO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>5% pa or greater</td>
<td>20%</td>
</tr>
<tr>
<td>Between 5% pa and 3% pa</td>
<td>Pro-rata between 20% and 4%</td>
</tr>
<tr>
<td>3% pa</td>
<td>4%</td>
</tr>
<tr>
<td>Less than 3% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

provided that, notwithstanding above, but subject to the Rules, no Award Shares shall vest pursuant to this NTO Target unless the three-year constant currency compound annual growth rate of underlying adjusted operating profit exceeds the compound annual growth rate of the threshold performance level for underlying adjusted operating profit, as defined annually in the International Executive Incentive Scheme (as approved by the Board).

c. For the purposes of this NTO Target, compound annual growth of Net Turnover (expressed as a percentage) is calculated as follows:

\[
\left\{ \left( \frac{NTO_3}{NTO_0} \right)^{\frac{1}{3}} - 1 \right\} \times 100
\]

Where:

\( NTO_0 \) = Net Turnover in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and

\( NTO_3 \) = Net Turnover in the final Financial Year of the Performance Period (being “Year 3”),

measured at constant rates of exchange, for which purpose the value of \( NTO_0 \) and \( NTO_3 \) shall be taken as index values, with the value for \( NTO_0 \) being the base index value (representing Net Turnover in Year 0), with the purpose of such index being to reflect changes over the Performance Period in Net Turnover of the Company as measured on a constant currency basis, and \( NTO_3 \) being taken as the value of such
index for Year 3, and where the values for NTO3 and/or NTO9 shall be adjusted in such manner as is determined by the Board to exclude any Net Turnover attributable to any business acquired or disposed of during the Performance Period or otherwise with the intention that the growth in Net Turnover is assessed by reference to organic growth.

7. Exchange rates
In this Schedule:
“current rates of exchange” means exchange rates applied for each year relevant to a given calculation based on the average exchange rate in that year; and
“constant rates of exchange” means exchange rates applied based on a re-translation, at prior year exchange rates, of the current year information, in order that the same exchange rates are applied for each year relevant to a given calculation.

8. Adjustment to vesting outcome
a. After the performance targets in paragraphs 3 to 6 have been assessed, the Board may make such adjustment to the percentage of Shares of the Award Shares that vest pursuant to one or more of such performance targets to ensure a fair result for both the Participants and shareholders.

b. An adjustment pursuant to this paragraph 8 may be either positive (but, for the avoidance of doubt, not so that the percentage of the Award Shares which vests pursuant to any one of the performance targets in paragraphs 3 to 6 exceeds the maximum percentage of the Award Shares which may vest pursuant to that performance target, as set out in paragraph 1) or negative (including reducing the percentage of Awards Shares which vest to nil). For the avoidance of doubt, where the Board makes any adjustment pursuant to this paragraph 8 the percentage of Award Shares to be transferred shall be the percentage as adjusted by the Board notwithstanding the outcome of the performance targets as set out in paragraphs 3 to 6.

c. For the avoidance of doubt, vesting outcomes are subject to any forfeiture or reduction of Awards pursuant to Rule 15 (Claw-back).

9. Adjustments to performance targets
a. In the event of:
   i. a change to the accounting standards of the Company or similar event;
   ii. any events which affect any of the companies comprised in the Comparator Group (such as a merger or de-listing);
   iii. any variation of capital of the Company or a demerger, delisting, special dividend, rights issue or other event which may, in the opinion of the Board, affect the current or future value of the Company’s shares; or
   iv. any other similar event the Board considers relevant which may unduly affect the calculation of the performance targets set out in paragraphs 3 to 6,
the Board may make such adjustments to the terms of this Performance Condition as it determines appropriate to reflect such event with the intention of ensuring that this Performance Condition continues to assess the performance of the Company on a consistent basis over the Performance Period.

b. This Performance Condition may be amended in accordance with Rule 5.4 of the Plan.
General

10. References in this Schedule 1A to a paragraph are to a paragraph of this Schedule 1A.
SCHEDULE 1B

PERFORMANCE CONDITION APPLICABLE TO AWARDS GRANTED IN 2016, 2017, 2018, 2019, 2020 and 2021

TO EXECUTIVE DIRECTORS OF THE COMPANY

1. Subject to the Rules, the extent to which the Shares in respect of which an Award is granted (the “Award Shares”) may vest shall be determined:
   a. as to 40% of the Award Shares, by reference to the performance target based on Earnings per Share specified in paragraph 3 below is satisfied
   b. as to 20% of the Award Shares, by reference to the performance target based on Total Shareholder Return specified in paragraph 4 below;
   c. as to 20% of the Award Shares, by reference to the performance target based on the Operating Cash Flow Conversion Ratio specified in paragraph 5 below; and
   d. as to 20% of the Award Shares, by reference to the performance target based on Net Turnover specified in paragraph 6 below.

2. The Performance Period for:
   a. Awards granted in 2016 shall commence on 1 January 2016 and end on 31 December 2018;
   b. Awards granted in 2017 shall commence on 1 January 2017 and end on 31 December 2019;
   c. Awards granted in 2018 shall commence on 1 January 2018 and end on 31 December 2020;
   d. Awards granted in 2019 shall commence on 1 January 2019 and end on 31 December 2021;
   e. Awards granted in 2020 shall commence on 1 January 2020 and end on 31 December 2022; and
   f. Awards granted in 2021 shall commence on 1 January 2021 and end on 31 December 2023.

3. Earnings per Share
   a. The performance target in this paragraph 3 (the “EPS Target”) shall consist of two equal, independent elements such that the number of Award Shares which vest pursuant to this EPS Target shall be the aggregate of the number of Award Shares which vest pursuant to each element.
   b. Each element of the EPS Target operates by calculating the compound annual growth in adjusted diluted earnings per share for the Company, in the case of the first element measured at current rates of exchange, and in the case of the second element measured at constant rates of exchange.
EPS Target: current rates of exchange

c. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at current rates of exchange, as follows:

<table>
<thead>
<tr>
<th>Compound annual growth rate in adjusted diluted EPS (measured at current rates of exchange) over the Performance Period</th>
<th>% of the Award Shares which may vest pursuant to this element of the EPS Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% pa or greater</td>
<td>20%</td>
</tr>
<tr>
<td>Between 10% pa and 5% pa</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>5% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 5% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

EPS Target: constant rates of exchange

d. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at constant rates of exchange, as follows:

<table>
<thead>
<tr>
<th>Compound annual growth rate in adjusted diluted EPS (measured at constant rates of exchange) over the Performance Period</th>
<th>% of the Award Shares which may vest pursuant to this element of the EPS Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% pa or greater</td>
<td>20%</td>
</tr>
<tr>
<td>Between 10% pa and 5% pa</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>5% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 5% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

e. For the purposes of paragraphs 3.c and 3.d above, compound annual growth in adjusted diluted earnings per share over the Performance Period (expressed as a percentage) is calculated as follows:

\[
\left[ \left\{ \left( \frac{E^3}{E^0} \right)^{1/3} \right\} - 1 \right] \times 100
\]

Where:

- \(E^0\) = adjusted diluted earnings per share of the Company in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and
- \(E^3\) = adjusted diluted earnings per share of the Company in the final Financial Year of the Performance Period (being “Year 3”), measured at:
  i. current rates of exchange for the purposes of paragraph 3.c; and
  ii. constant rates of exchange for the purposes of paragraph 3.d, for which purpose the value of \(E^0\) and \(E^3\) shall be taken as index values, with the value for \(E^0\) being the base index value (representing adjusted diluted earnings per share in Year 0), with the purpose of such index being to reflect changes over the Performance Period in adjusted diluted earnings per share of the Company as measured on a constant currency basis, and \(E^3\) being taken as the value of such index for Year 3.
4. **TSR Target**

   a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 4 (the “TSR Target”) depends upon the Company’s Total Shareholder Return over the Performance Period relative to the Total Shareholder Return of the Comparator Group:

<table>
<thead>
<tr>
<th>Ranked position of the Company’s TSR against the relevant comparator companies</th>
<th>% of the Award Shares which vest pursuant to this TSR Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper quartile or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between upper quartile and median</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>Median</td>
<td>3%</td>
</tr>
<tr>
<td>Below median</td>
<td>0%</td>
</tr>
</tbody>
</table>

   b. For the purpose of this TSR Target:

   i. The Comparator Group shall comprise the following companies:

      | [Altria Group] | Heineken | Nestlé |
      | ---------------|----------|--------|
      | Anheuser-Busch InBev | Imperial Brands | PepsiCo Inc |
      | Campbell Soup Company | Japan Tobacco | Pernod Ricard |
      | Carlsberg A/S | Johnson & Johnson | Philip Morris International |
      | Coca-Cola | Kellogg | Procter & Gamble |
      | Colgate-Palmolive | Kimberley-Clark | Reckitt Benckiser |
      | Danone | LVMH | [SABMiller]4 |
      | Diageo | Mondelēz International | Unilever |

   ii. The Total Shareholder Return of the Company and each of the relevant comparator companies over the relevant Performance Period (expressed as a percentage) shall be computed as follows:

   \[
   \left\{ \left( \frac{TSR^3}{TSR^0} \right)^{\frac{1}{3}} - 1 \right\}
   \]

   Where:

   - \(TSR^0\) = the average return index of the relevant companies as calculated by Datastream (or other such data provider as determined by the Board) (excluding Saturdays and Sundays) in the three months preceding the beginning of the Performance Period; and
   - \(TSR^3\) = the average return index (calculated in the same manner as for \(TSR^0\)) in the 3 months preceding the end of the Performance Period.

3 Included only for Awards granted from 2019
4 Included only for Awards granted in 2016
iii. The Total Shareholder Return for the Company and each of the relevant comparator companies shall be calculated on a local currency basis.

iv. The Company and the companies in the Comparator Group shall be ranked by the resulting Total Shareholder Return figures, with the company with the highest figure having the highest ranking, and median and upper quartile performance shall be determined on such basis as the Board, acting reasonably, may specify from time to time.

5. Operating Cash Flow Conversion Ratio Target

a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 5 (the “Operating Cash Flow Conversion Ratio Target”) depends upon the Company’s average Operating Cash Flow as a percentage of Adjusted Operating Profit over the Performance Period:

<table>
<thead>
<tr>
<th>Average Operating Cash Flow Conversion Ratio over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to the Operating Cash Flow Conversion Ratio Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between 95% and 85%</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>85%</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 85% of Adjusted Operating Profit</td>
<td>0%</td>
</tr>
</tbody>
</table>

b. For the purpose of this Operating Cash Flow Conversion Ratio Target:

i. the “Average Operating Cash Flow Conversion Ratio” is the aggregate of the Operating Cash Flow Conversion Ratios for each Financial Year in the Performance Period, divided by the number of Financial Years in the Performance Period; and

ii. the “Operating Cash Flow Conversion Ratio” for a Financial Year (expressed as a percentage) is calculated as follows:

\[
\left( \frac{\text{Operating Cash Flow}}{\text{Adjusted Operating Profit}} \right) \times 100
\]

Where:

“Operating Cash Flow” in respect of a Financial Year is the adjusted profit from operations (excluding associates) plus depreciation, amortisation and impairment, plus other non-cash items, less the increase / (decrease) in working capital, less net capital expenditure, in each case for such Financial Year. All of these items are excluding costs and movements relating to restructuring and integration in the Financial Year; and
"Adjusted Operating Profit" in respect of a Financial Year is derived by excluding the adjusting items from the profit from operations for such Financial Year. Adjusting items include restructuring and integration costs, amortisation and impairment of trademarks and similar intangibles, a gain on deemed partial disposal of a trademark and a payment and release of a provision relating to non-tobacco litigation.

For the purpose of this Operating Cash Flow Conversion Ratio Target, Operating Cash Flow and Adjusted Operating Profit are calculated at current rates of exchange.

6. **Net Turnover Target**

   a. The performance target in this paragraph 6 (the "NTO Target") operates by calculating the compound annual growth in the Net Turnover of the Company, measured at constant rates of exchange on an organic basis.

   b. The percentage of the Award Shares which may vest pursuant to this NTO Target depends upon the compound annual growth in Net Turnover over the Performance Period as follows:

<table>
<thead>
<tr>
<th>Compound annual growth of Net Turnover over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this NTO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>5% pa or greater</td>
<td>20%</td>
</tr>
<tr>
<td>Between 5% pa and 3% pa</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>3% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 3% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

   provided that, notwithstanding above, but subject to the Rules, no Award Shares shall vest pursuant to this NTO Target unless the three-year constant currency compound annual growth rate of underlying adjusted operating profit exceeds the compound annual growth rate of the threshold performance level for underlying adjusted operating profit, as defined annually in the International Executive Incentive Scheme (as approved by the Board).

   c. For the purposes of this NTO Target, compound annual growth of Net Turnover (expressed as a percentage) is calculated as follows:

   $$\left[ \left\{ \left( \frac{\text{NTO}}{\text{NTO}^0} \right)^{\frac{1}{3}} \right\} - 1 \right] \times 100$$

   Where:

   $\text{NTO}^0$ = Net Turnover in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and

   $\text{NTO}^3$ = Net Turnover in the final Financial Year of the Performance Period (being “Year 3”), measured at constant rates of exchange, for which purpose the value of $\text{NTO}^0$ and $\text{NTO}^3$ shall be taken as index values, with the value for $\text{NTO}^0$ being the base index value (representing Net Turnover in Year 0), with the purpose of such index being to reflect changes over the Performance Period in Net Turnover of the Company as measured on a constant currency basis, with $\text{NTO}^3$ being taken as the value of such index for Year 3, and where the values for $\text{NTO}^3$ and/or $\text{NTO}^0$ shall be adjusted in such manner as is determined by the Board to exclude any Net Turnover attributable to any business acquired or disposed of during the Performance Period or otherwise with the intention that the growth in Net Turnover is assessed by reference to organic growth.
7. **Exchange rates**

   In this Schedule:

   “current rates of exchange” means exchange rates applied for each year relevant to a given calculation based on the average exchange rate in that year; and

   “constant rates of exchange” means exchange rates applied based on a re-translation, at prior year exchange rates, of the current year information, in order that the same exchange rates are applied for each year relevant to a given calculation.

8. **Adjustment to vesting outcome**

   a. After the performance targets in paragraphs 3 to 6 have been assessed, the Board may make such adjustment to the percentage of Shares of the Award Shares that vest pursuant to one or more of such performance targets to ensure a fair result for both the Participants and shareholders.

   b. An adjustment pursuant to this paragraph 8 may be either positive (but, for the avoidance of doubt, not so that the percentage of the Award Shares which vests pursuant to any one of the performance targets in paragraphs 3 to 6 exceeds the maximum percentage of the Award Shares which may vest pursuant to that performance target, as set out in paragraph 1) or negative (including reducing the percentage of Awards Shares which vest to nil). For the avoidance of doubt, where the Board makes any adjustment pursuant to this paragraph 8 the percentage of Award Shares to be transferred shall be the percentage as adjusted by the Board notwithstanding the outcome of the performance targets as set out in paragraphs 3 to 6.

   c. For the avoidance of doubt, vesting outcomes are subject to any forfeiture or reduction of Awards pursuant to Rule 15 (Claw-back).

9. **Adjustments to performance targets**

   a. In the event of:

      i. a change to the accounting standards of the Company or similar event;

      ii. any events which affect any of the companies comprised in the Comparator Group (such as a merger or de-listing);

      iii. any variation of capital of the Company or a demerger, delisting, special dividend, rights issue or other event which may, in the opinion of the Board, affect the current or future value of the Company’s shares; or

      iv. any other similar event the Board considers relevant which may unduly affect the calculation of the performance targets set out in paragraphs 3 to 6,

   the Board may make such adjustments to the terms of this Performance Condition as it determines appropriate to reflect such event with the intention of ensuring that this Performance Condition continues to assess the performance of the Company on a consistent basis over the Performance Period.

   b. This Performance Condition may be amended in accordance with Rule 5.4 of the Plan.
General

10. References in this Schedule 1B to a paragraph are to a paragraph of this Schedule 1B.
SCHEDULE 1C

PERFORMANCE CONDITION APPLICABLE TO AWARDS GRANTED IN 2022

TO PARTICIPANTS OTHER THAN EXECUTIVE DIRECTORS

1. Subject to the Rules, the extent to which the Shares in respect of which an Award is granted (the “Award Shares”) may vest shall be determined:
   a. as to 15% of the Award Shares, by reference to the performance target based on Group Net Turnover specified in paragraph 3 below;
   b. as to 15% of the Award Shares, by reference to the performance target based on New Categories Net Turnover specified in paragraph 4 below;
   c. as to 30% of the Award Shares, by reference to the performance target based on Earnings per Share specified in paragraph 5 below is satisfied
   d. as to 20% of the Award Shares, by reference to the performance target based on the Operating Cash Flow Conversion Ratio specified in paragraph 6 below;
   e. as to 20% of the Award Shares, by reference to the performance target based on Total Shareholder Return specified in paragraph 7 below; and

2. The Performance Period for Awards granted in 2022 shall commence on 1 January 2022 and end on 31 December 2024.

3. Net Turnover Target
   a. The performance target in this paragraph 3 (the “NTO Target”) operates by calculating the compound annual growth in the Net Turnover of the Company, measured at constant rates of exchange on an organic basis.
   b. The percentage of the Award Shares which may vest pursuant to this NTO Target depends upon the compound annual growth in Net Turnover over the Performance Period as follows:

<table>
<thead>
<tr>
<th>Compound annual growth of Net Turnover over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this NTO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>5% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 5% pa and 3% pa</td>
<td>Pro-rata between 15% and 3%</td>
</tr>
<tr>
<td>3% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 3% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

provided that, notwithstanding above, but subject to the Rules, no Award Shares shall vest pursuant to this NTO Target unless the three-year constant currency compound annual growth rate of underlying adjusted operating profit exceeds the compound annual growth rate of the threshold performance level for underlying adjusted operating profit, as defined annually in the International Executive Incentive Scheme (as approved by the Board).
c. For the purposes of this NTO Target, compound annual growth of Net Turnover (expressed as a percentage) is calculated as follows:

\[
\left\{ \left( \frac{NTO^3}{NTO^0} \right)^{1/3} \right\} - 1 \right\} \times 100
\]

Where:

\(NTO^0\) = Net Turnover in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and

\(NTO^3\) = Net Turnover in the final Financial Year of the Performance Period (being “Year 3”), measured at constant rates of exchange, for which purpose the value of \(NTO^0\) and \(NTO^3\) shall be taken as index values, with the value for \(NTO^0\) being the base index value (representing Net Turnover in Year 0), with the purpose of such index being to reflect changes over the Performance Period in Net Turnover of the Company as measured on a constant currency basis, and \(NTO^3\) being taken as the value of such index for Year 3, and where the values for \(NTO^3\) and/or \(NTO^0\) shall be adjusted in such manner as is determined by the Board to exclude any Net Turnover attributable to any business acquired or disposed of during the Performance Period or otherwise with the intention that the growth in Net Turnover is assessed by reference to organic growth.

4. New Categories Net Turnover Target

a. The performance target in this paragraph 4 (the “NC NTO Target”) operates by calculating the compound annual growth in the New Categories Net Turnover of the Company, measured at constant rates of exchange on an organic basis.

b. The percentage of the Award Shares which may vest pursuant to this NC NTO Target depends upon the compound annual growth in New Categories Net Turnover over the Performance Period as follows:

<table>
<thead>
<tr>
<th>Compound annual growth of Net Turnover over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this NTO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>30% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 30% pa and 20% pa</td>
<td>Pro-rata between 15% and 3%</td>
</tr>
<tr>
<td>20% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 20% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

c. For the purposes of this NC NTO Target, compound annual growth of New Categories Net Turnover (expressed as a percentage) is calculated as follows:

\[
\left\{ \left( \frac{NC\ NTO^3}{NC\ NTO^0} \right)^{1/3} \right\} - 1 \right\} \times 100
\]
Where:

\( NC \text{ NTO}^0 \) – New Categories Net Turnover in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and

\( NC \text{ NTO}^3 \) – New Categories Net Turnover in the final Financial Year of the Performance Period (being “Year 3”), measured at constant rates of exchange, for which purpose the value of \( NC \text{ NTO}^0 \) and \( NC \text{ NTO}^3 \) shall be taken as index values, with the value for \( NC \text{ NTO}^0 \) being the base index value (representing New Categories Net Turnover in Year 0), with the purpose of such index being to reflect changes over the Performance Period in New Categories Net Turnover of the Company as measured on a constant currency basis, and \( NC \text{ NTO}^3 \) being taken as the value of such index for Year 3, and where the values for \( NC \text{ NTO}^3 \) and/or \( NC \text{ NTO}^0 \) may be adjusted in such manner as is determined by the Board to exclude any New Categories Net Turnover attributable to any business acquired or disposed of during the Performance Period or otherwise with the intention that the growth in New Categories Net Turnover is assessed by reference to organic growth.

5. Earnings per Share

a. The performance target in this paragraph 5 (the “EPS Target”) shall consist of two equal, independent elements such that the number of Award Shares which vest pursuant to this EPS Target shall be the aggregate of the number of Award Shares which vest pursuant to each element.

b. Each element of the EPS Target operates by calculating the compound annual growth in adjusted diluted earnings per share (unless the Board determines that an alternative definition of earnings per share is more appropriate) for the Company, in the case of the first element measured at current rates of exchange, and in the case of the second element measured at constant rates of exchange.

**EPS Target: current rates of exchange**

c. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at current rates of exchange, as follows:

<table>
<thead>
<tr>
<th>Compound annual growth rate in adjusted diluted EPS (measured at current rates of exchange) over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this element of the EPS Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 10% pa and 5% pa</td>
<td>Pro-rata between 15% and 3%</td>
</tr>
<tr>
<td>5% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 5% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>
EPS Target: constant rates of exchange

d. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at constant rates of exchange, as follows:

<table>
<thead>
<tr>
<th>Compound annual growth rate in adjusted diluted EPS (measured at constant rates of exchange) over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this element of the EPS Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 10% pa and 5% pa</td>
<td>Pro-rata between 15% and 3%</td>
</tr>
<tr>
<td>5% pa</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 5% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

e. For the purposes of paragraphs 5.c and 5.d above, compound annual growth in adjusted diluted earnings per share over the Performance Period (expressed as a percentage) is calculated as follows:

\[
\left[ \left\{ \left( \frac{E^3}{E^0} \right)^{1/3} - 1 \right\} \times 100 \right]
\]

Where:

- \( E^0 \) = adjusted diluted earnings per share of the Company in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and
- \( E^3 \) = adjusted diluted earnings per share of the Company in the final Financial Year of the Performance Period (being “Year 3”), measured at:
  i. current rates of exchange for the purposes of paragraph 5.c; and
  ii. constant rates of exchange for the purposes of paragraph 5.d, for which purpose the value of \( E^0 \) and \( E^3 \) shall be taken as index values, with the value for \( E^0 \) being the base index value (representing adjusted diluted earnings per share in Year 0), with the purpose of such index being to reflect changes over the Performance Period in adjusted diluted earnings per share of the Company as measured on a constant currency basis, and \( E^3 \) being taken as the value of such index for Year 3,

and in either case provided that if the Board determines that a measurement of earnings per share other than adjusted diluted earnings per share is more appropriate the calculation shall be on that other basis and this paragraph 5 shall apply accordingly.)
6. **Operating Cash Flow Conversion Ratio Target**

   a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 6 (the “Operating Cash Flow Conversion Ratio Target”) depends upon the Company’s average Operating Cash Flow as a percentage of Adjusted Operating Profit over the Performance Period:

<table>
<thead>
<tr>
<th>Average Operating Cash Flow Conversion Ratio over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to the Operating Cash Flow Conversion Ratio Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between 95% and 85%</td>
<td>Pro-rata between 20% and 4%</td>
</tr>
<tr>
<td>85%</td>
<td>4%</td>
</tr>
<tr>
<td>Less than 85% of Adjusted Operating Profit</td>
<td>0%</td>
</tr>
</tbody>
</table>

   b. For the purpose of this Operating Cash Flow Conversion Ratio Target:

   i. the “Average Operating Cash Flow Conversion Ratio” is the aggregate of the Operating Cash Flow Conversion Ratios for each Financial Year in the Performance Period, divided by the number of Financial Years in the Performance Period; and

   ii. the “Operating Cash Flow Conversion Ratio” for a Financial Year (expressed as a percentage) is calculated as follows:

   $$ \left( \frac{\text{Operating Cash Flow}}{\text{Adjusted Operating Profit}} \right) \times 100 $$

   Where:

   “Operating Cash Flow” in respect of a Financial Year is the adjusted profit from operations (excluding associates) plus depreciation, amortisation and impairment, plus other non-cash items, less the increase / (decrease) in working capital, less net capital expenditure, in each case for such Financial Year. All of these items are excluding costs and movements relating to restructuring and integration in the Financial Year; and

   “Adjusted Operating Profit” in respect of a Financial Year is derived by excluding the adjusting items from the profit from operations for such Financial Year. Adjusting items include restructuring and integration costs, amortisation and impairment of trademarks and similar intangibles, a gain on deemed partial disposal of a trademark and a payment and release of a provision relating to non-tobacco litigation.

   For the purpose of this Operating Cash Flow Conversion Ratio Target, Operating Cash Flow and Adjusted Operating Profit are calculated at current rates of exchange, unless the Board determines otherwise.
7. **TSR Target**

a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 7 (the “TSR Target”) depends upon the Company’s Total Shareholder Return over the Performance Period relative to the Total Shareholder Return of the Comparator Group:

<table>
<thead>
<tr>
<th>Ranked position of the Company’s TSR against the relevant comparator companies</th>
<th>% of the Award Shares which vest pursuant to this TSR Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper quartile or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between upper quartile and median</td>
<td>Pro-rata between 20% and 4%</td>
</tr>
<tr>
<td>Median</td>
<td>4%</td>
</tr>
<tr>
<td>Below median</td>
<td>0%</td>
</tr>
</tbody>
</table>

b. For the purpose of this TSR Target:

i. The Comparator Group shall comprise the following companies:

<table>
<thead>
<tr>
<th>Altria Group</th>
<th>PepsiCo Inc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anheuser-Busch InBev</td>
<td>Pernod Ricard</td>
</tr>
<tr>
<td>Carlsberg A/S</td>
<td>Philip Morris International</td>
</tr>
<tr>
<td>Coca Cola</td>
<td>Procter &amp; Gamble</td>
</tr>
<tr>
<td>Diageo</td>
<td>Reckitt Benckiser</td>
</tr>
<tr>
<td>Heineken</td>
<td>Swedish Match</td>
</tr>
<tr>
<td>Imperial Brands</td>
<td>Unilever</td>
</tr>
<tr>
<td>Japan Tobacco</td>
<td></td>
</tr>
</tbody>
</table>

ii. The Total Shareholder Return of the Company and each of the relevant comparator companies over the relevant Performance Period (expressed as a percentage) shall be computed as follows:

\[
\left[ \left\{ \left( \frac{\text{TSR}^3}{\text{TSR}^0} \right)^{1/3} \right\} - 1 \right] \times 100
\]

Where:

**TSR\(^0\)** = the average return index of the relevant companies as calculated by Datastream (or other such data provider as determined by the Board) (excluding Saturdays and Sundays) in the three months preceding the beginning of the Performance Period; and

**TSR\(^3\)** = the average return index (calculated in the same manner as for TSRR\(^0\)) in the 3 months preceding the end of the Performance Period.

iii. Unless the Board determines otherwise, the Total Shareholder Return for the Company and each of the relevant comparator companies shall be calculated on a local currency basis.

iv. The Company and the companies in the Comparator Group shall be ranked by the resulting Total Shareholder Return figures, with the company with the highest figure having the highest ranking, and median and upper quartile performance shall be determined on such basis as the Board, acting reasonably, may specify from time to time.
8. Exchange rates
In this Schedule:
“current rates of exchange” means exchange rates applied for each year relevant to a given calculation based on the average exchange rate in that year; and
“constant rates of exchange” means exchange rates applied based on a re-translation, at prior year exchange rates, of the current year information, in order that the same exchange rates are applied for each year relevant to a given calculation.

9. Adjustment to vesting outcome
a. After the performance targets in paragraphs 3 to 7 have been assessed, the Board may make such adjustment to the percentage of Shares of the Award Shares that vest pursuant to one or more of such performance targets to ensure a fair result for both the Participants and shareholders.

b. An adjustment pursuant to this paragraph 9 may be either positive (but, for the avoidance of doubt, not so that the percentage of the Award Shares which vests pursuant to any one of the performance targets in paragraphs 3 to 7 exceeds the maximum percentage of the Award Shares which may vest pursuant to that performance target, as set out in paragraph 1) or negative (including reducing the percentage of Awards Shares which vest to nil). For the avoidance of doubt, where the Board makes any adjustment pursuant to this paragraph 9 the percentage of Award Shares to be transferred shall be the percentage as adjusted by the Board notwithstanding the outcome of the performance targets as set out in paragraphs 3 to 7.

c. For the avoidance of doubt, vesting outcomes are subject to any forfeiture or reduction of Awards pursuant to Rule 15 (Claw-back).

10. Adjustments to performance targets
a. In the event of:
   i. a change to the accounting standards of the Company or similar event;
   ii. any events which affect any of the companies comprised in the Comparator Group (such as a merger or de-listing);
   iii. any variation of capital of the Company or a demerger, delisting, special dividend, rights issue or other event which may, in the opinion of the Board, affect the current or future value of the Company’s shares; or
   iv. any other similar event the Board considers relevant which may unduly affect the calculation of the performance targets set out in paragraphs 3 to 7,

   the Board may make such adjustments to the terms of this Performance Condition as it determines appropriate to reflect such event with the intention of ensuring that this Performance Condition continues to assess the performance of the Company on a consistent basis over the Performance Period.

b. This Performance Condition may be amended in accordance with Rule 5.4 of the Plan.

General

11. References in this Schedule 1C to a paragraph are to a paragraph of this Schedule 1C.
SCHEDULE 1D

PERFORMANCE CONDITION APPLICABLE TO AWARDS GRANTED IN 2022

FOR EXECUTIVE DIRECTORS OF THE COMPANY

1. Subject to the Rules, the extent to which the Shares in respect of which an Award is granted (the “Award Shares”) may vest shall be determined:
   a. as to 15% of the Award Shares, by reference to the performance target based on Group Net Turnover specified in paragraph 3 below;
   b. as to 15% of the Award Shares, by reference to the performance target based on New Categories Net Turnover specified in paragraph 4 below;
   c. as to 30% of the Award Shares, by reference to the performance target based on Earnings per Share specified in paragraph 5 below is satisfied
   d. as to 20% of the Award Shares, by reference to the performance target based on the Operating Cash Flow Conversion Ratio specified in paragraph 6 below;
   e. as to 20% of the Award Shares, by reference to the performance target based on Total Shareholder Return specified in paragraph 7 below; and

2. The Performance Period for Awards granted in 2022 shall commence on 1 January 2022 and end on 31 December 2024.

3. Net Turnover Target
   a. The performance target in this paragraph 3 (the “NTO Target”) operates by calculating the compound annual growth in the Net Turnover of the Company, measured at constant rates of exchange on an organic basis.
   b. The percentage of the Award Shares which may vest pursuant to this NTO Target depends upon the compound annual growth in Net Turnover over the Performance Period as follows:

<table>
<thead>
<tr>
<th>Compound annual growth of Net Turnover over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this NTO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>5% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 5% pa and 3% pa</td>
<td>Pro-rata between 15% and 2.25%</td>
</tr>
<tr>
<td>3% pa</td>
<td>2.25%</td>
</tr>
<tr>
<td>Less than 3% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

   provided that, notwithstanding above, but subject to the Rules, no Award Shares shall vest pursuant to this NTO Target unless the three-year constant currency compound annual growth rate of underlying adjusted operating profit exceeds the compound annual growth rate of the threshold performance level for underlying adjusted operating profit, as defined annually in the International Executive Incentive Scheme (as approved by the Board).
For the purposes of this NTO Target, compound annual growth of Net Turnover (expressed as a percentage) is calculated as follows:

\[
\left\{ \left( \frac{NTO^3}{NTO^0} \right)^{1/3} - 1 \right\} \times 100
\]

Where:

\(NTO^0\) = Net Turnover in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and

\(NTO^3\) = Net Turnover in the final Financial Year of the Performance Period (being “Year 3”),

measured at constant rates of exchange, for which purpose the value of \(NTO^0\) and \(NTO^3\) shall be taken as index values, with the value for \(NTO^0\) being the base index value (representing Net Turnover in Year 0), with the purpose of such index being to reflect changes over the Performance Period in Net Turnover of the Company as measured on a constant currency basis, and \(NTO^3\) being taken as the value of such index for Year 3, and where the values for \(NTO^3\) and/or \(NTO^0\) shall be adjusted in such manner as is determined by the Board to exclude any Net Turnover attributable to any business acquired or disposed of during the Performance Period or otherwise with the intention that the growth in Net Turnover is assessed by reference to organic growth.

4. **New Categories Net Turnover Target**
   a. The performance target in this paragraph 4 (the “NC NTO Target”) operates by calculating the compound annual growth in the New Categories Net Turnover of the Company, measured at constant rates of exchange on an organic basis.
   b. The percentage of the Award Shares which may vest pursuant to this NC NTO Target depends upon the compound annual growth in New Categories Net Turnover over the Performance Period as follows:

<table>
<thead>
<tr>
<th>Compound annual growth of Net Turnover over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this NTO Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>30% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 30% pa and 20% pa</td>
<td>Pro-rata between 15% and 2.25%</td>
</tr>
<tr>
<td>20% pa</td>
<td>2.25%</td>
</tr>
<tr>
<td>Less than 20% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

c. For the purposes of this NC NTO Target, compound annual growth of New Categories Net Turnover (expressed as a percentage) is calculated as follows:

\[
\left\{ \left( \frac{NC\ NTO^3}{NC\ NTO^0} \right)^{1/3} - 1 \right\} \times 100
\]
Where:

\[ NC\ NTO^0 = \text{New Categories Net Turnover in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and} \]

\[ NC\ NTO^3 = \text{New Categories Net Turnover in the final Financial Year of the Performance Period (being “Year 3”),} \]

measured at constant rates of exchange, for which purpose the value of \( NC\ NTO^0 \) and \( NC\ NTO^3 \) shall be taken as index values, with the value for \( NC\ NTO^0 \) being the base index value (representing New Categories Net Turnover in Year 0), with the purpose of such index being to reflect changes over the Performance Period in New Categories Net Turnover of the Company as measured on a constant currency basis, and \( NC\ NTO^3 \) being taken as the value of such index for Year 3, and where the values for \( NC\ NTO^3 \) and/or \( NC\ NTO^0 \) may be adjusted in such manner as is determined by the Board to exclude any New Categories Net Turnover attributable to any business acquired or disposed of during the Performance Period or otherwise with the intention that the growth in New Categories Net Turnover is assessed by reference to organic growth.

5. Earnings per Share

a. The performance target in this paragraph 5 (the “EPS Target”) shall consist of two equal, independent elements such that the number of Award Shares which vest pursuant to this EPS Target shall be the aggregate of the number of Award Shares which vest pursuant to each element.

b. Each element of the EPS Target operates by calculating the compound annual growth in adjusted diluted earnings per share (unless the Board determines that an alternative definition of earnings per share is more appropriate) for the Company, in the case of the first element measured at current rates of exchange, and in the case of the second element measured at constant rates of exchange.

**EPS Target: current rates of exchange**

c. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at current rates of exchange, as follows:

<table>
<thead>
<tr>
<th>Compound annual growth rate in adjusted diluted EPS (measured at current rates of exchange) over the Performance Period</th>
<th>% of the Award Shares which may vest pursuant to this element of the EPS Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 10% pa and 5% pa</td>
<td>Pro-rata between 15% and 2.25%</td>
</tr>
<tr>
<td>5% pa</td>
<td>2.25%</td>
</tr>
<tr>
<td>Less than 5% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>
**EPS Target: constant rates of exchange**

d. The percentage of the Award Shares which may vest pursuant to this element of the EPS Target depends upon the compound annual growth in adjusted diluted earnings per share over the Performance Period, measured at constant rates of exchange, as follows:

<table>
<thead>
<tr>
<th>Compound annual growth rate in adjusted diluted EPS (measured at constant rates of exchange) over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to this element of the EPS Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% pa or greater</td>
<td>15%</td>
</tr>
<tr>
<td>Between 10% pa and 5% pa</td>
<td>Pro-rata between 15% and 2.25%</td>
</tr>
<tr>
<td>5% pa</td>
<td>2.25%</td>
</tr>
<tr>
<td>Less than 5% pa</td>
<td>0%</td>
</tr>
</tbody>
</table>

e. For the purposes of paragraphs 5.c and 5.d above, compound annual growth in adjusted diluted earnings per share over the Performance Period (expressed as a percentage) is calculated as follows:

\[
\left\{ \left\{ \frac{E_3}{E_0} \right\}^{1/3} - 1 \right\} \times 100
\]

Where:
- \(E_0\) = adjusted diluted earnings per share of the Company in the Financial Year immediately preceding the Financial Year in which the Performance Period begins (being “Year 0”); and
- \(E_3\) = adjusted diluted earnings per share of the Company in the final Financial Year of the Performance Period (being “Year 3”), measured at:
  - current rates of exchange for the purposes of paragraph 5.c; and
  - constant rates of exchange for the purposes of paragraph 5.d, for which purpose the value of \(E_0\) and \(E_3\) shall be taken as index values, with the value for \(E_0\) being the base index value (representing adjusted diluted earnings per share in Year 0), with the purpose of such index being to reflect changes over the Performance Period in adjusted diluted earnings per share of the Company as measured on a constant currency basis, and \(E_3\) being taken as the value of such index for Year 3, and in either case provided that if the Board determines that a measurement of earnings per share other than adjusted diluted earnings per share is more appropriate the calculation shall be on that other basis and this paragraph 5 shall apply accordingly).

6. **Operating Cash Flow Conversion Ratio Target**

a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 6 (the “Operating Cash Flow Conversion Ratio Target”) depends upon the Company’s average Operating Cash Flow as a percentage of Adjusted Operating Profit over the Performance Period:

<table>
<thead>
<tr>
<th>Average Operating Cash Flow Conversion Ratio over the Performance Period</th>
<th>% of the Award Shares which vest pursuant to the Operating Cash Flow Conversion Ratio Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between 95% and 85%</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>85%</td>
<td>3%</td>
</tr>
<tr>
<td>Less than 85% of Adjusted Operating Profit</td>
<td>0%</td>
</tr>
</tbody>
</table>
b. For the purpose of this Operating Cash Flow Conversion Ratio Target:

i. the “Average Operating Cash Flow Conversion Ratio” is the aggregate of the Operating Cash Flow Conversion Ratios for each Financial Year in the Performance Period, divided by the number of Financial Years in the Performance Period; and

ii. the “Operating Cash Flow Conversion Ratio” for a Financial Year (expressed as a percentage) is calculated as follows:

\[
\text{Operating Cash Flow Conversion Ratio} = \left( \frac{\text{Operating Cash Flow}}{\text{Adjusted Operating Profit}} \right) \times 100
\]

Where:

“Operating Cash Flow” in respect of a Financial Year is the adjusted profit from operations (excluding associates) plus depreciation, amortisation and impairment, plus other non-cash items, less the increase / (decrease) in working capital, less net capital expenditure, in each case for such Financial Year. All of these items are excluding costs and movements relating to restructuring and integration in the Financial Year; and

“Adjusted Operating Profit” in respect of a Financial Year is derived by excluding the adjusting items from the profit from operations for such Financial Year. Adjusting items include restructuring and integration costs, amortisation and impairment of trademarks and similar intangibles, a gain on deemed partial disposal of a trademark and a payment and release of a provision relating to non-tobacco litigation.

For the purpose of this Operating Cash Flow Conversion Ratio Target, Operating Cash Flow and Adjusted Operating Profit are calculated at current rates of exchange, unless the Board determines otherwise.

7. TSR Target

a. The percentage of the Award Shares which may vest pursuant to the performance target in this paragraph 7 (the “TSR Target”) depends upon the Company’s Total Shareholder Return over the Performance Period relative to the Total Shareholder Return of the Comparator Group:

<table>
<thead>
<tr>
<th>Ranked position of the Company’s TSR against the relevant comparator companies</th>
<th>% of the Award Shares which vest pursuant to this TSR Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper quartile or above</td>
<td>20%</td>
</tr>
<tr>
<td>Between upper quartile and median</td>
<td>Pro-rata between 20% and 3%</td>
</tr>
<tr>
<td>Median</td>
<td>3%</td>
</tr>
<tr>
<td>Below median</td>
<td>0%</td>
</tr>
</tbody>
</table>
b. For the purpose of this TSR Target:

i. The Comparator Group shall comprise the following companies:

<table>
<thead>
<tr>
<th>Altria Group</th>
<th>PepsiCo Inc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anheuser-Busch InBev</td>
<td>Pernod Ricard</td>
</tr>
<tr>
<td>Carlsberg A/S</td>
<td>Philip Morris International</td>
</tr>
<tr>
<td>Coca-Cola</td>
<td>Procter &amp; Gamble</td>
</tr>
<tr>
<td>Diageo</td>
<td>Reckitt Benckiser</td>
</tr>
<tr>
<td>Heineken</td>
<td>Swedish Match</td>
</tr>
<tr>
<td>Imperial Brands</td>
<td>Unilever</td>
</tr>
<tr>
<td>Japan Tobacco</td>
<td></td>
</tr>
</tbody>
</table>

ii. The Total Shareholder Return of the Company and each of the relevant comparator companies over the relevant Performance Period (expressed as a percentage) shall be computed as follows:

\[
\left[ \left( \frac{\text{TSR}_0}{\text{TSR}_3} \right)^{\frac{1}{3}} - 1 \right] \times 100
\]

Where:

\( \text{TSR}_0 \) = the average return index of the relevant companies as calculated by Datastream (or other such data provider as determined by the Board) (excluding Saturdays and Sundays) in the three months preceding the beginning of the Performance Period; and

\( \text{TSR}_3 \) = the average return index (calculated in the same manner as for TSR\(_0\)) in the 3 months preceding the end of the Performance Period.

iii. Unless the Board determines otherwise, the Total Shareholder Return for the Company and each of the relevant comparator companies shall be calculated on a local currency basis.

iv. The Company and the companies in the Comparator Group shall be ranked by the resulting Total Shareholder Return figures, with the company with the highest figure having the highest ranking, and median and upper quartile performance shall be determined on such basis as the Board, acting reasonably, may specify from time to time.

8. Exchange rates

In this Schedule:

"current rates of exchange" means exchange rates applied for each year relevant to a given calculation based on the average exchange rate in that year; and

"constant rates of exchange" means exchange rates applied based on a re-translation, at prior year exchange rates, of the current year information, in order that the same exchange rates are applied for each year relevant to a given calculation.
9. Adjustment to vesting outcome
   a. After the performance targets in paragraphs 3 to 7 have been assessed, the Board may make such adjustment to the percentage of Shares of the Award Shares that vest pursuant to one or more of such performance targets to ensure a fair result for both the Participants and shareholders.
   b. An adjustment pursuant to this paragraph 9 may be either positive (but, for the avoidance of doubt, not so that the percentage of the Award Shares which vests pursuant to any one of the performance targets in paragraphs 3 to 7 exceeds the maximum percentage of the Award Shares which may vest pursuant to that performance target, as set out in paragraph 1) or negative (including reducing the percentage of Awards Shares which vest to nil). For the avoidance of doubt, where the Board makes any adjustment pursuant to this paragraph 9 the percentage of Award Shares to be transferred shall be the percentage as adjusted by the Board notwithstanding the outcome of the performance targets as set out in paragraphs 3 to 7.
   c. For the avoidance of doubt, vesting outcomes are subject to any forfeiture or reduction of Awards pursuant to Rule 15 (Claw-back).

10. Adjustments to performance targets
   a. In the event of:
      i. a change to the accounting standards of the Company or similar event;
      ii. any events which affect any of the companies comprised in the Comparator Group (such as a merger or de-listing);
      iii. any variation of capital of the Company or a demerger, delisting, special dividend, rights issue or other event which may, in the opinion of the Board, affect the current or future value of the Company's shares; or
      iv. any other similar event the Board considers relevant which may unduly affect the calculation of the performance targets set out in paragraphs 3 to 7,
      
the Board may make such adjustments to the terms of this Performance Condition as it determines appropriate to reflect such event with the intention of ensuring that this Performance Condition continues to assess the performance of the Company on a consistent basis over the Performance Period.
   b. This Performance Condition may be amended in accordance with Rule 5.4 of the Plan.

General

11. References in this Schedule 1D to a paragraph are to a paragraph of this Schedule 1D.
BRITISH AMERICAN TOBACCO P.L.C.

RULES

of the

BRITISH AMERICAN TOBACCO

2019 DEFERRED ANNUAL SHARE BONUS SCHEME

Adopted by the Board on 10 December 2018
and amended by the Board on 3 June 2019
and amended by the Board on 19 February 2021
and amended by the Board on 8 February 2022

Herbert Smith Freehills LLP

HSF Ref: 30889176
<table>
<thead>
<tr>
<th>Clause</th>
<th>Heading</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>INTERPRETATION AND CONSTRUCTION</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>SCHEME LIMITS</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>AWARDS</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>AWARDS ARE NON-TRANSFERABLE</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>ADDITIONAL VESTING CONDITION</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>VESTING</td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>CESSATION OF OFFICE OR EMPLOYMENT</td>
<td>6</td>
</tr>
<tr>
<td>8</td>
<td>CORPORATE ACTIONS</td>
<td>7</td>
</tr>
<tr>
<td>9</td>
<td>DIVIDEND EQUIVALENT</td>
<td>8</td>
</tr>
<tr>
<td>10</td>
<td>CASH ALTERNATIVE</td>
<td>9</td>
</tr>
<tr>
<td>11</td>
<td>TAX LIABILITY</td>
<td>9</td>
</tr>
<tr>
<td>12</td>
<td>VESTED SHARE ACCOUNTS</td>
<td>10</td>
</tr>
<tr>
<td>13</td>
<td>CLAW-BACK</td>
<td>10</td>
</tr>
<tr>
<td>14</td>
<td>VARIATION OF CAPITAL</td>
<td>11</td>
</tr>
<tr>
<td>15</td>
<td>ADMINISTRATION</td>
<td>12</td>
</tr>
<tr>
<td>16</td>
<td>AMENDMENTS</td>
<td>12</td>
</tr>
<tr>
<td>17</td>
<td>DATA PROTECTION</td>
<td>12</td>
</tr>
<tr>
<td>18</td>
<td>GENERAL</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>APPENDIX 1: OPERATION OF CLAW-BACK</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>APPENDIX 2: AWARDS GRANTED TO U.S. TAXPAYERS</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>1. INTERPRETATION</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>2. APPLICATION</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>3. TERMS OF AWARD</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>4. DELIVERY OF SHARES</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>5. DIVIDEND EQUIVALENT</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>6. CASH ALTERNATIVE</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>7. CLAWBACK</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>8. CODE SECTION 409A</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>ADDENDUM 1: AWARDS GRANTED TO RAI PARTICIPANTS</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>1. APPLICATION</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>2. MODIFICATION</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>3. RETIREMENT PLAN</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>4. TERMS</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>5. SETTLEMENT</td>
<td>20</td>
</tr>
</tbody>
</table>
RULES OF THE BRITISH AMERICAN TOBACCO P.L.C. DEFERRED ANNUAL SHARE BONUS SCHEME

1. INTERPRETATION AND CONSTRUCTION

1.1 For the purposes of the Scheme, the following terms shall have the meaning indicated below unless the context clearly indicates otherwise:

“Additional Vesting Condition” means any additional condition determined by the Board under Rule 5 (Vesting Condition) to which the vesting of any Award is subject.

“Award” means a right to receive a transfer of Shares following vesting of the Award;

“Board” means the board of directors of the Company or a committee duly authorised by the board of directors or, following any Corporate Action, the Board or duly authorised committee as constituted immediately prior to the Corporate Action;

“Claw-back” means a recovery of value by the Company from a Participant in accordance with the provisions of Rule 13 (Claw-back) and Appendix 1 (Operation of Claw-back);

“Company” means British American Tobacco p.l.c. (registered in England and Wales under No. 3407696);

“Control” has the meaning given by Section 995 of the Income Tax Act 2007;

“Corporate Action” means any of the events referred to in:

(A) Rules 8.1 to 8.5 (but excluding a Reorganisation as defined in Rule 8.7); or
(B) if the Board determines that Awards will vest pursuant to such Rule, Rule 8.6;

“Cross-Border Merger” means a merger pursuant to the implementation in any relevant jurisdiction of Directive 2005/56/EC (on cross-border mergers of limited liability companies);

“Dealing Day” means any day on which the London Stock Exchange is open for trading;

“Dealing Restriction” means any restriction on the dealing in shares, whether direct or indirect, pursuant to any law, regulation, code or enactment in England and Wales and/or the jurisdiction in which the Participant is resident, or any share dealing code of the Company;

“Eligible Employee” means an employee or former employee (including an executive director) of any Group Company;

“Employees’ Share Scheme” has the meaning given by Section 1166 of the Companies Act 2006;

“Financial Year” means the financial year of the Company within the meaning of Section 390 of the Companies Act 2006;

“Grant Date” means the date on which an Award is granted;

“Group” means the Company and any company which from time to time is a subsidiary of the Company, within the meaning of section 1159 of the Companies Act 2006 (each a “Group Company”);

“Market Value” means, in relation to a Share on any day, the mid-closing price of a Share on such day (as derived from the Daily Official List of the London Stock Exchange);

“Normal Vesting Date” means the third anniversary of the Grant Date or any later date determined by the Board;

“Participant” means an Eligible Employee who has received an Award to the extent it has not been released and has not lapsed (or, following his death, his Personal Representatives);

“Personal Representatives” means, following his death, the Participant’s personal representatives, or a person fulfilling a similar function in any jurisdiction;
“Rule” means a rule of this Scheme;
“Scheme” means this British American Tobacco 2019 Deferred Annual Share Bonus Scheme, as amended from time to time;
“Share” means a fully paid ordinary share in the capital of the Company;
“Treasury Shares” means Shares to which Sections 724 to 732 of the Companies Act 2006 apply;
“Trust” means any employee benefit trust from time to time established by the Company;
“U.S. Taxpayer” has the meaning given in Rule 3.10 (U.S. Taxpayers); and
“vesting” means Shares subject to an Award becoming due to be transferred to the Participant (and “vest” shall be construed accordingly).

1.2 In this Scheme unless the context requires otherwise:

1.2.1 the headings are inserted for convenience only and do not affect the interpretation of any Rule;
1.2.2 a reference to a statute or statutory provision includes a reference:
   (A) to that statute or statutory provision as from time to time consolidated, modified, re-enacted or replaced by any statute or statutory provision;
   (B) to any repealed statute or statutory provision which it re-enacts (with or without modification); and
   (C) to any subordinate legislation made under it;
1.2.3 words in the singular include the plural, and vice versa;
1.2.4 a reference to the masculine shall be treated as a reference to the feminine and vice versa;
1.2.5 a reference to a person shall include a reference to a body corporate; and
1.2.6 a reference to writing or written form shall include any legible format capable of being reproduced on paper, irrespective of the medium used.

1.3 In this Scheme:

1.3.1 a provision obliging, or permitting, any company to do any thing shall be read as obliging, or permitting, such company to do that thing, or procure that thing to be done; and
1.3.2 the use of the word “including” shall mean including without limitation and without prejudice to the generality of the foregoing.

2. SCHEME LIMITS

2.1 No Shares may be issued and no Treasury Shares may be transferred for the purposes of the Scheme.

3. AWARDS

Eligibility

3.1 The Scheme shall operate in connection with the award of annual bonuses to such Eligible Employees as may be determined by the Board.

Bonus deferral

3.2 Prior to the amount of an Eligible Employee’s annual bonus being determined, the Board may specify a proportion of the Eligible Employee’s annual bonus that shall be deferred. An Eligible Employee shall have no entitlement to receive the proportion of the annual bonus that is deferred under this Rule 3.2.
3.3 The Board shall grant to an Eligible Employee whose annual bonus is subject to deferral under Rule 3.2 an Award over such number of Shares as have an aggregate Relevant Value on the Grant Date equal to the proportion of the Eligible Employee’s annual bonus that is deferred under Rule 3.2.

In this Rule 3.3, the “Relevant Value” of a Share subject to an Award means either (as determined by the Board): (i) the Market Value of a Share on the Dealing Day immediately preceding the Grant Date; or (ii) the average of the Market Values of a Share over such number of Dealing Days preceding the Grant Date as the Board may determine.

3.4 Where an Eligible Employee’s annual bonus is denominated in a currency other than pounds sterling, for the purposes of Rule 3.3 above such annual bonus amount shall be converted into pounds sterling on such basis as the Board may reasonably determine.

Method of grant

3.5 An Award shall be granted by the Board.

3.6 An Award shall be granted by deed.

3.7 No payment for the grant of an Award shall be made by the Participant.

3.8 A Participant may within 30 days of the Grant Date release an Award (in full but not in part) by written notice to the Company. Where a Participant does not release an Award within such period, the Participant shall be deemed to have accepted the Award on the terms set out in the Rules. Alternatively, it may be a term of the grant of an Award that the Participant shall be required to accept the terms of the Award within such period following grant as may be determined by the Board and, where the Board specifies such period, the Award shall lapse at the end of such period if the terms of the Award have not been accepted by the Participant.

Award notification

3.9 As soon as practicable following the Grant Date the Company shall notify a Participant of the grant of an Award. Such notification shall specify:

3.9.1 the Grant Date;
3.9.2 the Normal Vesting Date;
3.9.3 the number of Shares in respect of which the Award is granted;
3.9.4 if applicable, details of any Additional Vesting Condition;
3.9.5 if applicable, that the dividend equivalent provisions of Rule 9 (Dividend equivalent) shall apply; and
3.9.6 that the Award is subject to the claw-back provisions of Rule 13 (Claw-back) and Appendix 1 (Operation of Claw-back).

U.S. Taxpayers

3.10 The provisions of Appendix 2 (Awards Granted to U.S. Taxpayers) shall apply to an Award that is held by any Participant while he or she is subject to taxation under the U.S. Internal Revenue Code of 1986, as amended (“U.S. Taxpayers”).

4. AWARDS ARE NON-TRANSFERABLE

4.1 A Participant may not transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, any part of his interest in an Award. An Award shall (unless the Board determines otherwise) lapse on the Participant doing so (whether voluntarily or involuntarily), being deprived of the beneficial ownership of an Award by operation of law, or becoming bankrupt.

4.2 Rule 4.1 does not restrict the transmission of an Award to the Participant’s Personal Representatives following his death.
5. ADDITIONAL VESTING CONDITION

The vesting of an Award shall be subject to such additional condition as the Board may determine.

6. VESTING

Normal vesting

6.1 An Award shall vest on the Normal Vesting Date.

Vesting subject to Dealing Restrictions

6.2 An Award shall not vest unless, and vesting shall be delayed until, the Board is satisfied that at that time:

6.2.1 such vesting;

6.2.2 the transfer of Shares to the Participant and the sale of Shares pursuant to Rule 11 (Tax Liability); and

6.2.3 any action needed to be taken by the Company to give effect to such vesting

is not contrary to any Dealing Restriction.

Extent of vesting

6.3 Where an Award vests it shall vest in full, save that the extent to which an Award which is subject to an Additional Vesting Condition shall be capable of vesting (if at all) shall, unless the Board determines otherwise, be determined by reference to the extent to which such Additional Vesting Condition is satisfied, and at the end of any period over which an Additional Vesting Condition is assessed the Award shall lapse to the extent that such Additional Vesting Condition is not met.

6.4 Where an Award which is subject to an Additional Vesting Condition becomes capable of vesting (pursuant to Rule 6.7 (International transfers), 7 (Cessation of employment) or 8 (Corporate Actions) prior to the end of the period over which any element of the Additional Vesting Condition is assessed, such element may be assessed on such basis as the Board shall determine.

Effect of vesting

6.5 The effect of the vesting of an Award is that the Shares in respect of which an Award vests shall be transferred to the Participant as soon as is reasonably practicable (which may include transferring the Shares on more than one consecutive Dealing Day on such basis as the Board may determine).

Disciplinary proceedings

6.6 Unless the Board determines otherwise, an Award shall not vest while a Participant is subject to an investigation process and/or formal disciplinary process (or similar), or where a Participant has been served with notice that such a process may be instigated without such notice having been rescinded, and vesting shall (subject to the Award lapsing to any extent prior to or as a result of the conclusion of such process pursuant to Rule 7 (Cessation of office or employment) or 13 (Claw-back)) be delayed until the conclusion of such process.

International transfers

6.7 Where a Participant, whilst continuing to hold an office or employment with a Group Company, is to be transferred to work in another country, and as a result the Board considers that following such transfer either he or a Group Company is likely to suffer a tax disadvantage in respect of an Award or, due to securities or exchange control laws, the Participant is likely to be restricted in his ability to receive Shares pursuant to an Award
and/or to hold or deal in Shares, the Board may decide that an Award shall vest on such date as it may determine, in which case the proportion of the Award which may vest shall be limited (unless the Board determines otherwise) to a pro rata proportion on the basis of the number of months (rounded up to the nearest whole month) which have elapsed from the Grant Date to such vesting date, as compared to the number of whole months within the period from the Grant Date to the Normal Vesting Date. Any remainder of the Award shall lapse.

7. **CESSATION OF OFFICE OR EMPLOYMENT**

   **Cessation where Awards lapse**

   7.1 An Award shall lapse:

   7.1.1 on the Participant ceasing to hold office or employment with any Group Company; or

   7.1.2 if the Participant gives or receives notice of such cessation, on such earlier date as may be determined by the Board, save in each case where Rule 7.2 or Rule 7.4 applies.

   **Reasons for cessation where Awards remain capable of vesting**

   7.2 An Award shall not lapse pursuant to Rule 7.1 where the reason for the cessation or notice is:

   7.2.1 disability, ill-health or injury (as evidenced to the satisfaction of the Board);

   7.2.2 redundancy (within the meaning of the Employment Rights Act 1996);

   7.2.3 the transfer of the Participant’s employment in connection with the disposal of a business or undertaking, or a part-business or part-undertaking;

   7.2.4 the company with which the Participant holds office or employment ceasing to be a Group Company; or

   7.2.5 any other reason, if the Board so determines.

   Where the Board exercises its discretion under Rule 7.2.5 the Board may impose additional conditions on the Award (including as to when the Award may vest).

   **Cessation prior to the Normal Vesting Date**

   7.3 Where prior to the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons specified in Rule 7.2 an Award shall vest on the date of such cessation, unless the Board determines that the Award shall not vest at such time and shall instead continue to be capable of vesting in accordance with the Rules.

   For the avoidance of doubt, the Board may make the determination in this Rule 7.3 on a standing basis (subject to revocation of such determination at any time) in respect of all Awards to be granted to a specified Eligible Employee or Eligible Employees.

   **Death**

   7.4 An Award shall vest on the Participant’s death.

   **Meaning of cessation of office or employment**

   7.5 No provision of this Rule 7 shall apply in respect of any cessation of office or employment if immediately following the cessation the Participant holds an office or employment with any Group Company, or in respect of any notice of cessation if arrangements are in place that mean immediately following the notice becoming effective the Participant will hold an office or employment with any Group Company.
Cessation of office or employment prior to grant

7.6 The provisions of Rules 6.6, 6.7, 7.1, 7.2 and 7.3 shall not apply to Awards granted to a Participant following the date on which the Participant ceased to hold office or employment with any Group Company.

8. CORPORATE ACTIONS

General offers

8.1 Awards shall vest:

8.1.1 upon a person obtaining Control of the Company as a result of making a general offer to acquire Shares;

8.1.2 upon a person, having obtained Control of the Company, making a general offer to acquire Shares; or

8.1.3 if a person makes a general offer to acquire Shares that would result in that person obtaining Control of the Company and the Board so determines, on the date which the Board determines to be the last practicable date prior to the date on which it expects such person to obtain Control of the Company,

in each case being a general offer to acquire all of the Shares (other than Shares held by the person making the offer and any person connected to that person).

Compulsory acquisition

8.2 Awards shall vest upon a person becoming entitled to acquire Shares under Sections 979 to 982 of the Companies Act 2006.

Scheme of compromise or arrangement

8.3 Awards shall vest upon a Court sanctioning a compromise or arrangement which, on becoming effective, would result in:

8.3.1 any person obtaining Control of the Company;

8.3.2 the undertaking, property and liabilities of the Company being transferred to another existing or new company; or

8.3.3 the undertaking, property and liabilities of the Company being divided among and transferred to two or more companies, whether existing or new.

Merger

8.4 Awards shall vest upon a competent authority approving a Cross-Border Merger, pursuant to which the Company shall cease to exist.

Voluntary winding-up

8.5 Awards shall vest in the event of a notice being given of a resolution for the voluntary winding-up of the Company.

Demerger or special dividend

8.6 If the Board so determines, Awards may vest following the announcement of a demerger of a substantial part of the Group’s business, a special dividend or a similar event affecting the value of Shares to a material extent on such date specified by the Board.
Roll-over of Award on a Reorganisation or takeover

8.7 Unless the Board determines otherwise, an Award shall not vest pursuant to this Rule 8 if, as a result of any event that would otherwise be a Corporate Action, a company will obtain Control of the Company or will obtain substantially all of the assets of the Company (the “Acquiring Company”), and either:

8.7.1 the Acquiring Company will immediately following such event have (either directly or indirectly) substantially the same shareholders and approximate shareholdings as those of the Company prior to such event (a “Reorganisation”); or

8.7.2 the Board, with the agreement of the Acquiring Company, determines that the Award shall not vest as a result of such event and so notifies the Participant prior to the occurrence of the date on which the Award would otherwise vest.

In such case the existing Award (the “Old Award”) shall lapse on the occurrence of the relevant event, provided that the New Parent Company shall grant a replacement right to receive shares (the “New Award”) over such number of shares in the New Parent Company which are of equivalent value to the number of Shares in respect of which the Old Award was outstanding. The New Award shall be granted on the terms of the Scheme, but as if the New Award had been granted at the same time as the Old Award.

For the purposes of this Rule 8.7:

8.7.3 the “New Parent Company” shall be the Acquiring Company, or, if different the company that is the ultimate parent company of the Acquiring Company within the meaning of section 1159 of the Companies Act 2006; and

8.7.4 the terms of the Scheme shall following the date of the relevant event be construed as if the reference to “British American Tobacco p.l.c.” in the definition of “Company” in Rule 1 (Interpretation and construction) were a reference to the company which is the New Parent Company.

Compulsory winding-up

8.8 An Award shall lapse on the passing of an effective resolution, or the making of a Court order, for the compulsory winding-up of the Company.

Concert parties

8.9 For the purposes of this Rule 8, a person shall be deemed to have Control of the Company where he and any others acting in concert with him together have Control of the Company.

9. DIVIDEND EQUIVALENT

9.1 If at any time in the period between the Grant Date and the date on which the Award vests a dividend is declared on Shares, the Company shall, unless the Board determines otherwise:

9.1.1 make a cash payment to the Participant equal to the amount of such dividend the Participant would have received in respect of the number of Shares which are subject to the Award had the Participant been the full legal and beneficial owner of such Shares on the record date of such dividend; or

9.1.2 transfer to the Participant such number of Shares as have an aggregate Market Value on the date on which the relevant dividend is paid equal to the amount determined in accordance with Rule 9.1.1 above.

9.2 Any cash payment or transfer of Shares under Rule 9.1 will be made by the Company to the Participant as soon as reasonably practicable following the date on which the relevant dividend is paid, unless the Board determines that such amount shall instead be payable or such Shares shall be transferred when (and to the extent that) the Award vests.

9.3 A cash payment under Rule 9.1 may be made in a currency other than pounds sterling, in which case the amount of such payment shall be converted into such other currency on such basis as is determined by the Board.
10. **CASH ALTERNATIVE**

10.1 This Rule 10 shall not apply in respect of any Award granted to a Participant resident in any jurisdiction where the grant of an Award which provides for a cash alternative would be unlawful, fall outside any applicable exemption under securities, exchange control or similar regulations, or would cause adverse tax or social security (or similar) contribution consequences for the Company or the Participant (in each case as determined by the Board) or where the Board determines prior to the Grant Date that this Rule 10 shall not apply.

10.2 The Board may determine prior to the Grant Date that an Award shall only be satisfied in cash, in which case the Award shall not be a right to acquire Shares, and the vesting of the Award shall be satisfied in full by the payment of a cash equivalent amount, in substitution for the transfer of Shares.

10.3 Where the Board has made no determination pursuant to Rule 10.1 or 10.2 in respect of any Award the Board may determine at any time prior to the transfer of Shares pursuant to such Award that the vesting of the Award (or a part thereof) shall be satisfied by the payment of a cash equivalent amount, in substitution for the transfer of Shares.

10.4 A "cash equivalent amount" shall be calculated as the number of Shares which would otherwise be transferred in respect of the relevant vesting but which are being substituted for the cash equivalent amount, multiplied by the Market Value of a Share on the date on which the Award vests (or, where only a part of the Award is to be satisfied with payment of a cash equivalent amount, on the date on which Shares are transferred to the Participant pursuant to the Award).

10.5 A cash equivalent amount shall be paid as soon as reasonably practicable following the relevant vesting.

10.6 A cash equivalent amount may be paid in a currency other than pounds sterling, in which case the cash equivalent amount shall be converted into such other currency on such basis as is determined by the Board.

11. **TAX LIABILITY**

11.1 When any Tax Liability arises in respect of an Award, the Participant authorises any Group Company:

11.1.1 to retain and sell legal title to such number of the Shares which would otherwise have been transferred to the Participant (notwithstanding that beneficial title shall pass) as may be sold for aggregate proceeds equal to the Group Company’s estimate of the amount of the Tax Liability;

11.1.2 to deduct an amount equal to the Group Company’s estimate of the Tax Liability from any cash payment made under the Scheme; and/or

11.1.3 where the amount realised under Rule 11.1.1 or deducted under Rule 11.1.2 is insufficient to cover the full amount of the Tax Liability, to deduct any further amount as is necessary through payroll,

and in each case to apply such amount in paying the amount of the Tax Liability to the relevant revenue authority or in reimbursing the relevant Group Company for any such payment, provided that, where the amount realised under Rule 11.1.1 or deducted under Rule 11.1.2 is greater than the actual Tax Liability, the Group Company shall repay the excess to the Participant as soon as reasonably practicable.

The Group Company shall be entitled to make the estimates referred to in this Rule 11.1 on the basis of the highest rates of tax and/or social security applicable at the relevant time in the jurisdiction in which the Group Company is liable to account for the Tax Liability, notwithstanding that the Tax Liability may not arise at such rates.
11.2 “Tax Liability” shall mean any amount of tax and/or social security (or similar) contributions which any Group Company becomes liable to pay on behalf of the Participant to the revenue authorities in any jurisdiction, together with all or such proportion (if any) of employer’s social security contributions which would otherwise be payable by any Group Company as is determined to be recoverable from the Participant (to the extent permitted by law) by the Board, or which the Participant has agreed to pay or which are subject to recovery pursuant to an election to which paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992 applies.

12. VESTED SHARE ACCOUNTS

12.1 Legal title to any Shares which are due to be transferred to the Participant pursuant to the Scheme may be transferred to a person (the “Vested Share Account Provider”) appointed by the Company from time to time to hold legal title to such Shares on behalf of the Participant.

12.2 The Vested Share Account Provider shall receive and hold Shares on behalf of the Participant in accordance with such terms and conditions as are agreed by the Company from time to time, and by participating in the Scheme the Participant irrevocably agrees to those terms and conditions (which shall be available to the Participant on request to the Company).

12.3 The transfer of any Shares to the Vested Share Account Provider shall satisfy any obligation of the Company under the Scheme to transfer Shares to the Participant (and references in the Scheme to Shares (or legal title thereof) having been transferred to the Participant shall be read accordingly).

12.4 The terms and conditions referred to in Rule 12.2 above may include terms that the Participant shall not be entitled to transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, some or all of the Shares if to do so would be in breach of the Participant’s obligations under the Company’s shareholding requirements as they apply to such Participant.

13. CLAW-BACK

Claw-back events

13.1 The Board may at any time prior to the third anniversary of the Grant Date of an Award determine that a Claw-back shall apply in respect of the Award, if the Board determines that:

13.1.1 there has been a material misrepresentation in relation to the performance of any Group Company, relevant business unit and/or the Participant on the basis of which the extent to which the annual bonus in respect of which the Award was granted was determined (which may include, but shall not be limited to: (i) a misstatement of the financial results and/or health of any Group Company; (ii) an erroneous calculation in relation to any Group Company’s results or other performance benchmark; (iii) errors in any Group Company’s financial statements; or (iv) discrepancies in the financial accounts, and, for the avoidance of doubt, notwithstanding that such misrepresentation may not arise from fraud or reckless behaviour); or

13.1.2 an erroneous calculation was made in assessing the amount of such annual bonus or the number of Shares over which the Award was granted,

and, in either case the annual bonus was awarded and/or the Award was granted to a greater extent than would have been the case had there not been such a misrepresentation or had such error not been made, or

13.1.3 there has been a significant failure within any Group Company which has a material impact on the value of the Group (taken as a whole), including but not limited to circumstances where the Company or any other Group Company has entered into an involuntary administration or insolvency process or there has been a significant reduction in, or cessation of, the ability of any material Group Company (or group of Group Companies) to continue normal operations.
13.2 The Board may at any time prior to legal title to Shares having been transferred to the Participant pursuant to an Award determine that a Claw-back shall apply in respect of the Award if the Board determines that any event has occurred which justifies such application of Claw-back.

13.3 The Board may at any time (whether before or after vesting) determine that a Claw-back shall apply in respect of an Award where the Participant is found to have:

13.3.1 committed at any time prior to the vesting of the Award, including prior to grant, an act or omission which justifies, or in the opinion of the Board would have justified, summary dismissal or service of notice of termination of office or employment on the grounds of misconduct;

13.3.2 engaged in, at any time prior to the vesting of the Award:

(A) reckless, negligent or wilful action or inaction; or

(B) inappropriate behaviour or behaviour that is not aligned with any employee policy or handbook or Group values, and in either case the Board determines that such circumstances have contributed to a material loss for any Group Company; or

13.3.3 contributed, at any time prior to vesting of the Award, to circumstances which give rise to a sufficiently negative impact on the reputation of any Group Company or business unit (or would have if such circumstances had been made public).

13.4 Rules 13.1.3, 13.3.2 and 13.3.3 shall only apply to Awards granted on or after 1 January 2022.

Applying Claw-back

13.5 A Claw-back shall be applied in accordance with the provisions of Appendix 1 (Operation of Claw-back).

Lapse of Awards to give effect to claw-back of other awards

13.6 By participating in the Scheme, the Participant acknowledges that the Board may lapse any Award to such extent as it determines to be necessary (including in full) in order to give effect to a claw-back under the terms of the Scheme or any other Employees’ Share Scheme or bonus scheme operated from time to time by any Group Company.

No Claw-back following Corporate Action

13.7 No Claw-back shall be capable of being applied at any time following any Corporate Action, save where the determination that the Claw-back shall apply was made prior to such event (and, for the avoidance of doubt, a Corporate Action does not include a Reorganisation).

Interaction with the cash bonus schemes

13.8 No provision of the rules of this Scheme relating Claw-back shall in any way limit or restrict, or be limited or restricted by, the operation of any provision of any cash bonus scheme or similar operated by any Group Company from time to time.

14. VARIATION OF CAPITAL

14.1 In the event of any variation of the share capital of the Company, or in the event of the demerger of a substantial part of the Group’s business, a special dividend or similar event affecting the value of Shares to a material extent (which shall not include the payment of any ordinary dividend) the Board may make such adjustments to Awards as it may determine to be appropriate.
14.2 For the avoidance of doubt Rule 14.1 shall not apply in respect of any Awards pursuant to which legal title to Shares has been transferred prior to the date of the relevant event (such that the recipient of such legal title shall participate in such event as a holder of Shares) including pursuant to the vesting of an Award under Rule 8.6 (Demerger or special dividend).

15. **ADMINISTRATION**
15.1 Any notice or other communication under or in connection with this Scheme may be given by the Company (or its agents) to a Participant personally, by email or by post, or by a Participant to the Company or any Group Company either personally or by post to the Secretary of the Company. Items sent by post shall be pre-paid and shall be deemed to have been received 48 hours after posting. Items sent by email shall be deemed to have been received immediately.

15.2 A Participant shall not be entitled to:
   - 15.2.1 receive copies of accounts or notices sent to holders of Shares;
   - 15.2.2 exercise voting rights; or
   - 15.2.3 receive dividends,
   in respect of Shares subject to an Award legal title to which has not been transferred to the Participant.

15.3 Any discretion (including the power to make any determination) of the Board under or in connection with the Scheme may be exercised by the Board in its absolute discretion.

15.4 Any exercise of discretion (including the making of any determination) by the Board under or in connection with the Scheme shall be final and binding.

15.5 Any disputes regarding the interpretation of the Rules or the terms of any Award shall be determined by the Board (upon such advice as the Board determines to be necessary) and any decision in relation thereto shall be final and binding.

16. **AMENDMENTS**
16.1 Subject to Rule 16.2, the Board may at any time add to or alter the Scheme or any Award made thereunder in any respect.

16.2 No alteration or addition shall be made under Rule 16.1 which would abrogate or adversely affect the subsisting rights of a Participant unless it is made:
   - 16.2.1 with the consent in writing of the Participant;
   - 16.2.2 with the consent in writing of such number of Participants as hold Awards under the Scheme in relation to 75 per cent. of the Shares subject to all Awards under the Scheme; or
   - 16.2.3 by a resolution at a meeting of Participants passed by not less than 75 per cent. of the Participants who attend and vote either in person or by proxy,
   and for the purpose of Rule 16.2.2 or 16.2.3 the Participants shall be treated as the holders of a separate class of share capital and the provisions of the Articles of Association of the Company relating to class meetings shall apply mutatis mutandis.

17. **DATA PROTECTION**
17.1 From time to time the personal data of the Participant will be collected, used, stored, transferred and otherwise processed for the purposes described in Rule 17.2 and 17.3. The legal grounds for this processing will (depending on the nature and purpose of any specific instance of processing) be one of: (i) such processing being necessary for the purposes of the legitimate interests of the Company and each other Group Company in incentivising their officers and employees and operating the Scheme; (ii) such processing being necessary for the purposes of any relevant data controller in respect of such personal data complying with its legal obligations; and (iii) such processing being necessary for the performance of the contractual obligations arising under the Scheme. The collection and processing of such personal data for such purposes is a contractual requirement of participation in the Scheme.
17.2 The purposes for which personal data shall be processed as referred to in this Rule 17 shall be in order to allow the Company and any other relevant Group Companies to incentivise their officers and employees and to operate the Scheme and to fulfil its or their obligations to the Participant under the Scheme, and for other purposes relating to or which may become related to the Participant’s office or employment, the operation of the Scheme or the business of the Group or to comply with legal obligations. Such processing will principally be for, but will not be limited to, personnel, administrative, financial, regulatory or payroll purposes as well as for the purposes of introducing and administering the Scheme.

17.3 The personal data to be processed as referred to in this Rule 17 may be disclosed or transferred to, and/or processed by:

17.3.1 any professional advisors of any Group Company, HM Revenue & Customs or any other revenue, regulatory or governmental authorities;

17.3.2 a trustee of a Trust; any registrars, brokers, payroll provider or other third party administrator appointed in connection with any employee share or incentive plans operated by any Group Company; or any person appointed (whether by the Participant or any Group Company) to act as nominee on behalf of (or provide a similar service to) the Participant;

17.3.3 subject to appropriate confidentiality undertakings, any prospective purchasers of, and/or any person who obtains control of or acquires, the Company or the whole or part of the business of the Group; or

17.3.4 any Group Company and officers, employees or agents of such Group Company.

17.4 Further information in relation to the processing of personal data referred to in this Rule 17, including the details and identity of the data controller and of the Participant’s rights in respect of such personal data, is available in the Employee Data Protection Policy (or otherwise on request to the Company Secretary).

17.5 To the extent that the processing of personal data of a Participant referred to in this Rule 17 is subject to the laws or regulations of any jurisdiction that is not an EU member state and under which the legal grounds for processing described in Rule 17.1 do not provide a sufficient legal basis under such other laws or regulations for the processing referred to in Rule 17.1 to 17.3, by participating in the Scheme such Participant consents to such processing for the purposes of such other laws or regulations (but shall not be deemed to consent to such processing for the purposes of EU Regulation 2016/679).

17.6 In this Rule 17, “personal data” and “data controller” each have the meaning given in EU Regulation 2016/679 and “Employee Data Protection Policy” means such privacy policy or similar operated by any Group Company in relation to the processing of personal data as amended from time to time and as is applicable to the Participant.

18. GENERAL

18.1 In the event of any discrepancy between these Rules in English and (i) any copy of these Rules translated into any other language; or (ii) any communications, notices or materials issued in connection with this Scheme, these Rules in English shall prevail.

18.2 The Board may at any time, and without notice to any person, discontinue and terminate the Scheme, provided that such termination shall be without prejudice to any subsisting rights of Participants.

18.3 Save as otherwise provided under the Scheme Shares to be transferred pursuant to the Scheme will be transferred free of all liens, charges and encumbrances and together with all rights attaching thereto, except they will not rank for any rights attaching to Shares by reference to a record date preceding the date of transfer.
18.4 Any transfer of Shares under the Scheme is subject to such consent, if any, of any authorities in any jurisdiction as may be required, and the Participant shall be responsible for complying with the requirements to obtain or obviate the necessity for such consents.

18.5 The terms of any individual’s office or employment with any past or present Group Company, and the rights and obligations of the individual thereunder, shall not be affected by his participation in the Scheme and the Scheme shall not form part of any contract of employment between the individual and any such company.

18.6 An Eligible Employee shall have no right to participate in the Scheme and participation in the Scheme is at the discretion of the Company.

18.7 Participation in the Scheme by, or any Award under it to, a Participant in any year does not create any right to or expectation of participation in the Scheme or the grant of any award in any future year, even if the Participant has previously participated in the Scheme (or any similar scheme) over a long period of time and/or if participation in the Scheme and/or an Award under it (or any similar scheme) has been granted (including repeatedly) without the relevant Group Company specifically expressing the voluntary and discretionary nature at the time of each such participation or award.

18.8 By participating in the Scheme, the Participant waives all and any rights to compensation or damages in consequence of the termination of his office or employment with any past or present Group Company for any reason whatsoever, whether lawfully or otherwise, insofar as those rights arise or may arise from his ceasing to have rights under the Scheme (including ceasing to be entitled to exercise any Option) as a result of such termination, or from the loss or diminution in value of such rights or entitlements, including by reason of the operation of the terms of the Scheme, any determination by the Board pursuant to a discretion contained in the Scheme or the provisions of any statute or law relating to taxation.

18.9 Benefits under the Scheme shall not form part of a Participant’s remuneration for any purpose and shall not be pensionable.

18.10 The invalidity or non-enforceability of any provision or Rule of the Scheme shall not affect the validity or enforceability of the remaining provisions and Rules of the Scheme which shall continue in full force and effect.

18.11 These Rules shall be governed by and construed in accordance with English Law.

18.12 The English courts shall have exclusive jurisdiction to determine any dispute which may arise out of, or in connection with, the Scheme.
APPENDIX 1: OPERATION OF CLAW-BACK

Claw-back prior to the transfer of Shares in respect of an Award (or “malus”)

1. Where the Board determines (pursuant to Rule 13 (Claw-back)) that a Claw-back shall apply in respect of an Award prior to legal title to Shares having been transferred to the Participant pursuant to the Award (whether before or after vesting), the Claw-back shall be applied by the Board reducing the number of Shares in respect of which the Award may vest (or after vesting by reducing the number of Shares legal title to which may be transferred pursuant to the Award) by up to the number of Shares determined by the Board to be the excess number of Shares in respect of which the Award was granted and/or is outstanding (and the Award shall lapse to the extent so reduced, which may be in full).

Claw-back following the transfer of Shares in respect of an Award

2. Where the Board determines (pursuant to Rule 13 (Claw-back)) that a Claw-back shall apply in respect of an Award following legal title to Shares having been transferred to the Participant pursuant to the Award (a “Post-Transfer Claw-back”), the Board shall determine:
   a. the excess number of Shares in respect of which the Award vested (the “Excess Shares”); and
   b. the aggregate Market Value of such Excess Shares (as determined by the Board) on the date on which the Award vested (the “Equivalent Value”).

3. In the case of a Post-Transfer Claw-back any cash payment made pursuant to Rule 9 (Dividend equivalent) in respect of such Award shall be subject to the Claw-back to the extent that the Board determines that such cash payment or Shares relate to the Excess Shares.

4. A Post-Transfer Claw-back may be effected in such manner as may be determined by the Board, and notified to the Participant, including by any one or more of the following:
   a. by reducing the number of Shares and/or amount of cash in respect of which an Outstanding Award vests or may vest (or has vested, but in respect of which no Shares have yet been transferred or cash payment made), whether before or after the assessment of performance conditions in respect of such Outstanding Award, by the number of Excess Shares and/or the Equivalent Value (and such Outstanding Award shall lapse to the extent so reduced);
   b. by setting-off against any amounts payable by any Group Company to the Participant an amount up to the Equivalent Value (including from any bonus payment which may otherwise become payable to the Participant); and/or
   c. by requiring the Participant to immediately transfer to the Company a number of Shares equal to the Excess Shares or a cash amount equal to the Equivalent Value (which shall be an immediately payable debt due to the Company), provided that the Board may reduce the number of Excess Shares or the amount of the Equivalent Value subject to the Claw-back in order to take account of any Tax Liability (as defined in Rule 11 (Tax Liability)) which arose on the Excess Shares (howsoever delivered to the Participant).

5. For the avoidance of doubt, nothing in Rule 13 (Clawback) or this Appendix shall in any way restrict a Participant from being able to transfer or otherwise deal in Shares acquired on vesting of an Award.
6. In paragraph 4 above:

“Outstanding Award” means any other Award under the Scheme, any award or option under any other Employees’ Share Scheme operated from time to time by any Group Company (other than any award or option granted under any arrangement which satisfies the provisions of Schedules 2 or 3, or (unless the terms of such arrangement state that shares acquired thereunder are subject to claw-back) 4 or 5, of the Income Tax (Earnings and Pensions) Act 2003), or any bonus award under any bonus scheme operated from time to time by any Group Company, in each case which is either held by the Participant at the time of a determination that a Claw-back shall be applied or which are granted to the Participant following such a determination; and

“vests” shall include shares or cash subject to an award becoming due to be transferred or paid, and in the case of an option, the option becoming exercisable.
1. INTERPRETATION

1.1 This Appendix shall form part of the Rules of the Scheme.

1.2 In this Appendix a reference to a “Paragraph” is to a paragraph of this Appendix.

1.3 Capitalized terms used in this Appendix that are not otherwise defined in this Appendix shall have the meanings set forth in the Scheme.

2. APPLICATION

2.1 This Appendix contains provisions that modify certain terms of the Scheme in relation to Participants who are U.S. Taxpayers with respect to an Award that is held by any such Participant while he or she is a U.S. Taxpayer.

2.2 To the extent that any provision of this Appendix is inconsistent with any Rule of the Scheme, such provision of this Appendix shall take precedence.

3. TERMS OF AWARD

3.1 In the case of a Participant who is a U.S. Taxpayer on the relevant “Determination Date” (as such term is defined in Appendix 4 of the British American Tobacco P.L.C. International Executive Incentive Scheme (the “IEIS”)) or becomes a U.S. Taxpayer after such Determination Date but during the relevant “Performance Period” (as defined in the IEIS), the terms of such U.S. Taxpayer’s Award shall be established in accordance with Paragraph 3 of Appendix 4 of the IEIS. Any award notification made to a U.S. Taxpayer pursuant to Rule 3.9 shall reflect the Award terms previously established in accordance with Paragraph 3 of Appendix 4 of the IEIS.

3.2 In the case of a Participant who becomes a U.S. Taxpayer after the end of the relevant Performance Period but prior to the date on which Shares subject to the applicable Award are delivered, the Board shall, prior to the end of the calendar year in which such Participant becomes a U.S. Taxpayer, establish such terms that are described in Paragraph 3.1 of Appendix 4 of the IEIS in respect of such U.S. Taxpayer’s Award as are necessary to achieve compliance with Section 409A of the U.S. Internal Revenue Code of 1986, as amended (for purposes of this Appendix, “Code Section 409A”) (and in the absence of such action by the Board, the terms set forth in clauses (i) through (iv) of Paragraph 3.1 of Appendix 4 of the IEIS that would apply in the absence of Board action as described therein shall apply).

4. DELIVERY OF SHARES

4.1 Notwithstanding anything in the Scheme to the contrary, if a U.S. Taxpayer becomes entitled to receive Shares subject to an Award, such Shares shall, in all events, be paid to the U.S. Taxpayer during the 60-day period (90-day period in the case of (e) below) following the first to occur of the following events (provided that the U.S. Taxpayer shall not have the right to designate the payment date): (a) the Normal Vesting Date; (b) the U.S. Taxpayer’s “separation from service” (as such term is defined in Code Section 409A); (c) the U.S. Taxpayer ceases to hold office or employment with any Group Company where the reason for the cessation is (1) the transfer of the U.S. Taxpayer’s employment in connection with the disposal of a business or undertaking or a part-business or part-undertaking or (2) the company with which the U.S. Taxpayer holds office or employment ceases to be a Group Company, as described in Rules 7.2.3 and 7.2.4, but only if the event described in (1) or (2) of this Paragraph 4.1 constitutes a “change in control event” under Code Section 409A; (d) an event described in Rule 8 that constitutes a “change in control event” under Code Section 409A; or (e) the U.S. Taxpayer’s death.

4.2 If Shares cannot be delivered in accordance with Paragraph 4.1 because of the application of Rule 6.2, such Award shall instead be satisfied by the payment of a cash equivalent amount pursuant to Rule 10 (as such Rule is amended by Paragraph 6) and shall be paid at the applicable time set forth in Paragraph 4.1.
5. **DIVIDEND EQUIVALENT**

Any payment to which a U.S. Taxpayer may become entitled under Rule 9 with respect to an Award shall be paid to such U.S. Taxpayer within sixty (60) days following the date on which the applicable dividends are paid on the Shares underlying the U.S. Taxpayer’s Award.

6. **CASH ALTERNATIVE**

Any cash payment to which a U.S. Taxpayer may become entitled under Rule 10 with respect to an Award shall be paid to such U.S. Taxpayer at the same time as the Shares would have been paid to such U.S. Taxpayer, as set forth in Paragraph 4.1.

7. **CLAWBACK**

The Board may not exercise its authority under Rule 13 or under Appendix 1 of the Scheme to the extent that the exercise of such authority would cause a U.S. Taxpayer to have an amount includible in the U.S. Taxpayer’s gross income for U.S. federal income tax purposes under Code Section 409A.

8. **CODE SECTION 409A**

To the extent applicable, it is intended that the Scheme, and all amounts payable in cash or Shares in respect of Awards thereunder, shall comply with the provisions of Code Section 409A so that the income inclusion provisions of Code Section 409A(a)(1) do not apply to any U.S. Taxpayer. The Scheme and the Awards paid thereunder will be interpreted and administered in a manner consistent with this intent. A U.S. Taxpayer shall not have the right to designate any payment date with respect to his or her Award.

Notwithstanding anything in the Scheme to the contrary, in the event that a U.S. Taxpayer is deemed to be a “specified employee” on the date of his or her “separation from service,” as such term is defined in Code Section 409A (other than by reason of death), determined pursuant to identification methodology adopted by a Group Company in compliance with Code Section 409A, and if any portion of the Shares or other payments to be received by such U.S. Taxpayer in respect of an Award upon separation from service would constitute a “deferral of compensation” subject to Code Section 409A, then to the extent necessary to comply with Code Section 409A, Shares or amounts that would otherwise be delivered or payable pursuant to this Scheme, as amended by this Appendix, during the six (6) month period immediately following the date of such U.S. Taxpayer’s separation from service shall instead be delivered or paid, as applicable, either (a) during the period commencing on the date that is six (6) months and one (1) day following the date of such U.S. Taxpayer’s separation from service and ending fifteen (15) days following the first business day of the seventh month after the date of such separation from service, provided that the U.S. Taxpayer shall not have the right to designate the delivery or payment date, or (b) if earlier, as soon as practicable (and in any event within ninety (90) days) after the U.S. Taxpayer’s death.

Notwithstanding any provision of the Scheme to the contrary, the Company reserves the right to make amendments to the Scheme as the Company deems necessary or desirable to avoid the imposition of taxes or penalties under Code Section 409A. In any case, a U.S. Taxpayer shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on such U.S. Taxpayer in connection with the Scheme (including any taxes and penalties under Code Section 409A), and neither the Company nor any of its affiliates shall have any obligation to indemnify or otherwise hold a U.S. Taxpayer harmless from any or all of such taxes or penalties.
ADDENDUM I: AWARDS GRANTED TO RAI PARTICIPANTS

1. APPLICATION
   This Addendum applies to Participants who are employees of Reynolds American Inc. or a subsidiary of Reynolds American Inc. (collectively, “RAI” and such Participants, “RAI Participants”).

   This Addendum sets out certain additional terms which currently apply in respect of Awards granted under the Scheme to RAI Participants. References in this Addendum to a “Rule” is to the Rule of the Scheme. Capitalized terms used in this Addendum shall, save where otherwise defined herein, have the meaning given in the Rules. To the extent that any provision of this Addendum is inconsistent with any Rule of the Scheme, such provision of this Addendum shall take precedence.

2. MODIFICATION
   The Board may at any time, and without notice to any person, add or alter or discontinue the terms of this Addendum in any respect without prior notice to any Participant.

3. RETIREMENT PLAN
   Notwithstanding Rule 18.9, the amount payable to a RAI Participant in respect of any Award under the Scheme shall be treated as compensation under the RAI Non-Qualified Retirement Plan to the extent provided therein and subject to the provisions thereof. Notwithstanding, for the avoidance of doubt, the terms of the RAI Non-Qualified Retirement Plan shall not, in any way, be amended by the preceding sentence.

4. TERMS
   Retirement
   1.1 Pursuant to Rule 7.2.5 (Reasons for cessation where Award remain capable of vesting) it has been determined that Rule 7.1 (Cessation where Awards lapse) shall not apply in respect of an RAI Participant who ceases to hold office or employment with any Group Company (within the meaning of Rule 7.5 (Meaning of cessation of office or employment)) in circumstances where the RAI Participant meets the criteria set out below (provided that this provision shall not apply where, in the opinion of the Board, the RAI Participant has committed an act or omission which justifies, or in the opinion of the Board would have justified, summary dismissal of service or notice of cessation of employment on the grounds of misconduct). The criteria referred to are: a RAI Participant’s voluntary termination of his or her employment with RAI (i) on or after his or her 65th birthday, (ii) on or after his or her 55th birthday with 10 or more years of service with RAI, or (iii) on or after his or her 50th birthday with 20 or more years of service with RAI. RAI shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence, including the form and timing of the RAI Participant’s notice of the RAI Participant’s intent to retire.

   Disability
   1.2 With respect to RAI Participants, the reference to “disability” in Rule 7.2.1 (Reasons for cessation where Awards remain capable of vesting) shall mean that the RAI Participant has become eligible for and is in receipt of benefits under RAI’s Long-Term Disability Plan. RAI shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence.
5. SETTLEMENT

Awards granted to RAI Participants may, at the discretion of the Board, be satisfied by the transfer of British American Tobacco p.l.c. American Depositary Shares, and references in the Plan (including any Appendix or Addendum thereto) to “Shares” shall be read accordingly.
BRITISH AMERICAN TOBACCO P.L.C.

RULES

of the

BRITISH AMERICAN TOBACCO

RESTRICTED SHARE PLAN

Adopted by the Board on 2 December 2019
Approved by Shareholders on 30 April 2020
and amended by the Board on 8 February 2022

Herbert Smith Freehills LLP

HSF Ref: 31026953
<table>
<thead>
<tr>
<th>Clause</th>
<th>Heading</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>INTERPRETATION AND CONSTRUCTION</td>
<td>2</td>
</tr>
<tr>
<td>2.</td>
<td>PLAN LIMITS</td>
<td>3</td>
</tr>
<tr>
<td>3.</td>
<td>AWARDS</td>
<td>4</td>
</tr>
<tr>
<td>4.</td>
<td>AWARDS ARE NON-TRANSFERABLE</td>
<td>6</td>
</tr>
<tr>
<td>5.</td>
<td>VESTING</td>
<td>6</td>
</tr>
<tr>
<td>6.</td>
<td>CESATION OF OFFICE OR EMPLOYMENT</td>
<td>7</td>
</tr>
<tr>
<td>7.</td>
<td>CORPORATE ACTIONS</td>
<td>9</td>
</tr>
<tr>
<td>8.</td>
<td>OPTIONS</td>
<td>11</td>
</tr>
<tr>
<td>9.</td>
<td>DIVIDEND EQUIVALENT</td>
<td>11</td>
</tr>
<tr>
<td>10.</td>
<td>CASH ALTERNATIVE</td>
<td>11</td>
</tr>
<tr>
<td>11.</td>
<td>TAX LIABILITY</td>
<td>12</td>
</tr>
<tr>
<td>12.</td>
<td>VESTED SHARE ACCOUNTS</td>
<td>13</td>
</tr>
<tr>
<td>13.</td>
<td>CLAW-BACK</td>
<td>13</td>
</tr>
<tr>
<td>14.</td>
<td>VARIATION OF CAPITAL</td>
<td>14</td>
</tr>
<tr>
<td>15.</td>
<td>ADMINISTRATION</td>
<td>14</td>
</tr>
<tr>
<td>16.</td>
<td>AMENDMENTS</td>
<td>15</td>
</tr>
<tr>
<td>17.</td>
<td>DATA PROTECTION</td>
<td>15</td>
</tr>
<tr>
<td>18.</td>
<td>GENERAL</td>
<td>16</td>
</tr>
</tbody>
</table>

**APPENDIX 1: OPERATION OF CLAW-BACK**

**APPENDIX 2: AWARDS GRANTED TO U.S. TAXPAYERS**

1. INTERPRETATION
2. APPLICATION
3. SERVICE CONDITION
4. APPLICATION OF PARAGRAPHS 5 AND 6
5. AWARDS WHERE RULE 6.3.2 (THE “WAIT AND SEE” APPROACH) SHALL APPLY OR THAT OTHERWISE ARE NOT EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL
6. AWARDS WHERE THE “WAIT AND SEE” APPROACH DOES NOT APPLY AND THAT ARE OTHERWISE EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL
7. DIVIDEND EQUIVALENTS
8. CASH ALTERNATIVE
9. CODE § 409A EXEMPTION AND COMPLIANCE
10. COOPERATION
11. SETTLEMENT

**ADDENDUM I: AWARDS GRANTED TO RAI PARTICIPANTS**

1. APPLICATION
2. MODIFICATION
3. TERMS
4. SETTLEMENT

1
RULES OF THE BRITISH AMERICAN TOBACCO P.L.C. RESTRICTED SHARE PLAN

1. INTERPRETATION AND CONSTRUCTION

1.1 For the purposes of the Plan, the following terms shall have the meaning indicated below unless the context clearly indicates otherwise:

“Award” means one of a Conditional Award or an Option;

“Board” means the board of directors of the Company or a committee duly authorised by the board of directors or, following any Corporate Action, the Board or duly authorised committee as constituted immediately prior to the Corporate Action;

“Claw-back” means a recovery of value by the Company from a Participant in accordance with the provisions of Rule 13 (Claw-back) and Appendix 1 (Operation of Claw-back);

“Company” means British American Tobacco p.l.c. (registered in England and Wales under No. 3407696);

“Conditional Award” means a right to receive a transfer of Shares following vesting of the Award;

“Control” has the meaning given by Section 995 of the Income Tax Act 2007;

“Corporate Action” means any of the events referred to in:

(A) Rules 7.1 to 7.5 (but excluding a Reorganisation as defined in Rule 7.8); or

(B) if the Board determines that Awards will vest pursuant to such Rule, Rule 7.6;

“Cross-Border Merger” means a merger pursuant to the implementation in any relevant jurisdiction of Directive 2005/56/EC (on cross-border mergers of limited liability companies);

“Dealing Day” means any day on which the London Stock Exchange is open for trading;

“Dealing Restriction” means any restriction on the dealing in shares, whether direct or indirect, pursuant to any law, regulation, code or enactment in England and Wales and/or the jurisdiction in which the Participant is resident, or any share dealing code of the Company;

“Eligible Employee” means an employee of any Group Company, other than an executive director of the Company;

“Employees’ Share Scheme” has the meaning given by Section 1166 of the Companies Act 2006;

“Financial Year” means the financial year of the Company within the meaning of Section 390 of the Companies Act 2006;

“Grant Date” means the date on which a Conditional Award or Option is granted;

“Group” means the Company and any company which from time to time is a subsidiary of the Company, within the meaning of section 1159 of the Companies Act 2006 (each a “Group Company”);

“Market Value” means, in relation to a Share on any day, the mid-closing price of a Share on such day (as derived from the Daily Official List of the London Stock Exchange);

“Normal Vesting Date” means the third anniversary of the Grant Date or such other date as may be determined by the Board prior to the Grant Date;

“Option” means a right to acquire Shares, which may be exercised by the Participant following the vesting of the Award during any period permitted for exercise;

“Option Price” shall be nil, or such other amount as the Board may determine (provided that the Board may reduce or waive such amount at any time);
“Participant” means an Eligible Employee who has received an Award to the extent it has not been released and has not lapsed (or, following his death, his Personal Representatives);

“Personal Representatives” means, following his death, the Participant’s personal representatives, or a person fulfilling a similar function in any jurisdiction;

“Plan” means this British American Tobacco Restricted Share Plan, as amended from time to time;

“Rule” means a rule of this Plan;

“Share” means a fully paid ordinary share in the capital of the Company;

“Treasury Shares” means Shares to which Sections 724 to 732 of the Companies Act 2006 apply;

“Trust” means any employee benefit trust from time to time established by the Company;

“U.S. Taxpayer” has the meaning given in Rule 3.10 (U.S. Taxpayers); and

“vesting” means:

(A) Shares subject to a Conditional Award becoming due to be transferred to the Participant; or

(B) an Option becoming exercisable,

(and “vest” shall be construed accordingly).

1.2 In this Plan unless the context requires otherwise:

1.2.1 the headings are inserted for convenience only and do not affect the interpretation of any Rule;

1.2.2 a reference to a statute or statutory provision includes a reference:

(A) to that statute or statutory provision as from time to time consolidated, modified, re-enacted or replaced by any statute or statutory provision;

(B) to any repealed statute or statutory provision which it re-enacts (with or without modification); and

(C) to any subordinate legislation made under it;

1.2.3 words in the singular include the plural, and vice versa;

1.2.4 a reference to one gender shall be treated as a reference to any gender;

1.2.5 a reference to a person shall include a reference to a body corporate; and

1.2.6 a reference to writing or written form shall include any legible format capable of being reproduced on paper, irrespective of the medium used.

1.3 In this Plan:

1.3.1 a reference to the “transfer of Shares” (or similar) shall include both the issue and allotment of Shares and the transfer of Treasury Shares; and

1.3.2 a provision obliging, or permitting, any company to do any thing shall be read as obliging, or permitting, such company to do that thing, or procure that thing to be done; and

1.3.3 the use of the word “including” shall mean including without limitation and without prejudice to the generality of the foregoing.

2. PLAN LIMITS

2.1 Subject to Rule 2.2, the Board may not grant a Conditional Award or Option pursuant to the Plan if the number of Shares subject to such proposed Award (the “Relevant Shares”) would cause either of the limits in Rules 2.3 or 2.4 to be breached.
2.2 Rule 2.1 shall not apply in respect of a Conditional Award or Option granted on terms that it shall not be capable of being satisfied by the issue of Shares.

5 per cent limit: discretionary Employees’ Share Scheme

2.3 The number of Relevant Shares, when added to the aggregate of:

2.3.1 the number of Shares subject to outstanding options or awards granted within the previous 10 years under the Plan or any other discretionary Employees’ Share Scheme adopted by the Company which may be satisfied by the issue of Shares; and

2.3.2 the number of Shares actually issued within the previous 10 years under the Plan, under any other discretionary Employees’ Share Scheme or to a Trust (but excluding any of those Shares that were used to satisfy an option or award granted more than 10 years previously, and without double counting any Shares which the Board has determined are to be used to satisfy options or awards counted under Rule 2.3.1 above),

may not exceed such number as represents 5 per cent of the Company’s issued share capital immediately prior to such proposed grant or issue.

10 per cent limit: Employees’ Share Scheme

2.4 The number of Relevant Shares, when added to the aggregate of:

2.4.1 the number of Shares subject to outstanding options or awards granted within the previous 10 years under the Plan or any other Employees’ Share Scheme adopted by the Company which may be satisfied by the issue of Shares; and

2.4.2 the number of Shares actually issued within the previous 10 years under the Plan, under any other Employees’ Share Scheme or to a Trust (but excluding any of those Shares: that were used to satisfy an option or award granted more than 10 years previously, and without double counting any Shares which the Board has determined are to be used to satisfy options or awards counted under Rule 2.4.1 above),

may not exceed such number as represents 10 per cent of the Company’s issued share capital immediately prior to such proposed grant or issue.

Treasury Shares

2.5 References in this Rule 2 to the issue of Shares shall include the transfer of Treasury Shares, but only until such time as the guidelines issued by institutional investor bodies cease to provide that they should be so included.

Shareholder Approval

2.6 No Shares may be issued or Treasury Shares transferred to satisfy entitlements under the Plan before the date on which the Plan is approved by shareholders of the Company in general meeting.

3. AWARDS

Eligibility

3.1 Awards may be granted to Eligible Employees selected by the Board.
Timing of grants

3.2 An Award may only be granted:

3.2.1 during the period of 42 days commencing on the Dealing Day immediately following the day on which the Company announces its results for the preceding financial year, half-year or other period;

3.2.2 in respect of an Award to be granted in respect of the recruitment or promotion of an Eligible Employee, as soon as reasonably practicable after the Eligible Employee commences holding office or employment with any Group Company or the promotion of such Eligible Employee takes effect (as relevant); and/or

3.2.3 at such time at which the Board determines that exceptional circumstances exist which justify the grant of the Award, or, in any such case, if the grant of Awards during such period or at such time would be contrary to any Dealing Restriction, as soon as reasonably practicable after such restriction ceases to apply.

Individual limit

3.3 An Award may not be granted to an Eligible Employee where it would cause the aggregate Relevant Value of the Shares subject to such Award and any Award(s) granted to the Eligible Employee in the same Financial Year to exceed an amount equal to 250% of the gross annual basic salary of that Eligible Employee as at the Grant Date.

An Award granted in breach of this limit shall immediately lapse in respect of the number of Shares which cause this limit to be breached. Awards which have been released or have lapsed, or which are granted in connection with the recruitment of an Eligible Employee in lieu of incentive awards granted by the individual’s former employer which are forfeited (i.e., a “buy-out”), and any right to receive Shares as a dividend equivalent, shall be ignored for this purpose.

In this Rule 3.3, the “Relevant Value” of a Share subject to an Award means either (as determined by the Board): (i) the Market Value of a Share on the Dealing Day immediately preceding the Grant Date; or (ii) the average of the Market Values of a Share over such number of Dealing Days preceding the Grant Date as the Board may determine (all being within the period of 30 days preceding the Grant Date and, where the Award is granted within the period in Rule 3.2.1, being on or after the date of the results announcement).

3.4 Where an Eligible Employee’s gross annual basic salary is denominated in a currency other than pounds sterling, for the purposes of Rule 3.3 above such gross annual basic salary shall be converted into pounds sterling on such basis as the Board may reasonably determine.

Method of grant

3.5 An Award shall be granted by the Board.

3.6 A Conditional Award or an Option shall be granted by deed.

3.7 No payment for the grant of an Award shall be made by the Participant.

3.8 A Participant may, within 30 days of the Grant Date, release an Award (in full but not in part) by written notice to the Company. Where a Participant does not release an Award within such period, the Participant shall be deemed to have accepted the Award on the terms set out in the Rules. Alternatively, it may be a term of the grant of an Award that the Participant shall be required to accept the terms of the Award within such period following grant as may be determined by the Board and, where the Board specifies such period, the Award shall lapse at the end of such period if the terms of the Award have not been accepted by the Participant.
Award notification

3.9 As soon as practicable following the Grant Date the Company shall notify a Participant of the grant of an Award. Such notification shall specify:

3.9.1 whether the Award takes the form of a Conditional Award or an Option;
3.9.2 the Grant Date;
3.9.3 the Normal Vesting Date;
3.9.4 the number of Shares in respect of which the Award is granted;
3.9.5 in relation to an Option, the Option Price (if any);
3.9.6 if applicable, that the dividend equivalent provisions of Rule 9 (Dividend equivalent) shall apply; and
3.9.7 that the Award is subject to the claw-back provisions of Rule 13 (Claw-back) and Appendix 1 (Operation of Claw-back).

U.S. Taxpayers

3.10 The provisions of Appendix 2 (Awards Granted to U.S. Taxpayers) shall apply to a Conditional Award or an Option that is held by any Participant while he or she is subject to taxation under the U.S. Internal Revenue Code of 1986, as amended (a “U.S. Taxpayer”). References to Code §409A are to §409A of the U.S. Internal Revenue Code of 1986, as amended.

4. AWARDS ARE NON-TRANSFERABLE

4.1 A Participant may not transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, any part of his interest in an Award. An Award shall (unless the Board determines otherwise) lapse on the Participant doing so (whether voluntarily or involuntarily), being deprived of the beneficial ownership of an Award by operation of law, or becoming bankrupt.

4.2 Rule 4.1 does not restrict the transmission of an Award to the Participant’s Personal Representatives following his death.

5. VESTING

Normal vesting

5.1 An Award shall vest on the Normal Vesting Date.

Vesting subject to Dealing Restrictions

5.2 A Conditional Award shall not vest unless, and vesting shall be delayed until, the Board is satisfied that at that time:

5.2.1 such vesting;
5.2.2 the transfer of Shares to the Participant and the sale of Shares pursuant to Rule 11 (Tax Liability); and
5.2.3 any action needed to be taken by the Company to give effect to such vesting

is not contrary to any Dealing Restriction.

Effect of vesting

5.3 The effect of the vesting of an Award is that:

5.3.1 the Shares in respect of which a Conditional Award vests shall be transferred to the Participant as soon as is reasonably practicable (which may include transferring the Shares on more than one consecutive Dealing Day on such basis as the Board may determine); and
5.3.2 an Option shall, to the extent that it vests, become exercisable in accordance with Rule 8 (Options).
Disciplinary proceedings

5.4 Unless the Board determines otherwise, an Award shall not vest while a Participant is subject to an investigation process and/or formal disciplinary process (or similar), or where a Participant has been served with notice that such a process may be instigated without such notice having been rescinded, and vesting shall (subject to the Award lapsing to any extent prior to or as a result of the conclusion of such process pursuant to Rule 6 (Cessation of office or employment) or 13 (Claw-back)) be delayed until the conclusion of such process.

International transfers

5.5 Where a Participant, whilst continuing to hold an office or employment with a Group Company, is to be transferred to work in another country, and as a result the Board considers that following such transfer either he or a Group Company is likely to suffer a tax disadvantage in respect of an Award or, due to securities or exchange control laws, the Participant is likely to be restricted in his ability to receive Shares pursuant to an Award, to exercise an Option and/or to hold or deal in Shares, the Board may decide that an Award shall vest on such date as it may determine, in which case:

5.5.1 the proportion of the Award which may vest shall be limited (unless the Board determines otherwise) to a pro rata proportion on the basis of the number of days which have elapsed from the Grant Date to such vesting date, as compared to the number of days between the Grant Date and the Normal Vesting Date. Any remainder of the Award shall lapse; and

5.5.2 an Option may be exercised during such period as may be determined by the Board ending no later than the date on which the Participant’s transfer takes effect.

6. CESSATION OF OFFICE OR EMPLOYMENT

Cessation where Awards lapse

6.1 An Award shall lapse:

6.1.1 on the Participant ceasing to hold office or employment with any Group Company; or

6.1.2 if the Participant gives or receives notice of such cessation, on such earlier date as may be determined by the Board, save in each case where Rule 6.2 or Rule 6.6 applies.

Reasons for cessation where Awards remain capable of vesting

6.2 An Award shall not lapse pursuant to Rule 6.1 where the reason for the cessation or notice is:

6.2.1 disability, ill-health or injury (as evidenced to the satisfaction of the Board);

6.2.2 redundancy (within the meaning of the Employment Rights Act 1996);

6.2.3 the transfer of the Participant’s employment in connection with the disposal of a business or undertaking, or a part-business or part-undertaking;

6.2.4 the company with which the Participant holds office or employment ceasing to be a Group Company; or

6.2.5 any other reason, if the Board so determines.

Where the Board exercises its discretion under Rule 6.2.5 the Board may impose additional conditions on the Award (including as to when the Award may vest).
Cessation prior to the Normal Vesting Date

6.3 Where prior to the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons specified in Rule 6.2:

6.3.1 the Award shall vest on the date of cessation (in which case an Option may be exercised during the period of six months, or such other period as may be determined by the Board, from such vesting date, and shall lapse at the expiry of such period); or

6.3.2 the Board may determine that an Award shall not vest at the date of such cessation, but shall continue to be capable of vesting (in which case an Option may be exercised during the period of six months, or such other period as may be determined by the Board, from such date on which the Award may vest, and shall lapse at the expiry of such period).

For the avoidance of doubt, the Board may make the determination in Rule 6.3.2 on a standing basis (subject to revocation of such determination at any time) in respect of all Awards to be granted to a specified Eligible Employee or Eligible Employees.

6.4 Where prior to the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons specified in Rule 6.2, unless the Board determines otherwise, the proportion of the Award which may vest (under any Rule) shall be limited to a pro rata proportion on the basis of the number of days which have elapsed from the Grant Date to the date of cessation, as compared to the number of days between the Grant Date and the Normal Vesting Date. Any remainder of the Award shall lapse.

Exercise period in the event of cessation on or after the Normal Vesting Date

6.5 Where on or after the Normal Vesting Date a Participant ceases to hold office or employment with any Group Company for any of the reasons specified in Rule 6.2, an Option shall lapse at the expiry of the period of six months, or such other period as may be determined by the Board, from the date of cessation.

Death

6.6 An Award shall vest in full on the Participant’s death. An Option may be exercised (by the Participant’s Personal Representatives) during a period of one year from the date of the Participant’s death and shall lapse at the expiry of such period. Where a Participant dies during an exercise period pursuant to either Rule 6.3 or 6.5 an Option shall not lapse as a result of such Rule until the expiry of the twelve month period in this Rule 6.6 (for the avoidance of doubt, in such circumstances the Option shall only remain exercisable to the extent previously vested).

Cessation following a Corporate Action

6.7 Where a Participant ceases to hold office or employment with any Group Company following a Corporate Action within the relevant exercise period referred to in Rule 7 (Corporate Actions), an Option shall not lapse pursuant to this Rule 6 until the expiry of the relevant exercise period in Rule 7 (Corporate Actions). This Rule 6.7 shall not apply where the cessation is by way of (or occurs where there are circumstances which the Board determines would have justified) summary dismissal or service of notice of termination of office or employment on the grounds of misconduct.

Meaning of cessation of office or employment

6.8 No provision of this Rule 6 shall apply in respect of any cessation of office or employment if immediately following the cessation the Participant holds an office or employment with any Group Company, or in respect of any notice of cessation if arrangements are in place that mean immediately following the notice becoming effective the Participant will hold an office or employment with any Group Company.
7. CORPORATE ACTIONS

General offers

7.1 Awards shall vest:

7.1.1 upon a person obtaining Control of the Company as a result of making a general offer to acquire Shares;

7.1.2 upon a person, having obtained Control of the Company, making a general offer to acquire Shares; or

7.1.3 if a person makes a general offer to acquire Shares that would result in that person obtaining Control of the Company and the Board so determines, on the date which the Board determines to be the last practicable date prior to the date on which it expects such person to obtain Control of the Company,

in each case being a general offer to acquire all of the Shares (other than Shares held by the person making the offer and any person connected to that person).

Options may be exercised during the period of six months from the date of any such event (but if not exercised, Options shall not lapse at the expiry of such period).

Compulsory acquisition

7.2 Awards shall vest upon a person becoming entitled to acquire Shares under Sections 979 to 982 of the Companies Act 2006.

Options may be exercised during a period of one month from the date on which that person first becomes so entitled, and shall lapse at the expiry of such period.

Scheme of compromise or arrangement

7.3 Awards shall vest upon a Court sanctioning a compromise or arrangement which, on becoming effective, would result in:

7.3.1 any person obtaining Control of the Company;

7.3.2 the undertaking, property and liabilities of the Company being transferred to another existing or new company; or

7.3.3 the undertaking, property and liabilities of the Company being divided among and transferred to two or more companies, whether existing or new.

Options may be exercised during a period of six months from the date of a Court sanctioning such a compromise or arrangement (or, if earlier, to the day prior to the date on which a transfer as described in Rule 7.3.2 or Rule 7.3.3 is to become effective), and shall lapse at the expiry of such period.

Merger

7.4 Awards shall vest upon a competent authority approving a Cross-Border Merger, pursuant to which the Company shall cease to exist.

Options may be exercised during the period from the date of a competent authority approving a Cross-Border Merger until the day prior to the date on which the Cross-Border Merger is to become effective, and shall lapse at the expiry of such period.

Voluntary winding-up

7.5 Awards shall vest in the event of a notice being given of a resolution for the voluntary winding-up of the Company.

Options may be exercised during a period of two months from the date of such a notice being given and shall lapse at the expiry of such period.
Demerger or special dividend

7.6 If the Board so determines, Awards may vest following the announcement of a demerger of a substantial part of the Group’s business, a special dividend or a similar event affecting the value of Shares to a material extent on such date specified by the Board. Where the Board makes such determination, Options may be exercised during a period of two months (or such other period as the Board may determine) from the date specified by the Board and, unless the Board determines otherwise, shall lapse at the expiry of such period.

Extent of vesting on a Corporate Action

7.7 Where an Award vests (and, in the case of an Option, is exercised) pursuant to any of Rules 7.1 to 7.6, the proportion of the Award which may vest shall be limited (unless the Board determines otherwise) to a pro rata proportion on the basis of the number of days which have elapsed from the Grant Date to the date of the Corporate Action, as compared to the number of days within the period between the Grant Date and the Normal Vesting Date. Any remainder of the Award shall lapse.

Roll-over of Award on a Reorganisation or takeover

7.8 Unless the Board determines otherwise, an Award shall not vest pursuant to this Rule 7 if, as a result of any event that would otherwise be a Corporate Action, a company will obtain Control of the Company or will obtain substantially all of the assets of the Company (the “Acquiring Company”), and either:

7.8.1 the Acquiring Company will immediately following such event have (either directly or indirectly) substantially the same shareholders and approximate shareholdings as those of the Company prior to such event (a “Reorganisation”); or

7.8.2 the Board, with the agreement of the Acquiring Company, determines that the Award shall not vest as a result of such event and so notifies the Participant prior to the occurrence of the date on which the Award would otherwise vest.

In such case the existing Option or Conditional Award (the “Old Award”) shall lapse on the occurrence of the relevant event, provided that the New Parent Company shall grant a replacement right to receive shares (the “New Award”) over such number of shares in the New Parent Company which are of equivalent value to the number of Shares in respect of which the Old Award was outstanding. The New Award shall be granted on the terms of the Plan, but as if the New Award had been granted at the same time as the Old Award.

For the purposes of this Rule 7.8:

7.8.3 the “New Parent Company” shall be the Acquiring Company, or, if different the company that is the ultimate parent company of the Acquiring Company within the meaning of section 1159 of the Companies Act 2006; and

7.8.4 the terms of the Plan shall following the date of the relevant event be construed as if:

(A) the reference to “British American Tobacco p.l.c.” in the definition of “Company” in Rule 1 (Interpretation and construction) were a reference to the company which is the New Parent Company, and

(B) save where the New Parent Company is listed, Rule 16.2 (Amendments) were omitted.

Compulsory winding-up

7.9 An Award shall lapse on the passing of an effective resolution, or the making of a Court order, for the compulsory winding-up of the Company.
Concert parties

7.10 For the purposes of this Rule 7, a person shall be deemed to have Control of the Company where he and any others acting in concert with him together have Control of the Company.

8. OPTIONS

8.1 An Option may be exercised, in full or in any number of parts, by the delivery to the Company (or such other person nominated by the Company) of a valid notice of exercise in such form as the Board may prescribe together with payment of the Option Price for the Shares in respect of which the Option is exercised (if any).

8.2 An Option shall lapse on the tenth anniversary of the Grant Date (or such earlier date as the Board may determine prior to the Grant Date).

8.3 Any Shares in respect of which the Option is exercised shall be transferred to the Participant as soon as reasonably practicable (which may include transferring the Shares on more than one consecutive Dealing Days on such basis as the Board may determine).

8.4 An Option may not be exercised unless the Board is satisfied that at such time:

8.4.1 such exercise,
8.4.2 the transfer of Shares to the Participant and the sale of Shares pursuant to Rule 11; and
8.4.3 any action needed to be taken by the Company to give effect to such exercise,

is not contrary to any Dealing Restriction. Where the exercise, transfer or dealing in Shares is contrary to any Dealing Restriction on the last Dealing Day in any of the periods referred to in Rules 6.3, 6.5 or 6.6 (Rule 6 being in relation to cessation of office or employment) or Rules 7.1 to 7.3 or 7.6 (Rule 7 being in relation to Corporate Actions), such period shall be extended to the end of the first Dealing Day thereafter on which the Board is satisfied that the exercise, transfer and dealing in Shares is not contrary to any Dealing Restriction.

8.5 An Option shall lapse on the earliest date provided under any Rule (save only as expressly provided in Rules 6.6 (Death) and 6.7 (Cessation following a Corporate Action)).

9. DIVIDEND EQUIVALENT

9.1 If at any time prior to the Normal Vesting Date the Board so determines, on or following the date on which an Award vests the Company may:

9.1.1 make a cash payment to the Participant equal to the amount of any dividends that the Participant would have received in respect of the number of Shares in respect of which the Award vests had the Participant been the full legal and beneficial owner of such Shares during the period from the Grant Date to the date the Award vests; or
9.1.2 transfer to the Participant such number of additional Shares as have an aggregate Market Value on the date on which the Award vests equal to the amount determined in accordance with Rule 9.1.1 above.

9.2 A cash payment under Rule 9.1 may be made in a currency other than pounds sterling, in which case the amount of such payment shall be converted into such other currency on such basis as is determined by the Board.

10. CASH ALTERNATIVE

10.1 This Rule 10 shall not apply in respect of any Award granted to a Participant resident in any jurisdiction where the grant of an Award which provides for a cash alternative would be unlawful, fall outside any applicable exemption under securities, exchange control or similar regulations, or would cause adverse tax or social security (or similar) contribution consequences for the Company or the Participant (in each case as determined by the Board) or where the Board determines prior to the Grant Date that this Rule 10 shall not apply.
10.2 The Board may determine prior to the Grant Date that an Award shall only be satisfied in cash, in which case the Award shall not be a right to acquire Shares, and the vesting of the Conditional Award or exercise of the Option shall be satisfied in full by the payment of a cash equivalent amount, in substitution for the transfer of Shares.

10.3 Where the Board has made no determination pursuant to Rule 10.1 or 10.2 in respect of an Award, the Board may determine at any time prior to the transfer of Shares pursuant to such Award that the vesting of the Conditional Award or the exercise of the Option (or a part thereof) shall be satisfied by the payment of a cash equivalent amount, in substitution for the transfer of Shares.

10.4 A “cash equivalent amount” shall be calculated as the number of Shares which would otherwise be transferred in respect of the relevant vesting or exercise but which are being substituted for the cash equivalent amount, multiplied by an amount equal to the relevant value less, in the case of an Option, the Option Price (if any), where the “relevant value” is the Market Value of a Share on the date on which the Award vests or, in the case of an Option, is exercised (or, in any case, where only a part of the Award is to be satisfied with payment of a cash equivalent amount, is the Market Value of a Share on the date on which Shares are transferred to the Participant pursuant to the Award).

10.5 A cash equivalent amount shall be paid as soon as reasonably practicable following the relevant vesting or exercise.

10.6 A cash equivalent amount may be paid in a currency other than pounds sterling, in which case the cash equivalent amount shall be converted into such other currency on such basis as is determined by the Board.

11. TAX LIABILITY

11.1 When any Tax Liability arises in respect of an Award, the Participant authorises any Group Company:

11.1.1 to retain and sell legal title to such number of the Shares which would otherwise have been transferred to the Participant on vesting or exercise of the Award, or any part thereof, (notwithstanding that beneficial title shall pass) as may be sold for aggregate proceeds equal to the Group Company’s estimate of the amount of the Tax Liability;

11.1.2 to deduct an amount equal to the Group Company’s estimate of the Tax Liability from any cash payment made under the Plan; and/or

11.1.3 where the amount realised under Rule 11.1.1 or deducted under Rule 11.1.2 is insufficient to cover the full amount of the Tax Liability, to deduct any further amount as is necessary through payroll, and in each case to apply such amount in paying the amount of the Tax Liability to the relevant revenue authority or in reimbursing the relevant Group Company for any such payment, provided that, where the amount realised under Rule 11.1.1 or deducted under Rule 11.1.2 is greater than the actual Tax Liability, the Group Company shall repay the excess to the Participant as soon as reasonably practicable.

The Group Company shall be entitled to make the estimates referred to in this Rule 11.1 on the basis of the highest rates of tax and/or social security applicable at the relevant time in the jurisdiction in which the Group Company is liable to account for the Tax Liability, notwithstanding that the Tax Liability may not arise at such rates.

11.2 “Tax Liability” shall mean any amount of tax and/or social security (or similar) contributions which any Group Company becomes liable to pay on behalf of the Participant to the revenue authorities in any jurisdiction, together with all or such proportion (if any) of employer’s social security contributions which would otherwise be payable by any Group Company as is determined to be recoverable from the Participant (to the extent permitted by law) by the Board, or which the Participant has agreed to pay or which are subject to recovery pursuant to an election to which paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992 applies.
12. VESTED SHARE ACCOUNTS

12.1 Legal title to any Shares which are due to be transferred to the Participant pursuant to the Plan may be transferred to a person (the “Vested Share Account Provider”) appointed by the Company from time to time to hold legal title to such Shares on behalf of the Participant.

12.2 The Vested Share Account Provider shall receive and hold Shares on behalf of the Participant in accordance with such terms and conditions as are agreed by the Company from time to time, and by participating in the Plan the Participant irrevocably agrees to those terms and conditions (which shall be available to the Participant on request to the Company).

12.3 The transfer of any Shares to the Vested Share Account Provider shall satisfy any obligation of the Company under the Plan to transfer Shares to the Participant (and references in the Plan to Shares (or legal title thereof) having been transferred to the Participant shall be read accordingly).

12.4 The terms and conditions referred to in Rule 12.2 above may include terms that the Participant shall not be entitled to transfer, assign, pledge, charge or otherwise dispose of, or grant any form of security or other interest over, some or all of the Shares if to do so would be in breach of the Participant’s obligations under the Company’s shareholding requirements as they apply to such Participant.

13. CLAW-BACK

Claw-back events

13.1 The Board may at any time prior to the fifth anniversary of the Grant Date of an Award determine that a Claw-back shall apply in respect of the Award, if the Board determines that:

13.1.1 there has been a material misrepresentation in relation to the performance of any Group Company, relevant business unit and/or the Participant on the basis of which the Award was determined (which may include, but shall not be limited to: (i) a misstatement of the financial results and/or health of any Group Company; (ii) an erroneous calculation in relation to any Group Company’s results or other performance benchmark; (iii) errors in any Group Company’s financial statements; or (iv) discrepancies in the financial accounts, and, for the avoidance of doubt, notwithstanding that such misrepresentation may not arise from fraud or reckless behaviour); or

13.1.2 an erroneous calculation was made in assessing the extent to which the Award was granted or is to be capable of vesting, or vested, and, in either case, the Award was granted or is capable of vesting, or vested, in respect of a greater number of Shares than would have been the case had there not been such a misrepresentation or had such error not been made; or

13.1.3 there has been a significant failure within any Group Company which has a material impact on the value of the Group (taken as a whole), including but not limited to circumstances where the Company or any other Group Company has entered into an involuntary administration or insolvency process or there has been a significant reduction in, or cessation of, the ability of any material Group Company (or group of Group Companies) to continue normal operations.

13.2 The Board may at any time (whether before or after vesting) determine that a Claw-back shall apply in respect of an Award where the Participant is found to have:

13.2.1 committed at any time prior to the vesting of the Award, including prior to grant, an act or omission which justifies, or in the opinion of the Board would have justified, summary dismissal or service of notice of termination of office or employment on the grounds of misconduct;
13.2.2 engaged in, at any time prior to the vesting of the Award:
   (A) reckless, negligent or wilful action or inaction; or
   (B) inappropriate behaviour or behaviour that is not aligned with any employee policy or handbook or Group values,
   and in either case the Board determines that such circumstances have contributed to a material loss for any Group Company; or
13.2.3 contributed, at any time prior to vesting of the Award, to circumstances which give rise to a sufficiently negative impact on the
   reputation of any Group Company or business unit (or would have if such circumstances had been made public).

13.3 Rules 13.1.3, 13.2.2 and 13.2.3 shall only apply to awards granted on or after 1 January 2022.

Applying Claw-back

13.4 A Claw-back shall be applied in accordance with the provisions of Appendix 1 (Operation of Claw-back).

Lapse of Awards to give effect to claw-back of other awards

13.5 By participating in the Plan, the Participant acknowledges that the Board may lapse any Award to such extent as it determines to be necessary
   (including in full) in order to give effect to a claw-back under the terms of the Plan or any other Employees’ Share Scheme or bonus scheme
   operated from time to time by any Group Company.

No Claw-back following Corporate Action

13.6 No Claw-back shall be capable of being applied at any time following any Corporate Action, save where the determination that the Claw-back
   shall apply was made prior to such event (and, for the avoidance of doubt, a Corporate Action does not include a Reorganisation).

14. VARIATION OF CAPITAL

14.1 In the event of any variation of the share capital of the Company, or in the event of the demerger of a substantial part of the Group’s business, a
   special dividend or similar event affecting the value of Shares to a material extent (which shall not include the payment of any ordinary dividend)
   the Board may make such adjustments to Awards as it may determine to be appropriate.

14.2 For the avoidance of doubt Rule 14.1 shall not apply in respect of any Awards pursuant to which legal title to Shares has been transferred prior to
   the date of the relevant event (such that the recipient of such legal title shall participate in such event as a holder of Shares) including pursuant to
   the vesting of an Award under Rule 7.6 (Demerger or special dividend).

15. ADMINISTRATION

15.1 Any notice or other communication under or in connection with this Plan may be given by the Company (or its agents) to a Participant
   personally, by email or by post, or by a Participant to the Company or any Group Company either personally or by post to the Secretary of the
   Company. Items sent by post shall be pre-paid and shall be deemed to have been received 48 hours after posting. Items sent by email shall be
   deemed to have been received immediately.

15.2 A Participant shall not be entitled to:
   15.2.1 receive copies of accounts or notices sent to holders of Shares;
   15.2.2 exercise voting rights; or
   15.2.3 receive dividends,
in respect of Shares subject to an Award legal title to which has not been transferred to the Participant.

15.3 Any discretion (including the power to make any determination) of the Board under or in connection with the Plan may be exercised by the Board in its absolute discretion.

15.4 Any exercise of discretion (including the making of any determination) by the Board under or in connection with the Plan shall be final and binding.

15.5 Any disputes regarding the interpretation of the Rules or the terms of any Award shall be determined by the Board (upon such advice as the Board determines to be necessary) and any decision in relation thereto shall be final and binding.

16. AMENDMENTS

16.1 Subject to Rules 16.2 and 16.4, the Board may at any time add to or alter the Plan or any Award made thereunder in any respect.

16.2 Subject to Rule 16.3, no addition or alteration to the advantage of present or future Participants relating to eligibility, the limits on participation, the overall limits on the issue of Shares or the transfer of Treasury Shares, the basis for determining a Participant’s entitlement to, or the terms of, Shares or cash provided pursuant to the Plan and the provisions for adjustments on a variation of share capital shall be made without the prior approval by ordinary resolution of the shareholders of the Company in general meeting.

16.3 Rule 16.2 shall not apply to any alteration or addition which is necessary or desirable in order to comply with or take account of the provisions of any proposed or existing legislation, law or other regulatory requirements or to take advantage of any changes in legislation, law or other regulatory requirements, or to obtain or maintain favourable taxation, exchange control or regulatory treatment of any Group Company or any Participant or to make minor amendments to benefit the administration of the Plan.

16.4 No alteration or addition shall be made under Rule 16.1 which would abrogate or adversely affect the subsisting rights of a Participant unless it is made:

16.4.1 with the consent in writing of the Participant;

16.4.2 with the consent in writing of such number of Participants as hold Awards under the Plan in relation to 75 per cent. of the Shares subject to all Awards under the Plan; or

16.4.3 by a resolution at a meeting of Participants passed by not less than 75 per cent. of the Participants who attend and vote either in person or by proxy,

and for the purpose of Rule 16.4.2 or 16.4.3 the Participants shall be treated as the holders of a separate class of share capital and the provisions of the Articles of Association of the Company relating to class meetings shall apply mutatis mutandis.

16.5 The Board may, in respect of Eligible Employees who are or who may become subject to taxation outside the United Kingdom on their remuneration, establish such plans or sub-plans based on the Plan but subject to such modifications as the Board determines to be necessary or desirable to take account of or to mitigate or to comply with relevant overseas taxation, securities or exchange control laws, provided that the terms of awards made under such plans or sub-plans are not overall more favourable than the terms of Awards made under the Plan and provided that awards made, and Shares issued, pursuant to such plans or sub-plans shall count towards the limits set out in Rules 2 (Plan limits) and 3.3 (Individual limit).

17. DATA PROTECTION

17.1 From time to time the personal data of the Participant will be collected, used, stored, transferred and otherwise processed for the purposes described in Rule 17.2 and 17.3. The legal grounds for this processing will (depending on the nature and purpose of any specific instance of processing) be one of: (i) such processing being necessary for the purposes of the legitimate interests of the Company and each other Group Company in
incentivising their officers and employees and operating the Plan; (ii) such processing being necessary for the purposes of any relevant data controller in respect of such personal data complying with its legal obligations; and (iii) such processing being necessary for the performance of the contractual obligations arising under the Plan. The collection and processing of such personal data for such purposes is a contractual requirement of participation in the Plan.

17.2 The purposes for which personal data shall be processed as referred to in this Rule 19 shall be in order to allow the Company and any other relevant Group Companies to incentivise their officers and employees and to operate the Plan and to fulfil its or their obligations to the Participant under the Plan, and for other purposes relating to or which may become related to the Participant’s office or employment, the operation of the Plan or the business of the Group or to comply with legal obligations. Such processing will principally be for, but will not be limited to, personnel, administrative, financial, regulatory or payroll purposes as well as for the purposes of introducing and administering the Plan.

17.3 The personal data to be processed as referred to in this Rule 17 may be disclosed or transferred to, and/or processed by:

17.3.1 any professional advisors of any Group Company, HM Revenue & Customs or any other revenue, regulatory or governmental authorities;

17.3.2 a trustee of a Trust; any registrars, brokers, payroll provider or appointed in connection with any employee share or incentive plans operated by any Group Company; or any person appointed (whether by the Participant or any Group Company) to act as nominee on behalf of (or provide a similar service to) the Participant;

17.3.3 subject to appropriate confidentiality undertakings), any prospective purchasers of, and/or any person who obtains control of or acquires, the Company or the whole or part of the business of the Group; or

17.3.4 any Group Company and officers, employees or agents of such Group Company.

17.4 Further information in relation to the processing of personal data referred to in this Rule 19, including the details and identity of the data controller and of the Participant’s rights in respect of such personal data, is available in the Employee Data Protection Policy (or otherwise on request to the Company Secretary).

17.5 To the extent that the processing of personal data of a Participant referred to in this Rule 19 is subject to the laws or regulations of any jurisdiction that is not an EU member state and under which the legal grounds for processing described in Rule 19.1 do not provide a sufficient legal basis under such other laws or regulations for the processing referred to in Rule 17.1 to 17.3, by such processing for the purposes of such other laws or regulations (but shall not be deemed to consent to such processing for the purposes of EU Regulation 2016/679).

17.6 In this Rule17, “personal data” and “data controller” each have the meaning given in EU Regulation 2016/679 and “Employee Data Protection Policy” means such privacy policy or similar operated by any Group Company in relation to the processing of personal data as amended from time to time and as is applicable to the Participant.

18. GENERAL

18.1 In the event of any discrepancy between these Rules in English and (i) any copy of these Rules translated into any other language; or (ii) any communications, notices or materials issued in connection with this Plan, these Rules in English shall prevail.

18.2 The Plan shall terminate on the 10th anniversary of the approval of the Plan by the shareholders of the Company in general meeting, or at any earlier time by resolution of the Board or an ordinary resolution of the shareholders in general meeting. Such termination shall be without prejudice to the subsisting rights of Participants.
18.3 Save as otherwise provided under the Plan:

18.3.1 Shares issued and allotted pursuant to the Plan will rank pari passu in all respects with the Shares then in issue at the date of such allotment, except that they will not rank for any rights attaching to Shares by reference to a record date preceding the date of allotment; and

18.3.2 Shares to be transferred pursuant to the Plan will be transferred free of all liens, charges and encumbrances and together with all rights attaching thereto, except they will not rank for any rights attaching to Shares by reference to a record date preceding the date of transfer.

18.4 If and so long as the Shares are admitted to listing and/or for trading on any stock exchange or market, the Company shall apply for any Shares issued and allotted pursuant to the Plan to be so admitted as soon as practicable.

18.5 Any transfer of Shares under the Plan is subject to such consent, if any, of any authorities in any jurisdiction as may be required, and the Participant shall be responsible for complying with the requirements to obtain or obviate the necessity for such consents.

18.6 The terms of any individual’s office or employment with any past or present Group Company, and the rights and obligations of the individual thereunder, shall not be affected by his participation in the Plan and the Plan shall not form part of any contract of employment between the individual and any such company.

18.7 An Eligible Employee shall have no right to receive an Award under the Plan and participation in the Plan and the grant of any Award is at the discretion of the Company.

18.8 Participation in the Plan by, or the grant of any Award under it to, a Participant in any year does not create any right to or expectation of participation in the Plan or the grant of any Award in any future year, even if the Participant has previously participated in the Plan (or any similar plan) over a long period of time and/or if participation in the Plan and/or an Award under it (or any similar plan) has been granted (including repeatedly) without the relevant Group Company specifically expressing the voluntary and discretionary nature at the time of each such participation or Award.

18.9 By participating in the Plan, the Participant waives all and any rights to compensation or damages in consequence of the termination of his office or employment with any past or present Group Company for any reason whatsoever, whether lawfully or otherwise, insofar as those rights arise or may arise from his ceasing to have rights under the Plan (including ceasing to be entitled to exercise any Option) as a result of such termination, or from the loss or diminution in value of such rights or entitlements, including by reason of the operation of the terms of the Plan, any determination by the Board pursuant to a discretion contained in the Plan or the provisions of any statute or law relating to taxation.

18.10 Benefits under the Plan shall not form part of a Participant’s remuneration for any purpose and shall not be pensionable.

18.11 The invalidity or non-enforceability of any provision or Rule of the Plan shall not affect the validity or enforceability of the remaining provisions and Rules of the Plan which shall continue in full force and effect.

18.12 These Rules shall be governed by and construed in accordance with English Law.

18.13 The English courts shall have exclusive jurisdiction to determine any dispute which may arise out of, or in connection with, the Plan.
Claw-back prior to the transfer of Shares in respect of an Award (or “malus”)

1. Where the Board determines (pursuant to Rule 13 (Claw-back)) that a Claw-back shall apply in respect of an Award prior to legal title to Shares having been transferred to the Participant pursuant to the Award (whether before or after vesting), the Claw-back shall be applied by the Board reducing the number of Shares in respect of which the Award may vest or, in the case of an Option, be exercised (or after vesting by reducing the number of Shares legal title to which may be transferred pursuant to the Award) by up to the number of Shares determined by the Board to be the excess number of Shares in respect of which the Award was granted and/or is outstanding (and the Award shall lapse to the extent so reduced, which may be in full).

Claw-back following the transfer of Shares in respect of an Award

2. Where the Board determines (pursuant to Rule 13 (Claw-back)) that a Claw-back shall apply in respect of an Award following legal title to Shares having been transferred to the Participant pursuant to the Award (a “Post-Transfer Claw-back”), the Board shall determine:
   a. the excess number of Shares in respect of which the Award vested (the “Excess Shares”); and
   b. the aggregate Market Value of such Excess Shares (as determined by the Board) on the date on which the Award vested or, in the case of an Option, the date the Option was exercised (the “Equivalent Value”).

3. In the case of a Post-Transfer Claw-back, any cash payment made or additional Shares transferred pursuant to Rule 9 (Dividend equivalent) in respect of such Award shall be subject to the Claw-back to the extent that the Board determines that such cash payment or Shares relate to the Excess Shares.

4. A Post-Transfer Claw-back may be effected in such manner as may be determined by the Board, and notified to the Participant, including by any one or more of the following:
   a. by reducing the number of Shares and/or amount of cash in respect of which an Outstanding Award vests or may vest (or has vested, but in respect of which no Shares have yet been transferred or cash payment made), whether before or after the assessment of performance conditions in respect of such Outstanding Award, by the number of Excess Shares and/or the Equivalent Value (and such Outstanding Award shall lapse to the extent so reduced);
   b. by setting-off against any amounts payable by any Group Company to the Participant an amount up to the Equivalent Value (including from any bonus payment which may otherwise become payable to the Participant); and/or
   c. by requiring the Participant to immediately transfer to the Company a number of Shares equal to the Excess Shares or a cash amount equal to the Equivalent Value (which shall be an immediately payable debt due to the Company), provided that the Board may reduce the number of Excess Shares or the amount of the Equivalent Value subject to the Claw-back in order to take account of any Tax Liability (as defined in Rule 11 (Tax Liability)) which arose on the Excess Shares (howsoever delivered to the Participant).

5. For the avoidance of doubt, nothing in Rule 13 (Clawback) or this Appendix shall in any way restrict a Participant from being able to transfer or otherwise deal in Shares acquired on vesting or exercise of an Award.
6. In paragraph 4 above:

“Outstanding Award” means any other Award under the Plan, any award or option under any other Employees’ Share Scheme operated from time to time by any Group Company (other than any award or options granted under any arrangement which satisfies the provisions of Schedules 2 or 3, or (unless the terms of such arrangement state that shares acquired thereunder are subject to claw-back) 4 or 5, of the Income Tax (Earnings and Pensions) Act 2003), or any bonus award under any bonus scheme operated from time to time by any Group Company, in each case which is either held by the Participant at the time of a determination that a Claw-back shall be applied or which are granted to the Participant following such a determination; and

“vests” shall include shares or cash subject to an award becoming due to be transferred or paid, and in the case of an option, the option becoming exercisable.
APPENDIX 2: AWARDS GRANTED TO U.S. TAXPAYERS

1. INTERPRETATION
1.1 This Appendix shall form part of the Rules of the Plan.
1.2 In this Appendix a reference to a “Paragraph” is to a paragraph of this Appendix.
1.3 Capitalized terms used in this Appendix that are not otherwise defined in this Appendix shall have the meanings set forth in the Plan.

2. APPLICATION
2.1 The provisions of this Appendix shall apply to an Award that is held by any Participant while he or she is a U.S. Taxpayer.
2.2 To the extent that any provision of Paragraphs 4 to 11 is inconsistent with any Rule of the Plan, such provision of this Appendix shall take precedence. Paragraph 3 is included to aid interpretation.

3. SERVICE CONDITION

Rule 6 – Cessation of Office or Employment
3.1 All Awards to which this Appendix applies are subject to a service condition which applies until the Award’s Normal Vesting Date or any earlier vesting date.

Paragraph 5 – Awards where the “wait and see approach” shall apply or the Awards otherwise are not exempt from Code § 409A as a short-term deferral
3.2 Notwithstanding the date on which a Conditional Award that is subject to Paragraph 5 vests, the Shares in respect of which such Award vests shall not be transferred to the U.S. Taxpayer until the Normal Vesting Date (subject to any earlier date specified in Paragraph 5.5). Shares in respect of an Option that is subject to Paragraph 5 shall be deemed to be exercised on the date on which such Option vests pursuant to the Plan, as amended by this Appendix.

Paragraph 6 – Awards where the “wait and see” approach does not apply and are otherwise exempt from Code § 409A as a short-term deferral
3.3 An Award that is subject to Paragraph 6 will be subject to a service condition until the date on which it vests, and (a) Shares in respect of a Conditional Award will be transferred to the U.S. Taxpayer no later than the 15th day of the third month following the end of the calendar year in which the Award is no longer subject to a substantial risk of forfeiture (within the meaning of Code § 409A) and (b) Shares in respect of an Option shall be deemed to be exercised on the date on which such Option vests.

Rules 5, 6 and 7 – Vesting, Cessation of Office or Employment and Corporate Actions
3.4 Where an Award vests prior to the Normal Vesting Date, the extent of vesting shall be determined by such applicable Rule.

Lapse
3.5 Awards to which this Appendix applies shall lapse at any time specified in the Rules or this Appendix.

4. APPLICATION OF PARAGRAPHS 5 AND 6
An Award to which this Appendix applies shall be subject to Paragraph 5 or 6, but shall only be capable of being subject to one of Paragraph 5 or Paragraph 6, and which such Paragraph the Award is subject to shall be determined without any involvement of the U.S. Taxpayer and shall not be capable of change for any reason.
5. AWARDS WHERE RULE 6.3.2 (THE “WAIT AND SEE” APPROACH) SHALL APPLY OR THAT OTHERWISE ARE NOT EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL

5.1 An Award shall be subject to this Paragraph 5 if:

5.1.1 on the Grant Date the U.S. Taxpayer is a member of the Management Board of the Company (unless determined otherwise by the Board prior to the Grant Date);

5.1.2 such Award is otherwise not exempt from Code § 409A by reason of complying with the short-term deferral exemption from Code § 409A; and/or

5.1.3 it is so determined by the Board prior to the Grant Date.

5.2 An Award which is subject to this Paragraph 5 shall vest on the earliest of:

5.2.1 the Normal Vesting Date;

5.2.2 any date on which the Award vests pursuant to Rule 7 (subject to Paragraph 5.3);

5.2.3 the U.S. Taxpayer’s death; or

5.2.4 any earlier vesting date determined by the Board pursuant to Rule 5.5 or Rule 6.2 (subject to Paragraph 5.3).

5.3 An Award subject to this Paragraph 5:

5.3.1 may only vest under Rule 7 if the event falling within Rule 7 which would give rise to such vesting constitutes a “change in control event” as described in U.S. Treasury Regulations or other guidance issued pursuant to Code § 409A; and

5.3.2 to the extent it does not vest by such time, shall lapse on any date on which an Option would lapse pursuant to Rule 7.2 to 7.6.

5.4 An Award subject to this Paragraph 5 that is an Option shall be deemed to be automatically exercised to the fullest extent permitted by the Rules on the date on which it vests pursuant to the Plan, as amended by this Appendix, and the Shares subject to such automatic exercise shall be transferred to the U.S. Taxpayer within 60 days (90 days if such Option vests pursuant to Paragraph 5.2.3) of such date of automatic exercise.

5.5 Any Shares in respect of a Conditional Award that is subject to this Paragraph 5 that vest pursuant to the Plan, as amended by this Appendix, shall be transferred to the U.S. Taxpayer within 60 days (90 days in the case of Paragraph 5.5.2(ii) below) of the earlier of:

5.5.1 the Normal Vesting Date; or

5.5.2 if applicable, (i) the date set forth in Paragraph 5.2.2; (ii) the date set forth in Paragraph 5.2.3 or (iii) any applicable date described in Paragraph 5.2.4 (provided that such date is a “permissible payment” event within the meaning of Treasury Regulation § 1.409A-3(a)), and shall be transferred within such period (and, for the avoidance of doubt, not prior to such period).

6. AWARDS WHERE THE “WAIT AND SEE” APPROACH DOES NOT APPLY AND THAT ARE OTHERWISE EXEMPT FROM CODE § 409A AS A SHORT-TERM DEFERRAL

6.1 An Award shall be subject to this Paragraph 6 if the Award is not subject to Paragraph 5.

6.2 An Award which is subject to this Paragraph 6 shall, vest on the earliest of:

6.2.1 the Normal Vesting Date;

6.2.2 any date on which the Award vests pursuant to Rule 7;
6.2.3 the Participant’s death;

6.2.4 any earlier vesting date determined by the Board pursuant to Rule 5.5; and

6.2.5 the date on which the U.S. Taxpayer ceases to hold office or employment with any Group Company for any of the reasons specified in Rule 6.2 (for the avoidance of doubt subject to Rule 6.8).

6.3 An Award subject to this Paragraph 6 that is an Option shall be deemed to be automatically exercised to the fullest extent permitted by the Rules on the date on which it vests pursuant to the Plan, as amended by this Appendix, and the Shares subject to such automatic exercise shall be transferred to the U.S. Taxpayer no later than the 15th day of March in the calendar year immediately following the calendar year in which the Award is no longer subject to a substantial risk of forfeiture (within the meaning of Code § 409A).

6.4 Any Shares in respect of a Conditional Award that is subject to this Paragraph 6 that vest pursuant to the Plan, as amended by this Appendix, shall be transferred to the U.S. Taxpayer no later than the 15th day of March in the calendar year immediately following the calendar year in which the Award is no longer subject to a substantial risk of forfeiture (within the meaning of Code § 409A).

6.5 Rule 6.3.2 shall not apply to an Award which is subject to this Paragraph 6.

7. DIVIDEND EQUIVALENTS

Any payment to which a U.S. Taxpayer may become entitled under Rule 9 with respect to an Award shall be paid to the U.S. Taxpayer at the same time as the transfer of Shares under Paragraph 5.4, 5.5, 6.3 or 6.4, as applicable.

8. CASH ALTERNATIVE

8.1 If Shares cannot be delivered in accordance with Paragraph 5.4, 5.5, 6.3 or 6.4, as applicable, because of a Dealing Restriction, such Award shall instead be satisfied by the payment of a cash equivalent amount pursuant to Rule 10 (as such Rule is amended by Paragraph 8.2).

8.2 Any cash payment to which a U.S. Taxpayer may become entitled under Rule 10 with respect to an Award shall be paid to the U.S. Taxpayer at the same time as the transfer of Shares would have occurred under Paragraph 5.4, 5.5, 6.3 or 6.4, as applicable.

9. CODE § 409A EXEMPTION AND COMPLIANCE

9.1 Awards subject to Paragraph 6 are intended to be exempt from Code § 409A to the maximum extent possible under the exemption for “short-term deferrals” specified in the Treasury Regulations, and the provisions of this Appendix and the Plan, as it applies to such Award, shall be construed, interpreted and applied accordingly. Without limiting the foregoing, the Board shall not exercise any discretion that is otherwise afforded to it under the Plan in a manner that is inconsistent with such treatment. For the avoidance of doubt, any Award subject to Paragraph 6 shall, in all events, be paid within the short-term deferral period specified in Treasury Regulation § 1.409A-1(b)(4).

9.2 To the extent that any Award to which this Appendix applies is subject to Code § 409A, the provisions of this Appendix and the Plan, as it applies to such Award, shall be construed, interpreted and applied in such a way as to comply with the applicable provisions of Code § 409A to the maximum extent possible. If an Award is subject to Code § 409A, then: (i) any payment or transfer of Shares on account of a change in control shall be made only if the change in control qualifies as a “change in control event,” as defined for purposes of Code § 409A; (ii) any provision in the Plan that is inconsistent with the requirements of Code § 409A shall not apply to such Award; (iii) the Board shall exercise discretion otherwise afforded to it under the Plan (including under Appendix 1 to the Plan) only to the extent that such exercise of discretion is consistent with the requirements of Code § 409A; and (iv) the U.S. Taxpayer shall not have the right to designate any payment date with respect to such Award.
9.3 In the event that a U.S. Taxpayer is deemed to be a “specified employee” on the date of his or her “separation from service,” as defined for purposes of Code § 409A (other than by reason of death), determined pursuant to identification methodology adopted by a Group Company in compliance with Code § 409A, and if any portion of the Shares or other payments to be received by such U.S. Taxpayer in respect of an Award upon separation from service would constitute a “deferral of compensation” subject to Code § 409A, then to the extent necessary to comply with Code § 409A, Shares or amounts that would otherwise be delivered or payable pursuant to this Plan, as amended by this Appendix, during the six (6) month period immediately following the date of such U.S. Taxpayer’s separation from service shall instead be delivered or paid either (i) during the period commencing on the date that is six (6) months and one (1) day following the date of such U.S. Taxpayer’s separation from service and ending fifteen (15) days following the first business day of the seventh month after the date of such separation from service, provided that the U.S. Taxpayer shall not have the right to designate the delivery or payment date, or (ii) if earlier, as soon as practicable (and in any event within ninety (90) days) after the U.S. Taxpayer’s death.

9.4 Each Award hereunder shall constitute a separate payment within the meaning of Treasury Regulation §1.409A-2(b)(2).

10. COOPERATION

In the event that the terms of this Plan would subject any U.S. Taxpayer to taxes or penalties under Code § 409A (“409A Penalties”), the Board, the Company and such U.S. Taxpayer shall cooperate diligently to amend the terms of the Plan and the U.S. Taxpayer’s Award agreement to avoid such 409A Penalties, to the extent possible, provided that in no event shall any Group Company be responsible for any 409A Penalties that arise in connection with any amounts payable in respect of any Award granted under this Plan.

11. SETTLEMENT

No Award subject to paragraph 5 of this Appendix shall be settled with Shares from a trust.
ADDENDUM I: AWARDS GRANTED TO RAI PARTICIPANTS

1. APPLICATION
1.1 This Addendum applies to Participants who are employees of Reynolds American Inc. or a subsidiary of Reynolds American Inc. (collectively, “RAI” and such Participants, “RAI Participants”).
1.2 This Addendum sets out certain additional terms which currently apply in respect of Awards granted under the Plan to RAI Participants.
1.3 References in this Addendum to a “Rule” is to the Rule of the Plan. Capitalized terms used in this Addendum shall, save where otherwise defined herein, have the meaning given in the Rules. To the extent that any provision of this Addendum is inconsistent with any Rule of the Plan, such provision of this Addendum shall take precedence.

2. MODIFICATION
The Board may at any time, and without notice to any person, add or alter or discontinue the terms of this Addendum in any respect without prior notice to any Participant.

3. TERMS
Disability
3.1 With respect to RAI Participants, the reference to “disability” in Rule 6.2 (Reasons for cessation where Awards remain capable of vesting) shall mean that the RAI Participant has become eligible for and is in receipt of benefits under RAI’s Long-Term Disability Plan. RAI shall establish such policies, procedures, rules and guidelines as it determines to be appropriate to administer the preceding sentence.

4. SETTLEMENT
4.1 Awards granted to RAI Participants may, at the discretion of the Board, be satisfied by the transfer of British American Tobacco p.l.c. American Depositary Shares, and references in the Plan (including any Appendix, Schedule or Addendum thereto) to “Shares” shall be read accordingly.
4.2 No Award subject to this Addendum shall be settled with Shares from a trust.
Exhibit II

Corporate Governance

Code of Ethics for the Chief Executive and Senior Financial Officers

A. Formation and Purpose

British American Tobacco p.l.c. (“BAT”) has an established Standards of Business Conduct (“SoBC”), which is a code of conduct and ethics applicable to all directors and employees of BAT. In addition, BAT has adopted this Code of Ethics (“Code of Ethics”) for its Chief Executive, its Finance Director and other senior financial officers performing similar functions set forth in Annex I hereto (collectively, the “Senior Officers”). The Senior Officers subject to this Code of Ethics will be designated from time to time and informed of such designation by BAT’s Director, Legal and External Affairs. A list of such Senior Officers will be maintained by BAT’s Group Company Secretary.

B. Standards

In addition to the SoBC, the Senior Officers are subject to the following additional specific obligations:

1. Each Senior Officer shall act with honesty and integrity in the performance of his or her duties and shall use reasonable efforts to comply with, and promote BAT’s compliance with, all applicable governmental laws, rules and regulations, the SoBC and this Code of Ethics.

2. The Senior Officers will promote full, fair, accurate, timely and understandable disclosure in all reports and other documents that BAT files with, or furnishes or submits to, the US Securities and Exchange Commission, the UK Financial Conduct Authority, or any other regulatory agency.

3. The Senior Officers shall promptly bring to the attention of the Group Head of Audit any information they may have concerning any suspected or actual:
   - matters that may affect the disclosures made by BAT in its public filings and/or furnishings;
   - material weakness and/or significant deficiencies in the design or operation of BAT’s internal controls over financial reporting which could adversely affect BAT’s ability to record, process, summaries and report financial data;
   - fraud or inappropriate accounting or auditing matter that involves management or other employees who have a significant role in BAT’s financial reporting, disclosures or internal controls;
   - violation of this Code of Ethics or the SoBC by or involving any Senior Officer, including any actual or apparent conflict of interest between personal and professional relationships that might impair (or be perceived to impair) the independence of any judgment he or she may need to make on behalf of BAT and as outlined in the SoBC; or
   - material violation of the securities or other laws, rules or regulations applicable to BAT and the operation of its business, by BAT.

C. Exceptions

4. Waivers or exceptions to this Code of Ethics will be granted only in advance and only under exceptional circumstances. Any waiver must be made by the Main Board and will be promptly disclosed to the extent required under applicable law and regulation.

Adopted 25 July 2017
Annex I

Designated Senior Officers

Chief Executive
Finance Director
the Group Financial Controller
Group Chief Accountant
EXHIBIT 12

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jack Bowles, certify that:

1. I have reviewed this annual report on Form 20-F of British American Tobacco p.l.c.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4. The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   (c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   (d) Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5. The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
   (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
   (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Signature: /s/ Jack Bowles Date: 8 March 2022

Jack Bowles
Chief Executive
EXHIBIT 12
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Tadeu Marroco, certify that:

1. I have reviewed this annual report on Form 20-F of British American Tobacco p.l.c.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4. The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   (c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   (d) Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5. The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
   (c) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
   (d) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Signature: /s/ Tadeu Marroco Date: 8 March 2022
Tadeu Marroco
Finance and Transformation Director
EXHIBIT 13

CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 20-F (the “Report”) of British American Tobacco p.l.c., a public limited company incorporated in England and Wales (the “Company”), for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof, each of the undersigned officers certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

<table>
<thead>
<tr>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>/s/ Jack Bowles</td>
<td>8 March 2022</td>
</tr>
<tr>
<td>Jack Bowles</td>
<td></td>
</tr>
<tr>
<td>Chief Executive</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>/s/ Tadeu Marroco</td>
<td>8 March 2022</td>
</tr>
<tr>
<td>Tadeu Marroco</td>
<td></td>
</tr>
<tr>
<td>Finance and Transformation Director</td>
<td></td>
</tr>
</tbody>
</table>
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the registration statements (Nos. 333-219440, 333-223678 and 333-237186) on Form S-8 and the registration statement (No. 333-232691) on Form F-3 of our report dated February 10, 2022, with respect to the consolidated financial statements of British American Tobacco p.l.c. and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP
London, United Kingdom
March 8, 2022